PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Sharma, HS; Ali, SF; Hussain, SM; Schlager, JJ; Sharma, A				Sharma, Hari S.; Ali, Syed F.; Hussain, Saber M.; Schlager, John J.; Sharma, Aruna			Influence of Engineered Nanoparticles from Metals on the Blood-Brain Barrier Permeability, Cerebral Blood Flow, Brain Edema and Neurotoxicity. An Experimental Study in the Rat and Mice Using Biochemical and Morphological Approaches	JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY			English	Article; Proceedings Paper	1st International Symposium on Nanoneuroscience - Nanoeuroprotection and Nanoeurotoxicity	AUG 20-26, 2007	Killithea, GREECE			Engineered Nanoparticles; Silver; Copper; Aluminum; Blood-Brain Barrier; Brain Edema; Cerebral Blood Flow; Neuropathology; Astrocytes; Myelin; Evans Blue	SPINAL CORD BARRIER; CARBON-NANOTUBES; TRAUMATIC INJURY; OXIDATIVE STRESS; HEAT-STRESS; METHAMPHETAMINE INTOXICATION; TISSUE DISTRIBUTION; PYROLYSIS PRODUCTS; DRUG-DELIVERY; HEALTH-RISKS	Influence of nanoparticles on brain function following in vivo exposures is not well known. Depending on the magnitude and intensity of nanoparticle exposure from the environment, food and/or water source, neuronal function could be affected and may lead to neurotoxicity and neuropathology. This hypothesis was examined in present investigation using systemic or intracerebroventricular administration of engineered nanoparticles from metals, i.e., Al, Ag and Cu (approximate to 50 to 60 nm) on neurotoxicity in rats and mice. Intraperitoneal (50 mg/kg), intravenous (30 mg/kg), intracarotid (2.5 mg/kg) or intracerebroventricular administration (20 mu g) of nanoparticles significantly altered the blood-brain barrier (BBB) function to Evans blue and radioiodine in several regions of the brain and spinal cord at 24 h after their administration. Marked decreases in local cerebral blood flow (CBF) and pronounced brain edema was seen in regional areas associated with BBB leakage. Neuronal cell injuries, glial cell activation, heat shock protein (HSP) upregulation and loss of myelinated fibers are quite common in effected brain areas. The observed pathological changes were most pronounced in mice compared to rats. Exposures to Cu and Ag nanoparticles showed most marked effects on brain pathology when administered into systemic circulation or into the brain ventricular spaces as compared to Al nanoparticles. Our results are the first to show that nanoparticles from metals are able to induce selective and specific neurotoxicity that depends on the type of metals, route of administration and the species used.	[Sharma, Hari S.; Sharma, Aruna] Uppsala Univ, Univ Hosp, Lab Cerebrovasc Res Anesthesiol & Intens Care, SE-75185 Uppsala, Sweden; [Ali, Syed F.] US FDA, Neurochem Lab, Div Neurotoxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; [Hussain, Saber M.; Schlager, John J.] USAF, Res Lab, Appl Biotechnol Branch, Human Effectiveness Directorate, Wright Patterson AFB, OH 45433 USA	Sharma, HS (corresponding author), Uppsala Univ, Univ Hosp, Lab Cerebrovasc Res Anesthesiol & Intens Care, SE-75185 Uppsala, Sweden.		Sharma, Aruna/D-4430-2011				Amidi M, 2006, J CONTROL RELEASE, V111, P107, DOI 10.1016/j.jconrel.2005.11.014; Borm PJA, 2006, PART FIBRE TOXICOL, V3, DOI 10.1186/1743-8977-3-11; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; CAVAGNA G, 1961, Med Lav, V52, P251; COLEMAN WE, 1968, AM IND HYG ASSOC J, V29, P33, DOI 10.1080/00028896809342978; DEY P K, 1984, Indian Journal of Physiology and Pharmacology, V28, P177; Dunning MD, 2004, J NEUROSCI, V24, P9799, DOI 10.1523/JNEUROSCI.3126-04.2004; Euliss LE, 2006, CHEM SOC REV, V35, P1095, DOI 10.1039/b600913c; Fabian E, 2008, ARCH TOXICOL, V82, P151, DOI 10.1007/s00204-007-0253-y; Fang Jia-You, 2006, Chang Gung Med J, V29, P358; Farokhzad OC, 2006, ADV DRUG DELIVER REV, V58, P1456, DOI 10.1016/j.addr.2006.09.011; Fenoglio I, 2006, FREE RADICAL BIO MED, V40, P1227, DOI 10.1016/j.freeradbiomed.2005.11.010; Gordh T, 2006, PAIN, V124, P211, DOI 10.1016/j.pain.2006.05.020; GRIFFITH FD, 1973, AM IND HYG ASSOC J, V34, P176, DOI 10.1080/0002889738506828; He W, 2006, TISSUE ENG, V12, P2457, DOI 10.1089/ten.2006.12.2457; Johnston CJ, 1996, TOXICOL APPL PHARM, V140, P154, DOI 10.1006/taap.1996.0208; Johnston CJ, 2000, TOXICOL APPL PHARM, V168, P208, DOI 10.1006/taap.2000.9037; Kim JS, 2006, TOXICOL SCI, V89, P338, DOI 10.1093/toxsci/kfj027; Kiyatkin EA, 2007, EUR J NEUROSCI, V26, P1242, DOI 10.1111/j.1460-9568.2007.05741.x; Koziara JM, 2006, J NANOSCI NANOTECHNO, V6, P2712, DOI 10.1166/jnn.2006.441; Kurbitz S, 2001, APPL PHYS B-LASERS O, V73, P333, DOI 10.1007/s003400100657; Lam CW, 2006, CRIT REV TOXICOL, V36, P189, DOI 10.1080/10408440600570233; Lanone S, 2006, CURR MOL MED, V6, P651, DOI 10.2174/156652406778195026; Manna SK, 2005, NANO LETT, V5, P1676, DOI 10.1021/nl0507966; Mertens H, 2006, NANO LETT, V6, P2622, DOI 10.1021/nl061494m; Mills NL, 2006, AM J RESP CRIT CARE, V173, P426, DOI 10.1164/rccm.200506-865OC; Moghimi S. Moein, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P553; Oberdorster G, 2000, Res Rep Health Eff Inst, P5; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Oberdorster G, 1996, PARTICLE OVERLOAD IN THE RAT LUNG AND LUNG CANCER, P73; Rapoport S. I., 1976, BLOOD BRAIN BARRIER; Sharma, 2004, BLOOD SPINAL CORD BR, P437; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P295, DOI 10.1196/annals.1403.022; Sharma H.S., 2009, HDB NEUROCHEM MOL NE, V24, P163; Sharma HS, 2009, J CHEM NEUROANAT, V37, P18, DOI 10.1016/j.jchemneu.2008.08.002; Sharma HS, 2008, EXPERT OPIN PHARMACO, V9, P2773, DOI [10.1517/14656566.9.16.2773, 10.1517/14656566.9.16.2773 ]; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P197, DOI 10.1196/annals.1403.014; Sharma HS, 2007, PROG BRAIN RES, V162, P173, DOI 10.1016/S0079-6123(06)62010-4; Sharma HS, 2007, PROG BRAIN RES, V162, P245, DOI 10.1016/S0079-6123(06)62013-X; Sharma HS, 2006, ANN NY ACAD SCI, V1074, P198, DOI 10.1196/annals.1369.020; Sharma HS, 2006, INDIAN J MED RES, V123, P629; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5073, DOI 10.1166/jnn.2009.GR10; SHARMA HS, 1995, NEUROSCI RES, V21, P241, DOI 10.1016/0168-0102(94)00855-A; SHARMA HS, 1990, BRAIN RES, V517, P215, DOI 10.1016/0006-8993(90)91029-G; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Sharma HS, 1998, PROG BRAIN RES, V115, P351; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; SHARMA HS, 1986, NEUROPHARMACOLOGY, V25, P161, DOI 10.1016/0028-3908(86)90037-7; SHARMA HS, 1987, NEUROPHARMACOLOGY, V26, P85, DOI 10.1016/0028-3908(87)90049-9; Sharma HS, 2002, AMINO ACIDS, V23, P261, DOI 10.1007/s00726-001-0137-z; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; SHARMA HS, 1992, NEUROSCIENCE, V48, P889, DOI 10.1016/0306-4522(92)90277-9; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; Sharma HS, 2004, BLOOD SPINAL CORD BR, P117; Shvedova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL698, DOI 10.1152/ajplung.00084.2005; Shvedova AA, 2004, BIOCHEMISTRY-MOSCOW+, V69, P23, DOI 10.1023/B:BIRY.0000016347.35373.39; Teeguarden JG, 2007, TOXICOL SCI, V95, P300, DOI 10.1093/toxsci/kfl165; Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006-1211; Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228; Williams David, 2006, Med Device Technol, V17, P8; Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k; Zhang WW, 2003, J COLLOID INTERF SCI, V257, P237, DOI 10.1016/S0021-9797(02)00056-5; Zhu SQ, 2006, MAR ENVIRON RES, V62, pS5, DOI 10.1016/j.marenvres.2006.04.059	64	121	123	1	30	AMER SCIENTIFIC PUBLISHERS	VALENCIA	26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA	1533-4880	1533-4899		J NANOSCI NANOTECHNO	J. Nanosci. Nanotechnol.	AUG	2009	9	8					5055	5072		10.1166/jnn.2009.GR09			18	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	470QO	WOS:000267994100071	19928185				2021-06-18	
J	Bogner, J; Corrigan, JD				Bogner, Jennifer; Corrigan, John D.			Reliability and Predictive Validity of the Ohio State University TBI Identification Method With Prisoners	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						screening; substance use disorders; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CALIFORNIA PSYCHOLOGICAL INVENTORY; NEUROPSYCHIATRIC INTERVIEW MINI; ADDICTION SEVERITY INDEX; SICKNESS IMPACT PROFILE; SUBSTANCE-ABUSE; AGGRESSION QUESTIONNAIRE; SOCIALIZATION SCALE; PSYCHOMETRIC PROPERTIES; SCREENING TOOL	Objectives: Evaluate the psychometric properties of indices of lifetime exposure to traumatic brain injury (TBI) among prisoners. Participants: Convenience samples recruited from male (N = 105) and female (N = 105) state prison facilities. Design: Assess test/retest reliability and criterion-related validity. Primary Measures: Summary indices of the number, severity, timing, and effects of lifetime exposure to TBI calculated from data elicited via a structured interview. Results: Test/retest reliability ranged from acceptable to high. Factor analysis showed that indices of lifetime exposure could be characterized by (1) age of onset (especially childhood onset), (2) combinations of number and likely severity of injuries, and (3) number of symptoms and functional effects. Age at injury, number of TBIs with loss of consciousness, and symptoms persisting contributed independently to the prediction of common cognitive and behavioral consequences of TBI. Conclusion: These results provide further support for the reliability and validity of summary indices of lifetime exposure to TBI when elicited via a structured interview.	[Bogner, Jennifer; Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Bogner, J (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.	bogner.1@osu.edu	Corrigan, John D./E-2921-2011		National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention [U491CE000359-01]	Preparation of this manuscript was supported by a grant from the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention grant U491CE000359-01.	Adami H, 2002, PSYCHIAT RES, V113, P295, DOI 10.1016/S0165-1781(02)00265-2; Barnfield TV, 1998, BRAIN INJURY, V12, P951, DOI 10.1080/026990598122007; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Beck A.T., 1987, BECK DEPRESSION INVE; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BECKER JV, 1991, CHILD ABUSE NEGLECT, V15, P531, DOI 10.1016/0145-2134(91)90037-E; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Black DW, 2004, J AM ACAD PSYCHIATRY, V32, P158; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Center for Disease Control and Prevention, 2004, MMWR, V53; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2008, BRAIN INJURY, V22, P223, DOI 10.1080/02699050801938967; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; DAVIS GL, 1991, J OFFENDER REHABIL, V17, P77; DEFRANCESCO JJ, 1993, J PSYCHOPATHOL BEHAV, V15, P53, DOI 10.1007/BF00964323; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Donnellan MB, 2002, PERS INDIV DIFFER, V33, P727; Fox S, 2003, PERS INDIV DIFFER, V34, P1467, DOI 10.1016/S0191-8869(02)00128-9; Ge XJ, 2003, J AM ACAD PSYCHIATRY, V31, P68; GORDON W, 2002, AM C REH MED OCT 4 P; Gough Harrison G., 1957, MANUAL CALIFORNIA PS; GOUGH HG, 1992, J CLIN PSYCHOL, V48, P298, DOI 10.1002/1097-4679(199205)48:3<298::AID-JCLP2270480306>3.0.CO;2-X; GOUGH HG, 1994, PSYCHOL REP, V75, P651, DOI 10.2466/pr0.1994.75.1.651; Gough HG, 1987, MANUAL CALIFORNIA PS; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Harris JA, 1997, BEHAV RES THER, V35, P1047, DOI 10.1016/S0005-7967(97)00064-8; Heinemann AW, 2004, REHABIL PSYCHOL, V49, P156, DOI 10.1037/0090-5550.49.2.156; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Kadden RM, 1996, PSYCHOL ADDICT BEHAV, V10, P131, DOI 10.1037/0893-164X.10.3.131; Kenny DT, 2007, COMTEMPORARY ISSUES, V107, P1; Kolakowsky-Hayner SA, 2001, BRAIN INJURY, V15, P53, DOI 10.1080/02699050150209138; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Lejuez C, 2003, J ADOLESCENCE, V26, P475, DOI 10.1016/S0140-1971(03)00036-8; LEZAK M, 1999, NEUROPSYCHOLOGICAL A; MALLOY P, 1990, ADDICT BEHAV, V15, P431, DOI 10.1016/0306-4603(90)90029-W; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; Megargee EI, 1972, CALIFORNIA PSYCHOL I; Morrell RF, 1998, J OFFENDER REHABIL, V27, P1, DOI DOI 10.1300/J076V27N03_01; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; *PSYCH CORP INC, 1997, WAIS 3 WMS 3 TECHN M; Sandoval AMR, 2000, J PERS ASSESS, V74, P262, DOI 10.1207/S15327752JPA7402_7; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Sheehan DV, 1997, EUR PSYCHIAT, V12, P232, DOI 10.1016/S0924-9338(97)83297-X; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Spitzer RL, 1990, STRUCTURED CLIN INTE; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; TEASDALE G, 1984, CLOSED HEAD INJURY P, P4; Thurman DJ., 1995, GUIDELINES SURVEILLA; *TRAUM BRAIN INJ N, 2003, TRAUM BRAIN INJ MOD; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Wang EW, 1999, BEHAV SCI LAW, V17, P377, DOI 10.1002/(SICI)1099-0798(199907/09)17:3<377::AID-BSL351>3.3.CO;2-D; Warner M, 2005, INJURY PREV, V11, P282, DOI 10.1136/ip.2004.006965; WARNER M, 2000, VITAL HLTH STAT, V10, P202; Whiteneck G, 2001, COLORADO TRAUMATIC B; Williams TY, 1996, PSYCHOL ASSESSMENT, V8, P398, DOI 10.1037/1040-3590.8.4.398	65	121	121	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					279	291		10.1097/HTR.0b013e3181a66356			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000007	19625867				2021-06-18	
J	Ayr, LK; Yeates, KO; Taylor, HG; Browne, M				Ayr, Lauren K.; Yeates, Keith Owen; Taylor, H. Gerry; Browne, Michael			Dimensions of postconcussive symptoms in children with mild traumatic brain injuries	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Nervous system trauma; Pediatric; Postconcussion syndrome; Factor analysis; Parent-child agreement; Prospective studies; Head injuries	HEAD-INJURY; NEUROBEHAVIORAL SYMPTOMS; SAMPLE-SIZE; AGREEMENT; VALIDITY; CRITERIA	The dimensions of postconcussive Symptoms (PCS) were examined in a prospective, longitudinal study of 196 8 to 15 year old children with mild traumatic brain injuries (TBI). Parents and children completed a 50-item questionnaire within 2 weeks of injury and again at 3 months after injury, rating the frequency of PCS on a 4-point scale. Common factor analysis with target rotation was used to rotate the ratings to four hypothesized dimensions, representing cognitive, somatic, emotional, and behavioral symptoms. The rotated factor matrix for baseline parent ratings was consistent with the target matrix. The rotated matrix for baseline child ratings was consistent with the target matrix for cognitive and somatic symptoms but not for emotional and behavioral symptoms. The rotated matrices for ratings obtained 3 months after injury were largely consistent with the target matrix derived from analyses of baseline ratings, except that parent ratings of behavioral symptoms did not cluster as before. Parent and child ratings of PCS following mild TBI yield consistent factors reflecting cognitive and somatic symptom dimensions, but dimensions of emotional and behavioral symptoms are less robust across time and raters. (JINS, 2009. 15, 19-30.)	[Ayr, Lauren K.; Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Ctr Biobehav Hlth, Res Inst, Columbus, OH 43205 USA; [Ayr, Lauren K.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Browne, Michael] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Ctr Biobehav Hlth, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD39834, K02 HD44099]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	The research reported here served as the basis for a dissertation Submitted by the first author to The Ohio State University in partial fulfillment of the requirements for a doctoral degree. Portions of the research were presented at the annual meeting of the International Neuropsychological Society, Boston, February 2006. The larger project from which the research was derived was supported by grants R01 HD39834 and K02 HD44099 from the National Institute of Child Health and Human Development to the second author.	Achenbach TM, 2006, CURR DIR PSYCHOL SCI, V15, P94, DOI 10.1111/j.0963-7214.2006.00414.x; Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Browne M. W., 2004, CEFA COMPREHENSIVE E; Browne MW, 2001, MULTIVAR BEHAV RES, V36, P111, DOI 10.1207/S15327906MBR3601_05; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; EDELBROCK C, 1986, J CHILD PSYCHOL PSYC, V27, P181, DOI 10.1111/j.1469-7610.1986.tb02329.x; Fabrigar LR, 1999, PSYCHOL METHODS, V4, P272, DOI 10.1037/1082-989X.4.3.272; Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gorsuch R. L., 1983, FACTOR ANAL; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GUADAGNOLI E, 1988, PSYCHOL BULL, V103, P265, DOI 10.1037/0033-2909.103.2.265; HODGES K, 1990, J CHILD PSYCHOL PSYC, V31, P427, DOI 10.1111/j.1469-7610.1990.tb01579.x; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MacCallum RC, 1999, PSYCHOL METHODS, V4, P84, DOI 10.1037/1082-989x.4.1.84; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Millsap R. E., 2007, FACTOR ANAL 100 HIST, P131; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; TEASDALE G, 1974, LANCET, V2, P81; Velicer WF, 1998, PSYCHOL METHODS, V3, P231, DOI 10.1037/1082-989X.3.2.231; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; YEATES KO, PEDIATRICS IN PRESS	47	121	121	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2009	15	1					19	30		10.1017/S1355617708090188			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	398NR	WOS:000262739300003	19128525	Green Accepted			2021-06-18	
J	Wijnen, VJM; van Boxtel, GJM; Eilander, HJ; de Gelder, B				Wijnen, V. J. M.; van Boxtel, G. J. M.; Eilander, H. J.; de Gelder, B.			Mismatch negativity predicts recovery from the vegetative state	CLINICAL NEUROPHYSIOLOGY			English	Article						mismatch negativity; vegetative state; minimally conscious state; consciousness	MINIMALLY CONSCIOUS STATE; EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN INJURY; EVOKED-POTENTIALS; MEDICAL ASPECTS; WORKING PARTY; COMA; MANAGEMENT; GUIDELINES; DISORDERS	Objective: Mismatch negativity (MMN) is an automatic event related brain response, well investigated in the acute phase after severe brain injury: the presence of a MMN is often found to predict the emergence from coma, and the exclusion of shifting into a vegetative state (VS). In the present study MMN was examined during recovery from VS. Methods: Ten vegetative patients were repeatedly examined every 2 weeks for an average period of 3.5 months. Amplitudes and latencies were related to the patients' recovery from VS to consciousness, and to a healthy norm group. In addition, MMN was examined on its prognostic value in VS patients, in predicting recovery to consciousness and long-term functional outcome. Results: With recovery to consciousness MMN-amplitudes increased. A sudden increase was seen in MMN amplitude when patients started to show inconsistent behavioural responses to simple commands. At this level MMN resembled the MMN response as was seen in the norm group. In addition, the MMN-amplitude and latency during the first measurement predicted the patients' outcome on recovery to consciousness. Conclusions: With recovery from VS to consciousness the ability to process auditory stimulus deviance increases. A sudden enhancement in MMN-amplitude preceded overt communication with the environment. This might be indicative of the consolidation of neural networks underlying overt communication. Moreover, MMN can be helpful in identifying the ability to recover from VS. Significance: MMN can be used to track recovery from the vegetative state in the post-acute phase after severe brain injury. In addition, MMN can be used to predict the ability to recover from the vegetative state. (c) 2006 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Tilburg Univ, Dept Psychol & Hlth, Cognit & Affect Neurosci Lab, NL-5000 LE Tilburg, Netherlands; Rehabil Ctr Leijpark, Div Res, Project VLB NAH, NL-5022 KE Tilburg, Netherlands; Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA	van Boxtel, GJM (corresponding author), Tilburg Univ, Dept Psychol & Hlth, Cognit & Affect Neurosci Lab, Warandelaan 2, NL-5000 LE Tilburg, Netherlands.	G.J.M.vBoxtel@uvt.nl	Wijnen, Viona/G-1328-2016	Wijnen, Viona/0000-0001-7797-1882; van Boxtel, Geert/0000-0002-9105-7963			Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; Ansell BJ, 1989, W NEURO SENSORY STIM, P24; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bates D, 2003, CLIN MED, V3, P249; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; EILANDER HJ, UNPUB RELIABILITY VA; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIARD MH, 1990, PSYCHOPHYSIOLOGY, V27, P627, DOI 10.1111/j.1469-8986.1990.tb03184.x; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Jennett B, 2005, NEUROPSYCHOL REHABIL, V15, P163, DOI 10.1080/09602010443000632; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1996, NEUROTRAUMA, P3; JONES R, 1994, ARCH PHYS MED REHAB, V75, P164; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Keselman HJ, 2001, BRIT J MATH STAT PSY, V54, P1, DOI 10.1348/000711001159357; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Kotchoubey B, 2003, NEUROSCI LETT, V352, P129, DOI 10.1016/j.neulet.2003.08.045; Kotchoubey B, 2001, NEUROSCI LETT, V301, P37, DOI 10.1016/S0304-3940(01)01600-7; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Luaute J, 2005, ARCH PHYS MED REHAB, V86, P917, DOI 10.1016/j.apmr.2004.08.011; Morlet D, 2000, AUDIOL NEURO-OTOL, V5, P198, DOI 10.1159/000013881; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; Naatanen R, 2004, CLIN NEUROPHYSIOL, V115, P140, DOI 10.1016/j.clinph.2003.04.001; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schiff Nicholas D., 2002, Thalamus & Related Systems, V2, P55, DOI 10.1017/S1472928802000286; Schroger E, 1998, BEHAV RES METH INS C, V30, P131, DOI 10.3758/BF03209423; Tremblay K, 1998, NEUROREPORT, V9, P3557, DOI 10.1097/00001756-199811160-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	39	121	131	0	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAR	2007	118	3					597	605		10.1016/j.clinph.2006.11.020			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	144CJ	WOS:000244772600012	17239656	Green Published			2021-06-18	
J	Jackson, JC; Hart, RP; Gordon, SM; Hopkins, RO; Girard, TD; Ely, EW				Jackson, James C.; Hart, Robert P.; Gordon, Sharon M.; Hopkins, Ramona O.; Girard, Timothy D.; Ely, E. Wesley			Post-traumatic stress disorder and post-traumatic stress symptoms following critical illness in medical intensive care unit patients: assessing the magnitude of the problem	CRITICAL CARE			English	Article							QUALITY-OF-LIFE; RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN INJURY; CUMULATIVE ADVERSITY; SEPTIC SHOCK; SURVIVORS; HEALTH; MEMORY; ADULTS; PREVALENCE	Introduction Post-traumatic stress disorder (PTSD) is a potentially serious psychiatric disorder that has traditionally been associated with traumatic stressors such as participation in combat, violent assault, and survival of natural disasters. Recently, investigators have reported that the experience of critical illness can also lead to PTSD, although details of the association between critical illness and PTSD remain unclear. Methods We conducted keyword searches of MEDLINE and Psych Info and investigations of secondary references for all articles pertaining to PTSD in medical intensive care unit (ICU) survivors. Results From 78 screened papers, 16 studies (representing 15 cohorts) and approximately 920 medical ICU patients met inclusion criteria. A total of 10 investigations used brief PTSD screening tools exclusively as opposed to more comprehensive diagnostic methods. Reported PTSD prevalence rates varied from 5% to 63%, with the three highest prevalence estimates occurring in studies with fewer than 30 patients. Loss to follow-up rates ranged from 10% to 70%, with average loss to follow-up rates exceeding 30%. Conclusion Exact PTSD prevalence rates cannot be determined due to methodological limitations such as selection bias, loss to follow-up, and the wide use of screening (as opposed to diagnostic) instruments. In general, the high prevalence rates reported in the literature are likely to be overestimates due to the limitations of the investigations conducted to date. Although PTSD may be a serious problem in some survivors of critical illness, data on the whole population are inconclusive. Because the magnitude of the problem posed by PTSD in survivors of critical illness is unknown, there remains a pressing need for larger and more methodologically rigorous investigations of PTSD in ICU survivors.	VA Tennessee Valley GRECC, CRCOE, Nashville, TN 37212 USA; Vanderbilt Univ, Div Allergy Pulm Crit Care Med, Med Ctr T1218, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Hlth Serv Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37212 USA; Virginia Commonwealth Univ, Med Ctr, Dept Psychiat, West Hosp, Richmond, VA 23298 USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; LDS Hosp, Dept Med, Div Pulm & Crit Care, Salt Lake City, UT 84113 USA	Jackson, JC (corresponding author), VA Tennessee Valley GRECC, CRCOE, 1310 24th Ave S, Nashville, TN 37212 USA.	james.c.jackson@vanderbilt.edu	Ely, E. Wesley/Z-2018-2019; Girard, Timothy/I-3008-2019	Ely, E. Wesley/0000-0003-3957-2172; Girard, Timothy/0000-0002-9833-4871			Alonzo AA, 2000, SOC SCI MED, V50, P1475, DOI 10.1016/S0277-9536(99)00399-8; Averill PM, 2000, J ANXIETY DISORD, V14, P133, DOI 10.1016/S0887-6185(99)00045-6; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blanchard EB, 2004, BEHAV RES THER, V42, P569, DOI 10.1016/S0005-7967(03)00162-1; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Boscarino JA, 2004, ANN NY ACAD SCI, V1032, P141, DOI 10.1196/annals.1314.011; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Breslau N, 2002, CAN J PSYCHIAT, V47, P923; Brewin CR, 2005, J TRAUMA STRESS, V18, P53, DOI 10.1002/jts.20007; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Brewin CR, 2000, J TRAUMA STRESS, V13, P499, DOI 10.1023/A:1007741526169; Bruce M, 2006, CLIN PSYCHOL REV, V26, P233, DOI 10.1016/j.cpr.2005.10.002; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Capuzzo M, 2005, Minerva Anestesiol, V71, P167; Creamer M, 2005, J AFFECT DISORDERS, V86, P175, DOI 10.1016/j.jad.2005.01.015; Cuthbertson BH, 2004, INTENS CARE MED, V30, P450, DOI 10.1007/s00134-003-2004-8; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; Deja M, 2006, CRIT CARE, V10, DOI 10.1186/cc5070; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2701; Eddleston JM, 2000, CRIT CARE MED, V28, P2293, DOI 10.1097/00003246-200007000-00018; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Fazel M, 2005, LANCET, V365, P1309, DOI 10.1016/S0140-6736(05)61027-6; FOREMAN M, 2004, PRIMARY PSYCHIAT, V11, P46; Frans O, 2005, ACTA PSYCHIAT SCAND, V111, P291, DOI 10.1111/j.1600-0447.2004.00463.x; Galea S, 2005, EPIDEMIOL REV, V27, P78, DOI 10.1093/epirev/mxi003; Hopkins RO, 2005, CURR OPIN CRIT CARE, V11, P369, DOI 10.1097/01.ccx.0000166399.88635.a5; Jones C, 2003, CRIT CARE MED, V31, P2456, DOI 10.1097/01.CCM.0000089938.56725.33; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Kangas M, 2002, CLIN PSYCHOL REV, V22, P499, DOI 10.1016/S0272-7358(01)00118-0; Kapfhammer HP, 2004, AM J PSYCHIAT, V161, P45, DOI 10.1176/appi.ajp.161.1.45; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kimerling R, 2000, J TRAUMA STRESS, V13, P115, DOI 10.1023/A:1007729116133; Kimerling R, 1999, AIDS EDUC PREV, V11, P321; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; Lasiuk GC, 2006, PERSPECT PSYCHIATR C, V42, P72, DOI 10.1111/j.1744-6163.2006.00056.x; Lloyd DA, 2003, AM J ORTHOPSYCHIAT, V73, P381, DOI 10.1037/0002-9432.73.4.381; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Miranda Jeanne, 1999, J Ment Health Policy Econ, V2, P73, DOI 10.1002/(SICI)1099-176X(199906)2:2<73::AID-MHP40>3.0.CO;2-3; Nelson BJ, 2000, CRIT CARE MED, V28, P3626, DOI 10.1097/00003246-200011000-00013; Nickel Marius, 2004, J Intensive Care Med, V19, P285, DOI 10.1177/0885066604267684; Parkin AJ, 1999, CURR BIOL, V9, pR582, DOI 10.1016/S0960-9822(99)80378-9; Rattray JE, 2005, ANAESTHESIA, V60, P1085, DOI 10.1111/j.1365-2044.2005.04336.x; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; Schelling G, 2001, BIOL PSYCHIAT, V50, P978, DOI 10.1016/S0006-3223(01)01270-7; Schelling G, 1999, CRIT CARE MED, V27, P2678, DOI 10.1097/00003246-199912000-00012; Scragg P, 2001, ANAESTHESIA, V56, P9, DOI 10.1046/j.1365-2044.2001.01714.x; Seedat S, 2005, CNS DRUGS, V19, P411, DOI 10.2165/00023210-200519050-00004; Shaw RJ, 2001, PSYCHOSOMATICS, V42, P35, DOI 10.1176/appi.psy.42.1.35; Shemesh E, 2006, PSYCHOSOMATICS, V47, P231, DOI 10.1176/appi.psy.47.3.231; Smith MY, 1999, PSYCHO-ONCOLOGY, V8, P521, DOI 10.1002/(SICI)1099-1611(199911/12)8:6<521::AID-PON423>3.0.CO;2-X; Spindler H, 2005, PSYCHOSOM MED, V67, P715, DOI 10.1097/01.psy.0000174995.96183.9b; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Stoll C, 1999, INTENS CARE MED, V25, P697, DOI 10.1007/s001340050932; Tedstone JE, 2003, CLIN PSYCHOL REV, V23, P409, DOI 10.1016/S0272-7358(03)00031-X; Tedstone JE, 1997, BURNS, V23, P550, DOI 10.1016/S0305-4179(97)00083-1; Turner RJ, 1995, J HEALTH SOC BEHAV, V36, P360, DOI 10.2307/2137325; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Weinert C, 2005, CURR OPIN CRIT CARE, V11, P376, DOI 10.1097/01.ccx.0000168529.23078.64	63	121	126	0	18	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1466-609X			CRIT CARE	Crit. Care		2007	11	1							R27	10.1186/cc5707			11	Critical Care Medicine	General & Internal Medicine	185OT	WOS:000247721000027	17316451	DOAJ Gold, Green Published			2021-06-18	
J	Walker, WC; Pickett, TC				Walker, William C.; Pickett, Treven C.			Motor impairment after severe traumatic brain injury: A longitudinal multicenter study	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						ataxia; brain injury; closed head injury; dyskinesias; measurement; neurological examination; outcomes; paresis; postural balance; rehabilitation	HEAD-INJURY; GOOD RECOVERY; BALANCE; REHABILITATION; DEFICITS; SWAY; INDIVIDUALS; PERFORMANCE; OUTCOMES; CHILDREN	Neuromotor impairment is a common sequela of severe traumatic brain injury (TBI) but has been understudied relative to neurocognitive outcomes. This multicenter cohort study describes the longitudinal course of neurological examination-based motor abnormalities after severe TBI. Subjects were enrolled from the four lead Department of Veterans Affairs and Defense and Veterans Brain Injury Center sites. The study cohort consisted of 102 consecutive patients (active duty, veteran, or military dependent) with severe TBI who consented during acute rehabilitation for data collection and completed all follow-up evaluations. Paresis, ataxia, and postural instability measures showed a pattern of improvement over time, with the greatest improvement occurring between the inpatient (baseline) and 6-month follow-up assessments. Involuntary movement disorders were rare at all time points. Two years following acute rehabilitation, more than one-third of subjects continued to display a neuromotor abnormality on basic neurological examination. Persistence of tandem gait abnormality was particularly common.	[Walker, William C.; Pickett, Treven C.] Vet Affairs Med Ctr, Hunter Holmes McGuire Dept, Richmond, VA USA; [Walker, William C.; Pickett, Treven C.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Walker, William C.; Pickett, Treven C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA	Walker, WC (corresponding author), MCV Campus,POB 980661, Richmond, VA 23298 USA.	wcwalker@mail2.vcu.edu	Walker, William C/N-3162-2014				Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; Bode RK, 2002, ARCH PHYS MED REHAB, V83, P100, DOI 10.1053/apmr.2002.26073; Brown KE, 2006, ARCH PHYS MED REHAB, V87, P76, DOI 10.1016/j.apmr.2005.08.003; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; *COMM ACCR REH FAC, 2002, STAND MAN INT GUID M; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; Di Russo F, 2005, J NEUROTRAUM, V22, P297; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; GUERTS ACH, 1996, ARCH PHYSICAL MED RE, V77, P639; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hillier SL, 1997, BRAIN INJURY, V11, P661; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; Juneja G, 1998, AM J PHYS MED REHAB, V77, P388, DOI 10.1097/00002060-199809000-00005; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RADFARBAUBLITZ LS, 2006, AM J PHYS MED REHABI, V85, P256; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SALAZAR AM, 1999, BRAIN INJ SOURCE, V3, P8; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P289, DOI 10.1016/S1388-2457(03)00348-1; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	35	121	123	1	30	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					975	982		10.1682/JRRD.2006.12.0158			8	Rehabilitation	Rehabilitation	253NL	WOS:000252524800010	18075954	Bronze			2021-06-18	
J	Wood, RLL; Rutterford, NA				Wood, Rodger L. L.; Rutterford, Neil A.			Demographic and cognitive predictors of long-term psychosocial outcome following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain injuries; outcome studies; demographic factors; neuropsychological tests; injury severity; social adjustment	COMMUNITY INTEGRATION QUESTIONNAIRE; CLOSED-HEAD INJURY; QUALITY-OF-LIFE; HOSPITAL ANXIETY; DISABILITY; SATISFACTION; IMPAIRMENT; HANDICAP; MODERATE; RETURN	Demographic factors and cognitive impairment have been found previously to have associations with outcome after brain injury. Kendall and Terry (1996) suggest that preinjury psychosocial functioning, neurological factors, and cognitive impairment have a direct relationship with multidimensional psychosocial adjustment, but that cognitive impairment also has an indirect relationship by means of the mediation of appraisal and coping variables. The aim of this study was to explore these theoretical relationships at very late stages of recovery after brain injury. A total of 131 participants who were more than 10 years after injury (mean = 15.31 yr) completed a neuropsychological assessment, plus outcome measures that included employment status, community integration, life satisfaction, quality of life (QoL), and emotion. Results indicated that injury severity was predictive of life satisfaction; gender and relationship status predicted community integration; and age at injury predicted employment status. Impairment in working memory directly predicted all outcomes except QoL and anxiety. An indirect relationship was also evident between working memory, life satisfaction, and depression. Results partially support Kendall and Terry's model but the variables that significantly influence outcome seem to be determined by the outcome dimensions selected.	Univ Coll Swansea, Sch Human Sci, Dept Psychol, Swansea SA2 8PP, W Glam, Wales	Wood, RLL (corresponding author), Univ Coll Swansea, Sch Human Sci, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk					ABACHNICK BG, 2001, USING MULTIVARIATE S; ADDELEY A, 1992, SPEED CAPACITY LANGU; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BARTLETT MS, 1954, J ROY STAT SOC B, V16, P296; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KAISER HF, 1970, PSYCHOMETRIKA, V35, P401, DOI 10.1007/BF02291817; KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MCAULEY E, 1992, PERS SOC PSYCHOL B, V18, P566, DOI 10.1177/0146167292185006; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MOOREY S, 1991, BRIT J PSYCHIAT, V158, P255, DOI 10.1192/bjp.158.2.255; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Reitan RM., 1985, HALSTEAD REITAN NEUR; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; Schwarzer R., 1993, MEASUREMENT PERCEIVE; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Shallice, 1997, HAYLING BRIXTON TEST; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, BRAIN INJURY REHABIL, P355; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; WOOD RL, IN PRESS J NEUROLOGY; WOOD RL, IN PRESS ARCH CLIN N; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	51	121	122	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2006	12	3					350	358		10.1017/S1355617706060498			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	046PP	WOS:000237823800005	16903127				2021-06-18	
J	Haas, S; Weidner, N; Winkler, J				Haas, S; Weidner, N; Winkler, J			Adult stem cell therapy in stroke	CURRENT OPINION IN NEUROLOGY			English	Article						cerebral ischemia; hematopoietic stem cell; neurogenesis; transdifferentiation	MARROW STROMAL CELLS; FIBROBLAST GROWTH FACTOR-2; COLONY-STIMULATING FACTOR; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; BONE-MARROW; IN-VIVO; NEUROTROPHIC FACTOR; NEURAL PROGENITORS; DENTATE GYRUS	Purpose of review: Acute cerebral infarction causes irreversible locally restricted loss of the neuronal circuitry and supporting glial cells with consecutive functional deficits and disabilities. The currently available and effective therapy targets fast vessel recanalization accompanied by symptomatic measures. Research activities focusing on stem cells, which represent a promising source for organotypic cell replacement and functional recovery after stroke, have gained momentum in recent years, making regenerative cell-based therapies a much more feasible realistic approach. This review provides an update about preclinical and clinical cell-based studies in stroke focusing on stem cells derived from the adult central nervous and hematopoetic systems. Recent findings: Endogenous neural stem cells, which have been shown to reside throughout life in the central nervous system, have the capacity to replace lost neurons in models for numerous disorders, including cerebral ischemia. Considering adult neural stem cell transplantation as a regenerative strategy after stroke, progress has been made in isolating human adult neural stem cells and demonstrating the feasibility of autologous neural stem cell transplantation. An increasing number of studies provide evidence that hematopoietic stem cells, either after stimulation of endogenous stem cell pools or after exogenous hematopoietic stem cell application (transplantation), improve functional outcome after ischemic brain lesions. Various underlying mechanisms such as transdifferentiation into neural lineages, neuroprotection through trophic support, and cell fusion have been deciphered. Summary: Many preclinical studies employing adult stem cell-based strategies hold great promise. For endogenous approaches the correlate of cell replacement underlying functional improvement needs to be demonstrated. Transplantation approaches on the experimental level need further development before clinical application can be considered.	Univ Regensburg, Dept Neurol, D-93053 Regensburg, Germany	Winkler, J (corresponding author), Univ Regensburg, Dept Neurol, Univ Str 84, D-93053 Regensburg, Germany.	juergen.winkler@klinik.uni-regensburg.de					AIHARA N, 1994, BRAIN RES BULL, V33, P483, DOI 10.1016/0361-9230(94)90072-8; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; AOKI H, 1993, NEUROSCIENCE, V56, P345, DOI 10.1016/0306-4522(93)90336-E; Arsenijevic Y, 2001, EXP NEUROL, V170, P48, DOI 10.1006/exnr.2001.7691; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chmielnicki E, 2004, J NEUROSCI, V24, P2133, DOI 10.1523/JNEUROSCI.1554-03.2004; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FARBER SD, 1988, PROG BRAIN RES, V78, P103; Gustafsson E, 2003, EUR J NEUROSCI, V17, P2667, DOI 10.1046/j.1460-9568.2003.02713.x; HIRSCH MC, 2004, INTERBRAIN TOPOGRAPH; ICKENSTEIN G, 2004, 56 ANN M AM AC NEUR; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; Kee NJ, 2001, EXP BRAIN RES, V136, P313, DOI 10.1007/s002210000591; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kempermann G, 2000, Prog Brain Res, V127, P35; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Larsson E, 2002, EXP NEUROL, V177, P1, DOI 10.1006/exnr.2002.7992; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Palmer TD, 1999, J NEUROSCI, V19, P8487; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; PFEIFER K, 2003, 33 ANN M SOC NEUR 8; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rice CM, 2004, LANCET, V364, P193, DOI 10.1016/S0140-6736(04)16633-6; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Wachs FP, 2003, LAB INVEST, V83, P949, DOI 10.1097/01.LAB.0000075556.74231.A5; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Yamamoto S, 2001, J NEUROSCI, V21, P9814, DOI 10.1523/JNEUROSCI.21-24-09814.2001; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhang Q, 2003, DEFENCE SCI J, V53, P259, DOI 10.14429/dsj.53.2274; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	56	121	148	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	FEB	2005	18	1					59	64		10.1097/00019052-200502000-00012			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	901PR	WOS:000227294900011	15655404				2021-06-18	
J	Ikeda, M; Sugiyama, K; Kang, CT; Takagaki, T; Oka, Y				Ikeda, M; Sugiyama, K; Kang, CT; Takagaki, T; Oka, Y			Comminuted fractures of the radial head - Comparison of resection and internal fixation	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							OPEN REDUCTION; CLOSED FRACTURE; FOLLOW-UP; EXCISION; ELBOW; JOINT; VALGUS; ADULTS; SCREW	Background: Satisfactory internal fixation of comminuted radial head fractures is often difficult to achieve, and radial head resection has been the accepted treatment. In this study, we compared the results of radial head resection with those of open reduction and internal fixation in patients with a comminuted radial head fracture. Methods: Twenty-eight patients with a Mason type-III radial head fracture (some with associated injuries) were enrolled in the study. Fifteen patients underwent radial head resection as the initial treatment (Group I), and thirteen patients underwent open reduction and internal fixation (Group II). The age at the operation averaged 41.1 and 38.2 years, respectively, and the duration of follow-up averaged ten and three years, respectively. The outcomes were assessed on the basis of pain, motion, radiographic findings, and strength measured with Cybex testing. The overall outcome was rated with the functional rating score described by Broberg and Morrey and with the American Shoulder and Elbow Surgeons Elbow Assessment Form. Results: Elbow motion averaged 15.5degrees (extension loss) to 131.4degrees (flexion) in Group I and 7.1degrees to 133.8degrees in Group II. The carrying angle and ulnar variance averaged 8.2degrees and 1.9 mm in Group I and 1.5degrees and 0.5 mm in Group II. Compared with Group II, Group I had a loss of strength in extension, pronation, and supination (p < 0.01). The Broberg and Morrey functional rating score averaged 81.4 points in Group I and 90.7 points in Group II (p = 0.0034). The score on the American Shoulder and Elbow Surgeons Elbow Assessment Form averaged 87.3 points in Group I and 94.6 points in Group II (p = 0.0031). Conclusions: The patients in whom the comminuted radial head fracture was treated with open reduction and internal fixation had satisfactory joint motion, with greater strength and better function than the patients who had undergone radial head resection. These results support a recommendation for open reduction and internal fixation in the treatment of this fracture. Level of evidence.	Tokai Univ, Oiso Hosp, Dept Orthopaed Surg, Oio, Kanagawa 2590198, Japan	Ikeda, M (corresponding author), Tokai Univ, Oiso Hosp, Dept Orthopaed Surg, 21-1 Gakkyo, Oio, Kanagawa 2590198, Japan.	zenryo@oiso.u-tokai.ac.jp					ADLER J B, 1964, J Trauma, V4, P115, DOI 10.1097/00005373-196401000-00009; BAKALIM G, 1970, ACTA ORTHOP SCAND, V41, P320, DOI 10.3109/17453677008991518; BROBERG MA, 1986, J BONE JOINT SURG AM, V68A, P669, DOI 10.2106/00004623-198668050-00005; BUNKER TD, 1985, INJURY, V16, P621, DOI 10.1016/0020-1383(85)90011-7; COLEMAN DA, 1987, J BONE JOINT SURG AM, V69A, P385; ESSER RD, 1995, J ORTHOP TRAUMA, V9, P318, DOI 10.1097/00005131-199509040-00008; Frankle MA, 1999, J SHOULDER ELB SURG, V8, P355, DOI 10.1016/S1058-2746(99)90160-X; Fuchs S, 1999, J SHOULDER ELB SURG, V8, P247, DOI 10.1016/S1058-2746(99)90137-4; Geel C W, 1990, J Orthop Trauma, V4, P270, DOI 10.1097/00005131-199004030-00006; GEEL CW, 1992, CLIN ORTHOP RELAT R, P79; GOLDBERG I, 1986, J BONE JOINT SURG AM, V68A, P675, DOI 10.2106/00004623-198668050-00006; GUSTILO RB, 1990, J BONE JOINT SURG AM, V72A, P299, DOI 10.2106/00004623-199072020-00023; Hotchkiss, 1997, J Am Acad Orthop Surg, V5, P1; Ikeda A, 2003, J BONE JOINT SURG BR, V85B, P1040, DOI 10.1302/0301-620X.85B7.13823; Janssen RPA, 1998, J BONE JOINT SURG BR, V80B, P231, DOI 10.1302/0301-620X.80B2.8255; Jensen SL, 1999, J SHOULDER ELB SURG, V8, P238, DOI 10.1016/S1058-2746(99)90135-0; JOHNSTON G W, 1962, Ulster Med J, V31, P51; King G J, 1991, J Orthop Trauma, V5, P21, DOI 10.1097/00005131-199103000-00004; King GJW, 1999, J SHOULDER ELB SURG, V8, P351; Kuntz DG, 1999, ORTHOP CLIN N AM, V30, P37, DOI 10.1016/S0030-5898(05)70060-2; MASON ML, 1954, BRIT J SURG, V42, P123, DOI 10.1002/bjs.18004217203; MCARTHUR RA, 1987, CLIN ORTHOP RELAT R, P79; MEZERA K, 2001, ROCKWOOD GREENS FRAC, V1, P940; MIKIC ZD, 1983, CLIN ORTHOP RELAT R, P220; MORREY BF, 1991, CLIN ORTHOP RELAT R, P187; Morrey BF, 1997, J BONE JOINT SURG AM, V79A, P460, DOI 10.2106/00004623-199703000-00023; MORREY BF, 1979, J BONE JOINT SURG AM, V61, P63, DOI 10.2106/00004623-197961010-00012; Morrey BF, 2000, ELBOW ITS DISORDERS, P341; Pearce MS, 1996, J ROY SOC MED, V89, pP340; REGAN W, 1989, J BONE JOINT SURG AM, V71A, P1348, DOI 10.2106/00004623-198971090-00011; Ring D, 2002, J BONE JOINT SURG AM, V84A, P1811, DOI 10.2106/00004623-200210000-00011; Sanchez-Sotelo J, 2000, J ORTHOP TRAUMA, V14, P354, DOI 10.1097/00005131-200006000-00009; SANDERS RA, 1986, AM J SPORT MED, V14, P130, DOI 10.1177/036354658601400206; Shepard MF, 2001, J BONE JOINT SURG AM, V83A, P92, DOI 10.2106/00004623-200101000-00013; SOWA DT, 1995, CLIN ORTHOP RELAT R, P106; STEPHEN IBM, 1981, ACTA ORTHOP SCAND, V52, P409, DOI 10.3109/17453678109050121; SUTRO CJ, 1985, B HOSP JOINT DIS ORT, V45, P65; TAYLOR TKF, 1964, J BONE JOINT SURG BR, V46, P83	38	121	133	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	JAN	2005	87A	1					76	84		10.2106/JBJS.C.01323			9	Orthopedics; Surgery	Orthopedics; Surgery	887OR	WOS:000226315900011	15634816				2021-06-18	
J	Perlstein, WM; Cole, MA; Demery, JA; Seignourel, PJ; Dixit, NK; Larson, MJ; Briggs, RW				Perlstein, WM; Cole, MA; Demery, JA; Seignourel, PJ; Dixit, NK; Larson, MJ; Briggs, RW			Parametric manipulation of working memory load in traumatic brain injury: Behavioral and neural correlates	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	32nd Annual Meeting of the Society-for-Neuroscience	NOV 02-07, 2002	ORLANDO, FL	Soc Neurosci		traumatic brain injury; working memory; functional magnetic resonance imaging	PREFRONTAL CORTEX DYSFUNCTION; DUAL-TASK PERFORMANCE; CARD SORTING TEST; EXECUTIVE FUNCTIONS; HEAD-INJURY; DEFICITS; ACTIVATION; SYSTEM; IMPAIRMENTS; RELATIVES	Traumatic brain injury (TBI) is often associated with enduring impairments in high-level cognitive functioning, including working memory (WM). We examined WM function in predominantly chronic patients with mild, moderate and severe TBI and healthy comparison subjects behaviorally and, in a small subset of moderate-to-severe TBI patients, with event-related functional magnetic resonance imaging (fMRI), using a visual n-back task that parametrically varied WM load. TBI patients showed severity-dependent and load-related WM deficits in performance accuracy, but not reaction time. Performance of mild TBI patients did not differ from controls; patients with moderate and severe TBI were impaired, relative to controls and mild TBI patients, but only at higher WM-load levels. fMRI results show that TBI patients exhibit altered patterns of activation in a number of WM-related brain regions, including the dorsolateral prefrontal cortex and Broca's area. Examination of the pattern of behavioral responding and the temporal course of activations suggests that WM deficits in moderate-to-severe TBI are due to associative or strategic aspects of WM, and not impairments in active maintenance of stimulus representations. Overall, results demonstrate that individuals with moderate-to-severe TBI exhibit WM deficits that are associated with dysfunction within a distributed network of brain regions that support verbally mediated WM.	Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL USA; Univ Texas, SW Med Ctr, Dept Radiol, Dallas, TX USA	Perlstein, WM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HSC Box 100165, Gainesville, FL 32610 USA.	wmp@grove.ufl.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01 MH01857] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH001857] Funding Source: NIH RePORTER		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS KM, 1985, J CLIN EXP NEUROPSYC, V7, P445, DOI 10.1080/01688638508401276; Baddeley A. D., 1986, WORKING MEMORY; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; BRAVER SL, 1993, PSYCHOL BULL, V113, P379, DOI 10.1037/0033-2909.113.2.379; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; Burgess P. W., 1997, METHODOLOGY FRONTAL, P81, DOI DOI 10.1024//1016-264X.10.2.123; Callicott JH, 1999, CEREB CORTEX, V9, P20, DOI 10.1093/cercor/9.1.20; CHAPMAN LJ, 1989, J ABNORM PSYCHOL, V98, P357, DOI 10.1037/0021-843X.98.4.357; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Dreher JC, 2003, CEREB CORTEX, V13, P329, DOI 10.1093/cercor/13.4.329; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P153; HUMPHREYS MS, 1984, PSYCHOL REV, V91, P153, DOI 10.1037/0033-295X.91.2.153; Huynh H, 1976, J EDUC STATIST, V1, P69, DOI DOI 10.3102/10769986001001069; Jonides J, 1997, STUD COGNIT, P243; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keppel G., 1982, DESIGN ANAL RES HDB, V2nd; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Miller E, 1970, Cortex, V6, P121; Miller GA, 2001, J ABNORM PSYCHOL, V110, P40, DOI 10.1037//0021-843X.110.1.40; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyake Akira, 2000, Seminars in Speech and Language, V21, P169, DOI 10.1055/s-2000-7563; NOLL DC, 1995, JMRI-J MAGN RESON IM, V5, P49, DOI 10.1002/jmri.1880050112; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PASHLER H, 1994, PSYCHOL BULL, V116, P220, DOI 10.1037/0033-2909.116.2.220; Perlstein WM, 2003, NEUROSCI LETT, V342, P191, DOI 10.1016/S0304-3940(03)00226-X; Perlstein WM, 2001, AM J PSYCHIAT, V158, P1105, DOI 10.1176/appi.ajp.158.7.1105; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Phillips LH, 1997, Methodology of frontal " and executive function, P191; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Price CJ, 2001, HDB FUNCTIONAL NEURO, P379; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Spielberger C.D., 1970, STATE TRAIT ANXIETY; Strauss ME, 2001, J ABNORM PSYCHOL, V110, P6, DOI 10.1037//0021-843X.110.1.6; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Szameitat AJ, 2002, J COGNITIVE NEUROSCI, V14, P1184, DOI 10.1162/089892902760807195; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Weinberger DR, 1996, PHILOS T R SOC B, V351, P1495, DOI 10.1098/rstb.1996.0135; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	70	121	123	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2004	10	5					724	741		10.1017/S1355617704105110			18	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	848XZ	WOS:000223502700009	15327720				2021-06-18	
J	Saatman, KE; Abai, B; Grosvenor, T; Vorwerk, CK; Smith, DH; Meaney, DF				Saatman, KE; Abai, B; Grosvenor, T; Vorwerk, CK; Smith, DH; Meaney, DF			Traumatic axonal injury results in biphasic calpain activation and retrograde transport impairment in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						axonal transport; brain injury; cytoskeleton; neurofilament; optic nerve; spectrin	AMYLOID PRECURSOR PROTEIN; RETINAL GANGLION-CELLS; SPINAL-CORD INJURY; PIG OPTIC-NERVE; BRAIN INJURY; HEAD-INJURY; CALCIUM INFLUX; NEUROFILAMENT SUBUNITS; MEDIATED PROTEOLYSIS; INDUCED DEGENERATION	Traumatic axonal injury (TAI) is one of the most important pathologies associated with closed head injury, and contributes to ensuing morbidity. The authors evaluated the potential role of calpains in TAI using a new model of optic nerve stretch injury in mice. Male C57BL/6 mice were anesthetized, surgically prepared, and subjected to a 2.0-mm optic nerve stretch injury (n = 34) or sham injury (n = 18). At various intervals up to 2 weeks after injury, optic nerves were examined for neurofilament proteins and calpain-mediated spectrin breakdown products using immunohistochemistry. In addition, fluorescent tracer was injected into the superior colliculi of mice I day before they were killed, to investigate the integrity of retrograde axonal transport to the retina. Optic nerve stretch injury resulted in persistent disruption of retrograde axonal transport by day 1, progressive accumulation and dephosphorylation of neurofilament protein in swollen and disconnected axons, and subsequent loss of neurofilament protein in degenerating axons at day 14. Calpains were transiently activated in intact axons in the first minutes to hours after stretch injury. A second stage of calpain-mediated proteolysis was observed at 4 days in axonal swellings, bulbs, and fragments. These data suggest that early calpain activation may contribute to progressive intraaxonal structural damage, whereas delayed calpain activation may be associated with axonal degeneration.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Otto Von Guericke Univ, Dept Ophthalmol, Magdeburg, Germany	Saatman, KE (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 5712, P50-NS08803, NS 38104] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 312712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER		Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cenni MC, 1996, EUR J NEUROSCI, V8, P1735, DOI 10.1111/j.1460-9568.1996.tb01317.x; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Levkovitch-Verbin H, 2000, INVEST OPHTH VIS SCI, V41, P4169; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; National Research Council, 1996, GUIDE CARE USE LAB A, P1; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SCHLAEPFER WW, 1974, BRAIN RES, V69, P203, DOI 10.1016/0006-8993(74)90002-X; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P2382; Wang MS, 2000, J NEUROPATH EXP NEUR, V59, P599, DOI 10.1093/jnen/59.7.599; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	45	121	131	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2003	23	1					34	42		10.1097/01.WCB.0000035040.10031.B0			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	629LW	WOS:000180052000004	12500089	Bronze			2021-06-18	
J	Holly, LT; Kelly, DF; Counelis, GJ; Blinman, T; McArthur, DL; Cryer, HG				Holly, LT; Kelly, DF; Counelis, GJ; Blinman, T; McArthur, DL; Cryer, HG			Cervical spine trauma associated with moderate and severe head injury: incidence, risk factors, and injury characteristics	JOURNAL OF NEUROSURGERY			English	Article						cervical spine injury; traumatic brain injury; spinal stabilization	CORD INJURY; FLUOROSCOPY; PREDICTOR; PATIENT	Object. Diagnosing and managing cervical spine trauma in head-injured patients is problematic due to an altered level of consciousness in such individuals. The reported incidence of cervical spine trauma in head-injured patients has generally ranged from 4 to 8%. In this retrospective study the authors sought to define the incidence of cervical injury in association with moderate or severe brain injury, emphasizing the identification of high-risk patients. Methods. The study included 447 consecutive moderately (209 cases) or severely (238 cases) head injured patients who underwent evaluation at two Level 1 trauma centers over a 40-month period. Of the 447 patients, 24 (5.4%) suffered a cervical spine injury (17 men and seven women; mean age 39 years; median Glasgow Coma Scale [GCS] score of 6, range 3-14). Of these 24 patients, 14 (58.3%) sustained spinal cord injuries (SCIs). 14 sustained injuries in the occiput-C3 region, and 10 underwent a stabilization procedure. Of the 14 patients with SCIs, nine experienced an early hypotensive and/or hypoxic insult. Regarding the mechanism of injury, cervical injuries occurred in 21 (8.2%) of 256 patients involved in motor vehicle accidents (MVAs), either as passengers or pedestrians, compared with three (1.6%) of 191 patients with non-MVA-associated trauma (p < 0.01). In the subset of 131 MVA passengers, 13 (9.9%) sustained cervical injuries, Patients with an initial GCS score less than or equal to 8 were more likely to sustain a cervical injury than those with a score higher than 8 (odds ratio [OR] 2.77, 95% confidence interval [CI] = 1.11-7.73) and were more likely to sustain a cervical SCI (OR 5.5, 95% CI 1.22-24.85). At 6 months or more postinjury, functional neurological recovery had occurred in nine patients (37.5%) and eight (33.3%) had died. Conclusions. Head-injured patients sustaining MVA-related trauma and those with an initial GCS score less than or equal to 8 are at highest risk for concomitant cervical spine injury. A disproportionate number of these patients sustain high cervical injuries, the majority of which are mechanically unstable and involve an SCI. The development of safer and more rapid means of determining cervical spine integrity should remain a high priority in the care of head-injured patients.	Univ Calif Los Angeles, Med Ctr, Dept Surg, Div Neurosurg,Ctr Hlth Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Epidemiol, Div Neurosurg, Hlth Sci Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Harbor Med Ctr, Div Neurosurg, Torrance, CA 90509 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Kelly, DF (corresponding author), Univ Calif Los Angeles, Med Ctr, Dept Surg, Div Neurosurg,Ctr Hlth Sci, Room 18-219 NPI,Box 957039, Los Angeles, CA 90095 USA.	dfkelly@ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline; ODCDC CDC HHS [R49/CCR903622] Funding Source: Medline		*ASS ADV AUT MED, 1990, ABBR INJ SCAL; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BUCHOLZ RW, 1979, J TRAUMA, V19, P768, DOI 10.1097/00005373-197910000-00009; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Chendrasekhar A, 1998, AM SURGEON, V64, P604; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; D'Alise MD, 1999, J NEUROSURG, V91, P54, DOI 10.3171/spi.1999.91.1.0054; DAVIS JW, 1995, J TRAUMA, V39, P435; Davis JW, 2001, J TRAUMA, V50, P1044, DOI 10.1097/00005373-200106000-00011; FERGUSON J, 1993, INJURY, V24, P454, DOI 10.1016/0020-1383(93)90148-Y; FRYE G, 1994, ANN EMERG MED, V23, P797, DOI 10.1016/S0196-0644(94)70316-7; HARRIS OA, 2001, J NEUROSURG, V94, pA413; HILLS MW, 1993, J TRAUMA, V34, P549, DOI 10.1097/00005373-199304000-00011; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; JENNETT B, 1975, LANCET, V1, P480; Kaups KL, 1998, J TRAUMA, V44, P865, DOI 10.1097/00005373-199805000-00020; MARCIANO FF, 1997, NEUROSURGERY, V41, P740; MARION D, 2000, DET CERV SPIN STAB T; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; Sees DW, 1998, J TRAUMA, V45, P768, DOI 10.1097/00005373-199810000-00026; SHRAGO GG, 1973, AM J ROENTGENOL, V118, P670, DOI 10.2214/ajr.118.3.670; TATOR CH, 1996, NEUROTRAUMA, P1059; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; WILLIAMS J, 1992, ANN EMERG MED, V21, P719, DOI 10.1016/S0196-0644(05)82786-6	24	121	130	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2002	96	3		S			285	291		10.3171/spi.2002.96.3.0285			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	537JB	WOS:000174754200006	11990836				2021-06-18	
J	Bigler, ED; Andersob, CV; Blatter, DD				Bigler, ED; Andersob, CV; Blatter, DD			Temporal lobe morphology in normal aging and traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							APOLIPOPROTEIN-E GENOTYPE; AGE-RELATED-CHANGES; HIPPOCAMPAL VOLUME; ALZHEIMERS-DISEASE; GRAY-MATTER; ENTORHINAL CORTEX; QUANTITATIVE MR; PREFRONTAL GRAY; AXONAL INJURY; ATROPHY	BACKGROUND AND PURPOSE: Little is known regarding changes in the temporal lobe associated with traumatic brain injury (TBI) in early-to-mid adulthood. We report on two quantitative MR studies: study 1 addressed age-related changes of the temporal lobe in subjects aged 16-72 years; information obtained in this study provided a normative database for comparison with findings in 118 patients with TBI who were included in study 2. We expected stable morphology in healthy subjects and trauma-related atrophy in patients with TBI. METHODS: MR multispectral tissue segmentation was used to calculate bilateral temporal lobe gyrus and sulcus, sylvian fissure CSF, hippocampus, and temporal horn volumes and to measure the white matter (WM) temporal stem. RESULTS: With normal aging, gyral volume remained stable, decreasing approximately 0.26% per year (total, approximate to11%). Sulcal CSF volume doubled. Hippocampal volume decreased (minimally, significantly); temporal horn volume increased (not significantly) and was minimally related to hippocampal volume. WM measurements were constant. Trauma changed morphology; WM measures decreased. Gyral volumes were not different between the groups. In TBI, CSF volume increased significantly, was most related to reduced WM measurements, and was relatively independent of gyral volume. Temporal horn dilatation was related more to WM atrophy than to hippocampal atrophy. In TBI, subarachnoid sulcal and temporal horn CSF volumes were most related to WM atrophy, which was relatively independent of gyral volume; gyral and hippocampal volumes and WM measures were related to memory performance. CONCLUSION. Age-related changes cause minimal temporal lobe gyral, hippocampal, temporal horn, and WM atrophy. Only subarachnoid sulcal CSF volume changed robustly. Trauma produced disproportionate WM loss associated with increased temporal horn and sulcal CSF volumes; it caused substantial hippocampal atrophy, which was related to memory impairment. Gyral volume did not decrease, although it was related to memory performance.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; LDS Hosp, Salt Lake City, UT 84143 USA; Univ Utah, Salt Lake City, UT 84112 USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1082 SWKT, Provo, UT 84602 USA.						Arnold SE, 1996, SCHIZOPHRENIA BULL, V22, P5, DOI 10.1093/schbul/22.1.5; Barber R, 1999, ARCH NEUROL-CHICAGO, V56, P961, DOI 10.1001/archneur.56.8.961; Bartzokis G, 2001, ARCH GEN PSYCHIAT, V58, P461, DOI 10.1001/archpsyc.58.5.461; Bertoni MA, 1998, INT J NEURORADIOL, V4, P291; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2000, AM J NEURORADIOL, V21, P1857; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Double KL, 1996, NEUROBIOL AGING, V17, P513; Fox NC, 2000, ARCH NEUROL-CHICAGO, V57, P339, DOI 10.1001/archneur.57.3.339; Fox NC, 2000, NEUROLOGY, V54, P807, DOI 10.1212/WNL.54.4.807; Fox NC, 1999, NEUROLOGY, V52, P1687, DOI 10.1212/WNL.52.8.1687; Frisoni GB, 1999, NEUROLOGY, V52, P91, DOI 10.1212/WNL.52.1.91; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gean A, 1994, IMAGING HEAD TRAUMA; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Geroldi C, 1999, NEUROLOGY, V53, P1825, DOI 10.1212/WNL.53.8.1825; Geroldi C, 2000, J NEUROL NEUROSUR PS, V68, P93, DOI 10.1136/jnnp.68.1.93; Giedd JN, 1996, CEREB CORTEX, V6, P551, DOI 10.1093/cercor/6.4.551; Giedd JN, 1996, J COMP NEUROL, V366, P223, DOI 10.1002/(SICI)1096-9861(19960304)366:2<223::AID-CNE3>3.0.CO;2-7; GOLDSTEIN FC, 1990, TRAUMATIC BRAIN INJU, P51; Goldstein JM, 1999, ARCH GEN PSYCHIAT, V56, P537, DOI 10.1001/archpsyc.56.6.537; Goldszal AF, 2000, BIOMED EN S, P185; Gur RE, 2000, ARCH GEN PSYCHIAT, V57, P769, DOI 10.1001/archpsyc.57.8.769; HARRIS GJ, 1994, AM J NEURORADIOL, V15, P225; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; *IM TREAM, 1999, SPSS GRAD PACK 10 0; Insausti R, 1998, AM J NEURORADIOL, V19, P659; Jack CR, 1998, ANN NEUROL, V43, P303, DOI 10.1002/ana.410430307; Jack CR, 1998, NEUROLOGY, V51, P993, DOI 10.1212/WNL.51.4.993; Jack CR, 1999, NEUROLOGY, V52, P1397, DOI 10.1212/WNL.52.7.1397; JESSELL TM, 1991, PRINCIPLES NEURAL SC, P258; Juottonen K, 1999, AM J NEURORADIOL, V20, P139; Kidron D, 1997, NEUROLOGY, V49, P1504, DOI 10.1212/WNL.49.6.1504; Killiany RJ, 2000, ANN NEUROL, V47, P430, DOI 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.3.CO;2-9; Kohler S, 1998, NEUROPSYCHOLOGIA, V36, P901, DOI 10.1016/S0028-3932(98)00017-7; Laidlaw DH, 2000, BIOMED EN S, P195; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Mathern GW, 1996, BRAIN, V119, P965, DOI 10.1093/brain/119.3.965; Matsumae M, 1996, J NEUROSURG, V84, P982, DOI 10.3171/jns.1996.84.6.0982; McDonald B, 2000, AM J PSYCHIAT, V157, P40, DOI 10.1176/ajp.157.1.40; Mu QW, 1999, AM J NEURORADIOL, V20, P207; Mueller EA, 1998, NEUROLOGY, V51, P1555, DOI 10.1212/WNL.51.6.1555; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Petersen RC, 2000, NEUROLOGY, V54, P581, DOI 10.1212/WNL.54.3.581; Pfefferbaum A, 1998, ARCH GEN PSYCHIAT, V55, P905, DOI 10.1001/archpsyc.55.10.905; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268; Reddick WE, 1998, MAGN RESON IMAGING, V16, P413, DOI 10.1016/S0730-725X(98)00014-9; Reiman EM, 1998, ANN NEUROL, V44, P288, DOI 10.1002/ana.410440226; Resnick SM, 2000, CEREB CORTEX, V10, P464, DOI 10.1093/cercor/10.5.464; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Salat DH, 1999, ARCH NEUROL-CHICAGO, V56, P338, DOI 10.1001/archneur.56.3.338; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; Smith CD, 1999, J NEUROIMAGING, V9, P2, DOI 10.1111/jon1999912; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Soininen HS, 1996, TRENDS NEUROSCI, V19, P224, DOI 10.1016/0166-2236(96)10027-8; Stout JC, 1999, NEUROPSYCHOLOGY, V13, P188, DOI 10.1037/0894-4105.13.2.188; Symonds LL, 1999, J NEUROIMAGING, V9, P201, DOI 10.1111/jon199994201; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thompson PM, 1998, CEREB CORTEX, V8, P492, DOI 10.1093/cercor/8.6.492; Utsunomiya H, 1999, AM J NEURORADIOL, V20, P717; VanHoesen GW, 1997, J NEUROPSYCH CLIN N, V9, P331; von Gunten A, 2000, J NEUROPSYCH CLIN N, V12, P493, DOI 10.1176/appi.neuropsych.12.4.493; Weschler D., 1987, WESCHLER MEMORY SCAL	75	121	122	0	11	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2002	23	2					255	266					12	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	532JX	WOS:000174472300015	11847051				2021-06-18	
J	Karni, A; Holtzman, R; Bass, T; Zorman, G; Carter, L; Rodriguez, L; Bennett-Shipman, VJ; Lottenberg, L				Karni, A; Holtzman, R; Bass, T; Zorman, G; Carter, L; Rodriguez, L; Bennett-Shipman, VJ; Lottenberg, L			Traumatic head injury in the anticoagulated elderly patient: A lethal combination	AMERICAN SURGEON			English	Article; Proceedings Paper	69th Annual Meeting of the Southeastern-Surgical-Congress	FEB 02-06, 2001	NEW ORLEANS, LOUISIANA	SE Surg Congress			WARFARIN	Warfarin is the most common oral anticoagulant used for chronic anticoagulation therapy. Even without any antecedent trauma overanticoagulation can result in intracranial hemorrhage. The triad of anticoagulation with warfarin, age greater than 65 years, and traumatic head injury frequently produces a lethal brain hemorrhage. A retrospective review of more than 2000 patients admitted to the Trauma Service between September 1998 and May 2000 produced 278 patients with head injury and CT-documented intracranial hemorrhage. Of these patients 21 were admitted with an elevated prothrombin time (PT) due to anticoagulation with warfarin. Eighteen patients (86%) were above the age of 70. The most common indications for anticoagulation were atrial fibrillation (71%), deep venous thrombosis (19%), aortic valve replacement (9%), and ischemic cerebral infarcts (9%). Fourteen injuries were the result of a fall, one resulted from a gunshot wound, and one resulted from an assault. The remaining five patients were excluded as their history, workup, and evaluation by neurosurgery suggested a spontaneous bleed leading to fall rather than a fall causing a traumatic bleed. The average Glasgow Coma Score on admission was 11. The average PT and International Normalized Ratio (INR) on admission were 19.2 and 2.99 respectively. Eight of the 16 patients analyzed died. The risk of intracranial hemorrhage with relatively minor head injury is increased dramatically in the anticoagulated patient. A mortality rate of 50 per cent far exceeds the mortality rate in patients with similar head injuries who are not anticoagulated. In addition the risk/benefit equation of anticoagulation for the elderly is more complex and differs from that for younger patients. Perhaps more frequent and judicious monitoring of prothrombin time levels with lower therapeutic ranges (INR 1.5-2) is necessary.	Mem Reg Trauma Ctr, Hollywood, FL USA	Karni, A (corresponding author), Mem Reg Trauma Ctr, Hollywood, FL USA.						Butler AC, 1998, BLOOD REV, V12, P35, DOI 10.1016/S0268-960X(98)90028-5; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; MATHIESEN T, 1995, ACTA NEUROL SCAND, V91, P208; Nagurney JT, 1998, ACAD EMERG MED, V5, P678, DOI 10.1111/j.1553-2712.1998.tb02485.x; Nakagawa Takao, 1995, Neurologia Medico-Chirurgica, V35, P156, DOI 10.2176/nmc.35.156; Saab M, 1996, J ACCID EMERG MED, V13, P208; SCHWAB CW, 2000, TRAUMA, P1099; Volans AP, 1998, J ACCID EMERG MED, V15, P159	8	121	125	0	4	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	NOV	2001	67	11					1098	1100					3	Surgery	Surgery	493DD	WOS:000172206000018	11730229				2021-06-18	
J	Bloom, DR; Levin, HS; Ewing-Cobbs, L; Saunders, AE; Song, J; Fletcher, JM; Kowatch, RA				Bloom, DR; Levin, HS; Ewing-Cobbs, L; Saunders, AE; Song, J; Fletcher, JM; Kowatch, RA			Lifetime and novel psychiatric disorders after pediatric traumatic brain injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; pediatric; attention-deficit/hyperactivity disorder; psychiatric disorders	DEPRESSIVE SYMPTOMATOLOGY IDS; CLOSED-HEAD-INJURY; DIAGNOSTIC INTERVIEW; CHILDREN; ADOLESCENTS; INVENTORY; PARENT	Objective: To assess lifetime and current psychiatric disorders at least 1 year after traumatic brain injury (TBI) in children and adolescents. Method: Forty-six youths who sustained a TBI between the ages of 6 through 15 years were evaluated at least 1 year post-TBI to identify the presence of lifetime and/or novel psychiatric disorders. Semistructured interviews of the parent and child and standardized parent self report rating instruments were used. Results: Attention-deficit/hyperactivity disorder and depressive disorders were the most common lifetime and novel diagnoses. A wide variety and high rate of never psychiatric disorders were identified; 74% of these disorders persisted in 48% of the injured children. Internalizing disorders were more likely to resolve than externalizing disorders; Both interviews and parent ratings were Sensitive to current externalizing behaviors; interviews more often detected internalizing disorders, whereas parent ratings also identified cognitive difficulties. Conclusions: Findings were generally consistent with previous research demonstrating the high rate of novel psychiatric disorders following pediatric TBI. Psychiatric interviews were Sensitive in identifying both lifetime and novel disorders.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Houston, TX 77225 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, SW Med Sch, Dept Psychiat & Behav Sci, Dallas, TX 75230 USA	Bloom, DR (corresponding author), Texas Childrens Hosp, 6621 Fannin,MC3-2340, Houston, TX 77030 USA.		fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		Barkley R. A., 1997, ADHD NATURE SELF CON; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Ewing-Cobbs L, 1999, COGNITIVE ASPECTS OF CHRONIC ILLNESS IN CHILDREN, P262; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; HERJANIC B, 1982, J ABNORM CHILD PSYCH, V10, P307, DOI 10.1007/BF00912324; Jennett B, 1981, MANAGEMENT HEAD INJU; KASHANI JH, 1985, J AM ACAD CHILD PSY, V24, P437, DOI 10.1016/S0002-7138(09)60561-6; Kovacs M., 1992, CHILDRENS DEPRESSION; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rush AJ, 1996, PSYCHOL MED, V26, P477, DOI 10.1017/S0033291700035558; RUSH AJ, 1986, PSYCHOPHARMACOL BULL, V22, P985; Shaffer D, 1975, Ciba Found Symp, P191; SYLVESTER CE, 1987, J AM ACAD CHILD PSY, V26, P668, DOI 10.1097/00004583-198709000-00010; TEASDALE G, 1974, LANCET, V2, P81; Wirt RD, 1990, MULTIDIMENSIONAL DES	29	121	121	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	MAY	2001	40	5					572	579		10.1097/00004583-200105000-00017			8	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	425UE	WOS:000168309400017	11349702				2021-06-18	
J	Vickery, CD; Berry, DTR; Inman, TH; Harris, MJ; Orey, SA				Vickery, CD; Berry, DTR; Inman, TH; Harris, MJ; Orey, SA			Detection of inadequate effort on neuropsychological testing: A meta-analytic review of selected procedures	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; FORCED-CHOICE METHOD; SIMULATED MEMORY IMPAIRMENT; MMPI-2 VALIDITY SCALES; REY 15-ITEM TEST; SYMPTOM VALIDITY; MALINGERING DETECTION; BELIEVABLE DEFICITS; PERFORMANCE; PROSPECTS	Thirty-two studies of commonly researched neuropsychological malingering tests were meta-analytically reviewed to evaluate their effectiveness in discriminating between honest responders and dissimulators. Overall, studies using the Digit Memory Test (DMT), Portland Digit Recognition Test (PDRT), 15-Item Test, 21-Item Test, and the Dot Counting Test had average effect sizes indicating that dissimulators obtain scores that are approximately 1.1 standard deviations below those of honest responders. The DMT separated the means of groups of honest and dissimulating responders by approximately 2 standard deviations, whereas the 21-Item Test and the PDRT separated the groups by nearly 1.5 and 1.25 standard deviations, respectively. The 15-Item Test and the Dot Counting Test were less effective, separating group means by approximately 3/4 of a standard deviation. Although the DMT, PDRT, 15-, and 21-Item Tests all demonstrated very high specificity rates, at the level of individual classification, the DMT had the highest sensitivity and overall hit-rate parameters. The PDRT and 15-Item Test demonstrated moderate sensitivity, whereas the 21-Item Test demonstrated poor sensitivity. The less than perfect sensitivities of all the measures included in this review argue against their use in isolation as malingering screening devices. (C) 2000 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA	Berry, DTR (corresponding author), Univ Kentucky, Dept Psychol, 115 Kastle Hall, Lexington, KY 40506 USA.						ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; Binks PG, 1997, ARCH CLIN NEUROPSYCH, V12, P41, DOI 10.1016/S0887-6177(96)00019-4; CERCY S, 1993, THESIS SO ILLINOIS U; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Etcoff LM, 1996, NEUROPSYCHOL REV, V6, P171, DOI 10.1007/BF01874896; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; GLAROS AG, 1988, J CLIN PSYCHOL, V44, P1013, DOI 10.1002/1097-4679(198811)44:6<1013::AID-JCLP2270440627>3.0.CO;2-Z; GOLA T, 1994, THESIS WAYNE STATE U; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Haines ME, 1995, NEUROPSYCHOL REV, V5, P125, DOI 10.1007/BF02208438; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Hedges L.V., 1985, STAT METHODS META AN; HISCOCK CK, 1994, J PSYCHOPATHOL BEHAV, V16, P95, DOI 10.1007/BF02232721; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; IVERSON GL, 1994, ARCH CLIN NEUROPSYCH, V9, P437, DOI 10.1016/0887-6177(94)90006-X; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Johnson B. T, 1993, DSTAT SOFTWARE METAA; King C., 1992, THESIS CALIFORNIA SC; LARRABEE GJ, 1992, FORENSIC REPORTS, V5, P257; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MILLIKIN C, 1993, THESIS U WINDSOR WIN; MILLIS SR, 1995, CLIN NEUROPSYCHOL, V9, P241, DOI 10.1080/13854049508400486; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Paul D. S., 1992, INT J CLIN NEUROPSYC, V14, P1; Prigatano GP, 1997, ARCH CLIN NEUROPSYCH, V12, P609, DOI 10.1016/S0887-6177(97)00020-6; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; PRITCHARD D, 1992, FORENSIC REPORTS, V5, P287; Rey A, 1964, EXAMEN CLIN PSYCHOL; REYNOLDS C, 1998, DETECTION MALINGERIN; Rogers R., 1997, CLIN ASSESSMENT MALI, V2nd; ROSEI EA, 1995, J HYPERTENS, V13, P349; Rosenthal R., 1991, META ANAL PROCEDURES, V1st; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tukey J.W., 1977, EXPLORATORY DATA ANA; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	53	121	123	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2001	16	1					45	73		10.1016/S0887-6177(99)00058-X			29	Psychology, Clinical; Psychology	Psychology	389UN	WOS:000166257200005	14590192	Bronze			2021-06-18	
J	Finset, A; Andersson, S				Finset, A; Andersson, S			Coping strategies in patients with acquired brain injury: relationships between coping, apathy, depression and lesion location	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; POSTSTROKE DEPRESSION; MAJOR DEPRESSION; SYMPTOMS; RELIABILITY; ACTIVATION; TOMOGRAPHY; PREVALENCE; DISTRESS; VALIDITY	Coping strategies in individuals suffering severe traumatic brain injury (TBI), cerebrovascular accidents (CVA), or hypoxic brain injury (HBI) were investigated in relation to apathy, depression, and lesion location. Seventy patients (27 with TBI, 30 with CVA, and 13 with HBI) filled in a coping questionnaire (COPE) and were evaluated with respect to apathy and depression. A comparison sample of 71 students also filled in COPE. Patients coping strategies were similar to the comparison group, but patients tended to display less differentiated coping styles. A factor analysis indicated two dimensions of coping in the patient sample; approach oriented and avoidance oriented coping. Approach and avoidance coping sum scores, based on subscales from the two factors, were positively correlated in the patient sample, but not in the comparison group. Lack of active approach oriented coping was associated with apathy, whereas avoidant coping was associated with depression. Coping styles were not related to lesion location. Apathy was related to subcortical and right hemisphere lesions. In bivariate analyses, depression was unrelated to lesion location, but, in a MANCOVA, avoidant coping, apathy and lesion location (left hemisphere lesions) contributed to the variance in positive depressive symptoms. The consistent relationships between coping strategies and neuropsychiatric symptoms were interpreted as two dimensions of adaptational behaviour: an active vs. passive dimension and a depression-distress-avoidance dimension.	Univ Oslo, Dept Behav Sci Med, N-0317 Oslo, Norway; Sunnaas Rehabil Hosp, Neuropsychol Lab, Nesoddtangen, Norway	Finset, A (corresponding author), Univ Oslo, Dept Behav Sci Med, POB 1111 Blindern, N-0317 Oslo, Norway.						ANDERSSON S, 1999, PSYCHOL MED; [Anonymous], 1994, DIAGN CRIT DSM 4; ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; Beauregard M, 1998, NEUROREPORT, V9, P3253, DOI 10.1097/00001756-199810050-00022; BENCH CJ, 1993, PSYCHOL MED, V23, P579, DOI 10.1017/S0033291700025368; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; Bruder GE, 1998, PSYCHOPHYSIOLOGY, V35, P54, DOI 10.1111/1469-8986.3510054; CARVER CS, 1993, J PERS SOC PSYCHOL, V65, P375, DOI 10.1037/0022-3514.65.2.375; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; DANTZER R, 1993, PSYCHOSOMATIC DELUSI; ENDLER NS, 1990, J PERS SOC PSYCHOL, V58, P844, DOI 10.1037/0022-3514.58.5.844; FEIFEL H, 1989, PSYCHOL AGING, V4, P26, DOI 10.1037/0882-7974.4.1.26; FINSET A, 1988, CEREBRAL HEMISPHERE, P49; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P571, DOI 10.1037/0022-3514.50.3.571; Folkman S., 1988, MANUAL WAYS COPING Q; FRANKENHAEUSER M, 1980, COPING HLTH, P203; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; Henry JP, 1977, STRESS HLTH SOCIAL E; Herrmann N, 1998, STROKE, V29, P618, DOI 10.1161/01.STR.29.3.618; Hosking SG, 1996, NEUROPSYCHOL REV, V6, P107, DOI 10.1007/BF01874894; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; LAPLANE D, 1990, REV NEUROL, V146, P397; LAPLANE D, 1989, BRAIN, V112, P699, DOI 10.1093/brain/112.3.699; Macdonald EM, 1998, BRIT J PSYCHIAT, V172, P122, DOI 10.1192/S0007125000297778; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Mann R. S., 1996, REV PSYCHIAT, V15, P205; MARIN RS, 1993, J AFFECT DISORDERS, V28, P117, DOI 10.1016/0165-0327(93)90040-Q; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Middelboe T, 1997, ACTA PSYCHIAT SCAND, V96, P188, DOI 10.1111/j.1600-0447.1997.tb10150.x; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; ROHDE P, 1990, J PERS SOC PSYCHOL, V58, P499, DOI 10.1037/0022-3514.58.3.499; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; ROTH S, 1986, AM PSYCHOL, V41, P813, DOI 10.1037/0003-066X.41.7.813; Shimoda K, 1999, BIOL PSYCHIAT, V45, P187, DOI 10.1016/S0006-3223(98)00178-4; Smari J, 1997, SCAND J PSYCHOL, V38, P151, DOI 10.1111/1467-9450.00021; SNAITH RP, 1986, BRIT J PSYCHIAT, V148, P599, DOI 10.1192/bjp.148.5.599; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; STARKSTEIN SE, 1992, AM PSYCHIAT PRESS TX, P449; Tandberg E, 1997, ARCH NEUROL-CHICAGO, V54, P625, DOI 10.1001/archneur.1997.00550170097020; Ursin H., 1978, PSYCHOBIOLOGY STRESS	47	121	121	1	21	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2000	14	10					887	905					19	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	364QG	WOS:000089902900004	11076135				2021-06-18	
J	Wang, CX; Nuttin, B; Heremans, H; Dom, R; Gybels, J				Wang, CX; Nuttin, B; Heremans, H; Dom, R; Gybels, J			Production of tumor necrosis factor in spinal cord following traumatic injury in rats	JOURNAL OF NEUROIMMUNOLOGY			English	Article						spinal cord injury; tumor necrosis factor	FACTOR-ALPHA; CEREBROSPINAL-FLUID; GENE-EXPRESSION; BRAIN; CYTOKINES; MODEL; INTERLEUKIN-6; INFLAMMATION; COMPRESSION; ASTROCYTES	Production of tumor necrosis factor (TNF) in the spinal cord following traumatic injury has been studied. In these experiments, the level of TNF was examined in the homogenate of the spinal cord, cerebrospinal fluid (CSF) and serum (n = 56). TNF could be detected in the injured spinal cord but not in the normal spinal cord. The TNF level increased in the spinal cord after the injury. At the lesion site, a maximal TNF concentration was observed 1 h after the injury, and the TNF concentration remained at this level until 8 h after the injury. Thereafter, it decreased gradually. However, TNF still could be detected 72 h after the injury. No TNF could be detected in the CSF and serum, collected from rats both with and without spinal cord injury (SCI). This study thus suggests that TNF is produced locally in the spinal cord following traumatic injury, and this TNF production is caused by the injury. The present results also demonstrate that TNF production is an acute and rapid reaction in the spinal cord following traumatic injury.	CATHOLIC UNIV LEUVEN,DEPT EXPT NEUROSURG,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,DEPT NEUROPATHOL,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,DEPT IMMUNOBIOL,B-3000 LOUVAIN,BELGIUM							Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; BAKHIT C, 1991, BRAIN RES, V554, P264, DOI 10.1016/0006-8993(91)90199-6; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; ENG LF, 1992, PROG BRAIN RES, V94, P353; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; HEREMANS H, 1992, EUR J IMMUNOL, V22, P2395, DOI 10.1002/eji.1830220932; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; KHAN M, 1983, CAN J NEUROL SCI, V10, P161, DOI 10.1017/S031716710004484X; KLIR JJ, 1993, AM J PHYSIOL, V265, pR512; LE JM, 1987, LAB INVEST, V56, P234; MCCRACKEN GH, 1989, PEDIATR INFECT DIS J, V8, P155; METHA VK, 1994, EUR J ENDOCRINOL, V130, P208; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; MOKATA T, 1991, J CBFM, V11, P966; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P460, DOI 10.1111/j.1600-0404.1988.tb03688.x; PRADO R, 1987, J NEUROSURG, V67, P745, DOI 10.3171/jns.1987.67.5.0745; RIVLIN AS, 1978, SURG NEUROL, V10, P39; ROTHWELL NJ, 1991, TRENDS PHARMACOL SCI, V12, P430, DOI 10.1016/0165-6147(91)90623-Z; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; TARLOV IM, 1952, ARCH NEUROL PSYCHIAT, V70, P813; TATOR CH, 1973, CAN J SURG, V16, P222; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1994, NEUROREPORT, V5, P585, DOI 10.1097/00001756-199401000-00013; TORRESPEIMBERT S, 1981, REV MEXICANA ASTR AP, V6, P315; Tracey KJ, 1994, CYTOKINE HDB, P289; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.immunol.10.1.411; VILCEK J, 1992, TUMOR NECROSIS FACTO, P269; WANG CX, 1993, NEUROSURGERY, V32, P269, DOI 10.1227/00006123-199302000-00016; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7	36	121	126	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	SEP	1996	69	1-2					151	156					6	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	VK244	WOS:A1996VK24400054	8823387				2021-06-18	
J	Nichol, A; French, C; Little, L; Haddad, S; Presneill, J; Arabi, Y; Bailey, M; Cooper, DJ; Duranteau, J; Huet, O; Mak, A; McArthur, C; Pettila, V; Skrifvars, M; Vallance, S; Varma, D; Wills, J; Bellomo, R				Nichol, Alistair; French, Craig; Little, Lorraine; Haddad, Samir; Presneill, Jeffrey; Arabi, Yaseen; Bailey, Michael; Cooper, D. James; Duranteau, Jacques; Huet, Olivier; Mak, Anne; McArthur, Colin; Pettilae, Ville; Skrifvars, Markus; Vallance, Shirley; Varma, Dinesh; Wills, Judy; Bellomo, Rinaldo		EPO-TBI Investigators; ANZICS Clinical Trials Grp	Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial	LANCET			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; CRITICALLY-ILL PATIENTS; GLASGOW OUTCOME SCALE; EPOETIN-ALPHA; PROGESTERONE; RECOVERY; EFFICACY	Background Erythropoietin might have neurocytoprotective effects. In this trial, we studied its effect on neurological recovery, mortality, and venous thrombotic events in patients with traumatic brain injury. Methods Erythropoietin in Traumatic Brain Injury (IEPO-TBI) was a double-blind, placebo-controlled trial undertaken in 29 centres (all university-affiliated teaching hospitals) in seven countries (Australia, New Zealand, France, Germany, Finland, Ireland, and Saudi Arabia). Within 24 h of brain injury, 606 patients were randomly assigned by a concealed web-based computer-generated randomisation schedule to erythropoietin (40 000 units subcutaneously) or placebo (0.9% sodium chloride subcutaneously) once per week for a maximum of three doses. Randomisation was stratified by severity of traumatic brain injury (moderate vs severe) and participating site. With the exception of designated site pharmacists, the site dosing nurses at all sites, and the pharmacists at the central pharmacy in France, all study personnel, patients, and patients' relatives were masked to treatment assignment. The primary outcome, assessed at 6 months by modified intention-to-treat analysis, was improvement in the patients' neurological status, summarised as a reduction in the proportion of patients with an Extended Glasgow Outcome Scale (GOS-E) of 1-4 (death, vegetative state, and severe disability). Two equally spaced preplanned interim analyses were done (after 202 and 404 participants were enrolled). This study is registered with ClinicalTrials.gov, number NCT00987454. Findings Between May 3, 2010, and Nov 1, 2014, 606 patients were enrolled and randomly assigned to erythropoietin (n=308) or placebo (n=298). Ten of these patients (six in the erythropoietin group and four in the placebo group) were lost to follow up at 6 months; therefore, data for the primary outcome analysis was available for 596 patients (302 in the erythropoietin group and 294 in the placebo group). Compared with placebo, erythropoietin did not reduce the proportion of patients with a GOS-E level of 1-4 (134 [44%] of 302 patients in the erythropoietin group vs 132 [45%] of 294 in the placebo group; relative risk [RR] 0.99 [95% CI 0.83-1.18], p=0.90). In terms of safety, erythropoietin did not significantly affect 6-month mortality versus placebo (32 [11%] of 305 patients had died at 6 months in the erythropoietin group vs 46 [16%] of 297 [16%] in the placebo group; RR 0.68 [95% CI 0.44-1.03], p=0.07) or increase the occurrence of deep venous thrombosis of the lower limbs (48 [16%] of 305 vs 54 [18%] of 298; RR 0.87 [95% CI 0.61-1.24], p=0.44). Interpretation Following moderate or severe traumatic brain injury, erythropoietin did not reduce the number of patients with severe neurological dysfunction (IGOS-E level 1-4) or increase the incidence of deep venous thrombosis of the lower limbs. The effect of erythropoietin on mortality remains uncertain.	[Nichol, Alistair; Little, Lorraine; Presneill, Jeffrey; Arabi, Yaseen; Bailey, Michael; Cooper, D. James; Huet, Olivier; Mak, Anne; McArthur, Colin; Pettilae, Ville; Vallance, Shirley; Wills, Judy; Bellomo, Rinaldo] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia; [French, Craig] Univ Melbourne, Melbourne, Vic, Australia; [Nichol, Alistair; Cooper, D. James; Mak, Anne; Vallance, Shirley] The Alfred, Melbourne, Vic, Australia; [Nichol, Alistair] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland; [Nichol, Alistair] St Vincents Univ Hosp, Dublin 4, Ireland; [French, Craig] Western Hlth, Melbourne, Vic, Australia; [Haddad, Samir] King Abdul Aziz Med City, Natl Guard Hlth Aff airs, Riyadh, Saudi Arabia; [Presneill, Jeffrey] Univ Queensland, Brisbane, Qld, Australia; [Presneill, Jeffrey] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia; [Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Arabi, Yaseen] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [Duranteau, Jacques] Univ Paris 11, Hop Bicetre, Assistance Publ Hop Paris, Dept Anesthesie Reanimat, Paris, France; [Huet, Olivier] CHU La Cavale Blanche, Dept Anaesthesiol & Intens Care Med, Brest, France; [Pettilae, Ville; Skrifvars, Markus] Univ Helsinki, Helsinki, Finland; [Pettilae, Ville; Skrifvars, Markus] Helsinki Univ Hosp, Helsinki, Finland; [McArthur, Colin] Auckland City Hosp, Auckland, New Zealand; [Bellomo, Rinaldo] Austin Hosp, Melbourne, Vic 3084, Australia	French, C (corresponding author), Western Hlth, Dept Intens Care, Gordon St, Footscray, Vic 3011, Australia.	craig.french@wh.org.au	Arabi, Yaseen/ABF-3316-2020; Cooper, D. James/G-7961-2013; Bailey, Michael J/A-4499-2012; Presneill, Jeffrey J/B-4894-2012; French, Craig/ABF-5087-2020	Arabi, Yaseen/0000-0001-5735-6241; Cooper, D. James/0000-0002-5872-9051; Bailey, Michael J/0000-0002-5551-1401; Presneill, Jeffrey J/0000-0001-7177-7667; French, Craig/0000-0003-1363-9711; Nichol, Alistair/0000-0002-4689-1238; Richards, Brent/0000-0003-2613-0308; Bellomo, Rinaldo/0000-0002-1650-8939; Huet, Olivier/0000-0001-7345-0334; Whitehead, Christina/0000-0003-4561-7082; Nichol, Alistair Dualta/0000-0002-4771-5615	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Transport Accident Commission; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [545902]; Transport Accident Commission of Victoria [D162]	The National Health and Medical Research Council and the Transport Accident Commission.; EPO-TBI was supported by grants from the National Health and Medical Research Council of Australia (grant 545902) and the Transport Accident Commission of Victoria (grant D162). The members of the writing committee assume responsibility for the overall content and integrity of the article.	Abrishamkar S, 2012, J RES MED SCI, V17, P51; Aloizos S, 2015, TURK NEUROSURG, V25, P552, DOI 10.5137/1019-5149.JTN.9685-14.4; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Cook DJ, 2005, J CRIT CARE, V20, P364, DOI 10.1016/j.jcrc.2005.09.010; Corwin HL, 2002, JAMA-J AM MED ASSOC, V288, P2827, DOI 10.1001/jama.288.22.2827; Corwin HL, 2007, CAN MED ASSOC J, V177, P747, DOI 10.1503/cmaj.071150; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Corwin HL, 2014, J TRAUMA ACUTE CARE, V77, P774, DOI 10.1097/TA.0000000000000442; Hebert PC, 2007, CAN MED ASSOC J, V177, P697, DOI 10.1503/cmaj.071223; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lykissas MG, 2007, CLIN NEUROL NEUROSUR, V109, P639, DOI 10.1016/j.clineuro.2007.05.013; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nichol A, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0528-6; Nichol A, 2014, JAMA-J AM MED ASSOC, V312, P1928, DOI 10.1001/jama.2014.12738; Nirula R, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/209848; Presneill Jeffrey, 2014, Trials, V15, P501, DOI 10.1186/1745-6215-15-501; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; US Food and Drug Administration, FDA STRENGTH SAF INF; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	30	120	126	1	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 19	2015	386	10012					2499	2506		10.1016/S0140-6736(15)00386-4			8	Medicine, General & Internal	General & Internal Medicine	CZ1LD	WOS:000366866400024	26452709				2021-06-18	
J	Lindvall, O; Kokaia, Z				Lindvall, Olle; Kokaia, Zaal			Stem Cell Research in Stroke How Far From the Clinic?	STROKE			English	Article						acute stroke; inflammation; neural stem cell; neurogenesis; neuroregeneration; stem cells; stroke recovery; transplantation	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; STROMAL CELLS; ADULT RATS; ENDOGENOUS NEUROGENESIS; FUNCTIONAL RECOVERY; NEURONAL DIFFERENTIATION; PROVIDE NEUROPROTECTION; FOREBRAIN NEUROGENESIS; THERAPEUTIC BENEFITS	Stem cell-based approaches hold much promise as potential novel treatments to restore function after stroke. Studies in animal models have shown that stem cell transplantation can improve function by replacing neurons or by trophic actions, modulation of inflammation, promotion of angiogenesis, remyelination and axonal plasticity, and neuroprotection. Endogenous neural stem cells are also potential therapeutic targets because they produce new neurons after stroke. Clinical trials are ongoing but there is currently no proven stem cell-based therapy for stroke. Preclinical studies and clinical research will be needed to optimize the therapeutic benefit and minimize the risks of stem cells in stroke. (Stroke. 2011;42:2369-2375.)	[Lindvall, Olle] Univ Hosp, Lab Neurogenesis & Cell Therapy, Wallenberg Neurosci Ctr, SE-22184 Lund, Sweden; [Kokaia, Zaal] Univ Hosp, Lab Neural Stem Cell Biol & Therapy, SE-22184 Lund, Sweden; [Lindvall, Olle; Kokaia, Zaal] Lund Stem Cell Ctr, Lund, Sweden	Lindvall, O (corresponding author), Univ Hosp, Lab Neurogenesis & Cell Therapy, Wallenberg Neurosci Ctr, SE-22184 Lund, Sweden.	olle.lindvall@med.lu.se	Kokaia, Zaal/AAL-6009-2020	Kokaia, Zaal/0000-0003-2296-2449	Swedish Research Council, EU through the European Stroke NetworkSwedish Research Council [201024]; Swedish Government Initiative for Strategic Research Areas	Our own work was supported by the Swedish Research Council, EU 7th work program through the European Stroke Network (grant no. 201024) and Swedish Government Initiative for Strategic Research Areas (StemTherapy).	Andrews EM, 2008, EXP NEUROL, V211, P588, DOI 10.1016/j.expneurol.2008.02.027; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Belayev L, 2009, BRAIN RES, V1280, P117, DOI 10.1016/j.brainres.2009.05.030; Bible E, 2009, BIOMATERIALS, V30, P2985, DOI 10.1016/j.biomaterials.2009.02.012; Bliss TM, 2010, NEUROBIOL DIS, V37, P275, DOI 10.1016/j.nbd.2009.10.003; Buhnemann C, 2006, BRAIN, V129, P3238, DOI 10.1093/brain/awl261; Burns TC, 2009, J COMP NEUROL, V515, P125, DOI 10.1002/cne.22038; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Carter ME, 2011, TRENDS MOL MED  0223; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Daadi MM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001644; Daadi MM, 2009, MOL THER, V17, P1282, DOI 10.1038/mt.2009.104; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Darsalia V, 2007, EUR J NEUROSCI, V26, P605, DOI 10.1111/j.1460-9568.2007.05702.x; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; Friling S, 2009, P NATL ACAD SCI USA, V106, P7613, DOI 10.1073/pnas.0902396106; Gaspard N, 2008, NATURE, V455, P351, DOI 10.1038/nature07287; Guzman R, 2007, P NATL ACAD SCI USA, V104, P10211, DOI 10.1073/pnas.0608519104; Hicks A, 2009, CELL STEM CELL, V5, P139, DOI 10.1016/j.stem.2009.07.009; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Honmou O, 2011, BRAIN           0414; Horie N, 2011, STEM CELLS      0114; Horita Y, 2006, J NEUROSCI RES, V84, P1495, DOI 10.1002/jnr.21056; Hou SW, 2008, STROKE, V39, P2837, DOI 10.1161/STROKEAHA.107.510982; Jin KL, 2011, BRAIN RES, V1374, P56, DOI 10.1016/j.brainres.2010.12.037; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jin KL, 2010, J CEREBR BLOOD F MET, V30, P534, DOI 10.1038/jcbfm.2009.219; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Kallur T, 2006, J NEUROSCI RES, V84, P1630, DOI 10.1002/jnr.21066; Kawai H, 2010, J CEREBR BLOOD F MET, V30, P1487, DOI 10.1038/jcbfm.2010.32; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kobayashi T, 2006, STROKE, V37, P2361, DOI 10.1161/01.STR.0000236025.44089.e1; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Kondziolka D, 2005, J NEUROSURG, V103, P38, DOI 10.3171/jns.2005.103.1.0038; Lee HJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000156; Lee HJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005586; Lee JS, 2010, STEM CELLS, V28, P1099, DOI 10.1002/stem.430; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Li JM, 2010, BRAIN RES, V1334, P65, DOI 10.1016/j.brainres.2010.03.080; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lindvall Olle, 2004, NeuroRx, V1, P382; Lindvall Olle, 2008, V52, P549; Liu H, 2006, BRAIN, V129, P2734, DOI 10.1093/brain/awl207; Liu YP, 2009, J CEREBR BLOOD F MET, V29, P780, DOI 10.1038/jcbfm.2009.1; Liu ZW, 2008, STROKE, V39, P2571, DOI 10.1161/STROKEAHA.107.511659; Liu ZW, 2010, J CEREBR BLOOD F MET, V30, P1288, DOI 10.1038/jcbfm.2010.8; Liu ZW, 2009, STROKE, V40, P2546, DOI 10.1161/STROKEAHA.109.547265; Love Z, 2007, J NUCL MED, V48, P2011, DOI 10.2967/jnumed.107.043166; Macas J, 2006, J NEUROSCI, V26, P13114, DOI 10.1523/JNEUROSCI.4667-06.2006; Mack GS, 2011, NAT BIOTECHNOL, V29, P95, DOI 10.1038/nbt0211-95; Marti-Fabregas J, 2010, NEUROLOGY, V74, P357, DOI 10.1212/WNL.0b013e3181cbccec; Minger SL, 2007, REGEN MED, V2, P69, DOI 10.2217/17460751.2.1.69; Modo M, 2004, NEUROIMAGE, V21, P311, DOI 10.1016/j.neuroimage.2003.08.030; Nelson PT, 2002, AM J PATHOL, V160, P1201, DOI 10.1016/S0002-9440(10)62546-1; Nomura T, 2005, NEUROSCIENCE, V136, P161, DOI 10.1016/j.neuroscience.2005.06.062; Ohira K, 2010, NAT NEUROSCI, V13, P173, DOI 10.1038/nn.2473; Onda T, 2008, J CEREBR BLOOD F MET, V28, P329, DOI 10.1038/sj.jcbfm.9600527; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Park DH, 2009, CELL TRANSPLANT, V18, P985, DOI 10.3727/096368909X471279; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Popa-Wagner A, 2010, STROKE, V41, P1027, DOI 10.1161/STROKEAHA.109.575621; Qu RJ, 2007, NEUROPATHOLOGY, V27, P355, DOI 10.1111/j.1440-1789.2007.00792.x; Ramos-Cabrer P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012779; Rueger MA, 2010, J NEUROSCI, V30, P6454, DOI 10.1523/JNEUROSCI.6092-09.2010; Savitz SI, 2011, STROKE, V42, P825, DOI 10.1161/STROKEAHA.110.601914; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Schwarting S, 2008, STROKE, V39, P2867, DOI 10.1161/STROKEAHA.108.513978; Seminatore C, 2010, STROKE, V41, P153, DOI 10.1161/STROKEAHA.109.563015; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shen LH, 2010, GLIA, V58, P1074, DOI 10.1002/glia.20988; Shen LH, 2007, STROKE, V38, P2150, DOI 10.1161/STROKEAHA.106.481218; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Toyama K, 2009, EXP NEUROL, V216, P47, DOI 10.1016/j.expneurol.2008.11.010; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797; Wakabayashi K, 2010, J NEUROSCI RES, V88, P1017, DOI 10.1002/jnr.22279; Wechsler LR, 2009, STROKE, V40, pS149, DOI 10.1161/STROKEAHA.108.533208; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yasuhara T, 2009, STEM CELLS DEV, V18, P1501, DOI 10.1089/scd.2009.0011; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zhang J, 2009, J CEREBR BLOOD F MET, V29, P1166, DOI 10.1038/jcbfm.2009.41; Zhang L, 2011, STROKE, V42, P1437, DOI 10.1161/STROKEAHA.110.593129; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	94	120	121	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	AUG	2011	42	8					2369	2375		10.1161/STROKEAHA.110.599654			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	796UE	WOS:000293077400054	21757669	Bronze			2021-06-18	
J	Bilotta, F; Caramia, R; Cernak, I; Paoloni, FP; Doronzio, A; Cuzzone, V; Santoro, A; Rosa, G				Bilotta, Federico; Caramia, Remo; Cernak, Ibolja; Paoloni, Francesca Paola; Doronzio, Andrea; Cuzzone, Vincenzo; Santoro, Antonio; Rosa, Giovanni			Intensive insulin therapy after severe traumatic brain injury: A randomized clinical trial	NEUROCRITICAL CARE			English	Article						traumatic brain injury; intensive insulin infusion; hypoglycemia	PLASMA-GLUCOSE CONCENTRATIONS; CRITICALLY-ILL PATIENTS; LACTATE/PYRUVATE RATIO; ISCHEMIC-STROKE; HYPOGLYCEMIA; HYPERGLYCEMIA; MANAGEMENT; DAMAGE	Introduction To investigate the risks and possible benefits of routine versus intensive insulin therapy, assessed by the frequency of hypoglycemic events defined as a glucose concentration less than 80 mg/dl (< 4.44 mmol/l) in patients admitted to the intensive care unit (ICU) after severe traumatic brain injury (TBI). Methods and Results Ninety-seven patients admitted after severe TBI, were enrolled and randomly assigned to two groups of target glycemia. Insulin was infused at conventional rates when blood glucose levels exceeded 220 mg/dl (12.22 mmol/l) or at intensive rates, to maintain glycemia at 80-120 mg/dl (4.44-6.66 mmol/l). The following primary and outcome variables were measured during follow-up: hypoglycemic episodes, duration of ICU stay, infection rate, and 6-month mortality and neurologic outcome measured using the Glasgow Outcome Scale (GOS). Episodes of hypoglycemia (defined as blood glucose < 80 mg/dl or 4.44 mmol/l) were significantly higher in patients receiving intensive insulin therapy: median (min-max) conventional insulin therapy 7 (range 0-11) vs. intensive insulin therapy 15 (range 6-33); P < 0.0001. Duration of ICU stay was shorter in patients receiving intensive insulin therapy (7.3 vs. 10.0 days; P < 0.05); while infection rates during ICU stay (25.0% vs. 38.8%, P = 0.15), and GOS scores and mortality at 6 months were similar in the two groups. Conclusions Intensive insulin therapy significantly increases the risk of hypoglycemic episodes. Even though patients receiving intensive insulin therapy have shorter ICU stays and infection rates similar to those receiving conventional insulin therapy, both groups have similar follow-up mortality and neurologic outcome. Hence if intensive insulin therapy is to be used, great effort must be taken to avoid hypoglycemia.	[Bilotta, Federico; Caramia, Remo; Doronzio, Andrea; Cuzzone, Vincenzo; Rosa, Giovanni] Univ Roma La Sapienza, Dept Anesthesiol Crit Care & Pain Med, I-00199 Rome, Italy; [Cernak, Ibolja] Johns Hopkins Univ, Appl Phys Lab, Biomed Business Area, Laurel, MD USA; [Paoloni, Francesca Paola] GIMEMA Data Ctr, Rome, Italy; [Santoro, Antonio] Univ Roma La Sapienza, Dept Neurosurg, Rome, Italy	Bilotta, F (corresponding author), Univ Roma La Sapienza, Dept Anesthesiol Crit Care & Pain Med, Viale Somalia 81, I-00199 Rome, Italy.	bilotta@tiscali.it		Ibolja, Cernak/0000-0003-3214-698X; SANTORO, Antonio/0000-0002-0798-6816			Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bhalla A, 2003, EUR J NEUROL, V10, P25, DOI 10.1046/j.1468-1331.2003.00504.x; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; BOYLE PJ, 1988, NEW ENGL J MED, V318, P1487, DOI 10.1056/NEJM198806093182302; Gavin JR, 1997, DIABETES CARE, V20, P1183; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; HORAN TC, 2004, HOSP EPIDEMIOLOGY IN, P1659; Krinsley JS, 2007, CRIT CARE MED, V35, P2262, DOI 10.1097/01.CCM.0000282073.98414.4B; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LI PA, 1994, NEUROSCI LETT, V177, P63, DOI 10.1016/0304-3940(94)90045-0; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Mechanick JI, 2007, CURR OPIN CLIN NUTR, V10, P193, DOI 10.1097/MCO.0b013e32802b7016; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Pittas AG, 2004, ARCH INTERN MED, V164, P2005, DOI 10.1001/archinte.164.18.2005; Preiser JC, 2007, CRIT CARE MED, V35, pS503, DOI 10.1097/01.CCM.0000278046.24345.C7; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Thomas G, 2007, NEPHROL DIAL TRANSPL, V22, P2849, DOI 10.1093/ndt/gfm401; Turina M, 2006, CRIT CARE MED, V34, pS291, DOI 10.1097/01.ccm.0000231887.84751.04; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van den Berghe G, 2006, DIABETES, V55, P3151, DOI 10.2337/db06-0855; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wass CT, 1996, MAYO CLIN PROC, V71, P801; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; WIDOM B, 1990, ANN INTERN MED, V112, P904, DOI 10.7326/0003-4819-112-12-904; Yamada K, 2007, CRIT CARE, V11, DOI 10.1186/cc5953; 2006, APSF NEWSLETTER  SUM	35	120	131	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2008	9	2					159	166		10.1007/s12028-008-9084-9			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	351RC	WOS:000259441300001	18373223				2021-06-18	
J	Brady, KM; Lee, JK; Kibler, KK; Easley, RB; Koehler, RC; Shaffner, DH				Brady, Ken M.; Lee, Jennifer K.; Kibler, Kathleen K.; Easley, R. Blaine; Koehler, Raymond C.; Shaffner, Donald H.			Continuous measurement of autoregulation by spontaneous fluctuations in cerebral perfusion pressure - Comparison of 3 methods	STROKE			English	Article						autoregulation; cerebral blood flow; hypotension; neonates; oxygenation; piglets	TRAUMATIC BRAIN-INJURY; CEREBROVASCULAR AUTOREGULATION; HEAD-INJURY; REACTIVITY	Background and Purpose-Clinical application of continuous autoregulation monitoring would benefit from a comparison of curves generated by online monitoring with standard autoregulation curves in animal models. We characterized the accuracy of 3 continuous monitors of autoregulation in a piglet model of hypotension. Methods-Piglets 5 to 10 days old with intracranial pressure (ICP) at naive or elevated (20 mm Hg) levels had gradual arterial hypotension induced by a balloon catheter in the inferior vena cava. Elevated ICP was maintained by a continuous infusion of artificial cerebrospinal fluid. Three indices of autoregulation were simultaneously and continuously calculated. A moving, linear Pearson's coefficient between spontaneous slow waves of cerebral perfusion pressure and slow waves of laser-Doppler flux or cortical oxygenation rendered the laser-Doppler index and cerebral-oximetry index, respectively. Similar correlation between slow waves of arterial blood pressure and ICP rendered the pressure-reactivity index. The lower limit of autoregulation was determined directly for each animal by plotting laser-Doppler cortical red blood cell flux as a function of cerebral perfusion pressure. Receiver-operator characteristics were determined for the 3 indices. Results-The areas under the receiver-operator characteristics curves for discriminating the individual lower limit of autoregulation at low and high ICP were 0.89 and 0.85 for the laser-Doppler index, 0.89 and 0.84 for the cerebral-oximetry index, and 0.79 and 0.79 for the pressure-reactivity index. The pressure-reactivity index performed equally well at low and high ICPs. Conclusions-Continuous monitoring of autoregulation by spontaneous slow waves of cerebral perfusion pressure can accurately detect loss of autoregulation due to hypotension in piglets by all 3 modalities.	[Brady, Ken M.; Lee, Jennifer K.; Kibler, Kathleen K.; Easley, R. Blaine; Koehler, Raymond C.; Shaffner, Donald H.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA	Brady, KM (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Anesthesiol & Crit Care Med, Dept Anesthesiol, 600 N Wolfe St,Blalock 904, Baltimore, MD 21287 USA.	kbrady5@jhmi.edu		SHAFFNER, DONALD/0000-0001-5530-0746	Hartwell Foundation; Foundation for Anesthesia Education and Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS020020] Funding Source: NIH RePORTER	This work was supported by grants from the Hartwell Foundation and the Foundation for Anesthesia Education and Research.	Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1997, NEUROSURGERY, V41, P17; Guendling K, 2006, ACTA NEUROCHIR SUPPL, V96, P108; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lemaire JJ, 2002, ACTA NEUROCHIR, V144, P243, DOI 10.1007/s007010200032; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MACKENZIE ET, 1979, STROKE, V10, P711, DOI 10.1161/01.STR.10.6.711; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2007, J NEUROTRAUMA S1, V24, pS59, DOI DOI 10.1089/NEU.2007.9987	16	120	120	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	SEP	2008	39	9					2531	2537		10.1161/STROKEAHA.108.514877			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	341PP	WOS:000258727000021	18669896	Green Accepted, Bronze			2021-06-18	
J	Powell, JM; Ferraro, JV; Dikmen, SS; Temkin, NR; Bell, KR				Powell, Janet M.; Ferraro, Joseph V.; Dikmen, Sureyya S.; Temkin, Nancy R.; Bell, Kathleen R.			Accuracy of mild traumatic brain injury diagnosis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain concussion; craniocerebral trauma; head injuries, closed; post-concussive syndrome; rehabilitation	MINOR HEAD-INJURY; RANDOMIZED-TRIAL	Objective: To determine how often emergency department (ED) patients meeting the Centers for Disease Control and Prevention (CDC) mild traumatic brain injury (TBI) criteria were diagnosed with a mild TBI by the ED physician. Design: Prospective identification of cases of mild TBI in the ED by study personnel using scripted interviews and medical record data was compared with retrospective review of ED medical record documentation of mild TBI. Setting: EDs of a level I trauma center and an academic nontrauma hospital. Participants: Prospective cohort of subjects (N=197; mean age, 32.6y; 70% men) with arrival at the ED within 48 hours of injury, Glasgow Coma Scale score of 13 to 15, and injury circumstances,alteration of consciousness, and memory dysfunction consistent with the CDC mild TBI definition. Interventions: Not applicable. Main Outcome Measure: ED medical record documentation of mild TBI. Results: Fifty-six percent of mild TBI cases identified by study personnel did not have a documented mild TBI-related diagnosis in the ED record. The greatest agreement between study personnel and ED physicians for positive mild TBI-related findings was for loss of consciousness (72% vs 65%) with the greatest discrepancy for confusion (94% vs 28%). Conclusions: The diagnosis of mild TBI was frequently absent from ED medical records despite patients reporting findings consistent with a mild TBI diagnosis when interviewed by study personnel. Asking a few targeted questions of ED patients with likely mechanisms of injury that could result in mild TBI could begin to improve diagnosis and, in turn, begin to improve patient management and the accuracy of estimates of mild TBI incidence.	[Powell, Janet M.] Univ Washington, Dept Rehabil Med, Div Occupat Therapy, Seattle, WA 98195 USA; [Dikmen, Sureyya S.; Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya S.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Ferraro, Joseph V.] N Florida S Georgia Vet Hlth Care Syst, Gainesville, FL USA	Powell, JM (corresponding author), Univ Washington, Dept Rehabil Med, Div Occupat Therapy, 1959 NE Pacific St,Box 345490, Seattle, WA 98195 USA.	jmpowell@u.washington.edu		Bell, Kathleen/0000-0002-0928-2046	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR023226] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BELL KR, J NEUROL NE IN PRESS; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; *DEP HLTH HUM SERV, 1989, INT CLASS DIS 9 REV; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Langlois J, 2005, TRAUMATIC BRAIN INJU; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosner B., 1995, FUNDAMENTALS BIOSTAT, V4th ed; Ruff RM, 1999, BRAIN INJURY, V13, P943; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Tellier A, 1999, BRAIN INJURY, V13, P463	31	120	120	1	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2008	89	8					1550	1555		10.1016/j.apmr.2007.12.035			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	336UP	WOS:000258390400018	18597735				2021-06-18	
J	Wilcock, DM; Lewis, MR; Van Nostrand, WE; Davis, J; Previti, ML; Gharkholonarehe, N; Vitek, MP; Colton, CA				Wilcock, Donna M.; Lewis, Matthew R.; Van Nostrand, William E.; Davis, Judianne; Previti, Mary Lou; Gharkholonarehe, Nastaran; Vitek, Michael P.; Colton, Carol A.			Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2	JOURNAL OF NEUROSCIENCE			English	Article						amyloid; tau; neurodegeneration; neuropeptide Y; cerebral amyloid angiopathy; Alzheimer's disease	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; NEUROPEPTIDE-Y; BETA-PROTEIN; NEUROFIBRILLARY DEGENERATION; MEMORY DEFICITS; PERITONEAL-MACROPHAGES; OXIDATIVE STRESS; CELL-SURVIVAL; EARLY-ONSET	Alzheimer's disease (AD) is characterized by three primary pathologies in the brain: amyloid plaques, neurofibrillary tangles, and neuron loss. Mouse models have been useful for studying components of AD but are limited in their ability to fully recapitulate all pathologies. We crossed the APPSwDI transgenic mouse, which develops amyloid beta(A beta)-protein deposits only, with a nitric oxide synthase 2 (NOS2) knock-out mouse, which develops no AD-like pathology. APPSwDI/NOS2(-/-) mice displayed impaired spatial memory compared with the APPSwDI mice, yet they have unaltered levels of A beta. APPSwDI mice do not show tau pathology, whereas APPSwDI/NOS2(-/-) mice displayed extensive tau pathology associated with regions of dense microvascular amyloid deposition. Also, APPSwDI mice do not have any neuron loss, whereas the APPSwDI/NOS2(-/-) mice have significant neuron loss in the hippocampus and subiculum. Neuropeptide Y neurons have been shown to be particularly vulnerable in AD. These neurons appear to be particularly vulnerable in the APPSwDI/NOS2(-/-) mice as we observe a dramatic reduction in the number of NPY neurons in the hippocampus and subiculum. These data show that removal of NOS2 from an APP transgenic mouse results in development of a much greater spectrum of AD-like pathology and behavioral impairments.	[Wilcock, Donna M.; Lewis, Matthew R.; Gharkholonarehe, Nastaran; Vitek, Michael P.; Colton, Carol A.] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; [Van Nostrand, William E.; Davis, Judianne; Previti, Mary Lou] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA	Colton, CA (corresponding author), Duke Univ, Med Ctr, Div Neurol, Bryan Res Bldg,Box 2900,Res Dr, Durham, NC 27710 USA.	glia01@aol.com	Wilcock, Donna M/J-7517-2016	Vitek, Michael/0000-0001-8140-8048; Colton, Carol/0000-0003-3305-370X	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG19780, R01 AG019780, R01 AG019740, F32 AG030942, F32 AG030942-01, R01 AG019740-04, AG19740, AG030942, R01 AG019780-05] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055118, NS55118, R01 NS055118-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019780, F32AG030942, R01AG019740] Funding Source: NIH RePORTER		Akassoglou K, 2005, MOL PHARMACOL, V68, P952, DOI 10.1124/mol.105.017277; Alamed J, 2006, NAT PROTOC, V1, P1671, DOI 10.1038/nprot.2006.275; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Braak H, 1998, J NEURAL TRANSM-SUPP, P127; Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325; Brune B, 2005, ANTIOXID REDOX SIGN, V7, P497, DOI 10.1089/ars.2005.7.497; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Colton C, 1996, MOL CHEM NEUROPATHOL, V28, P15, DOI 10.1007/BF02815200; Colton CA, 2006, P NATL ACAD SCI USA, V103, P12867, DOI 10.1073/pnas.0601075103; Culmsee C, 2005, MOL PHARMACOL, V68, P1006, DOI 10.1124/mol.105.013086; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Diez M, 2003, NEUROBIOL DIS, V14, P579, DOI 10.1016/j.nbd.2003.08.003; Diez M, 2000, NEUROSCIENCE, V100, P259, DOI 10.1016/S0306-4522(00)00261-X; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; Duport S, 2005, NEUROSCIENCE, V135, P1155, DOI 10.1016/j.neuroscience.2005.06.035; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P45, DOI 10.1038/jcbfm.1987.7; Eriksen JL, 2007, BEHAV GENET, V37, P79, DOI 10.1007/s10519-006-9118-z; FLOOD JF, 1987, BRAIN RES, V421, P280, DOI 10.1016/0006-8993(87)91297-2; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Goedert M, 2005, MOVEMENT DISORD, V20, pS45, DOI 10.1002/mds.20539; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hewett SJ, 2005, FREE RADICAL BIO MED, V39, P1478, DOI 10.1016/j.freeradbiomed.2005.07.007; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1998, EXP GERONTOL, V33, P883, DOI 10.1016/S0531-5565(98)00045-X; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huang Y, 2006, CELL BIOCHEM BIOPHYS, V46, P35, DOI 10.1385/CBB:46:1:35; Iqbal K, 1997, MOL PSYCHIATR, V2, P178, DOI 10.1038/sj.mp.4000269; IQBAL K, 1994, MOL NEUROBIOL, V9, P119, DOI 10.1007/BF02816111; KOBARI M, 1993, BRAIN RES BULL, V31, P443, DOI 10.1016/0361-9230(93)90107-M; KOHLER C, 1986, J COMP NEUROL, V244, P384, DOI 10.1002/cne.902440310; KOWALL NW, 1988, ANN NEUROL, V23, P105, DOI 10.1002/ana.410230202; Kroncke KD, 2000, ANTIOXID REDOX SIGN, V2, P585, DOI 10.1089/15230860050192341; Kroncke KD, 2001, INT IMMUNOPHARMACOL, V1, P1407, DOI 10.1016/S1567-5769(01)00087-X; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; LeBlanc AC, 2003, PROG NEURO-PSYCHOPH, V27, P215, DOI 10.1016/S0278-5846(03)00017-4; Lewis J, 2000, NAT GENET, V25, P402; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; MARTIGNONI E, 1992, J NEURAL TRANSM-PARK, V4, P191, DOI 10.1007/BF02260903; Miao J, 2005, AM J PATHOL, V167, P505, DOI 10.1016/S0002-9440(10)62993-8; Minthon L, 1990, J Neural Transm Suppl, V30, P57; MORRISSETTE DA, 2007, SOC NEUR ABSTR, V33, P888; Nagy Z, 1998, ALZ DIS ASSOC DIS, V12, P182, DOI 10.1097/00002093-199809000-00010; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oshima K, 2006, ACTA NEUROPATHOL, V111, P510, DOI 10.1007/s00401-006-0070-z; Pannu R, 2006, NEUROCHEM INT, V49, P170, DOI 10.1016/j.neuint.2006.04.010; Redrobe JP, 2004, J MOL NEUROSCI, V22, P159, DOI 10.1385/JMN:22:3:159; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schwab C, 2004, EXP NEUROL, V188, P52, DOI 10.1016/j.expneurol.2004.03.016; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; SUZUKI Y, 1989, J CEREBR BLOOD F MET, V9, P268, DOI 10.1038/jcbfm.1989.44; Tang XQ, 2006, LIFE SCI, V79, P870, DOI 10.1016/j.lfs.2006.03.010; Thomas DD, 2004, P NATL ACAD SCI USA, V101, P8894, DOI 10.1073/pnas.0400453101; Vitek MP, 2006, ANTIOXID REDOX SIGN, V8, P893, DOI 10.1089/ars.2006.8.893; WEINBERG JB, 1995, BLOOD, V86, P1184; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Wink DA, 2001, ANTIOXID REDOX SIGN, V3, P203, DOI 10.1089/152308601300185179; Xu F, 2007, NEUROSCIENCE, V146, P98, DOI 10.1016/j.neuroscience.2007.01.043	67	120	121	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 13	2008	28	7					1537	1545		10.1523/JNEUROSCI.5066-07.2008			9	Neurosciences	Neurosciences & Neurology	262LM	WOS:000253150000002	18272675	Bronze, Green Published, Green Accepted			2021-06-18	
J	Perianez, JA; Rios-Lago, M; Rodriguez-Sanchez, JM; Adrover-Roig, D; Sanchez-Cubillo, I; Crespo-Facorro, B; Quemada, JI; Barcelo, F				Perianez, J. A.; Rios-Lago, M.; Rodriguez-Sanchez, J. M.; Adrover-Roig, D.; Sanchez-Cubillo, I.; Crespo-Facorro, B.; Quemada, J. I.; Barcelo, F.			Trail Making Test in traumatic brain injury, schizophrenia, and normal ageing: Sample comparisons and normative data	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						attentional control; brain damage; clinical norms; executive function; neuropsychological assessment; schizophrenia	EXECUTIVE SYSTEM IMPAIRMENT; PREFRONTAL CORTEX; CULTURAL NEUROPSYCHOLOGY; DYSEXECUTIVE SYNDROME; PRACTICAL SCALE; TEST INDEXES; STROOP TEST; MAKING TEST; PART-B; AGE	The Trail Making Test (TMT) has been a useful assessment tool to investigate executive function. Several studies have recently improved the existing TMT norms by mean of large samples of healthy individuals stratified by a number of demographic variables from different populations. In contrast, criticisms have been raised about the utility of norms from healthy samples to detect changes across time in clinical samples where TMT performance used to be altered. In addition, few studies have compared groups of patients with deficits in TMT performance, making it difficult to decide whether a single set of norms is sufficient to assess different clinical populations. We provide normative data from three large samples of patients with traumatic brain injury (TBI) (n = 90), schizophrenia spectrum disorders (n = 127), and healthy Spanish speakers (it = 223). Differences between healthy participants and patients in all TMT direct (TMT-A, TMT-B) and derived (B-A, B:A, B-A/A) scores were found. TMT performance was poorer in TBI patients than in schizophrenia patients except for the B:A and B-A/A scores, suggesting a similar underlying executive deficit. Normal ageing impaired both direct and derived TMT indices, as revealed by lower scores in the healthy elderly group (55-80 years old) as compared with young (16-24) and middle-aged (25-54) healthy participants. Three different sets of norms stratified by age, education, or both are presented for clinical use. Recommendations on TMT scores are made for future research. (c) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Balearic Isl, Dept Psychol, Palma de Mallorca 07122, Spain; IUNICS, Baleares, Spain; Hosp Beata Maria Ana, Brain Damage Unit, Madrid, Spain; Univ Nacl Educ Distancia, Dept Basic Psychol 2, Madrid, Spain; Hosp Univ Marques Valdecilla, Santander, Spain; Hosp Aita Menni, Brain Damage Unit, Bilbao, Spain; Univ Cantabria, Sch Med, Dept Psychiat, E-39005 Santander, Spain	Perianez, JA (corresponding author), Univ Balearic Isl, Dept Psychol, Ctra Valldemossa Km 7-5,Edif Beatriu Pinos Desp 2, Palma de Mallorca 07122, Spain.	ja.perianez@uib.es	Rios-Lago, Marcos/C-9568-2012; Perianez, Jose/AAI-3988-2021; Rios-Lago, Marcos/P-6930-2019; Adrover-Roig, Daniel/B-9645-2009; Barcelo, Francisco/B-3629-2011	Rios-Lago, Marcos/0000-0003-0187-5047; Rios-Lago, Marcos/0000-0003-0187-5047; Adrover-Roig, Daniel/0000-0002-4337-1325; Barcelo, Francisco/0000-0001-6012-7116; , BENEDICTO/0000-0003-0033-7132; Perianez, Jose A./0000-0003-4310-4021			Albert MS, 2001, J INT NEUROPSYCH SOC, V7, P631, DOI 10.1017/S1355617701755105; Amodio P, 2002, AGING CLIN EXP RES, V14, P117, DOI 10.1007/BF03324425; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; ARDILA A, 1995, J CLIN EXP NEUROPSYC, V17, P143, DOI 10.1080/13803399508406589; Ardila A, 2005, NEUROPSYCHOL REV, V15, P185, DOI 10.1007/s11065-005-9180-y; Army Individual Test Battery, 1944, MAN DIR SCOR; Bilder RM, 2000, AM J PSYCHIAT, V157, P549, DOI 10.1176/appi.ajp.157.4.549; Brazo P, 2005, PSYCHIAT RES, V133, P45, DOI 10.1016/j.psychres.2004.10.001; Brink TL., 1982, CLIN GERONTOLOGIST, V1, P37, DOI [10.1300/J018v01n01_06, DOI 10.1300/J018V01N01_06]; Chao LL, 1997, CEREB CORTEX, V7, P63, DOI 10.1093/cercor/7.1.63; Ciaramelli E, 2006, BRAIN COGNITION, V60, P198; Crespo-Facorro B, 2000, BIOL PSYCHIAT, V48, P110, DOI 10.1016/S0006-2332(00)00238-9; Crespo-Facorro B, 2006, J CLIN PSYCHIAT, V67, P1511, DOI 10.4088/JCP.v67n1004; Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.0.CO;2-K; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Drane DL, 2002, NEUROPSY NEUROPSY BE, V15, P39; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GAUDINO EA, 1995, J CLIN EXP NEUROPSYC, V17, P529, DOI 10.1080/01688639508405143; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; Hashimoto R, 2006, PSYCHIAT CLIN NEUROS, V60, P422, DOI 10.1111/j.1440-1819.2006.01526.x; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; Hester RL, 2005, CLIN NEUROPSYCHOL, V19, P45, DOI 10.1080/13854040490524137; Kennepohl S, 1999, BRAIN COGNITION, V41, P365, DOI 10.1006/brcg.1999.1138; Kizilbash A, 2000, Pediatr Rehabil, V4, P71; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; Krabbendam L, 1999, CLIN NEUROPSYCHOL, V13, P370, DOI 10.1076/clin.13.3.370.1739; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A, V3, P650; LOWE C, 1997, METHODOLOGY FRONTAL, P39; Lu Lei, 2002, Appl Neuropsychol, V9, P219, DOI 10.1207/S15324826AN0904_4; Manoach DS, 2003, SCHIZOPHR RES, V60, P285, DOI 10.1016/S0920-9964(02)00294-3; Miner T, 1998, BRAIN COGNITION, V38, P246, DOI 10.1006/brcg.1998.1034; Mitrushina M., 2005, HDB NORMATIVE DATA N; Mitrushina M., 1999, HDB NORMATIVE DATA N; Perianez JA, 2001, REV NEUROLOGIA, V33, P611, DOI 10.33588/rn.3307.2001045; Raz N, 2004, NEUROBIOL AGING, V25, P377, DOI 10.1016/S0197-4580(03)00118-0; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan R. M., 1992, TRAIL MAKING TEST MA; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Rios M., 2004, ATENCION CONTROL EJE; Rodriguez-Sanchez JM, 2005, SCHIZOPHR RES, V77, P279, DOI 10.1016/j.schres.2005.04.023; Salat DH, 1999, ARCH NEUROL-CHICAGO, V56, P338, DOI 10.1001/archneur.56.3.338; SALTHOUSE TA, 1995, NEUROPSYCHOLOGY, V9, P518, DOI 10.1037/0894-4105.9.4.518; Salthouse TA, 2000, NEUROPSYCHOLOGY, V14, P102, DOI 10.1037/0894-4105.14.1.102; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seo EH, 2006, INT J GERIATR PSYCH, V21, P844, DOI 10.1002/gps.1570; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Soukup V M, 1998, Appl Neuropsychol, V5, P65, DOI 10.1207/s15324826an0502_2; Spreen O., 1998, COMPENDIUM NEUROPSYC; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Szoke A, 2005, PSYCHOL MED, V35, P771, DOI 10.1017/S0033291704003460; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Tisserand DJ, 2002, NEUROIMAGE, V17, P657, DOI 10.1006/nimg.2002.1173; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Turner-Stokes L., 2005, COCHRANE DATABASE SY, V3; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P83, DOI 10.1016/j.acn.2005.07.008	69	120	123	1	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2007	22	4					433	447		10.1016/j.acn.2007.01.022			15	Psychology, Clinical; Psychology	Psychology	182OP	WOS:000247514200002	17336493	Bronze			2021-06-18	
J	Wen, L; Yang, XF; Liu, WG; Shen, G; Zheng, XS; Cao, F; Li, G				Wen Liang; Yang Xiaofeng; Liu Weiguo; Shen Gang; Zheng Xuesheng; Cao Fei; Li Gu			Cranioplasty of large cranial defect at an early stage after decompressive craniectomy performed for severe head trauma	JOURNAL OF CRANIOFACIAL SURGERY			English	Article						cranioplasty; decompressive craniectomy; traumatic brain injury					jediwen@163.com						0	120	131	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1049-2275	1536-3732		J CRANIOFAC SURG	J. Craniofac. Surg.	MAY	2007	18	3					526	532					7	Surgery	Surgery	175BF	WOS:000246986300011	17538313				2021-06-18	
J	Cotton, BA; Snodgrass, KB; Fleming, SB; Carpenter, RO; Kemp, CD; Arbogast, PG; Morris, JA				Cotton, Bryan A.; Snodgrass, Kimberly B.; Fleming, Sloan B.; Carpenter, Robert O.; Kemp, Clinton D.; Arbogast, Patrick G.; Morris, John A., Jr.			Beta-blocker exposure is associated with improved survival after severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		beta-blocker; trauma; brain injury	SEVERE HEAD-INJURY; WALL-MOTION ABNORMALITIES; SUBARACHNOID HEMORRHAGE; MYOCARDIAL-ISCHEMIA; NONCARDIAC SURGERY; PROPENSITY SCORE; PROPRANOLOL; MORTALITY; DEATH; CATECHOLAMINES	Background: Beta-blocker use in elective noncardiac surgery has been associated with a reduction in mortality and cardiovascular complications. Traumatic brain injury (TBI) is often associated with a hyperadrenergic state. We hypothesized that adrenergic blockade would confer improved survival among TBI patients. Methods: Retrospective review of the Trauma Registry of the American College of Surgeons database at a Level I trauma center was conducted. All trauma patients admitted from January 2004 to March 2005 with head Abbreviated Injury Scale score of 3 or greater were evaluated. Patients with length of stay < 4 or > 30 days were excluded. Beta-blocker exposure was defined as receiving beta-blockers for 2 or more consecutive days. Results: In all, 420 patients met inclusion criteria: 174 patients exposed to beta-blockers [BB(+)] and 246 not exposed [BB(-)]. Mean age in BB(+) group was 50 years and 36 years in BB(-) group (p < 0.001). Mean Injury Severity Score was 33.6 for BB(+) group and 30.8 for BB(-) group (p = 0.01). Predicted survival (by Trauma and Injury Severity Score) for BB(+) group was 59.1% compared with 70.3% for BB(-) group (p < 0.001). Observed mortality for BB(+) group was 5.1%, 10.8% for BB(-) group (p = 0.036). Adjusted incidence rate ratio of mortality among those exposed to beta-blockers compared with those not exposed was 0.29 (95% confidence interval). Conclusions: Beta-blocker exposure was associated with a significant reduction in mortality in patients with severe TBI. This reduction in mortality is even more impressive, considering that the BB(+) group was older, more severely injured, and had lower predicted survival.	Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37212 USA; Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37212 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37212 USA	Cotton, BA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, 1211 21st Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	bryan.cotton@vanderbilt.edu	Cotton, Bryan/A-7107-2009				Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Deng JP, 2004, AM J PHYSIOL-CELL PH, V287, pC730, DOI 10.1152/ajpcell.00562.2003; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; FEIBEL JH, 1981, ANN NEUROL, V9, P340, DOI 10.1002/ana.410090405; Fonseca RB, 2005, J TRAUMA, V59, P884, DOI 10.1097/01.ta.0000187653.64300.f5; GREENDYKE RM, 1986, J NERV MENT DIS, V174, P290, DOI 10.1097/00005053-198605000-00005; GREENHOO.JH, 1969, J NEUROSURG, V30, P521, DOI 10.3171/jns.1969.30.5.0521; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; HADFIELD JM, 1992, INJURY, V23, P177, DOI 10.1016/S0020-1383(05)80040-3; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hart DW, 2002, ANN SURG, V236, P450, DOI 10.1097/00000658-200210000-00007; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; KRAUS J, 1985, J NEUROSURG, V63, P537, DOI 10.3171/jns.1985.63.4.0537; Lindenauer PK, 2005, NEW ENGL J MED, V353, P349, DOI 10.1056/NEJMoa041895; MALING HM, 1958, AM J PHYSIOL, V194, P590; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MCLEOD AA, 1982, BRIT HEART J, V47, P221; MOREL DR, 1984, INTENS CARE MED, V10, P133, DOI 10.1007/BF00265802; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Neil-Dwyer G, 1990, Acta Neurochir Suppl (Wien), V47, P102; NEILDWYER G, 1981, BRIT J CLIN PHARMACO, V11, P549, DOI 10.1111/j.1365-2125.1981.tb01169.x; NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990; NEILDWYER G, 1985, EUR J CLIN PHARMACOL, V28, P25, DOI 10.1007/BF00543706; NEILDWYER G, 1986, SURG NEUROL, V25, P163, DOI 10.1016/0090-3019(86)90287-9; Newgard CD, 2004, ACAD EMERG MED, V11, P953, DOI 10.1197/j.aem.2004.02.530; OPPENHEIMER SM, 1990, ARCH NEUROL-CHICAGO, V47, P513, DOI 10.1001/archneur.1990.00530050029008; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; Poulat P, 1998, EUR J PHARMACOL, V344, P251, DOI 10.1016/S0014-2999(97)01569-0; Randell T, 1999, J NEUROSURG ANESTH, V11, P163, DOI 10.1097/00008506-199907000-00001; Roe SY, 1997, J NEUROTRAUM, V14, P399, DOI 10.1089/neu.1997.14.399; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; SPARKS HV, 1970, CARDIOVASC RES, V4, P363, DOI 10.1093/cvr/4.3.363; STONE JG, 1988, ANESTHESIOLOGY, V68, P495, DOI 10.1097/00000542-198804000-00004; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Urban MK, 2000, ANESTH ANALG, V90, P1257, DOI 10.1097/00000539-200006000-00001; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; WEIR BK, 1978, J NEUROSURG, V49, P502, DOI 10.3171/jns.1978.49.4.0502; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	57	120	123	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2007	62	1					26	33		10.1097/TA.0b013e31802d02d0			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	126CP	WOS:000243490100004	17215730				2021-06-18	
J	Robertson, CL; Puskar, A; Hoffman, GE; Murphy, AZ; Saraswati, M; Fiskum, G				Robertson, CL; Puskar, A; Hoffman, GE; Murphy, AZ; Saraswati, M; Fiskum, G			Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats	EXPERIMENTAL NEUROLOGY			English	Article						brain mitochondria; progesterone; neuroprotection; apoptosis; hippocampus	CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; OVARIECTOMIZED RATS; LIPID-PEROXIDATION; COGNITIVE RECOVERY; GENDER-DIFFERENCES; BINDING-PROTEIN; NEURONAL LOSS; SPINAL-CORD; CNS TRAUMA	Growing literature suggests important sex-based differences in Outcome following traumatic brain injury (TBI) in animals and humans. Progesterone has emerged as a key hormone involved in many potential neuroprotective pathways after acute brain injury and may be responsible for some of these differences. Many studies have utilized supraphysiologic levels of post-traumatic progesterone to reverse pathologic processes after TBI, but few Studies have focused on the role of endogenous physiologic levels of progesterone in neuroprotection. We hypothesized that progesterone at physiologic serum levels Would be neuroprotective in female rats after TBI and that progesterone would reverse early mitochondrial dysfunction seen in this model. Female, Sprague-Dawley rats were ovariectomized and implanted with silastic capsules containing either low or high physiologic range progesterone at 7 days prior to TBI. Control rats received ovariectomy with implants containing no hormone. Rats underwent controlled cortical impact to the left parietotemporal cortex and were evaluated for evidence of early mitochondrial dysfunction (1 h) and delayed hippocampal neuronal injury and cortical tissue loss (7 clays) after injury. Progesterone in the low physiologic range reversed the early postinjury alterations seen in mitochondrial respiration and reduced hippocampal neuronal loss in both the CA1 and CA3 subfields. Progesterone in the high physiologic range had a more limited pattern of hippocampal neuronal preservation in the CA3 region only. Neither progesterone dose significantly reduced cortical tissue loss. These findings have implications in understanding the sex-based differences in Outcome following acute brain injury. (c) 2005 Elsevier Inc. All rights reserved.	Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA	Robertson, CL (corresponding author), Univ Maryland, Sch Med, Dept Pediat, 22 S Greene St,N5E13, Baltimore, MD 21201 USA.	croberts@peds.umaryland.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS42805] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS042805] Funding Source: NIH RePORTER		Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Biggio G, 2001, INT REV NEUROBIOL, V46, P207; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Conti AC, 1998, J NEUROSCI, V18, P5663; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Follesa P, 2004, EUR J PHARMACOL, V500, P413, DOI 10.1016/j.ejphar.2004.07.041; GEORGE MS, 1994, BIOL PSYCHIAT, V35, P775, DOI 10.1016/0006-3223(94)91139-8; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hoffman GE, 2003, EXP NEUROL, V182, P124, DOI 10.1016/S0014-4886(03)00104-3; Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Krebs CJ, 2000, P NATL ACAD SCI USA, V97, P12816, DOI 10.1073/pnas.97.23.12816; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Le WW, 1997, BRAIN RES, V778, P272, DOI 10.1016/S0006-8993(97)00971-2; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; VERECZKI V, IN PRESS J CEREB BLO; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wise PM, 2001, ENDOCRINOLOGY, V142, P969, DOI 10.1210/en.142.3.969; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu R, 1996, MOL BRAIN RES, V41, P163	55	120	127	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2006	197	1					235	243		10.1016/j.expneurol.2005.09.014			9	Neurosciences	Neurosciences & Neurology	001LI	WOS:000234534200024	16259981				2021-06-18	
J	McGarry, LJ; Thompson, D; Millham, FH; Cowell, L; Snyder, PJ; Lenderking, WR; Weinstein, MC				McGarry, LJ; Thompson, D; Millham, FH; Cowell, L; Snyder, PJ; Lenderking, WR; Weinstein, MC			Outcomes and costs of acute treatment of traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						brain injury; outcomes assessment; cost of illness; abbreviated injury scale; retrospective studies	HEAD-INJURY; SEVERITY; STAY; EPIDEMIOLOGY; CHARGES; LENGTH; TRENDS	Background. Although there are nearly a quarter of a million hospitalizations for traumatic brain injury (TBI) in the United States each year, data on the outcomes and costs of TBI treatment in the acute-care setting are limited. Methods. Using a large, geographically diverse, multihospital database, we examined inpatient records for persons aged 16 years or older who were hospitalized for TBI between January 1, 1997, and June 30, 1999. Patients were stratified by TBI severity using an adaptation of the Abbreviated Injury Scale for administrative data (ICD/AIS), as follows: 2 = "moderate"; 3 = "serious"; 4 = "severe"; and 5 = "critical." Patient characteristics, pat-terns of treatment, and outcomes and costs were examined by injury severity and mechanism of injury. Results. Of 8,717 study subjects identified, 12.5% had moderate, 44.8% had serious, 29.6% had severe, and 13.2% had critical TBI. Falls were the most common reported cause of injury (40.8%), followed by motor vehicle crashes (39.3%), blows to the head (11.3%), and gunshot wounds (2.4%). Average length of stay in hospital ranged from 6.7 days for moderate TBI to 17.5 days for critical TBI. The overall rate of death in hospital was relatively low among patients with moderate (1.3%), serious (5.7%), and severe (8.7%) TBIs, but much higher among the most critically injured patients (52.0%). Costs of hospitalization averaged $8,189 for moderate, $14,603 for serious, $16,788 for severe, and $33,537 for critical TBI. Costs also varied by injury type, averaging $20,084 for gunshot wounds, $20,522 for motor vehicle crashes, $15,860 for falls, and $19,949 for blows to the head. Conclusion. The economic burden of TBI in the acute-care setting is substantial; treatment outcomes and costs vary considerably by TBI severity and mechanism of injury.	Innovus Res Inc, Medford, MA 02155 USA; Boston Univ, Med Ctr, Boston, MA USA; Ctr Neurol Recovery, Newton, MA USA; Univ Connecticut, Storrs, CT USA; Pfizer Global Res & Dev, Groton, CT USA; Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA	Thompson, D (corresponding author), Innovus Res Inc, 10 Cabot Rd,Suite 102, Medford, MA 02155 USA.	dthompson@innovus.com		Snyder, Peter/0000-0003-0555-4654			*ASS ADV AUT MED, 1990, ABBR INJ SCAL REV ED; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; FIFE D, 1984, J NEUROSURG, V60, P697, DOI 10.3171/jns.1984.60.4.0697; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; *MMWR, 1997, MMWR-MORBID MORTAL W, V46, P8; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954	19	120	121	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2002	53	6					1152	1159		10.1097/00005373-200212000-00020			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	625NT	WOS:000179823100026	12478043				2021-06-18	
J	Devor, M; Zalkind, V				Devor, M; Zalkind, V			Reversible analgesia, atonia, and loss of consciousness on bilateral intracerebral microinjection of pentobarbital	PAIN			English	Article						anesthesia; barbiturate; coma; consciousness; microinjection; pentobarbital; loss of consciousness; mesopontine reticular formation	PONTINE RETICULAR-FORMATION; EYE-MOVEMENT SLEEP; GABA(A) RECEPTOR; REM-SLEEP; GENERAL-ANESTHESIA; RAT-BRAIN; CARBACHOL; PATHWAYS; REGIONS; NEURONS	Concussion, asphyxia, and systemically administered general anesthetics all induce reversible depression of the organism's response to noxious stimuli as one of the elements of loss of consciousness. This is so even for barbiturate anesthetics, which have only modest analgesic efficacy at subanesthetic doses. Little is known about the neural circuits involved in this form of antinociception, although for anesthetic agents, at least, it is usually presumed that the drugs act in widely distributed regions of the nervous system. We now report the discovery of a focal zone in the brainstem mesopontine tegmentum in rats at which microinjection of minute quantities of pentobarbital induces a transient, reversible anesthetic-like state with non-responsiveness to noxious stimuli, flaccid atonia, and absence of the righting reflex. The behavioral suppression is accompanied by slow-wave EEG and, presumably, loss of consciousness. This zone, which we refer to as the mesopontine tegmental anesthesia locus (MPTA), apparently contains a barbiturate-sensitive 'switch' for both cortical and spinal activity. The very existence of the MPTA locus has implications for an understanding of the neural circuits that control motor functions and pain sensation, and for the cerebral representation of consciousness. (C) 2001 International Association for the Study of Pain. Published by Elsevier Science BN. All rights reserved.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel	Devor, M (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel.						BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; Bjorvatn B, 1998, PHYSIOL BEHAV, V63, P413, DOI 10.1016/S0031-9384(97)00460-5; Bland BH, 1998, NEUROSCI BIOBEHAV R, V22, P259, DOI 10.1016/S0149-7634(97)00013-4; BOLANDER HG, 1984, ACTA PHARMACOL TOX, V54, P33; BOURGIN P, 1995, NEUROREPORT, V6, P532, DOI 10.1097/00001756-199502000-00031; BROWNING RA, 1981, EPILEPSIA, V22, P583, DOI 10.1111/j.1528-1157.1981.tb04130.x; CARLI G, 1965, ARCH ITAL BIOL, V103, P751; COLLINS JG, 1995, TRENDS NEUROSCI, V18, P549, DOI 10.1016/0166-2236(95)98377-B; DEBLAS AL, 1988, J NEUROSCI, V8, P602; ELAZAR Z, 1990, NEUROSCI LETT, V115, P226, DOI 10.1016/0304-3940(90)90459-M; FIELD KJ, 1993, LAB ANIM, V27, P258, DOI 10.1258/002367793780745471; Fields HB, 1999, TXB PAIN, P309; FOLKMAN J, 1968, ANESTHESIOLOGY, V29, P419, DOI 10.1097/00000542-196805000-00007; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRENCH JD, 1953, AMA ARCH NEUROL PSY, V69, P519, DOI 10.1001/archneurpsyc.1953.02320280107010; GNADT JW, 1986, BRAIN RES, V384, P29, DOI 10.1016/0006-8993(86)91216-3; Hajnik T, 2000, J NEUROPHYSIOL, V84, P1942; Heier T, 1996, ACTA ANAESTH SCAND, V40, P1087, DOI 10.1111/j.1399-6576.1996.tb05570.x; Hodgson PS, 1999, ANESTHESIOLOGY, V91, P1687, DOI 10.1097/00000542-199912000-00021; Johnston GAR, 1996, PHARMACOL THERAPEUT, V69, P173, DOI 10.1016/0163-7258(95)02043-8; Jones Barbara E., 1995, P155; KILLAM EK, 1962, PHARMACOL REV, V14, P175; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; KOSAKA T, 1988, EXP BRAIN RES, V70, P605; LAI YY, 1988, J NEUROSCI, V8, P4790; Lai YY, 1999, NEUROSCIENCE, V90, P469, DOI 10.1016/S0306-4522(98)00429-1; LAMBERT JJ, 1995, TRENDS PHARMACOL SCI, V16, P295, DOI 10.1016/S0165-6147(00)89058-6; LIEBESKIND JC, 1976, SENSORY FUNCTIONS SK, P561; LIEGHTON KM, 1970, J CAN ANAESTHESIOL S, V17, P112; LINDSLEY DB, 1950, ELECTROEN CLIN NEURO, V2, P483, DOI 10.1016/0013-4694(50)90086-1; LIVINGSTONE MS, 1981, NATURE, V291, P554, DOI 10.1038/291554a0; Magni F, 1959, ARCH ITAL BIOL, V97, P33; MAGOUN HW, 1946, J NEUROPHYSIOL, V9, P166; Maloney KJ, 2000, J NEUROSCI, V20, P4669, DOI 10.1523/JNEUROSCI.20-12-04669.2000; MARK LC, 1958, J PHARMACOL EXP THER, V123, P70; Marks GA, 1998, NEUROSCIENCE, V86, P29, DOI 10.1016/S0306-4522(98)00005-0; Mendelson WB, 1996, LIFE SCI, V59, P1821, DOI 10.1016/S0024-3205(96)00400-6; MILLER RD, 1993, ANESTHESIA, V1, P229; MONTAGNECLAVEL J, 1995, NEUROSCI LETT, V196, P69, DOI 10.1016/0304-3940(95)11847-P; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; MYERS RD, 1978, BRAIN RES BULL, V3, P601, DOI 10.1016/0361-9230(78)90006-0; MYERS RD, 1966, PHYSIOL BEHAV, V1, P171, DOI 10.1016/0031-9384(66)90064-3; Nunez A, 1998, BRAIN RES, V804, P144, DOI 10.1016/S0006-8993(98)00681-7; Patel AJ, 1999, NAT NEUROSCI, V2, P422; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; RYE DB, 1987, J COMP NEUROL, V259, P483, DOI 10.1002/cne.902590403; SANDKUHLER J, 1987, EXP BRAIN RES, V68, P168; SANDKUHLER J, 1987, PAIN, V31, P381, DOI 10.1016/0304-3959(87)90166-7; Starmark J.-E., 1996, TRAUMA CARE, P27; Steriade M, 1996, SCIENCE, V272, P225, DOI 10.1126/science.272.5259.225; Steriade M., 1990, BRAINSTEM CONTROL WA; STRYKER MP, 1987, J COMP NEUROL, V258, P297, DOI 10.1002/cne.902580209; TAGUCHI O, 1992, BRAIN RES, V595, P107, DOI 10.1016/0006-8993(92)91458-Q; TSOU K, 1964, SCI SINICA, V13, P1099; Tverskoy M, 1996, ANAESTHESIA, V51, P652; VERTES RP, 1984, PROG NEUROBIOL, V22, P241, DOI 10.1016/0301-0082(84)90020-0; WHELAN G, 1992, LAB ANIM-UK, V26, P153, DOI 10.1258/002367792780740602; Xi MC, 1999, J NEUROPHYSIOL, V82, P2015; YAKSH TL, 1976, BRAIN RES, V114, P83, DOI 10.1016/0006-8993(76)91009-X; Yanagida H, 1971, Masui, V20, P51; ZHANG JH, 1991, J COMP NEUROL, V303, P637, DOI 10.1002/cne.903030409; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	63	120	123	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	OCT	2001	94	1					101	112		10.1016/S0304-3959(01)00345-1			12	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	484EW	WOS:000171678100011	11576749				2021-06-18	
J	Henshall, DC; Clark, RSB; Adelson, PD; Chen, M; Watkins, SC; Simon, RP				Henshall, DC; Clark, RSB; Adelson, PD; Chen, M; Watkins, SC; Simon, RP			Alterations in bcl-2 and caspase gene family protein expression in human temporal lobe epilepsy	NEUROLOGY			English	Article							SUSTAINED ELECTRICAL-STIMULATION; NONCONVULSIVE SEIZURES DAMAGE; TRAUMATIC BRAIN INJURY; CELL-DEATH; RAT-BRAIN; HIPPOCAMPAL-NEURONS; PERFORANT PATH; MESSENGER-RNA; KAINIC ACID; PROTOONCOGENE BCL-2	Objective: To address the role of cell death regulatory genes of the bcl-2 and caspase families in the neuropathology of human epilepsy using tissue extracted from patients undergoing temporal lobectomy for intractable seizures. Methods: Using Western blotting and immunohistochemistry, the authors investigated the expression of bcl-2, bcl-x(L), bar, caspase-1, and caspase-3 in temporal cortex samples from patients who had undergone temporal lobectomy surgery for intractable epilepsy (n = 19). Nonepileptic postmortem tissue from a brain bank served as control (n = 6). Results: Western blot analysis demonstrated significant increases in levels of bcl-2 and bcl-x(L) protein in seizure brain compared to control. Cleavage of caspase-1 was evidenced by a reduction in levels of the 45 kDa proenzyme form and an increase in levels of the p10 fragment. Levels of the 32 kDa proenzyme form of caspase-3 were elevated in seizure patients, as were levels of the 12 kDa cleaved fragment. Bcl-2, bar, and caspase-3 immunoreactivity was increased predominantly in cells with the morphologic appearance of neurons, whereas bcl-x(L) immunoreactivity was increased in cells with the appearance of glia. DNA fragmentation was detected in some but not all sections from epileptic brain samples. Conclusions: Cell death regulatory genes of the bcl-2 and caspase families may play a role in ongoing neuropathologic processes in human epilepsy, and offer novel targets as an adjunct to anticonvulsant therapy.	Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Physiol & Cell Biol, Pittsburgh, PA 15260 USA	Simon, RP (corresponding author), Legacy Clin Res & Technol Ctr, 1225 NE 2nd Ave, Portland, OR 97208 USA.		Henshall, David/C-3364-2012; Adelson, David/W-2083-2019	watkins, simon/0000-0003-4092-1552; Henshall, David/0000-0001-6237-9632	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39016] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1K08 01946, HP30 28836] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039016] Funding Source: NIH RePORTER		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Aminoff MJ, 1998, ARCH NEUROL-CHICAGO, V55, P119, DOI 10.1001/archneur.55.1.119; Aschner M, 1998, NEUROTOXICOLOGY, V19, P7; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Chen J, 1998, J NEUROSCI, V18, P4914; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; DOURNAUD P, 1994, NEUROSCIENCE, V61, P755, DOI 10.1016/0306-4522(94)90399-9; Drache B, 1997, J NEUROSCI RES, V47, P98; DU F, 1993, NEUROSCIENCE, V55, P975, DOI 10.1016/0306-4522(93)90312-4; Enari M, 1998, NATURE, V391, P43; Eriksson C, 1999, NEUROSCIENCE, V93, P915, DOI 10.1016/S0306-4522(99)00178-5; Faherty CJ, 1999, MOL BRAIN RES, V70, P159, DOI 10.1016/S0169-328X(99)00143-6; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FILIPKOWSKI RK, 1994, NEUROREPORT, V5, P1538, DOI 10.1097/00001756-199407000-00032; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; Graham SH, 1996, RESTOR NEUROL NEUROS, V9, P243, DOI 10.3233/RNN-1996-9407; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HAWRYLAK N, 1993, BRAIN RES, V603, P309, DOI 10.1016/0006-8993(93)91253-O; Kalviainen R, 1998, NEUROLOGY, V50, P1377, DOI 10.1212/WNL.50.5.1377; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Lopez E, 1999, NEUROSCIENCE, V91, P1461, DOI 10.1016/S0306-4522(98)00704-0; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mathern GW, 1997, BRAIN, V120, P1937, DOI 10.1093/brain/120.11.1937; Meldrum B.S., 1992, GREENFIELDS NEUROPAT, P1246; Namura S, 1998, J NEUROSCI, V18, P3659; NIQUET J, 1994, J NEUROCYTOL, V23, P641, DOI 10.1007/BF01191558; OLNEY JW, 1983, BRAIN RES BULL, V10, P699, DOI 10.1016/0361-9230(83)90038-2; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Salmenpera T, 1998, LANCET, V351, P35, DOI 10.1016/S0140-6736(05)78092-2; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Sloviter RS, 1998, NEUROLOGY, V50, P846, DOI 10.1212/WNL.50.4.846; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; SLOVITER RS, 1983, BRAIN RES BULL, V10, P675, DOI 10.1016/0361-9230(83)90037-0; Spencer SS, 1999, EPILEPSIA, V40, P708, DOI 10.1111/j.1528-1157.1999.tb00767.x; Tasch E, 1999, ANN NEUROL, V45, P568, DOI 10.1002/1531-8249(199905)45:5<568::AID-ANA4>3.0.CO;2-P; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WETZEL DM, 1994, BRAIN RES, V649, P117, DOI 10.1016/0006-8993(94)91054-5; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117; Zhang LX, 1998, MOL BRAIN RES, V55, P198, DOI 10.1016/S0169-328X(97)00316-1	50	120	132	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JUL 25	2000	55	2					250	257		10.1212/WNL.55.2.250			8	Clinical Neurology	Neurosciences & Neurology	337FA	WOS:000088345700016	10908900				2021-06-18	
J	Azbill, RD; Mu, X; Springer, JE				Azbill, RD; Mu, X; Springer, JE			Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes	BRAIN RESEARCH			English	Article						riluzole; spinal cord; glutamate uptake; amyotrophic lateral sclerosis; excitotoxicity; G protein	TRAUMATIC BRAIN INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; TRANSPORTER GLT-1; XENOPUS-OOCYTES; NMDA RECEPTORS; GRANULE CELLS; INHIBITION; MECHANISM	The purpose of this study was to examine the effect of the anti-convulsant agent, riluzole, on high-affinity glutamate uptake as measured in rat spinal cord synaptosomes. The rate of glutamate uptake was significantly increased in the presence of 0.1 mu M and 1.0 mu M riluzole, but not at the higher concentrations examined. Kinetics analysis demonstrated that riluzole (0.1 mu M) decreased the apparent K-m by 21% and increased the V-max by 31%. Glutamate uptake also was significantly increased in spinal cord synaptosomes obtained from rats treated with 8 mg/kg (i.p.) of riluzole and sacrificed 4 h later. The increase in glutamate uptake in vitro was not affected by pretreatment either with H7, an inhibitor of PKA and PKC, or with the PKC activating phorbol ester, 12-O-tetradecanoylphorbol 13-acetate. Previous studies have shown that some of the actions of riluzole are mediated by G proteins sensitive to pertussis toxin. Surprisingly, treatment of synaptosomes with pertussis toxin alone increased the rate of glutamate uptake, while having no effect on uptake in the presence of riluzole. However, pretreatment with cholera toxin was found to completely block the effects of riluzole on glutamate uptake. These results reveal an additional mechanism by which riluzole can affect glutamatergic neurotransmission, and provides further support that riluzole may prove beneficial in the treatment of traumatic central nervous system injuries involving the excitotoxic actions of glutamate. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Kentucky, Med Ctr, Spinal Cord & Brain Injury Res Ctr, Dept Neurobiol & Anat, Lexington, KY 40536 USA	Springer, JE (corresponding author), Univ Kentucky, Med Ctr, Spinal Cord & Brain Injury Res Ctr, Dept Neurobiol & Anat, Lexington, KY 40536 USA.			Azbill, David/0000-0001-7989-1771	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030248] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30248] Funding Source: Medline		Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Barneoud P, 1996, NEUROSCIENCE, V74, P971, DOI 10.1016/S0306-4522(96)00249-7; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; CHERAMY A, 1992, NEUROSCI LETT, V147, P209, DOI 10.1016/0304-3940(92)90597-Z; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Conradt M, 1997, J NEUROCHEM, V68, P1244, DOI 10.1046/j.1471-4159.1997.68031244.x; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; DOBLE A, 1992, NEUROSCI LETT, V140, P251, DOI 10.1016/0304-3940(92)90114-M; Doble A, 1996, NEUROLOGY, V47, pS233, DOI 10.1212/WNL.47.6_Suppl_4.233S; Dowd LA, 1996, MOL PHARMACOL, V49, P465; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; HUBERT JP, 1994, BRIT J PHARMACOL, V113, P261, DOI 10.1111/j.1476-5381.1994.tb16203.x; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; MARTIN D, 1993, EUR J PHARMACOL, V250, P473, DOI 10.1016/0014-2999(93)90037-I; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; Pisano P, 1996, NEUROPHARMACOLOGY, V35, P541, DOI 10.1016/0028-3908(96)84624-7; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; Rao VLR, 1998, J NEUROCHEM, V70, P2020; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Springer JE, 1997, J NEUROCHEM, V68, P2469; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; TORP R, 1995, EXP BRAIN RES, V103, P51; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; VOLTERRA A, 1994, ANN NY ACAD SCI, V738, P153; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; Wokke J, 1996, LANCET, V348, P795, DOI 10.1016/S0140-6736(96)03181-9; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	38	120	124	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 21	2000	871	2					175	180		10.1016/S0006-8993(00)02430-6			6	Neurosciences	Neurosciences & Neurology	337TG	WOS:000088377300002	10899284				2021-06-18	
J	Rao, VLR; Dogan, A; Bowen, KK; Dempsey, RJ				Rao, VLR; Dogan, A; Bowen, KK; Dempsey, RJ			Traumatic brain injury leads to increased expression of peripheral-type benzodiazepine receptors, neuronal death, and activation of astrocytes and microglia in rat thalamus	EXPERIMENTAL NEUROLOGY			English	Article						astrocytes; microglia; mRNA; peripheral-type benzodiazepine receptor; PK11195; quantitative autoradiography; traumatic brain injury	TUMOR-NECROSIS-FACTOR; GLOBAL FOREBRAIN ISCHEMIA; CORTICAL IMPACT INJURY; PROTEIN MESSENGER-RNA; LIGAND H-3 PK11195; BINDING-SITES; PORTACAVAL ANASTOMOSIS; QUANTITATIVE AUTORADIOGRAPHY; CULTURED ASTROCYTES; ENHANCED EXPRESSION	In mammalian CNS, the peripheral-type benzodiazepine receptor (PTBR) is localized on the outer mitochondrial membrane within the astrocytes and microglia. PTBR transports cholesterol to the site of neurosteroid biosynthesis. Several neurodegenerative disorders were reported to be associated with increased densities of PTBR. In the present study, we evaluated the changes in the PTBR density and gene expression in the brains of rats as a function of time (6 h to 14 days) after traumatic brain injury (TBI). Sham-operated rats served as control. Between 3 and 14 days after TBI, there was a significant increased in the binding of PTBR antagonist [H-3]PK11195 (by 106 to 185%, P < 0.01, as assessed by quantitative autoradiography and in vitro filtration binding) and PTBR mRNA expression (by 2- to 3.4-fold, P < 0.01, as assessed by RT-PCR) in the ipsilateral thalamus. At 14 days after the injury, the neuronal number decreased significantly (by 85 to 90%, P < 0.01) in the ipsilateral thalamus. At the same time point, the ipsilateral thalamus also showed increased numbers of the glial fibrillary acidic protein positive cells (astrocytes, by similar to 3.5-fold) and the ED-1 positive cells (microglia/macrophages, by similar to 36-fold), the two cell types known to be associated with PTBR, Increased PTBR expression following TBI seems to be associated with microglia/macrophages than astrocytes as PTBR density at different periods after TBI correlated better with the number of ED-1 positive cells (r(2) = 0.95) than the GFAP positive cells (r(2) = 0.56). TBI-induced increased PTBR expression is possibly an adaptive response to cellular injury and may play a role in the pathophysiology of TBI. (C) 2000 Academic Press.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA; William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA	Rao, VLR (corresponding author), Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA.		Dogan, Aclan/AAF-8305-2019				AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BLACK KL, 1990, CANCER, V65, P93, DOI 10.1002/1097-0142(19900101)65:1<93::AID-CNCR2820650120>3.0.CO;2-1; BOURDIOL F, 1991, BRAIN RES, V543, P194, DOI 10.1016/0006-8993(91)90028-T; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conway EL, 1998, NEUROSCIENCE, V82, P805; CORNU P, 1992, ACTA NEUROCHIR, V119, P146, DOI 10.1007/BF01541799; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; Desjardins P, 1997, BRAIN RES, V758, P255, DOI 10.1016/S0006-8993(97)00339-9; DESJARDINS P, 1999, IN PRESS NEUROCHEM I; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Frye CA, 1998, PSYCHONEUROENDOCRINO, V23, P385, DOI 10.1016/S0306-4530(98)00009-2; GarciaSegura LM, 1996, CELL MOL NEUROBIOL, V16, P225, DOI 10.1007/BF02088178; Gavish M, 1997, CLIN NEUROPHARMACOL, V20, P473, DOI 10.1097/00002826-199712000-00001; Gehlert DR, 1997, NEUROCHEM INT, V31, P705, DOI 10.1016/S0197-0186(97)00007-7; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; GROOM GN, 1995, J NUCL MED, V36, P2207; GUILARTE TR, 1995, NEUROTOXICOLOGY, V16, P441; GUTH L, 1994, P NATL ACAD SCI USA, V91, P12308, DOI 10.1073/pnas.91.25.12308; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; ITZHAK Y, 1993, GLIA, V9, P211, DOI 10.1002/glia.440090306; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; JosephLiauzun E, 1997, J BIOL CHEM, V272, P28102, DOI 10.1074/jbc.272.44.28102; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Krueger KE, 1995, BBA-REV BIOMEMBRANES, V1241, P453, DOI 10.1016/0304-4157(95)00016-X; Lacor P, 1996, NEUROSCI LETT, V220, P61, DOI 10.1016/S0304-3940(96)13187-6; LAVOIE J, 1990, HEPATOLOGY, V11, P874, DOI 10.1002/hep.1840110524; LEONG DK, 1994, J CEREBR BLOOD F MET, V14, P100, DOI 10.1038/jcbfm.1994.14; Leong DK, 1996, ALCOHOL CLIN EXP RES, V20, P601, DOI 10.1111/j.1530-0277.1996.tb01101.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; McGeer E G, 1988, Alzheimer Dis Assoc Disord, V2, P331, DOI 10.1097/00002093-198802040-00001; MCPHERSON GA, 1994, RADLIG MANUAL VERSIO; Meziane H, 1996, PSYCHOPHARMACOLOGY, V126, P323, DOI 10.1007/BF02247383; MOHLER H, 1977, SCIENCE, V198, P849, DOI 10.1126/science.918669; Panizzon KL, 1998, NEUROREPORT, V9, P4131, DOI 10.1097/00001756-199812210-00024; Papadopoulos V, 1998, P SOC EXP BIOL MED, V217, P130; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RAMSAY SC, 1992, LANCET, V339, P1054, DOI 10.1016/0140-6736(92)90576-O; Rao V. L. Raghavendra, 1993, Pediatric Research, V34, P777; RAO VLR, 1994, DIGEST DIS SCI, V39, P1055; Rao VLR, 1997, BRAIN RES, V765, P169, DOI 10.1016/S0006-8993(97)00652-5; Rao VLR, 1997, EUR J PHARMACOL, V340, P89, DOI 10.1016/S0014-2999(97)01395-2; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Schumacher M, 1996, DEV NEUROSCI-BASEL, V18, P6, DOI 10.1159/000111391; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Todd KG, 1999, GLIA, V25, P190, DOI 10.1002/(SICI)1098-1136(19990115)25:2<190::AID-GLIA9>3.0.CO;2-B; Urani A, 1998, BRAIN RES, V799, P64, DOI 10.1016/S0006-8993(98)00469-7; Verma A, 1998, MOL MED, V4, P40, DOI 10.1007/BF03401728; Vowinckel E, 1997, J NEUROSCI RES, V50, P345, DOI 10.1002/(SICI)1097-4547(19971015)50:2<345::AID-JNR22>3.0.CO;2-5; Waters SL, 1997, AM J PHYSIOL-RENAL, V273, pF869; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; ZAVALA F, 1990, J PHARMACOL EXP THER, V255, P442; Zhu WJ, 1997, J NEUROSCI, V17, P4022; Zisterer DM, 1997, GEN PHARMACOL-VASC S, V29, P305, DOI 10.1016/S0306-3623(96)00473-9	62	120	120	1	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2000	161	1					102	114		10.1006/exnr.1999.7269			13	Neurosciences	Neurosciences & Neurology	290FU	WOS:000085666300009	10683277				2021-06-18	
J	Sullivan, PG; Rabchevsky, AG; Hicks, RR; Gibson, TR; Fletcher-Turner, A; Scheff, SW				Sullivan, PG; Rabchevsky, AG; Hicks, RR; Gibson, TR; Fletcher-Turner, A; Scheff, SW			Dose-response curve and optimal dosing regimen of cyclosporin A after traumatic brain injury in rats	NEUROSCIENCE			English	Article						mitochondria; neuroprotective agents; fluid percussion; neurotrauma; immunosuppression; cortical contusion	CENTRAL-NERVOUS-SYSTEM; MITOCHONDRIAL PERMEABILITY TRANSITION; TRANSIENT FOREBRAIN ISCHEMIA; LATERAL FLUID-PERCUSSION; EXCITATORY AMINO-ACIDS; METHYL-D-ASPARTATE; HIPPOCAMPAL-NEURONS; CORTICAL CONTUSION; NMDA RECEPTORS; CELL-DEATH	Acute neuropathology following experimental traumatic brain injury results in the rapid necrosis of cortical tissue at the site of injury. This primary injury is exacerbated in the ensuing hours and days via the progression of secondary injury mechanism(s) leading to significant neurological dysfunction, Recent evidence from our laboratory demonstrates that the immunosuppressant cyclosporin A significantly ameliorates cortical damage following traumatic brain injury. The present study extends the previous findings utilizing a unilateral controlled cortical impact model of traumatic brain injury in order to establish a dose-response curve and optimal dosing regimen of cyclosporin A. Following injury to adult rats, cyclosporin A was administrated at various dosages and the therapy was initiated at different times post-injury. In addition to examining the effect of cyclosporin A on the acute disruption of the blued-brain barrier following controlled cortical impact, we also assessed the efficacy of cyclosporin A to reduce tissue damage utilizing the fluid percussion model of traumatic brain injury. The findings demonstrate that the neuroprotection afforded by cyclosporin A is dose-dependent and that a therapeutic window exists up to 24 h post-injury. Furthermore, the optimal cyclosporin dosage and regimen markedly reduces disruption of the blood-brain barrier acutely following a cortical contusion injury, and similarly affords significant neuroprotection following fluid percussion injury. These findings clearly suggest that the mechanisms responsible for tissue necrosis following traumatic brain injury are amenable to pharmacological intervention. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98102 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.		Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline		ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BELAYEV L, 1995, BRAIN RES, V702, P266, DOI 10.1016/0006-8993(95)01127-9; BERDEN JHM, 1985, LANCET, V1, P219; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; Choi D W, 1990, Adv Exp Med Biol, V268, P501; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; Dessi F, 1995, NEUROSCI LETT, V201, P53, DOI 10.1016/0304-3940(95)12128-Q; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Du C, 1996, J NEUROTRAUM, V13, P215, DOI 10.1089/neu.1996.13.215; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; DUGAN LL, 1995, J NEUROSCI, V15, P6377; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAMIGLIO L, 1989, TRANSPLANTATION, V48, P316, DOI 10.1097/00007890-198908000-00025; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friberg H, 1998, J NEUROSCI, V18, P5151; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Kochi S, 1999, EUR J PHARMACOL, V372, P287, DOI 10.1016/S0014-2999(99)00247-2; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; Kristal BS, 1997, J NEUROCHEM, V69, P524; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McNair ND, 1999, NURS CLIN N AM, V34, P637; Miller RD, 1996, J NEUROL SCI, V136, P37, DOI 10.1016/0022-510X(95)00309-P; NAG S, 1992, ACTA NEUROPATHOL, V84, P471, DOI 10.1007/BF00304465; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Povlishock J T, 1992, Hum Cell, V5, P345; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Prehn JHM, 1998, N-S ARCH PHARMACOL, V357, P316, DOI 10.1007/PL00005173; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; Scanlon JM, 1998, J NEUROCHEM, V71, P2392; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; STEVENS MK, 1990, J CEREBR BLOOD F MET, V10, P77, DOI 10.1038/jcbfm.1990.10; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 1999, J NEUROSCI, V19, P6248; THAYER SA, 1995, CLIN EXP PHARMACOL P, V22, P303, DOI 10.1111/j.1440-1681.1995.tb02004.x; Tibbs RE, 1998, ANAT REC, V253, P167; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WALKER RW, 1988, NEUROL CLIN, V6, P261, DOI 10.1016/S0733-8619(18)30869-7; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; White RJ, 1996, J NEUROSCI, V16, P5688; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; ZAIDAN E, 1994, J NEUROCHEM, V63, P1812	70	120	127	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	101	2					289	295		10.1016/S0306-4522(00)00380-8			7	Neurosciences	Neurosciences & Neurology	378BX	WOS:000165562800004	11074152				2021-06-18	
J	WEBB, CR; WRIGLEY, M; YOELS, W; FINE, PR				WEBB, CR; WRIGLEY, M; YOELS, W; FINE, PR			EXPLAINING QUALITY-OF-LIFE FOR PERSONS WITH TRAUMATIC BRAIN INJURIES 2 YEARS AFTER INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SPINAL-CORD INJURY; HEAD-INJURY; REHABILITATION; DISABILITY; PREDICTION; ADMISSION; HANDICAP; OUTCOMES; DISTRESS	Objective: To model the complex effects of demographic, psychosocial, physical, and rehabilitation variables on quality of life 2 years after hospital discharge. Design: Medical record and longitudinal survey data on traumatic brain injury (TBI) survivors who did or did not receive formal rehabilitation services after being injured were analyzed. Setting: The study sample was selected from a representative sample of hospitals in north-central Alabama. Participants: Criteria for inclusion were: (1) 18 years and older with TBI; (2) discharged after hospital stay of 3 or more days; and (3) resided and injured in Alabama. There were 293 persons eligible for the 24-month follow-up survey, 186 (63%) of whom participated; the focus was on the 116 persons (of 186) who responded to the surveys themselves. Main Outcome Measure: A causal model of hypothesized direct and indirect effects of several variables on quality of life outcomes. Results: Employment was the strongest contributor of improved quality of life. Persons unable to pay for health care showed less improvement in functional independence 12 to 24 months postinjury and reported a poorer quality of life. The psychosocial variables of self-blame and family support improved quality of life by reducing impairments and increasing the likelihood of employment. Family support also improved quality of life by increasing functional independence. Fewer physical impairments and gains in functional independence directly improved quality of life. Conclusion: The interrelationships between psychosocial and physical variables are important when examining quality of life. Interventions are recommended targeting psychosocial variables and functional independence in efforts to improve quality of life. (C) 1995 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	UNIV ALABAMA, INJURY CONTROL RES CTR, BIRMINGHAM, AL 35294 USA					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR403641] Funding Source: Medline		BACH JR, 1994, ARCH PHYS MED REHAB, V75, P626, DOI 10.1016/0003-9993(94)90183-X; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BULMAN RJ, 1977, J PERS SOC PSYCHOL, V35, P351, DOI 10.1037/0022-3514.35.5.351; Chase B W, 1990, Int J Rehabil Res, V13, P325, DOI 10.1097/00004356-199012000-00006; CLAYTON KS, 1994, ARCH PHYS MED REHAB, V75, P633, DOI 10.1016/0003-9993(94)90184-8; COBB N, 1990, ARCH PHYS MED REHAB, V11, P330; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DEVIVO MJ, 1987, ARCH PHYS MED REHAB, V68, P494; Drewes A M, 1989, Int Disabil Stud, V11, P178; ENSEL WM, 1991, J HEALTH SOC BEHAV, V32, P321, DOI 10.2307/2137101; FABIAN ES, 1991, REHABIL COUNS BULL, V34, P344; FRATTALI CM, 1992, APHASIOLOGY, V6, P63, DOI 10.1080/02687039208248577; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HOSUE JS, 1985, SOCIAL SUPPORT HLTH, P83; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; JOHNSTON MV, 1991, AM J PHYS MED REHAB, V70, P40, DOI 10.1097/00002060-199102000-00008; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; KARPMAN T, 1985, J APPL REHABILITATIO, V17, P28; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KIM J, 1975, STATISTICAL PACKAGE, P383; Koehler M L, 1989, Rehabil Nurs, V14, P9; KOSKA MT, 1988, HOSPITALS, V62, P63; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KRAUSE JS, 1987, REHABIL PSYCHOL, V32, P205; KWASNICA CM, 1994, ARCH PHYS MED REHAB, V75, P384, DOI 10.1016/0003-9993(94)90159-7; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LUNDQVIST C, 1991, SPINE, V16, P78, DOI 10.1097/00007632-199101000-00014; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Nieves C C, 1991, Rehabil Nurs, V16, P129; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OLSON DH, 1979, FAM PROCESS, V18, P3, DOI 10.1111/j.1545-5300.1979.00003.x; PATRICK DL, 1990, ANNU REV PUBL HEALTH, V11, P165; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SHOLOMSKAS DE, 1990, J APPL SOC PSYCHOL, V20, P548, DOI 10.1111/j.1559-1816.1990.tb00427.x; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; TATE D, 1994, AM J PHYS MED REHAB, V73, P175, DOI 10.1097/00002060-199406000-00006; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519	47	120	122	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1995	76	12					1113	1119		10.1016/S0003-9993(95)80118-9			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	TJ667	WOS:A1995TJ66700004	8540786				2021-06-18	
J	UOMOTO, JM; ESSELMAN, PC				UOMOTO, JM; ESSELMAN, PC			TRAUMATIC BRAIN INJURY AND CHRONIC PAIN - DIFFERENTIAL TYPES AND RATES BY HEAD-INJURY SEVERITY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURIES; HEADACHE; INTRACTABLE; PAIN	SYMPTOMS			UOMOTO, JM (corresponding author), UNIV WASHINGTON,SCH MED,DEPT REHABIL MED,RJ-30,SEATTLE,WA 98195, USA.		Uomoto, Jay/AAF-4809-2019				ANDERSON JM, 1990, ARCH PHYS MED REHAB, V71, P703; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CARTLIDGE NEF, 1981, MAJOR PROBLEMS NEURO, V10, P95; COSGROVE JL, 1989, AM J PHYS MED REHAB, V68, P15, DOI 10.1097/00002060-198902000-00005; HORN LJ, 1990, REHABILITATION ADULT, P107; LIDVALL HF, 1974, ACTA NEUROL SCAND S, V56, P7; NORRIS SH, 1983, J BONE JOINT SURG BR, V65, P608; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWBOTHAM GF, 1941, COMPLICATIONS SEQUEL, V205, P379; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; TEASDALE G, 1974, LANCET, V2, P81; UOMOTO JM, 1990, HDB PHYSICAL MED REH, P1252; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950	14	120	120	1	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1993	74	1					61	64					4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	KF917	WOS:A1993KF91700012	8420522				2021-06-18	
J	DENNIS, M; BARNES, MA				DENNIS, M; BARNES, MA			KNOWING THE MEANING, GETTING THE POINT, BRIDGING THE GAP, AND CARRYING THE MESSAGE - ASPECTS OF DISCOURSE FOLLOWING CLOSED HEAD-INJURY IN CHILDHOOD AND ADOLESCENCE	BRAIN AND LANGUAGE			English	Article										DENNIS, M (corresponding author), HOSP SICK CHILDREN,DEPT PSYCHOL,DUNDAS SUITE,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.						ABELSON RP, 1981, AM PSYCHOL, V36, P715, DOI 10.1037/0003-066X.36.7.715; ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; ANDREWS J, 1986, COMMUN COGNITION, V19, P281; ASSAL G, 1973, NEUROCHIRURGIE, V19, P399; Baddeley A. D., 1987, WORKING MEMORY; BOLLER F, 1979, AUDITORY COMPREHENSI; Bowey J., 1984, METALINGUISTIC AWARE, V15, P73; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; COMETA MS, 1978, CHILD DEV, V49, P649, DOI 10.1111/j.1467-8624.1978.tb02365.x; DENNIS M, 1980, LANGUAGE DEV APHASIA, P45; DENNIS M, 1990, DISCOURSE ABILITY BR, P199; DENNIS M, 1989, CLIN NEUROPSYCHOL, V3, P203; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1985, SPEECH LANGUAGE EVAL, P71; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; GLUCKSBERG S, 1989, METAPHOR SYMB ACT, V4, P125, DOI 10.1207/s15327868ms0403_2; GOLDMAN R, 1974, GOLDMANFRISTOEWOODCO; Guttmann E, 1942, BRAIN, V65, P205, DOI 10.1093/brain/65.2.205; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; Holland A., 1982, CLIN APH P C, P345; JOHNSON J, 1989, J EXP CHILD PSYCHOL, V48, P1, DOI 10.1016/0022-0965(89)90038-6; JONES J, 1989, LEARN DISABILITY Q, V12, P251, DOI 10.2307/1510208; Keil F. C., 1979, SEMANTIC CONCEPTUAL; KEIL FC, 1986, COGNITIVE DEV, V1, P73, DOI 10.1016/S0885-2014(86)80024-7; KEYSAR B, 1989, J MEM LANG, V28, P375, DOI 10.1016/0749-596X(89)90017-X; KOGAN N, 1980, MONOGR SOC RES CHILD, V45, P1, DOI 10.2307/1165832; LEVIN HS, 1979, CHILD BRAIN, V5, P281; MACKAY DG, 1970, ADV PSYCHOLINGUIST, P76; MCCLELLAND JL, 1987, ATTENTION PERFORM, V12, P3; Miller G.A., 1979, METAPHOR THOUGHT, V1st, P202, DOI DOI 10.1017/CBO9781139173865.019; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; MISTLERLACHMAN JL, 1972, J VERB LEARN VERB BE, V11, P614, DOI 10.1016/S0022-5371(72)80045-8; NIEBERGALL G, 1974, Z KINDER JUGENDPSYCH, V2, P1; OELSCHLAEGER ML, 1974, J COMMUN DISORD, V9, P281; Olson D., 1983, WRITING FOCUS, P291; OLSON DR, 1988, METAPHOR SYMB ACT, V3, P215, DOI 10.1207/s15327868ms0304_2; ORTONY A, 1979, PSYCHOL REV, V86, P161, DOI 10.1037/0033-295X.86.3.161; PALERMO DS, 1989, ADV CHILD DEV BEHAV, V21, P269, DOI 10.1016/S0065-2407(08)60290-6; SATZ P, 1981, ACQUIRED APHASIA, P399; Schank R., 1977, SCRIPTS PLANS GOALS; Schank RC, 1982, DYNAMIC MEMORY; SCHANK RC, 1989, CURR CONTENTS, V38, P14; Secord, 1989, TEST LANGUAGE COMPET; Spreen O, 1969, NEUROSENSORY CTR COM; SWINNEY DA, 1979, J VERB LEARN VERB BE, V18, P645, DOI 10.1016/S0022-5371(79)90355-4; THOMPSON JG, 1985, CHILD DEV, V56, P1134, DOI 10.1111/j.1467-8624.1985.tb00182.x; VANDONGEN HR, 1977, CORTEX, V13, P131, DOI 10.1016/S0010-9452(77)80004-X; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wiig E. H., 1988, NEUROPSYCHOLOGICAL S, P186; WIIG EH, 1978, PERCEPT MOTOR SKILL, V46, P959, DOI 10.2466/pms.1978.46.3.959; Winner E., 1988, POINT WORDS CHILDREN; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; YUILL N, 1989, BRIT J PSYCHOL, V80, P351, DOI 10.1111/j.2044-8295.1989.tb02325.x	55	120	120	0	3	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0093-934X			BRAIN LANG	Brain Lang.	OCT	1990	39	3					428	446		10.1016/0093-934X(90)90149-B			19	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	EM337	WOS:A1990EM33700006	2285861				2021-06-18	
J	Stanley, D; Mason, LJ; Mackin, KE; Srilchanta, YN; Lyras, D; Prakash, MD; Nurgali, K; Venegas, A; Hill, MD; Moore, RJ; Wong, CHY				Stanley, Dragana; Mason, Linda J.; Mackin, Kate E.; Srilchanta, Yogitha N.; Lyras, Dena; Prakash, Monica D.; Nurgali, Kulmira; Venegas, Andres; Hill, Michael D.; Moore, Robert J.; Wong, Connie H. Y.			Translocation and dissemination of commensal bacteria in post-stroke infection	NATURE MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; VENTILATOR-ASSOCIATED PNEUMONIA; CENTRAL-NERVOUS-SYSTEM; STAPHYLOCOCCUS-AUREUS; ASPIRATION PNEUMONIA; STROKE; COMPLICATIONS; DYSFUNCTION; RESISTANCE; MICROBIOTA	Bacterial infection is highly prevalent in patients who have had a stroke. Despite the potential contribution of micro-aspiration in post-stroke pneumonia, we found that the majority of the microorganisms detected in the patients who developed infections after having a stroke were common commensal bacteria that normally reside in the intestinal tracts. In a mouse model of ischemic stroke, post-stroke infection was only observed in mice that were born and raised in specific-pathogen-free facilities; this was not seen in mice that were born and raised in germ-free facilities. Using high-throughput 16S rRNA gene amplicon sequencing and bioinformatics analyses, we provide evidence demonstrating that the source of the bacteria forming the microbial community in the lungs of post-stroke mice was indeed the host small intestine. Additionally, stroke-induced gut barrier permeability and dysfunction preceded the dissemination of orally inoculated bacteria to peripheral tissues. This study identifies a novel pathway in which stroke promotes the translocation and dissemination of selective strains of bacteria that originated from the host gut microbiota.	[Stanley, Dragana] Cent Queensland Univ, Sch Med & Appl Sci, Rockhampton, Qld, Australia; [Mason, Linda J.] Monash Univ, Dept Biochem, Clayton, Vic, Australia; [Mackin, Kate E.; Srilchanta, Yogitha N.; Lyras, Dena; Moore, Robert J.] Monash Univ, Monash Biomed Discovery Inst, Infect & Immun Program, Clayton, Vic, Australia; [Mackin, Kate E.; Srilchanta, Yogitha N.; Lyras, Dena; Moore, Robert J.] Monash Univ, Dept Microbiol, Clayton, Vic, Australia; [Prakash, Monica D.; Nurgali, Kulmira] Victoria Univ, Coll Hlth & Biomed, Ctr Chron Dis, St Albans, Vic, Australia; [Venegas, Andres; Hill, Michael D.] Univ Calgary, Dept Clin Neurosci, Stroke Unit, Calgary, AB, Canada; [Venegas, Andres; Hill, Michael D.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Moore, Robert J.] RMIT Univ, Sch Sci, Bundoora, Vic, Australia; [Wong, Connie H. Y.] Monash Univ, Sch Clin Sci, Dept Med, Ctr Inflammatory Dis, Clayton, Vic, Australia	Wong, CHY (corresponding author), Monash Univ, Sch Clin Sci, Dept Med, Ctr Inflammatory Dis, Clayton, Vic, Australia.	connie.wong@monash.edu	Moore, Robert J./D-8352-2011; Prakash, Monica/AAK-1548-2021; Hill, Michael D/C-9073-2012; Stanley, Dragana/AAC-2596-2020	Moore, Robert J./0000-0002-0776-5861; Hill, Michael D/0000-0002-6269-1543; Stanley, Dragana/0000-0001-7019-4726; Wong, Connie/0000-0002-9020-1847; Lyras, Dena/0000-0003-2345-9271; Nurgali, Kulmira/0000-0002-2597-6929; Prakash, Monica/0000-0002-2814-7560; Srikhanta, Yogitha/0000-0002-7513-9969	Australia Research Council (ARC)Australian Research Council; Australian National Heart Foundation (NHF)National Heart Foundation of Australia; Australian National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; Alberta Innovates [201300690] Funding Source: researchfish	We thank the staff at Monash Animal Research Facilities, Monash Micromon, Monash Micro Imaging and Monash Histology Platform, which are managed by Monash University The bioinformatics data was analyzed using the Isaac Newton high-performance computing system at Central Queensland University We wish to acknowledge the help from J. Bell that was provided for all aspects of the high-performance computing. We thank E.A. Palombo (Swinburne University of Technology) for providing a streptomycin-resistant derivative of the E. coli strain ATCC700927 (EDL933), designated DLL206. The work was supported by the Australia Research Council (ARC) (D.S. and C.H.Y.W.), the Australian National Heart Foundation (NHF) (C.H.Y.W.) and the Australian National Health and Medical Research Council (NHMRC) (C.H.Y.W.).	Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Benakis C, 2016, NAT MED, V22, P516, DOI 10.1038/nm.4068; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Furness JB, 2012, NAT REV GASTRO HEPAT, V9, P286, DOI 10.1038/nrgastro.2012.32; Gauguet S, 2015, INFECT IMMUN, V83, P4003, DOI 10.1128/IAI.00037-15; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hannawi Y, 2013, CEREBROVASC DIS, V35, P430, DOI 10.1159/000350199; Hill LT, 2013, NUTRITION, V29, P948, DOI 10.1016/j.nut.2012.12.023; Ho PL, 2009, CHEST, V136, P1119, DOI 10.1378/chest.09-0285; Kalra L, 2015, LANCET, V386, P1835, DOI 10.1016/S0140-6736(15)00126-9; Knights D, 2011, NAT METHODS, V8, P761, DOI 10.1038/nmeth.1650; Langhorne P, 2000, STROKE, V31, P1223, DOI 10.1161/01.STR.31.6.1223; Lopez NE, 2012, J TRAUMA ACUTE CARE, V72, P1562, DOI 10.1097/TA.0b013e3182569875; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Marik PE, 1999, CHEST, V115, P178, DOI 10.1378/chest.115.1.178; Martinez RM, 2014, J CLIN MICROBIOL, V52, P30, DOI 10.1128/JCM.02072-13; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Menuet Magalie, 2008, J Med Case Rep, V2, P373, DOI 10.1186/1752-1947-2-373; Messika J, 2012, INTENS CARE MED, V38, P2007, DOI 10.1007/s00134-012-2699-5; Miller RF, 2005, INT J STD AIDS, V16, P763, DOI 10.1258/095646205774763243; Pavlov VA, 2003, MOL MED, V9, P125, DOI 10.1007/BF03402177; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Sheth K, 2001, Curr Opin Crit Care, V7, P99, DOI 10.1097/00075198-200104000-00008; Stechmiller J K, 1997, Am J Crit Care, V6, P204; Ulluwishewa D, 2011, J NUTR, V141, P769, DOI 10.3945/jn.110.135657; Umar Shahid, 2010, Curr Gastroenterol Rep, V12, P340, DOI 10.1007/s11894-010-0130-3; Valentine S., 2013, EXAMINATION BEHAV BA; Westendorp WF, 2015, LANCET, V385, P1519, DOI 10.1016/S0140-6736(14)62456-9; Westendorp WF, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-110; Winek K, 2016, STROKE, V47, P1354, DOI 10.1161/STROKEAHA.115.011800; Wong CHY, 2013, NAT IMMUNOL, V14, P785, DOI 10.1038/ni.2631; Wong CHY, 2011, SCIENCE, V334, P101, DOI 10.1126/science.1210301	35	119	129	13	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2016	22	11					1277	1284		10.1038/nm.4194			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	EB3XK	WOS:000387302300020	27694934				2021-06-18	
J	Iverson, GL; Silverberg, ND; Mannix, R; Maxwell, BA; Atkins, JE; Zafonte, R; Berkner, PD				Iverson, Grant L.; Silverberg, Noah D.; Mannix, Rebekah; Maxwell, Bruce A.; Atkins, Joseph E.; Zafonte, Ross; Berkner, Paul D.			Factors Associated With Concussion-like Symptom Reporting in High School Athletes	JAMA PEDIATRICS			English	Article							SPORTS-RELATED CONCUSSION; BASE-LINE VALUES; NEUROCOGNITIVE PERFORMANCE; SEX-DIFFERENCES; MANAGEMENT; RECOVERY; CONSEQUENCES; HISTORY; STRESS; INJURY	IMPORTANCE Every state in the United States has passed legislation for sport-related concussion, making this health issue important for physicians and other health care professionals. Safely returning athletes to sport after concussion relies on accurately determining when their symptoms resolve. OBJECTIVE To evaluate baseline concussion-like symptom reporting in uninjured adolescent student athletes. DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional, observational study, we studied 31 958 high school athletes from Maine with no concussion in the past 6 months who completed a preseason baseline testing program between 2009 and 2013. RESULTS Symptom reporting was more common in girls than boys. Most students with preexisting conditions reported one or more symptoms (60%-82% of boys and 73%-97% of girls). Nineteen percent of boys and 28% of girls reported having a symptom burden resembling an International Classification of Diseases, 10th Revision (ICD-10) diagnosis of postconcussional syndrome (PCS). Students with preexisting conditions were even more likely to endorse a symptom burden that resembled PCS (21%-47% for boys and 33%-72% for girls). Prior treatment of a psychiatric condition was the strongest independent predictor for symptom reporting in boys, followed by a history of migraines. For girls, the strongest independent predictors were prior treatment of a psychiatric condition or substance abuse and attention-deficit/hyperactivity disorder. The weakest independent predictor of symptoms for both sexes was history of prior concussions. CONCLUSIONS AND RELEVANCE In the absence of a recent concussion, symptom reporting is related to sex and preexisting conditions. Consideration of sex and preexisting health conditions can help prevent misinterpretation of symptoms in student athletes who sustain a concussion.	[Iverson, Grant L.; Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Massachusetts Gen Hosp, Children Sports Concuss Program, Boston, MA 02114 USA; [Iverson, Grant L.; Zafonte, Ross] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Maxwell, Bruce A.] Colby Coll, Dept Comp Sci, Waterville, ME 04901 USA; [Atkins, Joseph E.] Colby Coll, Dept Psychol, Waterville, ME USA; [Berkner, Paul D.] Colby Coll, Hlth Serv, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Dept Biol, Waterville, ME 04901 USA	Iverson, GL (corresponding author), Harvard Univ, Sch Med, Ctr Hlth & Rehabil, Dept Phys Med & Rehabil, 79-96 13th St Charlestown Navy Yard, Charlestown, MA 02129 USA.	giverson@mgh.harvard.edu	Mannix, Rebekah/AAD-8702-2020	Iverson, Grant/0000-0001-7348-9570	Goldfarb Center for Public Policy and Civic Engagement/Colby College; Bill and Joan Alfond Foundation; Harvard Integrated Program to Protect and Improve the Health of National Football League Players Association Members; Mooney-Reed Charitable Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	This study was supported by the Goldfarb Center for Public Policy and Civic Engagement/Colby College, the Bill and Joan Alfond Foundation, the Harvard Integrated Program to Protect and Improve the Health of National Football League Players Association Members (Dr Zafonte), and the Mooney-Reed Charitable Foundation (Drs Iverson and Zafonte).	Albinson CB, 2003, J SPORT REHABIL, V12, P306, DOI 10.1123/jsr.12.4.306; Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, pix; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Gershon J, 2002, J Atten Disord, V5, P143, DOI 10.1177/108705470200500302; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; ImPACT Applications Inc, 2007, IMPACT IMM POSTC ASS; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Shuer ML, 1997, WESTERN J MED, V166, P104; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	40	119	119	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	DEC	2015	169	12					1132	1140		10.1001/jamapediatrics.2015.2374			9	Pediatrics	Pediatrics	CY3UE	WOS:000366334600017	26457403	Green Accepted, Bronze			2021-06-18	
J	Rice, RA; Spangenberg, EE; Yamate-Morgan, H; Lee, RJ; Arora, RPS; Hernandez, MX; Tenner, AJ; West, BL; Green, KN				Rice, Rachel A.; Spangenberg, Elizabeth E.; Yamate-Morgan, Hana; Lee, Rafael J.; Arora, Rajan P. S.; Hernandez, Michael X.; Tenner, Andrea J.; West, Brian L.; Green, Kim N.			Elimination of Microglia Improves Functional Outcomes Following Extensive Neuronal Loss in the Hippocampus	JOURNAL OF NEUROSCIENCE			English	Article						behavior; glia; inflammation; lesion; spines; synapse	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; TAU PATHOLOGY; IN-VIVO; CELLS; MICE; EXPRESSION; MONOCYTES; MODEL; MEMORY	With severe injury or disease, microglia become chronically activated and damage the local brain environment, likely contributing to cognitive decline. We previously discovered that microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for survival in the healthy adult brain, and we have exploited this dependence to determine whether such activated microglia contribute deleteriously to functional recovery following a neuronal lesion. Here, we induced a hippocampal lesion in mice for 25 d via neuronal expression of diphtheria toxin A-chain, producing both a neuroinflammatory reaction and behavioral alterations. Following the 25 d lesion, we administered PLX3397, a CSF1R inhibitor, for 30 d to eliminate microglia. This post-lesion treatment paradigm improved functional recovery on elevated plus maze and Morris water maze, concomitant with reductions in elevated proinflammatory molecules, as well as normalization of lesion-induced alterations in synaptophysin and PSD-95. Further exploration of the effects of microglia on synapses in a second cohort of mice revealed that dendritic spine densities are increased with long-term microglial elimination, providing evidence that microglia shape the synaptic landscape in the adult mouse brain. Furthermore, in these same animals, we determined that microglia play a protective role during lesioning, whereby neuronal loss was potentiated in the absence of these cells. Collectively, we demonstrate that microglia exert beneficial effects during a diphtheria toxin-induced neuronal lesion, but impede recovery following insult.	[Rice, Rachel A.; Spangenberg, Elizabeth E.; Yamate-Morgan, Hana; Lee, Rafael J.; Arora, Rajan P. S.; Hernandez, Michael X.; Tenner, Andrea J.; Green, Kim N.] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Dept Neurobiol & Behav, Irvine, CA 92697 USA; [West, Brian L.] Plexxikon Inc, Berkeley, CA 94710 USA	Green, KN (corresponding author), Univ Calif Irvine, 3208 Biol Sci 3, Irvine, CA 92697 USA.	kngreen@uci.edu		West, Brian/0000-0002-5320-3691	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS083801, P50 AG016573, F31NS086409, PPG AG 00538, T32 AG000096]; Whitehall Foundation; American Federation of Aging Research; Alzheimer's AssociationAlzheimer's Association; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS086409, R01NS083801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000096, P50AG016573, P01AG000538] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health under awards 1R01NS083801 (NINDS) and P50 AG016573 (NIA) to K.N.G., F31NS086409 (NINDS) to R.A.R., PPG AG 00538 (NIA) to A.J.T., T32 AG000096 (NIA) to M.X.H., the Whitehall Foundation to K.N.G., American Federation of Aging Research to K.N.G., and the Alzheimer's Association to K.N.G. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Baglietto-Vargas D, 2013, BIOL PSYCHIAT, V74, P357, DOI 10.1016/j.biopsych.2012.12.003; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Butovsky O, 2012, J CLIN INVEST, V122, P3063, DOI 10.1172/JCI62636; Castello NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091453; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Erblich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026317; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Fiala M, 2002, EUR J CLIN INVEST, V32, P360, DOI 10.1046/j.1365-2362.2002.00994.x; Gao L, 2015, J EXP MED, V212, P469, DOI 10.1084/jem.20132423; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Ji K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056293; Kitazawa M, 2011, J IMMUNOL, V187, P6539, DOI 10.4049/jimmunol.1100620; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; Lee P, 1998, P NATL ACAD SCI USA, V95, P11371, DOI 10.1073/pnas.95.19.11371; Liu JSH, 1998, J IMMUNOL, V161, P1989; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Myczek K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106009; Neely KM, 2011, J NEUROSCI, V31, P2781, DOI 10.1523/JNEUROSCI.5156-10.2010; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Perry VH, 2010, ASN NEURO, V2, P281, DOI 10.1042/AN20100024; Pessac B, 2001, B ACAD NAT MED PARIS, V185, P337, DOI 10.1016/S0001-4079(19)34561-3; PETERS A, 1970, AM J ANAT, V127, P321, DOI 10.1002/aja.1001270402; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; RENNO T, 1995, J IMMUNOL, V154, P944; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schilling M, 2009, NEUROSCIENCE, V161, P806, DOI 10.1016/j.neuroscience.2009.04.025; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Valero J, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00083; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wirenfeldt M, 2005, J NEUROSCI RES, V82, P507, DOI 10.1002/jnr.20659; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Yamasaki TR, 2007, J NEUROSCI, V27, P11925, DOI 10.1523/JNEUROSCI.1627-07.2007; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Zhan Y, 2014, NAT NEUROSCI, V17, P400, DOI 10.1038/nn.3641	39	119	123	1	21	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 8	2015	35	27					9977	9989		10.1523/JNEUROSCI.0336-15.2015			13	Neurosciences	Neurosciences & Neurology	CN2LT	WOS:000358253400018	26156998	Green Published, Bronze			2021-06-18	
J	Jiang, T; Yu, JT; Tian, Y; Tan, L				Jiang, Teng; Yu, Jin-Tai; Tian, Yan; Tan, Lan			Epidemiology and Etiology of Alzheimer's disease: From Genetic to Non-Genetic Factors	CURRENT ALZHEIMER RESEARCH			English	Article						Alzheimer's disease; epidemiology; etiology; risk factor; genetic; environmental	MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; TRAUMATIC BRAIN-INJURY; BODY-MASS INDEX; CARDIOVASCULAR RISK-FACTORS; LIFE ASSOCIATED REGULATION; FREQUENCY MAGNETIC-FIELDS; APOLIPOPROTEIN-E GENOTYPE; TOTAL CHOLESTEROL LEVEL; OCCUPATIONAL-EXPOSURE	At present, the etiology of Alzheimer's disease (AD) is still unclear, but both genetic and non-genetic factors are thought to take part in the etiopathogenesis of AD. Epidemiologic researches revealed that genetic factors played a decisive role in the development of both early-onset AD (EOAD) and late-onset AD (LOAD). The mutations in APP, PSEN1 and PSEN2 are inherited in a Mendelian fashion and directly lead to the EOAD, while recent genome-wide association studies have identified numbers of risky genes, which influences the susceptibility to LOAD. Although genetic factors are inherited and fixed, non-genetic factors, such as occupational exposures (exposure to pesticides, electromagnetic fields, organic solvents and volatile anesthetics), pre-existing medical conditions (cerebrovascular disease, hypertension, diabetes, dyslipidemia, traumatic brain injury, depression and cancer) and lifestyle factors (smoking, consumptions of alcohol and coffee, body mass index, physical activity and cognitive activity), are partly environmentally-determined. Timely interventions targeted at these non-genetic risk factors may offer opportunities for prevention and treatment of AD. In the future, more high-quality and large-sample epidemiologic studies are needed to identify risk factors for AD, and the interaction models between genetic and non-genetic risk factors required further investigation. In addition, public health campaigns targeted at modification of non-genetic risk factors should be developed among population at high risk of AD.	[Jiang, Teng; Yu, Jin-Tai; Tan, Lan] Nanjing Med Univ, Qingdao Municipal Hosp, Dept Neurol, Nanjing, Peoples R China; [Yu, Jin-Tai; Tian, Yan; Tan, Lan] Qingdao Univ, Sch Med, Qingdao Municipal Hosp, Dept Neurol, Qingdao 266071, Shandong, Peoples R China; [Yu, Jin-Tai; Tan, Lan] Ocean Univ China, Coll Med & Pharmaceut, Qingdao, Peoples R China	Yu, JT (corresponding author), Qingdao Univ, Sch Med, Qingdao Municipal Hosp, Dept Neurol, 5 Donghai Middle Rd, Qingdao 266071, Shandong, Peoples R China.	yu-jintai@163.com; dr.tanlan@163.com		Yu, Jin-Tai/0000-0002-7686-0547	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81000544, 81171209]; Shandong Provincial Natural Science Foundation, ChinaNatural Science Foundation of Shandong Province [ZR2010HQ004, ZR2011HZ001]; Shandong Provincial Outstanding Medical Academic Professional Program	This work was supported by grants from the National Natural Science Foundation of China (81000544, 81171209), the Shandong Provincial Natural Science Foundation, China (ZR2010HQ004, ZR2011HZ001) and the Shandong Provincial Outstanding Medical Academic Professional Program.	Abraham R, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-44; Akbaraly TN, 2009, NEUROLOGY, V73, P854, DOI 10.1212/WNL.0b013e3181b7849b; Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Alim I, 2010, BRAIN RES, V1330, P72, DOI 10.1016/j.brainres.2010.02.076; Allan LM, 2007, J NEUROL NEUROSUR PS, V78, P671, DOI 10.1136/jnnp.2006.102343; Alzheimers Assoc, 2012, ALZHEIMERS DEMENT, V8, P131, DOI 10.1016/j.jalz.2012.02.001; Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x; Anstey KJ, 2008, AM J GERIAT PSYCHIAT, V16, P343, DOI 10.1097/JGP.0b013e31816b72d4; Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116; Anttila T, 2004, BMJ-BRIT MED J, V329, P539, DOI 10.1136/bmj.38181.418958.BE; Arendash GW, 2006, NEUROSCIENCE, V142, P941, DOI 10.1016/j.neuroscience.2006.07.021; Arvanitakis Z, 2011, STROKE, V42, P722, DOI 10.1161/STROKEAHA.110.595082; Ashford JW, 2002, J ALZHEIMERS DIS, V4, P169, DOI 10.3233/JAD-2002-4307; Avidan MS, 2011, J ALZHEIMERS DIS, V24, P201, DOI 10.3233/JAD-2011-101680; BAKER EL, 1994, J OCCUP ENVIRON MED, V36, P1079, DOI 10.1097/00043764-199410000-00010; Baldi I, 2003, AM J EPIDEMIOL, V157, P409, DOI 10.1093/aje/kwf216; Barnes DE, 2012, ARCH GEN PSYCHIAT, V69, P493, DOI 10.1001/archgenpsychiatry.2011.1481; Beecham GW, 2009, AM J HUM GENET, V84, P35, DOI 10.1016/j.ajhg.2008.12.008; Behrens MI, 2009, CURR ALZHEIMER RES, V6, P196, DOI 10.2174/156720509788486608; Belleville J, 2002, NUTRITION, V18, P173, DOI 10.1016/S0899-9007(01)00721-3; Bennett DA, 2012, CURR ALZHEIMER RES, V9, P628; Bertram L, 2008, AM J HUM GENET, V83, P623, DOI 10.1016/j.ajhg.2008.10.008; Bilotta F, 2010, J ALZHEIMERS DIS, V22, pS81, DOI 10.3233/JAD-2010-100825; BLAIN PG, 1990, ADVERSE DRUG REACT T, V9, P37; Blum S, 2012, NEUROLOGY, V78, P38, DOI 10.1212/WNL.0b013e31823ed0cc; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Brown BM, 2013, MOL PSYCHIATR, V18, P875, DOI 10.1038/mp.2012.107; Buchman AS, 2012, NEUROLOGY, V78, P1323, DOI 10.1212/WNL.0b013e3182535d35; Cai H, 2012, CURR ALZHEIMER RES, V9, P5, DOI 10.2174/156720512799015064; Cao CH, 2012, J ALZHEIMERS DIS, V30, P559, DOI 10.3233/JAD-2012-111781; Cao CH, 2011, J ALZHEIMERS DIS, V25, P323, DOI 10.3233/JAD-2011-110110; Cao CH, 2009, J ALZHEIMERS DIS, V17, P681, DOI 10.3233/JAD-2009-1071; Caraci F, 2010, EUR J PHARMACOL, V626, P64, DOI 10.1016/j.ejphar.2009.10.022; Carrasquillo MM, 2009, NAT GENET, V41, P192, DOI 10.1038/ng.305; Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925; Cataldo JK, 2010, J ALZHEIMERS DIS, V19, P465, DOI 10.3233/JAD-2010-1240; Chang-Quan H, 2011, INT J CLIN PRACT, V65, P1295, DOI 10.1111/j.1742-1241.2011.02810.x; Chen XS, 2010, J ALZHEIMERS DIS, V20, pS127, DOI 10.3233/JAD-2010-1376; Chua LW, 2009, J ALZHEIMERS DIS, V17, P223, DOI 10.3233/JAD-2009-1043; Coon KD, 2007, J CLIN PSYCHIAT, V68, P613, DOI 10.4088/JCP.v68n0419; Corasaniti M T, 1991, Funct Neurol, V6, P385; Cordonnier C, 2011, BRAIN, V134, P335, DOI 10.1093/brain/awq321; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Craft S, 2012, ARCH NEUROL-CHICAGO, V69, P29, DOI 10.1001/archneurol.2011.233; Davanipour Z, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-13; Davies NM, 2011, J ALZHEIMERS DIS, V26, P699, DOI 10.3233/JAD-2011-110347; Doruk H, 2010, J NUTR HEALTH AGING, V14, P834, DOI 10.1007/s12603-010-0113-y; Dotson VM, 2010, NEUROLOGY, V75, P27, DOI 10.1212/WNL.0b013e3181e62124; Dridi S, 2009, J NUTR BIOCHEM, V20, P831, DOI 10.1016/j.jnutbio.2009.06.003; Driver JA, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1442; Duron E, 2009, AM J HYPERTENS, V22, P1020, DOI 10.1038/ajh.2009.119; Elias PK, 2004, HYPERTENSION, V44, P631, DOI 10.1161/01.HYP.0000145858.07252.99; Eskelinen MH, 2010, J ALZHEIMERS DIS, V20, pS167, DOI 10.3233/JAD-2010-1404; Eskelinen MH, 2009, J ALZHEIMERS DIS, V16, P85, DOI 10.3233/JAD-2009-0920; Feldman HH, 2010, NEUROLOGY, V74, P956, DOI 10.1212/WNL.0b013e3181d6476a; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Finder VH, 2010, J ALZHEIMERS DIS, V22, pS5, DOI 10.3233/JAD-2010-100975; Fitzpatrick AL, 2009, ARCH NEUROL-CHICAGO, V66, P336, DOI 10.1001/archneurol.2008.582; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; Garcia AM, 2008, INT J EPIDEMIOL, V37, P329, DOI 10.1093/ije/dym295; Garcia AM, 2010, J ALZHEIMERS DIS, V20, P577, DOI 10.3233/JAD-2010-1399; Garcia-Alloza M, 2011, BRAIN, V134, P3694, DOI 10.1093/brain/awr300; Garcia-Mesa Y, 2011, J ALZHEIMERS DIS, V24, P421, DOI 10.3233/JAD-2011-101635; Gasparini M, 2002, NEUROL SCI, V23, P11, DOI 10.1007/s100720200017; Gatz M, 2006, ARCH GEN PSYCHIAT, V63, P168, DOI 10.1001/archpsyc.63.2.168; Gatz M, 1997, J GERONTOL A-BIOL, V52, pM117, DOI 10.1093/gerona/52A.2.M117; Gauthier E, 2001, ENVIRON RES, V86, P37, DOI 10.1006/enrs.2001.4254; Gelber RP, 2011, J ALZHEIMERS DIS, V23, P607, DOI 10.3233/JAD-2010-101428; Green RC, 2002, JAMA-J AM MED ASSOC, V287, P329, DOI 10.1001/jama.287.3.329; Grupe A, 2007, HUM MOL GENET, V16, P865, DOI 10.1093/hmg/ddm031; Gun RT, 1997, ALZ DIS ASSOC DIS, V11, P21, DOI 10.1097/00002093-199703000-00005; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Haag MDM, 2009, NEUROLOGY, V72, P1727, DOI 10.1212/01.wnl.0000345062.86148.3f; Haag MDM, 2009, J NEUROL NEUROSUR PS, V80, P13, DOI 10.1136/jnnp.2008.150433; Hamer M, 2009, PSYCHOL MED, V39, P3, DOI 10.1017/S0033291708003681; Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440; Harwood DG, 2010, INT J GERIATR PSYCH, V25, P511, DOI 10.1002/gps.2372; Hayden KM, 2010, NEUROLOGY, V74, P1524, DOI 10.1212/WNL.0b013e3181dd4423; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hebert LE, 2001, ALZ DIS ASSOC DIS, V15, P169, DOI 10.1097/00002093-200110000-00002; Ho AJ, 2010, NEUROBIOL AGING, V31, P1326, DOI 10.1016/j.neurobiolaging.2010.04.006; Hoffman LB, 2009, NEUROLOGY, V72, P1720, DOI 10.1212/01.wnl.0000345881.82856.d5; Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803; Honig LS, 2003, ARCH NEUROL-CHICAGO, V60, P1707, DOI 10.1001/archneur.60.12.1707; Huang WY, 2002, J CLIN EPIDEMIOL, V55, P959, DOI 10.1016/S0895-4356(02)00462-6; Hughes TF, 2009, NEUROLOGY, V72, P1741, DOI 10.1212/WNL.0b013e3181a60a58; Hulse GK, 2005, INT PSYCHOGERIATR, V17, pS109, DOI 10.1017/S1041610205001985; Inaba M, 2011, J AM GERIATR SOC, V59, P1484, DOI 10.1111/j.1532-5415.2011.03490.x; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Jequier E, 2002, ANN NY ACAD SCI, V967, P379, DOI 10.1111/j.1749-6632.2002.tb04293.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kamel F, 2004, ENVIRON HEALTH PERSP, V112, P950, DOI 10.1289/ehp.7135; Kennelly SP, 2009, AGEING RES REV, V8, P61, DOI 10.1016/j.arr.2008.11.001; KIMBROUGH RD, 1971, ARCH ENVIRON HEALTH, V22, P460, DOI 10.1080/00039896.1971.10665879; Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447; Kivipelto M, 2002, ANN INTERN MED, V137, P149, DOI 10.7326/0003-4819-137-3-200208060-00006; Kroner Z, 2009, ALTERN MED REV, V14, P373; KUKULL WA, 1995, AM J EPIDEMIOL, V141, P1059, DOI 10.1093/oxfordjournals.aje.a117370; Lahiri DK, 2009, MOL PSYCHIATR, V14, P992, DOI 10.1038/mp.2009.82; Lahiri DK, 2007, CURR ALZHEIMER RES, V4, P219, DOI 10.2174/156720507780362164; Lahiri DK, 2010, EXP GERONTOL, V45, P291, DOI 10.1016/j.exger.2010.01.001; Laitala VS, 2009, AM J CLIN NUTR, V90, P640, DOI 10.3945/ajcn.2009.27660; Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439; Landau SM, 2012, ARCH NEUROL-CHICAGO, V69, P623, DOI 10.1001/archneurol.2011.2748; Larrieu S, 2004, J Nutr Health Aging, V8, P150; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Launer LJ, 2011, ANN NEUROL, V70, P774, DOI 10.1002/ana.22520; Le Freche H, 2012, ANESTHESIOLOGY, V116, P779, DOI 10.1097/ALN.0b013e31824be8c7; Lee JH, 2011, ARCH NEUROL-CHICAGO, V68, P320, DOI 10.1001/archneurol.2010.292; LEE PN, 1994, NEUROEPIDEMIOLOGY, V13, P131, DOI 10.1159/000110372; Li CY, 2002, J OCCUP ENVIRON MED, V44, P66, DOI 10.1097/00043764-200201000-00011; Li H, 2008, ARCH NEUROL-CHICAGO, V65, P45, DOI 10.1001/archneurol.2007.3; Li J, 2011, LIFE SCI, V89, P86, DOI 10.1016/j.lfs.2011.04.024; Lieb W, 2009, JAMA-J AM MED ASSOC, V302, P2565, DOI 10.1001/jama.2009.1836; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; LINDSTROM K, 1984, SCAND J WORK ENV HEA, V10, P321, DOI 10.5271/sjweh.2322; Lu KP, 2004, TRENDS BIOCHEM SCI, V29, P200, DOI 10.1016/j.tibs.2004.02.002; Maes A, 2012, J APPL TOXICOL, V32, P81, DOI 10.1002/jat.1724; Maloney B, 2012, CURR ALZHEIMER RES, V9, P589, DOI 10.2174/156720512800617955; Maruszak A, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-115; Matsuzaki T, 2010, NEUROLOGY, V75, P764, DOI 10.1212/WNL.0b013e3181eee25f; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mielke MM, 2005, NEUROLOGY, V64, P1689, DOI 10.1212/01.WNL.0000161870.78572.A5; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; Naj AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001130; Ninomiya T, 2011, HYPERTENSION, V58, P22, DOI 10.1161/HYPERTENSIONAHA.110.163055; Nomura S, 2009, J ATHEROSCLER THROMB, V16, P878; Noonan CW, 2002, SCAND J WORK ENV HEA, V28, P42, DOI 10.5271/sjweh.645; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Olsson T, 1998, BIOL PSYCHIAT, V44, P374; Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7; Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530; Paul CA, 2008, ARCH NEUROL-CHICAGO, V65, P1363, DOI 10.1001/archneur.65.10.1363; Pedersen NL, 2004, ANN NEUROL, V55, P180, DOI 10.1002/ana.10999; Peila R, 2006, STROKE, V37, P1165, DOI 10.1161/01.STR.0000217653.01615.93; Peila R, 2002, DIABETES, V51, P1256, DOI 10.2337/diabetes.51.4.1256; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Perucho J, 2010, J ALZHEIMERS DIS, V19, P1245, DOI 10.3233/JAD-2010-1318; Peters R, 2008, AGE AGEING, V37, P505, DOI 10.1093/ageing/afn095; Pietropaolo S, 2008, BEHAV BRAIN RES, V192, P42, DOI 10.1016/j.bbr.2008.03.014; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Poduslo SE, 2009, AM J MED GENET B, V150B, P50, DOI 10.1002/ajmg.b.30767; Potkin SG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006501; Power DA, 2001, DEMENT GERIATR COGN, V12, P167, DOI 10.1159/000051252; Power MC, 2011, EPIDEMIOLOGY, V22, P646, DOI 10.1097/EDE.0b013e31822708b5; Prasad K, 2011, DEMENT GERIATR COGN, V31, P431, DOI 10.1159/000330019; Prasanthi JRP, 2010, FREE RADICAL BIO MED, V49, P1212, DOI 10.1016/j.freeradbiomed.2010.07.007; Presecki P, 2011, COLLEGIUM ANTROPOL, V35, P115; Profenno LA, 2010, BIOL PSYCHIAT, V67, P505, DOI 10.1016/j.biopsych.2009.02.013; Purandare N, 2012, AM J PSYCHIAT, V169, P300, DOI 10.1176/appi.ajp.2011.11010009; Qiu CX, 2004, EPIDEMIOLOGY, V15, P687, DOI 10.1097/01.ede.0000142147.49297.9d; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; Raiha I, 1996, LANCET, V347, P573, DOI 10.1016/S0140-6736(96)91272-6; Reiman EM, 2007, NEURON, V54, P713, DOI 10.1016/j.neuron.2007.05.022; Reitz C, 2008, STROKE, V39, P36, DOI 10.1161/STROKEAHA.107.490334; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI 10.1038/nrneurol.2011.2; Rimm EB, 1999, BMJ-BRIT MED J, V319, P1523, DOI 10.1136/bmj.319.7224.1523; Roberts RO, 2008, ARCH NEUROL-CHICAGO, V65, P1066, DOI 10.1001/archneur.65.8.1066; Ronnemaa E, 2008, NEUROLOGY, V71, P1065, DOI 10.1212/01.wnl.0000310646.32212.3a; Rovio S, 2005, LANCET NEUROL, V4, P705, DOI 10.1016/S1474-4422(05)70198-8; Ruitenberg A, 2005, ANN NEUROL, V57, P789, DOI 10.1002/ana.20493; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; Run XQ, 2010, J ALZHEIMERS DIS, V22, pS49, DOI 10.3233/JAD-2010-100813; Rusanen M, 2010, DEMENT GERIATR COGN, V30, P277, DOI 10.1159/000320484; Rusanen M, 2011, ARCH INTERN MED, V171, P333, DOI 10.1001/archinternmed.2010.393; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saczynski JS, 2010, NEUROLOGY, V75, P35, DOI 10.1212/WNL.0b013e3181e62138; Sano M, 2011, NEUROLOGY, V77, P556, DOI 10.1212/WNL.0b013e318228bf11; Santos C, 2010, J ALZHEIMERS DIS, V20, pS175, DOI 10.3233/JAD-2010-091303; Santos C, 2010, J ALZHEIMERS DIS, V20, pS187, DOI 10.3233/JAD-2010-091387; Sato T, 2011, NEUROBIOL AGING, V32, P1626, DOI 10.1016/j.neurobiolaging.2009.10.009; Sattler C, 2012, PSYCHIAT RES, V196, P90, DOI 10.1016/j.psychres.2011.11.012; Scarmeas N, 2011, AM J GERIAT PSYCHIAT, V19, P471, DOI 10.1097/JGP.0b013e3181eb00a9; Schellenberg GD, 2012, ACTA NEUROPATHOL, V124, P305, DOI 10.1007/s00401-012-0996-2; Schneider JA, 2010, STROKE, V41, pS144, DOI 10.1161/STROKEAHA.110.598326; Seidler A, 2007, OCCUP ENVIRON MED, V64, P108, DOI 10.1136/oem.2005.024190; Seitz DP, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-83; Serrano-Pozo A, 2010, ALZ DIS ASSOC DIS, V24, P220, DOI 10.1097/WAD.0b013e3181d61fea; Seshadri S, 2010, JAMA-J AM MED ASSOC, V303, P1832, DOI 10.1001/jama.2010.574; Sherva R, 2011, J ALZHEIMERS DIS, V23, P349, DOI 10.3233/JAD-2010-100714; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Smargiassi A, 1998, NEUROTOXICOLOGY, V19, P709; Sobel E, 1996, NEUROLOGY, V47, P1594, DOI 10.1212/WNL.47.6.1594; Sparks DL, 2010, NEURODEGENER DIS, V7, P183, DOI 10.1159/000295660; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Stern C, 2010, INT J EVID-BASED HEA, V8, P2, DOI 10.1111/j.1744-1609.2010.00150.x; Stranahan AM, 2012, CURR ALZHEIMER RES, V9, P86; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Theodoropoulou A, 2012, J NUTR HEALTH AGING, V16, P472, DOI 10.1007/s12603-012-0058-4; Thinnes FP, 2012, MOL GENET METAB, V107, P630, DOI 10.1016/j.ymgme.2012.06.016; TIRUMALASETTI F, 1991, J AM GERIATR SOC, V39, P840, DOI 10.1111/j.1532-5415.1991.tb02713.x; Tyas SL, 1996, ADDICT BIOL, V1, P237, DOI 10.1080/1355621961000124856; Tyas SL, 2001, INT J EPIDEMIOL, V30, P590, DOI 10.1093/ije/30.3.590; Une K, 2011, EUR J NEUROL, V18, P1006, DOI 10.1111/j.1468-1331.2010.03194.x; van Heemst D, 2005, EXP GERONTOL, V40, P11, DOI 10.1016/j.exger.2004.10.001; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vanderweyde T, 2010, J ALZHEIMERS DIS, V22, pS91, DOI 10.3233/JAD-2010-100843; Verghese J, 2003, NEUROLOGY, V61, P1667, DOI 10.1212/01.WNL.0000098934.18300.BE; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Vidoni ED, 2011, NEUROLOGY, V77, P1913, DOI 10.1212/WNL.0b013e318238eec1; Vilalta-Franch J, 2013, INT J GERIATR PSYCH, V28, P341, DOI 10.1002/gps.3826; Vingtdeux V, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S6; Warren MW, 2012, J ALZHEIMERS DIS, V29, P151, DOI 10.3233/JAD-2012-111385; Watson GS, 2005, AM J GERIAT PSYCHIAT, V13, P950, DOI 10.1176/appi.ajgp.13.11.950; Whitmer RA, 2005, NEUROLOGY, V64, P277, DOI 10.1212/01.WNL.0000149519.47454.F2; Whitmer RA, 2005, BMJ-BRIT MED J, V330, P1360, DOI 10.1136/bmj.38446.466238.E0; Wijsman EM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001308; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Wilson RS, 2007, NEUROLOGY, V69, P1911, DOI 10.1212/01.wnl.0000271087.67782.cb; Wilson RS, 2008, ARCH GEN PSYCHIAT, V65, P439, DOI 10.1001/archpsyc.65.4.439; Wysocki M, 2012, AM J GERIAT PSYCHIAT, V20, P179, DOI 10.1097/JGP.0b013e31820ee833; Xu WL, 2011, NEUROLOGY, V76, P1568, DOI 10.1212/WNL.0b013e3182190d09; Xu WL, 2009, DIABETOLOGIA, V52, P1031, DOI 10.1007/s00125-009-1323-x; Xu WL, 2009, DIABETES, V58, P71, DOI 10.2337/db08-0586; Zhang YY, 2012, ANN NEUROL, V71, P687, DOI 10.1002/ana.23536; Zuo CS, 2010, DEMENT GERIATR COGN, V29, P233, DOI 10.1159/000295114	222	119	121	0	87	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2050	1875-5828		CURR ALZHEIMER RES	Curr. Alzheimer Res.	OCT	2013	10	8					852	867					16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	224EF	WOS:000324864400008	23919770				2021-06-18	
J	Farahvar, A; Gerber, LM; Chiu, YL; Carney, N; Hartl, R; Ghajar, J				Farahvar, Arash; Gerber, Linda M.; Chiu, Ya-Lin; Carney, Nancy; Haertl, Roger; Ghajar, Jamshid			Increased mortality in patients with severe traumatic brain injury treated without intracranial pressure monitoring Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; mortality rate; traumatic brain injury; evidence-based guidelines	SEVERE HEAD-INJURY; INTENSIVE-CARE; OUTCOMES; GUIDELINES; AGE	Object. Evidence-based guidelines recommend intracranial pressure (ICP) monitoring for patients with severe traumatic brain injury (TBI), but there is limited evidence that monitoring and treating intracranial hypertension reduces mortality. This study uses a large, prospectively collected database to examine the effect on 2-week mortality of ICP reduction therapies administered to patients with severe TBI treated either with or without an ICP monitor. Methods. From a population of 2134 patients with severe TBI (Glasgow Coma Scale [GCS] Score < 9), 1446 patients were treated with ICP-lowering therapies. Of those, 1202 had an ICP monitor inserted and 244 were treated without monitoring. Patients were admitted to one of 20 Level I and two Level II trauma centers, part of a New York State quality improvement program administered by the Brain Trauma Foundation between 2000 and 2009. This database also contains information on known independent early prognostic indicators of mortality, including age, admission GCS score, pupillary status, CT scanning findings, and hypotension. Results. Age, initial GCS score, hypotension, and CT scan findings were associated with 2-week mortality. In addition, patients of all ages treated with an ICP monitor in place had lower mortality at 2 weeks (p = 0.02) than those treated without an ICP monitor, after adjusting for parameters that independently affect mortality. Conclusions. In patients with severe TBI treated for intracranial hypertension, the use of an ICP monitor is associated with significantly lower mortality when compared with patients treated without an ICP monitor. Based on these findings, the authors conclude that ICP-directed therapy in patients with severe TBI should be guided by ICP monitoring. (http://thejns.org/doi/abs/10.3171/2012.7.JNS111816)	[Ghajar, Jamshid] Brain Trauma Fdn, World Trade Ctr 7, New York, NY 10007 USA; [Farahvar, Arash] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Gerber, Linda M.; Chiu, Ya-Lin] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA; [Haertl, Roger; Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA; [Carney, Nancy] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA	Ghajar, J (corresponding author), Brain Trauma Fdn, World Trade Ctr 7, 34th Floor,250 Greenwich St, New York, NY 10007 USA.	ghajar@braintrauma.org			New York State Department of Health; New York Presbyterian Hospital TBI fund	The authors thank the New York State Department of Health and the New York Presbyterian Hospital TBI fund for their financial support. Dr. Hard is a consultant for Brainlab, Synthes, and Spine-Wave. Dr. Ghajar is president of the Brain Trauma Foundation. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Akopian G, 2007, AM SURGEON, V73, P447; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Bhullar IS, 2010, AM SURGEON, V76, P966; BORN JD, 1984, NEUROCHIRURGIE, V30, P329; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; BULLOCK R, 2000, MANAGEMENT PROGNOSIS; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Edwards WH, 2005, CLIN PERINATOL, V32, P97, DOI 10.1016/j.clp.2004.11.009; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; FALCAO ALE, 1995, ARQ NEURO-PSIQUIAT, V53, P390, DOI 10.1590/S0004-282X1995000300004; Falk AC, 2010, DEV NEUROREHABIL, V13, P315, DOI 10.3109/17518423.2010.496766; Farahvar A, 2011, J NEUROSURG, V115, P191, DOI 10.3171/2011.4.JNS101116a; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Roberts Susan R, 2004, Crit Care Nurs Clin North Am, V16, P537, DOI 10.1016/j.ccell.2004.06.008; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stover JF, 2006, CRIT CARE MED, V34, P1582, DOI 10.1097/01.CCM.0000216697.37348.FC; STUART GG, 1983, J NEUROSURG, V59, P601, DOI 10.3171/jns.1983.59.4.0601; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003	30	119	130	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2012	117	4					729	734		10.3171/2012.7.JNS111816			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	015YZ	WOS:000309485600022	22900846	Bronze			2021-06-18	
J	Babbage, DR; Yim, J; Zupan, B; Neumann, D; Tomita, MR; Willer, B				Babbage, Duncan R.; Yim, Jackki; Zupan, Barbra; Neumann, Dawn; Tomita, Machiko R.; Willer, Barry			Meta-Analysis of Facial Affect Recognition Difficulties After Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						affect recognition; emotion perception; traumatic brain injury; meta-analysis	CLOSED-HEAD INJURY; EMOTION RECOGNITION; SOCIAL-BEHAVIOR; PERCEPTION DEFICITS; COMMUNICATION; EXPRESSION; INDIVIDUALS; ADULTS; MIND; EPIDEMIOLOGY	Difficulties in communication and social relationships present a formidable challenge for many people after traumatic brain injury (TBI). These difficulties are likely to be partially attributable to problems with emotion perception. Mounting evidence shows facial affect recognition to be particularly difficult after TBI. However, no attempt has been made to systematically estimate the magnitude of this problem or the frequency with which it occurs. Method: A meta-analysis is presented examining the magnitude of facial affect recognition difficulties after TBI. From this, the frequency of these impairments in the TBI population is estimated. Effect sizes were calculated from 13 studies that compared adults with moderate to severe TBI to matched healthy controls on static measures of facial affect recognition. Results: The studies collectively presented data from 296 adults with TBI and 296 matched controls. The overall weighted mean effect size for the 13 studies was -1.11, indicating people with TBI on average perform about 1.1 SD below healthy peers on measures of facial affect recognition. Based on estimation of the TBI population standard deviation and modeling of likely distribution shape, it is estimated that between 13% and 39% of people with moderate to severe TBI may have significant difficulties with facial affect recognition, depending on the cut-off criterion used. Conclusion: This is clearly an area that warrants attention, particularly examining techniques for the rehabilitation of these deficits.	[Babbage, Duncan R.; Yim, Jackki] Massey Univ, Sch Psychol, Wellington 6140, New Zealand; [Zupan, Barbra] Brock Univ, Dept Appl Linguist, St Catharines, ON L2S 3A1, Canada; [Neumann, Dawn] Indiana Univ, Sch Med, Dept Phys Med & Rehabil, Bloomington, IN 47405 USA; [Tomita, Machiko R.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Rehabil Sci, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Sch Med & Biomed Sci, Dept Psychiat & Rehabil Med, Buffalo, NY 14260 USA	Babbage, DR (corresponding author), Massey Univ, Sch Psychol, POB 756, Wellington 6140, New Zealand.	D.R.Babbage@massey.ac.nz		Babbage, Duncan/0000-0002-9259-9246; Barbra, Zupan/0000-0002-4603-333X			Addington J, 2008, BRIT J PSYCHIAT, V192, P67, DOI 10.1192/bjp.bp.107.039784; Allerdings MD, 2006, BRAIN COGNITION, V60, P193, DOI 10.1016/j.bandc.2004.09.018; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Borgaro SR, 2004, BRAIN INJURY, V18, P33, DOI 10.1080/0269905031000110562; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Ekman P., 1978, FACIAL ACTION CODING; Ekman P., 1976, PICTURES FACIAL AFFE; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Guercio JM, 2004, BRAIN INJURY, V18, P593, DOI 10.1080/02699050310001646116; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hedges L. V., 1981, J EDUC STAT, V6, P107; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; KUBU CS, 1993, J CLIN EXP NEUROPSYC, V15, P59; Kubu CS, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P451; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lipsey M.W., 2001, PRACTICAL META ANAL; Matsumoto D, 2004, JAPANESE CAUCASIAN F; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S., 2005, BRAIN IMPAIR, V6, P56, DOI DOI 10.1375/BRIM.6.1.56.65481; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Orwin R. G., 1983, J EDUC STAT, V8, P157, DOI [10.3102/10769986008002157., DOI 10.2307/1164923]; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; Prigatano G. P., 1995, BNI Q, V9, P2; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; SPENCE SH, 1980, SOCIAL SKILLS TRAINI; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wood RLL, 2009, BRAIN INJURY, V23, P649, DOI 10.1080/02699050902970786; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; Zupan B, 2009, J COMMUN DISORD, V42, P1, DOI 10.1016/j.jcomdis.2008.06.001	53	119	120	1	23	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	MAY	2011	25	3					277	285		10.1037/a0021908			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	765ZO	WOS:000290748100001	21463043				2021-06-18	
J	Beauchamp, KM; Kashuk, J; Moore, EE; Bolles, G; Rabb, C; Seinfeld, J; Szentirmai, O; Sauaia, A				Beauchamp, Kathryn M.; Kashuk, Jeffry; Moore, Ernest E.; Bolles, Gene; Rabb, Craig; Seinfeld, Joshua; Szentirmai, Oszkar; Sauaia, Angela			Cranioplasty After Postinjury Decompressive Craniectomy: Is Timing of the Essence?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Cranioplasty; Decompressive craniectomy	TRAUMATIC BRAIN-INJURY; BONE FLAP; DELAYED CRANIOPLASTY; HYDROCEPHALUS; PRESERVATION; CRANIOTOMY; CHILDREN	Background: The appropriate timing of cranioplasty after decompressive craniectomy for trauma is unknown. Potential benefits of delayed intervention (>6 weeks) for reducing the risk of infection must be balanced by persistent altered cerebrospinal fluid dynamics leading to hydrocephalus. We reviewed our recent 5-year experience in an effort to improve patient throughput and develop a rational decision making plan. Methods: A 5-year query (2003-2007) of our level I neurotrauma database. From 2,400 head injuries, we performed a total of 350 craniotomies. Of the 350 patients who underwent craniotomy for trauma, 70 patients (20%) underwent decompressive craniectomy requiring cranioplasty. Timing of cranioplasty, cranioplasty material, postoperative infections, and incidence of hydrocephalus were evaluated with logistic regression to study potential associations between complications and timing, adjusted for risk factors. Results: No specific time frame was predictive of hydrocephalus or infection, and logistic regression failed to identify significant predictors among the collected variables. Conclusion: In our experience, the prior practice of delayed cranioplasty (3-6 months postdecompressive craniectomy), requiring repeat hospital admission, does not seem to lower postcranioplasty infection rates nor the need for cerebrospinal fluid diversion procedures. Our current practice emphasizes cranioplasty during the initial hospital admission, as soon as there is resolution on computed tomography scan of brain swelling outside of the cranial vault with concurrent clinical examination. This occurs as early as 2 weeks postcraniectomy and should lower the overall cost of care by eliminating the need for additional hospital admissions.	[Beauchamp, Kathryn M.; Bolles, Gene; Rabb, Craig; Seinfeld, Joshua; Szentirmai, Oszkar] Denver Hlth Med Ctr, Rocky Mt Reg Trauma Ctr, Div Neurosurg, Denver, CO 80304 USA; [Kashuk, Jeffry; Moore, Ernest E.] Denver Hlth Med Ctr, Rocky Mt Reg Trauma Ctr, Dept Surg, Denver, CO 80304 USA; [Sauaia, Angela] Univ Colorado Denver Hlth Sci, Denver, CO USA	Beauchamp, KM (corresponding author), Denver Hlth Med Ctr, Rocky Mt Reg Trauma Ctr, Div Neurosurg, 777 Bannock MC 0206, Denver, CO 80304 USA.	kathryn.beauchamp@dhha.org					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aciduman A, 2007, SURG NEUROL, V68, P349, DOI 10.1016/j.surneu.2006.10.073; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; AZIZ T Z, 1990, British Journal of Neurosurgery, V4, P417, DOI 10.3109/02688699008992764; Blum KS, 1997, PEDIATR NEUROSURG, V26, P33, DOI 10.1159/000121158; Bruce JN, 2003, J NEUROSURG, V98, P1203, DOI 10.3171/jns.2003.98.6.1203; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Flannery T, 2001, BRIT J NEUROSURG, V15, P518, DOI 10.1080/02688690120097732; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Jankowitz BT, 2006, NEUROSURGERY, V59, P585, DOI 10.1227/01.NEU.0000231849.12751.B9; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Krishnan P, 2006, NEUROL INDIA, V54, P291; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678; Tokoro K, 1989, Neurol Med Chir (Tokyo), V29, P196, DOI 10.2176/nmc.29.196; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526	20	119	123	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2010	69	2					270	274		10.1097/TA.0b013e3181e491c2			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	638JN	WOS:000280890800005	20699735				2021-06-18	
J	Zweifel, C; Lavinio, A; Steiner, LA; Radolovich, D; Smielewski, P; Timofeev, I; Hiler, M; Balestreri, M; Kirkpatrick, PJ; Pickard, JD; Hutchinson, P; Czosnyka, M				Zweifel, Christian; Lavinio, Andrea; Steiner, Luzius A.; Radolovich, Danila; Smielewski, Peter; Timofeev, Ivan; Hiler, Magdalena; Balestreri, Marcella; Kirkpatrick, Peter J.; Pickard, John D.; Hutchinson, Peter; Czosnyka, Marek			Continuous monitoring of cerebrovascular pressure reactivity in patients with head injury	NEUROSURGICAL FOCUS			English	Article						cerebral perfusion pressure; cerebrovascular pressure reactivity; head injury; intracranial pressure monitoring; static rate of autoregulation	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; BLOOD-FLOW; DECOMPRESSIVE CRANIECTOMY; AUTO-REGULATION; PREDICTIVE-VALUE; AUTOREGULATION; METABOLISM; MANAGEMENT	Object. Cerebrovascular pressure reactivity is the ability of cerebral vessels to respond to changes in transmural pressure. A cerebrovascular pressure reactivity index (PRx) can be determined as the moving correlation coefficient between mean intracranial pressure (ICP) and mean arterial blood pressure. Methods. The authors analyzed a database consisting of 398 patients with head injuries who underwent continuous monitoring of cerebrovascular pressure reactivity. In 298 patients, the PRx was compared with a transcranial Doppler ultrasonography assessment of cerebrovascular autoregulation (the mean index [Mx]), in 17 patients with the PET-assessed static rate of autoregulation, and in 22 patients with the cerebral metabolic rate for O-2. Patient outcome was assessed 6 months after injury. Results. There was a positive and significant association between the PRx and Mx (R-2 = 0.36, p < 0.001) and with the static rate of autoregulation (R-2 = 0.31, p = 0.02). A PRx > 0.35 was associated with a high mortality rate (> 50%). The PRx showed significant deterioration in refractory intracranial hypertension, was correlated with outcome, and was able to differentiate patients with good outcome, moderate disability, severe disability, and death. The graph of PRx compared with cerebral perfusion pressure (CPP) indicated a U-shaped curve, suggesting that too low and too high CPP was associated with a disturbance in pressure reactivity. Such an optimal CPP was confirmed in individual cases and a greater difference between current and optimal CPP was associated with worse outcome (for patients who, on average, were treated below optimal CPP [R-2 = 0.53, p < 0.001] and for patients whose mean CPP was above optimal CPP [R-2 = -0.40, p < 0.05]). Following decompressive craniectomy, pressure reactivity initially worsened (median -0.03 [interquartile range -0.13 to 0.06] to 0.14 [interquartile range 0.12-0.22]; p < 0.01) and improved in the later postoperative course. After therapeutic hypothermia, in 17 (70.8%) of 24 patients in whom rewarming exceeded the brain temperature threshold of 37 degrees C, ICP remained stable, but the average PRx increased to 0.32 (p < 0.0001), indicating significant derangement in cerebrovascular reactivity. Conclusions. The PRx is a secondary index derived from changes in ICP and arterial blood pressure and can be used as a surrogate marker of cerebrovascular impairment. In view of an autoregulation-guided CPP therapy, a continuous determination of a PRx is feasible, but its value has to be evaluated in a prospective controlled trial.	[Zweifel, Christian; Lavinio, Andrea; Radolovich, Danila; Smielewski, Peter; Timofeev, Ivan; Hiler, Magdalena; Balestreri, Marcella; Kirkpatrick, Peter J.; Pickard, John D.; Hutchinson, Peter; Czosnyka, Marek] Univ Cambridge, Sch Clin, Acad Neurosurg Unit, Cambridge, England; [Steiner, Luzius A.] Univ Basel Hosp, Dept Anaesthesia, CH-4031 Basel, Switzerland	Czosnyka, M (corresponding author), Addenbrookes Hosp, Box 167, Cambridge CB2 2QQ, England.	MC141@medschl.cam.ac.uk	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011; Lavinio, Andrea/M-1778-2016; Timofeev, Ivan/AAE-7019-2019	Smielewski, Peter/0000-0001-5096-3938; Timofeev, Ivan/0000-0002-1168-0393	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986, G0601025, G0001237, ID 65883] Funding Source: Medline		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Balestreri M, 2005, ACT NEUR S, V95, P25; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Lang E W, 1995, New Horiz, V3, P400; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; Menon DK, 2004, ANAESTHESIA, V59, P785, DOI 10.1111/j.1365-2044.2004.03800.x; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Smielewski P, 2005, ACT NEUR S, V95, P43; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	37	119	124	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	OCT	2008	25	4							E2	10.3171/FOC.2008.25.10.E2			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	355HX	WOS:000259701100002	18828700	Bronze			2021-06-18	
J	Lai, YC; Hickey, RW; Chen, YM; Bayir, H; Sullivan, ML; Chu, CT; Kochanek, PM; Dixon, CE; Jenkins, LW; Graham, SH; Watkins, SC; Clark, RSB				Lai, Yichen; Hickey, Robert W.; Chen, Yaming; Bayir, Huelya; Sullivan, Mara L.; Chu, Charleen T.; Kochanek, Patrick M.; Dixon, C. Edward; Jenkins, Larry W.; Graham, Steven H.; Watkins, Simon C.; Clark, Robert S. B.			Autophagy is increased after traumatic brain injury in mice and is partially inhibited by the antioxidant gamma-glutamylcysteinyl ethyl ester	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						autophagosome; controlled cortical impact; GCEE; head injury; LC3; mitophagy	INDUCED OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; NEURONAL INJURY; TRANSGENIC MICE; DISEASE; RATS; MACROAUTOPHAGY; DEGENERATION; INVOLVEMENT; GLUTATHIONE	Autophagy is a homeostatic process for recycling of proteins and organelles, induced by nutrient deprivation and regulated by oxygen radicals. Whether autophagy is induced after traumatic brain injury (TBI) is not established. We show that TBI in mice results in increased ultrastructural and biochemical evidence of autophagy. Specifically, autophagosomal vacuoles and secondary lysosomes were frequently observed in cell processes and axons in ipsilateral brain regions by electron microscopy, and lipidated microtubule-associated protein light chain 3, a biochemical footprint of autophagy referred to as LC3 II, was increased at 2 and 24 h after TBI versus controls. Since oxygen radicals are believed to be important in the pathogenesis of TBI and are essential for the process of starvation-induced autophagy in vitro, we also sought to determine if treatment with the antioxidant gamma-glutamylcysteinyl ethyl ester (GCEE) reduced autophagy and influenced neurologic outcome after TBI in mice. Treatment with GCEE reduced oxidative stress and partially reduced LC3 II formation in injured brain at 24 h after TBI versus vehicle. Treatment with GCEE also led to partial improvement in behavioral and histologic outcome versus vehicle. Taken together, these data show that autophagy occurs after experimental TBI, and that oxidative stress contributes to overall neuropathology, in part by initiating or influencing autophagy.	[Lai, Yichen; Chen, Yaming; Bayir, Huelya; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Lai, Yichen; Chen, Yaming; Bayir, Huelya; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; [Hickey, Robert W.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Bayir, Huelya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; [Sullivan, Mara L.; Watkins, Simon C.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; [Chu, Charleen T.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; [Dixon, C. Edward; Jenkins, Larry W.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA	Clark, RSB (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Chu, Charleen T/B-1601-2008	Chu, Charleen T/0000-0002-5052-8271; watkins, simon/0000-0003-4092-1552; Lai, Yi-Chen/0000-0002-9450-5506; Kochanek, Patrick/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD 40686, K08 HD040848, K08 HD 040848] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 38620, P50 NS 30318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, P50NS030318] Funding Source: NIH RePORTER		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS68; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Boland Barry, 2006, Molecular Aspects of Medicine, V27, P503, DOI 10.1016/j.mam.2006.08.009; Chu CT, 2006, J NEUROPATH EXP NEUR, V65, P423, DOI 10.1097/01.jnen.0000229233.75253.be; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Drake J, 2003, J NEUROSCI RES, V74, P917, DOI 10.1002/jnr.10810; Drake J, 2002, J NEUROSCI RES, V68, P776, DOI 10.1002/jnr.10266; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hariri M, 2000, MOL BIOL CELL, V11, P255, DOI 10.1091/mbc.11.1.255; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; JENKINS LW, 1981, ACTA NEUROPATHOL, V55, P205, DOI 10.1007/BF00691320; KALIMO H, 1982, J CEREBR BLOOD F MET, V2, pS19; Koike M, 2005, AM J PATHOL, V167, P1713, DOI 10.1016/S0002-9440(10)61253-9; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kouno T, 2005, J BIOL CHEM, V280, P24610, DOI 10.1074/jbc.M413565200; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2006, AUTOPHAGY, V2, P302, DOI 10.4161/auto.2945; NEELY N, 1974, BIOCHEM BIOPH RES CO, V59, P680; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wang QJ, 2006, J NEUROSCI, V26, P8057, DOI 10.1523/JNEUROSCI.2261-06.2006; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x; Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	37	119	124	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2008	28	3					540	550		10.1038/sj.jcbfm.9600551			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	266DA	WOS:000253410400011	17786151	Bronze			2021-06-18	
J	Cutler, SM; Cekic, M; Miller, DM; Wali, B; VanLandingham, JW; Stein, DG				Cutler, Sarah M.; Cekic, Milos; Miller, Darren M.; Wali, Bushra; VanLandingham, Jacob W.; Stein, Donald G.			Progesterone improves acute recovery after traumatic brain injury in the aged rat	JOURNAL OF NEUROTRAUMA			English	Article						aging; frontal cortex; inflammation; progesterone; recovery; traumatic brain injury	INFLAMMATORY RESPONSE; CEREBRAL-ISCHEMIA; P-GLYCOPROTEIN; FEMALE RATS; ACTIVATION; REMYELINATION; CONTRIBUTES; HIPPOCAMPUS; DYSFUNCTION; MECHANISMS	Recent evidence has demonstrated that treatment with progesterone can attenuate many of the pathophysiological events following traumatic brain injury (TBI) in young adult rats, but this effect has not been investigated in aged animals. In this study, 20-month-old male Fischer 344 rats with bilateral contusions of the frontal cortex (n = 4 per group) or sham operations received 8, 16, or 32 mg/kg of progesterone or vehicle. Locomotor activity was measured at 72 h to assess behavioral recovery. Brain tissue was harvested at 24, 48, and 72 h, and Western blotting was performed for inflammatory and apoptotic factors. Edema was assessed at 48 h by measuring brain water content. Injured animals treated with 8 and 16 mg/kg progesterone showed decreased expression of COX-2, IL-6, and NF kappa B at all time points, indicating a reduction in the acute inflammatory process compared to vehicle. The 16 mg/kg group also showed reduced apoptosis at all time points as well as decreased edema and improved locomotor outcomes. Thus, in aged male rats, treatment with 16 mg/kg progesterone improves short-term motor recovery and attenuates edema, secondary inflammation, and cell death after TBI.	Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; Mt Union Coll, Dept Psychol, Alliance, OH USA; Florida State Univ, Dept Biomed Sci, Tallahassee, FL USA	Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA.	donald.stein@emory.edu	Cekic, Milos/AAR-8250-2020; Stein, Donald/AAJ-5139-2020		NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008169] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1R01N538664, 1R01N540825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008169] Funding Source: NIH RePORTER		Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Bazan NG, 2005, ANN NY ACAD SCI, V1053, P137, DOI 10.1196/annals.1344.011; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Campbell SJ, 2007, NEUROPATH APPL NEURO, V33, P108, DOI 10.1111/j.1365-2990.2006.00773.x; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Chang LL, 1999, J CELL BIOCHEM, V73, P563; Dazert P, 2006, NEUROSCIENCE, V142, P1071, DOI 10.1016/j.neuroscience.2006.07.056; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gangula PRR, 2002, BIOL REPROD, V67, P1881, DOI 10.1095/biolreprod.102.007682; Geula C, 2003, J COMP NEUROL, V455, P249, DOI 10.1002/cne.10475; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Godbout JP, 2004, J NEUROIMMUNOL, V147, P141, DOI 10.1016/j.jneuroim.2003.10.031; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Griffin R, 2006, J NEUROCHEM, V99, P1263, DOI 10.1111/j.1471-4159.2006.04165.x; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; Johnson TE, 2006, EXP GERONTOL, V41, P1243, DOI 10.1016/j.exger.2006.09.006; Karssen AM, 2004, ANN NY ACAD SCI, V1032, P308, DOI 10.1196/annals.1314.048; Kovacs EJ, 2005, EXP GERONTOL, V40, P549, DOI 10.1016/j.exger.2005.04.009; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Laumer R, 1992, Fortschr Med, V110, P241; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LIPSITZ LA, 2004, SCI AGING KNOWLEDGE, pPE16; Lowery D. W., 2002, J NEUROTRAUM, V19, P1286; Maher FO, 2005, NEUROBIOL AGING, V26, P717, DOI 10.1016/j.neurobiolaging.2004.07.002; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; Meng QY, 2007, MECH AGEING DEV, V128, P286, DOI 10.1016/j.mad.2006.12.008; Mima T, 1999, NEUROL RES, V21, P209, DOI 10.1080/01616412.1999.11740920; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Niewiadomska G, 2002, NEUROBIOL AGING, V23, P601, DOI 10.1016/S0197-4580(01)00345-1; Raza M, 2007, NEUROSCI LETT, V418, P77, DOI 10.1016/j.neulet.2007.03.005; ROOF RL, 1997, J NEUROTRAUM, V14, P760; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Ruppel RA, 2002, NEUROSURG CLIN N AM, V13, P169, DOI 10.1016/S1042-3680(01)00005-5; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; Verma A, 2000, J HEAD TRAUMA REHAB, V15, P1149, DOI 10.1097/00001199-200010000-00008; Williams BJ, 2006, PSYCHOPHARMACOLOGY, V188, P605, DOI 10.1007/s00213-006-0477-1; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932	50	119	121	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2007	24	9					1475	1486		10.1089/neu.2007.0294			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	214ZT	WOS:000249777600006	17892409				2021-06-18	
J	Parry-Jones, BL; Vaughan, FL; Cox, WM				Parry-Jones, Beth L.; Vaughan, Frances L.; Cox, W. Miles			Traumatic brain injury and substance misuse: A systematic review of prevalence and outcomes research (1994-2004)	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							BLOOD-ALCOHOL LEVEL; HEAD-INJURY; COGNITIVE STATUS; ABUSE; PSYCHOPATHOLOGY; ADOLESCENTS; POPULATION; DISABILITY	A systematic review of the evidence on substance misuse prevalence in patients with traumatic brain injury (TBI) and outcomes associated with this population is presented. Building upon an earlier review of the area by Corigan (1995), this review is limited to research published between 1994 and 2004. Psycinfo and Medline abstract databases were searched for English-language publications citing research from Western countries on the epidemiology and outcomes of adult TBI patients (aged 15 years or older). The majority of reviewed studies were undertaken in the USA and the investigation foci and methods used were multifarious, constraining the generalisation of the review findings. Prevalence for alcohol intoxication at time of injury in the review was found to be almost identical to that in Corrigan's review: 37-51% and 36-51%, respectively. Pre-TBI history of alcohol misuse was found to be less prevalent in the present as opposed to Corrigan's review: 37-51% and 55-66%, respectively. Outcome findings were mixed (also found by Corrigan), but mainly in the expected direction of poorer outcomes (neurological, medical, neuropsychological, and functional) in patients with pre-TBI substance misuse. Further research and implications for services are outlined.	Univ Wales, Bangor, Gwynedd, Wales	Parry-Jones, BL (corresponding author), Univ Wales, Bangor, Gwynedd, Wales.	beth.parry-jones@nww-tr.wales.nhs.uk					Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; Cherner M, 2001, ARCH PHYS MED REHAB, V82, P780, DOI 10.1053/apmr.2001.23263; Christensen M A, 2001, J Neurosci Nurs, V33, P184; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Drubach D A, 1993, Md Med J, V42, P989; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jong CN, 1999, BRAIN INJURY, V13, P1017; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Miller NS, 1995, ALCOHOLISM TREATMENT, V13, P15, DOI 10.1300/J020v13n03_02; Mulrow C. D., 1995, SYSTEMATIC REV, P1; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; Roberts RE, 1998, AM J PSYCHIAT, V155, P715; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Schmidt M., 1996, REY AUDITORY VERBAL; Schmidt MF, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P211; SELZER ML, 1975, J STUD ALCOHOL, V36, P127; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; *STAT U NEW YORK B, 1990, GUID US UN DAT SET M; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; *WAR DEV, 1944, ARM IND TEST BATT MA; Wechsler D., 1987, MANUAL WECHSLER MEMO; Wechsler D., 1981, WAIS R MANUAL WECHSL	49	119	120	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	OCT	2006	16	5					537	560		10.1080/09602010500231875			24	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	096FI	WOS:000241362600002	16952892				2021-06-18	
J	Arnold, G; Boone, KB; Lu, P; Dean, A; Wen, J; Nitch, S; McPherson, S				Arnold, G; Boone, KB; Lu, P; Dean, A; Wen, J; Nitch, S; McPherson, S			Sensitivity and specificity of finger tapping test scores for the detection of suspect effort	CLINICAL NEUROPSYCHOLOGIST			English	Article							REITAN NEUROPSYCHOLOGICAL TESTS; SEX-DIFFERENCES; NORMATIVE DATA; HEAD-INJURY; HALSTEAD; PERFORMANCE; PATTERNS; ANXIETY; AGE	Past studies indicate that patients with incentive to fake neuropsychological symptoms are likely to have lower finger tapping scores than credible patients. The present study builds upon past research by investigating finger tapping performance for seven groups: (a) noncredible patients (as determined by failed psychometric and behavioral criteria), and patients with (h) closed head injury, (c) dementia, (d) mental retardation, (e) psychosis, or (f) depression, and (g) healthy older controls. Results showed that men tapped faster than women, requiring that groups be divided by gender. Noncredible male and female patients tapped slower than their comparison group counterparts. Dominant hand score proved to be more sensitive to noncredible performance than other scores (nondominant, sum of both hands, difference between dominant and nondominant), especially for women. Sensitivity, specificity, and positive and negative predictive values tables are presented. With specificity set at 90% for the comparison groups combined, a dominant hand cutoff score of <= 35 for men yielded 50% sensitivity, while a score of <= 28 yielded 61% sensitivity for women. Specificity values for specific cutoff scores varied significantly across the comparison groups, indicating that cutoffs should he adjusted for the particular differential diagnosis. In conclusion, results indicate that when using finger tapping scores to detect noncredible performance: (a) Dominant hand performance is more sensitive, and (b) cutoffs should be selected based on gender and claimed diagnosis.	Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA; Kaiser Permanente Los Angeles Med Ctr, Dept Psychiat, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA	Boone, KB (corresponding author), Harbor UCLA Med Ctr, Dept Psychiat, Bldg F-9,W Carson St, Torrance, CA 90509 USA.	kboone@rei.edu					ARDILA A, 1989, DEV NEUROPSYCHOL, V5, P307, DOI 10.1080/87565648909540441; BAK JS, 1980, J CONSULT CLIN PSYCH, V48, P395, DOI 10.1037/0022-006X.48.3.395; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; BORNSTEIN RA, 1987, CLIN NEUROPSYCHOL, V1, P209; CHAVEZ EL, 1983, PERCEPT MOTOR SKILL, V56, P923, DOI 10.2466/pms.1983.56.3.923; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DODRILL CB, 1979, J CLIN PSYCHOL, V35, P236, DOI 10.1002/1097-4679(197904)35:2<236::AID-JCLP2270350202>3.0.CO;2-9; ECHTERNACHT R, 1981, CLIN NEUROPSYCHOLOGY, V3, P8; FILSKOV SB, 1986, HDB CLIN NEUROPSYCHO, V2; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; GOLDSTEIN SG, 1974, PERCEPT MOTOR SKILL, V38, P1139, DOI 10.2466/pms.1974.38.3c.1139; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; HARRIS M, 1981, ARCH CLIN NEUROPSYCH, V8, P525; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heaton RK, 1986, NEUROPSYCHOLOGICAL A; HOFFMAN DT, 1969, PERCEPT MOTOR SKILL, V29, P676, DOI 10.2466/pms.1969.29.2.676; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; KING GD, 1978, J CONSULT CLIN PSYCH, V46, P375, DOI 10.1037/0022-006X.46.2.375; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; MCKEEVER WF, 1991, J CLIN EXP NEUROPSYC, V13, P91; MORRISON MW, 1979, PERCEPT MOTOR SKILL, V48, P139, DOI 10.2466/pms.1979.48.1.139; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; ROGERS R, 1988, CLIN ASSESSMENT MALI; RUFF RM, 1993, PERCEPT MOTOR SKILL, V76, P1219, DOI 10.2466/pms.1993.76.3c.1219; RUSSELL EW, 1993, ARCH CLIN NEUROPSYCH, V8, P327, DOI 10.1016/0887-6177(93)90023-T; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; SURE J, 1997, J CLIN EXPT NEUROPSY, V19, P500; TRAHAN DE, 1987, 15 ANN M INT NEUR SO; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; VILLARDITA C, 1985, ARCH GERONTOL GERIAT, V4, P311, DOI 10.1016/0167-4943(85)90038-X; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; YEUDALL LT, 1987, J CLIN PSYCHOL, V43, P346, DOI 10.1002/1097-4679(198705)43:3<346::AID-JCLP2270430308>3.0.CO;2-Q	36	119	121	1	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	2005	19	1					105	120		10.1080/13854040490888567			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	912YF	WOS:000228115300008	15814482				2021-06-18	
J	Zhang, L; Plotkin, RC; Wang, G; Sandel, ME; Lee, S				Zhang, L; Plotkin, RC; Wang, G; Sandel, ME; Lee, S			Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						acetylcholine; brain injuries; cognition disorders; rehabilitation	ALZHEIMERS-DISEASE; DOUBLE-BLIND; ACETYLCHOLINE; SYSTEMS	Objective: To examine effects of donepezil on short-term memory and sustained attention in postacute patients with traumatic brain injury (TBI). Design: A 24-week, randomized, placebo-controlled, double-blind crossover trial. Setting: Outpatient clinics in 2 teaching hospitals. Participants: Eighteen postacute TBI patients with cognitive impairment. Intervention: Patients were randomly assigned to group A or group B. Patients in group A received donepezil for the first 10 weeks and then a placebo for another 10 weeks. The 2 treatment phases were separated by a washout period of 4 weeks. Patients in group B received the preparations in the opposite order. Main Outcome Measures: Short-term memory and sustained attention were assessed by 2 indexes (Auditory Immediate Index [All], Visual Immediate Index [VII]) of the Wechsler Memory Scale-III and the Paced Auditory Serial Addition Test (PASAT), at baseline, week 10, and week 24 of the trial. Results: Intragroup comparison of different phases of the trial in both groups showed that donepezil significantly increased the testing scores of the All and VII, as well as PASAT scores, compared with baseline. There was no significant change in the testing scores between assessment at baseline and the end of the placebo phase in group B. Intergroup comparison at the 10-week assessment showed significantly improved testing scores in group A with donepezil over group B with the placebo. The improved testing scores with donepezil in group A were sustained after the washout period and placebo phase, suggesting a carry-over effect of the medication. Conclusions: Donepezil increased neuropsychologic testing scores in short-term memory and sustained attention in post-acute TBI patients. Cholinergic augmentation may be a viable approach to restore memory and attention after TBI. (C) 2004 by the American Congress of Rehabilitation Medici. ne and the American Academy of Physical Medicine and Rehabilitation.	Univ Texas, Hlth Sci Ctr, Dept Rehabil Med, San Antonio, TX 78285 USA; Dept Vet Affairs Med Ctr, San Antonio, TX USA; Univ Penn, Ctr Med, Philadelphia, PA 19104 USA; SUNY Syracuse, Upstate Med Univ, Syracuse, NY 13210 USA; Kaiser Fdn Rehabil Ctr, Vallejo, CA USA	Zhang, L (corresponding author), San Antonio Brain & Spine Consultants, 19114 La Verita, San Antonio, TX 78258 USA.	neurorehab@yahoo.com					Brown H., 1999, APPL MIXED MODELS ME; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; Cohen J., 1977, STAT POWER ANAL BEHA, P1; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jones S, 1999, TRENDS NEUROSCI, V22, P555, DOI 10.1016/S0166-2236(99)01471-X; Kato K, 1999, NEUROSCI LETT, V260, P5, DOI 10.1016/S0304-3940(98)00943-4; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Lawrence AD, 1998, NEUROCHEM RES, V23, P787, DOI 10.1023/A:1022419712453; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEVIN HS, 1988, SCAND J REHABIL MED, P33; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; MYSIW WJ, 1997, PHYS MED REH CLIN N, V89, P781; *PSYCH CORP, 1997, WMS 3 ADM SCOR MAN; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rasmusson DD, 2000, BEHAV BRAIN RES, V115, P205, DOI 10.1016/S0166-4328(00)00259-X; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Spreen O., 1991, COMPENDIUM NEUROPSYC; SQUIRE LR, 1988, TRENDS NEUROSCI, V11, P170, DOI 10.1016/0166-2236(88)90144-0; Staff RT, 2000, NUCL MED COMMUN, V21, P37, DOI 10.1097/00006231-200001000-00007; Taverni JP, 1998, BRAIN INJURY, V12, P77; TEASDALE G, 1974, LANCET, V2, P81; Tulsky DS, 2000, PSYCHOL ASSESSMENT, V12, P253, DOI 10.1037//1040-3590.12.3.253; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003	38	119	122	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2004	85	7					1050	1055		10.1016/j.apmr.2003.10.014			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	835XU	WOS:000222519600002	15241749				2021-06-18	
J	Hallam, TM; Floyd, CL; Folkerts, MM; Lee, LL; Gong, QZ; Lyeth, BG; Muizelaar, JP; Berman, RF				Hallam, TM; Floyd, CL; Folkerts, MM; Lee, LL; Gong, QZ; Lyeth, BG; Muizelaar, JP; Berman, RF			Comparison of behavioral deficits and acute neuronal degeneration in rat lateral fluid percussion and weight-drop brain injury models	JOURNAL OF NEUROTRAUMA			English	Article						fluoro-Jade; hypoxia; lateral fluid percussion; memory; motor behavior; neuronal degeneration; traumatic brain injury; weight-drop impact acceleration	IMPACT-ACCELERATION INJURY; METABOTROPIC GLUTAMATE ANTAGONIST; WATER MAZE PERFORMANCE; VOLATILE ANESTHETICS; CEREBRAL-ISCHEMIA; FLUORO-JADE; HEAD-INJURY; COGNITIVE IMPAIRMENT; HIPPOCAMPUS; MOTOR	The behavioral and histological effects of the lateral fluid percussion (LFP) brain injury model were compared with the weight drop impact-acceleration model with 10 min of secondary hypoxia (WDIA+H). LFP injury resulted in significant motor deficits on the beam walk and inclined plane, and memory deficits on the radial arm maze and Morris water maze. Motor deficits following LFP remained throughout 6 weeks of behavioral testing. WDIA+H injury produced significant motor deficits on the beam walk and inclined plane immediately following injury, but these effects were transient and recovered by 14 days post-injury. In contrast to the LFP injury, the WDIA+H injured animals showed no memory deficits on the radial arm maze and Morris water maze. In order to determine if the differences in behavioral outcome between models were due to differences in injury mechanism or injury severity, 10 LFP-injured animals were matched with 10 WDIA-injured animals based on injury severity (i.e., time to regain righting reflex after brain injury). The LFP-matched injury group showed greater impairment than the WDIA+H matched injury group on the radial arm maze and Morris water maze. Histological examination of LFP-injured brains with Fluoro-Jade staining 24 h, 48 h, and 7 days post-injury revealed degenerating neurons in the cortex, thalamus, hippocampus, caudate-putamen, brainstem, and cerebellum, with degenerating fibers tracts in the corpus callosum and other major tracts throughout the brain. Fluoro-Jade staining following WDIA+H injury revealed damage to fibers in the optic tract, lateral olfactory tract, corpus callosum, anterior commissure, caudate-putamen, brain stem, and cerebellum. While both models produce reliable and characteristic behavioral and neuronal pathologies, their differences are important to consider when choosing a brain injury model.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA	Berman, RF (corresponding author), Univ Calif Davis, Dept Neurosurg, Neurotrauma Res Labs, 1 Shields Ave, Davis, CA 95616 USA.	rfberman@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045136, R01NS029995, R01NS039090] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 45136, NS 39090] Funding Source: Medline		BAUGHMAN VL, 1988, ANESTHESIOLOGY, V69, P192, DOI 10.1097/00000542-198808000-00007; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Beaumont A, 2000, NEUROL RES, V22, P665; Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; Kudo M, 2001, ANESTHESIOLOGY, V95, P756, DOI 10.1097/00000542-200109000-00031; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MICHENFELDER JD, 1987, ANESTHESIOLOGY, V67, P336, DOI 10.1097/00000542-198709000-00010; Miyazaki H, 1997, ANESTHESIOLOGY, V86, P1359, DOI 10.1097/00000542-199706000-00018; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OLTON DS, 1979, NEUROPSYCHOLOGIA, V17, P669, DOI 10.1016/0028-3932(79)90042-3; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; RUTA TS, 1991, CAN J ANAESTH, V38, P129, DOI 10.1007/BF03009176; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SWANSON LW, 1998, BRAIN MAPS STRUCTURE; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; WARNER DS, 1991, J CEREBR BLOOD F MET, V11, P794, DOI 10.1038/jcbfm.1991.137; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; Wilson JX, 2002, J NEUROSURG ANESTH, V14, P66, DOI 10.1097/00008506-200201000-00014; Wise-Faberowski L, 2001, ANESTH ANALG, V93, P1281, DOI 10.1097/00000539-200111000-00051; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	60	119	123	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					521	539		10.1089/089771504774129865			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900004	15165361				2021-06-18	
J	Cherian, L; Hlatky, R; Robertson, CS				Cherian, L; Hlatky, R; Robertson, CS			Nitric oxide in traumatic brain injury	BRAIN PATHOLOGY			English	Article							CORTICAL IMPACT INJURY; CEREBRAL BLOOD-FLOW; L-ARGININE; HEAD-INJURY; SYNTHASE EXPRESSION; INTRACRANIAL HYPERTENSION; CEREBROSPINAL-FLUID; ENDOTHELIAL-CELLS; NERVOUS-SYSTEM; BINDING-SITES	Nitric oxide (NO) is a gaseous chemical messenger which has functions in the brain in a variety of broad physiological processes, including control of cerebral blood flow, interneuronal communications, synaptic plasticity, memory formation, receptor functions, intracellular signal transmission, and release of neurotransmitters. As might be expected from the numerous and complex roles that NO normally has, it can have both beneficial and detrimental effects in disease states, including traumatic brain injury. There are two periods of time after injury when NO accumulates in the brain, immediately after injury and then again several hours-days later. The initial immediate peak in NO after injury is probably due to the activity of endothelial NOS and neuronal NOS. Pre-injury treatment with 7-nitroindazole, which probably inhibits this immediate increase in NO by neuronal NOS, is effective in improving neurological outcome in some models of traumatic brain injury (TBI). After the initial peak in NO, there can be a period of relative deficiency in NO. This period of low NO levels is associated with a low cerebral blood flow (CBF). Administration of L-arginine at this early time improves CBF, and outcome in many models. The late peak in NO after traumatic injury is probably due primarily to the activity of inducible NOS. Inhibition of inducible NOS has neuroprotective effects in most models.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline		BALCIOGLU A, 1993, J NEUROCHEM, V61, P2311, DOI 10.1111/j.1471-4159.1993.tb07475.x; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHERIAN L, 2004, IN PRESS J NEUROTRAU; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; DALKARA T, 1994, NEUROPHARMACOLOGY, V33, P1447, DOI 10.1016/0028-3908(94)90048-5; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GOADSBY PJ, 1992, BRAIN RES, V595, P167, DOI 10.1016/0006-8993(92)91470-Y; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; GROSS SS, 1992, J BIOL CHEM, V267, P25722; Henley CM, 1997, J NEUROCHEM, V69, P259; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HOVDA DA, 1990, ACT NEUR S, V51, P331; HU JG, 1994, NEUROSCI LETT, V175, P41, DOI 10.1016/0304-3940(94)91073-1; Huk I, 1997, CIRCULATION, V96, P667; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; JIA YS, 1994, NEUROREPORT, V5, P793, DOI 10.1097/00001756-199403000-00014; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KNOWLES RG, 1990, BIOCHEM J, V269, P207, DOI 10.1042/bj2690207; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Koppenol WH, 1996, METHOD ENZYMOL, V268, P3; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LEE SM, 1997, J CEREB BLOOD FLOW S, V17, pS592; LEONE AM, 1991, J BIOL CHEM, V266, P23790; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Liu PK, 2001, TRENDS NEUROSCI, V24, P581, DOI 10.1016/S0166-2236(00)01918-4; Liu Q, 1996, METHOD ENZYMOL, V268, P311; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Ma JY, 1996, AM J PHYSIOL-HEART C, V270, pH1085; Ma JY, 1996, AM J PHYSIOL-HEART C, V271, pH1717; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARLETTA MA, 1994, J MED CHEM, V37, P1899, DOI 10.1021/jm00039a001; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P70, DOI 10.1038/jcbfm.1993.9; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Park CO, 2001, YONSEI MED J, V42, P518, DOI 10.3349/ymj.2001.42.5.518; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RENGASAMY A, 1991, J PHARMACOL EXP THER, V259, P310; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Salter M, 1996, J NEUROCHEM, V66, P1683; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sparapani M, 1997, EXP NEUROL, V148, P157, DOI 10.1006/exnr.1997.6627; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; TAHA Z, 1992, BIOCHEM BIOPH RES CO, V188, P734, DOI 10.1016/0006-291X(92)91117-9; UMANS JG, 1995, ANNU REV PHYSIOL, V57, P771, DOI 10.1146/annurev.ph.57.030195.004011; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WADA K, 1997, J NEUROTRAUM, V14, P760; Wei G, 1999, BBA-MOL BASIS DIS, V1455, P23, DOI 10.1016/S0925-4439(99)00051-4; Yamada K, 1997, J NEUROCHEM, V68, P1234; YUAN X-Q, 1990, Journal of Neurotrauma, V7, P141, DOI 10.1089/neu.1990.7.141	92	119	132	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	APR	2004	14	2					195	201		10.1111/j.1750-3639.2004.tb00053.x			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	820SZ	WOS:000221410900010	15193032				2021-06-18	
J	Wilkins, JC; McLeod, TCV; Perrin, DH; Gansneder, BM				Wilkins, JC; McLeod, TCV; Perrin, DH; Gansneder, BM			Performance on the balance error scoring system decreases after fatigue	JOURNAL OF ATHLETIC TRAINING			English	Article						balance; exertion; concussion; injury assessment	MILD HEAD-INJURY; UNILATERAL POSTURAL CONTROL; PERCEIVED EXERTION; MUSCULAR FATIGUE; STABILITY; CONCUSSION; EXERCISE	Objective: To determine the immediate effects of a whole-body fatigue protocol on performance of the Balance Error Scoring System (BESS), a postural-stability test commonly used as part of a concussion-assessment battery. Design and Setting: Subjects were assigned to a fatigue or control group and were assessed before and immediately after a 20-minute fatigue protocol or rest period. Subjects: Fourteen fatigue subjects and 13 control subjects participated in this study. All subjects were male and free of vestibular disorders, and none had suffered a mild head injury or lower extremity injury in the preceding 6 months, as described through self-report. Measurements: We measured performance on the BESS for 9 stance-surface conditions and summed each condition to obtain a total score. Using the Borg scale, we also measured ratings of perceived exertion before, during, and after the fatigue protocol or rest period. Results: We found a significant increase in total errors from pretest to posttest in the fatigue group (14.36 +/- 4.73 versus 16.93 +/- 4.32), a significant decrease in errors in the control group (13.32 +/- 3.77 versus 11.08 +/- 3.88), and a significant difference between groups on the posttest. The rating of perceived exertion scores were significantly different between the fatigue and control groups at the middle (13.29 +/- 1.59 versus 6.23 +/- 0.83) and end (15.86 +/- 2.38 versus 6.15 +/- 0.55) of the fatigue or rest period. Conclusions: The BESS error scores increased immediately after the fatigue protocol, demonstrating that balance ability diminished. Clinicians who use the BESS as part of their sideline assessment for concussion should not administer the test immediately after a concussion due to the effects of fatigue.	Arizona Sch Hlth Sci, Dept Sports Hlth Care, Mesa, AZ 85205 USA; Lakewood High Sch, Hebron, OH USA; Univ N Carolina, Greensboro, NC 27412 USA; Univ Virginia, Charlottesville, VA 22903 USA	McLeod, TCV (corresponding author), Arizona Sch Hlth Sci, Dept Sports Hlth Care, 5850 E Still Circle, Mesa, AZ 85205 USA.	tvalovich@ashs.edu	McLeod, Tamara/AAU-9435-2020				Alderton A.-K., 1996, Scandinavian Journal of Medicine and Science in Sports, V6, P211; Arnold BL, 1998, J ATHL TRAINING, V33, P323; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BROOKS GA, 1996, EXERCISE PHYSL; Crowell DH, 2001, J ATHL TRAINING, V36, pS; Derave W, 1998, ERGONOMICS, V41, P782, DOI 10.1080/001401398186630; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1996, J SPORT REHABIL, V5, P45, DOI 10.1123/jsr.5.1.45; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; Guskiewicz KM, 2002, ORTHOP PHYS THER CLI, V11, P143; Hoffman M, 1998, J ATHL TRAINING, V33, P319; Johnston RB, 1998, MED SCI SPORT EXER, V30, P1703, DOI 10.1097/00005768-199812000-00008; Lee C T, 1998, SPUMS J, V28, P125; Lepers R, 1997, EUR J APPL PHYSIOL, V76, P55, DOI 10.1007/s004210050212; LUNDIN TM, 1993, J APPL BIOMECH, V9, P191, DOI 10.1123/jab.9.3.191; Mahon AD, 1997, MED SCI SPORT EXER, V29, P1332, DOI 10.1097/00005768-199710000-00009; MANCUSO JJ, 2002, J ATHL TRAINING, V37, pS10; McComas AJ, 1996, SKELETAL MUSCLE FORM, P230; Nardone A, 1997, ELECTROMYOGR MOTOR C, V105, P309, DOI 10.1016/S0924-980X(97)00040-4; Nardone A, 1998, ARCH PHYS MED REHAB, V79, P920, DOI 10.1016/S0003-9993(98)90088-0; Ochsendorf DT, 2000, J ATHL TRAINING, V35, P26; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 1997, J SPORT REHABIL, V6, P283, DOI 10.1123/jsr.6.3.283; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Robertson RJ, 2000, MED SCI SPORT EXER, V32, P2120, DOI 10.1097/00005768-200012000-00024; Rozzi S, 2000, PROPRIOCEPTION AND NEUROMUSCULAR CONTROL IN JOINT STABILITY, P375; SELIGA R, 1991, AM IND HYG ASSOC J, V52, P417, DOI 10.1202/0002-8894(1991)052<0417:EOWLAR>2.0.CO;2; SKINNER HB, 1986, J ORTHOP RES, V4, P112, DOI 10.1002/jor.1100040115; Sparto PJ, 1997, J ORTHOP SPORT PHYS, V25, P3, DOI 10.2519/jospt.1997.25.1.3; THOMAS JR, 1975, MED SCI SPORT EXER, V7, P203; Valovich TC, 2003, J ATHL TRAINING, V38, P51; VALOVICH TC, 2002, USE STANDARDIZED ASS; Vuillerme N, 2001, NEUROSCI LETT, V308, P103, DOI 10.1016/S0304-3940(01)01987-5; Westcott Sarah L., 1994, Physical and Occupational Therapy in Pediatrics, V14, P1, DOI 10.1300/J006v14n01_01; Yaggie J. A., 1999, Medicine and Science in Sports and Exercise, V31, pS284, DOI 10.1097/00005768-199905001-01399	38	119	122	0	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2004	39	2					156	161					6	Sport Sciences	Sport Sciences	825EQ	WOS:000221739200006					2021-06-18	
J	Meyers, JE; Volbrecht, ME				Meyers, JE; Volbrecht, ME			A validation of multiple malingering detection methods in a large clinical sample	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						neuropsychology; malingering; token test; finger tapping; Forced Choice Test; rey complex figure; dichotic listening; reliable digits; sentence repetition; rey auditory verbal learning test; judgment of line orientation	CLOSED-HEAD-INJURY; MEMORY; PERFORMANCE; BATTERY; SCALES; FAKING; TESTS	The purpose of this study is to further previous research that has shown that common neuropsychological tests can do "double duty" as test of motivation/malingering. Using a large clinical sample of 796 participants, it was found that the nine neuropsychological tests (when used together) were able to correctly identify litigant and nonlitigating groups. Failure on any two of the malingering tests suggested motivational/malingering issues. The groups consisted of mild, moderate, and severe traumatic brain-injured patients; chronic pain, depressed, community controls, and "malingering actors." Institutionalized and noninstitutionalized patient performance were also examined. This method showed 83% sensitivity and 100% specificity. A 0% false positive rate was found, suggesting good reliability especially in litigating settings. A group of patients for whom this method of motivational assessment might not be appropriate was also identified. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	Mercy Rehabil Clin, Sioux City, IA 51101 USA; Sioux Valley Hosp, Sioux Falls, SD USA	Meyers, JE (corresponding author), Mercy Rehabil Clin, 500 Jackson St,Ste 360, Sioux City, IA 51101 USA.	jmeyers@mstar2.net					*AUD ST LOUIS, 1991, DICH WORD LIST TEST; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1992, ARCH CLIN NEUROPSYCH, V7, P155, DOI 10.1016/0887-6177(92)90009-C; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; DAMASIO H, 1979, NEUROLOGY, V29, P644, DOI 10.1212/WNL.29.5.644; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Kozel JJ, 1998, ARCH CLIN NEUROPSYCH, V13, P327, DOI 10.1016/S0887-6177(97)00036-X; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Meyer-Abich KM, 2000, FORSCH KOMP KLAS NAT, V7, P154, DOI 10.1159/000021332; Meyers J, 1995, REY COMPLEX FIGURE R; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/S15324826AN0804_6; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Meyers J E, 1996, Appl Neuropsychol, V3, P89, DOI 10.1207/s15324826an0302_8; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P79, DOI 10.1016/S0887-6177(00)00105-0; MEYERS JE, 1988, APPL NEUROPSYCHOLOGY, V5, P120; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; OBERG RGE, 1985, NEUROBEHAVIOURAL MET, P130; Pilgrim B M, 1999, Appl Neuropsychol, V6, P243, DOI 10.1207/s15324826an0604_7; REITAN R, 1985, HALSTREADREITAN NEUR; RISSE GL, 1989, ARCH NEUROL-CHICAGO, V46, P437, DOI 10.1001/archneur.1989.00520400097026; Roberts M A, 1994, Appl Neuropsychol, V1, P45, DOI 10.1207/s15324826an0101&2_9; RUSSELL ML, 1993, 21 ANN M INT NEUR SO; SHIMOYAMA I, 1990, ARCH NEUROL-CHICAGO, V47, P681, DOI 10.1001/archneur.1990.00530060095025; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O., 1998, COMPENDIUM NEUROPSYC; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Volbrecht ME, 2000, ARCH CLIN NEUROPSYCH, V15, P251, DOI 10.1016/S0887-6177(99)00016-5; WARD LC, 1990, J CLIN PSYCHOL, V46, P436, DOI 10.1002/1097-4679(199007)46:4<436::AID-JCLP2270460411>3.0.CO;2-M; Wechsler D., 1997, MANUAL WECHSLER ADUL	44	119	121	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	APR	2003	18	3					261	276	PII S0887-6177(02)00136-1	10.1016/S0887-6177(02)00136-1			16	Psychology, Clinical; Psychology	Psychology	666FJ	WOS:000182166200003	14591459	Bronze			2021-06-18	
J	Levin, HS; Brown, SA; Song, JX; McCauley, SR; Boake, C; Contant, CF; Goodman, H; Kotrla, KJ				Levin, HS; Brown, SA; Song, JX; McCauley, SR; Boake, C; Contant, CF; Goodman, H; Kotrla, KJ			Depression and Posttraumatic stress disorder at three months after mild to moderate traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; MAJOR DEPRESSION; SOCIAL SUPPORT; LOBE DYSFUNCTION; COMMUNITY SAMPLE; SEQUELAE; CONSEQUENCES; IMPAIRMENT; SYMPTOMS; MEMORY	To investigate the frequency and risk factors of major depressive disorder (MDD) after mild to moderate traumatic brain injury (TBI), 69 TBI and 52 general trauma (GT) patients were prospectively recruited and studied at 3-months postinjury. There was a nonsignificant difference in the proportion of MDD patients in the TBI and GT groups. Therefore, a composite MDD group (TBI and GT patients) was compared to patients who were nondepressed. Female gender was related to MDD, but no other risk factors were identified. MDD was associated with disability (Glasgow Outcome Scale, Community Integration Questionnaire) and cognitive impairment. MDD was comorbid with posttraumatic stress disorder. Implications for postacute management of mild to moderate TBI are discussed.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr Houston, Dept Phys Med & Rehabil, Houston, TX USA	Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1333 Moursund Ave,A 205, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [258-0020-308] Funding Source: Medline; ODCDC CDC HHS [R49-CCR612707] Funding Source: Medline		AITKEN RCB, 1969, P ROY SOC MED, V62, P989, DOI 10.1177/003591576906201005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barefoot JC, 2000, AM J CARDIOL, V86, P438, DOI 10.1016/S0002-9149(00)00961-9; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; Blanchard EB, 1998, J ANXIETY DISORD, V12, P21, DOI 10.1016/S0887-6185(97)00047-9; BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; BOYD JH, 1982, ARCH GEN PSYCHIAT, V39, P1195; BRAND N, 1987, PSYCHOL MED, V17, P145, DOI 10.1017/S0033291700013040; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; *COMM INJ SCAL, 1990, ABBR INJ SCAL; DAVIS GC, 1994, PSYCHIAT CLIN N AM, V17, P289; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; First M., 1995, STRUCTURED CLIN INTE; FLAHERTY JA, 1983, AM J PSYCHIAT, V140, P473; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRONWALL D, 1974, LANCET, V2, P605; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; HART RP, 1987, PSYCHOL AGING, V2, P111, DOI 10.1037/0882-7974.2.2.111; Heaton R., 1993, WISCONSIN CARD SORTI; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; JENNETT B, 1975, LANCET, V1, P480; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1986, EXPT TECHNIQUES HUMA, P309; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; Matthews C, 1964, INSTRUCTION MANUAL A; MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; RUTHERFORD WH, 1977, LANCET, V1, P1; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Smith A., 1982, SYMBOL DIGIT MODALIT; Stevens M M, 1982, J Neurosurg Nurs, V14, P239; TEASDALE G, 1974, LANCET, P281; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TRICHARD C, 1995, PSYCHOL MED, V25, P79, DOI 10.1017/S0033291700028105; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	76	119	122	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					754	769		10.1076/jcen.23.6.754.1021			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200005	11910542				2021-06-18	
J	Paterakis, K; Karantanas, AH; Komnos, A; Volikas, Z				Paterakis, K; Karantanas, AH; Komnos, A; Volikas, Z			Outcome of patients with diffuse axonal injury: The significance and prognostic value of MRI in the acute phase	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							HEAD-INJURY; BRAIN-INJURY; TRAUMA; FEATURES; LESIONS	Background: To compare the magnetic resonance imaging (MRI) findings in the acute phase with outcome in patients with diffuse axonal injury (DAI). Methods: A group of 33 patients with closed head injury and discrepancy be tween the apparently normal computed tomographic scan findings and their neurologic statuses were studied with MRI during the First 48 hours. Among them, 24 were found to suffer from DAI-type lesions. According to the Glasgow Coma Scale (GCS), 19 patients suffered from severe head injury (GCS score <8) and 5 patients had moderate head injury (GCS score of 9-12), Four MRI sequences in various planes were applied. Patients were divided into three groups, according to staging described in the literature. Results: in five patients, MRI demonstrated nonhemorrhagic DAI lesions stage 1, In 11 patients, findings were consistent with DAI lesions stage 2, eight nonhemorrhagic and three hemorrhagic, Eight patients showed DAI lesions stage 3, six of which were nonhemorrhagic, Conclusions: MRI is more sensitive compared with computed tomography in the detection of traumatic brain lesions, especially the nonhemorrhagic DAI, The presence of hemorrhage in DAI-type lesions and the association with traumatic space-occupying lesions is a poor prognostic sign, Isolated nonhemorrhagic DAI-type lesions are not associated with poor clinical outcome.	Larissa Gen Hosp, CT MRI Dept, Larisa 41221, Greece; Univ Hosp, Dept Neurosurg, Larisa, Greece; Larissa Gen Hosp, ISU Dept, Larisa 41221, Greece; Univ Hosp, Dept Neurosurg, Alexandroupolis, Greece	Karantanas, AH (corresponding author), Larissa Gen Hosp, CT MRI Dept, 1 Tsakalof St, Larisa 41221, Greece.	apolsen@yahoo.com	Karantanas, Apostolos/AAE-6820-2020; Paterakis, Konstantinos/AAH-4554-2019	Karantanas, Apostolos/0000-0002-0927-2403; 			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; COLQUHOUN IR, 1989, CLIN RADIOL, V40, P619, DOI 10.1016/S0009-9260(89)80324-1; EVANS SJJ, 1999, MRI, P1347; Gean A, 1994, IMAGING HEAD TRAUMA; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gentry LR., 1996, MAGNETIC RESONANCE I, P611; GREENBERG MS, 1998, HDB NEUROSURGERY; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; LINDENBERG R, 1955, AM J PATHOL, V31, P297; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; OKAWA T, 1992, ACTA NEUROCHIR, V55, P8; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SKLAR EML, 1992, RADIOL CLIN N AM, V30, P353; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; ZIMMERMAN RA, 1992, CRANIAL MRI CT, P509	27	119	142	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2000	49	6					1071	1075		10.1097/00005373-200012000-00016			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	383XG	WOS:000165909500017	11130491				2021-06-18	
J	Koo, DDH; Welsh, KI; McLaren, AJ; Roake, JA; Morris, PJ; Fuggle, SV				Koo, DDH; Welsh, KI; McLaren, AJ; Roake, JA; Morris, PJ; Fuggle, SV			Cadaver versus living donor kidneys: Impact of donor factors on antigen induction before transplantation	KIDNEY INTERNATIONAL			English	Article; Proceedings Paper	Forefronts in Nephrology In and Out of Control - The Regulation of Renal Cell Growth	JUN 13-16, 1998	JACKSON HOLE, WYOMING	Int Soc Nephrol		adhesion molecules; rejection; renal transplantation; cadaver organ donors; allografts	RENAL-ALLOGRAFT REJECTION; CELL-ADHESION MOLECULES; CLASS-II ANTIGENS; MONOCLONAL-ANTIBODY; BRAIN-DEATH; E-SELECTIN; EPITHELIAL-CELLS; P-SELECTIN; EXPRESSION; LEUKOCYTE	Background. It is widely recognized that living-related donor (LRD) renal allografts have a higher overall graft survival than cadaver donor transplants. We tested the hypothesis that part of this is attributable to LRD kidneys being obtained under optimal conditions from healthy donors, whereas cadaveric kidneys may have experienced injury as a result of inflammatory events around the time of brain death. Methods. We have performed a comparative immunohistochemical analysis of pretransplant donor biopsies from cadaveric (N = 65) and LRD (N = 29) kidneys to determine any differences that may predispose them to subsequent damage. Cryostat sections were stained with antibodies to leukocytes, adhesion molecules, and human leukocyte antigen (HLA)-DR antigens, and the expression was assessed semiquantitatively. Results. High levels of endothelial E-selectin and proximal tubular expression of HLA-DR antigens, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 were detected in biopsies from cadaveric kidneys, whereas expression of these markers was markedly reduced in LRD kidneys. High levels of tubular antigen expression were significantly associated with traumatic death, prolonged ventilation, and episodes of infection in cadaver donors. Furthermore, the expression of pretransplant tubular antigens in cadaver donor kidneys was significantly associated with early acute rejection following transplantation, suggesting that such kidneys are predisposed to subsequent immune-mediated attack following transplantation. Conclusions. These results may explain, in part, the superior outcome of LRD allografts compared with cadaver renal allografts.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Oxford Transplant Ctr, Oxford OX3 9DU, England	Fuggle, SV (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England.						ABBASSI O, 1993, J CLIN INVEST, V92, P2719, DOI 10.1172/JCI116889; AMADO JA, 1995, METABOLISM, V44, P812, DOI 10.1016/0026-0495(95)90198-1; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BEVERLEY PCL, 1981, EUR J IMMUNOL, V11, P329, DOI 10.1002/eji.1830110412; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BISHOP GA, 1989, KIDNEY INT, V36, P1078, DOI 10.1038/ki.1989.303; BROCKMEYER C, 1993, TRANSPLANTATION, V55, P610; CECKA JM, 1994, CLIN TRANSPLANT, V8, P324; CECKA JM, 1996, TRANSPLANT REV, V10, P216; DALCHAU R, 1980, EUR J IMMUNOL, V10, P737, DOI 10.1002/eji.1830101003; FAULL RJ, 1989, TRANSPLANTATION, V48, P226, DOI 10.1097/00007890-198908000-00009; FUGGLE SV, 1986, TRANSPLANTATION, V42, P144, DOI 10.1097/00007890-198608000-00008; Fuggle SV, 1998, TRANSPLANTATION, V65, P763, DOI 10.1097/00007890-199803270-00001; FUGGLE SV, 1993, TRANSPLANTATION, V55, P117, DOI 10.1097/00007890-199301000-00022; FUGGLE SV, 1987, TRANSPLANTATION, V44, P214, DOI 10.1097/00007890-198708000-00008; GRUNDMANN R, 1981, TRANSPLANTATION, V32, P184, DOI 10.1097/00007890-198109000-00003; Guesde R, 1998, LANCET, V352, P1178, DOI 10.1016/S0140-6736(98)05456-7; HASHEMI S, 1993, J CELL PHYSIOL, V154, P496, DOI 10.1002/jcp.1041540307; Herijgers P, 1996, TRANSPLANTATION, V62, P330, DOI 10.1097/00007890-199608150-00005; HILL PA, 1995, KIDNEY INT, V47, P1383, DOI 10.1038/ki.1995.194; Hirschl MM, 1996, NEPHROL DIAL TRANSPL, V11, P173; HOGG N, 1984, IMMUNOLOGY, V53, P753; JONES JW, 1994, TRANSPLANTATION, V57, P512; JONES RM, 1988, BRIT J SURG, V75, P4, DOI 10.1002/bjs.1800750104; KANWAR S, 1995, BLOOD, V86, P2760; KELLY PMA, 1988, J CLIN PATHOL, V41, P510, DOI 10.1136/jcp.41.5.510; KIRBY JA, 1993, KIDNEY INT, V43, pS124; Koo DDH, 1998, AM J PATHOL, V153, P557, DOI 10.1016/S0002-9440(10)65598-8; Langeron O, 1996, BRIT J ANAESTH, V76, P783; LAWRENCE MB, 1993, J IMMUNOL, V151, P6338; LIN Y, 1992, CLIN EXP IMMUNOL, V90, P111; LIN Y, 1993, CLIN EXP IMMUNOL, V92, P145; Lowell JA, 1996, SURGERY, V119, P538, DOI 10.1016/S0039-6060(96)80264-9; MANUCCI PM, 1990, ANNU REV MED, V41, P55; MANUCCI PM, 1988, BLOOD, V72, P1449; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MERTES PM, 1994, TRANSPLANTATION, V58, P414, DOI 10.1097/00007890-199408270-00004; Morgan J D, 1994, Transpl Immunol, V2, P326, DOI 10.1016/0966-3274(94)90010-8; MORRIS PJ, 1994, KIDNEY TRANSPLANTATI, P504; Opelz G, 1997, TRANSPLANTATION, V64, P1473, DOI 10.1097/00007890-199711270-00017; PELOSI G, 1986, EUR J ANAESTH, V3, P209; Pratschke J, 1999, TRANSPLANTATION, V67, P343, DOI 10.1097/00007890-199902150-00001; RAFTERY MJ, 1989, TRANSPLANTATION, V48, P238, DOI 10.1097/00007890-198908000-00011; SERON D, 1991, NEPHROL DIAL TRANSPL, V6, P917, DOI 10.1093/ndt/6.12.917; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Suzuki MM, 1997, BRIT MED BULL, V53, P854; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; THIEL G, 1997, PROCUREMENT PRESERVA, P367; WUN T, 1995, J LAB CLIN MED, V126, P401	50	119	122	0	2	BLACKWELL SCIENCE INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	0085-2538			KIDNEY INT	Kidney Int.	OCT	1999	56	4					1551	1559		10.1046/j.1523-1755.1999.00657.x			9	Urology & Nephrology	Urology & Nephrology	237GV	WOS:000082648200063	10504507				2021-06-18	
J	Maas, AIR; Steyerberg, EW; Murray, GD; Bullock, R; Baethmann, A; Marshall, LF; Teasdale, GM				Maas, AIR; Steyerberg, EW; Murray, GD; Bullock, R; Baethmann, A; Marshall, LF; Teasdale, GM			Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations	NEUROSURGERY			English	Article						clinical trials; head injury; neuroprotection; outcome; prognosis; statistical analysis	TRAUMATIC SUBARACHNOID HEMORRHAGE; TIRILAZAD MESYLATE; MULTICENTER; NIMODIPINE; GUIDELINES; MANAGEMENT; RELEASE; ADULTS; BRAIN; RAT	AN OVERVIEW OF the results of recent trials of neuroprotective agents in head injury is presented. None of the trials showed efficacy in the general population of patients with a severe head injury. A critical analysis of the possible reasons for this failure is given. Specific attention is focused on the heterogeneity of the patient population, the importance of baseline prognostic indicators, and the problems caused by the distribution of outcome and the dichotomization of these outcomes in the Glasgow Outcome Scale. Recommendations are presented for consideration in the design and analysis of future trials in head injury.	Erasmus Univ, Acad Hosp Rotterdam Dijkzigt, Dept Neurosurg, NL-3015 GD Rotterdam, Netherlands; Erasmus Univ, Ctr Clin Decis Sci, Dept Publ Hlth, NL-3015 GD Rotterdam, Netherlands; Univ Edinburgh, Sch Med, Med Stat Unit, Edinburgh, Midlothian, Scotland; Univ Glasgow, Dept Neurosurg, Glasgow, Lanark, Scotland; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Univ Munich, Klinikum Grosshadern, Inst Chirurg Forsch, D-8000 Munich, Germany; Univ Calif San Diego, Dept Neurol Surg, San Diego, CA 92103 USA	Maas, AIR (corresponding author), Erasmus Univ, Acad Hosp Rotterdam Dijkzigt, Dept Neurosurg, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.		Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1996, J NEUROTRAUM, V13, P643; BULLOCK R, 1994, P 9 INT S ICP ITS RE, P264; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; CHOI SC, 1996, NEUROTRAUMA, P779; Davis SM, 1997, LANCET, V349, P32, DOI 10.1016/S0140-6736(05)62166-6; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fleishaker JC, 1997, J PHARM SCI, V86, P434, DOI 10.1021/js960410e; Fleishaker Joseph C., 1995, Am J Ther, V2, P553, DOI 10.1097/00045391-199508000-00007; GAIL MH, 1984, BIOMETRIKA, V71, P431; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Hardy RJ, 1996, STAT MED, V15, P619, DOI 10.1002/(SICI)1097-0258(19960330)15:6<619::AID-SIM188>3.0.CO;2-A; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HOGAN MJ, 1995, EXP NEUROL, V134, P56, DOI 10.1006/exnr.1995.1036; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KAKARIEKA A, 1997, TRAUMATIC SUBARACHNO; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; Knaus WA, 1996, CRIT CARE MED, V24, P46, DOI 10.1097/00003246-199601000-00010; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; MURRAY GD, IN PRESS ACTA NEUROC; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NISSEN JJ, 1995, J NEUROL NEUROSUR PS, V59, P206; RAPPORT RL, 1973, J NEUROSURG, V38, P159, DOI 10.3171/jns.1973.38.2.0159; Robinson LD, 1991, INT STAT REV, V58, P227; ROBINSON MJ, 1990, CEREBROVAS BRAIN MET, V2, P205; STRAW RN, 1995, PRELIMINARY EFFICACY; TEASDALE GM, IN PRESS ACTA NEUROC; Topol E, 1997, NEW ENGL J MED, V337, P1118; Treasure T, 1998, BRIT MED J, V317, P362; Vollmer DG, 1991, J NEUROSURG S, V75, P37; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Zauner A, 1996, ACT NEUR S, V67, P40	44	119	121	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JUN	1999	44	6					1286	1298		10.1097/00006123-199906000-00076			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	201HB	WOS:000080588400065					2021-06-18	
J	Roberts, I; Schierhout, G; Alderson, P				Roberts, I; Schierhout, G; Alderson, P			Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: a systematic review	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injuries; systematic review; meta-analysis; randomised controlled trials	TRAUMATIC BRAIN INJURY; PRESSURE; TRIALS; MANNITOL	Objectives-To assess the effectiveness of interventions routinely used in the intensive care management of severe head injury, specifically, the effectiveness of hyperventilation, mannitol, CSF drainage, barbiturates, and corticosteroids. Methods-Systematic review of all unconfounded randomised trials, published or unpublished, that were available by August 1996. Results-None of the interventions has been reliably shown to reduce death or disability after severe head injury. One trial of hyperventilation was identified of 77 participants. The relative risk for death was 0.73 (95% confidence interval (95% CI) 0.36-1.49), and for death or disability it was 1.14 (95% CI 0.82-1.58), One trial of mannitol was identified of 41 participants. The relative risk for death was 1.75 (95% CI 0.48-6.38), no data were available for disability. No randomised trials of CSF drainage were identified. Two randomised trials of barbiturate therapy were identified, including 126 participants. The pooled relative risk for death was 1.12 (95% CI 0.81-1.54). Disability data were available for one trial. The relative risk for death or disability was 0.96 (95% CI 0.62-1.49). Thirteen randomised trials of corticosteroids were identified, comprising 2073 participants. The pooled relative risk for death was 0.95 (0.84 to 1.07) and for death or disability it was 1.01 (95% CI 0.91 to 1.11). On the basis of the currently available randomised evidence, for every intervention studied it is impossible to refute either a moderate increase or a moderate decrease in the risk of death or disability. Conclusion-Existing trials have been too small to support or refute the existence of a real benefit from using hyperventilation, mannitol, CSF drainage, barbiturates, or corticosteroids. Further large scale randomised trials of these interventions are required.	Univ London, Inst Child Hlth, Dept Epidemiol & Publ Hlth, Child Hlth Monitoring Unit, London WC1N 1EH, England; Cochrane Ctr, Oxford, England	Roberts, I (corresponding author), Univ London, Inst Child Hlth, Dept Epidemiol & Publ Hlth, Child Hlth Monitoring Unit, 30 Guilford St, London WC1N 1EH, England.			Schierhout, Gill/0000-0002-6399-7624			Alderson P, 1998, BRIT MED J, V316, P396; Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; ALDERSON P, 1998, INJURIES GROUP MODUL; ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; [Anonymous], 1997, LANCET, V349, P1263; BOHN DJ, 1989, CRIT CARE MED S, V118, P17; Brain Trauma Foundation, 1995, GUID MAN SEV HEAD IN; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FANCONI S, 1988, INTENS CARE MED, V14, P163; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; ROBERTS I, 1998, INJURIES GROUP MODUL; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Sayre MR, 1996, ACAD EMERG MED, V3, P840, DOI 10.1111/j.1553-2712.1996.tb03528.x; SCHIERHOUT G, 1998, INJURIES GROUP MODUL; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; YANO M, 1981, Neurologia Medico-Chirurgica, V21, P163	24	119	122	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	1998	65	5					729	733		10.1136/jnnp.65.5.729			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	133VC	WOS:000076706400022	9810947	Green Published, Bronze			2021-06-18	
J	Levine, B; Stuss, DT; Milberg, WP; Alexander, MP; Schwartz, M; MacDonald, R				Levine, B; Stuss, DT; Milberg, WP; Alexander, MP; Schwartz, M; MacDonald, R			The effects of focal and diffuse brain damage on strategy application: Evidence from focal lesions, traumatic brain injury and normal aging	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	Annual Meeting of the American-Psychological-Association	AUG 09-12, 1996	TORONTO, CANADA	Amer Psychol Assoc		executive functioning; strategy application; frontal lobe; traumatic brain injury; aging	FRONTAL-LOBE LESIONS; CLOSED-HEAD-INJURY; SPATIAL WORKING-MEMORY; CARD SORTING TEST; SUSTAINED ATTENTION; CORTEX; AGE; BEHAVIOR; COMA; DISTURBANCE	A new test of strategy application was designed to be relatively free of the constraints that limit the standard neuropsychological assessment of supervisory abilities. The validity of the test was assessed in 3 samples of participants with varying degrees of supervisory deficits and frontal systems dysfunction: focal frontal lesions, traumatic brain injury (TBI), and normal aging. Inefficient strategy application varied systematically across the 3 groups and was not due to extraneous factors such as forgetting the test instructions. Previous case studies have emphasized strategy application deficits in the face of normal neuropsychological test performance. In this study, it was shown that strategically impaired participants from a consecutive series can include those both with and without deficient neuropsychological test performance. When neuropsychological impairment was present, it was greatest on executive functioning tasks. Among participants with nonstrategic performance, there was evidence for a dissociation of knowledge from action. This finding was not specific to focal frontal lesions. A number of supervisory processes contributing to strategy application were identified. Exploratory analyses indicated differential effects of lesion location on these processes, especially inferior medial frontal and right hemisphere lesions. Overall, the results supported the use of unstructured tasks in the assessment of supervisory abilities.	Baycrest Ctr Geriatr Care, Rotman Res Inst, N York, ON M6A 2E1, Canada; Univ Toronto, Toronto, ON, Canada; Harvard Univ, Sch Med, Dept Psychiat, W Roxbury, MA USA; Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, W Roxbury, MA USA; Boston VAMC, Memory Disorders Res Ctr, Boston, MA USA; Harvard Univ, Sch Med Neurol, Boston, MA USA; Sunnybrook Hlth Sci Ctr, Dept Neurosurg, Toronto, ON M4N 3M5, Canada	Levine, B (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, N York, ON M6A 2E1, Canada.	blevine@rotman-baycrest.on.ca	Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Milberg, William/0000-0002-6078-7066			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALBERT MS, 1990, PSYCHOL AGING, V5, P94, DOI 10.1037/0882-7974.5.1.94; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Army Individual Test Battery, 1944, MAN DIR SCOR; Baddeley A. D., 1986, WORKING MEMORY; Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; Blom G., 1958, STAT ESTIMATES TRANS; Cabeza R, 1997, J NEUROSCI, V17, P391; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; COFFEY CE, 1992, NEUROLOGY, V42, P527, DOI 10.1212/WNL.42.3.527; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; CRAIK FIM, 1987, PSYCHOL AGING, V2, P79, DOI 10.1037/0882-7974.2.1.79; CREASEY H, 1985, ANN NEUROL, V17, P2, DOI 10.1002/ana.410170103; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; Damasio H., 1989, LESION ANAL NEUROPSY; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DUNCAN J, 1995, NEUROPSYCHOLOGIA, V33, P261, DOI 10.1016/0028-3932(94)00124-8; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FLOOD DG, 1988, NEUROBIOL AGING, V9, P453, DOI 10.1016/S0197-4580(88)80098-8; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GLOSSER G, 1990, J CLIN EXP NEUROPSYC, V12, P485, DOI 10.1080/01688639008400995; GOLDBERG E, 1981, BRAIN LANG, V14, P144, DOI 10.1016/0093-934X(81)90072-9; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDSTEIN FC, 1989, CORTEX, V25, P541, DOI 10.1016/S0010-9452(89)80016-4; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GUR RC, 1987, ARCH GEN PSYCHIAT, V44, P617; Handler J., 1994, HANDB NEUR, P125; Harlow JM, 1848, BOSTON MED SURG J, V39, P389, DOI DOI 10.1056/NEJM184812130392001; HASLAM C, 1995, NEUROPSYCHOLOGY, V9, P599, DOI 10.1037/0894-4105.9.4.599; Heaton R., 1993, WISCONSIN CARD SORTI; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; Kaplan E., 1983, BOSTON NAMING TEST; KARNATH HO, 1991, NEUROPSYCHOLOGIA, V29, P271, DOI 10.1016/0028-3932(91)90042-7; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; KNIGHT RT, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P139; KONOW A, 1970, NEUROPSYCHOLOGIA, V8, P489, DOI 10.1016/0028-3932(70)90044-8; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Levine B, 1997, NEUROPSYCHOLOGY, V11, P367, DOI 10.1037/0894-4105.11.3.367; LURIA AR, 1981, HIGHER CORTICAL FUNC; LURIA AR, 1973, WORKING BRAIN INTRO, P187; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MESULAM MM, 1986, ANN NEUROL, V19, P320, DOI 10.1002/ana.410190403; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P100, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; Miotto EC, 1996, CORTEX, V32, P613, DOI 10.1016/S0010-9452(96)80034-7; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Penfield W, 1935, BRAIN, V58, P115, DOI 10.1093/brain/58.1.115; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PODELL K, 1995, J NEUROPSYCH CLIN N, V7, P491; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; Schacter DL, 1996, NEUROREPORT, V7, P1165, DOI 10.1097/00001756-199604260-00014; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T, 1993, ATTENTION SELECTION, P171; Sheerer M., 1941, PSYCHOL MONOGRAPHS, V53; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [DOI 10.1037/0894-4105.8.3.355, 10.1037/0894-4105.8.3.355]; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 1996, PSYCHOL AGING, V11, P387, DOI 10.1037/0882-7974.11.3.387; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; STUSS DT, 1994, HDB NEUROPSYCHOLOGY, V9, P149; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 1985, WECHSLER ADULT INTEL; Wechsler D., 1987, WECHSLER MEMORY SCAL; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212	92	119	119	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	1998	4	3					247	264		10.1017/S1355617798002471			18	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	103FA	WOS:000075146400003	9623000				2021-06-18	
J	Springer, JE; Azbill, RD; Kennedy, SE; George, J; Geddes, JW				Springer, JE; Azbill, RD; Kennedy, SE; George, J; Geddes, JW			Rapid calpain I activation and cytoskeletal protein degradation following traumatic spinal cord injury: Attenuation with riluzole pretreatment	JOURNAL OF NEUROCHEMISTRY			English	Article						microtubule-associated protein 2; spectrin; cytoskeleton; glutamate; calcium; calpain I; riluzole; CNS injury	MICROTUBULE-ASSOCIATED PROTEIN-2; EXCITATORY AMINO-ACIDS; FOCAL CEREBRAL-ISCHEMIA; BRAIN INJURY; NERVOUS-SYSTEM; RAT-BRAIN; NEUTRAL PROTEASE; MU-CALPAIN; CALCIUM; PROTEOLYSIS	Immunocytochemical and immunoblotting techniques were used to investigate calpain I activation and the stability of the calpain-sensitive cytoskeletal proteins microtubule-associated protein 2 (MAP2) and spectrin at 1, 4, and 24 h after contusion injury to the spinal cord. Spinal cord injury resulted in the activation of calpain I at all time points examined, with the highest level of activation occurring at 1 h. At the same early time point, there was a loss of dendritic MAP2 staining in spinal cord sections, accompanied by pronounced perikaryal accumulation. The loss in MAP2 staining in the injured spinal cord progressed over the 24-h survival period to affect regions 3 mm distant to the site of injury. The presence of calpain I-specific spectrin degradation was apparent in neuronal cell bodies and fibers as early as 1 h after injury, with the most intense staining occurring within and juxtaposed to the injury site. Spectrin breakdown products in neuronal cell bodies declined rapidly at 4 h and were nearly undetectable at 24 h after injury. Immunoblot studies confirmed the immunocytochemical results by demonstrating a significant increase in calpain I activation, a significant decrease in MAP2 levels, and a significant increase in spectrin breakdown. Finally, treatment of animals with riluzole, an inhibitor of glutamate release, before surgery reduced significantly the loss of MAP2 levels observed at 24 h after injury. These results demonstrate that Ca2+-dependent protease activation and degradation of critical cytoskeletal proteins are early events after spinal cord injury and that treatments that minimize the actions of glutamate may limit their breakdown.	UNIV KENTUCKY,MED CTR,SANDERS BROWN CTR AGING,LEXINGTON,KY 40536	Springer, JE (corresponding author), UNIV KENTUCKY,MED CTR,DEPT ANAT & NEUROBIOL,800 ROSE ST,LEXINGTON,KY 40536, USA.		springer, joe/B-2581-2014	springer, joe/0000-0001-9611-8107; Azbill, David/0000-0001-7989-1771	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R35AG008974] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-08974] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30248] Funding Source: Medline		ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; ARLINGHAUS L, 1991, EUR J PHARMACOL, V209, P123, DOI 10.1016/0014-2999(91)90022-I; BANIK NL, 1987, METAB BRAIN DIS, V2, P117, DOI 10.1007/BF00999722; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; CANER H, 1993, BRAIN RES, V607, P354, DOI 10.1016/0006-8993(93)91531-V; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CONG JY, 1989, J BIOL CHEM, V264, P10096; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; Doble A, 1996, NEUROLOGY, V47, pS233, DOI 10.1212/WNL.47.6_Suppl_4.233S; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; IWASAKI Y, 1987, BRAIN RES, V406, P99, DOI 10.1016/0006-8993(87)90773-6; IWASAKI Y, 1985, BRAIN RES, V347, P124, DOI 10.1016/0006-8993(85)90897-2; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KAMPFL A, 1995, NEUROSCI LETT, V194, P149, DOI 10.1016/0304-3940(95)11745-I; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; MORIYA T, 1994, J NEUROTRAUM, V11, P255, DOI 10.1089/neu.1994.11.255; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PERLMUTTER LS, 1988, SYNAPSE, V2, P79, DOI 10.1002/syn.890020111; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; SAIDO TC, 1994, FASEB J, V8, P814; SAMIS JA, 1987, BIOCHEM J, V246, P481, DOI 10.1042/bj2460481; SCHLAEPFER WW, 1985, ANN NY ACAD SCI, V455, P552, DOI 10.1111/j.1749-6632.1985.tb50435.x; SIMAN R, 1985, BRAIN RES, V347, P399, DOI 10.1016/0006-8993(85)90208-2; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; ZIMMERMAN UJP, 1984, PROG NEUROBIOL, V23, P63, DOI 10.1016/0301-0082(84)90012-1; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P192, DOI 10.1016/0167-4838(91)99009-H	60	119	120	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	OCT	1997	69	4					1592	1600		10.1046/j.1471-4159.1997.69041592.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	XX057	WOS:A1997XX05700028	9326288	Bronze			2021-06-18	
J	Yousem, DM; Geckle, RJ; Bilker, WB; McKeown, DA; Doty, RL				Yousem, DM; Geckle, RJ; Bilker, WB; McKeown, DA; Doty, RL			Posttraumatic olfactory dysfunction: MR and clinical evaluation	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article						brain, magnetic resonance; head, injuries; nerves, olfactory (I)	SMELL IDENTIFICATION TEST; POST-TRAUMATIC ANOSMIA; KALLMANN SYNDROME; INTERNAL CONSISTENCY; HEAD TRAUMA; TASTE; RELIABILITY	PURPOSE: To evaluate the sites of injury in patients with posttraumatic olfactory deficits and to compare damage with findings on clinical olfactory tests. METHODS: Twenty-five patients with posttraumatic olfactory dysfunction were examined by means of olfactory testing, endoscopy, and MR imaging. MR surface-coil scans through the olfactory bulbs and tracts and head-coil scans of the temporal lobes were evaluated. Quantitative and qualitative gradings of damage to the olfactory bulbs, tracts, subfrontal region, hippocampus, and temporal lobes were compared with results on tests of odor identification, detection, memory, and discrimination. RESULTS: Twelve patients were anosmic, eight had severe impairment, and five were mildly impaired. Injuries to the olfactory bulbs and tracts (88% of patients), subfrontal region (60%), and temporal lobes (32%) were found, but these did not correlate well with individual olfactory test scores. Volumetric analysis showed that patients without smell function had greater volume loss in olfactory bulbs and tracts than did those posttraumatic patients who retained some sense of smell. Qualitative and quantitative assessments of damage showed few significant correlations with olfactory tests, probably because of multifocal injuries, primary olfactory nerve damage, and the constraints of a small sample size on the detection of clinically significant differences. CONCLUSION: MR imaging shows abnormalities in patients with posttraumatic olfactory dysfunction at a very high rate (88%), predominantly in the olfactory bulbs and tracts and the inferior frontal lobes.	UNIV PENN,MED CTR,CTR SMELL & TASTE,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT BIOSTAT & EPIDEMIOL,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,CTR CLIN EPIDEMIOL & BIOSTAT,PHILADELPHIA,PA 19104	Yousem, DM (corresponding author), UNIV PENN,MED CTR,DEPT RADIOL,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Doty, Richard L/G-1602-2013; Doty, Richard L/B-7623-2012		NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [5 PO1 DC 00161-15] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P01DC000161] Funding Source: NIH RePORTER		[Anonymous], 1942, Proc R Soc Med, V35, P601; BICK DP, 1993, AM J NEURORADIOL, V14, P852; BROMLEY SM, 1995, CORTEX, V31, P25, DOI 10.1016/S0010-9452(13)80103-7; CONSTANZO RM, 1985, BRAIN RES, V361, P258; Costanzo RM, 1991, SMELL TASTE HLTH DIS, P711; COSTANZO RM, 1987, NY ACAD SCI, V510, P242; DOTY RL, 1985, CHEM SENSES, V10, P297; Doty RL, 1995, CHEM SENSES, V20, P645, DOI 10.1093/chemse/20.6.645; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; DOTY RL, 1989, PERCEPT PSYCHOPHYS, V45, P381, DOI 10.3758/BF03210709; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HOTCHBERG Y, 1988, BIOMETRIKA, V75, P800; IIDA Y, 1994, ARCH OTOLARYNGOL, V120, P869; JAFEK BW, 1989, ARCH NEUROL-CHICAGO, V46, P300, DOI 10.1001/archneur.1989.00520390066018; KNORR JR, 1993, AM J NEURORADIOL, V14, P845; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leigh AD, 1943, LANCET, V1, P38; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; LI C, 1994, AM J ROENTGENOL, V162, P411, DOI 10.2214/ajr.162.2.8310937; MOTT AE, 1991, MED CLIN N AM, V75, P1321, DOI 10.1016/S0025-7125(16)30391-1; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; SCHECHTER PJ, 1974, J NEUROL NEUROSUR PS, V37, P802, DOI 10.1136/jnnp.37.7.802; SMITH RS, 1993, PERCEPT PSYCHOPHYS, V54, P649, DOI 10.3758/BF03211788; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; TRUWIT CL, 1993, AM J NEURORADIOL, V14, P827; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; VOGL TJ, 1994, RADIOLOGY, V191, P53, DOI 10.1148/radiology.191.1.8134597; VOLLMECKE TA, 1985, CHEM SENSES, V10, P413; YOUSEM DM, 1993, AM J NEURORADIOL, V14, P839; YOUSEM DM, 1996, AJR AM J ROENTGENOL, V166, P711; ZUSHO H, 1982, ARCH OTOLARYNGOL, V108, P90	31	119	126	0	4	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	JUN-JUL	1996	17	6					1171	1179					9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	UQ749	WOS:A1996UQ74900027	8791933				2021-06-18	
J	LEVIN, H; KRAUS, MF				LEVIN, H; KRAUS, MF			THE FRONTAL LOBES AND TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CLOSED-HEAD-INJURY; DOUBLE-BLIND; POSTSTROKE DEPRESSION; METHYLPHENIDATE; DAMAGE; MEMORY; ORGANIZATION; PERFORMANCE; STRATEGIES; DEFICITS	The authors review 1) the pathophysiological, neuroimaging, and neurobehavioral evidence for frontal lobe involvement in closed head injury; 2) studies elucidating the cognitive deficits and behavioral disturbance related to frontal lobe lesions associated with head injury; and 3) pharmacologic treatment of the neuropsychiatric manifestations of frontal lobe injury, including emerging therapies.	JOHNS HOPKINS UNIV HOSP,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	LEVIN, H (corresponding author), UNIV MARYLAND MED SYST,DIV NEUROSURG,22 S GREENE ST,BALTIMORE,MD 21201, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Andersson Stein, 1992, Tidsskrift for den Norske Laegeforening, V112, P2070; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; BLUMBERGS P, 1989, J NEUROL NEUROSUR PS, V52, P938; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; CAMPBELL JJ, 1994, J NEUROPSYCH CLIN N, V6, P411; CHUGANI HT, 1991, J NUCL MED, V32, P23; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; DENNEY DR, 1973, DEV PSYCHOL, V9, P275, DOI 10.1037/h0035092; DIAMOND A, 1989, BEHAV NEUROSCI, V103, P526, DOI 10.1037/0735-7044.103.3.526; DREWE E A, 1975, Cortex, V11, P8; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; EVANS R, 1987, J NERV MENT DIS, V162, P366; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GOLDSTEIN FC, 1991, BRAIN COGNITION, V17, P23, DOI 10.1016/0278-2626(91)90063-E; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; HIRST W, 1988, BRAIN COGNITION, V8, P379, DOI 10.1016/0278-2626(88)90060-7; ICHISE M, 1994, J NUCL MED, V35, P217; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; KAUFMANN MW, 1984, CAN J PSYCHIAT, V29, P46, DOI 10.1177/070674378402900112; KRAUS MF, 1992, SOUTHERN MED J, V85, P985, DOI 10.1097/00007611-199210000-00012; Kuczenski R, 1983, STIMULANTS NEUROCHEM, P31; LAZARUS LW, 1992, J CLIN PSYCHIAT, V53, P447; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LINGAM VR, 1988, J CLIN PSYCHIAT, V49, P151; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; Luria A. R., 1963, RESTORATION FUNCTION; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; MILNER B, 1985, HUM NEUROBIOL, V4, P137; OSCARBERMAN M, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P230; OTA Y, 1969, LATE EFFECTS HEAD IN, P110; PARKS RW, 1992, J NEUROPSYCH CLIN N, V4, P109; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; PORTEUS SD, 1962, J MENT SCI, V108, P53; PRAYER L, 1993, ACTA RADIOL, V34, P593; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; SALLOWAY SP, 1994, J NEUROPSYCH CLIN N, V6, P388; SCHULMAN EA, 1992, NEUROLOGY, V42, P16; SEMLITSCH HV, 1992, J NEURAL TRANSM-PARK, V4, P319, DOI 10.1007/BF02260080; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHEFTELL FD, 1992, NEUROLOGY, V42, P32; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; Silver Jonathan M., 1994, P631; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; WICKENS DD, 1970, PSYCHOL REV, V77, P1, DOI 10.1037/h0028569; WOODS SW, 1986, J CLIN PSYCHIAT, V47, P12; ZATORRE RJ, 1983, BRAIN COGNITION, V2, P331, DOI 10.1016/0278-2626(83)90017-9	60	119	120	0	16	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	1994	6	4					443	454					12	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	PN731	WOS:A1994PN73100012	7841815				2021-06-18	
J	Fenn, AM; Hall, JCE; Gensel, JC; Popovich, PG; Godbout, JP				Fenn, Ashley M.; Hall, Jodie C. E.; Gensel, John C.; Popovich, Phillip G.; Godbout, Jonathan P.			IL-4 Signaling Drives a Unique Arginase (+)/IL-1 beta(+) Microglia Phenotype and Recruits Macrophages to the Inflammatory CNS: Consequences of Age-Related Deficits in IL-4R alpha after Traumatic Spinal Cord Injury	JOURNAL OF NEUROSCIENCE			English	Article						advanced age; IL-4; inflammation; M2a; microglia; spinal cord injury	ALTERNATIVE ACTIVATION; GERIATRIC-PATIENTS; MICE EXHIBIT; BRAIN-INJURY; T-CELLS; RECOVERY; PROMOTES; EXPRESSION; INTERLEUKIN-4; NEUROINFLAMMATION	Alternative activation of microglia/ macrophages (M2a) by interleukin (IL)-4 is purported to support intrinsic growth and repair processes after CNS injury. Nonetheless, alternative activation of microglia is poorly understood in vivo, particularly in the context of inflammation, injury, and aging. Here, we show that aged mice (18 -19 months) had reduced functional recovery after spinal cord injury (SCI) associated with impaired induction of IL-4 receptor alpha (IL-4R alpha) on microglia. The failure to successfully promote an IL-4/ IL-4R alpha response in aged mice resulted in attenuated arginase (M2a associated), IL-1, and chemokine ligand 2 (CCL2) expression, and diminished recruitment of IL-4R macrophages to the injured spinal cord. Furthermore, the link between reduced IL-4R beta expression and reduced arginase, IL-1, and CCL2 expression was confirmed using adult IL-4R beta knock-out (IL-4R alpha(KO)) mice. To better understand IL-4R -mediated regulation of active microglia, a series of studies was completed in mice that were peripherally injected with lipopolysaccharide and later provided IL-4 by intracerebroventricular infusion. These immune-based studies demonstrate that inflammatoryinduced IL-4R alpha upregulation on microglia was required for the induction of arginase by IL-4. In addition, IL-4-mediated reprogramming of active microglia enhanced neurite growth ex vivo and increased inflammatory gene expression (i. e., IL-1 beta and CCL2) and the corresponding recruitment of CCR2 alpha / IL-4R -/ arginase myeloid cells in vivo. IL-4 reprogrammed active microglia to a unique and previously unreported phenotype (arginase alpha/IL-1 beta+) that augmented neurite growth and enhanced recruitment of peripheral IL-4R alpha+ myeloid cells to the CNS. Moreover, this key signaling cascade was impaired with age corresponding with reduced functional recovery after SCI.	[Fenn, Ashley M.; Hall, Jodie C. E.; Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Gensel, John C.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Inst Behav Med Res, Columbus, OH 43210 USA	Godbout, JP (corresponding author), Ohio State Univ, 259 IBMR Bldg,460 Med Ctr Dr, Columbus, OH 43210 USA.	jonathan.godbout@osumc.edu	Zhang, Xiaolei/E-2761-2012	Zhang, Xiaolei/0000-0003-0117-7599; Hall, Jodie/0000-0002-4820-6070; , John/0000-0001-8980-108X	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG-033028]; Howard Hughes Medical InstituteHoward Hughes Medical Institute; Ohio State Presidential Fellowship; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033028] Funding Source: NIH RePORTER	This research was supported by National Institute on Aging Grant R01-AG-033028 to J. P. G. A. M. F. was supported by a Med into Grad Fellowship from the Howard Hughes Medical Institute and is currently supported by an Ohio State Presidential Fellowship. We thank Zhen Guan (Ohio State University, OSU), Yan Huang (OSU), and Dr. Nicole Powell (OSU) for their technical assistance.	Barrette B, 2010, BRAIN BEHAV IMMUN, V24, P1254, DOI 10.1016/j.bbi.2010.07.249; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bronte V, 2003, J IMMUNOL, V170, P270, DOI 10.4049/jimmunol.170.1.270; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Butti E, 2008, GENE THER, V15, P504, DOI 10.1038/gt.2008.10; Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005; Chen HY, 1997, NEUROEPIDEMIOLOGY, V16, P241, DOI 10.1159/000109693; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Fassett DR, 2007, J NEUROSURG-SPINE, V7, P277, DOI 10.3171/SPI-07/09/277; Fenn A.M., 2013, BIOL PSYCHIAT; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Gensel JC, 2009, J NEUROSCI, V29, P3956, DOI 10.1523/JNEUROSCI.3992-08.2009; Gwak YS, 2004, NEUROSCI LETT, V362, P232, DOI 10.1016/j.neulet.2004.03.019; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Huang Y, 2008, NEUROBIOL AGING, V29, P1744, DOI 10.1016/j.neurobiolaging.2007.04.012; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kitamura Y, 2000, J NEUROIMMUNOL, V106, P95, DOI 10.1016/S0165-5728(00)00239-3; Kohanbash G, 2013, CANCER RES, V73, P6413, DOI 10.1158/0008-5472.CAN-12-4124; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kwon MJ, 2013, J NEUROSCI, V33, P15095, DOI 10.1523/JNEUROSCI.0278-13.2013; Lee DC, 2013, NEUROBIOL AGING, V34, P1610, DOI 10.1016/j.neurobiolaging.2012.12.014; Lee SI, 2010, J NEUROSCI RES, V88, P2409, DOI 10.1002/jnr.22411; Lyons A, 2007, J NEUROCHEM, V101, P771, DOI 10.1111/j.1471-4159.2006.04370.x; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; National SCI Statistical Center, 2013, FACTS FIG GLANC; Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000371; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Puntambekar SS, 2011, BRAIN BEHAV IMMUN, V25, P629, DOI 10.1016/j.bbi.2010.12.016; Guerrero AR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-40; Saiwai H, 2013, J NEUROCHEM, V125, P74, DOI 10.1111/jnc.12135; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Slegenthaler MM, 2008, EXP NEUROL, V210, P207, DOI 10.1016/j.expneurol.2007.10.019; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Stirling DP, 2014, BRAIN, V137, P707, DOI 10.1093/brain/awt341; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Wohleb ES, 2012, PSYCHONEUROENDOCRINO, V37, P1491, DOI 10.1016/j.psyneuen.2012.02.003; Wohleb ES, 2011, J NEUROSCI, V31, P6277, DOI 10.1523/JNEUROSCI.0450-11.2011; Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x; Zhao WH, 2006, J NEUROCHEM, V99, P1176, DOI 10.1111/j.1471-4159.2006.04172.x	48	118	122	0	17	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUN 25	2014	34	26					8904	8917		10.1523/JNEUROSCI.1146-14.2014			14	Neurosciences	Neurosciences & Neurology	AK9HI	WOS:000338737800024	24966389	Bronze, Green Published			2021-06-18	
J	Petrie, EC; Cross, DJ; Yarnykh, VL; Richards, T; Martin, NM; Pagulayan, K; Hoff, D; Hart, K; Mayer, C; Tarabochia, M; Raskind, MA; Minoshima, S; Peskind, ER				Petrie, Eric C.; Cross, Donna J.; Yarnykh, Vasily L.; Richards, Todd; Martin, Nathalie M.; Pagulayan, Kathleen; Hoff, David; Hart, Kim; Mayer, Cynthia; Tarabochia, Matthew; Raskind, Murray A.; Minoshima, Satoshi; Peskind, Elaine R.			Neuroimaging, Behavioral, and Psychological Sequelae of Repetitive Combined Blast/Impact Mild Traumatic Brain Injury in Iraq and Afghanistan War Veterans	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; macromolecular proton fraction; mild traumatic brain injury; positron emission tomography; veterans	POSTTRAUMATIC-STRESS-DISORDER; WHITE-MATTER; AXONAL INJURY; MULTIPLE-SCLEROSIS; STEADY-STATE; FDG-PET; MODERATE; DIFFUSE; DISEASE; DAMAGE	Whether persisting cognitive complaints and postconcussive symptoms (PCS) reported by Iraq and Afghanistan war veterans with blast- and/or combined blast/impact-related mild traumatic brain injuries (mTBIs) are associated with enduring structural and/or functional brain abnormalities versus comorbid depression or posttraumatic stress disorder (PTSD) remains unclear. We sought to characterize relationships among these variables in a convenience sample of Iraq and Afghanistan-deployed veterans with (n=34) and without (n=18) a history of one or more combined blast/impact-related mTBIs. Participants underwent magnetic resonance imaging of fractional anisotropy (FA) and macromolecular proton fraction (MPF) to assess brain white matter (WM) integrity; [F-18]-fluorodeoxyglucose positron emission tomography imaging of cerebral glucose metabolism (CMRglu); structured clinical assessments of blast exposure, psychiatric diagnoses, and PTSD symptoms; neurologic evaluations; and self-report scales of PCS, combat exposure, depression, sleep quality, and alcohol use. Veterans with versus without blast/impact-mTBIs exhibited reduced FA in the corpus callosum; reduced MPF values in subgyral, longitudinal, and cortical/subcortical WM tracts and gray matter (GM)/WM border regions (with a possible threshold effect beginning at 20 blast-mTBIs); reduced CMRglu in parietal, somatosensory, and visual cortices; and higher scores on measures of PCS, PTSD, combat exposure, depression, sleep disturbance, and alcohol use. Neuroimaging metrics did not differ between participants with versus without PTSD. Iraq and Afghanistan veterans with one or more blast-related mTBIs exhibit abnormalities of brain WM structural integrity and macromolecular organization and CMRglu that are not related to comorbid PTSD. These findings are congruent with recent neuropathological evidence of chronic brain injury in this cohort of veterans.	[Petrie, Eric C.; Pagulayan, Kathleen; Hoff, David; Hart, Kim; Mayer, Cynthia; Tarabochia, Matthew; Raskind, Murray A.; Peskind, Elaine R.] VA Puget Sound, MIRECC, Vet Affairs VA Northwest Network VISN 20, Seattle, WA 98108 USA; [Petrie, Eric C.; Pagulayan, Kathleen; Raskind, Murray A.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Petrie, Eric C.; Cross, Donna J.; Yarnykh, Vasily L.; Richards, Todd; Martin, Nathalie M.; Minoshima, Satoshi] Univ Washington, Dept Radiol, Seattle, WA 98195 USA	Petrie, EC (corresponding author), VA Puget Sound, MIRECC, 1660 S Columbian Way,Mail Code S-116, Seattle, WA 98108 USA.	epetrie@uw.edu	Yarnykh, Vasily/G-8757-2016; Yarnykh, Vasiliy/N-7635-2014; Pagulayan, Kati/AAR-9225-2020	Yarnykh, Vasily/0000-0002-1583-8979; Minoshima, Satoshi/0000-0002-0043-3047; Cross, Donna/0000-0003-1918-2214; Petrie, Eric/0000-0003-1188-6321	Department of Veterans Affairs Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [B77421]; VA Clinical Science Research and Development CAREER development award [TK2 CX000516]; VA Northwest Network MIRECC; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG05136, 5K08AG23670, R21EB009908]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD083091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB009908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136, K08AG023670] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000521, I01RX001612] Funding Source: NIH RePORTER	This material is based on work supported, in part, by the Department of Veterans Affairs Rehabilitation Research and Development Service (B77421), VA Clinical Science Research and Development CAREER development award TK2 CX000516, and VA Northwest Network MIRECC; National Institute of Health grants AG05136, 5K08AG23670, and R21EB009908; and an anonymous foundation.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ayling E, 2012, CURR PSYCHIAT REP, V14, P197, DOI 10.1007/s11920-012-0273-z; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BOOKSTEIN FL, 1989, IEEE T PATTERN ANAL, V11, P567, DOI 10.1109/34.24792; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Edden RA, 2011, J NEUROSCI METH, V201, P213, DOI 10.1016/j.jneumeth.2011.07.025; Eibner C, 2009, NEW ENGL J MED, V361, P537; First M.B., 2002, STRUCTURED CLINICAL; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hosaka K, 2005, EUR J NUCL MED MOL I, V32, P92, DOI 10.1007/s00259-004-1576-z; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kang XJ, 2012, MAGN RESON IMAGING, V30, P1111, DOI 10.1016/j.mri.2012.04.004; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEGROS C, 1936, J ANAT, V71, P7; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu XD, 2009, INT GEOSCI REMOTE SE, P885, DOI 10.1109/IGARSS.2009.5418166; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; MARTINEZMARTIN P, 1994, MOVEMENT DISORD, V9, P76, DOI 10.1002/mds.870090112; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1992, J NUCL MED, V33, P1579; MINOSHIMA S, 1993, J NUCL MED, V34, P322; MINOSHIMA S, 1994, J NUCL MED, V35, P949; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Minoshima S, 2002, J GERIATR PSYCH NEUR, V15, P200, DOI 10.1177/089198870201500405; Minoshima S., 2009, PRINCIPLES AND PRACT, P500; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Oishi K., 2011, MRI ATLAS OF HUMAN W; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Rausch M, 2009, MULT SCLER, V15, P16, DOI 10.1177/1352458508096006; Samsonov A, 2012, NEUROIMAGE, V62, P1390, DOI 10.1016/j.neuroimage.2012.05.077; Schmierer K, 2007, J MAGN RESON IMAGING, V26, P41, DOI 10.1002/jmri.20984; Sigford B, 2009, NEW ENGL J MED, V361, P536, DOI 10.1056/NEJMc096180; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Skinner TE, 1997, MAGN RESON MED, V37, P628, DOI 10.1002/mrm.1910370426; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Talairach J, 1988, CO PLANAR STEREOTAXI; Tustison N. J., 2012, HUM BRAIN MAPP, DOI [10.1002/hbm.22211, DOI 10.1002/HBM.22211.EPUB]; Underhil HR, 2009, NEUROIMAGE, V47, P1568, DOI 10.1016/j.neuroimage.2009.05.075; Underhill HR, 2011, NEUROIMAGE, V54, P2052, DOI 10.1016/j.neuroimage.2010.10.065; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Yarnykh VL, 2007, MAGN RESON MED, V57, P192, DOI 10.1002/mrm.21120; Yarnykh VL, 2012, MAGN RESON MED, V68, P166, DOI 10.1002/mrm.23224; Yarnykh VL, 2010, MAGN RESON MED, V63, P1610, DOI 10.1002/mrm.22394; Yarnykh VL, 2004, NEUROIMAGE, V23, P409, DOI 10.1016/j.neuroimage.2004.04.029; Yarnykh VL, 2002, MAGNET RESON MED, V47, P929, DOI 10.1002/mrm.10120	71	118	119	1	29	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					425	436		10.1089/NEU.2013.2952			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600241	24102309	Green Published			2021-06-18	
J	Hu, JZ; Huang, JH; Zeng, L; Wang, G; Cao, M; Lu, HB				Hu, Jian-Zhong; Huang, Jiang-Hu; Zeng, Lei; Wang, Guan; Cao, Min; Lu, Hong-Bin			Anti-Apoptotic Effect of MicroRNA-21 after Contusion Spinal Cord Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						antagomir-21; apoptosis; miRNA; SCI	TRAUMATIC BRAIN-INJURY; TUMOR-SUPPRESSOR PDCD4; EXPRESSION; MIR-21; PROTECTS; DEATH; INVOLVEMENT; PATHWAY; TARGETS; SYSTEM	Multiple cellular, molecular, and biochemical changes contribute to the etiology and treatment outcome of contusion spinal cord injury (SCI). Dysregulation of microRNAs (miRNAs) has been found following SCI in recent studies. However, little is known about the functional significance of the unique role of miRNAs in SCI. We analyzed the miRNA expression patterns 1 and 3 days following rat SCI using miRNA microarray. Microarray data revealed that nine miRNAs were upregulated and five miRNAs were downregulated 1 day post-injury, and that three miRNAs were upregulated and five miRNAs were downregulated 3 days post-injury, in the sites of contused when compared with sham rat spinal cords. Because miR-21 was one of the miRNAs being most significantly upregulated, we investigated its function. Knockdown of miR-21 by antagomir-21 led to attenuated recovery in hindlimb motor function, increased lesion size, and decreased tissue sparing in rats. Compared with the negative control group, treatment with antagomir-21 significantly increased apoptosis following SCI. Pro-apoptosis genes Fas ligand (FasL), phosphatase and tensin homolog (PTEN), and programmed cell death protein 4 (PDCD4) were proved to be direct targets of miR-21 in many diseases and cell types. In vivo treatment with antagomir-21 increased the expression of FasL and PTEN, but did not affect PDCD4. These results suggested that miR-21 played an important role in limiting secondary cell death following SCI, and that the protective effects of miR-21 might have been the result of its regulation on pro-apoptotic genes. Thus, miR-21 may play an important role in the pathophysiology of SCI.	[Hu, Jian-Zhong; Huang, Jiang-Hu; Zeng, Lei; Wang, Guan; Cao, Min] Cent S Univ, Dept Spine Surg, Res Ctr Sports Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Lu, Hong-Bin] Cent S Univ, Dept Sports Med, Res Ctr Sports Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China	Lu, HB (corresponding author), Cent S Univ, Dept Sports Med, Res Ctr Sports Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.	hongbinlu@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171698]; Hunan Provincial Natural Science Foundation of ChinaNatural Science Foundation of Hunan Province [09JJ3047]	This work is supported by the National Natural Science Foundation of China (No. 81171698) and the Hunan Provincial Natural Science Foundation of China (No. 09JJ3047).	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Benveniste E. N., 2004, BRAIN RES REV, V44, P65; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Caggiano AO, 2005, J NEUROTRAUM, V22, P226, DOI 10.1089/neu.2005.22.226; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen Y, 2008, CANCER LETT, V272, P197, DOI 10.1016/j.canlet.2008.06.034; Cheng YH, 2010, CARDIOVASC RES, V87, P431, DOI 10.1093/cvr/cvq082; De Biase A, 2005, PHYSIOL GENOMICS, V22, P368, DOI 10.1152/physiolgenomics.00081.2005; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dong SM, 2009, J BIOL CHEM, V284, P29514, DOI 10.1074/jbc.M109.027896; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Haverty PM, 2008, GENE CHROMOSOME CANC, V47, P530, DOI 10.1002/gcc.20558; He Q, 2013, MOL CARCINOGEN, V52, P286, DOI 10.1002/mc.21859; Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986; Johnson R, 2008, NEUROBIOL DIS, V29, P438, DOI 10.1016/j.nbd.2007.11.001; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Liu C, 2010, J NEUROCHEM, V112, P1500, DOI 10.1111/j.1471-4159.2009.06561.x; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Shi GD, 2011, BIOCHEM BIOPH RES CO, V404, P941, DOI 10.1016/j.bbrc.2010.12.085; Strickland ER, 2011, NEUROSCIENCE, V186, P146, DOI 10.1016/j.neuroscience.2011.03.063; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Xu XL, 2012, KIDNEY INT, V82, P1167, DOI 10.1038/ki.2012.241; Yed D., 2010, J BIOL CHEM, V285, P20; Yoshino O, 2004, SPINE, V29, P1394, DOI 10.1097/01.BRS.0000129894.34550.48; Yunta M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034534; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhang L, 2012, GLIA, V60, P1888, DOI 10.1002/glia.22404; Zhang QG, 2007, FEBS LETT, V581, P495, DOI 10.1016/j.febslet.2006.12.055	41	118	128	0	27	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2013	30	15					1349	1360		10.1089/neu.2012.2748			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	191WY	WOS:000322446800336	23647386	Green Published			2021-06-18	
J	Stevens, MC; Lovejoy, D; Kim, J; Oakes, H; Kureshi, I; Witt, ST				Stevens, Michael C.; Lovejoy, David; Kim, Jinsuh; Oakes, Howard; Kureshi, Inam; Witt, Suzanne T.			Multiple resting state network functional connectivity abnormalities in mild traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						TBI; Functional connectivity; DTI; Resting state; Postconcussive	WHITE-MATTER INJURY; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; DEFAULT-MODE; WORKING-MEMORY; STRUCTURAL CONNECTIVITY; REACTION-TIME; FMRI; CT; CORTEX	Several reports show that traumatic brain injury (TBI) results in abnormalities in the coordinated activation among brain regions. Because most previous studies examined moderate/severe TBI, the extensiveness of functional connectivity abnormalities and their relationship to postconcussive complaints or white matter microstructural damage are unclear in mild TBI. This study characterized widespread injury effects on multiple integrated neural networks typically observed during a task-unconstrained "resting state" in mild TBI patients. Whole brain functional connectivity for twelve separate networks was identified using independent component analysis (ICA) of fMRI data collected from thirty mild TBI patients mostly free of macroscopic intracerebral injury and thirty demographically-matched healthy control participants. Voxelwise group comparisons found abnormal mild TBI functional connectivity in every brain network identified by ICA, including visual processing, motor, limbic, and numerous circuits believed to underlie executive cognition. Abnormalities not only included functional connectivity deficits, but also enhancements possibly reflecting compensatory neural processes. Postconcussive symptom severity was linked to abnormal regional connectivity within nearly every brain network identified, particularly anterior cingulate. A recently developed multivariate technique that identifies links between whole brain profiles of functional and anatomical connectivity identified several novel mild TBI abnormalities, and represents a potentially important new tool in the study of the complex neurobiological sequelae of TBI.	[Stevens, Michael C.] Olin Neuropsychiat Res Ctr, Inst Living, Hartford, CT 06106 USA; [Stevens, Michael C.; Witt, Suzanne T.] Hartford Hosp, Olin Neuropsychiat Res Ctr, Inst Living, Hartford, CT 06115 USA; [Stevens, Michael C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Lovejoy, David; Oakes, Howard; Kureshi, Inam] Hartford Hosp, Dept Neurosurg, Hartford, CT 06115 USA; [Lovejoy, David; Oakes, Howard] Univ Connecticut, Dept Emergency Med & Traumatol, Sch Med, Farmington, CT USA; [Kim, Jinsuh] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; [Kureshi, Inam] Univ Connecticut, Sch Med, Dept Surg, Farmington, CT USA	Stevens, MC (corresponding author), Olin Neuropsychiat Res Ctr, Inst Living, 200 Retreat Ave,Whitehall Bldg, Hartford, CT 06106 USA.	msteven@harthosp.org	Stevens, Michael/M-7678-2017	Stevens, Michael/0000-0002-3799-5465; Witt, Suzanne/0000-0002-5530-0807	Hartford Hospital	This study was funded by a Hartford Hospital Open Competition Grant.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf M, 2010, NEUROIMAGE, V53, P247, DOI 10.1016/j.neuroimage.2010.05.067; Atlas S., 2001, IMAGING BRAIN SPINE; Babiloni C, 2004, BEHAV NEUROSCI, V118, P687, DOI 10.1037/0735-7044.118.4.687; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P227, DOI 10.1016/S0887-6177(00)00081-0; Bigler ED, 2005, TXB TRAUMATIC BRAIN; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1993, ACTA NEUROL BELG, V93, P23; Botvinick MM, 2007, COGN AFFECT BEHAV NE, V7, P356, DOI 10.3758/CABN.7.4.356; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Cauda F, 2010, J NEUROL NEUROSUR PS, V81, P806, DOI 10.1136/jnnp.2009.188631; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cordes D, 2000, AM J NEURORADIOL, V21, P1636; D'Esposito M, 2007, PHILOS T R SOC B, V362, P761, DOI 10.1098/rstb.2007.2086; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deco G, 2011, NEUROSCIENTIST, V17, P107, DOI 10.1177/1073858409354384; Deco G, 2011, NAT REV NEUROSCI, V12, P43, DOI 10.1038/nrn2961; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dosenbach NUF, 2008, TRENDS COGN SCI, V12, P99, DOI 10.1016/j.tics.2008.01.001; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Eickhoff SB, 2011, CLIN EEG NEUROSCI, V42, P107, DOI 10.1177/155005941104200211; Eisenberg H. M., 1989, MILD HEAD INJURY; Erhardt EB, 2011, HUM BRAIN MAPP, V32, P2075, DOI 10.1002/hbm.21170; Etkin A, 2011, TRENDS COGN SCI, V15, P85, DOI 10.1016/j.tics.2010.11.004; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; First MB., 2002, STRUCTURED CLIN INTE; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Freire L, 2002, IEEE T MED IMAGING, V21, P470, DOI 10.1109/TMI.2002.1009383; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Friston KJ, 2002, PROG NEUROBIOL, V68, P113, DOI 10.1016/S0301-0082(02)00076-X; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Gazzaley Adam, 2004, Cognitive Affective & Behavioral Neuroscience, V4, P580, DOI 10.3758/CABN.4.4.580; Gean A. D., 1984, IMAGING HEAD TRAUMA; Gentilini M., 1989, MILD HEAD INJURY; Glahn DC, 2010, P NATL ACAD SCI USA, V107, P1223, DOI 10.1073/pnas.0909969107; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius M, 2008, CURR OPIN NEUROL, V21, P424, DOI 10.1097/WCO.0b013e328306f2c5; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Griffin SL, 2002, ARCH CLIN NEUROPSYCH, V17, P497, DOI 10.1016/S0887-6177(01)00136-6; GRONWALL D, 1989, MILD HEAD INJURY; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENKINS A, 1986, LANCET, V2, P445; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kiviniemi V, 2009, HUM BRAIN MAPP, V30, P3865, DOI 10.1002/hbm.20813; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Laird AR, 2009, J NEUROSCI, V29, P14496, DOI 10.1523/JNEUROSCI.4004-09.2009; Lamm C, 2011, NEUROIMAGE, V54, P2492, DOI 10.1016/j.neuroimage.2010.10.014; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Li YO, 2007, HUM BRAIN MAPP, V28, P1251, DOI 10.1002/hbm.20359; Linden DEJ, 2007, NEUROSCIENTIST, V13, P257, DOI 10.1177/1073858406298480; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Ma N, 2010, NEUROIMAGE, V49, P738, DOI 10.1016/j.neuroimage.2009.08.037; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; ORRISON WW, 2000, NEUROIMAGING; Ploner M, 2011, CEREB CORTEX, V21, P719, DOI 10.1093/cercor/bhq146; Posner MI, 2007, COGN AFFECT BEHAV NE, V7, P391, DOI 10.3758/CABN.7.4.391; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Roth JK, 2007, NEUROIMAGE, V38, P617, DOI 10.1016/j.neuroimage.2007.06.037; Rudebeck PH, 2008, COGN AFFECT BEHAV NE, V8, P485, DOI 10.3758/CABN.8.4.485; Ruff R. M., 1989, MILD HEAD INJURY; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schmahmann JD, 2006, FIBER PATHWAYS BRAIN; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Seminowicz DA, 2007, J NEUROPHYSIOL, V97, P3651, DOI 10.1152/jn.01210.2006; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sheline YI, 2010, P NATL ACAD SCI USA, V107, P11020, DOI 10.1073/pnas.1000446107; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Sui J, 2011, NEUROIMAGE, V57, P839, DOI 10.1016/j.neuroimage.2011.05.055; Teipel SJ, 2010, NEUROIMAGE, V49, P2021, DOI 10.1016/j.neuroimage.2009.10.067; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Upadhyay J, 2010, BRAIN, V133, P2098, DOI 10.1093/brain/awq138; van de Ven VG, 2004, HUM BRAIN MAPP, V22, P165, DOI 10.1002/hbm.20022; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Woodward TS, 2006, NEUROSCIENCE, V139, P317, DOI 10.1016/j.neuroscience.2005.05.043; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Zaki J, 2007, SOC NEUROSCI-UK, V2, P276, DOI 10.1080/17470910701401973	134	118	118	0	28	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		293	318		10.1007/s11682-012-9157-4			26	Neuroimaging	Neurosciences & Neurology	967LI	WOS:000305908900010	22555821				2021-06-18	
J	Risling, M; Plantman, S; Angeria, M; Rostami, E; Bellander, BM; Kirkegaard, M; Arborelius, U; Davidsson, J				Risling, M.; Plantman, S.; Angeria, M.; Rostami, E.; Bellander, B. -M.; Kirkegaard, M.; Arborelius, U.; Davidsson, J.			Mechanisms of blast induced brain injuries, experimental studies in rats	NEUROIMAGE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SHELL SHOCK; EXPRESSION; BIOMARKERS; EXPOSURE	Traumatic brain injuries (TBI) potentially induced by blast waves from detonations result in significant diagnostic problems. It may be assumed that several mechanisms contribute to the injury. This study is an attempt to characterize the presumed components of the blast induced TBI. Our experimental models include a blast tube in which an anesthetized rat can be exposed to controlled detonations of explosives that result in a pressure wave with a magnitude between 130 and 260 kPa. In this model, the animal is fixed with a metal net to avoid head acceleration forces. The second model is a controlled penetration of a 2 mm thick needle. In the third model the animal is subjected to a high-speed sagittal rotation angular acceleration. Immunohistochemical labeling for amyloid precursor protein revealed signs of diffuse axonal injury (DAI) in the penetration and rotation models. Signs of punctuate inflammation were observed after focal and rotation injury. Exposure in the blast tube did not induce DAI or detectable cell death, but functional changes. Affymetrix Gene arrays showed changes in the expression in a large number of gene families including cell death, inflammation and neurotransmitters in the hippocampus after both acceleration and penetration injuries. Exposure to the primary blast wave induced limited shifts in gene expression in the hippocampus. The most interesting findings were a downregulation of genes involved in neurogenesis and synaptic transmission. These experiments indicate that rotational acceleration may be a critical factor for DAI and other acute changes after blast TBI. The further exploration of the mechanisms of blast TBI will have to include a search for long-term effects. (C) 2010 Elsevier Inc. All rights reserved.	[Risling, M.; Plantman, S.; Angeria, M.; Rostami, E.; Arborelius, U.] Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; [Bellander, B. -M.] Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-10401 Stockholm, Sweden; [Kirkegaard, M.] Karolinska Inst, Dept Clin Neurosci, Ctr Hearing & Commun Res, S-17177 Stockholm, Sweden; [Davidsson, J.] Chalmers Tech Univ, Div Vehicle Safety, Gothenburg, Sweden	Risling, M (corresponding author), Karolinska Inst, Dept Neurosci, Retzius Vag 8, S-17177 Stockholm, Sweden.	Marten.Risling@ki.se	Davidsson, Johan/A-3229-2016; Kirkegaard, Mette/G-9731-2016	Davidsson, Johan/0000-0002-1717-1514; Kirkegaard, Mette/0000-0003-3568-0360	Karolinska institutetKarolinska Institutet; Swedish Defense	Funding for the project has been provided by Karolinska institutet and the Swedish Defense.	Abrams MB, 2007, EUR J NEUROSCI, V26, P1118, DOI 10.1111/j.1460-9568.2007.05725.x; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Anderson R, 2005, HEAD INJURY PATHOPHY, P26; Anderson RJ, 2008, MOL INTERV, V8, P204, DOI 10.1124/mi.8.5.2; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Burbridge B, 2004, CAN ASSOC RADIOL J, V55, P326; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; CLEMEDSON CARL-JOHAN, 1955, JOUR AVIATION MED, V26, P373; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336; CLEMEDSON CJ, 1956, NATURE, V177, P380, DOI 10.1038/177380a0; Davidsson J., 2009, 2009 INT IRC C BIOM, P43; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Kirkegaard M, 2006, NEUROSCIENCE, V142, P425, DOI 10.1016/j.neuroscience.2006.06.037; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Lidman O, 2003, J NEUROSCI, V23, P9817; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Macleod AD, 2004, J ROY SOC MED, V97, P86, DOI 10.1258/jrsm.97.2.86; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Murai N, 2008, J NEUROTRAUM, V25, P72, DOI 10.1089/neu.2007.0346; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Risling M, 2004, PROCEEDINGS OF THE 7TH INTERNATIONAL NEUROTRAUMA SYMPOSIUM, P119; Risling M, 2002, FOIR0757SE SWED DEF, P1; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Swanberg M, 2005, NAT GENET, V37, P486, DOI 10.1038/ng1544; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	39	118	119	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN	2011	54			1			S89	S97		10.1016/j.neuroimage.2010.05.031			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600013	20493951				2021-06-18	
J	Elder, GA; Mitsis, EM; Ahlers, ST; Cristian, A				Elder, Gregory A.; Mitsis, Effie M.; Ahlers, Stephen T.; Cristian, Adrian			Blast-induced Mild Traumatic Brain Injury	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Blast-related brain injury; Improvised explosive device; Posttraumatic stress disorder; Traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; CENTRAL-NERVOUS-SYSTEM; DIFFUSE AXONAL INJURY; ADULT-RAT BRAIN; PERSISTENT POSTCONCUSSIVE SYMPTOMS; TYMPANIC-MEMBRANE PERFORATION; LASTING IMPULSE NOISE; NON-PENETRATIVE BLAST; WHITE-MATTER INJURY; HEAD-INJURY	Traumatic brain injury (TBI) has been a major cause of mortality and morbidity in the wars in Iraq and Afghanistan Blast exposure has been the most common cause of TBI, occurring through multiple mechanisms What is less clear is whether the primary blast wave causes brain damage through mechanisms that are distinct from those common in civilian TBI and whether multiple exposures to low-level blast can lead to long-term sequelae Complicating TBI in soldiers is the high prevalence of posttraumatic stress disorder At present the relationship is unclear Resolution of these issues will affect both treatment strategies and strategies for the protection of troops in the field	[Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA; [Elder, Gregory A.; Mitsis, Effie M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Mitsis, Effie M.; Cristian, Adrian] James J Peters Vet Affairs Med Ctr, Rehabil Med Serv, Bronx, NY 10468 USA; [Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Silver Spring, MD 20910 USA; [Cristian, Adrian] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Elder, GA (corresponding author), James J Peters Vet Affairs Med Ctr, Neurol Serv, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.						Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Alvarez L, 2008, NY TIMES, pA1; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bochicchio GV, 2008, AM SURGEON, V74, P267; BOGO V, 1971, EFFECTS AIRBLAST DIS, V2659, P1; Brookings Institution, 2010, IR IND TRACK VAR REC; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336; COHEN H, 1946, ARCH PATHOL, V42, P12; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs/ Department of Defense ( VA/ DoD), 2009, VA DOD CLIN PRACT GU; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Hoffman SW, 2009, CLIN NEUROPSYCHOL, V23, P1400, DOI 10.1080/13854040903369433; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; Kluger Yoram, 2007, Am J Disaster Med, V2, P21; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Mott FW, 1916, LANCET, V1, P441; Newberg AB, 2003, SEMIN NUCL MED, V33, P136, DOI 10.1053/snuc.2003.127299; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; PESKIND ER, NEUROIMAGE; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Phillips Y., 1990, TXB MILITARY MED 1, V5, P221; PHILLIPS YY, 1988, J TRAUMA, V28, pS149, DOI 10.1097/00005373-198801001-00030; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Van Heertum RL, 2004, SEMIN NUCL MED, V34, P300, DOI 10.1053/j.semnuclmed.2004.03.003; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Walilko T, 2009, J TRAUMA, V67, P1311, DOI 10.1097/TA.0b013e31819adc36; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Zhang Jiangyue, 2009, Biomed Sci Instrum, V45, P119; Zhang Jiangyue, 2008, Biomed Sci Instrum, V44, P129; Zhang JY, 2009, STAPP CAR CRASH JO, V53, P215	105	118	118	0	20	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	DEC	2010	33	4					757	+		10.1016/j.psc.2010.08.001			26	Psychiatry	Psychiatry	694TA	WOS:000285320700003	21093677				2021-06-18	
J	Skandsen, T; Kvistad, KA; Solheim, O; Strand, IH; Folvik, M; Vik, A				Skandsen, Toril; Kvistad, Kjell Arne; Solheim, Ole; Strand, Ingrid Haavde; Folvik, Mari; Vik, Anne			Prevalence and impact of diffuse axonal injury in patients with moderate and severe head injury: a cohort study of early magnetic resonance imaging findings and 1-year outcome	JOURNAL OF NEUROSURGERY			English	Article						craniocerebral trauma; diffuse axonal injury; magnetic resonance imaging; Glasgow Outcome Scale; treatment outcome; cohort study	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; STEM; CLASSIFICATION; LESION; MRI; PROGNOSIS; CHILDREN; RECOVERY; DAMAGE	Object. In this prospective cohort study the authors examined patients with moderate to severe head injuries using MR imaging in the early phase. The objective was to explore the occurrence of diffuse axonal injury (DAI) and determine whether DAI was related to level of consciousness and patient outcome. Methods. One hundred and fifty-nine patients (age range 5-65 years) with traumatic brain injury, who survived the acute phase, and who had a Glasgow Coma Scale (GCS) score of 3-13 were admitted between October 2004 and August 2008. Of these 159 patients, 106 were examined using MR imaging within 4 weeks postinjury. Patients were classified into 1 of 3 stages of DAI: Stage 1, in which lesions were confined to the lobar white matter; Stage 2, in which there were callosal lesions; and Stage 3, in which lesions occurred in the dorsolateral brainstem. The outcome measure used 12 months postinjury was the Glasgow Outcome Scale Extended (GOSE). Results. Diffuse axonal injury was detected in 72% of the patients and a combination of DAI and contusions or hematomas was found in 50%. The GCS score was significantly lower in patients with "pure DAI" (median GCS Score 9) than in patients without DAI (median GCS Score 12; p < 0.001). The GCS score was related to outcome only in those patients with DAI (r = 0.47; p = 0.001). Patients with DAI had a median GOSE score of 7, and patients without DAI had a median GOSE score of 8 (p = 0.10). Outcome was better in patients with DAI Stage I (median GOSE Score 8) and DAI Stage 2 (median GOSE Score 7.5) than in patients with DAI Stage 3 (median GOSE Score 4; p < 0.001). Thus, in patients without any brainstem injury, there was no difference in good recovery between patients with DAI (67%) and patients without DAI (66%). Conclusions. Diffuse axonal injury was found in almost three-quarters of the patients with moderate and severe head injury who survived the acute phase. Diffuse axonal injury influenced the level of consciousness, and only in patients with DAI was GCS score related to outcome. Finally, DAI was a negative prognostic sign only when located in the brainstem. (DOI: 10.3171/2009.9.JNS09626)	[Skandsen, Toril] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway; [Kvistad, Kjell Arne; Strand, Ingrid Haavde; Folvik, Mari] Univ Trondheim Hosp, St Olavs Hosp, Dept Diagnost Imaging, N-7006 Trondheim, Norway; [Skandsen, Toril; Solheim, Ole; Vik, Anne] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, N-7006 Trondheim, Norway; [Skandsen, Toril; Solheim, Ole; Vik, Anne] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, Trondheim, Norway; [Kvistad, Kjell Arne] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Imaging, Trondheim, Norway	Skandsen, T (corresponding author), Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway.	toril.skandsen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Solheim, Ole/0000-0002-5954-4817			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Altman D, 1991, PRACTICAL STAT MED R; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; LeGrand SA, 2007, J NEUROTRAUM, V24, P1437, DOI 10.1089/neu.2007.0293; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LD, 1991, J NEUROSURG, V75, P514; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woischneck D, 2003, CHILD NERV SYST, V19, P174, DOI 10.1007/s00381-002-0703-z; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	35	118	122	1	14	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					556	563		10.3171/2009.9.JNS09626			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100019	19852541				2021-06-18	
J	Wafaisade, A; Lefering, R; Tjardes, T; Wutzler, S; Simanski, C; Paffrath, T; Fischer, P; Bouillon, B; Maegele, M				Wafaisade, Arasch; Lefering, Rolf; Tjardes, Thorsten; Wutzler, Sebastian; Simanski, Christian; Paffrath, Thomas; Fischer, Philipp; Bouillon, Bertil; Maegele, Marc		Trauma Registry DGU	Acute Coagulopathy in Isolated Blunt Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Coagulopathy; Outcome; Mortality; Pre-hospital care	SEVERE HEAD-INJURY; DISSEMINATED INTRAVASCULAR COAGULATION; MANAGEMENT; HEMORRHAGE; DISORDERS; MODERATE; REGISTRY; SURGERY; CARE	The role of acute coagulopathy after traumatic brain injury (TBI) on outcome has gained increasing appreciation over the recent years. This study was conducted to assess the frequency, outcome, and risk factors associated with this complication. Using the large, multi-center population-based Trauma Registry of the German Society for Trauma Surgery (TR-DGU), we retrospectively analyzed adult patients with isolated blunt TBI (intracranial AIS(HEAD) a parts per thousand yen 3 and extracranial AIS scores < 3) for the presence of acute post-traumatic coagulopathy upon emergency room (ER) arrival. Coagulopathy was defined as prothrombin time test (Quick's value) < 70% and/or platelets < 100,000/mu l. From a total of 3,114 eligible patients with isolated TBI, 706 (22.7%) presented with coagulopathy upon ER arrival. Coagulopathy was associated with higher rates of craniotomies (P = 0.02), of single and multiple organ failure and with less intubation-free days. In surviving patients, ICU length of stay and hospital length of stay were significantly longer, if coagulopathy had been present at admission. The overall hospital mortality was 50.4% (n = 356) in patients with coagulopathy vs. 17.3% (n = 417) in non-coagulopathic patients (all P < 0.001). Multivariate analysis identified AIS(HEAD) severity grade, GCS a parts per thousand currency sign 8 at scene, the presence of hypotension at scene and/or at ER, pre-hospital i.v.-fluids a parts per thousand yen2,000 ml and age a parts per thousand yen75 years as independent risk factors for coagulopathy after TBI. Acute coagulopathy in TBI had an adjusted odds ratio for hospital mortality of 2.97 (CI95: 2.30-3.85; P < 0.001). Coagulopathy upon ER admission is frequent after isolated blunt TBI and represents a powerful, independent predictor related to prognosis. Future research should aim to determine the beneficial effects of early treatment of TBI-associated coagulopathy.	[Wafaisade, Arasch; Tjardes, Thorsten; Simanski, Christian; Paffrath, Thomas; Bouillon, Bertil; Maegele, Marc] Univ Witten Herdecke, Dept Trauma & Orthoped Surg, Cologne Merheim Med Ctr CMMC, D-51109 Cologne, Germany; [Wafaisade, Arasch; Lefering, Rolf; Fischer, Philipp; Maegele, Marc] Univ Witten Herdecke, Inst Res Operat Med IFOM, Cologne Merheim Med Ctr CMMC, D-51109 Cologne, Germany; [Wutzler, Sebastian] Goethe Univ Frankfurt, Dept Trauma Surg, Frankfurt, Germany; [Trauma Registry DGU] German Soc Trauma Surg DGU, Comm Emergency Med Intens & Trauma Care Sekt NIS, Berlin, Germany	Wafaisade, A (corresponding author), Univ Witten Herdecke, Dept Trauma & Orthoped Surg, Cologne Merheim Med Ctr CMMC, Ostmerheimerstr 200, D-51109 Cologne, Germany.	araschw@hotmail.com					Affonseca CA, 2007, J PEDIAT-BRAZIL, V83, P274, DOI [10.1590/S0021-75572007000400014, 10.2223/JPED.1639]; [Anonymous], 1990, ABBR INJ SCAL AIS 19; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARDENHEUE M, 1994, UNFALLCHIRURG, V97, P230; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Coats TJ, 2006, EMERG MED J, V23, P846, DOI 10.1136/emj.2006.036574; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Dutton Richard P, 2003, Curr Opin Crit Care, V9, P503, DOI 10.1097/00075198-200312000-00007; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Kauvar DS, 2005, CRIT CARE, V9, P1, DOI 10.1186/cc3779; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; LUTZE G, USEFUL FACTS COAGULA; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Pathak A, 2005, Neurol India, V53, P178; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Schreiber MA, 2004, CRIT CARE CLIN, V20, P101, DOI 10.1016/S0749-0704(03)00095-2; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; THOMAS L, 2000, LABOR DIAGNOSE INDIK, V5; WAGNER C, 2000, LABOR DIAGNOSE, P613; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	38	118	130	1	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2010	12	2					211	219		10.1007/s12028-009-9281-1			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	573IL	WOS:000275905800011	19806475				2021-06-18	
J	Berry, C; Ley, EJ; Tillou, A; Cryer, G; Margulies, DR; Salim, A				Berry, Cherisse; Ley, Eric J.; Tillou, Areti; Cryer, Gil; Margulies, Daniel R.; Salim, Ali			The Effect of Gender on Patients With Moderate to Severe Head Injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Traumatic brain injury; Gender; Outcome; Mortality	TRAUMATIC BRAIN-INJURY; PROGESTERONE; RATS; ESTROGEN; WOMEN; SHOCK; DIMORPHISM; MECHANISM; OUTCOMES; FEMALES	Background: Male and female nervous systems respond differently to traumatic brain injury (TBI) and in vivo research relates this difference to neuroprotection from female sex hormones. Attempts to replicate female sex hormone-related neuroprotection in clinical studies have been unsuccessful. The objective of this study was to determine whether gender or menopausal status affects mortality in patients with moderate to severe TBI. Methods: A retrospective review of all patients with isolated moderate to severe TBI was undertaken using data from the National Trauma Database version 6.2 (2000-2005). Isolated TBI was defined as head Abbreviated Injury Score >= 3 in patients without significant extracranial injuries (Abbreviated Injury Score <3 for other anatomic regions). Demographics. Injury Severity Score, and outcomes (mortality, intensive care unit and hospital length of stay, and complications) were compared. The population was stratified into age subgroups: 14 to 45 years (premenopausal), 46 to 55 years (perimenopausal), and older than 55 years (postmenopausal). Logistic regression analysis was used to determine the relationship among female gender, mortality, and development of complications after moderate to severe TBI. Results: A total of 72,294 patients with moderate to severe TBI were evaluated. Females showed a significantly lower risk in both mortality (adjusted odds ratios [AOR], 0.82; 95% confidence intervals [CI], 0.77-0.87; p < 0.0001) and in developing any type of complications (AOR, 0.88; 95% CI, 0.84-0.93; p < 0.0001) than the male population after adjusting for differences in patient characteristics. After age stratification, perimenopausal women (46-55 years) and postmenopausal women (older than 55 years) showed a significantly lower risk in mortality (AOR, 0.76 95% CI 0.63-0.92; p < 0.0044 and AOR, 0.79: 95% CI, 0.73-0.86; p < 0.0001. respectively). There was no difference in mortality in premenopausal women compared with their male age-matched counterparts (AOR, 1.09: 95% CI, 0.99-1.21; p = 0.0917). Conclusions: Female gender is independently associated with reduced mortality and decreased complications after TBI. As peri- and postmenopausal women demonstrated improved survival, and premenopausal women did not, estrogen unlikely confers neuroprotection in women after TBI. Future TBI treatment may benefit with Further research focused on why peri- and postmenopausal women show decreased mortality after TBI.	[Berry, Cherisse; Ley, Eric J.; Margulies, Daniel R.; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Tillou, Areti; Cryer, Gil] Univ Calif Los Angeles, Div Trauma, Dept Surg, Los Angeles, CA USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Berry, Cherisse/AAO-5701-2020				Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Deitch EA, 2007, ANN SURG, V246, P447, DOI 10.1097/SLA.0b013e318148566; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Haider AH, 2007, ARCH SURG-CHICAGO, V142, P875, DOI 10.1001/archsurg.142.9.875; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Jarrar D, 2000, SURGERY, V128, P246, DOI 10.1067/msy.2000.107376; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; OCONNOR CA, 2005, PHARM RES, V52, P119; Phelan HA, 2007, J TRAUMA, V63, P1127, DOI 10.1097/TA.0b013e318154c1b8; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Sperry JL, 2008, CRIT CARE MED, V36, P1838, DOI 10.1097/CCM.0b013e3181760c14; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10	18	118	123	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2009	67	5					950	953		10.1097/TA.0b013e3181ba3354			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	518XO	WOS:000271729500009	19901653				2021-06-18	
J	Howard, JL; Cipolle, MD; Anderson, M; Sabella, V; Shollenberger, D; Li, PM; Pasquale, MD				Howard, Jerry Lee; Cipolle, Mark D.; Anderson, Meredith; Sabella, Victoria; Shollenberger, Daniele; Li, P. Mark; Pasquale, Michael D.			Outcome after decompressive craniectomy for the treatment of severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		craniectomy; decompressive craniectomy; severe traumatic brain injury; trauma; long-term; functional outcome; outcome	MANAGEMENT; SCALE	Background: Using decompressive craniectomy as part of the treatment regimen for severe traumatic brain injury (STBI) has become more common at our Level I trauma center. This study was designed to examine this practice with particular attention to long-term functional outcome. Methods: A retrospective review of prospectively collected data was performed for patients with STBI admitted from January 1, 2003 to December 31, 2005. Our institution manages patients using the Brain Trauma Foundation Guidelines. Data collected from patients undergoing decompressive craniectomy included: age, Injury Severity Score, admission and follow-up Glasgow Coma Score, timing of, and indication for decompressive craniectomy, and procedure-related complications. The Extended Glasgow Outcome Scale (GOSE) was performed by a experienced trauma clinical research coordinator using a structured phone interview to assess long-term outcome in the survivors. Student's t test and chi(2) were used to examine differences between groups. Results: Forty STBI patients were treated with decompressive craniectomy; 24 were performed primarily in conjunction with urgent evacuation of extra-axial hemorrhage and 16 were performed primarily in response to increased intracranial pressure with 4 of these after an initial craniotomy. Decompressive craniectomy was very effective at lowering intracranial pressure in these 16 patients (35.0 mm Hg +/- 13.5 mm Hg to 14.6 mm Hg 8.7 mm H g, p = 0.005). Twenty-two decompressive craniectomy patients did not survive to hospital discharge, whereas admission Glasgow Coma Score and admission pupil size and reactivity correlated with outcome, age, and Injury Severity Score did not At a mean of 11 months (range, 3-26 months) after decompressive craniectomy, 6 survivors had a poor functional outcome (GOSE 1-4), whereas 12 survivors had a good outcome (GOSE 5-8). Therefore, 70% of these patients had an unfavorable outcome (death or severe disability), and 30% had a favorable long-term functional outcome. Fifteen of 18 survivors went on to cranioplasty, whereas 4 of 18 had cerebrospinal infection. Conclusion: The majority of survivors after decompressive craniectomy have a good functional outcome as analyzed by GOSE. Overall, 30% of patients with STBI who underwent decompressive craniectomy had a favorable long-term outcome. Improving patient selection and optimizing timing of this procedure may further improve outcome in these very severely brain injured patients.	[Howard, Jerry Lee; Cipolle, Mark D.; Anderson, Meredith; Sabella, Victoria; Shollenberger, Daniele; Li, P. Mark; Pasquale, Michael D.] Lehigh Valley Hosp, Dept Surg, Div Trauma Surg Crit Care, Allentown, PA 18105 USA	Howard, JL (corresponding author), Lehigh Valley Hosp, Dept Surg, Div Trauma Surg Crit Care, Cedar Crest & I-78,POB 689, Allentown, PA 18105 USA.	sally.lutz@lvh.com					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; BULLOCK MR, 1958, NEUROSURGERY S3, V58; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; CZOSNYKA M, 1996, NEUROCHIRURGICA, V138, P541; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Grady MS, 2006, J NEUROSURG, V104, P467, DOI 10.3171/jns.2006.104.4.467; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hutcherson DA, 2004, BIOL BLOOD MARROW TR, V10, P104, DOI 10.1016/j.bbmt.2003.12.286; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kunze E, 1998, ACT NEUR S, V71, P16; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Schneider GH, 2002, ACT NEUR S, V81, P77; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	23	118	129	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2008	65	2					380	385		10.1097/TA.0b013e31817c50d4			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	337US	WOS:000258461600028	18695475				2021-06-18	
J	Rotondi, AJ; Sinkule, J; Balzer, K; Harris, J; Moldovan, R				Rotondi, Armando J.; Sinkule, Jennifer; Balzer, Kathleen; Harris, Jeffrey; Moldovan, Rene			A qualitative needs assessment of persons who have experienced traumatic brain injury and their primary family caregivers	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						family needs; needs assessment; patient needs; person with TBI needs; traumatic brain injury	CRITICAL INCIDENT TECHNIQUE; CHRONIC ILLNESS; OF-LIFE; STROKE; RELATIVES; INTERVENTION; CONSEQUENCES; SERVICES; TBI	Objectives: To determine the expressed needs of persons with traumatic brain injury (TBI) and their primary family caregivers. Design: Semistructured interviews with content-analytic techniques to identify respondents' needs. Participants: Eighty persons with TBI, with an average time since their most severe TBI of 5.8 years, and 85 primary support persons. Results: Respondents described their needs via phases that paralleled transition's in settings, treatments, and responsibilities (ie, acute care, i.n-patient rehabilitation, return home, and living in the community). Prominent themes during in-patient phases included provider quality, emotional support, and understanding the injuries. Prominent themes during the latter 2 phases included guidance, life planning, community integration, and behavioral and emotional issues. Conclusions: Participants reported insufficient education and preparation for the future. Current methods of identifying needs may not be based on these populations' perceptions, and often miss the natural divisions of needs that occur over the course of treatment and rehabilitation. To meet their needs, services must be responsive to changes in needs over time, accessible to consumers of services for as long as they are required, and designed to be directed and customized by users.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA; George Mason Univ, Dept Psychiat, Fairfax, VA USA	Rotondi, AJ (corresponding author), 612B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	rotondi@pitt.edu					Allen SM, 1997, MED CARE, V35, P1132, DOI 10.1097/00005650-199711000-00005; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; BRUZY S, 1977, SPECIALE, V26, P77; Bull M J, 1990, West J Nurs Res, V12, P758, DOI 10.1177/019394599001200605; Callan RJ, 1998, TOURISM MANAGE, V19, P93, DOI 10.1016/S0261-5177(97)00078-2; Campbell C H, 1988, Rehabil Nurs, V13, P320; CAMPLAIR PS, 1990, COMMUNITY INTEGRATIO, P207; CARNWATH TCM, 1987, BRIT MED J, V294, P409, DOI 10.1136/bmj.294.6569.409; Cleeland C S, 1986, J Pain Symptom Manage, V1, P209, DOI 10.1016/S0885-3924(86)80043-4; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Dixon L, 2001, PSYCHIAT SERV, V52, P903, DOI 10.1176/appi.ps.52.7.903; DRAPER BM, 1992, J AM GERIATR SOC, V40, P896, DOI 10.1111/j.1532-5415.1992.tb01986.x; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; GLASS TA, 1993, STROKE, V24, P64, DOI 10.1161/01.STR.24.1.64; Hallberg N, 1999, METHOD INFORM MED, V38, P66; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; King RB, 1996, STROKE, V27, P1467, DOI 10.1161/01.STR.27.9.1467; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCCUBBIN MA, 1996, HDB CHILD HLTH ASSES, P227; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Miles M.B., 1994, QUALITATIVE DATA ANA; MOLTER NC, 1979, HEART LUNG, V8, P332; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Olvingson C, 2002, INT J MED INFORM, V68, P165, DOI 10.1016/S1386-5056(02)00074-6; Panting A., 1972, REHABILITATION, V38, P33; POULSHOCK SW, 1984, J GERONTOL, V39, P230, DOI 10.1093/geronj/39.2.230; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Rotondi AJ, 2002, J CRIT CARE, V17, P16, DOI 10.1053/jcrc.2002.33033; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Smith J E, 2000, Care Manag J, V2, P27; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Vadhan NP, 2001, J NERV MENT DIS, V189, P637, DOI 10.1097/00005053-200109000-00011; VOGT TM, 1992, J CLIN EPIDEMIOL, V45, P659, DOI 10.1016/0895-4356(92)90138-D; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Whyte J, 1998, REHABILITATION MED P, P1191; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303; 1998, NIH CONSENS STATEMEN, V16, P1	46	118	121	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2007	22	1					14	25		10.1097/00001199-200701000-00002			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	130SX	WOS:000243820400002	17235227				2021-06-18	
J	Davis, DP; Idris, AH; Sise, MJ; Kennedy, F; Eastman, AB; Velky, T; Vilke, GM; Hoyt, DB				Davis, DP; Idris, AH; Sise, MJ; Kennedy, F; Eastman, AB; Velky, T; Vilke, GM; Hoyt, DB			Early ventilation and outcome in patients with moderate to severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; ventilation; intubation; resuscitation; head trauma; hyperventilation	SEVERE HEAD-INJURY; RAPID-SEQUENCE INTUBATION; CEREBRAL BLOOD-FLOW; RESPIRATORY-DISTRESS-SYNDROME; INDUCED LUNG INJURY; INTRACELLULAR CALCIUM-CONCENTRATION; KINASE-IV ACTIVITY; ENDOTRACHEAL INTUBATION; MECHANICAL VENTILATION; INTRACRANIAL-PRESSURE	Objectives: An increase in mortality has been reported with early intubation in severe traumatic brain injury, possibly due to suboptimal ventilation. This analysis explores the impact of early ventilation on outcome in moderate to severe traumatic brain injury. Design: Retrospective, registry-based analysis. Setting. This study was conducted in a large county trauma system that includes urban, suburban, and rural jurisdictions. Patients: Nonarrest trauma victims with a Head Abbreviated Injury Score of :3 were identified from our county trauma registry. Interventions. Intubated patients were stratified into 5 mm Hg arrival Pco(2) increments. Logistic regression was used to calculate odds ratios for each increment, adjusting for age, gender, mechanism of injury, year of injury, preadmission Glasgow Coma Scale score, hypotension, Head Abbreviated Injury Score, Injury Severity Score, POD and base deficit. Increments with the highest relative survival were used to define the optimal Pco(2), range. Outcomes for patients with arrival Pco(2) values inside and outside this optimal range were then explored for both intubated and nonintubated patients, adjusting for the same factors as defined previously. In addition, the independent outcome effect of hyperventilation and hypoventilation was assessed. Measurements and Main Results: A total of 890 intubated and 2,914 nonintubated patients were included. Improved survival was observed for the arrival Pco(2) range 30-49 mm Hg. Patients with arrival Pco(2) values inside this optimal range had improved survival and a higher incidence of good outcomes. Conversely, there was no improvement in outcomes for patients within this optimal Pco(2) range for nonintubated patients after adjusting for all of the factors defined previously. Both hyperventilation and hypoventilation were associated with worse outcomes in intubated but not nonintubated patients. The proportion of arrival Pco(2) values within the optimal range was lower for intubated vs. nonintubated patients. Conclusions. Arrival hypercapnia and hypocapnia are common and associated with worse outcomes in intubated but not spontaneously breathing patients with traumatic brain injury.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Univ Texas SW, Div Trauma, Dallas, TX USA; Scripps Mercy Hosp, San Diego, CA 92103 USA; Sharp Mem Hosp & Rehabil Ctr, San Diego, CA 92123 USA; Scripps Mem Hosp, La Jolla, CA 92037 USA	Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA.			Idris, Ahamed/0000-0001-7113-6499			Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Ausina A, 1998, ACT NEUR S, V71, P1; Bao Yinghui, 2000, Chin J Traumatol, V3, P210; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; Bloomfield GL, 1997, CRIT CARE MED, V25, P496, DOI 10.1097/00003246-199703000-00020; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Bruehl C, 2003, J NEUROPHYSIOL, V89, P2489, DOI 10.1152/jn.01083.2002; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; Citerio G, 2001, CRIT CARE MED, V29, P1466, DOI 10.1097/00003246-200107000-00027; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; COURNAND A, 1948, AM J PHYSIOL, V152, P162; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DAVIS DP, IN PRESS J TRAUMA; DAVIS DP, 2006, IN PRESS PREHOSP EME; di Bartolomeo S, 2003, EUR J EMERG MED, V10, P268, DOI 10.1097/01.mej.0000103466.32882.7b; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Falcone R E, 1996, Air Med J, V15, P163, DOI 10.1016/S1067-991X(96)90024-3; FEWELL JE, 1980, CIRC RES, V46, P125, DOI 10.1161/01.RES.46.1.125; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; Fritz KI, 2004, NEUROCHEM RES, V29, P791, DOI 10.1023/B:NERE.0000018852.85899.85; Fritz KI, 2003, NEUROSCI LETT, V352, P211, DOI 10.1016/j.neulet.2003.08.049; Fritz KI, 2001, PEDIATR RES, V50, P586, DOI 10.1203/00006450-200111000-00009; GERVAIS HW, 1987, CRIT CARE MED, V15, P761, DOI 10.1097/00003246-198708000-00010; GUERCI AD, 1985, CIRC RES, V56, P20, DOI 10.1161/01.RES.56.1.20; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; HENNING R, 1986, ANAESTH INTENS CARE, V14, P267, DOI 10.1177/0310057X8601400307; HURST JM, 1989, J TRAUMA, V29, P1637, DOI 10.1097/00005373-198912000-00008; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; MATTA B, 1994, J NEUROSURG ANESTH, V6, P280; MATTLE HP, 1995, NEUROLOGY, V45, P498, DOI 10.1212/WNL.45.3.498; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; OUYANG YB, 1994, EXP BRAIN RES, V101, P265, DOI 10.1007/BF00228746; OUYANG YB, 1994, BRAIN RES, V646, P65, DOI 10.1016/0006-8993(94)90058-2; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; Pepe PE, 2003, J TRAUMA, V54, P1048, DOI 10.1097/01.TA.0000064280.05372.7C; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PORTH CJM, 1984, HEART LUNG, V13, P507; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Potapenko E, 2004, NEUROCHEM RES, V29, P1659, DOI 10.1023/B:NERE.0000035800.65411.3e; Rosenthal RJ, 1998, J AM COLL SURGEONS, V187, P32, DOI 10.1016/S1072-7515(98)00126-4; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Schneider GH, 1998, ACT NEUR S, V71, P62; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Slutsky A S, 2000, Respir Res, V1, P73, DOI 10.1186/rr15; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; SYVERUD SA, 1988, ANN EMERG MED, V17, P236, DOI 10.1016/S0196-0644(88)80114-8; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Tobias JD, 1996, PEDIATR EMERG CARE, V12, P249, DOI 10.1097/00006565-199608000-00003; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/00003246-200208000-00003; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; VADEBONCOEUR TF, 2006, IN PRESS J EMERG MED; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vilke Gary M., 1994, Journal of Emergency Medicine, V12, P217, DOI 10.1016/0736-4679(94)90702-1; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Wilson MR, 2003, J APPL PHYSIOL, V95, P1385, DOI 10.1152/japplphysiol.00213.2003; Zhang HB, 2002, ANESTHESIOLOGY, V97, P1426, DOI 10.1097/00000542-200212000-00014; Zornow MH, 2002, CRIT CARE MED, V30, P2774, DOI 10.1097/00003246-200212000-00026	81	118	122	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	APR	2006	34	4					1202	1208		10.1097/01.CCM.0000208359.74623.1C			7	Critical Care Medicine	General & Internal Medicine	025YH	WOS:000236303000038	16484927				2021-06-18	
J	He, J; Hoffman, SW; Stein, DG				He, J; Hoffman, SW; Stein, DG			Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						cortical injury; neurosteroids; allopregnanolone; progesterone; GABA; neuroprotection	CORTICAL CONTUSION INJURY; PREFRONTAL CORTEX; NEUROSTEROID ALLOPREGNANOLONE; MEDIODORSAL NUCLEUS; GABA(A) RECEPTOR; FEMALE RATS; HEAD-INJURY; IN-VITRO; EXCITOTOXICITY; INFUSION	Purpose: In the Current study we investigated whether allopregnanolone, a metabolite of progesterone, could replicate progesterone's beneficial effects in promoting spatial learning ability after bilateral medial prefrontal cortex contusions in rats. Allopregnanolone has been shown to enhance GABA neurotransmission, whereas its isomer epiallopregnanolone does not have this property. Thus, epiallopregnanolone was chosen as a control substance to examine further the role of GABA transmission in post-trauma neuroprotection. Methods: After the contusion, rats were given 4 mg/kg treatment of either allopregnanolone or epiallopregnanolone for five consecutive days beginning 1 hr post-injury. Control groups only received vehicle treatment at the same time points. A spatial learning task (Morris Water Maze, MWM) was performed at 7 clays post-injury for 10 days. Subsequent histological analyses of brain tissue were conducted to determine quantitatively the neuronal losses in both the mediodorsal nucleus of the thalamus (MDN) and the nucleus basalis magnocellularis (NBM). Results: Allopregnanolone-treated rats showed better performance in the MWM compared to the vehicle-treated injury group. The histological analyses also revealed that the allopregnanolone-treated injury group had less neuronal loss in both the MDN and the NBM compared to the vehicle-treated injury group. In contrast, epiallopregnanolone did not facilitate MWM performance or reduce neuronal loss in the MDN and the NBM after TBI. Conclusion: Based on our findings, we Suggest that allopregnanolone may mediate the effects of progesterone in promoting cognitive and morphological recovery from TBI through, among others. its direct or indirect effects on GABA-modulated neurons in the MDN and the NBM.	Emory Univ, Dept Psychol, Brain Res Lab, Atlanta, GA 30322 USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Dept Psychol, Brain Res Lab, 1648 Pierce Dr,Evans Bldg Room 261, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038664] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38664] Funding Source: Medline		AKHONDZADEH S, 1995, BRIT J PHARMACOL, V115, P527, DOI 10.1111/j.1476-5381.1995.tb16366.x; AKHONDZADEH S, 1995, BRAIN RES, V677, P311, DOI 10.1016/0006-8993(95)00165-M; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Brot MD, 1997, EUR J PHARMACOL, V325, P1, DOI 10.1016/S0014-2999(97)00096-4; Cavalli R, 1999, INT J PHARM, V182, P59, DOI 10.1016/S0378-5173(99)00066-6; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; CLARK AS, 1989, J CHEM NEUROANAT, V2, P259; Czlonkowska AI, 2001, POL J PHARMACOL, V53, P385; Darnaudery M, 1999, NEUROSCIENCE, V92, P583, DOI 10.1016/S0306-4522(99)00019-6; Dazzi L, 1996, BRAIN RES, V710, P275, DOI 10.1016/0006-8993(95)01478-0; di Michele F, 2000, NEUROSCI LETT, V284, P65, DOI 10.1016/S0304-3940(00)00965-4; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; FIBIGER HC, 1982, BRAIN RES REV, V4, P327, DOI 10.1016/0165-0173(82)90011-X; Galli R, 2001, EPILEPSIA, V42, P216, DOI 10.1046/j.1528-1157.2001.4220216.x; Ghezzi P, 2000, EUR CYTOKINE NETW, V11, P464; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GOSS CW, 2001, J NEUROTRAUM, V18, P1175; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hoffman S. W, 2001, ACAD EMERG MED, V8, P496; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Kajta M, 1999, POL J PHARMACOL, V51, P531; Khateb A, 1998, NEUROSCIENCE, V86, P937, DOI 10.1016/S0306-4522(98)00094-3; Laconi MR, 2001, EUR J PHARMACOL, V417, P111, DOI 10.1016/S0014-2999(01)00865-2; Ladurelle N, 2000, BRAIN RES, V858, P371, DOI 10.1016/S0006-8993(00)01953-3; Landgren S, 1998, ACTA PHYSIOL SCAND, V162, P77; LASALLE GL, 1988, EXP NEUROL, V101, P411, DOI 10.1016/0014-4886(88)90052-0; Limmroth V, 1996, BRIT J PHARMACOL, V117, P99, DOI 10.1111/j.1476-5381.1996.tb15160.x; LYETH BG, 1992, J NEUROTRAUMA S2, V9, P463; Mahesh VB, 1996, J STEROID BIOCHEM, V56, P209, DOI 10.1016/0960-0760(95)00238-3; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Matthews DB, 2002, ALCOHOL CLIN EXP RES, V26, P1747, DOI 10.1097/01.ALC.0000037219.79257.17; Maurice T, 1999, JPN J PHARMACOL, V81, P125, DOI 10.1254/jjp.81.125; Miller L, 1998, J IMMUNOL, V160, P5098; Muir JK, 1996, J CEREBR BLOOD F MET, V16, P1211, DOI 10.1097/00004647-199611000-00015; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; OLNEY JW, 1994, J NEURAL TRANSM-SUPP, P47; Oyoshi T, 1996, J NEUROSCI, V16, P5812; PARKCHUNG MJ, 1994, MOL PHARMACOL, V46, P146; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PIROT S, 1994, EUR J NEUROSCI, V6, P1225, DOI 10.1111/j.1460-9568.1994.tb00621.x; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; RODRIGUEZITHURRALDE D, 1994, J NEUROL SCI, V124, P52, DOI 10.1016/0022-510X(94)90176-7; Romanides AJ, 1999, NEUROSCIENCE, V92, P97, DOI 10.1016/S0306-4522(98)00747-7; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rupprecht R, 1999, PSYCHOPHARMACOLOGY, V143, P29, DOI 10.1007/s002130050916; SAVOLAINEN K, 1994, NEUROTOXICOLOGY, V15, P493; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; SCHMIDT RH, 1995, J NEUROSURG, V83, P495; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; Stein DG, 1991, J NEUROTRAUM, V8, P281, DOI 10.1089/neu.1991.8.281; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Urani A, 1998, BRAIN RES, V799, P64, DOI 10.1016/S0006-8993(98)00469-7; Wang MD, 2000, ACTA PHYSIOL SCAND, V169, P333, DOI 10.1046/j.1365-201x.2000.00744.x	59	118	123	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2004	22	1					19	31					13	Neurosciences	Neurosciences & Neurology	818NH	WOS:000221251300003	15096691				2021-06-18	
J	Valovich, TC; Perrin, DH; Gansneder, BM				Valovich, TC; Perrin, DH; Gansneder, BM			Repeat administration elicits a practice effect with the balance error scoring system but not with the standardized assessment of concussion in high school athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						postural stability; serial assessments; cognitive assessment	MILD HEAD-INJURY; REPEATED NEUROPSYCHOLOGICAL ASSESSMENTS; POSTURAL STABILITY; FOOTBALL PLAYERS; PERFORMANCE; COLLEGIATE; SPORTS; EPIDEMIOLOGY; RECOVERY; SIDELINE	Objective: To assess whether repeated administration of the Standardized Assessment of Concussion (SAC) and Balance Error Scoring System (BESS) demonstrates a practice effect in high school athletes. Design and Setting: Subjects were assigned to either a control or practice group. Subjects in the control group were assessed twice, 30 days apart. Subjects in the practice group were assessed on 5 occasions. Four assessments were performed within a 7-day period and 1 more assessment 30 days after the initial test. Subjects: Thirty-two uninjured high school athletes participated in this investigation. Sixteen were randomly assigned to a control group and 16 to a practice group. Measurements: We measured performance on the SAC and on 6 test conditions of the BESS. Results: We found a significant time-by-group interaction on BESS performance on the day-30 test session. A significant practice effect of the BESS was found during the course of repeated administrations in the practice group. After repeated testing, the number of BESS errors decreased with each test session, and error scores on day 5 (10.94 +/- 2.17) and day 7 (9.44 +/- 3.32) were significantly lower than the baseline score (12.88 +/- 3.34). We did not find group differences or a practice effect on the SAC (baseline score = 26.16). Conclusions: Our results revealed no practice effect with the SAC and a slight practice effect with repeated administrations of the BESS, especially with the single-leg stance on foam. Clinicians must acknowledge the potential for practice effects when readministering these concussion assessments to track recovery of an athlete or as a guide in return-to-play decision making.	Arizona Sch Hlth Sci, Dept Sports Hlth Care, Mesa, AZ 85206 USA; Univ N Carolina, Greensboro, NC 27412 USA; Univ Virginia, Charlottesville, VA USA	Valovich, TC (corresponding author), Arizona Sch Hlth Sci, Dept Sports Hlth Care, 5850 E Still Circle, Mesa, AZ 85206 USA.		McLeod, Tamara/AAU-9435-2020				BARR WB, 2001, J INT NEUROPSYCH SOC, V7, P396; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT., 1989, MILD HEAD INJURY, P257; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; EKDAHL C, 1989, SCAND J REHABIL MED, V21, P187; Gerberich SG, 1997, NEUROEPIDEMIOLOGY, V16, P1, DOI 10.1159/000109665; Gronwall D, 1989, MILD HEAD INJURY, P153; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HAMMAN R, 1995, J OTOLARYNGOL, V24, P221; HAMMAN RG, 1992, ARCH PHYS MED REHAB, V73, P738; Hertel J, 2000, J SPORT REHABIL, V9, P104, DOI 10.1123/jsr.9.2.104; JAMIESON M, 1998, NZ J SPORTS MED, V26, P50; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; MCCAFFREY RJ, 1993, ARCH CLIN NEUROPSYCH, V8, P519; MCCAFFREY RJ, 1992, CLIN NEUROPSYCHOL, V6, P32, DOI DOI 10.1080/13854049208404115; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; Nordahl SHG, 2000, AVIAT SPACE ENVIR MD, V71, P889; Oliaro SM, 1998, J ATHL TRAINING, V33, P36; Onate JA, 2000, J ATHL TRAINING, V35, P155; Powell JW, 1999, J ATHL TRAINING, V34, P277; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 1997, J SPORT REHABIL, V6, P283, DOI 10.1123/jsr.6.3.283; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003	35	118	119	0	13	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JAN-MAR	2003	38	1					51	56					6	Sport Sciences	Sport Sciences	662VJ	WOS:000181969300008					2021-06-18	
J	Jagoda, AS; Cantrill, SV; Wears, RL; Valadka, A; Gallagher, EJ; Gottesfeld, SH; Pietrzak, MP; Bolden, J; Bruns, JJ; Zimmerman, R				Jagoda, AS; Cantrill, SV; Wears, RL; Valadka, A; Gallagher, EJ; Gottesfeld, SH; Pietrzak, MP; Bolden, J; Bruns, JJ; Zimmerman, R			Clinical policy: Neuroimaging and decisionmaking in adult mild traumatic brain injury in the acute setting	ANNALS OF EMERGENCY MEDICINE			English	Article							MINOR HEAD-INJURY; CRANIAL COMPUTED-TOMOGRAPHY; SIGNIFICANT INTRACRANIAL INJURY; HIGH-YIELD CRITERIA; COMA-SCALE SCORE; LOW-RISK; EXTRADURAL HEMATOMAS; SKULL RADIOGRAPHY; CT SCANS; MANAGEMENT		Mt Sinai Sch Med, Dept Emergency Med, IBIA, New York, NY 10029 USA; Denver Hlth Med Ctr, Dept Emergency Med, Denver, CO USA; Univ Florida, Sch Med, Dept Emergency Med, ACEP, Jacksonville, FL USA; Baylor Coll Med, Dept Neurosurg,Sect Neurotrauma & Crit Care, Amer Assoc Neurol Surgeons, Congress Neurol Surgeons, Houston, TX 77030 USA; Ben Taub Gen Hosp, Houston, TX 77030 USA; Albert Einstein Coll Med, Dept Emergency Med, New York, NY USA; Int Brain Injury Assoc, Alexandria, VA USA; Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA; New York Presbyterian, Dept Radiol, New York, NY USA	Jagoda, AS (corresponding author), Mt Sinai Sch Med, Dept Emergency Med, IBIA, New York, NY 10029 USA.		Wright, David/F-1209-2013; Wears, Robert/N-5959-2014	Wright, David/0000-0002-7145-9105; Wears, Robert/0000-0001-9826-954X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [200-2007-21367] Funding Source: Medline		Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; Bergman DA, 1999, PEDIATRICS, V104, P1407; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cook L S, 1994, Acad Emerg Med, V1, P227; COOPER PR, 1983, NEUROSURGERY, V13, P136, DOI 10.1227/00006123-198308000-00005; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Holmes JF, 1997, ACAD EMERG MED, V4, P788, DOI 10.1111/j.1553-2712.1997.tb03786.x; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; LEE ST, 1995, ACTA NEUROCHIR, V135, P136, DOI 10.1007/BF02187757; LEVITT MA, 1994, AM J EMERG MED, V12, P172, DOI 10.1016/0735-6757(94)90240-2; LEWIS LM, 1992, SOUTHERN MED J, V85, P348, DOI 10.1097/00007611-199204000-00004; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MADDEN C, 1995, ACAD EMERG MED, V2, P240; Marx JA, 2000, NEW ENGL J MED, V343, P138, DOI 10.1056/NEJM200007133430212; MASTERS SJ, 1980, AM J ROENTGENOL, V135, P539, DOI 10.2214/ajr.135.3.539; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MCCLEAN PM, 1984, ANN EMERG MED, V13, P607, DOI 10.1016/S0196-0644(84)80287-5; MIKHAIL MG, 1992, AM J EMERG MED, V10, P24, DOI 10.1016/0735-6757(92)90119-I; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MILLS ML, 1986, ANN EMERG MED, V15, P1167, DOI 10.1016/S0196-0644(86)80859-9; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MORAN SG, 1994, AM SURGEON, V60, P533; MURSHID WR, 1994, ACTA NEUROCHIR, V129, P11, DOI 10.1007/BF01400866; Nagurney JT, 1998, ACAD EMERG MED, V5, P678, DOI 10.1111/j.1553-2712.1998.tb02485.x; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Nee PA, 1999, J NEUROL NEUROSUR PS, V66, P470, DOI 10.1136/jnnp.66.4.470; POZZATI E, 1980, J TRAUMA, V20, P795, DOI 10.1097/00005373-198009000-00015; RAM Z, 1989, J NEUROSURG, V71, P608, DOI 10.3171/jns.1989.71.4.0608; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; Riesgo P, 1997, SURG NEUROL, V48, P226, DOI 10.1016/S0090-3019(97)00194-8; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTS CJ, 1980, LANCET, V2, P1234; Ruff RM, 1999, BRAIN INJURY, V13, P943; SAUNDERS CE, 1986, ANN EMERG MED, V15, P160, DOI 10.1016/S0196-0644(86)80012-9; SCHYNOLL W, 1993, AM J EMERG MED, V11, P321, DOI 10.1016/0735-6757(93)90160-D; SERVADEI F, 1988, J NEUROL NEUROSUR PS, V51, P526, DOI 10.1136/jnnp.51.4.526; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SHAFFER MA, 1982, ANN EMERG MED, V11, P303, DOI 10.1016/S0196-0644(82)80128-5; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TUNCER R, 1993, ACTA NEUROCHIR, V121, P48, DOI 10.1007/BF01405182; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Vilke GM, 2000, AM J EMERG MED, V18, P159, DOI 10.1016/S0735-6757(00)90009-3; Volans AP, 1998, J ACCID EMERG MED, V15, P159; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wysoki MG, 1998, RADIOLOGY, V208, P125, DOI 10.1148/radiology.208.1.9646802; ZIMMERMAN RA, 1978, AM J ROENTGENOL, V131, P27, DOI 10.2214/ajr.131.1.27; Zwimpfer TJ, 1997, J NEUROSURG, V86, P433, DOI 10.3171/jns.1997.86.3.0433	86	118	122	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	AUG	2002	40	2					231	249		10.1067/mem.2002.125782			19	Emergency Medicine	Emergency Medicine	579GR	WOS:000177170700014	19285163				2021-06-18	
J	Schwarz, S; Georgiadis, D; Aschoff, A; Schwab, S				Schwarz, S; Georgiadis, D; Aschoff, A; Schwab, S			Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke	STROKE			English	Article						brain edema; hypertonic solution; saline; intracranial pressure; stroke	CEREBRAL-ARTERY INFARCTION; RANDOMIZED CLINICAL-TRIAL; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; MANNITOL; HYPERTENSION; EDEMA; RESUSCITATION; INFUSIONS; DEXTRAN	Background and Purpose-The aim of this study was to evaluate the effects of hypertonic saline in stroke patients with increased intracranial pressure (ICP) after conventional therapy with mannitol had failed. Methods-Twenty-two episodes of ICP crisis occurred in 8 patients in whom the standard treatment of 200 mL of 20% mannitol was not effective. ICP crisis was defined as an increase in ICP of 20 nun Hg (n = 18), pupillary abnormality (n=3), or a combination of both (n=1). The patients were treated with 75 mL of 10% saline over the course of 15 minutes. ICP, mean arterial blood pressure, and cerebral perfusion pressure were monitored for 4 hours. Blood gases, hematocrit, hemoglobin, pH, osmolarity, and electrolytes levels were measured before and 15 and 60 minutes after the start of infusion. Treatment was regarded as effective if ICP decreased >10% or the pupillary reaction had normalized. Results-Treatment was effective in all 22 episodes. The maximum ICP decrease was 9.9 mm Hg 35 minutes after the start of infusion. Thereafter, ICP began to rise again. There was no constant effect on mean arterial blood pressure, whereas cerebral perfusion pressure was consistently increased. Blood osmolarity rose by 9 mmol/L and serum sodium by 5.6 mmol/L. Potassium levels, hemoglobin, hematocrit, and pH were slightly decreased. No unexpected side effects were noted. Conclusions-Infusion of 75 mL hypertonic (10%) saline decreases elevated ICP and increases cerebral perfusion pressure in stroke patients in whom mannitol had failed. The effect on the ICP and cerebral perfusion pressure reaches its maximum after the end of infusion and is seen for 4 hours.	Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Neurosurg, D-69120 Heidelberg, Germany	Schwarz, S (corresponding author), Univ Heidelberg, Dept Neurol, 400 Neuenheimer Feld, D-69120 Heidelberg, Germany.						Bereczki D, 2000, STROKE, V31, P2719, DOI 10.1161/01.STR.31.11.2719; Biestro A, 1997, ACTA NEUROCHIR, V139, P725, DOI 10.1007/BF01420045; CANDELISE L, 1988, LANCET, V1, P318; DUBICK MA, 1995, SHOCK, V3, P137, DOI 10.1097/00024382-199503020-00009; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hartl R, 1997, ZBL CHIR, V122, P181; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JENNETT B, 1975, LANCET, V1, P480; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kirkpatrick PJ, 1996, NEUROSURGERY, V39, P714, DOI 10.1097/00006123-199610000-00013; KRAMER GC, 1986, SURGERY, V100, P239; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Schatzmann C, 1998, ACT NEUR S, V71, P31; Schwab S, 1997, NEUROLOGY, V48, P1608, DOI 10.1212/WNL.48.6.1608; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003	29	118	132	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	JAN	2002	33	1					136	140		10.1161/hs0102.100877			5	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	509KV	WOS:000173147700029	11779902	Bronze			2021-06-18	
J	Kolakowsky-Hayner, SA; Miner, KD; Kreutzer, JS				Kolakowsky-Hayner, SA; Miner, KD; Kreutzer, JS			Long-term life quality and family needs after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; family needs; quality of life; support systems	SEVERE HEAD-INJURY; OF-LIFE; RELATIVES	Objectives: This investigation assessed the life quality and long-term family needs of caregivers of persons with brain injury. Design: Respondents completed the Virginia Traumatic Brain Injury Family Needs Assessment survey. Setting: Community-based sample. Participants: Respondents included 57 caregivers of persons with traumatic brain injury who were at least 4 years after injury and who resided in Virginia. Respondents ranged in age from 19 to 82 years and were primarily women and Caucasian. Outcome Measures: The Family Needs Questionnaire (FNQ) and quality of life questions. Results: Results indicate diminished life quality after injury. With regard to family needs, Health Information (51.43%) and involvement with Care (47.93%) needs were most often rated as met. Instrumental Support (31.52%) and Professional Support (28.38%) needs were most often rated as not met. Conclusions: Family needs and support systems for those needs change over time. This investigation provides evidence that unmet family needs extend well beyond the acute setting and that caregiver life quality diminishes over time. The importance of appreciating long-term family needs and other life quality issues should not be underestimated.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Kolakowsky-Hayner, SA (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Med Coll Virginia Campus,1200 E Broad St,Room 3-1, Richmond, VA 23298 USA.		Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909			BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BRUZY S, 1997, SOCIAL WORK HLTH CAR, V26, P77; Campbell C H, 1988, Rehabil Nurs, V13, P320; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; GRAFFI S, 1989, J APPL SOC SCI, V3, P293; GRANINGER W, 1992, CLIN INFECT DIS, V15, P49, DOI 10.1093/clinids/15.1.49; Hickey AM, 1997, PSYCHOL HEALTH, V12, P827, DOI 10.1080/08870449708406743; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2000, NEUROREHABILITATION, V14, P151; Kolakowsky-Hayner SA, 1999, NEUROREHABILITATION, V13, P27; KOSCIULEK JF, 1996, J APPL REHABILITATIO, V27, P8; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Moules S, 1999, BRAIN INJURY, V13, P983; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A., 1972, REHABILITATION, V38, P33; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303	32	118	119	1	9	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2001	16	4					374	385		10.1097/00001199-200108000-00007			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	459YA	WOS:000170278000007	11461659				2021-06-18	
J	Bigler, ED				Bigler, ED			Quantitative magnetic resonance imaging in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						computed tomography; magnetic resonance imaging; neuroimaging; traumatic brain injury	CORTICAL ATROPHY; LESION VOLUME; WHITE-MATTER; HEAD-INJURY; MEMORY; DEGENERATION; ENLARGEMENT; NEUROLOGY; DAMAGE; MR	Quantitative neuroimaging has now become a well-established method for analyzing magnetic resonance imaging in traumatic brain injury (TBI). A general review of studies that have examined quantitative changes following TBI is presented. The consensus of quantitative neuroimaging studies is that most brain structures demonstrate changes in volume or surface area after injury. The patterns of atrophy are consistent with the generalized nature of brain injury and diffuse axonal injury. Various clinical caveats are provided including how quantitative neuroimaging findings can be used clinically and in predicting rehabilitation outcome. The future of quantitative neuroimaging also is discussed.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; LDS Hosp, Salt Lake City, UT USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1082 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu					ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; BIGLER ED, 1984, INT J NEUROSCI, V24, P295, DOI 10.3109/00207458409089820; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; BIGLER ED, 1996, HDB HUMAN BRAIN FUNC; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BOWEN JM, 1997, DEV MED CHILD NEUROL, P39; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; CONNOR PD, 1995, J INT NEUROPSYCH SOC, V1, P174; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENNARELLI TA, 1998, NEUROSCIENTIST, P4; HAUG JO, 1962, ACTA PSYCHIAT SCAND, V165, P1; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KESLER SR, 2000, IN PRESS BRAIN INJUR; Klingberg T, 2000, NEURON, V25, P493, DOI 10.1016/S0896-6273(00)80911-3; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; LAKLLAW DH, 1998, IEEE T MED IMAGING, V20, P100; LEVIN HS, 2000, REDUCTION CORPUS CAL, V54, P647; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASSMAN PJ, 1986, INT J NEUROSCI, V30, P87, DOI 10.3109/00207458608985659; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; ORRISON WW, 2000, NEUROIMAGING; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT., 1996, NEUROTRAUMA, P1325; Primus EA, 1997, BRAIN INJURY, V11, P577; RYSER DK, 1996, INT PERSPECTIVES TRA, P79; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SALAZAR AM, 1986, NEUROLOGY, V36, P459, DOI 10.1212/WNL.36.4.459; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; TATE DF, 2000, IN PRESS LEARNING ME; TURKHEIMER E, 1990, NEUROPSYCHOLOGIA, V28, P1011, DOI 10.1016/0028-3932(90)90136-C; WOOD DMG, 1995, BRAIN RES BULL, V38, P545, DOI 10.1016/0361-9230(95)02026-0	46	118	121	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2001	16	2					117	134		10.1097/00001199-200104000-00003			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	422HH	WOS:000168112100002	11275574				2021-06-18	
J	Liu, DX; Ling, X; Wen, J; Liu, J				Liu, DX; Ling, X; Wen, J; Liu, J			The role of reactive nitrogen species in secondary spinal cord injury: Formation of nitric oxide, peroxynitrite, and nitrated protein	JOURNAL OF NEUROCHEMISTRY			English	Article						secondary spinal cord injury; nitric oxide; peroxynitrite; nitrotyrosine; protein nitration; Mn(III) tetrakis(4-benzoic acid)porphyrin	FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; SUPEROXIDE-DISMUTASE; NERVOUS-SYSTEM; L-ARGININE; NEURODEGENERATIVE DISEASES; GLUTAMATE NEUROTOXICITY; LIQUID-CHROMATOGRAPHY; SYNTHASE INHIBITION	To determine whether reactive nitrogen species contribute to secondary damage in CNS injury, the time courses of nitric oxide, peroxynitrite, and nitrotyrosine production were measured following impact injury to the rat spinal cord. The concentration of nitric oxide measured by a nitric oxide-selective electrode dramatically increased immediately following injury and then quickly declined. Nitro-L-arginine reduced nitric oxide production. The extracellular concentration of peroxynitrite, measured by perfusing tyrosine through a microdialysis fiber into the cord and quantifying nitrotyrosine in the microdialysates, significantly increased after injury to 3.5 times the basal level, and superoxide dismutase and nitro-L-arginine completely blocked peroxynitrite production. Tyrosine nitration examined immunohistochemically significantly increased at 12 and 24 h postinjury, but not in sham-control sections. Mn(III) tetrakis(4-benzoic acid)porphyrin (a novel cell-permeable superoxide dismutase mimetic) and nitro-L-arginine significantly reduced the numbers of nitrotyrosine-positive cells. Protein-bound nitrotyrosine was significantly higher in the injured tissue than in the sham-operated controls. These results demonstrate that traumatic injury increases nitric oxide and peroxynitrite production, thereby nitrating tyrosine, including protein-bound tyrosine. Together with our previous report that trauma increases superoxide, our results suggest that reactive nitrogen species cause secondary damage by nitrating protein through the pathway superoxide + nitric oxide --> peroxynitrite --> protein nitration.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77550 USA	Liu, DX (corresponding author), Univ Texas, Med Branch, Dept Neurol, Gail Borden Bldg,Room 4-468C, Galveston, TX 77555 USA.			liu, danxia/0000-0001-8172-2344	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035119, R29NS034048] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35119, NS34048] Funding Source: Medline		Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Arstall MA, 1999, CIRC RES, V85, P829, DOI 10.1161/01.RES.85.9.829; ASHWAL S, 1995, PEDIATR RES, V38, P652, DOI 10.1203/00006450-199511000-00004; Balentine JD, 1985, CENTRAL NERVOUS SYST, P455; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, PROG BRAIN RES, V103, P371; BELAND FA, 1979, J CHROMATOGR, V174, P177, DOI 10.1016/S0021-9673(00)87048-X; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; BRUCE AJ, 1995, FREE RADICAL BIO MED, V18, P993, DOI 10.1016/0891-5849(94)00218-9; BUCHAN AM, 1994, NEUROSCIENCE, V61, P1, DOI 10.1016/0306-4522(94)90054-X; CAZEVIEILLE C, 1993, FREE RADICAL BIO MED, V14, P389, DOI 10.1016/0891-5849(93)90088-C; CHOI DW, 1987, J NEUROSCI, V7, P357; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Cuzzocrea S, 1999, BRIT J PHARMACOL, V128, P1241, DOI 10.1038/sj.bjp.0702826; Cuzzocrea S, 1999, FREE RADICAL BIO MED, V26, P25, DOI 10.1016/S0891-5849(98)00142-7; DAWSON DA, 1992, NEUROSCI LETT, V142, P151, DOI 10.1016/0304-3940(92)90361-A; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; Dora CD, 1998, J NEUROTRAUM, V15, P473, DOI 10.1089/neu.1998.15.473; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hare P E, 1977, Methods Enzymol, V47, P3; Hensley K, 1997, ANAL BIOCHEM, V251, P187, DOI 10.1006/abio.1997.2281; HESS DT, 1994, NEUROPHARMACOLOGY, V33, P1283, DOI 10.1016/0028-3908(94)90028-0; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; ICHIMORI K, 1994, REV SCI INSTRUM, V65, P1; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Kamii H, 1996, J CEREBR BLOOD F MET, V16, P1153, DOI 10.1097/00004647-199611000-00009; Keller JN, 1998, J NEUROSCI, V18, P687; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; KOZNIEWSKA E, 1995, STROKE, V26, P282, DOI 10.1161/01.STR.26.2.282; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; LIU DX, 1994, J NEUROCHEM, V62, P37; LIU DX, 1993, J BIOCHEM BIOPH METH, V27, P281, DOI 10.1016/0165-022X(93)90009-D; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; LUO D, 1993, NEUROSCIENCE, V57, P897, DOI 10.1016/0306-4522(93)90035-E; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; NISHIKAWA T, 1993, STROKE, V24, P1717, DOI 10.1161/01.STR.24.11.1717; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; Patel M, 1998, J NEUROCHEM, V71, P1068, DOI 10.1046/j.1471-4159.1998.71031068.x; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Qian H, 1997, NEUROCHEM RES, V22, P1231, DOI 10.1023/A:1021980929422; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; VLIET A, 1994, FEBS LETT, V339, P89; WU WT, 1993, NEUROSCI LETT, V153, P121, DOI 10.1016/0304-3940(93)90303-3; YAMAMOTO S, 1992, J CEREBR BLOOD F MET, V12, P717, DOI 10.1038/jcbfm.1992.102; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; Young W, 1992, J NEUROTRAUMA S1, V9, P9; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	72	118	121	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	NOV	2000	75	5					2144	2154		10.1046/j.1471-4159.2000.0752144.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	365AA	WOS:000089925200039	11032904	Bronze			2021-06-18	
J	Turner, CP; Bergeron, M; Matz, P; Zegna, A; Noble, LJ; Panter, SS; Sharp, FR				Turner, CP; Bergeron, M; Matz, P; Zegna, A; Noble, LJ; Panter, SS; Sharp, FR			Heme oxygenase-1 is induced in glia throughout brain by subarachnoid hemoglobin	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						heme; iron; neurotrauma; stress genes; stroke	CENTRAL-NERVOUS-SYSTEM; TRANSIENT FOREBRAIN ISCHEMIA; HUMAN-SKIN FIBROBLASTS; HSP32 MESSENGER-RNA; HEAT-SHOCK PROTEIN; RAT-BRAIN; NITRIC-OXIDE; CARBON-MONOXIDE; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE	The heme oxygenase-1 gene, HO-1, induced by heme, ischemia, and heat shock, metabolizes heme to biliverdin, free iron, and carbon monoxide. Though the distribution of HO-1 has been described in normal rat brain, little is known about how extracellular heme proteins in the subarachnoid space distribute in brain. To address this issue, hemoglobin was injected into the cisterna magna of adult rats. Expression of HO-1 in these animals was compared with saline-injected, BSA-injected, and uninjected controls. Western blot analysis showed that 24 hours after injection oxyhemoglobin increased HO-1 levels approximately four-to fivefold in all brain regions studied compared with saline-injected and BSA-injected controls. In the brain, HO-1 immunoreactivity was evident at 4 hours and peaked at 24 hours after oxyhemoglobin injections, returning to control levels by 4 to 8 days. This HO-1 induction was detected mainly in cells with small, rounded somas bearing two to four truncated processes, a morphology consistent with that of microglia. These cells were double-stained with the microglial marker, OX42, in every brain region examined. II is proposed that subarachnoid hemoglobin may be taken up into a microglia wherein heme induces HO-1.	Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Neurosurg, San Francisco, CA 94143 USA	Turner, CP (corresponding author), Vet Adm Med Ctr, Dept Neurol V127, 4150 Clement St, San Francisco, CA 94121 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL053040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543, R01NS028167] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL53040] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543, NS28167] Funding Source: Medline		ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1992, J BIOL CHEM, V267, P21894; APPLEGATE LA, 1991, CANCER RES, V51, P974; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1995, AM J PHYSIOL-LUNG C, V268, pL321; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BASUMODAK S, 1993, CANCER RES, V53, P4505; Bergeron M, 1996, NEUROL RES, V18, P64, DOI 10.1080/01616412.1996.11740380; BERNABEU R, 1995, NEUROREPORT, V6, P516, DOI 10.1097/00001756-199502000-00027; BING O, 1995, NEUROREPORT, V6, P1369, DOI 10.1097/00001756-199507100-00002; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BROADWELL RD, 1993, EXP NEUROL, V120, P245, DOI 10.1006/exnr.1993.1059; CONNOR JR, 1992, ANN NEUROL, V32, pS51, DOI 10.1002/ana.410320710; CONNOR JR, 1994, J NEUROSCI RES, V37, P461, DOI 10.1002/jnr.490370405; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; DAWSON DA, 1994, CEREBROVAS BRAIN MET, V6, P299; DELGADO TJ, 1985, STROKE, V16, P595, DOI 10.1161/01.STR.16.4.595; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; DWYER BE, 1995, NEUROREPORT, V6, P973, DOI 10.1097/00001756-199505090-00006; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; GROTE E, 1988, NEUROSURGERY, V22, P654, DOI 10.1227/00006123-198804000-00006; GUTTERIDGE JMC, 1987, BIOCHIM BIOPHYS ACTA, V917, P219, DOI 10.1016/0005-2760(87)90125-1; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; KEYSE SM, 1990, CARCINOGENESIS, V11, P787, DOI 10.1093/carcin/11.5.787; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KOEPPEN AH, 1993, ANN NEUROL, V34, P646, DOI 10.1002/ana.410340505; KONDO Y, 1995, J CEREBR BLOOD F MET, V15, P216, DOI 10.1038/jcbfm.1995.27; KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177; LASH A, 1995, ANN CLIN LAB SCI, V25, P20; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Lee JC, 1960, NEUROLOGY, V10, P814, DOI 10.1212/WNL.10.9.814; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; MAINES MD, 1988, FASEB J, V2, P2557; MAINES MD, 1993, J PHARMACOL EXP THER, V264, P457; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; Matz P, 1996, STROKE, V27, P504, DOI 10.1161/01.STR.27.3.504; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1996, J NEUROSURG, V85, P892, DOI 10.3171/jns.1996.85.5.0892; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; MCDONAGH AF, 1990, CLIN PERINATOL, V17, P359; MITANI K, 1991, BIOCHEM J, V277, P895, DOI 10.1042/bj2770895; MONCADA S, 1989, BIOCHEM SOC T, V17, P642, DOI 10.1042/bst0170642; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; MULLER RM, 1987, J BIOL CHEM, V262, P6795; MURPHY BJ, 1991, BRIT J CANCER, V64, P69, DOI 10.1038/bjc.1991.241; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Nimura T, 1996, MOL BRAIN RES, V37, P201, DOI 10.1016/0169-328X(95)00315-J; OHYAGI Y, 1994, J NEUROL SCI, V126, P237, DOI 10.1016/0022-510X(94)90281-X; OKINAGA S, 1993, EUR J BIOCHEM, V212, P167, DOI 10.1111/j.1432-1033.1993.tb17647.x; PASCHEN W, 1994, NEUROSCI LETT, V180, P5, DOI 10.1016/0304-3940(94)90900-8; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; ROBERTS RL, 1993, J CELL SCI, V104, P521; ROSEN AD, 1979, EXP NEUROL, V66, P277, DOI 10.1016/0014-4886(79)90080-3; RUBLEVSKAYA I, 1994, J BIOL CHEM, V269, P26390; SCHACTER BA, 1988, SEMIN HEMATOL, V25, P349; SHIBAHARA S, 1993, J BIOCHEM-TOKYO, V113, P214, DOI 10.1093/oxfordjournals.jbchem.a124028; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUN Y, 1990, J BIOL CHEM, V265, P8212; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; TRAKSHEL GM, 1989, J BIOL CHEM, V264, P1323; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VILLEGAS JC, 1993, J NEUROCYTOL, V22, P67, DOI 10.1007/BF01181571; VINCENT SR, 1994, NEUROSCIENCE, V63, P223, DOI 10.1016/0306-4522(94)90018-3; WEBER CM, 1994, J NEUROCHEM, V63, P953; WELLER RO, 1992, BRAIN PATHOL, V2, P277, DOI 10.1111/j.1750-3639.1992.tb00704.x; WHITESELL L, 1993, P NATL ACAD SCI USA, V90, P4665, DOI 10.1073/pnas.90.10.4665; WILLIAMS MA, 1993, CURR OPIN NEUROL, V6, P847, DOI 10.1097/00019052-199312000-00004; YEE F, 1994, CELL MOL NEUROBIOL, V14, P475, DOI 10.1007/BF02088832; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	81	118	120	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	1998	18	3					257	273		10.1097/00004647-199803000-00004			17	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	YZ707	WOS:000072282800004	9498842	Bronze			2021-06-18	
J	Max, JE; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ; Stierwalt, JAG; Castillo, CS				Max, JE; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ; Stierwalt, JAG; Castillo, CS			Traumatic brain injury in children and adolescents: Psychiatric disorders at two years	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; children; adolescents; psychiatric disorder	HEAD-INJURY; RELIABILITY; SCALE; COMA	Objective: To extend findings regarding predictive factors of psychiatric outcome from the first to the second year after traumatic brain injury (TBI) in children and adolescents. Method: Subjects were children aged 6 to 14 years at the time they were hospitalized after TBI. The study used a prospective follow-up design. Assessments of preinjury psychiatric, behavioral, adaptive functioning, family functioning and family psychiatric history status were conducted. Severity of injury was assessed by standard clinical scales and neuroimaging was analyzed. The outcome measure was the presence of a psychiatric disorder, not present before the injury (''novel''), during the second year after TBI. Results: Fifty subjects enrolled, and the analyses focused on 42 subjects followed at 24 months. Severity of injury, preinjury family function, and preinjury lifetime psychiatric history predicted the development of a ''novel'' psychiatric disorder present in the second year. Conclusion: These data suggest that there are children, identifiable through clinical assessment, at increased risk for ''novel'' psychiatric disorders in the second year after TBI.	UNIV IOWA,DEPT RADIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT SPEECH PATHOL & AUDIOL,IOWA CITY,IA 52242; CEDAR CTR,PSYCHIAT GRP,CEDAR RAPIDS,IA; UNIV MONTANA,MISSOULA,MT 59812	Max, JE (corresponding author), UNIV IOWA,DEPT PSYCHIAT,1876 JPP,IOWA CITY,IA 52242, USA.		Robin, Donald/F-2109-2010	Sato, Yutaka/0000-0002-5245-232X			ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Black P, 1981, BRAIN DYSFUNCTION CH, P171; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; GERSON AC, 1993, SCI P ANN M AM ACAD; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Hoover H.D., 1986, MANUAL SCH ADM IOWA; KRAUS JF, 1987, PEDIATRICS, V79, P501; Last CG, 1996, J AM ACAD CHILD PSY, V35, P1502, DOI 10.1097/00004583-199611000-00019; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; MARSHALL LD, 1991, J NEUROSURG, V75, P514; Max J. E., 1992, NEUROPSYCHIATRIC RAT; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; Max JE, 1997, NEUROCASE, V3, P127; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Sparrow S., 1984, VINELAND ADAPTIVE BE; *SPSS, 1995, SPSS WIND PROF STAT; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81	24	118	118	0	8	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	SEP	1997	36	9					1278	1285		10.1097/00004583-199709000-00021			8	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	XT950	WOS:A1997XT95000022	9291730				2021-06-18	
J	Verweij, BH; Muizelaar, JP; Vinas, FC; Peterson, PL; Xiong, Y; Lee, CP				Verweij, BH; Muizelaar, JP; Vinas, FC; Peterson, PL; Xiong, Y; Lee, CP			Mitochondrial dysfunction after experimental and human brain injury and its possible reversal with a selective N-type calcium channel antagonist (SNX-111)	NEUROLOGICAL RESEARCH			English	Article						brain mitochondria; traumatic brain injury; Ca2+; Ca channel blocker	CEREBRAL-ISCHEMIA; GLUTAMATE RELEASE; POTASSIUM	have recently demonstrated in a rat model that traumatic brain injury induces perturbation of cellular calcium homeostasis with an overload oi cytosolic calcium and excessive calcium adsorbed on the mitochondrial membrane, consequently the mitochondrial respiratory chain-linked oxidative phosphorylation was impaired. We report the effect of a selective N-type calcium channel blocker, SNX-111 on mitochondrial dysfunction induced by a controlled cortical impact. Intravenous administration of SNX-111 al varying times post injury was made. The concentration titration profile revealed SNX-111 at 4 mg kg(-1) to be optimal, and the time window to De administration at 4 h post-injury, in line with that reported on the effect of SNX-111 in experimental stroke. Under optimal conditions, SNX-111 significantly improved the mitochondrial respiratory chain-linked functions, such as the electron transfer activities with both succinate and NAD-linked substrates, and the accompanied energy coupling capacities measured as respiratory control indices (RCI) and ATP synthesis (P/O ratio), and the energy linked Ca2+ transport in order to assess the applicability of these data to the clinical setting, we have initiated studies with brain tissue which has to be resected during surgical treatment. Five patients suffered from brain trauma, one from intracranial hypertension due to stroke (noninfarcted tissue was taken), and one from epilepsy. Our data revealed that brain mitochondria derived from the patient with intracranial hypertension and the patient with epilepsy were tightly coupled with good respiratory rates with glutamate and malate as substrates, and high P/O ratios. The rates of respiration and A TP synthesis were severely impaired in the brain mitochondria isolated from traumatized patients. These results indicate that investigation of brain mitochondrial functions can be used as a measure for trauma-induced impairment of brain energy metabolism. The rime window for the effect of SNX-111 in mitochondrial function and the (preliminary) similarity between mitochondrial dysfunction in experimental animals and humans make the drug appear to be well suited for clinical trials in severe head injury.	WAYNE STATE UNIV, SCH MED, DEPT NEUROSURG, HLTH CTR 6E, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT NEUROL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA				Xiong, Ye/0000-0001-9770-6031			BUCHAN AL, 1994, J CEREB BLOOD FLOW M, V14, P906; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; HOVDA DA, 1994, ACTA NEUROCHIR, P521; IKEDA Y, 1990, NEUROSURGERY, V27, P1; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Lee C. P., 1993, V2, P41; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAHARA I, 1991, J NEUROCHEM, V57, P839, DOI 10.1111/j.1471-4159.1991.tb08227.x; Nedergaard J, 1979, Methods Enzymol, V55, P3; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SMITH ML, 1993, J CEREB BLOOD FLOW S, V13, pS700; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TAKIZAWA S, 1995, J CEREBR BLOOD F MET, V15, P611, DOI 10.1038/jcbfm.1995.75; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V150, P459, DOI 10.1111/j.1748-1716.1994.tb09713.x	23	118	120	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	1997	19	3					334	339		10.1080/01616412.1997.11740821			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	XC468	WOS:A1997XC46800020	9192388				2021-06-18	
J	MIDDELBOE, T; ANDERSEN, HS; BIRKETSMITH, M; FRIIS, ML				MIDDELBOE, T; ANDERSEN, HS; BIRKETSMITH, M; FRIIS, ML			MINOR HEAD-INJURY - IMPACT ON GENERAL HEALTH AFTER 1 YEAR - A PROSPECTIVE FOLLOW-UP-STUDY	ACTA NEUROLOGICA SCANDINAVICA			English	Article						MINOR HEAD INJURY; FOLLOW-UP; POSTCONCUSSIONAL SEQUELAE; STRESS RESPONSE	CONCUSSION	A prospective follow-up study of 51 patients hospitalized due to minor head injury (MHI) was performed. After one year 28 patients answered the General Health Questionnaire, the Impact of Event Scale and a symptom checklist. A significant impact on general wellbeing attributed to head injury, was indicated. Half of the patients reported some sequelae from head injury, only 25% to a degree that resulted in a case score on General Health Questionnaire. Incidence of prominent post-traumatic stress symptoms was around 20%. Outcome seemed without correlation to trauma severity. Patients with sequelae after one year reported more symptoms at one week after trauma, and the results point to the magnitude of the health problems due to sequelae throughout follow-up. Aspects of prevention and treatment are discussed.	NORDVANG HOSP,INST PERSONALITY THEORY & PSYCHOPATHOL,COPENHAGEN,DENMARK; BISPEBJERG HOSP,DEPT PSYCHIAT,DK-2400 COPENHAGEN,DENMARK	MIDDELBOE, T (corresponding author), BISPEBJERG HOSP,DEPT NEUROL,DK-2400 COPENHAGEN,DENMARK.						ANDERSEN H S, 1989, Ugeskrift for Laeger, V151, P2242; Edna T H, 1987, J Oslo City Hosp, V37, P41; Goldberg D. P., 1988, USERS GUIDE GENERAL; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KELLY R, 1981, J ROY SOC MED, V74, P242; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KHALEK AIA, 1983, BR J CLIN PRACT  JUN, P209; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; LISHMAN WA, 1987, ORGANIC PSYCHIATRY, P139; MALT UF, 1989, ACTA PSYCHIAT SCAND, V80, P103, DOI 10.1111/j.1600-0447.1989.tb05260.x; MELLERGARD M, 1967, THESIS COPENHAGEN; MILLON T, 1982, MILLON BEHAVIORAL HL; MODLIN HC, 1967, AM J PSYCHIAT, V123, P1008, DOI 10.1176/ajp.123.8.1008; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTHERFORD WH, 1977, LANCET           JAN, P1; SABERS A, 1988, Ugeskrift for Laeger, V150, P1161; SKINHOJ E, 1954, UGESKRIFT LAEGER, V45, P1595; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SUNDHEDSSTYRELSEN, 1988, TIARSOVERSIGT SUNDHE, V4, P2; 1987, DIAGNOSTIC STATISTIC	25	118	118	0	3	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	JAN	1992	85	1					5	9					5	Clinical Neurology	Neurosciences & Neurology	GZ634	WOS:A1992GZ63400002	1546534				2021-06-18	
J	Shinozaki, Y; Shibata, K; Yoshida, K; Shigetomi, E; Gachet, C; Ikenaka, K; Tanaka, KF; Koizumi, S				Shinozaki, Youichi; Shibata, Keisuke; Yoshida, Keitaro; Shigetomi, Eiji; Gachet, Christian; Ikenaka, Kazuhiro; Tanaka, Kenji F.; Koizumi, Schuichi			Transformation of Astrocytes to a Neuroprotective Phenotype by Microglia via P2Y(1) Receptor Downregulation	CELL REPORTS			English	Article							TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; INTESTINAL EPITHELIAL-CELLS; BLOOD-BRAIN-BARRIER; IN-VIVO; NEURONAL DEGENERATION; REACTIVE ASTROCYTES; GENE-EXPRESSION; TRANSGENIC MICE; SCAR FORMATION	Microglia and astrocytes become reactive following traumatic brain injury (TBI). However, the coordination of this reactivity and its relation to pathophysiology are unclear. Here, we show that microglia transform astrocytes into a neuroprotective phenotype via downregulation of the P2Y(1) purinergic receptor. TBI initially caused microglial activation in the injury core, followed by reactive astrogliosis in the peri-injured region and formation of a neuroprotective astrocyte scar. Equivalent changes to astrocytes were observed in vitro after injury. This change in astrocyte phenotype resulted from P2Y(1) receptor downregulation, mediated by microglia-derived cytokines. In mice, astrocyte-specific P2Y(1) receptor overexpression (Astro-P2Y(1)OE) counteracted scar formation, while astrocyte-specific P2Y(1) receptor knockdown (Astro-P2Y(1)KD) facilitated scar formation, suggesting critical roles of P2Y(1) receptors in the transformation. Astro-P2Y(1)OE and Astro-P2Y(1)KD mice showed increased and reduced neuronal damage, respectively. Altogether, our findings indicate that microglia-astrocyte interaction, involving a purinergic signal, is essential for the formation of neuroprotective astrocytes.	[Shinozaki, Youichi; Shibata, Keisuke; Shigetomi, Eiji; Koizumi, Schuichi] Univ Yamanashi, Interdisciplinary Grad Sch Med, Dept Neuropharmacol, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan; [Yoshida, Keitaro; Tanaka, Kenji F.] Keio Univ, Sch Med, Dept Neuropsychiat, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan; [Gachet, Christian] INSERM, U 311, Etab Transfus Sanguine, 10 Rue Spielmann,BP 36, F-67065 Strasbourg, France; [Ikenaka, Kazuhiro] Natl Inst Physiol Sci, Div Neurobiol & Bioinformat, 5-1 Higashiyama, Okazaki, Aichi 4448787, Japan	Koizumi, S (corresponding author), Univ Yamanashi, Interdisciplinary Grad Sch Med, Dept Neuropharmacol, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan.	skoizumi@yamanashi.ac.jp	Shinozaki, Youichi/E-8594-2010; Gachet, Christian/H-9156-2016; Shinozaki, Youichi/AAC-9431-2019; SHIGETOMI, EIJI/I-2372-2012; Koizumi, Schuichi/E-8568-2010	Shinozaki, Youichi/0000-0002-6448-1304; Shinozaki, Youichi/0000-0002-6448-1304; Koizumi, Schuichi/0000-0001-6184-3106; Tanaka, Kenji/0000-0003-2511-0057; Shigetomi, Eiji/0000-0002-5267-6155; Yoshida, Keitaro/0000-0003-2196-7635	Japan Society for the Promotion of Science (JSPS) KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23700442, 16H04669, 25670622, 25117003]; Uehara FoundationUehara Memorial Foundation; Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED); Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16H04669, 16K18390] Funding Source: KAKEN	We thank Drs. Morizawa, Hirayama, and Imura and Mr. Hayashi and Mr. Komatsu (University of Yamanashi) for fruitful discussions. PLX5622 was provided under Materials Transfer Agreement (MTA) by Plexxikon Inc. This study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI grants 23700442 to Y.S. and 16H04669, 25670622, and 25117003 to S.K., the Uehara Foundation to Y.S., grants-in-aid from the Japan Agency for Medical Research and Development (AMED) to S.K.	Alexianu ME, 2001, NEUROLOGY, V57, P1282, DOI 10.1212/WNL.57.7.1282; Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Batchelor PE, 1999, J NEUROSCI, V19, P1708; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bilodeau MS, 2015, BIOCHEM CELL BIOL, V93, P38, DOI 10.1139/bcb-2014-0098; Braun N, 2000, EUR J NEUROSCI, V12, P4357, DOI 10.1046/j.1460-9568.2000.01342.x; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Campbell IL, 2014, J NEUROSCI, V34, P2503, DOI 10.1523/JNEUROSCI.2830-13.2014; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chucair-Elliott AJ, 2014, GLIA, V62, P1418, DOI 10.1002/glia.22689; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Degagne E, 2012, FEBS J, V279, P2957, DOI 10.1111/j.1742-4658.2012.08676.x; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; Faideau M, 2010, HUM MOL GENET, V19, P3053, DOI 10.1093/hmg/ddq212; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Foka P, 2009, INT J BIOCHEM CELL B, V41, P1189, DOI 10.1016/j.biocel.2008.10.024; Friedle SA, 2011, GLIA, V59, P1, DOI 10.1002/glia.21071; Halassa MM, 2010, ANNU REV PHYSIOL, V72, P335, DOI 10.1146/annurev-physiol-021909-135843; Hamby ME, 2012, J NEUROSCI, V32, P14489, DOI 10.1523/JNEUROSCI.1256-12.2012; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; HED J, 1983, HISTOCHEMISTRY, V79, P105, DOI 10.1007/BF00494347; Heine P, 2001, EUR J BIOCHEM, V268, P364, DOI 10.1046/j.1432-1033.2001.01896.x; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Inoue K, 2008, CELL MOL LIFE SCI, V65, P3074, DOI 10.1007/s00018-008-8210-3; Kanemaru K, 2013, P NATL ACAD SCI USA, V110, P11612, DOI 10.1073/pnas.1300378110; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; Leon C, 1999, THROMB HAEMOSTASIS, V81, P775; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Mukhopadhyay A, 2001, J BIOL CHEM, V276, P31906, DOI 10.1074/jbc.M105252200; Nedeljkovic N, 2006, CELL BIOL INT, V30, P541, DOI 10.1016/j.cellbi.2006.03.001; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Noguchi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057898; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109; PETITO CK, 1990, J CEREBR BLOOD F MET, V10, P850, DOI 10.1038/jcbfm.1990.141; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rothaug M, 2016, BBA-MOL CELL RES, V1863, P1218, DOI 10.1016/j.bbamcr.2016.03.018; Safiulina VF, 2006, J BIOL CHEM, V281, P23464, DOI 10.1074/jbc.M601627200; Sapp E, 2001, J NEUROPATH EXP NEUR, V60, P161, DOI 10.1093/jnen/60.2.161; Schmid B, 2001, ENDOCRINOLOGY, V142, P1380, DOI 10.1210/en.142.4.1380; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shibata K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023510; Shinozaki Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep04329; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; Suzuki T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Tanaka KF, 2010, BIOL PSYCHIAT, V67, P770, DOI 10.1016/j.biopsych.2009.12.020; Tong XP, 2014, NAT NEUROSCI, V17, P694, DOI 10.1038/nn.3691; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Valdearcos M, 2014, CELL REP, V9, P2124, DOI 10.1016/j.celrep.2014.11.018; Vig S, 2012, INT J BIOCHEM CELL B, V44, P113, DOI 10.1016/j.biocel.2011.10.004; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Weiss T, 1998, J IMMUNOL, V161, P3136; Yang P, 2012, EXP NEUROL, V236, P19, DOI 10.1016/j.expneurol.2012.03.019; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zimmermann H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/ddr.1097	70	117	119	2	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	MAY 9	2017	19	6					1151	1164		10.1016/j.celrep.2017.04.047			14	Cell Biology	Cell Biology	EV9SC	WOS:000402124700008	28494865	DOAJ Gold			2021-06-18	
J	Sierink, JC; Treskes, K; Edwards, MJR; Beuker, JA; den Hartog, D; Hohmann, J; Dijkgraaf, MGW; Luitse, JSK; Beenen, LFM; Hollmann, MW; Goslings, JC				Sierink, Joanne C.; Treskes, Kaij; Edwards, Michael J. R.; Beuker, J. A.; den Hartog, Dennis; Hohmann, Joachim; Dijkgraaf, Marcel G. W.; Luitse, Jan S. K.; Beenen, Ludo F. M.; Hollmann, Markus W.; Goslings, J. Carel		REACT-2 Study Grp	Immediate total-body CT scanning versus conventional imaging and selective CT scanning in patients with severe trauma (REACT-2): a randomised controlled trial	LANCET			English	Article							MULTISLICE COMPUTED-TOMOGRAPHY; EMERGENCY-ROOM MANAGEMENT; SEVERE BLUNT TRAUMA; MAJOR TRAUMA; INCIDENTAL FINDINGS; INJURED PATIENTS; MULTIPLE TRAUMA; METAANALYSIS; MORTALITY; SURVIVAL	Background Published work suggests a survival benefit for patients with trauma who undergo total-body CT scanning during the initial trauma assessment; however, level 1 evidence is absent. We aimed to assess the effect of total-body CT scanning compared with the standard work-up on in-hospital mortality in patients with trauma. Methods We undertook an international, multicentre, randomised controlled trial at four hospitals in the Netherlands and one in Switzerland. Patients aged 18 years or older with trauma with compromised vital parameters, clinical suspicion of life-threatening injuries, or severe injury were randomly assigned (1:1) by ALEA randomisation to immediate total-body CT scanning or to a standard work-up with conventional imaging supplemented with selective CT scanning. Neither doctors nor patients were masked to treatment allocation. The primary endpoint was in-hospital mortality, analysed in the intention-to-treat population and in subgroups of patients with polytrauma and those with traumatic brain injury. The. chi(2) test was used to assess differences in mortality. This trial is registered with ClinicalTrials.gov, number NCT01523626. Findings Between April 22, 2011, and Jan 1, 2014, 5475 patients were assessed for eligibility, 1403 of whom were randomly assigned:702 to immediate total-body CT scanning and 701 to the standard work-up. 541 patients in the immediate total-body CT scanning group and 542 in the standard work-up group were included in the primary analysis. In-hospital mortality did not differ between groups (total-body CT 86 [16%] of 541 vs standard work-up 85 [16%] of 542; p=0.92). In-hospital mortality also did not differ between groups in subgroup analyses in patients with polytrauma (total-body CT 81 [22%] of 362 vs standard work-up 82 [25%] of 331; p=0.46) and traumatic brain injury (68 [38%] of 178 vs 66 [44%] of 151; p=0.31). Three serious adverse events were reported in patients in the total-body CT group (1%), one in the standard work-up group (<1%), and one in a patient who was excluded after random allocation. All five patients died. Interpretation Diagnosing patients with an immediate total-body CT scan does not reduce in-hospital mortality compared with the standard radiological work-up. Because of the increased radiation dose, future research should focus on the selection of patients who will benefit from immediate total-body CT.	[Sierink, Joanne C.; Treskes, Kaij; Luitse, Jan S. K.; Goslings, J. Carel] Acad Med Ctr, Dept Surg, Trauma Unit, NL-1105 AZ Amsterdam, Netherlands; [Dijkgraaf, Marcel G. W.] Acad Med Ctr, Clin Res Unit, Amsterdam, Netherlands; [Beenen, Ludo F. M.] Acad Med Ctr, Dept Radiol, Amsterdam, Netherlands; [Hollmann, Markus W.] Acad Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands; [Edwards, Michael J. R.] Radboud Univ Nijmegen, Med Ctr, Dept Surg, Trauma Unit, Nijmegen, Netherlands; [Beuker, J. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Trauma Unit, Groningen, Netherlands; [den Hartog, Dennis] Univ Med Ctr Rotterdam, Erasmus MC, Dept Surg, Trauma Res Unit, Rotterdam, Netherlands; [Hohmann, Joachim] Univ Basel Hosp, Dept Radiol & Nucl Med, Basel, Switzerland	Goslings, JC (corresponding author), Acad Med Ctr, Dept Surg, Trauma Unit, NL-1105 AZ Amsterdam, Netherlands.	j.c.goslings@amc.nl	Hohmann, Joachim/B-4483-2014; Beenen, Ludo F/AAA-3114-2021; Treskes, Kaij/AAI-4686-2021; Edwards, M.J.R./H-8026-2014; Brink, Monique/P-6085-2015; Tromp, Tjarda N/A-6583-2016	Beenen, Ludo F/0000-0001-9204-1026; Treskes, Kaij/0000-0002-9462-5372; Brink, Monique/0000-0002-4146-1052; Klimek, Markus/0000-0002-0122-9929; Tromp, Tjarda/0000-0003-2037-8388	ZonMw, the Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development	ZonMw, the Netherlands Organisation for Health Research and Development.	American College of Surgeons Committee on Trauma, 2012, STUDENT COURSE MANUA; [Anonymous], 1996, GUIDELINE GOOD CLIN; Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; Barrett TW, 2009, AM J EMERG MED, V27, P428, DOI 10.1016/j.ajem.2008.03.025; Beenen LFM, 2015, ACTA RADIOL, V56, P873, DOI 10.1177/0284185114539319; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2004, RADIOLOGY, V232, P735, DOI 10.1148/radiol.2323031095; Bruns B, 2008, J TRAUMA, V65, P1217, DOI 10.1097/TA.0b013e318184ee63; Caputo ND, 2014, J TRAUMA ACUTE CARE, V77, P534, DOI 10.1097/TA.0000000000000414; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Healy DA, 2014, EMERG MED J, V31, P101, DOI 10.1136/emermed-2012-201892; Hilbert P, 2007, INJURY, V38, P552, DOI 10.1016/j.injury.2006.12.023; Hoffstetter P, 2008, ROFO-FORTSCHR RONTG, V180, P120, DOI 10.1055/s-2007-963594; Huber-Wagner S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068880; Huber-Wagner S, 2009, LANCET, V373, P1455, DOI 10.1016/S0140-6736(09)60232-4; Hutter M, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-73; Jiang LB, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0054-2; Kanz Karl-Georg, 2010, J Trauma Manag Outcomes, V4, P4, DOI 10.1186/1752-2897-4-4; Kimura A, 2013, J TRAUMA ACUTE CARE, V75, P202, DOI 10.1097/TA.0b013e3182905ef7; Mettler FA, 2008, RADIOLOGY, V248, P254, DOI 10.1148/radiol.2481071451; Salim A, 2006, ARCH SURG-CHICAGO, V141, P468, DOI 10.1001/archsurg.141.5.468; Sedlic A, 2013, EMERG RADIOL, V20, P401, DOI 10.1007/s10140-013-1139-3; Sierink JC, 2014, INJURY, V45, P840, DOI 10.1016/j.injury.2013.10.009; Sierink JC, 2013, EMERG RADIOL, V20, P507, DOI 10.1007/s10140-013-1147-3; Sierink JC, 2012, BRIT J SURG, V99, P52, DOI 10.1002/bjs.7760; Sierink JC, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-4; Statline, CONS PRIC PRIC IND 2; Surendran A, 2014, J TRAUMA ACUTE CARE, V76, P1122, DOI 10.1097/TA.0000000000000178; van Vugt R, 2012, J TRAUMA ACUTE CARE, V72, P553, DOI 10.1097/TA.0b013e31822dd93b; Venugopal K, 2012, EUR J EMERG MED, V19, P193, DOI 10.1097/MEJ.0b013e32834ada14; Wada D, 2013, CRIT CARE, V17, DOI 10.1186/cc12861; Weninger P, 2007, J TRAUMA, V62, P584, DOI 10.1097/01.ta.0000221797.46249.ee; Wurmb TE, 2011, EMERG MED J, V28, P300, DOI 10.1136/emj.2009.082164; Wurmb TE, 2009, J TRAUMA, V66, P658, DOI 10.1097/TA.0b013e31817de3f4; Yeguiayan JM, 2012, CRIT CARE, V16, DOI 10.1186/cc11375	36	117	120	1	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	2016	388	10045					673	683		10.1016/S0140-6736(16)30932-1			11	Medicine, General & Internal	General & Internal Medicine	DT1UX	WOS:000381268700027	27371185				2021-06-18	
J	Barrio, JR; Small, GW; Wong, KP; Huang, SC; Liu, J; Merrill, DA; Giza, CC; Fitzsimmons, RP; Omalu, B; Bailes, J; Kepe, V				Barrio, Jorge R.; Small, Gary W.; Wong, Koon-Pong; Huang, Sung-Cheng; Liu, Jie; Merrill, David A.; Giza, Christopher C.; Fitzsimmons, Robert P.; Omalu, Bennet; Bailes, Julian; Kepe, Vladimir			In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						traumatic brain injury; chronic traumatic encephalopathy; [F-18]FDDNP PET; tau imaging; concussions	INTRINSIC CONNECTIVITY; LIVING BRAIN; INJURY; TAU; NEUROPATHOLOGY; PATHOLOGY; DEGENERATION; VALIDATION; DISORDER; SPECTRUM	Chronic traumatic encephalopathy (CTE) is an acquired primary tauopathy with a variety of cognitive, behavioral, and motor symptoms linked to cumulative brain damage sustained from single, episodic, or repetitive traumatic brain injury (TBI). No definitive clinical diagnosis for this condition exists. In this work, we used [F-18]FDDNP PET to detect brain patterns of neuropathology distribution in retired professional American football players with suspected CTE (n = 14) and compared results with those of cognitively intact controls (n = 28) and patients with Alzheimer's dementia (AD) (n = 24), a disease that has been cognitively associated with CTE. [F-18]FDDNP PET imaging results in the retired players suggested the presence of neuropathological patterns consistent with models of concussion wherein brainstem white matter tracts undergo early axonal damage and cumulative axonal injuries along subcortical, limbic, and cortical brain circuitries supporting mood, emotions, and behavior. This deposition pattern is distinctively different from the progressive pattern of neuropathology [paired helical filament (PHF)-tau and amyloid-beta] in AD, which typically begins in the medial temporal lobe progressing along the cortical default mode network, with no or minimal involvement of subcortical structures. This particular [F-18]FDDNP PET imaging pattern in cases of suspected CTE also is primarily consistent with PHF-tau distribution observed at autopsy in subjects with a history of mild TBI and autopsy-confirmed diagnosis of CTE.	[Barrio, Jorge R.; Wong, Koon-Pong; Huang, Sung-Cheng; Liu, Jie; Kepe, Vladimir] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Small, Gary W.; Merrill, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Small, Gary W.; Merrill, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg & Pediat, Los Angeles, CA 90095 USA; [Fitzsimmons, Robert P.] Fitzsimmons Law Off, Wheeling, WV 26003 USA; [Omalu, Bennet] Univ Calif Davis, Sch Med, Dept Med Pathol & Lab Med, Sacramento, CA 95817 USA; [Bailes, Julian] NorthShore Univ Hlth Syst, Dept Neurosurg, Evanston, IL 60201 USA; [Bailes, Julian] Univ Chicago, Pritzker Sch Med, Evanston, IL 60201 USA	Barrio, JR (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.	jbarrio@mednet.ucla.edu; vkepe@mednet.ucla.edu	Wong, Koon-Pong/AAI-3780-2020	Wong, Koon-Pong/0000-0002-6095-4645	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-AG025831, M01-RR00865]; Toulmin Foundation; Robert and Marion Wilson; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG025831] Funding Source: NIH RePORTER	We thank Natacha Donoghue and Jacqueline Martinez for subject scheduling and management; John Williams, University of California, Los Angeles, Nuclear Medicine Clinic, for performing the PET scans; and Shelley West, Billy West, and Bus Cook for guidance with subject referral and for their helpful input. Funding from the National Institutes of Health (P01-AG025831 and M01-RR00865), the Toulmin Foundation, and Robert and Marion Wilson is highly appreciated. No company provided research funding for this study.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barrio JR, 2009, ACCOUNTS CHEM RES, V42, P842, DOI 10.1021/ar800189x; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brown HJ, 2014, MED SCI SPORT EXER, V46, P1610, DOI 10.1249/MSS.0000000000000263; Buss A, 2004, BRAIN, V127, P34, DOI 10.1093/brain/awh001; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Gardner RC, 2013, ANN NEUROL, V73, P603, DOI 10.1002/ana.23844; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; Harada R, 2013, EUR J NUCL MED MOL I, V40, P125, DOI 10.1007/s00259-012-2261-2; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kepe V, 2006, METHOD ENZYMOL, V412, P144, DOI 10.1016/S0076-6879(06)12010-8; Kepe V, 2013, J ALZHEIMERS DIS, V36, P145, DOI 10.3233/JAD-130032; Landau M, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001080; Liu J, 2007, MOL IMAGING BIOL, V9, P6, DOI 10.1007/s11307-006-0061-4; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLachlan GJ, 1992, DISCRIMINANT ANAL ST; Millspaugh J., 1937, US NAVAL MED B, V35, P297; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Pannekoek JN, 2013, J AFFECT DISORDERS, V145, P29, DOI 10.1016/j.jad.2012.07.006; Prater KE, 2013, DEPRESS ANXIETY, V30, P234, DOI 10.1002/da.22014; Price JL, 2010, NEUROPSYCHOPHARMACOL, V35, P192, DOI 10.1038/npp.2009.104; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Protas HD, 2012, NEUROIMAGE, V61, P749, DOI 10.1016/j.neuroimage.2012.02.056; Ramasubbu R, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00017; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Robinson JL, 2013, ACTA NEUROPATHOL, V125, P121, DOI 10.1007/s00401-012-1055-8; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Small GW, 2006, NEW ENGL J MED, V355, P2652, DOI 10.1056/NEJMoa054625; Smid LM, 2013, J ALZHEIMERS DIS, V36, P261, DOI 10.3233/JAD-122434; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; STRICH SJ, 1961, LANCET, V2, P443; Tantawy MN, 2009, NUCL MED BIOL, V36, P931, DOI 10.1016/j.nucmedbio.2009.06.007; US Pharmacopeial Convention, 2013, POS EM TOM DRUGS COM	54	117	118	2	49	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	APR 21	2015	112	16					E2039	E2047		10.1073/pnas.1409952112			9	Multidisciplinary Sciences	Science & Technology - Other Topics	CG4FJ	WOS:000353239100012	25848027	Green Published, Bronze			2021-06-18	
J	Rashid, B; Destrade, M; Gilchrist, MD				Rashid, Badar; Destrade, Michel; Gilchrist, Michael D.			Mechanical characterization of brain tissue in tension at dynamic strain rates	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Traumatic brain injury; TBI; Impact; Dynamic; Ogden; Axonal	IN-VIVO; MODEL; BEHAVIOR; INJURY; SHEAR; DEFORMATION; STRETCH; DEVICE; COMPRESSION; ELASTICITY	Mechanical characterization of brain tissue at high loading velocities is crucial for modeling Traumatic Brain Injury (TBI). During severe impact conditions, brain tissue experiences compression, tension and shear. Limited experimental data is available for brain tissue in extension at dynamic strain rates. In this research, a High Rate Tension Device (HRTD) was developed to obtain dynamic properties of brain tissue in extension at strain rates of <= 90/s. In vitro tensile tests were performed to obtain properties of brain tissue at strain rates of 30, 60 and 90/s up to 30% strain. The brain tissue showed a stiffer response with increasing strain rates, showing that hyperelastic models are not adequate. Specifically, the tensile engineering stress at 30% strain was 3.1+/-0.49 kPa, 4.3+/-0.86 kPa, 6.5+/-0.76 kPa (mean+/-SD) at strain rates of 30, 60 and 90/s, respectively.. Force relaxation tests in tension were also conducted at different strain magnitudes (10-60% strain) with the average rise time of 24 ms, which were used to derive time dependent parameters. One-term Ogden, Fung and Gent models were used to obtain material parameters from the experimental data. Numerical simulations were performed using a one-term Ogden model to analyze hyperelastic behavior of brain tissue up to 30% strain. The material parameters obtained in this study will help to develop biofidelic human brain finite element models, which can subsequently be used to predict brain injuries under impact conditions and as a reconstruction and simulation tool for forensic investigations. (C) 2012 Elsevier Ltd. All rights reserved.	[Rashid, Badar; Destrade, Michel; Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland; [Destrade, Michel] Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland	Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland.	Badar.Rashid@ucdconnect.ie; michel.destrade@nuigalway.ie; michael.gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017; Destrade, Michel/O-5825-2019	Gilchrist, Michael D/0000-0003-1765-429X; Destrade, Michel/0000-0002-6266-1221	Irish Research Council for Science, Engineering and Technology (IRCSET), IrelandIrish Research Council for Science, Engineering and Technology	The authors thank John Gahan, Tony Dennis and Pat McNally of University College Dublin for their assistance in machining components and developing electronic circuits for the experimental setup. This work was supported for the first author by a Postgraduate Research Scholarship awarded by the Irish Research Council for Science, Engineering and Technology (IRCSET), Ireland.	Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; ESTES MS, 1970, 70BHF13 ASME; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Finan JD, 2012, ANN BIOMED ENG, V40, P70, DOI 10.1007/s10439-011-0394-2; Fung Y., 1993, BIOMECHANICS MECH PR; FUNG YC, 1979, AM J PHYSIOL, V237, pH620; FUNG YCB, 1967, AM J PHYSIOL, V213, P1532; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gent AN, 1996, RUBBER CHEM TECHNOL, V69, P59, DOI 10.5254/1.3538357; Gilchrist MD, 2004, STRAIN, V40, P180, DOI 10.1111/j.1475-1305.2004.00168.x; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Meaney D. F., 1990, INT C BIOM IMP IRCOB; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Ogden R., 1997, NONLINEAR ELASTIC DE; Ogden RW, 2004, COMPUT MECH, V34, P484, DOI 10.1007/s00466-004-0593-y; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; Pervin F, 2011, NEUROIMAGE, V54, pS98, DOI 10.1016/j.neuroimage.2010.03.077; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Prange M T, 2000, Stapp Car Crash J, V44, P205; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rashid B, 2012, J MECH BEHAV BIOMED, V14, P113, DOI 10.1016/j.jmbbm.2012.04.005; Rashid B, 2012, P I MECH ENG P-J SPO, V226, P170, DOI 10.1177/1754337112436900; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Rueda MAF, 2009, FORENSIC SCI INT, V191, P52, DOI 10.1016/j.forsciint.2009.06.007; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Tamura A., 2008, J BIOMECH SCI ENG, V3, P263, DOI DOI 10.1299/JBSE.3.263; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Zhang JY, 2011, J BIOMECH, V44, P391, DOI 10.1016/j.jbiomech.2010.10.024; Zhang L, 2001, Stapp Car Crash J, V45, P369	59	117	118	1	44	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	MAY	2014	33				SI		43	54		10.1016/j.jmbbm.2012.07.015			12	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	AG1VW	WOS:000335205300005	23127641	Green Published			2021-06-18	
J	Grossman, EJ; Jensen, JH; Babb, JS; Chen, Q; Tabesh, A; Fieremans, E; Xia, D; Inglese, M; Grossman, RI				Grossman, E. J.; Jensen, J. H.; Babb, J. S.; Chen, Q.; Tabesh, A.; Fieremans, E.; Xia, D.; Inglese, M.; Grossman, R. I.			Cognitive Impairment in Mild Traumatic Brain Injury: A Longitudinal Diffusional Kurtosis and Perfusion Imaging Study	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							GAUSSIAN WATER DIFFUSION; AXONAL INJURY; HEAD-INJURY; SPECT; DYSFUNCTION; INVENTORY; SEVERITY; STATE	BACKGROUND AND PURPOSE: Cognitive impairment is frequent among patients with mild traumatic brain injury despite the absence of detectable damage on conventional MR imaging. In this study, the quantitative MR imaging techniques DTI, DKI, and ASL were used to measure changes in the structure and function in the thalamus and WM of patients with MTBI during a short follow-up period, to determine whether these techniques can be used to investigate relationships with cognitive performance and to predict outcome. MATERIALS AND METHODS: Twenty patients with MTBI and 16 controls underwent MR imaging at 3T and a neuropsychological battery designed to yield measures for attention, concentration, executive functioning, memory, learning, and information processing. MK, FA, MD, and CBF were measured in the thalamus by using region-of-interest analysis and inWMby using tract-based spatial statistics. Analyses were performed comparing regional imaging measures of subject groups and the results of testing of their associations with neuropsychological performance. RESULTS: Patients with MTBI exhibited significant differences from controls for DTI, DKI, and ASL measures in the thalamus and various WM regions both within 1 month after injury and >9 months after injury. At baseline, DTI and DKI measures in the thalamus and various WM regions were significantly associated with performance in different neuropsychological domains, and cognitive impairment was significantly associated with MK in the thalamus and FA in optic radiations. CONCLUSIONS: Combined application of DTI, DKI, and ASL to study MTBI might be useful for investigating dynamic changes in the thalamus andWMas well as cognitive impairment during a short follow-up period, though the small number of patients examined did not predict outcome.	[Grossman, E. J.; Babb, J. S.; Chen, Q.; Fieremans, E.; Xia, D.; Inglese, M.; Grossman, R. I.] NYU, Dept Radiol, Ctr Biomed Imaging, Sch Med, New York, NY 10016 USA; [Grossman, E. J.] NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; [Jensen, J. H.; Tabesh, A.] Med Univ S Carolina, Dept Radiol & Radiol Sci, Charleston, SC 29425 USA; [Inglese, M.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA	Grossman, EJ (corresponding author), NYU, Dept Radiol, Ctr Biomed Imaging, Sch Med, 660 First Ave,4th Floor,Room 420, New York, NY 10016 USA.	Elan.Grossman@nyumc.org	Jensen, Jens H/A-8334-2009; Inglese, Matilde/AAH-3189-2020	Jensen, Jens H/0000-0003-3219-4287; Inglese, Matilde/0000-0002-9610-0297; Fieremans, Els/0000-0002-1384-8591; Babb, James/0000-0003-1798-1186; Xia, Ding/0000-0002-1396-4082	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS039135, R01NS051623]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135, R01NS051623] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grants R01NS039135 and R01NS051623.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Buxton RB, 2005, J MAGN RESON IMAGING, V22, P723, DOI 10.1002/jmri.20462; Cancelliere C, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-17; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Feig SL, 2000, EUR J NEUROSCI, V12, P2195, DOI 10.1046/j.1460-9568.2000.00093.x; Fieremans E, 2011, NEUROIMAGE, V58, P177, DOI 10.1016/j.neuroimage.2011.06.006; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Grossman Elan J, 2010, Top Magn Reson Imaging, V21, P379, DOI 10.1097/RMR.0b013e31823e65b8; Grossman EJ, 2009, J MAGN RESON IMAGING, V29, P1425, DOI 10.1002/jmri.21794; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jacobs A, 1996, J NUCL MED, V37, P1605; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lu HZ, 2006, NMR BIOMED, V19, P236, DOI 10.1002/nbm.1020; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Sherman S. M., 2006, EXPLORING THALAMUS I; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stamatakis EA, 2002, J NUCL MED, V43, P476; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; WOOD DMG, 1995, BRAIN RES BULL, V38, P545, DOI 10.1016/0361-9230(95)02026-0; Wu EX, 2010, NMR BIOMED, V23, P836, DOI 10.1002/nbm.1506; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	40	117	127	3	26	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2013	34	5					951	957		10.3174/ajnr.A3358			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	301MR	WOS:000330536900014	23179649	Other Gold, Green Published, Green Accepted			2021-06-18	
J	Metting, Z; Wilczak, N; Rodiger, LA; Schaaf, JM; van der Naalt, J				Metting, Z.; Wilczak, N.; Rodiger, L. A.; Schaaf, J. M.; van der Naalt, J.			GFAP and S100B in the acute phase of mild traumatic brain injury	NEUROLOGY			English	Article							FIBRILLARY ACIDIC PROTEIN; MODERATE HEAD-INJURY; SERUM; WORK; PREDICTION; BIOMARKERS; COMPLAINTS; S-100B; RETURN; DAMAGE	Objective: The biomarkers glial fibrillary acid protein (GFAP) and S100B are increasingly used as prognostic tools in severe traumatic brain injury (TBI). Data for mild TBI are scarce. This study aims to analyze the predictive value of GFAP and S100B for outcome in mild TBI and the relation with imaging. Methods: In 94 patients biomarkers were determined directly after admission. Collected data included injury severity, patient characteristics, admission CT, and MRI 3 months postinjury. Six months postinjury outcome was determined with Glasgow Outcome Scale Extended (GOSE) and return to work (RTW). Results: Mean GFAP was 0.25 mu g/L (SD 1.08) and S100B 0.54 mu g/L (SD 1.18). In 63% GFAP was not discernible. GFAP was increased in patients with an abnormal CT (1.20 mu g/L, SD 2.65) compared to normal CT (0.05 mu g/L, SD 0.17, p < 0.05). Also in patients with axonal injury on MRI GFAP was higher (0.65 mu g/L, SD 0.91 vs 0.07 mu g/L, SD 0.2, p < 0.05). GFAP was increased in patients with incomplete RTW compared to complete RTW (0.69 mu g/L, SD 2.11 vs 0.12 mu g/L, SD 0.38, p < 0.05). S100B was not related to outcome or imaging studies. In multivariate analysis GFAP was not predictive for outcome determined by GOSE and RTW. Conclusions: A relation between GFAP with imaging studies and outcome (determined by RTW) was found in contrast to S100B. As the positive predictive value of GFAP is limited in this category of TBI patients, this biomarker is not suitable for prediction of individual patient outcome. Neurology (R) 2012;78:1428-1433	[Metting, Z.; Wilczak, N.; van der Naalt, J.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Rodiger, L. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, Groningen, Netherlands; [Schaaf, J. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, Groningen, Netherlands	van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands.	j.van.der.naalt@umcg.nl					Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Konrad C, 2010, PSYCHOL MED; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Missler U, 1999, CLIN CHEM, V45, P138; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Webster MJ, 2001, BRAIN BEHAV IMMUN, V15, P388, DOI 10.1006/brbi.2001.0646; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	28	117	124	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY	2012	78	18					1428	1433		10.1212/WNL.0b013e318253d5c7			6	Clinical Neurology	Neurosciences & Neurology	935DB	WOS:000303498000014	22517109				2021-06-18	
J	Davenport, ND; Lim, KO; Armstrong, MT; Sponheim, SR				Davenport, Nicholas D.; Lim, Kelvin O.; Armstrong, Michael T.; Sponheim, Scott R.			Diffuse and spatially variable white matter disruptions are associated with blast-related mild traumatic brain injury	NEUROIMAGE			English	Article						Traumatic brain injury; White matter; Diffusion tensor imaging; Blast	PERSISTENT POSTCONCUSSIVE SYMPTOMS; TENSOR; CONCUSSION; IRAQ; AFGHANISTAN; SEQUELAE	Mild traumatic brain injury (mTBI) due to explosive blast is common among military service members and often associated with long term psychological and cognitive disruptions. Little is known about the neurological effects of blast-related mTBI and whether they differ from those of civilian, non-blast mTBI. Given that brain damage from blasts may be diffuse and heterogeneous, we tested the hypothesis that blast mTBI is associated with subtle white matter disruptions in the brain that are spatially inconsistent across individuals. We used diffusion tensor imaging to examine white matter integrity, as quantified by fractional anisotropy (FA), in a group of American military service members with (n = 25) or without (n = 33) blast-related rnTBI who had been deployed as part of Operation Iraqi Freedom or Operation Enduring Freedom. History of civilian non-blast mTBI was equally common across groups, which enabled testing of both blast and non-blast mTBI effects on measures sensitive to (1) concentrated, spatially consistent (average FA within a region of interest [ROI]), (2) concentrated, spatially variable (number of ROIs with low average FA), and (3) diffuse (number of voxels with low FA) disruptions of white matter integrity. Blast mTBI was associated with a diffuse, global pattern of lower white matter integrity, and this pattern was not affected by previous civilian mTBI. Neither type of mTBI had an effect on the measures sensitive to more concentrated and spatially consistent white matter disruptions. Additionally, individuals with more than one blast mTBI tended to have a larger number of low FA voxels than individuals with a single blast injury. These results indicate that blast mTBI is associated with disrupted integrity of several white matter tracts, and that these disruptions are diluted by averaging across the large number of voxels within an ROI. The reported pattern of effects supports the conclusion that the neurological effects of blast mTBI are diffuse, widespread, and spatially variable. (C) 2011 Elsevier Inc. All rights reserved.	[Davenport, Nicholas D.; Lim, Kelvin O.; Armstrong, Michael T.; Sponheim, Scott R.] Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA; [Lim, Kelvin O.; Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55454 USA	Davenport, ND (corresponding author), Minneapolis VA Med Ctr, 1 Vet Dr, Minneapolis, MN 55417 USA.	daven012@umn.edu; kolim@umn.edu; Michael.Armstrong@va.gov; sponh001@umn.edu	Lim, Kelvin/AAF-6833-2020; Sponheim, Scott/J-3857-2017; Lim, Kelvin/C-2201-2012; Davenport, Nicholas/AAY-8057-2020	Sponheim, Scott/0000-0002-2782-0856; Davenport, Nicholas/0000-0002-3441-7256; Lim, Kelvin/0000-0002-2390-7268	Minnesota Veterans Research Institute (MVRI); Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-08-2-0038]	This work was supported by grants from the Minnesota Veterans Research Institute (MVRI) and the Congressionally Directed Medical Research Program (W81XWH-08-2-0038) to Scott R. Sponheim. We are grateful to Nikki Fraser for assistance with acquisition of imaging data; Molly J. Charlesworth for efforts with recruitment and clinical assessment; and Amanda Ferrier-Auerbach, Nathaniel W. Nelson, James Hoelzle, and Kathryn A. McGuire for efforts characterizing the head injuries of participants.	Andersson J.L.R., 2007, TR07JA1 FMRIB; Andersson J.L.R., 2007, NONLINEAR REGISTRATI; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; First MB., 2002, STRUCTURED CLIN INTE; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Mori S., 2005, MRI ATLAS HUMAN WHIT; Nelson NW, 2011, BRAIN INJURY, V25, P511, DOI 10.3109/02699052.2011.558040; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055	35	117	118	0	18	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	FEB 1	2012	59	3					2017	2024		10.1016/j.neuroimage.2011.10.050			8	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	881NS	WOS:000299494000005	22040736				2021-06-18	
J	Zygun, DA; Nortje, J; Hutchinson, PJ; Timofeev, I; Menon, DK; Gupta, AK				Zygun, David A.; Nortje, Jurgens; Hutchinson, Peter J.; Timofeev, Ivan; Menon, David K.; Gupta, Arun K.			The effect of red blood cell transfusion on cerebral oxygenation and metabolism after severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						critical care; transfusion; craniocerebral trauma; anemia; microdialysis	SEVERE HEAD-INJURY; CARDIOPULMONARY BYPASS; CARE; MICRODIALYSIS; POPULATION; HEMATOCRIT; MORTALITY; ISCHEMIA; MODERATE; ANEMIA	Objective: There is evidence to suggest that anemia after severe traumatic brain injury (sTBI) is detrimental. However, there is a paucity of evidence supporting the use of transfusion of packed red blood cells in patients with sTBI. To understand the acute effect of packed red blood cell transfusion on cerebral oxygenation and metabolism in patients with sTBI. Design: Prospective clinical study. Setting: Addenbrooke's Neurosciences Critical Care Unit, a 21-bed tertiary academic unit. Patients: Thirty patients with sTBI. Interventions: Patients were randomized by computer random number generator to one of three transfusion thresholds: 8, 9, or 10 g/dL. When the patients' hemoglobin concentration fell below their assigned threshold, two units of packed red blood cells were transfused over 2 hours. A 1-hour period of stabilization was observed before final data collection. Measurements and Main Results: The primary outcome was change in brain tissue oxygen (P(bt)o(2)). Secondary outcomes included dependence of baseline hemoglobin concentration and baseline P(bt)o(2) on the relationship of transfusion and P(bt)o(2), and the effect of transfusion on lactate pyruvate ratio (LPR) and brain pH as markers of cerebral metabolic state. Fifty-seven percent of patients experienced an increase in P(bt)o(2) during the course of the study, whereas in 43% of patients, P(bt)o(2) either did not change or decreased. Multivariable generalized estimating equation analysis revealed change in hemoglobin concentration to significantly and positively associated with change in P(bt)o(2) [0.10 kPa/(g/dL) 95% confidence interval 0.03-0.17, p = 0.003]. Improvement in P(bt)o(2) was not associated with baseline hemoglobin concentration or low P(bt)o(2) (<1 kPa). Fifty-six percent of patients experienced an increase in LPR. No significant relationship between change in LPR or transfusion on pH(bt) and change in hemoglobin could be demonstrated. Conclusions: Transfusion of packed red blood cells acutely results in improved brain tissue oxygen without appreciable effect on cerebral metabolism.	[Zygun, David A.] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Zygun, David A.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Menon, David K.; Gupta, Arun K.] Univ Cambridge, Neurosci Crit Care Unit, Cambridge CB2 1TN, England; [Nortje, Jurgens; Menon, David K.; Gupta, Arun K.] Univ Cambridge, Dept Anaesthesia, Cambridge CB2 1TN, England; [Hutchinson, Peter J.; Timofeev, Ivan] Addenbrookes Hosp, Acad Neurosurg, Cambridge, England; [Timofeev, Ivan; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England	Zygun, DA (corresponding author), Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada.	david.zygun@calgaryhealthregion.ca	Timofeev, Ivan/AAE-7019-2019	Timofeev, Ivan/0000-0002-1168-0393	Association of Anesthetists of Great Britain and Ireland [G9439390 ID, 56833]; Royal College of Physicians and Surgeons of Canada; Meredith Graduate Master's Scholarship; University of Calgary, the Worker's Compensation Board of Alberta (DAZ); Academy of Medical Sciences/The Health Foundation-Senior Surgical Scientist Fellowship (PJH); British Journal of Anesthesia/Royal College of Anesthetists Research Fellowship (JN); Codman (Johnson & Johnson), the Evelyn Trust and a BP-TNK Kapitza scholarship (IT)Johnson & JohnsonJohnson & Johnson USA; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986] Funding Source: researchfish	Supported, in part, by G9439390 ID 56833 from Association of Anesthetists of Great Britain and Ireland, Intensive Care Society and Acute Brain Injury Program in the Wolfson Brain Imaging Centre, which was funded by the MRC. Supported by, the Detweiler Traveling Fellowship of the Royal College of Physicians and Surgeons of Canada, the Meredith Graduate Master's Scholarship, University of Calgary, the Worker's Compensation Board of Alberta (DAZ); the Academy of Medical Sciences/The Health Foundation-Senior Surgical Scientist Fellowship (PJH); British Journal of Anesthesia/Royal College of Anesthetists Research Fellowship (JN); Codman (Johnson & Johnson), the Evelyn Trust and a BP-TNK Kapitza scholarship (IT).	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; BEUTLER E, 1969, J LAB CLIN MED, V74, P300; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; GAEHTGENS P, 1987, J CEREBR BLOOD F MET, V7, P259, DOI 10.1038/jcbfm.1987.61; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Habib RH, 2003, J THORAC CARDIOV SUR, V125, P1438, DOI 10.1016/S0022-5223(02)73291-1; Hare GMT, 2003, J NEUROTRAUM, V20, P1134; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Jonas RA, 2003, J THORAC CARDIOV SUR, V126, P1765, DOI 10.1016/j.jtcvs.2003.04.003; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Pendem S, 2006, NEUROCRIT CARE, V4, P63, DOI 10.1385/NCC:4:1:063; Pickett JL, 1999, AM J KIDNEY DIS, V33, P1122, DOI 10.1016/S0272-6386(99)70150-2; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2006, CRIT CARE MED, V34, P1850, DOI 10.1097/01.CCM.0000219370.99823.5B; Weiskopf RB, 2000, ANESTHESIOLOGY, V92, P1646, DOI 10.1097/00000542-200006000-00023; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	26	117	120	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2009	37	3					1074	1078		10.1097/CCM.0b013e318194ad22			5	Critical Care Medicine	General & Internal Medicine	413FW	WOS:000263779300039	19237920				2021-06-18	
J	Aitken, ME; McCarthy, ML; Slomine, BS; Ding, R; Durbin, DR; Jaffe, KM; Paidas, CN; Dorsch, AM; Christensen, JR; MacKenzie, EJ				Aitken, Mary E.; McCarthy, Melissa L.; Slomine, Beth S.; Ding, Ru; Durbin, Dennis R.; Jaffe, Kenneth M.; Paidas, Charles N.; Dorsch, Andrea M.; Christensen, James R.; MacKenzie, Ellen J.		CHAT Study Grp	Family Burden After Traumatic Brain Injury in Children	PEDIATRICS			English	Article						traumatic brain injury; health-related quality of life; PedsQL; family burden	QUALITY-OF-LIFE; GENERIC CORE SCALES; PROBLEM-SOLVING INTERVENTION; PRELIMINARY EFFICACY; ASSESSMENT DEVICE; INITIAL YEAR; RELIABILITY; VALIDITY; PEDSQL(TM)-4.0; PREDICTORS	OBJECTIVE. Traumatic brain injury has a substantial impact on caregivers. This study describes the burden experienced by caregivers of children with traumatic brain injury and examines the relationship between child functioning and family burden during the first year after injury. PATIENTS AND METHODS. Children aged 5 to 15 years hospitalized for traumatic brain injury at 4 participating trauma centers were eligible. Caregivers completed baseline and 3- and 12-month telephone interviews measuring the child's health-related quality of life using the Pediatric Quality of Life Inventory. The emotional impact scale of the Child Health Questionnaire was used to identify caregivers with substantial distress, including general worry or interference with family routine. Caregiver perceptions of whether health care needs were met or unmet and days missed from work were also measured. RESULTS. A total of 330 subjects enrolled; follow-up was conducted with 312 at 3 months and 288 at 12 months. Most subjects were white (68%) and male (69%). Abnormal Pediatric Quality of Life Inventory subscores were related to substantial caregiver burden (either general worry or interference in routine). These abnormalities were reported by > 75% of patients at 3 months and persisted to 1 year in some patients. Parental perception of unmet health care needs was strongly related to family burden outcomes, with up to 69% of this subset of parents reporting substantial worry, and nearly one quarter reporting interference with daily routine/concentration 1 year after injury. Child dysfunction predicted parental burden at 3 and 12 months. Burden was greater when health care need was unmet. Abnormalities on the Pediatric Quality of Life Inventory predicted the amount of work missed by parents, especially in the presence of unmet needs. CONCLUSIONS. Caregivers are more likely to report family burden problems when child functioning is poorer and health care needs are unmet. Improved identification and provision of services is a potentially modifiable factor that may decrease family burden after pediatric traumatic brain injury. Pediatrics 2009;123:199-206	[Aitken, Mary E.] Univ Arkansas Med Sci, Coll Med, Dept Pediat, Arkansas Childrens Hosp,Res Inst, Little Rock, AR 72202 USA; [McCarthy, Melissa L.; Ding, Ru] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA; [Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; [Christensen, James R.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Christensen, James R.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; [Durbin, Dennis R.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Jaffe, Kenneth M.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; [Dorsch, Andrea M.] Univ Washington, Childrens Hosp & Reg Med Ctr, Sch Med, Div Rehabil Psychol, Seattle, WA USA; [Paidas, Charles N.] Univ S Florida, Dept Surg, Tampa, FL 33620 USA; [MacKenzie, Ellen J.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA	Aitken, ME (corresponding author), Univ Arkansas Med Sci, Coll Med, Dept Pediat, 800 Marshall St,Slot 512-26, Little Rock, AR 72202 USA.	aitkenmarye@uams.edu	ding, ru/B-1615-2009	Aitken, Mary/0000-0002-8318-9755	National Center for Injury Prevention and Control of the Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR319701]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR020146]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR020146] Funding Source: NIH RePORTER	We express our appreciation to the study coordinators who worked hard to successfully recruit of all of the injured children and families involved: Eileen Houseknecht, RN, BSN; Patricia Klotz, RN, BSN; Patricia Korehbandi, RN, MS, CHES; Vinita Misra Knight, MPH, CSTR; Donna Parnell, RN, MNSc; and Susan Ziegfeld, MSN, CRNP.	Aitken ME, 2004, ARCH PHYS MED REHAB, V85, P567, DOI 10.1016/j.apmr.2003.06.018; Bastiaansen D, 2004, QUAL LIFE RES, V13, P489, DOI 10.1023/B:QURE.0000018483.01526.ab; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; Eiser C, 2003, CHILD CARE HLTH DEV, V29, P95, DOI 10.1046/j.1365-2214.2003.00318.x; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; LANDGRAF JM, 1996, CHQ USERS MANUAL; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Miller IW, 2000, FAM PROCESS, V39, P141, DOI 10.1111/j.1545-5300.2000.39112.x; Minkovitz CS, 2005, PEDIATRICS, V115, P306, DOI 10.1542/peds.2004-0341; Minkovitz CS, 2002, AMBUL PEDIATR, V2, P85, DOI 10.1367/1539-4409(2002)002<0085:ABMACH>2.0.CO;2; Mowbray CT, 2005, COMMUNITY MENT HLT J, V41, P687, DOI 10.1007/s10597-005-6425-4; Osberg JS, 1996, PEDIATRICS, V98, P890; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Schwimmer JB, 2003, JAMA-J AM MED ASSOC, V289, P1813, DOI 10.1001/jama.289.14.1813; SILLS MR, 2007, PEDIATRICS, V119; SLOMINE BS, 2006, PEDIATRICS, V117; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Varni JW, 2002, ARTHRITIS RHEUM, V46, P714, DOI 10.1002/art.10095; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Varni JW, 2003, DIABETES CARE, V26, P631, DOI 10.2337/diacare.26.3.631; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110	41	117	118	0	21	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JAN	2009	123	1					199	206		10.1542/peds.2008-0607			8	Pediatrics	Pediatrics	388UZ	WOS:000262046400034	19117883				2021-06-18	
J	Belanger, HG; Uomoto, JM; Vanderploeg, RD				Belanger, Heather G.; Uomoto, Jay M.; Vanderploeg, Rodney D.			The Veterans Health Administration System of Care for Mild Traumatic Brain Injury: Costs, Benefits, and Controversies	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						screening; TBI; Veterans Health Administration	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSION-LIKE SYMPTOMS; OIF/OEF SERVICE MEMBERS; GULF-WAR VETERANS; MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL OUTCOMES; COGNITIVE PERFORMANCE; CLINICAL MANAGEMENT; EXPLOSION INJURIES; MAJOR DEPRESSION	The Veterans Health Administration's (VHA!s) Polytrauma System of Care, developed in response to a new cohort of patients back from Iraq and Afghanistan, is described with particular focus on the assessment and treatment of Mild traumatic bra-In Injury (mild TBI). The development of systemwide TBI screening within the VHA has been an ambitious and historic undertaking. As with any population-wide screening tool, there are benefits and costs associated with it. The purpose of this article is to identify and discuss the strengths and weaknesses of the VHA's TBI clinical reminder and subsequent evaluation and treatment processes. Complicating factors such as increased media attention and other contextual factors are discussed.	[Belanger, Heather G.; Vanderploeg, Rodney D.] James A Haley VA, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Belanger, Heather G.; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Uomoto, Jay M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA; [Uomoto, Jay M.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA	Belanger, HG (corresponding author), James A Haley Vet Hosp, Dept Psychol, 13000 Bruce B Downs Blvd 117, Tampa, FL 33612 USA.	Heather.Belanger@va.gov	Uomoto, Jay/AAF-4809-2019		Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health Administration (VHA)US Department of Veterans Affairs	The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA). Further support was provided by the James A. Haley Veterans' Hospital. The views expressed herein are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2008, ARCH CLIN NEUROPSYCH, V23, P731; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; *DEF VET BRAIN INJ, BLAST INJ FAQS; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; DICKER BG, 1992, J HEAD TRAUMA REHAB, V7, P83; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hunt SC, 2002, MIL MED, V167, P414; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Johnston SC, 2005, NEUROLOGY, V65, P360; Kashida Hiroshi, 2006, Int J Clin Oncol, V11, P1, DOI 10.1007/s10147-005-0550-5; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lesho EP, 2005, MIL MED, V170, P243, DOI 10.7205/MILMED.170.3.243; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mercado JM, 2008, ARCH CLIN NEUROPSYCH, V23, P731; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MITTENBERG W, 1997, J INT NEUROPSYCH SOC, V3, P13; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Vanderploeg RD, 2006, PSYCHOLOGICAL KNOWLEDGE IN COURT: PTSD, PAIN, AND TBI, P279, DOI 10.1007/0-387-25610-5_16; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	62	117	117	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2009	24	1					4	13		10.1097/HTR.0b013e3181957032			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	427GT	WOS:000264768500003	19158591				2021-06-18	
J	Levin, HS; Wilde, EA; Chu, ZL; Yallampalli, R; Hanten, GR; Li, XQ; Chia, J; Vasquez, AC; Hunter, JV				Levin, Harvey S.; Wilde, Elisabeth A.; Chu, Zili; Yallampalli, Ragini; Hanten, Gerri R.; Li, Xiaoqi; Chia, Jon; Vasquez, Ana C.; Hunter, Jill V.			Diffusion tensor imaging in relation to cognitive and functional outcome of traumatic brain injury in children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children; cognition diffusion tensor imaging; global outcome; traumatic brain injury	WHITE-MATTER ARCHITECTURE; AXONAL INJURY; MAGNETIC-RESONANCE; HEAD-INJURY; CORPUS-CALLOSUM; PRACTICAL SCALE; MATURATION; ANISOTROPY; CHILDHOOD; MRI	Objective: To investigate the relation of white matter integrity using diffusion tensor imaging (DTI) to cognitive and functional outcome of moderate to severe traumatic brain injury (TBI) in children. Design: Prospective observational study of children who had sustained moderate to severe TBI and a comparison group of children who had sustained orthopedic injury (01). Participants: Thirty-two children who had sustained moderate to severe TBI and 36 children with OI were studied. Methods: Fiber tracking analysis of DTI acquired at 3-month postinjury and assessment of global outcome and cognitive function within 2 weeks of brain imaging. Global outcome was assessed using the Glasgow Outcome Scale and the Flanker task was used to measure cognitive processing speed and resistance to interference. Results: Fractional anisotropy and apparent diffusion coefficient values differentiated the groups and both cognitive and functional outcome measures were related to the DTI findings. Dissociations were present wherein the relation of Fractional anisotropy to cognitive performance differed between the TBI and OI groups. A DTI composite measure of white matter integrity was related to global outcome in the children with TBI Conclusions: DTI is sensitive to white matter injury at 3 months following moderate to severe TBI in children, including brain regions that appear normal on conventional magnetic resonance imaging. DTI measures reflecting diffusion of water parallel and perpendicular to white matter tracts as calculated by fiber tracking analysis are related to global outcome, cognitive processing speed, and speed of resolving interference in children with moderate to severe TBI. Longitudinal data are needed to determine whether these relations between DTI and neurobehavioral outcome of TBI in children persist at longer follow-up intervals.	[Levin, Harvey S.; Wilde, Elisabeth A.; Yallampalli, Ragini; Hanten, Gerri R.; Li, Xiaoqi; Vasquez, Ana C.] Univ Texas Houston, Sch Med, Baylor Coll Med, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Yallampalli, Ragini] Univ Houston, Dept Psychol, Houston, TX USA; [Chia, Jon] Philips Med Syst, Cleveland, OH USA	Levin, HS (corresponding author), Univ Texas Houston, Sch Med, Baylor Coll Med, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889, R01 NS021889, R01 NS021889-24] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1975, LANCET, V1, P480; Kanaan RA, 2006, PSYCHIAT RES-NEUROIM, V146, P73, DOI 10.1016/j.pscychresns.2005.11.002; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Mukherjee P, 2001, RADIOLOGY, V221, P349, DOI 10.1148/radiol.2212001702; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; Olesen PJ, 2003, COGNITIVE BRAIN RES, V18, P48, DOI 10.1016/j.cogbrainres.2003.09.003; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Schmithorst VJ, 2008, HUM BRAIN MAPP, V29, P696, DOI 10.1002/hbm.20431; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Sheskin DJ, HDB PARAMETRIC NONPA; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; TEASDALE G, 1974, LANCET, V2, P81; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	44	117	118	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2008	23	4					197	208		10.1097/01.HTR.0000327252.54128.7c			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	331KU	WOS:000258011900002	18650764	Green Accepted			2021-06-18	
J	Narayan, RK; Maas, AIR; Servadei, F; Skolnick, BE; Tillinger, MN; Marshall, LF				Narayan, Raj K.; Maas, Andrew I. R.; Servadei, Franco; Skolnick, Brett E.; Tillinger, Michael N.; Marshall, Lawrence F.		Traumatic Intracerebral Hemorrhage	Progression of traumatic intracerebral hemorrhage: A prospective observational study	JOURNAL OF NEUROTRAUMA			English	Article						cerebral contusions; deep vein thrombosis; intracerebral hemorrhage; thromboembolic complications; traumatic brain injury	SEVERE HEAD-INJURY; INTRA-CEREBRAL HEMATOMAS; BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; CRANICAL PRESSURE; CLINICAL-TRIALS; CT; COAGULOPATHY; THROMBOCYTOPENIA; PROGNOSIS	Preliminary evidence has shown that intracerebral hemorrhages, either spontaneous (sICH) or traumatic (tICH) often expand over time. An association between hemorrhage expansion and clinical outcomes has been described for sICH. The intent of this prospective, observational study was to characterize the temporal profile of hemorrhage progression, as measured by serial computed tomography (CT) scanning, with the aim of better understanding the natural course of hemorrhage progression in tICH. There was also a desire to document the baseline adverse event (AE) profile in this patient group. An important motive for performing this study was to set the stage for subsequent studies that will examine the role of a new systemic hemostatic agent in tICH. Subjects were enrolled if they had tICH lesions of at least 2 mL on a baseline CT scan obtained within 6 h of a head injury. CT scans were repeated at 24 and 72 h. Clinical outcomes and pre-defined AEs were documented. The data showed that 51% of the subjects demonstrated an increase in tICH volume, and that most of the increase occurred early. In addition, larger hematomas exhibited the greatest expansion. Thromboembolic complications were identified in 13% of subjects. This study demonstrates that tICH expansion between the baseline and 24-h CT scans occurred in approximately half of the subjects. The earlier after injury that the initial CT scan is obtained, the greater is the likelihood that the hematoma will expand on subsequent scans. The time frame during which hemorrhagic expansion occurs provides an opportunity for early intervention to limit a process with adverse prognostic implications.	[Narayan, Raj K.] Univ Cincinnati, Dept Neurosurg, Inst Neurosci, Univ Hosp, Cincinnati, OH 45267 USA; [Narayan, Raj K.] Mayfield Clin, Cincinnati, OH 45267 USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Servadei, Franco] Univ Hosp, Osped Maggiore, Neurosurg Neurotrauma Unit, Parma, Italy; [Tillinger, Michael N.] Novo Nordisk Inc, Princeton, NJ USA; [Marshall, Lawrence F.] Univ Calif San Diego, Div Neurosurg, San Diego, CA 92103 USA	Narayan, RK (corresponding author), Univ Cincinnati, Dept Neurosurg, Inst Neurosci, Univ Hosp, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	raj.narayan@uc.edu	Skolnick, Brett e/B-5140-2009; Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264; Servadei, Franco/0000-0002-3595-3464; Hitchon, Patrick/0000-0002-8175-9136; Theodore, Nicholas/0000-0001-5355-2683; Kaufmann, Anthony/0000-0001-6144-0382			BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Fainardi E, 2004, ACTA NEUROCHIR, V146, P257, DOI 10.1007/s00701-003-0207-y; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; Kannus P, 2001, JAMA-J AM MED ASSOC, V286, P673, DOI 10.1001/jama.286.6.673; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Luukinen H, 1999, J AM GERIATR SOC, V47, P1451, DOI 10.1111/j.1532-5415.1999.tb01566.x; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pace MC, 2006, MINERVA ANESTESIOL, V72, P235; Procaccio F, 2000, J Neurosurg Sci, V44, P1; REILLY PL, 1975, LANCET, V2, P375; SERVADEI F, 2000, EUR BRAIN INJ CONSUT, V46, P70; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; Zimmerman RD, 2006, AM J NEURORADIOL, V27, P666	35	117	128	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					629	639		10.1089/neu.2007.0385			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900006	18491950	Green Published			2021-06-18	
J	Chen, G; Shi, JX; Hu, ZG; Hang, CH				Chen, Gang; Shi, Jixin; Hu, Zhigang; Hang, Chunhua			Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: A potential neuroprotective mechanism of N-acetylcysteine	MEDIATORS OF INFLAMMATION			English	Article							FACTOR-KAPPA-B; NECROSIS-FACTOR-ALPHA; INDUCED APOPTOSIS; AXONAL INJURY; EXPRESSION; ACTIVATION; RELEASE	Although N-acetylcysteine (NAC) has been shown to be neuroprotective for traumatic brain injury (TBI), the mechanisms for this beneficial effect are still poorly understood. Cerebral inflammation plays an important role in the pathogenesis of secondary brain injury after TBI. However, it has not been investigated whether NAC modulates TBI-induced cerebral inflammatory response. In this work, we investigated the effect of NAC administration on cortical expressions of nuclear factor kappa B (NF-kappa B) and inflammatory proteins such as interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and intercellular adhesion molecule-1 (ICAM-1) after TBI. As a result, we found that NF-kappa B, proinflammatory cytokines, and ICAM-1 were increased in all injured animals. In animals given NAC post-TBI, NF-kappa B, IL-1 beta, TNF-alpha, and ICAM-1 were decreased in comparison to vehicle-treated animals. Measures of IL-6 showed no change after NAC treatment. NAC administration reduced brain edema, BBB permeability, and apoptotic index in the injured brain. The results suggest that post-TBI NAC administration may attenuate inflammatory response in the injured rat brain, and this may be one mechanism by which NAC ameliorates secondary brain damage following TBI. Copyright (C) 2008 Gang Chen et al.	[Chen, Gang; Shi, Jixin; Hu, Zhigang; Hang, Chunhua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Jiangsu 210002, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Jiangsu 210002, Peoples R China.	nju_neurosurgery@163.com		Chen, Gang/0000-0002-0758-1907			Akca T, 2005, J SURG RES, V129, P38, DOI 10.1016/j.jss.2005.05.026; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Carroll JE, 1998, MOL BRAIN RES, V56, P186, DOI 10.1016/S0169-328X(98)00045-X; Chen G, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/93431; Conti AC, 1998, J NEUROSCI, V18, P5663; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FERRARI G, 1995, J NEUROSCI, V15, P2857; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffer E, 2002, MEDIAT INFLAMM, V11, P321, DOI 10.1080/09629350210000015737; Hsu BG, 2006, LIFE SCI, V79, P2010, DOI 10.1016/j.lfs.2006.06.040; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Li J, 2002, J NUTR, V132, P3286; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tanel A, 2007, J PHARMACOL EXP THER, V321, P73, DOI 10.1124/jpet.106.114678; Vink R, 2003, ACT NEUR S, V86, P257; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yi JH, 2006, J NEUROTRAUM, V23, P86, DOI 10.1089/neu.2006.23.86	30	117	124	0	5	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2008	2008								716458	10.1155/2008/716458			8	Cell Biology; Immunology	Cell Biology; Immunology	314IL	WOS:000256803000001	18483565	DOAJ Gold, Green Published			2021-06-18	
J	Slobounov, S; Slobounov, E; Sebastianelli, W; Cao, C; Newell, K				Slobounov, Semyon; Slobounov, Elena; Sebastianelli, Wayne; Cao, Cheng; Newell, Karl			Differential rate of recovery in athletes after first and second concussion episodes	NEUROSURGERY			English	Article						balance; mild traumatic brain injury; recurrent concussions; visual-kinesthetic integration	TRAUMATIC BRAIN-INJURY; CEREBRAL CONCUSSION; POSTURAL CONTROL; HIGH-SCHOOL; COLLEGIATE; PERFORMANCE; MANAGEMENT; RESPONSES; HISTORY; MOTION	OBJECTIVE: Clinical observations suggest that a history of previous concussions may cause a slower recovery of neurological function after recurrent concussion episodes. However, direct examination of this notion has not been provided. This report investigates the differential rate of restoring the visual-kinesthetic integration in collegiate athletes experiencing single versus recurrent concussion episodes. METHODS: One hundred sixty collegiate athletes were tested preseason using multimodal research methodology. Of these, 38 experienced mild traumatic brain injury (MTBI) and were tested on Days 10, 15, and 30 after injury. Nine of these MTBI patients experienced a second MTBI within 1 year after the first brain injury and were retested. The postconcussion symptoms checklist, neuropsychological evaluations, and postural responses to visual field motion were recorded using a virtual reality environment. RESULTS: All patients were asymptomatic at Day 10 of testing and were cleared for sport participation based on clinical symptoms resolution. Balance deficits, as evident by incoherence with visual field motion postural responses, were present at least 30 days after injury (P < 0.001). Most importantly, the rate of balance symptoms restoration was significantly reduced after a recurrent, second concussion (P < 0.001) compared with those after the first concussion. CONCLUSION:The findings of this study confirm our previous research indicating the presence of long-term residual visual-motor disintegration in concussed individuals with normal neuropsychological measures. Most importantly, athletes with a history of previous concussion demonstrate significantly slower rates of recovery of neurological functions after the second episode of MTBI.	Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Hall, University Pk, PA 16802 USA.	sms18@psu.edu					Barth JT, 2001, J ATHL TRAINING, V36, P253; Bluml S, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P197, DOI 10.1007/0-387-32565-4_9; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; CANTU R, 2003, CONC ATHL 3 ANN SEM; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collins MW, 2003, NEUROSURGERY, V53, P247, DOI 10.1227/01.NEU.0000072307.16102.F4; Cooper SJ, 2005, NEUROSCI BIOBEHAV R, V28, P851, DOI 10.1016/j.neubiorev.2004.09.009; CORKIN S, 1989, J NEUROSCI, V9, P3876; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hallett M, 2001, BRAIN RES REV, V36, P169, DOI 10.1016/S0165-0173(01)00092-3; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Keshner EA, 2000, J VESTIBUL RES-EQUIL, V10, P207; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Randolph C, 2001, J ATHL TRAINING, V36, P288; Schubert T, 2003, COGNITIVE BRAIN RES, V17, P733, DOI 10.1016/S0926-6410(03)00198-8; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; SLOBOUNOV S, 2006, FDN SPORT RELATED BR, P2; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Streepey JW, 2007, EXP BRAIN RES, V176, P182, DOI 10.1007/s00221-006-0677-2; Thatcher RW, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P241, DOI 10.1007/0-387-32565-4_11; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090	34	117	117	2	20	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2007	61	2					338	344		10.1227/01.NEU.0000280001.03578.FF			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	197AN	WOS:000248525400026	17762746				2021-06-18	
J	Chamelian, L; Feinstein, A				Chamelian, L; Feinstein, A			The effect of major depression on subjective and objective cognitive deficits in mild to moderate traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	15th Annual Meeting of the American-Neuropsychiatric-Association	FEB 21-24, 2004	Bal Harbour, FL	Amer Neuropsychiat Assoc			HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; TEST-PERFORMANCE; MEMORY DEFICITS; SYMPTOMS; RECOVERY; QUESTIONNAIRE; CONCUSSION; COMPLAINTS; ATTENTION	The effect of major depression on subjective and objective cognitive deficits 6 months following mild to moderate traumatic brain injury (TBI) was assessed in 63 subjects. Patients with subjective cognitive complaints (n = 63) were more likely to be women, with higher Glasgow Coma Scale (GCS) scores and have a diagnosis of major depression. They also performed significantly more poorly on various measures of memory, attention and executive functioning. Group differences on most but not all cognitive measures disappeared in a multivariate analysis when controlling for depression. In mild to moderate TBI, subjective cognitive deficits are linked in large measure to comorbid major depression. However, other mechanisms may also account for these deficits.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Traumat Brain Injury Clin, Toronto, ON M4N 3M5, Canada	Feinstein, A (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Room FG08,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	antfeinstein@aol.com					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BEASONHAZEN S, 1994, J NEUROPSYCH CLIN N, V6, P43; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Delis DC, 2000, CALIFORNIA VERBAL LE; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; First M.B., 1996, STRUCTURED CLIN INTE; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; GREEN WP, 1996, WORD MEMORY TEST USE; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Heaton R., 1993, WISCONSIN CARD SORTI; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KAPUR N, 1983, BRIT J PSYCHOL, V74, P409, DOI 10.1111/j.2044-8295.1983.tb01872.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kujala P, 1996, ACTA NEUROL SCAND, V93, P329; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; McAllister T., 2001, J NEUROPSYCHIATRY CL, V13, P141; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCCULLAGH S, 2005, TXB TRAUMATIC BRAIN; Poutiainen E, 1996, J Int Neuropsychol Soc, V2, P219; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; TAYLOR R, 1990, BRIT J CLIN PSYCHOL, V29, P251, DOI 10.1111/j.2044-8260.1990.tb00882.x; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	45	117	119	0	14	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2006	18	1					33	38		10.1176/appi.neuropsych.18.1.33			6	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	014YU	WOS:000235519900005	16525068				2021-06-18	
J	Kan, P; Amini, A; Hansen, K; White, GL; Brockmeyer, DL; Walker, ML; Kestle, JRW				Kan, Peter; Amini, Aminullah; Hansen, Kristine; White, George L., Jr.; Brockmeyer, Douglas L.; Walker, Marion L.; Kestle, John R. W.			Outcomes after decompressive craniectomy for severe traumatic brain injury in children	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; outcome; decompressive craniectomy; pediatric neurosurgery	SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; HYPERTONIC SALINE; MANAGEMENT; PRESSURE; DIAGNOSIS; BIOPSIES; SEIZURES; SCALE; COMA	Object. Severe traumatic brain injury (TBI) is often accompanied by early death due to transtentorial herniation. Decompressive craniectomy, performed alone or in conjunction with evacuation of the mass lesion, can reduce the incidence of raised intracranial pressure (ICP). In this paper the authors evaluate mortality and morbidity and long-term outcomes in children who underwent decompressive craniectomy for severe TBI at a single institution. Methods. Children with severe TBI who underwent decompressive craniectomy at the Primary Children's Medical Center between 1996 and 2005 were identified retrospectively. Descriptive statistics were used to report postoperative mortality and morbidity rates. Long-term recovery in patients who survived was reported using the King's Outcome Scale for Closed Head Injury (KOSCHI). Fifty-one children with a mean follow-up period of 18.6 months were identified. Nonaccidental trauma accounted for 23.5% of cases. The mean preoperative Glasgow Coma Scale (GCS) score was 4.6. Six patients underwent decompressive craniectomy for elevated ICP only; all other patients underwent decompressive craniectomy in conjunction with removal of the mass lesion. The mean postoperative GCS score was 9.7, and 69.4% of patients had normal ICP levels immediately after surgery. Sixteen children (31.4%) died, including five of six children who underwent decompressive craniectomy for raised ICP alone. Among surviving patients, 2.9% required a tracheostomy, 11.4% required a gastrostomy, 40% experienced posttraumatic shunt-dependent hydrocephalus, and 20% suffered posttraumatic epilepsy requiring antiepileptic agents. The mean KOSCHI score at the last follow-up examination was 4.5 and the mean time to cranioplasty was 2.3 months. Conclusions. Posttraumatic hydrocephalus and epilepsy were common complications encountered by children with severe TBI who underwent decompressive craniectomy. In patients who underwent decompressive surgery for raised ICP only, the mortality rate was exceedingly high.	Univ Utah, Primary Childrens Med Ctr, Dept Neurosurg, Div Pediat Neurosurg, Salt Lake City, UT 84113 USA	Kestle, JRW (corresponding author), Univ Utah, Primary Childrens Med Ctr, Dept Neurosurg, Div Pediat Neurosurg, 100 N Med Dr, Salt Lake City, UT 84113 USA.	john.kestle@hsc.utah.edu					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GOLDSTEIN S, 1987, J NEUROSURG, V67, P341, DOI 10.3171/jns.1987.67.3.0341; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRUNERT P, 1994, NEUROSURG REV, V17, P59, DOI 10.1007/BF00309989; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JOSAN VA, 2006, CHILDS NERV SYS 0222; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Munch E, 2000, NEUROSURGERY, V47, P315; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Rekate Harold L., 2001, Child's Nervous System, V17, P632, DOI 10.1007/s003810100487; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; SHAPIRO K, 1985, J NEUROSURG, V63, P76, DOI 10.3171/jns.1985.63.1.0076; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	34	117	124	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	2006	105	5		S			337	342		10.3171/ped.2006.105.5.337			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	102HC	WOS:000241800600002	17328254				2021-06-18	
J	Gao, JL; Prough, DS; McAdoo, DJ; Grady, JJ; Parsley, MO; Ma, L; Tarensenko, YI; Wu, P				Gao, Junling; Prough, Donald S.; McAdoo, David J.; Grady, James J.; Parsley, Margaret O.; Ma, Long; Tarensenko, Yevgeniya I.; Wu, Ping			Transplantation of primed human fetal neural stem cells improves cognitive function in rats after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; neural stem cell; transplantation; glial-cell-line-derived neurotrophic factor; hippocampus; cognitive function	CENTRAL-NERVOUS-SYSTEM; FLUID-PERCUSSION MODEL; NEUROTROPHIC FACTOR; PROGENITOR CELLS; DOPAMINERGIC-NEURONS; ADULT-RAT; INDUCED EXCITOTOXICITY; SENSORIMOTOR FUNCTION; CHOLINERGIC NEURONS; GENE-EXPRESSION	Traumatic brain injury (TBI) often produces cognitive impairments by primary or secondary neuronal loss. Stem cells are a potential tool to treat TBI. However, most previous studies using rodent stem or progenitor cells failed to correlate cell grafting and cognitive improvement. Furthermore, the efficacy of fetal human neural stem cells (hNSCs) for ameliorating TBI cognitive dysfunction is undetermined. This study therefore characterized phenotypic differentiation, neurotrophic factor expression and release and functional outcome of grafting hNSCs into TBI rat brains. Adult Sprague-Dawley rats underwent a moderate parasagittal fluid percussion TBI followed by ipsilateral hippocampal transplantation of hNSCs or vehicle I day post-injury. Prior to grafting, hNSCs were treated in vitro for 7 days with our previously developed priming procedure. Significant spatial learning and memory improvements were detected by the Morris water maze (MWM) test in rats 10 days after receiving hNSC grafts. Morphological analyses revealed that hNSCs survived and differentiated mainly into neurons in the injured hippocampus at 2 weeks after grafting. Furthermore, hNSCs expressed and released glial-cell-line-derived neurotrophic factor (GDNF) in vitro and when grafted in vivo, as detected by RT-PCR, inummostaining, microdialysis and ELISA. This is the first direct demonstration of the release of a neurotrophic factor in conjunction with stem cell grafting. In conclusion, human fetal neural stem cell grafts improved cognitive function of rats with acute TB L Grafted cells survived and differentiated into neurons and expressed and released GNDF in vivo, which may help protect host cells from secondary damage and aid host regeneration. (c) 2006 Elsevier Inc. All tights reserved.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Off Biostat, Galveston, TX 77555 USA	Wu, P (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, 301 Univ Blvd,MRB 10-138, Galveston, TX 77555 USA.	piwu@utmb.edu	Prough, Donald S/G-5793-2013; wu, Ping/G-8958-2011	Prough, Donald S/0000-0001-7994-532X; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS046025, NS042849] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046025, R01NS042849] Funding Source: NIH RePORTER		Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Bedell EA, 2004, J NEUROTRAUM, V21, P1212; Bonde C, 2000, NEUROREPORT, V11, P4069, DOI 10.1097/00001756-200012180-00032; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Brodhun M, 2004, EXP TOXICOL PATHOL, V56, P103, DOI 10.1016/j.etp.2004.04.004; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Gao J, 2005, NEUROSCIENCE, V131, P257, DOI 10.1016/j.neuroscience.2004.10.033; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kitagawa H, 1999, J CEREBR BLOOD F MET, V19, P1336, DOI 10.1097/00004647-199912000-00007; Kohn D., 1997, ANESTHESIA ANALGESIA; Kulbatski I, 2005, CURR DRUG TARGETS, V6, P111, DOI 10.2174/1389450053345037; LEON A, 1990, STROKE, V21, P95; Liberatore GT, 1997, NEUROREPORT, V8, P3097, DOI 10.1097/00001756-199709290-00018; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; NIETOSAMPEDRO M, 1987, ANN NY ACAD SCI, V495, P108, DOI 10.1111/j.1749-6632.1987.tb23670.x; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; Ourednik J, 2004, CELL TRANSPLANT, V13, P307, DOI 10.3727/000000004783983963; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; SAUER H, 1995, P NATL ACAD SCI USA, V92, P8935, DOI 10.1073/pnas.92.19.8935; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Serkova N, 2004, MOL INTERV, V4, P97, DOI 10.1124/mi.4.2.7; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Sheen VL, 1999, EXP NEUROL, V158, P47, DOI 10.1006/exnr.1999.7104; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Snyder EY, 1996, CLIN NEUROSCI, V3, P310; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wright LS, 2003, J NEUROCHEM, V86, P179, DOI 10.1046/j.1471-4159.2003.01826.x; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Wu P, 2002, GENE THER, V9, P245, DOI 10.1038/sj.gt.3301646	71	117	138	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2006	201	2					281	292		10.1016/j.expneurol.2006.04.039			12	Neurosciences	Neurosciences & Neurology	096RG	WOS:000241393900002	16904107				2021-06-18	
J	Chang, EF; Meeker, M; Holland, MC				Chang, EF; Meeker, M; Holland, MC			Acute traumatic intraparenchymal hemorrhage: Risk factors for progression in the early post-injury period	NEUROSURGERY			English	Article						computed tomography; contusion; intraparenchymal hematoma; progression; risk factors; traumatic brain injury	HEAD-INJURY; INTRACEREBRAL HEMATOMAS; SUBARACHNOID HEMORRHAGE; BRAIN-INJURY; BLOOD-FLOW; CT-SCAN; LESIONS; MANAGEMENT; CONTUSIONS; ISCHEMIA	OBJECTIVE: To characterize the natural course of traumatic intraparenchymal contusions and hematomas (IPHs) and to identify risk factors for IPH progression in the acute post-injury period. METHODS: A retrospective analysis was performed on a prospective observational database containing 113 head trauma patients exhibiting 229 initially nonoperated acute IPHs. The main outcome variable was radiographic evidence of IPH progression on serially obtained head computed tomographic (CT) scans. Secondary outcomes included the actual amount Of IPH growth and later surgical evacuation. Univariate and multivariate analyses (using a generalized estimate equation) were applied to both demographic and initial radiographic features to identify risk factors for IPH progression and surgery. RESULTS: Overall, 10 IPHs (4%) shrank, 133 (58%) remained unchanged, and 86 (38%) grew between the first and second heat! CT scan. IPH progression was independently associated with the presence of subarachnoid hemorrhage (odds ratio [OR], 1.6; 95% confidence interval [Cl], 1.12-2.3), presence of a subdural hematoma (OR, 1.1-3.43), and initial size (OR, 1.11; 95% Cl, 1.02-1.21, for each cm(3) 1.94; 95% Cl, volume). Size of initial IPH proportionately correlated with the amount of subsequent growth (linear regression, P < 0.001). Worsened Glasgow Coma Score between initial and follow-up head CT scan (OR, 8.6; 95% Cl, 1.5-50), IPH growth greater than 5 cm(3) (OR, 7.3; 95%, CI, 1.6-34), and effacement of basal cisterns on initial CT scan (OR, 9.0; 95% Cl, 1.5-52) were strongly associated with late surgical evacuation. CONCLUSION: A large proportion of IPHs progress in the acute post-injury period. IPHs associated with subarachnoid hemorrhage, a subdural hematoma, or large initial size should be monitored carefully for progression with repeat head CT imaging. Effacement of cisterns on the initial head CT scan was strongly predictive of failure of nonoperative management, thereby leading to surgical evacuation. These findings should be important factors in the understanding and management of IPH.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA	Chang, EF (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M 779, San Francisco, CA 94143 USA.	echang@itsa.ucsf.edu					BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Chieregato A, 2004, J NEUROTRAUM, V21, P655, DOI 10.1089/0897715041269669; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Gean A, 1994, IMAGING HEAD TRAUMA; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Naff NJ, 2001, NEUROSURGERY, V49, P614, DOI 10.1097/00006123-200109000-00015; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; PAPO I, 1980, NEUROSURGERY, V7, P337, DOI 10.1227/00006123-198010000-00005; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2002, ACT NEUR S, V81, P81; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019	21	117	126	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2006	58	4					647	655		10.1227/01.NEU.0000197101.68538.E6			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	036BZ	WOS:000237047200020	16575328				2021-06-18	
J	Winkler, D; Unsworth, C; Sloan, S				Winkler, D; Unsworth, C; Sloan, S			Factors that lead to successful community integration following severe traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						challenging; behaviour; disability; participation; predictors; severity of injury	QUALITY-OF-LIFE; HEAD-INJURY; PREMORBID INTELLIGENCE; QUESTIONNAIRE; DISABILITY; RECOVERY; OUTCOMES; REHABILITATION; POSTDISCHARGE; SATISFACTION	Objective: To assess and identify predictive factors of community integration of people 3 to 15 years after severe traumatic brain injury (TBI). Participants: Forty participants with severe TBI (an average of 8.8 years postinjury). Main Outcome Measures: The Community Integration Questionnaire, the Community Integration Measure, and the Sydney Psychosocial Reintegration Scale. Data related to factors that may predict community integration were also collected. Results: There was considerable variation in the level of community integration. Discriminant function analyses identified the following factors as predictive of the level of community integration: severity of injury, age at the time of injury, level of disability and challenging behavior. Conclusion: Interventions that minimize challenging behavior and disability may make a significant difference to the level of community integration experienced by people with severe TBI.	Monash Univ, Sch Primary Hlth Care, Melbourne, Vic 3004, Australia; Osborn Sloan & Assciates, Melbourne, Vic, Australia	Winkler, D (corresponding author), Monash Univ, Sch Primary Hlth Care, Melbourne, Vic 3004, Australia.	ypiresearch@optusnet.com.au		Winkler, Di/0000-0003-3899-6248; Unsworth, Carolyn/0000-0001-6430-2823			BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BARRY P, 1989, ARCH PHYS MED REHAB, V63, P118; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bogdan R., 1991, BUILDING STRONGER CO; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brzuzy S, 1996, J HEAD TRAUMA REHAB, V11, P74, DOI 10.1097/00001199-199606000-00011; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Carnevale GJ, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199602000-00005; CHARLTON JRH, 1983, J EPIDEMIOL COMMUN H, V37, P296, DOI 10.1136/jech.37.4.296; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; *CTR OUTC MEAS BRA, CRAIG HOSP INV ENV F; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; ELSASS L, 1989, 14 ANN BRAIN IMP C M; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming J, 1999, BRAIN INJURY, V13, P417; Fortune N, 1999, DEFINITION INCIDENCE; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HALL K, 1997, J REHABIL OUTCOMES M, V1, P63; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Jennett B, 1981, MANAGEMENT HEAD INJU; Karlovits T, 1999, BRAIN INJURY, V13, P845; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; MAHONEY F I, 1965, Md State Med J, V14, P61; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; Nelson HE, 1982, NATL ADULT READING T; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Connor P., 1999, NEEDS OPPORTUNITIES; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; OCARROLL RE, 1986, BRIT J CLIN PSYCHOL, V25, P157, DOI 10.1111/j.2044-8260.1986.tb00690.x; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PATRICK D, 1981, 3 BIENN C HLTH SURV; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROGERS W, 1992, MEASURING FUNCTIONIN, P24; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; *SPSS INC, 1999, SPSS COMP PROGR VERS; *STAT U NEW YORK B, 1997, GUID UNDAT SET MED R; TABACHNICK BG, 2001, USING MULTIVARIATE S, P456; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1994, BRAIN INJURY, V8, P647, DOI 10.3109/02699059409151017; WILLER B, 1994, COMMUNITY INTEGRATIO; Willer B., 1993, J HEAD TRAUMA REHABI, V8, P11; World Health Organization, 2001, INT CLASS FUNCT DIS; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	62	117	118	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2006	21	1					8	21		10.1097/00001199-200601000-00002			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	004WW	WOS:000234784300002	16456388				2021-06-18	
J	Calhoun, SL; Mayes, SD				Calhoun, SL; Mayes, SD			Processing speed in children with clinical disorders	PSYCHOLOGY IN THE SCHOOLS			English	Article							ATTENTION-DEFICIT DISORDER; TRAUMATIC HEAD-INJURY; WISC-III; LEARNING-DISABILITIES; ACADEMIC-ACHIEVEMENT; HYPERACTIVITY DISORDER; STRATEGY INSTRUCTION; READING DISABILITIES; SUBTEST PATTERNS; PROFILE TYPES	The Processing Speed Index (PSI) was first introduced on the Wechsler Intelligence Scale, Third Edition (WISC-III; D. Wechsler, 1991), and little is known about its clinical significance. In a referred sample (N = 980), children with neurological disorders (ADHD, autism, bipolar disorder, and LD) had mean PSI and Freedom from Distractibility Index (FDI) scores that were below the group mean IQ and lower than Verbal Comprehension (VCI) and Perceptual Organization (POI). For these groups, Coding was lower than Symbol Search. The majority of these children had learning, attention, writing, and processing speed weaknesses. This pattern was not found in the other clinical groups. For children with depression, only PSI was low. Children with anxiety disorders, oppositional -defiant disorder, and mental retardation had no PSI weakness. PSI and POI were both low in children with traumatic brain injury and spina bifida. Implications for a revision of the WISC-III (WISC-IV; D. Wechsler, 2003) are discussed. (c) 2005 Wiley Periodicals, Inc.	Milton S Hershey Med Ctr, Dept Psychiat, Hershey, PA 17033 USA; Penn State Univ, Coll Med, University Pk, PA 16802 USA	Mayes, SD (corresponding author), Milton S Hershey Med Ctr, Dept Psychiat, H073,POB 850, Hershey, PA 17033 USA.	SMayes@psu.edu					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson JA, 2001, J EMOT BEHAV DISORD, V9, P106, DOI 10.1177/106342660100900205; BARKLEY RA, 1990, J CONSULT CLIN PSYCH, V58, P775, DOI 10.1037/0022-006X.58.6.775; Biederman J, 2001, J AM ACAD CHILD PSY, V40, P871, DOI 10.1097/00004583-200108000-00007; Bray MA, 1998, SCHOOL PSYCHOL INT, V19, P209, DOI 10.1177/0143034398193002; CANTWELL DP, 1992, J AM ACAD CHILD PSY, V31, P432, DOI 10.1097/00004583-199205000-00008; Carlson CL, 2002, J CLIN CHILD ADOLESC, V31, P123, DOI 10.1207/153744202753441738; Casey JE, 1996, CHILD NEUROPSYCHOL, V2, P83, DOI 10.1080/09297049608401354; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DANOFF B, 1993, J READING BEHAV, V25, P295, DOI 10.1080/10862969009547819; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; *FED REG, 1999, IND DIS ED ACT IDEA; FIEDOROWICZ C, 2001, MULTIDISCIPLINARY J, V11, P61; Fletcher J., 1998, LEARNING DISABILITIE, V13, P186; Fletcher JM, 1999, PEDIATR CLIN N AM, V46, P885, DOI 10.1016/S0031-3955(05)70161-9; Glassberg LA, 1999, BEHAV DISORDERS, V25, P9; GLUTTING JJ, 1994, SCHOOL PSYCHOL REV, V23, P619; GOODYEAR P, 1992, J CLIN CHILD PSYCHOL, V21, P273, DOI 10.1207/s15374424jccp2103_9; Graham S., 2001, LEARN DISABIL RES PR, V16, P74, DOI [DOI 10.1111/0938-8982.00009, 10.1111/0938- 8982.00009]; Gresham FM, 1996, J LEARN DISABIL, V29, P570, DOI 10.1177/002221949602900601; Hale JB, 2001, SCHOOL PSYCHOL QUART, V16, P31, DOI 10.1521/scpq.16.1.31.19158; HALL SJ, 1997, J ATTEN DISORD, V1, P235; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Hooper SR, 2002, J LEARN DISABIL-US, V35, P57, DOI 10.1177/002221940203500105; Hooper SR, 1997, ADV CLIN CHILD PSYCH, V19, P133; Hoskyn M, 2000, SCHOOL PSYCHOL REV, V29, P102; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1088, DOI 10.1001/archpsyc.56.12.1088; Jimenez JE, 2003, J LEARN DISABIL-US, V36, P34, DOI 10.1177/00222194030360010501; Kaufman A.S., 1994, INTELLIGENT TESTING; Kay JB, 1999, J CLIN EXP NEUROPSYC, V21, P186, DOI 10.1076/jcen.21.2.186.927; Keith TZ, 1997, SCHOOL PSYCHOL QUART, V12, P89, DOI 10.1037/h0088950; KRAMER JH, 1993, PSYCHOL ASSESSMENT, V5, P193; LANE SE, 1994, J PSYCHOEDUC ASSESS, V12, P142, DOI 10.1177/073428299401200204; *LEARN DIS ROUNDT, 2002, SPEC LEARN DIS FIND; MacArthur CA, 1996, J LEARN DISABIL, V29, P344, DOI 10.1177/002221949602900403; MacArthur CA, 2000, TOP LANG DISORD, V20, P85, DOI 10.1097/00011363-200020040-00008; Mayes S., 1998, J ATTEN DISORD, V2, P217, DOI DOI 10.1177/108705479800200402; Mayes SD, 1998, PSYCHOL SCHOOLS, V35, P309; Mayes SD, 2000, J LEARN DISABIL-US, V33, P417, DOI 10.1177/002221940003300502; Mayes SD, 2003, J AUTISM DEV DISORD, V33, P329, DOI 10.1023/A:1024462719081; MAYES SD, 2003, ANN M AM PSYCH ASS S; McBurnett K, 2001, J ABNORM CHILD PSYCH, V29, P207, DOI 10.1023/A:1010377530749; MCDERMOTT PA, 1990, J PSYCHOEDUC ASSESS, V8, P290, DOI 10.1177/073428299000800307; McNaughton D., 1997, LEARNING DISABILITIE, V12, P16; Mealer C, 1996, J ATTEN DISORD, V1, P133, DOI DOI 10.1177/108705479600100302; Naglieri JA, 2003, J PSYCHOEDUC ASSESS, V21, P32, DOI 10.1177/073428290302100103; NEWBY RF, 1993, J PSYCHOEDUC ASSESS, P87; Nyden A, 2001, DEV MED CHILD NEUROL, V43, P165, DOI 10.1017/S0012162201000329; Oh HJ, 1999, J PSYCHOEDUC ASSESS, V17, P362, DOI 10.1177/073428299901700406; PRIFITERA A, 1993, J PSYCHOEDUC ASSESS, P43; Prifitera A., 1998, WISC 3 CLIN USE INTE, P1, DOI DOI 10.1016/B978-012564930-8/50002-4; Raskind WH, 2001, LEARN DISABILITY Q, V24, P141, DOI 10.2307/1511240; Saklofske D. H., 1995, CANADIAN J SCH PSYCH, V10, P167, DOI [10.1177/082957359501000210, DOI 10.1177/082957359501000210]; Sattler JM, 2002, ASSESSMENT CHILDREN; SAWYER RJ, 1992, J EDUC PSYCHOL, V84, P340, DOI 10.1037/0022-0663.84.3.340; SCHWEAN VL, 1993, J PSYCHOEDUC ASSESS, P56; SEIDMAN LJ, 1995, J AM ACAD CHILD PSY, V34, P1015, DOI 10.1097/00004583-199508000-00011; Snow JB, 2000, PSYCHOL REP, V87, P759, DOI 10.2466/PR0.87.7.759-765; Tannock R., 2000, ATTENTION DEFICIT DI; TRAMONTANA MG, 1990, J AM ACAD CHILD PSY, V29, P265, DOI 10.1097/00004583-199003000-00016; Vaughn S, 2000, EXCEPT CHILDREN, V67, P99; Ward TJ, 1999, SCHOOL PSYCHOL REV, V28, P629; Wechsler D, 2003, WISC 4 TECHNICAL INT; Wechsler D, 1992, MANUAL WECHLSER INDI; Wechsler D., 1991, WECHSLER INTELLIGENC	66	117	122	0	50	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0033-3085	1520-6807		PSYCHOL SCHOOLS	Psychol. Schools	APR	2005	42	4					333	343		10.1002/pits.20067			11	Psychology, Educational	Psychology	912BT	WOS:000228052800001					2021-06-18	
J	Holbrook, TL; Hoyt, DB; Coimbra, R; Potenza, B; Sise, M; Anderson, JP				Holbrook, TL; Hoyt, DB; Coimbra, R; Potenza, B; Sise, M; Anderson, JP			Long-term posttraumatic stress disorder persists after major trauma in adolescents: New data on risk factors and functional outcome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 29-OCT 02, 2004	Maui, HI	Amer Assoc Surg Trauma			QUALITY-OF-LIFE; MOTOR-VEHICLE ACCIDENTS; RECOVERY PROJECT; MULTIPLE TRAUMA; GENERAL HEALTH; INJURY; IMPACT; CHILDREN; GENDER; WOMEN	Background: Little is known about long-term psychological outcomes after major trauma in adolescents, a leading cause of death and preventable morbidity in this age group. A prospective epidemiologic study was conducted to examine quality of life (QoL) and posttramnatic stress disorder (PTSD) outcomes in injured adolescents. The specific objectives of the present report are to describe long-term PTSD and to identify risk factors for long-term PTSD and the impact of PTSD on QoL. Methods: Between April 26, 1999, and November 13, 2002, 401 eligible trauma patients aged 12 to 19 years triaged to five participating trauma center hospitals in a regionalized trauma system were enrolled in the study. The admission criteria for patients were as follows: age 12 to 19 years and injury diagnoses excluding severe traumatic brain injury or spinal cord injury. PTSD was diagnosed with the Impact of Events Scale-Revised; scores of 24+ were used to diagnose PTSD. QoL after trauma was measured using the Quality of Well-Being scale, a sensitive and well-validated functional index (range: 0 = death to 1.000 = optimum functioning). Patient outcomes were assessed at discharge and at 3, 6, 12, 18, and 24 months after discharge. Results: The rate of long-term PTSD was 27%, with high rates over the follow-up period. Risk factors for long-term PTSD were perceived threat to life (odds ratio [OR], 2.2; p < 0.001.); death of a family member at the scene (OR, 4.7; p < 0.001); no control over injury event (OR, 1.7; p < 0.05), and violence-related injury (OR, 2.2; p < 0.05). PTSD in adolescents was significantly and strongly associated with female gender, older age, low socioeconomic status, drug and alcohol abuse, and other adolescent behavioral problems. Long-term PTSD was also associated with marked and significant QoL deficits throughout the 24-month follow-up interval. Conclusion: High rates of long-term PTSD persist after major trauma in adolescents. Injury events such as perceived threat to life and control over the event are strongly associated with PTSD risk. Prolonged PTSD severely impacts QoL outcomes. Early identification and treatment of risk factors for long-term PTSD will be important to improve outcomes in injured adolescents.	Univ Calif San Diego, Med Ctr, Dept Family & Prevent Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Surg, Div Trauma, San Diego, CA 92103 USA; Mercy Hosp, Ctr Trauma, San Diego, CA USA	Holbrook, TL (corresponding author), Univ Calif San Diego, Med Ctr, Dept Family & Prevent Med, 8896,200 W Arbor Dr, San Diego, CA 92103 USA.	tholbrook@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851	AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01 HS 07611] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS007611] Funding Source: NIH RePORTER		ANDERSON JP, 1986, MED CARE, V24, P454, DOI 10.1097/00005650-198605000-00008; ANDERSON JP, 1988, J CLIN EPIDEMIOL, V41, P127, DOI 10.1016/0895-4356(88)90087-X; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BLANCHARD EB, 1995, BEHAV RES THER, V33, P529, DOI 10.1016/0005-7967(94)00079-Y; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Brown ES, 2000, COMPR PSYCHIAT, V41, P19, DOI 10.1016/S0010-440X(00)90126-3; Bryant RA, 1996, J TRAUMA STRESS, V9, P223, DOI 10.1002/jts.2490090206; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; Caffo E, 2003, CHILD ADOL PSYCH CL, V12, P493, DOI 10.1016/S1056-4993(03)00004-X; Chaffin M, 2001, CHILD ABUSE NEGLECT, V25, P401, DOI 10.1016/S0145-2134(00)00257-X; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; GREEN BL, 1991, J AM ACAD CHILD PSY, V30, P945, DOI 10.1097/00004583-199111000-00012; Holbrook TL, 2002, J TRAUMA, V53, P882, DOI 10.1097/00005373-200211000-00012; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holbrook TL, 2001, J TRAUMA, V50, P91, DOI 10.1097/00005373-200101000-00016; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; KAPLAN J, 2001, WORKINT PREVENT CONT; KAPLAN RM, 1984, J CHRON DIS, V37, P85, DOI 10.1016/0021-9681(84)90050-X; KAPLAN RM, 1988, J CONSULT CLIN PSYCH, V56, P1; Kaplan RM, 1982, HEALTH PSYCHOL, V1, P61, DOI DOI 10.1037/0278-6133.1.1.61; KAPLAN RM, 1978, P AM STAT ASSOC, P704; LANDSMAN IS, 1990, J BEHAV MED, V13, P561, DOI 10.1007/BF00844735; MacKenzie EJ, 1996, J TRAUMA, V41, P799, DOI 10.1097/00005373-199611000-00006; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Michaels AJ, 1998, J TRAUMA, V44, P644, DOI 10.1097/00005373-199804000-00013; Michaels AJ, 1999, J TRAUMA, V47, P867, DOI 10.1097/00005373-199911000-00009; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; Ott R, 1996, UNFALLCHIRURG, V99, P267; PYNOOS RS, 1993, BRIT J PSYCHIAT, V163, P239, DOI 10.1192/bjp.163.2.239; Richmond TS, 1998, J TRAUMA, V44, P635, DOI 10.1097/00005373-199804000-00012; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES; Seekamp A, 1996, INJURY, V27, P133, DOI 10.1016/0020-1383(95)00178-6; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; Winston FK, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e90	41	117	119	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2005	58	4					764	769		10.1097/01.TA.0000159247.48547.7D			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	919VS	WOS:000228646300029	15824653				2021-06-18	
J	Anderson, VA; Morse, SA; Catroppa, C; Haritou, F; Rosenfeld, JV				Anderson, VA; Morse, SA; Catroppa, C; Haritou, F; Rosenfeld, JV			Thirty month outcome from early childhood head injury: a prospective analysis of neurobehavioural recovery	BRAIN			English	Article						traumatic brain injury; children; IQ; language; memory	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; CRANIAL IRRADIATION; FOLLOW-UP; AGE; PREDICTORS; SEVERITY; ADOLESCENTS; SEQUELAE; SKILLS	Traumatic brain injury (TBI) is a common cause of acquired disability during childhood. While much is now known about outcome following TBI in the school-aged population, recovery in infants and young children is less well documented. The aim of this study was to examine neurobehavioural function following TBI during early childhood, to plot recovery over the 30 months post-injury and to identify predictors of outcome. The study compared three groups of children, sustaining injuries of different severity (mild = 14, moderate = 46, severe = 24), aged 2.0-6.11 years at injury, with a healthy control group (n = 33). The groups were similar with respect to pre-injury adaptive and behavioural function, psychosocial characteristics, age and gender. Using a prospective, longitudinal design, intellectual, language and memory functions were investigated acutely post-injury and again at 12 and 30 months post-injury. Results suggested a strong association between injury severity across all neurobehavioural domains. Further, 30 month outcome was predicted by multiple factors including injury severity, socio-economic status, pre-injury adaptive abilities and age, with pre-injury child behaviour and specific lesion characteristics playing surprisingly little role. In conclusion, children with more severe injuries, lower pre-injury adaptive abilities and lower socio-economic status are at greatest risk of long-term neurobehavioural impairment, even several years post-injury.	Univ Melbourne, Melbourne, Vic, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Alfred Hosp, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia	Anderson, VA (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Rosenfeld, Jeffrey V/B-7249-2011				AMACHER AL, 1988, PEDIAT HEAD INJURIES; ANDERSON V, 1994, ARCH DIS CHILD, V70, P476, DOI 10.1136/adc.70.6.476; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V., 1995, NEUROPSYCHOLOGICAL A; ANDERSON V, 2004, IN PRESS J NEUROL NE; ANDERSON V, 2001, DEV NEUROPSYCHOLOY C; Anderson V., 1988, BRAIN IMPAIRMENT, P223; ANDERSON V, 2000, PED REHABIL, V3, P159; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson VA, 2000, BRIT J CANCER, V82, P255; Aram DM, 1986, DEV NEUROPSYCHOL, V2, P155, DOI 10.1080/87565648609540339; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BAYLEY N, 1969, BAYLYS SCALES INFANT; BEGALI V, 1992, HEAD INJURY CHILDREN; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BRESLAU N, 1990, ARCH GEN PSYCHIAT, V47, P15; CARROWWOOLFOLK E, 1985, EXAMINERS MANUAL TES; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Christensen AL, 1979, LURIAS NEUROPSYCHOLO; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 1996, J NEURO-ONCOL, V29, P91, DOI 10.1007/BF00165522; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1985, J CLIN EXP NEUROPSYC, V7, P526, DOI 10.1080/01688638508401283; DENNIS M, 1980, BRAIN LANG, V10, P287, DOI 10.1016/0093-934X(80)90058-9; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Dunn L., 1981, PEABODY PICTURE VOCA; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; FINGER S, 1982, BRAIN DAMAGE RECOVER; FLETCHER EJ, 1995, RECEPTOR CHANNEL, V3, P21; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GARDNER MF, 1979, MANUAL EXPRESSIVE ON; Gronwall D, 1997, J INT NEUROPSYCH SOC, V6, P592; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Kraus J., 1995, TRAUMATIC HEAD INJUR, P117; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LACHAR D, 1992, PERSONALITY INVENT S; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; LARSON CP, 1988, AM J DIS CHILD, V142, P1052, DOI 10.1001/archpedi.1988.02150100046023; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVINE MA, 1988, PHYS SCRIPTA, VT22, P157, DOI 10.1088/0031-8949/1988/T22/024; LHERMITTE J, 1972, REV NEUROL, V74, P20; McCarthy D., 1972, MANUAL MCCARTHY SCAL; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; NOLLER P, 1988, UNPUB ICPS FAMILY FU; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RENFREW C, 1995, RENFREW BUS STORY MA; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SMITH A, 1983, J CONSULT CLIN PSYCH, V51, P768, DOI 10.1037/0022-006X.51.5.768; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TAYLOR HG, 1993, J CLIN CHILD PSYCHOL, V22, P196, DOI 10.1207/s15374424jccp2202_6; TEASDALE G, 1974, LANCET, V2, P81; TEUBER H, 1962, Dev Med Child Neurol, V4, P3; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Todd JA, 1996, NEUROPSYCHOL REHABIL, V6, P81, DOI 10.1080/713755500; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; WECHSLER D, 1991, MANUAL WECHSLER SCAL, V3; Wechsler D, 1989, MANUAL PRESCHOOL PRI; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	92	117	119	0	21	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	DEC	2004	127		12				2608	2620		10.1093/brain/awh320			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	874PE	WOS:000225361500007	15537678	Bronze			2021-06-18	
J	Cernak, I; Vink, R; Zapple, DN; Cruz, MI; Ahmed, F; Chang, T; Fricke, ST; Faden, AI				Cernak, I; Vink, R; Zapple, DN; Cruz, MI; Ahmed, F; Chang, T; Fricke, ST; Faden, AI			The pathobiology of moderate diffuse traumatic brain injury as identified using a new experimental model of injury in rats	NEUROBIOLOGY OF DISEASE			English	Article						diffuse traumatic brain injury; rat; model; manganese-enhanced magnetic resonance	CLOSED-HEAD-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; INTRACELLULAR FREE MAGNESIUM; CONTROLLED CORTICAL IMPACT; AXONAL INJURY; COGNITIVE IMPAIRMENT; CA CHANNELS; TIME-COURSE; LONG-TERM; EDEMA	Experimental models of traumatic brain injury have been developed to replicate selected aspects of human head injury, such as contusion, concussion, and/or diffuse axonal injury. Although diffuse axonal injury is a major feature of clinical head injury, relatively few experimental models of diffuse traumatic brain injury (TBI) have been developed, particularly in smaller animals such as rodents. Here, we describe the pathophysiological consequences of moderate diffuse TBI in rats generated by a newly developed, highly controlled, and reproducible model. This model of TBI caused brain edema beginning 20 min after injury and peaking at 24 h post-trauma, as shown by wet weight/dry weight ratios and diffusion-weighted magnetic resonance imaging. Increased permeability of the blood-brain barrier was present up to 4 h post-injury as evaluated using Evans blue dye. Phosphorus magnetic resonance spectroscopy showed significant declines in brain-free magnesium concentration and reduced cytosolic phosphorylation potential at 4 h post-injury. Diffuse axonal damage was demonstrated using manganese-enhanced magnetic resonance imaging, and intracerebral injection of a fluorescent vital dye (Fluoro-Ruby) at 24-h and 7-day post-injury. Morphological evidence of apoptosis and caspase-3 activation were also found in the cerebral hemisphere and brainstent at 24 h after trauma. These results show that this model is capable of reproducing major biochemical and neurological changes of diffuse clinical TBI. (C) 2004 Elsevier Inc. All rights reserved.	Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA; Univ Adelaide, Dept Pathol, Adelaide, SA, Australia; Georgetown Univ, Off Informat Serv, Adv Res Comp, Washington, DC 20057 USA; Childrens Hosp, Dept Pediat Neurol, Washington, DC USA	Cernak, I (corresponding author), Georgetown Univ, Dept Neurosci, 3970 Reservoir Rd NW,Res Bldg,Room EP04, Washington, DC 20057 USA.	ifc@georgetown.edu	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012; Cernak, Ibolja/A-6399-2008	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Chang, Taeun/0000-0002-1797-8449; Ibolja, Cernak/0000-0003-3214-698X			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Aoki I, 2003, MAGNET RESON MED, V50, P7, DOI 10.1002/mrm.10528; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BECKMAN DL, 1970, J APPL PHYSIOL, V29, P631; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; De Mulder G, 2000, ACT NEUR S, V76, P409; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goldsmith W, 2001, CRIT REV BIOMED ENG, V29, P441, DOI 10.1615/CritRevBiomedEng.v29.i56.10; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Hall E.D., 1995, CENTRAL NERVOUS SYST, P213; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KITA H, 1994, ACTA NEUROCHIR, P452; KLATZO I, 1987, Z KARDIOL, V76, P67; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Li FH, 1996, DRUG TODAY, V32, P615; Lighthall J.W., 1994, NEUROBIOLOGY CENTRAL, P3; Lin YJ, 1997, MAGN RESON MED, V38, P378, DOI 10.1002/mrm.1910380305; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Mahoney EJ, 2003, J TRAUMA, V55, P1065, DOI 10.1097/01.TA.0000100381.89107.93; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morita H, 2002, NEUROSCI LETT, V326, P101, DOI 10.1016/S0304-3940(02)00330-0; NARITA K, 1990, BRAIN RES, V510, P289, DOI 10.1016/0006-8993(90)91379-U; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; Piper IR, 1996, J NEUROSCI METH, V69, P171, DOI 10.1016/S0165-0270(96)00046-5; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; ROZSA L, 1989, NEUROSURG REV, V12, P133, DOI 10.1007/BF01741486; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHIBUYA I, 1993, CELL CALCIUM, V14, P33, DOI 10.1016/0143-4160(93)90016-Y; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Tannock GW, 1992, LACTIC ACID BACTERIA, P21; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teasdale GM, 1999, ACT NEUR S, V73, P111; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; Vink R, 1996, J NEUROCHEM, V66, P2477; Vink R, 2002, EXPERT OPIN INV DRUG, V11, P1375, DOI 10.1517/13543784.11.10.1375; Vink R, 1997, J CEREBR BLOOD F MET, V17, P50, DOI 10.1097/00004647-199701000-00007; VINK R, 2003, ENCY NEUROSCIENCE; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan XQ, 1991, J NEUROTRAUM, V8, P219, DOI 10.1089/neu.1991.8.219; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	78	117	130	1	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	OCT	2004	17	1					29	43		10.1016/j.nbd.2004.05.011			15	Neurosciences	Neurosciences & Neurology	855AC	WOS:000223944200004	15350963				2021-06-18	
J	Ewing-Cobbs, L; Prasad, MR; Landry, SH; Kramer, L; DeLeon, R				Ewing-Cobbs, L; Prasad, MR; Landry, SH; Kramer, L; DeLeon, R			Executive functions following traumatic brain injury in young children: A preliminary analysis	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; ATTENTION DEFICIT/HYPERACTIVITY DISORDER; WORKING-MEMORY; INHIBITORY CONTROL; FRONTAL-LOBE; INDIVIDUAL-DIFFERENCES; HUMAN INFANTS; AGE; CHILDHOOD; SEVERITY	To examine executive processes in young children with traumatic brain injury (TBI), we evaluated performance of 44 children who sustained moderate-to-severe TBI prior to age 6 and to 39 comparison children on delayed response (DR), stationary boxes, and spatial reversal (SR) tasks. The tasks have different requirements for holding mental representations in working memory (WM) over a delay, inhibiting prepotent responses, and shifting response set. Age at the time of testing was divided into 10- to 35- and 36- to 85-month ranges. In relation to the community comparison group, children with moderate-to-severe TBI scored significantly lower on indexes of WM/inhibitory control (IC) on DR and stationary boxes tasks. On the latter task, the Age x Group interaction indicated that performance efficiency was significantly reduced in the older children with TBI relative to the older comparison group; performance was similar in younger children irrespective of injury status. The TBI and comparison groups did not differ on the SR task, suggesting that shifting response set was not significantly altered by TBI. In both the TBI and comparison groups, performance improved with age on the DR and stationary boxes tasks. Age at testing was not significantly related to scores on the SR task. The rate of acquisition of working memory (WM) and IC increases steeply during preschool years, but the abilities involved in shifting response set show less increase across age groups (Espy, Kaufmann, Glisky, 2001; Luciana & Nelson, 1998). The findings of our study are consistent with the rapid development hypothesis, which predicts that skills in a rapid stage of development will be vulnerable to disruption by brain injury.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX 77030 USA; Univ Houston, Dept Psychol, Houston, TX USA	Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,Suite 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 29462] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER		ADAMS KM, 1985, J CLIN EXP NEUROPSYC, V7, P445, DOI 10.1080/01688638508401276; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Baddeley A. D., 1986, WORKING MEMORY; Barkley R. A., 1997, ADHD NATURE SELF CON; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bayley N., 2006, BAYLEY SCALES INFANT; BJORKLUND DF, 1990, DEV REV, V10, P48, DOI 10.1016/0273-2297(90)90004-N; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Breslau N, 2001, AM J EPIDEMIOL, V154, P711, DOI 10.1093/aje/154.8.711; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Bryan J, 2001, J CLIN EXP NEUROPSYC, V23, P608, DOI 10.1076/jcen.23.5.608.1250; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; CHAPPELL JE, 1995, IEEE AERO EL SYS MAG, V10, P5; Chiappe P, 2000, MEM COGNITION, V28, P8, DOI 10.3758/BF03211570; Chugani HT, 1998, PREV MED, V27, P184, DOI 10.1006/pmed.1998.0274; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins P, 1998, J COGNITIVE NEUROSCI, V10, P332, DOI 10.1162/089892998562771; Constantinidis C, 2002, NAT NEUROSCI, V5, P175, DOI 10.1038/nn799; DEMPSTER FN, 1991, INTELLIGENCE, V15, P157, DOI 10.1016/0160-2896(91)90028-C; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DENNIS M, 1988, MASTER LECT SERIES C, P89; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DIAMOND A, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P339; DIAMOND A, 1990, P637; Diamond A, 2001, DEV COGN NEUROSCI, P433; DIAMOND A, 1989, EXP BRAIN RES, V74, P24; DIAMOND A, 1997, MONOGRAPHS SOC RES C, V62; Espy KA, 1999, DEV NEUROPSYCHOL, V15, P447, DOI 10.1080/87565649909540761; Espy KA, 1999, BRAIN COGNITION, V41, P178, DOI 10.1006/brcg.1999.1117; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; GATHERCOLE SE, 1990, BRIT J PSYCHOL, V81, P439, DOI 10.1111/j.2044-8295.1990.tb02371.x; GEARY DC, 1993, PSYCHOL BULL, V114, P345, DOI 10.1037/0033-2909.114.2.345; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.1111/j.1467-8624.1987.tb01404.x; Griffith EM, 1999, CHILD DEV, V70, P817, DOI 10.1111/1467-8624.00059; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; HUTTENLOCHER PR, 1997, DEV PREFRONTAL CORTE, P69; Jacobsen CF, 1935, ARCH NEURO PSYCHIATR, V33, P558, DOI 10.1001/archneurpsyc.1935.02250150108009; KAUFMANN PM, 1990, J CLIN EXP NEUROPSYC, V12, P69; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Konrad KN, 2000, BRAIN INJURY, V14, P859; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levy R, 2000, EXP BRAIN RES, V133, P23, DOI 10.1007/s002210000397; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marzocchi GM, 2002, DEV NEUROPSYCHOL, V21, P73, DOI 10.1207/S15326942DN2101_4; Matsuzawa J, 2001, CEREB CORTEX, V11, P335, DOI 10.1093/cercor/11.4.335; MCEVOY RE, 1993, J CHILD PSYCHOL PSYC, V34, P563, DOI 10.1111/j.1469-7610.1993.tb01036.x; Mishkin M., 1964, FRONTAL GRANULAR COR; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyake A, 2001, J EXP PSYCHOL GEN, V130, P163, DOI 10.1037//0096-3445.130.2.163; Ozonoff S, 2001, J AUTISM DEV DISORD, V31, P257, DOI 10.1023/A:1010794902139; PENNINGTON BF, 1994, MAC FDN MEN, P243; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; PRASAD M, 2002, PEDIAT NEUROSURGERY, V36, P4; Roberts RJ, 1996, DEV NEUROPSYCHOL, V12, P105, DOI 10.1080/87565649609540642; RONCADIN C, 2002, THESIS YORK U TORONT; Savoy, 1998, SOC NEUR ABSTR, V24, P1251; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Swanson HL, 1996, J EXP CHILD PSYCHOL, V63, P358, DOI 10.1006/jecp.1996.0054; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; THORNDIKE RL, 1986, STANFORDBINET INTELL; Turkstra LS, 1998, J SPEECH LANG HEAR R, V41, P137, DOI 10.1044/jslhr.4101.137; Webb SJ, 2001, DEV NEUROPSYCHOL, V19, P147, DOI 10.1207/S15326942DN1902_2; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Zacks R. T., 1998, PSYCHOL LEARN MOTIV, P193	81	117	118	0	15	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	26	1					487	512		10.1207/s15326942dn2601_7			26	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	844BO	WOS:000223132300007	15276906				2021-06-18	
J	Zemper, ED				Zemper, ED			Two-year prospective study of relative risk of a second cerebral concussion	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						brain concussion; traumatic brain injury; relative risk; athletic injuries; football	TRAUMATIC BRAIN-INJURY; MANAGEMENT; SPORT	Objective: To prospectively measure the relative risk of cerebral concussion among those with a history of concussion compared with those having no previous concussions by using a population of high school and college football players. Design: A representative national sample of high school and college football players was followed for two football seasons over a 2-yr period (1997-1998) as part of a national football injury surveillance project. There were a total of 15,304 player-seasons and over 1 million athlete-exposures to the possibility of injury in practices and games; 975 of the player-seasons (6.4%) had a history of concussion in the previous 5 yr. Results: There were 572 concussions recorded, 161 among those with a history (16.5%) and 411 among those with no history (2.9%). Relative risk for individuals with a history of concussion is 5.8 times greater than for individuals with no history (95% confidence interval, 4.8-6.8). Conclusion: This large prospective cohort study indicates the risk of sustaining a cerebral concussion is nearly six times greater for individuals with a history of concussion than for individuals with no such history.	Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; Exercise Res Associates, Ann Arbor, MI USA	Zemper, ED (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 1500 E Med Ctr Dr,D4100 MPB, Ann Arbor, MI 48109 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; THOMPSON N, 1987, AM J SPORT MED, V15, P117, DOI 10.1177/036354658701500204; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; ZEMPER ED, 1994, AM SOC TEST MATER, V1229, P116, DOI 10.1520/STP12808S; ZEMPER ED, 1989, PHYSICIAN SPORTSMED, V17, P100, DOI 10.1080/00913847.1989.11709915; ZEMPER ED, 1990, SPORTS TRAIN MED REH, V1, P287; ZEMPER ED, 1993, PRIMARY CARE SPORTS, P63; ZEMPER ED, 1996, SAFETY AM FOOTBALL; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	24	117	121	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP	2003	82	9					653	659		10.1097/01.PHM.0000083666.74494.BA			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	714LT	WOS:000184916300001	12960905				2021-06-18	
J	Reinert, M; Barth, A; Rothen, HU; Schaller, B; Takala, J; Seiler, RW				Reinert, M; Barth, A; Rothen, HU; Schaller, B; Takala, J; Seiler, RW			Effects of cerebral perfusion pressure and increased fraction of inspired oxygen on brain tissue oxygen, lactate and glucose in patients with severe head injury	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; brain tissue oxygen; energy metabolites; hyperoxygenation	FREE-RADICAL PRODUCTION; FLUID-PERCUSSION INJURY; ENERGY-METABOLISM; EXTRACELLULAR POTASSIUM; HYPERBARIC-OXYGEN; GLUTAMATE RELEASE; BLOOD-FLOW; ISCHEMIA; TENSION; PO2	Objective. The purpose of the study was to measure the effects of increased inspired oxygen on patients suffering severe head injury and consequent influences on the correlations between CPP and brain tissue oxygen (PtiO2) and the effects on brain microdialysate glucose and lactate. Methods. In a prospective, observational study 20 patients suffering severe head injury (GCSless than or equal to8) were studied between January 2000 and December 2001. Each patient received an intraparenchymal ICP device and an oxygen sensor and, in 17 patients brain microdialysis was performed at the cortical-subcortical junction. A 6 h 100% oxygen challenge (FIO2 1.0) (Period A) was performed as early as possible in the first 24 hours after injury and compared with a similar 6 hour period following the challenge (Period B). Statistics were performed using the linear correlation analysis, one sample t-test, as well as the Lorentzian peak correlation analysis. Results. FIO2 was positively correlated with PtiO2 (p<0.0001) over the whole study period. PtiO2 was significantly higher (p<0.001) during Period A compared to Period B. CPP was positively correlated with PtiO2 (p<0.001) during the whole study. PtiO2 peaked at a CPP value of 78 mmHg performing a Lorentzian peak correlation analysis of all patients over the whole study. During Period A the brain microdialysate lactate was significantly lower (p=0.015) compared with Period B. However the brain microdialysate glucose remained unchanged. Conclusion. PtiO2 is significantly positively correlated with FIO2, meaning that PtiO2 can be improved by the simple manipulation of increasing FIO2 and ABGAO2. PtiO2 is positively correlated with CPP, peaking at a CPP value of 78 mmHg. Brain microdialysate lactate can be lowered by increasing PtiO2 values, as observed during the oxygen challenge, whereas microdialysate glucose is unchanged during this procedure. Extension of the oxygen challenge time and measurement of the intermediate energy metabolite pyruvate may clarify the metabolic effects of the intervention. Prospective comparative studies, including analysis of outcome on a larger multicenter basis, are necessary to assess the long term clinical benefits of this procedure.	Univ Bern, Inselspital, Dept Neurosurg, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Dept Intens Care Med, CH-3010 Bern, Switzerland	Reinert, M (corresponding author), Univ Bern, Inselspital, Dept Neurosurg, CH-3010 Bern, Switzerland.	michael.reinert@neurochirurgie-bern.ch	Reinert, Michael/AAA-3929-2019; Reinert, Michael/E-4964-2011; Rothen, Hans Ulrich/H-7100-2018	Reinert, Michael/0000-0002-0971-9543; Schaller, Benoit/0000-0002-6861-2340			AGARDH CD, 1991, INT J DEV NEUROSCI, V9, P127, DOI 10.1016/0736-5748(91)90003-5; BARBER RE, 1970, NEW ENGL J MED, V283, P1478, DOI 10.1056/NEJM197012312832702; Bardt TF, 1998, ACT NEUR S, V71, P153; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Bruzzone P, 1998, ACT NEUR S, V71, P111; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CAO W, 2002, NEUROSCI LETT, V26, P233; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Dings J, 1998, NEUROL RES, V20, pS71; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; HOELPER B, 2002, UNPUB; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kiening KL, 1998, ACT NEUR S, V71, P172; LEVASSEUR J, 1998, J NEUROTRAUM, V15, P879; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; MAAS A, 1993, INTRACRANIAL PRESSUR, V8; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; MAGISTRETTI PJ, 1993, DEV NEUROSCI-BASEL, V15, P306, DOI 10.1159/000111349; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARSHALL LF, 1995, J NEUROTRAUM, V12, P929, DOI 10.1089/neu.1995.12.929; Menzel M, 1998, ACT NEUR S, V71, P183; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MINK RB, 1995, CRIT CARE MED, V23, P1398, DOI 10.1097/00003246-199508000-00014; Morimoto T, 1996, J CEREBR BLOOD F MET, V16, P92, DOI 10.1097/00004647-199601000-00011; Muizelaar JP, 1996, NEUROTRAUMA, P553; Murakami N, 2001, CRIT CARE MED, V29, P814, DOI 10.1097/00003246-200104000-00027; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; QUINONESHINOJOS.A, 2001, J NEUROTRAUM, V18, P1137; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; ROCKSWOLD G, 1996, NEUROTRAUMA, P393; Rossi S, 1999, J NEUROSURG, V91, P1065; Rossi S, 2000, ACTA NEUROCHIR SUPPL, V76, P199; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Schneider GH, 1998, ACT NEUR S, V71, P62; Schousboe A, 1997, GLIA, V21, P99; Schurr A, 1999, J NEUROSCI, V19, P34; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SINGER MM, 2002, NEW ENGL J MED, V283, P1473; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 1998, ACT NEUR S, V71, P162; THOMPSON RF, 2000, EYEBLINK CLASSICAL C, V2, P17; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; VANDEWATER JM, 2002, NEW ENGL J MED, V283, P621; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	70	117	119	1	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		2003	145	5					341	350		10.1007/s00701-003-0027-0			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	691YG	WOS:000183633100002	12820040	Green Published			2021-06-18	
J	Mussack, T; Biberthaler, P; Kanz, KG; Wiedemann, E; Gippner-Steppert, C; Mutschler, W; Jochum, M				Mussack, T; Biberthaler, P; Kanz, KG; Wiedemann, E; Gippner-Steppert, C; Mutschler, W; Jochum, M			Serum S-100B and interleukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						serum markers; traumatic brain injury; cardiac arrest; resuscitation; cytokines; S-100 protein; interleukins	CARDIOPULMONARY-RESUSCITATION; CEREBROSPINAL-FLUID; REPERFUSION INJURY; HEAD TRAUMA; PROTEIN; DAMAGE; BLOOD; ISCHEMIA; RECOVERY; STROKE	Objective: To compare S-100B and interleukin-8 serum values on scene/at admission and 12 hrs later with respect to neurologic long-term outcome 12 months after cardiac arrest and return of spontaneous circulation; as well as after severe traumatic brain injury. Design: Prospective comparative cohort study. Setting: On scene; intensive care units of a university hospital. Patients: Twenty patients with out-of-hospital cardiac arrest. Twenty patients with severe traumatic brain injury. Interventions: Therapy was adjusted to the standards of modern prehospital and intensive care management by physicians who were not involved in the study. Measurements and Main Results: First median S-100B values of the cardiac arrest group (4.42 ng/mL) mounted as high as those of the traumatic brain injury group (4.11 ng/ml.). Within 12 hrs, S-100B levels significantly decreased to 0.75 ng/mL in cardiac arrest patients and to 0.68 ng/mL in traumatic brain injury patients but remained significantly elevated compared with the controls (0.04 ng/mL). Interleukin-8 levels of the cardiac arrest patients on scene (30.33 pg/mL) were clearly elevated above normal (12.60 pg/mQ and increased significantly to 101.40 pg/mL after 12 hrs. They showed no significant difference compared with those of the traumatic brain injury patients (78.75 pg/mL and 96.00 pg/mL, respectively). Multivariate Cox regression analysis in cardiac arrest patients identified only the S-100B level measured 12 hrs after study entry as an independent predictor for unfavorable neurologic outcome according to the Glasgow Outcome Scale score. In contrast, S-100B as well as interleukin-8 levels quantified 12 hrs after admission significantly predicted an unfavorable neurologic course in the traumatic brain injury group. Conclusions. Significantly elevated S-100B and interleukin-8 serum levels 12 hrs after cardiac arrest suggest that primary brain damage and systemic inflammatory response are comparably serious with that of traumatic brain injury. In both collectives, increased S-100B values measured 12 hrs after insult correlated well with an unfavorable neurologic outcome after 12 months.	Univ Munich, Chirurg Klin & Poliklin Innenstadt, Munich, Germany; Univ Munich, Klin Chem Abt, Munich, Germany; Univ Munich, Klin Biochem Innenstadt, Munich, Germany; Univ Munchen Klinikum, Munich, Germany	Mussack, T (corresponding author), Univ Munich, Chirurg Klin & Poliklin Innenstadt, Munich, Germany.						Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; BATES D, 1993, J NEUROL NEUROSUR PS, V56, P589, DOI 10.1136/jnnp.56.6.589; BEREK K, 1995, STROKE, V26, P543, DOI 10.1161/01.STR.26.4.543; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Ewy GA, 2000, NEW ENGL J MED, V342, P1599, DOI 10.1056/NEJM200005253422109; FUJIOKA M, 1994, STROKE, V25, P2091, DOI 10.1161/01.STR.25.10.2091; Gisvold SE, 1996, CRIT CARE MED, V24, pS69; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hammon JW, 2000, J THORAC CARDIOV SUR, V119, P130, DOI 10.1016/S0022-5223(00)70227-3; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Jean WC, 1998, NEUROSURGERY, V43, P1382, DOI 10.1097/00006123-199812000-00076; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Jorgensen EO, 1999, RESUSCITATION, V42, P173, DOI 10.1016/S0300-9572(99)00116-1; KIRSCH TD, 1999, EMERGENCY MED COMP S, P1631; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; METINKO AP, 1992, J CLIN INVEST, V90, P791, DOI 10.1172/JCI115953; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Mussack T, 2000, ACT NEUR S, V76, P393; Mussack T, 2001, WORLD J SURG, V25, P539, DOI 10.1007/s002680020082; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; OLSEN TS, 1986, BRAIN, V109, P393, DOI 10.1093/brain/109.3.393; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; Shaffner DH, 1999, CRIT CARE MED, V27, P1335, DOI 10.1097/00003246-199907000-00026; Shyu KG, 1997, AM HEART J, V134, P551, DOI 10.1016/S0002-8703(97)70094-2; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; STUMP DA, 1995, ANN THORAC SURG, V59, P1340, DOI 10.1016/0003-4975(95)00108-W; USUI A, 1989, CLIN CHEM, V35, P1942; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Westfal RE, 1996, AM J EMERG MED, V14, P364, DOI 10.1016/S0735-6757(96)90050-9; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Zhang WD, 1999, J NEUROIMMUNOL, V101, P148, DOI 10.1016/S0165-5728(99)00137-X	42	117	129	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2002	30	12					2669	2674		10.1097/00003246-200212000-00010			6	Critical Care Medicine	General & Internal Medicine	633AP	WOS:000180257300010	12483057				2021-06-18	
J	Bergsneider, M; Hovda, DA; McArthur, DL; Etchepare, M; Huang, SC; Sehati, N; Satz, P; Phelps, ME; Becker, DP				Bergsneider, M; Hovda, DA; McArthur, DL; Etchepare, M; Huang, SC; Sehati, N; Satz, P; Phelps, ME; Becker, DP			Metabolic recovery following human traumatic brain injury based on FDG-PET: Time course and relationship to neurological disability	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						diaschisis; Disability Rating Scale; Glasgow coma scale; head injury; positron emission tomography; single photon emission tomography (SPECT)	POSITRON EMISSION TOMOGRAPHY; CEREBRAL GLUCOSE-UTILIZATION; CLOSED-HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; BLOOD-FLOW; MILD; PERFUSION; CT; CONSCIOUSNESS	Objective: Utilizing [F-18]fluoroaeoxyglucose positron emission tomography (FDG-PET), we assessed the temporal pattern and the correlation of functional and metabolic recovery following human traumatic brain injury Design and Subjects: Fifty-four patients with injury severity ranging from mild to severe were studied. Thirteen of these patients underwent both an acute and delayed FDG-PET study Results: Analysis of the pooled global cerebral metabolic rate of glucose (CMRglc) values revealed that the intermediate metabolic reduction phase begins to resolve approximately one month following injury regardless of injury severity. The correlation, in the 13 patients studied twice, between the extent of change in neurologic disability, assessed by the Disability Rating Scale (DRS), and the change in CMRglc from the early to late period was modest (r = -0.42). Potential explanations for this rather poor correlation are discussed. A review of the pertinent literature regarding the use of PET and related imaging modalities, including single photon emission tomography (SPECT) for the assessment of patients following traumatic brain injury is given. Conclusion: The dynamic profile of CMRglc that changes following traumatic brain injury is seemingly stereotypic across a broad range and severity of injury types. Quantitative FDG-PET cannot be used as a surrogate technique for estimating degree of global functional recovery following traumatic brain injury.	Univ Calif Los Angeles, Harbor Med Ctr, Brain Res Inst, Div Neurosurg,Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Dept Surg, Div Neurosurg,Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Surg, Div Neurosci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA	Bergsneider, M (corresponding author), Univ Calif Los Angeles, Harbor Med Ctr, Brain Res Inst, Div Neurosurg,Dept Surg, Box 957039, Los Angeles, CA 90095 USA.	mbergsneider@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314			ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; Abu-Judeh HH, 1998, J NUCL MED, V39, P1357; Alavi A, 1997, J NUCL MED, V38, P1717; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; Alavi A, 1996, J NUCL MED, V37, P1170; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAY BG, 1992, J NUCL MED, V33, P52; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HERNANDEZ TD, 1994, BRAIN RES, V635, P300, DOI 10.1016/0006-8993(94)91451-6; HOVDA DA, 1996, NEUROTRAUMA, P1459; HUANG SC, 1980, AM J PHYSIOL, V238, pE69; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Imahori Y, 1999, NEUROREPORT, V10, P117; JACOBS A, 1994, J NUCL MED, V35, P942; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KOBAYASHI M, 1977, J NEUROCHEM, V29, P53, DOI 10.1111/j.1471-4159.1977.tb03923.x; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Lin KP, 1996, PHYS MED BIOL, V41, P2775, DOI 10.1088/0031-9155/41/12/014; Mattioli F, 1996, CORTEX, V32, P121, DOI 10.1016/S0010-9452(96)80021-9; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; POWELL MJD, 1964, COMPUT J, V7, P155, DOI 10.1093/comjnl/7.2.155; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; ROPER SN, 1991, J NUCL MED, V32, P1684; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TALAIRACH J, 1988, COPLANAR STEREOTAXIC, P84; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Umile EM, 1998, BRAIN INJURY, V12, P577; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; WORLEY G, 1995, DEV MED CHILD NEUROL, V37, P213; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	49	117	118	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2001	16	2					135	148		10.1097/00001199-200104000-00004			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	422HH	WOS:000168112100003	11275575				2021-06-18	
J	Palmer, S; Bader, MK; Qureshi, A; Palmer, J; Shaver, T; Borzatta, M; Stalcup, C				Palmer, S; Bader, MK; Qureshi, A; Palmer, J; Shaver, T; Borzatta, M; Stalcup, C			The impact on outcomes in a community hospital setting of using the AANS traumatic brain injury guidelines	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; intracranial pressure; neurotrauma; Sjo(2) monitoring	SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; CEREBRAL OXYGENATION; CLINICAL-TRIAL; MANAGEMENT; HYPERVENTILATION; VENTRICULOSTOMY; SATURATION; PROGRAM	Background: Traumatic brain injury poses a serious public health challenge, Treatment paradigms have dramatically shifted with the introduction of the American Association of Neurologic Surgeons (AANS) Guidelines for the Management of Severe Head Injury, Implementation of the AANS guidelines positively affects patient outcomes and can be successfully introduced in a community hospital setting. Methods: Data were collected both retrospectively and prospectively from the records of all trauma patients between 1994 and 1999, A cohort of 93 patients was selected. Thirty-seven patients were treated before the implementation of the AANS guidelines, and these were statistically compared with 56 patients treated after the implementation of the guidelines. Results: Implementation of the recommendations in the AANS guidelines in a standardized protocol resulted in a 9.13 times higher odds ratio of a good outcome relative to the odds of a poor outcome or death compared with a group managed before the practice change. A Glasgow Coma Scale (GCS) admission score > 8 was associated with a 6.58 times higher odds ratio of a good outcome compared with a GCS admission score less than or equal to 8, Odds ratio of a good outcome decreased by a factor of 0.92 for each year increase in age of patients starting at age 9, A dedicated neurotrauma team and comprehensive treatment algorithms are critical elements to this success. Hospital charges increased by more than $97,000 per patient, but are justifiable in the face of significantly improved outcomes. Conclusion: Implementation of a traumatic brain injury protocol in a community hospital setting is practical and efficacious. Appropriate invasive monitoring of systemic and cerebral parameters guides care decisions. The protocol results in an increase in resource usage, but it also results in statistically improved outcomes justifying the increase in expenditures.	Mission Hosp Reg Med Ctr, Mission Viejo, CA USA; Sisters St Joseph Orange Corp, St Joseph Hlth Syst, Orange, CA USA	Palmer, S (corresponding author), 26732 Crown Valley Pkwy,Suite 561, Mission Viejo, CA 92691 USA.						Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BADER MK, 1995, HEART LUNG, V24, P166, DOI 10.1016/S0147-9563(05)80012-3; Baethmann A, 1998, ACT NEUR S, V71, P107; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1995, GUIDELINES MANAGEMEN; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chestnut R. M., 1996, NEUROTRAUMA, P445; DeWitt D S, 1995, New Horiz, V3, P376; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Feldman Z, 1997, CRIT CARE CLIN, V13, P51, DOI 10.1016/S0749-0704(05)70296-7; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Kelly DF, 1996, NEUROTRAUMA, P71; KELLY DF, 1995, NEUROLOGICAL SURG; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; McKinely BA, 1999, J TRAUMA, V46, P271, DOI 10.1097/00005373-199902000-00013; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Prough DS, 1997, J TRAUMA, V42, pS10, DOI 10.1097/00005373-199705001-00003; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sikes P J, 1994, Crit Care Nurs Q, V17, P9; Simons R, 1999, J TRAUMA, V46, P811, DOI 10.1097/00005373-199905000-00008; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Woodman T, 1996, NEUROTRAUMA, P519; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	35	117	121	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2001	50	4					657	664		10.1097/00005373-200104000-00010			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	424QP	WOS:000168243200018	11303160				2021-06-18	
J	Matser, JT; Kessels, AGH; Lezak, MD; Troost, J				Matser, JT; Kessels, AGH; Lezak, MD; Troost, J			A dose-response relation of headers and concussions with cognitive impairment in professional soccer players	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							BRAIN; INJURY; SPORTS	The purpose of this study was to determine the effects of headers and concussions on cognitive impairment in professional soccer players. A group of 84 active professional soccer players from several premier league soccer clubs underwent neuropsychological evaluations. The dose-response relation between the number of headers in one professional season and the number of soccer-related concussions on cognitive functioning was investigated. It was found that the number of headers in one season was related to poorer results on tests measuring focused attention and visual / verbal memory. Soccer-related concussions were related to poorer results on tests measuring sustained attention and visuoperceptual processing. The findings suggest that headers as well as concussions separately contribute to cognitive impairment.	Erasmus Univ, Dept Anat, Rotterdam, Netherlands; Univ Hosp Maastricht, Res Unit Patient Care, Maastricht, Netherlands; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA; Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands	Matser, JT (corresponding author), St Anna Hosp, Dept Psychol Med, Postbus 90, NL-5660 AB Geldrop, Netherlands.						American Academy of Pediatrics, 1988, PHYSICIAN SPORTSMED, V16, P165; Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOUMA A, 1996, HDB NEUROPSYCHOLOGIS, P2; Deelman B, 1980, NEUROPSYCHOLOGIE NED; Golden C., 1978, STROOP COLOR WORD TE; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Keller D., 1979, LEISTUNGSSPORT, V9, P394; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Luteyn F, 1966, DUTCH J PSYCHOL, V2, P675; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Raven J., 1960, GUIDE STANDARD PROGR; SANFORD W, 1985, APPL LINEAR REGRESSI, P76; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Spreen O., 1991, COMPENDIUM NEUROPSYC; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Van De Loo L., 1956, TIJIKSCHRIFT PSYCHOL, V2, P33; VANDERVLUGT H, 1979, LATERALISATIES HERSE; VONSCHNEIDER PG, 1975, SPORTARTZ SPORTMEDIZ, V26, P222; Wechsler, 1981, WAIS R MANUAL; Wechsler D, 1974, WECHSLER MEMORY SCAL; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P104	31	117	118	0	22	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					770	774		10.1076/jcen.23.6.770.1029			5	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200006	11910543				2021-06-18	
J	Abdel-Dayem, HM; Abu-Judeh, H; Kumar, M; Atay, S; Naddaf, S; El-Zeftawy, H; Luo, JQ				Abdel-Dayem, HM; Abu-Judeh, H; Kumar, M; Atay, S; Naddaf, S; El-Zeftawy, H; Luo, JQ			SPECT brain perfusion abnormalities in mild or moderate traumatic brain injury	CLINICAL NUCLEAR MEDICINE			English	Article						SPECT brain perfusion imaging; Tc-99m ECD; Tc-99m HMPAO; traumatic brain injury	HM-PAO-SPECT; HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; CEREBRAL PERFUSION; CT; ATROPHY; ALWAYS	The purpose of this atlas is to present a review of the literature showing the advantages of SPECT brain perfusion imaging (BPI) in mild or moderate traumatic brain injury (TBI) over other morphologic imaging modalities such as x-ray CT or MRI. The authors also present the technical recommendations for SPECT brain perfusion currently practiced at their center. For the radiopharmaceutical of choice, a comparison between early and delayed images using Tc-99m HMPAO and Tc-99m ECD showed that Tc-99m HMPAO is more stable in the brain with no washout over time. Therefore, the authors feel that Tc-99m HMPAO is preferable to Tc-99m ECD. Recommendations regarding standardizing intravenous injection, the acquisition, processing parameters, and interpretation of scans using a ten grade color scale, and use of the cerebellum as the reference organ are presented. SPECT images of 228 patients (age range, 11 to 88; mean, 40.8 years) with mild or moderate TBI and no significant medical history that interfered with the results of the SPECT BP were reviewed. The etiology of the trauma was in the following order of frequency: motor vehicle accidents (45%) followed by blow to the head (36%) and a fall (19%). Frequency of the symptoms was headache (60.9%), memory problems (27.6%), dizziness (26.7%), and sleep disorders (8.7%). Comparison between patients imaged early (<3 months) Versus those imaged delayed (>3 months) from the time of the accident, showed that early imaging detected more lesions (4.2 abnormal lesions per study compared to 2.7 in those imaged more than 3 months after the accident). Of 41 patients who had mild traumatic injury without loss of consciousness and had normal CT, 28 studies were abnormal. Focal areas of hypoperfusion were seen in 77% (176 patients, 612 lesions) of the group of 228 patients. The sites of abnormalities were in the following order: basal ganglia and thalami, 55.2%, frontal lobes, 23.8%, temporal lobes, 13%, parietal, 3.7%, insular and occipital lobes together, 4.6%.	St Vincents Hosp & Med Ctr, Nucl Med Sect, Dept Radiol, New York, NY 10011 USA; New York Med Coll, Valhalla, NY 10595 USA; UNMD, Dept Radiol, Newark, NJ USA	Abdel-Dayem, HM (corresponding author), St Vincents Hosp & Med Ctr, Nucl Med Sect, Dept Radiol, 153 W 11th St, New York, NY 10011 USA.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; AbdelDayem HM, 1997, CLIN NUCL MED, V22, P310, DOI 10.1097/00003072-199705000-00007; ABDELDAYEM HM, 1997, J NUCL MED TECH, V25, P141; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Goncalves J M, 1992, Acta Neurochir Suppl (Wien), V55, P11; GRAY BG, 1992, J NUCL MED, V33, P52; ICHISE M, 1994, J NUCL MED, V35, P217; Ichise M, 1997, J NUCL MED, V38, P1253; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; KESTER N, 1993, BRAIN INJURY, V7, P469; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; MASDEU CJ, 1995, J NEUROIMAGING, V5, pS53; Masdeu J C, 1994, J Neuroimaging, V4, P177; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; *NIH, 1994, INT HEAD INJ TASK FO; PARKER R, 1995, J NEUROL ORTH MED S, V16, P118; Parker RS, 1996, NEUROPSYCHOL REV, V6, P135, DOI 10.1007/BF01874895; PARKER RS, 1995, J COGNITIVE REHABILI, V13, P14; PARKER RS, 1994, J NEUROL ORTH MED S, V15, P123; PRAYER L, 1993, ACTA RADIOL, V34, P593; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; SYED GMS, 1992, NUCL MED COMMUN, V13, P811, DOI 10.1097/00006231-199211000-00007; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29	33	117	121	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0363-9762	1536-0229		CLIN NUCL MED	Clin. Nucl. Med.	MAY	1998	23	5					309	317		10.1097/00003072-199805000-00009			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	ZK831	WOS:000073368100009	9596157				2021-06-18	
J	Grimm, MR; Vrahas, MS; Thomas, KA				Grimm, MR; Vrahas, MS; Thomas, KA			Pressure-volume characteristics of the intact and disrupted pelvic retroperitoneum	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	13th Annual Meeting of the Orthopaedic-Trauma-Association	OCT 17-19, 1997	LOUISVILLE, KY	Orthopaed Trauma Assoc			MULTIPLE TRAUMA; FRACTURES; HEMORRHAGE; MANAGEMENT; MORTALITY; RING; CLASSIFICATION; EMBOLIZATION; ANGIOGRAPHY; INJURIES	Hemorrhage is a major cause of mortality in pelvic fractures. Bleeding can be controlled in hypotensive patients by direct ligation, angiographic embolization, pelvic packing, and acute external fixation. Acute application of an external fixator can reduce pelvic volume and reduce bleeding fractures to effect tamponade. This therapy assumes that the pelvis represents a closed space, which clearly is not true anatomically. However, the premise may hold functionally. This study explored the relationship between pressure and volume in the intact and disrupted pelvic retroperitoneum. In cadaveric specimens, the external iliac vein was dissected, ruptured, and cannulated. This method allowed controlled pow of fluid, with simultaneous measurement of pressure, into the intact retroperitoneum. Open book pelvic fractures were created by applying external rotation to the pelvis through the femoral heads. The pressure-volume measurements, without and with external fixation applied, were repeated after the fracture, as well as after a laparotomy. In the intact retroperitoneum, pressures rapidly rose to an average of 30 mm Hg after infusion of 5 liters of fluid. After fracture, up to 20 liters of fluid could be infused at pressures not exceeding 35 mm Hg. External fixation increased pressures approximately 3 mm Hg at low fluid volumes, and approximately 11 mm Hg at the highest fluid volumes. Laparotomy decreased retroperitoneal pressure from approximately 35 mm Hg to approximately 15 mm Hg. The results of the study suggest that low-pressure venous hemorrhage may be tamponaded by an external fixator, given that enough fluid volume is present in the pelvic retroperitoneum. However, external fixation may not generate sufficient pressure to stop arterial bleeding. In any case, it seems that a large volume of fluid must be lost into the pelvis before an external fixator can have much effect on retroperitoneal pressures.	Louisiana State Univ, Med Ctr, Dept Orthopaed Surg, Bioengn Lab, New Orleans, LA 70112 USA	Thomas, KA (corresponding author), Louisiana State Univ, Med Ctr, Dept Orthopaed Surg, Bioengn Lab, 2025 Gravier St,Suite 400, New Orleans, LA 70112 USA.	kthoma@lsumc.edu					Berger J J, 1995, Surg Annu, V27, P107; BURGESS AR, 1990, J TRAUMA, V30, P848, DOI 10.1097/00005373-199007000-00015; DALAL SA, 1989, J TRAUMA, V29, P981, DOI 10.1097/00005373-198907000-00012; FAILINGER MS, 1992, J BONE JOINT SURG AM, V74A, P781, DOI 10.2106/00004623-199274050-00020; FLINT LM, 1979, ANN SURG, V189, P709, DOI 10.1097/00000658-197906000-00006; GANZ R, 1991, CLIN ORTHOP RELAT R, P71; GHANAYEM AJ, 1995, J TRAUMA, V38, P396, DOI 10.1097/00005373-199503000-00020; GILLILAND MG, 1982, AM J SURG, V144, P744, DOI 10.1016/0002-9610(82)90562-1; GRUEN GS, 1994, J TRAUMA, V36, P706, DOI 10.1097/00005373-199405000-00019; HANSON PB, 1991, J BONE JOINT SURG BR, V73, P325; HENAO F, 1985, SURG GYNECOL OBSTET, V161, P106; HUITTINEN VM, 1973, SURGERY, V73, P454; KELLAM JF, 1987, ORTHOP CLIN N AM, V18, P25; KELLAM JF, 1989, CLIN ORTHOP RELAT R, P66; MANSOUR MA, 1990, J TRAUMA, V30, P1417, DOI 10.1097/00005373-199011000-00021; MARGOLIES MN, 1972, NEW ENGL J MED, V287, P317, DOI 10.1056/NEJM197208172870701; MATTA JM, 1989, CLIN ORTHOP RELAT R, P83; MCMURTRY R, 1980, CLIN ORTHOP RELAT R, P22; MORENO C, 1986, J TRAUMA, V26, P987, DOI 10.1097/00005373-198611000-00005; MUCHA P, 1988, SURG CLIN N AM, V68, P757; PANETTA T, 1985, J TRAUMA, V25, P1021; PELTIER LF, 1965, J BONE JOINT SURG AM, VA 47, P1060, DOI 10.2106/00004623-196547050-00018; POOLE GV, 1991, ANN SURG, V213, P532, DOI 10.1097/00000658-199106000-00002; RIEMER BL, 1993, J TRAUMA, V35, P671, DOI 10.1097/00005373-199311000-00003; ROTHENBERGER DA, 1978, SURGERY, V84, P356; Rubash H E, 1983, Instr Course Lect, V32, P329; SELIVANOV V, 1984, J TRAUMA, V24, P1022, DOI 10.1097/00005373-198412000-00004; STOCK JR, 1980, CLIN ORTHOP RELAT R, P31; Tile M., 1995, FRACTURES PELVIS ACE	29	117	122	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1998	44	3					454	459		10.1097/00005373-199803000-00006			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	ZD780	WOS:000072723100005	9529171				2021-06-18	
J	Hicks, RR; Numan, S; Dhillon, HS; Prasad, MR; Seroogy, KB				Hicks, RR; Numan, S; Dhillon, HS; Prasad, MR; Seroogy, KB			Alterations in BDNF and NT-3 mRNAs in rat hippocampus after experimental brain trauma	MOLECULAR BRAIN RESEARCH			English	Article						traumatic brain injury; lateral fluid percussion; brain-derived neurotrophic factor; neurotrophin-3; hybridization, in situ; neuronal plasticity	NERVE GROWTH-FACTOR; NEUROTROPHIN-3 MESSENGER-RNAS; PHOSPHATIDYLINOSITOL BISPHOSPHATE; DOPAMINERGIC-NEURONS; KAINIC ACID; AMINO-ACIDS; INJURY; EXPRESSION; FOREBRAIN; VULNERABILITY	Previous studies have suggested that the neurotrophins brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) are neuroprotective or neurotrophic for certain subpopulations of hippocampal neurons following various brain insults. In the present study, the expression of BDNF and NT-3 mRNAs in rat hippocampus was examined after traumatic brain injury. Following lateral fluid percussion (FP) brain injury of moderate severity (2.0-2.1 atm) or sham injury, the hippocampi from adult rats were processed for the in situ hybridization localization of BDNF and NT-3 mRNAs using S-35-labeled cRNA. probes at post-injury survival times of 1, 3, 6, 24 and 72 h. Unilateral FP injury markedly increased hybridization for BDNF mRNA in the dentate gyrus bilaterally which peaked at 3 h and remained above control levels for up to 72 h post-injury. A moderate increase in BDNF mRNA expression was also observed bilaterally in the CA3 region of the hippocampus at 1, 3, and 6 h after FP injury, but expression declined to control levels by 24 h. Conversely, NT-3 mRNA was significantly decreased in the dentate gyrus following FP injury at the 6 and 24 h survival times. These results demonstrate that FP brain injury differentially modulates expression of BDNF and NT-3 mRNAs in the hippocampus, and suggest that neurotrophin plasticity is a functional response of hippocampal neurons to brain trauma. (C) 1997 Elsevier Science B.V.	UNIV KENTUCKY, DEPT ANAT & NEUROBIOL, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT CLIN SCI, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT SURG, LEXINGTON, KY 40536 USA					NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH010806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031816, R01NS035164, R55NS031816] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH10806] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35164, NS31816] Funding Source: Medline		BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GALL C, 1992, DENTATE GYRUS ITS RO, P171; GALL CM, 1992, MOL CELL NEUROSCI, V3, P56, DOI 10.1016/1044-7431(92)90009-Q; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1995, NEUROSCI LETT, V191, P121, DOI 10.1016/0304-3940(95)11561-X; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; ISACKSON PJ, 1995, CURR OPIN NEUROBIOL, V5, P350, DOI 10.1016/0959-4388(95)80048-4; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOKAIA Z, 1994, NEUROREPORT, V5, P1241, DOI 10.1097/00001756-199406020-00021; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Murray KD, 1996, NEUROSCIENCE, V70, P617, DOI 10.1016/S0306-4522(96)83002-8; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Padmaperuma B, 1996, BRAIN RES, V714, P19, DOI 10.1016/0006-8993(95)01579-5; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PRASAD MR, 1994, J NEUROCHEM, V63, P773; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RUDGE JS, 1995, J NEUROSCI, V15, P6856; SCHREIBER SS, 1995, TRENDS NEUROSCI, V18, P446, DOI 10.1016/0166-2236(95)94495-Q; Seroogy K., 1997, NEUROCHEMISTRY PRACT, P121; SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TSUKAHARA T, 1994, NEUROSURGERY, V34, P323, DOI 10.1227/00006123-199402000-00016; WETMORE C, 1994, J NEUROSCI, V14, P1688; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	48	117	121	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	SEP	1997	48	2					401	406		10.1016/S0169-328X(97)00158-7			6	Neurosciences	Neurosciences & Neurology	XV868	WOS:A1997XV86800023	9332737	Green Published			2021-06-18	
J	MCDONALD, S				MCDONALD, S			PRAGMATIC LANGUAGE-SKILLS AFTER CLOSED HEAD-INJURY - ABILITY TO MEET THE INFORMATIONAL NEEDS OF THE LISTENER	BRAIN AND LANGUAGE			English	Article							VERBAL IMPAIRMENT; DISCOURSE; APHASIA			MCDONALD, S (corresponding author), LIDCOMBE HOSP, DEPT NEUROPSYCHOL, JOSEPH ST, LIDCOMBE, NSW 2141, AUSTRALIA.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ARMSTRONG E, 1987, CLIN APHASIOLOGY, V17, P210; BRAUN CMJ, 1987, CLIN APHASIOLOGY, V17, P326; Cronbach L.J., 1972, DEPENDABILITY BEHAVI; DEANE A, 1987, THESIS MACQUARIE U S; Edgington E. S., 1980, RANDOMIZATION TESTS; FLAVELL JH, 1975, DEV ROLE TAKING COMM; Flood J., 1984, UNDERSTANDING READIN; Grice H.P., 1978, SYNTAX SEMANTICS, V9; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; Halliday MAK, 1985, LANGUAGE CONTEXT TEX; Hasan R, 1985, LANGUAGE CONTEXT TEX; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; HOLLAND AL, 1984, CLIN APHASIOLOGY, V14, P345; KERTESZ A, 1981, W APHASIA BATTERY; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milton S. B., 1984, CLIN APHASIOLOGY, V14, P114; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; ROLLINS J, 1987, LANGUAGE HEAD INJURY; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1988, SCAND J REHABIL MED, P55; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SNOW P, 1986, BRAIN IMPAIRMENT; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0; ULATOWSKA HK, 1983, BRAIN LANG, V19, P317, DOI 10.1016/0093-934X(83)90074-3; Walsh K. W., 1985, UNDERSTANDING BRAIN	32	117	121	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	JAN	1993	44	1					28	46		10.1006/brln.1993.1003			19	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	KK455	WOS:A1993KK45500003	8467376				2021-06-18	
J	MILLER, LP; LYETH, BG; JENKINS, LW; OLENIAK, L; PANCHISION, D; HAMM, RJ; PHILLIPS, LL; DIXON, CE; CLIFTON, GL; HAYES, RL				MILLER, LP; LYETH, BG; JENKINS, LW; OLENIAK, L; PANCHISION, D; HAMM, RJ; PHILLIPS, LL; DIXON, CE; CLIFTON, GL; HAYES, RL			EXCITATORY AMINO-ACID RECEPTOR SUBTYPE BINDING FOLLOWING TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article									VET ADM MED CTR,NEUROSCI LAB 151S,WASHINGTON,DC 20422; GEORGETOWN UNIV,SCH MED,DEPT PHARMACOL,WASHINGTON,DC; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,DEPT ANAT,RICHMOND,VA 23298				Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458, NS12587, NS19550] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, R01NS019550, R01NS021458, P01NS012587] Funding Source: NIH RePORTER		BECKER DP, 1989, J CEREB BLOOD FLO S1, V9, pS302; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAYES R, 1987, IEEE T SOFTWARE ENG, V13, P1254, DOI 10.1109/TSE.1987.232879; HAYES R L, 1988, Society for Neuroscience Abstracts, V14, P1153; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; HAYES RL, 1988, J NEUROTRAUM, V5, P287; Hayes RL, 1989, MILD HEAD INJURY, P54; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, IN PRESS NEUROTRAUMA, V4; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; JENKINS LW, 1989, MICHIGAN S SERIES TR, V1, P47; KATAYAMA Y, 1988, Society for Neuroscience Abstracts, V14, P1154; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH B G, 1987, Society for Neuroscience Abstracts, V13, P1253; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, IN PRESS BRAIN RES; McINTOSH T., 1988, NEUROL NEUR, P653; MENA EE, 1982, BRAIN RES, V243, P378, DOI 10.1016/0006-8993(82)90265-7; Miyazaki S, 1989, INTRACRANIAL PRESSUR, P651; MONAGHAN DT, 1985, BRAIN RES, V340, P378, DOI 10.1016/0006-8993(85)90936-9; MURPHY DE, 1987, NEUROCHEM RES, V12, P775, DOI 10.1007/BF00971514; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; WESTERBERG E, 1989, J NEUROSCI, V9, P798; WIELOCH T, 1989, J CEREB BLOOD FLO S1, V9, pS6	33	117	120	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 27	1990	526	1					103	107		10.1016/0006-8993(90)90254-9			5	Neurosciences	Neurosciences & Neurology	DZ703	WOS:A1990DZ70300013	1964103				2021-06-18	
J	Okonkwo, DO; Shutter, LA; Moore, C; Temkin, NR; Puccio, AM; Madden, CJ; Andaluz, N; Chesnut, RM; Bullock, MR; Grant, GA; McGregor, J; Weaver, M; Jallo, J; LeRoux, PD; Moberg, D; Barber, J; Lazaridis, C; Diaz-Arrastia, RR				Okonkwo, David O.; Shutter, Lori A.; Moore, Carol; Temkin, Nancy R.; Puccio, Ava M.; Madden, Christopher J.; Andaluz, Norberto; Chesnut, Randall M.; Bullock, M. Ross; Grant, Gerald A.; McGregor, John; Weaver, Michael; Jallo, Jack; LeRoux, Peter D.; Moberg, Dick; Barber, Jason; Lazaridis, Christos; Diaz-Arrastia, Ramon R.			Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase-II: A Phase II Randomized Trial	CRITICAL CARE MEDICINE			English	Article						brain oxygenation; hypoxia, intensive care unit monitoring; randomized clinical trial; traumatic brain injury	SEVERE HEAD-INJURY; TISSUE OXYGEN; PRESSURE; THERAPY; TENSION; HYPOXIA; SCALE	Objectives: A relationship between reduced brain tissue oxygenation and poor outcome following severe traumatic brain injury has been reported in observational studies. We designed a Phase II trial to assess whether a neurocritical care management protocol could improve brain tissue oxygenation levels in patients with severe traumatic brain injury and the feasibility of a Phase III efficacy study. Design: Randomized prospective clinical trial. Setting: Ten ICUs in the United States. Patients: One hundred nineteen severe traumatic brain injury patients. Interventions: Patients were randomized to treatment protocol based on intracranial pressure plus brain tissue oxygenation monitoring versus intracranial pressure monitoring alone. Brain tissue oxygenation data were recorded in the intracranial pressure-only group in blinded fashion. Tiered interventions in each arm were specified and impact on intracranial pressure and brain tissue oxygenation measured. Monitors were removed if values were normal for 48 hours consecutively, or after 5 days. Outcome was measured at 6 months using the Glasgow Outcome Scale Extended. Measurements and Main Results: A management protocol based on brain tissue oxygenation and intracranial pressure monitoring reduced the proportion of time with brain tissue hypoxia after severe traumatic brain injury (0.45 in intracranial pressure-only group and 0.16 in intracranial pressure plus brain tissue oxygenation group; p < 0.0001). Intracranial pressure control was similar in both groups. Safety and feasibility of the tiered treatment protocol were confirmed. There were no procedure-related complications. Treatment of secondary injury after severe traumatic brain injury based on brain tissue oxygenation and intracranial pressure values was consistent with reduced mortality and increased proportions of patients with good recovery compared with intracranial pressure-only management; however, the study was not powered for clinical efficacy. Conclusions: Management of severe traumatic brain injury informed by multimodal intracranial pressure and brain tissue oxygenation monitoring reduced brain tissue hypoxia with a trend toward lower mortality and more favorable outcomes than intracranial pressure-only treatment. A Phase III randomized trial to assess impact on neurologic outcome of intracranial pressure plus brain tissue oxygenation-directed treatment of severe traumatic brain injury is warranted.	[Okonkwo, David O.; Shutter, Lori A.; Puccio, Ava M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA; [Moore, Carol] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Temkin, Nancy R.; Chesnut, Randall M.; Barber, Jason] Univ Washington, Seattle, WA 98195 USA; [Madden, Christopher J.] UT Southwestern Med Ctr, Dallas, TX USA; [Andaluz, Norberto] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Bullock, M. Ross] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Grant, Gerald A.] Stanford Univ, Stanford, CA 94305 USA; [McGregor, John] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Weaver, Michael] Temple Univ, Philadelphia, PA 19122 USA; [Jallo, Jack] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [LeRoux, Peter D.] Lankenau Med Ctr, Wynnewood, PA USA; [Moberg, Dick] Moberg Res, Ambler, PA USA; [Lazaridis, Christos] Baylor St Lukes Med Ctr, Houston, TX USA; [Diaz-Arrastia, Ramon R.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA	Okonkwo, DO (corresponding author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.	okonkwodo@upmc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628; Jallo, Jack/0000-0002-5512-1729; Chesnut, Randall/0000-0001-6377-3666	National Institutes of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS061860]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Integra Life Sciences; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Integra Lifesciences; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061860] Funding Source: NIH RePORTER	Supported, in part, by the National Institutes of Neurological Disorders and Stroke (R01 NS061860).; Drs. Okonkwo, Shutter, Moore, Temkin, Puccio, Madden, Chesnut, McGregor, Weaver, LeRoux, and Diaz-Arrastia received support for article research from the National Institutes of Health (NIH). Dr. Okonkwo disclosed off-label product use of intracranial pressure monitors and brain tissue oxygenation monitors (Integra LifeSciences, Plainsboro, NJ). Dr. Shutter's institution received funding from the NIH; she received funding from legal firms for expert testimony on cases not related to this study; and she disclosed that her spouse was briefly an independent contractor for medical sales with Raumedic, who makes a medical device that measures brain tissue oxygen. The Raumedic device was not used in this study (total compensation was $3,500). Drs. Temkin's and Barber's institution received funding from the NIH/National Institute of Neurological Disorders and Stroke. Dr. Temkin disclosed that her salary through her institution comes primarily from grants and contracts with various U.S. federal agencies; and she received funding from various pharmaceutical companies and academic institutions (data and safety monitoring boards and statistical consulting) and from reviewing grants for various federal agencies and for nonprofits. Dr. Chesnut disclosed that he holds the Integra Endowed Professorship in Neurotrauma at the University of Washington, which was established in total, with no further contributions, prior to the origin of this work. Dr. Grant received funding from honorarium for talk about brain oxygen monitoring from Integra Life Sciences in 2016, 2 years after completion of Brain Oxygen Optimization in Severe TBI Phase-II trial. Dr. McGregor's institution received funding from the NIH. Dr. LeRoux's institution received funding from the NIH; he received other support from consulting for Integra and Codman; he receives research funding from Integra Lifesciences; and he is a consultant for Integra Lifesciences, Codman, Depuy-Synthes, and Neurologica and a member of the scientific advisory board of Cerebrotech and Edge Therapeutics. Mr. Moberg's institution received funding from the NIH; he disclosed that he is the founder, CEO, and shareholder of a company that provided data collection equipment and expertise for the project; and he has a proprietary interest in Moberg ICU Solutions, which manufactures the data collection device used in the study Dr. Diaz-Arrastia's institution received funding from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Artru F, 1998, NEUROL RES, V20, pS48; Bardt TF, 1998, ACT NEUR S, V71, P153; Bohman LE, 2011, NEUROCRIT CARE, V14, P361, DOI 10.1007/s12028-011-9526-7; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Centers for Disease and Control, 2016, INJ PREV CONTR TRAUM; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut R, 2014, NEUROCRIT CARE, V21, P64, DOI 10.1007/s12028-014-0048-y; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Le Roux P, 2014, NEUROCRIT CARE, V21, P297, DOI 10.1007/s12028-014-0081-x; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Nangunoori R, 2012, NEUROCRIT CARE, V17, P131, DOI 10.1007/s12028-011-9621-9; Pascual JL, 2011, J TRAUMA, V70, P535, DOI 10.1097/TA.0b013e31820b59de; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valadka AB, 1998, CRIT CARE MED; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Veenith TV, 2016, JAMA NEUROL, V73, P542, DOI 10.1001/jamaneurol.2016.0091; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	27	116	121	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2017	45	11					1907	1914		10.1097/CCM.0000000000002619			8	Critical Care Medicine	General & Internal Medicine	FO8BM	WOS:000417107000052	29028696	Green Accepted	Y	N	2021-06-18	
J	Nakka, VP; Prakash-babu, P; Vemuganti, R				Nakka, Venkata Prasuja; Prakash-babu, Phanithi; Vemuganti, Raghu			Crosstalk Between Endoplasmic Reticulum Stress, Oxidative Stress, and Autophagy: Potential Therapeutic Targets for Acute CNS Injuries	MOLECULAR NEUROBIOLOGY			English	Article						ER stress; Oxidative stress; Autophagy; Crosstalk; Acute CNS injury	UNFOLDED PROTEIN RESPONSE; TRANSIENT CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; INITIATION-FACTOR 2-ALPHA; CYTOCHROME-C BINDS; N-TERMINAL KINASE; ER STRESS; RAT MODEL; NADPH OXIDASE	Endoplasmic reticulum (ER) stress induces a variety of neuronal cell death pathways that play a critical role in the pathophysiology of stroke. ER stress occurs when unfolded/misfolded proteins accumulate and the folding capacity of ER chaperones exceeds the capacity of ER lumen to facilitate their disposal. As a consequence, a complex set of signaling pathways will be induced that transmit from ER to cytosol and nucleus to compensate damage and to restore the normal cellular homeostasis, collectively known as unfolded protein response (UPR). However, failure of UPR due to severe or prolonged stress leads to cell death. Following acute CNS injuries, chronic disturbances in protein folding and oxidative stress prolong ER stress leading to sustained ER dysfunction and neuronal cell death. While ER stress responses have been well studied after stroke, there is an emerging need to study the association of ER stress with other cell pathways that exacerbate neuronal death after an injury. In this review, we summarize the current understanding of the role for ER stress in acute brain injuries, highlighting the diverse molecular mechanisms associated with ER stress and its relation to oxidative stress and autophagy. We also discussed the existing and developing therapeutic options aimed to reduce ER stress to protect the CNS after acute injuries.	[Nakka, Venkata Prasuja; Vemuganti, Raghu] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53792 USA; [Nakka, Venkata Prasuja; Prakash-babu, Phanithi] Univ Hyderabad, Sch Life Sci, Dept Biotechnol & Bioinformat, Hyderabad 500134, Andhra Pradesh, India	Vemuganti, R (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53792 USA.	vemuganti@neurosurgery.wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS082957, R03NS083007] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03 NS083007, R21 NS082957] Funding Source: Medline		Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Aoyama K, 2005, J CEREBR BLOOD F MET, V25, P358, DOI 10.1038/sj.jcbfm.9600043; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Beresewicz M, 2006, NEUROCHEM INT, V48, P568, DOI 10.1016/j.neuint.2005.11.020; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Bertolotti A, 2000, NAT CELL BIOL, V2, P326; Bhandary B, 2013, INT J MOL SCI, V14, P434, DOI 10.3390/ijms14010434; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Boland Barry, 2006, Molecular Aspects of Medicine, V27, P503, DOI 10.1016/j.mam.2006.08.009; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Cherubini A, 2005, FREE RADICAL BIO MED, V39, P841, DOI 10.1016/j.freeradbiomed.2005.06.025; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Cooper LL, 2013, J PHYSIOL-LONDON, V591, P5895, DOI 10.1113/jphysiol.2013.260521; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; DeGracia DJ, 2002, J CEREBR BLOOD F MET, V22, P127, DOI 10.1097/00004647-200202000-00001; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188; Egawa N, 2011, J BIOL CHEM, V286, P7947, DOI 10.1074/jbc.M110.156430; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujita E, 2007, HUM MOL GENET, V16, P618, DOI 10.1093/hmg/ddm002; Gao B, 2013, ACTA PHARMACOL SIN, V34, P657, DOI 10.1038/aps.2013.34; Gao YQ, 2005, J CEREBR BLOOD F MET, V25, P694, DOI 10.1038/sj.jcbfm.9600062; Ghosh R, 2014, CELL, V158, P534, DOI 10.1016/j.cell.2014.07.002; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Gogvadze V, 2006, BBA-BIOENERGETICS, V1757, P639, DOI 10.1016/j.bbabio.2006.03.016; Gorman AM, 2012, PHARMACOL THERAPEUT, V134, P306, DOI 10.1016/j.pharmthera.2012.02.003; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Gotoh T, 2006, ARTERIOSCL THROM VAS, V26, P1439, DOI 10.1161/01.ATV.0000223900.67024.15; Gupta S, 2010, INT J CELL BIOL, V2010, DOI DOI 10.1155/2010/17021520169117; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hamanaka RB, 2005, MOL BIOL CELL, V16, P5493, DOI 10.1091/mbc.E05-03-0268; Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harraz MM, 2008, STROKE, V39, P286, DOI 10.1161/STROKEAHA.107.511857; Hayashi T, 2005, J CEREBR BLOOD F MET, V25, P41, DOI 10.1038/sj.jcbfm.9600005; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; He ZH, 2012, EXP NEUROL, V238, P218, DOI 10.1016/j.expneurol.2012.08.025; Hetz C, 2014, NAT REV NEUROSCI, V15, P233, DOI 10.1038/nrn3689; Hetz C, 2009, GENE DEV, V23, P2294, DOI 10.1101/gad.1830709; Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631; Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Hu BR, 2000, J NEUROSCI, V20, P3191, DOI 10.1523/JNEUROSCI.20-09-03191.2000; Iadecola C, 1997, J NEUROSCI, V17, P9157; Itoh T, 2009, NEUROTOX RES, V16, P378, DOI 10.1007/s12640-009-9081-6; Jacobson J, 2002, J CELL SCI, V115, P1175; Jing CH, 2012, NEUROSCIENCE, V213, P144, DOI 10.1016/j.neuroscience.2012.03.055; Kahles T, 2012, CELL MOL LIFE SCI, V69, P2345, DOI 10.1007/s00018-012-1011-8; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Klee M, 2009, EMBO J, V28, P1757, DOI 10.1038/emboj.2009.90; Kohno K, 1997, NEUROSCI LETT, V224, P17, DOI 10.1016/S0304-3940(97)13459-0; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Kolattukudy PE, 2012, CIRC RES, V110, P174, DOI 10.1161/CIRCRESAHA.111.243212; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015; Kregel KC, 2007, AM J PHYSIOL-REG I, V292, pR18, DOI 10.1152/ajpregu.00327.2006; Kudo T, 2008, CELL DEATH DIFFER, V15, P364, DOI 10.1038/sj.cdd.4402276; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Lange PS, 2008, J EXP MED, V205, P1227, DOI 10.1084/jem.20071460; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee HY, 2013, SCI REP-UK, V3, DOI 10.1038/srep03398; Lehotsky J, 2009, CELL MOL NEUROBIOL, V29, P917, DOI 10.1007/s10571-009-9376-4; Lerner AG, 2012, CELL METAB, V16, P250, DOI 10.1016/j.cmet.2012.07.007; Li G, 2010, J CELL BIOL, V191, P1113, DOI 10.1083/jcb.201006121; Li G, 2009, J CELL BIOL, V186, P783, DOI 10.1083/jcb.200904060; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Martinez JA, 2006, J PHYSIOL BIOCHEM, V62, P303, DOI 10.1007/BF03165759; Matsuyama D, 2014, SPINAL CORD, V52, P9, DOI 10.1038/sc.2013.118; Mengesdorf T, 2002, EXP NEUROL, V177, P538, DOI 10.1006/exnr.2002.8002; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Moro MA, 2005, FREE RADICAL BIO MED, V39, P1291, DOI 10.1016/j.freeradbiomed.2005.07.010; Mouw G, 2003, NEUROREPORT, V14, P183, DOI 10.1097/00001756-200302100-00004; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakka VP, 2014, J NEUROTRAUM, V31, pA107; Nakka VP, 2008, MOL NEUROBIOL, V37, P7, DOI 10.1007/s12035-007-8013-9; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Ness JM, 2006, BRAIN RES, V1099, P150, DOI 10.1016/j.brainres.2006.04.132; Niizuma K, 2009, STROKE, V40, P618, DOI 10.1161/STROKEAHA.108.524447; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ohri SS, 2011, GLIA, V59, P1489, DOI 10.1002/glia.21191; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Owen CR, 2005, J NEUROCHEM, V94, P1235, DOI 10.1111/j.1471-4159.2005.03276.x; Paschen W, 1998, MOL BRAIN RES, V60, P115, DOI 10.1016/S0169-328X(98)00180-6; Paschen W, 2003, J CEREBR BLOOD F MET, V23, P449, DOI 10.1097/01.WCB.0000054216.21675.AC; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Penas C, 2007, J NEUROCHEM, V102, P1242, DOI 10.1111/j.1471-4159.2007.04671.x; Perez-Pinzon MA, 1999, J CEREBR BLOOD F MET, V19, P39, DOI 10.1097/00004647-199901000-00004; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; Qi X, 2004, J PHARMACOL EXP THER, V311, P388, DOI 10.1124/jpet.104.069088; Rami A, 2008, AUTOPHAGY, V4, P422, DOI 10.4161/auto.5778; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rodrigues TMP, 2002, J CEREBR BLOOD F MET, V22, P463, DOI 10.1097/00004647-200204000-00010; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roussel BD, 2013, LANCET NEUROL, V12, P105, DOI 10.1016/S1474-4422(12)70238-7; Ruiz A, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.31; Ruiz A, 2009, CELL CALCIUM, V46, P273, DOI 10.1016/j.ceca.2009.08.005; Sanges D, 2006, APOPTOSIS, V11, P1629, DOI 10.1007/s10495-006-9006-2; Santos CXC, 2009, ANTIOXID REDOX SIGN, V11, P2409, DOI [10.1089/ars.2009.2625, 10.1089/ARS.2009.2625]; Satoh T, 2008, J NEUROCHEM, V104, P1116, DOI 10.1111/j.1471-4159.2007.05039.x; Schubert U, 2000, NATURE, V404, P770; Sekiguchi F, 2004, NEUROSCI LETT, V365, P111, DOI 10.1016/j.neulet.2004.04.069; Semenza GL, 2008, AUTOPHAGY, V4, P534, DOI 10.4161/auto.5956; Sheng R, 2010, AUTOPHAGY, V6, P482, DOI 10.4161/auto.6.4.11737; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shoichet Molly S., 2008, P221; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Srinivasan K, 2011, BEHAV BRAIN RES, V225, P110, DOI 10.1016/j.bbr.2011.07.004; Sugawara T, 1999, J NEUROSCI, V19, part. no.; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Tabas I, 2010, CIRC RES, V107, P839, DOI 10.1161/CIRCRESAHA.110.224766; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Terpolilli NA, 2012, J CEREBR BLOOD F MET, V32, P1332, DOI 10.1038/jcbfm.2012.12; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; UCHIKAWA O, 2008, Patent No. 2008016131; Upton JP, 2012, SCIENCE, V338, P818, DOI 10.1126/science.1226191; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vidal RL, 2012, HUM MOL GENET, V21, P2245, DOI 10.1093/hmg/dds040; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Vosler PS, 2009, STROKE, V40, P3149, DOI 10.1161/STROKEAHA.108.543769; Wei H, 2008, HUM MOL GENET, V17, P469, DOI 10.1093/hmg/ddm324; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Xilouri M, 2010, CNS NEUROL DISORD-DR, V9, P701, DOI 10.2174/187152710793237421; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yan F, 2014, NEUROSCI LETT, V563, P160, DOI 10.1016/j.neulet.2014.01.058; Yao CY, 2014, MOL MED REP, V9, P69, DOI 10.3892/mmr.2013.1778; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhang HY, 2014, MOL NEUROBIOL; Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005	161	116	124	1	64	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JAN	2016	53	1					532	544		10.1007/s12035-014-9029-6			13	Neurosciences	Neurosciences & Neurology	DB0CN	WOS:000368176300046	25482050	Green Accepted			2021-06-18	
J	Morgan, CD; Zuckerman, SL; Lee, YM; King, L; Beaird, S; Sills, AK; Solomon, GS				Morgan, Clinton D.; Zuckerman, Scott L.; Lee, Young M.; King, Lauren; Beaird, Susan; Sills, Allen K.; Solomon, Gary S.			Predictors of postconcussion syndrome after sports-related concussion in young athletes: a matched case-control study	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; sports; mild traumatic brain injury; ImPACT; postconcussion syndrome; trauma	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; COLLEGIATE FOOTBALL PLAYERS; EMERGENCY-DEPARTMENT; HIGH-SCHOOL; RECOVERY-TIME; POSTTRAUMATIC MIGRAINE; PERSISTENT SYMPTOMS; MISERABLE MINORITY; ETHNIC DISPARITIES	OBJECT Sport-related concussion (SRC) is a major public health problem. Approximately 90% of SRCs in high school athletes are transient; symptoms recover to baseline within 1 week. However, a small percentage, of patients remain symptomatic several months after injury, with a condition known as postconcussion syndrome (PCS). The authors aimed to identify risk factors for PCS development in a cohort of exclusively young athletes (9-18 years of age) who sustained SRCs while playing a sport. METHODS The authors conducted a retrospective case-control study by using the Vanderbilt Sports Concussion Clinic database. They identified 40 patients with PCS and matched them by age at injury and sex to SRC control patients (1 PCS to 2 control). PCS patients were those experiencing persistent symptoms at 3 months after an SRC. Control patients were those with documented resolution of symptoms within 3 weeks of an SRC. Data were collected in 4 categories: 1) demographic variables; 2) key medical, psychiatric, and family history; 3) acute-phase Postinjury symptoms (at 0-24 hours); and 4) subacute-phase postinjury features (at 0-3 weeks). The chi-square Fisher exact test was used to assess categorical variables, and the Mann-Whitney U-test was used to evaluate continuous variables. Forward step-wise regression models (P-in= 0.05, P-out=0.10) were used to identify variables associated with PCS. RESULTS PCS patients were more likely than control patients to have a concussion history (p = 0.010), premorbid mood disorders (p = 0.002), other psychiatric illness (p = 0.039), or significant life stressors (p = 0.036). Other factors that increased the likelihood of PCS development were a family history of mood disorders, other psychiatric illness, and migraine. Development of PCS was not predicted by race, insurance status, body mass index, sport, helmet use, medication use, and type of symptom endorsement. A final logistic regression analysis of candidate variables showed PCS to be predicted by a history of concussion (OR 1.8, 95% Cl 1.1-2.8, p = 0.016), preinjury mood disorders (OR 17.9, 95% CI 2.9-113.0, p = 0.002), family history of mood disorders (OR 3.1, 95% Cl 1.1-8.5, p = 0.026), and delayed symptom onset (OR 20.7, 95% Cl 3.2-132.0, p < 0.001). CONCLUSIONS In this age- and sex-matched case-control study of risk factors for PCS among youth with SRC, risk for development of PCS was higher in those with a personal and/or family history of mood disorders, other psychiatric illness, and migraine. These findings highlight the unique nature of SRC in youth. For this population, providers must recognize the value of establishing the baseline health and psychiatric status of children and their primary caregivers with regard to symptom reporting and recovery expectations. In addition, delayed symptom onset was an unexpected but strong risk factor for PCS in this cohort. Delayed symptoms could potentially result in late removal from play, rest, and care by qualified health care professionals. Taken together, these results may help practitioners identify young athletes with concussion who are at a greater danger for PCS and inform larger prospective studies for validation of risk factors from this cohort.	[Morgan, Clinton D.; Zuckerman, Scott L.; Lee, Young M.; Sills, Allen K.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37212 USA; [King, Lauren; Beaird, Susan] Vanderbilt Univ, Sch Med, Div Pediat Neurol, Nashville, TN 37212 USA	Zuckerman, SL (corresponding author), Vanderbilt Dept Neurol Surg, 1211 Med Ctr Dr,Med Ctr North T-4224, Nashville, TN 37212 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019	Morgan, Clinton/0000-0002-7511-0488	Rawlings	Support for this study came from an unrestricted educational grant from Rawlings. Dr. Solomon is a consultant for ImPACT, Nashville Predators, and Tennessee Titans.	Babcock L, 2013, PEDIATR EMERG CARE, V29, P458, DOI 10.1097/PEC.0b013e31828a202d; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Blume H, 2012, CURR OPIN PEDIATR, V24, P724, DOI 10.1097/MOP.0b013e328359e4cc; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Coker TR, 2009, ACAD PEDIATR, V9, P89, DOI 10.1016/j.acap.2008.11.007; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Flores G, 2008, PEDIATRICS, V121, pE286, DOI 10.1542/peds.2007-1243; Flores G, 2010, PEDIATRICS, V125, pE979, DOI 10.1542/peds.2010-0188; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Herring SA, 2011, MED SCI SPORTS EXERC, V43, P2412; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Meehan WP, AM J SPORTS MED, V38, P2405; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Moser Rosemarie Scolaro, 2012, Front Neurol, V3, P171, DOI 10.3389/fneur.2012.00171; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Smyth K, 2014, DEV MED CHILD NEUROL, V56, P73, DOI 10.1111/dmcn.12263; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Upchurch C., 2014, CLIN J SPORT MED; Wojcik SM, 2014, BRAIN INJURY, V28, P422, DOI 10.3109/02699052.2014.884241; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	70	116	116	0	50	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUN	2015	15	6					589	598		10.3171/2014.10.PEDS14356			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CI8OL	WOS:000355031500007	25745949	Bronze			2021-06-18	
J	Lee, YK; Hou, SW; Lee, CC; Hsu, CY; Huang, YS; Su, YC				Lee, Yi-Kung; Hou, Sheng-Wen; Lee, Ching-Chih; Hsu, Chen-Yang; Huang, Yung-Sung; Su, Yung-Cheng			Increased Risk of Dementia in Patients with Mild Traumatic Brain Injury: A Nationwide Cohort Study	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; PREVALENCE; ACCURACY	Background: It is known that the risk of dementia in patients with moderate to severe traumatic brain injury (TBI) is higher. However, the relationship between mild traumatic brain injury (mTBI) and dementia has never been established. Objectives: We investigated the incidences of dementia among patients with mTBI in Taiwan to evaluate if there is higher risk compared with general population. Methods: We utilized a sampled National Health Insurance (NHI) claims data containing one million beneficiaries. We followed all adult beneficiaries from January 1, 2005 till December 31, 2009 to see if they had been diagnosed with dementia. We further identify patients with mTBI and compared their risk of dementia with the general population. Results: We identified 28551 patients with mTBI and 692382 without. After controlled for age, gender, urbanization level, socioeconomic status, diabetes, hypertension, coronary artery disease, hyperlipidemia, history of alcohol intoxication, history of ischemic stroke, history of intracranial hemorrhage and Charlson Comorbidity Index Score, the adjusted hazard ratio is 3.26 (95% Confidence interval, 2.69-3.94). Conclusions: TBI is an independent significant risk factor of developing dementia even in the mild type.	[Lee, Yi-Kung; Su, Yung-Cheng] Buddhist Tzu Chi Dalin Gen Hosp, Emergency Dept, Chiayi, Taiwan; [Lee, Yi-Kung; Lee, Ching-Chih; Su, Yung-Cheng] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Hou, Sheng-Wen] Shin Kong Wu Ho Mem Hosp, Emergency Dept, Taipei, Taiwan; [Lee, Ching-Chih] Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan; [Lee, Ching-Chih] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; [Lee, Ching-Chih] Buddhist Dalin Tzu Chi Gen Hosp, Dept Otolaryngol, Chiayi, Taiwan; [Lee, Ching-Chih] Buddhist Dalin Tzu Chi Gen Hosp, Ctr Canc, Chiayi, Taiwan; [Hsu, Chen-Yang] Natl Taiwan Univ, Dept Publ Hlth, Taipei 10764, Taiwan; [Huang, Yung-Sung] Buddhist Dalin Tzu Chi Gen Hosp, Dept Internal Med, Div Neurol, Chiayi, Taiwan	Su, YC (corresponding author), Buddhist Tzu Chi Dalin Gen Hosp, Emergency Dept, Chiayi, Taiwan.	drsu119@gmail.com					American Psychiatric Association, 1994, AM PSYCHIAT ASS DIAG; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Corrada MM, 2008, NEUROLOGY, V71, P337, DOI 10.1212/01.wnl.0000310773.65918.cd; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Fuh J-L., 2008, TAIWAN GERIATR GERON, V3, P169; Hebert LE, 2004, NEUROLOGY, V62, P2021, DOI 10.1212/01.WNL.0000129258.93137.4B; Howards PP, 2012, AM J EPIDEMIOL, V176, P506, DOI 10.1093/aje/kws127; Jawaid A, 2009, NEURODEGENER DIS, V6, P219, DOI 10.1159/000258704; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kovacic JC, 2012, MT SINAI J MED, V79, P664, DOI 10.1002/msj.21347; Lee CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035923; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pouryamout L, 2012, DRUGS, V72, P789, DOI 10.2165/11631830-000000000-00000; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Sattler C, 2012, PSYCHIAT RES, V196, P90, DOI 10.1016/j.psychres.2011.11.012; Schmidt R, 2008, NEUROPSYCHIATRIE, V22, P1; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Shively S, 2012, ARCH NEUROL-CHICAGO, P1; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Tan ZS, 2003, ARCH INTERN MED, V163, P1053, DOI 10.1001/archinte.163.9.1053; Tang BL, 2009, CELL ADHES MIGR, V3, P118, DOI 10.4161/cam.3.1.7254; Xu WL, 2004, NEUROLOGY, V63, P1181, DOI 10.1212/01.WNL.0000140291.86406.D1	25	116	117	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2013	8	5							e62422	10.1371/journal.pone.0062422			7	Multidisciplinary Sciences	Science & Technology - Other Topics	147KY	WOS:000319167000044	23658727	DOAJ Gold, Green Published			2021-06-18	
J	Tremblay, S; De Beaumont, L; Henry, LC; Boulanger, Y; Evans, AC; Bourgouin, P; Poirier, J; Theoret, H; Lassonde, M				Tremblay, Sebastien; De Beaumont, Louis; Henry, Luke C.; Boulanger, Yvan; Evans, Alan C.; Bourgouin, Pierre; Poirier, Judes; Theoret, Hugo; Lassonde, Maryse			Sports Concussions and Aging: A Neuroimaging Investigation	CEREBRAL CORTEX			English	Article						aging; neuroimaging; sports concussion	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; MAGNETIC-RESONANCE-SPECTROSCOPY; ALZHEIMERS-DISEASE; FOOTBALL PLAYERS; WHITE-MATTER; LONG-TERM; H-1; ENCEPHALOPATHY; DECLINE	Recent epidemiological and experimental studies suggest a link between cognitive decline in late adulthood and sports concussions sustained in early adulthood. In order to provide the first in vivo neuroanatomical evidence of this relation, the present study probes the neuroimaging profile of former athletes with concussions in relation to cognition. Former athletes who sustained their last sports concussion >3 decades prior to testing were compared with those with no history of traumatic brain injury. Participants underwent quantitative neuroimaging (optimized voxel-based morphometry hippocampal volume, and cortical thickness), proton magnetic resonance spectroscopy (H-1 MRS; medial temporal lobes and prefrontal cortices), and neuropsychological testing, and they were genotyped for APOE polymorphisms. Relative to controls, former athletes with concussions exhibited: 1) Abnormal enlargement of the lateral ventricles, 2) cortical thinning in regions more vulnerable to the aging process, 3) various neurometabolic anomalies found across regions of interest, 4) episodic memory and verbal fluency decline. The cognitive deficits correlated with neuroimaging findings in concussed participants. This study unveiled brain anomalies in otherwise healthy former athletes with concussions and associated those manifestations to the long-term detrimental effects of sports concussion on cognitive function. Findings from this study highlight patterns of decline often associated with abnormal aging.	[Tremblay, Sebastien; Henry, Luke C.; Theoret, Hugo; Lassonde, Maryse] CHUM Hosp St Luc, Ctr Rech Neuropsychol & Cognit, Montreal, PQ, Canada; [De Beaumont, Louis] CHUM Hosp St Luc, Montreal Sacre Coeur Hosp Res Ctr, Montreal, PQ, Canada; [Boulanger, Yvan] CHUM Hosp St Luc, Dept Radiol, Montreal, PQ, Canada; [Bourgouin, Pierre] Univ Montreal, Dept Radiol, Montreal, PQ H3C 3J7, Canada; [Theoret, Hugo; Lassonde, Maryse] Univ Montreal, St Justine Hosp Res Ctr, Montreal, PQ H3C 3J7, Canada; [De Beaumont, Louis] Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ GA9 5H7, Canada; [Evans, Alan C.] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ, Canada; [Poirier, Judes] McGill Univ, Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada	Lassonde, M (corresponding author), Univ Montreal, Dept Psychol, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	maryse.lassonde@umontreal.ca	Evans, Alan C/B-2373-2013	Evans, Alan C/0000-0003-3841-6098; Tremblay, Sebastien/0000-0001-6251-9797; Theoret, Hugo/0000-0002-7458-8797	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Fonds de la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec; Canadian Foundation for InnovationCanada Foundation for Innovation; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; Canada Research Chair programCanada Research Chairs	This work was supported by the Canadian Institutes of Health Research, the Fonds de la Recherche en Sante du Quebec, the Canadian Foundation for Innovation, the Natural Sciences and Engineering Research Council of Canada, and the Canada Research Chair program. Conflict of Interest: none declared.	Allen J.S., 2005, NEUROBIOL AGING, V26, P79; Allen JS, 2005, NEUROBIOL AGING, V26, P1245, DOI 10.1016/j.neurobiolaging.2005.05.023; Barbeau E, 2004, NEUROLOGY, V62, P1317, DOI 10.1212/01.WNL.0000120548.24298.DB; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Chantal S, 2004, BRAIN RES, V1003, P26, DOI 10.1016/j.brainres.2003.11.074; Chao LL, 2010, NEUROBIOL AGING, V31, P368, DOI 10.1016/j.neurobiolaging.2008.05.004; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chou YY, 2010, NEUROBIOL AGING, V31, P1386, DOI 10.1016/j.neurobiolaging.2010.05.001; CHRISTIANSEN P, 1993, MAGN RESON IMAGING, V11, P107, DOI 10.1016/0730-725X(93)90418-D; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 2002, NEUROSURGERY, V51, P80; Comerchero MD, 1999, CLIN NEUROPHYSIOL, V110, P24, DOI 10.1016/S0168-5597(98)00033-1; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Fjell AM, 2009, CEREB CORTEX, V19, P2001, DOI 10.1093/cercor/bhn232; Fleisher AS, 2008, NEUROLOGY, V70, P191, DOI 10.1212/01.wnl.0000287091.57376.65; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fotenos AF, 2005, NEUROLOGY, V64, P1032, DOI 10.1212/01.WNL.0000154530.72969.11; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Giza CC, 2001, J ATHL TRAINING, V36, P228; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Haga KK, 2009, NEUROBIOL AGING, V30, P353, DOI 10.1016/j.neurobiolaging.2007.07.005; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Jack CR, 2005, NEUROLOGY, V65, P1227, DOI 10.1212/01.wnl.0000180958.22678.91; Kantarci K, 2007, NEUROBIOL AGING, V28, P1330, DOI 10.1016/j.neurobiolaging.2006.06.018; Kantarci K, 2008, ARCH NEUROL-CHICAGO, V65, P1621, DOI 10.1001/archneur.65.12.1621; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Klein J, 2000, J NEURAL TRANSM, V107, P1027, DOI 10.1007/s007020070051; Klunk WE, 1996, NEUROBIOL AGING, V17, P349, DOI 10.1016/0197-4580(96)00035-8; Kopp B, 2006, J COGNITIVE NEUROSCI, V18, P949, DOI 10.1162/jocn.2006.18.6.949; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Loewenstein DA, 2004, J INT NEUROPSYCH SOC, V10, P91; Lyttelton O, 2007, NEUROIMAGE, V34, P1535, DOI 10.1016/j.neuroimage.2006.10.041; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; Miller G, 2009, SCIENCE, V325, P670, DOI 10.1126/science.325_670; MONSCH AU, 1992, ARCH NEUROL-CHICAGO, V49, P1253, DOI 10.1001/archneur.1992.00530360051017; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Salmon DP, 2002, NEUROLOGY, V59, P1022, DOI 10.1212/WNL.59.7.1022; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Valenzuela MJ, 2001, NEUROLOGY, V56, P592, DOI 10.1212/WNL.56.5.592; Walhovd K.B., 2005, NEUROBIOL AGING, V26, P75; Walhovd KB, 2005, NEUROBIOL AGING, V26, P1261, DOI 10.1016/j.neurobiolaging.2005.05.020; Wang ZQ, 2009, ACTA RADIOL, V50, P312, DOI 10.1080/02841850802709219	76	116	116	0	58	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	MAY	2013	23	5					1159	1166		10.1093/cercor/bhs102			8	Neurosciences	Neurosciences & Neurology	133KO	WOS:000318137500015	22581847	Green Published, Bronze			2021-06-18	
J	Kaindl, AM; Degos, V; Peineau, S; Gouadon, E; Chhor, V; Loron, G; Le Charpentier, T; Josserand, J; Ali, C; Vivien, D; Collingridge, GL; Lombet, A; Issa, L; Rene, F; Loeffler, JP; Kavelaars, A; Verney, C; Mantz, J; Gressens, P				Kaindl, Angela M.; Degos, Vincent; Peineau, Stephane; Gouadon, Elodie; Chhor, Vibol; Loron, Gauthier; Le Charpentier, Tifenn; Josserand, Julien; Ali, Carine; Vivien, Denis; Collingridge, Graham L.; Lombet, Alain; Issa, Lina; Rene, Frederique; Loeffler, Jean-Philippe; Kavelaars, Annemieke; Verney, Catherine; Mantz, Jean; Gressens, Pierre			Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain	ANNALS OF NEUROLOGY			English	Article							PERIVENTRICULAR WHITE-MATTER; DATA-ACQUISITION PROGRAM; MEDIATED NEUROTOXICITY; EXCITOTOXIC LESIONS; GLUTAMATE UPTAKE; NMDA; EXPRESSION; CYTOKINES; INTERLEUKIN-1-BETA; NEUROPROTECTION	Objective: Activated microglia play a central role in the inflammatory and excitotoxic component of various acute and chronic neurological disorders. However, the mechanisms leading to their activation in the latter context are poorly understood, particularly the involvement of N-methyl-D-aspartate receptors (NMDARs), which are critical for excitotoxicity in neurons. We hypothesized that microglia express functional NMDARs and that their activation would trigger neuronal cell death in the brain by modulating inflammation. Methods and Results: We demonstrate that microglia express NMDARs in the murine and human central nervous system and that these receptors are functional in vitro. We show that NMDAR stimulation triggers microglia activation in vitro and secretion of factors that induce cell death of cortical neurons. These damaged neurons are further shown to activate microglial NMDARs and trigger a release of neurotoxic factors from microglia in vitro, indicating that microglia can signal back to neurons and possibly induce, aggravate, and/or maintain neurologic disease. Neuronal cell death was significantly reduced through pharmacological inhibition or genetically induced loss of function of the microglial NMDARs. We generated Nr1 LoxP(+/+) LysM Cre(+/-) mice lacking the NMDAR subunit NR1 in cells of the myeloid lineage. In this model, we further demonstrate that a loss of function of the essential NMDAR subunit NR1 protects from excitotoxic neuronal cell death in vivo and from traumatic brain injury. Interpretation: Our findings link inflammation and excitotoxicity in a potential vicious circle and indicate that an activation of the microglial NMDARs plays a pivotal role in neuronal cell death in the perinatal and adult brain. ANN NEUROL 2012;72:536549	[Kaindl, Angela M.; Degos, Vincent; Peineau, Stephane; Chhor, Vibol; Loron, Gauthier; Le Charpentier, Tifenn; Josserand, Julien; Verney, Catherine; Mantz, Jean; Gressens, Pierre] Hop Robert Debre, French Inst Hlth & Med Res, U676, F-75019 Paris, France; [Kaindl, Angela M.; Degos, Vincent; Peineau, Stephane; Chhor, Vibol; Loron, Gauthier; Le Charpentier, Tifenn; Josserand, Julien; Verney, Catherine; Mantz, Jean; Gressens, Pierre] Univ Paris 07, Denis Diderot Fac Med, Paris, France; [Kaindl, Angela M.; Degos, Vincent; Peineau, Stephane; Chhor, Vibol; Loron, Gauthier; Le Charpentier, Tifenn; Verney, Catherine; Mantz, Jean; Gressens, Pierre] PremUP, Paris, France; [Kaindl, Angela M.; Issa, Lina] Charite, Dept Pediat Neurol, D-13353 Berlin, Germany; [Kaindl, Angela M.; Lombet, Alain; Issa, Lina] Charite, Inst Neurobiol & Cell Biol, D-13353 Berlin, Germany; [Peineau, Stephane; Collingridge, Graham L.; Lombet, Alain] MRC, Ctr Synapt Plast, Dept Anat, Sch Med Sci, Bristol, Avon, England; [Gouadon, Elodie; Lombet, Alain] Natl Ctr Sci Res, UMR 8162, Le Plessis Robinson, France; [Gouadon, Elodie] Marie Lannelongue Hosp, Le Plessis Robinson, France; [Gouadon, Elodie] Univ Paris S, Le Plessis Robinson, France; [Ali, Carine; Vivien, Denis] French Inst Hlth & Med Res, U919, Caen, France; [Ali, Carine; Vivien, Denis] Natl Ctr Sci Res, Mixed Unit Res 6232, Caen, France; [Collingridge, Graham L.] Seoul Natl Univ, Dept Brain & Cognit Sci, Seoul, South Korea; [Rene, Frederique; Loeffler, Jean-Philippe] French Inst Hlth & Med Res, U692, Strasbourg, France; [Kavelaars, Annemieke] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Mantz, Jean] Publ Assistance Hosp Paris, Anesthesiol & Intens Care Serv, Paris, France; [Gressens, Pierre] Univ London Imperial Coll Sci Technol & Med, Ctr Developing Brain Inst Reprod & Dev Biol, London, England	Kaindl, AM (corresponding author), Charite, Inst Cell Biol & Neurobiol, Augustenburger Pl 1, D-13353 Berlin, Germany.	angela.kaindl@charite.de; pierre.gressens@inserm.fr	gressens, pierre/M-7557-2017; LOEFFLER, Jean-Philippe/AAS-4401-2020; Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020	gressens, pierre/0000-0002-0909-4221; Collingridge, Graham L/0000-0002-9572-5359; Ali, Carine/0000-0001-8007-7910; Kaindl, Angela/0000-0001-9454-206X; VIVIEN, DENIS/0000-0002-7636-2185; LORON, Gauthier/0000-0001-9536-9510; Peineau, Stephane/0000-0002-4721-6795	InsermInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission; Universite Paris 7; Leducq FoundationLeducq Foundation; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [LSHM-CT-2006-036534/neobrain]; PremUP; Institut pour la Recherche sur la Moelle epiniere et l'Encephale; Fondation des Gueules Cassees; Fondation Motrice; ELA Foundation; Fondation Grace de Monaco; Sonnenfeld Stiftung; German Research FoundationGerman Research Foundation (DFG) [SFB665]; Berliner Krebsgesellschaft e.V.; Societe Francaise d'Anesthesie Reanimation, MRC (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); APHP (Contrat d'Interface); EUEuropean Commission; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601841B, G0601813] Funding Source: researchfish	This work was supported by Inserm, Universite Paris 7, Leducq Foundation, Sixth Framework Program of the European Commission (contract No. LSHM-CT-2006-036534/neobrain), PremUP, Institut pour la Recherche sur la Moelle epiniere et l'Encephale, Fondation des Gueules Cassees, Fondation Motrice, ELA Foundation, Fondation Grace de Monaco, Sonnenfeld Stiftung, German Research Foundation (SFB665), Berliner Krebsgesellschaft e.V., Societe Francaise d'Anesthesie Reanimation, MRC (UK), and APHP (Contrat d'Interface to P.G.).; A.K.: employment, University Medical Center Utrecht; grants/grants pending, EU, NIH.	AGNATI LF, 1995, NEUROSCIENCE, V69, P711, DOI 10.1016/0306-4522(95)00308-6; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Anderson WW, 2007, J NEUROSCI METH, V162, P346, DOI 10.1016/j.jneumeth.2006.12.018; Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; Aronica E, 2005, J NEUROIMMUNOL, V160, P188, DOI 10.1016/j.jneuroim.2004.11.015; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boucsein C, 2003, EUR J NEUROSCI, V17, P2267, DOI 10.1046/j.1460-9568.2003.02663.x; Cacci E, 2005, J NEUROSCI RES, V80, P789, DOI 10.1002/jnr.20531; Cheret C, 2008, J NEUROSCI, V28, P12039, DOI 10.1523/JNEUROSCI.3568-08.2008; Chung S, 1998, NEUROSCI LETT, V249, P139, DOI 10.1016/S0304-3940(98)00409-1; Chung S, 1998, NEUROSCI LETT, V242, P73, DOI 10.1016/S0304-3940(98)00029-9; Dazy AC, 2003, TOXICOL IN VITRO, V17, P575, DOI 10.1016/S0887-2333(03)00092-4; Degos V, 2010, J NEURAL TRANSM, V117, P1009, DOI 10.1007/s00702-010-0411-x; Dommergues MA, 2000, ANN NEUROL, V47, P54, DOI 10.1002/1531-8249(200001)47:1<54::AID-ANA10>3.3.CO;2-P; Eriksson C, 2000, MOL BRAIN RES, V85, P103, DOI 10.1016/S0169-328X(00)00251-5; Farber K, 2005, BRAIN RES REV, V48, P133, DOI 10.1016/j.brainresrev.2004.12.003; Fontaine RH, 2008, CELL DEATH DIFFER, V15, P1542, DOI 10.1038/cdd.2008.79; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; GASPAR P, 1989, J COMP NEUROL, V279, P249, DOI 10.1002/cne.902790208; GEHRMANN J, 1992, J CEREBR BLOOD F MET, V12, P257, DOI 10.1038/jcbfm.1992.36; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gottlieb M, 1997, J CEREBR BLOOD F MET, V17, P290, DOI 10.1097/00004647-199703000-00006; Gressens P, 1997, J CLIN INVEST, V100, P390, DOI 10.1172/JCI119545; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hansen HS, 1997, J NEUROCHEM, V69, P753; Husson I, 2002, ANN NEUROL, V51, P82, DOI 10.1002/ana.10072; Kaindl AM, 2007, PROTEOM CLIN APPL, V1, P640, DOI 10.1002/prca.200600696; Kalia LV, 2006, EMBO J, V25, P4971, DOI 10.1038/sj.emboj.7601342; Kaur C, 2005, J PINEAL RES, V39, P294, DOI 10.1111/j.1600-079X.2005.00245.x; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Liang JF, 2010, BRAIN RES, V1322, P8, DOI 10.1016/j.brainres.2010.01.083; Liao SL, 2001, NEUROSCI LETT, V299, P113, DOI 10.1016/S0304-3940(01)01499-9; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; MARRET S, 1995, J NEUROPATH EXP NEUR, V54, P358, DOI 10.1097/00005072-199505000-00009; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; MILLIGAN CE, 1991, J COMP NEUROL, V314, P125, DOI 10.1002/cne.903140112; Moller T, 2000, BRAIN RES, V853, P49, DOI 10.1016/S0006-8993(99)02244-1; Monier A, 2007, J NEUROPATH EXP NEUR, V66, P372, DOI 10.1097/nen.0b013e3180517b46; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; Murugan M, 2011, GLIA, V59, P521, DOI 10.1002/glia.21121; Nair A, 2006, J NEUROIMMUNOL, V171, P72, DOI 10.1016/j.jneuroim.2005.09.012; Newcombe J, 2008, BRAIN PATHOL, V18, P52, DOI 10.1111/j.1750-3639.2007.00101.x; Newell EW, 2005, J PHYSIOL-LONDON, V567, P869, DOI 10.1113/jphysiol.2005.092056; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1989, J NEUROSCI, V9, P1701; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Salinska E, 2005, FOLIA NEUROPATHOL, V43, P322; Sharp FR, 2000, J CEREBR BLOOD F MET, V20, P1011, DOI 10.1097/00004647-200007000-00001; Tahraoui SL, 2001, BRAIN PATHOL, V11, P56; THERY C, 1991, EUR J NEUROSCI, V3, P1155, DOI 10.1111/j.1460-9568.1991.tb00050.x; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Tilleux S, 2007, J NEUROSCI RES, V85, P2059, DOI 10.1002/jnr.21325; Titomanlio L, 2011, STEM CELLS DEV, V20, P865, DOI 10.1089/scd.2010.0302; Tribouillard-Tanvier D, 2009, J VIROL, V83, P11244, DOI 10.1128/JVI.01413-09; Verney C, 2010, J ANAT, V217, P436, DOI 10.1111/j.1469-7580.2010.01245.x	60	116	120	2	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	OCT	2012	72	4					536	549		10.1002/ana.23626			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	030CG	WOS:000310544900011	23109148				2021-06-18	
J	Wilk, JE; Herrell, RK; Wynn, GH; Riviere, LA; Hoge, CW				Wilk, Joshua E.; Herrell, Richard K.; Wynn, Gary H.; Riviere, Lyndon A.; Hoge, Charles W.			Mild Traumatic Brain Injury (Concussion), Posttraumatic Stress Disorder, and Depression in US Soldiers Involved in Combat Deployments: Association With Postdeployment Symptoms	PSYCHOSOMATIC MEDICINE			English	Article						concussion; PTSD; depression; combat; deployment	POSTCONCUSSION-LIKE SYMPTOMS; MENTAL-HEALTH PROBLEMS; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; IRAQ; AFGHANISTAN; VETERANS; CARE; PREVALENCE; CRITERIA	Objectives: Several studies have examined the relationship between concussion/mild traumatic brain injury (mTBI), posttraumatic stress disorder (PTSD), depression, and postdeployment symptoms. These studies indicate that the multiple factors involved in postdeployment symptoms are not accounted for in the screening processes of the Department of Defense/Veteran's Affairs months after concussion injuries. This study examined the associations of single and multiple deployment-related mTBIs on postdeployment health. Methods: A total of 1502 U.S. Army soldiers were administered anonymous surveys 4 to 6 months after returning from deployment to Iraq or Afghanistan assessing history of deployment-related concussions, current PTSD, depression, and presence of postdeployment physical and neurocognitive symptoms. Results: Of these soldiers, 17% reported an mTBI during their previous deployment. Of these, 59% reported having more than one. After adjustment for PTSD, depression, and other factors, loss of consciousness was significantly associated with three postconcussive symptoms, including headaches (odds ratio [OR] = 1.5, 95% confidence interval [Cl] = 1.1-2.3). However, these symptoms were more strongly associated with PTSD and depression than with a history of mTBI. Multiple mTBIs with loss of consciousness increased the risk of headache (OR = 4.0, 95% CI = 2.4-6.8) compared with a single occurrence, although depression (OR = 4.2, 95% Cl = 2.6-6.8) remained as strong a predictor. Conclusions: These data indicate that current screening tools for mTBI being used by the Department of Defense/Veteran's Affairs do not optimally distinguish persistent postdeployment symptoms attributed to mTBI from other causes such as PTSD and depression. Accumulating evidence strongly supports the need for multidisciplinary collaborative care models of treatment in primary care to collectively address the full spectrum of postwar physical and neurocognitive health concerns.	[Wilk, Joshua E.] USA, Dept Mil Psychiat, Div Psychiat & Neurosci, Walter Reed Army Inst Res,Med Res & Mat Command, Silver Spring, MD 20910 USA	Wilk, JE (corresponding author), USA, Dept Mil Psychiat, Div Psychiat & Neurosci, Walter Reed Army Inst Res,Med Res & Mat Command, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	joshua.wilk@amedd.army.mil					[Anonymous], 2005, SPSS WIND COMP PROGR; [Anonymous], 2008, STATA COMP PROGR VER; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Bliese PD, 2005, ARMY MED RES UNIT EU; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Defense and Veterans Brain Injury Center, 2006, DEF VET BRAIN INJ CT; Department of Defence Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Department of Veterans Affairs Department of Defense, 2009, VA DOD CLIN GUID MAN; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Gaetz M, 2000, BRAIN INJURY, V14, P1077; *GOV ACC OFF, 2008, GAO08276; Government Accountability Office, 2008, GAO08615; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2008, MILD TRAUMATIC BRAIN; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ryan PB, 2011, BRAIN INJURY, V25, P1019, DOI 10.3109/02699052.2011.597044; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Southwick S., 2005, NEUROPSYCHOLOGY PTSD, P27; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F.W., 1993, 9 ANN C ISTSS SAN AN; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	51	116	117	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0033-3174	1534-7796		PSYCHOSOM MED	Psychosom. Med.	APR	2012	74	3					249	257		10.1097/PSY.0b013e318244c604			9	Psychiatry; Psychology; Psychology, Multidisciplinary	Psychiatry; Psychology	930JS	WOS:000303136300003	22366583				2021-06-18	
J	Maas, AIR; Menon, DK; Lingsma, HF; Pineda, JA; Sandel, ME; Manley, GT				Maas, Andrew I. R.; Menon, David K.; Lingsma, Hester F.; Pineda, Jose A.; Sandel, M. Elizabeth; Manley, Geoffrey T.			Re-Orientation of Clinical Research in Traumatic Brain Injury: Report of an International Workshop on Comparative Effectiveness Research	JOURNAL OF NEUROTRAUMA			English	Article						comparative effectiveness research; clinical research; clinical trials; methodology; systems biology; traumatic brain injury	SEVERE HEAD-INJURY; QUALITY-OF-LIFE; CEREBRAL PERFUSION-PRESSURE; INTENSIVE-CARE MANAGEMENT; PLACEBO-CONTROLLED TRIAL; COMMON DATA ELEMENTS; INTRACRANIAL-PRESSURE; SUBARACHNOID HEMORRHAGE; NEUROCRITICAL CARE; CONSORTIUM SURVEY	During the National Neurotrauma Symposium 2010, the DG Research of the European Commission and the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) organized a workshop on comparative effectiveness research (CER) in traumatic brain injury (TBI). This workshop reviewed existing approaches to improve outcomes of TBI patients. It had two main outcomes: First, it initiated a process of re-orientation of clinical research in TBI. Second, it provided ideas for a potential collaboration between the European Commission and the NIH/NINDS to stimulate research in TBI. Advances in provision of care for TBI patients have resulted from observational studies, guideline development, and meta-analyses of individual patient data. In contrast, randomized controlled trials have not led to any identifiable major advances. Rigorous protocols and tightly selected populations constrain generalizability. The workshop addressed additional research approaches, summarized the greatest unmet needs, and highlighted priorities for future research. The collection of high-quality clinical databases, associated with systems biology and CER, offers substantial opportunities. Systems biology aims to identify multiple factors contributing to a disease and addresses complex interactions. Effectiveness research aims to measure benefits and risks of systems of care and interventions in ordinary settings and broader populations. These approaches have great potential for TBI research. Although not new, they still need to be introduced to and accepted by TBI researchers as instruments for clinical research. As with therapeutic targets in individual patient management, so it is with research tools: one size does not fit all.	[Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Menon, David K.] Univ Cambridge, Cambridge, England; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Pineda, Jose A.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Pineda, Jose A.] Washington Univ, Sch Med, Dept Neurol, Div Crit Care Med, St Louis, MO 63110 USA; [Sandel, M. Elizabeth] Kaiser Fdn Rehabil Ctr, Vallejo, CA USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, San Francisco, CA USA	Maas, AIR (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Maas, Andrew IR/C-5584-2013; Pineda, Jose/W-2806-2019	Maas, Andrew IR/0000-0003-1612-1264; 	European CommissionEuropean CommissionEuropean Commission Joint Research Centre; National Institutes of Health/National Institute of Neurological Diseases and Stroke (NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986] Funding Source: researchfish	The workshop on CER was supported by the European Commission DG Research and the National Institutes of Health/National Institute of Neurological Diseases and Stroke (NIH/NINDS). We are grateful to Dr. Ramona Hicks (NIH/NINDS) and Dr. Patrizia Tosetti (DG Research, European Commission) for their insightful planning and coordination of the workshop. The authors of this manuscript were all speakers at the workshop. We wish to express our gratitude to Dr. Kenneth Curley, Dr. Alan Faden, and Prof. Nicole von Steinbuechel for contributing to the panel discussions. We are grateful to all attendees who participated in the workshop, many of whom traveled from afar specifically to attend the workshop, and for their contributions to the general discussions. Their input was essential in making this workshop a success. A particular word of thanks is due to Dr. Toril Skandsen (Trondheim, Norway), for providing her notes of the discussions, to Dr. Kenneth Curley for input in drafting the manuscript, to Eno Lavrysen for administrative support in preparing the manuscript, and to Sir Graham Teasdale for advice in editing the final version.	Aarabi Bizhan, 2001, Journal of Trauma Injury Infection and Critical Care, V51, pS1; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bischofs IB, 2009, P NATL ACAD SCI USA, V106, P6459, DOI 10.1073/pnas.0810878106; Black N, 1996, BRIT MED J, V312, P1215; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Carney NA, 2003, PEDIATR CRIT CARE ME, V4, P1; Carr BG, 2010, CURR OPIN PEDIATR, V22, P326, DOI 10.1097/MOP.0b013e3283392a48; Chen J, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-73; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Correspondence NEJM, 2009, NEW ENGL J MED, V361, P536; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; DeWitt D S, 1995, New Horiz, V3, P376; Dhruva SS, 2008, ARCH INTERN MED, V168, P136, DOI 10.1001/archinternmed.2007.56; Drummond MF, 2008, INT J TECHNOL ASSESS, V24, P244, DOI 10.1017/S0266462308080343; Edwards P, 2005, LANCET, V365, P1957; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Forsyth RJ, 2008, PEDIATR CRIT CARE ME, V9, P8, DOI 10.1097/01.PCC.0000298759.78616.3A; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Green AR, 2002, CLIN EXP PHARMACOL P, V29, P1030, DOI 10.1046/j.1440-1681.2002.03767.x; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoh NZ, 2010, J NEUROTRAUM, V27, P1413, DOI 10.1089/neu.2009.1256; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Institute of Medicine (IOM), 2009, IN NAT PRIOR COMP EF; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1980, J NEUROL NEUROSUR PS, V43, P289, DOI 10.1136/jnnp.43.4.289; JENNETT B, 1976, LANCET, V1, P1031; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kapapa T, 2010, J CHILD NEUROL, V25, P409, DOI 10.1177/0883073809340697; Kochanek PM, 2007, J NEUROTRAUM, V24, P1, DOI 10.1089/neu.2006.0209; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas Andrew I R, 2009, Crit Care, V13, P1016, DOI 10.1186/cc8163; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Natale JE, 2006, DEV NEUROSCI-BASEL, V28, P276, DOI 10.1159/000094154; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Parekh AK, 2010, JAMA-J AM MED ASSOC, V303, P1303, DOI 10.1001/jama.2010.381; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schweikhart SA, 2009, J INVEST MED, V57, P748, DOI 10.2310/JIM.0b013e3181b91b3a; Sears DD, 2009, P NATL ACAD SCI USA, V106, P18745, DOI 10.1073/pnas.0903032106; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Servadei F, 2000, NEUROSURGERY, V46, P70; Sox HC, 2010, CROAT MED J, V51, P191, DOI 10.3325/cmj.2010.51.191; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Spiro PA, 1997, P NATL ACAD SCI USA, V94, P7263, DOI 10.1073/pnas.94.14.7263; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Suarez JI, 2004, CRIT CARE MED, V32, P2311, DOI 10.1097/01.CCM.0000146132.29042.4c; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Tricoci P, 2009, JAMA-J AM MED ASSOC, V301, P831, DOI 10.1001/jama.2009.205; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; UK National Institute for Health and Clinical Excellence, 2003, HEAD INJ TRIAG ASS I, P4; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Walker PA, 2009, J TRAUMA, V67, pS120, DOI 10.1097/TA.0b013e3181ad323a; Wilde EA, 2010, J NEUROTRAUM, V27, P975, DOI 10.1089/neu.2009.1193; Winthrop AL, 2010, CURR OPIN PEDIATR, V22, P346, DOI 10.1097/MOP.0b013e3283394351; World Health Organization, 2009, GLOB STAT REP ROAD S	114	116	121	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					32	46		10.1089/neu.2010.1599			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300003	21545277	Green Published			2021-06-18	
J	Laker, SR				Laker, Scott R.			Epidemiology of Concussion and Mild Traumatic Brain Injury	PM&R			English	Article							EMERGENCY-DEPARTMENT VISITS; HIGH-SCHOOL SPORTS; UNITED-STATES; SEX-DIFFERENCES; SYMPTOMS; OUTCOMES; TRENDS; MECHANISM; IRAQ	Mild traumatic brain injury (mTBI) is a common public health concern that affects millions of people each year. The available epidemiology of mTBI may contain insights that can guide future identification, prevention, and treatment efforts. This article discusses epidemiology of both non sports-related mTBI and sports-related concussion. Specific occupational factors, emergency department data, and meta-analysis regarding mTBI are reviewed and discussed. With regard to sports concussion, the article will discuss data related to the sport played, the individual's position, level of play, and gender differences. Although males make up a larger percentage of cases than do females throughout the majority of reviewed non sports-related mTBI data, the sports literature indicates that rates are higher in women when similar sports are compared. Identifiable risk factors within sports include female gender, sport, and position played. Emerging trends across mTBI include increased incidence and decreased rate of hospitalization for mTBI. PM R 2011;3:S354-S358	Univ Colorado, Dept Phys Med & Rehabil, Aurora, CO 80045 USA	Laker, SR (corresponding author), Univ Colorado, Dept Phys Med & Rehabil, Mail Stop F493,12631 E 17th Ave,Room 2513, Aurora, CO 80045 USA.	scott.laker@ucdenver.edu					Adler RH, 2011, PM R, V3, pS472; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; [Anonymous], 2006, TRAUM BRAIN INJ US; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, TAK CONC OUT PLAY LE; Colantonio A, 2010, CAN J PUBLIC HEALTH, V101, pS58, DOI 10.1007/BF03403848; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Ivins BJ, 2010, NEUROREHABILITATION, V26, P199, DOI 10.3233/NRE-2010-0556; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; National Federation of State High School Associations, 2010, 2009 10 HIGH SCH ATH; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Shields BJ, 2006, PEDIATRICS, V117, P122, DOI 10.1542/peds.2005-1139; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wrona RM, 2006, J SAFETY RES, V37, P75, DOI 10.1016/j.jsr.2005.08.008	38	116	117	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2011	3	10		3			S354	S358		10.1016/j.pmrj.2011.07.017			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	966YK	WOS:000305873100002	22035677				2021-06-18	
J	Bazarian, JJ; Cernak, I; Noble-Haeusslein, L; Potolicchio, S; Temkin, N				Bazarian, Jeffrey J.; Cernak, Ibolja; Noble-Haeusslein, Linda; Potolicchio, Samuel; Temkin, Nancy			Long-term Neurologic Outcomes After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Alzheimer's disease; amyotrophic lateral sclerosis; dementia; dementia pugilistica; endocrine disorders; epilepsy; multiple sclerosis; ocular disorders; postconcussive symptoms; postconcussive syndrome; parkinsonism; Parkinson's disease; seizure; traumatic brain injury; visuomotor disorders	AMYOTROPHIC-LATERAL-SCLEROSIS; POST-CONCUSSION SYNDROME; QUALITY-OF-LIFE; HEAD-INJURY; ALZHEIMERS-DISEASE; RISK-FACTORS; PARKINSONS-DISEASE; PITUITARY INSUFFICIENCY; POSTTRAUMATIC SEIZURES; COGNITIVE IMPAIRMENT	Objective: To determine the relations between traumatic brain injury (TBI) and several neurologic Outcomes 6 months or more after TBI. Participants: Not applicable. Design: Systematic review of the published, peer-reviewed literature. Primary Measures: Not applicable. Results: We identified 75 studies that examined the relations between TBI and neurologic outcomes. Unprovoked seizures are causally related to penetrating TBI as well as to moderate and severe TBI. There was only limited evidence of an association between seizures and mild TBI. Dementia of the Alzheimer's type (DAT) was associated with moderate and severe TBI, but not with mild TBI unless there was loss of consciousness (LOC); the evidence for the latter was limited. Parkinsonism was associated with moderate and severe TBI, but there was only modest evidence of a link with mild TBI without LOC. Dementia pugilistica was associated with professional boxing. There was insufficient evidence to support an association between TBI and both multiple sclerosis and amyotrophic lateral sclerosis. TBI appeared to produce a host of postconcussive symptoms (eg, memory problems, dizziness, and irritability). Moderate and severe TBI were associated with endocrine problems such as hypopituitarism and growth hormone deficiency and possibly with diabetes insipidus. There was only limited evidence of an association between mild TBI and the development of ocular/visual motor deterioration. Conclusion: TBI is strongly associated with several neurologic disorders 6 months or more after injury. Clinicians caring for TBI patients should monitor them closely for the development of these disorders. While some of these disorders can be treated after they arise (eg, seizures), a greater public health benefit would be achieved by preventing them before they develop. Research efforts to develop therapies aimed at secondary prevention are currently underway.	[Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; [Cernak, Ibolja] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD USA; [Noble-Haeusslein, Linda] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Noble-Haeusslein, Linda] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA; [Potolicchio, Samuel] George Washington Univ, Med Ctr, Dept Neurol, Washington, DC 20037 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, 601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu		Ibolja, Cernak/0000-0003-3214-698X	US Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159, R01NS077767] Funding Source: NIH RePORTER	The study was supported by a contract from the US Department of Veterans Affairs to the National Academy of Sciences, Institute of Medicine.	Aarsland D, 2002, J NEUROL NEUROSUR PS, V72, P708, DOI 10.1136/jnnp.72.6.708; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; CAVENESS WF, 1962, J NEUROSURG, V19, P122, DOI 10.3171/jns.1962.19.2.0122; CAVENESS WF, 1963, J NEUROSURG, V20, P570, DOI 10.3171/jns.1963.20.7.0570; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P810; Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P818; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Emre M, 2004, NEW ENGL J MED, V351, P2509, DOI 10.1056/NEJMoa041470; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; EVANS JH, 1962, NEUROLOGY, V12, P665, DOI 10.1212/WNL.12.10.665; Farlow MR, 2005, DEMENT GERIATR COGN, V20, P192, DOI 10.1159/000087301; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; FULCO C, 2009, J HEAD TRAUMA REHABI; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Goldacre MJ, 2006, J NEUROL NEUROSUR PS, V77, P351, DOI 10.1136/jnnp.2005.077693; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; *I MED, 2006, AM LAT SCLER VET; JENNETT B, 1973, SCOT MED J, V18, P8, DOI 10.1177/003693307301800103; Jennett W. B., 1969, LATE EFFECTS HEAD IN, P201; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; KURLAND LT, 1994, ANN NEUROL, V36, pS33, DOI 10.1002/ana.410360711; KURTZKE JF, 1980, NEUROLOGY, V30, P453, DOI 10.1212/WNL.30.5.453; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Loewenstein DA, 2004, AM J GERIAT PSYCHIAT, V12, P395, DOI 10.1176/appi.ajgp.12.4.395; Marr JE, 2005, DEV MED CHILD NEUROL, V47, P815, DOI 10.1017/S0012162205001726; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MILLER JD, 1968, LANCET, V2, P991; *NIH, 2006, ALZH DIS FACT SHEET; Noonan CW, 2002, NEUROLOGY, V58, P136, DOI 10.1212/WNL.58.1.136; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Porter MD, 2003, CLIN J SPORT MED, V13, P339, DOI 10.1097/00042752-200311000-00002; Porter MD, 1996, CLIN J SPORT MED, V6, P90, DOI 10.1097/00042752-199604000-00005; Roberts A. H., 1979, SEVERE ACCIDENTAL HE, P89; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE, P102; Russell W. R., 1969, LATE EFFECTS HEAD IN, P189; RUSSELL WR, 1968, JOHNS HOPKINS MED J, V122, P250; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sargent P, 1921, BRAIN, V44, P95, DOI 10.1093/brain/44.2.95; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; Singer R B, 2001, J Insur Med, V33, P42; Stevenson WE, 1931, BRAIN, V54, P214, DOI 10.1093/brain/54.2.214; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.3.CO;2-R; VANDUIJN CM, 1994, GENET EPIDEMIOL, V11, P539, DOI 10.1002/gepi.1370110609; Wagstaffe WW, 1928, LANCET, V2, P861; Watson CW, 1946, RES PUBL ASSOC RES N, V26, P516; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; Zazryn T, 2007, SPORTS MED, V37, P467	89	116	119	0	56	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2009	24	6					439	451		10.1097/HTR.0b013e3181c15600			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	528VW	WOS:000272476100004	19940677				2021-06-18	
J	Robertson, SD; Matthies, HJG; Galli, A				Robertson, S. D.; Matthies, H. J. G.; Galli, A.			A Closer Look at Amphetamine-Induced Reverse Transport and Trafficking of the Dopamine and Norepinephrine Transporters	MOLECULAR NEUROBIOLOGY			English	Article						Amphetamine; AMPH; Norepinephrine transporter; NET; Dopamine transporter; DAT; Monoamine transporter; Neurotransmitter transporter; Monoamines; Efflux; Trafficking	PROTEIN-KINASE-C; CARRIER-MEDIATED RELEASE; NEUROTRANSMITTER TRANSPORTERS; SEROTONIN TRANSPORTER; DEPENDENT MECHANISM; SURFACE EXPRESSION; EXCHANGE DIFFUSION; SYNAPTIC VESICLES; ADRENAL-MEDULLA; XENOPUS OOCYTES	Amphetamine (AMPH) and its derivatives are regularly used in the treatment of a wide array of disorders such as attention-deficit hyperactivity disorder (ADHD), obesity, traumatic brain injury, and narcolepsy (Prog Neurobiol 75:406-433, 2005; J Am Med Assoc 105:2051-2054, 1935; J Am Acad Child Adolesc Psychiatry 41:514-521, 2002; Neuron 43:261-269, 2004; Annu Rev Pharmacol Toxicol 47:681-698, 2007; Drugs Aging 21:67-79, 2004). Despite the important medicinal role for AMPH, it is more widely known for its psychostimulant and addictive properties as a drug of abuse. The primary molecular targets of AMPH are both the vesicular monoamine transporters (VMATs) and plasma membrane monoamine-dopamine (DA), norepinephrine (NE), and serotonin (5-HT)-transporters. The rewarding and addicting properties of AMPH rely on its ability to act as a substrate for these transporters and ultimately increase extracellular levels of monoamines. AMPH achieves this elevation in extracellular levels of neurotransmitter by inducing synaptic vesicle depletion, which increases intracellular monoamine levels, and also by promoting reverse transport (efflux) through plasma membrane monoamine transporters (J Biol Chem 237:2311-2317, 1962; Med Exp Int J Exp Med 6:47-53, 1962; Neuron 19:1271-1283, 1997; J Physiol 144:314-336, 1958; J Neurosci 18:1979-1986, 1998; Science 237:1219-1223, 1987; J Neurosc 15:4102-4108, 1995). This review will focus on two important aspects of AMPH-induced regulation of the plasma membrane monoamine transporters-transporter mediated monoamine efflux and transporter trafficking.	[Robertson, S. D.; Matthies, H. J. G.; Galli, A.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; [Robertson, S. D.] Vanderbilt Univ, Neurosci Grad Program, Nashville, TN USA	Galli, A (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.	aurelio.galli@Vanderbilt.Edu	Matthies, Heinrich/AAD-2375-2019; Matthies, Heinrich/B-7284-2017	Matthies, Heinrich/0000-0003-3615-7571; Matthies, Heinrich/0000-0003-3615-7571; Robertson, Sabrina/0000-0003-4598-6929	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH058921, DA13975, MH084755]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH058921, F31MH084755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA013975, R56DA013975] Funding Source: NIH RePORTER	We thank Dr. Kevin Erreger and Jessica Moore for helpful and insightful discussions. This work was supported by NIH grants MH058921 (Galli, A.), DA13975 (Galli, A.), and MH084755 (Robertson, S. D.).	Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; AXELROD JULIUS, 1965, RECENT PROG HORMONE RES, V21, P597; Binda F, 2008, MOL PHARMACOL, V74, P1101, DOI 10.1124/mol.108.048447; Boudanova E, 2008, MOL CELL NEUROSCI, V39, P211, DOI 10.1016/j.mcn.2008.06.011; Boudanova E, 2008, NEUROPHARMACOLOGY, V54, P605, DOI 10.1016/j.neuropharm.2007.11.007; BRUSS M, 1995, J BIOL CHEM, V270, P9197; BURN JH, 1958, J PHYSIOL-LONDON, V144, P314, DOI 10.1113/jphysiol.1958.sp006104; Burnette WB, 1996, ANAL CHEM, V68, P2932, DOI 10.1021/ac960022x; CARLSSON A, 1962, MED EXP, V6, P47; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Carvelli L, 2008, P NATL ACAD SCI USA, V105, P14192, DOI 10.1073/pnas.0802214105; Cervinski MA, 2005, J BIOL CHEM, V280, P40442, DOI 10.1074/jbc.M501969200; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Chi LM, 2003, J PHARMACOL EXP THER, V307, P729, DOI 10.1124/jpet.103.055095; CHU PC, 1986, DIABETES, V35, P481, DOI 10.2337/diabetes.35.4.481; Cowell RM, 2000, EUR J PHARMACOL, V389, P59, DOI 10.1016/S0014-2999(99)00828-6; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Dipace C, 2007, MOL PHARMACOL, V71, P230, DOI 10.1124/mol.106.026690; Doolen S, 2001, J PHARMACOL EXP THER, V296, P931; Erreger K, 2008, J NEUROSCI, V28, P976, DOI 10.1523/JNEUROSCI.2796-07.2008; FISCHER JF, 1979, J PHARMACOL EXP THER, V208, P203; Fleckenstein AE, 1997, J PHARMACOL EXP THER, V282, P834; Fleckenstein AE, 2007, ANNU REV PHARMACOL, V47, P681, DOI 10.1146/annurev.pharmtox.47.120505.105140; Fog JU, 2006, NEURON, V51, P417, DOI 10.1016/j.neuron.2006.06.028; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; Forrest LR, 2008, P NATL ACAD SCI USA, V105, P10338, DOI 10.1073/pnas.0804659105; Foster JD, 2008, J NEUROCHEM, V105, P1683, DOI 10.1111/j.1471-4159.2008.05262.x; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; Galici R, 2003, NEUROENDOCRINOLOGY, V77, P132, DOI 10.1159/000068650; Garcia BG, 2005, MOL PHARMACOL, V68, P102, DOI 10.1124/mol.104.009092; GIAMBALVO CT, 1992, NEUROPHARMACOLOGY, V31, P1211, DOI 10.1016/0028-3908(92)90049-U; Gnegy ME, 2004, MOL PHARMACOL, V66, P137, DOI 10.1124/mol.66.1.137; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; Gulley JM, 2002, J NEUROCHEM, V83, P400, DOI 10.1046/j.1471-4159.2002.01133.x; HEIKKILA RE, 1975, J PHARMACOL EXP THER, V194, P47; Hersch SM, 1997, J COMP NEUROL, V388, P211; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jayanthi LD, 2006, J BIOL CHEM, V281, P23326, DOI 10.1074/jbc.M601156200; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; Johnson LA, 2005, NEUROPHARMACOLOGY, V49, P750, DOI 10.1016/j.neuropharm.2005.08.018; Johnson LA, 2005, J BIOL CHEM, V280, P10914, DOI 10.1074/jbc.M413887200; Jones SR, 1998, J NEUROSCI, V18, P1979; Kahlig KM, 2004, J BIOL CHEM, V279, P8966, DOI 10.1074/jbc.M303976200; Kahlig KM, 2003, EUR J PHARMACOL, V479, P153, DOI 10.1016/j.ejphar.2003.08.065; Kahlig KM, 2005, P NATL ACAD SCI USA, V102, P3495, DOI 10.1073/pnas.0407737102; Kahlig KM, 2006, MOL PHARMACOL, V70, P542, DOI 10.1124/mol.106.023952; Kantor L, 1999, J NEUROSCI, V19, P3801; Kantor L, 1998, J PHARMACOL EXP THER, V284, P592; Kantor L, 2004, J PHARMACOL EXP THER, V311, P1044, DOI 10.1124/jpet.104.071068; Kantor L, 2001, J PHARMACOL EXP THER, V297, P1016; Karkanias GB, 1997, HORM BEHAV, V32, P19, DOI 10.1006/hbeh.1997.1401; Khoshbouei H, 2004, PLOS BIOL, V2, P387, DOI 10.1371/journal.pbio.0020078; Khoshbouei H, 2003, J BIOL CHEM, V278, P12070, DOI 10.1074/jbc.M212815200; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; Knutson B, 2004, NEURON, V43, P261, DOI 10.1016/j.neuron.2004.06.030; Li LB, 2004, J BIOL CHEM, V279, P21012, DOI 10.1074/jbc.M311972200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Lute BJ, 2008, BIOCHEM BIOPH RES CO, V372, P656, DOI 10.1016/j.bbrc.2008.05.091; Martinsson L, 2004, DRUG AGING, V21, P67, DOI 10.2165/00002512-200421020-00001; Mazei-Robison MS, 2008, J NEUROSCI, V28, P7040, DOI 10.1523/JNEUROSCI.0473-08.2008; Melikian HE, 1999, J NEUROSCI, V19, P7699; Olfson M, 2002, J AM ACAD CHILD PSY, V41, P514, DOI 10.1097/00004583-200205000-00008; Owens WA, 2005, J NEUROCHEM, V94, P1402, DOI 10.1111/j.1471-4159.2005.03289.x; PARKER EM, 1988, J PHARMACOL EXP THER, V245, P199; Pierce RC, 1997, J NEUROSCI, V17, P3254; Pifl C, 1999, MOL PHARMACOL, V56, P1047; Pifl C, 2004, NEUROPHARMACOLOGY, V46, P223, DOI 10.1016/j.neuropharm.2003.09.007; Pifl C, 1997, BRIT J PHARMACOL, V121, P205, DOI 10.1038/sj.bjp.0701137; PIFL C, 1995, MOL PHARMACOL, V47, P368; Prinzmetal M, 1935, J AMER MED ASSOC, V105, P2051; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.0.CO;2-K; RAITERI M, 1979, J PHARMACOL EXP THER, V208, P195; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Saitoh A, 1998, PHARMACOL BIOCHEM BE, V60, P161, DOI 10.1016/S0091-3057(97)00588-1; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schenk James O, 2002, Prog Drug Res, V59, P111; Seidel S, 2005, MOL PHARMACOL, V67, P140, DOI 10.1124/mol.67.1.140; SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pharmtox.33.1.639; Shi L, 2008, MOL CELL, V30, P667, DOI 10.1016/j.molcel.2008.05.008; Sitte HH, 1998, J NEUROCHEM, V71, P1289; Sonders MS, 1997, J NEUROSCI, V17, P960; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Sulzer D, 2005, PROG NEUROBIOL, V75, P406, DOI 10.1016/j.pneurobio.2005.04.003; SULZER D, 1995, J NEUROSCI, V15, P4102; Sung U, 2003, J NEUROSCI, V23, P1697; Wei Y, 2007, MOL PHARMACOL, V71, P835, DOI 10.1124/mol.106.026351; Williams J, 2007, PLOS BIOL, V5, P2369, DOI 10.1371/journal.pbio.0050274; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; ZACZEK R, 1991, J PHARMACOL EXP THER, V257, P830; Zhu MY, 2000, J PHARMACOL EXP THER, V295, P951	90	116	119	0	25	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	APR	2009	39	2					73	80		10.1007/s12035-009-8053-4			8	Neurosciences	Neurosciences & Neurology	418YD	WOS:000264185100001	19199083	Green Accepted			2021-06-18	
J	Vinclair, M; Broux, C; Faure, P; Brun, J; Genty, C; Jacquot, C; Chabre, O; Payen, JF				Vinclair, Marc; Broux, Christophe; Faure, Patrice; Brun, Julien; Genty, Celine; Jacquot, Claude; Chabre, Olivier; Payen, Jean-Francois			Duration of adrenal inhibition following a single dose of etomidate in critically ill patients	INTENSIVE CARE MEDICINE			English	Article						etomidate; adrenal; corticotropin; critical care	TRAUMATIC BRAIN-INJURY; RAPID-SEQUENCE INTUBATION; SEPTIC SHOCK; ENDOTRACHEAL INTUBATION; EMERGENCY-DEPARTMENT; CORTISOL RESPONSE; INDUCTION AGENT; INSUFFICIENCY; ANESTHESIA; SEPSIS	Objective: To determine the incidence and duration of adrenal inhibition induced by a single dose of etomidate in critically ill patients. Design: Prospective, observational cohort study. Setting: Three intensive care units in a university hospital. Patients: Forty critically ill patients without sepsis who received a single dose of etomidate for facilitating endotracheal intubation. Measurements and main results: Serial serum cortisol and 11 beta-deoxycortisol samples were taken at baseline and 60 min after corticotropin stimulation test (250 mu g 1-24 ACTH) at 12, 24, 48, and 72 h after etomidate administration. Etomidate-related adrenal inhibition was defined by the combination of a rise in cortisol less than 250 nmol/l (9 mu g/dl) after ACTH stimulation and an excessive accumulation of serum 11 beta-deoxycortisol concentrations at baseline. At 12 h after etomidate administration, 32/40 (80%) patients fulfilled the diagnosis criteria for etomidate-related adrenal insufficiency. This incidence was significantly lower at 48 h (9%) and 72 h (7%). The cortisol to 11 beta-deoxycortisol ratio (F/S ratio), reflecting the intensity of the 11 beta-hydroxylase enzyme blockade, improved significantly over time. Conclusions: A single bolus infusion of etomidate resulted in wide adrenal inhibition in critically ill patients. However, this alteration was reversible by 48 h following the drug administration. The empirical use of steroid supplementation for 48 h following a single dose of etomidate in ICU patients without septic shock should thus be considered. Concomitant serum cortisol and 11 beta-deoxycortisol dosages are needed to provide evidence for adrenal insufficiency induced by etomidate in critically ill patients.	[Vinclair, Marc; Broux, Christophe; Brun, Julien; Jacquot, Claude; Payen, Jean-Francois] Albert Michallon Hosp, Dept Anesthesiol & Crit Care, F-38043 Grenoble, France; [Faure, Patrice] Albert Michallon Hosp, Dept Biol, Grenoble, France; [Faure, Patrice] INSERM, ER 117, Lab HP2, Grenoble, France; [Genty, Celine] Univ Grenoble 1, UMR 5525, THEMA TIMC, Grenoble, France	Payen, JF (corresponding author), Albert Michallon Hosp, Dept Anesthesiol & Crit Care, BP 217, F-38043 Grenoble, France.	jfpayen@ujf-grenoble.fr	Payen, Jean-Francois/L-6667-2014	CHABRE, Olivier/0000-0001-8756-7218			Absalom A, 1999, ANAESTHESIA, V54, P861; Annane D, 2005, INTENS CARE MED, V31, P325, DOI 10.1007/s00134-005-2560-1; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Annane D, 2006, AM J RESP CRIT CARE, V174, P1319, DOI 10.1164/rccm.200509-1369OC; Arbous MS, 2001, ANAESTHESIA, V56, P1141, DOI 10.1046/j.1365-2044.2001.02051.x; Bernard F, 2006, BRIT J ANAESTH, V96, P72, DOI 10.1093/bja/aei277; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; den Brinker M, 2005, J CLIN ENDOCR METAB, V90, P5110, DOI 10.1210/jc.2005-1107; DUTHIE DJR, 1985, BRIT J ANAESTH, V57, P156, DOI 10.1093/bja/57.2.156; GOODING JM, 1979, ANESTH ANALG, V58, P40; Hoen S, 2002, ANESTHESIOLOGY, V97, P807, DOI 10.1097/00000542-200210000-00010; Jackson WL, 2005, CHEST, V127, P1031, DOI 10.1378/chest.127.3.1031; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Kamp R, 2007, CRIT CARE, V11, DOI 10.1186/cc5939; Liouber-Friedman D, 2007, CRIT CARE MED, V35, P1012, DOI 10.1097/01.CCM.0000259465.92018.6E; Malerba G, 2005, INTENS CARE MED, V31, P388, DOI 10.1007/s00134-004-2550-8; Mohammad Z, 2006, CRIT CARE, V10, DOI 10.1186/cc4979; Morris C, 2005, ANAESTHESIA, V60, P737, DOI 10.1111/j.1365-2044.2005.04325.x; Murray H, 2005, CHEST, V127, P707, DOI 10.1378/chest.127.3.707; Oglesby AJ, 2004, EMERG MED J, V21, P655, DOI 10.1136/emj.2003.009043; Ray DC, 2007, CRIT CARE, V11, DOI 10.1186/cc5916; Reich DL, 2005, ANESTH ANALG, V101, P622, DOI 10.1213/01.ANE.0000175214.38450.91; Salgado DR, 2006, CRIT CARE, V10, DOI 10.1186/cc5077; Schenarts CL, 2001, ACAD EMERG MED, V8, P1, DOI 10.1111/j.1553-2712.2001.tb00537.x; Siraux V, 2005, CRIT CARE MED, V33, P2479, DOI 10.1097/01.CCM.0000185641.87051.7C; Smith DC, 2000, J EMERG MED, V18, P13, DOI 10.1016/S0736-4679(99)00154-7; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; WAGNER RL, 1984, NEW ENGL J MED, V310, P1415, DOI 10.1056/NEJM198405313102202	29	116	120	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	APR	2008	34	4					714	719		10.1007/s00134-007-0970-y			6	Critical Care Medicine	General & Internal Medicine	278BV	WOS:000254259400017	18092151				2021-06-18	
J	Greve, KW; Ord, J; Curtis, KL; Bianchini, KJ; Brennan, A				Greve, Kevin W.; Ord, Jonathan; Curtis, Kelly L.; Bianchini, Kevin J.; Brennan, Adrianne			Detecting malingering in traumatic brain injury and chronic pain: A comparison of three forced-choice symptom validity tests	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	26th Annual Meeting of the National-Academy-of-Neuropsychology	OCT 25-28, 2006	San Antonio, TX	Natl Acad Neuropsychol			FAKE-BAD SCALE; DIGIT RECOGNITION TEST; CLOSED-HEAD INJURY; NEUROCOGNITIVE DYSFUNCTION; CLASSIFICATION ACCURACY; NEUROPSYCHOLOGICAL TESTS; RESPONSE BIAS; MONEY MATTERS; MMPI-2; VALIDATION	Individual and joint malingering detection accuracy of the Portland Digit Recognition Test (PDRT), Test of Memory Malingering (TOMM), and Word Memory Test (WMT) was examined in traumatic brain injury (TBI; 43 non-malingering, 27 malingering) and chronic pain (CP; 42 non-malingering, 58 malingering) using a known-groups design. At published cutoffs, the PDRT and TOMM were very specific but failed to detect about 50% of malingerers; the WMT was sensitive but prone to false positive errors. ROC analyses demonstrated comparable accuracy across all three tests. Joint classification accuracy was superior to that of the individual tests. Clinical and research implications are discussed.	[Greve, Kevin W.; Ord, Jonathan; Curtis, Kelly L.; Bianchini, Kevin J.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Curtis, Kelly L.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Metairie, LA USA; [Brennan, Adrianne] Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bianchini K. J., 2004, J FORENSIC NEUROPSYC, V4, P65; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BIANCHINI KJ, 2007, CLASSIFICATION ACCUR; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1993, PORTLAND DIGIT RECOG; BLANCHINI KB, 2001, CLIN NEUROPSYCHOL, V15, P461; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Gansler DA, 1996, ARCH CLIN NEUROPSYCH, V11, P393, DOI 10.1016/0887-6177(96)83889-3; Gervais R.O., 2001, J FORENSIC NEUROPSYC, V2, DOI [DOI 10.1300/J151V02N02_01, https://doi.org/10.1300/J151v02n02_01]; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 2005, GREENS WORD MEMORY T; GREEN P, 1996, MANUAL WORD MEMORY T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P816, DOI 10.1080/13854040500346610; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P117, DOI 10.1016/j.acn.2005.06.009; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Gunstad J, 2001, CLIN NEUROPSYCHOL, V15, P397, DOI 10.1076/clin.15.3.397.10271; Harris I, 2005, JAMA-J AM MED ASSOC, V293, P1644, DOI 10.1001/jama.293.13.1644; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson GL, 2003, HANDBOOK OF FORENSIC NEUROPSYCHOLOGY, P137; Iverson GL, 2002, PSYCHOL REP, V90, P131, DOI 10.2466/PR0.90.1.131-136; Ju D, 2000, Appl Neuropsychol, V7, P201, DOI 10.1207/S15324826AN0704_1; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; ORD J, 2007, 35 ANN M INT NEUR SO; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; Ross SR, 2006, CLIN NEUROPSYCHOL, V20, P798, DOI 10.1080/13854040500328477; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; TYDECKS S, 2006, INT J FORENSIC PSYCH, V1, P29; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; VICTOR TL, 2006, 34 ANN M INT NEUR SO; WASYLIW OE, 1985, BEHAV SCI LAW, V3, P149, DOI DOI 10.1002/BSL.2370030204; Wechsler D., 1997, WECHSLER ADULT INTEL; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	68	116	116	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2008	22	5					896	918		10.1080/13854040701565208			23	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	342HP	WOS:000258775500010	18756391				2021-06-18	
J	Noreau, L; Lepage, C; Boissiere, L; Picard, R; Fougeyrollas, P; Mathieu, J; Desmarais, G; Nadeau, L				Noreau, Luc; Lepage, Celine; Boissiere, Lucie; Picard, Roger; Fougeyrollas, Patrick; Mathieu, Jean; Desmarais, Gilbert; Nadeau, Line			Measuring participation in children with disabilities using the assessment of life habits	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							HANDICAP SITUATIONS; CEREBRAL-PALSY; SOCIAL-PARTICIPATION; REHABILITATION; RELIABILITY; CONSEQUENCES; ASSOCIATION; VALIDATION	The objectives of this study were: (1) to examine the psychometric properties of the Assessment of Life Habits (LIFE-H) for children; and (2) to draw a profile of the level of participation among children of 5 to 13 years of age with various impairments. The research team adapted the adult version of the LIFE-H in order to render it more appropriate for the daily life experiences of children. Content validity was verified by an expert panel of 29 people, made up of parents, paediatric clinicians, and researchers. Reliability and construct validity of the LIFE-H for children (interview-administered form) was tested during an experiment that comprised three sessions of interviews with a group of 94 parents of children with disabilities (36 males, 58 females; mean age 8y 10mo [SD 2y 6 mo]; diagnostic groups: cerebral palsy, myelomeningocoele, sensory-motor neuropathy, traumatic brain injury, and developmental delay). Overall, the LIFE-H showed high intrarater reliability with intraclass correlation coefficient values of 0.78 or higher for 10 out of 11 categories. The correlations between the LIFE-H and the tools used in pediatric rehabilitation varied, and categories with similar constructs generally led to higher correlations. The psychometric properties of the LIFE-H are appropriate and its content allows a complete description of participation among children with disabilities.	Univ Laval, Fac Med, Rehabil Dept, Quebec City, PQ G1K 7P4, Canada; CIRRIS, Quebec City, PQ G1M 2S8, Canada; Inst Rehabil, Quebec City, PQ, Canada; Neuromuscular Clin, Jonquiere, PQ, Canada	Noreau, L (corresponding author), CIRRIS, 525 Blvd Hamel, Quebec City, PQ G1M 2S8, Canada.	Luc.Noreau@rea.ulaval.ca					Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; COSTER W, 1998, SCHOOL FUNCTION ASSE; Desrosiers J, 2002, DISABIL REHABIL, V24, P774, DOI 10.1080/09638280210125814; Detmar SB, 2005, CLIN REHABIL, V19, P73, DOI 10.1191/0269215505cr825oa; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Fougeyrollas P., 2001, HDB DISABILITY STUDI, P171; FOUGEYROLLAS P, 1989, RESEAU INT CIDIH, V2, P21; HALEY SM, 1991, PEDIATRIC PHYSICAL T, V3, P177; Jette AM, 2003, J REHABIL MED, V35, P145, DOI 10.1080/16501970310010501; King GA, 2007, CHILD CARE HLTH DEV, V33, P28, DOI 10.1111/j.1365-2214.2006.00613.x; King Gillian, 2002, Physical and Occupational Therapy in Pediatrics, V22, P53, DOI 10.1300/J006v22n02_04; Law M, 2004, SCAND J OCCUP THER, V11, P156, DOI [DOI 10.1080/11038120410020755, 10.1080/110.381.20410020755, DOI 10.1080/110.381.20410020755]; LAW M, 2002, PHYS OCCUP THER PEDI, V22, P103; Lepage C, 1998, SCAND J REHABIL MED, V30, P263; Lepage C, 1998, PHYS THER, V78, P458, DOI 10.1093/ptj/78.5.458; Machin D, 1997, SAMPLE SIZE TABLES C, V2nd; Morris C, 2005, CHILD CARE HLTH DEV, V31, P397, DOI 10.1111/j.1365-2214.2005.00519.x; Noreau L, 2004, DISABIL REHABIL, V26, P346, DOI 10.1080/09638280410001658649; Noreau L, 2000, DISABIL REHABIL, V22, P170; Noreau L, 2002, TECHNOL DISABIL, V14, P113, DOI [10.3233/TAD-2002-14306, DOI 10.3233/TAD-2002-14306]; Ottenbacher KJ, 1996, DEV MED CHILD NEUROL, V38, P907; Rankin G, 1998, CLIN REHABIL, V12, P187, DOI 10.1191/026921598672178340; Rochette A, 2001, DISABIL REHABIL, V23, P559; Rosenbaum P, 2003, BRIT MED J, V326, P970, DOI 10.1136/bmj.326.7396.970; Simeonsson RJ, 2001, DISABIL REHABIL, V23, P49; World Health Organization, 2001, INT CLASS FUNCT DIS	27	116	117	1	18	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	SEP	2007	49	9					666	671		10.1111/j.1469-8749.2007.00666.x			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	203HU	WOS:000248966500008	17718822	Bronze			2021-06-18	
J	Parsons, TD; Bowerly, T; Buckwalter, JG; Rizzo, AA				Parsons, Thomas D.; Bowerly, Todd; Buckwalter, J. Galen; Rizzo, Albert A.			A controlled clinical comparison of attention performance in children with ADHD in a virtual reality classroom compared to standard neuropsychological methods	CHILD NEUROPSYCHOLOGY			English	Article						virtual reality; attention deficit hyperactivity disorder; neurocognitive	DEFICIT-HYPERACTIVITY DISORDER; ALLOCENTRIC SPATIAL MEMORY; TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE FUNCTIONS; DEFICIT/HYPERACTIVITY DISORDER; ECOLOGICAL VALIDITY; DSM-IV; INHIBITION DEFICIT; REHABILITATION; CHILDHOOD	In this initial pilot study, a controlled clinical comparison was made of attention perforance in children with attention deficit-hyperactivity disorder (ADHD) in a virtual reality (VR) classroom. Ten boys diagnosed with ADHD and ten normal control boys participated in the study. Groups did not significantly differ in mean age, grade level, ethnicity, or handedness. No participants reported simulator sickness following VR exposure. Children with ADHD exhibited more omission errors, commission errors, and overall body movement than normal control children in the VR classroom. Children with ADHD were more impacted by distraction in the VR classroom. VR classroom measures were correlated with traditional ADHD assessment tools and the flatscreen CPT. Of note, the small sample size incorporated in each group and higher WISC-III scores of normal controls might have some beating on the overall interpretation of results. These data suggested that the Virtual Classroom had good potential for controlled performance assessment within an ecologically valid environment and appeared to parse out significant effects due to the presence of distraction stimuli	Univ So Calif, Inst Creat Technol, Marina Del Rey, CA 90292 USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; So Calif Kaiser Permanente Med Grp, Pasadena, CA USA	Parsons, TD (corresponding author), Univ So Calif, Inst Creat Technol, 13274 Fiji Way,Off 301, Marina Del Rey, CA 90292 USA.	tparsons@ict.usc.edu		Parsons, Thomas/0000-0003-0331-5019			ABIKOFF H, 1993, J ABNORM CHILD PSYCH, V21, P519, DOI 10.1007/BF00916317; BARKLEY RA, 1991, J ABNORM CHILD PSYCH, V19, P149, DOI 10.1007/BF00909976; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; Barkley RA, 2000, J AM ACAD CHILD PSY, V39, P1064, DOI 10.1097/00004583-200008000-00025; Barkley RA, 2004, PSYCHIAT CLIN N AM, V27, P233, DOI 10.1016/S0193-953X(03)00091-1; BARKLEY RA, 1994, CLIN NEUROPSYCHOL, V8, P121, DOI 10.1080/13854049408401552; Barkley RA, 1997, J DEV BEHAV PEDIATR, V18, P271; Baumgartner T, 2006, CYBERPSYCHOL BEHAV, V9, P30, DOI 10.1089/cpb.2006.9.30; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Biederman J, 2005, BIOL PSYCHIAT, V57, P1215, DOI 10.1016/j.biopsych.2004.10.020; Bleckley MK, 2003, PSYCHON B REV, V10, P884, DOI 10.3758/BF03196548; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Brooks BM, 2003, NEUROREHABILITATION, V18, P147; Buckwalter J G, 1997, Stud Health Technol Inform, V39, P17; Burgess N, 2006, REV NEUROSCIENCE, V17, P239; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Cho BH, 2004, CYBERPSYCHOL BEHAV, V7, P519, DOI 10.1089/1094931042403055; Cho BH, 2002, ST HEAL T, V85, P89; Cho BH, 2002, CYBERPSYCHOL BEHAV, V5, P129, DOI 10.1089/109493102753770516; Clancy TA, 2006, J CLIN CHILD ADOLESC, V35, P203, DOI 10.1207/s15374424jccp3502_4; Conners C. K., 2000, CONNERS CPT 2 WINDOW; CORKUM PV, 1993, J CHILD PSYCHOL PSYC, V34, P1217, DOI 10.1111/j.1469-7610.1993.tb01784.x; ELIASON MJ, 1987, J LEARN DISABIL, V20, P614, DOI 10.1177/002221948702001007; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Farias ST, 2003, ARCH CLIN NEUROPSYCH, V18, P655, DOI 10.1016/S0887-6177(02)00159-2; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; GOLDEN C, 1978, STROOP COLOR WORLD T; Grodzinsky GM, 1999, CLIN NEUROPSYCHOL, V13, P12, DOI 10.1076/clin.13.1.12.1983; GRODZINSKY GM, 1992, DEV NEUROPSYCHOL, V8, P427, DOI 10.1080/87565649209540536; Kaplan E., 1983, BOSTON NAMING TEST; KENNEDY RS, 1992, AVIAT SPACE ENVIR MD, V63, P588; KORKMAN M, 1997, NEPSY; Lahey BB, 2006, J CHILD PSYCHOL PSYC, V47, P472, DOI 10.1111/j.1469-7610.2005.01590.x; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Losier BJ, 1996, J CHILD PSYCHOL PSYC, V37, P971, DOI 10.1111/j.1469-7610.1996.tb01494.x; McClusky DA, 2005, AM SURGEON, V71, P13; Morganti F, 2004, ST HEAL T, V99, P55; Nichols SL, 2004, CHILD PSYCHIAT HUM D, V34, P297; Nigg JT, 1999, J ABNORM CHILD PSYCH, V27, P393, DOI 10.1023/A:1021980002473; Odhuba RA, 2005, BRIT J CLIN PSYCHOL, V44, P269, DOI 10.1348/014466505X29431; Pani JR, 2005, COGNITIVE PSYCHOL, V51, P285, DOI 10.1016/j.cogpsych.2005.06.002; Parslow DM, 2005, ACTA PSYCHOL, V118, P123, DOI 10.1016/j.actpsy.2004.10.006; Parsons TD, 2004, NEUROPSYCHOLOGIA, V42, P555, DOI 10.1016/j.neuropsychologia.2003.08.014; Phelps A, 2004, ST HEAL T, V98, P298; Pineda D, 1998, INT J NEUROSCI, V96, P177, DOI 10.3109/00207459808986466; Plehn K, 2004, CLIN NEUROPSYCHOL, V18, P101, DOI 10.1080/13854040490507190; Rapport LJ, 2001, CLIN NEUROPSYCHOL, V15, P479, DOI 10.1076/clin.15.4.479.1878; Rapport MD, 2000, J CLIN CHILD PSYCHOL, V29, P555, DOI 10.1207/S15374424JCCP2904_8; Ready RE, 2001, CLIN NEUROPSYCHOL, V15, P314, DOI 10.1076/clin.15.3.314.10269; Reitan R. M., 1992, TRAIL MAKING TEST MA; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Reitan RM, 2004, ARCH CLIN NEUROPSYCH, V19, P281, DOI 10.1016/S0887-6177(03)00042-8; Rizzo A A, 1997, Stud Health Technol Inform, V39, P22; Rizzo AA, 2006, CNS SPECTRUMS, V11, P35, DOI 10.1017/S1092852900024196; Rizzo AA, 2004, COMPUTER, V37, P87, DOI 10.1109/MC.2004.23; Rizzo AA, 2003, CLIN NEUROPSYCHOL, V17, P100; Rizzo AA, 1997, ST HEAL T, V44, P123; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Sayal K, 2005, ACTA PSYCHIAT SCAND, V111, P460, DOI 10.1111/j.1600-0447.2004.00487.x; Schachar R, 2000, J ABNORM CHILD PSYCH, V28, P227, DOI 10.1023/A:1005140103162; Scheres A, 2004, ARCH CLIN NEUROPSYCH, V19, P569, DOI 10.1016/j.acn.2003.08.005; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P378, DOI 10.1097/00001199-200210000-00002; Scotti JR, 1996, J CONSULT CLIN PSYCH, V64, P1177, DOI 10.1037/0022-006X.64.6.1177; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Swanson JM, CATEGORICAL DIMENSIO; Wechsler D., 1991, WECHSLER INTELLIGENC; Wolbers T, 2004, COGNITIVE BRAIN RES, V21, P401, DOI 10.1016/j.cogbrainres.2004.06.013	68	116	120	2	38	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	JUL	2007	13	4					363	381		10.1080/13825580600943473			19	Clinical Neurology	Neurosciences & Neurology	207ZU	WOS:000249290400005	17564852				2021-06-18	
J	Opii, WO; Nukala, VN; Sultana, R; Pandya, JD; Day, KM; Merchant, ML; Klein, JB; Sullivan, PG; Butterfield, DA				Opii, Wycliffe O.; Nukala, Vidya N.; Sultana, Rukhsana; Pandya, Jignesh D.; Day, Kristen M.; Merchant, Michael L.; Klein, Jon B.; Sullivan, Patrick G.; Butterfield, D. Allan			Proteomic identification of oxidized mitochondrial proteins following experimental traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; mitochondria; oxidative stress; proteomics; reactive oxygen species; traumatic brain injury	ALZHEIMERS-DISEASE BRAIN; PYRUVATE-DEHYDROGENASE COMPLEX; ALPHA-KETOGLUTARATE DEHYDROGENASE; CEREBRAL OXIDATIVE-METABOLISM; ISOVALERYL-COA DEHYDROGENASE; CYTOCHROME-C; CYCLOSPORINE-A; PERMEABILITY TRANSITION; LIPID-PEROXIDATION; CELL-DEATH	Experimental traumatic brain injury (TBI) results in a significant loss of cortical tissue at the site of injury, and in the ensuing hours and days a secondary injury exacerbates this primary injury, resulting in significant neurological dysfunction. The mechanism of the secondary injury is not well understood, but evidence implicates a critical role for mitochondria in this cascade. This mitochondrial dysfunction is believed to involve excitotoxicity, disruption of Ca2+ homeostasis, production of reactive oxygen species (ROS), ATP depletion, oxidative damage of mitochondrial proteins, and an overall breakdown of mitochondrial bioenergetics. Although oxidative damage occurs following TBI, the identities of proteins undergoing oxidative modification after TBI have not been investigated. In the present study, we utilized the 3-h post-injury controlled cortical impact model of experimental TBI in 20 young adult male Sprague-Dawley rats, coupled with proteomics to identify specific mitochondrial fraction proteins from the cortex and hippocampus that were oxidatively modified after TBI. We identified, from the cortex, pyruvate dehydrogenase, voltage-dependent anion channel, fumarate hydratase 1, ATP synthase, and prohibitin. From the hippocampus, we identified cytochrome C oxidase Va, isovaleryl coenzyme A dehydrogenase, enolase-1, and glyceraldehyde-3-phosphate dehydrogenase as proteins that had undergone oxidative modification following TBI. In addition, we have also shown that, following TBI, there is a reduction in the activities of pyruvate dehydrogenase (PDH), complex 1, and complex IV. These findings demonstrate that, following TBI, several proteins involved in mitochondrial bioenergetics are highly oxidatively modified, which may possibly underlie the massive breakdown of mitochondrial energetics and eventual cell death known to occur in this model. The identification of these proteins provides new insights into the mechanisms that take place following TBI and may provide avenues for possible therapeutic interventions after TBI.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40506 USA; Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40506 USA; Univ Louisville, Dept Med, Core Proteom Lab, Kidney Dis Program, Louisville, KY 40292 USA	Butterfield, DA (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.	dabcns@uky.edu	Merchant, Michael/F-7109-2013; Klein, Jon/B-9833-2013; Merchant, Michael/N-7444-2013	Merchant, Michael/0000-0003-4128-4057	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS046426, R01NS048191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010836] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-10836, AG-05119] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-46426, NS-48191] Funding Source: Medline		Aksenova M, 2002, J NEUROTRAUM, V19, P491, DOI 10.1089/08977150252932433; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baldwin SA, 1996, GLIA, V16, P266; Basso M, 2004, PROTEOMICS, V4, P3943, DOI 10.1002/pmic.200400848; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Butterfield DA, 2004, INT REV NEUROBIOL, V61, P161; Butterfield DA, 2004, BRAIN RES, V1000, P1, DOI 10.1016/j.brainres.2003.12.012; Butterfield DA, 2003, J NEUROCHEM, V86, P1313, DOI 10.1046/j.1471-4159.2003.01948.x; Butterfield DA, 2003, CELL MOL BIOL, V49, P747; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; Castegna A, 2004, J NEUROCHEM, V88, P1540, DOI 10.1046/j.1471-4159.2003.02288.x; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; DEMEIRLEIR L, 1993, PEDIATR NEUROL, V9, P216, DOI 10.1016/0887-8994(93)90088-T; Drake J, 2003, J NEUROSCI RES, V74, P917, DOI 10.1002/jnr.10810; Eaton P, 2003, J AM SOC NEPHROL, V14, pS290, DOI 10.1097/01.ASN.0000078024.50060.C6; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Gibson GE, 2004, J BIOENERG BIOMEMBR, V36, P335, DOI 10.1023/B:JOBB.0000041764.45552.f3; Gibson GE, 1998, ANN NEUROL, V44, P676, DOI 10.1002/ana.410440414; Giege P, 2003, PLANT CELL, V15, P2140, DOI 10.1105/tpc.012500; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hara MR, 2006, BBA-MOL BASIS DIS, V1762, P502, DOI 10.1016/j.bbadis.2006.01.012; Hard ML, 2001, ALCOHOL, V25, P1, DOI 10.1016/S0741-8329(01)00156-2; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HENSLEY K, 1995, J NEUROCHEM, V65, P2146; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Kadenbach B, 2004, BBA-BIOENERGETICS, V1655, P400, DOI 10.1016/j.bbabio.2003.06.005; LAMANNA JC, 1981, BRAIN RES, V204, P87, DOI 10.1016/0006-8993(81)90654-5; Lauderback CM, 2001, J NEUROCHEM, V78, P413, DOI 10.1046/j.1471-4159.2001.00451.x; LAVOIE J, 1995, ALCOHOL CLIN EXP RES, V19, P1073, DOI 10.1111/j.1530-0277.1995.tb00991.x; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Leyva JA, 2003, MOL MEMBR BIOL, V20, P27, DOI 10.1080/0968768031000066532; Liaud MF, 2000, MOL BIOL EVOL, V17, P213, DOI 10.1093/oxfordjournals.molbev.a026301; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Liu XH, 2004, PROTEOMICS, V4, P3167, DOI 10.1002/pmic.200300845; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Maurer MH, 2005, J PROTEOME RES, V4, P96, DOI 10.1021/pr049841l; McNair ND, 1999, NURS CLIN N AM, V34, P637; Mohsen AA, 1998, BIOCHEMISTRY-US, V37, P10325, DOI 10.1021/bi973096r; Mohsen AWA, 2001, MOL GENET METAB, V73, P126, DOI 10.1006/mgme.2001.3183; Nicholls D. G., 2002, BIOENERGETICS, V3; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Pocernich CB, 2003, NEUROTOX RES, V5, P515, DOI 10.1007/BF03033161; Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458; Poon HF, 2004, NEUROSCIENCE, V126, P915, DOI 10.1016/j.neuroscience.2004.04.046; Poona HF, 2005, NEUROCHEM INT, V46, P159, DOI 10.1016/j.neuint.2004.07.008; Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389; Rosenthal RE, 2003, STROKE, V34, P1311, DOI 10.1161/01.STR.0000066868.95807.91; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHEU KFR, 1985, ANN NEUROL, V17, P444; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; SORBI S, 1983, ANN NEUROL, V13, P72, DOI 10.1002/ana.410130116; Sriram K, 1998, J NEUROSCI, V18, P10287; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sultana R, 2004, NEUROCHEM RES, V29, P2215, DOI 10.1007/s11064-004-7028-0; Sultana R, 2006, NEUROBIOL AGING, V27, P918, DOI 10.1016/j.neurobiolaging.2005.05.005; Szewczyk A, 2002, PHARMACOL REV, V54, P101, DOI 10.1124/pr.54.1.101; Tabatabaie T, 1996, ARCH BIOCHEM BIOPHYS, V336, P290, DOI 10.1006/abbi.1996.0560; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Thongboonkerd V, 2002, KIDNEY INT, V62, P1461, DOI 10.1046/j.1523-1755.2002.00565.x; Tibbs RE, 1998, ANAT REC, V253, P167; TUBOI S, 1990, ADV ENZYME REGUL, V30, P289; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Volchenboum SL, 2000, J BIOL CHEM, V275, P7958, DOI 10.1074/jbc.275.11.7958; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WHARTON DC, 1964, J BIOL CHEM, V239, P2036; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yoo BC, 2001, ELECTROPHORESIS, V22, P172, DOI 10.1002/1522-2683(200101)22:1<172::AID-ELPS172>3.0.CO;2-P; Zaidan E, 1998, J NEUROCHEM, V70, P233; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	92	116	121	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2007	24	5					772	789		10.1089/neu.2006.0229			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	167YT	WOS:000246489300003	17518533				2021-06-18	
J	Foreman, BP; Caesar, RR; Parks, J; Madden, C; Gentilello, LM; Shafi, S; Carlile, MC; Harper, CR; Diaz-Arrastia, RR				Foreman, Brandon P.; Caesar, R. Ruth; Parks, Jennifer; Madden, Christopher; Gentilello, Larry M.; Shafi, Shahid; Carlile, Mary C.; Harper, Caryn R.; Diaz-Arrastia, Ramon R.			Usefulness of the abbreviated injury score and the injury severity score in comparison to the Glasgow Coma Scale in predicting outcome after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						abbreviated injury scale; Glasgow Coma Scale; injury severity scale; traumatic brain injury	SEVERE HEAD-INJURY; VARIABLES; CLASSIFICATION; REGRESSION; MORTALITY; TREE	Background: Assessment of injury severity is important in the management of patients with brain trauma. We aimed to analyze the usefulness of the head abbreviated injury score (AIS), the injury severity score (ISS), and the Glasgow Coma Scale (GCS) as measures of injury severity and predictors of outcome after traumatic brain injury (TBI). Methods: Data were prospectively collected from 410 patients with TBI. AIS, ISS, and GCS were recorded at admission. Subjects' outcomes after TBI were measured using the Glasgow Outcome Scale (GOS-E) at 12 months postinjury. Uni- and multivariate analyses were performed. Results: Outcome information was obtained from 270 patients (66%). ISS was the best predictor of GOS-E (r(s) = -0.341, p < 0.001), followed by GCS score (r(s) = 0.227, p < 0.001), and head AIS (r(s) = -0.222, p < 0.001). When considered in combination, GCS score and ISS modestly improved the correlation with GOS-E (R = 0.335, p < 0.001). The combination of GCS score and head AIS had a similar effect (R = 0.275, p < 0.001). Correlations were stronger from patients <= 48 years old. We found comparable correlations between patients who suffered severe injuries (GCS <= 58) and those who suffered mild and moderate injuries (GCS > 8). Conclusions: GCS score, AIS, and ISS are weakly correlated with 12-month outcome. However, anatomic measures modestly outperform GCS as predictors of GOS-E. The combination of GCS and AIS/ISS correlate with outcome better than do any of the three measures alone. Results support the addition of anatomic measures such as AIS and ISS in clinical studies of TBI. Additionally, most of the variance in outcome is not accounted for by currently available measures of injury severity.	Baylor Inst Rehabil, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neurosurg, Dallas, TX 75235 USA	Harper, CR (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	caryn.harper@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594; Foreman, Brandon/0000-0002-5418-674X			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; STATES JD, 1971, JAMA-J AM MED ASSOC, V215, P277; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1974, LANCET, V2, P81; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	19	116	118	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2007	62	4					946	950		10.1097/01.ta.0000229796.14717.3a			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	157DJ	WOS:000245698500024	17426553				2021-06-18	
J	Treggiari, MM; Schutz, N; Yanez, ND; Romand, JA				Treggiari, Miriam M.; Schutz, Nicolas; Yanez, N. David; Romand, Jacques-Andre			Role of intracranial pressure values and patterns in predicting outcome in traumatic brain injury: a systematic review	NEUROCRITICAL CARE			English	Article						neurotrauma; Glasgow outcome score; ICP; TBI; head injury; neuromonitoring	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; INTRA-CRANICAL PRESSURE; AGGRESSIVE TREATMENT; MANAGEMENT; HYPERTENSION; EXPERIENCE; MANNITOL; CARE; ICP	Introduction Raised intracranial pressure (ICP) has been consistently associated with poor neurological outcome. Our purpose was to systematically review the literature to estimate the association between ICP values and patterns and short- and long-term vital and neurological outcome. Methods Systematic review of studies identified from MEDLINE, EMBASE, and COCHRANE Registry search from 1966 to 2005, and reference lists of identified articles, with independent assessment of methodological quality, population, ICP values and patterns, management of raised ICP and neurological outcomes. Summary odds ratios (OR) were calculated for the main outcomes using proportional odds models and logistic regression. Results Four prospective studies (409 patients) reported the effect of ICP values, and five studies (677 patients) reported the effect of ICP patterns on neurological outcome. No study reported neurological outcomes beyond I year. Relative to normal ICP (< 20 mmHg), raised ICP was associated with elevated OR of death: 3.5 [95%CI: 1.7, 7.3] for ICP 20-40, and 6.9 [95%CI: 3.9, 12.4] for ICP > 40. Raised but reducible ICP was associated with a 3-4-fold increase in the OR of death or poor neurological outcome. Refractory ICP pattern was associated with a dramatic increase in the relative risk of death (OR 114.3 [95%CI: 40.5, 322.3]). Conclusions Refractory ICP and response to treatment of raised ICP could be better predictors of neurological outcome than absolute ICP values. Limitations in the design of the studies analyzed precluded identification of the role of ICP monitoring in predicting short- and long-term outcomes.	Univ Washington, Sch Med, Dept Anesthesiol, Harborview Med Ctr, Seattle, WA 98104 USA; Univ Hosp Geneva, Div Intens Care, Dept Anesthesiol Pharmacol & Intens Care, Geneva, Switzerland; Univ Washington, Dept Biostat, Seattle, WA 98104 USA	Treggiari, MM (corresponding author), Univ Washington, Sch Med, Dept Anesthesiol, Harborview Med Ctr, 325 9th Ave,Box 359724, Seattle, WA 98104 USA.	treggmm@u.washington.edu					Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Biestro A, 1998, ACT NEUR S, V71, P5; Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P513; BUXTON RL, 1970, LANCET, V2, P498; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; FOWLER S, 1999, J NEUROSCI N7URS, V31, P370; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KOBAYASHI S, 1983, INTRACRANIAL PRESSUR, V5; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Marmarou A, 2005, ACT NEUR S, V95, P277; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; McCullagh P., 1989, GEN LINEAR MODELS; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; ROBERTS I, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000033; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SMITH HP, 1986, J NEUROSURG, V65, P820, DOI 10.3171/jns.1986.65.6.0820; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P521, DOI [10.1089/neu.2000.17.521, DOI 10.1089/NEU.2000.17.521]; TROUPP J, 1965, J TRAUMA, V29, P373; TSUTSUMI H, 1986, INTRACRANIAL PRESSUR, V6, P661; 2000, J NEUROTRAUMA, V17, P479	35	116	129	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2007	6	2					104	112		10.1007/s12028-007-0012-1			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	179DW	WOS:000247270700006	17522793				2021-06-18	
J	Collie, A; Makdissi, M; Maruff, P; Bennell, K; McCrory, P				Collie, A; Makdissi, M; Maruff, P; Bennell, K; McCrory, P			Cognition in the days following concussion: comparison of symptomatic versus asymptomatic athletes	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; TEST-PERFORMANCE; REACTION-TIME; HEAD-INJURY; IMPAIRMENT; CONSISTENCY; SEVERITY; RECOVERY	Background: Concussion is a common neurological injury occurring during contact sport. Current guidelines recommend that no athlete should return to play while symptomatic or displaying cognitive dysfunction. This study compared post-concussion cognitive function in recently concussed athletes who were symptomatic/asymptomatic at the time of assessment with that of non-injured (control) athletes. Methods: Prospective study of 615 male Australian Rules footballers. Before the season, all participants (while healthy) completed a battery of baseline computerised (CogSport) and paper and pencil cognitive tasks. Sixty one injured athletes (symptomatic=25 and asymptomatic=36) were reassessed within 11 days of being concussed; 84 controls were also reassessed. The serial cognitive function of the three groups was compared using analysis of variance. Results: The performance of the symptomatic group declined at the post-concussion assessment on computerised tests of simple, choice, and complex reaction times compared with the asymptomatic and control groups. The magnitude of changes was large according to conventional statistical criteria. On paper and pencil tests, the symptomatic group displayed no change at reassessment, whereas large improvements were seen in the other two groups. Conclusion: Injured athletes experiencing symptoms of concussion displayed impaired motor function and attention, although their learning and memory were preserved. These athletes displayed no change in performance on paper and pencil tests in contrast with the improvement observed in asymptomatic and non-injured athletes. Athletes experiencing symptoms of concussion should be withheld from training and competition until both symptoms and cognitive dysfunction have resolved.	Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia; La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3083, Australia	Collie, A (corresponding author), 92B Abbeville Rd, London SW4 9NA, England.	acollie@unimelb.edu.au	Maruff, Paul/AAD-2454-2021; McCrory, Paul/Q-8688-2019; Maruff, Paul/ABA-1673-2020; Bennell, Kim/C-7022-2014	Maruff, Paul/0000-0002-6947-9537; Collie, Alex/0000-0003-2617-9339; Bennell, Kim/0000-0003-4982-5639			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BLAND M, 1996, LANCET, V1, P307; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; *COL MED SOC, 1991, REP SPORTS MED COMM; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Darby D, 2002, NEUROLOGY, V59, P1042, DOI 10.1212/WNL.59.7.1042; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Luce R.D., 1986, RESPONSE TIMES THEIR; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, THESIS U MELBOURNE M; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory PR, 1999, BRIT J SPORT MED, V33, P297; MOLLICA C, IN PRESS J INT NEURO; MOLLICA C, IN PRESS HUM PSYCHOP; Pardini D., 2004, BR J SPORTS MED, V38, P661; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Silbert BS, 2004, BRIT J ANAESTH, V92, P814, DOI 10.1093/bja/aeh157; STUDEBAKER GA, 1985, J SPEECH HEAR RES, V28, P455, DOI 10.1044/jshr.2803.455; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VVANZOMEREN AH, 1981, REACTION TIME ATTENT; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; WESCHLER D, 1981, WESCHLER ADULT INTEL; Wolfson D., 1993, HALSTEAD REITAN NEUR	43	116	117	1	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2006	77	2					241	245		10.1136/jnnp.2005.073155			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	011QY	WOS:000235284400026	16421129	Green Published			2021-06-18	
J	Bonnefont, X; Lacampagne, A; Sanchez-Hormigo, A; Fino, E; Creff, A; Mathieu, MN; Smallwood, S; Carmignac, D; Fontanaud, P; Travo, P; Alonso, G; Courtois-Coutry, N; Pincus, SM; Robinson, ICAF; Mollard, P				Bonnefont, X; Lacampagne, A; Sanchez-Hormigo, A; Fino, E; Creff, A; Mathieu, MN; Smallwood, S; Carmignac, D; Fontanaud, P; Travo, P; Alonso, G; Courtois-Coutry, N; Pincus, SM; Robinson, ICAF; Mollard, P			Revealing the large-scale network organization of growth hormone-secreting cells	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						biological rhythms; endocrinology; systems biology; connectivity; calcium	TRAUMATIC BRAIN-INJURY; ANTERIOR-PITUITARY; CONSCIOUS MALE; MICE; RAT; PROLACTIN; SURVIVORS; PROFILES; RELEASE; PEPTIDE	Pituitary growth hormone (GH)-secreting cells regulate growth and metabolism in animals and humans. To secrete highly ordered GH pulses (up to 1,000-fold rise in hormone levels in vivo), the pituitary GH cell population needs to mount coordinated responses to GH secretagogues, yet GH cells display an apparently heterogeneous scattered distribution in 2D histological studies. To address this paradox, we analyzed in 3D both positioning and signaling of GH cells using reconstructive, two-photon excitation microscopy to image the entire pituitary in GH-EGFP transgenic mice. Our results unveiled a homologous continuum of GH cells connected by adherens junctions that wired the whole gland and exhibited the three primary features of biological networks: robustness of architecture across lifespan, modularity correlated with pituitary GH contents and body growth, and connectivity with spatially stereotyped motifs of cell synchronization coordinating cell activity. These findings change our view of GH cells, from a collection of dispersed cells to a geometrically connected homotypic network of cells whose local morphology and connectivity can vary, to alter the timing of cellular responses to promote more coordinated pulsatile secretion. This large-scale 3D view of cell functioning provides a powerful approach to identify and understand other networks of endocrine cells that are thought to be scattered in situ. Many dispersed endocrine systems exhibit pulsatile outputs. We suggest that cell positioning and associated cell-cell connection mechanisms will be critical parameters that determine how well such systems can deliver a coordinated secretory pulse of hormone to their target tissues.	Univ Montpellier I, CNRS, INSERM, Inst Funct Genom,U661,Unite Mixte Rech 5203,Dept, 141 Rue Cardonille, F-34094 Montpellier, France; Univ Montpellier 2, CNRS, INSERM, Inst Funct Genom,U661,Unite Mixte Rech 5203,Dept, F-34094 Montpellier, France; Ctr Hosp Univ Arnaud de Villeneuve, INSERM, U637, F-34295 Montpellier, France; Natl Inst Med Res, Div Mol Neuroendocrinol, London NW7 1AA, England; CNRS, Montpellier RIO Imaging, Ctr Rech Biochim Macromol, F-34293 Montpellier, France	Mollard, P (corresponding author), Univ Montpellier I, CNRS, INSERM, Inst Funct Genom,U661,Unite Mixte Rech 5203,Dept, 141 Rue Cardonille, F-34094 Montpellier, France.	patrice.mollard@igf.cnrs.fr	Lacampagne, Alain/S-3719-2016; Fino, Elodie/M-6586-2014; BONNEFONT, Xavier/AAH-3882-2019; Smallwood, Sebastien/M-9783-2014; COUTRY, Nathalie/O-9352-2017	Lacampagne, Alain/0000-0003-0264-1787; Fino, Elodie/0000-0003-1453-7784; BONNEFONT, Xavier/0000-0003-4778-4060; COUTRY, Nathalie/0000-0001-5830-4013			Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Alon U, 2003, SCIENCE, V301, P1866, DOI 10.1126/science.1089072; Alonso G, 2003, EUR J NEUROSCI, V18, P1889, DOI 10.1046/j.1460-9568.2003.02927.x; Asa SL, 2002, NAT REV CANCER, V2, P836, DOI 10.1038/nrc926; Baker B.L., 1974, HDB PHYSIOLOGY END 1, V4, P45; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BOWERS CY, 1990, J CLIN ENDOCR METAB, V70, P975, DOI 10.1210/jcem-70-4-975; BRAZEAU P, 1982, P NATL ACAD SCI-BIOL, V79, P7909, DOI 10.1073/pnas.79.24.7909; CLARK RG, 1986, J ENDOCRINOL, V111, P27, DOI 10.1677/joe.0.1110027; CLARK RG, 1985, J ENDOCRINOL, V106, P281, DOI 10.1677/joe.0.1060281; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Dasen JS, 2001, ANNU REV NEUROSCI, V24, P327, DOI 10.1146/annurev.neuro.24.1.327; DENK W, 1994, J NEUROSCI METH, V54, P151, DOI 10.1016/0165-0270(94)90189-9; Fauquier T, 2002, TRENDS ENDOCRIN MET, V13, P304, DOI 10.1016/S1043-2760(02)00616-1; Fauquier T, 2001, P NATL ACAD SCI USA, V98, P8891, DOI 10.1073/pnas.151339598; Feyrter F., 1938, UBER DIFFUSE ENDOKRI; GAGE PJ, 1995, ENDOCRINOLOGY, V136, P1161, DOI 10.1210/en.136.3.1161; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Gleeson HK, 2004, ENDOCR-RELAT CANCER, V11, P589, DOI 10.1677/erc.1.00779; Guerineau NC, 1998, J BIOL CHEM, V273, P10389, DOI 10.1074/jbc.273.17.10389; GUILLEMIN RC, 1983, SYNERGETICS BRAIN, P155; HARTMAN ML, 1993, HORM RES, V40, P37, DOI 10.1159/000183766; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; KOSTYO JL, 1999, HORMONAL CONTROL GRO; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; Magoulas C, 2000, ENDOCRINOLOGY, V141, P4681, DOI 10.1210/en.141.12.4681; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; PEARSE AGE, 1976, CLIN ENDOCRINOL, V5, pS229, DOI 10.1111/j.1365-2265.1976.tb03832.x; Pincus SM, 2000, AM J PHYSIOL-ENDOC M, V279, pE417; Pincus SM, 1996, AM J PHYSIOL-ENDOC M, V270, pE107; PLOTSKY PM, 1985, SCIENCE, V230, P461, DOI 10.1126/science.2864742; Robinson IC, 1999, HORMONAL CONTROL GRO, P329; Rubinek T, 2003, J CLIN ENDOCR METAB, V88, P3724, DOI 10.1210/jc.2003-030090; SARTOR O, 1985, ENDOCRINOLOGY, V116, P952, DOI 10.1210/endo-116-3-952; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SLABAUGH MB, 1982, ENDOCRINOLOGY, V110, P1489, DOI 10.1210/endo-110-5-1489; STEWART JK, 1985, ENDOCRINOLOGY, V116, P1; Sweet Ian R, 2004, Diabetes Technol Ther, V6, P652, DOI 10.1089/dia.2004.6.652; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; Tannenbaum GS, 2001, ENDOCRINOLOGY, V142, P4599, DOI 10.1210/en.142.11.4599; Veldhuis J D, 2000, Novartis Found Symp, V227, P163; Wick MR, 2000, AM J CLIN PATHOL, V113, P331, DOI 10.1309/ETJ3-QBUK-13QD-J8FP; Young EA, 2004, FRONT NEUROENDOCRIN, V25, P69, DOI 10.1016/j.yfrne.2004.07.001	45	116	116	0	3	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	NOV 15	2005	102	46					16880	16885		10.1073/pnas.0508202102			6	Multidisciplinary Sciences	Science & Technology - Other Topics	986PT	WOS:000233462900064	16272219	Green Published, Bronze			2021-06-18	
J	Bell, KR; Temkin, NR; Esselman, PC; Doctor, JN; Bombardier, CH; Fraser, RT; Hoffman, JM; Powell, JM; Dikmen, S				Bell, KR; Temkin, NR; Esselman, PC; Doctor, JN; Bombardier, CH; Fraser, RT; Hoffman, JM; Powell, JM; Dikmen, S			The effect of a scheduled telephone intervention on outcome after moderate to severe traumatic brain injury: A randomized trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; telephone; treatment outcome	CARE; REHABILITATION; MANAGEMENT; SYSTEMS; MODEL; DEPRESSION; FAMILIES; SCALE; RACE	Objective: To measure the effectiveness of a scheduled telephone intervention offering counseling and education to people with traumatic brain injury (TBI) on behavioral outcomes compared with standard follow-up at 1 year postinjury. Design: Two-group randomized, prospective clinical trial throughout the first year after injury. Setting: Subjects' homes via telephone in an urban-rural catchment area from a level I trauma center. Participants: Subjects (N = 171; age range, 18-70y) with a primary diagnosis of TBI who were discharged from an acute rehabilitation unit. They were randomly assigned to the telephone intervention (n = 85) or to standard follow-up (n = 86) groups at discharge. Of these, 79 participated in the intervention and completed the outcome assessment (3 withdrew; 3 were lost to follow-up), and 78 participated in usual care and completed the outcome assessment (8 were lost to follow-up). Interventions: Subjects were randomly assigned to receive telephone calls at 2 and 4 weeks and 2, 3, 5, 7, and 9 months after discharge. The calls consisted of brief motivational interviewing, counseling, and education, plus facilitating usual care or usual care alone through follow-up appointments and therapy prescriptions. Main Outcome Measures: A composite outcome was used as the primary endpoint on an intent-to-treat basis. Secondary analyses were conducted with individual measures, including the FIM instrument, Disability Rating Scale, Community Integration Questionnaire, Neurobehavioral Functioning Inventory, Functional Status Examination, Glasgow Outcome Scale-Extended, Medical Outcomes Study 36-Item Short-Form Health Survey, Brief Symptom Inventory, EuroQol, and Modified Perceived Quality of Life scale. The primary analysis was a blocked Mann-Whitney U test. Results: At 1-year follow-up, those who had received scheduled telephone intervention fared significantly better on the primary composite outcome index (P = .002). In addition, this group fared better on specific composites such as functional status (P = .003) and quality of well-being (P = .006). There were no significant differences on vocational status (P = .08) or community integration status (P = .13). Conclusions: Scheduled telephone counseling and education resulted in improved overall outcome, particularly for functional status and quality of well-being, when compared with usual outpatient care. Telephone counseling shows promise as a low-cost, widely available rehabilitation intervention for TBI.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Med Educ & Med Informat, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Bell, KR (corresponding author), Univ Washington, Dept Rehabil Med, 1959 NE Pacific St,Box 356490, Seattle, WA 98195 USA.	krbell@u.washington.edu		Bell, Kathleen/0000-0002-0928-2046			Anderson LM, 2003, AM J PREV MED, V24, P68, DOI 10.1016/S0749-3797(02)00657-8; ATKINS BJ, 1980, J REHABIL, V46, P40; Austin JS, 1996, ARTHRIT CARE RES, V9, P391, DOI 10.1002/1529-0131(199610)9:5<391::AID-ANR1790090508>3.0.CO;2-V; Balas EA, 1997, JAMA-J AM MED ASSOC, V278, P152, DOI 10.1001/jama.278.2.152; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Bell KR, 2004, J HEAD TRAUMA REHAB, V19, P502, DOI 10.1097/00001199-200411000-00007; Bostrom J, 1996, APPL NURS RES, V9, P47, DOI 10.1016/S0897-1897(96)80402-2; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Campbell C H, 1988, Rehabil Nurs, V13, P320; Clark M, 2001, PATIENT EDUC COUNS, V42, P247, DOI 10.1016/S0738-3991(00)00128-2; COPE DN, 1990, REHABILITATION ADULT, P253; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dornelas EA, 2000, PREV MED, V30, P261, DOI 10.1006/pmed.2000.0644; Dunn C, 2001, ADDICTION, V96, P1725, DOI 10.1046/j.1360-0443.2001.961217253.x; Engli M, 1993, J Neurosci Nurs, V25, P78; Fuhrer MJ, 1998, AM J PHYS MED REHAB, V77, P557, DOI 10.1097/00002060-199811000-00022; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; Katon W, 2001, ARCH GEN PSYCHIAT, V58, P241, DOI 10.1001/archpsyc.58.3.241; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KEMENADE VEV, 1994, BR J CLIN PSYCHOL 3, V33, P367; Kreutzer JS, 1997, J HEAD TRAUMA REHAB, V12, P63, DOI 10.1097/00001199-199712000-00006; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; Marascuilo LA., 1977, NONPARAMETRIC DISTRI; Martin EM, 2003, AM J NURS, V103, P75, DOI 10.1097/00000446-200310000-00036; Miller WR, 1991, MOTIVATIONAL INTERVI; *NAT COUNC DIS, 1999, LIFT EV VOIC MOD DIS; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Paterson B, 2001, Rehabil Nurs, V26, P48; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Snyder RE, 2000, MED CARE RES REV, V57, P196, DOI 10.1177/107755870005700204; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WARE JE, 1993, SF36 HLTH SURV MAN I; WEINBERGER M, 1993, ARTHRITIS RHEUM, V36, P243, DOI 10.1002/art.1780360216; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393	51	116	117	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2005	86	5					851	856		10.1016/j.apmr.2004.09.015			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	928NM	WOS:000229278500001	15895327				2021-06-18	
J	Whyte, J; Katz, D; Long, D; DiPasquale, MC; Polansky, M; Kalmar, K; Giacino, J; Childs, N; Mercer, W; Novak, P; Maurer, P; Eifert, B				Whyte, J; Katz, D; Long, D; DiPasquale, MC; Polansky, M; Kalmar, K; Giacino, J; Childs, N; Mercer, W; Novak, P; Maurer, P; Eifert, B			Predictors of outcome in prolonged posttraumatic disorders of consciousness and assessment of medication effects: A multicenter study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amantadine; brain injuries; dantrolene; minimally conscious state; persistent vegetative state; projections and predictions; rehabilitation; treatment outcome	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; PERSISTENT VEGETATIVE STATE; HEAD-INJURY; COMMON-DRUGS; RECOVERY; AMANTADINE; COMA; BROMOCRIPTINE; STIMULATION	Objectives: To develop predictive models of recovery from the vegetative state (VS) and minimally conscious state (MCS) after traumatic brain injury (TBI) and to gather preliminary evidence on the impact of various psychotropic medications on the recovery process to support future randomized controlled trials. Design: Longitudinal observational cohort design, in which demographic information, injury and acute care history, neuroimaging data, and an initial Disability Rating Scale (DRS) score were collected at the time of study enrollment. Weekly follow-up data, consisting of DRS score, current psychoactive medications, and medical complications, were gathered until discharge from inpatient rehabilitation. Setting: Seven acute inpatient rehabilitation facilities in the United States and Europe with specialized programs for treating patients in the VS and MCS. Participants: People with TBI (N = 124) who were in the VS or MCS 4 to 16 weeks after injury. Interventions: Not applicable. Main Outcome Measures: DRS score at 16 weeks after injury and time until commands were first followed (among those participants demonstrating no command following at study enrollment). Results: DRS score at enrollment, time between injury and enrollment, and rate of DRS change during the first 2 weeks of poststudy observation were all highly predictive of both outcomes. No variables related to injury characteristics or lesions on neuroimaging were significant predictors. Of the psychoactive medications, amantadine hydrochloride was associated with greater recovery and dantrolene sodium was associated with less recovery, in terms of the DRS score at 16 weeks but not the time until commands were followed. More detailed analysis of the timing of functional improvement, with respect to the initiation of amantadine provided suggestive, but not definitive, evidence of the drug's causal role. Conclusions: These findings show the feasibility of improving outcome prediction from the VS and MCS using readily available clinical variables and provide suggestive evidence for the effects of amantadine and dantrolene, but these results require confirmation through randomized controlled trials. (C) 2005 by American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	MossRehab, Inst Res, Albert Einstein Healthcare Network, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA; HealthS Braintree Rehabil Hosp, Braintree, MA USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA; Bryn Mawr Rehab Hosp, Malvern, PA USA; Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA; JFK Johnson Rehabil Inst, Edison, NJ USA; New Jersey Neurosci Inst, Edison, NJ USA; Texas NeuroRehab Ctr, Austin, TX USA; Sunnyview Hosp, Schenectady, NY USA; Rehabil Ctr, Schenectady, NY USA; Fachkrankenhaus Neresheim Hosp, Neresheim, Germany	Whyte, J (corresponding author), MossRehab, Inst Res, Albert Einstein Healthcare Network, 1200 W Tabor Rd,Korman Bldg,Ste 213, Philadelphia, PA 19141 USA.	jwhyte@einstein.edu	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Whyte, John/0000-0002-4381-1474			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; *AM C REH MED, 1995, ARCH PHYS MED REHAB, V76, P397; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; Borer-Alafi N, 2002, BRAIN INJURY, V16, P593, DOI 10.1080/02699050110119484; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CRISMON ML, 1988, CLIN NEUROPHARMACOL, V11, P462, DOI 10.1097/00002826-198810000-00007; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Forsyth R, 2003, COCHRANE DB SYST REV; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2003, J HEAD TRAUMA REHAB, V18, P4, DOI 10.1097/00001199-200301000-00003; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Giacino JT, 1996, NEUROREHABILITATION, V6, P69, DOI 10.3233/NRE-1996-6108; GIACINO JT, IN PRESS REHABILITAT; Goldstein LB, 1998, ARCH NEUROL-CHICAGO, V55, P454, DOI 10.1001/archneur.55.4.454; Goldstein LB, 1997, CURR OPIN NEUROL, V10, P52, DOI 10.1097/00019052-199702000-00011; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2002, J NEUROL NEUROSUR PS, V73, P355, DOI 10.1136/jnnp.73.4.355; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; JOHNSON DA, 1993, BRAIN INJURY, V7, P491, DOI 10.3109/02699059309008176; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kater K M, 1989, West J Nurs Res, V11, P20, DOI 10.1177/019394598901100103; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Laborde A, 1997, J HEAD TRAUMA REHAB, V12, P90, DOI 10.1097/00001199-199708000-00009; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; Laureys S, 2002, ACTA NEUROL BELG, V102, P176; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Lombardi F, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001427; LONG DF, 1989, NEUROPSYCHOLOGICAL T, P39; Meythaler JM, 2001, BRAIN INJURY, V15, P321, DOI 10.1080/026990501750111274; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; *MULT SOC TASK FOR, 1994, NEW ENGL J MED, V26, P1572; ODELL MW, 1996, MED REHABILITATION T, P103; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; ROSS ED, 1981, NEUROLOGY, V31, P1435, DOI 10.1212/WNL.31.11.1435; Sazbon L, 1991, Brain Inj, V5, P1, DOI 10.3109/02699059108998504; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schneider WN, 1999, BRAIN INJURY, V13, P863; Showalter PEC, 2000, BRAIN INJURY, V14, P997; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; WOOD R L, 1991, Brain Injury, V5, P401, DOI 10.3109/02699059109008113; WROBLEWSKI BA, 1994, J HEAD TRAUMA REHAB, V9, P19, DOI 10.1097/00001199-199409000-00004; Wroblewski Bruno, 1993, Brain Injury, V7, P353, DOI 10.3109/02699059309034962; Xie K, 2003, ACT NEUR S, V87, P19; Yamamoto T, 2003, ACTA NEUROCHIR SUPPL, V87, P15; Yamamoto T, 2002, ACT NEUR S, V79, P79; Zafonte RD, 1998, BRAIN INJURY, V12, P617; ZASLER ND, 1995, J HEAD TRAUMA REHAB, V10, P101, DOI 10.1097/00001199-199508000-00010	70	116	124	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2005	86	3					453	462		10.1016/j.apmr.2004.05.016			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	904DB	WOS:000227475200016	15759228				2021-06-18	
J	D'Ambrosio, R; Fender, JS; Fairbanks, JP; Simon, EA; Born, DE; Doyle, DL; Miller, JW				D'Ambrosio, R; Fender, JS; Fairbanks, JP; Simon, EA; Born, DE; Doyle, DL; Miller, JW			Progression from frontal-parietal to mesial-temporal epilepsy after fluid percussion injury in the rat	BRAIN			English	Article						trauma; drug screening; electrocorticography; partial seizures; gliosis	TRAUMATIC BRAIN-INJURY; GENETIC ABSENCE EPILEPSY; LOBE EPILEPSY; POSTTRAUMATIC EPILEPSY; HIPPOCAMPAL SCLEROSIS; WAVE DISCHARGES; SEIZURE; STIMULATION; PATTERNS; FEATURES	We recently described an in vivo model of post-traumatic epilepsy (PTE) in the rat where chronic spontaneous recurrent seizures appear following a single episode of fluid percussion injury (FPI). PTE, studied during the first 2 months post-injury, was focal and seizures originated predominantly from the frontal-parietal neocortex at or around the injury site. However, rarer bilateral seizures originating from a different and undefined focus were also observed. To shed light on the Posttraumatic Epileptogenic mechanisms and on the generation of bilateral seizures, we studied rats up to 7 months post-injury. In vivo paired epidural and depth-electrode recordings indicated that the anterior hippocampus evolves into an epileptic focus which initiates bilateral seizures. The rate of frontal-parietal seizures remained constant over time after 2 weeks post-injury, while the rate of hippocampal seizures greatly increased over time, suggesting that different mechanisms mediate neocortical and hippocampal post-traumatic epileptogenesis. Because of different temporal evolution of these foci, the epileptic syndrome was characterized by predominant frontal-parietal seizures early after injury, but by predominant mesio-temporal seizures at later time points. Pathological analysis demonstrated progressive hippocampal and temporal cortex pathology that paralleled the increase in frequency and duration of bilateral seizures. These results demonstrate that FPI-induced frontal-parietal epilepsy (FPE) progresses to mesial-temporal lobe epilepsy (MTLE) with dual pathology. These observations establish numerous similarities between FPI-induced and human PTE and further validate it as a clinically relevant model of PTE.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Sch Med, Reg Epilepsy Ctr, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Sch Med, Dept Pathol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Sch Med, Ctr Human Dev & Disabil, Seattle, WA 98104 USA	D'Ambrosio, R (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurosurg, Box 359915,325 9th Ave, Seattle, WA 98104 USA.	raid@u.washington.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040823] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040823, NS040823, R01 NS040823-02] Funding Source: Medline		Annegers JF, 1996, MAYO CLIN PROC, V71, P570, DOI 10.4065/71.6.570; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arruda F, 1996, ANN NEUROL, V40, P446, DOI 10.1002/ana.410400314; Benbadis SR, 2003, SEIZURE-EUR J EPILEP, V12, P167, DOI 10.1016/S1059-1311(02)00320-5; Bertram EH, 1999, NEUROSCIENCE, V92, P15, DOI 10.1016/S0306-4522(98)00712-X; BROWNING RA, 1986, EXP NEUROL, V93, P546, DOI 10.1016/0014-4886(86)90174-3; Browning RA, 1987, EPILEPSY RETICULAR F, P137; CAVAZOS JE, 1990, BRAIN RES, V527, P1, DOI 10.1016/0006-8993(90)91054-K; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2004, PHARMACOL THERAPEUT, V103, P95, DOI 10.1016/j.pharmthera.2004.05.004; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DAMBROSIO R, 2003, YOUMANS NEUROLOGICAL, P2449; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DollemanVanderWeel MJ, 1997, J NEUROSCI, V17, P5640; ENGEL JJ, 1991, KINDLING SYNAPTIC PL, P196; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Fuerst D, 2003, ANN NEUROL, V53, P413, DOI 10.1002/ana.10509; Gale K, 1988, MECHANISMS EPILEPTOG, P111; GODDARD GV, 1967, NATURE, V214, P1020, DOI 10.1038/2141020a0; Golarai G, 2001, J NEUROSCI, V21, P8523; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Holmes GL, 2002, NEUROLOGY, V59, pS3, DOI 10.1212/WNL.59.9_suppl_5.S3; INOUE M, 1990, PHYSIOL BEHAV, V48, P199, DOI 10.1016/0031-9384(90)90285-C; JUULJENSEN P, 1986, INTRACTABLE EPILEPSY, P5; Kelly Kevin M, 2004, Epilepsy Curr, V4, P160, DOI 10.1111/j.1535-7597.2004.44015.x; Kuba R, 2003, EUR J NEUROL, V10, P641, DOI 10.1046/j.1468-1331.2003.00684.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARESCAUX C, 1992, J NEURAL TRANSM-GEN, P37; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKhann GM, 2003, NEUROSCIENCE, V122, P551, DOI 10.1016/S0306-4522(03)00562-1; PIREDDA S, 1985, NATURE, V317, P623, DOI 10.1038/317623a0; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Salanova V, 2002, EPILEPSIA, V43, P170, DOI 10.1046/j.1528-1157.2002.33800.x; Salin P, 1995, J NEUROSCI, V15, P8234; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Satow T, 2002, EPILEPSIA, V43, P1425, DOI 10.1046/j.1528-1157.2002.34501.x; Schauwecker PE, 2002, PROG BRAIN RES, V135, P139; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; SLOVITER RS, 1983, BRAIN RES BULL, V10, P675, DOI 10.1016/0361-9230(83)90037-0; SNEAD OC, 1999, JASPERS BASIC MECH E, P253; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Tinuper P, 1998, J NEUROL NEUROSUR PS, V64, P231, DOI 10.1136/jnnp.64.2.231; VADASZ C, 1995, AM J MED GENET, V60, P55, DOI 10.1002/ajmg.1320600111; VANLUIJTELAAR ELJM, 1986, NEUROSCI LETT, V70, P393, DOI 10.1016/0304-3940(86)90586-0; Vergnes M, 2003, EXP NEUROL, V184, P549, DOI 10.1016/S0014-4886(03)00098-0; WILLIAMSON PD, 1986, EPILEPSIA, V27, pS46, DOI 10.1111/j.1528-1157.1986.tb05740.x; WILLOUGHBY JO, 1992, LAB ANIM SCI, V42, P551	56	116	119	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JAN	2005	128		1				174	188		10.1093/brain/awh337			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	885WK	WOS:000226187800019	15563512	Bronze, Green Accepted			2021-06-18	
J	Barber, RC; Aragaki, CC; Rivera-Chavez, FA; Purdue, GF; Hunt, JL; Horton, JW				Barber, RC; Aragaki, CC; Rivera-Chavez, FA; Purdue, GF; Hunt, JL; Horton, JW			TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury	JOURNAL OF MEDICAL GENETICS			English	Article							TUMOR-NECROSIS-FACTOR; INTERLEUKIN-6 PROMOTER POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; MULTIPLE ORGAN DYSFUNCTION; SEPTIC SHOCK; SIGNAL-TRANSDUCTION; GENE; MORTALITY; PLASMA; TIME	Context: Sepsis, organ failure, and shock remain common among patients with moderate to severe burn injuries. The inability of clinical factors to identify at-risk patients suggests that genetic variation may influence the risk for serious infection and the outcome from severe injury. Objective: Resolution of genetic variants associated with severe sepsis following burn injury. Patients: A total of 159 patients with burns greater than or equal to 20% of their total body surface area or any smoke inhalation injury without significant non-burn related trauma ( injury severity score (ISS)greater than or equal to 16), traumatic or anoxic brain injury, or spinal cord injury and who survived more than 48 h post- admission. Methods: Candidate single nucleotide polymorphisms (SNPs) within bacterial recognition (TLR4 + 896, CD14 - 159) and inflammatory response (TNF-alpha 2308, IL-1beta-31, IL-6 -174) loci were evaluated for association with increased risk for severe sepsis ( sepsis plus organ dysfunction or septic shock) and mortality. Results: After adjustment for age, full-thickness burn size, ethnicity, and gender, carriage of the TLR4 + 896 G-allele imparted at least a 1.8-fold increased risk of developing severe sepsis following a burn injury, relative to AA homozygotes (adjusted odds ratio (aOR) 6.4; 95% confidence interval (CI) 1.8 to 23.2). Carriage of the TNF-alpha -308 A-allele imparted a similarly increased risk, relative to GG homozygotes (aOR = 4.5; 95% CI 1.7 to 12.0). None of the SNPs examined were significantly associated with mortality. Conclusions: The TLR4 + 896 and TNF-alpha -308 polymorphisms were significantly associated with an increased risk for severe sepsis following burn trauma.	Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75390 USA; Univ Texas, Hlth Sci Ctr Houston, Sch Publ Hlth, Div Epidemiol, Dallas, TX 75230 USA; Univ Texas, Hlth Sci Ctr Houston, Sch Publ Hlth, Div Biostat, Dallas, TX 75230 USA	Barber, RC (corresponding author), Univ Texas, SW Med Ctr, Dept Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	robert.barber@utsouthwestern.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P50 GM021681-38, 5P50GM021681-38] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P50GM021681] Funding Source: NIH RePORTER		Abraham E, 2000, CRIT CARE MED, V28, P232, DOI 10.1097/00003246-200001000-00039; Abraham LJ, 1999, J LEUKOCYTE BIOL, V66, P562; Agnese DM, 2002, J INFECT DIS, V186, P1522, DOI 10.1086/344893; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alderborn A, 2000, GENOME RES, V10, P1249, DOI 10.1101/gr.10.8.1249; An HZ, 2002, IMMUNOLOGY, V106, P38, DOI 10.1046/j.1365-2567.2002.01401.x; Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107001-00035; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Arslan E, 2000, BURNS, V26, P521, DOI 10.1016/S0305-4179(00)00024-3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; Brull DJ, 2001, ARTERIOSCL THROM VAS, V21, P1458, DOI 10.1161/hq0901.094280; Chapes SK, 2001, J LEUKOCYTE BIOL, V69, P381; Cumming J, 2001, J TRAUMA, V50, P510, DOI 10.1097/00005373-200103000-00016; DROST AC, 1993, J TRAUMA, V35, P335, DOI 10.1097/00005373-199309000-00001; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; ENDO S, 1993, BURNS, V19, P124, DOI 10.1016/0305-4179(93)90033-5; Ferrand PE, 2002, MOL HUM REPROD, V8, P1031, DOI 10.1093/molehr/8.11.1031; Fishman D, 1998, EUR CYTOKINE NETW, V9, P364; Fitzwater J, 2003, J TRAUMA, V54, P959, DOI 10.1097/01.TA.0000029382.26295.AB; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; Ingalls RR, 2000, J ENDOTOXIN RES, V6, P411, DOI 10.1179/096805100101532261; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; Knight JC, 1999, P ASSOC AM PHYSICIAN, V111, P290, DOI 10.1046/j.1525-1381.1999.99237.x; Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7; Kroeger KM, 2000, CYTOKINE, V12, P110, DOI 10.1006/cyto.1999.0529; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Leveque G, 2003, INFECT IMMUN, V71, P1116, DOI 10.1128/IAI.71.3.1116-1124.2003; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; MARANO MA, 1990, SURG GYNECOL OBSTET, V170, P32; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mira JP, 1999, JAMA-J AM MED ASSOC, V282, P561, DOI 10.1001/jama.282.6.561; Nadel S, 1996, J INFECT DIS, V174, P878, DOI 10.1093/infdis/174.4.878; O'Keefe GE, 2002, J TRAUMA, V52, P817, DOI 10.1097/00005373-200205000-00001; O'Keefe GE, 2001, J AM COLL SURGEONS, V192, P153, DOI 10.1016/S1072-7515(00)00785-7; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Sankaran D, 1999, KIDNEY INT, V56, P281, DOI 10.1046/j.1523-1755.1999.00536.x; Schluter B, 2002, CRIT CARE MED, V30, P32, DOI 10.1097/00003246-200201000-00005; Schwartz DA, 2002, INT J HYG ENVIR HEAL, V205, P221, DOI 10.1078/1438-4639-00117; Smirnova I, 2000, GENOME BIOL, V1; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; Wang Y, 2003, HEPATOLOGY, V37, P65, DOI 10.1053/jhep.2003.50017; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195	47	116	124	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-2593	1468-6244		J MED GENET	J. Med. Genet.	NOV	2004	41	11					808	U1		10.1136/jmg.2004.021600			6	Genetics & Heredity	Genetics & Heredity	867IA	WOS:000224834700002	15520404	Bronze, Green Accepted, Green Published			2021-06-18	
J	Mizoe, J; Tsujii, H; Kamada, T; Matsuoka, Y; Tsuji, H; Osaka, Y; Hasegawa, A; Yamamoto, N; Ebihara, S; Konno, A				Mizoe, J; Tsujii, H; Kamada, T; Matsuoka, Y; Tsuji, H; Osaka, Y; Hasegawa, A; Yamamoto, N; Ebihara, S; Konno, A		Organizing Committee for the Wo	Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer	INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS			English	Article						carbon ion radiotherapy; head-and-neck cancer; high LET radiotherapy; phase I/II clinical trial; dose escalation study	NEUTRON RADIATION-THERAPY; CHARGED-PARTICLE IRRADIATION; PERSPECTIVE; CARCINOMA; TUMORS; TRIAL	Purpose: To evaluate the toxicity and efficacy of carbon ion radiotherapy for head-and-neck cancer in a Phase I/II dose escalation clinical trial. Methods and Materials: Between June 1994 and January 1997, 36 patients with locally advanced, histologically proven, and new or recurrent cancer of the head and neck were treated with carbon ions. A dose escalation study was conducted, delivering 18 fractions through 6 weeks for 17 patients (Group A) and 16 fractions through 4 weeks for 19 patients (Group B). Eligibility and ineligibility criteria were the same in both groups. The dosages were escalated in increments of 10% after careful observation of at least 3 patients treated with the same dosages. The endpoints of the study were a Grade 3 reaction of the skin and the mucous membrane or local control of the tumors. Results: Follow-up time ranged from 77 to 108 months with a median of 90 months. Grade 3 acute reaction of the skin was detected in I of the 2 patients in Group A who were treated with 70.2 GyE/18 fractions/6 weeks. In Group B, Grade 3 acute skin reaction was detected in 20% (115), 27% (2/11), and 67% (2/3) patients treated with 52.8 GyE, 57.6 GyE, and 64.0 GyE through 16 fractions for 4 weeks, respectively. There was only 1 patient with a Grade 3 acute reaction of the mucous membrane. Only 1 patient developed a Grade 2 late reaction of the mucous membrane (superficial ulcer), which was located close to the tumor. No other Grade 2 or greater late reaction was noted until the time of analysis. Acute tumor reactions in 34 patients consisted of 10 patients of complete response 19 of partial response, 4 of no change, and 1 of progressive disease. Local control of 34 patients calculated by the Kaplan-Meier method was 75% at 5 years. Five years' local control of five malignant melanomas showed 100%, and that of 9 patients with adenoid cystic carcinoma was 90%. Also, local control of 8 patients of salivary glands and 4 patients of ears was 100% at 56 months and 5 years. Conclusions: The dose fractionation methods of 70.2 GyE through 18 fractions for 6 weeks and 64.0 GyE through 16 fractions for 4 weeks showed equal clinical outcome in terms of morbidity and local control. The outcome of carbon ion radiotherapy showed a specific effectiveness in local control of non-squamous cell carcinoma such as adenoid cystic carcinomas and malignant melanomas. From the results of this study, it can be concluded that carbon ion radiotherapy will deliver a high local control rate without unacceptable injuries to the surrounding normal tissues. (C) 2004 Elsevier Inc.	Natl Inst Radiol Sci Hosp, Res Ctr Charged Particle, Inage Ku, Chiba 2638555, Japan; Iwate Cent Prefectural Hosp, Dept Radiol, Morioka, Iwate, Japan; Hokkaido Univ Hosp, Dept Radiol, Sapporo, Hokkaido 060, Japan; Natl Canc Ctr Hosp, Dept Head & Neck Surg, Kashiwa, Chiba, Japan; So Tohoku Res Inst Neurosci, Ctr Allerg Head & Neck Dis, Koriyama, Fukushima, Japan	Mizoe, J (corresponding author), Natl Inst Radiol Sci Hosp, Res Ctr Charged Particle, Inage Ku, Anagawa 4-9-1, Chiba 2638555, Japan.	j_mizoe@nirs.go.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [14570897] Funding Source: KAKEN		Ando K, 1999, INT J RADIAT BIOL, V75, P505, DOI 10.1080/095530099140438; BLAKELY EA, 1992, RADIAT ENVIRON BIOPH, V31, P181, DOI 10.1007/BF01214826; CASTRO JR, 1994, INT J RADIAT ONCOL, V29, P647, DOI 10.1016/0360-3016(94)90550-9; CASTRO JR, 1988, INT J RADIAT ONCOL, V14, P711, DOI 10.1016/0360-3016(88)90093-4; CASTRO JR, 1995, RADIAT ENVIRON BIOPH, V34, P45, DOI 10.1007/BF01210545; COHEN L, 1981, INT J RADIAT ONCOL, V7, P179, DOI 10.1016/0360-3016(81)90434-X; DUNCAN W, 1987, INT J RADIAT ONCOL, V13, P171, DOI 10.1016/0360-3016(87)90124-6; FEEHAN PE, 1992, INT J RADIAT ONCOL, V23, P881, DOI 10.1016/0360-3016(92)90663-3; GRIFFIN TW, 1984, INT J RADIAT ONCOL, V10, P2217, DOI 10.1016/0360-3016(84)90226-8; GRIFFIN TW, 1992, CRIT REV ONCOL HEMAT, V13, P17, DOI 10.1016/1040-8428(92)90014-H; Hirao Y., 1992, NUCL, V538, P541, DOI [10.1016/0375-9474(92)90803-R, DOI 10.1016/0375-9474(92)90803-R]; Kanai T, 1999, INT J RADIAT ONCOL, V44, P201, DOI 10.1016/S0360-3016(98)00544-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOH WJ, 1994, ACTA ONCOL, V33, P293, DOI 10.3109/02841869409098420; Laramore GE, 1997, SEMIN ONCOL, V24, P672; LINSTADT DE, 1991, INT J RADIAT ONCOL, V20, P761, DOI 10.1016/0360-3016(91)90020-5; PAKER RG, 1976, CANCER, V38, P1118; Schultz PW, 2000, J SOC ISSUES, V56, P391, DOI 10.1111/0022-4537.00174; SVENSSON H, 1994, ACTA ONCOL, V33, P227, DOI 10.3109/02841869409098412; TOBIAS CA, 1982, INT J RADIAT ONCOL, V8, P2109, DOI 10.1016/0360-3016(82)90554-5; TSUJII H, 2002, PROGR RADIO ONCOLOGY, V7, P393; TSUJII H, 1997, J BRACHYTHERAPY INT, V13, P1; WAMBERSIE A, 1994, ACTA ONCOL, V33, P261, DOI 10.3109/02841869409098416; WHO, 1979, WHO OFFS PUBL, V48, P23	24	116	126	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0360-3016			INT J RADIAT ONCOL	Int. J. Radiat. Oncol. Biol. Phys.	OCT 1	2004	60	2					358	364		10.1016/j.ijrobp.2004.02.067			7	Oncology; Radiology, Nuclear Medicine & Medical Imaging	Oncology; Radiology, Nuclear Medicine & Medical Imaging	855IJ	WOS:000223966500003	15380567				2021-06-18	
J	Lavoie, A; Ratte, S; Clas, D; Demers, J; Moore, L; Martin, M; Bergeron, E				Lavoie, A; Ratte, S; Clas, D; Demers, J; Moore, L; Martin, M; Bergeron, E			Preinjury warfarin use among elderly patients with closed head injuries in a trauma center	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						anticoagulant; head injuries; outcome	BRAIN-INJURY; MORTALITY; IMPACT; RISK	Background. This study aimed to determine the impact of warfarin use on the severity of injury among elderly patients presenting with closed head injuries. Methods. A cohort of patients 55 years of age or older with closed head injuries taken to a tertiary trauma center between April 1993 and March 2001 was retrospectively identified. Patient characteristics, mechanism of injury, type and severity of injury, and hospital survival data were obtained from the trauma registry. Each case then was reviewed for completeness of information, assessment of preinjury warfarin use, and comorbidity. Results: Among the 384 patients presenting with closed head injuries, 35 (9%) were receiving warfarin before their trauma. As compared with nonusers, anticoagulated patients had a higher frequency of isolated head trauma (54% vs. 32%; p = 0.008), more severe head injuries (65.7% vs. 44.1%; p = 0.02), and a higher rate of mortality (40% vs. 21%, p = 0.01). These associations remained evident even after population differences in age, gender, comorbidities, and mechanism of injury were taken into account. Indeed, according to multivariate logistic regression models, warfarin use was associated with a statistically significant risk of death (odds ratio [OR], 2.73; 95% confidence interval [CI], 1.22-6.12), statistically significant odds for more severe head injury (OR, 2.39; 95% CI, 1.10-5.17), and odds for isolated head injury that almost reached statistical significance (OR, 1.79; 95% Cl, 0.82-3.90). Conclusions:. Among patients 55 years of age or older who present with closed head injury, the use of warfarin before trauma appears to be associated with a higher frequency of isolated head trauma, more severe head trauma, and a higher likelihood of death. The findings of this retrospective study support the concern about the adverse effects of anticoagulants in cases of head trauma.	Hop Charles LeMoyne, Choc Trauma Monteregie, Quebec City, PQ J4V 2H1, Canada; Affilie Univ Quebec, Ctr Hosp, Quebec City, PQ, Canada; Univ Laval, Quebec City, PQ, Canada; Univ Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada	Bergeron, E (corresponding author), Hop Charles LeMoyne, Choc Trauma Monteregie, 3120 Blvd Taschereau,Greenfield Pk, Quebec City, PQ J4V 2H1, Canada.	eric.bergeron@traumaquebec.org					*ASS ADV AUT MED, 1990, ABBR INJ SEV SCAL; Fleming B, 2001, CAN FAM PHYSICIAN, V47, P727; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MATTLE H, 1989, J NEUROL NEUROSUR PS, V52, P829, DOI 10.1136/jnnp.52.7.829; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nagurney JT, 1998, ACAD EMERG MED, V5, P678, DOI 10.1111/j.1553-2712.1998.tb02485.x; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Saab M, 1996, J ACCID EMERG MED, V13, P208; SCHWAB CW, 2000, TRAUMA, P1099; STEIN J, 1995, ARCH PHYS MED REHAB, V76, P840, DOI 10.1016/S0003-9993(95)80549-4; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wellman M, 1999, J Fam Pract, V48, P498; WINTZEN AR, 1982, ARCH NEUROL-CHICAGO, V39, P69, DOI 10.1001/archneur.1982.00510140003001; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	24	116	119	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2004	56	4					802	807		10.1097/01.TA.0000066183.02177.AF			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	818TZ	WOS:000221268700019	15187746				2021-06-18	
J	Manly, T; Owen, AM; McAvinue, L; Datta, A; Lewis, GH; Scott, SK; Rorden, C; Pickard, J; Robertson, IH				Manly, T; Owen, AM; McAvinue, L; Datta, A; Lewis, GH; Scott, SK; Rorden, C; Pickard, J; Robertson, IH			Enhancing the sensitivity of a sustained attention task to frontal damage: Convergent clinical and functional imaging evidence	NEUROCASE			English	Article						frontal cortex; brain injury; PET; sustained attention	CLOSED HEAD-INJURY; MEMORY; DYSFUNCTION; LOCALIZATION; SUPPRESSION; DEFICITS; LESIONS	Despite frequent reports of poor concentration following traumatic brain injury, studies have generally failed to find disproportionate time-on-task decrements using vigilance measures in this patient group. Using a rather different definition, neuropsychological and functional imaging research has however linked sustained attention performance to right prefrontal function - a region likely to be compromised by such injuries. These studies have emphasised more transitory lapses of attention during dull and ostensibly unchallenging activities. Here, an existing attention measure was modified to reduce its apparent difficulty or 'challenge'. Compared with the standard task, its capacity to discriminate traumatically head-injured participants from a control group was significantly enhanced. Unlike existing functional imaging studies, that have compared a sustained attention task with a no-task control, in study 2 we used positron emission tomography to contrast the two levels of the same task. Significantly increased blood flow in the dorsolateral region of the right prefrontal cortex was associated with the low challenge condition. While the results are discussed in terms of a frontal system involved in the voluntary maintenance of performance under conditions of low stimulation, alternative accounts in terms of strategy application are considered.	Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Cambridge CB2 2QQ, England; Wolfson Brain Imaging Ctr, Cambridge, England; Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Inst Neurosci, Dublin 2, Ireland; Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England; Inst Cognit Neurosci, London, England	Manly, T (corresponding author), Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Box 58, Cambridge CB2 2QQ, England.	tom.manly@mrc-cbu.cam.ac.uk	Scott, Sophie K/A-1843-2010; Owen, Adrian M/B-4997-2015	Scott, Sophie K/0000-0001-7510-6297; Robertson, Ian H/0000-0001-8637-561X; Rorden, Chris/0000-0002-7554-6142	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission [090961] Funding Source: Medline		Benson D F, 1970, Cortex, V6, P19; BOLLER F, 1973, LANCET, V1, P1143; Bor D, 2003, NEURON, V37, P361, DOI 10.1016/S0896-6273(02)01171-6; Bor D, 2001, SCAND J PSYCHOL, V42, P217, DOI 10.1111/1467-9450.00232; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; COHEN RM, 1992, EXP BRAIN RES, V92, P165; COHEN RM, 1988, NEUROPSY NEUROPSY BE, V1, P3; Colby CL, 1998, NEURON, V20, P15, DOI 10.1016/S0896-6273(00)80429-8; Conkey RC, 1938, ARCH PSYCHOL, P5; de Zubicaray GI, 2000, NEUROPSYCHOLOGIA, V38, P1280, DOI 10.1016/S0028-3932(00)00033-6; de Zubicaray GI, 2000, NEUROPSYCHOLOGIA, V38, P1292, DOI 10.1016/S0028-3932(00)00026-9; DERENZI E, 1965, CORTEX, V1, P410; Duncan J, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P567; FUSTER JM, 1982, J NEUROSCI, V2, P361; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268; HEILMAN KM, 1987, HDB PHYSL 1, V5, P461; HOWES D, 1975, BRAIN, V98, P317, DOI 10.1093/brain/98.2.317; Lewin JS, 1996, J COMPUT ASSIST TOMO, V20, P695, DOI 10.1097/00004728-199609000-00002; Manly T., 2000, CLIN NEUROPSYCHOLOGI, V3, P167; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; NAATANEN R, 1982, PSYCHOL BULL, V92, P605; OScalaidhe SP, 1997, SCIENCE, V278, P1135, DOI 10.1126/science.278.5340.1135; Owen AM, 1996, BRAIN, V119, P1597, DOI 10.1093/brain/119.5.1597; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Petrides M., 1994, HDB NEUROPSYCHOLOGY, P59; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; POSNER MI, 1993, ATTENTION SELECTION, P390; Rainer G, 1998, NATURE, V393, P577, DOI 10.1038/31235; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROA SC, 1997, SCIENCE, V276, P821; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; SPIKMAN JM, 1996, J CLIN EXPT NEUROPSY, V18, P1; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; STUSS DT, 1989, J NEUROL NEUROSUR PS, V79, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; TECCE JJ, 1972, PSYCHOL BULL, V77, P73, DOI 10.1037/h0032177; TENNANT A, 1995, TRAUMATIC BRAIN INJU, P12; WHITEHEAD R, 1991, J COGNITIVE NEUROSCI, V3, P329, DOI 10.1162/jocn.1991.3.4.329; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; Wilson, 1991, NATL ADULT READING T; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212	50	116	116	0	8	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1355-4794	1465-3656		NEUROCASE	Neurocase	AUG	2003	9	4					340	349		10.1076/neur.9.4.340.15553			10	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	707YT	WOS:000184538100006	12925947				2021-06-18	
J	Chung, SY; Han, SH				Chung, SY; Han, SH			Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition	JOURNAL OF PINEAL RESEARCH			English	Article						epilepsy; kainic acid; melatonin; microglia; neurodegeneration; oxidative stress	CENTRAL-NERVOUS-SYSTEM; LIPID-PEROXIDATION; KAINATE; DAMAGE; RECEPTORS; GLUTAMATE; NEURONS; NEUROTRANSMITTER; LOCALIZATION; ANTAGONISTS	The antioxidant and anti-inflammatory effects of melatonin on kainic acid (KA)-induced neurodegeneration in the hippocampus were evaluated in vivo. It has been suggested that the pineal secretory product, melatonin, protects neurons in vitro from excitotoxicity mediated by kainate-sensitive glutamate receptors, and from oxidative stress-induced DNA damage and apoptosis. In this study, we injected 10 mg/kg kainate intraperitoneally (i.p.) into adult male Sprague-Dawley rats. This results in selective neuronal degeneration accompanied by intense microglial activation and triggers DNA damage in the hippocampus. We tested the in vivo efficacy of melatonin in preventing KA-induced neurodegeneration, oxidative stress and neuroinflammation in the hippocampus. Melatonin (2.5 mg/kg, i.p.) was given 20 min before, immediately after, and 1 and 2 hr after KA administration. Rats were killed 72 hr later and their hippocampi were examined for evidence of DNA damage (in situ dUTP end-labeling, i.e. TUNEL staining), cell viability (hematoxylin and eosin staining), and microglial (isolectin-B4 histochemistry) and astroglial responses (glial fibrillary acidic protein immunohistochemistry), as well as lipid peroxidation (4-hydroxynonenal immunohistochemistry). A cumulative dose of 10 mg/kg melatonin attenuates KA-induced neuronal death, lipid peroxidation, and microglial activation, and reduces the number of DNA breaks. A possible mechanism for melatonin-mediated neuroprotection involves its antioxidant and anti-inflammatory actions. The present data suggest that melatonin is potentially useful in the treatment of acute brain pathologies associated with oxidative stress-induced neuronal damage such as epilepsy, stroke, and traumatic brain injury.	Chungbuk Natl Univ, Med Res Inst, Chungbuk Natl Univ Hosp, Dept Neurol, Chungbuk 361711, South Korea; Catholic Univ, Coll Med, Our Lady Mercy Hosp, Dept Pediat, Inchon, South Korea	Han, SH (corresponding author), Chungbuk Natl Univ, Med Res Inst, Chungbuk Natl Univ Hosp, Dept Neurol, 62 Gaeshin Dong, Chungbuk 361711, South Korea.		Tiwari, Prafulla/I-1320-2014	Tiwari, Prafulla/0000-0001-7913-5386			Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Cuzzocrea S, 1998, FREE RADICAL BIO MED, V24, P450, DOI 10.1016/S0891-5849(97)00280-3; DYKENS JA, 1987, J NEUROCHEM, V49, P1222, DOI 10.1111/j.1471-4159.1987.tb10014.x; FERKANY JW, 1982, NATURE, V298, P757, DOI 10.1038/298757a0; Gilad E, 1997, LIFE SCI, V60, P169; Giusti P, 1996, FASEB J, V10, P891; Hsu CH, 2002, J PINEAL RES, V32, P53, DOI 10.1034/j.1600-079x.2002.10809.x; Keller JN, 1998, REV NEUROSCIENCE, V9, P105; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kruman I, 1997, J NEUROSCI, V17, P5089; LEES GJ, 1992, J NEUROL SCI, V108, P221, DOI 10.1016/0022-510X(92)90055-P; Li XJ, 2002, J PINEAL RES, V32, P47, DOI 10.1034/j.1600-079x.2002.10831.x; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; Matsuoka Y, 1999, NEUROPHARMACOLOGY, V38, P825, DOI 10.1016/S0028-3908(99)00020-9; MELCHIORRI D, 1995, FASEB J, V9, P1205; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; Nalder J.V., 1980, J COMP NEUROL, V192, P333; OLNEY JW, 1974, BRAIN RES, V77, P507, DOI 10.1016/0006-8993(74)90640-4; PALMER AM, 1992, ANN NY ACAD SCI, V648, P361, DOI 10.1111/j.1749-6632.1992.tb24583.x; Pappolla MA, 2002, J PINEAL RES, V32, P135, DOI 10.1034/j.1600-079x.2002.1o838.x; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Pei Z, 2002, J PINEAL RES, V32, P168, DOI 10.1034/j.1600-079x.2002.1o847.x; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ, 2001, ANN NY ACAD SCI, V939, P200; Shen YX, 2002, J PINEAL RES, V32, P85, DOI 10.1034/j.1600-079x.2002.1819.x; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V381, P683; Tan D-X, 1993, ENDOCR J, V1, P57; Tan DX, 1998, J NEUROSCI RES, V54, P382, DOI 10.1002/(SICI)1097-4547(19981101)54:3<382::AID-JNR9>3.0.CO;2-Y; Uz T, 1996, NEUROSCIENCE, V73, P631, DOI 10.1016/0306-4522(96)00155-8; VIRGILI M, 1992, NEUROPHARMACOLOGY, V31, P469, DOI 10.1016/0028-3908(92)90085-4; Waeg G, 1996, FREE RADICAL RES, V25, P149, DOI 10.3109/10715769609149920; WASTERLAIN CG, 1993, EPILEPSIA, V34, pS37, DOI 10.1111/j.1528-1157.1993.tb05905.x	37	116	124	0	5	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0742-3098			J PINEAL RES	J. Pineal Res.	MAR	2003	34	2					95	102		10.1034/j.1600-079X.2003.00010.x			8	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	641JM	WOS:000180741700003	12562500	Bronze			2021-06-18	
J	Temkin, NR				Temkin, NR			Risk factors for posttraumatic seizures in adults	EPILEPSIA			English	Article						head injury; epilepsy; risk factors; posttraumatic seizures	EPILEPSY; PREVENTION	Purpose: Traumatic brain injury has long been known to be a cause of epilepsy. Most information on risk factors for developing posttraumatic seizures is from before computed tomography (CT) scanning became universal. This article looks at factors about the injury or individual that put people at especially high risk of developing posttraumatic seizures. Methods: We considered 783 cases at high risk of developing seizures, followed up for 2 years as part of seizure prophylaxis studies. Cumulative incidence of seizures in subgroups and standardized incidence ratios were used to identify factors related to unprovoked seizure risk. Results: Subgroups with significantly elevated risk include those with evacuation of a subdural hematoma; surgery for an intracerebral hematoma; Glasgow Coma Scale in the severe range of 3 to 8; early seizures, especially delayed early seizures; time to following commands of a week or more; depressed skull fracture that was not surgically elevated; dural penetration by injury; at least one nonreactive pupil; and parietal lesions on CT scan. Conclusions: Both the risk factors and the time course of the risk are important for designing seizure-prophylaxis studies and, if an effective prophylactic regimen is identified, for deciding on appropriate candidates for prophylaxis.	Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA	Temkin, NR (corresponding author), Univ Washington, Dept Neurol Surg, 710 9th Ave,Room 306, Seattle, WA 98104 USA.						Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Jennett B, 1975, EPILEPSY NONMISSILE; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	8	116	126	0	4	BLACKWELL PUBLISHING INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	0013-9580			EPILEPSIA	Epilepsia		2003	44			10			18	20		10.1046/j.1528-1157.44.s10.6.x			3	Clinical Neurology	Neurosciences & Neurology	733YK	WOS:000186028100004	14511390				2021-06-18	
J	Tokutomi, T; Morimoto, K; Miyagi, T; Yamaguchi, S; Ishikawa, K; Shigemori, M				Tokutomi, T; Morimoto, K; Miyagi, T; Yamaguchi, S; Ishikawa, K; Shigemori, M			Optimal temperature for the management of severe traumatic brain injury: Effect of hypothermia on intracranial pressure, systemic and intracranial hemodynamics, and metabolism	NEUROSURGERY			English	Article						hemodynamics; hypothermia; intracranial pressure; metabolism; traumatic brain injury	CEREBRAL-BLOOD-FLOW; FLUID-PERCUSSION INJURY; CORTICAL IMPACT INJURY; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; HEAD-INJURY; POSTTRAUMATIC HYPOTHERMIA; CEREBROSPINAL-FLUID; ADHESION MOLECULES; RADICAL PRODUCTION	OBJECTIVE: We studied the effect of hypothermia on intracranial pressure, systemic and intracranial hemodynamics, and metabolism in patients with severe traumatic brain injury to clarify the optimal temperature for hypothermia, with a view toward establishing the proper management techniques for such patients. METHODS: The study was performed in 31 patients with severe head injury (Glasgow Coma Scale score as high as 5). All patients were sedated, paralyzed, ventilated, and cooled to 33degreesC. Brain temperature, core temperature, intracranial pressure, cerebral perfusion pressure, jugular venous oxygen saturation, mixed venous oxygen saturation, cardiac output, oxygen delivery, oxygen consumption, and testing energy expenditure were monitored continuously. RESULTS: Intracranial pressure decreased significantly at brain temperatures below 37degreesC and decreased more sharply at temperatures 35 to 36degreesC, but no differences were observed at temperatures below 35degreesC. Cerebral perfusion pressure peaked at 35.0 to 35.9degreesC and decreased with further decreases in temperature. jugular venous oxygen saturation and mixed venous oxygen saturation remained in the normal range during hypothermia. Resting energy expenditure and cardiac output decreased progressively with hypothermia. Oxygen delivery and oxygen consumption decreased to abnormally low levels at rectal temperatures below 35degreesC, and the correlation between them became less significant at less than 35degreesC than that when temperatures were 35degreesC or higher. Brain temperature was consistently higher than rectal temperature by 0.5 +/- 0.3degreesC. CONCLUSION: These results suggest that, after traumatic brain injury, decreasing body temperature to 35 to 35.5degreesC can reduce intracranial hypertension while maintaining sufficient cerebral perfusion pressure without cardiac dysfunction or oxygen debt. Thus, 35 to 35.5degreesC seems to be the optimal temperature at which to treat patients with severe traumatic brain injury.	Kurume Univ, Sch Med, Dept Neurosurg, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Sch Med, Dept Anesthesiol, Kurume, Fukuoka 8300011, Japan	Tokutomi, T (corresponding author), Kurume Univ, Sch Med, Dept Neurosurg, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	toku@mail.med.kurume-u.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18591617] Funding Source: KAKEN		Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHEN RYZ, 1978, AM J PHYSIOL, V235, pH136; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Maeda T, 1998, J NEUROTRAUM, V15, P655, DOI 10.1089/neu.1998.15.655; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; Mori K, 1998, NEUROL RES, V20, P719; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; PATEL PM, 1994, BRAIN RES, V650, P205, DOI 10.1016/0006-8993(94)91783-3; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SCHUBERT A, 1995, J NEUROSURG ANESTH, V7, P139, DOI 10.1097/00008506-199504000-00021; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SPRUNG J, 1992, ACTA ANAESTH SCAND, V36, P825, DOI 10.1111/j.1399-6576.1992.tb03572.x; VANOSS CJ, 1980, J RETICULOENDOTH SOC, V27, P561; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	46	116	121	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2003	52	1					102	111		10.1097/00006123-200301000-00013			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	631YL	WOS:000180195800021	12493106				2021-06-18	
J	Kline, AE; Massucci, JL; Marion, DW; Dixon, CE				Kline, AE; Massucci, JL; Marion, DW; Dixon, CE			Attenuation of working memory and spatial acquisition deficits after a delayed and chronic bromocriptine treatment regimen in rats subjected to traumatic brain injury by controlled cortical impact	JOURNAL OF NEUROTRAUMA			English	Article						dopamine; dopamine agonist; function; learning; memory; Morris water maze	FRONTAL-LOBE DYSFUNCTION; WATER MAZE PERFORMANCE; COGNITIVE DEFICITS; HEAD-INJURY; CELL-DEATH; EXPERIENCE; IMPAIRMENT; RECOVERY; IMPROVES; AGONIST	Cognitive impairments are pervasive and persistent sequelae of human traumatic brain injury (TBI). In vivo models of TBI, such as the controlled cortical impact (CCI) and fluid percussion (FP), are utilized extensively to produce deficits reminiscent of those seen clinically with the hope that empirical study will lead to viable therapeutic interventions. Both CCI and FP produce spatial learning acquisition deficits, but only the latter has been reported to impair working memory in rats tested in the Morris water maze (MWM). We hypothesized that a CCI injury would impair working memory similarly to that produced by FP, and that delayed and chronic treatment with the D2 receptor agonist bromocriptine would attenuate both working memory and spatial learning acquisition deficits. To test these hypotheses, isoflurane-anesthetized adult male rats received either a CCI (2.7 mm deformation, 4 m/sec) or sham injury, and 24 h later were administered bromocriptine (5 mg/kg, i.p.) or vehicle, with continued daily injections until all behavioral assessments were completed. Motor function was assessed on beam balance and beam walking tasks on postoperative days 1-5 and cognitive function was evaluated in the MWM on days 11-15 for working memory (experiment 1) and on days 14-18 for spatial learning acquisition (experiment 2). Histological examination (hippocampal CA(1) and CA(3) cell loss/survival and cortical lesion volume) was conducted 4 weeks after surgery. All injured groups exhibited initial impairments in motor function, working memory, and spatial learning acquisition. Bromocriptine did not affect motor function, but did ameliorate working memory and significantly attenuated spatial acquisition deficits relative to the injured vehicle-treated controls. Additionally, the injured bromocriptine-treated group exhibited significantly more morphologically intact CA(3) neurons than the injured vehicle-treated group (55.60 +/- 3.10% vs. 38.34 +/- 7.78% [p = 0.03]). No significant differences were observed among TBI groups in CA(1) cell survival (bromocriptine, 40.26 +/- 4.74% vs. vehicle, 29.13 +/- 6.63% [p = 0.14]) or cortical lesion volume (bromocriptine, 17.78 +/- 0.62 mm(3) vs. vehicle, 19.01 +/- 1.49 mm(3) [p > 0.05]). These data reveal that CCI produces working memory deficits in rats that are similar to those observed following FP, and that the delayed and chronic bromocriptine treatment regimen conferred cognitive and neural protection after TBI.	Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, 3434 5th Ave,Ste 201, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Marion, Donald/AAR-5749-2021		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318, NS33150, NS40125] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS040125, P20NS030318, P01NS030318, R01NS033150] Funding Source: NIH RePORTER		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Allain P, 2001, BRAIN COGNITION, V45, P21, DOI 10.1006/brcg.2000.1249; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOISSARD CG, 1992, NEUROSCIENCE, V48, P807, DOI 10.1016/0306-4522(92)90268-7; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; BRANNAN T, 1993, J NEURAL TRANSM-PARK, V6, P81, DOI 10.1007/BF02261001; Chen YK, 2001, BRAIN RES, V896, P165, DOI 10.1016/S0006-8993(01)02081-9; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1999, AM J PHYSIOL, V277, P1196; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Golden K. M., 2000, Journal of Neurotrauma, V17, P960; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Jackson David M., 1995, Naunyn-Schmiedeberg's Archives of Pharmacology, V351, P146; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; KLINE AE, 2002, IN PRESS NEUROSCI LE; KLINE AE, 2001, MO CL BI CC, V2, P267; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LIU XH, 1995, J NEUROL SCI, V129, P9, DOI 10.1016/0022-510X(94)00239-K; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MHarzi M, 1997, PHARMACOL BIOCHEM BE, V56, P663, DOI 10.1016/S0091-3057(96)00423-6; Mizoguchi K, 2000, J NEUROSCI, V20, P1568; Muralikrishnan D, 1998, FASEB J, V12, P905; O'Neill MJ, 1998, EUR J PHARMACOL, V352, P37, DOI 10.1016/S0014-2999(98)00333-1; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; PULASKI KH, 1994, AM J OCCUP THER, V48, P263, DOI 10.5014/ajot.48.3.263; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Seifert W, 1983, NEUROBIOLOGY HIPPOCA, P405; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Tanaka K, 2001, NEUROCHEM RES, V26, P31, DOI 10.1023/A:1007672414239; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	65	116	118	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2002	19	4					415	425		10.1089/08977150252932370			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	542XP	WOS:000175071200003	11990348				2021-06-18	
J	Cicerone, KD				Cicerone, KD			Remediation of 'working attention' in mild traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD INJURY; DEFICITS; MEMORY	Several studies have reported beneficial effects of treatments for attentional deficits following traumatic brain injury. Improvements in speed of processing appear to be less robust than improvements on non-speeded tasks, while several studies suggest greater benefits of training more complex forms of attention. The present study presents preliminary results concerning the effectiveness of an intervention for attentional deficits after mild traumatic brain injury. The treatment was based upon the conceptualization of deficits and interventions as a function of the central executive component of working memory, or 'working attention'. A prospective, case-comparison design was employed comparing four treatment participants with an untreated comparison sample. Treatment tasks were derived from experimental procedures which have been demonstrated to elicit working memory demands, consisting of 'n-back', random generation, and dual-task procedures. The intervention emphasized the conscious and deliberate use of strategies to effectively allocate attentional resources and manage the rate of information during task performance. Treatment participants were more likely to exhibit clinically significant improvement on measures of attention and reduction of self-reported attentional difficulties in their daily functioning. Further analysis suggested that the principal effect of the intervention was on working memory, i.e. the ability to temporarily maintain and manipulate information during task performance, with no direct effect on processing speed. The results are consistent with a strategy training model of remediation, in which the benefits of treatment are due to participants' improved ability to compensate for residual deficits and adopt strategies for the more effective allocation of their remaining attentional resources.	JFK Johnson Rehabil Inst, Edison, NJ 08820 USA	Cicerone, KD (corresponding author), JFK Johnson Rehabil Inst, 2048 Oak Tree Rd, Edison, NJ 08820 USA.						Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A., 1993, ATTENTION SELECTION, P152; Baddeley A. D., 1994, Neuropsychology, V8, P485, DOI [10.1037/0894-4105.8.4.485., 10.1037/0894-4105.8.4.485]; Basso A, 2000, NEUROPSYCHOL REHABIL, V10, P219, DOI 10.1080/096020100389138; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; CICERONE KD, 2000, UNPUB NATURE ATTENTI; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; Heaton R.K., 1991, COMPREHENSIVE NORMS; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; MATEER CA, 1990, COGNITIVE REHABILITA, P68; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; Reason J., 1993, ATTENTION SELECTION, P406; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; RUFF RM, 1996, RUFF 2 7 SELECTIVE A; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526	22	116	116	0	29	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2002	16	3					185	195		10.1080/02699050110103959			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	526HP	WOS:000174124800001	11874612				2021-06-18	
J	Tate, MC; Shear, DA; Hoffman, SW; Stein, DG; Archer, DR; LaPlaca, MC				Tate, MC; Shear, DA; Hoffman, SW; Stein, DG; Archer, DR; LaPlaca, MC			Fibronectin promotes survival and migration of primary neural stem cells transplanted into the traumatically injured mouse brain	CELL TRANSPLANTATION			English	Article; Proceedings Paper	8th Annual Conference of the American-Society-for-Neural-Transplantation-and-Repair	MAY 03-06, 2001	CLEARWATER, FLORIDA	Amer Soc Neural Transplantat & Repair		traumatic brain injury; tissue engineering; fibronectin; extracellular matrix; neural progenitor cells; stem cells	RAT SPINAL-CORD; CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; FUNCTIONAL RECOVERY; RESTRICTED PRECURSORS; PERIPHERAL-NERVE; GRAFT-SURVIVAL; GROWTH; MODEL; TISSUE	Multipotential stem cells are an attractive choice for cell therapy after traumatic brain injury (TBI), as replacement of multiple cell types may be required for functional recovery. In the present study, neural stem cells (NSCs) derived from the germinal zone of E14.5 GFP-expressing mouse brains were cultured as neurospheres in FGF2-enhanced medium. When FGF2 was removed in vitro, NSCs expressed phenotypic markers for neurons, astrocytes, and oligodendrocytes and exhibited migratory behavior in the presence of adsorbed fibronectin (FN). NSCs (10(5) cells) were transplanted into mouse brains 1 week after a unilateral, controlled, cortical contusion (depth = 1 mm, velocity = 6 m/s, duration = 150 ms) (it = 19). NSCs were injected either directly into the injury cavity with or without an injectable FN-based scaffold [collagen I (CnI)/ FN gel; n = 14] or into the striatum below the injury cavity (n = 5). At all time points examined (1 week to 3 months posttransplant), GFP+ cells were confined to the ipsilateral host brain tissue. At 1 week, cells injected into the injury cavity lined the injury penumbra while cells inserted directly into the striatum remained in or around the needle track. Striatal transplants had a lower number of surviving GFP+ cells relative to cavity injections at the 1 week time point (p < 0.01). At the longer survival times (3 weeks-3 months), 63-76% of transplanted cells migrated into the fimbria hippocampus regardless of injection site, perhaps due to cues from the degenerating hippocampus. Furthermore, cells injected into the cavity within a FN-containing matrix showed increased survival and migration at 3 weeks (p < 0.05 for both) relative to injections of cells alone. These results suggest that FGF2-responsive NSCs present a promising approach for cellular therapy following trauma and that the transplant location and environment may play an important role in graft survival and integration.	Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; Emory Univ, Dept Pediat, Atlanta, GA 30322 USA	LaPlaca, MC (corresponding author), Georgia Inst Technol, Coulter Dept Biomed Engn, 315 Ferst Dr, Atlanta, GA 30332 USA.		Shear, Deborah/B-3607-2011; Stein, Donald/AAJ-5139-2020				Baldwin SP, 1996, INT J DEV NEUROSCI, V14, P351, DOI 10.1016/0736-5748(96)00018-4; Branton RL, 1998, NEUROREPORT, V9, P3223, DOI 10.1097/00001756-199810050-00017; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Chauhan NB, 1999, INT J DEV NEUROSCI, V17, P255, DOI 10.1016/S0736-5748(99)00003-9; Chow SY, 2000, BRAIN RES, V874, P87, DOI 10.1016/S0006-8993(00)02443-4; DAVIES SJA, 1993, EUR J NEUROSCI, V5, P95, DOI 10.1111/j.1460-9568.1993.tb00474.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOUCETTE R, 1994, BRAIN RES, V649, P334, DOI 10.1016/0006-8993(94)91083-9; Duan WM, 2000, NEUROSCIENCE, V100, P521, DOI 10.1016/S0306-4522(00)00299-2; EGAN RA, 1991, BRAIN RES, V568, P330, DOI 10.1016/0006-8993(91)91421-V; Fulop ZL, 1997, INT J NEUROSCI, V90, P203, DOI 10.3109/00207459709000639; Gray JA, 2000, CELL TRANSPLANT, V9, P153, DOI 10.1177/096368970000900203; HOOVLER DW, 1991, ACTA NEUROPATHOL, V81, P303, DOI 10.1007/BF00305872; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jacques TS, 1998, DEVELOPMENT, V125, P3167; KOZLOVA EN, 1990, DOKL AKAD NAUK SSSR+, V313, P1241; LEFCORT F, 1992, DEVELOPMENT, V116, P767; LESCAUDRON L, 1990, NEUROPSYCHOLOGIA, V28, P585, DOI 10.1016/0028-3932(90)90036-N; Levison SW, 1997, J NEUROSCI RES, V48, P83, DOI 10.1002/(SICI)1097-4547(19970415)48:2<83::AID-JNR1>3.3.CO;2-4; LIESI P, 1984, EMBO J, V3, P683, DOI 10.1002/j.1460-2075.1984.tb01867.x; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; MATHEWS GA, 1995, J NEUROBIOL, V26, P171, DOI 10.1002/neu.480260203; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Milward EA, 1997, J NEUROSCI RES, V50, P862, DOI 10.1002/(SICI)1097-4547(19971201)50:5<862::AID-JNR22>3.3.CO;2-O; MIZUTANI K, 1987, ACTA HISTOCHEM CYTOC, V20, P87, DOI 10.1267/ahc.20.87; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Rao MS, 1999, ANAT RECORD, V257, P137; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.ne.14.030191.002531; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SHIHABUDDIN LS, 1995, J NEUROSCI, V15, P6666; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; Tornqvist N, 2000, EXP NEUROL, V164, P130, DOI 10.1006/exnr.2000.7411; VALOUSKOVA V, 1995, NEUROSCI LETT, V186, P103, DOI 10.1016/0304-3940(95)11295-8; VANDERWOLF CH, 1990, EXP BRAIN RES, V81, P426; Watts C, 2000, EXP NEUROL, V163, P85, DOI 10.1006/exnr.1999.7341; Wells MR, 1997, EXP NEUROL, V146, P395, DOI 10.1006/exnr.1997.6543; Woerly S, 1999, TISSUE ENG, V5, P467, DOI 10.1089/ten.1999.5.467; Woerly S, 2000, NEUROSURG REV, V23, P59	43	116	127	0	8	COGNIZANT COMMUNICATION CORP	ELMSFORD	3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA	0963-6897			CELL TRANSPLANT	Cell Transplant.		2002	11	3					283	295					13	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	561LD	WOS:000176141400012	12075994				2021-06-18	
J	Stahl, N; Mellergard, P; Hallstrom, A; Ungerstedt, U; Nordstrom, CH				Stahl, N; Mellergard, P; Hallstrom, A; Ungerstedt, U; Nordstrom, CH			Intracerebral microdialysis and bedside biochemical analysis in patients with fatal traumatic brain lesions	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						head injury; cerebral ischemia; microdialysis; glucose; glutamate; glycerol; lactate; pyruvate	CEREBRAL-ISCHEMIA; VOLUME REGULATION; INCOMPLETE ISCHEMIA; ENERGY-METABOLISM; HEAD-INJURY; GLYCEROL; DEGRADATION; PRINCIPLES; PRESSURE; SEIZURES	Background: Microdialysis with bedside biochemical analysis was used to monitor cerebral biochemical alterations that precede and accompany increase in intracranial pressure (ICP), resulting in a complete cessation of cerebral blood flow. Methods: Seven patients, who died due to an untreatable increase in ICP, were included. The patients originate from a large, consecutive series of severely head injured patients (n: 95) monitored with intracerebral microdialysis (perfusion rate 0.3 mul/min). One microdialysis catheter was inserted via a separate burr hole frontally to that used for the intraventricular catheter ("better" position) and one catheter was inserted into cerebral cortex surrounding an evacuated focal contusion or underlying an evacuated haematoma ("worse" position). Biochemical analyses of glucose, lactate, glycerol, urea, glutamate, and pyruvate were performed at the bedside. All samples were frozen for subsequent HPLC (high-performance liquid chromatography) analyses of amino acids and ions. Results: Decreases in glucose and pyruvate and increases in lactate, glycerol, glutamate, and lactate/ pyruvate (la/py) ratio characterized cerebral ischaemia. The measured markers give information regarding substrate availability (glucose), redox state of the tissue (la/py ratio), degradation of glycerophospholipids in cell membranes (glycerol), and extracellular concentration of excitatory amino acids (glutamate). In the "worse" position biochemical deterioration occurred before the increase in ICP. In the "better" position biochemical deterioration was usually observed after the increase in ICP. Conclusion: Changes of cerebral energy metabolism that accompany cerebral ischaemia follow a certain pattern and may be detected at the bedside by intracerebral microdialysis before the secondary damage causes an increase in ICP.	Univ Lund Hosp, Dept Clin Neurosci, S-22185 Lund, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden	Nordstrom, CH (corresponding author), Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden.						ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P922, DOI 10.1111/j.1399-6576.1995.tb04199.x; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BERTRAND N, 1992, NEUROSCI LETT, V148, P81, DOI 10.1016/0304-3940(92)90809-L; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; GERCKEN G, 1973, PFLUG ARCH EUR J PHY, V344, P207, DOI 10.1007/BF00588461; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; GRANDE PO, 1997, J TRAUMA, V42, P23; HARPER HA, 1963, REV PHYSL CHEM; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Kongstad L, 1999, ACTA ANAESTH SCAND, V43, P501, DOI 10.1034/j.1399-6576.1999.430503.x; LINDROTH P, 1979, ANAL CHEM, V51, P1167; LJUNGGREN B, 1974, BRAIN RES, V77, P173, DOI 10.1016/0006-8993(74)90782-3; LUNDBERG N, 1960, ACTA PSYCHIAT NEUR S, V149; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORDSTROM CH, 1978, STROKE, V9, P327, DOI 10.1161/01.STR.9.4.327; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Saveland H, 1996, NEUROSURGERY, V38, P12, DOI 10.1097/00006123-199601000-00004; Siesj_o B K, 1978, BRAIN ENERGY METABOL; TEASDALE G, 1974, LANCET, V2, P81; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971	29	116	119	0	1	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2001	45	8					977	985		10.1034/j.1399-6576.2001.450810.x			9	Anesthesiology	Anesthesiology	478ZX	WOS:000171380400010	11576049				2021-06-18	
J	Wright, DW; Bauer, ME; Hoffman, SW; Stein, DG				Wright, DW; Bauer, ME; Hoffman, SW; Stein, DG			Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats	JOURNAL OF NEUROTRAUMA			English	Article						head injury; neuroprotection; neurosteroids; progesterone; traumatic brain injury	SEVERE HEAD-INJURY; PERIPHERAL NERVOUS-SYSTEM; SEX STEROID-HORMONES; GLIAL-CELLS; CORTICAL CONTUSION; LIPID-PEROXIDATION; ARTERY OCCLUSION; NEUROSTEROIDS; RECEPTORS; CORTEX	Previous animal research suggests that progesterone may have powerful neuroprotective effects in traumatic brain injury (TBI). This experiment tested the hypothesis that progesterone levels correlate with decreased cerebral edema in male rats with bilateral medial frontal cortex injuries. Three groups of male Sprague-Dawley rats were used: injured given progesterone (4 mg/kg), injured given vehicle (oil), and uninjured controls given vehicle. Progesterone or vehicle was administered intraperitoneally at 1, 6, and 24 h postinjury. At 48 h postinjury, the rats were killed, brains extracted, and assayed for edema. Percent difference in water content of the area surrounding the lesion was compared to posterior cortex. A strong inverse relationship was found between serum progesterone levels and percent cerebral edema; the higher the progesterone levels, the lower the percent edema. Both progesterone and oil-treated animals had some edema compared to sham-operated controls. The brains of the injured animals given control solution were higher in water content than either the uninjured group or injured progesterone-treated rats 48 h postinjury. These findings confirm that progesterone significantly decreases cerebral edema after TBI in adult male subjects.	Emory Univ, Sch Med, Dept Emergency Med, Emergency Med Res Ctr, Atlanta, GA 30322 USA; Emory Univ, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	Wright, DW (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, Emergency Med Res Ctr, Atlanta, GA 30322 USA.		Stein, Donald/AAJ-5139-2020; Wright, David/F-1209-2013	Wright, David/0000-0002-7145-9105			AKWA Y, 1991, J STEROID BIOCHEM, V40, P71, DOI 10.1016/0960-0760(91)90169-6; Allolio B, 1995, EUR J ENDOCRINOL, V133, P696, DOI 10.1530/eje.0.1330696; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; BACKSTROM T, 1984, ACTA NEUROL SCAND, V69, P240; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; BAULIEU EE, 1992, ADV BIOCHEM PSYCHOPH, V47, P1; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; Baulieu EE, 1997, MULT SCLER J, V3, P105, DOI 10.1177/135245859700300209; Bergeron R, 1996, J NEUROSCI, V16, P1193; BETZ AL, 1990, ACT NEUR S, V51, P256; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Bitran D, 1996, PSYCHOPHARMACOLOGY, V125, P65, DOI 10.1007/BF02247394; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CamachoArroyo I, 1996, NEUROSCI LETT, V214, P25; CAMACHOARROYO I, 1994, J STEROID BIOCHEM, V50, P299, DOI 10.1016/0960-0760(94)90135-X; Cargill RS, 1999, J NEUROTRAUM, V16, P983; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; *DIAGN PROD CORP, 1998, IMM PROG; FARLEY D, 1990, FDA CONSUM, V24, P8; GANONG WF, 1987, REV MED PHYSL, P346; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Genazzani A R, 1997, Eur J Contracept Reprod Health Care, V2, P63; GENAZZANI AR, 1996, 1 TUSC C REPR MED PI; Goldfien A, 1989, BASIC CLIN PHARM, P493; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GOUJARD J, 1977, LANCET, V1, P482; HOCHBERG RB, 1990, SER FDN S BUD HUNG; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Jung-Testas I, 1998, J STEROID BIOCHEM, V65, P243, DOI 10.1016/S0960-0760(97)00191-X; JUNGTESTAS I, 1994, J STEROID BIOCHEM, V48, P145, DOI 10.1016/0960-0760(94)90261-5; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Lancel M, 1996, AM J PHYSIOL-ENDOC M, V271, pE763; Limmroth V, 1996, BRIT J PHARMACOL, V117, P99, DOI 10.1111/j.1476-5381.1996.tb15160.x; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1995, J NEUROTRAUM, V12, P929, DOI 10.1089/neu.1995.12.929; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; MURAD F, GOODMAN GILMANS PHAR, P1384; Reddy DS, 1996, PSYCHOPHARMACOLOGY, V128, P280, DOI 10.1007/s002130050136; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1994, SOC NEUR MIAM BEACH; ROOF RL, 1996, 26 SOC NEUR M BETH M; ROOF RL, 1996, SOC NEUR WASH DC; ROOF RL, 1997, J NEUROTRAUM, V14, P760; Schumacher M, 1995, CIBA F SYMP, V191, P90; SUTTON RL, 1998, COMP BIOCH PHYSL A, V119, P711; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Unterberg AW, 1997, ACT NEUR S, V70, P106; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Waynforth HB, 1980, EXPT SURG TECHNIQUE	59	116	123	0	14	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2001	18	9					901	909		10.1089/089771501750451820			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	471TP	WOS:000170945000006	11565602				2021-06-18	
J	Sinson, G; Bagley, LJ; Cecil, KM; Torchia, M; McGowan, JC; Lenkinski, RE; McIntosh, TK; Grossman, RI				Sinson, G; Bagley, LJ; Cecil, KM; Torchia, M; McGowan, JC; Lenkinski, RE; McIntosh, TK; Grossman, RI			Magnetization transfer imaging and proton MR spectroscopy in the evaluation of axonal injury: Correlation with clinical outcome after traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Neurological-Surgeons	APR 25-30, 1998	PHILADELPHIA, PA	Amer Assoc Neurol Surgeons			SEVERE HEAD-INJURY; REMITTING MULTIPLE-SCLEROSIS; PROBABLE ALZHEIMERS-DISEASE; N-ACETYL-ASPARTATE; RESONANCE SPECTROSCOPY; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC VALUE; WHITE-MATTER; HISTOPATHOLOGIC CORRELATION; PARKINSONS-DISEASE	BACKGROUND AND PURPOSE: Current imaging does not permit quantification of neural injury after traumatic brain injury (TBI) and therefore limits both the development of new treatments and the appropriate counseling of patients concerning prognosis. We evaluated the utility of magnetization transfer ratio (MTR) and proton MR spectroscopy in identifying patients with neuronal injury after TBI. METHODS: Thirty patients with TBI (21-77 years old; mean age, 42 years; admission Glasgow Coma Scale (GOS) scores 3-15; mean score, 11) were studied on a 1.5-T system with magnetization transfer imaging and MR spectroscopy of the splenium, Magnetization transfer imaging was also performed in the brain stem in all patients, and other areas of the brain were sampled in one patient. The splenium of the corpus callosum and brain stem were studied because these are often affected by diffuse axonal injury. Scans were obtained 2 to 1129 days after injury (median, 41 days). MTR was considered abnormal if it was more than 2 SD below normal. Proton MR spectroscopy was used to calculate the N-acetylaspartate (NAA)/creatine (Cr) ratio, GOS was determined at least 3 months after injury. RESULTS: In 10 patients with a GOS of 1 to 4, the mean NAA/Cr was 1.24 =/- 0.28; two of these patients had abnormal MTR in normal-appearing white matter (NAWM). In 20 patients with a GOS of 5, the mean NAA/Cr was 1.53 +/- 0.37 (P <.05); four of these patients had abnormal MTR in NAWM, MTR abnormalities in NAWM were Identified in six patients, but these changes did not correlate with GOS or MR spectroscopy changes. CONCLUSION: MTR and MR spectroscopy can quantify damage after TBI, and NAA levels may be a sensitive indicator of the neuronal damage that results in a worse clinical outcome.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiol, Philadelphia, PA 19104 USA	Sinson, G (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.		Lenkinski, Robert/F-9045-2014	Lenkinski, Robert/0000-0001-7371-5048; Cecil, Kim/0000-0001-8233-5485	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR002305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R29NS034353, P01NS008803, R55NS034353] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR-02305] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803, NS-34353] Funding Source: Medline		ALGES WM, 1996, NEUROTRAUMA, P947; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; BARKER PB, 1995, RADIOLOGY, V195, P58, DOI 10.1148/radiology.195.1.7892496; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHARLES HC, 1994, PROG NEURO-PSYCHOPH, V18, P995, DOI 10.1016/0278-5846(94)90125-2; Cheng LL, 1997, P NATL ACAD SCI USA, V94, P6408, DOI 10.1073/pnas.94.12.6408; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CHRISTIANSEN P, 1995, MAGN RESON IMAGING, V13, P457, DOI 10.1016/0730-725X(94)00113-H; CHRISTIANSEN P, 1993, MAGN RESON IMAGING, V11, P799, DOI 10.1016/0730-725X(93)90197-L; CLARKE DD, 1975, J NEUROCHEM, V24, P479, DOI 10.1111/j.1471-4159.1975.tb07665.x; COLLINS JG, 1990, VITAL HLTH STAT, V10, P175; Constantinidis I, 1996, BRIT J RADIOL, V69, P15, DOI 10.1259/0007-1285-69-817-15; DAVIES SEC, 1995, J NEUROCHEM, V64, P742; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; Falconer JC, 1996, J NEUROCHEM, V66, P717; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Federico F, 1997, J NEUROL NEUROSUR PS, V62, P239, DOI 10.1136/jnnp.62.3.239; Federico F, 1996, J NEUROL, V243, P241, DOI 10.1007/BF00868521; Fu L, 1996, NMR BIOMED, V9, P339, DOI 10.1002/(SICI)1099-1492(199612)9:8<339::AID-NBM422>3.0.CO;2-X; Fulton JC, 1999, AM J NEURORADIOL, V20, P1951; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Gillard JH, 1996, AM J NEURORADIOL, V17, P873; Gonen O, 2000, NEUROLOGY, V54, P15, DOI 10.1212/WNL.54.1.15; Gredal O, 1997, NEUROLOGY, V48, P878, DOI 10.1212/WNL.48.4.878; GROSSMAN RI, 1994, RADIOGRAPHICS, V14, P279, DOI 10.1148/radiographics.14.2.8190954; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hannay HJ, 1996, NEUROTRAUMA, P723; Harms L, 1997, J NEUROL NEUROSUR PS, V62, P27, DOI 10.1136/jnnp.62.1.27; Heun R, 1997, INT J GERIATR PSYCH, V12, P349, DOI 10.1002/(SICI)1099-1166(199703)12:3<349::AID-GPS508>3.0.CO;2-S; HIEHLE JF, 1994, MAGNET RESON MED, V32, P285, DOI 10.1002/mrm.1910320303; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Hu MTM, 1999, J NEUROL NEUROSUR PS, V67, P20, DOI 10.1136/jnnp.67.1.20; Iranzo A, 1999, J NEUROL NEUROSUR PS, V66, P520, DOI 10.1136/jnnp.66.4.520; JAARSMA D, 1994, J NEUROL SCI, V127, P230, DOI 10.1016/0022-510X(94)90077-9; JENNETT B, 1975, LANCET, V1, P480; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; Kimura H, 1996, AM J NEURORADIOL, V17, P1539; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; KLUNK WE, 1992, NEUROLOGY, V42, P1578, DOI 10.1212/WNL.42.8.1578; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1996, NEUROTRAUMA, P13; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Lazeyras F, 1998, PSYCHIAT RES-NEUROIM, V82, P95, DOI 10.1016/S0925-4927(98)00010-9; LEE JH, 1994, NEW ENGL J MED, V331, P439, DOI 10.1056/NEJM199408183310704; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; LIEN YHH, 1991, J CLIN INVEST, V88, P303, DOI 10.1172/JCI115292; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MacKay S, 1996, ARCH NEUROL-CHICAGO, V53, P167, DOI 10.1001/archneur.1996.00550020079018; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; Matthews PM, 1996, BRAIN, V119, P715, DOI 10.1093/brain/119.3.715; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MEYERHOFF DJ, 1994, ANN NEUROL, V36, P40; Miki Y, 1999, RADIOLOGY, V213, P395, DOI 10.1148/radiology.213.2.r99oc01395; Miller JD, 1996, NEUROTRAUMA, P61; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; OPPENHEIMER SM, 1995, MAGN RESON MED, V33, P61, DOI 10.1002/mrm.1910330109; Parnetti L, 1997, MECH AGEING DEV, V97, P9, DOI 10.1016/S0047-6374(97)01877-0; Passani LA, 1997, MOL CHEM NEUROPATHOL, V31, P97, DOI 10.1007/BF02815236; PATEL TB, 1980, BIOCHEM J, V188, P163, DOI 10.1042/bj1880163; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rose SE, 1999, MAGN RESON IMAGING, V17, P291, DOI 10.1016/S0730-725X(98)00168-4; Ross BD, 1996, NMR BIOMED, V9, P279, DOI 10.1002/(SICI)1099-1492(199610)9:7<279::AID-NBM435>3.0.CO;2-V; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Schuff N, 1998, RADIOLOGY, V207, P91, DOI 10.1148/radiology.207.1.9530304; SHIINO A, 1993, SURG NEUROL, V39, P143, DOI 10.1016/0090-3019(93)90093-G; SHONK TK, 1995, RADIOLOGY, V195, P65, DOI 10.1148/radiology.195.1.7892497; SIGNORETTI S, 1999, 17 ANN NAT NEUR S MI; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Tedeschi G, 1996, NEUROLOGY, V47, P696, DOI 10.1212/WNL.47.3.696; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; Wedekind C, 1999, J TRAUMA, V47, P44, DOI 10.1097/00005373-199907000-00010; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328	89	116	127	0	13	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2001	22	1					143	151					9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	397WK	WOS:000166720700024	11158900				2021-06-18	
J	Kerns, KA; Eso, K; Thomson, J				Kerns, KA; Eso, K; Thomson, J			Investigation of a direct intervention for improving attention in young children with ADHD	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	26th Annual Meeting of the International-Neuropsychological-Society	FEB 04-05, 1998	HONOLULU, HAWAII	Int Neuropsychol Soc			TRAUMATIC BRAIN INJURY; HYPERACTIVE-CHILDREN; SUSTAINED ATTENTION; DEFICIT DISORDER; BOYS; PERFORMANCE	The efficacy of a new set of child-oriented direct intervention materials, Pay Attention!(1994), was investigated in 14 children, ages 7 to 11 years, diagnosed with attention deficit hyperactivity disorder (ADHD). Treatment and control groups were matched for age, sex, and medication status. Both groups completed pre- and posttraining assessment batteries that included psychometric measures of attention, a measure of academic efficiency, and behavioral rating scales completed by parents and teachers. Results indicate that children who received the direct intervention did significantly better on a number of nontrained measures of attention and academic efficiency. Behavioral ratings of inattention-impulsivity and hyperactivity completed by parents did not differ following treatment, although a marginally significant improvement in inattention-impulsivity was noted by school teachers. These results suggest that direct interventions aimed at improving attention may be a valuable treatment option for improving cognitive efficiency in children with ADHD and warrant further investigation.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada; Calif State Coll Bakersfield, Bakersfield, CA 93309 USA; Univ Washington, Seattle, WA 98195 USA	Kerns, KA (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.						ABIKOFF H, 1991, J LEARN DISABIL, V24, P205, DOI 10.1177/002221949102400404; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baribeau J., 1989, J NEUROL REHABIL, V3, P71; Barkley R. A., 1997, ADHD NATURE SELF CON; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BENYISHAY Y, 1987, NEUROPSYCHOL REHABIL, P165; CECI SJ, 1984, CHILD DEV, V55, P2193; Diller L., 1974, STUDIES COGNITION RE; Doehring D. G., 1968, PATTERN IMPAIRMENT S; DOUGLAS VI, 1983, DEV NEUROPSYCHIATRY, P280; Ethier M, 1989, CANADIAN J REHABILIT, V2, P223; EVERETT J, 1991, CHILD PSYCHIAT HUM D, V22, P79, DOI 10.1007/BF00707786; FINLEY G, 1987, P AM ASSOC CANC RES, V28, P180; GERSTADT CL, 1994, COGNITION, V53, P129, DOI 10.1016/0010-0277(94)90068-X; Golden C., 1978, STROOP COLOR WORD TE; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; Heaton R., 1993, WISCONSIN CARD SORTI; *HOM ENT, 1994, FREDD FISH COMP SOFT; HOOKS K, 1994, J CLIN CHILD PSYCHOL, V23, P69, DOI 10.1207/s15374424jccp2301_9; Hooper, 1983, HOOPER VISUAL ORG TE; JUDD CM, 1989, DATA ANAL MODEL COMP, P372; KAGAN J, 1966, J ABNORM PSYCHOL, V71, P17, DOI 10.1037/h0022886; Kaufman A. S., 1990, MANUAL KAUFMAN BRIEF; KERNS KA, 1996, ECOLOGICAL VALIDITY, P147; KERNS KA, 1998, UNPUB DEV PRESCHOOL; LANDAU S, 1992, CHILD DEV, V63, P928; LAROSE S, 1989, PERCEPT MOTOR SKILL, V69, P851, DOI 10.2466/pms.1989.69.3.851; Lorys A R, 1990, Arch Clin Neuropsychol, V5, P119, DOI 10.1016/0887-6177(90)90033-L; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; MANNUZZA S, 1993, ARCH GEN PSYCHIAT, V50, P565; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; MATEER CA, 1990, COGNITIVE REHABILITA, P68; Mateer CA, 1988, NEUROPSYCHOLOGICAL S, P202; MCCARNEY SB, 1989, ATTENTION DEFICIT DI; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; PENNINGTON BF, 1991, DIAGNOSING LEARNING, P82; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; PRINZ RJ, 1984, J CLIN CHILD PSYCHOL, V13, P250, DOI 10.1207/s15374424jccp1303_6; RASKIN S, 1993, M AM COLL REH MED DE; Raskin S, 1998, 26 ANN INT NEUR SOC; REID MK, 1987, J EDUC PSYCHOL, V79, P296, DOI 10.1037/0022-0663.79.3.296; ROURKE BP, 1986, NEUROPSYCHOLOGICAL A; SEIDEL WT, 1990, J ABNORM CHILD PSYCH, V18, P217, DOI 10.1007/BF00910732; Semrud-Clikeman M., 1998, 26 ANN INT NEUR SOC; SEMRUDCLIKEMAN M, IN PRESS J LEARNING; SIVAK M, 1984, ARCH PHYS MED REHAB, V65, P163; Sohlberg M. M., 1989, ATTENTION PROCESS TR; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; *SUNB COMM, 1984, MEM CAST COMP SOFTW; Szatmari P., 1992, CHILD ADOL PSYCH CL, V1, P361, DOI [10.1016/S1056-4993(18)30592-3, DOI 10.1016/S1056-4993(18)30592-3]; Thomson JB, 1994, PAY ATTENTION; THOMSON JB, 23 ANN INT NEUR SOC; THOMSON JB, IN PRESS NEUROPSYCHO; TROMMER BL, 1988, ANN NEUROL, V24, P610, DOI 10.1002/ana.410240504; VANDERMEERE J, 1988, J ABNORM CHILD PSYCH, V16, P627, DOI 10.1007/BF00913474; WEBER AM, 1990, DEV NEUROPSYCHOL, V6, P13, DOI 10.1080/87565649009540446; Wechsler D., 1991, WECHSLER INTELLIGENC; Weiss G., 1993, HYPERACTIVE CHILDREN; WHALEN CK, 1985, J ABNORM CHILD PSYCH, V13, P391, DOI 10.1007/BF00912724; Williams D.J., 1989, THESIS U WASHINGTON; WILSON C, 1992, NEUROPSYCHOL REHABIL, V2, P193; Wood R L, 1987, Int Disabil Stud, V9, P149; 1992, MATH BLASTER COMPUTE	68	116	118	0	20	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		1999	16	2					273	295		10.1207/S15326942DN1602_9			23	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	238VX	WOS:000082736100009					2021-06-18	
J	Friedman, SD; Brooks, WM; Jung, RE; Hart, BL; Yeo, RA				Friedman, SD; Brooks, WM; Jung, RE; Hart, BL; Yeo, RA			Proton MR spectroscopic findings correspond to neuropsychological function in traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; QUANTIFICATION; QUANTITATION; METABOLITES; PREDICTION; EXPERIENCE; SPECTRA; PROTEIN	BACKGROUND AND PURPOSE: Traumatic brain injury (TBI) causes substantial irreversible damage to neurons. Our aim was to investigate whether proton MR spectroscopic measures of diffuse cellular integrity were related to neuropsychological dysfunction after TBI, METHODS: Twelve patients with TBI (mean, 53 +/- 23 days postinjury) and 14 control subjects were included in the study using paired MR spectroscopy and neuropsychological assessment. N-acetylaspartate (NAA), creatine, and choline were measured in normal-appearing occipitoparietal white and occipital gray matter using short-echo quantitative spectroscopy. A composite measure of neuropsychological function was calculated from z-scored individual tests probing the major functional domains commonly impaired after head trauma. RESULTS: Patients with TBI displayed reduced NAA in white matter and elevated choline in gray matter, suggestive of neuronal injury and inflammation, respectively. NAA and creatine in white and gray matter were significantly associated with composite neuropsychological function and many individual neuropsychological tests. Gray matter choline, although abnormal, was not related to neuropsychological function, CONCLUSION: The concordance between neurometabolic levels and behavioral function supports the hypothesis that diffuse axonal injury is an important contributor to brain dysfunction after TBI.	Univ New Mexico, Hlth Sci Ctr, Ctr Non Invas Diag, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Radiol, Albuquerque, NM 87131 USA	Brooks, WM (corresponding author), Univ New Mexico, Hlth Sci Ctr, Ctr Non Invas Diag, 1201 Yale Blvd NE, Albuquerque, NM 87131 USA.			friedman, seth/0000-0001-8785-7215; brooks, william/0000-0001-6227-7636			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; BIGLER ED, 1996, NEUROIMAGING, V2, P261; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BROOKS WM, IN PRESS J RHEUAMTOL; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CHRISTIANSEN P, 1993, MAGN RESON IMAGING, V11, P107, DOI 10.1016/0730-725X(93)90418-D; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; DICKMEN S, 1995, NEUROPSCYCHOLOGY, V9, P80; Feldman Z., 1996, NEUROTRAUMA, P43; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 1996, NEUROTRAUMA, P43; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; Henriksen O, 1995, NMR BIOMED, V8, P139, DOI 10.1002/nbm.1940080402; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KOLLER KJ, 1984, J NEUROCHEM, V43, P1136, DOI 10.1111/j.1471-4159.1984.tb12854.x; Kreis R, 1996, J CLIN INVEST, V97, P1142, DOI 10.1172/JCI118528; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P372; LopezVillegas D, 1997, P NATL ACAD SCI USA, V94, P9854, DOI 10.1073/pnas.94.18.9854; LUYTEN PR, 1986, RADIOLOGY, V161, P795, DOI 10.1148/radiology.161.3.3786735; PIJNAPPEL WWF, 1992, J MAGN RESON, V97, P122, DOI 10.1016/0022-2364(92)90241-X; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; ROSS B, 1994, MAGN RESON QUART, V10, P191; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Steiger HJ, 1996, STROKE, V27, P2048, DOI 10.1161/01.STR.27.11.2048; SUTTON LN, 1995, PEDIATR NEUROSURG, V22, P81, DOI 10.1159/000120881; VANDENBOOGAART A, 1994, MAGNET RESON MED, V31, P347, DOI 10.1002/mrm.1910310402; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Zampolini M, 1997, EUR J NEUROL, V4, P246, DOI 10.1111/j.1468-1331.1997.tb00343.x	42	116	122	0	3	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	NOV-DEC	1998	19	10					1879	1885					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	149DJ	WOS:000077589600018	9874540				2021-06-18	
J	Sander, AM; Kreutzer, JS; Rosenthal, M; Delmonico, R; Young, ME				Sander, AM; Kreutzer, JS; Rosenthal, M; Delmonico, R; Young, ME			A multicenter longitudinal investigation of return to work and community integration following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community integration; employment; longitudinal investigation; outcome	SEVERE HEAD-INJURY; PREDICTING RETURN; REHABILITATION; QUESTIONNAIRE	Objective: To characterize changes in employment status and community integration following tau matic brain injury and to investigate relationships among outcome, sociodemographic, and injury related variables. Design: Longitudinal analyses of employment (n=42) and community integration (n=53) were conducted, with data examined at three follow-up periods. Chi-square (chi(2)) and analysis of variance (ANOVA) were used to investigate the relationship between employment, time since injury, and demographic and injury-related variables. Repeated measures ANOVA and multiple regression analyses were utilized to investigate similar relationships for the community integration sample, Setting: Outpatient clinics affiliated with the TBI Model Systems programs. Participants: Patients with traumatic brain injury who received acute medical care at a Level 1 Trauma Center and received Inpatient rehabilitation, Mean age of subjects was 33.9 years. The full range of injury severity was represented. Main Outcome Measures: Employment status determined through structured interview and scores on the Community Integration Questionnaire. Results: Less than 40% of persons employed before injury were employed at any Follow-up interval. Fewer persons were employed at year 2 than at years 1 and years 3 or 4. Seventy-five percent of persons employed at year 1 were also employed at year 3 or 4. Fifty percent of persons unemployed It I ear 1 were either employed or otherwise productively engaged at year 3 or 4. Unemployed persons had Longer acute hospital stays than employed persons at all follow-up intervals. Conclusions: TBI has an adverse, long-term Impact on employment and productivity. Findings highlight the need for postacute rehabilitation programs with particular emphasis on vocational rehabilitation. Uncertainties remain about the impact of brain injury on socialization and home activity patterns, partly because of Limitations in measurement of community integration.	WAYNE STATE UNIV, DETROIT, MI USA; SANTA CLARA VALLEY MED CTR, SAN JOSE, CA 95128 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA	Sander, AM (corresponding author), VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, POB 980542, RICHMOND, VA 23298 USA.						Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1976, LANCET, V1, P1031; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1127, DOI 10.1136/jnnp.38.11.1127; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Millis S R, 1994, Int J Neurosci, V79, P165; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1984, CLOSED HEAD INJURY P; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wehman P., 1988, J HEAD TRAUMA REHAB, V3, P82, DOI DOI 10.1097/00001199-198812000-00012; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WHITENECK G, 1987, REHABILITATION OUTCO; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009	33	116	116	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1996	11	5					70	84		10.1097/00001199-199610000-00007			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VP053	WOS:A1996VP05300007					2021-06-18	
J	GRIMWOOD, K; ANDERSON, VA; BOND, L; CATROPPA, C; HORE, RL; KEIR, EH; NOLAN, T; ROBERTON, DM				GRIMWOOD, K; ANDERSON, VA; BOND, L; CATROPPA, C; HORE, RL; KEIR, EH; NOLAN, T; ROBERTON, DM			ADVERSE OUTCOMES OF BACTERIAL-MENINGITIS IN SCHOOL-AGE SURVIVORS	PEDIATRICS			English	Article						CHILD; MENINGITIS; SEQUELAE	INFLUENZAE TYPE-B; LONG-TERM SEQUELAE; CLOSED HEAD-INJURY; DEXAMETHASONE THERAPY; ACADEMIC-ACHIEVEMENT; CEREBROSPINAL-FLUID; CHILDREN; INFANTS	Objective. To determine the outcomes of bacterial meningitis in school-age survivors. Design. Prospective cohort study. Setting. Teaching pediatric hospital. Children. During 1983 through 1986, 158 meningitis survivors, ages 3 months to 14 years, treated at a single center were enrolled. Between 1991 and 1993, 130 children, 82% of the original cohort, were evaluated at a mean age of 8.4 years and a mean of 6.7 years after their meningitis. Outcome measures. Blinded neurologic, neuropsychologic, audiologic, behavior, and socio-demographic assessments were compared with those from grade- and sex-matched control children. Multivariate analyses adjusted for age at testing and socio-demographic variables. Results. There was a systematic increase in risk of abnormality or poorer functioning for children with meningitis, compared with control children, across all categories tested, which was significant for fine motor function, Intelligence quotient (IQ) scores, and tests of school behavior, neuropsychologic function, and auditory figure-ground differentiation. Eleven children who had experienced meningitis (8.5%) had major deficits (IQ <70, seizures, hydrocephalus, spasticity, blindness, or severe to profound hearing loss); a further 24 (18.5%) cases and 14 (10.8%) control children had minor deficits (IQ 70 to 80, inability to read, mild to moderate hearing loss, abnormalities in speech discrimination, or school behavior problems). Overall, children who had meningitis were at greater risk (26.9%) for disability. Children with acute neurologic complications had more adverse outcomes than those with uncomplicated meningitis and control children (39% vs 18% vs 11%, respectively). Conclusions. One in four school-age meningitis survivors has either serious and disabling sequelae or a functionally important behavior disorder, neuropsychologic or auditory dysfunction adversely affecting academic performance. As a group, survivors function less well than their classroom peers, and risk is greatest for, but not confined to, those who had acute neurologic complications. All survivors require careful follow-up, at least until school age.	ROYAL CHILDRENS HOSP,DEPT PSYCHOL,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT AUDIOL,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,DEPT PAEDIAT & CLIN EPIDEMIOL,MELBOURNE,VIC,AUSTRALIA; UNIV MELBOURNE,BIOSTAT UNIT,MELBOURNE,VIC,AUSTRALIA	GRIMWOOD, K (corresponding author), ROYAL CHILDRENS HOSP,DEPT GEN PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA.		Grimwood, Keith/F-9334-2011; Nolan, Terry/A-2236-2008	Nolan, Terry/0000-0001-6018-3863; BOND, LYNDAL/0000-0003-1693-5508; Grimwood, Keith/0000-0003-3174-9834			ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; ACHENBACHH TM, 1991, MANUAL TEACHERS REPO; ANDERSON V, 1994, ARCH DIS CHILD, V70, P476, DOI 10.1136/adc.70.6.476; BARAFF LJ, 1993, PEDIATR INFECT DIS J, V12, P389, DOI 10.1097/00006454-199305000-00008; BEERY KE, 1989, SCORING TEACHING MAN; BROOKHOUSER PE, 1988, LARYNGOSCOPE, V98, P940; COUSENS P, 1991, J PEDIATR PSYCHOL, V16, P475, DOI 10.1093/jpepsy/16.4.475; Daniel A. E., 1983, POWER PRIVILEGE PRES; DAVIES PA, 1989, DEV MED CHILD NEUROL, V31, P398; DEAN AG, 1990, EPI INFO, P30087; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; DODGE PR, 1984, NEW ENGL J MED, V311, P869, DOI 10.1056/NEJM198410043111401; EMMETT M, 1980, AUST PAEDIATR J, V16, P90; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FEIGIN RD, 1976, J PEDIATR-US, V88, P542, DOI 10.1016/S0022-3476(76)80002-9; FELDMAN HM, 1988, PEDIATRICS, V81, P339; FELDMAN WE, 1982, J PEDIATR-US, V100, P209, DOI 10.1016/S0022-3476(82)80636-7; GILBERT GL, 1990, PEDIATR INFECT DIS J, V9, P252, DOI 10.1097/00006454-199004000-00006; JADAVJI T, 1986, PEDIATRICS, V78, P21; KAPLAN SL, 1986, PEDIATR INFECT DIS J, V5, P626, DOI 10.1097/00006454-198611000-00005; KEIR EH, 1984, 4TH NAT C AUD SOC AU; KINNEY HC, 1988, J NEUROPATH EXP NEUR, V47, P217, DOI 10.1097/00005072-198805000-00003; KLASS PE, 1992, PEDIATR INFECT DIS J, V11, P702, DOI 10.1097/00006454-199209000-00005; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; KUPST MJ, 1983, PEDIATR INFECT DIS J, V2, P12, DOI 10.1097/00006454-198301000-00004; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; LINDBERG J, 1977, PEDIATRICS, V60, P1; MCINTYRE P, 1993, MED J AUSTRALIA, V159, P766, DOI 10.5694/j.1326-5377.1993.tb141344.x; NEALE MD, 1988, NEALE ANAL READING A; OBERKLAID F, 1989, CLIN PEDIATR, V28, P397, DOI 10.1177/000992288902800902; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PELTOLA H, 1989, LANCET          0610, P1281; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; POMEROY SL, 1990, NEW ENGL J MED, V323, P1651, DOI 10.1056/NEJM199012133232402; REY A, 1964, LEXMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROURKE BP, 1987, CLIN NEUROPSYCHOL, V1, P209, DOI DOI 10.1080/13854048708520056; SCHAAD UB, 1993, LANCET, V342, P457, DOI 10.1016/0140-6736(93)91592-A; SCHAAD UB, 1990, NEW ENGL J MED, V322, P141, DOI 10.1056/NEJM199001183220301; SELL SH, 1983, PEDIATR INFECT DIS J, V2, P90, DOI 10.1097/00006454-198303000-00003; SELL SH, 1987, PEDIATR INFECT DIS J, V6, P775, DOI 10.1097/00006454-198708000-00035; SELL SHW, 1972, PEDIATRICS, V49, P206; SELL SHW, 1972, PEDIATRICS, V49, P212; SPROLES ET, 1969, J PEDIATR-US, V75, P782, DOI 10.1016/S0022-3476(69)80300-8; TAYLOR HG, 1990, NEW ENGL J MED, V323, P1657, DOI 10.1056/NEJM199012133232403; TAYLOR HG, 1984, PEDIATRICS, V74, P198; TAYLOR HG, 1992, J LEARN DISABIL, V25, P630, DOI 10.1177/002221949202501002; TAYLOR HG, 1993, J CLIN CHILD PSYCHOL, V22, P196, DOI 10.1207/s15374424jccp2202_6; TEASDALE TW, 1987, NATURE, V325, P119, DOI 10.1038/325119a0; TEJANI A, 1982, DEV MED CHILD NEUROL, V24, P338; TOUWEN BCL, 1970, CLIN DEV MED; VIENNY H, 1984, PEDIATRICS, V73, P579; Wechsler D., 1974, MANUAL WECHSLER INTE; WRIGHT M, 1994, ARCH DIS CHILD, V71, P64, DOI 10.1136/adc.71.1.64; 1988, SAS STATISTICS GUIDE; 1985, STATISTICS EPIDEMIOL	56	116	116	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics	MAY	1995	95	5					646	656					11	Pediatrics	Pediatrics	QW479	WOS:A1995QW47900005	7536915				2021-06-18	
J	LEVIN, HS; SAYDJARI, C; EISENBERG, HM; FOULKES, M; MARSHALL, LF; RUFF, RM; JANE, JA; MARMAROU, A				LEVIN, HS; SAYDJARI, C; EISENBERG, HM; FOULKES, M; MARSHALL, LF; RUFF, RM; JANE, JA; MARMAROU, A			VEGETATIVE STATE AFTER CLOSED-HEAD INJURY - A TRAUMATIC COMA DATA-BANK REPORT	ARCHIVES OF NEUROLOGY			English	Article							IMPAIRED CONSCIOUSNESS; PROGNOSIS	To elucidate the clinical course of the vegetative state after severe closed-head injury, the Traumatic Coma Data Bank was analyzed for outcome at the time of discharge from the hospital and after follow-up intervals ranging up to 3 years after injury. Of 650 patients with closed-head injury available for analysis, 93 (14%) were discharged in a vegetative state. In comparison with conscious survivors, patients in a vegetative state sustained more severe closed-head injury as reflected by the Glasgow Coma Scale scores and pupillary findings and more frequently had diffuse injury complicated by swelling or shift in midline structures. Of 84 patients in a vegetative state who provided follow-up data, 41% became conscious by 6 months, 52% regained consciousness by 1 year, and 58% recovered consciousness within the 3-year follow-up interval. A logistic regression failed to identify predictors of recovery from the vegetative state.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23298; UNIV CALIF SAN DIEGO,DIV NEUROSURG,LA JOLLA,CA 92093; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; NIH,OFF BIOMETRY,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT NEUROSURG,CHARLOTTESVILLE,VA 22903					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032340, N01NS032339, N01NS032341] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-NS-3-2339, N01-NS-3-2340, N01-NS-3-2341] Funding Source: Medline		BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81	14	116	121	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	JUN	1991	48	6					580	585		10.1001/archneur.1991.00530180032013			6	Clinical Neurology	Neurosciences & Neurology	FP881	WOS:A1991FP88100006	2039378				2021-06-18	
J	Moretti, L; Cristofori, I; Weaver, SM; Chau, A; Portelli, JN; Grafman, J				Moretti, Laura; Cristofori, Irene; Weaver, Starla M.; Chau, Aileen; Portelli, Jaclyn N.; Grafman, Jordan			Cognitive decline in older adults with a history of traumatic brain injury	LANCET NEUROLOGY			English	Article							PENETRATING HEAD-INJURY; NONINVASIVE CORTICAL STIMULATION; RANDOMIZED CONTROLLED-TRIAL; APOLIPOPROTEIN-E GENOTYPE; ALZHEIMERS-DISEASE; RISK-FACTOR; AXONAL INJURY; GRAY-MATTER; FOLLOW-UP; REHABILITATION OUTCOMES	Traumatic brain injury (TBI) is an important public health problem with potentially serious long-term neurobehavioural sequelae. There is evidence to suggest that a history of TBI can increase a person's risk of developing Alzheimer's disease. However, individuals with dementia do not usually have a history of TBI, and survivors of TBI do not invariably acquire dementia later in life. Instead, a history of traumatic brain injury, combined with brain changes associated with normal ageing, might lead to exacerbated cognitive decline in older adults. Strategies to increase or maintain cognitive reserve might help to prevent exacerbated decline after TBI. Systematic clinical assessment could help to differentiate between exacerbated cognitive decline and mild cognitive impairment, a precursor of Alzheimer's disease, with important implications for patients and their families.	[Moretti, Laura; Cristofori, Irene; Weaver, Starla M.; Chau, Aileen; Portelli, Jaclyn N.; Grafman, Jordan] Kessler Fdn, Traumat Brain Injury Res Lab, W Orange, NJ USA	Grafman, J (corresponding author), Rehabil Inst Chicago, Chicago, IL 60611 USA.	jgrafman@ric.org		Cristofori, Irene/0000-0003-2339-1457; Grafman, Jordan H./0000-0001-8645-4457; Weaver, Starla/0000-0002-9559-8337			Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; [Anonymous], 2006, CDC INJ FACT BOOK; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Bach-y-Rita P, 2003, BRAIN INJURY, V17, P643, DOI 10.1080/0269905031000107133; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Boyke J, 2008, J NEUROSCI, V28, P7031, DOI 10.1523/JNEUROSCI.0742-08.2008; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brenner LA, 2008, J HEAD TRAUMA REHAB, V23, P401, DOI 10.1097/01.HTR.0000341436.59627.a5; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 2003, J NEUROL NEUROSUR PS, V74, P1014, DOI 10.1136/jnnp.74.8.1014; Brown DR, 2009, THESCIENTIFICWORLDJO, V9, P1061, DOI 10.1100/tsw.2009.111; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Collie A, 2004, NEUROLOGY, V63, P2460, DOI 10.1212/WNL.63.12.2460; Collie A, 2001, NEUROLOGY, V56, P1533, DOI 10.1212/WNL.56.11.1533; Constantinidou F, 2008, J HEAD TRAUMA REHAB, V23, P312, DOI 10.1097/01.HTR.0000336844.99079.2c; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; CORKIN S, 1989, J NEUROSCI, V9, P3876; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Glass L, 2013, CEREB CORTEX, V23, P1663, DOI 10.1093/cercor/bhs153; Gow AJ., 2007, J INDIVIDUAL DIFFERE, V28, P103, DOI [DOI 10.1027/1614-0001.28.3.103, 10.1027/1614-0001.28.3.103]; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.8.1120-1122; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; GRAFMAN J, 1986, J NEUROSCI, V6, P301; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Gunning-Dixon FM, 2009, INT J GERIATR PSYCH, V24, P109, DOI 10.1002/gps.2087; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hassing LB, 2004, AGE AGEING, V33, P355, DOI 10.1093/ageing/afh100; Herholz K, 2011, LANCET NEUROL, V10, P667, DOI 10.1016/S1474-4422(11)70123-5; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Jellinger KA, 2001, BMC NEUROL, V18, P1; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kang EK, 2009, RESTOR NEUROL NEUROS, V27, P645, DOI 10.3233/RNN-2009-0514; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kramer AF, 2004, J GERONTOL A-BIOL, V59, P940; Kraus J. F., 1996, NEUROLOGY AND TRAUMA, V2, P3, DOI DOI 10.1136/ip.2.3.212; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marner L, 2003, J COMP NEUROL, V462, P144, DOI 10.1002/cne.10714; MASLIAH E, 1993, AM J PATHOL, V142, P871; Masliah E, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P91; Mattila J, 2011, J ALZHEIMERS DIS, V27, P163, DOI 10.3233/JAD-2011-110365; Mauri M, 2006, FUNCT NEUROL, V21, P223; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mesulam NM, 1999, NEURON, V24, P521, DOI 10.1016/S0896-6273(00)81109-5; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nithianantharajah J, 2009, PROG NEUROBIOL, V89, P369, DOI 10.1016/j.pneurobio.2009.10.001; Olson-Madden JH, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/174579; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Pannese E, 2011, BRAIN STRUCT FUNCT, V216, P85, DOI 10.1007/s00429-011-0308-y; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Peters A, 2002, J NEUROCYTOL, V31, P581, DOI 10.1023/A:1025731309829; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rafnsson SB, 2007, J AM GERIATR SOC, V55, P700, DOI 10.1111/j.1532-5415.2007.01158.x; RAPOPORT M, 2004, CAN ALZHEIMERS DIS R, V1, P4; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rasmussen IA, 2008, J NEUROTRAUM, V25, P1057, DOI 10.1089/neu.2008.0520; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Raymont V, 2006, PROG BRAIN RES, V157, P199, DOI 10.1016/S0079-6123(06)57013-X; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rocca MA, 2007, NEUROLOGY, V69, P2136, DOI 10.1212/01.wnl.0000295504.92020.ca; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Ropacki MT, 2003, ARCH CLIN NEUROPSYCH, V18, P643, DOI 10.1016/S0887-6177(02)00153-1; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; Salat DH, 1999, ARCH NEUROL-CHICAGO, V56, P338, DOI 10.1001/archneur.56.3.338; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Salmond CH, 2006, J NEUROTRAUM, V23, P1049, DOI 10.1089/neu.2006.23.1049; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Soininen H, 2012, NEURODEGENER DIS, V10, P149, DOI 10.1159/000332600; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Strangman GE, 2008, ARCH PHYS MED REHAB, V89, P974, DOI 10.1016/j.apmr.2008.02.011; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tilvis RS, 2004, J GERONTOL A-BIOL, V59, P268; Tisserand DJ, 2002, NEUROIMAGE, V17, P657, DOI 10.1006/nimg.2002.1173; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; US Department of Defense, 1960, AFQT 7A DEP DEF FORM; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Victor M., 2001, ADAMS VICTORS PRINCI; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Wilson RS, 2007, ARCH GEN PSYCHIAT, V64, P234, DOI 10.1001/archpsyc.64.2.234; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zimmerman ME, 2006, AM J GERIAT PSYCHIAT, V14, P823, DOI 10.1097/01.JGP.0000238502.40963.ac	153	115	120	2	39	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2012	11	12					1103	1112		10.1016/S1474-4422(12)70226-0			10	Clinical Neurology	Neurosciences & Neurology	044CX	WOS:000311598100018	23153408				2021-06-18	
J	Badri, S; Chen, J; Barber, J; Temkin, NR; Dikmen, SS; Chesnut, RM; Deem, S; Yanez, ND; Treggiari, MM				Badri, Shide; Chen, Jasper; Barber, Jason; Temkin, Nancy R.; Dikmen, Sureyya S.; Chesnut, Randall M.; Deem, Steven; Yanez, N. David; Treggiari, Miriam M.			Mortality and long-term functional outcome associated with intracranial pressure after traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Intracranial pressure; Intracranial hypertension; Traumatic brain injury; Neuropsychological tests; Functional outcome; Critical care	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; MANAGEMENT; HYPERTENSION; EXPERIENCE; ICP	Elevated intracranial pressure (ICP) has been associated with increased mortality in patients with severe traumatic brain injury (TBI). We have examined whether raised ICP is independently associated with mortality, functional status and neuropsychological functioning in adult TBI patients. Data from a randomized trial of 499 participants were secondarily analyzed. The primary endpoints were mortality and a composite measure of functional status and neuropsychological function (memory, speed of information processing, executive function) over a 6-month period. The area under the curve of the ICP profile (average ICP) during the first 48 h of monitoring was the main predictor of interest. Multivariable regression was used to adjust for a priori defined confounders: age, Glasgow Coma Score, Abbreviated Injury Scale-head and hypoxia. Of the participants, 365 patients had complete 48-h ICP data. The overall 6-month mortality was 18 %. The adjusted odds ratio of mortality comparing 10-mmHg increases in average ICP was 3.12 (95 % confidence interval 1.79, 5.44; p < 0.01). Overall, higher average ICP was associated with decreased functional status and neuropsychological functioning (p < 0.01). Importantly, among survivors, increasing average ICP was not independently associated with worse performance on neuropsychological testing (p = 0.46). Average ICP in the first 48 h of monitoring was an independent predictor of mortality and of a composite endpoint of functional and neuropsychological outcome at the 6-month follow-up in moderate or severe TBI patients. However, there was no association between average ICP and neuropsychological functioning among survivors.	[Badri, Shide; Deem, Steven; Treggiari, Miriam M.] Univ Washington, Sch Med, Harborview Anesthesiol Res Ctr, Dept Anesthesiol & Pain Med,Harborview Med Ctr, Seattle, WA 98104 USA; [Badri, Shide] Amarex Clin Res, Safety Compliance & Coding Dept, Germantown, MD USA; [Chen, Jasper] Kaiser Permanente, Dept Anesthesiol, Redwood City, CA USA; [Barber, Jason; Temkin, Nancy R.; Dikmen, Sureyya S.; Chesnut, Randall M.; Treggiari, Miriam M.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [Chesnut, Randall M.] Univ Washington, Sch Med, Dept Orthoped Surg, Seattle, WA 98104 USA; [Temkin, Nancy R.; Yanez, N. David] Univ Washington, Dept Biostat, Seattle, WA 98104 USA; [Temkin, Nancy R.; Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Deem, Steven] Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98104 USA; [Treggiari, Miriam M.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Harborview Med Ctr, Seattle, WA 98104 USA	Treggiari, MM (corresponding author), Univ Washington, Sch Med, Harborview Anesthesiol Res Ctr, Dept Anesthesiol & Pain Med,Harborview Med Ctr, 325 9th Ave,Box 359724, Seattle, WA 98104 USA.	treggmm@u.washington.edu		Chesnut, Randall/0000-0001-6377-3666	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19643]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER	The study was supported by departmental funds. The original data were collected under NIH/NINDS grant R01 NS19643.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; BUXTON RL, 1970, LANCET, V2, P498; DAVIS RA, 1984, SURG GYNECOL OBSTET, V159, P597; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Marmarou A, 2005, ACT NEUR S, V95, P277; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Ross A M, 1992, J Neurosci Nurs, V24, P88; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; TROUPP J, 1965, J Trauma, V5, P373; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630	25	115	118	1	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	NOV	2012	38	11					1800	1809		10.1007/s00134-012-2655-4			10	Critical Care Medicine	General & Internal Medicine	026CN	WOS:000310250500009	23011528				2021-06-18	
J	Covassin, T; Elbin, RJ; Larson, E; Kontos, AP				Covassin, Tracey; Elbin, Robert J., III; Larson, Elizabeth; Kontos, Anthony P.			Sex and Age Differences in Depression and Baseline Sport-Related Concussion Neurocognitive Performance and Symptoms	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						neurocognitive testing; depression; ImPACT; concussion symptoms	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; NEUROPSYCHOLOGICAL FUNCTION; EPIDEMIOLOGY; PREDICTORS; RECOVERY; PLAY	Objective: To examine depression and baseline neurocognitive function and concussion symptoms in male and female high school and college athletes. Design: Cross sectional. Setting: Athletes completed testing at a designated computer laboratory at high schools and colleges. Participants: Participants included 1616 collegiate (n - 837) and high school (n - 779) athletes from 3 states participating in a variety of competitive sports. Interventions: Participants completed the baseline Immediate Postconcussion Assessment and Cognitive Test (ImPACT), symptom inventory, and Beck Depression Inventory II (BDI-II). Main Outcome Measures: Between-group comparisons for depression groups on ImPACT composite scores (verbal and visual memory, reaction time, motor processing speed), total symptoms, and symptom cluster (sleep, cognitive, emotional, somatic/migraine) scores. Between-group comparisons for age and sex on BDI-II, ImPACT, total symptoms, and symptom cluster scores. Results: The severe depression group scored worse on visual memory and reported more total, somatic/migraine, cognitive, emotional, and sleep symptoms than less depressed groups. High school athletes reported more somatic/migraine symptoms than collegiate athletes, whereas collegiate athletes reported more emotional and sleep symptoms than high school athletes. Women had higher verbal memory and reported more cognitive, emotional, and sleep symptom clusters compared with men. Women outperformed men on verbal memory, whereas collegiate athletes outperformed high school athletes on processing speed. Conclusions: Athletes with severe depression scored lower on visual memory than those with minimal depression. Athletes with severe depression report more concussion symptoms than athletes with minimal and moderate depression scores. Symptoms of depression should be included in baseline assessments to help disentangle depression from concussion symptoms.	[Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Elbin, Robert J., III; Kontos, Anthony P.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA 15261 USA; [Larson, Elizabeth] Humboldt State Univ, Dept Kinesiol & Recreat Adm, Arcata, CA 95521 USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA.	covassin@msu.edu		Kontos, Anthony/0000-0002-3749-4310	National Operating Committee on Standards for Athletic Equipment	The authors thank the National Operating Committee on Standards for Athletic Equipment for funding this study. They also thank all the certified athletic trainers for their contributions to this study.	Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT., 1989, MILD HEAD INJURY, P257; Bay E, 2007, ARCH PSYCHIAT NURS, V21, P2, DOI 10.1016/j.apnu.2006.07.005; Beck AT., 1996, BECK DEPRESSION INVE, V2; Brooks BL, 2010, APPL NEUROPSYCHOL, V17, P37, DOI 10.1080/09084280903526083; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gonzalez O., 2010, Morbidity and Mortality Weekly Report, V59, P1229; Iverson GL, 2006, CLIN NEUROPSYCHOL, V20, P695, DOI 10.1080/138540491005857; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Kelly MM, 2008, DEPRESS ANXIETY, V25, P839, DOI 10.1002/da.20341; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lovell MR, 2001, IMMEDIATE POSTCONCUS; MAJERES RL, 1988, INTELLIGENCE, V12, P149, DOI 10.1016/0160-2896(88)90013-X; MAJERES RL, 1990, INTELLIGENCE, V14, P357, DOI 10.1016/0160-2896(90)90023-M; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; *OFF APPL STUD, 2005, NSDUH SER H, V28; Piland SG, 2010, J ATHL TRAINING, V45, P273, DOI 10.4085/1062-6050-45.3.273; Randolph C, 2005, J ATHL TRAINING, V40, P139; Weekes NY, 2005, STRESS HEALTH, V21, P147, DOI 10.1002/smi.1046; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X; Yang JZ, 2007, CLIN J SPORT MED, V17, P481, DOI 10.1097/JSM.0b013e31815aed6b	31	115	115	1	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2012	22	2					98	104		10.1097/JSM.0b013e31823403d2			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	908RG	WOS:000301507200005	22246342				2021-06-18	
J	Salinas-Navarro, M; Alarcon-Martinez, L; Valiente-Soriano, FJ; Jimenez-Lopez, M; Mayor-Torroglosa, S; Aviles-Trigueros, M; Villegas-Perez, MP; Vidal-Sanz, M				Salinas-Navarro, Manuel; Alarcon-Martinez, Luis; Valiente-Soriano, Francisco J.; Jimenez-Lopez, Manuel; Mayor-Torroglosa, Sergio; Aviles-Trigueros, Marcelino; Paz Villegas-Perez, Maria; Vidal-Sanz, Manuel			Ocular hypertension impairs optic nerve axonal transport leading to progressive retinal ganglion cell degeneration	EXPERIMENTAL EYE RESEARCH			English	Article						ocular hypertension; adult albino rat retinal ganglion cells; retrograde axonal transport; fluorogold; dextran tetramethylrhodamine; Brn3a; RT97; fluorescent tracers; phosphorilated neurofilament heavy chain; neuronal degeneration	INTRAOCULAR-PRESSURE ELEVATION; TRANSIENT ISCHEMIA; MONOCLONAL-ANTIBODIES; TRABECULAR MESHWORK; MICROGLIAL CELLS; CIRCADIAN-RHYTHM; GENE-EXPRESSION; TIME-COURSE; RCS RAT; GLAUCOMA	Ocular hypertension (OHT) is the main risk factor of glaucoma, a neuropathy leading to blindness. Here we have investigated the effects of laser photocoagulation (LP)-induced OHT, on the survival and retrograde axonal transport (RAT) of adult rat retinal ganglion cells (RGC) from I to 12 wks. Active RAT was examined with fluorogold (FG) applied to both superior colliculi (SCi) 1 wk before processing and passive axonal diffusion with dextran tetramethylrhodamine (DTMR) applied to the optic nerve (ON) 2 d prior to sacrifice. Surviving RGCs were identified with FG applied 1 wk pre-LP or by Brn3a immunodetection. The ON and retinal nerve fiber layer were examined by RT97-neurofibrillar staining. RGCs were counted automatically and color-coded density maps were generated. OHT retinas showed absence of FG(+) or DTMR(+)RGCs in focal, pie-shaped and diffuse regions of the retina which, by two weeks, amounted to, approximately, an 80% of RGC loss without further increase. At this time, there was a discrepancy between the total number of surviving FG-prelabelled RGCs and of DMTR(+)RGCs, suggesting that a large proportion of RGCs had their RAT impaired. This was further confirmed identifying surviving RGCs by their Brn3a expression. From 3 weeks onwards, there was a close correspondence of DTMR(+)RGCs and FG(+)RGCs in the same retinal regions, suggesting axonal constriction at the ON head. Neurofibrillar staining revealed, in ONs, focal degeneration of axonal bundles and, in the retinal areas lacking backlabeled RGCs, aberrant staining of RT97 characteristic of axotomy. LP-induced OHT results in a crush-like injury to ON axons leading to the anterograde and protracted retrograde degeneration of the intraocular axons and RGCs. (C) 2009 Elsevier Ltd. All rights reserved.	[Salinas-Navarro, Manuel; Alarcon-Martinez, Luis; Valiente-Soriano, Francisco J.; Jimenez-Lopez, Manuel; Mayor-Torroglosa, Sergio; Aviles-Trigueros, Marcelino; Paz Villegas-Perez, Maria; Vidal-Sanz, Manuel] Univ Murcia, Fac Med, Dept Oftalmol, E-30100 Murcia, Spain	Vidal-Sanz, M (corresponding author), Univ Murcia, Fac Med, Dept Oftalmol, Campus Univ Espinardo, E-30100 Murcia, Spain.	ofmmv01@um.es	Vidal-Sanz, Manuel/J-6989-2016; Valiente-Soriano, Francisco J./Z-4980-2019; Aviles-Trigueros, Marcelino/K-2622-2012	Vidal-Sanz, Manuel/0000-0002-9216-1615; Aviles-Trigueros, Marcelino/0000-0001-9711-2196; Valiente-Soriano, Francisco J,/0000-0002-1837-6589; Jimenez Lopez, Manuel/0000-0002-8768-9968	Regional Government of Murcia Fundacion SenecaFundacion Seneca [05703/PI/07, 04446/GERM/07]; Spanish Ministry of Education and ScienceSpanish Government [SAF-2005-04812, SAF 2009-10385]; Spanish Ministry of HealthInstituto de Salud Carlos IIISpanish Government [ISCIII: FIS PIO06/0780, RD0710062/0001]	supported by research grants from the Regional Government of Murcia Fundacion Seneca 05703/PI/07, 04446/GERM/07; Spanish Ministry of Education and Science SAF-2005-04812, SAF 2009-10385; and Spanish Ministry of Health ISCIII: FIS PIO06/0780 and RD0710062/0001.	Agudo M, 2009, INVEST OPHTH VIS SCI, V50, P424, DOI 10.1167/iovs.08-2404; Agudo M, 2008, MOL VIS, V14, P1050; ALARCONMARTINEZ L, MOL VIS IN PRESS; ANDERTON BH, 1982, NATURE, V298, P84, DOI 10.1038/298084a0; Aviles-Trigueros M, 2003, EXP NEUROL, V184, P767, DOI 10.1016/S0014-4886(03)00298-X; BALKEMA GW, 1985, NATURE, V316, P630, DOI 10.1038/316630a0; Buckingham BP, 2008, J NEUROSCI, V28, P2735, DOI 10.1523/JNEUROSCI.4443-07.2008; Chidlow G, 2005, MOL VIS, V11, P387; Danias J, 2006, EXP EYE RES, V82, P219, DOI 10.1016/j.exer.2005.06.013; Danias J, 2003, INVEST OPHTH VIS SCI, V44, P5151, DOI 10.1167/iovs.02-1101; DRAGER UC, 1984, NATURE, V309, P624, DOI 10.1038/309624a0; Drouyer E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003931; Filippopoulos T, 2006, INVEST OPHTH VIS SCI, V47, P1968, DOI 10.1167/iovs.05-0955; FitzGibbon T, 1996, J COMP NEUROL, V375, P238; Gomez-Ramirez AM, 1999, INVEST OPHTH VIS SCI, V40, P414; GUILLERY RW, 1995, J NEUROSCI, V15, P4727; Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181; Jakobs TC, 2005, J CELL BIOL, V171, P313, DOI 10.1083/jcb.200506099; Jeffery G, 2008, NEUROSCIENCE, V157, P637, DOI 10.1016/j.neuroscience.2008.09.021; Jeffery G, 2001, PHYSIOL REV, V81, P1393; Jia LJ, 2000, INVEST OPHTH VIS SCI, V41, P1380; Johnson EC, 2000, INVEST OPHTH VIS SCI, V41, P431; KRISHNA R, 1995, OPHTHALMIC RES, V27, P163, DOI 10.1159/000267660; Lafuente MP, 2002, EXP EYE RES, V74, P181, DOI 10.1006/exer.2001.1122; Lafuente MP, 2002, NEUROSCIENCE, V109, P157, DOI 10.1016/S0306-4522(01)00458-4; Levkovitch-Verbin H, 2002, INVEST OPHTH VIS SCI, V43, P402; Lopez-Herrera MPL, 2002, EXP NEUROL, V178, P243, DOI 10.1006/exnr.2002.8043; MABUCHI F, 1994, INVEST OPHTH VIS SCI, V45, P4352; Marco-Gomariz MA, 2006, J COMP NEUROL, V498, P163, DOI 10.1002/cne.21028; Mayor-Torroglosa S, 2005, INVEST OPHTH VIS SCI, V46, P3825, DOI 10.1167/iovs.05-0392; MAYORTORROGLOSA S, 2004, OPHTHALMIC RES, V36, P19; MCKERRACHER L, 1990, J NEUROSCI, V10, P2834; MCKERRACHER L, 1990, J NEUROSCI, V10, P641; Moore CG, 1996, CURR EYE RES, V15, P185, DOI 10.3109/02713689608997412; MOORE CG, 1993, INVEST OPHTH VIS SCI, V34, P363; Morrison JC, 2005, PROG RETIN EYE RES, V24, P217, DOI 10.1016/j.preteyeres.2004.08.003; Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184; Morrison JC, 2008, PROG BRAIN RES, V173, P285, DOI 10.1016/S0079-6123(08)01121-7; Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267; Nash MS, 1999, INVEST OPHTH VIS SCI, V40, P1293; Nouri-Mahdavi K, 2004, OPHTHALMOLOGY, V111, P1627, DOI 10.1016/j.ophtha.2004.02.017; Pang IH, 2005, INVEST OPHTH VIS SCI, V46, P1313, DOI 10.1167/iovs.04-0829; Parrilla-Reverter G, 2009, VISION RES, V49, P2808, DOI 10.1016/j.visres.2009.08.020; Parrilla-Reverter G, 2009, EXP EYE RES, V89, P32, DOI 10.1016/j.exer.2009.02.015; Pease ME, 2000, INVEST OPHTH VIS SCI, V41, P764; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Quigley HA, 2000, INVEST OPHTH VIS SCI, V41, P3460; QUIGLEY HA, 1980, INVEST OPHTH VIS SCI, V19, P137; QUIGLEY HA, 1983, INVEST OPHTH VIS SCI, V24, P1305; QUIGLEY HA, 1976, INVEST OPHTH VISUAL, V15, P606; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009; QUIGLEY HA, 1977, INVEST OPHTH VIS SCI, V16, P640; Salinas-Navarro M, 2009, VISION RES, V49, P637, DOI 10.1016/j.visres.2009.01.010; Salinas-Navarro M, 2009, VISION RES, V49, P115, DOI 10.1016/j.visres.2008.09.029; Salinas-Navarro M., 2006, INVEST OPHTHALMOL VI, P47; SALINASNAVARRO M, MOL VIS IN PRESS; Salvador-Silva M, 2000, J COMP NEUROL, V417, P431, DOI 10.1002/(SICI)1096-9861(20000221)417:4<431::AID-CNE4>3.0.CO;2-G; Schlamp CL, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-66; Schlamp CL, 2001, MOL VIS, V7, P192; SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002; Sobrado-Calvo P, 2007, J COMP NEUROL, V501, P866, DOI 10.1002/cne.21279; Soto I, 2008, J NEUROSCI, V28, P548, DOI 10.1523/JNEUROSCI.3714-07.2008; THANOS S, 1989, J NEUROSCI RES, V22, P144, DOI 10.1002/jnr.490220206; Vidal-Sanz M, 2007, EYE, V21, pS42, DOI 10.1038/sj.eye.6702888; Vidal-Sanz M, 2001, SURV OPHTHALMOL, V45, pS261, DOI 10.1016/S0039-6257(01)00205-3; Vidal-Sanz M, 2000, NEUROTOX RES, V2, P215, DOI 10.1007/BF03033795; VIDALSANZ M, 1988, EXP NEUROL, V102, P92, DOI 10.1016/0014-4886(88)90081-7; VIDALSANZ M, 2005, OPHTHALMIC RES, V37, P48; VIDALSANZ M, 1993, NEUROPROTOCOLS, V3, P29; Villegas-Perez M, 2005, INVEST OPHTH VIS SCI, V46; Villegas-Perez MP, 1998, J COMP NEUROL, V392, P58, DOI 10.1002/(SICI)1096-9861(19980302)392:1<58::AID-CNE5>3.0.CO;2-O; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; VillegasPerez MP, 1996, NEUROREPORT, V7, P1995, DOI 10.1097/00001756-199608120-00028; Wang S, 2003, CURR EYE RES, V27, P183, DOI 10.1076/ceyr.27.3.183.16053; Wang SM, 2000, INVEST OPHTH VIS SCI, V41, P537; Woldemussie E, 2004, GLIA, V47, P109, DOI 10.1002/glia.20000; WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913; Zhou Y, 2005, MOL THER, V12, P402, DOI 10.1016/j.ymthe.2005.04.004	79	115	116	0	10	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0014-4835	1096-0007		EXP EYE RES	Exp. Eye Res.	JAN	2010	90	1					168	183		10.1016/j.exer.2009.10.003			16	Ophthalmology	Ophthalmology	542SW	WOS:000273516500022	19835874				2021-06-18	
J	Walker, WC; Marwitz, JH; Kreutzer, JS; Hart, T; Novack, TA				Walker, William C.; Marwitz, Jennifer H.; Kreutzer, Jeffrey S.; Hart, Tessa; Novack, Thomas A.			Occupational categories and return to work after traumatic brain injury: A multicenter study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; occupations; rehabilitation; treatment outcome	HEAD-INJURY; ACUTE PREDICTORS; EMPLOYMENT; REHABILITATION; DISABILITY; RECOVERY	Objective: To further evaluate determinants of return to work (RTW) after traumatic brain injury (TBI), with focus on the relation between preinjury occupational category and RTW outcome. Design: Prospective collaborative cohort study. Setting: Seventeen National Institute on Disability and Rehabilitation Research-designated Traumatic Brain Injury Model Systems. Participants: Consecutive sample of 1341 patients (age range, 18-62y) who were hospitalized with a TBI diagnosis, received both acute neurotrauma services and inpatient rehabilitation services, consented to participate, were employed before injury, and completed a 1-year follow-up assessment. Intervention: An inpatient interdisciplinary brain injury rehabilitation program. Main Outcome Measure: Competitive employment at 1 year postinjury. Results: Participants were categorized into 1 of 3 groups depending on preinjury occupational title: professional/managerial (n=192), skilled (n=751), or manual labor (n=398). Chi-square analyses were computed to examine changes across occupation groups between preinjury occupation group and postinjury RTW. The rate of successful RTW was greatest for professional/managerial (56%), lower for skilled (40%), and lowest for manual labor (32%), yielding an odds ratio of 2.959 between the highest and lowest groups. Of those with successful RTW, most did so within the same occupational category grouping. A multiple logistic regression showed that preinjury occupation, education level, discharge FIM score, age, sex, marital status, and hospital length of stay each influenced RTW. Conclusions: Prior research has shown that preinjury employment status (employed vs unemployed) greatly influences the odds of successful RTW after TBI. A related hypothesis, that occupational classification also influences RTW outcome, has been understudied and has yielded conflicting results. The current study shows convincingly that the type of occupation influences RTW outcome, with the best prospect for RTW among people with professional/managerial jobs. Occupational category should be examined in the future development of predictive models for RTW after TBI.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19107 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA	Walker, WC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980661, Richmond, VA 23298 USA.	wcwalker@mail2.vcu.edu	Walker, William C/N-3162-2014				Bell GD, 1998, B AM METEOROL SOC, V79, pS1; Berkman L F, 1997, IARC Sci Publ, P51; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CONDELUCI A, 1992, Brain Injury, V6, P543, DOI 10.3109/02699059209008151; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; CRISP R, 1992, J REHABIL, V58, P27; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; EVANS RL, 1992, AM J PHYS MED REHAB, V71, P140, DOI 10.1097/00002060-199206000-00003; Fleming J, 1999, BRAIN INJURY, V13, P417; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Regidor E, 2005, EUR J EPIDEMIOL, V20, P501, DOI 10.1007/s10654-005-4262-y; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; *STAT U NY, 1996, GUID UN DAT SET MED; *UN STAT DIV, 1988, INT STAND CLASS OCC; *US DEP COMM, 1992, 1990 OCC CLASS SYST; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	49	115	120	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2006	87	12					1576	1582		10.1016/j.apmr.2006.08.335			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	114OH	WOS:000242675000004	17141636				2021-06-18	
J	Kochanek, PM; Vagni, VA; Janesko, KL; Washington, CB; Crumrine, PK; Garman, RH; Jenkins, LW; Clark, RSB; Homanics, GE; Dixon, CE; Schnermann, J; Jackson, EK				Kochanek, PM; Vagni, VA; Janesko, KL; Washington, CB; Crumrine, PK; Garman, RH; Jenkins, LW; Clark, RSB; Homanics, GE; Dixon, CE; Schnermann, J; Jackson, EK			Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						controlled cortical impact; head injury; head trauma; purine; seizures	CONTROLLED CORTICAL IMPACT; TRANSIENT FOCAL ISCHEMIA; FLUID PERCUSSION INJURY; TERM CAFFEINE TREATMENT; TEMPORAL-LOBE EPILEPSY; ADENOSINE RECEPTORS; CEREBRAL-ISCHEMIA; IN-VITRO; KINDLED SEIZURES; MESSENGER-RNA	Adenosine, acting at A1 receptors, exhibits anticonvulsant effects in experimental epilepsy - and inhibits progression to status epilepticus ( SE). Seizures after traumatic brain injury (TBI) may contribute to pathophysiology. Thus, we hypothesized that endogenous adenosine, acting via A1 receptors, mediates antiepileptic benefit after experimental TBI. We subjected A1-receptor knockout (ko) mice, heterozygotes, and wild-type (wt) littermates (n = 115) to controlled cortical impact (CCI). We used four outcome protocols in male mice: ( 1) observation for seizures, SE, and mortality in the initial 2 h, ( 2) assessment of seizure score ( electroencephalogram ( EEG)) in the initial 2 h, ( 3) assessment of mortality at 24 h across injury levels, and ( 4) serial assessment of arterial blood pressure, heart rate, blood gases, and hematocrit. Lastly, to assess the influence of gender on this observation, we observed female mice for seizures, SE, and mortality in the initial 2 h. Seizure activity was noted in 83% of male ko mice in the initial 2 h, but was seen in no heterozygotes and only 33% of wt (P<0.05). Seizures in wt were brief (1 to 2 secs). In contrast, SE involving lethal sustained ( 41 h) tonic clonic activity was uniquely seen in ko mice after CCI ( 50% incidence in males), (P<0.05). Seizure score was twofold higher in ko mice after CCI versus either heterozygote or wt (P<0.05). An injury-intensity dose - response for 24 h mortality was seen in ko mice (P<0.05). Physiologic parameters were similar between genotypes. Seizures were seen in 100% of female ko mice after CCI versus 14% of heterozygotes and 25% wt (P<0.05) and SE was restricted to the ko mice ( 83% incidence). Our data suggest a critical endogenous anticonvulsant action of adenosine at A1 receptors early after experimental TBI.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Div Child Neurol, Pittsburgh, PA 15213 USA; Consultants Vet Pathol Inc, Murrysville, PA USA; Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; NIDDK, NIH, Bethesda, MD USA; Univ Pittsburgh, Sch Med, Ctr Clin Pharmacol, Pittsburgh, PA USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009; Homanics, Gregg/0000-0003-3641-8153	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK068575] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38087, NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [Z01DK043413, R01DK068575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038087, P01NS030318, P50NS030318, P20NS030318] Funding Source: NIH RePORTER		Avsar E, 2004, NEUROPHARMACOLOGY, V47, P427, DOI 10.1016/j.neuropharm.2004.04.015; BARRACO RA, 1984, NEUROSCI LETT, V46, P317, DOI 10.1016/0304-3940(84)90118-6; Bassin S, 2002, CRIT CARE, V6, P137, DOI 10.1186/cc1472; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chesi AJR, 1997, EXP BRAIN RES, V113, P303, DOI 10.1007/BF02450328; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DeLorenzo RJ, 2005, PHARMACOL THERAPEUT, V105, P229, DOI 10.1016/j.pharmthera.2004.10.004; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DRAGUNOW M, 1985, EPILEPSIA, V26, P480, DOI 10.1111/j.1528-1157.1985.tb05684.x; Dzhala V, 2000, ANN NEUROL, V48, P632, DOI 10.1002/1531-8249(200010)48:4<632::AID-ANA10>3.3.CO;2-V; Emptage NJ, 2001, NEURON, V29, P197, DOI 10.1016/S0896-6273(01)00190-8; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRANKLIN PH, 1989, J PHARMACOL EXP THER, V251, P1229; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Fredholm BB, 2005, ANNU REV PHARMACOL, V45, P385, DOI 10.1146/annurev.pharmtox.45.120403.095731; George FR, 1993, EXP CLIN PSYCHOPHARM, V1, P7, DOI 10.1037/1064-1297.1.1-4.7; Glass M, 1996, BRAIN RES, V710, P56, DOI 10.1016/0006-8993(95)01313-X; Golarai G, 2001, J NEUROSCI, V21, P8523; Gouder N, 2003, EPILEPSIA, V44, P877, DOI 10.1046/j.1528-1157.2003.03603.x; Gouder N, 2004, J NEUROSCI, V24, P692, DOI 10.1523/JNEUROSCI.4781-03.2004; Harrison PK, 2003, EUR J PHARMACOL, V471, P97, DOI 10.1016/S0014-2999(03)01783-7; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Higashi H, 2002, J NEUROSURG, V96, P117, DOI 10.3171/jns.2002.96.1.0117; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Jiang N, 1997, EUR J PHARMACOL, V320, P131, DOI 10.1016/S0014-2999(96)00905-3; JOHANSSON B, 1993, N-S ARCH PHARMACOL, V347, P407, DOI 10.1007/BF00165391; Johansson B, 1997, BRAIN RES, V762, P153, DOI 10.1016/S0006-8993(97)00378-8; Knutsen Lars J. S., 1997, P423; KOCHANEK PM, 2005, IN PRESS J CEREB BLO; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MURRAY TF, 1985, NEUROPHARMACOLOGY, V24, P761, DOI 10.1016/0028-3908(85)90010-3; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; OHIGASHI T, 1993, AM J PHYSIOL, V265, pC934; Olsson T, 2004, EUR J NEUROSCI, V20, P1197, DOI 10.1111/j.1460-9568.2004.03564.x; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Phillis JW, 2001, NEUROL RES, V23, P183, DOI 10.1179/016164101101198316; Pourgholami MH, 1997, BRAIN RES, V775, P37, DOI 10.1016/S0006-8993(97)00769-5; Pourgholami MH, 1997, BRAIN RES, V751, P259, DOI 10.1016/S0006-8993(96)01406-0; Robertson C, 2001, CRIT CARE MED, V29, pA190; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sachse KT, 2004, J NEUROTRAUM, V21, P1326; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sheng H, 2000, EXP NEUROL, V163, P392, DOI 10.1006/exnr.2000.7363; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Southam E, 2002, PHARMACOL BIOCHEM BE, V74, P111, DOI 10.1016/S0091-3057(02)00956-5; Sun DQ, 2001, P NATL ACAD SCI USA, V98, P9983, DOI 10.1073/pnas.171317998; Takigawa T, 2002, J PHYSIOL-LONDON, V539, P67, DOI 10.1113/jphysiol.2001.012883; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Von Lubitz DKJE, 1999, EUR J PHARMACOL, V371, P83, DOI 10.1016/S0014-2999(99)00135-1; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V253, P95, DOI 10.1016/0014-2999(94)90762-5; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; YOUNG D, 1994, NEUROSCIENCE, V58, P245, DOI 10.1016/0306-4522(94)90032-9; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	66	115	120	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2006	26	4					565	575		10.1038/sj.jcbfm.9600218			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	026LM	WOS:000236340400012	16121125	Bronze			2021-06-18	
J	McLeod, TCV; Perrin, DH; Guskiewicz, KM; Shultz, SJ; Diamond, R; Gansneder, BM				McLeod, TCV; Perrin, DH; Guskiewicz, KM; Shultz, SJ; Diamond, R; Gansneder, BM			Serial administration of clinical concussion assessments and learning effects in healthy young athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						mild head injury; SAC; BESS; practice effects; children	MILD HEAD-INJURY; POSTURAL STABILITY; STANDARDIZED ASSESSMENT; BRAIN-INJURIES; UNITED-STATES; HIGH-SCHOOL; COLLEGIATE; CHILDREN; SPORT; PERFORMANCE	Objective: To determine if serial administration of the Standardized Assessment of Concussion (SAC) and Balance Error Scoring System (BESS) would elicit a learning effect in young athletes and to determine the intratester reliability of scoring the BESS. Design: A prospective study of 50 healthy young athletes who were assigned to either the control or practice group. All subjects were administered the assessments on 2 occasions, 60 days apart. In addition, subjects in the practice group received serial administration of the assessments on 3 occasions in the week following the initial assessment. Setting: University Sports Medicine/Athletic Training Research Laboratory. Subjects: Fifty uninjured young athletes between 9 and 14 years of age. Main Outcome Measured: Scores on 2 clinical concussion assessments, the SAC and the BESS. Results: We found a significant learning effect upon serial BESS testing in the practice group. BESS error scores were significantly lower than baseline (15.0 +/- 14.6) on days 5 (11.3 +/- 5.33), 7 (12.4 +/- 6.2), oand 60 (12.6 +/- 6.2). We also found a significant learning effect upon the day 60 BESS administration across all subjects. We did not find a practice or learning effect with serial SAC test administration. The intratester reliability of the investigator's ability to score repeated observations of the same BESS test ranged from 0.87 to 0.98. Conclusions: Our results demonstrated that serial administration of the BESS elicited a learning effect, which was more prominent during the tandem conditions. Clinicians utilizing the BESS as a measure of postural stability should be aware of the potential for improvement with repeated testing. Clinicians should not expect improvement with the SAC, as scores remained relatively stable across all trials.	Arizona Sch Hlth Sci, Dept Sports Hlth Care, Mesa, AZ 85206 USA; Univ N Carolina, Greensboro, NC 27412 USA; Univ N Carolina, Chapel Hill, NC USA; Univ Virginia, Charlottesville, VA USA	McLeod, TCV (corresponding author), Arizona Sch Hlth Sci, Dept Sports Hlth Care, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	McLeod, Tamara/AAU-9435-2020	Guskiewicz, Kevin/0000-0002-8682-2130			Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ATWATER SW, 1990, PHYS THER, V70, P79, DOI 10.1093/ptj/70.2.79; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; HOLLIDAY PJ, 1979, AGRESSOLOGIE, V20, P225; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; LOMAX RG, 1992, STAT CONCEPTS; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; MANCUSO JJ, 2002, J ATHL TRAINING, V37, pS10; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; Nordahl SHG, 2000, AVIAT SPACE ENVIR MD, V71, P889; Oliaro SM, 1998, J ATHL TRAINING, V33, P36; Onate JA, 2000, J ATHL TRAINING, V35, P155; Randolph C, 2001, J ATHL TRAINING, V36, P288; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Westcott Sarah L., 1994, Physical and Occupational Therapy in Pediatrics, V14, P1, DOI 10.1300/J006v14n01_01; Westcott SL, 1997, PHYS THER, V77, P629, DOI 10.1093/ptj/77.6.629	32	115	116	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2004	14	5					287	295		10.1097/00042752-200409000-00007			9	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	943BX	WOS:000230327900007	15377968				2021-06-18	
J	Felmingham, KL; Baguley, IJ; Green, AM				Felmingham, KL; Baguley, IJ; Green, AM			Effects of diffuse axonal injury on speed of information processing following severe traumatic brain injury	NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; MULTIPLE-SCLEROSIS; DIVIDED ATTENTION; DEFICITS; REHABILITATION; FLEXIBILITY; VALIDATION; COGNITION; RECOVERY; LESIONS	To test the hypothesis that slowed information processing in traumatic brain injury is related to diffuse axonal injury (DAI), the authors compared 10 patients with predominant DAI (diffuse group) and minimal DAI (mixed injury group) on the Symbol Digit Modalities Test, simple and choice reaction time, Trail Making Tests A and B, and the Stroop Neuropsychological Screening Test. The diffuse group was slower than the mixed injury and control groups on basic speed of processing tasks. This difference was not apparent on complex speeded tasks once basic speed of processing was controlled for. The diffuse group's slower speed of processing was not accounted for by differences in injury severity, age, or time postinjury. The diffuse group showed greater recovery over time.	Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; Univ New S Wales, Dept Psychol, Sydney, NSW, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Archibald CJ, 2000, J CLIN EXP NEUROPSYC, V22, P686, DOI 10.1076/1380-3395(200010)22:5;1-9;FT686; Babor TF, 1989, ALCOHOL USE DISORDER; Bigler ED, 1998, MED PEDIATR ONCOL, P17; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; De Sonneville LMJ, 2002, NEUROPSYCHOLOGIA, V40, P1751, DOI 10.1016/S0028-3932(02)00041-6; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; JENNETT B, 1977, LANCET, V1, P878; JOHNSON SC, 1994, NEUROPSYCHOLOGY, V8, P301; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Llorente AM, 1998, J CLIN EXP NEUROPSYC, V20, P60, DOI 10.1076/jcen.20.1.60.1489; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MILLER EM, 1994, PERS INDIV DIFFER, V17, P803, DOI 10.1016/0191-8869(94)90049-3; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PARKER JR, 1990, ANN CLIN LAB SCI, V20, P220; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Salthouse T. A., 1985, HDB AGING HDB PSYCHO, P400; Salthouse T.A., 1994, NEUROPSYCHOLOGY, V8, P535, DOI [DOI 10.1037/0894-4105.8.4.535, 10.1037/0894-4105.8.4.535]; Salthouse TA, 2000, BIOL PSYCHOL, V54, P35, DOI 10.1016/S0301-0511(00)00052-1; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1973, SYMBOL DIGIT MODALIT; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Tomei G, 1991, J Neurosurg Sci, V35, P61; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Verhaeghen P, 1997, PSYCHOL BULL, V122, P231, DOI 10.1037/0033-2909.122.3.231; VILKKI J, 1994, NEUROPSYCHOLOGIA, V32, P1257, DOI 10.1016/0028-3932(94)90107-4; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	48	115	116	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2004	18	3					564	571		10.1037/0894-4105.18.3.564			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	838IK	WOS:000222706700017	15291734				2021-06-18	
J	Nordstrom, CH; Reinstrup, P; Xu, WB; Gadenfors, A; Ungerstedt, U				Nordstrom, CH; Reinstrup, P; Xu, WB; Gadenfors, A; Ungerstedt, U			Assessment of the lower limit for cerebral perfusion pressure in severe head injuries by bedside monitoring of regional energy metabolism	ANESTHESIOLOGY			English	Article							INTRACEREBRAL MICRODIALYSIS; VOLUME REGULATION; MANAGEMENT; HEMODYNAMICS; PRINCIPLES; THERAPY	Background: In patients with severe traumatic brain lesions, the lower limit for cerebral perfusion pressure (CPP) is controversial. The aim of this prospective study was to assess this limit from bedside measurements of cerebral energy metabolism and to clarify whether the penumbra zone surrounding a focal lesion is more sensitive to a decrease in CPP than less-injured areas. Methods: Fifty patients with severe head injury were included after evacuation of an intracranial hematoma and/or focal brain contusion. They were treated according to intensive care routine (Lund concept), including continuous monitoring of intracranial pressure. One microdialysis catheter was inserted in less-injured brain tissue ("better" position), and one or two catheters were inserted into the boundary of injured cerebral cortex ("worse" position). Concentrations of glucose, pyruvate, and lactate were analyzed and displayed bedside and were related to CPP (n = 29,495). Results. Mean interstitial glucose concentration was unaffectcd by the level of the CPP within the studied ranges. Increases in lactate concentration (P = 0.0008) and lactate-pyruvate ratio (P = 0.01) were obtained in the "worse" but not in the "better" position at CPP less than 50 mmHg compared with the same positions at CPP greater than 50 mmHg. Conclusions. The study results support the view that CPP may be reduced to 50 mmHg in patients with severe traumatic brain lesions, provided that the physiologic and pharmacologic principles of the Lund concept are recognized. In the individual patient, preservation of normal concentrations of energy metabolites within cerebral areas at risk can be guaranteed by intracerebral microdialysis and bedside biochemical analyses.	Univ Lund Hosp, Dept Clin Neurosci, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Anesthesiol & Intens Care, S-22185 Lund, Sweden; Kunming Med Coll, Affiliated Hosp 1st, Kunming, Peoples R China; Malmo Univ Hosp, Dept Anesthesia & Intens Care, Malmo, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden	Nordstrom, CH (corresponding author), Univ Lund Hosp, Dept Clin Neurosci, S-22185 Lund, Sweden.	carl-henrik.nordstrom@skane.se					ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P922, DOI 10.1111/j.1399-6576.1995.tb04199.x; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; FENSTERMACHER JD, 1984, EDEMA, P383; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Mayer SA, 2002, J INTENSIVE CARE MED, V17, P55, DOI 10.1046/j.1525-1489.2002.17201.x; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P827, DOI 10.1111/j.1399-6576.1995.tb04179.x; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SIESJO BK, 1970, ACTA NEUROL SCAND, V46, P187, DOI 10.1111/j.1600-0404.1970.tb05615.x; SIESJO BK, 1978, BRAIN ENERGY METABOL, P479; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860	21	115	118	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2003	98	4					809	814		10.1097/00000542-200304000-00004			6	Anesthesiology	Anesthesiology	660ZG	WOS:000181865500003	12657839				2021-06-18	
J	Kersel, DA; Marsh, NV; Havill, JH; Sleigh, JW				Kersel, DA; Marsh, NV; Havill, JH; Sleigh, JW			Psychosocial functioning during the year following severe traumatic brain injury	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; SOCIAL RECOVERY; IMPAIRMENT	The psychosocial functioning of a group of 65 adults with severe traumatic brain injury was assessed at 6 months and 1 year post-injury. Aspects of emotional, behavioural, and social functioning were investigated. The prevalence of depression remained constant (24%) over time, although there was some individual variation in the reporting of symptoms. Impatience was the most frequently reported behavioural problem at both assessments. Whilst there was a slight increase in the number of behavioural problems and level of distress reported over time, the most obvious change was in the type of behavioural problems that caused distress. At 1 year post-injury, problems with emotional control were found to be most distressing for the patients. A comparison with pre-morbid social functioning showed the loss of employment to be 70%, 30% returned to live with their parents, and relationship breakdown occurred for 38%. There was also a significant and ongoing decrease in all five aspects of social and leisure activities.	Univ Waikato, Dept Psychol, Hamilton, New Zealand; Univ Glasgow, Dept Psychol Med, Glasgow, Lanark, Scotland; Waikato Hosp, Intens Care Unit, Hamilton, New Zealand	Marsh, NV (corresponding author), Univ Waikato, Dept Psychol, Private Bag 3105, Hamilton, New Zealand.	nvmarsh@waikato.ac.nz	Marsh, Nigel V./F-5433-2019	Marsh, Nigel V./0000-0002-4060-6432			BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CRAWFORD C, 1983, NEW ZEAL MED J, V96, P972; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GRIMM BH, 1986, HDB CLIN NEUROPSYCHO, V2, P495; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HPAY H, 1971, HEAD INJURIES, P110; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1975, LANCET, V1, P480; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KERSEL DA, IN PRESS BRAIN INJUR; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KNIGHT RG, 1984, J CLIN PSYCHOL, V40, P751, DOI 10.1002/1097-4679(198405)40:3<751::AID-JCLP2270400320>3.0.CO;2-Y; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MARSH NV, 1999, BRAIN DAM B, P175; McKinlay W, 1999, REHABILITATION ADULT, V3, P74; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Smith L.M., 1995, FAMILY SUPPORT PROGR; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Taylor C.A., 1998, SEMINARS CLIN NEUROP, V3, P224; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	40	115	116	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2001	15	8					683	696		10.1080/02699050010013662			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462ZJ	WOS:000170452100003	11485609				2021-06-18	
J	Levin, HS; Boake, C; Song, J; McCauley, S; Contant, C; Diaz-Marchan, P; Brundage, S; Goodman, H; Kotrla, KJ				Levin, HS; Boake, C; Song, J; McCauley, S; Contant, C; Diaz-Marchan, P; Brundage, S; Goodman, H; Kotrla, KJ			Validity and sensitivity to change of the Extended Glasgow Outcome Scale in mild to moderate traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						Extended Glasgow Outcome Scale; traumatic brain injury	SEVERE HEAD-INJURY; DISABILITY; LONG	Using a structured outcome interview, this study addressed the validity and sensitivity to change of the Glasgow Outcome Scale (GOS) and the Extended GOS (GOSE) in a prospective study of patients who sustained mild (n = 30) to moderate (n = 13) traumatic brain injury (TBI) or general trauma (n = 44), The patients were recruited from the emergency center or inpatient units of Ben Taub General Hospital and invited to participate in follow-up examinations at 3 and 6 months. Using a series of functional outcome measures, assessment of affective status, and neuropsychological tests as criteria, the validity of the GOSE generally exceeded the GOS, Analysis of the outcome data for the patients who completed both the 3-month and 6-month assessments disclosed that the GOSE was more sensitive to change than the GOS, Comparison of the 3-month outcome data disclosed that the GOSE and GOS scores did not differ for the TBI and general trauma groups, These findings lend further support for utilization of the GOSE in clinical trials when it is based on a structured interview.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Phys Med & Rehabil, Houston, TX USA; Vet Affairs Med Ctr, Vet Integrated Serv Network 16, Mental Illness Res Educ & Clin Ctr, Houston, TX 77030 USA	Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Box 67,Suite 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR612707] Funding Source: Medline		AITKEN RCB, 1969, P ROY SOC MED, V1, pS45; *ASS ADV AUT MED C, 1990, ABB INJ SC; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; GRONWALL D, 1974, LANCET, V2, P605; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Heaton R., 1993, WISCONSIN CARD SORTI; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; Smith A., 1973, SYMBOL DIGIT MODALIT; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	31	115	115	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2001	18	6					575	584		10.1089/089771501750291819			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	445ZQ	WOS:000169488800001	11437080				2021-06-18	
J	de Kruijk, JR; Leffers, P; Menheere, PPCA; Meerhoff, S; Twijnstra, A				de Kruijk, JR; Leffers, P; Menheere, PPCA; Meerhoff, S; Twijnstra, A			S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients - A comparison with healthy controls	ACTA NEUROLOGICA SCANDINAVICA			English	Article						mild traumatic brain injury; neuron-specific enolase; S-100B; vomiting	SEVERE HEAD-INJURY; MYELIN BASIC-PROTEIN; COMPUTED-TOMOGRAPHY; DAMAGE	Objectives - The aim of the study was to determine whether serum concentrations of neuron-specific enolase (NSE) and S100-B in mild traumatic brain injury (MTBI) patients are higher than in serum of healthy controls. Material and methods - Blood samples from 104 MTBI patients were taken shortly after the trauma for measurement of S-100B and NSE in serum. In 92 healthy persons these markers were also measured. Marker concentrations in serum of patients and controls were compared. In the patient group the relation between serum-marker concentrations and clinical symptoms and signs, that occurred shortly after the traumatic event, were evaluated. Results - Median NSE concentration was only slightly higher in patients (9.8 mug/l; 10 to 90 percentile range 6.9 to 14.3,mug/l) than in controls (9.4 mug/l; 6.3 to 13.3 mug/l). Median S-100B concentration was significantly higher in patients (0.25 mug/l; 0.00 to 0.68 mug/l) than in controls (0.02 mug/l; 0.90 to 0.13 mug/l). An association was found between S-100B concentrations and vomiting in patients. Conclusions - S-100B is a useful marker for brain damage in MTBI patients and seems to be associated with the presence of vomiting after the trauma.	Univ Hosp Maastricht, Dept Neurol, NL-6229 HX Maastricht, Netherlands; Univ Hosp Maastricht, Dept Clin Chem, Maastricht, Netherlands; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands	de Kruijk, JR (corresponding author), Univ Hosp Maastricht, Dept Neurol, P Debeylaan 25, NL-6229 HX Maastricht, Netherlands.		Leffers, Pieter/B-8642-2009				Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; KATO K, 1982, BRAIN RES, V237, P441, DOI 10.1016/0006-8993(82)90455-3; LAMERS KJB, 1995, ACTA NEUROL SCAND, V92, P247; Nee PA, 1999, J NEUROL NEUROSUR PS, V66, P470, DOI 10.1136/jnnp.66.4.470; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; USUI A, 1989, CLIN CHEM, V35, P1942; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	14	115	119	0	3	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	MAR	2001	103	3					175	179		10.1034/j.1600-0404.2001.103003175.x			5	Clinical Neurology	Neurosciences & Neurology	404MN	WOS:000167104100006	11240565				2021-06-18	
J	White, JRM; Farukhi, Z; Bull, C; Christensen, J; Gordon, T; Paidas, C; Nichols, DG				White, JRM; Farukhi, Z; Bull, C; Christensen, J; Gordon, T; Paidas, C; Nichols, DG			Predictors of outcome in severely head-injured children	CRITICAL CARE MEDICINE			English	Article						pediatrics; traumatic brain injury; Glasgow Coma Scale; mannitol; supranormal blood pressure; length of stay; survival; outcome; risk factors; resource utilization	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; MANNITOL; MANAGEMENT; SURVIVAL; SEVERITY; THERAPY; SALINE	Objective: Determine variables in the acute care period associated with survival and pediatric intensive care unit (PICU) length of stay (LOS) for children with severe traumatic brain injury. Design: Retrospective cohort. Setting: Level 1 pediatric trauma center. Patients: Children (0-17 yrs) admitted 1991 to 1995 with nonpenetrating traumatic brain injury and admission Glasgow Coma Scale score of less than or equal to8. Interventions: None. Measurements and Main Result's: The first 72 hrs of hospitalization were analyzed in detail for 136 patients. The primary end point was survival; secondary end points were PICU LOS, cost, and day at which Glasgow Coma Scale score was greater than or equal to 14. Predictors of outcome were abstracted, including Pediatric Trauma Score, Glasgow Coma Scale score, Pediatric Risk of Mortality, physiologic variables, computed tomography evidence of brain injury, and neuroresuscitative medications. The fatality rate was 24%. Age and gender were similar between groups (p greater than or equal to .1). Survival was independently predicted by 6-hr Glasgow Coma Scale score (odds ratio [OR] 4.6; 95% confidence interval [CI] 2.06-11.9; p < .001) and maximum systolic blood pressure (OR 1.05; 95% CI 1.01-1.09; p < .02). Odds of survival increased 19-fold when maximum systolic blood pressure was greater than or equal to 135 mm Hg (OR 18.8; 95% CI 2.0-178.0; p < .01). By discharge, 67% of patients had an age-appropriate Glasgow Coma Scale score. Median hospital costs were $8,798 for survivors: only mannitol use independently predicted high cost (odds ratio 4.9; 95% CI 1.2-19.1; p < .01). For survivors, median PICU LOS was 2 days, although 25% had LOS >6 days. Six-hour Glasgow Coma Scale score (OR 0.62; 95% GI 0.48-0.80; p < .001) and mannitol (OR 7.9; 95% CI 2.3-27.3; p < .001) were each independently associated with a prolonged LOS among survivors. Conclusions: Patients with higher 6-hr Glasgow Coma Scale scores were more likely to survive. Adjusting for severity of injury, survival was associated with maximum systolic blood pressure greater than or equal to 135 mm Hg, suggesting that supranormal blood pressures are associated with improved outcome, Mannitol administration was associated with prolonged LOS, yet conferred no survival advantage. We suggest reevaluation of blood pressure targets and mannitol use in children with severe traumatic brain injury.	Childrens Natl Med Ctr, Div Pediat Crit Care Med, Washington, DC 20010 USA; Johns Hopkins Hosp, Div Pediat Crit Care Med, Baltimore, MD 21287 USA; Johns Hopkins Hosp, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; Johns Hopkins Hosp, Dept Surg, Baltimore, MD 21287 USA; Johns Hopkins Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA; Johns Hopkins Hosp, Dept Pediat Rehabil, Baltimore, MD USA; Johns Hopkins Hosp, Kennedy Krieger Inst, Baltimore, MD USA; Johns Hopkins Hosp, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Hosp, Dept Pediat, Baltimore, MD USA; Sch Med, Baltimore, MD USA	White, JRM (corresponding author), Childrens Natl Med Ctr, Div Pediat Crit Care Med, Washington, DC 20010 USA.						BISHOP MH, 1993, CRIT CARE MED, V21, P56, DOI 10.1097/00003246-199301000-00013; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; HARTWELL RC, 1993, NEUROSURGERY, V32, P444, DOI 10.1227/00006123-199303000-00017; JENNETT B, 1977, LANCET, V1, P878; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Luvisotto TL, 1996, NEUROSURGERY, V38, P131, DOI 10.1097/00006123-199601000-00031; MANTEL N, 1959, J NATL CANCER I, V22, P719; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; *NAT CTR HLTH STAT, 1996, VIT STAT US 1991 A, V2, P36; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PIGULA FA, 1993, J PEDIATR SURG, V28, P315; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAHR R, 1998, CONSUMER PRICE INDEX; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Soriano SG, 1996, CAN J ANAESTH, V43, P461, DOI 10.1007/BF03018107; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; WARD JD, 1995, MANAGEMENT PEDIAT TR, P177; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WINKLER SR, 1995, SURG NEUROL, V43, P59, DOI 10.1016/0090-3019(95)80039-J	30	115	118	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	2001	29	3					534	540		10.1097/00003246-200103000-00011			7	Critical Care Medicine	General & Internal Medicine	411WM	WOS:000167522400009	11373416				2021-06-18	
J	Gopinath, SP; Valadka, AB; Uzura, M; Robertson, CS				Gopinath, SP; Valadka, AB; Uzura, M; Robertson, CS			Comparison of jugular venous oxygen saturation and brain tissue Po-2 as monitors of cerebral ischemia after head injury	CRITICAL CARE MEDICINE			English	Article						cerebral oxygenation; cerebral ischemia; traumatic brain injury; jugular venous oxygen saturation; tissue Po-2	BLOOD-FLOW; COMATOSE PATIENTS; COMPUTERIZED-TOMOGRAPHY; CARDIOPULMONARY BYPASS; NEUROSURGICAL PATIENTS; PERFUSION-PRESSURE; SUBDURAL-HEMATOMA; METABOLISM; BULB; DESATURATION	Objective: To compare the characteristics of jugular venous oxygen saturation (Sjvo(2)) and brain tissue Po-2 (Pbto(2)) as monitors for cerebral ischemia after severe head injury. Sjvo(2) has been useful as a monitor for cerebral ischemia, but it is limited by its inability to identify regional cerebral ischemia. Pbto(2) may be superior to Sjvo(2) for this purpose, because oxygenation in localized areas of the brain can be monitored. Design: Sjvo(2) and Pbto(2) were successfully monitored in 58 patients with severe head injury. The changes in Sjvo(2) and Pbto(2) were compared during ischemic episodes. Setting: Neurosurgical intensive care unit of a level I trauma center. Measurements and Main Results: During the monitoring period, which averaged 90 hrs/patient, there were 54 episodes during which Sjvo(2) decreased to <50% and/or Pbto(2) decreased to <8 torr. Two of these episodes were caused by an infarction in the area of the Po-2 probe, leaving 52 episodes of global hypoxia/ischemia that were identified by one of the two monitors. The sensitivities of the two monitors for detecting ischemia, using the thresholds of 50% and 8 torr for Sjvo(2) and Pbto(2), respectively, were similar. The Sjvo(2) catheter detected 69.7% of the episodes and the Pbto(2) catheter detected 63.5% of the episodes. In most of the remaining episodes, both probes reflected a decrease in oxygenation, but not to levels below the defined thresholds. The major differences in the two measures of oxygenation included the following: a) Sjvo(2) more consistently reflected a reduction in oxygenation during hyperventilation; b) Pbto(2) was affected more by changes in arterial Po-2; and c) during severe global ischemia, Pbto(2) decreased to 0 and remained at 0, whereas Sjvo(2) initially decreased but then increased again as cerebral blood flow ceased, and the only blood in the jugular bulb was of extracerebral origin. Conclusions: The two monitors provide complimentary information, and neither monitor alone identifies all episodes of ischemia. The best strategy for using these monitors is to take advantage of the unique features of each monitor. Sjvo(2) should be used as a monitor of global oxygenation; but Pbto(2) should be used as a monitor of local oxygenation, ideally with the catheter placed in an area of the brain that is vulnerable to ischemia but that may be salvageable with appropriate treatment.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; CROUGHWELL ND, 1994, ANN THORAC SURG, V58, P1702, DOI 10.1016/0003-4975(94)91666-7; CRUZ J, 1985, CRIT CARE MED, V13, P284, DOI 10.1097/00003246-198504000-00047; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Dings J, 1996, ZBL NEUROCHIR, V57, P177; Feldman Z, 1997, CRIT CARE CLIN, V13, P51, DOI 10.1016/S0749-0704(05)70296-7; GARLICK R, 1987, SCAND J CLIN LAB INV, V47, P47; GIBBS EL, 1945, AM J PSYCHIAT, V102, P184, DOI 10.1176/ajp.102.2.184; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gopinath SP, 1996, ANESTH ANALG, V83, P1014, DOI 10.1097/00000539-199611000-00020; Hans P, 1991, Acta Anaesthesiol Belg, V42, P213; HANTSON P, 1992, INTENS CARE MED, V18, P59, DOI 10.1007/BF01706431; Hoffman WE, 1996, ANESTH ANALG, V82, P582, DOI 10.1097/00000539-199603000-00027; Hoffman WE, 1997, SURG NEUROL, V47, P455, DOI 10.1016/S0090-3019(97)82798-X; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; LASSEN NA, 1968, SCAND J CLIN LAB S D, V102; Lennox WG, 1935, ARCH NEURO PSYCHIATR, V34, P1001, DOI 10.1001/archneurpsyc.1935.02250230073006; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; MEYER JS, 1965, NEUROLOGY, V15, P892, DOI 10.1212/WNL.15.10.892; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; OVERGAARD J, 1983, J NEUROSURG, V59, P439, DOI 10.3171/jns.1983.59.3.0439; Ritter AM, 1996, J CLIN MONITOR, V12, P285, DOI 10.1007/BF02221748; RITTER AM, 1994, NEUROSURGICAL CLIN N, P633; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SALVANT JB, 1993, NEUROSURGERY, V33, P387; Sapire KJ, 1997, CRIT CARE MED, V25, P1655, DOI 10.1097/00003246-199710000-00014; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Souter M. J., 1995, Journal of Neurotrauma, V12, P471; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812	42	115	119	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	1999	27	11					2337	2345		10.1097/00003246-199911000-00003			9	Critical Care Medicine	General & Internal Medicine	258AA	WOS:000083814800002	10579245				2021-06-18	
J	Fleming, J; Tooth, L; Hassell, M; Chan, W				Fleming, J; Tooth, L; Hassell, M; Chan, W			Prediction of community integration and vocational outcome 2-5 years after traumatic brain injury rehabilitation in Australia	BRAIN INJURY			English	Article							DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; MULTICENTER ANALYSIS; FUNCTIONAL OUTCOMES; RECOVERY; RETURN; WORK; PROGNOSIS; MODERATE; VALIDITY	Objectives: To predict community integration and vocational outcomes 2-5 years after traumatic brain injury (TBI). Design: Multivariate correlational design incorporating retrospective data collection and questionnaire follow-up. Methods: Four hundred and forty six patients admitted to a Head Injury Unit between 1991 and 1995 were contacted. Data on predictor variables (demographic, injury severity and functional) were retrieved from hospital records. Community integration and vocational outcome was assessed by self-administered questionnaire. Two hundred and nine patients/carers completed and returned the questionnaires. Mean follow-up was 3.5 years. Data were analysed by descriptive statistics, multiple regression and discriminant analysis using SPSS. Results: Community integration was predicted by age, disability level and cognition. Length of PTA, cognition, disability levels, GCS, functional status, length of acute stay and prior occupation discriminated those who returned to work. A total of 46.5% returned to work with 74.5% in the same or similar jobs. Conclusion: Long term outcomes post-TBI can be predicted by demographic, injury severity and functional status variables.	Univ Queensland, Dept Occupat Therapy, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Brisbane, Qld 4102, Australia	Fleming, J (corresponding author), Univ Queensland, Dept Occupat Therapy, Brisbane, Qld 4072, Australia.		Fleming, Jennifer M/B-4436-2011; Tooth, Leigh/F-2769-2010	Tooth, Leigh/0000-0002-1569-934X			*AUSTR BUR STAT, 1990, ASCO OCC DEF AUSTR C; BARRY P, 1989, ARCH PHYS MED REHAB, V70, P902; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Brzuzy S, 1996, J HEAD TRAUMA REHAB, V11, P74, DOI 10.1097/00001199-199606000-00011; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cohen J., 1983, APPL MULTIPLE REGRES; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; CREPEAU F, 1993, NEUROPSYCHOLOGICAL R, V4, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EAMES P, 1995, BRAIN INJURY, V10, P631; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Fleming JM, 1997, J HEAD TRAUMA REHAB, V12, P27, DOI 10.1097/00001199-199706000-00004; Geffen G., 1994, AUST OCCUP THER J, V41, P31, DOI DOI 10.1111/J.1440-1630.1994.TB01809.X; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; Johnson R, 1987, Int Disabil Stud, V9, P49; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; *LAF INSTR COMP IN, LAF GROOV PEGB; MAHONEY F I, 1965, Md State Med J, V14, P61; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Millis S R, 1994, Int J Neurosci, V79, P165; NAJMAN JM, 1991, AUST NZ J SOCIOL, V27, P218; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; ROSENTHAL M, 1990, REHABILITATION ADULT, P516; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tabachnick BG, 2013, USING MULTIVARIATE S; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILSON B, 1991, RIVENNEAD BEHAV MEMO	48	115	117	0	17	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1999	13	6					417	431					15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	204DA	WOS:000080746600003	10401543				2021-06-18	
J	Schmand, B; Lindeboom, J; Schagen, S; Heijt, R; Koene, T; Hamburger, HL				Schmand, B; Lindeboom, J; Schagen, S; Heijt, R; Koene, T; Hamburger, HL			Cognitive complaints in patients after whiplash injury: the impact of malingering	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						whiplash injury; neuropsychological tests; cognition disorders; malingering	COMMON WHIPLASH; FOLLOW-UP; DEFICITS; INCENTIVES; SYMPTOMS; MEMORY; UPDATE	Objectives-The validity of memory and concentration complaints that are often reported after a whiplash trauma is controversial. The prevalence of malingering or under performance in post-whiplash patients, and its impact on their cognitive test results were studied. Methods-The Amsterdam short term memory (ASTM) test, a recently developed malingering test, was used as well as a series of conventional memory and concentration tests. The study sample was a highly selected group of patients, who were examined either as part of a litigation procedure (n=36) or in the normal routine of an outpatient clinic (n=72). Results-The prevalence of underperformance, as defined by a positive score on the malingering test, was 61% (95% CI: 45-77) in the context of litigation, and 29% (95% CI: 18-40) in the outpatient clinic (p=0.003). Furthermore, the scores on the memory and concentration test of malingering post-whiplash patients (n=43) and non-malingering post-whiplash patients (n=65) were compared with the scores of patients with closed head injury (n=20) and normal controls (n=46). The malingering post-whiplash patients scored as low as the patients with closed head injury on most tests. Conclusions-The prevalence of malingering or cognitive underperformance in late post-whiplash patients is substantial, particularly in litigation contexts. it is not warranted to explain the mild cognitive disorders of whiplash patients in terms of brain damage, as some authors have done. The cognitive complaints of non-malingering post-whiplash patients are more likely a result of chronic pain, chronic fatigue, or depression.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DD Amsterdam, Netherlands; Slotervaartziekenhuis, Dept Psychol, Amsterdam, Netherlands; Vrije Univ Amsterdam, Acad Ziekenhuis, Dept Med Psychol, Amsterdam, Netherlands; Slotervaartziekenhuis, Dept Neurol, Amsterdam, Netherlands; Slotervaartziekenhuis, Dept Clin Neurophysiol, Amsterdam, Netherlands	Schmand, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, H2-214,POB 22660, NL-1100 DD Amsterdam, Netherlands.						BAYER TL, 1985, SOC SCI MED, V20, P517, DOI 10.1016/0277-9536(85)90368-5; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bouma A., 1996, NEUROPSYCHOLOGISCHE; Cassens G, 1990, J Neuropsychiatry Clin Neurosci, V2, P202; DISTEFANO G, 1995, ACTA NEUROL SCAND, V91, P346; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; Haines ME, 1995, NEUROPSYCHOL REV, V5, P125, DOI 10.1007/BF02208438; Hammes JGW., 1978, STROOP KLEUR WOORD T; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luteijn F., 1983, GRONINGER INTELLIGEN; MossMorris R, 1996, J NEUROL NEUROSUR PS, V60, P474, DOI 10.1136/jnnp.60.5.474; Nelson HE, 1982, NATL ADULT READING T; OLSNES BT, 1989, ACTA NEUROL SCAND, V80, P584, DOI 10.1111/j.1600-0404.1989.tb03931.x; Otte A, 1996, EUR J NUCL MED, V23, P72, DOI 10.1007/BF01736993; PEARCE JMS, 1994, NEUROLOGY, V44, P1993, DOI 10.1212/WNL.44.11.1993; PEARCE JMS, 1995, COMMENTS NEUROLOGY, V45, P2116; *QUEB TASK FORC WH, 1995, SPINE S8, V20, pS12; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; Radanov BP, 1996, SPINE, V21, P392, DOI 10.1097/00007632-199602010-00029; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Schmand B., 1992, NEDERLANDSE LEESTEST; Schrader H, 1996, LANCET, V347, P1207, DOI 10.1016/S0140-6736(96)90733-3; Smed A, 1997, ACTA NEUROL SCAND, V95, P73, DOI 10.1111/j.1600-0404.1997.tb00072.x; Stinissen J, 1970, HANDLEIDING BIJ NEDE; Turk D, 1992, HDB PAIN ASSESSMENT, V2nd; Van den Burg W, 1985, 15 WOORDENTEST PROVI; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	31	115	120	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	1998	64	3					339	343		10.1136/jnnp.64.3.339			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	ZD117	WOS:000072653100011	9527145	Green Published, Bronze			2021-06-18	
J	Guskiewicz, KM; Perrin, DH; Gansneder, BM				Guskiewicz, KM; Perrin, DH; Gansneder, BM			Effect of mild head injury on postural stability in athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; balance; postural sway	SENSORY INTERACTION; BALANCE; SWAY; CONCUSSION; ADAPTATION; STANCE	Objective: Athletic trainers and team physicians are often faced with the dilemma of when to return athletes to participation following mild head injury. Unfortunately, clinicians rarely have quantitative information on which to base their decisions. The purpose of this investigation was to identify postural stability changes in athletes with acute mild head injury. Design and Setting: High school and college male athletes were prescreened for postural stability before the start of their season. Subjects suffering injury during the season returned for testing on days 1, 3, 5, and 10 following injury, and 1 month postseason. Control subjects were selected for comparisons. Subjects: Ten prescreened subjects (age = 17.4 +/- 2.2 yr; ht = 183.8 +/- 8.1 cm; wt = 87.7 +/- 17.3 kg) returned for testing following an injury. Ten matched control subjects (age = 18.6 +/- 2.6 yr; ht = 185.7 +/- 6.7 cm; wt = 84.5 +/- 19.5 kg) were selected for comparisons. Additionally, nine subjects (eight mate and one female) (age = 19.9 +/- 4.2 yr; ht = 182.3 +/- 10.9 cm; wt = 89.6 +/- 25.2 kg) who had sustained a mild head injury from other varsity sports teams were recruited. Nine matched controls (age = 22.1 +/- 3.3 yr; ht = 181.0 +/- 9.9 cm; wt = 84.9 +/- 25.6 kg) were again utilized. Measurements: Sway index and center of balance were measured using the Chattecx Balance System during three eye conditions and three surface conditions for all subjects. Results: Repeated measures analyses of Variance (ANOVA) for each prescreened subject's sway index revealed significant differences between injured subjects and control subjects on day 1 postinjury as compared with the prescreening and/or subsequent tests. The analysis for sway index and center of balance inclusive of all 19 subjects with mild head injury and all 19 control subjects demonstrated increased postural sway compared with control subjects on day 1 postinjury during all platform conditions, and on day 3 during the foam platform condition. The analysis for center of balance using the same subjects revealed that injured subjects maintained their center of balance farther away on day 1 postinjury compared with subsequent tests (p < .05). Conclusions: These findings suggest that computerized dynamic posturography is a useful tool in objectively assessing postural stability in subjects with mild head injuries. Subjects with mild head injury appear to demonstrate impaired postural stability 1 to 3 days following injury. This information should aid clinicians in determining when an athlete can safely return to participation.	UNIV VIRGINIA,CURRY SCH EDUC,DEPT HUMAN SERV,CHARLOTTESVILLE,VA 22903	Guskiewicz, KM (corresponding author), UNIV N CAROLINA,DEPT PHYS EDUC EXERCISE & SPORT SCI,CHAPEL HILL,NC 27514, USA.			Guskiewicz, Kevin/0000-0002-8682-2130			ADAMS J, 1975, HDB CLIN NEUROLOGY I, P35; ARCAN M, 1977, SCAND J REHABIL MED, V9, P165; BRUCE D, 1982, PRIMARY CARE, V11, P175; BYL NN, 1991, SPINE, V16, P325, DOI 10.1097/00007632-199103000-00012; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; CANTU RC, 1991, ADOLESC MED, V2, P141; *CHATT GROUP INC, 1992, BAL SYST CLIN DESK R, P4; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; GUYTON A, 1986, TXB MED PHYSL, P610; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; LEVIN H, 1994, P MILD BRAIN INJ SPO, P53; MAURITZ KH, 1979, BRAIN, V102, P461, DOI 10.1093/brain/102.3.461; MCINTOSH T, 1989, MILD MODERATE HEAD I, P35; NASHNER L, 1978, BRAIN RES, V150, P403, DOI 10.1016/0006-8993(78)90291-3; NASHNER LM, 1982, J NEUROSCI, V2, P536; NASHNER LM, 1982, TRENDS NEUROSCI, V5, P358, DOI 10.1016/0166-2236(82)90204-1; NASHNER LM, 1976, EXP BRAIN RES, V26, P59; *NAT ATHL TRAIN AS, 1994, P MILD BRAIN INJ SPO, P2; NEWTON R, 1989, BAL P AM PHYS THER A, P69; NORRE ME, 1993, J LARYNGOL OTOL, V107, P496, DOI 10.1017/S0022215100123564; Ommaya A, 1994, P MILD BRAIN INJ SPO, P72; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Weir Mitchell S, 1886, AM J MED SCI, V92, P363	30	115	115	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247	1062-6050			J ATHL TRAINING	J. Athl. Train.	OCT-DEC	1996	31	4					300	306					7	Sport Sciences	Sport Sciences	WA362	WOS:A1996WA36200003	16558414				2021-06-18	
J	MATTSON, MP; CHENG, B; BALDWIN, SA; SMITHSWINTOSKY, VL; KELLER, J; GEDDES, JW; SCHEFF, SW; CHRISTAKOS, S				MATTSON, MP; CHENG, B; BALDWIN, SA; SMITHSWINTOSKY, VL; KELLER, J; GEDDES, JW; SCHEFF, SW; CHRISTAKOS, S			BRAIN INJURY AND TUMOR NECROSIS FACTORS INDUCE CALBINDIN D-28K IN ASTROCYTES - EVIDENCE FOR A CYTOPROTECTIVE RESPONSE	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						ACIDOSIS; CALCIUM-BINDING PROTEIN; CORPUS CALLOSUM; CYTOKINE; EXCITOTOXICITY; FURA-2; HIPPOCAMPUS; KAINATE; NERVE GROWTH FACTOR; TRAUMATIC BRAIN INJURY	NERVE GROWTH-FACTOR; FACTOR-ALPHA; RAT-BRAIN; BINDING PROTEIN; SELECTIVE VULNERABILITY; MOLECULAR-CLONING; FACTOR RECEPTOR; MESSENGER-RNA; BIOLOGICAL CHARACTERIZATION; HIPPOCAMPAL-NEURONS	Calbindin is a 28 kDa calcium-binding protein expressed in restricted neuronal populations in the mammalian brain where it may play a role in protecting neurons against excitotoxic insults. Recent findings indicate that electrical activity and some neurotropic factors can induce the expression of calbindin in neurons. We now report that brain injury, effected by systemic administration of the excitotoxin kainate or mechanical trauma, induces expression of calbindin in cells of the corpus callosum and subcortical white matter. Immunohistochemical analysis using antibodies to the astrocyte-specific proteins (glial fibrillary acidic protein and S-100beta) established the identity of calbindin immunoreactive cells as astrocytes. Because brain injury is known to induce the expression of several neurotrophic factors and cytokines, we employed cultures of hippocampal and neocortical astrocytes to test the hypothesis that such factors can induce expression of calbindin in astrocytes. Tumor necrosis factors (TNFalpha and TNFbeta), cytokines that are expressed in response to brain injury, induced the expression of calbindin in cultured rat hippocampal and neocortical astrocytes. Two neurotrophic factors, basic fibroblast growth factor and nerve growth factor, did not induce calbindin in astrocytes. TNF-treated, calbindin-expressing astrocytes were resistant to acidosis and calcium ionophore toxicity, suggesting that TNFs and calbindin may serve a cytoprotective role in astrocytes in the injured brain.	UNIV KENTUCKY,DEPT ANAT & NEUROBIOL,LEXINGTON,KY 40506; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT BIOCHEM & MOLEC BIOL,NEWARK,NJ 07103	MATTSON, MP (corresponding author), UNIV KENTUCKY,SANDERS BROWN RES CTR AGING,211 SANDERS BROWN BLDG,LEXINGTON,KY 40506, USA.		Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030583, R01NS029001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG010678] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG10678] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30583, NS 29001] Funding Source: Medline		Aggarwal B B, 1992, Immunol Ser, V56, P61; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BALASINGAM V, 1994, J NEUROSCI, V14, P846; BEAL MF, 1993, J NEUROCHEM, V61, P1147, DOI 10.1111/j.1471-4159.1993.tb03633.x; BENVENISTE EN, 1989, J NEUROIMMUNOL, V25, P209, DOI 10.1016/0165-5728(89)90139-2; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; BIANCHI M, 1992, NEUROSCI LETT, V148, P76, DOI 10.1016/0304-3940(92)90808-K; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BOYES BE, 1986, NEUROSCIENCE, V17, P857, DOI 10.1016/0306-4522(86)90050-3; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CADELLI DS, 1992, EXP NEUROL, V115, P189, DOI 10.1016/0014-4886(92)90246-M; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHRISTAKOS S, 1987, METHOD ENZYMOL, V139, P534; CHUNG IY, 1990, J IMMUNOL, V144, P2999; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EDDY LJ, 1992, BIOCHEM BIOPH RES CO, V184, P1056, DOI 10.1016/0006-291X(92)90698-K; ELLIOTT EM, 1993, J NEUROCHEM, V61, P57, DOI 10.1111/j.1471-4159.1993.tb03537.x; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; FARRAH T, 1992, NATURE, V358, P26, DOI 10.1038/358026b0; FILLIT H, 1991, NEUROSCI LETT, V131, P318; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FREUND TF, 1990, EXP BRAIN RES, V83, P55; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GENDRON RL, 1991, INT J NEUROSCI, V60, P129, DOI 10.3109/00207459109082043; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; GOODMAN JH, 1993, BRAIN RES, V606, P309, DOI 10.1016/0006-8993(93)90999-4; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; HATTORI A, 1993, J BIOL CHEM, V268, P2577; HEIZMANN CW, 1992, TRENDS NEUROSCI, V15, P259, DOI 10.1016/0166-2236(92)90067-I; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HELLER RA, 1992, CELL, V70, P47; HOFFMAN SR, 1989, J NEUROPATH EXP NEUR, V48, P331, DOI 10.1097/00005072-198905000-00098; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; Kronke M, 1992, Immunol Ser, V56, P189; LAEMMLI UK, 1970, NATURE, V277, P680; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; LIBERSKI PP, 1993, NEURODEGENERATION, V2, P215; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LIU FC, 1992, J NEUROSCI, V12, P674; Loetscher H, 1992, Immunol Ser, V56, P161; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LOWENSTEIN DH, 1991, NEURON, V6, P627, DOI 10.1016/0896-6273(91)90065-8; MATTHEWSON AJ, 1985, BRAIN RES, V327, P61; MATTSON MP, 1993, HIPPOCAMPUS, V3, P73; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; MATTSON MP, 1993, SEMIN NEUROSCI, V5, P295; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; NADLER JV, 1980, BRAIN RES, V195, P47; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; OH YJ, 1992, J NEUROCHEM, V58, P2131, DOI 10.1111/j.1471-4159.1992.tb10955.x; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAMI A, 1992, J NEUROSCI RES, V31, P89, DOI 10.1002/jnr.490310113; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHARFMAN HE, 1989, SCIENCE, V246, P257, DOI 10.1126/science.2508225; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SEQUIER JM, 1990, EUR J NEUROSCI, V2, P1118, DOI 10.1111/j.1460-9568.1990.tb00023.x; SLOVITER RS, 1989, J COMP NEUROL, V280, P183, DOI 10.1002/cne.902800203; SMITH RA, 1992, IMMUNOL SER, V56, P149; SOLIVEN B, 1992, J NEUROSCI, V12, P2665; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; Turetskaya R L, 1992, Immunol Ser, V56, P35; YOSHIDA K, 1992, J NEUROCHEM, V59, P919, DOI 10.1111/j.1471-4159.1992.tb08331.x	77	115	118	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	OCT 15	1995	42	3					357	370		10.1002/jnr.490420310			14	Neurosciences	Neurosciences & Neurology	TC366	WOS:A1995TC36600009	8583504				2021-06-18	
J	HAMM, RJ; LYETH, BG; JENKINS, LW; ODELL, DM; PIKE, BR				HAMM, RJ; LYETH, BG; JENKINS, LW; ODELL, DM; PIKE, BR			SELECTIVE COGNITIVE IMPAIRMENT FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	BEHAVIOURAL BRAIN RESEARCH			English	Article						TRAUMATIC BRAIN INJURY; FLUID PERCUSSION; LEARNING; MEMORY; PASSIVE AVOIDANCE; MORRIS WATER MAZE; RAT	CLOSED-HEAD-INJURY; HIPPOCAMPAL-LESIONS; NUCLEUS BASALIS; KAINIC ACID; MEMORY; RECOVERY; DEFICITS; AMNESIA; DAMAGE; CORTEX	Impairment of cognitive abilities is a frequent and significant sequelae of traumatic brain injury (TBI). The purpose of this experiment was to examine the generality of the cognitive deficits observed after TBI. The performance of three tasks was evaluated. Two of the tasks (passive avoidance and a constant-start version of the Morris water maze) were chosen because they do not depend on hippocampal processing. The third task examined was the standard version of the Morris water maze which is known to rely on hippocampal processing. Rats were either injured at a moderate level (2.1 atm) of fluid percussion brain injury or surgically prepared but not injured (sham-injured control group). Nine days after fluid percussion injury, injured (n = 9) and sham-injured rats (n = 8) were trained on the one-trial passive avoidance task with retention assessed 24 h later. On days 11-15 following injury, injured (n = 9) and sham-injured (n = 8) rats were trained on a constant-start Version of the Morris water maze that has the animals begin the maze from a fixed start position on each trial. Additional injured (n = 8) and sham-injured (n = 8) animals were trained on days 11-15 after injury on the standard (i.e. using variable start positions) version of the Morris water maze. The results of this experiment revealed that performance of the passive avoidance and the constant-start Version of the Morris water maze were not impaired by fluid percussion TBI. However, performance on a task that is usually disrupted by hippocampal damage (variable-start version of the Morris water maze) was significantly impaired by TBI. Thus, the hippocampus appears to be selectively damaged following TBI.	VIRGINIA COMMONWEALTH UNIV,DEPT NEUROSURG,RICHMOND,VA 23284	HAMM, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,VCU BOX 2018,RICHMOND,VA 23284, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		BARTUS RT, 1986, PHARMACOL BIOCHEM BE, V24, P1287, DOI 10.1016/0091-3057(86)90186-3; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Deangelis M. M., 1992, Society for Neuroscience Abstracts, V18, P172; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNN LT, 1988, BEHAV NEUROSCI, V102, P3, DOI 10.1037/0735-7044.102.1.3; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; GRONWALL D, 1974, LANCET, V2, P605; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; JARRARD LE, 1980, PHYSIOL PSYCHOL, V8, P198; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MUNDY WR, 1988, NEUROTOXICOLOGY, V9, P511; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; OLTON DS, 1982, BRAIN RES, V233, P241, DOI 10.1016/0006-8993(82)91200-8; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PULSINELLI W, 1982, ANN NEUROL, P491; SANTUCCI AC, 1989, PHARMACOL BIOCHEM BE, V33, P485, DOI 10.1016/0091-3057(89)90535-2; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SUTHERLAND RJ, 1989, PSYCHOBIOLOGY, V17, P129; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TAGHZOUTI K, 1985, BRAIN RES, V344, P9, DOI 10.1016/0006-8993(85)91184-9; WINOCUR G, 1985, BEHAV BRAIN RES, V16, P135, DOI 10.1016/0166-4328(85)90088-9	32	115	116	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	DEC 31	1993	59	1-2					169	173		10.1016/0166-4328(93)90164-L			5	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	MW335	WOS:A1993MW33500020	8155285				2021-06-18	
J	HALL, ED				HALL, ED			LIPID ANTIOXIDANTS IN ACUTE CENTRAL-NERVOUS-SYSTEM INJURY	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	SYMP ON NEUROTRAUMA : CONCEPTS, CURRENT PRACTICE AND EMERGING THERAPIES	JUN 11-12, 1992	DEARBORN, MI	WAYNE STATE UNIV SCH MED, DEPT EMERGENCY MED		CENTRAL NERVOUS SYSTEM INJURY; LIPID ANTIOXIDANTS		Oxygen radical-mediated lipid peroxidation increasingly has been suggested to be an important factor in post-traumatic neuronal degeneration. Thus, numerous studies have evaluated the neuroprotective efficacy of pharmacologic agents with lipid antioxidant activity in models of spinal cord and brain injury. The glucocorticoid steroid methylprednisolone has been shown to possess significant antioxidant efficacy, and when administered to animals or human beings in antioxidant doses, it improves chronic neurologic recovery after spinal cord injury. This activity of methylprednisolone is independent of the steroid's glucocorticoid receptor-mediated actions and has been surpassed by the novel antioxidant 21-aminosteroids that have been developed that are devoid of glucocorticoid activity but have greater antioxidant efficacy than methylprednisolone. One of these, tirilazad mesylate (U-74006F), has been shown to be quite effective in animal models of brain and spinal cord injury and is the subject of phase Ill clinical trials. The consistent benefit afforded by antioxidant compounds further supports the concept that lipid peroxidation is an important therapeutic target for acute pharmacologic neuroprotection.		HALL, ED (corresponding author), UPJOHN CO,CNS DIS RES,KALAMAZOO,MI 49001, USA.		Hall, Edward D/F-8930-2013					0	115	122	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUN	1993	22	6					1022	1027		10.1016/S0196-0644(05)82745-3			6	Emergency Medicine	Emergency Medicine	LE338	WOS:A1993LE33800011	8503522				2021-06-18	
J	JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; SHURTLEFF, H; RIVARA, JB; WINN, HR				JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; SHURTLEFF, H; RIVARA, JB; WINN, HR			SEVERITY OF PEDIATRIC TRAUMATIC BRAIN INJURY AND EARLY NEUROBEHAVIORAL OUTCOME - A COHORT STUDY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						CHILDREN; CLOSED HEAD INJURY; OUTCOME; TRAUMATIC BRAIN INJURY	CLOSED-HEAD-INJURY; INTELLECTUAL ABILITY; FOLLOW-UP; CHILDREN; MEMORY; SEQUELAE; RECOVERY; ADOLESCENTS; PERFORMANCE	Traumatic brain injury (TBI) is a major cause of pediatric disability. Its neurobehavioral sequelae can often be difficult to distinguish from premorbid problems. To establish the early neurobehavioral consequences of TBI, we compared a cohort of brain injured children with controls, individually matched on premorbid characteristics. Ninety-eight children, aged 6 to 15 years, with mild, moderate, and severe closed head injuries, were consecutively identified on presentation to two regional medical centers. Individually selected controls were matched for age, gender, school grade, behavior, and academic performance. Intellectual, neuropsychologic. and academic assessments were undertaken 3 weeks after full orientation was achieved. No significant case-control differences were found on 20 variables measuring premorbid status. The pattern of decline in performance with increasing severity of brain injury was consistent for measures assessing intelligence, memory, speeded motor performance, adaptive problem solving, and academic performance. Moderately and severely injured patients performed at normal levels in reference to standardized intellectual norms, but they showed impairment when compared with their matched controls. The impairments uncovered in this study place moderately and severely brain injured children at risk for problems in the acquisition of academic skills and higher-order cognitive abilities.	UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,SEATTLE,WA 98195	JAFFE, KM (corresponding author), CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,POB C-5371,4800 SAND POINT WAY NE,SEATTLE,WA 98105, USA.			Shurtleff, Hillary/0000-0003-0959-2842	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ARMITAGE P, 1971, STATISTICAL METHODS; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BIJUR PE, 1990, PEDIATRICS, V86, P337; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Conover W.J., 1980, PRACTICAL NONPARAMET; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DELIS DC, 1989, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; GOTTFRIED AW, 1985, MERRILL PALMER QUART, V31, P85; GRONWALL D, 1974, LANCET, V2, P605; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Jastak S, 1984, WIDE RANGE ACHIEVEME; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; NBRUININKS RH, 1984, SCALES INDEPENDENT B; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SLATER EJ, 1988, AM J DIS CHILD, V142, P1048, DOI 10.1001/archpedi.1988.02150100042022; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; WALLER JA, 1988, J TRAUMA, V28, P1632, DOI 10.1097/00005373-198812000-00003; Wechsler D., 1974, MANUAL WECHSLER INTE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	38	115	115	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1992	73	6					540	547					8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HX739	WOS:A1992HX73900005	1622302				2021-06-18	
J	Cherry, JD; Tripodis, Y; Alvarez, VE; Huber, B; Kiernan, PT; Daneshvar, DH; Mez, J; Montenigro, PH; Solomon, TM; Alosco, ML; Stern, RA; Mckee, AC; Stein, TD				Cherry, Jonathan D.; Tripodis, Yorghos; Alvarez, Victor E.; Huber, Bertrand; Kiernan, Patrick T.; Daneshvar, Daniel H.; Mez, Jesse; Montenigro, Philip H.; Solomon, Todd M.; Alosco, Michael L.; Stern, Robert A.; McKee, Ann C.; Stein, Thor D.			Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						CTE; Neuroinflammation; Microglia; Repetitive head impacts; Mild traumatic brain injury; American football	BETA-AMYLOID DEPOSITION; BRAIN-INJURY; ALZHEIMERS-DISEASE; AXONAL INJURY; PATHOLOGY; INFLAMMATION; NEURODEGENERATION; PLAYERS	The chronic effects of repetitive head impacts (RHI) on the development of neuroinflammation and its relationship to chronic traumatic encephalopathy (CTE) are unknown. Here we set out to determine the relationship between RHI exposure, neuroinflammation, and the development of hyperphosphorylated tau (ptau) pathology and dementia risk in CTE. We studied a cohort of 66 deceased American football athletes from the Boston University-Veteran's Affairs-Concussion Legacy Foundation Brain Bank as well as 16 non-athlete controls. Subjects with a neurodegenerative disease other than CTE were excluded. Counts of total and activated microglia, astrocytes, and ptau pathology were performed in the dorsolateral frontal cortex (DLF). Binary logistic and simultaneous equation regression models were used to test associations between RHI exposure, microglia, ptau pathology, and dementia. Duration of RHI exposure and the development and severity of CTE were associated with reactive microglial morphology and increased numbers of CD68 immunoreactive microglia in the DLF. A simultaneous equation regression model demonstrated that RHI exposure had a significant direct effect on CD68 cell density (p < 0.0001) and ptau pathology (p < 0.0001) independent of age at death. The effect of RHI on ptau pathology was partially mediated through increased CD68 positive cell density. A binary logistic regression demonstrated that a diagnosis of dementia was significantly predicted by CD68 cell density (OR = 1.010, p = 0.011) independent of age (OR = 1.055, p = 0.007), but this effect disappeared when ptau pathology was included in the model. In conclusion, RHI is associated with chronic activation of microglia, which may partially mediate the effect of RHI on the development of ptau pathology and dementia in CTE. Inflammatory molecules may be important diagnostic or predictive biomarkers as well as promising therapeutic targets in CTE.	[Cherry, Jonathan D.; Alvarez, Victor E.; Huber, Bertrand; Kiernan, Patrick T.; Daneshvar, Daniel H.; Mez, Jesse; Montenigro, Philip H.; Solomon, Todd M.; Alosco, Michael L.; Stern, Robert A.; McKee, Ann C.; Stein, Thor D.] Boston Univ, Alzheimers Dis, Boston, MA 02215 USA; [Cherry, Jonathan D.; Alvarez, Victor E.; Huber, Bertrand; Kiernan, Patrick T.; Daneshvar, Daniel H.; Mez, Jesse; Montenigro, Philip H.; Solomon, Todd M.; Alosco, Michael L.; Stern, Robert A.; McKee, Ann C.; Stein, Thor D.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Cherry, Jonathan D.; Alvarez, Victor E.; Huber, Bertrand; Kiernan, Patrick T.; Mez, Jesse; Alosco, Michael L.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Montenigro, Philip H.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [McKee, Ann C.; Stein, Thor D.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [McKee, Ann C.; Stein, Thor D.] VA Boston Healthcare Syst, Boston, MA 02130 USA; [McKee, Ann C.; Stein, Thor D.] Dept Vet Affairs Med Ctr, Bedford, MA 01730 USA	Stein, TD (corresponding author), Boston Univ, Alzheimers Dis, Boston, MA 02215 USA.; Stein, TD (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.; Stein, TD (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.; Stein, TD (corresponding author), VA Boston Healthcare Syst, Boston, MA 02130 USA.; Stein, TD (corresponding author), Dept Vet Affairs Med Ctr, Bedford, MA 01730 USA.	tdstein@bu.edu	, Bob/ABA-8507-2020; Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Tripodis, Yorghos/0000-0003-2190-7608; Stein, Thor/0000-0001-6954-4477; Daneshvar, Daniel/0000-0003-3691-9513	Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award [I01-CX001038]; Alzheimer's AssociationAlzheimer's Association [NIRG-305779]; National Institute of AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1RF1AG054156-01]; Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering [U01NS086659-01]; National Institute of Aging Boston University AD Center [P30AG13846, 0572063345-5]; Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP) [13267017]; National Heart, Lung, and Blood Institute, Framingham Heart Study (NHLBI/NIH) [N01-HC-25195, R01AG08122]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1F32NS096803-01]; Concussion Legacy Foundation; Andlinger Foundation; WWE; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS096803, U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG046377, P30AG013846, RF1AG054156, R01AG008122] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award (I01-CX001038); Alzheimer's Association (NIRG-305779); National Institute of Aging (1RF1AG054156-01); Veterans Affairs Biorepository (CSP 501); Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C); National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering (U01NS086659-01); National Institute of Aging Boston University AD Center (P30AG13846; supplement 0572063345-5); Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP #13267017); National Heart, Lung, and Blood Institute, Framingham Heart Study (NHLBI/NIH #N01-HC-25195 and R01AG08122); NINDS (1F32NS096803-01); Concussion Legacy Foundation. This work was also supported by unrestricted gifts from the Andlinger Foundation and WWE. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We gratefully acknowledge the use of resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA) as well as all the individuals whose participation and contributions made this work possible.	Bachstetter AD, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0209-z; Bhaskar K, 2010, NEURON, V68, P19, DOI 10.1016/j.neuron.2010.08.023; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cherry JD, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00594; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cloots RJH, 2012, J MECH BEHAV BIOMED, V5, P41, DOI 10.1016/j.jmbbm.2011.09.012; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Duncan G. J., 2011, RES HUMAN DEV, V1, P59, DOI [10.1080/15427609.2004.9683330, DOI 10.1080/15427609.2004.9683330]; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Ghosh S, 2013, J NEUROSCI, V33, P5053, DOI 10.1523/JNEUROSCI.4361-12.2013; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hausman J.A., 1983, HDB EC, V1, P391, DOI [10.1016/S1573-4412(83)01011-9, DOI 10.1016/S1573-4412(83)01011-9]; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Lee S, 2010, AM J PATHOL, V177, P2549, DOI 10.2353/ajpath.2010.100265; Maphis N, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00196; Maphis N, 2015, BRAIN, V138, P1738, DOI 10.1093/brain/awv081; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montenigro P. H., 2016, J NEUROTRAUMA; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Piccinini AM, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/672395; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; VONSATTEL JPG, 1995, J NEUROPATH EXP NEUR, V54, P42; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015	38	114	115	1	31	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.	OCT 28	2016	4								112	10.1186/s40478-016-0382-8			9	Neurosciences	Neurosciences & Neurology	EA2RN	WOS:000386442500001	27793189	DOAJ Gold, Green Published			2021-06-18	
J	Cobb, BR; Urban, JE; Davenport, EM; Rowson, S; Duma, SM; Maldjian, JA; Whitlow, CT; Powers, AK; Stitzel, JD				Cobb, Bryan R.; Urban, Jillian E.; Davenport, Elizabeth M.; Rowson, Steven; Duma, Stefan M.; Maldjian, Joseph A.; Whitlow, Christopher T.; Powers, Alexander K.; Stitzel, Joel D.			Head Impact Exposure in Youth Football: Elementary School Ages 9-12 Years and the Effect of Practice Structure	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Brain injury; Biomechanics; Helmet; Linear; Rotational; Acceleration; Pediatrics; Children; Sports	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; HELMET IMPACTS; CONCUSSION; COLLEGIATE; PLAYERS; ACCELERATION; LOCATION; GAME; EPIDEMIOLOGY	Head impact exposure in youth football has not been well-documented, despite children under the age of 14 accounting for 70% of all football players in the United States. The objective of this study was to quantify the head impact exposure of youth football players, age 9-12, for all practices and games over the course of single season. A total of 50 players (age = 11.0 +/- A 1.1 years) on three teams were equipped with helmet mounted accelerometer arrays, which monitored each impact players sustained during practices and games. During the season, 11,978 impacts were recorded for this age group. Players averaged 240 +/- A 147 impacts for the season with linear and rotational 95th percentile magnitudes of 43 +/- A 7 g and 2034 +/- A 361 rad/s(2). Overall, practice and game sessions involved similar impact frequencies and magnitudes. One of the three teams however, had substantially fewer impacts per practice and lower 95th percentile magnitudes in practices due to a concerted effort to limit contact in practices. The same team also participated in fewer practices, further reducing the number of impacts each player experienced in practice. Head impact exposures in games showed no statistical difference. While the acceleration magnitudes among 9-12 year old players tended to be lower than those reported for older players, some recorded high magnitude impacts were similar to those seen at the high school and college level. Head impact exposure in youth football may be appreciably reduced by limiting contact in practices. Further research is required to assess whether such a reduction in head impact exposure will result in a reduction in concussion incidence.	[Cobb, Bryan R.; Rowson, Steven; Duma, Stefan M.] Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA; [Urban, Jillian E.; Davenport, Elizabeth M.; Maldjian, Joseph A.; Stitzel, Joel D.] Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, Winston Salem, NC 27157 USA; [Urban, Jillian E.; Davenport, Elizabeth M.] Wake Forest Sch Med, Winston Salem, NC 27157 USA; [Maldjian, Joseph A.; Whitlow, Christopher T.] Wake Forest Sch Med, Dept Radiol Neuroradiol, Winston Salem, NC 27157 USA; [Whitlow, Christopher T.] Wake Forest Sch Med, Translat Sci Inst, Winston Salem, NC 27157 USA; [Powers, Alexander K.] Wake Forest Sch Med, Dept Neurosurg, Winston Salem, NC 27157 USA; [Powers, Alexander K.; Stitzel, Joel D.] Wake Forest Sch Med, Childress Inst Pediat Trauma, Winston Salem, NC 27157 USA	Rowson, S (corresponding author), Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, 440 ICTAS Bldg,Stanger St, Blacksburg, VA 24061 USA.	srowson@vt.edu	Duma, Stefan/A-8368-2012; Cobb, Bryan/J-8647-2014; Stitzel, Joel/B-4045-2012; Rowson, Steven/B-1270-2012	Cobb, Bryan/0000-0003-1785-3774; Stitzel, Joel/0000-0001-9762-3033; Rowson, Steven/0000-0002-3227-0596; Maldjian, Joseph/0000-0002-6384-1072	Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center; National Highway Traffic Safety Administration	The authors would like to thank the Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center and the National Highway Traffic Safety Administration for providing support for this study as well as Elizabeth Lillie, Matt Bennett, Amanda Dunn, and the South Fork Panthers and Blacksburg youth football programs for their involvement.	Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Viano DC, 2012, ANN BIOMED ENG, V40, P97, DOI 10.1007/s10439-011-0377-3; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Viano DC, 2012, ANN BIOMED ENG, V40, P47, DOI 10.1007/s10439-011-0399-x; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1	33	114	115	0	38	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	DEC	2013	41	12					2463	2473		10.1007/s10439-013-0867-6			11	Engineering, Biomedical	Engineering	249UN	WOS:000326803700001	23881111	Other Gold, Green Published			2021-06-18	
J	Molina, DK; DiMaio, VJM				Molina, D. Kimberley; DiMaio, Vincent J. M.			Normal Organ Weights in Men Part II-The Brain, Lungs, Liver, Spleen, and Kidneys	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						autopsy; forensic pathology; normal organ weights; liver; kidney; spleen; lung; brain	HEART	Organomegaly can be a sign of disease and pathologic abnormality, although standard tables defining organomegaly have yet to be established and universally accepted. This study was designed to address the issue and to determine a normal weight for the major organs in adult human males. A prospective study of healthy men aged 18 to 35 years who died of sudden, traumatic deaths was undertaken. Cases were excluded if there was a history of medical illness including illicit drug use, if prolonged medical treatment was performed, if there was a prolonged period between the time of injury and death, if body length and weight could not be accurately assessed, or if any illness or intoxication was identified after gross and microscopic analysis including evidence of systemic disease. Individual organs were excluded if there was significant injury to the organ, which could have affected the weight. A total of 232 cases met criteria for inclusion in the study during the approximately 6-year period of data collection from 2005 to 2011. The decedents had a mean age of 23.9 years and ranged in length from 146 to 193 cm, with a mean length of 173 cm. The weight ranged from 48.5 to 153 kg, with a mean weight of 76.4 kg. Most decedents (87%) died of either ballistic or blunt force (including craniocerebral) injuries. The mean weight of the brain was 1407 g (range, 1070-1767 g), that of the liver was 1561 g (range, 838-2584 g), that of the spleen was 139 g (range, 43-344 g), that of the right lung was 445 g (range, 185-967 g), that of the left lung was 395 g (range, 186-885 g), that of the right kidney was 129 g (range, 79-223 g), and that of the left kidney was 137 g (range, 74-235 g). Regression analysis was performed and showed that there were insufficient associations between organ weight and body length, body weight, and body mass index to allow for predictability. The authors, therefore, propose establishing a reference range for organ weights in men, much like those in use for other laboratory tests including hemoglobin, hematocrit, or glucose. The following reference ranges (95% inclusion) are proposed: brain, 1179-1621 g; liver, 968-1860 g; spleen, 28-226 g; right lung, 155-720 g; left lung, 112-675 g; right kidney, 81-160 g; and left kidney, 83-176 g.	[Molina, D. Kimberley; DiMaio, Vincent J. M.] Bexar Cty Med Examiners Off, San Antonio, TX 78229 USA	Molina, DK (corresponding author), Bexar Cty Med Examiners Off, 7337 Louis Pasteur, San Antonio, TX 78229 USA.	kmolina@bexar.org					[Anonymous], 1997, 11622AIE A D CO LTD; Boyd E, 1933, ARCH PATHOL, V16, P350; Clinical Laboratory Standards Institute (CLSI), 2008, C28A3 CLSI; de la Grandmaison GL, 2001, FORENSIC SCI INT, V119, P149, DOI 10.1016/S0379-0738(00)00401-1; DELAND FH, 1968, RADIOLOGY, V91, P1195, DOI 10.1148/91.6.1195; DELAND FH, 1970, RADIOLOGY, V97, P589, DOI 10.1148/97.3.589; GARBY L, 1993, AM J HUM BIOL, V5, P291, DOI 10.1002/ajhb.1310050307; KASISKE BL, 1986, ARCH PATHOL LAB MED, V110, P55; Lindboe CF, 2003, CLIN NEUROPATHOL, V22, P263; MOAR JJ, 1988, AM J PHYS ANTHROPOL, V76, P105, DOI 10.1002/ajpa.1330760109; MYERS J, 1974, ARCH PATHOL, V98, P33; Sanchez R, 1997, Invest Clin, V38, P83; Smith HL, 1928, AM HEART J, V4, P79, DOI 10.1016/S0002-8703(29)90099-5; SprogoeJakobsen S, 1997, FORENSIC SCI INT, V88, P215, DOI 10.1016/S0379-0738(97)00103-5; WHIMSTER WF, 1971, AM REV RESPIR DIS, V103, P85; WHIMSTER WF, 1974, AM REV RESPIR DIS, V110, P478	16	114	115	1	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	2012	33	4					368	372		10.1097/PAF.0b013e31823d29ad			5	Medicine, Legal; Pathology	Legal Medicine; Pathology	041TK	WOS:000311423900024	22182984				2021-06-18	
J	Mayes, SD; Calhoun, SL; Murray, MJ; Zahid, J				Mayes, Susan Dickerson; Calhoun, Susan L.; Murray, Michael J.; Zahid, Jahanara			Variables Associated with Anxiety and Depression in Children with Autism	JOURNAL OF DEVELOPMENTAL AND PHYSICAL DISABILITIES			English	Article						Anxiety; Depression; Autism; Age; IQ	PERVASIVE DEVELOPMENTAL DISORDERS; TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; ASPERGER-SYNDROME; SPECTRUM DISORDERS; GENDER-DIFFERENCES; PROCESSING SPEED; ADHD SUBTYPES; SYMPTOMS; ADOLESCENTS	Mothers of 627 children with autism (ages 1-17, IQs 16-146) completed the Pediatric Behavior Scale. Maternal ratings of anxiety and depression increased with age and IQ, but were unrelated to gender, parent occupation, and race. Anxiety and depression were highly correlated with each other and with autism severity, somatic complaints, mood disturbance, and social problems. Remaining correlations with behavior problems, attention deficit, hyperactivity, and sleep problems were small. The strongest combined predictors of anxiety and depression were autism severity, verbal IQ, and age, explaining 25% and 23% of the variance. Findings suggest that anxiety and depression have a direct link with autism (increasing with autism severity) and a developmental component (increasing with age and IQ). Anxiety is present in most children with autism and depression is present in about half. Therefore, all children with autism should be screened for anxiety and depression and treated if indicated. Controlled studies are needed to determine what interventions are effective in reducing anxiety and depression in autism.	[Mayes, Susan Dickerson] Penn State Univ Hosp, Milton S Hershey Med Ctr, Dept Psychiat H073, Hershey, PA 17033 USA; [Mayes, Susan Dickerson; Calhoun, Susan L.; Murray, Michael J.; Zahid, Jahanara] Penn State Coll Med, Dept Psychiat, Hershey, PA USA	Mayes, SD (corresponding author), Penn State Univ Hosp, Milton S Hershey Med Ctr, Dept Psychiat H073, 500 Univ Dr, Hershey, PA 17033 USA.	smayes@psu.edu					Bellini S., 2004, FOCUS AUTISM DEV DIS, V19, P78, DOI DOI 10.1177/10883576040190020201; BENJAMIN RS, 1990, J ANXIETY DISORD, V4, P293, DOI 10.1016/0887-6185(90)90027-7; Brereton AV, 2006, J AUTISM DEV DISORD, V36, P863, DOI 10.1007/s10803-006-0125-y; Chalfant AM, 2007, J AUTISM DEV DISORD, V37, P1842, DOI 10.1007/s10803-006-0318-4; Chaplin TM, 2009, J EARLY ADOLESCENCE, V29, P307, DOI 10.1177/0272431608320125; Compas BE, 1997, J CONSULT CLIN PSYCH, V65, P617, DOI 10.1037/0022-006X.65.4.617; Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-199611000-00022; Frith U, 2004, J CHILD PSYCHOL PSYC, V45, P672, DOI 10.1111/j.1469-7610.2004.00262.x; Gadow KD, 2005, AUTISM, V9, P392, DOI 10.1177/1362361305056079; Gadow KD, 2008, J AUTISM DEV DISORD, V38, P1710, DOI 10.1007/s10803-008-0556-8; Ghaziuddin M, 1998, J INTELL DISABIL RES, V42, P279; Gillott A, 2001, AUTISM, V5, P277, DOI 10.1177/1362361301005003005; Gray C. A., 1993, FOCUS AUTISM OTHER D, V8, P1; Hankin BL, 1998, J ABNORM PSYCHOL, V107, P128, DOI 10.1037/0021-843X.107.1.128; Hartley SL, 2009, J AUTISM DEV DISORD, V39, P1715, DOI 10.1007/s10803-009-0810-8; Howlin P, 2003, J AUTISM DEV DISORD, V33, P3, DOI 10.1023/A:1022270118899; Hurtig T, 2009, AUTISM, V13, P583, DOI 10.1177/1362361309335719; Kanne SM, 2009, J AUTISM DEV DISORD, V39, P827, DOI 10.1007/s10803-008-0688-x; Kim J.A., 2000, AUTISM INT J RES PRA, V4, P117, DOI DOI 10.1177/1362361300004002002; Lemstra M, 2008, CAN J PUBLIC HEALTH, V99, P125, DOI 10.1007/BF03405459; Lewinsohn PM, 1998, J ABNORM PSYCHOL, V107, P109, DOI 10.1037/0021-843X.107.1.109; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; Lindgren S. D., 1987, ADV BEHAV ASSESSMENT, P57; Macintosh KE, 2004, J CHILD PSYCHOL PSYC, V45, P421, DOI 10.1111/j.1469-7610.2004.00234.x; MacNeil BM, 2009, RES AUTISM SPECT DIS, V3, P1, DOI 10.1016/j.rasd.2008.06.001; MANJIVIONA J, 1995, J AUTISM DEV DISORD, V25, P23, DOI 10.1007/BF02178165; Matson JL, 2007, RES DEV DISABIL, V28, P341, DOI 10.1016/j.ridd.2005.12.004; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Mayes SD, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P15; Mayes SD, 2004, J DEV PHYS DISABIL, V16, P257, DOI 10.1023/B:JODD.0000032301.07550.0e; Mayes SD, 2001, J ABNORM CHILD PSYCH, V29, P263, DOI 10.1023/A:1010337916636; Mayes SD, 1999, INFANT YOUNG CHILD, V12, P90, DOI 10.1097/00001163-199910000-00011; Mayes SD, 2008, J DEV BEHAV PEDIATR, V29, P206, DOI 10.1097/DBP.0b013e31816d924f; Mayes SD, 2007, CHILD NEUROPSYCHOL, V13, P469, DOI 10.1080/09297040601112773; Mayes SD, 2011, RES AUTISM SPECT DIS, V5, P474, DOI 10.1016/j.rasd.2010.06.012; Mayes SD, 2009, J ATTEN DISORD, V12, P540, DOI 10.1177/1087054708320402; Mayes SD, 2009, J AUTISM DEV DISORD, V39, P1682, DOI 10.1007/s10803-009-0812-6; Mayes SD, 2009, SLEEP MED CLIN, V4, P19, DOI 10.1016/j.jsmc.2008.12.004; Mayes SD, 2009, RES AUTISM SPECT DIS, V3, P931, DOI 10.1016/j.rasd.2009.04.002; Mayes SD, 2009, J PEDIATR PSYCHOL, V34, P328, DOI 10.1093/jpepsy/jsn083; Miller JN, 2000, J ABNORM PSYCHOL, V109, P227, DOI 10.1037/0021-843X.109.2.227; Miller JN, 1997, J CHILD PSYCHOL PSYC, V38, P247; Murray M. J., J AUTISM DE IN PRESS; Myhr G, 1998, CAN J PSYCHIAT, V43, P589, DOI 10.1177/070674379804300607; Nichols S, 2000, J PEDIATR PSYCHOL, V25, P545, DOI 10.1093/jpepsy/25.8.545; Ozonoff S., 2000, AUTISM, V4, P29, DOI [DOI 10.1177/1362361300041003, 10.1177/1362361300041003]; Posey DJ, 2006, J CHILD ADOL PSYCHOP, V16, P181, DOI 10.1089/cap.2006.16.181; Prior M, 1998, J CHILD PSYCHOL PSYC, V39, P893, DOI 10.1111/1469-7610.00389; Russell E, 2005, AUST NZ J PSYCHIAT, V39, P633, DOI 10.1111/j.1440-1614.2005.01637.x; Schopler E, 1996, J AUTISM DEV DISORD, V26, P109, DOI 10.1007/BF02276238; Schopler E., 1998, ASPERGER SYNDROME HI, P385; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Sofronoff K, 2005, J CHILD PSYCHOL PSYC, V46, P1152, DOI 10.1111/j.1469-7610.2005.00411.x; Sukhodolsky DG, 2008, J ABNORM CHILD PSYCH, V36, P117, DOI 10.1007/s10802-007-9165-9; SZATMARI P, 1995, J AM ACAD CHILD PSY, V34, P1662, DOI 10.1097/00004583-199512000-00017; TRYON P. A., 2006, FOCUS AUTISM OTHER D, V21, P2, DOI DOI 10.1177/10883576060210010101; Twenge JM, 2002, J ABNORM PSYCHOL, V111, P578, DOI 10.1037//0021-843X.111.4.578; Vickerstaff S, 2007, J AUTISM DEV DISORD, V37, P1647, DOI 10.1007/s10803-006-0292-x; Weisbrot DM, 2005, J CHILD ADOL PSYCHOP, V15, P477, DOI 10.1089/cap.2005.15.477; West L, 2009, J SPEC PEDIATR NURS, V14, P183, DOI 10.1111/j.1744-6155.2009.00196.x; White SW, 2009, J AUTISM DEV DISORD, V39, P1006, DOI 10.1007/s10803-009-0713-8; White SW, 2009, CLIN PSYCHOL REV, V29, P216, DOI 10.1016/j.cpr.2009.01.003; Wing Lorna, 1998, ASPERGER SYNDROME HI, P11; WOLRAICH ML, 1994, NEW ENGL J MED, V330, P301, DOI 10.1056/NEJM199402033300501; Wood JJ, 2009, J CHILD PSYCHOL PSYC, V50, P224, DOI 10.1111/j.1469-7610.2008.01948.x	67	114	114	0	58	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1056-263X	1573-3580		J DEV PHYS DISABIL	J. Dev. Phys. Disabil.	AUG	2011	23	4					325	337		10.1007/s10882-011-9231-7			13	Education, Special; Psychology, Developmental; Rehabilitation	Education & Educational Research; Psychology; Rehabilitation	788LU	WOS:000292447200005					2021-06-18	
J	Cederberg, D; Siesjo, P				Cederberg, David; Siesjo, Peter			What has inflammation to do with traumatic brain injury?	CHILDS NERVOUS SYSTEM			English	Article						Traumatic brain injury; Inflammation; Children; Markers; Secondary injury	SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; PROINFLAMMATORY CYTOKINE; MICE; INTERLEUKIN-6; EXPRESSION; ACTIVATION; CHILDREN; TISSUE; SERUM	Inflammation is an stereotypical response to tissue damage and has been extensively documented in experimental and clinical traumatic brain injury (TBI), including children. The initiation and orchestration of inflammation in TBI, as in other tissues, is complex and multifactorial encompassing pro- and anti-inflammatory cytokines, chemokines, adhesion molecules, complement factors, reactive oxygen and nitrogen species, and other undefined factors. It is evident that inflammation can have both beneficial and detrimental effects in TBI, but the mechanisms underlying this dichotomy are mostly unknown. Modification of the inflammatory response may be neuroprotective. Monitoring inflammation is now possible with techniques such as microdialysis; however, the prognostic value of measuring inflammatory mediators in TBI is still unclear with conflicting reports. Except for corticosteroids, no anti-inflammatory agents have been tested in TBI, and the negative results with these may have been flawed by their multiple side effects. Clinical trials with anti-inflammatory agents that target multiple or central and downstream pathways are warranted in adult and pediatric TBI. This review examines the mechanisms of inflammation after TBI, monitoring, and possible routes of intervention.	[Cederberg, David; Siesjo, Peter] Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden	Siesjo, P (corresponding author), Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden.	peter.siesjo@med.lu.se		Siesjo, Peter/0000-0002-5848-690X	SIDA [GUN 2072790]	This work is supported by a SIDA grant GUN 2072790. The authors have no conflicts of interest to declare.	Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Badie B, 2003, CLIN CANCER RES, V9, P872; Bell MJ, 1997, ACT NEUR S, V70, P96; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Garcia-Segura LM, 2009, FRONT NEUROENDOCRIN, V30, pV, DOI 10.1016/j.yfrne.2009.04.006; Grzybicki D, 1998, ACTA NEUROPATHOL, V95, P98, DOI 10.1007/s004010050770; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Juliet PAR, 2008, BRAIN RES, V1210, P230, DOI 10.1016/j.brainres.2008.02.099; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Ma YL, 2005, AM J PHYSIOL-REG I, V289, pR1297, DOI 10.1152/ajpregu.00260.2005; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MATHEW P, 1994, ACTA NEUROCHIR, P428; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; Moochhala SM, 2005, J TRAUMA, V59, P448, DOI 10.1097/01.ta.0000174858.79847.6d; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Moussaieff A, 2008, J CEREBR BLOOD F MET, V28, P1341, DOI 10.1038/jcbfm.2008.28; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Rock KL, 2008, ANNU REV PATHOL-MECH, V3, P99, DOI 10.1146/annurev.pathmechdis.3.121806.151456; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Weil ZM, 2008, PROG NEUROBIOL, V86, P48, DOI 10.1016/j.pneurobio.2008.06.001; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje	43	114	114	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	FEB	2010	26	2					221	226		10.1007/s00381-009-1029-x			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	539GK	WOS:000273241700013	19940996				2021-06-18	
J	Maloney-Wilensky, E; Gracias, V; Itkin, A; Hoffman, K; Bloom, S; Yang, W; Christian, S; LeRoux, PD				Maloney-Wilensky, Eileen; Gracias, Vicente; Itkin, Arthur; Hoffman, Katherine; Bloom, Stephanie; Yang, Wei; Christian, Susan; LeRoux, Peter D.			Brain tissue oxygen and outcome after severe traumatic brain injury: A systematic review	CRITICAL CARE MEDICINE			English	Article						brain tissue oxygen; Licox; intracranial pressure; monitoring; traumatic brain injury	INTRACRANIAL-PRESSURE MONITORS; CEREBRAL PERFUSION-PRESSURE; NEUROCRITICAL CARE; CLINICAL-TRIALS; HEAD; ISCHEMIA; TENSION; PO2; METABOLISM; DELIVERY	Objective: In this study, available medical literature were reviewed to determine whether brain hypoxia as measured by brain tissue oxygen (Bto(2)) levels is associated with increased risk of poor outcome after traumatic brain injury (TBI). A secondary objective was to examine the safety profile of a direct Bto(2) probe. Data Source and Extraction: Clinical studies published between 1993 and 2008 were identified from electronic databases, Index Medicus, bibliographies of pertinent articles, and expert consultation. The following inclusion criteria were applied for outcome analysis: 1) more than 10 patients described, 2) use of a direct Bto(2) monitor, 3) brain hypoxia defined as Bto(2) <10 mm Hg for >15 or 30 minutes, 4) 6-month outcome data, and 5) clear reporting of patient outcome associated with Bto(2). For the analysis, each selected article had to have adequate data to determine odds ratios (ORs) and confidence intervals (CIs). Thirteen studies met the initial inclusion criteria and three were included in the final outcome analysis. Safety data were abstracted from any report where it was mentioned. Data Synthesis. The three studies included 150 evaluable patients with severe TBI (Glasgow Coma Scale <= 8). Brain hypoxia was identified in 71 (47%) of these patients. Among the patients with brain hypoxia, 52 (73%) had unfavorable outcome including 39 (55%) who died. In the absence of brain hypoxia, 34 (43%) patients had an unfavorable outcome, including 17 (22%) who died. Overall brain hypoxia (Bto(2) <10 mm Hg >15 minutes) was associated with worse outcome (OR 4.0; 95% Cl 1.9-8.2) and increased mortality (OR 4.6; 95% Cl 2.2-9.6). We reviewed published safety data; in 292 patients monitored with a Bto(2) probe, only two adverse events were reported. Conclusion: Summary results indicate that brain hypoxia (<10 mm Hg) is associated with worse outcome after severe TBI and that Bto(2) probes are safe. These results imply that treating patients to increase Bto(2) may improve outcome after severe TBI. This question will require further study. (Crit Care Med 2009; 37:2057-2063)	[Maloney-Wilensky, Eileen; Bloom, Stephanie; LeRoux, Peter D.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Gracias, Vicente] Univ Penn, Sch Med, Div Trauma Surg & Surg Crit Care, Philadelphia, PA 19104 USA; [Yang, Wei] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Yang, Wei] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Itkin, Arthur; Hoffman, Katherine; Christian, Susan] Stat Trade Inc, Morrisville, PA USA	LeRoux, PD (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.	lerouxp@uphs.upenn.edu	Yang, Wei/A-9223-2009	Yang, Wei/0000-0001-8984-4389			*AANS CNS, 2007, J NEUROTRAUMA S1, V24, pS65; Bardt TF, 1998, ACT NEUR S, V71, P153; Birmingham K, 2002, NAT MED, V8, P5, DOI 10.1038/nm0102-5a; Bruzzone P, 1998, ACT NEUR S, V71, P111; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Davis JW, 2004, J TRAUMA, V57, P1173, DOI 10.1097/01.TA.0000151257.79108.FB; Dings J, 1998, NEUROL RES, V20, pS71; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; EDDY VA, 1995, AM SURGEON, V61, P24; FARRAR JK, 1991, J CEREB BLOOD FLOW M, V11, pS553; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Guyot LL, 1998, ACT NEUR S, V71, P47; Haitsma IK, 2007, PROG BRAIN RES, V161, P207, DOI 10.1016/S0079-6123(06)61014-5; Harris CH, 2002, AM SURGEON, V68, P787; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Heyland DK, 2001, JAMA-J AM MED ASSOC, V286, P944, DOI 10.1001/jama.286.8.944; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Jensen RL, 1997, SURG NEUROL, V47, P16, DOI 10.1016/S0090-3019(96)00276-5; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Khan SH, 1998, ACT NEUR S, V71, P50; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kiening KL, 1998, ACT NEUR S, V71, P172; KIENING KL, 2005, NEUROTRAUMA EVIDENCE; Kim DH, 2006, NEUROCRIT CARE, V4, P83, DOI 10.1385/NCC:4:1:083; Lane PL, 2000, CAN J SURG, V43, P442; Lang EW, 2007, NEUROSURG REV, V30, P99, DOI 10.1007/s10143-006-0062-4; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mazzeo AT, 2007, J NEUROL SCI, V261, P1, DOI 10.1016/j.jns.2007.04.026; Meixensberger J, 1998, ACT NEUR S, V71, P260; Meixensberger J, 2001, NEUROL RES, V23, P801, DOI 10.1179/016164101101199379; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Health Service (NHS) Centre for Reviews and Dissemination, 2001, UND SYST REV RES EFF; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2008, CRIT CARE MED, V36, P1984, DOI 10.1097/CCM.0b013e318176a9f6; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; Petitti D.B, 1994, METAANALYSIS DECISIO; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Rossi S, 1998, ACT NEUR S, V71, P91; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; SARRAFZADEH AS, 1997, SEVERE HEAD INJURIES, P109; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Shapiro S, 1996, SURG NEUROL, V45, P278, DOI 10.1016/0090-3019(95)00359-2; SPIOTTA A, 2005, P C NEUR SURG ANN M; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Wiesmann M, 2001, J CLIN NEUROSCI, V8, P126, DOI 10.1054/jocn.2000.0749	78	114	116	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2009	37	6					2057	2063		10.1097/CCM.0b013e3181a009f8			7	Critical Care Medicine	General & Internal Medicine	448ZK	WOS:000266300300032	19384213				2021-06-18	
J	Galarneau, MR; Woodruff, SI; Dye, JL; Mohrle, CR; Wade, AL				Galarneau, Michael R.; Woodruff, Susan I.; Dye, Judy L.; Mohrle, Charlene R.; Wade, Amber L.			Traumatic brain injury during operation Iraqi freedom: findings from the United States Navy-Marine Corps Combat Trauma Registry	JOURNAL OF NEUROSURGERY			English	Article						Navy-Marine Corps Combat Trauma Registry; operation Iraqi freedom; traumatic brain injury	SEVERITY SCORE	Object. The purpose of this study was to characterize traumatic brain injuries (TBIs) among military personnel (primarily Marines) during the second phase of Operation Iraqi Freedom from early in the medical care chain of evacuation through Landstuhl Regional Medical Center, a Level 4 American hospital in Germany. Methods. Data were obtained from the Navy-Marine Corps Combat Trauma Registry (CTR) and included both battle and nonbattle injuries. Follow-up of patients with TBI was conducted to examine the short-term medical and personnel-related effects of TBI among those surviving. Results. Those injured in battle were more likely than those not injured in battle to have multiple TBI diagnoses, a greater number of all diagnoses, more severe TBIs, and to be medically evacuated. Intracranial injuries (for example, concussions) were the predominant type of TBI, although skull fractures and open head wounds were also seen. Improvised explosive devices were the most common cause of TBIs among battle injuries; blunt trauma and motor vehicle crashes were the most common causes among nonbattle injuries. Short-term follow-up of surviving patients with TBI indicated higher morbidity and medical utilization among the patients with more severe TBI, although mental conditions were higher among patients with milder TBI. Conclusions. Data from the Navy-Marine Corps CTR provide useful information about combatants' TBIs identified early in the combat casualty process. Results may improve clinical care for those affected and suggest strategies for The CTR staff plans to conduct additional follow-up studies of this group of patients with TBI.	[Galarneau, Michael R.] USN, Hlt Res Ctr, Dept Med Modeling Simulat & Miss Support, San Diego, CA 92106 USA; [Woodruff, Susan I.; Dye, Judy L.; Mohrle, Charlene R.; Wade, Amber L.] Sci Applicat Int Corp Inc, Hlth Res & Appl Technol Div, San Diego, CA USA	Galarneau, MR (corresponding author), USN, Hlt Res Ctr, Dept Med Modeling Simulat & Miss Support, 140 Sylvester Rd, San Diego, CA 92106 USA.	michael.galarneau@med.navy.mil					Bagg Mark R, 2006, J Am Acad Orthop Surg, V14, pS7; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CAREY ME, 1987, MIL MED, V152, P6; *CDCP, 2006, NAT CTR INJ PREV CON; Coupland RM, 1999, BRIT MED J, V319, P410, DOI 10.1136/bmj.319.7207.410; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Gunderson EKE, 2005, MIL MED, V170, P172; Mabry RL, 2000, J TRAUMA, V49, P515, DOI 10.1097/00005373-200009000-00021; MATTHEWS DE, 2005, USING UNDERSTANDING; MCCRAKEN DL, TRAUMATIC BRAIN INJU; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SCOTT BA, 1986, NEUROSURGERY, V18, P107, DOI 10.1227/00006123-198601000-00020; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Thurman DJ, 2001, HEAD TRAUMA, P327; Thurman DJ., 1995, GUIDELINES SURVEILLA; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; Zouris JM, 2006, MIL MED, V171, P246, DOI 10.7205/MILMED.171.3.246	23	114	115	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2008	108	5					950	957		10.3171/JNS/2008/108/5/0950			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	293RE	WOS:000255351600008	18447712				2021-06-18	
J	Friese, RS; Diaz-Arrastia, R; McBride, D; Frankel, H; Gentilello, LM				Friese, Randall S.; Diaz-Arrastia, Ramon; McBride, Dara; Frankel, Heidi; Gentilello, Larry M.			Quantity and quality of sleep in the surgical intensive care unit: Are our patients sleeping?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	37th Annual Meeting of the Western-Trauma-Association	FEB 25-MAR 02, 2007	Steamboat Springs, CO	Western Trauma Assoc		sleep; intensive care unit; polysomnography; critical illness; injury	REDUCES NATURAL-KILLER; NOCTURNAL SLEEP; HOST-DEFENSE; DEPRIVATION; CYTOKINES; LYMPHOCYTE; METABOLISM; HUMANS	Background: The lack of adequate sleep during intensive care unit (ICU) admission is a frequently overlooked complication. Disrupted sleep is associated with immune system dysfunction, impaired resistance to infection, as well as alterations in nitrogen balance and wound healing. The effects of surgical ICU admission on patients' sleep quality and architecture remain poorly defined. The purpose of this study was to describe the quantity and quality of sleep as well as sleep architecture, as defined by polysomnography (PSG), in patients cared for in the surgical ICU. Methods: A prospective observational cohort study was performed at our urban Level 1 trauma center. A convenience sample of surgical or trauma ICU patients underwent continuous PSG for up to 24 hours to evaluate sleep patterns. A certified sleep technician performed, monitored, and scored all PSG recordings. A single neurologist trained in PSG interpretation reviewed all PSG recordings. chi(2) goodness-of-fit analysis was performed to detect differences in the proportion of time spent in stages 1 and 2 (superficial stages), stages 3 and 4 (deep stages), or rapid eye movement (REM) sleep between study patients and healthy historical controls. All PSG recordings were performed greater than 24 hours after the administration of a general anesthetic. Patients with traumatic brain injury were excluded. Results: Sixteen patients were selected to undergo PSG recordings. Median age was 37.5 years (range, 20-83), 81.3% were male patients, 62.5% were injured, and 31.3% were mechanically ventilated. Total PSG recording time was 315 hours (mean, 19.7 hours per patient), total sleep time captured by PSG was 132 hours (mean, 8.28 hours per patient), and there were 6.2 awakenings per hour of sleep measured. ICU patients had an increase in the proportion of time spent in the superficial stages of sleep, and a decrease in the proportion of time spent in the deeper stages of sleep as well as a decrease in REM sleep compared with healthy controls (p < 0.001). Conclusions: Patients do achieve measurable sleep while cared for in a surgical ICU setting. However, sleep is fragmented and the quality of sleep is markedly abnormal with significant reductions in stages 3 and 4 and REM, the deeper restorative stages of sleep. Further studies on the effects of a strategy to promote sleep during ICU care are warranted.	[Friese, Randall S.; McBride, Dara; Frankel, Heidi; Gentilello, Larry M.] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burn, Dallas, TX 75390 USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA	Friese, RS (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burn, 5323 Harry Blvd,Room E5-508, Dallas, TX 75390 USA.	randall.friese@utsouthwestern.edu	, 叶叶叶/ABE-1619-2020	Diaz-Arrastia, Ramon/0000-0001-6051-3594			BERTOUCH JV, 1983, BRIT MED J, V286, P1171, DOI 10.1136/bmj.286.6372.1171; Cooper AB, 2000, CHEST, V117, P809, DOI 10.1378/chest.117.3.809; Culebras A, 2002, SLEEP MEDICINE, P1; EVERSON CA, 1993, AM J PHYSIOL, V265, pR1148, DOI 10.1152/ajpregu.1993.265.5.R1148; Freedman NS, 1999, AM J RESP CRIT CARE, V159, P1155, DOI 10.1164/ajrccm.159.4.9806141; Gabor J Y, 2001, Curr Opin Crit Care, V7, P21, DOI 10.1097/00075198-200102000-00004; Gumustekin K, 2004, INT J NEUROSCI, V114, P1433, DOI 10.1080/00207450490509168; Hilton B A, 1976, J Adv Nurs, V1, P453, DOI 10.1111/j.1365-2648.1976.tb00932.x; IRWIN M, 1994, PSYCHOSOM MED, V56, P493, DOI 10.1097/00006842-199411000-00004; Irwin M, 2002, BRAIN BEHAV IMMUN, V16, P503, DOI 10.1016/S0889-1591(02)00003-X; Irwin M, 1996, FASEB J, V10, P643; JONES J, 1979, INTENS CARE MED, V5, P89, DOI 10.1007/BF01686054; KANT GJ, 1984, SLEEP, V7, P142, DOI 10.1093/sleep/7.2.142; Kapsimalis F, 2005, CURR OPIN PULM MED, V11, P481, DOI 10.1097/01.mcp.0000183062.98665.6b; KRACHMAN SL, 1995, CHEST, V107, P1713, DOI 10.1378/chest.107.6.1713; KRUEGER JM, 1990, CLIN IMMUNOL IMMUNOP, V57, P188, DOI 10.1016/0090-1229(90)90033-M; MOLDOFSKY H, 1995, INT J IMMUNOPHARMACO, V17, P649, DOI 10.1016/0192-0561(95)00051-3; MOOTE CA, 1988, ANESTHESIOLOGY, V69, P327, DOI 10.1097/00000542-198809000-00007; PALMBLAD J, 1976, J PSYCHOSOM RES, V20, P193, DOI 10.1016/0022-3999(76)90020-9; PALMBLAD J, 1979, PSYCHOSOM MED, V41, P273, DOI 10.1097/00006842-197906000-00001; Parthasarathy S, 2004, INTENS CARE MED, V30, P197, DOI 10.1007/s00134-003-2030-6; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Redwine L, 2004, BRAIN BEHAV IMMUN, V18, P333, DOI 10.1016/j.bbi.2004.01.001; SCRIMSHAW NS, 1966, AM J CLIN NUTR, V19, P313	24	114	119	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2007	63	6					1210	1214		10.1097/TA.0b013e31815b83d7			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	243AU	WOS:000251768100003	18212640				2021-06-18	
J	Maier, B; Lefering, R; Lehnert, M; Laurer, HL; Steudel, WI; Neugebauer, EA; Marzi, I				Maier, Bernd; Lefering, Rolf; Lehnert, Mark; Laurer, Helmut L.; Steudel, Wolf I.; Neugebauer, Edmund A.; Marzi, Ingo			Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma	SHOCK			English	Article						cytokine; late-onset MOF; multiple injuries; multiple organ failure; traumatic brain injury	SEVERE BLUNT TRAUMA; CEREBROSPINAL-FLUID; BRAIN-INJURY; INFLAMMATION; DYSFUNCTION; RECEPTOR; SERUM; P55; P75; PATHOPHYSIOLOGY	Although multiple organ failure (MOF) remains the leading cause of death after trauma, the pathogenic cellular and molecular mechanisms underlying MOF are poorly understood. In addition to proinflammatory and anti-inflammatory mediator cascades, the temporal onset of MOF has generated recent interest because the organ systems involved into MOF seem to deteriorate in a time-dependent fashion after trauma. We therefore investigated the temporal course of MOF in traumatized human patients and evaluated and compared the distribution patterns of cytokine expression, including interleukin (IL) 6, IL-8, IL-10, and the soluble tumor necrosis factor-a receptors sTNF-R p55 and sTNF-R p75 in early-onset versus late-onset MOF In addition, we analyzed the predictive value of cytokine biomarkers of MOF and lethal outcome. In a prospective observational cohort study conducted at three trauma centers, all patients (n = 352) admitted to two level 1 trauma centers in Germany were enrolled in the study based on the following inclusion criteria: severe traumatic brain injury (TBI) with a Glasgow Coma Scale (GCS) score of 8 or lower and/or distinct changes in cranial computed tomography and/or multiple injuries (MT) to the body (at least two regions had Abbreviated Injury Scale score of 3 or higher). The incidence of MOF was evaluated using the modified Goris-MOF score. The temporal onset of MOF was divided into early-onset MOF (EMOF, developing on days 0-3), late-onset MOF (LMOF, developing on days 4-10), combined early-onset and late-onset MOF (CMOF), and patients never showing signs of MOF during the observation period. In addition, the levels of the serum cytokine markers IL-6, IL-8, IL-10, sTNF-R p55, and sTNF-R p75 were analyzed at specific posttraumatic time points using established enzyme-linked immunosorbent assay techniques. A total of 352 patients (274 men and 78 women; TBI, 101; TBI + MT, 125; MT, 126) were enrolled into the study. Patients assigned to the EMOF group showed specific disruption of pulmonary and cardiocirculatory function, whereas LMOF was significantly associated with hepatic failure. The patients without signs of MOF and the EMOF patients had the same risk of lethal outcome (8.2% vs. 7.5%); LMOF and CMOF were found to be associated with a 3- to 4-fold increase in mortality (38.5% vs. 30.6%, respectively). Analysis of cytokine serum biomarkers revealed that patients with LMOF showed a biphasic elevation of IL-6 and significantly higher sTNF-R concentrations than did all other subgroups (P< 0.001). In addition, the initial values (days 0-1) of sTNF-R p55 and sTNF-R p75 expression levels had a good predictive capacity for the development of LMOF (p55, 0.75; p75, 0.72); values greater than 0.65 were accepted to have a predictive capacity. These results demonstrate that mortality differs significantly between the development of EMOF and LMOF after traumatic injury. Our results also suggest that serum cytokine measurements may be important early biochemical markers for predicting the development of delayed MOF.	Univ Frankfurt, Sch Med, Dept Trauma Hand & Reconstruct Surg, D-6000 Frankfurt, Germany; Univ Halle Wittenberg, Inst Res Operat Med, Cologne, Germany; Univ Saarland, Sch Med, Dept Neurosurg, D-6650 Homburg, Germany	Marzi, I (corresponding author), Univ Frankfurt, Klin Unfall Hand & Wiederherstellungschirurg, D-69590 Frankfurt, Germany.	marzi@trauma.uni-frankfurt.de					Baue AE, 2004, CRIT CARE MED, V32, P1440, DOI 10.1097/01.CCM.0000124853.82106.31; Baue AE, 2003, J TRAUMA, V55, P997, DOI 10.1097/01.TA.0000094631.54198.07; Baue AE, 2006, SHOCK, V26, P438, DOI 10.1097/01.shk.0000228172.32587.7a; BOUMA MG, 1997, IMMUNOCHEMISTRY, V2, P181; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; Durham RM, 2003, J TRAUMA, V55, P608, DOI 10.1097/01.TA.0000092378.10660.D1; EISEMAN B, 1977, SURG GYNECOL OBSTET, V144, P323; Frink M, 2007, SHOCK, V27, P151, DOI 10.1097/01.shk.0000239767.64786.de; Gomberg BFC, 1999, INJURY, V30, P431, DOI 10.1016/S0020-1383(99)00138-2; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GORIS RJA, 1989, SCHWEIZ MED WSCHR, V119, P347; Hans VHJ, 1999, NEUROREPORT, V10, P409; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Laan MP, 1998, ALLERGY, V53, P51, DOI 10.1111/j.1398-9995.1998.tb03773.x; LAW MM, 1994, J TRAUMA, V37, P100, DOI 10.1097/00005373-199407000-00017; Lefering R, 2002, LANGENBECK ARCH SURG, V387, P14, DOI 10.1007/s00423-001-0269-3; Lendemans S, 2004, UNFALLCHIRURG, V107, P203, DOI 10.1007/s00113-004-0729-7; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Peschon JJ, 1998, J IMMUNOL, V160, P943; Rixen D, 2001, UNFALLCHIRURG, V104, P230, DOI 10.1007/s001130050719; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; ROUMEN RMH, 1995, CRIT CARE MED, V23, P474, DOI 10.1097/00003246-199503000-00010; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Strecker W, 1999, J TRAUMA, V47, P358, DOI 10.1097/00005373-199908000-00025; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	33	114	118	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	DEC	2007	28	6					668	674		10.1097/shk.0b013e318123e64e			7	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	237VC	WOS:000251403500007	18092384				2021-06-18	
J	Brannvall, K; Bergman, K; Wallenquist, U; Svahn, S; Bowden, T; Hilborn, J; Forsberg-Nilsson, K				Brannvall, K.; Bergman, K.; Wallenquist, U.; Svahn, S.; Bowden, T.; Hilborn, J.; Forsberg-Nilsson, K.			Enhanced neuronal differentiation in a three-dimensional collagen-hyaluronan matrix	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						3D cultures; neural stem/progenitor cells; hydrogel; scaffold; neurogenesis	NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; RAT SPINAL-CORD; PROGENITOR CELLS; FUNCTIONAL RECOVERY; ADULT BRAIN; CNS STEM; IN-VITRO; TRANSPLANTATION	Efficient 3D cell systems for neuronal induction are needed for future use in tissue regeneration. In this study, we have characterized the ability of neural stem/ progenitor cells (NS/PC) to survive, proliferate, and differentiate in a collagen type I-hyaluronan scaffold. Embryonic, postnatal, and adult NS/PC were seeded in the present 3D scaffold and cultured in medium containing epidermal growth factor and fibroblast growth factor-2, a condition that stimulates NS/PC proliferation. Progenitor cells from the embryonic brain had the highest proliferation rate, and adult cells the lowest, indicating a difference in mitogenic responsiveness. NS/PC from postnatal stages down-regulated nestin expression more rapidly than both embryonic and adult NS/PC, indicating a faster differentiation process. After 6 days of differentiation in the 3D scaffold, NS/PC from the postnatal brain had generated up to 70% neurons, compared with 14% in 2D. NS/PC from other ages gave rise to approximately the same proportion of neurons in 3D as in 2D (9-26% depending on the source for NS/PC). In the postnatal NS/PC cultures, the majority of Pill-tubulin-positive cells expressed glutamate, gamma-aminobutyric acid, and synapsin I after 11 days of differentiation, indicating differentiation to mature neurons. Here we report that postnatal NS/PC survive, proliferate, and efficiently form synapsin I-positive neurons in a biocompatible hydrogel. (c) 2007 Wiley-Liss, Inc.	Uppsala Univ, Dept Biochem Med, Ctr Biomed, S-75123 Uppsala, Sweden; Univ Uppsala, Dept Mat Chem Poly Chem, Angstrom Lab, S-75105 Uppsala, Sweden	Forsberg-Nilsson, K (corresponding author), Uppsala Univ, Dept Biochem Med, Ctr Biomed, Box 582, S-75123 Uppsala, Sweden.	karin.nilsson@imbim.uu.se	Forsberg-Nilsson, Karin/D-9604-2019; Hilborn, Jons/W-2864-2018	Forsberg-Nilsson, Karin/0000-0003-0692-6245; Hilborn, Jons/0000-0001-6947-9601; Melander Bowden, Tim/0000-0003-0851-4316			Anton ES, 1999, NEURON, V22, P277, DOI 10.1016/S0896-6273(00)81089-2; Brannvall K, 2006, NEUROREPORT, V17, P623; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Chow SY, 2000, BRAIN RES, V874, P87, DOI 10.1016/S0006-8993(00)02443-4; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Georges-Labouesse E, 1998, CURR BIOL, V8, P983, DOI 10.1016/S0960-9822(98)70402-6; GROSS J, 1958, J BIOL CHEM, V233, P355; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; Herrera DG, 1999, ANN NEUROL, V46, P867, DOI 10.1002/1531-8249(199912)46:6<867::AID-ANA9>3.0.CO;2-Z; Hou S, 2006, NEUROSCIENCE, V137, P519, DOI 10.1016/j.neuroscience.2005.09.029; HOU S, 2005, IN PRESS NEUROSCIENC; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lewis MC, 2005, BIOTECHNOL BIOENG, V91, P607, DOI 10.1002/bit.20508; Ma W, 2004, EXP NEUROL, V190, P276, DOI 10.1016/j.expneurol.2003.10.016; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mehler MF, 2000, DEV NEUROSCI-BASEL, V22, P74, DOI 10.1159/000017429; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Mercier F, 2002, J COMP NEUROL, V451, P170, DOI 10.1002/cne.10342; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Teixeira AI, 2007, CELL RES, V17, P56, DOI 10.1038/sj.cr.7310141; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; Zhang ZQ, 1998, J NEUROSCI, V18, P6928; Zhou FC, 2000, EXP NEUROL, V164, P200, DOI 10.1006/exnr.2000.7425	38	114	117	0	41	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 1	2007	85	10					2138	2146		10.1002/jnr.21358			9	Neurosciences	Neurosciences & Neurology	196XO	WOS:000248516700008	17520747				2021-06-18	
J	Bishop, GM; Dringen, R; Robinson, SR				Bishop, Glenda M.; Dringen, Ralf; Robinson, Stephen R.			Zinc stimulates the production of toxic reactive oxygen species (ROS) and inhibits glutathione reductase in astrocytes	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						astrocyte; carmustine; epileptiform; glutathione reductase; hydrogen peroxide; ischemia; reactive oxygen species; stroke; traumatic brain injury; zinc	EXOGENOUS HYDROGEN-PEROXIDE; SYNAPTICALLY-RELEASED ZINC; CULTURED ASTROGLIAL CELLS; NEURONAL DEATH; BOVINE BRAIN; DETOXIFICATION; 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA; ACCUMULATION; PURIFICATION; PATHWAYS	The release of zinc (Zn) from glutamatergic synapses contributes to the neuropathology of ischemia, traumatic brain injury, and stroke. Astrocytes surround glutamatergic synapses, and are vulnerable to the toxicity of Zn, which impairs their antioxidative glutathione (GSH) system and elevates the production of reactive oxygen species (ROS). It is not known whether one or both of these actions are the primary cause of Zn-induced cell death in astrocytes. Using primary rat astrocyte cultures we have examined whether Zn-mediated impairment of GSH redox cycling is the main source of its toxicity. Zn acetate at concentrations of 100 mu M or greater were found to inactivate glutathione reductase (GR) via an NADPH-dependent mechanism, while concentrations of 150 mu M and above caused substantial cell death. Furthermore, Zn increased the ratio of GSSG:GSH in astrocytes, increased their export of GSSG, slowed their clearance of exogenous H2O2, and promoted the intracellular production of ROS. In contrast, the GR inhibitor, carmustine, did not induce cell death, cause the production of ROS, or alter the GSH thiol redox balance. Taken together these results indicate that Zn toxicity in astrocytes is primarily associated with the generation of intracellular ROS, rather than the inhibition of GR. (c) 2007 Elsevier Inc. All rights reserved.	Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3168, Australia; Univ Bremen, Fac Biol Chem 2, Ctr Biomol Interact, D-2800 Bremen 33, Germany	Bishop, GM (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Wellington Rd, Clayton, Vic 3168, Australia.	glenda.bishop@med.monash.edu.au	Robinson, Stephen R/B-7155-2013; Bishop, Glenda M/G-6031-2010	Robinson, Stephen/0000-0002-0987-0075; Dringen, Ralf/0000-0001-7869-1305; Bishop, Glenda/0000-0002-2736-0415			AKERBOOM TPM, 1989, METHOD ENZYMOL, V173, P523; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Bragadin M, 2004, ANN NY ACAD SCI, V1030, P348, DOI 10.1196/annals.1329.043; Brocardo PS, 2005, TOXICOLOGY, V207, P283, DOI 10.1016/j.tox.2004.09.012; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; COHEN MB, 1988, BIOCHEM PHARMACOL, V37, P3317, DOI 10.1016/0006-2952(88)90645-4; Dineley KE, 2000, NEUROBIOL DIS, V7, P310, DOI 10.1006/nbdi.2000.0303; Doroshenko N, 2003, EUR J PHARMACOL, V476, P185, DOI 10.1016/S0014-2999(03)02191-5; Dringen R, 2005, J NEUROSCI RES, V79, P157, DOI 10.1002/jnr.20280; Dringen R, 1997, BRAIN RES, V759, P67, DOI 10.1016/S0006-8993(97)00233-3; Dringen R, 1999, J NEUROCHEM, V72, P2523, DOI 10.1046/j.1471-4159.1999.0722523.x; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Dringen R, 1996, J NEUROCHEM, V67, P1375, DOI 10.1046/j.1471-4159.1996.67041375.x; Dringen R, 2002, METHOD ENZYMOL, V348, P281, DOI 10.1016/S0076-6879(02)48646-6; Dringen R, 1998, BRAIN RES PROTOC, V2, P223, DOI 10.1016/S1385-299X(97)00047-0; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; Gazaryan IG, 2002, J BIOL CHEM, V277, P10064, DOI 10.1074/jbc.M108264200; Gutterer JM, 1999, J NEUROCHEM, V73, P1422, DOI 10.1046/j.1471-4159.1999.0731422.x; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P341; Hoepken HH, 2004, J NEUROCHEM, V88, P1194, DOI 10.1046/j.1471-4159.2003.02236.x; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; KARPLUS PA, 1988, EUR J BIOCHEM, V171, P193, DOI 10.1111/j.1432-1033.1988.tb13775.x; Keppler D, 1999, FREE RADICAL BIO MED, V27, P985, DOI 10.1016/S0891-5849(99)00171-9; Kim D, 2003, NEUROREPORT, V14, P187, DOI 10.1097/00001756-200302100-00005; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lee JY, 1999, J NEUROSCI, V19, DOI 10.1523/jneurosci.19-11-j0002.1999; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAY JM, 1982, J BIOL CHEM, V257, P4362; Minich T, 2006, J NEUROCHEM, V97, P373, DOI 10.1111/j.1471-4159.2006.03737.x; MIZE CE, 1962, J BIOL CHEM, V237, P1589; Noh KM, 2000, J NEUROSCI, V20; Nolte C, 2004, GLIA, V48, P145, DOI 10.1002/glia.20065; Robinson SR, 2001, J NEUROSCI RES, V66, P972, DOI 10.1002/jnr.10057; Romero IA, 1996, TOXICOL APPL PHARM, V139, P94, DOI 10.1006/taap.1996.0146; Ryu JR, 2002, EXP BRAIN RES, V143, P257, DOI 10.1007/s00221-001-0991-7; Seefeldt T, 2005, J MED CHEM, V48, P5224, DOI 10.1021/jm050030i; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; Walther UI, 2003, ARCH TOXICOL, V77, P131, DOI 10.1007/s00204-002-0421-z; Wilhelm B, 2001, ARCH TOXICOL, V75, P388	43	114	121	3	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	APR 15	2007	42	8					1222	1230		10.1016/j.freeradbiomed.2007.01.022			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	154NJ	WOS:000245514000010	17382203				2021-06-18	
J	Ducrocq, SC; Meyer, PG; Orliaguet, GA; Blanot, S; Laurent-Vannier, A; Renier, D; Carli, PA				Ducrocq, Sarah C.; Meyer, Philippe G.; Orliaguet, Gilles A.; Blanot, Stephane; Laurent-Vannier, Anne; Renier, Dominique; Carli, Pierre A.			Epidemiology and early predictive factors of mortality and outcome in children with traumatic severe brain injury: Experience of a French pediatric trauma center	PEDIATRIC CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies	APR 28-MAY 13, 2001	Baltimore, MD	Pediat Acad Soc		severe traumatic brain injury; mortality; outcome; risks factors; pediatrics; trauma scores; child; critical care	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; PRACTICAL SCALE; DATA-BANK; MANAGEMENT; MULTIPLE; SCORE; CARE; AGE; LIMITATIONS	Objective. To describe the results of an integrated pre- and in-hospital approach to critical care in a large population of children with severe traumatic brain injury and to identify the early predictors of their outcome. Design: A 9-yr retrospective review of the data of a trauma data bank. Setting: Level III pediatric trauma center. Patients: All children (1 month to 15 yrs) with severe traumatic brain injury (Glasgow Coma Scale <= 8) hospitalized in our trauma center and followed until death or for >= 6 months after discharge. Interventions: None. Measurements and Main Results: Univariate and further multivariate analyses were performed to determine independent predictive factors of death and outcome at discharge and 6 months later. The Glasgow Outcome Scale was used to evaluate outcome; a poor outcome referred to Glasgow Outcome Scale >= 3. Receiver operating characteristic curves were drawn to determine the threshold values of predictors of death and outcome. Analysis concerned 585 children (67% male and 33% female). Mean age was 7 +/- 5 yrs. Predominant mechanisms of injury were road traffic accidents and falls. Mean values for Glasgow Coma Scale, Pediatric Trauma Score, and Injury Severity Score were 6 (3-8), 3 (-4,10), and 28 (4-75), respectively. Mortality rate was 22%; Glasgow Outcome Scale was <3 in 53% of the cases at discharge and 60% at 6 months. Multivariate analysis identified Glasgow Coma Scale, Injury Severity Score, and hypotension on arrival as independent predictors of death and poor outcome at discharge and at 6 months. Threshold values for death were 28 for Injury Severity Score and 5 for Glasgow Coma Scale. The same values were found for poor outcome, except for outcome at 6 months where threshold value for the Glasgow Coma Scale was 6. Conclusions: Initial hypotension, Glasgow Coma Scale, and Injury Severity Score are independent predictors of outcome in children with traumatic brain injury. Threshold values can be calculated for predicting poor outcome. These variables can be easily and detected early in this population and used for quality assessment.	Univ Paris 05, Hop Necker Enfants Malad, Div Pediat Anesthesia, F-75270 Paris 06, France; Univ Paris 05, Hop Necker Enfants Malad, Neurocrit Care Unit, F-75270 Paris 06, France; Univ Paris 05, Hop Necker Enfants Malad, Div Pediat Neurosurg, F-75270 Paris 06, France; Hop Natl St Maurice, Serv Reeduc Pathol Neurol Acquises, Div Pediat Rehabil, St Maurice, France	Ducrocq, SC (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, Div Pediat Anesthesia, F-75270 Paris 06, France.		Meyer, Philippe/ABE-4242-2020	Meyer, Philippe/0000-0002-3829-6631; Orliaguet, Gilles/0000-0003-0930-2251			ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Cantais E, 2001, INTENS CARE MED, V27, P1511, DOI 10.1007/s001340101039; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; HALL SC, 1994, INT ANESTHESIOL CLIN, V32, P1; Havill JH, 1998, ANAESTH INTENS CARE, V26, P642, DOI 10.1177/0310057X9802600605; HU XH, 1994, J TRAUMA, V37, P209, DOI 10.1097/00005373-199408000-00010; JENNETT B, 1975, LANCET, V1, P480; KEENAN HT, 2005, PEDIATR CRIT CARE ME, V6, P611; Kemp A, 1997, J ACCID EMERG MED, V14, P316; KLASEN HJ, 1996, UPDATE INTENSIVE CAR, P11; Lallier M, 1999, J PEDIATR SURG, V34, P1060, DOI 10.1016/S0022-3468(99)90564-X; Lam WH, 1999, PAEDIATR ANAESTH, V9, P377; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; Meyer P G, 1998, Curr Opin Anaesthesiol, V11, P285, DOI 10.1097/00001503-199806000-00008; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; NAKAYAMA DK, 1991, J TRAUMA, V31, P1521, DOI 10.1097/00005373-199111000-00010; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Orliaguet GA, 1998, ANESTH ANALG, V87, P537, DOI 10.1097/00000539-199809000-00006; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Prat R, 1998, ACTA NEUROCHIR, V140, P1257, DOI 10.1007/s007010050247; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SIMPSON D, 1982, LANCET, V2, P450; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Vernon DD, 1999, PEDIATRICS, V103, P20, DOI 10.1542/peds.103.1.20; WALKER ML, 1984, CHILD BRAIN, V11, P387; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011	42	114	118	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2006	7	5					461	467		10.1097/01.PCC.0000235245.49129.27			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	096PY	WOS:000241390500009	16885795				2021-06-18	
J	Morrison, B; Cater, HL; Benham, CD; Sundstrom, LE				Morrison, B; Cater, HL; Benham, CD; Sundstrom, LE			An in vitro model of traumatic brain injury utilising two-dimensional stretch of organotypic hippocampal slice cultures	JOURNAL OF NEUROSCIENCE METHODS			English	Article						deformation; neurodegeneration; neuron; glia; mechanical injury; brain	DIFFUSE AXONAL INJURY; MECHANICAL STRETCH; HEAD-INJURY; NEURAL TRAUMA; STRAIN-RATE; NEURONS; DEFORMATION; TISSUE; CELLS; NMDA	Traumatic brain injury (TBI) is caused by rapid deformation of the brain, resulting in a cascade of pathological events and ultimately neurodegeneration. Understanding how the biomechanics of brain deformation leads to tissue damage remains a considerable challenge. We have developed an in vitro model of TBI utilising organotypic hippocampal slice cultures on deformable silicone membranes, and an injury device, which generates tissue deformation through stretching the silicone substrate. Our injury device controls the biomechanical parameters of the stretch via feedback control, resulting in a reproducible and equi-biaxial deformation stimulus. Organotypic cultures remain well adhered to the membrane during deformation, so that tissue strain is 93 and 86% of the membrane strain in the x- and y-axis, respectively. Cell damage following injury is positively correlated with strain. In conclusion, we have developed a unique in vitro model to study the effects of mechanical stimuli within a complex cellular environment that mimics the in vivo environment. We believe this model could be a powerful tool to study the acute phases of TBI and the induced cell degeneration could provide a good platform for the development of potential therapeutic approaches and may be a useful in vitro alternative to animal models of TBI. (c) 2005 Elsevier B.V. All rights reserved.	Univ Southampton, Div Clin Neurosci, Southampton SO16 7PX, Hants, England; Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; GlaxoSmithKline Res & Dev Ltd, Neurol, Harlow CM19 5AW, Essex, England; GlaxoSmithKline Res & Dev Ltd, GI CEDD, Harlow CM19 5AW, Essex, England	Cater, HL (corresponding author), Univ Southampton, Div Clin Neurosci, Rm 6207,Biomed Sci Bldg,Boldrewood,Bassett Cresce, Southampton SO16 7PX, Hants, England.	hlcater@yahoo.co.uk	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864			Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; CATER HL, IN PRESS J BIOMECH; CLAESSENS M, 1997, STAPP CAR CRASH J, P41; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hardy W N, 2001, Stapp Car Crash J, V45, P337; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2002, BRIT J PHARMACOL, V137, P1255, DOI 10.1038/sj.bjp.0704986; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Pringle AK, 1996, STROKE, V27, P2124, DOI 10.1161/01.STR.27.11.2124; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; VORNOV JJ, 1991, EXP NEUROL, V114, P11, DOI 10.1016/0014-4886(91)90079-R; Wang CCB, 2002, J BIOMECH ENG-T ASME, V124, P557, DOI 10.1115/1.1503795; Weber JT, 2002, J NEUROTRAUM, V19, P1433, DOI 10.1089/089771502320914660; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Zhang JP, 2000, NEUROSCI LETT, V290, P21, DOI 10.1016/S0304-3940(00)01311-2; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; ZHOU C, 1995, STAPP CAR CRASH J, V39, P121	53	114	116	0	28	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JAN 30	2006	150	2					192	201		10.1016/j.jneumeth.2005.06.014			10	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	013OG	WOS:000235418000006	16098599				2021-06-18	
J	Greve, KW; Stickle, TR; Love, JA; Bianchini, KJ; Stanford, MS				Greve, KW; Stickle, TR; Love, JA; Bianchini, KJ; Stanford, MS			Latent structure of the Wisconsin Card Sorting Test: a confirmatory factor analytic study	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	31st Annual Meeting of the International-Neuropsychological-Society	FEB 05-08, 2003	HONOLULU, HI	Int Neuropsychol Soc		Wisconsin Card Sorting Test; confirmatory factor analysis; assessment; executive function	TRAUMATIC BRAIN-INJURY; TEST DIMENSIONS; PERFORMANCE; VALIDITY; SCHIZOPHRENIA; SAMPLE; WCST; ADOLESCENTS; AGGRESSION; DAMAGE	The present study represents the first large scale confirmatory factor analysis of the Wisconsin Card Sorting Test (WCST). The results generally support the three factor solutions reported in the exploratory factor analysis literature. However, only the first factor, which reflects general executive functioning, is statistically sound. The secondary factors, while likely reflecting meaningful cognitive abilities, are less stable except when all subjects complete all 128 cards. It is likely that having two discontinuation rules for the WCST has contributed to the varied factor analytic solutions reported in the literature and early discontinuation may result in some loss of useful information. Continued multivariate research will be necessary to better clarify the processes underlying WCST performance and their relationships to one another. (c) 2004 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jerrerson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kwgps@uno.edu					Axelrod BN, 1997, ASSESSMENT, V4, P41, DOI 10.1177/107319119700400105; Bell MD, 1997, J CLIN EXP NEUROPSYC, V19, P933, DOI 10.1080/01688639708403774; Bollen K.A., 1989, STRUCTURAL EQUATIONS, P514, DOI 10.1002/9781118619179; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; Bowden SC, 1998, NEUROPSYCHOL REHABIL, V8, P243, DOI 10.1080/713755573; CUESTA MJ, 1995, PSYCHIAT RES, V58, P45, DOI 10.1016/0165-1781(95)02649-H; Demakis GJ, 2003, NEUROPSYCHOLOGY, V17, P255, DOI 10.1037/0894-4105.17.2.255; GOLDMAN RS, 1996, ASSESSMENT, V3, P73, DOI DOI 10.1177/107319119600300108; GOODMAN LA, 1974, BIOMETRIKA, V61, P215, DOI 10.2307/2334349; Gorsuch R. L., 1983, FACTOR ANAL; GREVE KW, 1995, ARCH CLIN NEUROPSYCH, V10, P265, DOI 10.1016/0887-6177(94)00046-S; Greve KW, 1997, BRIT J CLIN PSYCHOL, V36, P283, DOI 10.1111/j.2044-8260.1997.tb01414.x; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; Greve KW, 1999, ARCH CLIN NEUROPSYCH, V14, P497; Greve KW, 1998, ARCH CLIN NEUROPSYCH, V13, P597; Heaton SK, 1993, WISCONSIN CARD SORTI; Kizilbash A, 1999, CHILD NEUROPSYCHOL, V5, P224, DOI 10.1076/0929-7049(199912)05:04;1-R;FT224; Kongs SK, 2000, WISCONSIN CARD SORTI; Koren D, 1998, NEUROPSYCHOLOGY, V12, P289, DOI 10.1037/0894-4105.12.2.289; Krueger RF, 1998, J ABNORM PSYCHOL, V107, P216, DOI 10.1037/0021-843X.107.2.216; Lazarsfeld P. F., 1968, LATENT STRUCTURE ANA; Lin CCH, 2000, J CLIN EXP NEUROPSYC, V22, P69, DOI 10.1076/1380-3395(200002)22:1;1-8;FT069; Loehlin J.C., 1998, LATENT VARIABLE MODE; Love JM, 2003, APPL NEUROPSYCHOL, V10, P246, DOI 10.1207/s15324826an1004_7; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; Merrick EE, 2003, CLIN NEUROPSYCHOL, V17, P153, DOI 10.1076/clin.17.2.153.16512; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P100, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; MUTHEN LK, 2001, MPLUS USERS GUIDE; PAOLO AM, 1995, ARCH CLIN NEUROPSYCH, V10, P463, DOI 10.1016/0887-6177(95)00052-6; *PSYCH ASS RES, 1990, WISC CARD SORT TEST; Rossi A, 2000, J PSYCHIAT RES, V34, P333, DOI 10.1016/S0022-3956(00)00025-X; Somsen RJM, 2000, ACTA PSYCHOL, V104, P227, DOI 10.1016/S0001-6918(00)00030-5; Stanford MS, 1997, PERS INDIV DIFFER, V23, P961, DOI 10.1016/S0191-8869(97)00120-7; Stickle TR, 2002, J PSYCHOPATHOL BEHAV, V24, P177, DOI 10.1023/A:1016062701325; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; SULLIVAN EV, 1993, PSYCHIAT RES, V46, P175, DOI 10.1016/0165-1781(93)90019-D; Tabachnick B.G., 1989, USING MULTIVARIATE S; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205	39	114	115	1	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2005	20	3					355	364		10.1016/j.acn.2004.09.004			10	Psychology, Clinical; Psychology	Psychology	919DN	WOS:000228598600007	15797171	Green Published, Bronze			2021-06-18	
J	Covassin, T; Swanik, CB; Sachs, ML				Covassin, T; Swanik, CB; Sachs, ML			Epidemiological considerations of concussions among intercollegiate athletes	APPLIED NEUROPSYCHOLOGY			English	Article						concussions; intercollegiate sports; male sports; female sports; National Collegiate Athletic Association; Injury Surveillance System; injury; athlete exposure; injury rate; incidence density ratio	TRAUMATIC BRAIN-INJURY; STANDARDIZED ASSESSMENT; CEREBRAL CONCUSSION; COLLEGE FOOTBALL; SOCCER PLAYERS; HOCKEY PLAYERS; CONTACT-SPORTS; GUIDELINES	The purpose of this study was to examine epidemiological trends of concussions among 15 different intercollegiate sports during the 1997-1998, 1998-1999, and 1999-2000 seasons. Data were collected using the National Collegiate Athletic Association (NCAA) Injury Surveillance System (ISS). For the 15 sports studied during the 3 academic years, the NCAA ISS documented 3,535 team-seasons, 40,547 reportable injuries, 5,566,924 practice athlete exposures (AEs), and 1,090,298 game AEs. Concussions accounted for 62% of all reported injuries during this 3-year study. Of all the reported injuries, women lacrosse players (13.9%) reported the highest percentage of suffering a concussion during a game followed by women's soccer (11.4%), men's ice hockey (10.3%), men's lacrosse (10.1%), football (8.8%), women's basketball, (8.5%), field hockey (7.2%), men's soccer (7.0%), wrestling (66%), men's basketball (5.0%), baseball (4.2 %), and women's volleyball (4.1%). Female athletes from all 7 sports were found to be at a lower risk for suffering concussions during practice sessions than the 8 male sports. However, female athletes were found to be at a greater risk for suffering concussions during games compared to male athletes. Injury trends over the 3-year period indicate concussions continue to be on the rise for athletes participating in collegiate football, men's soccer, and women's and men's basketball.	Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA	Swanik, CB (corresponding author), Temple Univ, Dept Kinesiol, Pearson Hall 127, Philadelphia, PA 19122 USA.		Swanik, Charles/C-4377-2014	Swanik, Charles/0000-0001-9701-2005			*AM MED ASS, 1966, SUBC CLADD SPORT INJ; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT., 1989, MILD HEAD INJURY, P257; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Brown J., 2001, LACROSSE MAGAZIN MAY, P26; Bruce D A, 1982, Clin Sports Med, V1, P495; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; KELLY J, 1995, CURRENT THERAPY SPOR; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; *NAT COLL ATHL ASS, NCAA INJ SURV SYST; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; *QUAL STAND SUBC A, 1997, NEUROBIOLOGY, V48, P1; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954	30	114	118	0	23	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	0908-4282			APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	1					12	22		10.1207/S15324826AN1001_3			11	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	780NF	WOS:000189386900003	12734071				2021-06-18	
J	Rule, RR; Shimamura, AP; Knight, RT				Rule, Randall R.; Shimamura, Arthur P.; Knight, Robert T.			Orbitofrontal cortex and dynamic filtering of emotional stimuli	COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE			English	Article							CLOSED-HEAD-INJURY; PREFRONTAL CORTEX; WORKING-MEMORY; MONKEYS; DYSFUNCTION; BEHAVIOR; LESIONS; DAMAGE; ERP	Event-related potentials (ERPs) were recorded in response to mildly aversive somatosensory and auditory stimuli. Patients with orbitofrontal lesions exhibited enhanced ERPs (i.e., P3 amplitudes), as compared with control subjects. Moreover, these patients did not habituate to somatosensory stimuli across blocks of trials. The results were specific to orbitofrontal damage, since patients with damage to the dorsolateral prefrontal cortex did not exhibit enhanced P3 amplitudes. These findings suggest that damage to the orbitofrontal cortex impairs the ability to modulate or inhibit neural responses to aversive stimuli. The findings are couched in terms of dynamic filtering theory, which suggests that the orbitofrontal cortex is involved in the selection and active inhibition of neural circuits associated with emotional responses.	Univ Calif Berkeley, Berkeley, CA 94720 USA; Vet Affairs Hlth Care Syst, Martinez, CA USA	Shimamura, AP (corresponding author), Univ Calif Berkeley, Dept Psychol MC1650, Berkeley, CA 94720 USA.	aps@socrates.berkeley.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA14110, NS21135]; Veterans Administration Research ServiceUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS021135, R01NS021135, R56NS021135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA014110] Funding Source: NIH RePORTER	This research was supported by NIH Grants DA14110 to A.P.S. and NS21135 to R.T.K. and by funding from the Veterans Administration Research Service. The authors thank Donatella Scabini and Clay Clayworth for advice and technical support. Address correspondence to A. P. Shimamura, Department of Psychology (MC1650), University of California, Berkeley, CA94720-1650(e-mail:aps@socrates.berkeley.edu).	Baldo JV, 2000, PSYCHOBIOLOGY, V28, P156; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BUTTER CM, 1964, SCIENCE, V144, P313, DOI 10.1126/science.144.3616.313; BUTTER CM, 1969, SCIENCE, V164, P1306, DOI 10.1126/science.164.3885.1306; Chao LL, 1996, COGNITIVE BRAIN RES, V4, P27, DOI 10.1016/0926-6410(95)00043-7; D'Esposito M, 1999, BRAIN COGNITION, V41, P66, DOI 10.1006/brcg.1999.1096; Damasio A.R, 1998, PREFRONTAL CORTEX EX, P103; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; Harlow J. M., 1993, HIST PSYCHIATR, V4, P274, DOI [10.1177/0957154X9300401407, DOI 10.1177/0957154X9300401407]; Harlow JM, 1848, BOSTON MED SURG J, V39, P389, DOI DOI 10.1056/NEJM184812130392001; Hartikainen K., 2000, SOC NEUR ABSTR, V26, P2023; IVERSEN SD, 1970, EXP BRAIN RES, V11, P376; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; Knight RT, 1999, ACTA PSYCHOL, V101, P159, DOI 10.1016/S0001-6918(99)00004-9; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Macmillan M., 1999, ODD KIND FAME STORIE; MACMILLAN MB, 1986, BRAIN COGNITION, V5, P67, DOI 10.1016/0278-2626(86)90062-X; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Opitz B, 1999, CEREB CORTEX, V9, P379, DOI 10.1093/cercor/9.4.379; Panksepp J., 1998, AFFECTIVE NEUROSCIEN; PETRIDES M, 1994, HDB NEUROPSYCHOLOGY, V9, P17; Petrides M, 1998, PREFRONTAL CORTEX EX, P103; PUCE A, 1995, J NEUROSURG, V83, P262, DOI 10.3171/jns.1995.83.2.0262; Roberts N. A., 2001, Society for Neuroscience Abstracts, V27, P1705; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Shallice T, 1993, ATTENTION SELECTION, P171; Shimamura A. P., HIST PHOTOG IN PRESS; Shimamura AP, 2000, PSYCHOBIOLOGY, V28, P207; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Soltani M., CRITICAL RE IN PRESS	40	114	114	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1530-7026	1531-135X		COGN AFFECT BEHAV NE	Cogn. Affect. Behav. Neurosci.	SEP	2002	2	3					264	270		10.3758/CABN.2.3.264			7	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	V32MG	WOS:000208954700006	12775190	Bronze			2021-06-18	
J	Hibbard, MR; Cantor, J; Charatz, H; Rosenthal, R; Ashman, T; Gundersen, N; Ireland-Knight, L; Gordon, W; Avner, J; Gartner, A				Hibbard, MR; Cantor, J; Charatz, H; Rosenthal, R; Ashman, T; Gundersen, N; Ireland-Knight, L; Gordon, W; Avner, J; Gartner, A			Peer support in the community: Initial findings of a mentoring program for individuals with traumatic brain injury and their families	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						families; participatory action research; peer support; self-help; traumatic brain injury	PARTICIPATORY ACTION RESEARCH; PARENT PROGRAMS; SOCIAL SUPPORT; FOLLOW-UP; DISTRESS; BURDEN; STRESS	Objectives: To evaluate the impact of a community-based peer support program for individuals and their family members following traumatic brain injury (TBI), Settings: Community-based sample of family members and individuals with traumatic brain injury, Participants: Twenty individuals who had participated in the peer support program (I I individuals with Till and 9 family members), Main Outcome Measures: Quantitative and qualitative approaches were used: a retrospective structured interview assessing self-reported impacts of peer support on empowerment, quality Of life, mood, skills and knowledge, and social supports; an in-depth qualitative interview with a subgroup of family members focused on the specific benefits/limitations of the peer support program. Results: participants in the peer support program reported positive impacts of peer support on increasing their knowledge of TBI, enhancing their overall quality of life, improving their general outlook, and enhancing their ability to cope with depression post TBI The peer support program was reported to have had a minimal impact on enhancing social support from families. friends, and the community, with varying impacts noted on levels of happiness, coping with anger and anxiety, communication with professionals, and control over one's life, Qualitative analysis suggests the merits of this tyye of community-based Support and areas of improvement for the peer support program itself. Conclusions: Preliminary data suggest that peer support is a promising approach to enhancing coping for both individuals and their family members after TBI.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; Brain Injury Assoc New York State, Albany, NY USA; Natl Self Help Clearing House, New York, NY USA	Hibbard, MR (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.		Ashman, Teresa/B-1621-2013				ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Andrews F. M., 1976, SOCIAL INDICATORS WE; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Bruyere S. M, 1993, J VOCATIONAL REHABIL, V3, P62; CHESLER MA, 1991, AM J COMMUN PSYCHOL, V19, P757, DOI 10.1007/BF00938043; Cornwall A, 1995, SOC SCI MED, V41, P1667, DOI 10.1016/0277-9536(95)00127-S; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dunst C., 1988, ENABLING EMPOWERING; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HARRISJK, 2001, BRIAN INJURY, V15, P223; Hartman A F, 1992, Issues Compr Pediatr Nurs, V15, P55, DOI 10.3109/01460869209078240; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KOSCIULEK JF, 1994, REHABIL COUNS BULL, V37, P244; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Perlesz A, 1998, INT J REHABIL RES, V21, P339, DOI 10.1097/00004356-199812000-00001; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PIERCE G, 1986, SOCIAL SUPPORT QUEST; Rogers ES, 1997, PSYCHIATR SERV, V48, P1042; Santelli B, 1996, INFANT YOUNG CHILD, V9, P53, DOI 10.1097/00001163-199607000-00007; Santelli B, 1998, J ASSOC PERS SEVERE, V23, P211, DOI 10.2511/rpsd.23.3.211; SANTELLI B, 1995, INFANT YOUNG CHILD, V8, P48, DOI 10.1097/00001163-199510000-00007; Santelli B, 1997, Pediatr Nurs, V23, P303; SANTELLI B, 1993, PARENT PARENT NATL S; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; SILVER JM, 1992, AM PSYCHIAT PRESS TX; SILVER JM, 1998, 9 ANN M AM NEUR ASS; Skell RL, 2000, BRAIN INJURY, V14, P705; Stevens PE, 1998, AIDS EDUC PREV, V10, P387; Taylor C.A., 1998, SEMINARS CLIN NEUROP, V3, P224; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; White G. W., 2001, J PREVENTION INTERVE, V21, P15; WILLER B, 1991, CAN J REHABIL, V33, P173	44	114	118	1	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2002	17	2					112	131		10.1097/00001199-200204000-00004			20	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	535YT	WOS:000174674500004	11909510				2021-06-18	
J	Gururaj, G				Gururaj, G			Epidemiology of traumatic brain injuries: Indian scenario	NEUROLOGICAL RESEARCH			English	Article						traumatic brain injury; epidemiology; road accidents; severity; impact; developing countries	ROAD TRAFFIC FATALITIES; MORTALITY; COUNTRIES; DELHI	Traumatic brain injuries (TBIs) are a leading cause of morbidity, mortality, disability and socioeconomic losses in India and other developing countries. Specific topics addressed in this paper include magnitude of the problem, causes, context of injury occurrence, risk factors, severity, outcome and impact of TBIs on rapidly transforming societies. It is estimated that nearly 1.5 to 2 million persons are injured and 1 million succumb to death every year in India. Road traffic injuries are the leading cause (60%) of TBIs followed by falls (20%-25%) and violence (10%). Alcohol involvement is known to be present among 15%-20% of TBIs at the time of injury. The rehabilitation needs of brain injured persons are significantly high and increasing from year to year. India and other developing countries face the major challenges of prevention, pre-hospital care and rehabilitation in their rapidly changing environments to reduce the burden of TBIs.	Natl Inst Mental Hlth & Neurosci, Dept Epidemiol, Bangalore 560029, Karnataka, India	Gururaj, G (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Epidemiol, Bangalore 560029, Karnataka, India.	guru@nimhans.kar.nic.in					[Anonymous], 1993, WORLD DEV REPORT INV; BHARTI P, 1993, NEUROL INDIA, V41, P49; CHANNABASAVANNA SM, PR31993 KARN STAT CO; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; *FDN RES HLTH SYST, 1999, HLTH MON; GOURIEDEVI M, 1995, NEUROEPIDEMIOLOGICAL; GOURIEDEVI M, 1996, NEUROEPIDEMIOLOGY DE; GURUAJ G, 2000, P 5 WORLD C INJ PREV, P549; GURURAJ G, 1993, WHO SCI WORKSH NEUR; GURURAJ G, 1991, P REG SCI M INT EP A; GURURAJ G, 1999, J ACAD HOSP ADM, V11, P9; GURURAJ G, 1998, ACTIONAID DISABILITY, V9, P27; KALYANARAMAN S, 1977, NEUROL INDIA, V25, P95; KRAUS JF, 1972, NEUROL INDIA, V32, P356; KRAUS JF, 1992, NEUROEPIDEMIOLOGY TR, P334; MAHESHWARI J, 1989, J TRAFFIC MED, V17, P23; MOHAN D, 1985, ACCIDENT ANAL PREV, V17, P33, DOI 10.1016/0001-4575(85)90006-5; NATARAJAN M, 1987, ADJUSTMENTAL PROBLEM; Odero W, 1997, TROP MED INT HEALTH, V2, P445, DOI 10.1046/j.1365-3156.1997.d01-296.x; ROMER C, 1999, PREVENTION CRITICAL; RYAN GA, 1993, P C AS ROAD SAF; SABESHAN S, 1993, J INDIAN MED ASSOC, V91, P37; SAHDEV P, 1994, ACCIDENT ANAL PREV, V26, P377, DOI 10.1016/0001-4575(94)90011-6; SAMBASIVAN M, 1993, NEUROL INDIA, V41, P3; Sethi D, 1999, EUR J PUBLIC HEALTH, V9, P65, DOI 10.1093/eurpub/9.1.65; Sidhu D S, 1993, J Indian Med Assoc, V91, P16; SODERLUND N, 1995, B WORLD HEALTH ORGAN, V73, P175; Tandon PN, 1986, NEUROL INDIA, V34, P1; TEASDALE G, 1974, LANCET, V2, P81; UNICEF, 2000, STAT WORLDS CHILDR 2; WHO, 1999, WORLD HLTH REP 1999; *WHO, 1999, INJ LEAD CAUS GLOB B; ZWI A, 1993, TROP DIS B, V90, P6039	33	114	116	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JAN	2002	24	1					24	28		10.1179/016164102101199503			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	519WJ	WOS:000173748200005	11783750				2021-06-18	
J	Touzani, O; Boutin, H; LeFeuvre, R; Parker, L; Miller, A; Luheshi, G; Rothwell, N				Touzani, O; Boutin, H; LeFeuvre, R; Parker, L; Miller, A; Luheshi, G; Rothwell, N			Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor	JOURNAL OF NEUROSCIENCE			English	Article						cerebrovascular accident; brain infarction; receptors; interleukin-1; mice; knock-out; cytokines	CEREBRAL-ARTERY OCCLUSION; ACCESSORY PROTEIN; ALZHEIMER-DISEASE; NEURONAL DAMAGE; RAT; ANTAGONIST; IL-1; MICE; EXPRESSION; CLONING	The cytokine interleukin-1 beta (IL-1 beta) contributes to ischemic, excitotoxic, and traumatic brain injury. IL-1 beta actions depend on interaction with a single receptor (IL-1RI), which associates with an accessory protein (IL-1RAcP), and is blocked by IL-1 receptor antagonist (IL-1ra). Here we show that in normal mice [wild-type (WT)], intracerebroventricular injection of IL-1ra markedly reduces (-50%; p < 0.01) ischemic brain damage caused by reversible occlusion of the middle cerebral artery, whereas injection of IL-1<beta> exacerbates damage (+45%; p < 0.05). Mice lacking IL-1RI [IL-1RI knock-out (KO)] exhibited ischemic brain damage that is almost identical to that of the WT (infarct volume 43.7 +/- 6.1 and 46.2 +/- 6.2 mm(3), respectively), but failed to respond to injection of IL-1ra. However, injection of IL-1<beta> (intracerebroventricularly) exacerbated ischemic brain damage in IL-1RI KO (+61%; p < 0.001) and in WT mice (+45%). This effect of IL-1<beta> was abolished by heat denaturation in all animals, and was reversed by IL-1ra in WT, but not IL-1RI KO mice. In contrast, IL-1RI KO mice were completely resistant to effects of IL-1 beta on food intake or body weight. IL-1RAcP mRNA was increased by stroke in WT, but reduced in IL-1RI KO mice compared with sham-operated mice. Type II IL-1 receptor mRNA was significantly increased 4 hr after ischemia in WT and IL-1RI KO (+20%) animals. These data show that IL-1 beta can exacerbate ischemic brain damage independently of IL-1RI and suggest the existence of additional signaling receptor or receptors for IL-1 in the brain.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	Rothwell, N (corresponding author), Univ Manchester, Sch Biol Sci, 1-124 Stopford Bldg, Manchester M13 9PT, Lancs, England.		Aston, Sam/F-9699-2010; TOUZANI, Omar/C-1897-2008; Le Feuvre, Rosalind/A-7034-2013	TOUZANI, Omar/0000-0002-9513-097X; Boutin, Herve/0000-0002-0029-5246			Allan SM, 2000, P NATL ACAD SCI USA, V97, P5580, DOI 10.1073/pnas.090464197; Anforth HR, 1998, EUR CYTOKINE NETW, V9, P279; Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Born TL, 2000, J BIOL CHEM, V275, P29946, DOI 10.1074/jbc.M004077200; Boutin H, 2001, J NEUROSCI, V21, P5528; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; Clark WM, 1997, NEUROL RES, V19, P641; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; Davies CA, 1999, J CEREBR BLOOD F MET, V19, P87, DOI 10.1097/00004647-199901000-00010; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; French RA, 1999, J NEUROIMMUNOL, V93, P194, DOI 10.1016/S0165-5728(98)00224-0; GARCIA JH, 1995, AM J PATHOL, V147, P1477; Glaccum MB, 1997, J IMMUNOL, V159, P3364; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hata R, 1998, J CEREBR BLOOD F MET, V18, P367, DOI 10.1097/00004647-199804000-00004; Josephs MD, 2000, AM J PHYSIOL-REG I, V278, pR824; Kluger M.J, 1996, CYTOKINES NERVOUS SY, P73; Labow M, 1997, J IMMUNOL, V159, P2452; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Legos JJ, 2000, NEUROSCI LETT, V282, P189, DOI 10.1016/S0304-3940(00)00907-1; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Liu CL, 1996, J NEUROIMMUNOL, V66, P41, DOI 10.1016/0165-5728(96)00016-1; Loddick SA, 1998, BRAIN RES REV, V26, P306, DOI 10.1016/S0165-0173(97)00037-4; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; Martinez Oscar J., 1994, GLOBAL BOUNDARIES WO, V1, P1, DOI [10.1163/9789401204774_002, DOI 10.4324/9780203211960]; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; Mrak RE, 2000, J NEUROPATH EXP NEUR, V59, P471, DOI 10.1093/jnen/59.6.471; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Roux-Lombard P, 1998, EUR CYTOKINE NETW, V9, P565; Stroemer RP, 1997, J CEREBR BLOOD F MET, V17, P597; Stroemer RP, 1998, J CEREBR BLOOD F MET, V18, P833, DOI 10.1097/00004647-199808000-00003; TAKAO T, 1992, J NEUROIMMUNOL, V41, P51, DOI 10.1016/0165-5728(92)90195-Q; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Zhu SG, 1999, J NEUROPATH EXP NEUR, V58, P582, DOI 10.1097/00005072-199906000-00002	43	114	120	0	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN	2002	22	1					38	43		10.1523/JNEUROSCI.22-01-00038.2002			6	Neurosciences	Neurosciences & Neurology	505GU	WOS:000172905700011	11756486	Bronze, Green Published			2021-06-18	
J	Makdissi, M; Collie, A; Maruff, P; Darby, DG; Bush, A; McCrory, P; Bennell, K				Makdissi, M; Collie, A; Maruff, P; Darby, DG; Bush, A; McCrory, P; Bennell, K			Computerised cognitive assessment of concussed Australian Rules footballers	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						concussion; football; neuropsychology; cognitive; head injury	NEUROPSYCHOLOGICAL ASSESSMENT; HEAD-INJURY	Background-"Paper and pencil" neuropsychological tests play an important role in the management of sports related concussions. They provide objective information on the athlete's cognitive function and thus facilitate decisions on safe return to sport. It has been proposed that computerised cognitive tests have many advantages over such conventional tests, but their role in this domain is yet to be established. Objectives-To measure cognitive impairment after concussion in a case series of concussed Australian Rules footballers, using both computerised and paper and pencil neuropsychological tests. To investigate the role of computerised cognitive tests in the assessment and follow up of sports related concussions. Methods-Baseline measures on the Digit Symbol Substitution Test (DSST), Trail Making Test-Part B (TMT), and a simple reaction time (SRT) test from a computerised cognitive test battery (CogState) were obtained in 240 players. Tests were repeated in players who had sustained a concussive injury. A group of non-injured players were used as matched controls. Results-Six concussions were observed over a period of nine weeks. At the follow up, DSST and TMT scores did not significantly differ from baseline scores in both control and concussed groups. However, analysis of the SRT data showed an increase in response variability and latency after concussion in the injured athletes. This was in contrast with a decrease in response variability and no change in latency on follow up of the control players (p<0.02). Conclusion-Increased variability in response time may be an important cognitive deficit after concussion. This has implications for consistency of an athlete's performance after injury, as well as for tests used in clinical assessment and follow up of head injuries.	Mental Hlth Res Inst Victoria, Neuropsychol Lab, Parkville, Vic 3052, Australia; Univ Melbourne, Ctr Sports Med Res Educ, Parkville, Vic 3052, Australia; Univ Melbourne, Ctr Neurosci, Parkville, Vic 3052, Australia; Mental Hlth Res Inst Victoria, Behav Neurol Lab, Parkville, Vic, Australia	Collie, A (corresponding author), Mental Hlth Res Inst Victoria, Neuropsychol Lab, Locked Bag 11, Parkville, Vic 3052, Australia.		Bush, Ashley I/A-1186-2007; Maruff, Paul/ABA-1673-2020; McCrory, Paul/Q-8688-2019; Maruff, Paul/AAD-2454-2021; Bush, Ashley/Y-2457-2019; Bennell, Kim/C-7022-2014	Bush, Ashley I/0000-0001-8259-9069; Maruff, Paul/0000-0002-6947-9537; Bush, Ashley/0000-0001-8259-9069; Collie, Alex/0000-0003-2617-9339; Bennell, Kim/0000-0003-4982-5639			Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; COLLIE A, 2001, BR J SPORTS MED, V34; GRONWALL D, 1975, LANCET, V2, P995; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Westerman R, 2001, ADF HLTH, V2, P29	19	114	115	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	OCT	2001	35	5					354	360		10.1136/bjsm.35.5.354			7	Sport Sciences	Sport Sciences	479FR	WOS:000171394800022	11579074	Green Published, Bronze			2021-06-18	
J	Citerio, G; Vascotto, E; Villa, F; Celotti, S; Pesenti, A				Citerio, G; Vascotto, E; Villa, F; Celotti, S; Pesenti, A			Induced abdominal compartment syndrome increases intracranial pressure in neurotrauma patients: A prospective study	CRITICAL CARE MEDICINE			English	Article						intracranial pressure; intracranial physiology; head injuries; respiratory mechanics; abdominal physiology; prospective studies; intensive care; intracranial pressure	ELEVATED INTRAABDOMINAL PRESSURE; LAPAROSCOPIC CHOLECYSTECTOMY; HEAD-INJURY; CONSEQUENCES; PULMONARY	pObjective: To evaluate the effect of a stepwise increase in intra-abdominal pressure (IAP) on intracranial pressure (ICP) and to further define the pressure transmission characteristics of different body compartments. Design: A prospective, nonrandomized study. Setting: A multidisciplinary intensive care unit at a university medical center. Patients: Fifteen patients with moderate-to-severe head injury. Interventions: All patients were studied after the initial stabilization and resolution of intracranial hypertension. Measurements were carried out before and 20 mins after IAP was increased by positioning a soft, 15-L water bag on the patient's abdomen. Measurements and Main Results: Placing weights upon the abdomen generated a significant increase in IAP, which rose from 4.7 +/- 2.9 to 15.5 +/- 4.1 mm Hg (p < .001). The rise in IAP caused concomitant and rapid increases in central venous pressure (from 6.2 +/- 2.4 to 10.4 +/- 2.9 mm Hg; p < .001), internal jugular pressure (from 11.9 +/- 3.2 to 14.3 +/- 2.4 mm Hg; p < .001), and ICP (from 12.0 +/- 4.2 to 15.5 +/- 4.4 mm Hg; p < .001). Thoracic transmural pressure, calculated as the difference between central venous pressure and esophageal pressure, remained constant during the protocol. Respiratory system compliance decreased from 58.9 +/- 9.8 to 44.9 +/- 9.4 mL/cm H2O (p < .001) in all patients because of decreased chest wall compliance. The mean arterial pressure increased from 94 +/- 11 to 100 +/- 13 mm Hg (p < .01), which allowed the maintenance of a stable cerebral perfusion pressure (82.4 +/- 10.3 vs. 84.7 +/- 11.5 mm Hg; p = NS) despite the ICP increase. Conclusions: Increased IAP causes a significant rise in ICP in head trauma patients. This effect seems to be the result of an increase in intrathoracic pressure, which causes a functional obstruction to cerebral venous outflow. Routine assessment of IAP may help clinicians to identify remediable causes of increased ICP. Caution should be used when applying laparoscopic techniques in neurotrauma patients.	Nuovo Osped San Gerardo, Dipartimento Anestesia & Rianimaz, Monza, Italy	Citerio, G (corresponding author), Nuovo Osped San Gerardo, Dipartimento Anestesia & Rianimaz, Monza, Italy.		Citerio, Giuseppe/B-1839-2015; Pesenti, Antonio/H-7483-2012	Citerio, Giuseppe/0000-0002-5374-3161; Pesenti, Antonio/0000-0003-2593-729X			BARNES GE, 1985, AM J PHYSIOL, V248, pR208; Bloomfield Geoffrey L., 1995, Surgical Forum, V46, P572; Bloomfield GL, 1997, CRIT CARE MED, V25, P496, DOI 10.1097/00003246-199703000-00020; Bloomfield GL, 1995, J TRAUMA, V39, P1168, DOI 10.1097/00005373-199512000-00028; CALDWELL CB, 1987, J SURG RES, V43, P14, DOI 10.1016/0022-4804(87)90041-2; Citerio G, 2000, ACTA NEUROCHIR, V142, P769, DOI 10.1007/s007010070091; CULLEN DJ, 1989, CRIT CARE MED, V17, P118, DOI 10.1097/00003246-198902000-00002; DHOOGHE TM, 1993, AM J OBSTET GYNECOL, V169, P1352, DOI 10.1016/0002-9378(93)90304-2; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; IBERTI TJ, 1987, CRIT CARE MED, V15, P1140, DOI 10.1097/00003246-198712000-00014; IRGAU I, 1995, ARCH SURG-CHICAGO, V130, P1011; JACQUES T, 1988, ANAESTH INTENS CARE, V16, P478, DOI 10.1177/0310057X8801600415; JOSEPHS LG, 1994, J TRAUMA, V36, P815, DOI 10.1097/00005373-199406000-00011; KASHTAN J, 1981, J SURG RES, V30, P249, DOI 10.1016/0022-4804(81)90156-6; KENDALL AP, 1995, ANAESTHESIA, V50, P286, DOI 10.1111/j.1365-2044.1995.tb04600.x; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; MCGREGOR M, 1979, NEW ENGL J MED, V301, P480, DOI 10.1056/NEJM197908303010905; NATHENS AB, 1998, CURR OPIN CRIT CARE, V4, P116; ORTELLS J, 1999, INTENSIVE CARE ME S1, V25, pS22; PELOSI P, 1995, AM J RESP CRIT CARE, V152, P531, DOI 10.1164/ajrccm.152.2.7633703; RICHARDS WO, 1983, ANN SURG, V197, P183, DOI 10.1097/00000658-198302000-00010; SAFRAN DS, 1985, AM J PHYSIOL, V248, pR208; SCHEIN M, 1995, J AM COLL SURGEONS, V180, P745; TEASDALE G, 1974, LANCET, V2, P81; WESTERBAND A, 1992, SURG GYNECOL OBSTET, V175, P535	26	114	125	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	2001	29	7					1466	1471		10.1097/00003246-200107000-00027			6	Critical Care Medicine	General & Internal Medicine	453XX	WOS:000169944400027	11445709				2021-06-18	
J	Zhou, F; Zhu, XW; Castellani, RJ; Stimmelmayr, R; Perry, G; Smith, MA; Drew, KL				Zhou, F; Zhu, XW; Castellani, RJ; Stimmelmayr, R; Perry, G; Smith, MA; Drew, KL			Hibernation, a model of neuroprotection	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; IN-GROUND SQUIRRELS; MICRODIALYSIS; MICROGLIA; DAMAGE; STROKE; TISSUE; SUPPRESSION; TOLERANCE	Hibernation, a natural model of tolerance to cerebral ischemia, represents a state of pronounced fluctuation in cerebral blood flow where no brain damage occurs. Numerous neuroprotective aspects may contribute in concert to such tolerance. The purpose of this study was to determine whether hibernating brain tissue is tolerant to penetrating brain injury modeled by insertion of microdialysis probes. Guide cannulae were surgically implanted in striatum of Arctic ground squirrels before any of the animals began to hibernate. Microdialysis probes were then inserted in some animals after they entered hibernation and in others while they remained euthermic. The brain tissue from hibernating and euthermic animals was examined 3 days after implantation of microdialysis probes. Tissue response, indicated by examination of hematoxylin and eosin-stained tissue sections and immunocytochemical identification of activated microglia, astrocytes, and hemeoxygenase-1 immunoreactivity, was dramatically attenuated around probe tracks in hibernating animals com pared to euthermic controls. No difference in tissue response around guide cannulae was observed between groups. Further study of the mechanisms underlying neuroprotective aspects of hibernation may lead to novel therapeutic strategies for stroke and traumatic brain injury.	Univ Alaska, Inst Arctic Biol, Fairbanks, AK 99775 USA; Univ Alaska, Dept Chem & Biochem, Fairbanks, AK 99775 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Drew, KL (corresponding author), Univ Alaska, Inst Arctic Biol, POB 757000, Fairbanks, AK 99775 USA.		Drew, Kelly L/B-7995-2013; Perry, George/A-8611-2009; Castellani, Rudy J/A-9555-2009; Smith, Mark A/A-9053-2009; Zhu, Xiongwei/A-9629-2009	Perry, George/0000-0002-6547-0172; Zhu, Xiongwei/0000-0003-2092-6508	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U54NS041069, R01NS038648] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41069, NS38648, R01 NS038648, U54 NS041069] Funding Source: Medline		BENVENISTE H, 1987, ACTA NEUROPATHOL, V74, P234, DOI 10.1007/BF00688186; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUZADZIC B, 1990, FREE RADICAL BIO MED, V9, P407, DOI 10.1016/0891-5849(90)90017-D; Clapp-Lilly KL, 1999, J NEUROSCI METH, V90, P129, DOI 10.1016/S0165-0270(99)00064-3; DELANGE ECM, 1995, BRAIN RES, V702, P261, DOI 10.1016/0006-8993(95)01184-X; Drew KL, 1999, BRAIN RES, V851, P1, DOI 10.1016/S0006-8993(99)01969-1; Du C, 1996, BRAIN RES, V718, P233, DOI 10.1016/0006-8993(96)00162-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRERICHS KU, 1994, J CEREBR BLOOD F MET, V14, P193, DOI 10.1038/jcbfm.1994.26; Frerichs KU, 1998, P NATL ACAD SCI USA, V95, P14511, DOI 10.1073/pnas.95.24.14511; Frerichs KU, 1998, J CEREBR BLOOD F MET, V18, P168, DOI 10.1097/00004647-199802000-00007; GARCIA JH, 1992, J NEUROPATH EXP NEUR, V51, P387, DOI 10.1097/00005072-199207000-00001; Gentile NT, 1996, NEUROCHEM RES, V21, P947, DOI 10.1007/BF02532345; GREGSON NA, 1999, CELLULAR RESPONSES P, P43; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HU Y, 1998, SOC NEUROSCI; Knight JE, 2000, MOL CELL BIOL, V20, P6374, DOI 10.1128/MCB.20.17.6374-6379.2000; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LYMAN CP, 1948, J EXP ZOOL, V109, P55, DOI 10.1002/jez.1401090105; MANNOJI H, 1986, ACTA NEUROPATHOL, V71, P341, DOI 10.1007/BF00688060; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCKENNA TM, 1968, P SOC EXP BIOL MED, V129, P720; Nagayama T, 2000, J NEUROCHEM, V75, P1716, DOI 10.1046/j.1471-4159.2000.0751716.x; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Osborne PG, 1999, BRAIN RES, V839, P1, DOI 10.1016/S0006-8993(99)01627-3; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Porkka-Heiskanen T, 1997, SCIENCE, V276, P1265, DOI 10.1126/science.276.5316.1265; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Shi J, 2000, NEUROBIOL AGING, V21, P357, DOI 10.1016/S0197-4580(00)00119-6; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIDKY YA, 1969, P SOC EXP BIOL MED, V132, P760; SNAPP BD, 1981, PHYSIOL ZOOL, V54, P297, DOI 10.1086/physzool.54.3.30159944; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; TOEIN O, IN PRESS AM J PHYSL; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; WAHLGREN NG, 1997, NEUROPROTECTIVE AGEN, P337; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	46	114	116	0	8	AMER SOC INVESTIGATIVE PATHOLOGY, INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA	0002-9440			AM J PATHOL	Am. J. Pathol.	JUN	2001	158	6					2145	2151		10.1016/S0002-9440(10)64686-X			7	Pathology	Pathology	439VN	WOS:000169138400031	11395392	Green Published			2021-06-18	
J	Hellawell, DJ; Taylor, R; Pentland, B				Hellawell, DJ; Taylor, R; Pentland, B			Cognitive and psychosocial outcome following moderate or severe traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; DEPRESSION; MANAGEMENT; COMPLAINTS; RELATIVES; SCALE; EPIDEMIOLOGY; IMPAIRMENT; PROFILE; ANXIETY	The outcome of 96 consecutive adult patients with moderate to severe head injury was sequentially measured at 6, 12 and 24 months post-injury. In addition to global outcome using the Glasgow Outcome Scale (GOS) and a battery of neuropsychological tests of cognitive function, the Head Injury Symptom Checklist (HISC) and Relative's Questionnaire (RQ) Were used. Although poorer GOS scores and severe cognitive impairments were typically associated with greater severity of initial injury, relatives reported similar functional problems irrespective of injury severity. This illustrates the legacy of moderate head injury in influencing many aspects of everyday life, supporting the argument that the needs of this group should not be overlooked.	Astley Ainslie Hosp, Rehabil Studies Unit, Edinburgh EH9 2HL, Midlothian, Scotland; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Pentland, B (corresponding author), Astley Ainslie Hosp, Rehabil Studies Unit, Edinburgh EH9 2HL, Midlothian, Scotland.	Brian.Pentland@ed.ac.uk					ANDERSON SI, 1994, CLIN REHABIL, V8, P301; ARMITAGE SG, 1946, PSYCHOL MONOGR, V60, P277; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; BENTON AL, 1964, J NERV MENT DIS, V139, P110, DOI 10.1097/00005053-196408000-00003; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brooks D N, 1979, Int Rehabil Med, V1, P166; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DILLER L, 1987, REHABILITATION OUTCO, P209; Eaker S, 1998, AM J EPIDEMIOL, V147, P74; Enderby P., 1987, FRENCHAY APHASIA SCR; ENGBERG A, 1995, ACTA NEUROLOGIC S164, V92, P10; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GOLDBERG RJ, 1995, AM J MED, V98, P278, DOI 10.1016/S0002-9343(99)80375-1; GREENWOOD RJ, 1994, BRIT MED J, V308, P1199, DOI 10.1136/bmj.308.6938.1199; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HENRY GK, 1990, J CLIN EXP NEUROPSYC, V12, P502, DOI 10.1080/01688639008400996; IVISON D, 1986, J CLIN EXP NEUROPSYC, V8, P317, DOI 10.1080/01688638608401322; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kaplan E., 1983, BOSTON NAMING TEST; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; McPherson K, 1997, NEUROPSYCHOL REHABIL, V7, P241, DOI 10.1080/713755530; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Nelson HE, 1982, NATL ADULT READING T; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Taylor L. B., 1979, FUNCTIONAL NEUROSURG, P165; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Tickle M, 1996, Community Dent Health, V13, P193; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; VANGIJN J, 1994, STROKE, V25, P1623, DOI 10.1161/01.STR.25.8.1623; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Wade DT, 1992, MEASUREMENT NEUROLOG; WALSH K, 1994, BRIT J GEN PRACT, V44, P118; Wechsler, 1981, WAIS R MANUAL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	69	114	116	1	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	1999	13	7					489	504					16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	215GT	WOS:000081374100003	10462147				2021-06-18	
J	Gupta, AK; Hutchinson, PJ; Al-Rawi, P; Gupta, S; Swart, M; Kirkpatrick, PJ; Menon, DK; Datta, AK				Gupta, AK; Hutchinson, PJ; Al-Rawi, P; Gupta, S; Swart, M; Kirkpatrick, PJ; Menon, DK; Datta, AK			Measuring brain tissue oxygenation compared with jugular venous oxygen saturation for monitoring cerebral oxygenation after traumatic brain injury	ANESTHESIA AND ANALGESIA			English	Article							SEVERE HEAD-INJURY; BLOOD-FLOW; NEUROSURGICAL PATIENTS; INTENSIVE-CARE; METABOLISM; PRESSURE	Jugular bulb oximetry is the most widely used method of monitoring cerebral oxygenation. More recently, measurement of brain tissue oxygenation has been reported in head-injured patients. We compared the changes in brain tissue oxygen partial pressure (PbO2) with changes in jugular venous oxygen saturation (SjVO(2)) in response to hyperventilation in areas of brain with and without focal pathology. Thirteen patients with severe head injuries were studied. A multiparameter sensor was inserted into areas of brain with focal pathology in five patients and outside areas of focal pathology in eight patients. A fiberoptic catheter was inserted into the right jugular bulb. Patients were hyperventilated in a stepwise manner from a PaCO2 of approximately 35 mm Hg to a PaCO2 of 22 mm Hg. There was no significant change in cerebral perfusion pressure or arterial partial pressure of oxygen with hyperventilation. In areas without focal pathology, there was a good correlation between changes in SjVO(2) and PbO2 (Delta SjVO(2) and Delta PbO2, r(2) = 0.69, P < 0.0001). In areas with focal pathology, there was no correlation between Delta SjVO(2), and Delta PbO2 (r(2) = 0.07, P = 0.23). In this study, we demonstrated that measurement of local tissue oxygenation can highlight focal differences in regional cerebral oxygenation that are disguised when measuring SjVO(2). Thus, monitoring of PbO2 is a useful addition to multimodal monitoring of patients with traumatic head injury. Implications: Brain oxygenation is currently monitored by using jugular bulb oximetry, which attracts a number of potential artifacts and may not reflect regional changes in oxygenation. We compared this method with measurement of brain tissue oxygenation using a multiparameter sensor inserted into brain tissue. The brain tissue monitor seemed to reflect regional brain oxygenation better than jugular bulb oximetry.	Univ Cambridge, Addenbrookes Hosp, Dept Anesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosci Crit Care, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England	Gupta, AK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Anesthesia, Level 4, Cambridge CB2 2QQ, England.	akg01@globalnet.co.uk					Andrews PJD, 1996, J NEUROSURG ANESTH, V8, P220, DOI 10.1097/00008506-199607000-00006; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bouma G J, 1995, New Horiz, V3, P384; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chieregato A, 1996, J NEUROSURG ANESTH, V8, P21, DOI 10.1097/00008506-199601000-00006; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; GUPTA AK, 1997, J NEUROSURG ANESTHES, V8, P325; Heath K, 1998, J NEUROSURG ANESTH, V10, P22, DOI 10.1097/00008506-199801000-00005; HOFFMAN WE, 1995, NEUROL RES, V17, P417, DOI 10.1080/01616412.1995.11740354; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; SALVANT JB, 1993, NEUROSURGERY, V33, P387; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812	21	114	121	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	1999	88	3					549	553		10.1097/00000539-199903000-00016			5	Anesthesiology	Anesthesiology	171AX	WOS:000078840900016	10072004				2021-06-18	
J	Hillier, SL; Sharpe, MH; Metzer, J				Hillier, SL; Sharpe, MH; Metzer, J			Outcomes 5 years post-traumatic brain injury (with further reference to neurophysical impairment and disability)	BRAIN INJURY			English	Article							HEAD-INJURY; ADULTS; SCALE	The assessment of recovery and outcomes post-traumatic brain injury (TBI) has often been poorly researched and reported in past Literature. Indeed, an accurate documentation of outcomes in this population had never been performed in the state of South Australia. To redress this situation this study collected data on people who had sustained a TBI 5 years previously, using medical records, personal interview/questionnaire and neurophysical assessment in order to investigate broad outcomes as well as the specific nature and prevalence of any residual physical impairment and disability. The results (n = 67) indicate that the subjects' living arrangements had not altered significantly, and nearly half had returned to some form of paid work, though over 50% were reliant on the welfare system. The majority (57%) felt they had improved in all areas, 19% partially improved and 8% felt they had actually deteriorated. Considering the physical data, the most frequent areas of residual impairment were headaches, followed by balance difficulties and fatigue/weakness. Functionally, 30% had some degree of deficit in upper limb activity and 9% required assistance for particular transfer tasks. Overall balance was impaired in 34% and gait was altered in 24% with 9% reliant on wheelchairs for mobility. Such data may be used in the education of people with TBI and those who live and/or work with them, as well as in future studies assessing the impact of various factors on recovery and outcomes. Evidence was also provided that residual physical issues should be considered along with the more researched areas of cognition and psychosocial issues.	UNIV S AUSTRALIA,SCH PHYSIOTHERAPY,ADELAIDE,SA 5001,AUSTRALIA; UNIV S AUSTRALIA,SCH PSYCHOL,ADELAIDE,SA 5001,AUSTRALIA			Hillier, Susan/Q-7713-2019; Hillier, Susan/D-4590-2009	Hillier, Susan/0000-0002-6071-6137; Hillier, Susan/0000-0002-6071-6137			BADCOCK KM, 1987, HEAD INJURY STUDY FL; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1990, REHABILITATION ADULT, P59; BRENNAN MA, 1981, IRISH MED J, V74, P5; COSTA LD, 1963, J CONSULT PSYCHOL, V10, P146; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; De Weerdt W, 1985, PHYSIOTHER CAN, V37, P65, DOI DOI 10.3138/PTC.37.2.065; DIAMOND SG, 1983, NEUROLOGY, V33, P1098, DOI 10.1212/WNL.33.8.1098; FREGLY AR, 1972, AEROSPACE MED, V43, P395; FREGLY AR, 1968, AEROSPACE MED, V39, P277; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Herdman S. J., 1990, J HEAD TRAUMA REHAB, V5, P63; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KAPLAN E, 1968, THESIS CLARKE U; KATZ DI, 1990, J HEAD TRAUMA REHAB, V5, P86; *LAF INSTR COMP, 1979, INSTR NORM DAT MOD 3, P1; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LINDMARK B, 1988, SCAND J REHABIL MED, V20, P111; LINDMARK B, 1988, SCAND J REHABIL MED, V20, P103; LYLE RC, 1981, INT J REHABIL RES, V4, P483, DOI 10.1097/00004356-198112000-00001; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RINEHART MA, 1983, PHYS THER, V63, P1975, DOI 10.1093/ptj/63.12.1975; ROBINSON JL, 1981, PHYS THER, V61, P351, DOI 10.1093/ptj/61.3.351; SABARI JS, 1991, AM J OCCUP THER, V45, P523, DOI 10.5014/ajot.45.6.523; SHARPE MH, 1983, NEUROPSYCHOLOGIA, V21, P455, DOI 10.1016/0028-3932(83)90002-7; SWEENEY JK, 1983, PHYS THER, V63, P2018, DOI 10.1093/ptj/63.12.2018; TALMAGE EW, 1983, PHYS THER, V63, P2010, DOI 10.1093/ptj/63.12.2010; TEASDALE G, 1974, LANCET, V2, P81; Tiffin J, 1948, J APPL PSYCHOL, V32, P234, DOI 10.1037/h0061266; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1980, INT CLASS IMP DIS HA; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	33	114	116	0	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1997	11	9					661	675					15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XT726	WOS:A1997XT72600005	9376834				2021-06-18	
J	Rivara, JB; Jaffe, KM; Polissar, NL; Fay, GC; Liao, SQ; Martin, KM				Rivara, JB; Jaffe, KM; Polissar, NL; Fay, GC; Liao, SQ; Martin, KM			Predictors of family functioning and change 3 years after traumatic brain injury in children	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							BLUNT HEAD-INJURY; HANDICAPPED-CHILDREN; CYSTIC-FIBROSIS; SPINA-BIFIDA; FOLLOW-UP; RELATIVES; PARENTS; IMPACT; STRESS; CARE	Objectives: To examine changes in family functioning from injury to 3 years after pediatric traumatic brain injury; to determine factors most predictive of family outcomes at 3 years and variables that promote positive outcomes and changes over time. Design: Prospective cohort study Setting: Two regional tertiary care centers; cases followed for 3 years into community. Participants: Families of 81 children, ages 6 to 15 years, who sustained closed head injury and loss of consciousness (mild=43, moderate=20, severe=18), consecutively en rolled over 15 months. Main Outcome Measures: Family Environment Scale, Family Assessment Device, Family Inventory of Life Events, Health Insurance Survey-General Well-Being, NYU Problem Checklist for Significant Others, Family Interview Rating Scale, Family Global Assessment Scale. All were obtained initially and at 3 months, 1 year, and 3 years postinjury. Predictor variables were selected from the instuments above, as well as from the parent and teacher versions of the Child Behavior Checklist, socioeconomic status, and injury severity. Results: Preinjury functioning was the best predictor of 3-year outcomes. Fewer changes in family functioning were reported over 3 years in the mild or moderate groups, whereas more deterioration occurred in the severe group. At 3 years, one third to one half of parents in either the moderate or severe groups reported medium to high strain in 19 of 34 problem areas. Low levels of family control and high levels of expressiveness correlated with better outcomes for severe group. Positive change for the severe group was marked by better preinjury levels of communication, expressiveness, problem solving, use of resources, role flexibility, greater activity orientation, and less conflict, control, and stress. Preinjury variables and severity explained from 26% to 69% of the variation in 3-year outcomes. Conclusions: Families at risk for poorer outcomes can prospectively identified and should be supported and encouraged in their efforts to develop new coping resources. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DIV NEUROL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,DEPT REHABIL MED,SEATTLE,WA 98195; STAT & EPIDEMIOL RES CORP,SEATTLE,WA; NORTHWEST HOSP,SEATTLE,WA	Rivara, JB (corresponding author), CHILDRENS HOSP & MED CTR,DEPT REHABIL MED CH71,4800 SAND POINT WAY NE,POB C-5371,SEATTLE,WA 98105, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Achenbach TM, 1986, MANUAL TEACHERS REPO; Austin J K, 1988, J Neurosci Nurs, V20, P174; BEAVERS J, 1986, FAM PROCESS, V25, P365, DOI 10.1111/j.1545-5300.1986.00365.x; BEGLEITER ML, 1976, SOC BIOL, V23, P260, DOI 10.1080/19485565.1976.9988237; BROOK RH, 1979, MED CARE S7, V7, pS16; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; DONAVAN AM, 1988, AM J MENT RETARD, V92, P502; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FREY KS, 1989, AM J MENT RETARD, V94, P240; GATH A, 1980, ARCH DIS CHILD, V55, P371, DOI 10.1136/adc.55.5.371; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P867; HAUSER ST, 1986, HEALTH PSYCHOL, V5, P273, DOI 10.1037/0278-6133.5.3.273; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KAY T, 1988, HEAD INJURY FAMILY I; KAZAK AE, 1989, J AUTISM DEV DISORD, V19, P501, DOI 10.1007/BF02212854; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KUPST MJ, 1988, J PEDIATR PSYCHOL, V13, P7, DOI 10.1093/jpepsy/13.1.7; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MARTIN DA, 1988, J LEARN DISABIL, V21, P464, DOI 10.1177/002221948802100803; MCCORMICK MC, 1986, DEV MED CHILD NEUROL, V28, P53; MCCUBBIN HI, 1983, SOCIAL STRESS FAMILY; McCubbin HI, 1980, FAMILY ASSESSMENT RE; MCCUBBIN MA, 1989, FAM RELAT, V38, P436, DOI 10.2307/585750; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Moos R. H., 1974, SOCIAL CLIMATE SCALE; MRAZEK D, 1985, P 32 ANN M AM AC CHI; ODDEY M, 1980, J NEUROL NEUROSUR PS, V43, P798; PATTERSON JM, 1985, FAM RELAT, V34, P79, DOI 10.2307/583760; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SPINETTA JJ, 1988, J PSYCHOSOC ONCOL, V6, P179; STEIN REK, 1984, PEDIATRICS, V73, P845; TEASDALE G, 1974, LANCET, V2, P81; TEW B, 1975, BRIT J PREV SOC MED, V29, P27; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WATSON SM, 1990, J ABNORM CHILD PSYCH, V18, P143, DOI 10.1007/BF00910727; WINER BJ, 1978, STATISTICAL PRINCIPL	46	114	114	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1996	77	8					754	764		10.1016/S0003-9993(96)90253-1			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	VA965	WOS:A1996VA96500004	8702368				2021-06-18	
J	SMITH, DH; OKIYAMA, K; GENNARELLI, TA; MCINTOSH, TK				SMITH, DH; OKIYAMA, K; GENNARELLI, TA; MCINTOSH, TK			MAGNESIUM AND KETAMINE ATTENUATE COGNITIVE DYSFUNCTION FOLLOWING EXPERIMENTAL BRAIN INJURY	NEUROSCIENCE LETTERS			English	Article						BRAIN INJURY; MEMORY; MAGNESIUM; KETAMINE; FLUID PERCUSSION	NEURONS; RELEASE; RAT; PHENCYCLIDINE; HIPPOCAMPUS; MEMBRANES; TRAUMA; DRUGS	We evaluated the therapeutic effects of two noncompetitive antagonists of the N-methyl-D-aspartate (NMDA) receptor, MgCl2 and ketamine, both individually and together, on cognitive dysfunction observed following parasagittal fluid-percussion (FP) brain injury in the rat. Using a modified Morris water maze technique, we found significant attenuation of post-traumatic memory dysfunction in animals treated with either MgCl2 (125 mumol) or ketamine (4 mg/kg) (P < 0.005). Combined MgCl2 and ketamine treatment also preserved memory function (P < 0.005), with no apparent additive effect.		SMITH, DH (corresponding author), UNIV PENN,DIV NEUROSURG,105 HAYDEN HALL,240 S 33RD ST,PHILADELPHIA,PA 19104, USA.		smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818, R55NS026818, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 08803, NS 26818] Funding Source: Medline		ALVES WM, 1992, CENTRAL NERVOUS SYST, P255; BLAIR JL, 1989, STROKE, V20, P1507; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1989, SCIENCE, V244, P789; FAGG GE, 1987, NEUROSCI LETT, V76, P221, DOI 10.1016/0304-3940(87)90719-1; Hicks R. R., 1992, Society for Neuroscience Abstracts, V18, P170; HOFFMAN WE, 1992, ANESTHESIOLOGY, V76, P755, DOI 10.1097/00000542-199205000-00014; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LOBNER D, 1990, NEUROSCI LETT, V117, P169, DOI 10.1016/0304-3940(90)90139-Z; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; McINTOSH T., 1988, NEUROL NEUR, P653; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PETERSEN EN, 1989, PHARMACOL TOXICOL, V65, P299, DOI 10.1111/j.1600-0773.1989.tb01177.x; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; Smith D. H., 1992, Society for Neuroscience Abstracts, V18, P170; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TSUDA T, 1991, HIPPOCAMPUS, P335; VINK R, 1988, J BIOL CHEM, V263, P757; WOLF G, 1991, NEUROSCIENCE, V43, P31, DOI 10.1016/0306-4522(91)90413-I	34	114	115	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUL 23	1993	157	2					211	214		10.1016/0304-3940(93)90739-8			4	Neurosciences	Neurosciences & Neurology	LR741	WOS:A1993LR74100022	8233056				2021-06-18	
J	COGBILL, TH; MOORE, EE; MORRIS, JA; HOYT, DB; JURKOVICH, GJ; MUCHA, P; ROSS, SE; FELICIANO, DV; SHACKFORD, SR; LANDERCASPER, J; MOORE, FA; VANAALST, JA; DAVIS, JW; OFFNER, PJ; RHODES, M; OMALLEY, KF; SWIERZEWSKI, MJ; SCHMOKER, JD; STRUTT, PJ				COGBILL, TH; MOORE, EE; MORRIS, JA; HOYT, DB; JURKOVICH, GJ; MUCHA, P; ROSS, SE; FELICIANO, DV; SHACKFORD, SR; LANDERCASPER, J; MOORE, FA; VANAALST, JA; DAVIS, JW; OFFNER, PJ; RHODES, M; OMALLEY, KF; SWIERZEWSKI, MJ; SCHMOKER, JD; STRUTT, PJ			DISTAL PANCREATECTOMY FOR TRAUMA - A MULTICENTER EXPERIENCE	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article								During a 5-year period, 74 patients with pancreatic injuries were managed by distal pancreatic resection at nine referral trauma centers. Patient ages ranged from 4 to 72 years. Injury mechanism was blunt trauma in 34 (46%) patients, gunshot wound in 27 (36%), stab wound in 11 (15%), and shotgun blast in two (3%). There were 19 class II, 50 class III, and 5 class IV pancreatic injuries. The resection comprised up to 33% of the pancreas in 21 (28%) patients, from 34% to 66% in 45 (61%), and greater than 67% in eight (11%). The pancreatic resection margin was closed with staples in 44 (59%), silk sutures in 20 (27%), and polypropylene sutures in eight (11%). Of 32 patients in whom the spleen was uninjured, the spleen was left intact in 17 (53%). There were nine (12%) deaths. The cause of death was irreversible shock in three patients, multiple organ failure in five, and severe head injury in one. Pancreas-related complications occurred in 32 (45%) of 71 patients who survived the initial operation. Intra-abdominal abscess developed in 24 patients; 11 were managed by percutaneous drainage alone. Pancreatic fistula developed in 10 patients; eight closed spontaneously from 6 to 54 days. Other pancreas-related morbidity included pancreatitis (6), pseudocyst (2), and hemorrhage (2). Exocrine insufficiency was not evident in any patient and diet-controlled hyperglycemia occurred in one individual following 80% pancreatic resection. We conclude: (1) distal pancreatectomy can be safely performed without concomitant splectomy; (2) pancreas-related morbidity is frequent after pancreatic resection for trauma, regardless of method of pancreatic closure; and (3) endocrine and exocrine insufficiency are rare after distal pancreatectomy for trauma.	GUNDERSEN LUTHERAN MED CTR, DEPT SURG, LA CROSSE, WI USA; DENVER GEN HOSP, DEPT SURG, DENVER, CO 80204 USA; UNIV COLORADO, HLTH SCI CTR, DEPT SURG, DENVER, CO 80262 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT SURG, NASHVILLE, TN 37232 USA; UNIV CALIF SAN DIEGO, MED CTR, DEPT SURG, SAN DIEGO, CA 92103 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT SURG, SEATTLE, WA 98104 USA; UNIV WASHINGTON, SCH MED, DEPT SURG, SEATTLE, WA 98195 USA; ALLENTOWN HOSP, LEHIGH VALLEY HOSP CTR, DEPT SURG, ALLENTOWN, PA 18102 USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT SURG, CAMDEN, NJ USA; UNIV ROCHESTER, MED CTR, DEPT SURG, ROCHESTER, NY 14642 USA; UNIV VERMONT, MED CTR, DEPT SURG, BURLINGTON, VT 05405 USA				landercasper, jeffrey/0000-0002-4000-4546			ADAMS DB, 1990, ARCH SURG-CHICAGO, V125, P1554; ANANESEFAH J, 1975, ARCH SURG-CHICAGO, V110, P161; ANDERSEN DK, 1980, J TRAUMA, V20, P347; [Anonymous], 1990, ABBREVIATED INJURY S; BACH RD, 1971, AM J SURG, V121, P20, DOI 10.1016/0002-9610(71)90073-0; BERNI GA, 1982, AM J SURG, V143, P602, DOI 10.1016/0002-9610(82)90173-8; BORLASE BC, 1990, J TRAUMA, V30, P1340, DOI 10.1097/00005373-199011000-00006; BOUWMAN DL, 1984, J TRAUMA, V24, P573, DOI 10.1097/00005373-198407000-00004; BURNWEIT C, 1990, J TRAUMA, V30, P1273, DOI 10.1097/00005373-199010000-00013; CARR ND, 1989, BRIT J SURG, V76, P1244, DOI 10.1002/bjs.1800761206; CIVIL ID, 1987, SURGICAL ROUNDS, P29; COGBILL TH, 1982, ARCH SURG-CHICAGO, V117, P722; DAWSON DL, 1986, J TRAUMA, V26, P1142, DOI 10.1097/00005373-198612000-00018; FABIAN TC, 1990, ANN SURG, V211, P724, DOI 10.1097/00000658-199006000-00011; FITZGIBBONS TJ, 1982, SURG GYNECOL OBSTET, V154, P225; FLYNN WJ, 1990, ARCH SURG-CHICAGO, V125, P1539; FREY CF, 1989, SURG CLIN N AM, V69, P499; GRAHAM JM, 1978, AM J SURG, V136, P744, DOI 10.1016/0002-9610(78)90349-5; HAYWARD SR, 1989, ARCH SURG-CHICAGO, V124, P745; HEITSCH RC, 1976, SURGERY, V80, P523; HORST HM, 1989, ARCH SURG-CHICAGO, V124, P1093; JEFFREY RB, 1983, RADIOLOGY, V147, P491, DOI 10.1148/radiology.147.2.6836127; JONES RC, 1985, AM J SURG, V150, P698, DOI 10.1016/0002-9610(85)90412-X; JONES RC, 1978, ANN SURG, V187, P555, DOI 10.1097/00000658-197805000-00015; JURKOVICH GJ, 1990, SURG CLIN N AM, V70, P575; KARL HW, 1977, AM J SURG, V134, P549, DOI 10.1016/0002-9610(77)90431-7; KELLUM JM, 1988, TRAUMA, V28, P700; KUDSK KA, 1986, J TRAUMA, V26, P320, DOI 10.1097/00005373-198604000-00003; LARAJA RD, 1986, J TRAUMA, V26, P1146, DOI 10.1097/00005373-198612000-00019; MALANGONI MA, 1986, ANN SURG, V203, P605, DOI 10.1097/00000658-198606000-00004; MARTIN FM, 1989, ARCH SURG-CHICAGO, V124, P571; MOORE EE, 1981, J TRAUMA, V21, P439; MOORE EE, 1990, J TRAUMA, V30, P1427, DOI 10.1097/00005373-199011000-00035; OLSEN WR, 1973, J TRAUMA, V13, P200, DOI 10.1097/00005373-197303000-00003; PACHTER HL, 1979, SURGERY, V85, P166; PACHTER HL, 1989, J TRAUMA, V29, P1352, DOI 10.1097/00005373-198910000-00010; PEDERZOLI P, 1986, SURG GYNECOL OBSTET, V163, P428; PEITZMAN AB, 1986, J TRAUMA, V26, P585, DOI 10.1097/00005373-198607000-00001; PRINZ RA, 1988, AM J SURG, V155, P36, DOI 10.1016/S0002-9610(88)80255-1; ROBEY E, 1982, ANN SURG, V196, P695, DOI 10.1097/00000658-198212001-00014; SCOTTCONNER CEH, 1989, SURG GYNECOL OBSTET, V168, P451; SIMS EH, 1984, J TRAUMA, V24, P125, DOI 10.1097/00005373-198402000-00006; SMEGO DR, 1985, J TRAUMA, V25, P771, DOI 10.1097/00005373-198508000-00007; STEELE M, 1973, ARCH SURG-CHICAGO, V106, P544; STONE HH, 1981, J TRAUMA, V21, P257, DOI 10.1097/00005373-198104000-00001; TAXIER M, 1980, SURG GYNECOL OBSTET, V150, P65; WALTERS RL, 1966, AM J SURG, V111, P364, DOI 10.1016/S0002-9610(66)80013-2; WISNER DH, 1990, ARCH SURG-CHICAGO, V125, P1109	48	114	120	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1991	31	12					1600	1606		10.1097/00005373-199112000-00006			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	GW885	WOS:A1991GW88500006	1749029				2021-06-18	
J	Jha, MK; Lee, WH; Suk, K				Jha, Mithilesh Kumar; Lee, Won-Ha; Suk, Kyoungho			Functional polarization of neuroglia: Implications in neuroinflammation and neurological disorders	BIOCHEMICAL PHARMACOLOGY			English	Article						Central nervous system; Neuroglia; Functional polarization; Neuroinflammation; Neurological disorders	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SATELLITE GLIAL-CELLS; DORSAL-ROOT GANGLIA; RHO-KINASE INHIBITOR; FACTOR-KAPPA-B; CHONDROITIN SULFATE PROTEOGLYCANS; CRITICAL TRANSCRIPTION FACTOR; PERIPHERAL-NERVE INJURY; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE	Recent neuroscience research has established the adult brain as a dynamic organ having a unique ability to undergo changes with time. Neuroglia, especially microglia and astrocytes, provide dynamicity to the brain. Activation of these glial cells is a major component of the neuroinflammatory responses underlying brain injury and neurodegeneration. Glial cells execute functional reaction programs in response to diverse microenvironmental signals manifested by neuropathological conditions. Activated microglia exist along a continuum of two functional states of polarization namely M1-type (classical/proinflammatory activation) and M2-type (alternative/anti-inflammatory activation) as in macrophages. The balance between classically and alternatively activated microglial phenotypes influences disease progression in the CNS. The classically activated state of microglia drives the neuroinflammatory response and mediates the detrimental effects on neurons, whereas in their alternative activation state, which is apparently a beneficial activation state, the microglia play a crucial role in tissue maintenance and repair. Likewise, in response to immune or inflammatory microenvironments astrocytes also adopt neurotoxic or neuroprotective phenotypes. Reactive astrocytes exhibit two distinctive functional phenotypes defined by pro- or anti-inflammatory gene expression profile. In this review, we have thoroughly covered recent advances in the understanding of the functional polarization of brain and peripheral glia and its implications in neuroinflammation and neurological disorders. The identifiable phenotypes adopted by neuroglia in response to specific insult or injury can be exploited as promising diagnostic markers of neuroinflammatory diseases. Furthermore, harnessing the beneficial effects of the polarized glia could undoubtedly pave the way for the formulation of novel glia-based therapeutic strategies for diverse neurological disorders. (C) 2015 Elsevier Inc. All rights reserved.	[Jha, Mithilesh Kumar; Suk, Kyoungho] Kyungpook Natl Univ, Brain Sci & Engn Inst, Dept Pharmacol, Plus KNU Biomed Convergence Program BK21, Daegu, South Korea; [Lee, Won-Ha] Kyungpook Natl Univ, Plus KNU Creat BioRes Grp BK21, Sch Life Sci, Daegu, South Korea	Suk, K (corresponding author), Kyungpook Natl Univ, Dept Pharmacol, Sch Med, 680 Gukchaebosang St, Daegu 700422, South Korea.	ksuk@knu.ac.kr		Jha, Mithilesh Kumar/0000-0002-9526-0053; Suk, Kyoungho/0000-0002-9555-4203	Korea Healthcare Technology RAMP;D Project, Ministry of Health AMP; Welfare, Republic of Korea [A111345, HI140331]; Basic Science Research Program through the National Research Foundation (NRF) - Korean Ministry of Education, Science, and Technology (MEST) [2008-0062282]	We apologize to those authors whose works are not cited owing to space constraints. This work was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111345, HI140331). This work was also supported by the Basic Science Research Program through the National Research Foundation (NRF) funded by the Korean Ministry of Education, Science, and Technology (MEST) (2008-0062282).	Ajmone-Cat MA, 2013, GLIA, V61, P1698, DOI 10.1002/glia.22550; Ambrosini E, 2003, GLIA, V41, P290, DOI 10.1002/glia.10193; Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Armati PJ, 2014, J PERIPHER NERV SYST, V19, P14, DOI 10.1111/jns5.12057; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Austin PJ, 2012, PAIN, V153, P1916, DOI 10.1016/j.pain.2012.06.005; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Baker BJ, 2009, TRENDS IMMUNOL, V30, P392, DOI 10.1016/j.it.2009.07.001; Barakat R., 2015, MED PRINC P IN PRESS; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; Blumenthal NR, 2014, P NATL ACAD SCI USA, V111, P16124, DOI 10.1073/pnas.1412740111; Bohacek I, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-191; Bolanos JP, 2010, TRENDS BIOCHEM SCI, V35, P145, DOI 10.1016/j.tibs.2009.10.006; Boumezbeur F, 2010, J CEREBR BLOOD F MET, V30, P211, DOI 10.1038/jcbfm.2009.197; Brambilla R, 2009, J IMMUNOL, V182, P2628, DOI 10.4049/jimmunol.0802954; Bramow S, 2010, BRAIN, V133, P2983, DOI 10.1093/brain/awq250; Bremer M, 2011, GLIA, V59, P1022, DOI 10.1002/glia.21173; Brifault C, 2015, STROKE, V46, P520, DOI 10.1161/STROKEAHA.114.006864; Burda J. E., 2015, EXP NEUROL IN PRESS; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044; Campuzano O, 2009, J NEUROSCI RES, V87, P2484, DOI 10.1002/jnr.22074; Cantarella G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.286; Carpentier PA, 2008, BRAIN BEHAV IMMUN, V22, P140, DOI 10.1016/j.bbi.2007.08.011; Chen C, 2014, ACTA PHARMACOL SIN, V35, P1428, DOI 10.1038/aps.2014.68; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Cohan CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124918; Criste G, 2014, HAND CLINIC, V122, P101, DOI 10.1016/B978-0-444-52001-2.00005-4; Cuevas CD, 2014, J VIROL, V88, P7703, DOI 10.1128/JVI.00050-14; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Delgado M, 2001, J BIOL CHEM, V276, P369, DOI 10.1074/jbc.M006923200; Dienel GA, 2001, J NEUROSCI RES, V66, P824, DOI 10.1002/jnr.10079; Dilger RN, 2008, J LEUKOCYTE BIOL, V84, P932, DOI 10.1189/jlb.0208108; Donega V, 2014, EXP NEUROL, V261, P53, DOI 10.1016/j.expneurol.2014.06.009; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Doring Axinia, 2011, Front Biosci (Schol Ed), V3, P846; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Dubovy P, 2013, INT REV NEUROBIOL, V108, P173, DOI 10.1016/B978-0-12-410499-0.00007-1; Ellert-Miklaszewska A, 2013, GLIA, V61, P1178, DOI 10.1002/glia.22510; Emmrich JV, 2013, FEBS J, V280, P5030, DOI 10.1111/febs.12401; Endo F, 2015, CELL REP, V11, P592, DOI 10.1016/j.celrep.2015.03.053; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fledrich R, 2014, NAT MED, V20, P1055, DOI 10.1038/nm.3664; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Fraussen J, 2014, AUTOIMMUN REV, V13, P1126, DOI 10.1016/j.autrev.2014.07.002; Fruhbeis C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00182; Fruhbeis C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00119; Gabrielli M, 2015, EMBO REP, V16, P213, DOI 10.15252/embr.201439668; Gaire BP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120203; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; Galvan-Pena S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00420; Gao C, 2013, NEUROIMMUNOMODULAT, V20, P334, DOI 10.1159/000353568; Garidou L, 2004, J IMMUNOL, V173, P2435, DOI 10.4049/jimmunol.173.4.2435; Gibbons HM, 2011, NEUROBIOL DIS, V41, P96, DOI 10.1016/j.nbd.2010.08.024; Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531; Goldmann T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/208093; Goncalves NP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0177-8; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graff JW, 2012, J BIOL CHEM, V287, P21816, DOI 10.1074/jbc.M111.327031; Gregori N, 2002, J NEUROSCI, V22, P248, DOI 10.1523/JNEUROSCI.22-01-00248.2002; Groh J, 2015, GLIA, V63, P977, DOI 10.1002/glia.22796; Gu WL, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-128; Gundersen GA, 2014, BRAIN STRUCT FUNCT, V219, P2181, DOI 10.1007/s00429-013-0629-0; Han MS, 2013, SCIENCE, V339, P218, DOI 10.1126/science.1227568; Hanani M, 2005, BRAIN RES REV, V48, P457, DOI 10.1016/j.brainresrev.2004.09.001; Hanani M, 2002, NEUROSCIENCE, V114, P279, DOI 10.1016/S0306-4522(02)00279-8; Hanani M, 2014, J CELL MOL MED, V18, P2367, DOI 10.1111/jcmm.12406; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harish G, 2015, J NEUROCHEM, V134, P156, DOI 10.1111/jnc.13082; Hashioka S, 2015, CNS NEUROL DISORD-DR, V14, P251, DOI 10.2174/1871527314666150217122305; Hayakawa K, 2014, J NEUROSCI RES, V92, P1647, DOI 10.1002/jnr.23448; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Herrera AJ, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3382/fncel.2015.00312, 10.3389/fncel.2015.00312]; Herrera J, 2001, EXP NEUROL, V171, P11, DOI 10.1006/exnr.2001.7729; Horiuchi M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-227; Horner PJ, 2000, J NEUROSCI, V20, P2218; Hosokawa Y, 2013, CELL IMMUNOL, V283, P8, DOI 10.1016/j.cellimm.2013.05.005; Hsiao HY, 2013, HUM MOL GENET, V22, P1826, DOI 10.1093/hmg/ddt036; Hu F, 2015, NEURO-ONCOLOGY, V17, P200, DOI 10.1093/neuonc/nou324; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2014, PROG NEUROBIOL, V119, P60, DOI 10.1016/j.pneurobio.2014.06.002; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Hua LWL, 2002, J NEUROCHEM, V83, P1120, DOI 10.1046/j.1471-4159.2002.01226.x; Jack C, 2005, J NEUROSCI RES, V81, P363, DOI 10.1002/jnr.20482; Jang E, 2013, J IMMUNOL, V191, P5204, DOI 10.4049/jimmunol.1301637; Jang E, 2013, FASEB J, V27, P1176, DOI 10.1096/fj.12-222257; Janssens K, 2015, GLIA, V63, P1729, DOI 10.1002/glia.22840; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Jha MK, 2015, J NEUROSCI, V35, P14353, DOI 10.1523/JNEUROSCI.1910-15.2015; Jha MK, 2015, NEUROSCI BIOBEHAV R, V49, P135, DOI 10.1016/j.neubiorev.2014.12.006; Jiang TY, 2013, AGING CELL, V12, P1021, DOI 10.1111/acel.12127; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Joshi P, 2015, INT J MOL SCI, V16, P4800, DOI 10.3390/ijms16034800; Jukkola P, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-70; Kang SS, 2012, J NEUROSCI, V32, P9277, DOI 10.1523/JNEUROSCI.1746-12.2012; Karve I. P., 2015, BR J PHARM IN PRESS; Kawabori M, 2015, J NEUROSCI, V35, P3384, DOI 10.1523/JNEUROSCI.2620-14.2015; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kimelberg HK, 2010, NEUROTHERAPEUTICS, V7, P338, DOI 10.1016/j.nurt.2010.07.006; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klein D, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0267-y; Klein D, 2014, GLIA, V62, P736, DOI 10.1002/glia.22638; Kobayashi M, 2015, GLIA, V63, P1073, DOI 10.1002/glia.22802; Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005; Kopatz J, 2013, GLIA, V61, P1122, DOI 10.1002/glia.22501; Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990; Lampron A, 2013, NEURON, V78, P214, DOI 10.1016/j.neuron.2013.04.005; Lanier LL, 2009, IMMUNOL REV, V227, P150, DOI 10.1111/j.1600-065X.2008.00720.x; LeComte MD, 2015, P NATL ACAD SCI USA, V112, P8726, DOI 10.1073/pnas.1501029112; Lees JG, 2015, CYTOKINE, V71, P207, DOI 10.1016/j.cyto.2014.10.028; Li R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094320; Li WC, 2013, INT J NEUROSCI, V123, P240, DOI 10.3109/00207454.2012.755181; Li YH, 2014, IMMUNOLOGY, V143, P219, DOI 10.1111/imm.12303; Lindner M, 2015, BRAIN, V138, P1875, DOI 10.1093/brain/awv102; Lisi L, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-125; Lisi L, 2014, ASN NEURO, V6, DOI 10.1042/AN20130045; Liston A, 2009, J IMMUNOL, V182, P3121, DOI 10.4049/jimmunol.0713169; Liu SM, 2015, PURINERG SIGNAL, V11, P161, DOI 10.1007/s11302-014-9439-y; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Lunde LK, 2015, BRAIN STRUCT FUNCT, V220, P2087, DOI 10.1007/s00429-014-0775-z; Ma ZF, 2014, INT J NEUROSCI, V124, P824, DOI 10.3109/00207454.2014.884088; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Magistretti PJ, 2011, EXP PHYSIOL, V96, P407, DOI 10.1113/expphysiol.2010.053157; Mallard C, 2015, STROKE, V46, P3006, DOI 10.1161/STROKEAHA.115.007776; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martini R, 2016, GLIA, V64, P475, DOI 10.1002/glia.22899; Martini R, 2013, AM J PATHOL, V183, P655, DOI 10.1016/j.ajpath.2013.06.002; Masuda T, 2012, CELL REP, V1, P334, DOI 10.1016/j.celrep.2012.02.014; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; Mayo L, 2014, NAT MED, V20, P1147, DOI 10.1038/nm.3681; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Meares GP, 2012, GLIA, V60, P771, DOI 10.1002/glia.22307; Mehan S, 2011, J MOL NEUROSCI, V43, P376, DOI 10.1007/s12031-010-9454-6; Mensah-Brown EP, 2011, J NEUROIMMUNOL, V232, P68, DOI 10.1016/j.jneuroim.2010.10.010; Mesci P, 2015, BRAIN, V138, P53, DOI 10.1093/brain/awu312; Mietto BS, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/251204; Millward JM, 2007, J IMMUNOL, V178, P8175, DOI 10.4049/jimmunol.178.12.8175; Min H, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0116-z; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Neher JJ, 2013, P NATL ACAD SCI USA, V110, pE4098, DOI 10.1073/pnas.1308679110; Ni JS, 2015, BRAIN BEHAV IMMUN, V49, P75, DOI 10.1016/j.bbi.2015.04.014; Nijaguna MB, 2015, J BIOL CHEM, V290, P23401, DOI 10.1074/jbc.M115.664037; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Ohara PT, 2009, NEUROSCIENTIST, V15, P450, DOI 10.1177/1073858409336094; Ohtori S, 2004, SPINE, V29, P1082, DOI 10.1097/00007632-200405150-00006; Orihuela R, 2015, BR J PHARM, DOI 10.1111/bph.13139; Pan LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099526; Parmar J, 2015, INT J DEV NEUROSCI, V43, P35, DOI 10.1016/j.ijdevneu.2015.03.010; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Patel JR, 2010, P NATL ACAD SCI USA, V107, P11062, DOI 10.1073/pnas.1006301107; Peferoen L, 2014, IMMUNOLOGY, V141, P302, DOI 10.1111/imm.12163; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Perera CJ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0253-4; Politis M, 2012, NEUROLOGY, V79, P523, DOI 10.1212/WNL.0b013e3182635645; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Popiolek-Barczyk K, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/676473; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Porrini V, 2015, NEUROSCIENCE, V302, P112, DOI 10.1016/j.neuroscience.2014.10.029; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; Przanowski P, 2014, J MOL MED, V92, P239, DOI 10.1007/s00109-013-1090-5; Qian L, 2012, J NEUROL, V259, P2111, DOI 10.1007/s00415-012-6465-y; Quattromani MJ, 2014, NEUROBIOL DIS, V66, P66, DOI 10.1016/j.nbd.2014.02.010; Rajendran L, 2014, J NEUROSCI, V34, P15482, DOI 10.1523/JNEUROSCI.3258-14.2014; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; Rodriguez JJ, 2011, MOL NEUROBIOL, V43, P87, DOI 10.1007/s12035-010-8157-x; Ruffell D, 2009, P NATL ACAD SCI USA, V106, P17475, DOI 10.1073/pnas.0908641106; Rusnakova V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069734; Salem M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-181; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Satoh T, 2010, NAT IMMUNOL, V11, P936, DOI 10.1038/ni.1920; Schlegelmilch T, 2011, CURR OPIN NEUROBIOL, V21, P5, DOI 10.1016/j.conb.2010.08.004; Seifert HA, 2014, TRANSL STROKE RES, V5, P543, DOI 10.1007/s12975-014-0349-7; Shin JY, 2005, J CELL BIOL, V171, P1001, DOI 10.1083/jcb.200508072; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sielska M, 2013, J PATHOL, V230, P310, DOI 10.1002/path.4192; Singh S, 2013, ACTA NEUROPATHOL, V125, P595, DOI 10.1007/s00401-013-1082-0; Smith AM, 2014, TRENDS NEUROSCI, V37, P125, DOI 10.1016/j.tins.2013.12.001; Smith AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080463; Smith AM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-85; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song DD, 2014, AM J PHYSIOL-GASTR L, V306, pG788, DOI 10.1152/ajpgi.00318.2013; Stevens SL, 2011, J NEUROSCI, V31, P8456, DOI 10.1523/JNEUROSCI.0821-11.2011; Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319; Streit WJ, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0142-6; Streit WJ, 2014, CURR OPIN IMMUNOL, V29, P93, DOI 10.1016/j.coi.2014.05.005; Streit WJ, 2013, CNS NEUROL DISORD-DR, V12, P763, DOI 10.2174/18715273113126660176; Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5; Suenaga J, 2015, EXP NEUROL, V272, P109, DOI 10.1016/j.expneurol.2015.03.021; Suh HS, 2009, CURR TOP MICROBIOL, V336, P63, DOI 10.1007/978-3-642-00549-7_4; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Szulzewsky F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116644; Takeda M, 2009, NEUROSCI BIOBEHAV R, V33, P784, DOI 10.1016/j.neubiorev.2008.12.005; Tanaka T, 2015, GLIA, V63, P595, DOI 10.1002/glia.22770; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Tannahill GM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00106; Tarassishin L, 2011, GLIA, V59, P1911, DOI 10.1002/glia.21233; Theodosis DT, 2008, PHYSIOL REV, V88, P983, DOI 10.1152/physrev.00036.2007; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; Trebst C, 2008, MULT SCLER, V14, P728, DOI 10.1177/1352458508089359; Turola E, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00149; Umschweif G, 2013, J CEREBR BLOOD F MET, V33, P524, DOI 10.1038/jcbfm.2012.193; van der Valk P, 2009, CURR OPIN NEUROL, V22, P207, DOI 10.1097/WCO.0b013e32832b4c76; Varin A, 2009, IMMUNOBIOLOGY, V214, P630, DOI 10.1016/j.imbio.2008.11.009; VESIN MF, 1995, J NEUROSCI, V15, P470; Vexler ZS, 2009, DEV NEUROSCI-BASEL, V31, P378, DOI 10.1159/000232556; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang JM, 2013, J CEREBR BLOOD F MET, V33, P1574, DOI 10.1038/jcbfm.2013.111; Wang X, 2012, TOXICOL SCI, V127, P412, DOI 10.1093/toxsci/kfs106; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Warwick RA, 2013, EUR J PAIN, V17, P571, DOI 10.1002/j.1532-2149.2012.00219.x; Weinstein JR, 2010, FUTUR NEUROL, V5, P227, DOI 10.2217/FNL.10.1; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Xanthos DN, 2014, NAT REV NEUROSCI, V15, P43, DOI 10.1038/nrn3617; Xiao BG, 1998, J NEUROL SCI, V157, P1, DOI 10.1016/S0022-510X(98)00049-5; Xu HX, 2012, NAT IMMUNOL, V13, P642, DOI 10.1038/ni.2304; Yang QW, 2011, J CEREBR BLOOD F MET, V31, P593, DOI 10.1038/jcbfm.2010.129; Ydens E, 2013, NEUROBIOL DIS, V55, P95, DOI 10.1016/j.nbd.2013.03.005; Yin F, 2013, BIOCHEM SOC T, V41, P101, DOI 10.1042/BST20120260; Yong V Wee, 2010, Rinsho Shinkeigaku, V50, P869; Yu ZW, 2015, J NEUROSCI, V35, P6350, DOI 10.1523/JNEUROSCI.2468-14.2015; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zeiner PS, 2015, BRAIN PATHOL, V25, P491, DOI 10.1111/bpa.12194; Zhang G, 2013, NATURE, V497, P211, DOI 10.1038/nature12143; Zhang Q., 2014, MOL NEUROBIOL; Zhao XR, 2015, J NEUROSCI, V35, P11281, DOI 10.1523/JNEUROSCI.1685-15.2015; Zhao YF, 2015, J MOL NEUROSCI, V55, P725, DOI 10.1007/s12031-014-0411-7; Zhong L, 2015, J BIOL CHEM, V290, P15866, DOI 10.1074/jbc.M115.645986; Zong H, 2012, EXPERT REV MOL DIAGN, V12, P383, DOI [10.1586/ERM.12.30, 10.1586/erm.12.30]	242	113	119	7	82	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952	1873-2968		BIOCHEM PHARMACOL	Biochem. Pharmacol.	MAR 1	2016	103						1	16		10.1016/j.bcp.2015.11.003			16	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DH5UW	WOS:000372858600001	26556658		Y	N	2021-06-18	
J	Corwin, DJ; Zonfrillo, MR; Master, CL; Arbogast, KB; Grady, MF; Robinson, RL; Goodman, AM; Wiebe, DJ				Corwin, Daniel J.; Zonfrillo, Mark R.; Master, Christina L.; Arbogast, Kristy B.; Grady, Matthew F.; Robinson, Roni L.; Goodman, Arlene M.; Wiebe, Douglas J.			Characteristics of Prolonged Concussion Recovery in a Pediatric Subspecialty Referral Population	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; 3RD INTERNATIONAL-CONFERENCE; HIGH-SCHOOL; CONSENSUS STATEMENT; SPORTS CONCUSSION; POSTTRAUMATIC MIGRAINE; SYMPTOMS; ZURICH; CONVERGENCE; PREDICTORS	Objective To identify pre-existing characteristics associated with prolonged recovery from concussion in a sample of patients referred to a pediatric sports medicine clinic. Study design This was a retrospective, exploratory cohort study of 247 patients age 5-18 years with concussion referred to a tertiary pediatric hospital-affiliated sports medicine clinic from July 1, 2010, through December 31, 2011. A random sample of all eligible patient visits (3740) was chosen for further review and abstraction. Statistical comparisons between subsets of patients were conducted using exact x(2) tests, logistic regression, quantile regression, and Kaplan-Meier survival curves. Results The median time until returning to school part-time was 12 days (IQR 6-21); until returning to school full-time without accommodations was 35 days (IQR 11-105); until becoming symptom-free was 64 days (IQR 18-119); and until being fully cleared to return to sports was 75 days (IQR 30-153). Furthermore, 73% of all patients were symptomatic for >4 weeks, 73% were prescribed some form of school accommodation, and 61% reported a decline in grades. Characteristics associated with a prolonged recovery included a history of depression or anxiety; an initial complaint of dizziness; abnormal convergence or symptom provocation following oculomotor examination on physical examination; and history of prior concussion. Conclusions Pediatric and adolescent patients with concussion may experience cognitive and emotional morbidity that can last for several months following injury. Clinicians should consider specific pre-existing characteristics and presenting symptoms that may be associated with a more complicated recovery for concussion patients.	[Corwin, Daniel J.; Zonfrillo, Mark R.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Wiebe, Douglas J.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Master, Christina L.; Arbogast, Kristy B.; Grady, Matthew F.; Wiebe, Douglas J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Master, Christina L.; Grady, Matthew F.; Robinson, Roni L.; Goodman, Arlene M.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA	Corwin, DJ (corresponding author), Childrens Hosp Philadelphia, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	corwind@email.chop.edu	Meijer, Anna/K-5118-2016; Zonfrillo, Mark R./H-9403-2017; Wiebe, Douglas J/Q-1168-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Arbogast, Kristy/0000-0002-1694-4562; Master, Christina/0000-0002-6717-4270	Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000003]; Children's Hospital of Philadelphia Clinical Translational Sciences Award; Comparative Effectiveness Program; Eunice Kennedy Shriver National Institute of Child HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Human Development [K08HD073241]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000003] Funding Source: NIH RePORTER	Supported by The Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative, the National Institutes of Health, National Center for Advancing Translational Sciences (UL1TR000003 for the University of Pennsylvania Health System), the Children's Hospital of Philadelphia Clinical Translational Sciences Award and Research Institute funding for the Comparative Effectiveness Program), and the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (K08HD073241 [to M.Z.]). The authors declare no conflicts of interest.	Atabaki SM, 2013, PEDIATR CLIN N AM, V60, P1107, DOI 10.1016/j.pcl.2013.06.001; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bade A, 2013, OPTOMETRY VISION SCI, V90, P988, DOI 10.1097/OPX.0000000000000012; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chamberlain G, 1994, ADV EC WORLD C, V2, P171, DOI DOI 10.1017/CCOL0521444594.005; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lavrich JB, 2010, CURR OPIN OPHTHALMOL, V21, P356, DOI 10.1097/ICU.0b013e32833cf03a; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2014, ANN INTERN MED, V160, DOI 10.7326/0003-4819-160-3-201402040-01002; Master CL, 2012, PEDIATR ANN, V41, pE174, DOI 10.3928/00904481-20120827-08; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Piland SG, 2003, J ATHL TRAINING, V38, P104; Preece MHW, 2007, BRAIN INJURY, V21, P951, DOI 10.1080/02699050701481647; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P123; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Scheiman M, 2011, OPTOMETRY VISION SCI, V88, P1343, DOI 10.1097/OPX.0b013e31822f4d7c; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thiagarajan P, 2013, OPTOMETRY VISION SCI, V90, P57, DOI 10.1097/OPX.0b013e31827a233e	50	113	113	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	DEC	2014	165	6					1207	1215		10.1016/j.jpeds.2014.08.034			9	Pediatrics	Pediatrics	AU3PS	WOS:000345526500028	25262302	Green Accepted			2021-06-18	
J	Collins, CL; Fletcher, EN; Fields, SK; Kluchurosky, L; Rohrkemper, MK; Comstock, RD; Cantu, RC				Collins, Christy L.; Fletcher, Erica N.; Fields, Sarah K.; Kluchurosky, Lisa; Rohrkemper, Mary Kay; Comstock, R. Dawn; Cantu, Robert C.			Neck Strength: A Protective Factor Reducing Risk for Concussion in High School Sports	JOURNAL OF PRIMARY PREVENTION			English	Article						Head injury; Prevention; Athlete; Soccer; Basketball; Lacrosse	SEGMENT DYNAMIC STABILIZATION; SEX-DIFFERENCES; UNITED-STATES; HEAD ACCELERATION; INJURIES; MANAGEMENT; RECOVERY; FOOTBALL; DISEASE; HEALTH	As the number of high school students participating in athletics continues to increase, so will the number of sports-related concussions unless effective concussion prevention programs are developed. We sought to develop and validate a cost-effective tool to measure neck strength in a high school setting, conduct a feasibility study to determine if the developed tool could be reliably applied by certified athletic trainers (ATs) in a high school setting, and conduct a pilot study to determine if anthropometric measurements captured by ATs can predict concussion risk. In the study's first phase, 16 adult subjects underwent repeated neck strength testing by a group of five ATs to validate the developed hand-held tension scale, a cost effective alternative to a hand-held dynamometer. In the second phase, during the 2010 and 2011 academic years, ATs from 51 high schools in 25 states captured pre-season anthropometric measurements for 6,704 high school athletes in boys' and girls' soccer, basketball, and lacrosse, as well as reported concussion incidence and athletic exposure data. We found high correlations between neck strength measurements taken with the developed tool and a hand-held dynamometer and the measurements taken by five ATs. Smaller mean neck circumference, smaller mean neck to head circumference ratio, and weaker mean overall neck strength were significantly associated with concussion. Overall neck strength (p < 0.001), gender (p < 0.001), and sport (p = 0.007) were significant predictors of concussions in unadjusted models. After adjusting for gender and sport, overall neck strength remained a significant predictor of concussion (p = 0.004). For every one pound increase in neck strength, odds of concussion decreased by 5 % (OR = 0.95, 95 % CI 0.92-0.98). We conclude that identifying differences in overall neck strength may be useful in developing a screening tool to determine which high school athletes are at higher risk of concussion. Once identified, these athletes could be targeted for concussion prevention programs.	[Collins, Christy L.; Fletcher, Erica N.] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH USA; [Fields, Sarah K.] Univ Colorado, Dept Commun, Denver, CO 80202 USA; [Kluchurosky, Lisa] Nationwide Childrens Hosp, Columbus, OH USA; [Rohrkemper, Mary Kay] Cent Ohio Primary Care, Columbus, OH USA; [Comstock, R. Dawn] Colorado Sch Publ Hlth, Dept Epidemiol, Pediat Injury Prevent Educ & Res PIPER Program, Aurora, CO 80045 USA; [Comstock, R. Dawn] Univ Colorado, Sch Med, Aurora, CO USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurol, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Cantu, Robert C.] Sports Legacy Inst, Waltham, MA USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Surg, Concord, MA USA; [Cantu, Robert C.] Brigham & Womens Hosp, Dept Neurosurg, Neurol Sports Injury Ctr, Boston, MA 02115 USA	Comstock, RD (corresponding author), Colorado Sch Publ Hlth, Dept Epidemiol, Pediat Injury Prevent Educ & Res PIPER Program, Aurora, CO 80045 USA.	dawn.comstock@ucdenver.edu					Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Conley MS, 1997, J APPL PHYSIOL, V83, P2105; Cross KM, 2003, CLIN SPORT MED, V22, P639, DOI 10.1016/S0278-5919(02)00099-6; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dietz WH, 1998, PEDIATRICS, V101, P518; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Mansell J, 2005, J ATHL TRAINING, V40, P310; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; National Federation of State High School Associations, 2012, 2011 2012 HIGH SCH A; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Patel Dilip R, 2002, Adolesc Med, V13, P569; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Prasad D S, 2009, Indian J Med Sci, V63, P33; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Salmon DM, 2011, AVIAT SPACE ENVIR MD, V82, P978, DOI 10.3357/ASEM.2841.2011; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0	27	113	113	2	75	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0278-095X	1573-6547		J PRIM PREV	J. Prim. Prev.	OCT	2014	35	5					309	319		10.1007/s10935-014-0355-2			11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	AO8UX	WOS:000341631600002	24930131				2021-06-18	
J	Guggenmos, DJ; Azin, M; Barbay, S; Mahnken, JD; Dunham, C; Mohseni, P; Nudo, RJ				Guggenmos, David J.; Azin, Meysam; Barbay, Scott; Mahnken, Jonathan D.; Dunham, Caleb; Mohseni, Pedram; Nudo, Randolph J.			Restoration of function after brain damage using a neural prosthesis	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						brain-machine-brain interface; neural plasticity; traumatic brain injury; closed-loop; long-term potentiation	LONG-TERM POTENTIATION; MOTOR CORTEX; CORTICAL STIMULATION; ELECTRICAL-STIMULATION; SENSORIMOTOR CORTEX; PLASTICITY; RECOVERY; STROKE; INJURY; NEOCORTEX	Neural interface systems are becoming increasingly more feasible for brain repair strategies. This paper tests the hypothesis that recovery after brain injury can be facilitated by a neural prosthesis serving as a communication link between distant locations in the cerebral cortex. The primary motor area in the cerebral cortex was injured in a rat model of focal brain injury, disrupting communication between motor and somatosensory areas and resulting in impaired reaching and grasping abilities. After implantation of microelectrodes in cerebral cortex, a neural prosthesis discriminated action potentials (spikes) in premotor cortex that triggered electrical stimulation in somatosensory cortex continuously over subsequent weeks. Within 1 wk, while receiving spike-triggered stimulation, rats showed substantially improved reaching and grasping functions that were indistinguishable from prelesion levels by 2 wk. Post hoc analysis of the spikes evoked by the stimulation provides compelling evidence that the neural prosthesis enhanced functional connectivity between the two target areas. This proof-of-concept study demonstrates that neural interface systems can be used effectively to bridge damaged neural pathways functionally and promote recovery after brain injury.	[Guggenmos, David J.; Barbay, Scott; Dunham, Caleb; Nudo, Randolph J.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Mahnken, Jonathan D.] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66160 USA; [Guggenmos, David J.; Barbay, Scott; Dunham, Caleb; Nudo, Randolph J.] Univ Kansas, Med Ctr, Landon Ctr Aging, Kansas City, KS 66160 USA; [Azin, Meysam; Mohseni, Pedram] Case Western Reserve Univ, Dept Elect Engn & Comp Sci, Cleveland, OH 44106 USA	Nudo, RJ (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA.	rnudo@kumc.edu			Department of Defense Traumatic Brain Injury-Investigator-Initiated Research Award Program [W81XWH-10-1-0741/0742]; American Heart AssociationAmerican Heart Association [09BGIA2280495]; Advanced Platform Technology Center-A Veterans Affairs Research Center of Excellence (Cleveland, OH)	The authors thank Andrea Pack and Alexandra Brown for technical assistance, Cam Teskey for invaluable comments on the discussion, and Casey Wood for artistic contributions. This research was funded by the Department of Defense Traumatic Brain Injury-Investigator-Initiated Research Award Program under Awards W81XWH-10-1-0741/0742 (to P. M. and R.J.N.) and the American Heart Association under Award 09BGIA2280495 (to P. M.). The fabrication costs for the chip in the microdevice were generously supported by the Advanced Platform Technology Center-A Veterans Affairs Research Center of Excellence (Cleveland, OH).	Adkins DL, 2008, EXP NEUROL, V212, P14, DOI 10.1016/j.expneurol.2008.01.031; Adkins-Muir DL, 2003, NEUROL RES, V25, P780, DOI 10.1179/016164103771953853; Azin M, 2011, IEEE T BIO-MED ENG, V58, P2589, DOI 10.1109/TBME.2011.2159603; Azin M, 2011, IEEE J SOLID-ST CIRC, V46, P731, DOI 10.1109/JSSC.2011.2108770; Baba T, 2009, STROKE, V40, pE598, DOI 10.1161/STROKEAHA.109.563627; Berger TW, 2012, IEEE T NEUR SYS REH, V20, P198, DOI 10.1109/TNSRE.2012.2189133; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Carter AR, 2012, NEUROIMAGE, V62, P2271, DOI 10.1016/j.neuroimage.2012.02.070; Catani M, 2008, CORTEX, V44, P911, DOI 10.1016/j.cortex.2008.05.001; Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, GUIDE CARE USE LAB A; Conner JM, 2005, NEURON, V46, P173, DOI 10.1016/j.neuron.2005.03.003; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Edwardson MA, 2013, EXP BRAIN RES, V224, P335, DOI 10.1007/s00221-012-3315-1; Fang PC, 2005, J COMP NEUROL, V490, P305, DOI 10.1002/cne.20665; Feldman DE, 2012, NEURON, V75, P556, DOI 10.1016/j.neuron.2012.08.001; Feldman DE, 2009, ANNU REV NEUROSCI, V32, P33, DOI 10.1146/annurev.neuro.051508.135516; Friel KM, 2005, J NEUROPHYSIOL, V94, P1312, DOI 10.1152/jn.01251.2004; Hawes SL, 2013, J NEUROPHYSIOL, V110, P2027, DOI 10.1152/jn.00115.2013; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Henderson AK, 2012, NEUROSCIENCE, V215, P98, DOI 10.1016/j.neuroscience.2012.04.040; Jackson A, 2006, NATURE, V444, P56, DOI 10.1038/nature05226; Jackson A, 2012, NAT REV NEUROL, V8, P690, DOI 10.1038/nrneurol.2012.219; Jahanshahi A, 2013, EXP BRAIN RES, V231, P165, DOI 10.1007/s00221-013-3680-4; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; McCulloch C.E., 2001, GEN LINEAR MIXED MOD; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Nishimura Y, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00057; Nudo RJ, 2011, J COMMUN DISORD, V44, P515, DOI 10.1016/j.jcomdis.2011.04.004; Nudo RJ, 2009, EVOLUTIONARY NEUROSC, P727; Perez MA, 2009, TOP STROKE REHABIL, V16, P254, DOI 10.1310/tsr1604-254; Plautz EJ, 2003, NEUROL RES, V25, P801, DOI 10.1179/016164103771953880; Plow EB, 2009, STROKE, V40, P1926, DOI 10.1161/STROKEAHA.108.540823; RACINE RJ, 1995, BRAIN RES, V702, P87, DOI 10.1016/0006-8993(95)01025-0; Rebesco JM, 2011, PROG BRAIN RES, V192, P83, DOI 10.1016/B978-0-444-53355-5.00006-3; Rebesco JM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00039; ROUILLER EM, 1993, SOMATOSENS MOT RES, V10, P269, DOI 10.3109/08990229309028837; Santos FJ, 2011, NEURON, V72, P197, DOI 10.1016/j.neuron.2011.10.004; SHATZ CJ, 1992, SCI AM, V267, P61, DOI 10.1038/scientificamerican0992-60; Skarpaas TL, 2009, NEUROTHERAPEUTICS, V6, P238, DOI 10.1016/j.nurt.2009.01.022; Trepel C, 1998, CEREB CORTEX, V8, P719, DOI 10.1093/cercor/8.8.719; Vicente R, 2008, P NATL ACAD SCI USA, V105, P17157, DOI 10.1073/pnas.0809353105; Webster Brian R, 2006, NeuroRx, V3, P474, DOI 10.1016/j.nurx.2006.07.008	42	113	116	0	29	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	DEC 24	2013	110	52					21177	21182		10.1073/pnas.1316885110			6	Multidisciplinary Sciences	Science & Technology - Other Topics	277ZW	WOS:000328858800074	24324155	Green Published, Bronze			2021-06-18	
J	Chen, T; Liu, WB; Chao, XD; Zhang, L; Qu, Y; Huo, JL; Fei, Z				Chen, Tao; Liu, WenBo; Chao, XiaoDong; Zhang, Lei; Qu, Yan; Huo, JunLi; Fei, Zhou			Salvianolic acid B attenuates brain damage and inflammation after traumatic brain injury in mice	BRAIN RESEARCH BULLETIN			English	Article						Salvianolic acid B; Traumatic brain injury; Neuroprotection; Cytokines; Anti-inflammation	CENTRAL-NERVOUS-SYSTEM; DEFICIENT MOUSE AORTA; SMOOTH-MUSCLE-CELLS; CLOSED-HEAD INJURY; TNF-ALPHA; IN-VIVO; CYTOKINE PRODUCTION; ENDOTHELIAL-CELLS; GROWTH-FACTOR; NITRIC-OXIDE	Salvianolic acid B (SalB), a bioactive compound isolated from the Chinese medicinal herb Danshen, has been shown to exert various anti-oxidative and anti-inflammatory activities in in vitro and in vivo studies. Here, we investigated the protective effects of SalB on traumatic brain injury (TBI) in mice. When administered within 2 h after TBI onset, SalB (25 mg/kg) reduced brain edema, lesion volume and motor functional deficits, and improved spatial learning and memory abilities. Moreover, SalB treatment inhibited the neutrophil infiltration and microglial activation at 48 h after TBI. Enzyme-linked immunosorbent assay (ELISA) for brain tissue homogenates was performed at 24 h after TBI to evaluate the expression of inflammation-related cytokines. The results showed that SalB suppressed the expression of pro-inflammatory cytokines TNE-alpha and IL-1 beta, whereas enhanced the expression of anti-inflammatory cytokines IL-10 and TGF-beta 1. All of these findings extended the protective role of SalB in the model of TBI and suggested that these protective effects might be associated with its anti-inflammatory activities. Thus SalB may have therapeutic potential for patients with TBI and perhaps other forms of acute brain injury. (C) 2010 Elsevier Inc. All rights reserved.	[Chen, Tao; Liu, WenBo; Chao, XiaoDong; Zhang, Lei; Qu, Yan; Huo, JunLi; Fei, Zhou] Fourth Mil Med Univ, Dept Neurosurg, Xijing Hosp, Xijing Inst Clin Neurosci, Xian 710032, Shaanxi, Peoples R China	Fei, Z (corresponding author), Fourth Mil Med Univ, Dept Neurosurg, Xijing Hosp, Xijing Inst Clin Neurosci, Xian 710032, Shaanxi, Peoples R China.	zhoufei@fmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30670796, 30930093]	This work was financially supported by the National Natural Science Foundation of China (Nos. 30670796 and 30930093).	Balasingam V, 1996, J NEUROSCI, V16, P2945; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chao X, 2010, BRAIN RES; Chen YH, 2000, ACTA PHARMACOL SIN, V21, P463; Chen YH, 2001, J CELL BIOCHEM, V82, P512, DOI 10.1002/jcb.1176; Chen YL, 2006, J CELL BIOCHEM, V98, P618, DOI 10.1002/jcb.20793; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Imanshahidi M, 2006, PHYTOTHER RES, V20, P427, DOI 10.1002/ptr.1898; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Ji XY, 2000, ACTA PHARMACOL SIN, V21, P1089; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Lin SJ, 2007, J CELL BIOCHEM, V100, P372, DOI 10.1002/jcb.21042; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; Pang L, 2001, STROKE, V32, P544, DOI 10.1161/01.STR.32.2.544; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Tang MK, 2006, BEHAV PHARMACOL, V17, P493, DOI 10.1097/00008877-200609000-00015; Tian JW, 2009, BRAIN RES, V1263, P114, DOI 10.1016/j.brainres.2009.01.034; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Townsend KP, 2005, FASEB J, V19, P1592, DOI 10.1096/fj.04-3620rev; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; Wang SX, 2010, NEUROCHEM RES, V35, P1029, DOI 10.1007/s11064-010-0151-1; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Yu SS, 2010, BRAIN RES, V1308, P167, DOI 10.1016/j.brainres.2009.10.037; Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630; Zhou Z, 2005, J CELL BIOCHEM, V96, P109, DOI 10.1002/jcb.20567	42	113	124	0	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	FEB 1	2011	84	2					163	168		10.1016/j.brainresbull.2010.11.015			6	Neurosciences	Neurosciences & Neurology	733YZ	WOS:000288301700008	21134421				2021-06-18	
J	Meehan, WP; Mannix, R				Meehan, William P., III; Mannix, Rebekah			Pediatric Concussions in United States Emergency Departments in the Years 2002 to 2006	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; COMPUTED-TOMOGRAPHY; HEAD-INJURY; FOOTBALL; MILD; EPIDEMIOLOGY; COLLEGIATE; MANAGEMENT; DISCHARGE	Objectives To estimate the incidence and demographics of concussions in children coming to emergency departments (EDs) in the United States and describe the rates of neuroimaging and follow-up instructions in these patients. Study design This is a cross-sectional study of children 0 to 19 years old diagnosed with concussion from the National Hospital Ambulatory Medical Care Survey. National Hospital Ambulatory Medical Care Survey collects data on approximately 25 000 visits annually to 600 randomly selected hospital emergency and outpatient departments. We examined visits to United States emergency departments between 2002 and 2006. Simple descriptive statistics were used. Results Of the 50 835 pediatric visits in the 5-year sample, 230 observations, representing 144 000 visits annually, were for concussions. Sixty-nine percent of concussion visits were by males. Thirty percent were sports-related. Sixty-nine percent of patients diagnosed with a concussion had head imaging. Twenty-eight percent of patients were discharged without specific instructions to follow-up with an outpatient provider for further treatment. Conclusions Approximately 144 000 pediatric patients present to emergency departments each year with a concussion. Most of these patients undergo computed tomography of the head, and nearly one-third are discharged without specific instructions to follow-up with an outpatient provider for further treatment. (J Pediatr 2010; 157: 889-93).	[Meehan, William P., III] Childrens Hosp, Sports Concuss Clin, Div Sports Med, Dept Orthoped, Boston, MA 02115 USA; [Meehan, William P., III; Mannix, Rebekah] Childrens Hosp, Div Emergency Med, Dept Med, Boston, MA 02115 USA	Meehan, WP (corresponding author), Childrens Hosp, Sports Concuss Clin, Div Sports Med, Dept Orthoped, 319 Longwood Ave, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		NIH through the Children's Hospital Child Health Research Center [K12 HD052896-01A1, T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128, K12HD052896] Funding Source: NIH RePORTER	Supported by the NIH through the Children's Hospital Child Health Research Center Award to R.M. (K12 HD052896-01A1) and T32 Award to W.M. (T32 HD040128-06A1). The authors declare no conflicts of interest.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brody AS, 2007, PEDIATRICS, V120, P677, DOI 10.1542/peds.2007-1910; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Cantu RC, 2009, NEUROSURGERY, V64, P786, DOI 10.1227/01.NEU.0000348539.13887.D3; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; MACMULLAN J, 2007, BOSTON GLOBE    0202; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; MEADOWS B, 2007, PEOPLE MAGAZINE 1008; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; NOWINSKI C, 2007, HEAD GAMES FOOTBALLS; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; SCHWARZ A, 2007, NY TIMES        0915; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0	38	113	113	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	DEC	2010	157	6					889	893		10.1016/j.jpeds.2010.06.040			5	Pediatrics	Pediatrics	681JG	WOS:000284307200007	20708747	Green Accepted			2021-06-18	
J	Honda, M; Tsuruta, R; Kaneko, T; Kasaoka, S; Yagi, T; Todani, M; Fujita, M; Izumi, T; Maekawa, T				Honda, Masahiro; Tsuruta, Ryosuke; Kaneko, Tadashi; Kasaoka, Shunji; Yagi, Takeshi; Todani, Masaki; Fujita, Motoki; Izumi, Tomonori; Maekawa, Tsuyoshi			Serum Glial Fibrillary Acidic Protein Is a Highly Specific Biomarker for Traumatic Brain Injury in Humans Compared With S-100B and Neuron-Specific Enolase	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head computed tomography; Brain-specific biomarker; Predictability	DAMAGE; GFAP; MARKER; S100B; MECHANISMS	Background: Serum glial fibrillary acidic protein (GFAP) is a specific predictor of brain damage and neurologic outcome in patients with traumatic brain injury (TBI). In this study, serum GFAP, S-100B, and neuron-specific enolase (NSE) were compared in the same samples from severe trauma patients to assess their ability to predict abnormalities detectable on head computed tomography (CT). Methods: This study was a retrospective analysis at a single university emergency center. Thirty-four trauma patients were included. Serum samples were collected from the patients for 3 days. Serum GFAP, S-100B, and NSE concentrations were measured with enzyme-linked immunosorbent assays and compared in patients with and without TBI, as evaluated by head CT. Results: Serum GFAP, S-100B, and NSE were significantly higher in the TBI patients than in the non-TBI patients (p < 0.05 for each protein). The receiver operating characteristic curves for TBI were compared for the three biomarkers for 3 days. Serum GFAP on day 1 had the largest area under the receiver operating characteristic curve (0.983), with 88.9% sensitivity and 100% specificity. Conclusions: Serum GFAP has remarkable diagnostic value for TBI, defined by abnormal head CT findings, in prehospital-triaged patients with severe trauma.	[Honda, Masahiro; Tsuruta, Ryosuke; Kaneko, Tadashi; Kasaoka, Shunji; Yagi, Takeshi; Todani, Masaki; Fujita, Motoki; Maekawa, Tsuyoshi] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Yamaguchi, Japan; [Izumi, Tomonori] Yamaguchi Univ, Grad Sch Med, Dept Stress & Bioresponse Med, Yamaguchi, Japan	Kaneko, T (corresponding author), Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, 1-1-1 Minamikogushi Ube, Yamaguchi, Japan.	kaneyui-ygc@umin.ac.jp			Japanese Ministry of Health, Labor, and WelfareMinistry of Health, Labour and Welfare, Japan [19791329]	Supported by the Japanese Ministry of Health, Labor, and Welfare research project grant 19791329.	Altura BM, 1999, ALCOHOL, V19, P119, DOI 10.1016/S0741-8329(99)00025-7; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; MERIC E, J EMERG MED IN PRESS; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Mussack T, 2000, ACT NEUR S, V76, P393; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ribotta MG, 2004, ACTA NEUROCHIR SUPPL, V89, P87; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; Vissers JLM, 2006, CLIN CHIM ACTA, V366, P336, DOI 10.1016/j.cca.2005.11.017; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 2002, ACT NEUR S, V81, P205	22	113	122	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2010	69	1					104	109		10.1097/TA.0b013e3181bbd485			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	627AQ	WOS:000280010600016	20093985				2021-06-18	
J	von Steinbuchel, N; Wilson, L; Gibbons, H; Hawthorne, G; Hofer, S; Schmidt, S; Bullinger, M; Maas, A; Neugebauer, E; Powell, J; von Wild, K; Zitnay, G; Bakx, W; Christensen, AL; Koskinen, S; Formisano, R; Sarajuuri, J; Sasse, N; Truelle, JL				von Steinbuechel, Nicole; Wilson, Lindsay; Gibbons, Henning; Hawthorne, Graeme; Hoefer, Stefan; Schmidt, Silke; Bullinger, Monika; Maas, Andrew; Neugebauer, Edmund; Powell, Jane; von Wild, Klaus; Zitnay, George; Bakx, Wilbert; Christensen, Anne-Lise; Koskinen, Sanna; Formisano, Rita; Sarajuuri, Jaana; Sasse, Nadine; Truelle, Jean-Luc		QOLIBRI Task Force	Quality of Life after Brain Injury (QOLIBRI): Scale Validity and Correlates of Quality of Life	JOURNAL OF NEUROTRAUMA			English	Article						health-related quality of life; multi-national study; outcome instrument; traumatic brain injury	HEAD-INJURY; CLINICAL-TRIALS; SELF-AWARENESS; HEALTH; SATISFACTION; DEPRESSION; DISABILITY; MODERATE; TBI	The QOLIBRI (Quality of Life after Brain Injury) is a novel health-related quality-of-life (HRQoL) instrument specifically developed for traumatic brain injury (TBI). It provides a profile of HRQoL in six domains together with an overall score. Scale validity and factors associated with HRQoL were investigated in a multi-center international study. A total of 795 adults with brain injury were studied from 3 months to 15 years post-injury. The majority of participants (58%) had severe injuries as assessed by 24-h worst Glasgow Coma Scale (GCS) score. Systematic relationships were observed between the QOLIBRI and the Glasgow Outcome Scale-Extended (GOSE), Hospital Anxiety and Depression Scale (HADS), and SF-36. Within each scale patients with disability reported having low HRQoL in two to three times as many areas as those who had made a good recovery. The main correlates of the total QOLIBRI score were emotional state (HADS depression and anxiety), functional status (amount of help needed and outcome on the GOSE), and comorbid health conditions. Together these five variables accounted for 58% of the variance in total QOLIBRI scores. The QOLIBRI is the first tool developed to assess disease-specific HRQoL in brain injury, and it contains novel information not given by other currently available assessments.	[von Steinbuechel, Nicole; Gibbons, Henning; Sasse, Nadine] Univ Gottingen, Dept Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany; [Wilson, Lindsay] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [Hawthorne, Graeme] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Psychiat, Melbourne, Vic, Australia; [Hoefer, Stefan] Med Univ Innsbruck, Dept Med Psychol, Innsbruck, Austria; [Schmidt, Silke] Ernst Moritz Arndt Univ Greifswald, Inst Psychol, Dept Hlth & Prevent, Greifswald, Germany; [Bullinger, Monika] Univ Hosp Eppendorf, Dept Med Psychol, Hamburg, Germany; [Maas, Andrew] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Neugebauer, Edmund] Private Univ Witten Herdecke, IFOM, Cologne, Germany; [Powell, Jane] Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; [von Wild, Klaus] Univ Munster, Clemens Hosp, Dept Neurosurg & Early Neurotraumatol Rehabil, Munster, Germany; [Zitnay, George] Assoc Martha Jefferson Hosp, Charlottesville, VA USA; [Bakx, Wilbert] Maastricht Univ, Maastricht, Netherlands; [Bakx, Wilbert] Hoensbroeck Rehabil Ctr, Hoensbroeck, Netherlands; [Christensen, Anne-Lise] Univ Kopenhagen, Ctr Cognit & Memory, Copenhagen, Denmark; [Christensen, Anne-Lise] Univ Kopenhagen, Ctr Rehabil Brain Injury, Copenhagen, Denmark; [Koskinen, Sanna; Sarajuuri, Jaana] Kapyla Rehabil Ctr, Helsinki, Finland; [Formisano, Rita] Rehabil Hosp, Santa Lucia Fdn, IRCCS, Rome, Italy; [Truelle, Jean-Luc] CHU Raymond Poincare, Serv Med Phys & Readapt, Garches, France	von Steinbuchel, N (corresponding author), Univ Gottingen, Dept Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany.	nvsteinbuechel@med.uni-goettingen.de	Maas, Andrew IR/C-5584-2013; Wilson, Lindsay/A-3659-2009; Hofer, Stefan/B-8393-2008; Hofer, Stefan/N-8253-2019; Wilson, Lindsay/O-8883-2019	Maas, Andrew IR/0000-0003-1612-1264; Wilson, Lindsay/0000-0003-4113-2328; Hofer, Stefan/0000-0002-6128-3687; Hofer, Stefan/0000-0002-6128-3687; Wilson, Lindsay/0000-0003-4113-2328; Koskinen, Sanna/0000-0002-3453-5084			Bampoe J, 2002, NEUROSURG QUART, V12, P132, DOI 10.1097/00013414-200206000-00006; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Chassany O, 2002, DRUG INF J, V36, P209, DOI 10.1177/009286150203600127; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P429, DOI 10.1348/014466501163904; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50241; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; FDA Ctr Drug Evaluation Res, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-79; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gladis MM, 1999, J CONSULT CLIN PSYCH, V67, P320, DOI 10.1037/0022-006X.67.3.320; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; GUYATT GH, 1989, CAN MED ASSOC J, V140, P1441; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hofer S, 2005, PSYCHOSOMATICS, V46, P212, DOI 10.1176/appi.psy.46.3.212; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; King MT, 2008, LANCET, V371, P709, DOI 10.1016/S0140-6736(08)60324-4; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Maas AIR, 2000, CNS DRUGS, V13, P139, DOI 10.2165/00023210-200013020-00007; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Patricia GF, 2007, ECON CHIL, V10, P137; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Power M, 2005, QUAL LIFE RES, V14, P2197, DOI 10.1007/s11136-005-7380-9; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Rickels E, 2006, SCHADEL HIRN VERLETZ; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; von Steinbuchel N, 2010, J NEUROTRAUMA, V27; von Steinbuchel Nicole, 2006, Eur J Ageing, V3, P116, DOI 10.1007/s10433-006-0024-2; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599	51	113	115	1	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1157	1165		10.1089/neu.2009.1077			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100001	20210602				2021-06-18	
J	Lee, JK; Kibler, KK; Benni, PB; Easley, RB; Czosnyka, M; Smielewski, P; Koehler, RC; Shaffner, DH; Brady, KM				Lee, Jennifer K.; Kibler, Kathleen K.; Benni, Paul B.; Easley, R. Blaine; Czosnyka, Marek; Smielewski, Peter; Koehler, Raymond C.; Shaffner, Donald H.; Brady, Ken M.			Cerebrovascular Reactivity Measured by Near-Infrared Spectroscopy	STROKE			English	Article						autoregulation; cerebral blood flow; hemoglobin; hypotension; near-infrared spectroscopy; neonate; piglet	DYNAMIC CEREBRAL AUTOREGULATION; BLOOD PRESSURE MEASUREMENTS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; PREMATURE-INFANTS; NEWBORN-INFANTS; OXYGENATION; CIRCULATION	Background and Purpose-The pressure reactivity index (PRx) describes cerebral vessel reactivity by correlation of slow waves of intracranial pressure (ICP) and arterial blood pressure. In theory, slow changes in the relative total hemoglobin (rTHb) measured by near-infrared spectroscopy are caused by the same blood volume changes that cause slow waves of ICP. Our objective was to develop a new index of vascular reactivity, the hemoglobin volume index (HVx), which is a low-frequency correlation of arterial blood pressure and rTHb measured with near-infrared spectroscopy. Methods-Gradual hypotension was induced in piglets while cortical laser-Doppler flux was monitored. ICP was monitored, and rTHb was measured continuously using reflectance near-infrared spectroscopy. The HVx was recorded as a moving linear correlation between slow waves (20 to 300 seconds) of arterial blood pressure and rTHb. Autoregulation curves were constructed by averaging values of the PRx or HVx in 5-mm Hg bins of cerebral perfusion pressure. Results-The laser-Doppler flux-determined lower limit of autoregulation was 29.4 +/- 6.7 mm Hg (+/- SD). Coherence between rTHb and ICP was high at low frequencies. HVx was linearly correlated with PRx. The PRx and HVx both showed higher values below the lower limit of autoregulation and lower values above the lower limit of autoregulation. Areas under the receiver operator characteristic curves were 0.88 and 0.85 for the PRx and HVx, respectively. Conclusions-Coherence between the rTHb and ICP waveforms at the frequency of slow waves suggests that slow waves of ICP are related to blood volume changes. The HVx has potential for further development as a noninvasive alternative to the PRx. (Stroke. 2009; 40: 1820-1826.)	[Lee, Jennifer K.; Kibler, Kathleen K.; Easley, R. Blaine; Koehler, Raymond C.; Shaffner, Donald H.; Brady, Ken M.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Benni, Paul B.] CAS Med Syst Inc, Branford, CT USA; [Czosnyka, Marek; Smielewski, Peter] Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge, England	Brady, KM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol, Div Pediat Anesthesiol Crit Care Med, 600 N Wolfe St,Blalock 904, Baltimore, MD 21287 USA.	kbrady5@jhmi.edu		Smielewski, Peter/0000-0001-5096-3938; SHAFFNER, DONALD/0000-0001-5530-0746	Hartwell Foundation; Foundation for Anesthesia Education and Research; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This work was supported by grants from the Hartwell Foundation and the Foundation for Anesthesia Education and Research.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Bassan H, 2005, PEDIATR RES, V57, P35, DOI 10.1203/01.PDR.0000147576.84092.F9; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Chambers IR, 2005, PHYSIOL MEAS, V26, P1019, DOI 10.1088/0967-3334/26/6/011; COPE M, 1988, MED BIOL ENG COMPUT, V26, P289, DOI 10.1007/BF02447083; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Lavinio A, 2007, STROKE, V38, P402, DOI 10.1161/01.STR.0000254551.92209.5c; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MACKENZIE ET, 1979, STROKE, V10, P711, DOI 10.1161/01.STR.10.6.711; MATCHER SJ, 1995, ANAL BIOCHEM, V227, P54, DOI 10.1006/abio.1995.1252; Panerai RB, 2008, PHYSIOL MEAS, V29, P497, DOI 10.1088/0967-3334/29/4/006; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023; Ragauskas A, 2005, ACTA NEUROCHIR SUPPL, V95, P367; Sammons EL, 2007, J APPL PHYSIOL, V103, P369, DOI 10.1152/japplphysiol.00271.2007; Soul JS, 2007, PEDIATR RES, V61, P467, DOI 10.1203/pdr.0b013e31803237f6; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STEINER LA, 2008, NEUROCRIT CARE  0920; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2007, J NEUROTRAUMA S1, V24, pS59, DOI DOI 10.1089/NEU.2007.9987; Tsuji M, 2000, PEDIATRICS, V106, P625, DOI 10.1542/peds.106.4.625; WYATT JS, 1986, LANCET, V2, P1063, DOI 10.1016/S0140-6736(86)90467-8	29	113	116	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	MAY	2009	40	5					1820	1826		10.1161/STROKEAHA.108.536094			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	438UB	WOS:000265579800044	19286593	Bronze, Green Published			2021-06-18	
J	Vaishnavi, S; Rao, V; Fann, JR				Vaishnavi, Sandeep; Rao, Vani; Fann, Jesse R.			Neuropsychiatric Problems After Traumatic Brain Injury: Unraveling the Silent Epidemic	PSYCHOSOMATICS			English	Article							HEAD-INJURY; PSYCHIATRIC-ILLNESS; AXIS-I; DEPRESSION; RECOVERY; IMPACT; PSYCHOPATHOLOGY; METHYLPHENIDATE; REHABILITATION; INDIVIDUALS	Background: Traumatic brain injury (TBI) is a significant public health concern. According to the Centers for Disease Control and Prevention, about 1.4 million people in the United States sustain a TBI annually. Objective: This review places particular emphasis on the current knowledge of effective treatment of TBI symptoms, and proposes directions for future research. Results: Neuropsychiatric problems are more prevalent and longer-lasting in TBI patients than in the general population. About 40% of TBI victims suffer from two or more psychiatric disorders, and a similar percentage experience at least one unmet need for cognitive, emotional, or job assistance 1 year after injury. The entire spectrum of TBI severity, from mild to severe, is associated with an increase in psychiatric conditions. Conclusion: Despite the high incidence of severe consequences of TBI, there are scarce empirical data to guide psychiatric treatment. Some approaches that have been helpful include cognitive and behavioral therapy and pharmacologic treatment. The authors list specific research recommendations that could further identify useful therapeutic interventions. (Psychosomatics 2009; 50: 198-205)	[Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Johns Hopkins Sch Med, Div Geriatr Psychiat & Neuropsychiat, Seattle, WA 98195 USA; Univ Washington, Alexian Bros Behav Health, Alexian Bros Neurosci Inst, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Johns Hopkins Sch Med, Div Geriatr Psychiat & Neuropsychiat, Box 356560, Seattle, WA 98195 USA.	fann@u.washington.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5K23MH066894, R21HD053736]; NIDRR [H133G070016]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD053736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066894] Funding Source: NIH RePORTER	Dr. Rao is supported by NIH Grant 5K23MH066894; Dr. Fann is supported by NIH Grants R21HD053736 and NIDRR Grant H133G070016.	Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BAKCHINE S, 1989, NEUROLOGY, V39, P777, DOI 10.1212/WNL.39.6.777; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Butler PV, 2000, AUST NZ J PSYCHIAT, V34, P684, DOI 10.1046/j.1440-1614.2000.00758.x; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; CLARK AF, 1987, BRIT J PSYCHIAT, V150, P841, DOI 10.1192/bjp.150.6.841; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; DAMASIO H, 1994, SCIENCE, V265, P1159; Deb S, 1999, AM J PSYCHIAT, V156, P374; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Gennarelli T. A., 1987, HEAD INJURY, P108; Giles GM, 2007, BRAIN INJURY, V21, P505, DOI 10.1080/02699050701311729; HALE MS, 1982, J NERV MENT DIS, V170, P362, DOI 10.1097/00005053-198206000-00006; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hart T, 2008, NEUROPSYCHOL REHABIL, V18, P1, DOI 10.1080/09602010601082359; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; HOGE CW, 2008, NEW ENGL J MED, V358, P525; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Khouzam HR, 1998, GEN HOSP PSYCHIAT, V20, P62, DOI 10.1016/S0163-8343(97)00097-2; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; POPE HG, 1988, COMPR PSYCHIAT, V29, P34, DOI 10.1016/0010-440X(88)90035-1; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; Umansky R, 2000, INT J NEUROPSYCHOPH, V3, P81, DOI 10.1017/S1461145700001723; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; WITOL AD, 1996, J VOCATIONAL REHABIL, V7, P159; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	62	113	120	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0033-3182			PSYCHOSOMATICS	Psychosomatics	MAY-JUN	2009	50	3					198	205		10.1176/appi.psy.50.3.198			8	Psychiatry; Psychology	Psychiatry; Psychology	464VV	WOS:000267537700003	19567758				2021-06-18	
J	Coburn, M; Maze, M; Franks, NP				Coburn, Mark; Maze, Mervyn; Franks, Nicholas P.			The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						neuroprotection; neuroprotectant; traumatic brain injury; xenon; helium; hyperbaric chamber	ORGANOTYPIC CULTURES; HYDROSTATIC-PRESSURE; HIPPOCAMPAL SLICES; UNITED-STATES; DAMAGE; ISOFLURANE; PROTECTION; ISCHEMIA; SYSTEM; NEUROTOXICITY	Objectives: The "inert" gas xenon has been shown to be an effective neuroprotectant in a variety of in vitro and in vivo models of neuronal injury. We examined its neuroprotective properties in an in vitro model of traumatic brain injury. Design. Controlled laboratory study. Setting: Academic research laboratory. Subjects. Organotypic hippocampal brain slices from mice pups. Interventions. The cultured brain slices were subjected to a focal mechanical trauma, and injury was monitored in the presence and absence of inert gases at normal and elevated pressures and under both normothermic and hypothermic conditions. Measurements and Main Results: Neuronal injury was quantified using propidium iodide, which becomes fluorescent only when it enters injured cells. Low pressures of both helium and xenon were effective neuroprotectants when applied in addition to 1 atm of air. Moreover, both gases were effective at normal pressures when they replaced nitrogen in a gas mixture. Conclusions. The inert gases helium and xenon are effective neuroprotectants in a model for traumatic brain injury, and this novel treatment warrants further investigation. Xenon was particularly effective at reducing the secondary injury that developed following the initial trauma and could be administered at least 3 hrs postinjury with only a small reduction in efficacy.	[Coburn, Mark] Univ Hosp RWTH Aachen, Dept Anesthesiol, D-52074 Aachen, Germany	Coburn, M (corresponding author), Univ Hosp RWTH Aachen, Dept Anesthesiol, Pauwelsstr 30, D-52074 Aachen, Germany.	mcoburn@ukaachen.de; n.franks@imperial.ac.uk		Coburn, Mark/0000-0002-7930-0270; Franks, Nicholas/0000-0003-4874-4212			Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; ASHFORD MLJ, 1982, J PHYSIOL-LONDON, V333, P531, DOI 10.1113/jphysiol.1982.sp014467; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; COLTON CA, 1982, BRAIN RES, V251, P221, DOI 10.1016/0006-8993(82)90740-5; Crain SM, 1998, METHODS, V16, P228, DOI 10.1006/meth.1998.0681; DANIELS S, 2003, BENNETT ELLIOTTS PHY, P265; David HN, 2003, J CEREBR BLOOD F MET, V23, P1168, DOI 10.1097/01.WCB.0000087342.31689.18; Davies A R, 2005, Crit Care Resusc, V7, P238; de Sousa SLM, 2000, ANESTHESIOLOGY, V92, P1055, DOI 10.1097/00000542-200004000-00024; Dean JB, 2003, J APPL PHYSIOL, V95, P883, DOI 10.1152/japplphysiol.00920.2002; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FAGNI L, 1987, EXP BRAIN RES, V65, P513; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; GROSSMAN Y, 1988, J NEUROPHYSIOL, V60, P1497; Hall EJ, 2003, HEALTH PHYS, V85, P31, DOI 10.1097/00004032-200307000-00008; Hamada N, 2007, J RADIAT RES, V48, P87, DOI 10.1269/jrr.06084; Hei TK, 2006, MOL CARCINOGEN, V45, P455, DOI 10.1002/mc.20219; Homi HM, 2003, ANESTHESIOLOGY, V99, P876, DOI 10.1097/00000542-200310000-00020; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; Lango T, 1996, UNDERSEA HYPERBAR M, V23, P247; LAWRENCE JH, 1947, J PHYSIOL-LONDON, V105, P197; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2006, J CEREBR BLOOD F MET, V26, P199, DOI 10.1038/sj.jcbfm.9600184; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Ma DQ, 2003, ANESTHESIOLOGY, V98, P690, DOI 10.1097/00000542-200303000-00017; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; Miura Y, 1998, ANESTHESIOLOGY, V89, P391, DOI 10.1097/00000542-199808000-00016; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Mulkey DK, 2003, J APPL PHYSIOL, V95, P922, DOI 10.1152/japplphysiol.00865.2002; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; Olney JW, 2003, CURR OPIN PHARMACOL, V3, P101, DOI 10.1016/S1471-4892(02)00002-4; PARMENTIER JL, 1981, UNDERSEA BIOMED RES, V8, P175; Petzelt C, 2003, LIFE SCI, V72, P1909, DOI 10.1016/S0024-3205(02)02439-6; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; ROSTAIN JC, 1983, J APPL PHYSIOL, V54, P1063; Sakai H, 2007, ANESTHESIOLOGY, V106, P92, DOI 10.1097/00000542-200701000-00017; Sanders RD, 2003, BRIT J ANAESTH, V91, P709, DOI 10.1093/bja/aeg232; Seppelt I, 2005, Crit Care Resusc, V7, P233; Sosin DM, 1996, BRAIN INJURY, V10, P47; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Talpalar AE, 2004, J NEUROPHYSIOL, V92, P3309, DOI 10.1152/jn.00178.2004; TASKER RC, 1992, J NEUROSCI, V12, P4298; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tisherman Samuel A, 2004, Curr Opin Crit Care, V10, P512; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wilhelm S, 2002, ANESTHESIOLOGY, V96, P1485, DOI 10.1097/00000542-200206000-00031	51	113	120	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2008	36	2					588	595		10.1097/01.CCM.0B013E3181611F8A6			8	Critical Care Medicine	General & Internal Medicine	257JB	WOS:000252794000030	18216607				2021-06-18	
J	Moser, RS; Iverson, GL; Echemendia, RJ; Lovell, MR; Schatz, P; Webbe, FM; Ruff, RM; Barth, JT				Moser, Rosemarie Scolaro; Iverson, Grant L.; Echemendia, Ruben J.; Lovell, Mark R.; Schatz, Philip; Webbe, Frank M.; Ruff, Ronald M.; Barth, Jeffrey T.		Nan Policy Planning Committee	Neuropsychological evaluation in the diagnosis and management of sports-related concussion	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						concussion; mild traumatic brain injury; sports; athletics; neuropsychological testing	INJURY SURVEILLANCE SYSTEM; COLLEGIATE FOOTBALL PLAYERS; ICE HOCKEY INJURIES; DESCRIPTIVE EPIDEMIOLOGY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; COGNITIVE IMPAIRMENT; BASKETBALL INJURIES; LACROSSE INJURIES; SOCCER INJURIES	A mild traumatic brain injury in sports is typically referred to as a concussion. This is a common injury in amateur and professional athletics, particularly in contact sports. This injury can be very distressing for the athlete, his or her family, coaches, and school personnel. Fortunately, most athletes recover quickly and fully from this injury. However, some athletes have a slow recovery, and there are reasons to be particularly concerned about re-injury during the acute recovery period. Moreover, some athletes who have experienced multiple concussions are at risk for long-term adverse effects. Neuropsychologists are uniquely qualified to assess the neurocognitive and psychological effects of concussion. The National Academy of Neuropsychology recommends neuropsychological evaluation for the diagnosis, treatment, and management of sports-related concussion at all levels of play. (C) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	[Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Lovell, Mark R.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; [Schatz, Philip] St Josephs Univ, Philadelphia, PA 19131 USA; [Webbe, Frank M.] Florida Inst Technol, Melbourne, FL 32901 USA; [Ruff, Ronald M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Barth, Jeffrey T.] Univ Virginia, Sch Med, Charlottesville, VA 22903 USA		r.moser@patmedia.net	Webbe, Frank/A-8074-2009; Echemendia, Ruben/R-6939-2019	Webbe, Frank/0000-0002-4370-5698; Schatz, Philip/0000-0002-6222-6545; Iverson, Grant/0000-0001-7348-9570			Agel J, 2007, J ATHL TRAINING, V42, P270; Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P202; Agel J, 2007, J ATHL TRAINING, V42, P249; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT, 2001, J ATHL TRAINING, V36, P253; Barth JT., 1989, MILD HEAD INJURY, P257; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dick R, 2007, J ATHL TRAINING, V42, P278; Dick R, 2007, J ATHL TRAINING, V42, P262; Dick R, 2007, J ATHL TRAINING, V42, P255; Dick R, 2007, J ATHL TRAINING, V42, P211; Dick R, 2007, J ATHL TRAINING, V42, P221; Dick R, 2007, J ATHL TRAINING, V42, P194; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 2006, SPORTS NEUROPSYCHOLO, P176; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sosin DM, 1996, BRAIN INJURY, V10, P47; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	73	113	116	0	34	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2007	22	8					909	916		10.1016/j.acn.2007.09.004			8	Psychology, Clinical; Psychology	Psychology	244AL	WOS:000251838300001	17988831	Bronze			2021-06-18	
J	Pistollato, F; Chen, HL; Schwartz, PH; Basso, G; Panchision, DM				Pistollato, Francesca; Chen, Hui-Ling; Schwartz, Philip H.; Basso, Giuseppe; Panchision, David M.			Oxygen tension controls the expansion of human CNS precursors and the generation of astrocytes and oligodendrocytes	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						brain; stem cells/Progenitor cells; oxygen; oligodendrocyte; astrocyte; CD133 antigen; bone morphogenetic proteins	BONE MORPHOGENETIC PROTEINS; NEURAL PROGENITOR CELLS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; ADULT HUMAN BRAIN; STEM-CELLS; IN-VITRO; OXIDATIVE STRESS; DOPAMINERGIC DIFFERENTIATION; SUBVENTRICULAR ZONE	Human neural precursor proliferation and potency is limited by senescence and loss of oligodendrocyte potential. We found that in vitro expansion of human postnatal brain CD133(+) nestin(+) precursors is enhanced at 5% oxygen, while raising oxygen tension to 20% depletes precursors and promotes astrocyte differentiation even in the presence of mitogens. Higher cell densities yielded more astrocytes regardless of oxygen tension. This was reversed by noggin at 5%, but not 20%, oxygen due to a novel repressive effect of low oxygen on bone morphogenetic protein (BMP) signaling. When induced to differentiate by mitogen withdrawal, 5% oxygen-expanded precursors generated 17-fold more oligodendrocytes than cells expanded in 20% oxygen. When precursors were expanded at 5% oxygen and then differentiated at 20% oxygen, oligodendrocyte maturation was further enhanced 2.5-fold. These results indicate that dynamic control of oxygen tension regulates different steps in fate and maturation and may be crucial for treating neurodegenerative diseases. (c) 2007 Elsevier Inc. All rights reserved.	Childrens Natl Med Ctr, Neurosci Res Ctr, Washington, DC 20010 USA; Univ Padua, Dept Pediat, Hematooncol Lab, I-35100 Padua, Italy; Childrens Hosp Orange Cty Res Inst, Orange, CA USA; Univ Calif Irvine, Irvine, CA USA	Panchision, DM (corresponding author), Childrens Natl Med Ctr, Neurosci Res Ctr, 5th Floor,Suite 5340,111 Michigan Ave NW, Washington, DC 20010 USA.	dpanchision@cnmcresearch.org	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; BASSO, GIUSEPPE/0000-0002-2634-9302			Adam AAG, 2004, JPN J VET RES, V52, P77; Adelman DM, 2000, ADV EXP MED BIOL, V475, P275; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Back SA, 2002, J NEUROSCI, V22, P455, DOI 10.1523/JNEUROSCI.22-02-00455.2002; Back SA, 1998, J NEUROSCI, V18, P6241; Bernier PJ, 2000, NEUROSCI RES, V37, P67, DOI 10.1016/S0168-0102(00)00102-4; Blakemore WF, 2002, GLIA, V38, P155, DOI 10.1002/glia.10067; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Caldwell MA, 2001, NAT BIOTECHNOL, V19, P475, DOI 10.1038/88158; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Carson S, 2005, CLIN REHABIL, V19, P819, DOI 10.1191/0269215505cr907oa; Casper KB, 2006, MOL CELL NEUROSCI, V31, P676, DOI 10.1016/j.mcn.2005.12.006; Catt J W, 2000, Hum Reprod, V15 Suppl 2, P199; Chandran S, 2004, GLIA, V47, P314, DOI 10.1002/glia.20011; Chen HL, 2007, STEM CELLS, V25, P63, DOI 10.1634/stemcells.2006-0339; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Das KC, 2004, AM J PHYSIOL-LUNG C, V286, pL87, DOI 10.1152/ajplung.00203.2002; DeAzevedo LC, 2003, J NEUROBIOL, V55, P288, DOI 10.1002/neu.10205; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; Fern R, 2000, J NEUROSCI, V20, P34, DOI 10.1523/JNEUROSCI.20-01-00034.2000; Gerstner B, 2006, J NEUROSCI RES, V84, P306, DOI 10.1002/jnr.20880; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Guyton AC, 2006, TXB MED PHYSL, Vxxxv; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hoge RD, 2001, J CHEM NEUROANAT, V22, P43, DOI 10.1016/S0891-0618(01)00114-4; Itahana K, 2004, BIOGERONTOLOGY, V5, P1, DOI 10.1023/B:BGEN.0000017682.96395.10; Ivanovic Z, 2004, STEM CELLS, V22, P716, DOI 10.1634/stemcells.22-5-716; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Kilani RT, 2003, PLACENTA, V24, P826, DOI 10.1016/S0143-4004(03)00129-2; Kim YT, 2006, EXP NEUROL, V199, P222, DOI 10.1016/j.expneurol.2006.03.015; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Limoli CL, 2004, P NATL ACAD SCI USA, V101, P16052, DOI 10.1073/pnas.0407065101; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Mabie PC, 1999, J NEUROSCI, V19, P7077, DOI 10.1523/JNEUROSCI.19-16-07077.1999; Madhavan L, 2006, STEM CELLS, V24, P2110, DOI 10.1634/stemcells.2006-0018; Mekki-Dauriac S, 2002, DEVELOPMENT, V129, P5117; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Milosevic J, 2005, J NEUROCHEM, V92, P718, DOI 10.1111/j.1471-4159.2004.02893.x; Morrison SJ, 2000, J NEUROSCI, V20, P7370; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nistor GI, 2005, GLIA, V49, P385, DOI 10.1002/glia.20127; Ostenfeld T, 2004, STEM CELLS, V22, P798, DOI 10.1634/stemcells.22-5-798; Panchision DM, 2001, GENE DEV, V15, P2094, DOI 10.1101/gad.894701; PANCHISION DM, 2007, IN PRESS STEM CELLS; Postovit LM, 2002, J BIOL CHEM, V277, P35730, DOI 10.1074/jbc.M204529200; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; Ramirez-Bergeron DL, 2004, DEVELOPMENT, V131, P4623, DOI 10.1242/dev.01310; Sailer MHM, 2005, J CELL SCI, V118, P5849, DOI 10.1242/jcs.02708; Saito A, 2005, MOL NEUROBIOL, V31, P105, DOI 10.1385/MN:31:1-3:105; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Schultz K, 2006, AM J PHYSIOL-HEART C, V290, pH2528, DOI 10.1152/ajpheart.01077.2005; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Storch A, 2001, EXP NEUROL, V170, P317, DOI 10.1006/exnr.2001.7706; Studer L, 2000, J NEUROSCI, V20, P7377; TOHYAMA T, 1992, LAB INVEST, V66, P303; Tokuda Y, 2000, J CELL PHYSIOL, V182, P414, DOI 10.1002/(SICI)1097-4652(200003)182:3<414::AID-JCP12>3.0.CO;2-5; Tsai RYL, 2000, J NEUROSCI, V20, P3725; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Ungerstedt U, 1997, Acta Anaesthesiol Scand Suppl, V110, P123; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vinals F, 2004, EMBO J, V23, P3527, DOI 10.1038/sj.emboj.7600360; Walton NM, 2006, DEVELOPMENT, V133, P3671, DOI 10.1242/dev.02541; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Wright LS, 2006, EXP CELL RES, V312, P2107, DOI 10.1016/j.yexcr.2006.03.012; Wu XQ, 2006, CIRC RES, V99, P240, DOI 10.1161/01.RES.0000237021.65103.24; Yanagisawa M, 2001, NEUROSCI RES, V41, P391, DOI 10.1016/S0168-0102(01)00297-8; Yu XB, 2002, DEVELOPMENT, V129, P505; Zecevic N, 2004, GLIA, V48, P27, DOI 10.1002/glia.20044; Zhang SC, 2000, J NEUROSCI RES, V59, P421, DOI 10.1002/(SICI)1097-4547(20000201)59:3<421::AID-JNR17>3.3.CO;2-3; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	83	113	116	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431			MOL CELL NEUROSCI	Mol. Cell. Neurosci.	JUL	2007	35	3					424	435		10.1016/j.mcn.2007.04.003			12	Neurosciences	Neurosciences & Neurology	190KL	WOS:000248057600003	17498968				2021-06-18	
J	Brennan, KC; Beltran-Parrazal, L; Lopez-Valdes, HE; Theriot, J; Toga, AW; Charles, AC				Brennan, Kevin C.; Beltran-Parrazal, Luis; Lopez-Valdes, Hector E.; Theriot, Jeremy; Toga, Arthur W.; Charles, Andrew C.			Distinct vascular conduction with cortical spreading depression	JOURNAL OF NEUROPHYSIOLOGY			English	Article							OPTICAL INTRINSIC SIGNALS; CALCIUM WAVES; BLOOD-FLOW; ARTERIOLAR DILATION; CEREBRAL-CORTEX; RATS; K+; REACTIVITY; RESPONSES; CATS	Cortical spreading depression (CSD) is associated with significant vasodilatation and vasoconstriction, but the relationship between the cortical parenchymal and vascular phenomena remains poorly understood. We used optical intrinsic signal (OIS) imaging and electrophysiology to simultaneously examine the vascular and parenchymal changes that occur with CSD in anesthetized mice and rats. CSD was associated with a propagated multiphasic change in optical reflectance, with correlated negative DC shift in field potential. Dilatation of cortical surface arterioles propagated with a significantly greater intrinsic velocity than the parenchymal CSD wavefront measured by OIS and electrophysiology. Dilatation traveled in a circuitous pattern along individual arterioles, indicating specific vascular conduction as opposed to concentric propagation of a parenchymal signal. Arteriolar dilatation propagated into areas beyond the spread of parenchymal OIS and electrophysiological changes of CSD. Conversely, vasomotor activity could be experimentally dissociated from the parenchymal CSD wave. Frequent repetitive CSD evoked by continuous stimulation was associated with a reduced or absent arteriolar response despite preserved parenchymal OIS and electrophysiological changes. Similarly, dimethylsulfoxide at high concentrations (10%) inhibited arteriolar reactivity despite preserved parenchymal OIS and electrophysiological changes. These results suggest a mechanism, intrinsic to the vasculature, for propagation of vasodilatation associated with CSD. Distinct vascular conduction could be important for the pathogenesis of conditions that involve CSD, including migraine, stroke, and traumatic brain injury.	Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Lab Neuro Imaging, Los Angeles, CA USA	Charles, AC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Neurosci Res Bldg,Room 575,635 Charles E Young Dr, Los Angeles, CA 90095 USA.	acharles@ucla.edu	Beltran-Parrazal, Luis/A-9330-2016; Lopez-Valdes, Hector Eduardo/J-9069-2017; Beltran-Parrazal, Luis/L-3424-2019	Beltran-Parrazal, Luis/0000-0002-4765-9051; Lopez-Valdes, Hector Eduardo/0000-0002-5980-6039; Beltran-Parrazal, Luis/0000-0002-4765-9051; Brennan, K.C./0000-0003-4193-5841	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH052083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P50DA005010] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [P50 DA005010] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH-052083] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-39961] Funding Source: Medline		Ayata C, 2004, J CEREBR BLOOD F MET, V24, P1172, DOI 10.1097/01.WCB.0000137057.92786.F3; Ba AM, 2002, J NEUROPHYSIOL, V88, P2726, DOI 10.1152/jn.00729.2001; Basarsky TA, 1998, J NEUROSCI, V18, P7189; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; COLONNA DM, 1994, STROKE, V25, P2463, DOI 10.1161/01.STR.25.12.2463; de Wit C, 2006, BIOL CHEM, V387, P3, DOI 10.1515/BC.2006.002; Domenighetti AA, 1998, J PHYSIOL-LONDON, V513, P103, DOI 10.1111/j.1469-7793.1998.103by.x; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978; FABRICIUS M, 1995, AM J PHYSIOL-HEART C, V269, pH23; FLORENCE G, 1994, AM J PHYSIOL, V266, pR1136; Gorji A, 2001, BRAIN RES REV, V38, P33, DOI 10.1016/S0165-0173(01)00081-9; Guiou M, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1852556; Horiuchi T, 2002, STROKE, V33, P2692, DOI 10.1161/01.STR.0000034791.52151.6B; Iadecola C, 1997, J NEUROPHYSIOL, V78, P651; Kunkler PE, 1998, J NEUROSCI, V18, P3416; LACOMBE P, 1992, EXP NEUROL, V117, P278, DOI 10.1016/0014-4886(92)90137-F; LAURITZEN M, 1982, ANN NEUROL, V12, P469, DOI 10.1002/ana.410120510; Leao AAP, 1944, J NEUROPHYSIOL, V7, P391, DOI 10.1152/jn.1944.7.6.391; NARAYAN SM, 1994, CEREB CORTEX, V4, P195, DOI 10.1093/cercor/4.2.195; Ngai AC, 2007, STROKE, V38, P124, DOI 10.1161/01.STR.0000252157.93998.47; O'Farrell AM, 2000, NEUROREPORT, V11, P2121, DOI 10.1097/00001756-200007140-00013; Osada T, 2006, NEUROREPORT, V17, P1365, DOI 10.1097/01.wnr.0000227992.00175.fa; Peters O, 2003, J NEUROSCI, V23, P9888; PIPER RD, 1991, AM J PHYSIOL, V261, pH96; PITTS LH, 1986, STROKE, V17, P483, DOI 10.1161/01.STR.17.3.483; Pouratian N., 2002, BRAIN MAPPING METHOD, P97, DOI [10.1016/b978-012693019-1/50007-1, DOI 10.1016/B978-012693019-1/50007-1]; Reuter U, 1998, AM J PHYSIOL-HEART C, V274, pH1979; Santos NC, 2003, BIOCHEM PHARMACOL, V65, P1035, DOI 10.1016/S0006-2952(03)00002-9; Seitz I, 2004, J CEREBR BLOOD F MET, V24, P526, DOI 10.1097/00004647-200405000-00006; SHIBATA M, 1991, AM J PHYSIOL, V261, pR828; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Sonn J, 2000, BRAIN RES, V882, P212, DOI 10.1016/S0006-8993(00)02827-4; Tomita M, 2005, J CEREBR BLOOD F MET, V25, P742, DOI 10.1038/sj.jcbfm.9600074; Tomita M, 2003, ACTA NEUROCHIR SUPPL, V86, P219; Tomita Y, 2002, NEUROSCI LETT, V322, P157, DOI 10.1016/S0304-3940(02)00072-1; VANHARREVELD A, 1957, AM J PHYSIOL, V189, P159; WAHL M, 1973, CIRC RES, V32, P162, DOI 10.1161/01.RES.32.2.162; WAHL M, 1987, BRAIN RES, V411, P72, DOI 10.1016/0006-8993(87)90682-2; Yashiro Y, 2000, CIRC RES, V87, P1048, DOI 10.1161/01.RES.87.11.1048	39	113	116	0	7	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	JUN	2007	97	6					4143	4151		10.1152/jn.00028.2007			9	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	188RY	WOS:000247938200030	17329631				2021-06-18	
J	Muller, K; Townend, W; Biasca, N; Unden, J; Waterloo, K; Romner, B; Ingebrigtsen, T				Muller, Kay; Townend, Will; Biasca, Nicola; Unden, Johan; Waterloo, Knut; Romner, Bertil; Ingebrigtsen, Tor			S100B serum level predicts computed tomography findings after minor head injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; guidelines; protein S100B; computed tomography	TRAUMATIC BRAIN INJURY; CEREBRAL INJURY; S-100 PROTEIN; MILD; ELIMINATION; GUIDELINES; MULTICENTER; MANAGEMENT; DIAGNOSIS; SURGERY	Background: Mild head injury (MHI) implies a risk for traumatic brain injury and even a small risk for development of an intracranial hematoma. Head computed tomography (CT) is recommended for early detection of such pathologic findings. The present multicenter study was performed to investigate whether determination of protein S100B in serum could contribute to the selection of patients for CT scanning. Methods: We included 226 patients with a history of head injury and a Glasgow Coma Scale (GCS) score of 13 to 15 at admission to hospital. Blood samples for S100B analysis and head CT were obtained within 12 hours after the injury. The diagnostic properties of S100B measurements for prediction of intracranial injury revealed by CT were tested with receiver operating characteristic (ROC) analysis and cross-table analysis at different cut-off levels. We also included analysis of S100B levels normalized to correspond to blood sampling I hour after the injury. Results: CT showed intracranial injury in 21 (9.3%) patients. S100B levels were significantly (p < 0.001) elevated in patients with intracranial injury (mean, 0.36; 95% CI, 0.21-0.50 mu g/L) compared with those in patients without intracranial injury (mean, 0.18; 95% CI, 0.16-0.20 mu g/L). ROC curve analysis showed a significant (p = 0.001) area under the curve (0.73; 95% CI, 0.62-0.84). Cross-table analysis showed that 20 of 21 (sensitivity 0.95) patients with intracranial injury were detected at a cut-off level of 0.10 mu g/L, but 141 of 205 (specificity 0.31) patients with no such injury also had a S100B level above this limit. Exclusion of cases with blood samples collected more than 3 hours after injury or normalization did not improve the diagnostic properties. Conclusion: Determination of serum S100B cannot replace the clinical examination or use of CT for patients with minor head injury, but adding S100B measurement to the clinical evaluation might support selection of patients for CT scanning.	Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway; Univ Hosp N Norway, Dept Neurol, Tromso, Norway; Univ Tromso, Inst Clin Med, Tromso, Norway; Hope Univ Hosp, Emergency Dept, Salford, Lancs, England; Spital Oberengadin, Dept Orthoped Surg Sports Med & Trauma Surg, Samedan St Moritz, Switzerland; Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden	Ingebrigtsen, T (corresponding author), Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway.	tor.ingebrigtsen@unn.no		Ingebrigtsen, Tor/0000-0001-5966-9786			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; *NAT I CLIN EXC, HEAD INJ TRIAG ASS I; ROMNER B, 2000, J NEURORRAUMA, V17, P473; Roy PM, 2005, BMJ-BRIT MED J, V331, P259, DOI 10.1136/bmj.331.7511.259; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Stiell IG, 2000, NEW ENGL J MED, V343, P1570; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217	27	113	120	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2007	62	6					1452	1456		10.1097/TA.0b013e318047bfaa			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	179YM	WOS:000247326600031	17563665				2021-06-18	
J	Garner, JP; Thogerson, CM; Wurbel, H; Murray, JD; Mench, JA				Garner, Joseph P.; Thogerson, Collette M.; Wuerbel, Hanno; Murray, James D.; Mench, Joy A.			Animal neuropsychology: Validation of the Intra-Dimensional Extra-Dimensional set shifting task for mice	BEHAVIOURAL BRAIN RESEARCH			English	Article						executive; prefrontal cortex; Wisconsin card sort test; autism; obsessive compulsive disorder; traumatic brain injury; trichotillomania	TEMPORAL-LOBE EXCISIONS; AMYGDALO-HIPPOCAMPECTOMY; LABORATORY ENVIRONMENT; PREFRONTAL CORTEX; BEHAVIORAL-TESTS; MOUSE BEHAVIOR; DISCRIMINATION; STANDARDIZATION; SCHIZOPHRENIA; STEREOTYPIES	Research in animal neuropsychology is providing an exciting new generation of behavioral tests for mice that promise to overcome many of the limitations of current high-throughput testing, and provide direct animal homologues of clinically important measures in human research. Set shifting tasks are some of the best understood and widely used human neuropsychological tasks, with clinical relevance to traumatic brain injury, schizophrenia, autism, obsessive compulsive disorder, trichotillomania, and many other disorders. Here we report the first successful modification of a human set shifting neuropsychological task, the Intra-Dimensional Extra-Dimensional (IDED) task, for use with mice. We presented mice with a series of compound discrimination and reversal tasks where one stimulus dimension consistently cued reward. Task performance improved with a new set of compound stimuli, as did reversal performance-indicating the formation of a cognitive-attentional set. We then overtrained a subset of the mice, and presented control and overtrained mice with a new compound discrimination where a novel stimulus dimension cued reward. As is the case in human control subjects, control mice persisted in responding to the now-incorrect stimulus dimension, performing poorly on this extra-dimensional shift compared with the previous intra-dimensional shift, thereby validating the task as a measure of set shifting. Furthermore, overtrained mice were impaired on this extra-dimensional shift compared with controls, further validating the task. The advantages and disadvantages of the IDED task compared to high-throughput approaches are discussed. (c) 2006 Elsevier B.V. All rights reserved.	Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA; Univ Giessen, Div Anim Welf & Ethol, D-35392 Giessen, Germany; Univ Calif Davis, Dept Anim Sci, Davis, CA 95616 USA	Garner, JP (corresponding author), Purdue Univ, Dept Anim Sci, 125 S Russell St, W Lafayette, IN 47907 USA.	jgarner@purdue.edu	Garner, Joseph P/C-8422-2009; Wurbel, Hanno/D-6281-2012; Citations, TLC SAB/C-4006-2011	Wurbel, Hanno/0000-0002-2934-3010; 	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5 R03 MH 63907-2] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R03MH063907] Funding Source: NIH RePORTER		Binder E, 2004, BEHAV BRAIN RES, V155, P197, DOI 10.1016/j.bbr.2004.04.017; Birrell JM, 2000, J NEUROSCI, V20, P4320; Brigman JL, 2005, BEHAV NEUROSCI, V119, P839, DOI 10.1037/0735-7044.119.3.839; Bussey TJ, 2001, BEHAV NEUROSCI, V115, P957, DOI 10.1037/0735-7044.115.4.957; Chesler EJ, 2002, NEUROSCI BIOBEHAV R, V26, P907, DOI 10.1016/S0149-7634(02)00103-3; Colacicco G, 2002, BEHAV BRAIN RES, V132, P95, DOI 10.1016/S0166-4328(01)00391-6; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; CRAWLEY JN, 2000, BEHAV PHENOTYPING TR, V13, P329; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; DIVAC I, 1972, PHYSIOL BEHAV, V8, P519, DOI 10.1016/0031-9384(72)90339-3; Garner JP, 2005, ILAR J, V46, P106, DOI 10.1093/ilar.46.2.106; Garner JP, 2004, COMPARATIVE MED, V54, P216; Garner JP, 2003, BEHAV BRAIN RES, V145, P125, DOI 10.1016/S0166-4328(03)00115-3; GARNER JP, UNPUB ETHOLOGY VALID; GARNER JP, 2003, P 37 INT C INT SOC A, P75; GARNER JP, IN PRESS STEREOTYPIC; Gerlai R, 1999, TRENDS NEUROSCI, V22, P47, DOI 10.1016/S0166-2236(98)01346-0; Gould TD, 2006, GENES BRAIN BEHAV, V5, P113, DOI 10.1111/j.1601-183X.2005.00186.x; GRAFEN A, 2002, MODERN STAT LIFE SCI, V15, P351; HEAD D, 1989, BIOL PSYCHIAT, V25, P929, DOI 10.1016/0006-3223(89)90272-2; Hossain SM, 2004, GENES BRAIN BEHAV, V3, P167, DOI 10.1111/j.1601-183x.2004.00069.x; HOWITT D, 1997, INTRO STAT PSYCHOL C, V12, P482; Kas MJH, 2004, TRENDS NEUROSCI, V27, P366, DOI 10.1016/j.tins.2004.04.011; Latham N, 2004, APPL ANIM BEHAV SCI, V86, P261, DOI 10.1016/j.applanim.2004.02.006; Laurent V, 2004, BEHAV PHARMACOL, V15, P141, DOI 10.1097/00008877-200403000-00006; LITTELL RC, 2002, SAS LINEAR MODELS, V12, P466; Mackintosh N.J, 1974, PSYCHOL ANIMAL LEARN, Vxiv, P730; MACKINTOSH NJ, 1962, J COMP PHYSIOL PSYCH, V55, P555; Marino MD, 2005, BEHAV BRAIN RES, V161, P197, DOI 10.1016/j.bbr.2005.02.005; Miller KA, 2005, APPL ANIM BEHAV SCI, V92, P113, DOI 10.1016/j.applanim.2004.10.016; Miller KA, 2006, ANIM BEHAV, V71, P1323, DOI 10.1016/j.anbehav.2005.08.018; Newman JA, 1997, ECOLOGY, V78, P1312; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; OWEN AM, 1991, NEUROPSYCHOLOGIA, V29, P993, DOI 10.1016/0028-3932(91)90063-E; Owen AM, 1996, BRAIN, V119, P1597, DOI 10.1093/brain/119.5.1597; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; Pfaff D, 2001, P NATL ACAD SCI USA, V98, P5957, DOI 10.1073/pnas.101128598; RAINE A, 1992, PSYCHIAT RES-NEUROIM, V45, P123, DOI 10.1016/0925-4927(92)90006-P; ROLLS ET, 1994, REV NEUROL-FRANCE, V150, P648; Russell W.M.S., 1959, PRINCIPLES HUMANE EX, P238; Turner M, 1997, AUTISM EXECUTIVE DIS, P57; Wahlsten D, 2003, TRENDS NEUROSCI, V26, P132, DOI 10.1016/S0166-2236(03)00033-X; Wurbel H, 2000, NAT GENET, V26, P263, DOI 10.1038/81541; Wurbel H, 2002, GENES BRAIN BEHAV, V1, P3, DOI 10.1046/j.1601-1848.2001.00006.x; Wurbel H, 2001, TRENDS NEUROSCI, V24, P207, DOI 10.1016/S0166-2236(00)01718-5; YOUNG RJ, 1994, ANIM BEHAV, V47, P1488, DOI 10.1006/anbe.1994.1202	46	113	113	1	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	OCT 2	2006	173	1					53	61		10.1016/j.bbr.2006.06.002			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	086DE	WOS:000240652500007	16842867				2021-06-18	
J	Betker, AL; Szturm, T; Moussavi, ZK; Nett, C				Betker, Aimee L.; Szturm, Tony; Moussavi, Zahra K.; Nett, Cristabel			Video game-based exercises for balance rehabilitation: A single-subject design	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	IASTED International Conference on Advances in Computer Science and Technology	JAN 23-25, 2006	Puerto Vallarta, MEXICO	Int Assoc Sci & Technol Dev, IASTED TCAI, IASTED TCCG, IASTED TCD, IASTED TC PDCS, IASTED TCSE		balance; biofeedback (psychology); exercise; movement; posture; pressure; rehabilitation; therapy, computer-assisted	INDUCED CORTICAL REORGANIZATION; INDUCED MOVEMENT THERAPY; CHRONIC MOTOR DEFICITS; TRUNK SWAY MEASURES; VIRTUAL-REALITY; STROKE PATIENTS; POSTURAL STABILITY; QUIET STANCE; BIOFEEDBACK; MOBILITY	Objectives: To investigate whether coupling foot center of pressure (COP)-controlled video games to standing balance exercises will improve dynamic balance control and to determine whether the motivational and challenging aspects of the video games would increase a subject's desire to perform the exercises and complete the rehabilitation process. Design: Case study, pre- and postexercise. Setting: University hospital outpatient clinic. Participants: A young adult with excised cerebellar tumor, 1 middle-aged adult with single right cerebrovascular accident, and I middle-aged adult with traumatic brain injury. Intervention: A COP-controlled, video game-based exercise system. Main Outcome Measures: The following were calculated during 12 different tasks: the number of falls, range of COP excursion, and COP path length. Results: Postexercise, subjects exhibited a lower fall count, decreased COP excursion limits for some tasks, increased practice volume, and increased attention span during training. Conclusions: The COP-controlled video game-based exercise regime motivated subjects to increase their practice volume and attention span during training. This in turn improved subjects' dynamic balance control.	Univ Manitoba, Sch Med Rehabil, Div Phys Therapy, Winnipeg, MB R3E 0T6, Canada; Univ Manitoba, Dept Elect & Comp Engn, Winnipeg, MB R3E 0T6, Canada	Szturm, T (corresponding author), Univ Manitoba, Sch Med Rehabil, Div Phys Therapy, R106,771 McDermot Ave, Winnipeg, MB R3E 0T6, Canada.	ptsturm@cc.umanitoba.ca					Allum JHJ, 2002, GAIT POSTURE, V16, P264, DOI 10.1016/S0966-6362(02)00011-5; Allum JHJ, 2001, GAIT POSTURE, V14, P227, DOI 10.1016/S0966-6362(01)00132-1; Baratto L, 2002, MOTOR CONTROL, V6, P246, DOI 10.1123/mcj.6.3.246; Barclay-Goddard R., 2004, COCHRANE DB SYST REV, V18; Betker AL, 2006, IEEE T BIO-MED ENG, V53, P686, DOI 10.1109/TBME.2006.870222; Betker AL, 2005, IEEE T BIO-MED ENG, V52, P345, DOI 10.1109/TBME.2004.840466; BETKER AL, 2006, P ADV COMP SCI TECHN; BOULT C, 1994, J GERONTOL, V49, pM28, DOI 10.1093/geronj/49.1.M28; Bourbonnais D, 2002, AM J PHYS MED REHAB, V81, P890, DOI 10.1097/00002060-200212000-00002; Broeren J, 2004, ARCH PHYS MED REHAB, V85, P1247, DOI 10.1016/j.apmr.2003.09.020; Carr J. H., 1998, NEUROLOGICAL REHABIL; Cauraugh JH, 2005, PROG NEUROBIOL, V75, P309, DOI 10.1016/j.pneurobio.2005.04.001; Cheng PT, 2001, ARCH PHYS MED REHAB, V82, P1650, DOI 10.1053/apmr.2001.26256; Cogan A., 1977, 4 ANN C SYST DEV DIS, P187; Creath R, 2005, NEUROSCI LETT, V377, P75, DOI 10.1016/j.neulet.2004.11.071; Cunningham D, 1999, ST HEAL T, V62, P90; Dean CM, 2000, ARCH PHYS MED REHAB, V81, P409, DOI 10.1053/mr.2000.3839; DEWEERDT WJ, 1985, PHYSIOTHERAPY, V71, P9; Di Nardo W, 1999, J DIABETES COMPLICAT, V13, P79, DOI 10.1016/S1056-8727(99)00032-X; Dozza M, 2005, ARCH PHYS MED REHAB, V86, P1401, DOI 10.1016/j.apmr.2004.12.036; Fried L. P., 1991, J AGING HEALTH, V3, P285, DOI [10.1177/089826439100300210, DOI 10.1177/089826439100300210]; Gatev P, 1999, J PHYSIOL-LONDON, V514, P915, DOI 10.1111/j.1469-7793.1999.915ad.x; Geiger RA, 2001, PHYS THER, V81, P995, DOI 10.1093/ptj/81.4.995; Gill J, 2001, J GERONTOL A-BIOL, V56, pM438, DOI 10.1093/gerona/56.7.M438; Glanz M, 1997, J ROY SOC MED, V90, P33, DOI 10.1177/014107689709000110; Gourlay D, 2000, INT J MED INFORM, V60, P255, DOI 10.1016/S1386-5056(00)00100-3; Harris JE, 2005, PHYS THER, V85, P150, DOI 10.1093/ptj/85.2.150; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282; Johansson Barbro B., 2004, Keio Journal of Medicine, V53, P231, DOI 10.2302/kjm.53.231; JORGENSEN HS, 1995, STROKE, V26, P1178, DOI 10.1161/01.STR.26.7.1178; KOZAK JJ, 1993, ERGONOMICS, V36, P777, DOI 10.1080/00140139308967941; Kriegsman DMW, 1997, J EPIDEMIOL COMMUN H, V51, P676, DOI 10.1136/jech.51.6.676; KUO AD, 1995, IEEE T BIO-MED ENG, V42, P87, DOI 10.1109/10.362914; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; LAZZARO N, 2004, P C HUM FACT COMP SY, P1093; Lee MY, 1996, IEEE ENG MED BIOL, V15, P112, DOI 10.1109/51.544518; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Lincoln NB, 1999, STROKE, V30, P573, DOI 10.1161/01.STR.30.3.573; LORD SR, 1993, DIABETIC MED, V10, P614, DOI 10.1111/j.1464-5491.1993.tb00133.x; Mackey DC, 2005, CLIN BIOMECH, V20, P776, DOI 10.1016/j.clinbiomech.2005.05.002; Malone T. W., 1982, P C HUM FACT COMP SY, P63; Marin L, 1999, HUM MOVEMENT SCI, V18, P31, DOI 10.1016/S0167-9457(98)00032-3; Messier SP, 2000, J AM GERIATR SOC, V48, P131, DOI 10.1111/j.1532-5415.2000.tb03903.x; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; Moore EG, 1999, DISABIL REHABIL, V21, P196; Nelson DL, 1996, AM J OCCUP THER, V50, P639, DOI 10.5014/ajot.50.8.639; PAI YC, 1994, PHYS THER, V74, P647, DOI 10.1093/ptj/74.7.647; Peterka RJ, 2002, J NEUROPHYSIOL, V88, P1097, DOI 10.1152/jn.2002.88.3.1097; Remple MS, 2001, BEHAV BRAIN RES, V123, P133, DOI 10.1016/S0166-4328(01)00199-1; Richards CL, 2004, NEUROREHAB NEURAL RE, V18, P199, DOI 10.1177/1545968304269397; Rogers MW, 2001, EXP BRAIN RES, V136, P514, DOI 10.1007/s002210000615; Schaechter JD, 2002, NEUROREHAB NEURAL RE, V16, P326, DOI 10.1177/154596830201600403; Schaechter JD, 2004, PROG NEUROBIOL, V73, P61, DOI 10.1016/j.pneurobio.2004.04.001; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Shan GB, 2004, NEUROCOMPUTING, V61, P341, DOI 10.1016/j.neucom.2003.05.002; Shepard N T, 1992, Am J Audiol, V1, P45, DOI 10.1044/1059-0889.0104.45; SHUMWAYCOOK A, 1988, ARCH PHYS MED REHAB, V69, P395; Sihvonen SE, 2004, GERONTOLOGY, V50, P87, DOI 10.1159/000075559; Szturm T, 1998, J VESTIBUL RES-EQUIL, V8, P381; TEASDALE N, 1991, J GERONTOL, V46, pB238, DOI 10.1093/geronj/46.6.B238; Todorov E, 1997, J MOTOR BEHAV, V29, P147, DOI 10.1080/00222899709600829; Tsang WWN, 2004, MED SCI SPORT EXER, V36, P658, DOI 10.1249/01.MSS.0000122077.87090.2E; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; WHIPPLE R, 1993, J GERONTOL, V48, P71, DOI 10.1093/geronj/48.Special_Issue.71; Wittenberg GF, 2003, NEUROREHAB NEURAL RE, V17, P48, DOI 10.1177/0888439002250456; You SH, 2005, STROKE, V36, P1166, DOI 10.1161/01.STR.0000162715.43417.91	67	113	120	0	51	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2006	87	8					1141	1149		10.1016/j.apmr.2006.04.010			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	072KW	WOS:000239673300018	16876562				2021-06-18	
J	Cohen, DB; Rinker, C; Wilberger, JE				Cohen, DB; Rinker, C; Wilberger, JE			Traumatic brain injury in anticoagulated patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; anticoagulation; outcomes	MINOR HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; PROTHROMBIN TIME; WARFARIN; RISK; ABNORMALITY; OUTPATIENTS; MANAGEMENT	Background. Coumadin is widely used in the elderly population. Despite its widespread use, little is known about its effect on the outcome of elderly traumatic brain-injured patients. This study was undertaken to describe the outcomes of such a cohort. Methods: Clinical material was identified from a Level I trauma center prospective head injury database, and a database obtained from the American College of Surgeons Committee on Trauma Verification and Review Committee from 1999 to 2002. Both databases contain many relevant variables, including age, sex, Glasgow Coma Scale (GCS) score, mechanism of injury, Injury Severity Score, International Normalized Ratio (INR), computed tomography (CT) findings, operative procedure, time to operating room, complications, length of stay, and outcome at hospital discharge. Results: For patients with GCS scores less than 8, average INR was 6.0, with almost 50% having an initial value greater than 5.0. Overall mortality was 91.5%. For the 77 patients with GCS scores of 13 to 15, average INR was 4.4. Overall mortality for this group was 80.6%. A subset of patients deteriorated to a GCS score of less than 10 just hours after injury, despite most having normal initial CT scans. Mortality in this group was 84%. Conclusions: All patients on warfarin should have an INR performed, and a CT scan should be done in most anticoagulated patients. All supratherapeutically anticoagulated patients, as well as any anticoagulated patient with a traumatic CT abnormality, should be admitted for neurologic observation and consideration given to short term reversal of anticoagulation. Routine repeat CT scanning at 12 to 18 hours or when even subtle signs of neurologic worsening occur is a strong recommendation. A multi-institutional, prospective trial using these guidelines would be a first step toward demonstrating improved outcomes in the anticoagulated patient population after head trauma.	Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA; Surg Associztes Bozeman, Bozeman, MT USA	Wilberger, JE (corresponding author), Allegheny Gen Hosp, Dept Neurosurg, 420 E N Ave,Suite 302, Pittsburgh, PA 15212 USA.	jwilberg@wpahs.org					BOLLINGER O, 1891, HIRSCHWALD, V70, P457; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Gilman AG, 1998, GOODMAN GILMANS PHAR; GURWITZ JH, 1992, ANN INTERN MED, V116, P901, DOI 10.7326/0003-4819-116-11-901; HART RG, 1995, STROKE, V26, P1471, DOI 10.1161/01.STR.26.8.1471; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Karni A, 2001, AM SURGEON, V67, P1098; KASE CS, 1985, NEUROLOGY, V35, P943, DOI 10.1212/WNL.35.7.943; LANDEFELD CS, 1989, AM J MED, V87, P153; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; PETITTI DB, 1989, J CLIN EPIDEMIOL, V42, P759, DOI 10.1016/0895-4356(89)90073-5; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Saab M, 1996, J ACCID EMERG MED, V13, P208; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; TEASDALE G, 1982, HEAD INJURY BASIC CL, P213; Volans AP, 1998, J ACCID EMERG MED, V15, P159; WINTZEN AR, 1984, ANN NEUROL, V16, P553, DOI 10.1002/ana.410160505; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	24	113	118	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2006	60	3					553	557		10.1097/01.ta.0000196542.54344.05			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	026WX	WOS:000236374900019	16531853				2021-06-18	
J	Heinly, MT; Greve, KW; Bianchini, KJ; Love, JM; Brennan, A				Heinly, MT; Greve, KW; Bianchini, KJ; Love, JM; Brennan, A			WAIS Digit Span-based indicators of malingered neurocognitive dysfunction - Classification accuracy in traumatic brain injury	ASSESSMENT			English	Article; Proceedings Paper	24th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 17-20, 2004	Seattle, WA	Natl Acad Neuropsychol		Digit Span; reliable digit span; malingering; response bias; traumatic brain injury; neuropsychological assessment	CARD SORTING TEST; ADULT INTELLIGENCE SCALE; HEAD-INJURY; PERFORMANCE PATTERNS; RELIABLE DIGITS; RESPONSE BIAS; MEMORY; IDENTIFICATION; SPECIFICITY; SENSITIVITY	The present study determined specificity and sensitivity to malingered neurocognitive dysfunction (MND) in traumatic brain injury (TBI) for several Wechsler Adult Intelligence Scale (WAIS) Digit Span scores. TBI patients (n = 344) were categorized into one of five groups: no incentive, incentive only, suspect, probable MND, and definite MND. Performance of 1,063 nonincentive patients (e.g., cerebrovascular accident, memory disorder) was also examined. Digit Span scores included reliable digit span, maximum span forward both trials correct, maximum span forward, combined maximum forward and backward span, Digit Span scaled score, maximum span backward both trials correct, and maximum span backward. In TBI, sensitivity to MND ranged from 15% to greater than 30% at specificities of 92% to 98%. Patient groups with documented brain pathology had higher false-positive error rates. These results replicate previous known-groups malingering studies and provide valuable data supporting the WAIS Digit Span scores in detection and diagnosis of malingering.	Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BABIKIAN T, IN PRESS CLIN NEUROP; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAND DIGIT RECOG; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Butters N, 1980, ALCOHOLIC KORSAKOFFS; CARLESIMO GA, 1994, ACTA NEUROL SCAND, V89, P132; Duncan SA, 2002, ASSESSMENT, V9, P56, DOI 10.1177/1073191102009001007; Etherton J, 2005, ASSESSMENT, V12, P130, DOI 10.1177/1073191105274859; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; ETHERTON JL, IN PRESS J CLIN EXPT; Gouvier WD, 1998, CRIT ISS NE, P55; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Heaton SK, 1993, WISCONSIN CARD SORTI; Hennekens CH, 1987, EPIDEMIOLOGY MED; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; KAGEHIRO DK, 1990, PSYCHOL SCI, V1, P194, DOI 10.1111/j.1467-9280.1990.tb00197.x; KIERNAN RJ, 1983, NEUROBEHAVIORAL COGN; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; MAPOU RL, 1995, CLIN NEUROPSYCHOL, P295; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Ramsay MC, 1995, NEUROPSYCHOL REV, V5, P151, DOI 10.1007/BF02214760; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tamura Itaru, 2003, No To Shinkei, V55, P335; Thorndike RL., 1986, STANFORD BINET INTEL, V4; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WECHSLER ADULT INTEL; Wechsler D., 1997, WECHSLER MEMORY SCAL, VIII; Wilde N, 2002, CLIN NEUROPSYCHOL, V16, P322, DOI 10.1076/clin.16.3.322.13858; Wilde NJ, 2004, J CLIN EXP NEUROPSYC, V26, P539, DOI 10.1080/13803390490496605	53	113	114	1	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	DEC	2005	12	4					429	444		10.1177/1073191105281099			16	Psychology, Clinical	Psychology	984AM	WOS:000233274800007	16244123				2021-06-18	
J	Mooney, G; Speed, J; Sheppard, S				Mooney, G; Speed, J; Sheppard, S			Factors related to recovery after mild traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; concussion; recovery; industrial injury; symptom validity testing	POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; CHRONIC PAIN; POSTCONCUSSIVE SYMPTOMS; RISK-FACTORS; MODERATE; DEPRESSION; MEMORY; PREDICTION	Primary objectives: To study the variables that relate to outcome after mild traumatic brain injury (TBI). Methods and procedures: Sixty-seven adults with disappointing recoveries after mild TBI most occurring in a compensation or litigation context were studied with regard to pre-injury, neuro-trauma, physical, emotional and cognitive variables on outcome. Validity of physical, emotional and cognitive symptoms was controlled for. Main outcomes and results: Except for prior psychological traumatization, neither pre-injury, neuro-trauma or cognitive variables were related to outcome. Variables most consistently related to outcome were depression, pain and symptom invalidity on measures of response bias. These factors accounted for the majority of variance in outcome. Conclusions: In cases of poor recovery after mild TBI where compensation or litigation may be a factor, most of the variance in recovery seems to be explained by depression, pain and symptom invalidity, rather than by the injury variables themselves.	Univ Utah, Div Phys Med & Rehabil, Salt Lake City, UT 84132 USA	Mooney, G (corresponding author), Univ Utah, Div Phys Med & Rehabil, 30 North 1900 East, Salt Lake City, UT 84132 USA.	gmooney@hsc.utah.edu					ALLEN LM, 1997, CARB 97 COMPUTERIZED; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BERNSTEIN EM, 1986, J NERV MENT DIS, V174, P727, DOI 10.1097/00005053-198612000-00004; Bierley RA, 2001, BRAIN INJURY, V15, P697, DOI 10.1080/02699050010013671; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; BRANDON AD, 1985, DIGITAL FINGER TAPPI; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; CICERONE K, 1993, 70 ANN SESS AM C REH; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; DEVORE JR, 1998, PHYSICAL MED REHABIL, V12, P111; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; GREEN WP, 1996, WORD MEMORY TEST USE; GREENE RL, 1991, MMPI 2 MMPI INTERPRE; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; Halstead WC, 1985, HALSTEAD REITAN NEUR; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; HATHAWAY SR, 1989, MINNESOTA MULTIPHASI, V2; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Hooper H.E., 1958, HOOPER VISUAL ORG TE; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kaplan E., 1983, BOSTON NAMING TEST; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kuhajda MC, 2002, PAIN, V97, P213, DOI 10.1016/S0304-3959(01)00488-2; LeesHaley PR, 1997, BRAIN INJURY, V11, P791; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Mooney G, 1997, NEUROREHABILITATION, V8, P223, DOI 10.3233/NRE-1997-8308; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; Prohl J, 2001, J NERV MENT DIS, V189, P602, DOI 10.1097/00005053-200109000-00005; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schofferman J., 1992, SPINE S6, V17, pS1380; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sosin DM, 1996, BRAIN INJURY, V10, P47; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; Tombaugh TN, 1996, TEST MEMORY MALINGER; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Umile EM, 1998, BRAIN INJURY, V12, P577; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	66	113	116	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2005	19	12					975	987		10.1080/02699050500110264			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZA	WOS:000233269700004	16263640				2021-06-18	
J	Ramaswamy, S; Goings, GE; Soderstrom, KE; Szele, FG; Kozlowski, DA				Ramaswamy, S; Goings, GE; Soderstrom, KE; Szele, FG; Kozlowski, DA			Cellular proliferation and migration following a controlled cortical impact in the mouse	BRAIN RESEARCH			English	Article						traumatic brain injury; subventricular zone; BrdU; migration; sensorimotor cortex	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; NEURAL STEM-CELLS; FLUORESCENT LATEX MICROSPHERES; MICROTUBULE-ASSOCIATED PROTEIN; SUBVENTRICULAR ZONE CELLS; NEWLY GENERATED NEURONS; ADULT MAMMALIAN BRAIN; NEUROTROPHIC FACTOR; PROGENITOR CELLS	Neurogenesis following neural degeneration has been demonstrated in many models of disease and injury. The present study further examines the early proliferative and migratory response of the brain to a controlled cortical impact (CCI) model of traumatic brain injury. The CCI was centered over the forelimb sensorimotor cortex, unilaterally, in the adult mouse. To examine proliferation, bromo-deoxyuridine (BrdU) was injected i.p. immediately post-injury and on post-injury days 1, 2, and 3. To assess migration, we labeled SVZ cells with inert latex microspheres immediately post-injury. By combining microsphere labeling with BrdU, we determined if migrating cells had gone through the S-phase of the cell cycle after the lesion. In addition, we used a marker of neurogenesis and migration, doublecortin, to further characterize the response of the SVZ to the injury. Lastly, we determined whether subregions of the SVZ respond differentially to injury. The current study demonstrates that 3 days following CCI cellular proliferation is seen around the cortex, in the SVZ, corpus callosum, and subcortical areas anatomically connected to, but not directly damaged by the impact. It delineates that an increase in proliferation occurs in the dorsal-most aspect of the ipsilateral SVZ following impact. Lastly, it demonstrates that proliferating cells migrate from the SVZ to cortical and subcortical structures affected by the injury and that some of these cells are migrating neuroblasts. (c) 2005 Elsevier B.V. All rights reserved.	De Paul Univ, Dept Biol Sci, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Childrens Mem Res Ctr, Chicago, IL 60614 USA	Kozlowski, DA (corresponding author), De Paul Univ, Dept Biol Sci, 2325 N Clifton, Chicago, IL 60614 USA.	dkozlows@depaul.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG42253] Funding Source: Medline		Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Alifragis P, 2002, EXP NEUROL, V174, P259, DOI 10.1006/exnr.2002.7870; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Benraiss A, 2001, J NEUROSCI, V21, P6718; Bernier PJ, 2002, P NATL ACAD SCI USA, V99, P11464, DOI 10.1073/pnas.172403999; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; COLIN W, 1989, BRAIN RES, V486, P334, DOI 10.1016/0006-8993(89)90520-9; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; Doetsch F, 1997, J NEUROSCI, V17, P5046; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; EMMETT CJ, 1988, BRAIN RES, V447, P223, DOI 10.1016/0006-8993(88)91123-7; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; Fitch MT, 1999, J NEUROSCI, V19, P8182; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; FRISEN J, 1995, NEUROSCIENCE, V65, P293, DOI 10.1016/0306-4522(94)00467-J; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Goings GE, 2002, NEUROSCI LETT, V329, P161, DOI 10.1016/S0304-3940(02)00611-0; Goldman SA, 1998, J NEUROBIOL, V36, P267, DOI 10.1002/(SICI)1097-4695(199808)36:2<267::AID-NEU12>3.0.CO;2-B; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUTH L, 1985, EXP NEUROL, V88, P1, DOI 10.1016/0014-4886(85)90109-8; HATTON JD, 1993, INT J DEV NEUROSCI, V11, P583, DOI 10.1016/0736-5748(93)90047-H; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Jankovski A, 1998, EUR J NEUROSCI, V10, P3853, DOI 10.1046/j.1460-9568.1998.00397.x; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Jones E.G., 1985, THALAMUS; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; KATZ LC, 1990, NEUROSCIENCE, V34, P511, DOI 10.1016/0306-4522(90)90159-2; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Lie DC, 2002, J NEUROSCI, V22, P6639; Liu JL, 1998, J NEUROSCI, V18, P7768; Loos M, 2003, NEUROSCIENCE, V122, P373, DOI 10.1016/S0306-4522(03)00498-6; Magavi SS, 2000, NATURE, V405, P951; Mason HA, 2001, J NEUROSCI, V21, P7654; MILLER MW, 1987, EXP BRAIN RES, V67, P339; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; Nolte J., 1993, HUMAN BRAIN INTRO IT; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Paxinos G., 2004, RAT NERVOUS SYSTEM, VThird; PEDERSEN PH, 1995, INT J CANCER, V62, P767, DOI 10.1002/ijc.2910620620; Pencea V, 2001, J NEUROSCI, V21, P6706; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Risold P. Y., 2004, RAT NERVOUS SYSTEM, P605, DOI DOI 10.1016/B978-012547638-6/50021-3; Romanko MJ, 2004, PROG NEUROBIOL, V74, P77, DOI 10.1016/j.pneurobio.2004.07.001; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Scharff C, 2000, NEURON, V25, P481, DOI 10.1016/S0896-6273(00)80910-1; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Sundholm-Peters NL, 2004, J NEUROCYTOL, V33, P153, DOI 10.1023/B:NEUR.0000029654.70632.3a; Suzuki Y, 1998, ANN NY ACAD SCI, V855, P252, DOI 10.1111/j.1749-6632.1998.tb10577.x; Szele FG, 1996, J COMP NEUROL, V368, P439, DOI 10.1002/(SICI)1096-9861(19960506)368:3<439::AID-CNE9>3.0.CO;2-6; van Praag H, 1999, NAT NEUROSCI, V2, P266; Yang HKC, 2004, J NEUROSCI RES, V76, P282, DOI 10.1002/jnr.20071; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004	73	113	120	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 16	2005	1053	1-2					38	53		10.1016/j.brainres.2005.06.042			16	Neurosciences	Neurosciences & Neurology	959YM	WOS:000231555500006	16051202				2021-06-18	
J	Vinchon, M; Defoort-Dhellemmes, S; Desurmont, M; Dhellemmes, P				Vinchon, M; Defoort-Dhellemmes, S; Desurmont, M; Dhellemmes, P			Accidental and nonaccidental head injuries in infants: a prospective study	JOURNAL OF NEUROSURGERY			English	Article						head injury; subdural hematoma; retinal hemorrhage; child abuse; infant	TRAUMATIC BRAIN-INJURY; ACUTE SUBDURAL-HEMATOMA; SHAKEN-BABY SYNDROME; YOUNG-CHILDREN; HEMORRHAGES; POPULATION; PATTERNS; DAMAGE; ABUSE	Object. Head injury is a major cause of morbidity and death in infants, and child abuse is among its chief causes. Retinal hemorrhages (RHs) are of paramount importance for the diagnosis of child abuse; however, their sensitivity and specificity are poorly estimated. Subdural hematoma (SDH) is a common feature; however, its incidence and causative factors are poorly documented. Methods. To study the epidemiology of head injuries in infants, factors predisposing to SDH, value of RH for the diagnosis of child abuse, and prognostic factors, the authors prospectively collected data from cases of head injury in infants who were hospitalized at their institution over a 3-year period. One hundred fifty cases were collected, 57 of which were due to child abuse. This prospective study allows the comparison of clinical, radiological, and ophthalmological features in accidental and nonaccidental trauma in infants. Conclusions. Subdural hematomas were significantly correlated with RH and with child abuse but not with idiopathic macrocranium. The sensitivity and specificity of RH for the diagnosis of child abuse were 75 and 93.2%, respectively. Retinal hemorrhages associated with accidental trauma were always mild, and the specificity of more severe RH for the diagnosis of child abuse was 100%. The grading of RH requires the expertise of a trained neuroophthalmologist. Child abuse was also significantly associated with antecedents of perinatal illness, absence of signs of impact, and seizures on presentation. Although child abuse represented just 38% of traumas, it was the cause of 71% of deaths and 90% of severe disability in this series. Abuse and the clinical severity on presentation were two significant and independent factors conditioning outcome.	CHRU Lille, Serv Neurochirurg Pediat, F-59037 Lille, France; CHRU Lille, Dept Pediat Neurosurg, F-59037 Lille, France	Vinchon, M (corresponding author), CHRU Lille, Serv Neurochirurg Pediat, F-59037 Lille, France.	m-vinchon@chru-lille.fr		Vinchon, Matthieu/0000-0002-9122-6165			AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; DEFOORTDHELLEMM.S, 2004, CHILD NERV SYST, V20, P279; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; IKEDA A, 1987, CHILD NERV SYST, V3, P19, DOI 10.1007/BF00707188; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; JENNETT B, 1975, LANCET, V1, P480; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; KRAUS JF, 1987, PEDIATRICS, V79, P501; LEESTMA JE, 1995, PEDIAT NEUROPATHOLOG, P243; MORI K, 1993, CHILD NERV SYST, V9, P282, DOI 10.1007/BF00306274; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; Papasian NC, 2000, PEDIATR NEUROSURG, V33, P188, DOI 10.1159/000055951; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Vinchon M, 2004, J NEUROSURG, V101, P44, DOI 10.3171/ped.2004.101.2.0044; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; Vinchon M, 2001, J NEUROSURG, V95, P249, DOI 10.3171/jns.2001.95.2.0249	26	113	116	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2005	102	4		S			380	384		10.3171/ped.2005.102.4.0380			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	928CV	WOS:000229249600006	15926388				2021-06-18	
J	Pfeifer, R; Borner, A; Krack, A; Sigusch, HH; Surber, R; Figulla, HR				Pfeifer, R; Borner, A; Krack, A; Sigusch, HH; Surber, R; Figulla, HR			Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale	RESUSCITATION			English	Article						cardiopulmonary resuscitation; outcome neuron-specific enolase; S-100 protein; Glasgow Coma Scale	HYPOXIC BRAIN-DAMAGE; NEUROLOGICAL RECOVERY; SERUM-LEVELS; HEAD-INJURY; BLOOD; PROGNOSIS; SURVIVAL; MARKERS	Background and purpose: Patients resuscitated from cardiac arrest are at risk of subsequent death or poor neurological outcome up to a persistent vegetative state. We investigated the prognostic value of several epidemiological and clinical markers and two neuroproteins, neuron-specific enolase (NSE) and S-100 protein (S-100), in 97 patients undergoing cardiopulmonary resuscitation (CPR) after non-traumatic cardiac arrest between 1998 and 2002. Results: 52.6% of the patients died, 28.8% survived with severe, moderate or without neurological disorders, and 18.6% remained in a persistent vegetative state. Unconsciousness > 48 h after CPR predicted a 60.6-fold (95% Cl 14.3287-257.205, p = 0.001) and a Glasgow Coma Scale (GCS) < 6 points after 72 h a 11.2-fold (CI 95%, 3.55-36.44, p < 0.001) risk of poor neurological outcome. Serum levels > 65 ng/ml for NSE and > 1.5 mu g/l for S-100 increased the risk of death and persistent vegetative state 16.8 (95% Cl 2.146-131.520)- and 12.6 (95% Cl 1.1093-99.210)- fold, respectively. By combination of the GCS with elevated serum concentrations of both neuroproteins above the cut off levels on third day after CPR a poor neurological outcome was predicted with a specificity of 100%. Conclusion: The combination of GCS with the serum levels of both neuroproteins at 72 It after CPR permit a more reliable prediction of outcome in post arrest coma than the single markers alone, independent of the application of anaesthetic agents. (c) 2004 Elsevier Ireland Ltd. All rights reserved.	Univ Jena, Dept Internal Med 1, Div Cardiol & Intens Care Med, D-07740 Jena, Germany; Univ Jena, Inst Clin Chem, D-07740 Jena, Germany; Univ Jena, Diagnost Lab, D-07740 Jena, Germany	Pfeifer, R (corresponding author), Univ Jena, Dept Internal Med 1, Div Cardiol & Intens Care Med, Erlanger Allee 101, D-07740 Jena, Germany.	Ruediger.Pfeifer@med.uni-jena.de					ABRAMSON NS, 1985, CRIT CARE MED, V13, P930, DOI 10.1097/00003246-198511000-00020; BATES D, 1977, ANN NEUROL, V2, P211, DOI 10.1002/ana.410020306; Berek K, 1997, EUR NEUROL, V37, P135, DOI 10.1159/000117426; BIALECKI L, 1995, CHEST, V108, P1009, DOI 10.1378/chest.108.4.1009; BOKONJIC N, 1961, CEREBRAL ANOXIA ELEC, P118; Bottiger BW, 2001, CIRCULATION, V103, P2694; Cooper S, 1997, RESUSCITATION, V35, P17, DOI 10.1016/S0300-9572(97)00020-8; deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; GRUBB NR, 1995, LANCET, V346, P417, DOI 10.1016/S0140-6736(95)92784-0; Hallstrom AP, 1996, CIRCULATION, V93, P2019, DOI 10.1161/01.CIR.93.11.2019; HERLITZ J, 1994, RESUSCITATION, V28, P27, DOI 10.1016/0300-9572(94)90051-5; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mullner M, 1997, J CEREBR BLOOD F MET, V17, P430; PAHLMAN S, 1984, TUMOUR BIOL, V5, P127; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; SCHAARSCHMIDT H, 1994, STROKE, V25, P558, DOI 10.1161/01.STR.25.3.558; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SELLMAN M, 1992, SCAND J THORAC CARD, V26, P39, DOI 10.3109/14017439209099051; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; SNYDER BD, 1977, NEUROLOGY, V27, P807, DOI 10.1212/WNL.27.9.807; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977	33	113	122	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572	1873-1570		RESUSCITATION	Resuscitation	APR	2005	65	1					49	55		10.1016/j.resuscitation.2004.10.011			7	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	919FY	WOS:000228605000008	15797275				2021-06-18	
J	Cho, KS; Yang, L; Lu, B; Ma, HF; Huang, XZ; Pekny, M; Chen, DF				Cho, KS; Yang, L; Lu, B; Ma, HF; Huang, XZ; Pekny, M; Chen, DF			Re-establishing the regenerative potential of central nervous system axons in postnatal mice	JOURNAL OF CELL SCIENCE			English	Article						astrocyte intermediate filament; GFAP; vimentin; Bcl-2; axon regeneration	FIBRILLARY ACIDIC PROTEIN; RETINAL GANGLION-CELLS; INTERMEDIATE-FILAMENTS; SPINAL-CORD; TRANSGENIC MICE; PROMOTE REGENERATION; NOGO-RECEPTOR; WHITE-MATTER; BCL-2; VIMENTIN	At a certain point in development, axons in the mammalian central nervous system lose their ability to regenerate after injury. Using the optic nerve model, we show that this growth failure coincides with two developmental events: the loss of Bcl-2 expression by neurons and the maturation of astrocytes. Before postnatal day 4, when astrocytes are immature, overexpression of Bcl-2 alone supported robust and rapid optic nerve regeneration over long distances, leading to innervation of brain targets by day 4 in mice. As astrocytes matured after postnatal day 4, axonal regeneration was inhibited in mice overexpressing Bcl-2. Concurrent induction of Bcl-2 and attenuation of reactive gliosis reversed the failure of CNS axonal re-elongation in postnatal mice and led to rapid axonal regeneration over long distances and reinnervation of the brain targets by a majority of severed optic nerve fibers up to 2 weeks of age. These results suggest that an early postnatal downregulation of Bcl-2 and post-traumatic reactive gliosis are two important elements of axon regenerative failure in the CNS.	Univ Gothenburg, Sahlgrenska Acad, Inst Clin Neurosci, Arvid Carlsson Inst Neurosci, SE-41390 Gothenburg, Sweden; Harvard Univ, Sch Med, Schepens Eye Res Inst, Program Neurosci, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA	Pekny, M (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Clin Neurosci, Arvid Carlsson Inst Neurosci, Medicinaregatan 9A, SE-41390 Gothenburg, Sweden.	milos.pekny@medkem.gu.se; dfchen@vision.eri.harvard.edu	Chen, Dong/AAJ-2444-2020	Cho, Kin-Sang/0000-0003-4285-615X	NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01 EY012983] Funding Source: Medline; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY012983] Funding Source: NIH RePORTER		Bonfanti L, 1996, J NEUROSCI, V16, P4186; Bregman BS, 1998, CURR OPIN NEUROBIOL, V8, P800, DOI 10.1016/S0959-4388(98)80124-4; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; Chen DF, 1998, CELL DEATH DIFFER, V5, P816, DOI 10.1038/sj.cdd.4400431; Chierzi S, 1999, J NEUROSCI, V19, P8367; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Cristino L, 2000, NEUROSCIENCE, V101, P451, DOI 10.1016/S0306-4522(00)00393-6; DAHL D, 1981, EUR J CELL BIOL, V24, P191; Davies SJA, 1997, NATURE, V390, P680; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; Hilton M, 1997, CURR BIOL, V7, P798, DOI 10.1016/S0960-9822(06)00339-3; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Huang XH, 2003, INVEST OPHTH VIS SCI, V44, P347, DOI 10.1167/iovs.02-0198; Hunt D, 2002, J NEUROCYTOL, V31, P93, DOI 10.1023/A:1023941421781; JHAVERI S, 1991, EXP BRAIN RES, V87, P371; JHAVERI S, 1992, GLIA, V6, P138, DOI 10.1002/glia.440060208; JIAO JW, 2005, IN PRESS EMBO J; Josephson A, 2002, J COMP NEUROL, V453, P292, DOI 10.1002/cne.10408; Karim F, 2001, BRAIN RES REV, V36, P204, DOI 10.1016/S0165-0173(01)00096-0; Khurgel M, 1996, GLIA, V16, P351, DOI 10.1002/(SICI)1098-1136(199604)16:4<351::AID-GLIA7>3.0.CO;2-2; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; Li Y, 2003, J NEUROSCI, V23, P7783; Lodovichi C, 2001, EUR J NEUROSCI, V13, P833, DOI 10.1046/j.1460-9568.2001.01440.x; Lundkvist A, 2004, J CELL SCI, V117, P3481, DOI 10.1242/jcs.01221; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McGee AW, 2003, TRENDS NEUROSCI, V26, P193, DOI 10.1016/S0166-2236(03)00062-6; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MERRY DE, 1994, DEVELOPMENT, V120, P301; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Oh YJ, 1996, NEUROSCI LETT, V202, P161, DOI 10.1016/0304-3940(95)12235-4; Ohmi K, 2003, P NATL ACAD SCI USA, V100, P1902, DOI 10.1073/pnas.252784899; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; SILVER J, 1994, J NEUROL, V242, pS22, DOI 10.1007/BF00939236; TAKADA M, 1986, HISTOL HISTOPATHOL, V1, P271; Vela JM, 1998, BRAIN RES REV, V26, P29, DOI 10.1016/S0165-0173(97)00055-6; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Williams SE, 2003, NEURON, V39, P919, DOI 10.1016/j.neuron.2003.08.017; Yin YQ, 2003, J NEUROSCI, V23, P2284; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	48	113	120	1	7	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0021-9533	1477-9137		J CELL SCI	J. Cell Sci.	MAR 1	2005	118	5					863	872		10.1242/jcs.01658			10	Cell Biology	Cell Biology	916IK	WOS:000228378400004	15731004	Other Gold, Green Accepted			2021-06-18	
J	Rapoport, MJ; McCullagh, S; Shammi, P; Feinstein, A				Rapoport, MJ; McCullagh, S; Shammi, P; Feinstein, A			Cognitive impairment associated with major depression following mild and moderate traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							EXECUTIVE FUNCTION; DEFICITS; RECOVERY; SYMPTOMS; DISORDER	Traumatic brain injury (TBI) and major depression are neuropsychiatric conditions that have been associated with cognitive dysfunction. The aim of this study was to explore the relationship between major depression and cognitive impairment following mild and moderate TBI. Seventy-four TBI patients were assessed for the presence of major depression using the Structured Clinical Interview for the DSM-IV and completed a neurocognitive assessment battery. Subjects with major depression (28.4%), compared to those without, were found to have significantly lower scores on measures of working memory, processing speed, verbal memory and executive function. Potential mechanisms and implications for treatment are discussed.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Traumat Brain Injury Clin, Toronto, ON M4N 3M5, Canada; Baycrest Ctr Geriatr Care, Dept Psychol, Toronto, ON, Canada	Rapoport, MJ (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, FG37,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	Mark.Rapoport@sw.ca	Rapoport, Mark/AAD-8581-2020				ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Benedict R., 1997, BRIEF VISUOSPATIAL M; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; First M.B., 1996, STRUCTURED CLIN INTE; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Heaton R., 1993, WISCONSIN CARD SORTI; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KILOH LG, 1961, ACTA PSYCHIAT SCAND, V37, P336, DOI 10.1111/j.1600-0447.1961.tb07367.x; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Mayberg Helen S, 2002, Semin Clin Neuropsychiatry, V7, P255, DOI 10.1053/scnp.2002.35223; MCCULLAGH S, 2004, TXB TRAUMATIC BRAIN, P321; Niemann H, 1996, NEUROPSYCHOL REV, V6, P11, DOI 10.1007/BF01875418; Ottowitz WE, 2002, HARVARD REV PSYCHIAT, V10, P86, DOI 10.1080/10673220216210; *PSYCHOL CORP, 1997, WECHSL AD INT SCAL T; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; RICHARDSON JTE, 2000, CLIN NEUROPSYCHOL, P97; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; The Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925	36	113	114	0	11	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FEB	2005	17	1					61	65		10.1176/appi.neuropsych.17.1.61			5	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	902RP	WOS:000227374500008	15746484				2021-06-18	
J	Andersen, TE; Arnason, A; Engebretsen, L; Bahr, R				Andersen, TE; Arnason, A; Engebretsen, L; Bahr, R			Mechanisms of head injuries in elite football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL SOCCER PLAYERS; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; ASSOCIATION FOOTBALL; VIDEO ANALYSIS; BALL; EPIDEMIOLOGY; MANAGEMENT; IMPAIRMENT; INCIDENTS	Objectives: The aim of this study was to describe, using video analysis, the mechanisms of head injuries and of incidents with a high risk of head injury in elite football. Methods: Videotapes and injury information were collected prospectively for 313 of the 409 matches played in the Norwegian ( 2000 season) and Icelandic ( 1999 and 2000 season) professional leagues. Video recordings of incidents where a player appeared to be hit in the head and the match was consequently interrupted by the referee were analysed and cross referenced with reports of acute time loss injuries from the team medical staff. Results: The video analysis revealed 192 incidents (18.8 per 1000 player hours). Of the 297 acute injuries reported, 17 (6%) were head injuries, which corresponds to an incidence of 1.7 per 1000 player hours (concussion incidence 0.5 per 1000 player hours). The most common playing action was a heading duel with 112 cases (58%). The body part that hit the injured player's head was the elbow/arm/hand in 79 cases (41%), the head in 62 cases (32%), and the foot in 25 cases (13%). In 67 of the elbow/arm/hand impacts, the upper arm of the player causing the incident was at or above shoulder level, and the arm use was considered to be active in 61 incidents (77%) and intentional in 16 incidents (20%). Conclusions: This study suggests that video analysis provides detailed information about the mechanisms for head injuries in football. The most frequent injury mechanism was elbow to head contact, followed by head to head contact in heading duels. In the majority of the elbow to head incidents, the elbow was used actively at or above shoulder level, and stricter rule enforcement or even changes in the laws of the game concerning elbow use should perhaps be considered, in order to reduce the risk of head injury.	Norwegian Univ Sport & Phys Educ, Oslo Sports Trauma Res Ctr, N-0806 Oslo, Norway	Andersen, TE (corresponding author), Norwegian Univ Sport & Phys Educ, Oslo Sports Trauma Res Ctr, POB 4014,Ulleval Stad, N-0806 Oslo, Norway.	thor.einar.andersen@nih.no	Bahr, Roald/B-6964-2014	Bahr, Roald/0000-0001-5725-4237; Andersen, Thor Einar/0000-0003-4172-4518; Arnason, Arni/0000-0003-1007-4719			Albert M, 1983, ATHLETIC TRAINING, V18, P218; Andersen TE, 2004, BRIT J SPORT MED, V38, P626, DOI 10.1136/bjsm.2003.007955; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Arnason A, 1996, SCAND J MED SCI SPOR, V6, P40, DOI 10.1111/j.1600-0838.1996.tb00069.x; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barnett C, 2003, INT J GERIATR PSYCH, V18, P88, DOI 10.1002/gps.728; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dvorak J, 2000, AM J SPORT MED, V28, pS3; EKSTRAND J, 1990, FOOT ANKLE, V11, P41, DOI 10.1177/107110079001100108; GRONWALL D, 1975, LANCET, V2, P995; Hawkins RD, 1996, BRIT J SPORT MED, V30, P165, DOI 10.1136/bjsm.30.2.165; Hawkins RD, 1999, BRIT J SPORT MED, V33, P196, DOI 10.1136/bjsm.33.3.196; Hawkins RD, 2001, BRIT J SPORT MED, V35, P43, DOI 10.1136/bjsm.35.1.43; INKLAAR H, 1994, SPORTS MED, V18, P55, DOI 10.2165/00007256-199418010-00006; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lewin G., 1989, PHYSIOTHERAPY, V75, P601; LOHNES JH, 1994, SPORTS INJURIES MECH; Luthje P, 1996, SCAND J MED SCI SPOR, V6, P180; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; NIELSEN AB, 1989, AM J SPORT MED, V17, P803, DOI 10.1177/036354658901700614; ORCHARD J, 1993, SPORT HLTH, V11, P39; Peterson L, 2000, AM J SPORT MED, V28, pS51; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sandelin J, 1985, Br J Sports Med, V19, P30; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421	43	113	113	0	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC 1	2004	38	6					690	696		10.1136/bjsm.2003.009357			7	Sport Sciences	Sport Sciences	873SH	WOS:000225300700008	15562161	Green Published, Bronze			2021-06-18	
J	Crisco, JJ; Chu, JJ; Greenwald, RM				Crisco, JJ; Chu, JJ; Greenwald, RM			An algorithm for estimating acceleration magnitude and impact location using multiple nonorthogonal single-axis accelerometers	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							PROFESSIONAL FOOTBALL; CONCUSSION; INJURIES	Accelerations of the head are the likely cause of concussion injury. but identifiing the specific etiology of concussion has been difficult due to the lack of a valid animal or computer model. Contact sports, in which concussions are a rising health care concern. offer a unique research laboratory environment. However measuring head acceleration in the field has many challenges including the need for large population sampling because of the relatively low incidence of concussions. We report a novel approach for calculating linear acceleration that can be incorporated into a head-mounted system for on-field use during contact sports. The advantages of this approach include the use of single axis linear accelerometers, which reduce costs, and a nonorthogonal arrangement of the accelerometers, which simplifies the design criteria for a head-mounted and helmet compatible system. The purpose of this study was to describe the algorithm and evaluate its accuracy for measuring linear acceleration magnitude and impact location using computer simulation and experimental tests with various accelerometer configurations. A 10% error in magnitude and a 10 deg error in impact location were achieved using as feu as six single-axis accelerometers mounted on a hemispherical headform.	Rhode Isl Hosp, Brown Med Sch, Dept Orthopaed, Providence, RI USA; Simbex LLC, Lebanon, NH USA; Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Crisco, JJ (corresponding author), Rhode Isl Hosp, Brown Med Sch, Dept Orthopaed, Providence, RI USA.	joseph_crisco@brown.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R43HD40473 01] Funding Source: Medline		CANTU RC, 1990, J SPINAL DISORD, V3, P227; Cervelli P, 2001, J GEOPHYS RES-SOL EA, V106, P11217, DOI 10.1029/2000JB900399; GREENWALD R, 2003, 27 AM SOC BIOM M; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Ivarsson J, 2003, J BIOMECH ENG-T ASME, V125, P523, DOI 10.1115/1.1590360; Melvin J.W., 1993, ACCIDENTAL INJURY BI, P268; MERTZ HJ, 1967, KINEMATICS KINETICS; MITAL NK, 1979, J APPL MECH-T ASME, V46, P925, DOI 10.1115/1.3424679; Moon D W, 1971, Med Sci Sports, V3, P44; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; NUSHOLTZ G, 1988, MATH BIOSCI, P85; NUSHOLTZ GS, 1991, EXP MECH, V31, P264, DOI 10.1007/BF02326070; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; SCHNEIDER R, 1965, CLIN NEUROSURG, V12, P226; SIEGMUND GP, 1997, 41 STAPP CAR CRASH C, P357	23	113	113	0	17	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	DEC	2004	126	6					849	854		10.1115/1.1824135			6	Biophysics; Engineering, Biomedical	Biophysics; Engineering	901XD	WOS:000227314700020	15796345				2021-06-18	
J	Meeuwisse, WH; Sellmer, R; Hagel, BE				Meeuwisse, WH; Sellmer, R; Hagel, BE			Rates and risks of injury during intercollegiate basketball	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							CRUCIATE LIGAMENT INJURY; HIGH-SCHOOL BASKETBALL; SPORTS INJURIES; PATTERNS; REGISTRY; PLAYERS; SOCCER; WOMEN; MEN	Background: Previous studies of basketball injury have not been able to assess injury incidence and risk. Purpose: To determine rates and risks of injury in Canadian intercollegiate basketball. Study Design: Prospective cohort study. Methods: Standardized data were collected with a validated instrument from 98.1% of the 318 athletes on the eight men's basketball teams in the Canada West Division of the Canadian Intercollegiate Athletic Union. Results: A total of 142 athletes sustained 215 injuries (44.7% of players injured) over the 2-year study period. The greatest number of injuries resulting in more than seven sessions of time loss involved the knee, whereas the most common injuries causing fewer than seven sessions of time loss involved the ankle. The most common mechanism of injury was contact with another player, especially in the "key." Injuries occurred 3.7 times more often in games than during practice. Centers had the highest rate of injury, followed by guards, and then forwards. The relative risk of reinjury was significantly increased by previous injuries to the elbow, shoulder, knee, hand, lower spine or pelvis, and by concussions. Conclusions: Risk factors for injury were previous injury, games as opposed to practice, player position, player contact, and court location. (C) 2003 American Orthopaedic Society for Sports Medicine.	Univ Calgary, Ctr Sports Med, Calgary, AB T2N 1N4, Canada	Meeuwisse, WH (corresponding author), Univ Calgary, Ctr Sports Med, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.		Hagel, Brent/AAK-3319-2020				ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Arendt EA, 1999, J ATHL TRAINING, V34, P86; Beachy G, 1997, AM J SPORT MED, V25, P675, DOI 10.1177/036354659702500515; CLARKE KS, 1980, AM J SPORT MED, V8, P187, DOI 10.1177/036354658000800308; DELOES M, 1995, INT J SPORTS MED, V16, P134, DOI 10.1055/s-2007-972980; Ellison L., 1995, CHRONIC DIS CAN, V16, P117; Finch C, 1998, BRIT J SPORT MED, V32, P220, DOI 10.1136/bjsm.32.3.220; GARRICK JG, 1978, PEDIATRICS, V61, P465, DOI 10.1542/peds.61.3.465; Gomez E, 1996, AM J SPORT MED, V24, P684, DOI 10.1177/036354659602400521; GUYETTE RF, 1993, CLIN SPORT MED, V12, P247; Harmon KG, 1998, CLIN J SPORT MED, V8, P260, DOI 10.1097/00042752-199810000-00002; HAYCOCK CE, 1976, JAMA-J AM MED ASSOC, V236, P163, DOI 10.1001/jama.236.2.163; Hickey GJ, 1997, CLIN J SPORT MED, V7, P252, DOI 10.1097/00042752-199710000-00002; Kingma J, 1998, PERCEPT MOTOR SKILL, V86, P675, DOI 10.2466/pms.1998.86.2.675; KUJALA UM, 1995, BRIT MED J, V311, P1465, DOI 10.1136/bmj.311.7018.1465; McKay G D, 1996, Aust J Sci Med Sport, V28, P12; Meeuwisse WH, 1997, SPORTS MED, V24, P184, DOI 10.2165/00007256-199724030-00008; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Meeuwisse WH, 1999, J INFORMATICS PRIM C, P2; MEEUWISSE WH, 1994, THESIS U CALGARY CAL; Messina DF, 1999, AM J SPORT MED, V27, P294, DOI 10.1177/03635465990270030401; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; THOMPSON N, 1987, AM J SPORT MED, V15, P117, DOI 10.1177/036354658701500204; Twellaar M, 1996, AM J SPORT MED, V24, P528, DOI 10.1177/036354659602400419; Whiteside P, 1980, PHYSICIAN SPORTSMED, V8, P130; Yde J, 1990, Br J Sports Med, V24, P51; ZELISKO JA, 1982, AM J SPORT MED, V10, P297, DOI 10.1177/036354658201000507	27	113	118	0	30	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	MAY-JUN	2003	31	3					379	385		10.1177/03635465030310030901			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	684CG	WOS:000183187400009	12750130				2021-06-18	
J	Kim, GM; Xu, J; Xu, JM; Song, SK; Yan, P; Ku, G; Xu, XM; Hsu, CY				Kim, GM; Xu, J; Xu, JM; Song, SK; Yan, P; Ku, G; Xu, XM; Hsu, CY			Tumor necrosis factor receptor deletion reduces nuclear factor-kappa B activation, cellular inhibitor of apoptosis protein 2 expression, and functional recovery after traumatic spinal cord injury	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; caspase-3; tumor necrosis factor; TNFR1; TNFR2; cytokine	AUTOIMMUNE-MEDIATED DEMYELINATION; FOCAL CEREBRAL-ISCHEMIA; TRANSCRIPTION FACTOR; BRAIN INJURY; TNF-ALPHA; MICE LACKING; INFLAMMATORY CYTOKINES; HIPPOCAMPAL-NEURONS; ENDOTHELIAL-CELLS; MOUSE MODEL	Tumor necrosis factor-alpha (TNF-alpha) expression has been documented extensively in animal models of traumatic spinal cord injury (SCI). However, the pathophysiological significance of TNF-alpha expression in the injured cord remains to be delineated. The TNF receptor (TNFR)-nuclear factor-kappaB (NF-kappaB) signal transduction pathway is important for maintaining cell viability. NF-kappaB exerts anti-apoptotic effects via an endogenous caspase inhibitory system mediated by cellular inhibitor of apoptosis protein 2 (c-IAP2). NF-kappaB transactivates c-IAP2 to inhibit caspase-3 activation. Progressive cell death, including morphological and biochemical features suggestive of apoptosis, has been noted after SCI. We explored the effects of TNFR1 or TNFR2 deletion on the apoptotic events downstream of NF-kappaB in relation to SCI pathology and functional recovery. Nuclear proteins from the injured cords of the TNFR1(-/-) mice had a reduced NF-kappaB binding activity compared with the wild-type controls. This decrease in NF-kappaB activation was accompanied by a reduction in c-IAP2 expression and an increase in the active form of caspase-3 protein. After SCI the TNFR1(-/-) mice had greater numbers of apoptotic cells, a larger lesion size, and worse functional recovery than wild-type mice. TNFR2-deficient mice had a similar, although not as pronounced, consequence as the TNFR1(-/-) mice. These findings support the argument that the TNFR-NF-kappaB pathway is beneficial for limiting apoptotic cell death after SCI and that a defective TNFR-NF-kappaB pathway results in a poorer neurological outcome. A worse functional outcome in TNFR-/- mice suggests that an endogenous apoptosis inhibitory mechanism mediated by TNFR activation, NF-kappaB, and c-IAP2 may be of pathophysiological importance.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63104 USA	Hsu, CY (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.			Hsu, Chung Y./0000-0002-5632-2733; Xu, Xiao-ming/0000-0002-7229-0081	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040162, R01NS036350, R01NS037230, P01NS039577] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40162, NS36350, NS39577, NS37230] Funding Source: Medline		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bilgen M, 2000, MAGN RESON MED, V43, P594; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DSOUZA S, 1995, J NEUROSCI, V15, P7293; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Farooque M, 2001, J NEUROTRAUM, V18, P105, DOI 10.1089/089771501750055811; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Glazner GW, 2000, EXP NEUROL, V161, P442, DOI 10.1006/exnr.1999.7242; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HACKNEY DB, 1994, NEUROSURGERY, V35, P1104, DOI 10.1227/00006123-199412000-00013; Han BH, 2000, NEUROBIOL DIS, V7, P38; Hisahara S, 2000, EMBO J, V19, P341, DOI 10.1093/emboj/19.3.341; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Katoh K, 1996, NEUROSCI LETT, V216, P9; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; Kumari M, 1997, HEAT MASS TRANSFER, V32, P393, DOI 10.1007/s002310050136; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li Qun, 1998, Society for Neuroscience Abstracts, V24, P738; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Ohta K, 1999, SPINAL CORD, V37, P580, DOI 10.1038/sj.sc.3100881; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; Riches DWH, 1998, J BIOL CHEM, V273, P22800, DOI 10.1074/jbc.273.35.22800; Rosenberg LJ, 1997, J NEUROTRAUM, V14, P823, DOI 10.1089/neu.1997.14.823; Rosenbluth J, 1997, EXP NEUROL, V147, P172, DOI 10.1006/exnr.1997.6583; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VAN AD, 1996, SCIENCE, V274, P787; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; Xu DG, 1999, J NEUROSCI, V19, P5026; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Xu J, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-01-j0001.2001; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yan P, 1999, J NEUROSCI, V19, P9355; Yang GY, 1998, NEUROREPORT, V9, P2131, DOI 10.1097/00001756-199806220-00041; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	86	113	120	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 1	2001	21	17					6617	6625					9	Neurosciences	Neurosciences & Neurology	467FC	WOS:000170690900020	11517251				2021-06-18	
J	Fichtenberg, NL; Putnam, SH; Mann, NR; Zafonte, RD; Millard, AE				Fichtenberg, NL; Putnam, SH; Mann, NR; Zafonte, RD; Millard, AE			Insomnia screening in postacute traumatic brain injury - Utility and validity of the Pittsburgh Sleep Quality Index	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; insomnia; Pittsburgh Sleep Quality Index; postacute rehabilitation	HEAD-INJURY; PERFORMANCE; RECOVERY; SCALE	Objective: To assess insomnia in a rehabilitation population, the authors examined the utility and validity of the Pittsburgh Sleep Quality Index (PSQI). The assessment of insomnia is relevant to the treatment of traumatic brain injury at the postacute level and routine screening for insomnia may be enhanced by the availability of a standardized, conveniently used, self-report sleep questionnaire. Design: The authors prospectively studied 91 consecutive patients with traumatic brain injury who were admitted to an outpatient neurorehabilitation program. Besides administering the PSQI, Beck Depression Inventory, Epworth Sleepiness Scale, and Multidimensional Pain Inventory, sleep diary and interview data were obtained and used to divide subjects into insomnia and noninsomnia groups according to the criteria established by the Diagnostic and Statistical Manual of Mental Disorders, ed 4. Results: Sensitivity and specificity rates to the clinical diagnosis of insomnia were 93% and 100%, respectively,for a PSQI Global Score of >8, and 83% and 100% for a diagnosis of insomnia based exclusively on PSQI-derived sleep variable data. Sleep diary data provided concurrent validity for PSQI estimates of sleep-onset latency, sleep duration, and sleep efficiency. The Beck Depression Inventory, Epworth Sleepiness Scale, and Multidimensional Pain Inventory established concurrent validity for individual PSQI items pertaining to mood, hypersomnia, and pain disturbance. Conclusion: The PSQI was demonstrated to be a valid and useful screening tool for assessing insomnia among postacute patients with traumatic brain injury.	Inst Rehabil, Detroit, MI USA; Wayne State Univ, Sch Med, Detroit, MI USA; Univ Michigan Hosp & Hlth Ctr, Ann Arbor, MI USA	Fichtenberg, NL (corresponding author), DMC Rehabil Ctr Novi, 42005 W 12 Mile Rd, Novi, MI 48377 USA.		Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604			Beck A.T., 1987, BECK DEPRESSION INVE; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BUYSSE DJ, 1991, SLEEP, V14, P331; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; DOUGLASS AB, 1994, SLEEP, V17, P160, DOI 10.1093/sleep/17.2.160; Hagen C., 1979, LEVELS COGNITIVE FUN; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; KRUEGER GP, 1989, WORK STRESS, V3, P129, DOI 10.1080/02678378908256939; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MOELLER AA, 1991, J ACQ IMMUN DEF SYND, V4, P1000; MONK TH, 1992, SLEEP, V15, P322, DOI 10.1093/sleep/15.4.322; NIERENBERG AA, 1994, AM J PSYCHIAT, V151, P1069; NORMAN SE, 1986, SLEEP RES, V15, P95; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; REYNOLDS CF, 1993, BIOL PSYCHIAT, V34, P791, DOI 10.1016/0006-3223(93)90068-O; ROSEN J, 1991, AM J PSYCHIAT, V148, P62; STEIN MB, 1993, PSYCHIAT RES, V49, P251, DOI 10.1016/0165-1781(93)90065-O; Zafonte RD, 1996, NEUROREHABILITATION, V7, P189, DOI 10.3233/NRE-1996-7304	20	113	115	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAY	2001	80	5					339	345		10.1097/00002060-200105000-00003			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	425BG	WOS:000168268000003	11327555				2021-06-18	
J	Moore, AH; Osteen, CL; Chatziioannou, AF; Hovda, DA; Cherry, SR				Moore, AH; Osteen, CL; Chatziioannou, AF; Hovda, DA; Cherry, SR			Quantitative assessment of longitudinal metabolic changes in vivo after traumatic brain injury in the adult rat using FDG-MicroPET	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						MicroPET; cerebral; glucose metabolism; conscious rat; traumatic; brain injury; positron emission tomography	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL GLUCOSE-UTILIZATION; IMAGING SMALL ANIMALS; PET SCANNER; RHESUS MACAQUES; RESOLUTION; MONKEYS; PERFORMANCE; DETECTORS	With the advent and emerging importance of neurobiology and its relation to behavior, scientists desire the capability to apply noninvasive, quantitative imaging of neuronal activity to small rodents. To this end, the authors' laboratory has developed microPET. a high-resolution positron emission tomography (PET) scanner that is capable of performing in vivo molecular imaging at a resolution sufficient to resolve major structures in the rat brain. The authors report in this article that, in conjunction with 2-[F-18]fluoro-2-deoxyglucose (FDG), microPET provides accurate rates of cerebral glucose metabolism (59.7 to 108.5 mu mol/100 g.min) in conscious adult rats as validated by within-subject autoradiographic measurements (59.5 to 136.2 mu mol/100 g.min; r = 0.88; F-[1.46] = 168.0; P < 0.001). By conducting repeated quantitative scanning, the authors demonstrate the sensitivity and accuracy of FDG- microPET to detect within-subject metabolic changes induced by traumatic brain injury. In addition, the authors report that longitudinal recovery From traumatic brain injury-induced metabolic depression, as measured by quantitative FDG-microPET, is significantly correlated (r = 0.65; P < 0.05) to recovery of behavioral dysfunction, as assessed by the Morris Water Maze performance of the same rats, after injury. This is the first study to demonstrate that FDG-microPET is quantitative, reproducible, and sensitive to metabolic changes, introducing a new approach to the longitudinal study of small animal models in neuroscience research.	Univ Calif Los Angeles, Sch Med, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Div Neurosurg, Neurotrauma Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	Cherry, SR (corresponding author), Univ Calif Los Angeles, Sch Med, Crump Inst Mol Imaging, 700 Westwood Plaza, Los Angeles, CA 90095 USA.		Cherry, Simon/AAH-1000-2019	Cherry, Simon/0000-0002-0155-5644			ACKERMANN RF, 1989, J CEREBR BLOOD F MET, V9, P774, DOI 10.1038/jcbfm.1989.111; Bloomfield PM, 1997, PHYS MED BIOL, V42, P389, DOI 10.1088/0031-9155/42/2/010; Bruyndonckx P, 1997, NUCL INSTRUM METH A, V392, P407, DOI 10.1016/S0168-9002(97)00281-7; Chatziioannou AF, 1999, J NUCL MED, V40, P1164; CHAVOIX C, 1995, HDB NEUROPSYCHOLOGY, V10, P483; Cherry SR, 1997, IEEE T NUCL SCI, V44, P1161, DOI 10.1109/23.596981; DelGuerra A, 1996, IEEE T NUCL SCI, V43, P1958, DOI 10.1109/23.507253; DOUDET D, 1995, AM J PSYCHIAT, V152, P1782; EBERLING JL, 1995, NEUROBIOL AGING, V16, P825, DOI 10.1016/0197-4580(95)00085-S; HOFFMAN EJ, 1979, J COMPUT ASSIST TOMO, V3, P299, DOI 10.1097/00004728-197906000-00001; JACOBS B, 1995, CEREB CORTEX, V5, P222, DOI 10.1093/cercor/5.3.222; Jeavons AP, 1999, IEEE T NUCL SCI, V46, P468, DOI 10.1109/23.775564; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; Kuge Y, 1997, J CEREBR BLOOD F MET, V17, P116, DOI 10.1097/00004647-199701000-00015; MARRIOTT CJ, 1994, J NUCL MED, V35, P1390; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore AH, 2000, DEV BRAIN RES, V120, P141, DOI 10.1016/S0165-3806(00)00005-5; Moore AH, 1999, J NEUROSCI METH, V88, P123, DOI 10.1016/S0165-0270(99)00013-8; MORI K, 1990, J NEUROCHEM, V54, P307, DOI 10.1111/j.1471-4159.1990.tb13316.x; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Qi JY, 1998, PHYS MED BIOL, V43, P1001, DOI 10.1088/0031-9155/43/4/027; SIEGEL S, 1992, IEEE T NUCL SCI, V39, P1117, DOI 10.1109/23.159770; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Watanabe M, 1997, IEEE T NUCL SCI, V44, P1277, DOI 10.1109/23.597001; Weber S, 1997, IEEE T MED IMAGING, V16, P684, DOI 10.1109/42.640759; YOSHINO A, 1991, BRAIN RES, V12, P996	27	113	116	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2000	20	10					1492	1501		10.1097/00004647-200010000-00011			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	360WN	WOS:000089690500011	11043912	Bronze			2021-06-18	
J	Kim, WK; Kan, YQ; Ganea, D; Hart, RP; Gozes, I; Jonakait, GM				Kim, WK; Kan, YQ; Ganea, D; Hart, RP; Gozes, I; Jonakait, GM			Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway	JOURNAL OF NEUROSCIENCE			English	Article						VIP; PACAP; TNF-alpha; microglia; cAMP; PKA; spinal cord injury; LPS	NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL TRAUMATIC INJURY; SUPERIOR CERVICAL-GANGLION; HUMAN MONOCYTIC CELLS; CLOSED-HEAD INJURY; TNF-ALPHA; MESSENGER-RNA; IN-VITRO; BRAIN INJURY	Tumor necrosis factor-alpha (TNF-alpha) production accompanies CNS insults of all kinds. Because the neuropeptide vasoactive intestinal peptide (VIP) and the structurally related peptide pituitary adenylyl cyclase-activating polypeptide (PACAP) have potent anti-inflammatory effects in the periphery, we investigated whether these effects extend to the CNS. TNF-alpha mRNA was induced within 2 hr after rat spinal cord transection, and its upregulation was suppressed by a synthetic VIP receptor agonist. Cultured rat microglia were used to examine the mechanisms underlying this inhibition because microglia are the likely source of TNF-alpha in injured CNS. In culture, increases in TNF-alpha mRNA resulting from lipopolysaccharide (LPS) stimulation were reduced significantly by 10(-7) M VIP and completely eliminated by PACAP at the same concentration. TNF-alpha protein levels were reduced 90% by VIP or PACAP at 10(-7) M. An antagonist of VPAC(1) receptors blocked the action of VIP and PACAP, and a PAC(1) antagonist blocked the action of PACAP. A direct demonstration of VIP binding on microglia and the existence of mRNAs for VPAC(1) and PAC(1) (but not VPAC(2)) receptors argue for a receptor-mediated effect. The action of VIP is cAMP-mediated because (1) activation of cAMP by forskolin mimics the action; (2) PKA inhibition by H89 reverses the neuropeptide-induced inhibition; and (3) the lipophilic neuropeptide mimic, stearyl-norleucine(17) VIP (SNV), which does not use a cAMP-mediated pathway, fails to duplicate the inhibition. We conclude that VIP and PACAP inhibit the production of TNF-alpha from activated microglia by a cAMP-dependent pathway.	Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel	Jonakait, GM (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.		Hart, Ronald/G-6530-2019; Hart, Ronald/D-5219-2009	Hart, Ronald/0000-0003-4836-8712; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21AI041786, R01AI041786] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI 41786-02] Funding Source: Medline		Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; ALBRECHT H, 1995, J INFLAMM, V45, P64; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BOUDARD F, 1991, J NEUROSCI RES, V29, P29, DOI 10.1002/jnr.490290104; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; BRENNEMAN DE, 1985, PEPTIDES, V6, P35, DOI 10.1016/0196-9781(85)90132-9; Bruccoleri A, 1998, J NEUROCHEM, V71, P1577; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; CHAO CC, 1995, DEV NEUROSCI-BASEL, V17, P97, DOI 10.1159/000111278; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; CHEEPSUNTHORN P, 1999, SOC NEUR ABSTR, V25; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Bock F, 1998, EUR J NEUROSCI, V10, P3107, DOI 10.1046/j.1460-9568.1998.00317.x; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; Delgado M, 1999, J IMMUNOL, V162, P4685; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 1999, J IMMUNOL, V162, P1707; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 1999, J IMMUNOL, V162, P1200; Dickinson T, 1999, TRENDS PHARMACOL SCI, V20, P324, DOI 10.1016/S0165-6147(99)01340-1; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; GOZES I, 1995, J PHARMACOL EXP THER, V273, P161; HART RP, 1999, SOC NEUR ABSTR, V25; Haviv R, 1999, J NEUROSCI RES, V55, P269; Hayashi Mito, 1997, Acta Anatomica Nipponica, V72, P209; Hisahara S, 1997, J NEUROCHEM, V69, P10; HYATTSACHS H, 1993, J NEUROSCI, V13, P1642; ICHINOSE M, 1994, REGUL PEPTIDES, V54, P457, DOI 10.1016/0167-0115(94)90543-6; Jonakait GM, 1996, DEV BIOL, V177, P85, DOI 10.1006/dbio.1996.0147; Jongeneel C V, 1994, Prog Clin Biol Res, V388, P367; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; KLIMASCHEWSKI L, 1995, NEUROSCI LETT, V195, P133, DOI 10.1016/0304-3940(95)11799-3; Klimaschewski L, 1996, NEUROSCIENCE, V72, P265, DOI 10.1016/0306-4522(95)00551-X; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Kong LY, 1999, NEUROSCIENCE, V91, P493, DOI 10.1016/S0306-4522(98)00606-X; Lafortune L, 1996, J NEUROPATH EXP NEUR, V55, P515, DOI 10.1097/00005072-199605000-00003; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pa.35.040195.003255; LEE SC, 1993, J IMMUNOL, V150, P2659; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Martinez C, 1996, J IMMUNOL, V156, P4128; Martinez C, 1998, J LEUKOCYTE BIOL, V63, P591; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; Moller K, 1997, BRAIN RES, V775, P156, DOI 10.1016/S0006-8993(97)00937-2; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; Parry GCN, 1997, J IMMUNOL, V159, P5450; RAO MS, 1993, J NEUROBIOL, V24, P571, DOI 10.1002/neu.480240504; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SEBIRE G, 1993, J IMMUNOL, V150, P1517; SELMAJ K, 1991, J NEUROCHEM, V57, P823, DOI 10.1111/j.1471-4159.1991.tb08225.x; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SHARIF SF, 1993, NEUROL RES, V15, P109; SHEHAB SAS, 1986, BRAIN RES, V372, P37, DOI 10.1016/0006-8993(86)91456-3; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SIRIANNI MC, 1992, REGUL PEPTIDES, V38, P79, DOI 10.1016/0167-0115(92)90074-5; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; TANG H, 1995, J INTERF CYTOK RES, V15, P993, DOI 10.1089/jir.1995.15.993; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; Vastag M, 1999, MICROVASC RES, V57, P52, DOI 10.1006/mvre.1998.2115; Viviani B, 1998, TOXICOL APPL PHARM, V150, P271, DOI 10.1006/taap.1998.8406; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wang HY, 1996, J IMMUNOL, V156, P3243; Wei RT, 1999, J NEUROIMMUNOL, V95, P8, DOI 10.1016/S0165-5728(98)00248-3; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; ZHANG X, 1993, EXP BRAIN RES, V93, P450; Zhang YZ, 1996, NEUROSCIENCE, V74, P1099, DOI 10.1016/S0306-4522(96)00168-6; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou XR, 1999, J NEUROSCI RES, V57, P953, DOI 10.1002/(SICI)1097-4547(19990915)57:6<953::AID-JNR21>3.3.CO;2-I	85	113	118	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 15	2000	20	10					3622	3630					9	Neurosciences	Neurosciences & Neurology	312JK	WOS:000086940000018	10804204				2021-06-18	
J	Durkin, MS; Laraque, D; Lubman, I; Barlow, B				Durkin, MS; Laraque, D; Lubman, I; Barlow, B			Epidemiology and prevention of traffic injuries to urban children and adolescents	PEDIATRICS			English	Article						adolescent; bicyclist; child; community; epidemiology evaluation; incidence; injury; motor vehicle; pedestrian; prevention; traffic	PEDESTRIAN INJURY; CHILDHOOD INJURIES; POISSON REGRESSION; RATES; PROGRAM; RISK; NEIGHBORHOODS; COMMUNITY; DEATHS	Objectives. To describe the incidence of severe traffic injuries before and after implementation of a comprehensive, hospital-initiated injury prevention program aimed at the prevention of traffic injuries to school-aged children in an urban community. Materials and Methods. Hospital discharge and death certificate data on severe pediatric injuries (ie, injuries resulting in hospital admission and/or death to persons age <17 years) in northern Manhattan over a 13-year period (1983-1995) were linked to census counts to compute incidence. Rate ratios with 95% CIs, both unadjusted and adjusted for annual trends, were calculated to test for a change in injury incidence after implementation of the Harlem Hospital Injury Prevention Program. This program was initiated in the fall of 1988 and continued throughout the study period. It included 1) school and community based traffic safety education implemented in classroom settings in a simulated traffic environment, Safety City, and via theatrical performances in community settings; 2) construction of new playgrounds as well as improvement of existing playgrounds and parks to provide expanded off-street play areas for children; 3) bicycle safety clinics and helmet distribution; and 4) a range of supervised recreational and artistic activities for children in the community. Primary Results. Traffic injuries were a leading cause of severe childhood injury in this population, accounting for nearly 16% of the injuries, second only to falls (24%). During the preintervention period (1983-1988), severe traffic injuries occurred at a rate of 147.2/100 000 children <17 years per year. Slightly <2% of these injuries were fatal. Pedestrian injuries accounted for two thirds of all severe traffic injuries in the population. Among school-aged children, average annual rates (per 100 000) of severe injuries before the intervention were 127.2 for pedestrian, 37.4 for bicyclist, and 25.5 for motor vehicle occupant injuries. Peak incidence of pedestrian and bicyclist injuries occurred during the summer months and afternoon hours, whereas motor vehicle occupant injuries showed little seasonal variation and were more common during evening and night-time hours. Age-specific rates showed peak incidence of pedestrian injuries among 6- to 10-year-old children, of bicyclist injuries among 9- to 15-year-old children, and of motor vehicle occupant injuries among: adolescents between the ages of 12 and 16 years. The peak age for all traffic injuries combined was 15 years, an age at which nearly 3 of every 1000 children each year in this population sustained a severe traffic injury. Among children hospitalized for traffic injuries during the preintervention period, 6.3% sustained major head trauma (including concussion with loss of consciousness for greater than or equal to 1 hour, cerebral laceration and/or cerebral hemorrhage), and 36.9% sustained minor head trauma (skull fracture and/or concussion with no loss of consciousness greater than or equal to 1 hour and no major head injury). The percentage of injured children with major and minor head trauma was higher among those injured in traffic than among those injured by all other means (43.2% vs 14.2%, respectively; chi(2) = 336; degrees of freedom = 1). The percentages of children sustaining head trauma were 45.4% of those who were injured as pedestrians, 40.2% of those who were injured as bicyclists, and 38.9% of those who were injured as motor vehicle occupants. During the intervention period, the average incidence of traffic injuries among school aged children declined by 36% relative to the preintervention period (rate ratio: .64; 95% CI: .58, .72). After adjusting for annual trends in incidence, pedestrian injuries declined during the intervention period among school aged children by 45% (adjusted rate ratio: .55; 95% CI: .38, .79). No comparable reduction occurred in nontargeted injuries among school-aged children (adjusted rate ratio: .89; 95% CI:.72, 1.09) or in traffic injuries among younger children who were not targeted specifically by the program (adjusted rate ratio: 1.32; 95% CI: .57, 3.07). Conclusion. Child traffic injuries, particularly those involving pedestrians, are a major public health problem in urban communities. Although the incidence of child pedestrian injuries is declining nationally and internationally, perhaps attributable to declines in walking, this trend may not be applicable in inner city communities such as northern Manhattan, in which walking remains a dominant mode of transportation. Community interventions involving the creation of safe and accessible play areas as well as traffic safety education and supervised activities for school-aged children may be effective in preventing traffic injuries to children in these communities. Additional controlled evaluations are needed to confirm the benefits of such interventions.	Columbia Univ, Gertrude H Sergievsky Ctr, Fac Med, New York, NY 10032 USA; Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Harlem Hosp, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; New York Dept Transportat, Safety Div, New York, NY USA; Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, Div Pediat & Pediat Surg, New York, NY 10032 USA	Durkin, MS (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, Fac Med, P&S Box 16,630 W 16th St, New York, NY 10032 USA.	durkinm@sergievsky.cpmc.columbia.edu	Durkin, Maureen/B-7834-2015		AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [FU01HSO7399] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [U01HS007399] Funding Source: NIH RePORTER		[Anonymous], 1997, MMWR Recomm Rep, V46, P1; BACKETT EM, 1959, BRIT MED J, V1, P409, DOI 10.1136/bmj.1.5119.409; BERGMAN AB, 1991, PEDIATRICS, V88, P69; BRILLINGER DR, 1986, BIOMETRICS, V42, P69; Davidson L L, 1992, Paediatr Perinat Epidemiol, V6, P153, DOI 10.1111/j.1365-3016.1992.tb00757.x; DAVIDSON LL, 1994, AM J PUBLIC HEALTH, V84, P580, DOI 10.2105/AJPH.84.4.580; Davidson LL, 1994, CHILD, V11, P3; *DIV SURV EP, 1995, EP INF; Durkin MS, 1996, J TRAUMA, V41, P667, DOI 10.1097/00005373-199610000-00012; DURKIN MS, 1994, AM J PUBLIC HEALTH, V84, P587, DOI 10.2105/AJPH.84.4.587; FIFE D, 1984, AM J PUBLIC HEALTH, V74, P473, DOI 10.2105/AJPH.74.5.473; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; GUYER B, 1985, PEDIATR CLIN N AM, V32, P163; HADDON W, 1961, J CHRON DIS, V14, P665; KENDRICK D, 1993, ARCH DIS CHILD, V68, P669, DOI 10.1136/adc.68.5.669; KUHN L, 1994, AM J EPIDEMIOL, V140, P943, DOI 10.1093/oxfordjournals.aje.a117183; LARAQUE D, 1994, AM J PUBLIC HEALTH, V84, P1691; LARQUE D, 1995, J N Y ACAD MED, V72, P16; MALEK M, 1990, ACCIDENT ANAL PREV, V22, P301, DOI 10.1016/0001-4575(90)90046-N; *NY CIT DEP HLTH, 1985, SUMM VIT STAT; PREUSSER DF, 1988, B NY ACAD MED, V6, P623; PRICE SC, 1992, CHILD INJ PREV Q FAL, P7; Rao R, 1997, B NEW YORK ACAD MED, V74, P65; ROBERTS I, 1995, BRIT MED J, V310, P91, DOI 10.1136/bmj.310.6972.91; ROBERTS I, 1993, BRIT MED J, V306, P1737, DOI 10.1136/bmj.306.6894.1737; ROBERTS I, 1994, AUST J PUBLIC HEALTH, V18, P209; Robertson L. S, 1998, INJURY EPIDEMIOLOGY; RUNYAN CW, 1985, AM J PUBLIC HEALTH, V75, P1429, DOI 10.2105/AJPH.75.12.1429; *SAS I, 1989, SAS PROPR SOFTW; SMITH GS, 1991, EPIDEMIOL REV, V13, P228, DOI 10.1093/oxfordjournals.epirev.a036070; *SOC AMB CAR PROF, 1995, PARTN PREV INN COMM, P10; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; *US BUR CENS, 1981, 1980 CENS; *US BUR CENS, 1996, PPL80 US BUR CENS; *US CENS BUR, 1990, C90STF3B US CENS BUR; WALLER AE, 1989, AM J PUBLIC HEALTH, V79, P310, DOI 10.2105/AJPH.79.3.310; WILLIAMS BC, 1990, PEDIATRICS, V86, P1067; World Health Organization, 1980, INT CLASS DIS; YTTERSTAD B, 1995, ACCIDENT ANAL PREV, V27, P111, DOI 10.1016/0001-4575(94)00036-L; 1992, MMMWR MORB MORTAL WK, V41, P249	41	113	115	0	16	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	1999	103	6	1						e74	10.1542/peds.103.6.e74			8	Pediatrics	Pediatrics	201UF	WOS:000080613400003	10353971	Bronze			2021-06-18	
J	Levin, HS; Mendelsohn, D; Lilly, MA; Yeakley, J; Song, J; Scheibel, RS; Harward, H; Fletcher, JM; Kufera, JA; Davidson, KC; Bruce, D				Levin, HS; Mendelsohn, D; Lilly, MA; Yeakley, J; Song, J; Scheibel, RS; Harward, H; Fletcher, JM; Kufera, JA; Davidson, KC; Bruce, D			Magnetic resonance imaging in relation to functional outcome of pediatric closed head injury: A test of the Ommaya-Gennarelli model	NEUROSURGERY			English	Article						closed head injury; magnetic resonance imaging; outcome	CHILDREN; CONSCIOUSNESS; ADOLESCENTS; COMA	OBJECTIVE: To characterize late neuropathological findings of pediatric closed head injury (CHI), to assess depth of brain lesion in relation to acute severity, and to assess long-term outcome to test the Ommaya-Gennarelli model. METHODS: Magnetic resonance imaging (MRI) at least 3 months postinjury in a prospective sample (n 5 169) and at least 3 years after CHI in a retrospective sample (n 5 82) was studied. Lesion volume was measured by planimetry. Acute CHI severity was measured by the Glasgow Coma Scale. Patients were classified according to the depth of the deepest parenchymal lesion into no lesion, cortical, subcortical, and deep central gray/brain stem groups. The outcomes were assessed by the Glasgow Outcome Scale and the Vineland Adaptive Behavior Scale, which were performed at the time of the MRI in the retrospective sample and up to 3 years postinjury in the prospective sample. RESULTS: Focal brain lesions were present in 55.4% of the total sample. Depth of brain lesion was directly related to severity of acute impairment of consciousness and inversely related to outcome, as measured by both the Glasgow Outcome Scale and the Vineland Adaptive Behavior Scale. A rostrocaudal gradient of hemispheric lesion frequency was observed, whereas the posterior lesions of the corpus callosum were particularly common. Total lesion volume could not explain the depth of lesion effect. CONCLUSION: Our findings extend support for the Ommaya-Gennarelli model to pediatric CHI, indicating that depth of brain lesion is related to functional outcome. The relative frequency of focal brain lesions revealed by late MRI is higher than that of previous findings using acute computed tomography. Future investigations could explore whether depth of lesion observed using late MRI is sensitive to neuroprotective interventions.	UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75235; UNIV TEXAS,SCH MED,DEPT RADIOL,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,CALLIER CTR COMMUN DISORDERS,DALLAS,TX 75235; NATL STUDY CTR TRAUMA & EMERGENCY MED SYST,BALTIMORE,MD; FSD DATA SERV INC,HOUSTON,TX	Levin, HS (corresponding author), BAYLOR COLL MED,PM&R RES OFF,DEPT PHYS MED & REHABIL,1333 MOURSUND AVE,ROOM A205,HOUSTON,TX 77030, USA.		fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020	Davidson, Kevin/0000-0001-5799-1325	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR02558] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; Damasio H., 1989, LESION ANAL NEUROPSY; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LINDENBERG R, 1955, AM J PATHOL, V31, P297; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; *PMIC, 1991, INT CLASS DIS 9 REV, V1; *PMIC, 1991, INT CLASS DIS 9 REV, V2; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	20	113	114	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	MAR	1997	40	3					432	440		10.1097/00006123-199703000-00002			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WJ763	WOS:A1997WJ76300005	9055281				2021-06-18	
J	Masson, F; Maurette, P; Salmi, LR; Dartigues, JF; Vecsey, J; Destaillats, JM; Erny, P				Masson, F; Maurette, P; Salmi, LR; Dartigues, JF; Vecsey, J; Destaillats, JM; Erny, P			Prevalence of impairments 5 years after a head injury, and their relationship with disabilities and outcome	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; HOSPITAL ADMISSIONS; COMMUNITY; EPIDEMIOLOGY; FRANCE; DEATHS; CONSCIOUSNESS; AQUITAINE; RECOVERY; COUNTY	To determine what consequences cognitive, behavioural or somatic impairments had on disabilities and recovery after a head injury (HI), a population-based sample of 231 adult patients was studied 5 years after an HI. Eighty lower-limb-injured (LLI) patients were considered as controls. Sixty-four LLI and 176 HI patients were reviewed (114 minor, 35 moderate, and 27 severe HI). Prevalence values of headaches (44-54%), dizziness (26-37%), and anxiety (47-63%) were not significantly different in the three HI severity groups, but were significantly lower in patients with an isolated limb injury (12-15%). Memory problems and depressive mood increased with injury severity. Mental impairments were frequent in severe HI patients (18-40% of patients). In minor and moderate HI patients, most disabilities were related to associated injuries. According to the Glasgow Outcome Scale (GOS), recovery was not considered as good because of somatic, behavioural or cognitive complaints in 2.5%, 5.7% and 59.2% of surviving patients in each of the above HI groups. Somatic or behavioural complaints may have considerable consequences in some minor HI patients, and the long-term management of certain patients needs improvement because these impairments are misunderstood.	UNIV BORDEAUX 2, DEPT EPIDEMIOL & INFORMAT MED, INSERM 330, BORDEAUX, FRANCE; HOP PELLEGRIN, SERV READAPTAT FONCT, BORDEAUX, FRANCE	Masson, F (corresponding author), HOP PELLEGRIN, DEPT ANESTHESIE REANIMAT, PL AMELIE RABA LEON, F-33076 BORDEAUX, FRANCE.		DARTIGUES, Jean Francois/T-4513-2019; Salmi, Louis-Rachid/T-1982-2019				ABENHAIM L, 1992, J CLIN EPIDEMIOL, V45, P103, DOI 10.1016/0895-4356(92)90002-5; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annoni J M, 1992, Disabil Rehabil, V14, P23; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GRONWALL D, 1974, LANCET, V2, P605; HOOK O, 1988, SCAND J REHABIL MED, P65; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; *JOINT COMM INJ SC, 1980, ABBR INJ SCAL 1980 R; JONES JH, 1992, ARCH PHYS MED REHAB, V73, P145; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MAURETTE P, 1992, J TRAUMA, V33, P728, DOI 10.1097/00005373-199211000-00023; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; *ORG MOND SANT, 1988, CLASS INT HAND DEF I; PARIENTE P, 1992, PSYCHOL MED, V22, P181, DOI 10.1017/S0033291700032839; RUNE V, 1970, ACTA PAEDIATR SCAND, P1; RUTHERFORD WH, 1977, LANCET, V1, P1; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Symonds C P, 1937, Proc R Soc Med, V30, P1081; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1989, AM J PUBLIC HEALTH, V79, P316, DOI 10.2105/AJPH.79.3.316; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; TRUELLE JL, 1992, SCAND J REHABIL MED, P115; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	39	113	114	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	1996	10	7					487	497		10.1080/026990596124205			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UU819	WOS:A1996UU81900002	8806009				2021-06-18	
J	Hamm, RJ; Temple, MD; ODell, DM; Pike, BR; Lyeth, BG				Hamm, RJ; Temple, MD; ODell, DM; Pike, BR; Lyeth, BG			Exposure to environmental complexity promotes recovery of cognitive function after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						environments; memory; Morris water maze; recovery; traumatic brain injury	PROTEIN-KINASE-C; CLOSED HEAD-INJURY; RATS; PERFORMANCE; ENRICHMENT; NEURONS; MEMORY; LESIONS; CORTEX; TASK	This study was designed to determine whether exposure to a complex environment after traumatic brain injury (TBI) would promote the recovery of cognitive function. Rats were injured at a moderate level of fluid percussion injury (2.1 atm) or were prepared for injury but were not injured (sham injury), Immediately after the injury or sham injury, the injured/complex (n = 8) and the sham/complex (n = 7) groups were placed into a complex environment. The complex environment was a 89 x 89-cm enclosure with different types of bedding and objects that provided motor, ol-factory, tactile, and visual stimulation. The injured/standard (n = 8) and the sham/standard (n = 8) groups were returned to the animal vivarium where they were housed individually in standard wire mesh cages (24 x 20 x 18 cm). On days 11-15 (postinjury), performance in the Morris water maze was assessed. Analysis of the latency to reach the goal platform indicated that injured animals recuperating in the complex environment performed significantly better than injured animals recovering in the standard environment (p < 0.01). In fact, injured animals in the complex environment performed as well as both sham-injured groups. The improved performance of injured rats recovering in the enriched environment occurred in the absence of environmentally induced alterations in brain weight. These results indicate that exposure to environmental complexity enhances recovery of cognitive function after TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23284	Hamm, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,POB 842018,RICHMOND,VA 23284, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER		BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BRENNER E, 1983, NEUROSCI LETT, V42, P13, DOI 10.1016/0304-3940(83)90414-7; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; DELAHUNTY TM, 1995, NEUROCHEM RES, V20, P335; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DONOVICK PJ, 1973, PHYSIOL BEHAV, V11, P543, DOI 10.1016/0031-9384(73)90041-3; EINON DF, 1980, Q J EXP PSYCHOL, V32, P137, DOI 10.1080/00335558008248239; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERCHMIN PA, 1987, PHARMACOL BIOCHEM BE, V26, P341, DOI 10.1016/0091-3057(87)90128-6; FERCHMIN PA, 1970, BRAIN RES, V20, P49, DOI 10.1016/0006-8993(70)90153-8; FERCHMIN PA, 1986, DEV PSYCHOBIOL, V10, P511; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GONZALEZLIMA F, 1994, DEV PSYCHOBIOL, V27, P343, DOI 10.1002/dev.420270603; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GREER ER, 1981, EXP NEUROL, V72, P366, DOI 10.1016/0014-4886(81)90230-2; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; Kolb B, 1991, CEREB CORTEX, V1, P189, DOI 10.1093/cercor/1.2.189; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LILJEQUIST R, 1993, BEHAV BRAIN RES, V56, P107, DOI 10.1016/0166-4328(93)90027-N; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MOHAMMED AK, 1986, BRAIN RES, V398, P6, DOI 10.1016/0006-8993(86)91243-6; MURTHA S, 1990, BEHAV BRAIN RES, V39, P249, DOI 10.1016/0166-4328(90)90031-9; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PAYLOR R, 1992, BEHAV BRAIN RES, V52, P49, DOI 10.1016/S0166-4328(05)80324-9; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; ROSENZWEIG M R, 1969, Developmental Psychobiology, V2, P87, DOI 10.1002/dev.420020208; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SCHWARTZ S, 1964, J COMP PHYSIOL PSYCH, V57, P72, DOI 10.1037/h0045518; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; WAINWRIGHT PE, 1993, NEUROTOXICOL TERATOL, V15, P11, DOI 10.1016/0892-0362(93)90040-U; WALSH RN, 1981, INT J NEUROSCI, V12, P33, DOI 10.3109/00207458108990671; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; Weiner N, 1985, PHARMACOL BASIS THER, P130; WHISHAW IQ, 1984, BEHAV NEURAL BIOL, V42, P183, DOI 10.1016/S0163-1047(84)91046-X; WILL BE, 1976, PHYSIOL BEHAV, V16, P603, DOI 10.1016/0031-9384(76)90221-3; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	53	113	113	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1996	13	1					41	47		10.1089/neu.1996.13.41			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TW167	WOS:A1996TW16700006	8714862				2021-06-18	
J	KOSKINIEMI, M; KYYKKA, T; NYBO, T; JARHO, L				KOSKINIEMI, M; KYYKKA, T; NYBO, T; JARHO, L			LONG-TERM OUTCOME AFTER SEVERE BRAIN INJURY IN PRESCHOOLERS IS WORSE THAN EXPECTED	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							CLOSED-HEAD-INJURY; CHILDREN; TRAUMA; ADOLESCENTS; PROGNOSIS; SCALE; COMA	Objective: To determine the long-term outcome after severe brain injury at preschool age. Design: Follow-up until adult life. Setting: A centralized guidance center for all traffic-associated injuries. Patients: Children with severe brain injury at preschool age between January 1959 and December 1969. Main Outcome Measure: Final evaluation in adulthood was performed by our team. The capability to work and live independently was rated. Results: Twenty three (59%) of 39 children attended a typical school, eight (21%) attended a school for the physically disabled, and seven (18%) attended a school for the mentally retarded; information was not available for one child. In adulthood, nine patients (23%) were able to work full-time, 10 (26%) worked at sheltered workplaces, 14 (36%) lived independently at home, and six (15%) needed physical and/or psychotherapeutic support. The difference between normal school performance (59%) and ca pability to work full-time (23%) was significant (P<.05). In evaluating different aspects after the severe brain injury, the sense of identity was the best indicator of final outcome. Conclusions: The final evaluation of severe brain injury at preschool age should be performed in adulthood. Normal school performance or normal intelligence functioning is not a guarantee for good long-term prognosis. To let the child develop a firm identity is essential for good outcome.	KAUNIALA HOSP DISABLED WAR VET,SF-02700 KAUNIAINEN,FINLAND; REHABIL CTR INSURANCE CO,KAUNIAINEN,FINLAND; UNIV HELSINKI,DEPT VIROL,HELSINKI,FINLAND							ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; COHADON F, 1991, J NEUROL SCI, V103, pS27; COSTEFF H, 1988, BRAIN DEV-JPN, V10, P371, DOI 10.1016/S0387-7604(88)80095-0; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DOBBING J, 1968, APPLIED NEUROCHEMIST; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GURLAND BJ, 1972, ARCH GEN PSYCHIAT, V27, P259; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; HENNES H, 1988, AM J DIS CHILD, V142, P1045, DOI 10.1001/archpedi.1988.02150100039021; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1993, CURR OPIN NEUROL, V6, P841, DOI 10.1097/00019052-199312000-00003; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; OVERGAARD J, 1973, LANCET, V2, P631; RIVARA F, 1987, PEDIATRICS, V80, P579; ZIMMERMAN RA, 1978, AM J ROENTGENOL, V131, P27, DOI 10.2214/ajr.131.1.27	24	113	114	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	MAR	1995	149	3					249	254		10.1001/archpedi.1995.02170150029004			6	Pediatrics	Pediatrics	QK484	WOS:A1995QK48400003	7532073				2021-06-18	
J	Abbas, K; Shenk, TE; Poole, VN; Breedlove, EL; Leverenz, LJ; Nauman, EA; Talavage, TM; Robinson, ME				Abbas, Kausar; Shenk, Trey E.; Poole, Victoria N.; Breedlove, Evan L.; Leverenz, Larry J.; Nauman, Eric A.; Talavage, Thomas M.; Robinson, Meghan E.			Alteration of Default Mode Network in High School Football Athletes Due to Repetitive Subconcussive Mild Traumatic Brain Injury: A Resting-State Functional Magnetic Resonance Imaging Study	BRAIN CONNECTIVITY			English	Article						concussion; default mode network; fMRI; football; functional connectivity; mTBI; resting state; subconcussive		Long-term neurological damage as a result of head trauma while playing sports is a major concern for football athletes today. Repetitive concussions have been linked to many neurological disorders. Recently, it has been reported that repetitive subconcussive events can be a significant source of accrued damage. Since football athletes can experience hundreds of subconcussive hits during a single season, it is of utmost importance to understand their effect on brain health in the short and long term. In this study, resting-state functional magnetic resonance imaging (rs-fMRI) was used to study changes in the default mode network (DMN) after repetitive subconcussive mild traumatic brain injury. Twenty-two high school American football athletes, clinically asymptomatic, were scanned using the rs-fMRI for a single season. Baseline scans were acquired before the start of the season, and follow-up scans were obtained during and after the season to track the potential changes in the DMN as a result of experienced trauma. Ten noncollision-sport athletes were scanned over two sessions as controls. Overall, football athletes had significantly different functional connectivity measures than controls for most of the year. The presence of this deviation of football athletes from their healthy peers even before the start of the season suggests a neurological change that has accumulated over the years of playing the sport. Football athletes also demonstrate short-term changes relative to their own baseline at the start of the season. Football athletes exhibited hyperconnectivity in the DMN compared to controls for most of the sessions, which indicates that, despite the absence of symptoms typically associated with concussion, the repetitive trauma accrued produced long-term brain changes compared to their healthy peers.	[Abbas, Kausar; Shenk, Trey E.; Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, 465 Northwestern Ave, W Lafayette, IN 47907 USA; [Poole, Victoria N.; Nauman, Eric A.; Talavage, Thomas M.; Robinson, Meghan E.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Poole, Victoria N.; Nauman, Eric A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Breedlove, Evan L.; Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Robinson, Meghan E.] VA Boston Healthcare Syst, Neuroimaging Res Vet NeRVe Ctr, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA USA	Talavage, TM (corresponding author), Purdue Univ, Sch Elect & Comp Engn, 465 Northwestern Ave, W Lafayette, IN 47907 USA.	tmt@purdue.edu		Poole, Victoria/0000-0003-0974-2564			Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Belson K., 2013, NY TIMES, pB14; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Breslow Jason M., 2013, FRONTLINE; Brett M., 2002, NEUROIMAGE, V16, pS497, DOI 10.1016/S1053-8119(02)90010-8.; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldsmith Werner, 2005, Critical Reviews in Biomedical Engineering, V33, P105, DOI 10.1615/CritRevBiomedEng.v33.i2.20; Gregory S., 2013, TIME MAGAZINE, P36; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jo HJ, 2013, J APPL MATH, DOI 10.1155/2013/935154; Jo HJ, 2010, NEUROIMAGE, V52, P571, DOI 10.1016/j.neuroimage.2010.04.246; Johnson BD, 2014, J NEUROTRAUMA; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jones TB, 2010, NEUROIMAGE, V49, P401, DOI 10.1016/j.neuroimage.2009.07.051; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Landau E., 2013, CNN HLTH; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shehzad Z, 2009, CEREB CORTEX, V19, P2209, DOI 10.1093/cercor/bhn256; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	59	112	114	2	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	2158-0014	2158-0022		BRAIN CONNECT	Brain Connect.	MAR	2015	5	2					91	101		10.1089/brain.2014.0279			11	Neurosciences	Neurosciences & Neurology	VG7FN	WOS:000448192300003	25242171				2021-06-18	
J	Jilka, SR; Scott, G; Ham, T; Pickering, A; Bonnelle, V; Braga, RM; Leech, R; Sharp, DJ				Jilka, Sagar R.; Scott, Gregory; Ham, Timothy; Pickering, Alan; Bonnelle, Valerie; Braga, Rodrigo M.; Leech, Robert; Sharp, David J.			Damage to the Salience Network and Interactions with the Default Mode Network	JOURNAL OF NEUROSCIENCE			English	Article						Default Mode Network; functional connectivity; psychophysiological interactions; salience network; traumatic brain injury	POSTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; CONNECTIVITY; ROBUST; IMPLEMENTATION; INHIBITION; ANATOMY; SYSTEM	Interactions between the Salience Network (SN) and the Default Mode Network (DMN) are thought to be important for cognitive control. However, evidence for a causal relationship between the networks is limited. Previously, we have reported that traumatic damage to white matter tracts within the SN predicts abnormal DMN function. Here we investigate the effect of this damage on network interactions that accompany changing motor control. We initially used fMRI of the Stop Signal Task to study response inhibition in humans. In healthy subjects, functional connectivity (FC) between the right anterior insula (rAI), a key node of the SN, and the DMN transiently increased during stopping. This change in FC was not seen in a group of traumatic brain injury (TBI) patients with impaired cognitive control. Furthermore, the amount of SN tract damage negatively correlated with FC between the networks. We confirmed these findings in a second group of TBI patients. Here, switching rather than inhibiting a motor response: (1) was accompanied by a similar increase in network FC in healthy controls; (2) was not seen in TBI patients; and (3) tract damage after TBI again correlated with FC breakdown. This shows that coupling between the rAI and DMN increases with cognitive control and that damage within the SN impairs this dynamic network interaction. This work provides compelling evidence for a model of cognitive control where the SN is involved in the attentional capture of salient external stimuli and signals the DMN to reduce its activity when attention is externally focused.	[Jilka, Sagar R.; Scott, Gregory; Braga, Rodrigo M.; Leech, Robert; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Ctr Neurosci, Computat Cognit & Clin Neuroimaging Lab, London W12 0NN, England; [Jilka, Sagar R.; Pickering, Alan] Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; [Braga, Rodrigo M.] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Fac Med, London W12 0NN, England; [Ham, Timothy] Univ Cambridge, Neurol Unit, Cambridge CB2 0SZ, England; [Bonnelle, Valerie] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	Sharp, DJ (corresponding author), Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Leech, Robert/AAE-8254-2019; Sharp, David J/A-2119-2013	Leech, Robert/0000-0002-5801-6318; Pickering, Alan/0000-0002-7301-5321; Scott, Gregory/0000-0001-8063-5871	Medical Research Council (United Kingdom)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute of Health Research Professorship [RP-011-048]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701951] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	This work was supported by the Medical Research Council (United Kingdom) and the National Institute of Health Research Professorship (RP-011-048).	Alderson RM, 2008, J ABNORM CHILD PSYCH, V36, P989, DOI 10.1007/s10802-008-9230-z; Allman JM, 2010, BRAIN STRUCT FUNCT, V214, P495, DOI 10.1007/s00429-010-0254-0; Baddeley AD, 2003, HDB MEMORY DISORDERS; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chen AC, 2013, P NATL ACAD SCI USA, V110, P19944, DOI 10.1073/pnas.1311772110; Chiong W, 2013, BRAIN, V136, P1929, DOI 10.1093/brain/awt066; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kim C, 2011, J NEUROSCI, V31, P4771, DOI 10.1523/JNEUROSCI.5923-10.2011; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Leech R, 2012, J NEUROSCI, V32, P215, DOI 10.1523/JNEUROSCI.3689-11.2012; Leech R, 2011, J NEUROSCI, V31, P3217, DOI 10.1523/JNEUROSCI.5626-10.2011; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; O'Reilly JX, 2012, SOC COGN AFFECT NEUR, V7, P604, DOI 10.1093/scan/nss055; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reitan RM, 2004, ARCH CLIN NEUROPSYCH, V19, P281, DOI 10.1016/S0887-6177(03)00042-8; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Singh AK, 2011, NEUROIMAGE, V58, P148, DOI 10.1016/j.neuroimage.2011.05.082; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; SUDEVAN P, 1987, J EXP PSYCHOL HUMAN, V13, P89, DOI 10.1037/0096-1523.13.1.89; Von Economo C., 1925, CYTOARCHITECTONIK HI; Wechsler D., 2011, WECHLSER ABBREVIATED; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Zuo XN, 2010, NEUROIMAGE, V49, P2163, DOI 10.1016/j.neuroimage.2009.10.080	49	112	116	0	30	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	AUG 13	2014	34	33					10798	10807		10.1523/JNEUROSCI.0518-14.2014			10	Neurosciences	Neurosciences & Neurology	AO0RJ	WOS:000341018900003	25122883	Green Accepted, Green Published, Other Gold			2021-06-18	
J	Glushakova, OY; Johnson, D; Hayes, RL				Glushakova, Olena Y.; Johnson, Danny; Hayes, Ronald L.			Delayed Increases in Microvascular Pathology after Experimental Traumatic Brain Injury Are Associated with Prolonged Inflammation, Blood-Brain Barrier Disruption, and Progressive White Matter Damage	JOURNAL OF NEUROTRAUMA			English	Article						BBB; CD 68; chronic TBI; GFAP; ICAM-1; microbleeds; microglia	CORTICAL IMPACT INJURY; MILD COGNITIVE IMPAIRMENT; CEREBRAL MICROBLEEDS; MICROGLIAL ACTIVATION; DISEASE; ASTROCYTES; IRON; RAT; DEGENERATION; DYSFUNCTION	Traumatic brain injury (TBI) is a significant risk factor for chronic traumatic encephalopathy (CTE), Alzheimer's disease (AD), and Parkinson's disease (PD). Cerebral microbleeds, focal inflammation, and white matter damage are associated with many neurological and neurodegenerative disorders including CTE, AD, PD, vascular dementia, stroke, and TBI. This study evaluates microvascular abnormalities observed at acute and chronic stages following TBI in rats, and examines pathological processes associated with these abnormalities. TBI in adult rats was induced by controlled cortical impact (CCI) of two magnitudes. Brain pathology was assessed in white matter of the corpus callosum for 24 h to 3 months following injury using immunohistochemistry (IHC). TBI resulted in focal microbleeds that were related to the magnitude of injury. At the lower magnitude of injury, microbleeds gradually increased over the 3 month duration of the study. IHC revealed TBI-induced focal abnormalities including blood-brain barrier (BBB) damage (IgG), endothelial damage (intercellular adhesion molecule 1 [ICAM-1]), activation of reactive microglia (ionized calcium binding adaptor molecule 1 [Iba1]), gliosis (glial fibrillary acidic protein [GFAP]) and macrophage-mediated inflammation (cluster of differentiation 68 [CD68]), all showing different temporal profiles. At chronic stages (up to 3 months), apparent myelin loss (Luxol fast blue) and scattered deposition of microbleeds were observed. Microbleeds were surrounded by glial scars and co-localized with CD68 and IgG puncta stainings, suggesting that localized BBB breakdown and inflammation were associated with vascular damage. Our results indicate that evolving white matter degeneration following experimental TBI is associated with significantly delayed microvascular damage and focal microbleeds that are temporally and regionally associated with development of punctate BBB breakdown and progressive inflammatory responses. Increased understanding of mechanisms underlying delayed microvascular damage following TBI could provide novel insights into chronic pathological responses to TBI and potential common mechanisms underlying TBI and neurodegenerative diseases.	[Glushakova, Olena Y.; Johnson, Danny; Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL 32615 USA	Glushakova, OY (corresponding author), Banyan Biomarkers Inc, 13400 Progress Blvd, Alachua, FL 32615 USA.	oglushakova@banyanbio.com			DoDUnited States Department of Defense [W81XWH-11-2-0002]	The authors thank Marda Jorgensen, at the University of Florida, McKnight Brain Institute Cell and Tissue Analysis Care (MBI CTAC) and the University of Florida Molecular Pathology Core for assistance with histology. This study was supported in part by DoD Award number W81XWH-11-2-0002.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brettschneider J, 2012, ACTA NEUROPATHOL, V123, P395, DOI 10.1007/s00401-011-0932-x; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Cordonnier C, 2011, BRAIN, V134, P335, DOI 10.1093/brain/awq321; Cordonnier Charlotte, 2010, Pract Neurol, V10, P94, DOI 10.1136/jnnp.2010.206086; De Reuck J, 2012, EUR J NEUROL, V19, P1355, DOI 10.1111/j.1468-1331.2012.03776.x; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Fisher M, 2010, STROKE, V41, P2782, DOI 10.1161/STROKEAHA.110.593657; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Gaasch JA, 2007, NEUROCHEM RES, V32, P1196, DOI 10.1007/s11064-007-9290-4; Gouw AA, 2011, J NEUROL NEUROSUR PS, V82, P126, DOI 10.1136/jnnp.2009.204685; Gregoire SM, 2013, STROKE, V44, P1267, DOI 10.1161/STROKEAHA.111.000245; Hainsworth AH, 2008, J CEREBR BLOOD F MET, V28, P1877, DOI 10.1038/jcbfm.2008.91; Haller S, 2010, RADIOLOGY, V257, P764, DOI 10.1148/radiol.10100612; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Imaizumi T, 2011, J NEUROIMAGING, V21, P359, DOI 10.1111/j.1552-6569.2011.00593.x; Irimia A, 2011, J NEUROTRAUM, V28, P2287, DOI 10.1089/neu.2011.1920; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kadota E, 2000, ACT NEUR S, V76, P69; Kakar P, 2012, JRSM CARDIOVASC DIS, V1, DOI 10.1258/cvd.2012.012006; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kurumatani T, 1998, STROKE, V29, P1058, DOI 10.1161/01.STR.29.5.1058; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; Lingor P, 2012, CELL TISSUE RES, V349, P289, DOI 10.1007/s00441-012-1362-3; Lok J, 2011, ACTA NEUROCHIR SUPPL, V111, P63, DOI 10.1007/978-3-7091-0693-8_11; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nisenbaum EJ, 2014, J NEUROTRAUM, V31, P301, DOI 10.1089/neu.2013.3102; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Sangiorgi S, 2013, J NEUROSURG, V118, P763, DOI 10.3171/2012.11.JNS12627; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Schrag M, 2010, ACTA NEUROPATHOL, V119, P291, DOI 10.1007/s00401-009-0615-z; Schreiber Stefanie, 2013, Exp Transl Stroke Med, V5, P4, DOI 10.1186/2040-7378-5-4; Seo SW, 2007, STROKE, V38, P1949, DOI 10.1161/STROKEAHA.106.477315; Seylaz J, 1999, J CEREBR BLOOD F MET, V19, P863, DOI 10.1097/00004647-199908000-00005; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Staekenborg SS, 2009, STROKE, V40, P1269, DOI 10.1161/STROKEAHA.108.531343; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Tang WK, 2012, PSYCHOSOMATICS, V53, P439, DOI 10.1016/j.psym.2012.04.001; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; Werring DJ, 2004, BRAIN, V127, P2265, DOI 10.1093/brain/awh253; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Woertgen C, 2002, ACT NEUR S, V81, P205; Yanagawa Youichi, 2011, J Emerg Trauma Shock, V4, P355, DOI 10.4103/0974-2700.83863; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	79	112	114	1	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1180	1193		10.1089/neu.2013.3080			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500007	24564198				2021-06-18	
J	Evans, TA; Barkauskas, DS; Myers, JT; Hare, EG; You, JQ; Ransohoff, RM; Huang, AY; Silver, J				Evans, Teresa A.; Barkauskas, Deborah S.; Myers, Jay T.; Hare, Elisabeth G.; You, Jing Qiang; Ransohoff, Richard M.; Huang, Alex Y.; Silver, Jerry			High-resolution intravital imaging reveals that blood-derived macrophages but not resident microglia facilitate secondary axonal dieback in traumatic spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Spinal cord injury; Two-photon microscopy; Microglia; Monocytes; Macrophages; Bone marrow chimera mice; Axonal dieback; Retraction bulb; CX3CR1; CCR2	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; FRACTALKINE RECEPTOR; CNS INJURY; IN-VIVO; FUNCTIONAL RECOVERY; TRANSGENIC MICE; BRAIN-BARRIER; REGENERATION; INFLAMMATION	After traumatic spinal cord injury, functional deficits increase as axons die back from the center of the lesion and the glial scar forms. Axonal dieback occurs in two phases: an initial axon intrinsic stage that occurs over the first several hours and a secondary phase which takes place over the first few weeks after injury. Here, we examine the secondary phase, which is marked by infiltration of macrophages. Using powerful time-lapse multi-photon imaging, we captured images of interactions between Cx3crl(+/GEP) macrophages and microglia and Thy-l(YFP) axons in a mouse dorsal column crush spinal cord injury model. Over the first few weeks after injury, axonal retraction bulbs within the lesion are static except when axonal fragments are lost by a blebbing mechanism in response to physical contact followed by phagocytosis by mobile Cx3Cr1(+/GFP) cells. Utilizing a radiation chimera model to distinguish marrow-derived cells from radio-resistant CNS-resident microglia, we determined that the vast majority of accumulated cells in the lesion are derived from the blood and only these are associated with axonal damage. Interestingly, CNS-resident CX3Cr1(+/GFP) microglia did not increasingly accumulate nor participate in neuronal destruction in the lesion during this time period. Additionally, we found that the blood-derived cells consisted mainly of singly labeled Ccr2(+/GFP) macrophages, singly labeled Cx3Cr1(+/GRP) macrophages and a small population of double-labeled cells. Since all axon destructive events were seen in contact with a Cx3Cr1(+/GFP) cell, we infer that the CCR2 single positive subset is likely not robustly involved in axonal dieback. Finally, in our model, deletion of CCR2, a chemokine receptor, did not alter the position of axons after dieback. Understanding the in vivo cellular interactions involved in secondary axonal injury may lead to clinical treatment candidates involving modulation of destructive infiltrating blood monocytes. (c) 2014 The Authors. Published by Elsevier Inc. All rights reserved.	[Evans, Teresa A.; Hare, Elisabeth G.; You, Jing Qiang; Silver, Jerry] Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; [Barkauskas, Deborah S.] Case Western Reserve Univ, Sch Med, Dept Biomed Engn, Cleveland, OH 44106 USA; [Barkauskas, Deborah S.; Myers, Jay T.; Huang, Alex Y.] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; [Ransohoff, Richard M.] Cleveland Clin Fdn, Lerner Res Inst, Neuroinflammat Res Ctr, Dept Neurosci, Cleveland, OH 44195 USA	Huang, AY (corresponding author), WRB 6528,2103 Cornell Rd, Cleveland, OH 44106 USA.	teresa.evans@case.edu; deborah.sim@case.edu; jay.myers@case.edu; ehare@laurelschool.org; jxy268@case.edu; ransohr@ccf.org; ayh3@case.edu; jxs10@case.edu	Zhang, Xiaolei/E-2761-2012; Huang, Alex/R-4662-2017	Zhang, Xiaolei/0000-0003-0117-7599; Huang, Alex/0000-0002-5701-4521; Barkauskas, Deborah S./0000-0002-1872-4109	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS25713]; NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA154656]; Dana Foundation; St. Baldrick's Foundation; Alex's Lemonade Stand Foundation; Gabrielle's Angel Foundation; Hyundai Hope-on-heels Research Program;  [MSTP T32 GM007250];  [5T32EB7509]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA154656] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32EB007509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS025713] Funding Source: NIH RePORTER	The following agencies provided critical funding support for this study: MSTP T32 GM007250 (T.A.E.), 5T32EB7509 (D.S.B.), NINDS RO1 NS25713 (J.S.), NCI R01 CA154656 (A.Y.H.), Dana Foundation (A.Y.H.), St. Baldrick's Foundation (A.Y.H.), Alex's Lemonade Stand Foundation (A.Y.H.), Gabrielle's Angel Foundation (A.Y.H.) and Hyundai Hope-on-heels Research Program (A.Y.H.). The authors are grateful to Dr. Izzy Charo, M.D., Ph.D. for the use of the CCR2 RFP mice, Hongmei Hu for technical help with genotyping, Ross Anderson for mounting the spinal stabilizing unit and Dr. Richard Zigmond, Ph.D., Dr. Marcello Chieppa, Ph.D. and Marc DePaul for thorough review and thoughtful critiques of the manuscript.	Abbadie C, 2003, P NATL ACAD SCI USA, V100, P7947, DOI 10.1073/pnas.1331358100; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; Babcock AA, 2003, J NEUROSCI, V23, P7922; Bhaskar K, 2010, NEURON, V68, P19, DOI 10.1016/j.neuron.2010.08.023; Bosco A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043602; Busch SA, 2010, J NEUROSCI, V30, P255, DOI 10.1523/JNEUROSCI.3705-09.2010; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; Cajal S.R.Y., 1907, NORDISKT MED ARK, V40, P1; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Corona AW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-93; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Dunay IR, 2008, IMMUNITY, V29, P306, DOI 10.1016/j.immuni.2008.05.019; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Filous A.R., 2013, SYNAPTIC LIKE CONNEC; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Gaupp S, 2003, AM J PATHOL, V162, P139, DOI 10.1016/S0002-9440(10)63805-9; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Hawthorne AL, 2011, J NEUROSCI, V31, P5605, DOI 10.1523/JNEUROSCI.6663-10.2011; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Huang D, 2006, FASEB J, V20, P896, DOI 10.1096/fj.05-5465com; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kierdorf K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058544; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Lee S, 2010, AM J PATHOL, V177, P2549, DOI 10.2353/ajpath.2010.100265; Li ED, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-148; Ma MH, 2002, J NEUROSCI RES, V68, P691, DOI 10.1002/jnr.10269; Mahad D, 2006, BRAIN, V129, P212, DOI 10.1093/brain/awh655; MATSUMOTO Y, 1987, J NEUROIMMUNOL, V17, P71, DOI 10.1016/0165-5728(87)90032-4; Mawhinney LA, 2012, J NEUROPATH EXP NEUR, V71, P180, DOI 10.1097/NEN.0b013e3182479b41; McPhail LT, 2004, EUR J NEUROSCI, V20, P1984, DOI 10.1111/j.1460-9568.2004.03662.x; Nijagal A., 2011, J VIS EXP, V47, pe2303; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Oshima T, 2006, BRIT J OPHTHALMOL, V90, P218, DOI 10.1136/bjo.2005.077875; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Powers BE, 2012, J NEUROSCI, V32, P5120, DOI 10.1523/JNEUROSCI.0002-12.2012; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schwartz M, 2006, J NEUROTRAUM, V23, P360, DOI 10.1089/neu.2006.23.360; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shen YJ, 2009, SCIENCE, V326, P592, DOI 10.1126/science.1178310; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Takeshita Y, 2012, IMMUNOL REV, V248, P228, DOI 10.1111/j.1600-065X.2012.01127.x; Titsworth WL, 2008, CNS NEUROL DISORD-DR, V7, P254, DOI 10.2174/187152708784936671; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001	59	112	115	0	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2014	254						109	120		10.1016/j.expneurol.2014.01.013			12	Neurosciences	Neurosciences & Neurology	AD5VM	WOS:000333321300012	24468477	Green Accepted, Other Gold			2021-06-18	
J	Bryan, CJ; Clemans, TA				Bryan, Craig J.; Clemans, Tracy A.			Repetitive Traumatic Brain Injury, Psychological Symptoms, and Suicide Risk in a Clinical Sample of Deployed Military Personnel	JAMA PSYCHIATRY			English	Article							HEAD-INJURY; ASSOCIATION; POPULATION; DEPRESSION; VETERANS; BEHAVIOR	IMPORTANCE Traumatic brain injury (TBI) is believed to be one factor contributing to rising suicide rates among military personnel and veterans. This study investigated the association of cumulative TBIs with suicide risk in a clinical sample of deployed military personnel referred for a TBI evaluation. OBJECTIVE To determine whether suicide risk is more frequent and heightened among military personnel with multiple lifetime TBIs than among those with no TBIs or a single TBI. DESIGN Patients completed standardized self-report measures of depression, posttraumatic stress disorder (PTSD), and suicidal thoughts and behaviors; clinical interview; and physical examination. Group comparisons of symptom scores according to number of lifetime TBIs were made, and generalized regression analyses were used to determine the association of cumulative TBIs with suicide risk. PARTICIPANTS Patients included 161 military personnel referred for evaluation and treatment of suspected head injury at a military hospital's TBI clinic in Iraq. MAIN OUTCOMES AND MEASURES Behavioral Health Measure depression subscale, PTSD Checklist-Military Version, concussion symptoms, and Suicide Behaviors Questionnaire-Revised. RESULTS Depression, PTSD, and TBI symptom severity significantly increased with the number of TBIs. An increased incidence of lifetime suicidal thoughts or behaviors was associated with the number of TBIs (no TBIs, 0%; single TBI, 6.9%; and multiple TBIs, 21.7%; P = .009), as was suicidal ideation within the past year (0%, 3.4%, and 12.0%, respectively; P = .04). The number of TBIs was associated with greater suicide risk (beta [SE] = .214 [.098]; P = .03) when the effects of depression, PTSD, and TBI symptom severity were controlled for. A significant interaction between depression and cumulative TBIs was also found (beta = .580 [.283]; P = .04). CONCLUSIONS AND RELEVANCE Suicide risk is higher among military personnel with more lifetime TBIs, even after controlling for clinical symptom severity. Results suggest that multiple TBIs, which are common among military personnel, may contribute to increased risk for suicide.	[Bryan, Craig J.] Natl Ctr Vet Studies, Salt Lake City, UT 84112 USA; [Clemans, Tracy A.] VA VISN 19 Mental Illness Res Educ Clin Ctr, Denver, CO USA	Bryan, CJ (corresponding author), Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA.	craig.bryan@utah.edu		Bryan, Craig/0000-0002-9714-0733	Department of DefenseUnited States Department of Defense; Department of the Air Force; San Antonio Life Sciences Institute	Dr Bryan reported receiving research grants from the Department of Defense, the Department of the Air Force, and the San Antonio Life Sciences Institute; speakers bureau honoraria from the American Association for Suicidology, the American Foundation for Suicide Prevention, and CMI Education; and salary from the American Association for Suicidology and Laredo Technical Services, for Department of Defense contracts to conduct military trainings.	Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Blount TH, 2010, ANN M ASS BEHAV COGN; Brenner L.A., 2008, J MENT HLTH COUNS, V30, P211; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Bryan CJ, 2012, PERS INDIV DIFFER, V52, P374, DOI 10.1016/j.paid.2011.10.045; Defense and Veterans Brain Injury Center, 2007, MIL AC CONC EV; Department of the Army, 2012, ARM 2020 GEN HLTH DI; DOD/VA Traumatic Brain Injury Task Force, 2008, REP SURG GEN TRAUM B; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Kopta SM, 2002, PSYCHOTHER RES, V12, P413, DOI 10.1093/ptr/12.4.413; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Osman A, 2001, ASSESSMENT, V8, P443, DOI 10.1177/107319110100800409; Ramchand R, 2011, WAR PREVENTING SUICI; Rudd MD, 2006, ASSESSMENT MANAGEMEN; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Simpson GK, 2007, MED J AUSTRALIA, V187, P229, DOI 10.5694/j.1326-5377.2007.tb01206.x; Skopp Nancy A, 2012, MSMR, V19, P7; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; VISN 19 Mental Illness Research Education and Clinical Center, 2009, TRAUM BRAIN INJ SUIC; Weathers F. W., 1993, ANN M INT SOC TRAUM	28	112	114	0	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	JUL	2013	70	7					686	691		10.1001/jamapsychiatry.2013.1093			6	Psychiatry	Psychiatry	197EA	WOS:000322831100008	23676987	Bronze			2021-06-18	
J	Guo, DJ; Zeng, LH; Brody, DL; Wong, M				Guo, Dongjun; Zeng, Linghui; Brody, David L.; Wong, Michael			Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; TEMPORAL-LOBE EPILEPSY; TUBEROUS SCLEROSIS COMPLEX; MAMMALIAN TARGET; STATUS EPILEPTICUS; SEIZURES; EPILEPTOGENESIS; THERAPY; INHIBITION; PREVENTION	Posttraumatic epilepsy is a major source of disability following traumatic brain injury (TBI) and a common cause of medically-intractable epilepsy. Previous attempts to prevent the development of posttraumatic epilepsy with treatments administered immediately following TBI have failed. Recently, the mammalian target of rapamycin complex 1 (mTORC1) pathway has been implicated in mechanisms of epileptogenesis and the mTORC1 inhibitor, rapamycin, has been proposed to have antiepileptogenic effects in preventing some types of epilepsy. In this study, we have tested the hypothesis that rapamycin has antiepileptogenic actions in preventing the development of posttraumatic epilepsy in an animal model of TBI. A detailed characterization of posttraumatic epilepsy in the mouse controlled cortical impact model was first performed using continuous video-EEG monitoring for 16 weeks following TBI. Controlled cortical impact injury caused immediate hyperactivation of the mTORC1 pathway lasting at least one week, which was reversed by rapamycin treatment. Rapamycin decreased neuronal degeneration and mossy fiber sprouting, although the effect on mossy fiber sprouting was reversible after stopping rapamycin and did not directly correlate with inhibition of epileptogenesis. Most posttraumatic seizures occurred greater than 10 weeks after TBI, and rapamycin treatment for one month after TBI decreased the seizure frequency and rate of developing posttraumatic epilepsy during the entire 16 week monitoring session. These results suggest that rapamycin may represent a rational treatment for preventing posttraumatic epilepsy in patients with TBI.	[Guo, Dongjun; Brody, David L.; Wong, Michael] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Guo, Dongjun; Brody, David L.; Wong, Michael] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [Zeng, Linghui] Zhejiang Univ City Coll, Dept Pharm, Hangzhou 310003, Zhejiang, Peoples R China	Wong, M (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.	wong_m@wustl.edu	Ritter, Stefanie L/D-9312-2012		National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS056872, NS057105]; Pfizer Inc. (Washington University/Pfizer Biomedical Research Agreement); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS057105, R01NS056872] Funding Source: NIH RePORTER	1) National Institutes of Health/National Institute of Neurological Disorders and Stroke: NS056872, NS057105. 2) Pfizer Inc. (Washington University/Pfizer Biomedical Research Agreement). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Buckmaster PS, 2011, J NEUROSCI, V31, P2337, DOI 10.1523/JNEUROSCI.4852-10.2011; Carson RP, 2012, NEUROBIOL DIS, V45, P369, DOI 10.1016/j.nbd.2011.08.024; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Chachua T, 2012, EPILEPSIA, V53, P2015, DOI 10.1111/j.1528-1167.2012.03674.x; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Galanopoulou AS, 2012, EPILEPSIA, V53, P1119, DOI 10.1111/j.1528-1167.2012.03506.x; Goto J, 2011, P NATL ACAD SCI USA, V108, pE1070, DOI 10.1073/pnas.1106454108; Hartman AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045156; Huang XX, 2010, NEUROBIOL DIS, V40, P193, DOI 10.1016/j.nbd.2010.05.024; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Ljungberg MC, 2009, DIS MODEL MECH, V2, P389, DOI 10.1242/dmm.002386; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Raffo E, 2011, NEUROBIOL DIS, V43, P322, DOI 10.1016/j.nbd.2011.03.021; Raible DJ, 2012, J NEUROTRAUM, V29, P2548, DOI 10.1089/neu.2012.2483; Russo E, 2012, NEUROPHARM      1022; Sliwa A, 2012, NEUROSCI LETT, V509, P105, DOI 10.1016/j.neulet.2011.12.051; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Talos DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035885; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; van Vliet EA, 2012, EPILEPSIA, V53, P1254, DOI 10.1111/j.1528-1167.2012.03513.x; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Wong M, 2010, EPILEPSIA, V51, P27, DOI 10.1111/j.1528-1167.2009.02341.x; Zeng LH, 2008, ANN NEUROL, V63, P444, DOI 10.1002/ana.21331; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009	42	112	123	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2013	8	5							e64078	10.1371/journal.pone.0064078			12	Multidisciplinary Sciences	Science & Technology - Other Topics	146RE	WOS:000319107400100	23691153	DOAJ Gold, Green Published			2021-06-18	
J	Jorge, RE; Acion, L; White, T; Tordesillas-Gutierrez, D; Pierson, R; Crespo-Facorro, B; Magnotta, VA				Jorge, Ricardo E.; Acion, Laura; White, Tonya; Tordesillas-Gutierrez, Diana; Pierson, Ronald; Crespo-Facorro, Benedicto; Magnotta, Vincent A.			White Matter Abnormalities in Veterans With Mild Traumatic Brain Injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							OPERATION-IRAQI-FREEDOM; EXPLOSIVE BLAST; CORPUS-CALLOSUM; MODERATE; CHILDREN; HEAD; MILITARY; EXPOSURE; RECOVERY; SEQUELAE	Objective: It has been estimated that 10%-20% of U.S. veterans of the wars in Iraq and Afghanistan experienced mild traumatic brain injury (TBI), mostly secondary to blast exposure. Diffusion tensor imaging (DTI) may detect subtle white matter changes in both the acute and chronic stages of mild TBI and thus has the potential to detect white matter damage in patients with TBI. The authors used DTI to examine white matter integrity in a relatively large group of veterans with a history of mild TBI. Method: DTI images from 72 veterans of the wars in Iraq and Afghanistan who had mild TBI were compared with DTI images from 21 veterans with no exposure to TBI during deployment. Conventional voxel-based analysis as well as a method of identifying spatially heterogeneous areas of decreased fractional anisotropy ("potholes") were used. Veterans also underwent psychiatric and neuropsychological assessments. Results: Voxel-based analysis did not reveal differences in DTI parameters between the veterans with mild TBI and those with no TBI. However, the veterans with mild TBI had a significantly higher number of potholes than those without TBI. The difference in the number of potholes was not influenced by age, time since trauma, a history of mild TBI unrelated to deployment, or coexisting psychopathology. The number of potholes was correlated with the severity of TBI and with performance in executive functioning tasks. Conclusions: Veterans who had blast-related mild TBI showed evidence of multifocal white matter abnormalities that were associated with severity of the injury and with relevant functional measures. Overall, white matter potholes may constitute a sensitive biomarker of axonal injury that can be identified in mild TBI at acute and chronic stages of its clinical course. (Am J Psychiatry 2012; 169:1284-1291)	[Jorge, Ricardo E.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Carver Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Iowa Consortium Subst Abuse Res & Evaluat, Iowa City, IA 52242 USA; Iowa City Vet Affairs VA Med Ctr, Iowa City, IA USA; Erasmus Univ, Med Ctr, Dept Child & Adolescent Psychiat, Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Radiol, Rotterdam, Netherlands; Univ Hosp Marques de Valdecilla, CIBERSAM, IFIMAV, Santander, Spain; Univ Cantabria, Dept Psychiat, Sch Med, E-39005 Santander, Spain; Brain Image Anal LLC, Coralville, IA USA	Jorge, RE (corresponding author), Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.	ricardo-jorge@uiowa.edu	Tordesillas-Gutierrez, Diana/H-6893-2015	Tordesillas-Gutierrez, Diana/0000-0003-1458-3932; Magnotta, Vincent/0000-0001-8639-5354; White, Tonya/0000-0003-0271-1896; Acion, Laura/0000-0001-5213-6012; , BENEDICTO/0000-0003-0033-7132	VA Merit Research Award [D7201I]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055827] Funding Source: NIH RePORTER	Supported by VA Merit Research Award D7201I to Dr. Jorge.	Alexander MP, 2003, BRAIN, V126, P1493, DOI 10.1093/brain/awg128; Allen RMRCC, 1996, RUFF 2 7 SELECTIVE A; Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Benedict R., 1997, BRIEF VISUOSPATIAL M; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu ZX, 2010, PROC SPIE, V7628, DOI 10.1117/12.844748; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Matthews C, 1964, INSTRUCTION MANUAL A; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Miller G, 2011, SCIENCE, V333, P514, DOI 10.1126/science.333.6042.514; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 1981, WAIS R MANUAL WECHSL; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412	45	112	112	1	47	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	DEC	2012	169	12					1284	1291		10.1176/appi.ajp.2012.12050600			8	Psychiatry	Psychiatry	052EC	WOS:000312179500011	23212059	Green Accepted			2021-06-18	
J	Vanderploeg, RD; Belanger, HG; Horner, RD; Spehar, AM; Powell-Cope, G; Luther, SL; Scott, SG				Vanderploeg, Rodney D.; Belanger, Heather G.; Horner, Ronnie D.; Spehar, Andrea M.; Powell-Cope, Gail; Luther, Stephen L.; Scott, Steven G.			Health Outcomes Associated With Military Deployment: Mild Traumatic Brain Injury, Blast, Trauma, and Combat Associations in the Florida National Guard	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Blast injuries; Brain concussion; Military personnel; Neurobehavioral manifestations; Outcome assessment; Rehabilitation; Sequelae	POSTTRAUMATIC-STRESS-DISORDER; PRIMARY-CARE; FUNCTIONAL IMPAIRMENT; IRAQ; VETERANS; AFGHANISTAN; SYMPTOMS; COMPLAINTS; SEVERITY; SEQUELAE	Objectives: To determine the association between specific military deployment experiences and immediate and longer-term physical and mental health effects, as well as examine the effects of multiple deployment-related traumatic brain injuries (TBIs) on health outcomes. Design: Online survey of cross-sectional cohort. Odds ratios were calculated to assess the association between deployment-related factors (ie, physical injuries, exposure to potentially traumatic deployment experiences, combat, blast exposure, and mild TBI) and current health status, controlling for potential confounders, demographics, and predeployment experiences. Setting: Nonclinical. Participants: Members (N=3098) of the Florida National Guard (1443 deployed, 1655 not deployed). Interventions: Not applicable. Main Outcome Measures: Presence of current psychiatric diagnoses and health outcomes, including postconcussive and non postconcussive symptoms. Results: Surveys were completed an average of 31.8 months (SD=24.4, range=0-95) after deployment. Strong, statistically significant associations were found between self-reported military deployment-related factors and current adverse health status. Deployment-related mild TBI was associated with depression, anxiety, posttraumatic stress disorder (PTSD), and postconcussive symptoms collectively and individually. Statistically significant increases in the frequency of depression, anxiety, PTSD, and a postconcussive symptom complex were seen comparing single to multiple TBIs. However, a predeployment TBI did not increase the likelihood of sustaining another TBI in a blast exposure. Associations between blast exposure and abdominal pain, pain on deep breathing, shortness of breath, hearing loss, and tinnitus suggested residual barotrauma. Combat exposures with and without physical injury were each associated not only with PTSD but also with numerous postconcussive and non postconcussive symptoms. The experience of seeing others wounded or killed or experiencing the death of a buddy or leader was associated with indigestion and headaches but not with depression, anxiety, or FTSD. Conclusions: Complex relationships exist between multiple deployment-related factors and numerous overlapping and co-occurring current adverse physical and psychological health outcomes. Various deployment-related experiences increased the risk for postdeployment adverse mental and physical health outcomes, individually and in combination. These findings suggest that an integrated physical and mental health care approach would be beneficial to postdeployment care.	[Vanderploeg, Rodney D.; Belanger, Heather G.] James A Haley Vet Hosp, Mental Hlth & Behav Sci Psychol Serv, Tampa, FL 33612 USA; [Scott, Steven G.] James A Haley Vet Hosp, Phys Med & Rehabil Serv, Tampa, FL 33612 USA; [Spehar, Andrea M.] James A Haley Vet Hosp, Res Serv, Tampa, FL 33612 USA; [Powell-Cope, Gail; Luther, Stephen L.] James A Haley Vet Hosp, Nursing Serv, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Spehar, Andrea M.; Powell-Cope, Gail; Luther, Stephen L.; Scott, Steven G.] James A Haley Vet Hosp, Hlth Serv Res & Dev HSR&D Rehabil Res & Dev RR&D, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Neurosci, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Powell-Cope, Gail; Luther, Stephen L.] Univ S Florida, Dept Publ Hlth, Tampa, FL USA; [Scott, Steven G.] Univ S Florida, Dept Internal Med, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Scott, Steven G.] James A Haley Vet Affairs Med Ctr, Def & Vet Brain Injury Ctr, Tampa, FL USA; [Horner, Ronnie D.] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Mental Hlth & Behav Sci Psychol Serv 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.Vanderploeg@va.gov		Powell-Cope, Gail/0000-0002-4608-0128	Department of Veterans Affairs, Veterans Health AdministrationUS Department of Veterans Affairs; Veterans Administration HSRD [CCN 06-164]; James A. Haley Veterans' HospitalUS Department of Veterans Affairs; HSR&D/RR&D Center of Excellence	Supported by the Department of Veterans Affairs, Veterans Health Administration, and Veterans Administration HSR&D (grant no. CCN 06-164). Further support was provided by the James A. Haley Veterans' Hospital and its HSR&D/RR&D/RR&D Center of Excellence. The views expressed herein are those of the authors and do not necessarily reflect the views or the official policy of the Department of Veterans Affairs or the US government.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BABOR TF, 1992, AUDIT ALC US DIS ID; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Deployment Health Clinical Center, 2010, POSTD HLTH ASS PDHA; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jones E, 2006, PHILOS T R SOC B, V361, P533, DOI 10.1098/rstb.2006.1814; Jones E, 2002, BMJ-BRIT MED J, V324, P321, DOI 10.1136/bmj.324.7333.321; Kehle SM, 2010, J TRAUMA STRESS, V23, P33, DOI 10.1002/jts.20480; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rittenhouse DR, 2009, JAMA-J AM MED ASSOC, V301, P2038, DOI 10.1001/jama.2009.691; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shea MT, 2010, J TRAUMA STRESS, V23, P100, DOI 10.1002/jts.20497; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; World Health Organization, 1992, ICD 10 INT STAT CLAS	35	112	112	0	38	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2012	93	11					1887	1895		10.1016/j.apmr.2012.05.024			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	031VQ	WOS:000310671100001	22705240				2021-06-18	
J	Baillargeon, A; Lassonde, M; Leclerc, S; Ellemberg, D				Baillargeon, Annie; Lassonde, Maryse; Leclerc, Suzanne; Ellemberg, Dave			Neuropsychological and neurophysiological assessment of sport concussion in children, adolescents and adults	BRAIN INJURY			English	Article						Sport concussion; event-related potentials; neuropsychology; children	TRAUMATIC BRAIN-INJURY; EVENT-RELATED POTENTIALS; HIGH-SCHOOL; SEX-DIFFERENCES; HEAD-INJURY; COLLEGIATE; CHILDHOOD; RECOVERY; SYMPTOMS; STATEMENT	Objective: To determine whether age differences exist with respect to neuropsychological and electrophysiological functioning following a sport concussion. Design: Cross-sectional study. Participants: Ninety-six athletes (9-12 years, n = 32; 13-16 years, n = 34; adults, n = 30), half of whom had a sport concussion. Intervention: Cognitive functioning was assessed using standardized neuropsychological tests and event-related potentials elicited by a visual 3-stimulus oddball paradigm. The PCSS was used to assess symptoms experienced at the time of injury. Main outcome measurements: Neuropsychological assessment with an adaptation of the battery used by the National Hockey League. Latencies and amplitudes of the P3a and P3b were analysed in terms of group (concussed vs. control) and age. Results: All concussed athletes had significantly lower amplitude for the P3b component compared to their non-injured teammates (p > 0.05). Adolescents also showed persistent deficits in working memory (p > 0.05). Conclusions: These data suggest persistent neurophysiological deficits that are present at least 6 months following a concussion. Moreover, adolescents are more sensitive to the consequences of concussions than are children or adults.	[Leclerc, Suzanne; Ellemberg, Dave] Univ Montreal, Dept Kinesiol, Montreal, PQ H3T 1J4, Canada; [Baillargeon, Annie; Lassonde, Maryse] Univ Montreal, Dept Psychol, Montreal, PQ H3T 1J4, Canada; [Baillargeon, Annie; Lassonde, Maryse; Ellemberg, Dave] Ctr Rech Neuropsychol & Cognit Montreal, Montreal, PQ, Canada; [Baillargeon, Annie; Lassonde, Maryse; Ellemberg, Dave] Ctr Rech Hop Ste JustineMontreal, Montreal, PQ, Canada	Ellemberg, D (corresponding author), Univ Montreal, Dept Kinesiol, 2100 Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.	dave.ellemberg@umontreal.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Canada Foundation for InnovationCanada Foundation for InnovationCGIAR	This research was funded by a grant from the Canadian Institutes of Health Research to D.E. and M.L. and a grant from the Canada Foundation for Innovation to D.E.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT., 1989, MILD HEAD INJURY, P257; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; COURCHESNE E, 1978, ELECTROEN CLIN NEURO, V45, P468, DOI 10.1016/0013-4694(78)90291-2; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; GRATTON G, 1983, PSYCHOPHYSIOLOGY, V20, P443; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Holguin SR, 1999, ALCOHOL CLIN EXP RES, V23, P582, DOI 10.1097/00000374-199904000-00003; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kelly JP, 1997, NEUROLOGY, V48, P581; Knight RT, 1997, J COGNITIVE NEUROSCI, V9, P75, DOI 10.1162/jocn.1997.9.1.75; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Luna B, 2010, BRAIN COGNITION, V72, P101, DOI 10.1016/j.bandc.2009.08.005; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; O'Hare ED, 2008, NEUROIMAGE, V42, P1678, DOI 10.1016/j.neuroimage.2008.05.057; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sawaki R, 2007, PSYCHOPHYSIOLOGY, V44, pS51; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; van der Stelt O, 1998, ALCOHOL CLIN EXP RES, V22, P1877, DOI 10.1097/00000374-199812000-00001	44	112	113	2	60	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2012	26	3					211	220		10.3109/02699052.2012.654590			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	899XD	WOS:000300849100002	22372409				2021-06-18	
J	Kishimoto, N; Shimizu, K; Sawamoto, K				Kishimoto, Norihito; Shimizu, Kohei; Sawamoto, Kazunobu			Neuronal regeneration in a zebrafish model of adult brain injury	DISEASE MODELS & MECHANISMS			English	Article							NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; SUBVENTRICULAR ZONE ASTROCYTES; VENTRICULAR ZONE; OLFACTORY-BULB; PROGENITOR CELLS; FOREBRAIN NEUROGENESIS; TELEOST FISH; RADIAL GLIA; IN-VIVO	Neural stem cells in the subventricular zone (SVZ) of the adult mammalian forebrain are a potential source of neurons for neural tissue repair after brain insults such as ischemic stroke and traumatic brain injury (TBI). Recent studies show that neurogenesis in the ventricular zone (VZ) of the adult zebrafish telencephalon has features in common with neurogenesis in the adult mammalian SVZ. Here, we established a zebrafish model to study injury-induced neurogenesis in the adult brain. We show that the adult zebrafish brain possesses a remarkable capacity for neuronal regeneration. Telencephalon injury prompted the proliferation of neuronal precursor cells (NPCs) in the VZ of the injured hemisphere, compared with in the contralateral hemisphere. The distribution of NPCs, viewed by BrdU labeling and ngn1-promoter-driven GFP, suggested that they migrated laterally and reached the injury site via the subpallium and pallium. The number of NPCs reaching the injury site significantly decreased when the fish were treated with an inhibitor of gamma-secretase, a component of the Notch signaling pathway, suggesting that injury-induced neurogenesis mechanisms are at least partly conserved between fish and mammals. The injury-induced NPCs differentiated into mature neurons in the regions surrounding the injury site within a week after the injury. Most of these cells expressed T-box brain protein (Tbr1), suggesting they had adopted the normal neuronal fate in this region. These results suggest that the telencephalic VZ contributes to neural tissue recovery following telencephalic injury in the adult zebrafish, and that the adult zebrafish is a useful model for regenerative medicine.	[Kishimoto, Norihito; Shimizu, Kohei; Sawamoto, Kazunobu] Nagoya City Univ, Grad Sch Med Sci, Dept Dev & Regenerat Biol, Nagoya, Aichi 4678601, Japan; [Kishimoto, Norihito] Keio Univ, Ctr Integrated Med Res, Shinjuku Ku, Tokyo 1608582, Japan	Sawamoto, K (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Dev & Regenerat Biol, Nagoya, Aichi 4678601, Japan.	sawamoto@med.nagoya-cu.ac.jp		Sawamoto, Kazunobu/0000-0003-1984-5129	Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20022035, LS104, 21670003]; Uehara Memorial FoundationUehara Memorial Foundation; International Human Frontier Science Program OrganizationHuman Frontier Science Program; Global COE at Keio University;  [20509005]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [20509005] Funding Source: KAKEN	This work was supported by the Funding Program for Next Generation World-Leading Researchers [LS104] (to K. Sawamoto); a Grant-in-Aid for Young Scientists (S) [21670003] (to K. Sawamoto); a Grant-in-Aid for Scientific Research on Priority Areas-Molecular Brain Science-from the Ministry of Education, Culture, Sports, Science and Technology of Japan [20022035] (to K. Sawamoto); by the Uehara Memorial Foundation (to K. Sawamoto); by The International Human Frontier Science Program Organization (to K. Sawamoto); by Global COE Programs at Keio University (to K. Sawamoto, N.K.); and by a Grant-in-Aid for Scientific Research (C) [20509005] (to N.K.).	Adolf B, 2006, DEV BIOL, V295, P278, DOI 10.1016/j.ydbio.2006.03.023; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; Alvarez-Buylla A, 1998, J NEUROSCI, V18, P1020; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Asakawa K, 2008, P NATL ACAD SCI USA, V105, P1255, DOI 10.1073/pnas.0704963105; Ayari B, 2010, J NEUROTRAUM, V27, P959, DOI 10.1089/neu.2009.0972; Blader P, 2003, MECH DEVELOP, V120, P211, DOI 10.1016/S0925-4773(02)00413-6; Byrd CA, 2001, NEUROSCIENCE, V105, P793, DOI 10.1016/S0306-4522(01)00215-9; Chapouton P, 2007, BIOESSAYS, V29, P745, DOI 10.1002/bies.20615; Chapouton P, 2010, J NEUROSCI, V30, P7961, DOI 10.1523/JNEUROSCI.6170-09.2010; Chojnacki AK, 2009, NAT REV NEUROSCI, V10, P153, DOI 10.1038/nrn2571; Clint SC, 2001, DEV BRAIN RES, V130, P15, DOI 10.1016/S0165-3806(01)00193-6; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Doetsch F, 2001, BRAIN BEHAV EVOLUT, V58, P306, DOI 10.1159/000057572; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Englund C, 2005, J NEUROSCI, V25, P247, DOI 10.1523/JNEUROSCI.2899-04.2005; Font E, 2001, BRAIN BEHAV EVOLUT, V58, P276, DOI 10.1159/000057570; Ganz J, 2010, GLIA, V58, P1345, DOI 10.1002/glia.21012; Garcia-Verdugo JM, 2002, BRAIN RES BULL, V57, P765, DOI 10.1016/S0361-9230(01)00769-9; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Givogri MI, 2006, DEV NEUROSCI-BASEL, V28, P81, DOI 10.1159/000090755; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Grandel H, 2006, DEV BIOL, V295, P263, DOI 10.1016/j.ydbio.2006.03.040; Ishikura N, 2005, P NATL ACAD SCI USA, V102, P886, DOI 10.1073/pnas.0408612101; Ito Y, 2010, DEV BIOL, V342, P26, DOI 10.1016/j.ydbio.2010.03.008; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Jankovski A, 1996, J COMP NEUROL, V371, P376; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kaneko N, 2009, NEUROSCI RES, V63, P155, DOI 10.1016/j.neures.2008.12.001; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kaslin J, 2008, PHILOS T R SOC B, V363, P101, DOI 10.1098/rstb.2006.2015; Kempermann G, 2002, E SCHERING RES FDN W, V35, P17; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kirsche W, 1965, Ergeb Anat Entwicklungsgesch, V38, P143; Kishimoto N, 2011, J COMP NEUROL, V519, P3549, DOI 10.1002/cne.22722; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; KOSAKA K, 1995, NEUROSCI RES, V23, P73, DOI 10.1016/0168-0102(95)00930-R; Lam CS, 2009, DEV DYNAM, V238, P475, DOI 10.1002/dvdy.21853; Marz M, 2010, GLIA, V58, P870, DOI 10.1002/glia.20971; Melchiorri D, 2001, EUR J NEUROSCI, V13, P1694, DOI 10.1046/j.1460-9568.2001.01549.x; Mueller T, 2002, MECH DEVELOP, V117, P123, DOI 10.1016/S0925-4773(02)00194-6; Ng KL, 2005, SCIENCE, V308, P1923, DOI 10.1126/science.1112103; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Palomero T, 2006, LEUKEMIA, V20, P1279, DOI 10.1038/sj.leu.2404258; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Prosser HM, 2007, P NATL ACAD SCI USA, V104, P648, DOI 10.1073/pnas.0606884104; Rothenaigner I, 2011, DEVELOPMENT, V138, P1459, DOI 10.1242/dev.058156; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Tatsumi K, 2010, J CHEM NEUROANAT, V39, P15, DOI 10.1016/j.jchemneu.2009.09.003; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Taylor KL, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-11; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; Wang XM, 2009, J CEREBR BLOOD F MET, V29, P1644, DOI 10.1038/jcbfm.2009.83; Westerfield M., 2000, ZEBRAFISH BOOK; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yang J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000363; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zupanc GKH, 2006, J COMP PHYSIOL A, V192, P649, DOI 10.1007/s00359-006-0104-y; Zupanc GKH, 1998, EXP NEUROL, V152, P221, DOI 10.1006/exnr.1998.6853; Zupanc GKH, 2005, J COMP NEUROL, V488, P290, DOI 10.1002/cne.20571; Zupanc GKH, 2001, BRAIN BEHAV EVOLUT, V58, P250, DOI 10.1159/000057569; Zupanc GKH, 1999, EXP NEUROL, V160, P78, DOI 10.1006/exnr.1999.7182; Zupanc GKH, 2006, REGEN MED, V1, P207, DOI 10.2217/17460751.1.2.207; Zupanc GKH, 2008, J PHYSIOL-PARIS, V102, P357, DOI 10.1016/j.jphysparis.2008.10.007; Zupanc MM, 2006, PROTEOMICS, V6, P677, DOI 10.1002/pmic.200500167	71	112	116	0	33	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	1754-8403	1754-8411		DIS MODEL MECH	Dis. Model. Mech.	MAR	2012	5	2					200	209		10.1242/dmm.007336			10	Cell Biology; Pathology	Cell Biology; Pathology	927IA	WOS:000302899700006	22028327	DOAJ Gold, Green Published			2021-06-18	
J	Sponheim, SR; McGuire, KA; Kang, SS; Davenport, ND; Aviyente, S; Bernat, EM; Lim, KO				Sponheim, Scott R.; McGuire, Kathryn A.; Kang, Seung Suk; Davenport, Nicholas D.; Aviyente, Selin; Bernat, Edward M.; Lim, Kelvin O.			Evidence of disrupted functional connectivity in the brain after combat-related blast injury	NEUROIMAGE			English	Article							INDUCED NEUROTRAUMA; MILITARY TBI; EEG; CONCUSSION; MECHANISMS; IRAQ; NEUROPSYCHOLOGY; AFGHANISTAN; MANAGEMENT; SYMPTOMS	Non-impact blast-related mild traumatic brain injury (mTBI) appears to be present in soldiers returning from deployments to Afghanistan and Iraq. Although mTBI typically results in cognitive deficits that last less than a month, there is evidence that disrupted coordination of brain activity can persist for at least several months following injury (Thatcher et al., 1989, 2001). In the present study we examined whether neural communication may be affected in soldiers months after blast-related mTBI, and whether coordination of neural function is associated with underlying white matter integrity. The investigation included an application of a new time-frequency based method for measuring electroencephalogram (EEG) phase synchronization (Aviyente et al., 2010) as well as fractional anisotropy measures of axonal tracts derived from diffusion tensor imaging (DTI). Nine soldiers who incurred a blast-related mTBI during deployments to Afghanistan or Iraq were compared with eight demographically similar control subjects. Despite an absence of cognitive deficits, the blast-related mTBI group exhibited diminished EEG phase synchrony of lateral frontal sites with contralateral frontal brain regions suggesting diminished interhemispheric coordination of brain activity as a result of blast injury. For blast injured (i.e., blast-related mTBI) soldiers we found that EEG phase synchrony was associated with the structural integrity of white matter tracts of the frontal lobe (left anterior thalamic radiations and the forceps minor including the anterior corpus callosum). Analyses revealed that diminished EEG phase synchrony was not the consequence of combat-stress symptoms (e. g., post-traumatic stress and depression) and commonly prescribed medications. Results provide evidence for poor coordination of frontal neural function after blast injury that may be the consequence of damaged anterior white matter tracts. Published by Elsevier Inc.	[Sponheim, Scott R.; McGuire, Kathryn A.; Kang, Seung Suk; Davenport, Nicholas D.; Lim, Kelvin O.] Vet Affairs Med Ctr, Minneapolis, MN USA; [Sponheim, Scott R.; McGuire, Kathryn A.; Kang, Seung Suk; Davenport, Nicholas D.; Lim, Kelvin O.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Sponheim, Scott R.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA; [Aviyente, Selin] Michigan State Univ, Dept Elect Engn, E Lansing, MI 48824 USA; [Bernat, Edward M.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA	Sponheim, SR (corresponding author), VA Med Ctr 116B, 1 Vet Dr, Minneapolis, MN 55417 USA.	sponh001@umn.edu	Davenport, Nicholas/AAY-8057-2020; Sponheim, Scott/J-3857-2017; Lim, Kelvin/AAF-6833-2020; Kang, Seung/AAO-7849-2020	Davenport, Nicholas/0000-0002-3441-7256; Sponheim, Scott/0000-0002-2782-0856; Aviyente, Selin/0000-0001-9023-107X; Lim, Kelvin/0000-0002-2390-7268	Minnesota Veterans Medical Research and Education Foundation (formerly Minnesota Veterans Research Institute [MVRI]); Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-08-2-0038]; Minnesota Veterans Medical Research and Education Foundation	This work was supported by grants from the Minnesota Veterans Medical Research and Education Foundation (formerly Minnesota Veterans Research Institute [MVRI]) and the Congressionally Directed Medical Research Program (W81XWH-08-2-0038) to Scott R. Sponheim and a grant from the Minnesota Veterans Medical Research and Education Foundation to Kathryn A. McGuire.	AVIYENTE S, 2010, HUM BRAIN MAPP; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; FABING HD, 1947, ARCH NEURO PSYCHIATR, V57, P14, DOI 10.1001/archneurpsyc.1947.02300240030002; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Georgopoulos AP, 2007, J NEURAL ENG, V4, P349, DOI 10.1088/1741-2560/4/4/001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hyvarinen A, 2000, NEURAL NETWORKS, V13, P411, DOI 10.1016/S0893-6080(00)00026-5; Jeyakumar SLE, 2004, EDUC PSYCHOL MEAS, V64, P71, DOI 10.1177/0013164403258407; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McMenamin BW, 2010, NEUROIMAGE, V49, P2416, DOI 10.1016/j.neuroimage.2009.10.010; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Mori S., 2005, MRI ATLAS HUMAN WHIT; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Solbakk AK, 2005, J CLIN EXP NEUROPSYC, V27, P205, DOI 10.1080/13803390490515739; Srinivasan R, 2007, J NEUROSCI METH, V166, P41, DOI 10.1016/j.jneumeth.2007.06.026; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F.W., 1991, PCL C DSM 4; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9	49	112	112	1	30	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	JAN	2011	54			1			S21	S29		10.1016/j.neuroimage.2010.09.007			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600004	20851190				2021-06-18	
J	Armistead-Jehle, P				Armistead-Jehle, Patrick			Symptom Validity Test Performance in U. S. Veterans Referred for Evaluation of Mild TBI	APPLIED NEUROPSYCHOLOGY			English	Article						mild TBI; MSVT; Symptom Validity Testing	POSTTRAUMATIC-STRESS-DISORDER; PSYCHOGENIC NONEPILEPTIC SEIZURES; BASE RATES; NEUROPSYCHOLOGICAL TESTS; DISABILITY INCENTIVES; BRAIN-INJURY; EXAGGERATION; CLAIMANTS; FAILURE; FIBROMYALGIA	The current study examined Medical Symptom Validity Test (MSVT) performance in U.S. veterans referred for evaluation of mild traumatic brain injury (TBI) after scoring positive on the Veterans Health Administration (VHA) TBI screening measures. Fifty-eight percent of the sample scored below the MSVT cut scores on subtests more sensitive to effort than to neurological insult. There were no differences among those who did and those who did not pass the MSVT as a function of gender, age, education, ethnicity, previous posttraumatic stress disorder or substance use disorder diagnoses, or Personality Assessment Inventory validity scales designed to measure negative impression management. A higher number of those who were service connected and previously diagnosed with a depressive condition failed the measure at a higher rate than those who were not. These results are discussed in relation to the specific nature of VHA patient populations.	[Armistead-Jehle, Patrick] Pacific Isl Hlth Care Syst, Dept Vet Affairs, Dept Mental Hlth, Honolulu, HI USA	Armistead-Jehle, P (corresponding author), Munson Army Hlth Ctr, 550 Pope Ave, Ft Leavenworth, KS 66027 USA.	patrick.jehle@armedd.army.mil	Armistead-Jehle, Patrick/AAU-5741-2020	Armistead-Jehle, Patrick/0000-0002-6784-1432			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Drane DL, 2006, EPILEPSIA, V47, P1879, DOI 10.1111/j.1528-1167.2006.00611.x; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; Gervais R, 1999, ARCH CLIN NEUROPSYCH, V14, P746, DOI 10.1016/S0887-6177(99)80247-9; Gervais R, 2000, ARCH CLIN NEUROPSYCH, V15, P841, DOI 10.1016/S0887-6177(00)80347-9; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gill David, 2007, Med Leg J, V75, P64; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Green, 2004, GREENS MED SYMPTOM V; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 2000, ARCH CLIN NEUROPSYCH, V15, P841, DOI 10.1016/S0887-6177(00)80346-7; Green P., 2003, GREENS WORD MEMORY T; Green P, 1996, MANUAL COMPUTERIZED; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; HOWE LL, 2008, CLIN NEUROPSYCHOL, V21, P1; IVERSON G, 1999, J COGN REHABIL, V17, P2; Iverson GL, 2006, APPL NEUROPSYCHOL, V13, P77, DOI 10.1207/s15324826an1302_3; Kurtz JE, 2007, J PERS ASSESS, V88, P1, DOI 10.1080/00223890709336828; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Morey L. C., 1991, PERSONALITY ASSESSME; Morey L. C., 2003, ESSENTIALS PAI ASSES; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Sullivan BK, 2007, APPL NEUROPSYCHOL, V14, P189, DOI 10.1080/09084280701509083; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tanielian T, 2008, INVISIBLE WOUNDS WAR; WHITNEY AW, 2009, ARCH CLIN NEUROPSYCH, V24, P145; Williamson David J., 2003, Epilepsia, V44, P13; Williamson DJ, 2004, EPILEPSIA, V45, P179	42	112	112	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282			APPL NEUROPSYCHOL	Appl. Neuropsychol.		2010	17	1					52	59	PII 919154983	10.1080/09084280903526182			8	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	554JY	WOS:000274432500007	20146122				2021-06-18	
J	Baumann, CR; Bassetti, CL; Valko, PO; Haybaeck, J; Keller, M; Clark, E; Stocker, R; Tolnay, M; Scammell, TE				Baumann, Christian R.; Bassetti, Claudio L.; Valko, Philipp O.; Haybaeck, Johannes; Keller, Morten; Clark, Erika; Stocker, Reto; Tolnay, Markus; Scammell, Thomas E.			Loss of Hypocretin (Orexin) Neurons With Traumatic Brain Injury	ANNALS OF NEUROLOGY			English	Article							CLOSED HEAD INJURY; PARKINSONS-DISEASE; NARCOLEPSY; LESIONS	Chronic, daytime sleepiness is a major, disabling symptom for many patients with traumatic brain injury (TBI), but thus far, its etiology is not Well understood. Extensive loss of the hypothalamic neurons that produce the wake-promoting neuropeptide hypocretin (orexin) causes the severe sleepiness of narcolepsy, and partial loss of these cells may contribute to the sleepiness of Parkinson disease and other disorders. We have found that the number of hypocretin neurons is significantly reduced in patients with severe TBI. This observation highlights the often overlooked hypothalamic injury in TBI and provides new insights into the causes of chronic sleepiness in patients with TBI.	[Baumann, Christian R.; Bassetti, Claudio L.; Valko, Philipp O.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Baumann, Christian R.; Clark, Erika; Scammell, Thomas E.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Haybaeck, Johannes; Tolnay, Markus] Univ Zurich Hosp, Dept Neuropathol, CH-8091 Zurich, Switzerland; [Keller, Morten] Univ Zurich Hosp, Dept Forens Med, CH-8091 Zurich, Switzerland; [Stocker, Reto] Univ Zurich Hosp, Dept Surg Intens Care, CH-8091 Zurich, Switzerland	Baumann, CR (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	christian.baumann@usz.ch	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Baumann, Christian/0000-0003-3417-1978	Foerderungskredit of the University of Zurich, Switzerland; Schweizerischer Versicherungsverband (SW), Switzerland; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH062589]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH062589] Funding Source: NIH RePORTER	This study was supported by the Foerderungskredit of the University of Zurich, Switzerland (Ch.B.), the Schweizerischer Versicherungsverband (SW), Switzerland (Ch.B.), and National Institutes of Health grant MH062589 (T.S.).	Adamantidis A, 2008, CELL MOL LIFE SCI, V65, P1475, DOI 10.1007/s00018-008-7521-8; Adamantidis AR, 2007, NATURE, V450, P420, DOI 10.1038/nature06310; Baumann CR, 2008, REGUL PEPTIDES, V147, P1, DOI 10.1016/j.regpep.2007.11.006; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Crocker A, 2005, NEUROLOGY, V65, P1184, DOI 10.1212/01.WNL.0000168173.71940.ab; CROMPTON MR, 1971, LANCET, V1, P669; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Espana RA, 2004, SLEEP, V27, P811; Fronczek R, 2007, BRAIN, V130, P1577, DOI 10.1093/brain/awm090; Guillery RW, 2002, J COMP NEUROL, V447, P1, DOI 10.1002/cne.10221; Hassani OK, 2009, P NATL ACAD SCI USA, V106, P2418, DOI 10.1073/pnas.0811400106; Karovitaki N, 2006, J NEUROL NEUROSUR PS, V77, P276, DOI 10.1136/jnnp.2005.070482; Peyron C, 2000, NAT MED, V6, P991, DOI 10.1038/79690; ROPPER AH, 1985, ANN NEUROL, V18, P80, DOI 10.1002/ana.410180114; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Scammell T., 2007, SLEEP DISORDERS NEUR, P117; SCAMMELL TE, 2007, INFORMA HEALTHCARE, V547, P559; Scammell TE, 2006, SLEEP, V29, P601, DOI 10.1093/sleep/29.5.601; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1; Thannickal TC, 2007, BRAIN, V130, P1586, DOI 10.1093/brain/awm097	24	112	115	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	OCT	2009	66	4					555	559		10.1002/ana.21836			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	507SJ	WOS:000270874700016	19847903	Green Accepted			2021-06-18	
J	Barr, RG; Rivara, FP; Barr, M; Cummings, P; Taylor, J; Lengua, LJ; Meredith-Benitz, E				Barr, Ronald G.; Rivara, Frederick P.; Barr, Marilyn; Cummings, Peter; Taylor, James; Lengua, Liliana J.; Meredith-Benitz, Emily			Effectiveness of Educational Materials Designed to Change Knowledge and Behaviors Regarding Crying and Shaken-Baby Syndrome in Mothers of Newborns: A Randomized, Controlled Trial	PEDIATRICS			English	Article						prevention; crying; shaken baby syndrome	TRAUMATIC BRAIN-INJURY; AGE-RELATED INCIDENCE; MULTIPLE IMPUTATION; INFANT SYNDROME; SLEEP POSITION; PERPETRATOR; TRIGGER; CURVE	BACKGROUND. Infant crying is an important precipitant for shaken-infant syndrome. OBJECTIVE. To determine if parent education materials (The Period of PURPLE Crying [PURPLE]) change maternal knowledge and behavior relevant to infant shaking. METHODS. This study was a randomized, controlled trial conducted in prenatal classes, maternity wards, and pediatric practices. There were 1374 mothers of newborns randomly assigned to the PURPLE intervention and 1364 mothers to the control group. Primary outcomes were measured by telephone 2 months after delivery. These included 2 knowledge scales about crying and the dangers of shaking; 3 scales about behavioral responses to crying generally and to unsoothable crying, and caregiver self-talk in response to unsoothable crying; and 3 questions concerning the behaviors of sharing of information with others about crying, walking away if frustrated, and the dangers of shaking. RESULTS. The mean infant crying knowledge score was greater in the intervention group (69.5) compared with controls (63.3). Mean shaking knowledge was greater for intervention subjects (84.8) compared with controls (83.5). For reported maternal behavioral responses to crying generally, responses to unsoothable crying, and for self-talk responses, mean scores for intervention mothers were similar to those for controls. For the behaviors of information sharing, more intervention mothers reported sharing information about walking away if frustrated and the dangers of shaking, but there was little difference in sharing information about infant crying. Intervention mothers also reported increased infant distress. CONCLUSIONS. Use of the PURPLE education materials seem to lead to higher scores in knowledge about early infant crying and the dangers of shaking, and in sharing of information behaviors considered to be important for the prevention of shaking. Pediatrics 2009;123:972-980	[Barr, Ronald G.] Univ British Columbia, Child & Family Res Inst, Ctr Community Child Hlth Res, Vancouver, BC V6H 3V4, Canada; [Barr, Ronald G.] Univ British Columbia, Dept Pediat, Vancouver, BC V6H 3V4, Canada; [Rivara, Frederick P.; Taylor, James] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Rivara, Frederick P.; Cummings, Peter] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Rivara, Frederick P.; Cummings, Peter; Meredith-Benitz, Emily] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Barr, Marilyn] Natl Ctr Shaken Baby Syndrome, Ogden, UT USA; [Lengua, Liliana J.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA	Barr, RG (corresponding author), Univ British Columbia, Child & Family Res Inst, Ctr Community Child Hlth Res, 4480 Oak St,L408, Vancouver, BC V6H 3V4, Canada.	rbarr@cw.bc.ca					*AM AC PED, 1994, TIPP BIRTH 6 MONTHS, P3; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr R. G., 1997, RONNICLOG BABYS DAY; Barr R. G., 2006, ENCY EARLY CHILDHOOD, P1; Barr R. G., 1985, BABYS DAY DIARY; Barr R.G, 2004, PERIOD PURPLE CRYING; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Barr RG, 2005, J DEV BEHAV PEDIATR, V26, P14; BARR RG, 1989, PEDIATRICS, V84, P514; BARR RG, 1988, ARCH DIS CHILD, V63, P380, DOI 10.1136/adc.63.4.380; BARR RG, 1990, DEV MED CHILD NEUROL, V32, P356; Barr RG, 2000, HDB DEV PSYCHOPATHOL, P327; Berger VW, 2005, STAT PRACT, P1, DOI 10.1002/0470863641; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; Brewster AL, 1998, CHILD ABUSE NEGLECT, V22, P91, DOI 10.1016/S0145-2134(97)00132-4; Brookes ST, 2004, J CLIN EPIDEMIOL, V57, P229, DOI 10.1016/j.jclinepi.2003.08.009; CALINOIU N, 1998, PROGRAM INT SOC INFA, P5; *CAN ASS CHIEFS PO, 2001, J PAEDIATR CHILD H, V6, P663; Catherine NLA, 2008, J DEV BEHAV PEDIATR, V29, P508, DOI 10.1097/DBP.0b013e31818d0c0c; Cummings P, 2001, INJURY CONTROL, P64; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; DIAS MS, 2003, AAP NEWS, V23, P16; DYKES LJ, 1986, CHILD ABUSE NEGLECT, V10, P211, DOI 10.1016/0145-2134(86)90082-7; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; HUNZIKER UA, 1986, PEDIATRICS, V77, P641; *I AM YOUR CHILD F, 2007, KEEP YOUR INF SAF; Kairys SW, 2001, PEDIATRICS, V108, P206; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KLEVENS J, 2003, INFLICTED CHILDHOOD, P269; Kramer MS, 2001, JAMA-J AM MED ASSOC, V286, P322, DOI 10.1001/jama.286.3.322; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; Lazoritz S, 1997, CHILD ABUSE NEGLECT, V21, P1009, DOI 10.1016/S0145-2134(97)00061-6; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; LEHTONEN L, 1998, INFANT BEHAV DEV, V21, pG16; Levitt CJ, 1994, CHILD ABUSE MED DIAG, P1; Little R, 2002, STAT ANAL MISSING DA, V2nd; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Lumley T, 2002, ANNU REV PUBL HEALTH, V23, P151, DOI 10.1146/annurev.publhealth.23.100901.140546; Majnemer A, 2006, J PEDIATR-US, V149, P623, DOI 10.1016/j.jpeds.2006.05.009; Raghunathan TE, 2004, ANNU REV PUBL HEALTH, V25, P99, DOI 10.1146/annurev.publhealth.25.102802.124410; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Schafer JL., 1997, ANAL INCOMPLETE MULT; Soltis J, 2004, BEHAV BRAIN SCI, V27, P443, DOI 10.1017/S0140525X0400010X; St James-Roberts I, 2006, PEDIATRICS, V117, pE1146, DOI 10.1542/peds.2005-2387; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; STARLING SP, 1995, PEDIATRICS, V95, P259; *STAT CORP, 2006, STAT STAT SOFTW COMP; STJAMESROBERTS I, 1993, ARCH DIS CHILD, V68, P82, DOI 10.1136/adc.68.1.82; *US DEP HHS, 2005, SAF SLEEP YOUR BAB; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Willinger M, 2000, JAMA-J AM MED ASSOC, V283, P2135, DOI 10.1001/jama.283.16.2135	53	112	113	0	20	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2009	123	3					972	980		10.1542/peds.2008-0908			9	Pediatrics	Pediatrics	413XH	WOS:000263825500033	19255028				2021-06-18	
J	Ruttan, L; Martin, K; Liu, A; Colella, B; Green, RE				Ruttan, Lesley; Martin, Krystle; Liu, Anita; Colella, Brenda; Green, Robin E.			Long-Term Cognitive Outcome in Moderate to Severe Traumatic Brain Injury: A Meta-Analysis Examining Timed and Untimed Tests at 1 and 4.5 or More Years After Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Neuropsychology; Rehabilitation	CLOSED-HEAD-INJURY; SELECTIVE ATTENTION; MEMORY PERFORMANCE; DIVIDED ATTENTION; RECOVERY; SPEED; IMPAIRMENTS; INHIBITION; PREDICTORS; PLASTICITY	Objectives: To examine long-term outcome of moderate to severe traumatic brain injury (TBI) on timed and untimed cognitive tests using meta-analysis. Design: Meta-analysis examining outcome at 2 epochs, 6 to 18 months postinjury (epoch 1) and 4.5 to 11 years postinjury (epoch 2). Setting: Data source was published articles (1966-2007) identified through electronic and manual search. Participants: A total of 1380 subjects with moderate to severe TBI participated in the 16 studies meeting inclusion criteria. Interventions: Not applicable. Main Outcome Measures: Timed and untimed neuropsychologic tests with quantitative results (means, SDs, t, and df tests) from studies containing a healthy comparison group and a mean time since injury falling within 1 of the 2 epochs. Results: Patient versus control weighted effect sizes were medium to large at epoch 1 for both untimed tasks (r=-.46; confidence interval [CI], -.32 to -.65) and timed tasks (r=-.46; CI, -.35 to -.59). At epoch 2, effect sizes were slightly smaller for untimed tasks (r=-.38; CI -.25 to -.60) and timed tasks (r=-.40; CI, -.32 to -.62). Conclusions: Patients showed robust, persisting impairments on both timed and untimed tests at recovery plateau (ie, 6-18mo postinjury) and many years later. These findings converge with previous studies, though using an alternative approach that obviates some of the methodologic problems of longitudinal studies, such as selective attrition.	[Ruttan, Lesley; Liu, Anita; Colella, Brenda; Green, Robin E.] Toronto Rehabil Inst, Toronto, ON M4G 1R7, Canada; [Green, Robin E.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5S 1A1, Canada; [Martin, Krystle] Univ Toronto, Ontario Inst Studies Educ, Toronto, ON, Canada	Ruttan, L (corresponding author), Toronto Rehabil Inst, 345 Rumsey Rd, Toronto, ON M4G 1R7, Canada.	ruttan.lesley@torontorehab.on.ca	Liu, Anita/F-7179-2010	Martin, Krystle/0000-0003-0419-8328; Green, Robin/0000-0001-9451-3963	Ministry of Health and Long-Term Care in OntarioMinistry of Health and Long-Term Care, Ontario	We thank Kadeen Johns, BA, Joel Verwegan, and Areeba Adnan for their valuable contributions to the preparation of this article. We are also grateful to Todd Girard, PhD, for his thoughtful and insightful input.; The authors acknowledge the support of Toronto Rehabilitation Institute who receives funding under the Provincial Rehabilitation Research Program from the Ministry of Health and Long-Term Care in Ontario. The views expressed do not necessarily reflect those of the Ministry.	Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brooks D N, 1979, Int Rehabil Med, V1, P166; Ciaramelli E, 2006, BRAIN COGNITION, V60, P198; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COLLINS JG, 1990, DHHS PUBLICATION, V175, P1; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; EVANS J, NEUROPSYCHOLOGICAL R, V18, P372; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; GRADY MS, 2002, DIS NERV SYST, P1793; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; Greiffenstein MF, 2007, J CLIN EXP NEUROPSYC, V29, P113, DOI 10.1080/13803390600781105; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hanks RA, 2004, DIFFERENTIAL DIAGNOSIS IN ADULT NEUROPSYCHOLOGICAL ASSESSMENT, P218; HANNAY HJ, 2004, NEUROPSYCHOLOGICAL A, P157; Hedges L.V., 1985, STAT METHODS META AN; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; HOWELL DC, 1992, STAT METHODS PSYCHOL; Howieson DB, 2004, NEUROPSYCHOLOGICAL A, P286; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kalechstein AD, 2003, J CLIN EXP NEUROPSYC, V25, P1186, DOI 10.1076/jcen.25.8.1186.16723; KAROL RL, 1989, CLIN NEUROPSYCHOL, V3, P244; KOLB B, 1996, RECOVERY FUNCTION FU, P539; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Orwin R. G., 1983, J EDUC STAT, V8, P157, DOI [10.3102/10769986008002157., DOI 10.2307/1164923]; PANIAK CE, 1989, J CLIN EXP NEUROPSYC, V11, P631, DOI 10.1080/01688638908400921; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; ROSENTHAL R, 1995, PSYCHOL BULL, V118, P183, DOI 10.1037/0033-2909.118.2.183; Rosenthal R, 2001, ANNU REV PSYCHOL, V52, P59, DOI 10.1146/annurev.psych.52.1.59; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P104, DOI 10.1037/0894-4105.18.1.104; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Simpson A, 2000, NEUROPSYCHOLOGY, V14, P310, DOI 10.1037//0894-4105.14.2.310; Spikman JM, 2004, J INT NEUROPSYCH SOC, V10, P851, DOI 10.1017/S1355617704106061; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; THURMAN DJ, 2003, C MILD TRAUM BRAIN I; TILL C, ARCH PHYS M IN PRESS; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; VANDERWERF E, 1992, ECOLOGY, V73, P1699, DOI 10.2307/1940021; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1994, CLIN NEUROPSYCHOLOGY, P250; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	83	112	113	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12		2			S69	S76		10.1016/j.apmr.2008.07.007			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	388DB	WOS:000261999400009	19081444				2021-06-18	
J	Milders, M; Ietswaart, M; Crawford, JR; Currie, D				Milders, Maarten; Ietswaart, Magdalena; Crawford, John R.; Currie, David			Social behavior following traumatic brain injury and its association with emotion recognition, understanding of intentions, and cognitive flexibility	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; social behavior; emotion recognition; theory of mind; cognitive flexibility; follow-up	CLOSED-HEAD INJURY; PSYCHOSOCIAL ADJUSTMENT; ECOLOGICAL VALIDITY; EXECUTIVE FUNCTION; FACIAL EXPRESSION; SELF-AWARENESS; MIND; DEFICITS; IMPAIRMENTS; PERSONALITY	Although the adverse consequences of changes in social behavior following traumatic brain injury (TBI) are well documented, relatively little is known about possible underlying neuropsychological deficits. Following a model originally developed for social behavior deficits in schizophrenia, we investigated whether impairments in emotion recognition, understanding of other people's intentions ("theory of mind"), and cognitive flexibility soon after first TBI or 1 year later were associated with self and proxy ratings of behavior following TBI. Each of the three functions was assessed with two separate tests, and ratings of behavior were collected oil three questionnaires. Patients with TBI (n = 33) were impaired in emotion recognition, "theory of mind." and cognitive flexibility compared with matched orthopedic controls (n = 341). Proxy ratings showed increases in behavioral problems I year following injury in the TBI group but not in the control group. However, test performance was not associated with questionnaire data. Severity of the impairments in emotion recognition. understanding intention. and flexibility were unrelated to the severity of behavioral problems following TBI. These findings failed to confirm the Used model for social behavior deficits and may cast doubt on the alleged link between deficits in emotion recognition or theory of mind and social functioning.	[Milders, Maarten; Crawford, John R.] Univ Aberdeen, Sch Psychol, Aberdeen AB24 2UB, Scotland; [Ietswaart, Magdalena] Northumbria Univ, Sch Psychol & Sport Sci, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England; [Currie, David] Aberdeen Royal Infirm, Dept Neurosurg, Aberdeen, Scotland	Milders, M (corresponding author), Univ Aberdeen, Sch Psychol, Aberdeen AB24 2UB, Scotland.	nn.milders@abdn.ac.uk	Crawford, John R/A-4165-2008; Milders, Maarten/C-5560-2008	Crawford, John R/0000-0003-3403-3428; Ietswaart, Magdalena/0000-0003-4576-9393	Chief Scientist Office of the Scottish Executive [CZH/4/14]	This research was supported by the Chief Scientist Office of the Scottish Executive (CZH/4/14).	Adolphs R, 2002, J COGNITIVE NEUROSCI, V14, P1264, DOI 10.1162/089892902760807258; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Bowers D, 1998, FLORIDA AFFECT BATTE; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Corrigan PW, 1997, PSYCHIATRY, V60, P309, DOI 10.1080/00332747.1997.11024809; Crawford J.R, 2005, EFFECTIVENESS REHABI, P233, DOI DOI 10.1093/ACPROF:OSO/9780198526544.003.0019; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; DOWNES JJ, 1993, BRAIN, V116, P887, DOI 10.1093/brain/116.4.887; Ekman P., 1976, PICTURES FACIAL AFFE; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Gregory C, 2002, BRAIN, V125, P752, DOI 10.1093/brain/awf079; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Happe F, 2001, NEUROPSYCHOLOGIA, V39, P83, DOI 10.1016/S0028-3932(00)00093-2; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hooker C, 2002, PSYCHIAT RES, V112, P41, DOI 10.1016/S0165-1781(02)00177-4; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; MARTIN AA, 1991, SULFUR LETT, V13, P225; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nelson LD, 1998, ARCH CLIN NEUROPSYCH, V13, P549, DOI 10.1016/S0887-6177(97)00052-8; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Office for National Statistics, 2005, NAT STAT SOC CLASS U; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; Prigatano GP, 2007, BRAIN INJURY, V21, P721, DOI 10.1080/02699050701481605; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Shallice, 1997, HAYLING BRIXTON TEST; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	63	112	114	0	37	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2008	14	2					318	326		10.1017/S1355617708080351			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	338VJ	WOS:000258537200014	18282329	Green Accepted, Green Published, Bronze			2021-06-18	
J	Sabet, AA; Christoforou, E; Zatlin, B; Genin, GM; Bayly, PV				Sabet, Arash A.; Christoforou, Eftychios; Zatlin, Benjamin; Genin, Guy M.; Bayly, Philip V.			Deformation of the human brain induced by mild angular head acceleration	JOURNAL OF BIOMECHANICS			English	Article						angular acceleration; brain trauma; strain; head injury; brain deformation; MRI	DIFFUSE AXONAL INJURY; MOTION; MODEL; CRITERIA; MRI	Deformation of the human brain was measured in tagged magnetic resonance images (MRI) obtained dynamically during angular acceleration of the head. This study was undertaken to provide quantitative experimental data to illuminate the mechanics of traumatic brain injury (TBI). Mild angular acceleration was imparted to the skull of a human volunteer inside an MR scanner, using a custom MR-compatible device to constrain motion. A grid of MR "tag" lines was applied to the MR images via spatial modulation of magnetization (SPAMM) in a fast gradient echo imaging sequence. Images of the moving brain were obtained dynamically by synchronizing the imaging process with the motion of the head. Deformation of the brain was characterized quantitatively via Lagrangian strain. Consistent patterns of radial-circumferential shear strain occur in the brain, similar to those observed in models of a viscoelastic gel cylinder subjected to angular acceleration. Strain fields in the brain, however, are clearly mediated by the effects of heterogeneity, divisions between regions of the brain (such as the central fissure and central sulcus) and the brain's tethering and suspension system, including the dura mater, falx cerebri, and tentorium membranes. (c) 2007 Elsevier Ltd. All rights reserved.	[Sabet, Arash A.; Genin, Guy M.; Bayly, Philip V.] Washington Univ, Dept Mech Aerosp & Struct Engn, St Louis, MO 63130 USA; [Bayly, Philip V.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA; [Christoforou, Eftychios] Univ Cyprus, Dept Elect & Comp Engn, Nicosia, Cyprus; [Zatlin, Benjamin] Univ So Calif, Los Angeles, CA 90089 USA	Bayly, PV (corresponding author), Washington Univ, Dept Mech Aerosp & Struct Engn, St Louis, MO 63130 USA.	pvb@me.wustl.edu		Bayly, Philip/0000-0003-4303-0704	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24-CA83060, R24 CA083060] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56 NS055951, R01 NS055951-02, R01 NS055951, NS-55951, R01 NS055951-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24CA083060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER		AXEL L, 1989, RADIOLOGY, V171, P841, DOI 10.1148/radiology.171.3.2717762; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; BAYLY PV, 2007, IN PRESS MAGNETIC RE; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Holbourn AHS, 1943, LANCET, V2, P438; Ji Songbai, 2004, Stapp Car Crash J, V48, P227; Ji SB, 2007, J BIOMECH, V40, P92, DOI 10.1016/j.jbiomech.2005.11.009; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; MARGULIES SS, 1990, J BIOMECH, V23, P832, DOI DOI 10.1016/0021-9290(90)90029-3; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Osman NF, 2000, IEEE T MED IMAGING, V19, P186, DOI 10.1109/42.845177; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; Reese TG, 2002, MAGN RESON MED, V47, P665, DOI 10.1002/mrm.10111; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; WEDEEN V, 1996, ENCY NUCL MAGNETIC R; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zou H, 2007, J BIOMECH, V40, P1183, DOI 10.1016/j.jbiomech.2006.06.018	24	112	112	1	22	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.		2008	41	2					307	315		10.1016/j.jbiomech.2007.09.016			9	Biophysics; Engineering, Biomedical	Biophysics; Engineering	263LY	WOS:000253219800009	17961577	Green Accepted			2021-06-18	
J	Yamasaki, TR; Blurton-Jones, M; Morrissette, DA; Kitazawa, M; Oddo, S; LaFerla, FM				Yamasaki, Tritia R.; Blurton-Jones, Mathew; Morrissette, Debbi A.; Kitazawa, Masashi; Oddo, Salvatore; LaFerla, Frank M.			Neural stem cells improve memory in an inducible mouse model of neuronal loss	JOURNAL OF NEUROSCIENCE			English	Article						transgenic; stem cells; neuronal death; functional recovery; memory; ablation	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; FUNCTIONAL RECOVERY; PROGENITOR-CELLS; SPINAL-CORD; NEUROTROPHIC FACTORS; RECOGNITION MEMORY; COGNITIVE FUNCTION; CEREBRAL-ISCHEMIA; PERIRHINAL CORTEX	Neuronal loss is a major pathological outcome of many common neurological disorders, including ischemia, traumatic brain injury, and Alzheimer disease. Stem cell-based approaches have received considerable attention as a potential means of treatment, although it remains to be determined whether stem cells can ameliorate memory dysfunction, a devastating component of these disorders. We generated a transgenic mouse model in which the tetracycline-off system is used to regulate expression of diphtheria toxin A chain. After induction, we find progressive neuronal loss primarily within the hippocampus, leading to specific impairments in memory. We find that neural stem cells transplanted into the brain after neuronal ablation survive, migrate, differentiate and, most significantly, improve memory. These results show that stem cells may have therapeutic value in diseases and conditions that result in memory loss.	Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA	LaFerla, FM (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, 1109 Gillespie Neurosci Bldg, Irvine, CA 92697 USA.	laferla@uci.edu	Kitazawa, Masashi/AAI-1721-2021; Yamasaki, Tritia/AAN-8831-2020; Morrissette, Debbi/AAR-3442-2021	Kitazawa, Masashi/0000-0003-2165-8197; Oddo, Salvatore/0000-0001-7304-7430; Blurton-Jones, Mathew/0000-0002-7770-7157	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM08620] Funding Source: Medline		Auerbach JM, 2000, EUR J NEUROSCI, V12, P1696, DOI 10.1046/j.1460-9568.2000.00067.x; Bernreuther C, 2006, J NEUROSCI, V26, P11532, DOI 10.1523/JNEUROSCI.2688-06.2006; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brown MW, 2001, NAT REV NEUROSCI, V2, P51, DOI 10.1038/35049064; Buffalo EA, 1998, HIPPOCAMPUS, V8, P330, DOI 10.1002/(SICI)1098-1063(1998)8:4<330::AID-HIPO3>3.3.CO;2-2; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Carmichael S Thomas, 2005, NeuroRx, V2, P396; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Englund U, 2002, P NATL ACAD SCI USA, V99, P17089, DOI 10.1073/pnas.252589099; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499; Jarrard LE, 2002, HIPPOCAMPUS, V12, P405, DOI 10.1002/hipo.10054; Jeltsch H, 2003, BEHAV BRAIN RES, V147, P217, DOI 10.1016/j.bbr.2003.09.018; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; Kokaia Z, 1998, EXP NEUROL, V154, P289, DOI 10.1006/exnr.1998.6888; Lee P, 1998, P NATL ACAD SCI USA, V95, P11371, DOI 10.1073/pnas.95.19.11371; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Mizumoto H, 2003, VISION RES, V43, P1699, DOI 10.1016/S0042-6989(03)00235-9; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Oliveira Alcyr A. Jr, 2005, Current Alzheimer Research, V2, P79, DOI 10.2174/1567205052772759; Parent JM, 1997, J NEUROSCI, V17, P3727; PARKINSON JK, 1988, J NEUROSCI, V8, P4159; Polito A, 2005, J ANAT, V207, P707, DOI 10.1111/j.1469-7580.2005.00454.x; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Toda H, 2001, NEUROSCI LETT, V316, P9, DOI 10.1016/S0304-3940(01)02331-X; TUSZYNSKI MH, 1995, MOL NEUROBIOL, V10, P151, DOI 10.1007/BF02740673; Veizovic T, 2001, STROKE, V32, P1012, DOI 10.1161/01.STR.32.4.1012; Vora N, 2006, NEURODEGENER DIS, V3, P101, DOI 10.1159/000092100; Vroemen M, 2005, EXP NEUROL, V195, P127, DOI 10.1016/j.expneurol.2005.04.012; Winters BD, 2004, J NEUROSCI, V24, P5901, DOI 10.1523/JNEUROSCI.1346-04.2004; Yasuhara T, 2006, J NEUROSCI, V26, P12497, DOI 10.1523/JNEUROSCI.3719-06.2006; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684; Ziv Y, 2006, P NATL ACAD SCI USA, V103, P13174, DOI 10.1073/pnas.0603747103	48	112	125	0	21	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 31	2007	27	44					11925	11933		10.1523/JNEUROSCI.1627-07.2007			9	Neurosciences	Neurosciences & Neurology	226HB	WOS:000250577600021	17978032	Bronze, Green Published			2021-06-18	
J	Yang, S; Xing, D; Zhou, Q; Xiang, L; Lao, Y				Yang, Sihua; Xing, Da; Zhou, Quan; Xiang, Liangzhong; Lao, Yeqi			Functional imaging of cerebrovascular activities in small animals using high-resolution photoacoustic tomography	MEDICAL PHYSICS			English	Article						photoacoustic imaging; photoacoustic signal; brain vascular; traumatic lesion; drug stimulation	CEREBRAL-BLOOD-FLOW; TIME-DOMAIN RECONSTRUCTION; IN-VIVO; THERMOACOUSTIC TOMOGRAPHY; BIOLOGICAL TISSUES; ACETAZOLAMIDE; BRAIN; ALGORITHM; ARCHITECTURE; STIMULATION	Photoacoustic imaging (PAI) is a noninvasive, nonionizing modality based on the differences in light absorption of various biological tissues. PAI utilizes the endogenous contrast characteristics of traditional optical imaging, while benefiting from high spatial resolution of the ultrasound imaging. A PAI system was developed to reconstruct the two-dimensional cross section image and to visualize the cerebrovascular activities of mouse in vivo. The spatial resolution of the PAI system was determined to be 0.110 mm by a two-point-source phantom with the Rayleigh criterion. The potential applications of the system were clearly demonstrated by successfully mapping a traumatic lesion in the mouse brain cerebral cortex, by its ability to monitor physiological changes in the brain due to carotid ligation and drug stimulation, and two-dimensional sliced images of a traumatic mouse brain at different depths were also provided. Our experimental results indicate that PAI has the potential for studying of traumatic brain injury and physiological functions of the brain. (c) 2007 American Association of Physicists in Medicine.	S China Normal Univ, MOE Key Lab Laser Life Sci, Guangzhou 510631, Peoples R China; S China Normal Univ, Inst Laser Life Sci, Guangzhou 510631, Peoples R China; Jinan Univ, Affiliated Hosp 1, Med Imaging Ctr, Guangzhou 510630, Peoples R China	Xing, D (corresponding author), S China Normal Univ, MOE Key Lab Laser Life Sci, Guangzhou 510631, Peoples R China.	xingda@scnu.edu.cn	Xiang, Liangzhong/C-8458-2016	Xiang, Liangzhong/0000-0002-7228-0510			Barton JK, 2001, PHOTOCHEM PHOTOBIOL, V73, P642, DOI 10.1562/0031-8655(2001)073<0642:CPITPT>2.0.CO;2; Bravata DM, 2003, STROKE, V34, P699, DOI 10.1161/01.STR.0000057578.26828.78; CHOLLET F, 1989, STROKE, V20, P458, DOI 10.1161/01.STR.20.4.458; Dijkhuizen RM, 2001, P NATL ACAD SCI USA, V98, P12766, DOI 10.1073/pnas.231235598; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GRINVALD A, 1988, PHYSIOL REV, V68, P1285; GRINVALD A, 1991, P NATL ACAD SCI USA, V88, P11559, DOI 10.1073/pnas.88.24.11559; HAUGE A, 1983, ACTA PHYSIOL SCAND, V117, P233, DOI 10.1111/j.1748-1716.1983.tb07202.x; Hoelen CGA, 1998, OPT LETT, V23, P648, DOI 10.1364/OL.23.000648; Hoge RD, 1999, MAGNET RESON MED, V42, P849, DOI 10.1002/(SICI)1522-2594(199911)42:5<849::AID-MRM4>3.0.CO;2-Z; HOJERPEDERSEN E, 1987, STROKE, V18, P887, DOI 10.1161/01.STR.18.5.887; Karabutov AA, 1999, P SOC PHOTO-OPT INS, V3601, P284, DOI 10.1117/12.350011; Kolkman RGM, 2004, PHYS MED BIOL, V49, P4745, DOI 10.1088/0031-9155/49/20/006; Kruger RA, 1999, MED PHYS, V26, P1832, DOI 10.1118/1.598688; Kruger Robert A, 2003, Mol Imaging, V2, P113, DOI 10.1162/153535003322331993; Liu PY, 1998, PHYS MED BIOL, V43, P667, DOI 10.1088/0031-9155/43/3/017; McPherson JA, 2001, ARTERIOSCL THROM VAS, V21, P791, DOI 10.1161/01.ATV.21.5.791; Niederhauser JJ, 2005, IEEE T MED IMAGING, V24, P436, DOI 10.1109/TMI.2004.843199; Norton SJ, 2003, J OPT SOC AM A, V20, P1859, DOI 10.1364/JOSAA.20.001859; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Paltauf G, 2002, J ACOUST SOC AM, V112, P1536, DOI 10.1121/1.1501898; Siphanto RI, 2005, OPT EXPRESS, V13, P89, DOI 10.1364/OPEX.13.000089; Vernieri F, 2001, STROKE, V32, P1552, DOI 10.1161/01.STR.32.7.1552; Vijungco Joseph, 2005, Perspect Vasc Surg Endovasc Ther, V17, P279, DOI 10.1177/153100350501700402; Villringer A, 1997, TRENDS NEUROSCI, V20, P435, DOI 10.1016/S0166-2236(97)01132-6; VORSTRUP S, 1986, STROKE, V17, P1291, DOI 10.1161/01.STR.17.6.1291; VORSTRUP S, 1984, J CLIN INVEST, V74, P1634, DOI 10.1172/JCI111579; Wang G, 1996, SCIENCE, V272, P1665, DOI 10.1126/science.272.5268.1665; WANG X, 2006, J BIOMED OPT, V11; Wang XD, 2004, OPT LETT, V29, P730, DOI 10.1364/OL.29.000730; Wang XD, 2003, OPT LETT, V28, P1739, DOI 10.1364/OL.28.001739; Wang XD, 2003, NAT BIOTECHNOL, V21, P803, DOI 10.1038/nbt839; Wang XD, 2002, MED PHYS, V29, P2799, DOI 10.1118/1.1521720; Wang Y, 2004, PHYS MED BIOL, V49, P3117, DOI 10.1088/0031-9155/49/14/006; Wang YW, 2004, NANO LETT, V4, P1689, DOI 10.1021/nl049126a; Xiang LZ, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2437752; Xu MH, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2195024; Xu MH, 2003, IEEE T BIO-MED ENG, V50, P1086, DOI 10.1109/TBME.2003.816081; Xu MH, 2002, IEEE T MED IMAGING, V21, P814, DOI 10.1109/TMI.2002.801176; Yamazaki M, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2137287; Yang DW, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2198488; Yang DW, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2119417; Yuan Z, 2005, OPT LETT, V30, P3054, DOI 10.1364/OL.30.003054; Yuan Z, 2007, MED PHYS, V34, P538, DOI 10.1118/1.2409234; Yuan Z, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2209883; Yuan Z, 2006, OPT EXPRESS, V14, P6749, DOI 10.1364/OE.14.006749; Zeng LM, 2007, MED PHYS, V34, P556, DOI 10.1118/1.2426406; Zeng YG, 2004, OPT LETT, V29, P1760, DOI 10.1364/OL.29.001760	48	112	128	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0094-2405	2473-4209		MED PHYS	Med. Phys.	AUG	2007	34	8					3294	3301		10.1118/1.2757088			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	202IP	WOS:000248895500022	17879793	Bronze			2021-06-18	
J	Nesic, O; Lee, J; Ye, Z; Unabia, GC; Rafati, D; Hulsebosch, CE; Perez-Polo, JR				Nesic, O.; Lee, J.; Ye, Z.; Unabia, G. C.; Rafati, D.; Hulsebosch, C. E.; Perez-Polo, J. R.			Acute and chronic changes in aquaporin 4 expression after spinal cord injury	NEUROSCIENCE			English	Article						spinal cord injury; astrocytes; aquaporin 4; water content; glia limitans	TRAUMATIC BRAIN-INJURY; WATER CHANNELS; RAT-BRAIN; EDEMA; MICE; BARRIER; DELETION; IMMUNOREACTIVITY; HYPONATREMIA; PERMEABILITY	The effect of spinal cord injury (SCI) on the expression levels and distribution of water channel aquaporin 4 (AQP4) has not been studied. We have found AQP4 in gray and white matter astrocytes in both uninjured and injured rat spinal cords. AQP4 was detected in astrocytic processes that were tightly surrounding neurons and blood vessels, but more robustly in glia limitans externa and interna, which were forming an interface between spinal cord parenchyma and cerebrospinal fluid (CSF). Such spatial distribution of AQP4 suggests a critical role that astrocytes expressing AQP4 play in the transport of water from blood/CSF to spinal cord parenchyma and vice versa. SCI induced biphasic changes in astrocytic AQP4 levels, including its early down-regulation and subsequent persistent up-regulation. However, changes in AQP4 expression did not correlate well with the onset and magnitude of astrocytic activation, when measured as changes in GFAP expression levels. It appears that reactive astrocytes began expressing increased levels of AQP4 after migrating to the wound area (thoracic region) two weeks after SCI, and AQP4 remained significantly elevated for months after SCI. We also showed that increased levels of AQP4 spread away from the lesion site to cervical and lumbar segments, but only in chronically injured spinal cords. Although overall AQP4 expression levels increased in chronically-injured spinal cords, AQP4 immunolabeling in astrocytic processes forming glia limitans externa was decreased, which may indicate impaired water transport through glia limitans externa. Finally, we also showed that SCI-induced changes in AQP4 protein levels correlate, both temporally and spatially, with persistent increases in water content in acutely and chronically injured spinal cords. Although correlative, this finding suggests a possible link between AQP4 and impaired water transport/edema/syringomyelia in contused spinal cords. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Texas, Med Branch, Dept BMB, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	Nesic, O (corresponding author), Univ Texas, Med Branch, Dept BMB, MRB 7-138G,301 Univ Blvd, Galveston, TX 77555 USA.	Olnesic@utmb.edu	Perez-Polo, Jose R./B-6250-2009; nesic, olivera/C-6456-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS039161] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS039161-05, NS39161, P01 NS039161] Funding Source: Medline		Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Bloch O, 2005, J NEUROCHEM, V95, P254, DOI 10.1111/j.1471-4159.2005.03362.x; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Carroll AM, 2005, SPINE, V30, P1206, DOI 10.1097/01.brs.0000162277.76012.0b; FRIGERI A, 1995, J CELL SCI, V108, P2993; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Gunnarson E, 2005, NEUROSCIENCE, V136, P105, DOI 10.1016/j.neuroscience.2005.07.027; Imura T, 2006, GLIA, V53, P277, DOI 10.1002/glia.20281; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Li S, 1999, SPINAL CORD, V37, P820, DOI 10.1038/sj.sc.3100941; Lo ACY, 2005, J CEREBR BLOOD F MET, V25, P998, DOI 10.1038/sj.jcbfm.9600108; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; MARMAROU A, 1994, AM J PHYSIOL, V267, pH514; Mautes AEM, 2000, PHYS THER, V80, P673, DOI 10.1093/ptj/80.7.673; Nesic O, 2005, J NEUROCHEM, V95, P998, DOI 10.1111/j.1471-4159.2005.03462.x; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; Oshio K, 2004, NEUROSCIENCE, V127, P685, DOI 10.1016/j.neuroscience.2004.03.016; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Perdiki M, 1998, ACTA NEUROPATHOL, V96, P8, DOI 10.1007/s004010050854; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Rash JE, 1999, CELL TISSUE RES, V296, P307, DOI 10.1007/s004410051291; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Sato S, 2000, ACTA NEUROCHIR SUPPL, V76, P239; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P422, DOI 10.1196/annals.1344.037; Simard M, 2004, NEUROSCIENCE, V129, P877, DOI 10.1016/j.neuroscience.2004.09.053; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Ulger H, 2002, ANAT HISTOL EMBRYOL, V31, P31, DOI 10.1046/j.1439-0264.2002.00357.x; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Vitellaro-Zuccarello L, 2005, GLIA, V51, P148, DOI 10.1002/glia.20196; WAGNER FC, 1981, J NEUROSURG, V54, P802, DOI 10.3171/jns.1981.54.6.0802; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; Zai LJ, 2005, BRAIN RES, V1052, P147, DOI 10.1016/j.brainres.2005.05.071; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	48	112	119	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 13	2006	143	3					779	792		10.1016/j.neuroscience.2006.08.079			14	Neurosciences	Neurosciences & Neurology	114DP	WOS:000242647200012	17074445	Green Accepted			2021-06-18	
J	Zhang, J; Li, Y; Lu, M; Cui, YS; Chen, JL; Noffsinger, L; Elias, SB; Chopp, M				Zhang, Jing; Li, Yi; Lu, Mei; Cui, Yisheng; Chen, Jieli; Noffsinger, Lori; Elias, Stanton B.; Chopp, Michael			Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						axonal loss; bone marrow stromal cells; experimental autoimmune encephalomyelitis; nerve growth factor	MESENCHYMAL STEM-CELLS; NERVE GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS LESIONS; RAT-BRAIN; INTRACEREBRAL TRANSPLANTATION; SYMPATHETIC NEURONS; THERAPEUTIC BENEFIT; FUNCTIONAL RECOVERY; CEREBRAL-ISCHEMIA	We investigated the ability of human bone marrow stromal cell (hBMSC) treatment to reduce axonal loss in experimental autoimmune encephalomyelitis (EAE) mice. EAE was induced in SJL/J mice by injection with proteolipid protein (PLP). Mice were injected intravenously with hBMSCs or PBS on the day of clinical onset, and neurological function was measured daily (score 0-5) until 45 weeks after onset. Mice were sacrificed at week 1, 10, 20, 34, and 45 after clinical onset. Bielshowsky silver was used to identify axons. Immunohistochemistry was performed to measure the expression of nerve growth factor (NGF) and MA131281, a marker of hBMSCs. hBMSC treatment significantly reduced the mortality, the disease severity, and the number of relapses in EAE mice compared with PBS treatment. Axonal density and NGF(+) cells in the EAE brain were significantly increased in the hBMSC group compared with the PBS group at 1, 10, 20, 34, and 45 weeks. Disease severity was significantly correlated with decreased axonal density and decreased NGF, and increased axonal density was significantly correlated with reduced loss of NGF expression after hBMSC treatment. Most of the NGF+ cells are brain parenchymal cells. Under 5% of MA131281(+) cells colocalized with NG2(+), a marker of oligodendrocyte progenitor cells. Nearly 10% of MA131281(+) cells colocalized with GFAP, a marker of astrocytes, and MAP-2, a marker of neurons. Our findings indicate that hBMSCs improve functional recovery and may provide a potential therapy aimed at axonal protection in EAE mice, in which NGF may play a vital role. (c) 2006 Wiley-Liss, Inc.	Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI 48202 USA; Cognate Therapeut Inc, Baltimore, MD USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA	Chopp, M (corresponding author), Henry Ford Hlth Sci Ctr, Dept Neurol, Educ & Res Bldg 3056,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045041, P01NS042345] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS45041, P01 NS42345, P01 NS042345, R01 NS045041] Funding Source: Medline		Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Aloe L, 1998, ARCH ITAL BIOL, V136, P247; Aloe L, 1997, ALLERGY, V52, P883, DOI 10.1111/j.1398-9995.1997.tb01247.x; Aloe Luigi, 2004, Ann Ist Super Sanita, V40, P89; Arredondo LR, 2001, EUR J IMMUNOL, V31, P625; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Bechtold DA, 2004, ANN NEUROL, V55, P607, DOI 10.1002/ana.20045; BERNSTEIN DC, 1988, ANN NY ACAD SCI, V532, P207, DOI 10.1111/j.1749-6632.1988.tb36339.x; Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921; Bjartmar C, 2003, NEUROTOX RES, V5, P157, DOI 10.1007/BF03033380; Bjartmar C, 2003, J NEUROL SCI, V206, P165, DOI 10.1016/S0022-510X(02)00069-2; Bonini S, 2003, INT ARCH ALLERGY IMM, V131, P80, DOI 10.1159/000070922; Bracci-Laudiero L, 2005, BLOOD, V106, P3507, DOI 10.1182/blood-2004-10-4055; Bracci-Laudiero L, 2002, J NEUROIMMUNOL, V123, P58, DOI 10.1016/S0165-5728(01)00475-1; Brophy PJ, 2004, NEURON, V43, P154, DOI 10.1016/j.neuron.2004.07.005; CANEVA L, 1995, BLOOD CELL MOL DIS, V21, P73, DOI 10.1006/bcmd.1995.0011; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chitnis T., 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P11, DOI 10.2174/1568008053174804; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Cohen RI, 1996, J NEUROSCI, V16, P6433; Conover W. J., 1998, PRACTICAL NONPARAMET; COX DR, 1984, ANAL SURVIVAL DATA; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood-2003-04-1193; EAVES CJ, 1991, BLOOD, V78, P110; Fainzilber Mike, 2002, EMBO Reports, V3, P1029, DOI 10.1093/embo-reports/kvf218; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Flugel A, 2001, EUR J IMMUNOL, V31, P11, DOI 10.1002/1521-4141(200101)31:1<11::AID-IMMU11>3.0.CO;2-G; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Furlan R, 2001, J IMMUNOL, V167, P1821, DOI 10.4049/jimmunol.167.3.1821; Grill RJ, 1997, EXP NEUROL, V148, P444, DOI 10.1006/exnr.1997.6704; Hemmer B, 2002, NAT REV NEUROSCI, V3, P291, DOI 10.1038/nrn784; HOLTZMAN DM, 1995, J NEUROSCI, V15, P7062; HOYLE GW, 1993, NEURON, V10, P1019, DOI 10.1016/0896-6273(93)90051-R; Jones LL, 2003, J NEUROSCI, V23, P9276; Karnezis T, 2004, NAT NEUROSCI, V7, P736, DOI 10.1038/nn1261; Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood-2002-07-2104; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Laurenzi MA, 1998, J LEUKOCYTE BIOL, V64, P228; Levitan IB, 2002, NEURON CELL MOL BIOL, P408; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Liechty KW, 2000, NAT MED, V6, P1282; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; MacInnis BL, 2003, NEUROPHARMACOLOGY, V45, P995, DOI 10.1016/S0028-3908(03)00273-9; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Maitra B, 2004, BONE MARROW TRANSPL, V33, P597, DOI 10.1038/sj.bmt.1704400; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Micera A, 2000, J NEUROIMMUNOL, V104, P116, DOI 10.1016/S0165-5728(99)00272-6; MOORE MAS, 1991, BLOOD, V78, P1; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Papadopoulos D, 2006, EXP NEUROL, V197, P373, DOI 10.1016/j.expneurol.2005.10.033; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; SAFFRAN BN, 1990, BRAIN RES, V525, P11, DOI 10.1016/0006-8993(90)91315-8; Saito T, 2002, ANN THORAC SURG, V74, P19, DOI 10.1016/S0003-4975(02)03591-9; Stampachiacchiere B, 2005, J NEUROIMMUNOL, V169, P20, DOI 10.1016/j.jneuroim.2005.07.022; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Triaca V, 2005, EXP NEUROL, V191, P53, DOI 10.1016/j.expneurol.2004.08.034; Villoslada P, 2000, J EXP MED, V191, P1799, DOI 10.1084/jem.191.10.1799; Walsh GS, 1999, J NEUROSCI, V19, P4155; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhang J, 2005, EXP NEUROL, V195, P16, DOI 10.1016/j.expneurol.2005.03.018; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	78	112	116	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 15	2006	84	3					587	595		10.1002/jnr.20962			9	Neurosciences	Neurosciences & Neurology	071FR	WOS:000239584700012	16773650				2021-06-18	
J	Parslow, RC; Morris, KP; Tasker, RC; Forsyth, RJ; Hawley, CA				Parslow, RC; Morris, KP; Tasker, RC; Forsyth, RJ; Hawley, CA		UK Paediat Traumat Brain Injury St; Paediat Intens Care Soc Study Grp	Epidemiology of traumatic brain injury in children receiving intensive care in the UK	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							HEAD-INJURY; HEALTH; SEVERITY; TRENDS	Aims: To describe the epidemiology of children with traumatic brain injury (TBI) admitted to paediatric intensive care units (PICUs) in the UK. Methods: Prospective collection of clinical and demographic information from paediatric and adult intensive care units in the UK and Eire between February 2001 and August 2003. Results: The UK prevalence rate for children ( 0-14 years) admitted to intensive care with TBI between February 2001 and August 2003 was 5.6 per 100 000 population per year ( 95% Poisson exact confidence intervals 5.17 to 6.05). Children admitted to PICUs with TBI were more deprived than the population as a whole ( mean Townsend score for TBI admissions 1.19 v 0). The commonest mechanism of injury was a pedestrian accident ( 36%), most often occurring in children over 10. There was a significant summer peak in admissions in children under 10 years. Time of injury peaked in the late afternoon and early evening, a pattern that remained constant across the days of the week. Injuries involving motor vehicles have the highest mortality rates ( 23% of vehicle occupants, 12% of pedestrians) compared with cyclists (8%) and falls (3%). In two thirds of admissions (65%) TBI was an isolated injury. Conclusions: TBI in children requiring intensive care is more common in those from poorer backgrounds who have been involved in accidents as pedestrians. The summer peak in injury occurrence for 0-10 year olds and late afternoon timing give clear targets for community based injury prevention.	Univ Leeds, Ctr Biostat & Epidemiol, Paediat Epidemiol Grp, Leeds LS2 9JT, W Yorkshire, England; Prince Wales Childrens Hosp, Birmingham, W Midlands, England; Univ Cambridge, Sch Clin, Dept Paediat, Addenbrookes Hosp, Cambridge, England; Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Sch Clin Med Sci, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Warwick, Warwick Med Sch, Div Hlth Community, Coventry CV4 7AL, W Midlands, England	Parslow, RC (corresponding author), Univ Leeds, Ctr Biostat & Epidemiol, Paediat Epidemiol Grp, 30 Hyde Terrace, Leeds LS2 9JT, W Yorkshire, England.	parslow@leeds.ac.uk	Forsyth, Rob J/I-9226-2012; Forsyth, Rob/H-9193-2019; Tasker, Robert C/R-5837-2019; Parslow, Roger/AAV-1477-2020; Hawley, Carol/AAG-3830-2019	Forsyth, Rob J/0000-0002-5657-4180; Forsyth, Rob/0000-0002-5657-4180; Tasker, Robert/0000-0003-3647-8113; Parslow, Roger/0000-0002-3945-5294			Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bunn F, 2003, INJURY PREV, V9, P200, DOI 10.1136/ip.9.3.200; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; EDWARDS JH, 1961, ANN HUM GENET, V25, P83, DOI 10.1111/j.1469-1809.1961.tb01501.x; General Register Office for Scotland, 2001, CENS STAND AR STAT S; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hippisley-Cox J, 2002, BRIT MED J, V324, P1132, DOI 10.1136/bmj.324.7346.1132; James HE, 1985, BRAIN INSULTS INFANT, P179; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kendrick D, 2004, ARCH DIS CHILD, V89, P330, DOI 10.1136/adc.2003.032052; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Liabo Kristin, 2003, Arch Dis Child, V88, P235, DOI 10.1136/adc.88.3.235; *N IR STAT RES AG, 2001, 2001 CENS STAD AR ST; *OFF NAT STAT, 2004, MORT STAT INJ PO DH4; *OFF NAT STAT, 2004, MORT STAT CHILDH DH3; *OFF NAT STAT, 2001 CENS STAND AR S; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; Segui-Gomez M, 2003, EPIDEMIOL REV, V25, P3, DOI 10.1093/epirev/mxg007; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; Stark AD, 2002, BRIT MED J, V324, P457, DOI 10.1136/bmj.324.7335.457; StataCorp, 2004, STAT STAT SOFTW REL; Williamson LM, 2002, J EPIDEMIOL COMMUN H, V56, P285, DOI 10.1136/jech.56.4.285; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	26	112	116	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	NOV	2005	90	11					1182	1187		10.1136/adc.2005.072405			6	Pediatrics	Pediatrics	976HI	WOS:000232723500025	16049060	Green Published, Bronze			2021-06-18	
J	Croker, V; McDonald, S				Croker, V; McDonald, S			Recognition of emotion from facial expression following traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; emotion recognition; perception; affect; facial expression	DIFFERENTIAL NEURAL RESPONSE; BLUNT HEAD-INJURY; SOCIAL-PERCEPTION; AMYGDALA DAMAGE; VISUAL-CORTEX; LOBE DAMAGE; FACE; IDENTITY; COMMUNICATION; IMPAIRMENTS	Primary Objective: To assess three domains of emotion recognition in people with traumatic brain injury (TBI). Research design: A between group comparison. Procedures: Twenty-four participants with severe TBI and 15 matched participants without brain damage were asked to label and match facial expressions with and without context. The participants with TBI were also interviewed regarding changes in subjective experience of emotion. Main outcomes and results: Participants with TBI were found to be significantly impaired on expression labelling and matching, but experienced some improvement when provided with context. Negative emotions were particularly affected. Affective semantic knowledge and face perception appeared to be relatively intact in this group. The majority of participants with TBI reported some change in the post-injury experience of everyday emotion, although the pattern of changes differed greatly between individuals. Reduced subjective experience, especially of sadness and fear, was associated with poor emotion matching but not emotion labelling.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			Adolphs R, 2002, J COGNITIVE NEUROSCI, V14, P1264, DOI 10.1162/089892902760807258; Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2004, J COGNITIVE NEUROSCI, V16, P453, DOI 10.1162/089892904322926782; Adolphs R, 2003, NEUROPSYCHOLOGIA, V41, P119, DOI 10.1016/S0028-3932(02)00142-2; Adolphs R, 1996, J NEUROSCI, V16, P7678; Argyle M., 1988, BODILY COMMUNICATION; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; BOROD JC, 1993, J NERV MENT DIS, V181, P495; BOWERS D, 1993, NEUROPSYCHOLOGY, V7, P433; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; Buchanan TW, 2004, BEHAV NEUROSCI, V118, P429, DOI 10.1037/0735-7044.118.2.429; Carroll JM, 1996, J PERS SOC PSYCHOL, V70, P205, DOI 10.1037/0022-3514.70.2.205; Cook, 1976, GAZE MUTUAL GAZE; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; DEKOSKY ST, 1980, BRAIN LANG, V9, P206, DOI 10.1016/0093-934X(80)90141-8; Eckman P, 1976, PICTURES FACIAL AFFE; GEORGE MS, 1993, J NEUROPSYCH CLIN N, V5, P384; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; HUMPHREYS GW, 1993, NEUROPSYCHOLOGIA, V31, P173, DOI 10.1016/0028-3932(93)90045-2; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Johnston PJ, 2001, BIOL PSYCHOL, V58, P203, DOI 10.1016/S0301-0511(01)00114-4; KALSBEEK WD, 1980, J NEUROSURGERY S, V53, P19; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LU ST, 1991, NEUROSCIENCE, V43, P287, DOI 10.1016/0306-4522(91)90293-W; Mandal MK, 1999, J NERV MENT DIS, V187, P603, DOI 10.1097/00005053-199910000-00003; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McHugo GJ, 1996, MOTIV EMOTION, V20, P85, DOI 10.1007/BF02253867; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Mehrabian A., 1971, SILENT MESSAGES; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; OHMAN A, 1986, PSYCHOPHYSIOLOGY, V23, P123, DOI 10.1111/j.1469-8986.1986.tb00608.x; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Phillips ML, 1999, PSYCHIAT RES-NEUROIM, V92, P11, DOI 10.1016/S0925-4927(99)00031-1; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Streit M, 1999, COGNITIVE BRAIN RES, V7, P481, DOI 10.1016/S0926-6410(98)00048-2; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; YOUNG AW, 1993, BRAIN, V116, P941, DOI 10.1093/brain/116.4.941	55	112	115	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2005	19	10					787	799		10.1080/02699050500110033			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	945EI	WOS:000230484800005	16175839				2021-06-18	
J	Marit, RS; Wilkosz, PA				Marit, RS; Wilkosz, PA			Disorders of diminished motivation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						abulia; akinetic mutism; anterior cingulum; apathy; cholinesterase inhibitor; disorders of diminished motivation; dopamine agonist; methylpbenidate; traumatic brain injury; ventral pallidum	TRAUMATIC BRAIN-INJURY; APATHY; RELIABILITY; STRATEGIES; ATTENTION; VALIDITY; DEFICITS; LOBE	Disorders of diminished motivation occur frequently in individuals with traumatic brain injury. Motivation is an ever-present, essential determinant of behavior and adaptation. The major syndromes of diminished motivation are apathy, abulia, and akinetic mutism. Depending on their etiology, disorders of diminished motivation may be a primary clinical disturbance, a symptom of another disorder, or a coexisting second disorder. This article presents a biopsychosocial approach to the assessment and management of motivational impairments in patients with traumatic brain injury. The recognition and differential diagnosis of disorders of diminished motivation, as well as the mechanism and clinical pathogenesis, are discussed.	Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA	Wilkosz, PA (corresponding author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA.	wilkpa@msx.upmc.edu					Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Atkinson J. W., 1978, INTRO MOTIVATION; Benson D. F., 1990, NEUROPSY NEUROPSY BE, V3, P36; BERRIOS GE, 1995, ACTA PSYCHIAT SCAND, V92, P161, DOI 10.1111/j.1600-0447.1995.tb09561.x; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999; Campbell JJ, 1997, PSYCHIAT ANN, V27, P44, DOI 10.3928/0048-5713-19970101-11; Cole G.D.H., 1955, NEBRASKA S MOTIVATIO, pv; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Finset A, 2000, BRAIN INJURY, V14, P887; Fisher C M, 1983, Clin Neurosurg, V31, P9; Gerring JP, 1996, PSYCHIAT RES, V63, P205, DOI 10.1016/0165-1781(96)02841-7; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GILES GM, 1988, AM J OCCUP THER, V42, P658, DOI 10.5014/ajot.42.10.658; GILES GM, 1993, BRAIN INJURY REHABIL; Goff DC, 2001, AM J PSYCHIAT, V158, P1367, DOI 10.1176/appi.ajp.158.9.1367; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; Hecaean H, 1975, PSYCHIATRIC ASPECTS, P137; Heimer L, 2003, AM J PSYCHIAT, V160, P1726, DOI 10.1176/appi.ajp.160.10.1726; HOEHNSARIC R, 1990, J CLIN PSYCHOPHARM, V32, P672; KALIVAS PW, 1993, LIMBIC MOTOR CIRCUIT; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LILLY R, 1983, NEUROLOGY, V33, P1141, DOI 10.1212/WNL.33.9.1141; Mann R. S., 1996, REV PSYCHIAT, V15, P205; Marin R.S., 1996, SEMIN CLIN NEUROPSYC, V1, P304, DOI [10.1053/SCNP00100304, DOI 10.1053/SCNP00100304]; Marin RS, 1997, PSYCHIAT ANN, V27, P30, DOI 10.3928/0048-5713-19970101-08; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 2000, HDB PSYCHIAT MEASURE, P409; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Mega MS, 1997, NEUROPSY NEUROPSY BE, V10, P254; MESULAM MM, 1983, TRENDS NEUROSCI, V6, P384, DOI 10.1016/0166-2236(83)90171-6; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; Palmese CA, 2000, BRAIN INJURY, V14, P535; Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; Ross E.D., 2000, PRINCIPLES BEHAV COG, P316; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Stuss DT., 2000, DIFFERENTIATION STAT, P340; WIDLOCHER DJ, 1983, PSYCHIAT CLIN N AM, V6, P27	49	112	116	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2005	20	4					377	388		10.1097/00001199-200507000-00009			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941MV	WOS:000230219800009	16030444				2021-06-18	
J	Scheff, SW; Price, DA; Hicks, RR; Baldwin, SA; Robinson, S; Brackney, C				Scheff, SW; Price, DA; Hicks, RR; Baldwin, SA; Robinson, S; Brackney, C			Synaptogenesis in the hippocampal CA1 field following traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; hippocampus; plasticity; stereology; synapse	LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; COMBINED FLUID PERCUSSION; LESION-INDUCED SYNAPTOGENESIS; ENTORHINAL CORTEX LESIONS; CLOSED HEAD-INJURY; MORRIS WATER MAZE; DENTATE GYRUS; ADULT-RAT; REACTIVE SYNAPTOGENESIS	Traumatic brain injury (TBI) results in both acute and chronic disruption of cognitive ability that may be mediated through a disruption of hippocampal circuitry. Experimental models of TBI have demonstrated that cortical contusion injuries can result in the loss of specific neurons in the CA3 subfield of the ipsilateral hippocampus, resulting in partial loss of afferents to the CA1 subfield. Numerous studies have documented the ability of the central nervous system to compensate for deafferentation by initiating a plasticity response capable of restoring lost synaptic contacts. The present study was designed to examine the time course of loss and replacement of synaptic contacts in stratum radiatum dendritic field of CA1. Young adult rats were subjected to a lateral cortical contusion injury and assayed for total synaptic numbers using unbiased stereology coupled with transmission electron microscopy. Injured animals demonstrated a 60% loss of synapses in CA1 at 2 days post-injury, followed by a reinnervation process that was apparent as early as 10 days post-injury. By 60 days post-injury, total synaptic numbers had approached pre-injury levels but were still significantly lower. Some animals were behaviorally tested for spatial memory in a Morris Water Maze at 15 and 30 days post-injury. While there was some improvement in spatial memory, injured animals continued to demonstrate a significant deficit in acquisition. These results show that the hippocampus ipsilateral to the cortical contusion is capable of a significant plasticity response but that synapse replacement in this area does not necessarily result in significant improvement in spatial learning.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown, Lexington, KY 40536 USA.	sscheff@email.uky.edu		Price, Douglas/0000-0003-3453-0643	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828, NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220, R01NS039828] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; ANDERSON KJ, 1986, J COMP NEUROL, V252, P374, DOI 10.1002/cne.902520306; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Calverley R.K.S., 1990, QUANTITATIVE QUALITA, P155; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Cotman C W, 1988, Adv Neurol, V47, P313; COTMAN CW, 1981, PHYSIOL REV, V61, P684; Cotman CW, 1976, NEURONAL RECOGNITION, P69; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DASH PK, 1995, J NEUROSCI, V15, P2030; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; GASBARRI A, 1994, BRAIN RES, V668, P71, DOI 10.1016/0006-8993(94)90512-6; Gasbarri A, 1996, EXP BRAIN RES, V112, P244; Geinisman Y, 2004, NEUROBIOL AGING, V25, P407, DOI 10.1016/j.neurobiolaging.2003.12.001; GOLDOWITZ D, 1980, BRAIN RES, V181, P325, DOI 10.1016/0006-8993(80)90616-2; GOLDOWITZ D, 1979, BRAIN RES, V170, P427, DOI 10.1016/0006-8993(79)90962-4; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GRONWALL D, 1974, LANCET, V2, P605; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOFF SF, 1982, J COMP NEUROL, V205, P246, DOI 10.1002/cne.902050304; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; KRAEMER PJ, 1995, PSYCHOBIOLOGY, V23, P144; LEE KS, 1977, EXP BRAIN RES, V29, P475; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LI XM, 1994, POTENTIAL ANAL, V3, P339, DOI 10.1007/BF01049807; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYNCH G, 1975, GOLGI CENTENNIAL S P, P305; Marrone DF, 2004, BRAIN RES, V996, P19, DOI 10.1016/j.brainres.2003.09.073; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NADLER JV, 1980, BRAIN RES, V191, P387, DOI 10.1016/0006-8993(80)91289-5; NYAKAS C, 1987, BRAIN RES BULL, V18, P533, DOI 10.1016/0361-9230(87)90117-1; OLTON DS, 1982, BRAIN RES, V233, P241, DOI 10.1016/0006-8993(82)91200-8; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pitkanen A, 2000, ANN NY ACAD SCI, V911, P369; RAMIREZ JJ, 1984, BEHAV BRAIN RES, V13, P53, DOI 10.1016/0166-4328(84)90029-9; Ramirez JJ, 2001, RESTOR NEUROL NEUROS, V19, P237; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; REEVES TM, 1995, EXP BRAIN RES, V106, P248; REEVES TM, 1986, EXP BRAIN RES, V65, P167; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHEFF SW, 1977, BEHAV BIOL, V21, P286, DOI 10.1016/S0091-6773(77)90374-1; SCHEFF SW, 1989, NEURAL REGENERATION, P137; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; STEWARD O, 1983, J COMP NEUROL, V214, P370, DOI 10.1002/cne.902140403; SWANSON LW, 1978, J COMP NEUROL, V181, P681, DOI 10.1002/cne.901810402; WEIBEL ER, 1979, STEREOLOGICAL METHOD, P101; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Witter M. P., 2004, RAT NERVOUS SYSTEM, P635, DOI [10.1016/B978-012547638-6/50022-5, DOI 10.1016/B978-012547638-6/50022-5]	82	112	114	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2005	22	7					719	732		10.1089/neu.2005.22.719			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	945VQ	WOS:000230530800001	16004576				2021-06-18	
J	Ramsey, D; Smithard, D; Kalra, L				Ramsey, D; Smithard, D; Kalra, L			Silent aspiration: What do we know?	DYSPHAGIA			English	Article						dysphagia; aspiration; deglutition disorders; stroke	FIBEROPTIC ENDOSCOPIC EVALUATION; BILATERAL STROKE PATIENTS; LARYNGEAL COUGH REFLEX; TRAUMATIC BRAIN-INJURY; ELDERLY-PATIENTS; GASTROESOPHAGEAL-REFLUX; MECHANICAL VENTILATION; SWALLOWING DYSFUNCTION; SYMPTOMLESS DYSPHAGIA; PULMONARY ASPIRATION	Although clinically evident aspiration is common in subjects with dysphagia, a significant proportion may aspirate silently, i.e., without any outward signs of swallowing difficulty. This article reviews the literature on the prevalence, etiology, and prognostic significance of silent aspiration. An electronic database search was performed using silent aspiration, aspiration, dysphagia, and stroke as search terms, together with hand-searching of articles. Silent aspiration has been described in many conditions and subgroups of patients (including normal individuals), using a number of detection methods, making comparisons a challenge. The best data are for acute stroke, in which 2%-25% of patients may aspirate silently. Mechanisms associated with silent aspiration may include central or local weakness/incoordination of the pharyngeal musculature, reduced laryngopharyngeal sensation, impaired ability to produce a reflexive cough, and low substance P or dopamine levels. In terms of prognosis, silent aspiration has been associated with increased morbidity and mortality in many but not all studies. However, some degree of silent aspiration at night may be normal in healthy individuals. The phenomenon of silent aspiration is poorly understood and further research is needed to improve methods of detection and thereby better define its prevalence and prognostic significance.	Univ London Kings Coll, GKT Med Sch, Dept Stroke Med, London SE5 9PJ, England; William Harvey Hosp, Hlth Care Older People Dept, Ashford, Kent, England	Ramsey, D (corresponding author), Univ London Kings Coll, GKT Med Sch, Dept Stroke Med, Bessemer Rd, London SE5 9PJ, England.	deborah.ramsey@kcl.ac.uk					Addington WR, 1999, ARCH PHYS MED REHAB, V80, P150, DOI 10.1016/S0003-9993(99)90112-0; ALESSI DM, 1989, ANN OTO RHINOL LARYN, V98, P586, DOI 10.1177/000348948909800803; Amberson J, 1937, INT ANESTHESIOL CLIN, V3, P126; Arai T, 2000, CHEST, V117, P1819, DOI 10.1378/chest.117.6.1819; Arai T, 1998, LANCET, V352, P115, DOI 10.1016/S0140-6736(98)85021-6; Arai T, 2003, NEUROLOGY, V61, P1625, DOI 10.1212/01.WNL.0000096395.80826.23; Arai T, 2003, J AM GERIATR SOC, V51, P1815, DOI 10.1046/j.1532-5415.2003.51572_2.x; ARVEDSON J, 1994, INT J PEDIATR OTORHI, V28, P173, DOI 10.1016/0165-5876(94)90009-4; Aviv JE, 1997, ANN OTO RHINOL LARYN, V106, P87; Balan KK, 1998, AM J GASTROENTEROL, V93, P946, DOI 10.1111/j.1572-0241.1998.00284.x; BARTLETT JG, 1975, CHEST, V68, P560, DOI 10.1378/chest.68.4.560; CAMERON JL, 1973, SURG GYNECOL OBSTET, V136, P68; Collins MJ, 1997, STROKE, V28, P1773, DOI 10.1161/01.STR.28.9.1773; CULVER GA, 1951, ANN SURG, V133, P289, DOI 10.1097/00000658-195103000-00001; Daniels S. K., 1997, AM J SPEECH-LANG PAT, V6, P17, DOI [DOI 10.1044/1058-0360.0604.17, 10.1044/ 1058- 0360.0604.17]; Daniels SK, 1998, ARCH PHYS MED REHAB, V79, P14, DOI 10.1016/S0003-9993(98)90200-3; ELPERN EH, 1994, CHEST, V105, P563, DOI 10.1378/chest.105.2.563; Frazier JB, 1996, DEV MED CHILD NEUROL, V38, P695, DOI 10.1111/j.1469-8749.1996.tb12139.x; Fuh JL, 1997, CLIN NEUROL NEUROSUR, V99, P106, DOI 10.1016/S0303-8467(97)00606-9; GARCIA PE, 1998, REV ESP ANESTESIOL R, V45, P298; GARDNER AMN, 1958, Q J MED, V27, P227; Garon BR, 1996, J NEUROL REHABIL, V10, P121; Gleeson K, 1997, CHEST, V111, P1266, DOI 10.1378/chest.111.5.1266; Harrington OB, 1998, ANN THORAC SURG, V65, P1599, DOI 10.1016/S0003-4975(98)00239-2; Harrington Z, 2003, INT J PROSTHODONT, V16, P54; Hiss SG, 2003, LARYNGOSCOPE, V113, P1386, DOI 10.1097/00005537-200308000-00023; HOLAS MA, 1994, ARCH NEUROL-CHICAGO, V51, P1051, DOI 10.1001/archneur.1994.00540220099020; HORNER J, 1993, NEUROLOGY, V43, P430, DOI 10.1212/WNL.43.2.430; HORNER J, 1990, NEUROLOGY, V40, P1686, DOI 10.1212/WNL.40.11.1686; HORNER J, 1988, NEUROLOGY, V38, P1359; HORNER J, 1988, NEUROLOGY, V38, P317, DOI 10.1212/WNL.38.2.317; Hughes PJ, 2000, HEAD NECK-J SCI SPEC, V22, P393, DOI 10.1002/1097-0347(200007)22:4<393::AID-HED13>3.0.CO;2-2; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; Ishizuka Chie, 2000, No To Hattatsu, V32, P390; KIDD D, 1993, Q J MED, V86, P825; KIKUCHI R, 1994, AM J RESP CRIT CARE, V150, P251, DOI 10.1164/ajrccm.150.1.8025758; Kluin KJ, 1996, J NEUROL SCI, V138, P49, DOI 10.1016/0022-510X(95)00329-Z; Kobayashi H, 1996, LANCET, V348, P1320, DOI 10.1016/S0140-6736(05)65809-6; Langmore SE, 1998, DYSPHAGIA, V13, P69, DOI 10.1007/PL00009559; Leder SB, 1999, J HEAD TRAUMA REHAB, V14, P448, DOI 10.1097/00001199-199910000-00005; Leder SB, 1998, DYSPHAGIA, V13, P19, DOI 10.1007/PL00009544; Leder SB, 2000, LARYNGOSCOPE, V110, P641, DOI 10.1097/00005537-200004000-00019; Leder SB, 2002, CHEST, V122, P1721, DOI 10.1378/chest.122.5.1721; Lefton-Greif MA, 2000, J PEDIATR-US, V136, P225, DOI 10.1016/S0022-3476(00)70106-5; Lim SHB, 2001, DYSPHAGIA, V16, P1, DOI 10.1007/s004550000038; LimDunham JE, 1997, AM J ROENTGENOL, V169, P1015, DOI 10.2214/ajr.169.4.9308454; LINDEN P, 1983, ARCH PHYS MED REHAB, V64, P281; Mann G, 2000, CEREBROVASC DIS, V10, P380, DOI 10.1159/000016094; MARTIN JH, 1994, ANN OTO RHINOL LARYN, V103, P749, DOI 10.1177/000348949410301001; Mathisen B, 1999, J PAEDIATR CHILD H, V35, P163, DOI 10.1046/j.1440-1754.1999.t01-1-00334.x; MEGURO K, 1992, TOHOKU J EXP MED, V167, P135, DOI 10.1620/tjem.167.135; Morgan A, 2002, J HEAD TRAUMA REHAB, V17, P220, DOI 10.1097/00001199-200206000-00004; Nakagawa T, 1997, ARCH INTERN MED, V157, P321, DOI 10.1001/archinte.157.3.321; NAKAGAWA T, 1995, LANCET, V345, P1447, DOI 10.1016/S0140-6736(95)92638-0; NAKAZAWA H, 1993, CHEST, V103, P1636, DOI 10.1378/chest.103.5.1636b; Niimi A, 2003, THORAX, V58, P152, DOI 10.1136/thorax.58.2.152; O'Donoghue S, 1999, FOLIA PHONIATR LOGO, V51, P158, DOI 10.1159/000021494; Ozcan M, 2003, ARCH OTOLARYNGOL, V129, P1006, DOI 10.1001/archotol.129.9.1006; Pannunzio T G, 1996, AACN Clin Issues, V7, P560, DOI 10.1097/00044067-199611000-00010; Perie S, 1998, AM J OTOLARYNG, V19, P18, DOI 10.1016/S0196-0709(98)90060-6; Pikus L, 2003, AM J ROENTGENOL, V180, P1613, DOI 10.2214/ajr.180.6.1801613; Ramsey DJC, 2003, STROKE, V34, P1252, DOI 10.1161/01.STR.0000066309.06490.B8; Sheikh S, 2001, CHEST, V120, P1190, DOI 10.1378/chest.120.4.1190; Silver Kenneth H., 1994, Dysphagia, V9, P107, DOI 10.1007/BF00714597; Smith CH, 1999, DYSPHAGIA, V14, P1, DOI 10.1007/PL00009579; Smith HA, 2000, AGE AGEING, V29, P495, DOI 10.1093/ageing/29.6.495; Smithard DG, 1998, AGE AGEING, V27, P99, DOI 10.1093/ageing/27.2.99; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; STANNERS AJ, 1993, AGE AGEING S2, V2, pA47; Stephens RE, 2003, AM J PHYS MED REHAB, V82, P379, DOI 10.1097/01.PHM.0000064730.54787.F5; Taenaka N, 1985, Masui, V34, P189; Tolep K, 1996, CHEST, V109, P167, DOI 10.1378/chest.109.1.167; Tonshoff G, 1996, NUKLEARMED, V35, P140; 1999, EVID REP TECHNOL ASS, V8, P1	74	112	125	0	16	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0179-051X			DYSPHAGIA	Dysphagia	SUM	2005	20	3					218	225		10.1007/s00455-005-0018-9			8	Otorhinolaryngology	Otorhinolaryngology	992UB	WOS:000233908400005	16362510				2021-06-18	
J	Corrigan, JD; Whiteneck, G; Mellick, D				Corrigan, JD; Whiteneck, G; Mellick, D			Perceived needs following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavioral control; cognitive problems; employment; needs; traumatic brain injury	QUALITY-OF-LIFE; HEAD-INJURIES; INDIVIDUALS; SEQUELAE	Objectives: (1) Provide population-based estimates of perceived needs following traumatic brain injury (TBI) and the prevalence of unmet needs 1 year postinjury; (2) identify relations among needs that define unique clusters of individuals; and (3) identify risk factors for experiencing selected needs. Design: Telephone survey 1 year after injury of a prospective cohort of all people hospitalized with TBI in the state of Colorado during 2000. Measures: Self-reported need for assistance in 13 areas of functioning. Results: A total of 58.8% of persons hospitalized with TBI experienced at least 1 need during the year following injury; 40.2% will experience at least 1 unmet need 1 year after injury. Most frequently experienced needs were "improving your memory, solving problems better"(34.1%), "managing stress, emotional upsets" (27.9%), and "managing your money, paying bills" (23.3%). Cluster analysis revealed 8 distinctive groupings of subjects. If a need existed, those least likely to be met involved cognitive abilities, employment, and alcohol and/or drug use. Conclusions: Results were consistent with findings from previous assessments of need for services based on surveys of convenience samples; however, the prevalence of unmet needs 1 year after injury may be higher than previously suspected. More post-hospital services addressing cognitive and emotional problems appear needed. Risk factors for experiencing needs suggest potential avenues for clinical intervention.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Craig Hosp, Dept Res, Englewood, CO USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Corrigan, John D./E-2921-2011		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [IC 09900] Funding Source: Medline; ODCDC CDC HHS [U17 CCU 812447] Funding Source: Medline		Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; *DEP HHS, 1989, INT CLASS DIS; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; MCKILLIP J, 1987, NEED ANAL TOOLS HUMA; PATRICK D, 1989, DISABLEMENT COMMUNIT, P1; RUTHERFORD WH, 1977, LANCET, V1, P1; Schootman M, 1999, BRAIN INJURY, V13, P995; SORIANO FL, 1995, CONDUCTING NEEDS ASS; *SPSS INC, 1999, SPSS BAS 10 0 APPL G; STRUPP HH, 1977, AM PSYCHOL, V32, P187, DOI 10.1037/0003-066X.32.3.187; Thurman DJ., 1995, GUIDELINES SURVEILLA; Witkin BR, 1995, PLANNING CONDUCTING	20	112	113	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2004	19	3					205	216		10.1097/00001199-200405000-00002			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	826JB	WOS:000221824300002	15247843				2021-06-18	
J	Junge, A; Cheung, K; Edwards, T; Dvorak, J				Junge, A; Cheung, K; Edwards, T; Dvorak, J			Injuries in youth amateur soccer and rugby players - comparison of incidence and characteristics	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							FOOTBALL INJURIES; PERFORMANCE PROJECT; SPORTS INJURIES; EPIDEMIOLOGY; PREVENTION; SCHOOL; EXERCISE; SEVERITY; ETIOLOGY; SEASON	Objectives: In reviewing the literature on sports injuries, few studies could be found in which exposure related incidences of injury in different types of sport were compared. These studies indicated that ice hockey, handball, basketball, soccer, and rugby are popular team sports with a relatively high risk of injury. The aim of the study was to compare the characteristics and incidence of injuries in male youth amateur soccer and rugby players. Methods: This prospective cohort study comprised an initial baseline examination to ascertain the characteristics of the players and their level of performance, and a one season observation period during which a physician visited the team weekly and documented all occurring injuries. Twelve soccer and 10 rugby school teams with male amateur players aged 14-18 years were selected for the study. 145 soccer and 123 rugby players could be followed up over one season. Results: Comparison of the incidence of soccer and rugby injuries indicated that rugby union football was associated with a significantly higher rate of injury than soccer. The differences were pronounced for contact injuries, injuries of the head, neck, shoulder, and upper extremity, as well as for concussion, fractures, dislocations, and strains. Rugby players incurred 1.5 times more overuse and training injuries in relation to exposure time, and 2.7 times more match injuries than soccer players. Three rugby players but no soccer players had to stop their participation in sport because of severe injury. Conclusion: The incidence of injury in New Zealand school teams playing soccer or rugby union is high, probably in part because of the low ratio of hours spent in training relative to hours spent playing matches. The development and implementation of preventive interventions to reduce the rate and severity of injury is recommended.	FIFA Med Assessment & Res Ctr, Schulthess Klin, CH-8008 Zurich, Switzerland; Univ Auckland, Goodfellow Unit, Auckland 1, New Zealand	Junge, A (corresponding author), FIFA Med Assessment & Res Ctr, Schulthess Klin, Lengghalde 2, CH-8008 Zurich, Switzerland.	ajunge@kws.ch					Addley K, 1988, Br J Sports Med, V22, P22; Arnason A, 1996, SCAND J MED SCI SPOR, V6, P40, DOI 10.1111/j.1600-0838.1996.tb00069.x; BACKX FJG, 1991, AM J SPORT MED, V19, P124, DOI 10.1177/036354659101900206; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; CLARK DR, 1990, S AFR MED J, V77, P559; DELOES M, 1988, INT J SPORTS MED, V9, P461, DOI 10.1055/s-2007-1025052; DELOES M, 1995, INT J SPORTS MED, V16, P134, DOI 10.1055/s-2007-972980; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; Dvorak J, 2000, AM J SPORT MED, V28, pS69; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Finch CF, 1997, SPORTS MED, V24, P157, DOI 10.2165/00007256-199724030-00002; FRIED T, 1992, SPORTS MED, V14, P269, DOI 10.2165/00007256-199214040-00005; GARRAWAY M, 1995, LANCET, V345, P1485; Hughes DC, 1994, CLIN J SPORT MED, V4, P249, DOI 10.1097/00042752-199410000-00007; INKLAAR H, 1994, SPORTS MED, V18, P81, DOI 10.2165/00007256-199418020-00002; Inklaar H, 1996, INT J SPORTS MED, V17, P229, DOI 10.1055/s-2007-972837; INKLAAR H, 1994, SPORTS MED, V18, P55, DOI 10.2165/00007256-199418010-00006; Junge A, 2000, AM J SPORT MED, V28, pS40; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; LINDENFELD TN, 1994, AM J SPORT MED, V22, P364, DOI 10.1177/036354659402200312; NATHAN M, 1983, S AFR MED J, V64, P132; Nicholl JP, 1995, BRIT J SPORT MED, V29, P232, DOI 10.1136/bjsm.29.4.232; NIELSEN AB, 1989, AM J SPORT MED, V17, P803, DOI 10.1177/036354658901700614; Peterson L, 2000, AM J SPORT MED, V28, pS51; Pringle RG, 1998, BRIT J SPORT MED, V32, P49, DOI 10.1136/bjsm.32.1.49; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; ROUX CE, 1987, S AFR MED J, V71, P307; Schmidt-Olsen S, 1985, Br J Sports Med, V19, P161; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002	33	112	114	1	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR 1	2004	38	2					168	172		10.1136/bjsm.2002.003020			5	Sport Sciences	Sport Sciences	805XB	WOS:000220397900016	15039253	Bronze, Green Published			2021-06-18	
J	Hang, CH; Shi, JX; Li, JS; Wu, W; Yin, HX				Hang, CH; Shi, JX; Li, JS; Wu, W; Yin, HX			Alterations of intestinal mucosa structure and barrier function following traumatic brain injury in rats	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article							MULTIPLE ORGAN FAILURE; HEAD-INJURY; PERMEABILITY; GUT; TRANSLOCATION; INFLAMMATION; ENDOTOXEMIA; INJECTION; SEVERITY	AIM: Gastrointestinal dysfunction is a common complication in patients with traumatic brain injury (TBI). However, the effect of traumatic brain injury on intestinal mucosa has not been studied previously. The aim of the current study was to explore the alterations of intestinal mucosa morphology and barrier function, and to determine how rapidly the impairment of gut barrier function occurs and how long it persists following traumatic brain injury. METHODS: Male Wistar rats were randomly divided into six groups (6 rats each group) including controls without brain injury and traumatic brain injury groups at hours 3, 12, 24, and 72, and on day 7. The intestinal mucosa structure was detected by histopathological examination and electron microscopy. Gut barrier dysfunction was evaluated by detecting serum endotoxin and intestinal permeability. The level of serum endotoxin and intestinal permeability was measured by using chromogenic limulus amebocyte lysate and lactulose/mannitol (L/M) ratio, respectively. RESULTS: After traumatic brain injury, the histopathological alterations of gut mucosa occurred rapidly as early as 3 hours and progressed to a serious state, including shedding of epithelial cells, fracture of villi, focal ulcer, fusion of adjacent villi, dilation of central chyle duct, mucosal atrophy, and vascular dilation, congestion and edema in the villous interstitium and lamina propria. Apoptosis of epithelial cells, fracture and sparseness of microvilli, loss of tight junction between enterocytes, damage of mitochondria and endoplasm, were found by electron microscopy. The villous height, crypt depth and surface area in jejunum decreased progressively with the time of brain injury. As compared with that of control group (183.7 +/- 41.8 EU/L), serum endotoxin level was significantly increased at 3, 12, and 24 hours following TBI (434.8 +/- 54.9 EU/L, 324.2 +/- 61.7 EU/L and 303.3 +/- 60.2 EU/L, respectively),and peaked at 72 hours (560.5 +/- 76.2 EU/L), then declined on day 7 (306.7 +/- 62.4 EU/L, P<0.01). Two peaks of serum endotoxin level were found at hours 3 and 72 following TBI. L/M ratio was also significantly higher in TBI groups than that in control group (control, 0.0172 +/- 0.0009; 12 h, 0.0303 +/- 0.0013; 24 h, 0.0354 +/- 0.0025; 72 h, 0.0736 +/- 0.0105; 7 d, 0.0588 +/- 0.0083; P<0.01). CONCLUSION: Traumatic brain injury can induce significant damages of gut structure and impairment of barrier function which occur rapidly as early as 3 hours following brain injury and lasts for more than 7 days with marked mucosal atrophy.	Coll Nanjing Univ, Dept Neurosurg, Jinling Hosp, Nanjing 210002, Jiangsu Provinc, Peoples R China; Nanjing Univ, Jinling Hosp, Res Inst Gen Surg, Sch Clin Med, Nanjing 210002, Jiangsu Provinc, Peoples R China	Hang, CH (corresponding author), Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Provinc, Peoples R China.	hang1965@public1.ptt.js.cn	Yin, Hong/AAC-5784-2020				Ahmed SH, 2000, STROKE, V31, P193, DOI 10.1161/01.STR.31.1.193; Bohatschek M, 2001, EXP NEUROL, V172, P137, DOI 10.1006/exnr.2001.7764; BROWN TH, 1989, GASTROINTEST ENDOSC, V35, P37, DOI 10.1016/S0016-5107(89)72683-3; Buttenschoen K, 2000, J TRAUMA, V48, P918, DOI 10.1097/00005373-200005000-00017; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; GLAVIN GB, 1992, ACTA PHYSIOL HUNG, V80, P107; Gong JP, 2002, WORLD J GASTROENTERO, V8, P923, DOI 10.3748/wjg.v8.i5.923; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; JACKSON MD, 1989, ARCH PHYS MED REHAB, V70, P553; KAMADA T, 1977, J TRAUMA, V17, P44, DOI 10.1097/00005373-197701000-00006; Kamei H, 2000, J SURG RES, V89, P20, DOI 10.1006/jsre.1999.5802; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; LANGKAMPHENKEN B, 1995, CRIT CARE MED, V23, P660, DOI 10.1097/00003246-199504000-00013; Lu WY, 1997, NEUROSURGERY, V41, P416, DOI 10.1097/00006123-199708000-00017; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; MonteroMenei CN, 1996, BRAIN RES, V724, P55, DOI 10.1016/0006-8993(96)00268-5; Moore FA, 1999, AM J SURG, V178, P449, DOI 10.1016/S0002-9610(99)00231-7; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; PEDOTO MJ, 1995, ARCH PHYS MED REHAB, V76, P871, DOI 10.1016/S0003-9993(95)80555-9; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; PHILIP P A, 1992, Brain Injury, V6, P351, DOI 10.3109/02699059209034949; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; SALZMAN AL, 1994, AM J PHYSIOL, V266, pG633; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; Shanahan F, 1999, Semin Gastrointest Dis, V10, P8; Suchner U, 1996, NUTRITION, V12, P13, DOI 10.1016/0899-9007(95)00016-X; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Wang XD, 1996, EUR SURG RES, V28, P402, DOI 10.1159/000129484; Zhu L, 2000, WORLD J GASTROENTERO, V6, P79, DOI 10.3748/wjg.v6.i1.79	34	112	125	0	10	BAISHIDENG PUBLISHING GROUP INC	PLEASANTON	8226 REGENCY DR, PLEASANTON, CA 94588 USA	1007-9327	2219-2840		WORLD J GASTROENTERO	World J. Gastroenterol.	DEC	2003	9	12					2776	2781					6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	757YY	WOS:000187606800030	14669332				2021-06-18	
J	Zhi, DS; Zhang, S; Lin, X				Zhi, DS; Zhang, S; Lin, X			Study on therapeutic mechanism and clinical effect of mild hypothermia in patients with severe head injury	SURGICAL NEUROLOGY			English	Article						severe head injury; mild hypothermia; prognosis	TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; TISSUE	BACKGROUND The therapeutic mechanism and clinical effect of mild hypothermia in patients with severe head injury were studied. METHODS All 396 patients with severe head injury [Glasgow Coma Scale score (GCS) equal to or less than 8 on admission] were randomly divided into the hypothermic group (198 cases) and the control group (198 cases). Hypothermia was induced within 24 hours of injury. Rewarming began 1 to 7 days (average 62.4 +/- 27.6 h) after the rectal temperature (RT) reached 32.0 to 35.0degreesC. Meanwhile, the vital signs, intracranial pressure (ICP), blood gas values, blood electrolytes, brain tissue oxygen pressure (PbtO2), brain tissue temperature (BT), cerebral blood flow (CBF), and jugular venous oxygen saturation (SjvO2) were measured. The rectal temperature of control patients was induced to 36.5 to 37.0degreesC. According to GOS, the prognosis of the patients was evaluated. RESULTS In comparison with control group, during mild hypothermia the high level of ICP, hyperglycemia and blood lactic acid significantly decreased (p < 0.05) and cerebral flow improved dominantly. The vital signs, blood gas values, and blood electrolytes did not change significantly. Decreased mortality and good recovery were also found in hypothermia group. CONCLUSIONS Mild hypothermia is safe and effective for preventing brain damage on patients with severe head injury, as well as reducing mortality and improving the prognosis. It is important to monitor PbtO2, BT, CBF, and SjvO2 in hypothermic therapy. (C) 2003 Elsevier Inc. All rights reserved.	Tianjin Huanbu Hosp, Tianjin 300060, Peoples R China	Zhi, DS (corresponding author), Tianjin Huanbu Hosp, Tianjin 300060, Peoples R China.						Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; JIANG J, 1997, CHIN J TRAUMATOL, V13, P13; Liu J, 1999, CHIN J TRAUMATOL, V15, P35; Maeda T, 1998, J NEUROTRAUM, V15, P655, DOI 10.1089/neu.1998.15.655; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; METZ C, 1996, J NEUROSURG, V85, P53; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; ZHANG S, 1999, TIANJIN MED, V27, P446; Zhi D, 2000, CHIN J NEUROSURG, V16, P239; Zhi DS, 1999, SURG NEUROL, V52, P393, DOI 10.1016/S0090-3019(99)00101-9	14	112	121	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	MAY	2003	59	5					381	385		10.1016/S0090-3019(03)00148-4			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	682JV	WOS:000183089200008	12765810				2021-06-18	
J	Sherer, M; Hart, T; Nick, TG; Whyte, J; Thompson, RN; Yablon, SA				Sherer, M; Hart, T; Nick, TG; Whyte, J; Thompson, RN; Yablon, SA			Early impaired self-awareness after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						awareness; brain injuries; rehabilitation	CLOSED-HEAD INJURY; REHABILITATION; PERCEPTIONS; DISABILITY; DEFICITS; COMA; CONSCIOUSNESS; RECOVERY; 1-YEAR; STAFF	Objectives: To evaluate predictors of early impaired self-awareness after traumatic brain injury (TBI); to examine interrelationships of the perceptions of patient, clinician, family, and significant other of how patients are functioning after TBI; and to determine how early impaired self-awareness helps to predict employability at rehabilitation discharge. Design: Inception cohort. Setting: Two inpatient rehabilitation programs. Participants: A total of 129 patients with TBI seen for inpatient rehabilitation at 1 of 2 rehabilitation centers. All subjects had emerged from posttraumatic amnesia before being assessed for this study. Interventions: Not applicable. Main Outcome Measures: Impaired self-awareness as measured by the Awareness Questionnaire (patient self-ratings, clinician ratings) and employability (rated on the Disability Rating Scale) at discharge from inpatient rehabilitation. Results: Regression analysis revealed that early impaired self-awareness was predicted by age and functional status (FIM(TM) instrument total score) at admission to inpatient rehabilitation. Spearman correlation coefficients revealed that clinician, family, and significant other ratings of patient functioning were related (r(s)=.42, P<.001), but were not related to patient self-ratings. Multiple logistic regression analysis revealed that early impaired self-awareness was predictive of employability at discharge from inpatient rehabilitation. Clinician ratings of patient functioning showed a positive relation to employability (P=.05), whereas patient self-ratings showed a trend toward a negative relation to employability (P=.09). Conclusions: Our results support the importance of early impaired self-awareness assessment, its predictive value for complex functional activities, and the need for further research to determine if treatment programs for impaired self-awareness enhance functional outcomes.	Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Moss Rehabil Res Inst, Philadelphia, PA USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA	Sherer, M (corresponding author), Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org		Whyte, John/0000-0002-4381-1474			Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hall KM, 1994, ARCH PHYS MED REHABI, V75, pSC; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kraus JF, 1993, HEAD INJURY, P1; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Newman AC, 2000, BRAIN INJURY, V14, P333; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; TEASDALE G, 1974, LANCET, V2, P81; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; YOUNGBLOOD JR, 1989, REHABIL PSYCHOL, V94, P217	45	112	114	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					168	176		10.1053/apmr.2003.50045			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700004	12601646				2021-06-18	
J	Anderson, MI; Parmenter, TR; Mok, M				Anderson, MI; Parmenter, TR; Mok, M			The relationship between neurobehavioural problems of severe traumatic brain injury (TBI), family functioning and the psychological wellbeing of the spouse/caregiver: path model analysis	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; RELATIVES; CAREGIVERS; DISTRESS; PATIENT; SYMPTOMS	This study used a modern theory of stress as a framework to strengthen the understanding of the relationship between neurobehavioural problems of TBI, family functioning and psychological distress in spouse/caregivers. The research was an ex post facto design utilising a cross-sectional methodology. Path analysis was used to determine the structural effect of neurobehavioural problems on family functioning and psychological distress. Forty-seven female and 17 male spouse/caregivers of partners with severe TBI were recruited. Spouse/caregivers who reported partners with TBI as having high levels of behavioural and cognitive problems experienced high levels of unhealthy family functioning. High levels of unhealthy family functioning were related to high levels of distress in spouse/caregivers, as family functioning had a moderate influence on psychological distress. Furthermore, indirect effects of behavioural and cognitive problems operating through family functioning intensified the level of psychological distress experienced by spouse/caregivers. Additionally, spouse/caregivers who reported high levels of behavioural, communication and social problems in their partners also experienced high levels of psychological distress. This study was significant because the impact of TBI on the spouse/caregiver from a multidimensional perspective is an important and under-researched area in the brain injury and disability field.	Avondale Coll, Fac Nursing & Hlth, Wahroonga, NSW, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; Hong Kong Inst Educ, Ctr Res & Int Collaborat, Hong Kong, Hong Kong, Peoples R China	Anderson, MI (corresponding author), Avondale Coll, Fac Nursing & Hlth, Sydney Adventist Hosp Campus, Wahroonga, NSW, Australia.		Mok, Magdalena M. C./G-1713-2017	Mok, Magdalena M. C./0000-0002-6503-8152; Anderson, Malcolm/0000-0003-2963-7497			Arbuckle J., 1995, AMOS USERS GUIDE; ARBUCKLE JL, 1994, AMOS 3 51; BENTLER PM, 1989, THEORY IMPLEMENTATIO; BIDDLE BJ, 1987, CHILD DEV, V58, P4, DOI 10.2307/1130287; BISHOP DS, 1986, ARCH PHYS MED REHAB, V67, P84, DOI 10.1016/0003-9993(86)90107-3; BISHOP DS, 1987, ARCH PHYS MED REHAB, V68, P610; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; Bragg RM, 1992, J HEAD TRAUMA REHAB, V7, P94; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAMPLAIR PS, 1989, THESIS VIRGINIA COMM; DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280; DEROGATIS LR, 1993, BRIEF SYSMPTOM INVEN; Elliott GR, 1982, STRESS HUMAN HLTH; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EPSTEIN NB, 1978, J MARRIAGE FAMILY CO, V4, P191; Frosch S, 1997, BRAIN INJURY, V11, P891; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hobfoll S.E., 1992, J FAM PSYCHOL, V6, P99, DOI [10.1037/0893-3200.6.2.99, DOI 10.1037/0893-3200.6.2.99]; JORESKOB KG, 1993, LISREL 8 USERS REFER; Kay Thomas, 1994, P533; KEITNER GI, 1987, COMPR PSYCHIAT, V28, P54; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LAMONT M, 1992, THESIS LA TROBE U ME; LEAF LE, 1993, BRAIN INJURY, V7, P543, DOI 10.3109/02699059309008182; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MacCallum RC, 1997, MULTIVAR BEHAV RES, V32, P193, DOI 10.1207/s15327906mbr3202_5; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McDonald RP, 1996, MULTIVAR BEHAV RES, V31, P239, DOI 10.1207/s15327906mbr3102_5; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER IW, 1986, COMPR PSYCHIAT, V27, P302, DOI 10.1016/0010-440X(86)90006-4; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PEDHAZUR EJ, 1997, MULTIPLE EGRESSION B; Schumacker R.E., 1996, BEGINNERS GUIDE STRU; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128	46	112	114	0	12	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2002	16	9					743	757		10.1080/02699050210128906			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	585PD	WOS:000177532800001	12217201				2021-06-18	
J	Knight, C; Alderman, N; Burgess, PW				Knight, C; Alderman, N; Burgess, PW			Development of a simplified version of the multiple errands test for use in hospital settings	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE LESIONS; STRATEGY APPLICATION; MULTITASKING; ATTENTION; DAMAGE	Problems with executive functioning may have catastrophic consequences following brain injury. Valid neuropsychological assessment procedures are required if the nature and extent of these are to be understood. However, some existing measures do not adequately reflect how executive impairments are manifested in the context of everyday functioning. Shallice and Burgess (1991) described one procedure, the Multiple Errands Test (MET), which did attain this goal. While successful, it was designed for people who performed within or above the normal range when tested using existing psychometric measures: however, it is acknowledged that many patients seen in routine clinical practice perform below normal limits. Furthermore, while the procedure was carried out in a public place a range of constraints may prevent this with some patients. In this paper the utility of a simplified MET designed for use within a hospital environment is explored. Twenty neurologically healthy participants and 20 people with acquired brain injury took part. People with acquired brain injury were clearly discriminated from healthy controls through the number of errors made. Furthermore, one category of error proved highly predictive of difficulties attributable to executive dysfunction observed in the context of everyday living. While one other test correlated almost as well with these difficulties, it was argued that MET methodology is more advantageous to clinicians regarding assessment and rehabilitation.	St Andrews Hosp, Kemsley Div, Northampton NN1 5DG, England; UCL, London WC1E 6BT, England	Knight, C (corresponding author), St Andrews Hosp, Kemsley Div, Billing Rd, Northampton NN1 5DG, England.	cknight@standrew.co.uk	Burgess, Paul W/A-1811-2010	Alderman, Nick/0000-0002-8523-4142			ACIMOVIC ML, 1993, J COGNITIVE REHABILI, V11, P8; ALDERMAN N, IN PRESS J INT NEURO; ALDERMAN N, 2000, IMP 2000 INT C BRAIN; Baddeley A. D., 1986, WORKING MEMORY; Broks P, 1996, BEHAV NEUROL, V9, P135, DOI 10.3233/BEN-1996-93-405; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1996, CORTEX, V32, P241, DOI 10.1016/S0010-9452(96)80049-9; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Christensen AL, 1974, LURIAS NEUROPSYCHOLO; COUGHLAN AK, 1985, ADULT MEMORY INFORMA; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P209, DOI 10.1080/713755574; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Everitt B., 1996, MAKING SENSE STAT PS; FOGEL BS, 1994, J NEUROPSYCH CLIN N, V6, P343; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; Howell D. C., 1997, STAT METHODS PSYCHOL; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; KNIGHT C, 1999, THESIS U BIRMINGHAM; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Loewenthal K.M., 1996, INTRO PSYCHOL TESTS; LURIA AR, 1981, HIGHER CORTICAL FUNC; MANLY T, UNPUB REHABILITATION; MILLER E, 1984, BRIT J CLIN PSYCHOL, V23, P53, DOI 10.1111/j.2044-8260.1984.tb00626.x; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Robertson I. H., 1994, TEST EVERYDAY ATTENT; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; Spitzer RL, 1978, PSYCHOPHARMACOLOGY G; Teuber H. L., 1964, FRONTAL GRANULAR COR; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Warrington E., 1991, VISUAL OBJECT SPACE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILLIAMS EJ, 1959, J ROY STAT SOC B, V21, P396; Wilson, 1991, NATL ADULT READING T; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1996, BEHAV ASSESSMENT DYS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	42	112	116	0	8	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUN	2002	12	3					231	255		10.1080/09602010244000039			25	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	561RG	WOS:000176155900003					2021-06-18	
J	Mooney, G; Speed, J				Mooney, G; Speed, J			The association between mild traumatic brain injury and psychiatric conditions	BRAIN INJURY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RECOVERY; SCALE	The majority of patients with mild traumatic brain injury (TBI) recover fairly quickly and are usually restored to their previous level of functioning. However, a significant minority have prolonged, complicated, or incomplete recoveries and have outcomes disproportionately worse than would have been predicted by the objective facts of the injury. This failure to recover as expected was the focus of this study. The participants were 80 adults with actual or suspected mild TBI who were referred to an outpatient mild TBI clinic. Most were characterized by problematic recoveries. The results indicated that those individuals who only had brain injuries made good recoveries, but that those with psychiatric comorbidity did not (chi (2) = 19.65, p=0.0002). Most of the new psychiatric conditions responsible for poor recovery consisted of depression, anxiety disorders or conversion disorder. Dissociative phenomena appeared common after mild TBI and scores on the Dissociative Experiences Scale predicted brain injury outcome with 77% accuracy.	Univ Utah, Div Phys Med & Rehabil, Salt Lake City, UT 84112 USA	Mooney, G (corresponding author), Univ Utah, Div Phys Med & Rehabil, Salt Lake City, UT 84112 USA.						Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BERNSTEIN EM, 1986, J NERV MENT DIS, V174, P727, DOI 10.1097/00005053-198612000-00004; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cantagallo A, 1999, BRAIN INJURY, V13, P219, DOI 10.1080/026990599121593; CHAMBLESS DL, 1984, J CONSULT CLIN PSYCH, V52, P1090, DOI 10.1037/0022-006X.52.6.1090; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; DEVORE JR, 1998, PHYSICAL MED REHABIL, V12, P111; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; HATHAWAY S. R., 1951, MMPI MANUAL; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOWENSTEIN RJ, 1988, DISSOCIATION, V1, P17; MARKS IM, 1979, BEHAV RES THER, V17, P263, DOI 10.1016/0005-7967(79)90041-X; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McNair DM, 1981, PROFILE MOOD STATES; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mooney G, 1997, NEUROREHABILITATION, V8, P223, DOI 10.3233/NRE-1997-8308; MOONEY G, 1994, 4 ANN C INT ASS STUD; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; ROSS CA, 1992, GEN HOSP PSYCHIAT, V14, P350, DOI 10.1016/0163-8343(92)90071-H; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Smyser C. H., 1993, DISSOCIATION, V6, P42; Sosin DM, 1996, BRAIN INJURY, V10, P47; UOMOTO JM, 1992, WESTERN J MED, V157, P665	39	112	114	0	11	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2001	15	10					865	877		10.1080/02699050110065286			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	483HF	WOS:000171627000003	11595083				2021-06-18	
J	Ashikaga, R; Araki, Y; Ishida, O				Ashikaga, R; Araki, Y; Ishida, O			MRI of head injury using FLAIR	NEURORADIOLOGY			English	Article						brain, injury; fluid-attenuated inversion-recovery (FLAIR) magnetic resonance imaging	PULSE SEQUENCES; TRAUMA; EXPERIENCE; FEATURES; BRAIN; CT	We studied the utility of fluid-attenuated inversion-recovery (FLAIR) MRI in the investigation of head injury. We examined 56 patients with head injuries with T2-weighted spin-echo (SE) and FLAIR sequences. In all cases, the sensitivity of FLAIR images to equal or superior to that of conventional SE images to the traumatic lesions. In 9 cases, central diffuse axonal injury of the fornix and corpus callosum could be seen only on sagittal FLAIR images.		Ashikaga, R (corresponding author), KINKI UNIV,SCH MED,DEPT RADIOL,377-1 OHNOHIGASHI,OSAKA,OSAKA 589,JAPAN.						COENE BD, 1992, AJNR, V13, P1555; DAVIS WL, 1994, DIAGNOSTIC NEURORADI, P199; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1991, MAGNETIC RESONANCE I, P439; HAJNAL JV, 1992, J COMPUT ASSIST TOMO, V16, P841, DOI 10.1097/00004728-199211000-00001; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; RYDBERG JN, 1994, RADIOLOGY, V193, P173, DOI 10.1148/radiology.193.1.8090888; WHITE SJ, 1992, MAGNET RESON MED, V28, P153, DOI 10.1002/mrm.1910280116	10	112	114	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0028-3940			NEURORADIOLOGY	Neuroradiology	APR	1997	39	4					239	242		10.1007/s002340050401			4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	WW392	WOS:A1997WW39200001	9144669				2021-06-18	
J	Clark, RSB; Kochanek, PM; Marion, DW; Schiding, JK; White, M; Palmer, AM; DeKosky, ST				Clark, RSB; Kochanek, PM; Marion, DW; Schiding, JK; White, M; Palmer, AM; DeKosky, ST			Mild posttraumatic hypothermia reduces mortality after severe controlled cortical impact in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain injury; controlled cortical impact; electroencephalogram; hypothermia; rat	TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; CARDIOPULMONARY BYPASS; CEREBRAL PROTECTION; CIRCULATORY ARREST; TEMPERATURE; SUPPRESSION; DISRUPTION	The effect of posttraumatic hypothermia (brain temperature controlled at 32 degrees C for 4 h) on mortality after severe controlled cortical impact (CCI) was studied in rats, Four posttraumatic brain temperatures were compared: 37 degrees C (n = 10), 36 degrees C (n = 4), 32 degrees C (n = 10), and uncontrolled (UC; n = 6). Rats were anesthetized and subjected to severe CCI (4.0-m/s velocity, 3.0-mm depth) to the exposed left parietal cortex. At 10 min posttrauma the rats were cooled or maintained at their target brain temperature, using external cooling or warming. Brain temperature in the UC group was recorded but not regulated, and rectal temperature was maintained at 37 +/- 0.5 degrees C. After 4 h, rats were rewarmed over a 1-h period to 37 degrees C, extubated, and observed for 24 h. In the 37 and 36 degrees C groups, 24-h mortality was 50% (37 degrees C = 5/10, 36 degrees C = 2/4). In the 32 degrees C group, 24-h mortality was 10% (1/10). In the UC group, brain temperature was 35.4 +/- 0.6 degrees C during the 4-h treatment period and 24-h mortality was 0% (0/6). Mortality was higher in groups with brain temperatures greater than or equal to 36 degrees C versus those with brain temperatures <36 degrees C (50 vs. 6%, respectively; p < 0.05). Additionally, electroencephalograms (EEG) were recorded in subsets of each temperature group and the percentage of time that the EEG was suppressed (isoelectric) was determined. Percentage of EEG suppression was greater in the hypothermic (32 degrees C, n = 6;UC, n = 4)groups than in the normothermic (36 degrees C, n = 3; 37 degrees C, n = 6) groups (23.3 +/- 14.3 vs. 1.2 +/- 3.1%, respectively; p < 0.05). Posttraumatic hypothermia suppressed EEG during treatment and reduced mortality after severe CCI. The threshold for this protective effect appears to be a brain temperature <36 degrees C. Thus, even mild hypothermia may be beneficial after severe brain trauma.	UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT NEUROL SURG, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PSYCHIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA 15260 USA			Palmer, Alan/AAP-8650-2020; Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318] Funding Source: Medline		BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; BOUZARTH WF, 1967, J AMER MED ASSOC, V199, P567; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GILLINOV AM, 1993, ANN THORAC SURG, V55, P1432, DOI 10.1016/0003-4975(93)91084-Z; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Hickey P R, 1987, J Cardiothorac Anesth, V1, P137, DOI 10.1016/0888-6296(87)90010-X; HICKS RG, 1981, J THORAC CARDIOV SUR, V81, P781; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KULUZ JW, 1993, AM J PHYSIOL, V265, pH824; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LOOMIS CW, 1986, CLIN PHARMACOL THER, V40, P304, DOI 10.1038/clpt.1986.181; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; MIZRAHI EM, 1989, ELECTROEN CLIN NEURO, V72, P81, DOI 10.1016/0013-4694(89)90033-3; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; ROSOMOFF HL, 1965, ARCH NEUROL-CHICAGO, V13, P337, DOI 10.1001/archneur.1965.00470040003001; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WOODCOCK TE, 1987, ANESTHESIOLOGY, V67, P218, DOI 10.1097/00000542-198708000-00011	37	112	112	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	1996	16	2					253	261		10.1097/00004647-199603000-00010			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	TW393	WOS:A1996TW39300010	8594057	Bronze			2021-06-18	
J	GREIFFENSTEIN, MF; GOLA, T; BAKER, WJ				GREIFFENSTEIN, MF; GOLA, T; BAKER, WJ			MMPI-2 VALIDITY SCALES VERSUS DOMAIN-SPECIFIC MEASURES IN DETECTION OF FACTITIOUS TRAUMATIC BRAIN INJURY	CLINICAL NEUROPSYCHOLOGIST			English	Article							FAKING; PROSPECTS; SEQUELAE; DEFICITS	A known group methodology was used to compare the predictive accuracies of MMPI-2 validity scales and malingered amnesia measures in the detection of real versus feigned traumatic brain-injury. The domain specific compliance measures were consistently more accurate in the separation of factitious brain-injury patients (n = 68) from severe brain-injury patients (N = 56). Among MMPI-2 measures, only scale Sc improved on base-rate predictions of probable malingering. Anti-social traits, as measured by Pd, had no relationship to malingered amnesia. Factor analysis suggested independent psychiatric and neurological malingering factors. The implications for DSM-IV malingering criteria and models of feigned illness are discussed.	PSYCHOL SYST INC,ROYAL OAK,MI 48057; WAYNE STATE UNIV,DETROIT,MI 48202							BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1993, CLIN NEUROPSYCHOL, V7, P104, DOI DOI 10.1080/13854049308401892; BRANDT J, 1992, NEUROPSYCHOLOGY MEMO, P156; Butcher JN., 1989, MMPI 2 MINNESOTA MUL; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CASEY VA, 1981, 9TH ANN M INT NEUR S; Cullum C, 1991, FORENSIC NEUROPSYCHO, P141; Dahlstrom W.G, 1972, MMPI HDB CLIN INTERP; DAHLSTROM WG, 1975, MMPI HDB, V1; DOER HO, 1991, FORENSIC NEUROPSYCHO; FAUST D, 1991, BRAIN DAMAGE CLAIMS; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; GOLA T, 1994, THESIS WAYNE STATE U; Gough H.G, 1950, J CONSULT PSYCHOL, V14, P408; Graham JR, 1990, MMPI 2 ASSESSING PER; GRANZEN MD, 1991, NEUROPSYCHOL REV, V1, P247; GREENE RL, 1991, MMPI MMPI 2 INTERPRE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, 11TH ANN C NAT AC NE; LAWTON MP, 1965, J CLIN PSYCHOL, V21, P269, DOI 10.1002/1097-4679(196507)21:3<269::AID-JCLP2270210311>3.0.CO;2-N; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MCCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041; MILLIS SR, 1992, CLIN NEUROPSYCHOLOGI, V7, P406; MITTENBERG W, 1994, ARCH CLIN NEUROPSYCH, V9; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; NOURSIS MJ, 1993, SPSS WINDOWS ADV STA; POPE KS, 1993, MMPI MMPI 2 MMPI A C; PRIGATANO G, 1994, J CLIN EXPT NEUROPSY, V15, P537; ROGERS R, 1990, PROF PSYCHOL-RES PR, V21, P182; RUTHERFORD WH, 1977, LANCET, V1, P1; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; Spreen O, 1990, COMPENDIUM NEUROPSYC; Timbrook R. E., 1993, PSYCHOL ASSESSMENT, V5, P53, DOI [10.1037/1040-3590.5.1.53, DOI 10.1037/1040-3590.5.1.53]; WIENER DN, 1948, J CONSULT PSYCHOL, V12, P43; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; 1994, DIAGNOSTIC STATISTIC	43	112	112	0	21	SWETS ZEITLINGER BV	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JUL	1995	9	3					230	240		10.1080/13854049508400485			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	RJ646	WOS:A1995RJ64600005					2021-06-18	
J	ANDREWS, PJD; DEARDEN, NM; MILLER, JD				ANDREWS, PJD; DEARDEN, NM; MILLER, JD			JUGULAR BULB CANNULATION - DESCRIPTION OF A CANNULATION TECHNIQUE AND VALIDATION OF A NEW CONTINUOUS MONITOR	BRITISH JOURNAL OF ANAESTHESIA			English	Article						BRAIN, HEAD INJURY; ISCHEMIA; EQUIPMENT, CONTINUOUS INVIVO OXIMETRY; MONITORING, JUGULAR BULB OXYGEN SATURATION	CEREBRAL BLOOD-FLOW; COMATOSE PATIENTS; HEAD-INJURY; HYPERTENSION; METABOLISM	We have compared in vivo oxygen saturation recordings obtained from the Oximetrix 3 with in vitro measurements using the Instrumentation Laboratories 282 Co-Oximeter. The small mean difference (0.85%) and close limits of agreement (-4% to 6%) are close enough for clinical purposes, provided in vivo calibration is performed after insertion of the fibreoptic catheter and repeated at least every 12 h. Continuous monitoring of jugular bulb oxygen saturation during intensive care of brain injured patients is now possible using fibreoptic technology. This technique may be of value in detecting global ischaemia, and as a predictor and monitor of cerebral perfusion pressure therapy.	UNIV EDINBURGH,WESTERN GEN HOSP,DEPT ANAESTHESIA,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND							ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; BRICOLO AP, 1981, J NEUROSURG, V55, P397, DOI 10.3171/jns.1981.55.3.0397; CRUZ J, 1984, Society for Neuroscience Abstracts, V10, P542; DEARDEN NM, 1989, INTRACRANIAL PRESSUR, V7; GARLICK R, 1987, SCAND J CLIN LAB INV, V47, P47; GETTINGER A, 1987, ANESTHESIOLOGY, V66, P373, DOI 10.1097/00000542-198703000-00017; GIBBS EL, 1945, AM J PSYCHIAT, V102, P184, DOI 10.1176/ajp.102.2.184; NELSON LD, 1986, ANN SURG, V203, P329, DOI 10.1097/00000658-198603000-00020; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1983, J CEREBRAL BLOOD F S, V1, P567; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; 1989, MINITAB REFERENCE MA	13	112	114	1	1	PROF SCI PUBL	LONDON	TAVISTOCK HOUSE EAST, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	NOV	1991	67	5					553	558		10.1093/bja/67.5.553			6	Anesthesiology	Anesthesiology	GP137	WOS:A1991GP13700008	1751268	Bronze			2021-06-18	
J	VANZOMEREN, AH; DEELMAN, BG				VANZOMEREN, AH; DEELMAN, BG			LONG-TERM RECOVERY OF VISUAL REACTION-TIME AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									STATE UNIV GRONINGEN,DEPT NEUROPSYCHOL,GRONINGEN,NETHERLANDS							BENTON AL, 1957, J ABNORM SOC PSYCH, V54, P109, DOI 10.1037/h0047176; BENTON AL, 1958, CONFIN NEUROL, V19, P247; Bruhn P, 1971, Cortex, V7, P278; Conover WJ, 1971, PRACTICAL NONPARAMET; COSTA LD, 1962, PERCEPT MOTOR SKILL, V14, P391; DIMOND S, 1970, Q J EXP PSYCHOL, V22, P513, DOI 10.1080/14640747008401928; FITTS PM, 1973, HUMAN PERFORMANCE; GRONWALL, 1974, LANCET, V2, P605; GRONWALL D, 1974, PSYCHOLOGICAL EFFECT; JENNETT B, 1975, LANCET, V1, P480; Kahneman D., 1973, ATTENTION EFFORT; KLENSCH H, 1973, FORTSCHR NEUROL PSYC, V41, P575; Miller E, 1970, Cortex, V6, P121; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; WINER BJ, 1970, STATISTICAL PRINCIPL	18	112	113	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1978	41	5					452	457		10.1136/jnnp.41.5.452			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	EZ315	WOS:A1978EZ31500012	660209	Bronze, Green Published			2021-06-18	
J	Asken, BM; McCrea, MA; Clugston, JR; Snyder, AR; Houck, ZM; Bauer, RM				Asken, Breton M.; McCrea, Michael A.; Clugston, James R.; Snyder, Aliyah R.; Houck, Zachary M.; Bauer, Russell M.			"Playing Through It'': Delayed Reporting and Removal From Athletic Activity After Concussion Predicts Prolonged Recovery	JOURNAL OF ATHLETIC TRAINING			English	Article						symptom reporting; window of vulnerability; mild traumatic brain injuries; collegiate athletes	METABOLIC BRAIN VULNERABILITY; SPORT-RELATED CONCUSSION; TEMPORAL WINDOW; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; EXTRACELLULAR POTASSIUM; POSTCONCUSSION SYNDROME; CONSENSUS STATEMENT; FOOTBALL PLAYERS; UP-REGULATION	Context: Preclinical research has demonstrated a window of vulnerability in the immediate aftermath of concussion wherein continued activity and stimulation can impair or prolong neurobehavioral recovery. However, this concept has not been quantified in a human population. Objective: To examine the effect of delayed reporting and removal from athletic activity after concussion on recovery time. Design: Cross-sectional study. Setting: A National Collegiate Athletic Association Division I university. Patients or Other Participants: Ninety-seven athletes who sustained a sport-related concussion between 2008 and 2015 were analyzed (age = 20.4 +/- 1.3 years). Athletes were grouped as immediate removal from activity (I-RFA) or delayed removal from activity (D-RFA). Main Outcome Measure(s): Days missed was defined as the number of days between the concussion-causing event and clearance for return to contact. Associations between RFA group and prolonged (8 or more days') versus normal (7 or fewer days') recovery were also analyzed. Results: Fifty (51.5%) of the 97 athletes did not immediately report concussion symptoms. The D-RFA athletes averaged 4.9 more days missed than the I-RFA athletes. Membership in the specific RFA group predicted days missed even after controlling for sex, concussion history, learning disability or attention-deficit/hyperactivity disorder diagnosis, diagnosed psychological disorder, and acute symptom severity (R-2 change = 0.097, beta = .319, P = .002). The D-RFA athletes were approximately 2.2 times more likely to have a prolonged recovery (8 or more days) compared with the I-RFA athletes (chi(2) = 10.268, P = .001, phi = 0.325). Conclusions: Athletes who do not immediately report symptoms of a concussion and continue to participate in athletic activity are at risk for longer recoveries than athletes who immediately report symptoms and are immediately removed from activity. Continuing to participate in athletic activity during the immediate aftermath of a concussion potentially exposes the already injured brain to compounded neuropathophysiologic processes.	[Asken, Breton M.; Snyder, Aliyah R.; Houck, Zachary M.; Bauer, Russell M.] Univ Florida, Dept Clin & Hlth Psychol, POB 100165, Gainesville, FL 32610 USA; [Clugston, James R.] Univ Florida, Dept Community Hlth & Family Med, POB 100165, Gainesville, FL 32610 USA; [Clugston, James R.] Univ Florida, Univ Athlet Assoc, POB 100165, Gainesville, FL 32610 USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Waukesha, WI USA	Asken, BM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HPNP, POB 100165, Gainesville, FL 32610 USA.	basken8@phhp.ufl.edu	Snyder, Aliyah/AAT-6250-2020	Snyder, Aliyah/0000-0003-1185-7424; Clugston, James/0000-0002-2103-1039; Asken, Breton/0000-0001-8419-142X			Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Blom G., 1958, STAT ESTIMATES TRANS; Concussion in Sport Group, 2013, BRIT J SPORT MED, V47, P259; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; GARLAND DJ, 1990, PERCEPT MOTOR SKILL, V70, P1299, DOI 10.2466/PMS.70.4.1299-1314; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hootman JM, 2007, J ATHL TRAINING, V42, P311; IBM Corp, 2013, IBM SPSS STAT SOFTW; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kilcoyne KG, 2014, SPORTS HEALTH, V6, P402, DOI 10.1177/1941738113491545; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Mann DTY, 2007, J SPORT EXERCISE PSY, V29, P457, DOI 10.1123/jsep.29.4.457; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Williams AM, 2006, PERCEPTION, V35, P317, DOI 10.1068/p5310	40	111	111	0	19	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR	2016	51	4					329	335		10.4085/1062-6050-51.5.02			7	Sport Sciences	Sport Sciences	DM6DQ	WOS:000376441000008	27111584	Green Published, Bronze			2021-06-18	
J	Rawji, KS; Mishra, MK; Michaels, NJ; Rivest, S; Stys, PK; Yong, VW				Rawji, Khalil S.; Mishra, Manoj K.; Michaels, Nathan J.; Rivest, Serge; Stys, Peter K.; Yong, V. Wee			Immunosenescence of microglia and macrophages: impact on the ageing central nervous system	BRAIN			English	Article						microglia; macrophage; white matter injury; ageing; rejuvenation	COLONY-STIMULATING FACTOR; MONOPHOSPHORYL-LIPID-A; AMYLOID-BETA; SPINAL-CORD; INFLAMMATORY RESPONSES; ALZHEIMERS-DISEASE; ANALYSIS REVEALS; IMMUNE CELLS; AGED MICE; BRAIN	The nervous system's capacity to repair itself declines with age. Rawji et al. discuss the effects of ageing on neurological diseases and propose that some of these effects may reflect differential senescence of macrophages and microglia. Therapeutic strategies to reverse macrophage/microglia senescence may promote regeneration in the ageing nervous system.The nervous system's capacity to repair itself declines with age. Rawji et al. discuss the effects of ageing on neurological diseases and propose that some of these effects may reflect differential senescence of macrophages and microglia. Therapeutic strategies to reverse macrophage/microglia senescence may promote regeneration in the ageing nervous system.Ageing of the central nervous system results in a loss of both grey and white matter, leading to cognitive decline. Additional injury to both the grey and white matter is documented in many neurological disorders with ageing, including Alzheimer's disease, traumatic brain and spinal cord injury, stroke, and multiple sclerosis. Accompanying neuronal and glial damage is an inflammatory response consisting of activated macrophages and microglia, innate immune cells demonstrated to be both beneficial and detrimental in neurological repair. This article will propose the following: (i) infiltrating macrophages age differently from central nervous system-intrinsic microglia; (ii) several mechanisms underlie the differential ageing process of these two distinct cell types; and (iii) therapeutic strategies that selectively target these diverse mechanisms may rejuvenate macrophages and microglia for repair in the ageing central nervous system. Most responses of macrophages are diminished with senescence, but activated microglia increase their expression of pro-inflammatory cytokines while diminishing chemotactic and phagocytic activities. The senescence of macrophages and microglia has a negative impact on several neurological diseases, and the mechanisms underlying their age-dependent phenotypic changes vary from extrinsic microenvironmental changes to intrinsic changes in genomic integrity. We discuss the negative effects of age on neurological diseases, examine the response of senescent macrophages and microglia in these conditions, and propose a theoretical framework of therapeutic strategies that target the different mechanisms contributing to the ageing phenotype in these two distinct cell types. Rejuvenation of ageing macrophage/microglia may preserve neurological integrity and promote regeneration in the ageing central nervous system.	[Rawji, Khalil S.; Mishra, Manoj K.; Michaels, Nathan J.; Stys, Peter K.; Yong, V. Wee] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; [Rawji, Khalil S.; Mishra, Manoj K.; Michaels, Nathan J.; Stys, Peter K.; Yong, V. Wee] Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada; [Rivest, Serge] Univ Laval, Fac Med, Dept Mol Med, CHU Quebec,Res Ctr,Neurosci Lab, Quebec City, PQ G1V 4G2, Canada	Yong, VW (corresponding author), Univ Calgary, 3330 Hosp Dr, Calgary, AB T2N 4N1, Canada.	vyong@ucalgary.ca	Mishra, Manoj/A-7105-2018	Mishra, Manoj/0000-0001-9636-4930; Yong, V. Wee/0000-0002-2600-3563; Rawji, Khalil Sherali/0000-0002-9687-8330	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Multiple Sclerosis Scientific Research Foundation; Multiple Sclerosis Society of Canada; Alberta Innovates - Health Solutions CRIO Team; Vanier Canada Graduate Scholarship; Alberta Innovates Health Solutions; Multiple Sclerosis Society of Canada Studentship; Eyes High Doctoral Scholarship from the University of Calgary; Canada Research Chair programCanada Research Chairs; Alberta Innovates [201300669] Funding Source: researchfish	We thank the Canadian Institutes of Health Research, the Multiple Sclerosis Scientific Research Foundation, the Multiple Sclerosis Society of Canada and Alberta Innovates - Health Solutions CRIO Team program for support of operating funds. K.S.R. is supported by a Vanier Canada Graduate Scholarship and a studentship from the University of Calgary Faculty of Medicine. M.K.M. was supported by a fellowship from Alberta Innovates Health Solutions. N.J.M. is supported by a Multiple Sclerosis Society of Canada Studentship and the Eyes High Doctoral Scholarship from the University of Calgary. V.W.Y., P.K.S. and S.R. acknowledge salary support from the Canada Research Chair program.	Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; Baruch K, 2013, BRAIN BEHAV IMMUN, V34, P11, DOI 10.1016/j.bbi.2013.04.002; Baruch K, 2013, P NATL ACAD SCI USA, V110, P2264, DOI 10.1073/pnas.1211270110; Beerman I, 2013, CELL STEM CELL, V12, P413, DOI 10.1016/j.stem.2013.01.017; Blasko I, 2004, AGING CELL, V3, P169, DOI 10.1111/j.1474-9728.2004.00101.x; Boehmer ED, 2004, J LEUKOCYTE BIOL, V75, P342, DOI 10.1189/jlb.0803389; Boehmer ED, 2005, MECH AGEING DEV, V126, P1305, DOI 10.1016/j.mad.2005.07.009; Boissonneault V, 2009, BRAIN, V132, P1078, DOI 10.1093/brain/awn331; Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chambers SM, 2007, PLOS BIOL, V5, P1750, DOI 10.1371/journal.pbio.0050201; Chang AS, 2012, ANN NEUROL, V72, P918, DOI 10.1002/ana.23693; Chelvarajan RL, 2005, J LEUKOCYTE BIOL, V77, P503, DOI 10.1189/jlb.0804449; Chen C, 2009, SCI SIGNAL, V2, pra75; Cohen M, 2014, EMBO J, V33, P2906, DOI 10.15252/embj.201489293; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conde JR, 2006, J NEUROPATH EXP NEUR, V65, P199, DOI 10.1097/01.jnen.0000202887.22082.63; Dai LY, 2001, INJURY, V32, P195, DOI 10.1016/S0020-1383(00)00176-5; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Doring A, 2015, J NEUROSCI, V35, P1136, DOI [10.1523/JNEUROSCI.1797-14.2015, 10.1523/JNEUROSCI.1797-14]; Doyle KP, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-62; Ergen AV, 2012, BLOOD, V119, P2500, DOI 10.1182/blood-2011-11-391730; Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030; Fan R, 2007, J NEUROSCI, V27, P3057, DOI 10.1523/JNEUROSCI.4371-06.2007; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Flanary BE, 2007, REJUV RES, V10, P61, DOI 10.1089/rej.2006.9096; Floden AM, 2011, J ALZHEIMERS DIS, V25, P279, DOI 10.3233/JAD-2011-101014; Florian MC, 2012, CELL STEM CELL, V10, P520, DOI 10.1016/j.stem.2012.04.007; Frenkel D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3030; Geiger H, 2013, NAT REV IMMUNOL, V13, P376, DOI 10.1038/nri3433; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Goldschmidt T, 2009, NEUROLOGY, V72, P1914, DOI 10.1212/WNL.0b013e3181a8260a; Gon Y, 1996, CLIN EXP IMMUNOL, V106, P120; Gosselin D, 2014, CELL, V159, P1327, DOI 10.1016/j.cell.2014.11.023; Greenhalgh AD, 2014, J NEUROSCI, V34, P6316, DOI 10.1523/JNEUROSCI.4912-13.2014; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kotter MR, 2006, J NEUROSCI, V26, P328, DOI 10.1523/JNEUROSCI.2615-05.2006; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lampron A, 2013, J COMP NEUROL, V521, P3863, DOI 10.1002/cne.23363; Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; Mayack SR, 2010, NATURE, V463, P495, DOI 10.1038/nature08749; Michaud JP, 2013, P NATL ACAD SCI USA, V110, P1941, DOI 10.1073/pnas.1215165110; Michell-Robinson MA, 2015, BRAIN, V138, P1138, DOI 10.1093/brain/awv066; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mishra MK, 2014, ANN CLIN TRANSL NEUR, V1, P409, DOI 10.1002/acn3.67; Natrajan MS, 2015, BRAIN, V138, P3581, DOI 10.1093/brain/awv289; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Njie EG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.008; Oh J, 2014, NAT MED, V20, P870, DOI 10.1038/nm.3651; Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Rawji KS, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/948976; Ruckh JM, 2012, CELL STEM CELL, V10, P96, DOI 10.1016/j.stem.2011.11.019; Rube CE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017487; Sacco RL, 1997, NEUROLOGY, V49, pS39, DOI 10.1212/WNL.49.5_Suppl_4.S39; Samanani S, 2013, CNS NEUROL DISORD-DR, V12, P741, DOI 10.2174/18715273113126660177; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sarkar S, 2014, NAT NEUROSCI, V17, P46, DOI 10.1038/nn.3597; Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179; Schwartz M, 2013, J NEUROSCI, V33, P17587, DOI 10.1523/JNEUROSCI.3241-13.2013; Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shemer A, 2015, TRENDS IMMUNOL, V36, P614, DOI 10.1016/j.it.2015.08.003; Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Tremblay ME, 2012, GLIA, V60, P541, DOI 10.1002/glia.22287; van Duin D, 2007, J IMMUNOL, V178, P970, DOI 10.4049/jimmunol.178.2.970; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; WHITELAW DM, 1972, CELL TISSUE KINET, V5, P311, DOI 10.1111/j.1365-2184.1972.tb00369.x; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006; Yamanaka M, 2012, J NEUROSCI, V32, P17321, DOI 10.1523/JNEUROSCI.1569-12.2012; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Zhao C, 2006, NEUROBIOL AGING, V27, P1298, DOI 10.1016/j.neurobiolaging.2005.06.008	86	111	112	1	24	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR 1	2016	139		3				653	661		10.1093/brain/awv395			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DF9PX	WOS:000371694600012	26912633	Bronze, Green Published			2021-06-18	
J	Ge, XT; Lei, P; Wang, HC; Zhang, AL; Han, ZL; Chen, X; Li, SH; Jiang, RC; Kang, CS; Zhang, JN				Ge, Xin-Tong; Lei, Ping; Wang, Hai-Chen; Zhang, An-Ling; Han, Zhao-Li; Chen, Xin; Li, Sheng-Hui; Jiang, Rong-Cai; Kang, Chun-Sheng; Zhang, Jian-Ning			miR-21 improves the neurological outcome after traumatic brain injury in rats	SCIENTIFIC REPORTS			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR STABILIZATION; CARDIAC-HYPERTROPHY; ANGIOGENESIS; EXPRESSION; CELLS; PROLIFERATION; ANGIOPOIETIN1/TIE2; OVEREXPRESSION; VULNERABILITY	The expression levels of microRNAs (miRNAs) including miR-21, have been reported to change in response to traumatic brain injury (TBI), suggesting that they may influence the pathophysiological process in brain injury. To analyze the potential effect of miR-21 on neurological function after TBI, we employed the fluid percussion injury rat model and manipulated the expression level of miR-21 in brain using intracerebroventricular infusion of miR-21 agomir or antagomir. We found that upregulation of miR-21 level in brain conferred a better neurological outcome after TBI by improving long-term neurological function, alleviating brain edema and decreasing lesion volume. To further investigate the mechanism underlying this protective effect, we evaluated the impact of miR-21 on apoptosis and angiogenesis in brain after TBI. We found that miR-21 inhibited apoptosis and promoted angiogenesis through regulating the expression of apoptosis-and angiogenesis-related molecules. In addition, the expression of PTEN, a miR-21 target gene, was inhibited and Akt signaling was activated in the procedure. Taken together, these data indicate that miR-21 could be a potential therapeutic target for interventions after TBI.	[Ge, Xin-Tong; Han, Zhao-Li; Chen, Xin; Li, Sheng-Hui; Jiang, Rong-Cai; Zhang, Jian-Ning] Tianjin Neurol Inst, Lab Neurotrauma, Tianjin, Peoples R China; [Ge, Xin-Tong; Lei, Ping; Zhang, An-Ling; Han, Zhao-Li; Chen, Xin; Li, Sheng-Hui; Jiang, Rong-Cai; Kang, Chun-Sheng; Zhang, Jian-Ning] Minist Educ, Key Lab Post Trauma Neurorepair & Regenerat Cent, Tianjin, Peoples R China; [Ge, Xin-Tong; Lei, Ping; Zhang, An-Ling; Han, Zhao-Li; Chen, Xin; Li, Sheng-Hui; Jiang, Rong-Cai; Kang, Chun-Sheng; Zhang, Jian-Ning] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin, Peoples R China; [Ge, Xin-Tong; Lei, Ping; Zhang, An-Ling; Chen, Xin; Li, Sheng-Hui; Jiang, Rong-Cai; Kang, Chun-Sheng; Zhang, Jian-Ning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Lei, Ping; Han, Zhao-Li] Tianjin Med Univ, Gen Hosp, Dept Geriatr, Tianjin, Peoples R China; [Lei, Ping; Han, Zhao-Li] Tianjin Geriatr Inst, Lab Neuro Trauma & Neurodegenerat Disorders, Tianjin, Peoples R China; [Wang, Hai-Chen] Duke Univ, Sch Med, Dept Neurol, Durham, NC USA; [Zhang, An-Ling; Kang, Chun-Sheng] Tianjin Neurol Inst, Lab Neurooncol, Tianjin, Peoples R China	Zhang, JN (corresponding author), Tianjin Neurol Inst, Lab Neurotrauma, Tianjin, Peoples R China.	jianningzhang@hotmail.com	Ge, Xintong/X-4889-2019; Kang, Chunsheng/AAM-5979-2021	Kang, Chunsheng/0000-0002-3255-3369; Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029, 81471252, 81271361]	This work was supported by grants from the National Natural Science Foundation of China (grant no. 81330029, 81471252 and 81271361). We express special acknowledgement to our senior professor Chun-Sheng Kang who contributes greatly on experiment design and guidance. The authors also appreciate Lei Han, Ying Li, Li Liu, Wei-Yun Cui, Fang-Lian Chen, Zhi-Fan Jia and Guang-Xiu Wang from Tianjin Neurological Institute, Bao-Cun Sun and Xiu-Lan Zhao from the Department of Pathology, Tianjin Medical University for their technical support.	Argaw AT, 2006, J IMMUNOL, V177, P5574, DOI 10.4049/jimmunol.177.8.5574; Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Chae JK, 2000, ARTERIOSCL THROM VAS, V20, P2573, DOI 10.1161/01.ATV.20.12.2573; Chen JL, 2009, J CELL MOL MED, V13, P1348, DOI 10.1111/j.1582-4934.2008.00380.x; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen X, 2010, NEUROL RES, V32, P1097, DOI 10.1179/016164110X12681290831162; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Cuello-Carrion FD, 1999, J HISTOCHEM CYTOCHEM, V47, P837, DOI 10.1177/002215549904700614; Cyran CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076009; Dong J, 2011, ARCH MED RES, V42, P8, DOI 10.1016/j.arcmed.2011.01.006; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Guillamo JS, 2009, CLIN CANCER RES, V15, P3697, DOI 10.1158/1078-0432.CCR-08-2042; Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176; Karuppagounder SS, 2007, NEUROBIOL DIS, V26, P353, DOI 10.1016/j.nbd.2007.01.011; LAI YL, 1983, J APPL PHYSIOL, V54, P1754; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Li T, 2014, J NEUROL SCI, V341, P88, DOI 10.1016/j.jns.2014.04.009; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Liu LZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019139; Nehme B, 2011, J NEUROSCI METH, V196, P281, DOI 10.1016/j.jneumeth.2011.01.018; Nixon K, 2008, NEUROBIOL DIS, V31, P218, DOI 10.1016/j.nbd.2008.04.009; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Ren Y, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-27; Schoknecht K, 2012, EPILEPSIA, V53, P7, DOI 10.1111/j.1528-1167.2012.03697.x; Senger DR, 2010, MOL BIOL CELL, V21, P377, DOI 10.1091/mbc.E09-07-0591; Silva CG, 2007, NEUROBIOL DIS, V27, P182, DOI 10.1016/j.nbd.2007.04.018; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Wang B, 2012, J NEUROL SCI, V319, P117, DOI 10.1016/j.jns.2012.04.015; Wang J, 2012, CELL RES, V22, P516, DOI 10.1038/cr.2011.132; Wang K, 2012, J BIOL CHEM, V287, P589, DOI 10.1074/jbc.M111.266940; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Wang Y, 2012, EXP BIOL MED, V237, P1424, DOI 10.1258/ebm.2012.012123; Xiong BH, 2013, INT J ONCOL, V42, P219, DOI 10.3892/ijo.2012.1707; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zacharek A, 2006, NEUROSCI LETT, V404, P28, DOI 10.1016/j.neulet.2006.05.027; Zhang D, 2013, NEUROSCIENCE, V238, P209, DOI 10.1016/j.neuroscience.2013.02.022; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126; Zhu Y, 2006, ACTA NEUROCHIR SUPPL, V96, P438; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	50	111	117	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	OCT 24	2014	4								6718	10.1038/srep06718			11	Multidisciplinary Sciences	Science & Technology - Other Topics	AR4ZJ	WOS:000343594500001	25342226	DOAJ Gold, Green Published			2021-06-18	
J	Dham, BS; Hunter, K; Rincon, F				Dham, Bhavpreet S.; Hunter, Krystal; Rincon, Fred			The Epidemiology of Status Epilepticus in the United States	NEUROCRITICAL CARE			English	Article						Status epilepticus; Epidemiology; Incidence; NHDS; National Hospital Discharge Survey	REFRACTORY STATUS EPILEPTICUS; CONVULSIVE STATUS EPILEPTICUS; 1ST EPISODE; SUBARACHNOID HEMORRHAGE; TERM MORTALITY; RISK-FACTORS; ADMISSIONS; MINNESOTA; MORBIDITY; ROCHESTER	To summarize trends in status epilepticus (SE) in the United States by age, race, sex, admission source, disposition, incidence rates, and mortality. Data from US National Hospital Discharge Survey were used from 1979 to 2010 to identify discharges with SE and common etiologies and complications of SE using International Classification of Diseases, 9th Revision, Clinical Modifications codes. Temporal trends in the incidence and in-hospital mortality of SE were examined with respect to age, sex, and race. We identified 760,117 discharges with SE over 32 years. The incidence of SE increased from 3.5 to 12.5/100,000 between 1979 and 2010, without a significant change in in-hospital mortality. Higher incidence, earlier age of onset, and higher mortality were observed among males. Age stratification revealed a "U-shaped" distribution with higher incidence at age < 10 years (14.3/100,000) and age > 50 years (approaching 28.4/100,000). In-hospital mortality, however, was the lowest (2.6 %) at age < 10 years and approached 20.2 % with age a parts per thousand yen80 years. The incidence of SE was higher among blacks (13.7/100,000), compared to whites (6.9/100,000) and other races (7.4/100,000). Mortality, however, was lower among blacks (7.2 %) compared to whites and other races (9.8 and 9.2 %, respectively). Black men had the highest incidence (15.0/100,000), relatively younger age of onset (39.3 years) and the lowest mortality (5.6 %). A net temporal decline in the reported prevalence of epilepsy, central nervous system infections, and traumatic brain injury was noted among SE cohort. The incidence of SE increased nearly fourfold with relatively unchanged mortality. Gender and racial disparities exist in the incidence of SE, and age is an important predictor of mortality.	[Dham, Bhavpreet S.] Cooper Univ Hosp, Dept Neurol, Camden, NJ USA; [Hunter, Krystal] Cooper Univ Hosp, Dept Biostat, Camden, NJ USA; [Rincon, Fred] Thomas Jefferson Univ, Div Crit Care & Neurotrauma, Dept Neurol & Neurol Surg, Philadelphia, PA 19107 USA; [Rincon, Fred] Jefferson Med Coll, Philadelphia, PA 19107 USA	Rincon, F (corresponding author), Thomas Jefferson Univ, Div Crit Care & Neurotrauma, Dept Neurol & Neurol Surg, 909 Walnut St,3rd Floor, Philadelphia, PA 19107 USA.	bhavpreet@hotmail.com; hunter-krystal@cooperhealth.edu; fred.rincon@jefferson.edu		Rincon, Fred/0000-0002-8510-118X			[Anonymous], 1981, Epilepsia, V22, P489; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Cascino GD, 1998, EPILEPSIA, V39, P829, DOI 10.1111/j.1528-1157.1998.tb01176.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chin RFM, 2004, EUR J NEUROL, V11, P800, DOI 10.1111/j.1468-1331.2004.00943.x; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2007, NEUROSURGERY, V61, P4; Claassen J, 2007, NEUROSURGERY, V61, P60, DOI 10.1227/01.neu.0000279724.05898.e7; DeLorenzo RJ, 1996, NEUROLOGY, V46, P1029, DOI 10.1212/WNL.46.4.1029; Diaz-Arrastia R, 2002, JAMA-J AM MED ASSOC, V287, P2917, DOI 10.1001/jama.287.22.2917; Fountain NB, 2000, EPILEPSIA, V41, pS23, DOI 10.1111/j.1528-1157.2000.tb01521.x; Gastaut H, 1983, Adv Neurol, V34, P15; Hesdorffer DC, 1998, NEUROLOGY, V50, P735, DOI 10.1212/WNL.50.3.735; Holtkamp M, 2005, J NEUROL NEUROSUR PS, V76, P534, DOI 10.1136/jnnp.2004.041947; Kulkarni SC, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-16; Logroscino G, 2005, EPILEPSIA, V46, P46, DOI 10.1111/j.1528-1167.2005.00409.x; Logroscino G, 2002, NEUROLOGY, V58, P537, DOI 10.1212/WNL.58.4.537; Logroscino G, 1997, EPILEPSIA, V38, P1344, DOI 10.1111/j.1528-1157.1997.tb00073.x; Logroscino G, 2001, EPILEPSIA, V42, P1031, DOI 10.1046/j.1528-1157.2001.0420081031.x; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; Lowenstein DH, 1999, EPILEPSIA, V40, P120, DOI 10.1111/j.1528-1157.1999.tb02000.x; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Mayer SA, 2002, ARCH NEUROL-CHICAGO, V59, P205, DOI 10.1001/archneur.59.2.205; Penberthy LT, 2005, SEIZURE-EUR J EPILEP, V14, P46, DOI 10.1016/j.seizure.2004.06.001; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rincon F, 2013, NEUROCRIT CARE, V19, P95, DOI 10.1007/s12028-012-9793-y; Rincon F, 2013, NEUROSURGERY, V73, P217, DOI 10.1227/01.neu.0000430290.93304.33; Rossetti AO, 2006, J NEUROL NEUROSUR PS, V77, P611, DOI 10.1136/jnnp.2005.080887; U.S. Census Bureau, 2010, AG SEX COMP; Urtecho J, 2013, CRIT CARE MED, V41, P1853, DOI 10.1097/CCM.0b013e31828a3994; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979; Wu YW, 2002, NEUROLOGY, V58, P1070, DOI 10.1212/WNL.58.7.1070; Xian Y, 2011, ANN INTERN MED, V154, P152, DOI 10.7326/0003-4819-154-3-201102010-00004	33	111	115	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2014	20	3					476	483		10.1007/s12028-013-9935-x			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AI7RH	WOS:000337092900018	24519080				2021-06-18	
J	Panzer, MB; Myers, BS; Capehart, BP; Bass, CR				Panzer, Matthew B.; Myers, Barry S.; Capehart, Bruce P.; Bass, Cameron R.			Development of a Finite Element Model for Blast Brain Injury and the Effects of CSF Cavitation	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Finite element model; Blast overpressure; Blast injury; Traumatic brain injury; Injury mechanism; CSF cavitation	CENTRAL-NERVOUS-SYSTEM; HEAD IMPACT MODEL; HYDROSTATIC-PRESSURE; DYNAMIC-RESPONSE; RISK-ASSESSMENT; TISSUE; CELLS; IRAQ; AFGHANISTAN; VISCOSITY	Blast-related traumatic brain injury is the most prevalent injury for combat personnel seen in the current conflicts in Iraq and Afghanistan, yet as a research community, we still do not fully understand the detailed etiology and pathology of this injury. Finite element (FE) modeling is well suited for studying the mechanical response of the head and brain to blast loading. This paper details the development of a FE head and brain model for blast simulation by examining both the dilatational and deviatoric response of the brain as potential injury mechanisms. The levels of blast exposure simulated ranged from 50 to 1000 kPa peak incident overpressure and 1-8 ms in positive-phase duration, and were comparable to real-world blast events. The frontal portion of the brain had the highest pressures corresponding to the location of initial impact, and peak pressure attenuated by 40-60% as the wave propagated from the frontal to the occipital lobe. Predicted brain pressures were primarily dependent on the peak overpressure of the impinging blast wave, and the highest predicted brain pressures were 30% less than the reflected pressure at the surface of blast impact. Predicted shear strain was highest at the interface between the brain and the CSF. Strain magnitude was largely dependent on the impulse of the blast, and primarily caused by the radial coupling between the brain and deforming skull. The largest predicted strains were generally less than 10%, and occurred after the shock wave passed through the head. For blasts with high impulses, CSF cavitation had a large role in increasing strain levels in the cerebral cortex and periventricular tissues by decoupling the brain from the skull. Relating the results of this study with recent experimental blast testing suggest that a rate-dependent strain-based tissue injury mechanism is the source primary blast TBI.	[Panzer, Matthew B.; Myers, Barry S.; Bass, Cameron R.] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Capehart, Bruce P.] Durham VA Med Ctr, OEF OIF Vet Program, Durham, NC 27705 USA; [Capehart, Bruce P.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC 27708 USA	Panzer, MB (corresponding author), Duke Univ, Dept Biomed Engn, 136 Hudson Hall,Box 90281, Durham, NC 27708 USA.	matthew.pan-zer@duke.edu; barry.myers@duke.edu; bruce.capehart@va.gov; dale.bass@duke.edu			Multidisciplinary Research Initiative (MURI) program through the Army Research Office (ARO) [W911MF-10-10526]; James H. McElhaney Biomechanics Fellowship	This work funded in part by the Multidisciplinary Research Initiative (MURI) program (W911MF-10-10526; University of Pennsylvania as prime institution) through the Army Research Office (ARO). We also acknowledge the support of the James H. McElhaney Biomechanics Fellowship for one of the authors (M. B. Panzer).	Ackerman MJ, 1998, P IEEE, V86, P504, DOI 10.1109/5.662875; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bass Cameron R Dale, 2005, Int J Occup Saf Ergon, V11, P347; BAZANT ZP, 1978, COMPUT METHOD APPL M, V16, P91, DOI 10.1016/0045-7825(78)90035-X; Bloomfield IG, 1998, PEDIATR NEUROSURG, V28, P246, DOI 10.1159/000028659; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Cronin D. S., 2008, NUMERICAL MODELING B; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Frey B, 2004, CELL MOL BIOL, V50, P459; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; GORDON C, 1989, TR89044 US ARM NAT R; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; Hallquist JO, 2007, LS DYNA KEYWORD USER; Herbert E, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.041603; Holland CM, 2008, STROKE, V39, P1127, DOI 10.1161/STROKEAHA.107.497438; Hyde DW, 2004, CONWEP 2 1 0 8 CONVE; IREMONGER MJ, 1997, SCI FDN TRAUMA, P189; Kaster T, 2011, J BIOMECH, V44, P1158, DOI 10.1016/j.jbiomech.2011.01.019; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Lynnerup N., 2005, HEAD FACE MED, V1, P1, DOI DOI 10.1186/1746-160X-1-13; Mahmadi K, 2004, MATER SCI FORUM, V465-466, P439, DOI 10.4028/www.scientific.net/MSF.465-466.439; Manas P, 2004, APPL ENVIRON MICROB, V70, P1545, DOI 10.1128/AEM.70.3.1545-1554.2004; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; MCELHANEY JH, 1966, J APPL PHYSIOL, V21, P1231; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; NUSHOLTZ GS, 1995, J NEUROTRAUM, V12, P707, DOI 10.1089/neu.1995.12.707; NUSHOLTZ GS, 1995, AVIAT SPACE ENVIR MD, V66, P661; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Panzer M. B., 2010, PASS QUEB CIT QC; Panzer MB, 2013, COMPUT METHOD BIOMEC, V16, P612, DOI 10.1080/10255842.2011.629615; Panzer MB, 2012, J TRAUMA ACUTE CARE, V72, P454, DOI 10.1097/TA.0b013e31821e8270; Prange M T, 2000, Stapp Car Crash J, V44, P205; Rafaels K. A., 2011, THESIS U VIRGINIA CH; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Richmond D. R., 1989, ANN OTOLRHINOLLARYNG, V140, P35; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Sack I, 2008, NMR BIOMED, V21, P265, DOI 10.1002/nbm.1189; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VALK PE, 1991, AM J NEURORADIOL, V12, P45; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wardlaw A., 2010, CAVITATION POSSIBLE; WILKINS ML, 1980, J COMPUT PHYS, V36, P281, DOI 10.1016/0021-9991(80)90161-8; Wood G. W., 2010, PASS QUEB CIT QC	56	111	111	2	37	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964			ANN BIOMED ENG	Ann. Biomed. Eng.	JUL	2012	40	7					1530	1544		10.1007/s10439-012-0519-2			15	Engineering, Biomedical	Engineering	959WL	WOS:000305348500012	22298329				2021-06-18	
J	Tong, XK; Lecrux, C; Hamel, E				Tong, Xin-Kang; Lecrux, Clotilde; Hamel, Edith			Age-Dependent Rescue by Simvastatin of Alzheimer's Disease Cerebrovascular and Memory Deficits	JOURNAL OF NEUROSCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; OXIDATIVE STRESS; TRANSGENIC MICE; MOUSE MODEL; SYNAPTIC PLASTICITY; SPATIAL MEMORY; IN-VIVO	Alzheimer's disease (AD) is now established as a progressive compromise not only of the neurons but also of the cerebral vasculature. Increasing evidence also indicates that cerebrovascular dysfunction may be a key or an aggravating pathogenic factor in AD, emphasizing the importance to properly control this deficit when aiming for effective therapy. Here, we report that simvastatin (3-6 months, 40 mg/kg/d) completely rescued cerebrovascular reactivity, basal endothelial nitric oxide synthesis, and activity-induced neurometabolic and neurovascular coupling in adult (6 months) and aged (12 months) transgenic mice overexpressing the Swedish and Indiana mutations of the human amyloid precursor protein (AD mice). Remarkably, simvastatin fully restored short-and long-term memory in adult, but not in aged AD mice. These beneficial effects occurred without any decreasing effect of simvastatin on brain amyloid-beta (A beta) levels or plaque load. However, in AD mice with recovered memory, protein levels of the learning-and memory-related immediate early genes c-Fos and Egr-1 were normalized or upregulated in hippocampal CA1 neurons, indicative of restored neuronal function. In contrast, the levels of phospholipase A2, enkephalin, PSD-95, synaptophysin, or glutamate NMDA receptor subunit type 2B were either unaltered in AD mice or unaffected by treatment. These findings disclose new sites of action for statins against A beta-induced neuronal and cerebrovascular deficits that could be predictive of therapeutic benefit in AD patients. They further indicate that simvastatin and, possibly, other brain penetrant statins bear high therapeutic promise in early AD and in patients with vascular diseases who are at risk of developing AD.	[Tong, Xin-Kang; Lecrux, Clotilde; Hamel, Edith] McGill Univ, Montreal Neurol Inst, Lab Cerebrovasc Res, Montreal, PQ H3A 2B4, Canada	Hamel, E (corresponding author), McGill Univ, Montreal Neurol Inst, Lab Cerebrovasc Res, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	edith.hamel@mcgill.ca	Lecrux, Clotilde/AAG-1415-2019	Lecrux, Clotilde/0000-0003-3521-5266	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-84275]; Heart & Stroke Foundation of Canada/Canadian Stroke Network	This work was supported by the Canadian Institutes of Health Research Grant MOP-84275 (to E. H.) and a fellowship from the Heart & Stroke Foundation of Canada/Canadian Stroke Network (to C. L.). We thank Dr. L. Mucke (Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, San Francisco, CA) and the J. David Gladstone Institutes for the APP transgenic mouse breeders. We are indebted to Ms. P. Fernandes [Montreal Neurological Institute (MNI), Montreal, Quebec, Canada] for the laser Doppler flowmetry experiments; J. Cakiroglu and Dr. B. Bedell (Small Animal Imaging Laboratory, MNI) for the MRI templates; Dr. P. Rosa-Neto (Brain Imaging Centre, MNI) for his help with the PET data analysis; Dr. N. Nicolakakis (MNI) for reviewing the manuscript; and P. Papadopoulos (MNI) for help with some treatments.	Aucoin JS, 2005, NEUROSCIENCE, V132, P73, DOI 10.1016/j.neuroscience.2004.11.047; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P744, DOI 10.1097/01.WCB.0000122745.72175.D5; Baumgartel K, 2008, NAT NEUROSCI, V11, P572, DOI 10.1038/nn.2113; Beretta S, 2011, NEUROPHARMACOLOGY, V60, P878, DOI 10.1016/j.neuropharm.2011.01.003; Blanchard J, 2008, NEUROBIOL AGING, V29, P1011, DOI 10.1016/j.neurobiolaging.2007.02.010; Bozon B, 2003, PHILOS T R SOC B, V358, P805, DOI 10.1098/rstb.2002.1224; Butterfield DA, 2011, EXP NEUROL, V228, P15, DOI 10.1016/j.expneurol.2010.12.014; Carloni S, 2009, EXP NEUROL, V220, P82, DOI 10.1016/j.expneurol.2009.07.026; Carlsson CM, 2008, J ALZHEIMERS DIS, V13, P187; Chuquet J, 2010, J NEUROSCI, V30, P15298, DOI 10.1523/JNEUROSCI.0762-10.2010; Cramer C, 2008, NEUROLOGY, V71, P344, DOI 10.1212/01.wnl.0000319647.15752.7b; Davis S, 2003, BEHAV BRAIN RES, V142, P17, DOI 10.1016/S0166-4328(02)00421-7; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; deIpolyi AR, 2008, NEUROBIOL AGING, V29, P253, DOI 10.1016/j.neurobiolaging.2006.10.021; Dickey CA, 2003, J NEUROSCI, V23, P5219; Drouin A, 2007, CARDIOVASC RES, V73, P73, DOI 10.1016/j.cardiores.2006.10.005; Erdos B, 2004, DIABETES, V53, P1352, DOI 10.2337/diabetes.53.5.1352; Fleischmann A, 2003, J NEUROSCI, V23, P9116; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gu ZL, 2009, J BIOL CHEM, V284, P10639, DOI 10.1074/jbc.M806508200; Haag MDM, 2009, J NEUROL NEUROSUR PS, V80, P13, DOI 10.1136/jnnp.2008.150433; Han BH, 2008, J NEUROSCI, V28, P13542, DOI 10.1523/JNEUROSCI.4686-08.2008; Hirao K, 2005, NEUROIMAGE, V28, P1014, DOI 10.1016/j.neuroimage.2005.06.066; Hong KW, 1996, AM J PHYSIOL-HEART C, V270, pH317; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Iadecola C, 1999, NAT NEUROSCI, V2, P157, DOI 10.1038/5715; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; KITAZONO T, 1993, AM J PHYSIOL, V265, pH581; Koehler RC, 2009, TRENDS NEUROSCI, V32, P160, DOI 10.1016/j.tins.2008.11.005; Kornblum HI, 2000, NAT BIOTECHNOL, V18, P655, DOI 10.1038/76509; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Li G, 2007, NEUROLOGY, V69, P878, DOI 10.1212/01.wnl.0000277657.95487.1c; Li G, 2010, J AM GERIATR SOC, V58, P1311, DOI 10.1111/j.1532-5415.2010.02906.x; Li L, 2006, ANN NEUROL, V60, P729, DOI 10.1002/ana.21053; Lloyd DJ, 2009, DIABETES OBES METAB, V11, P688, DOI 10.1111/j.1463-1326.2009.01034.x; Lopez J, 2008, J CARDIOVASC PHARM T, V13, P207, DOI 10.1177/1074248408321716; Maneen MJ, 2007, AM J PHYSIOL-HEART C, V292, pH1042, DOI 10.1152/ajpheart.00800.2006; Mans RA, 2010, NEUROSCIENCE, V166, P435, DOI 10.1016/j.neuroscience.2009.12.062; Meilandt WJ, 2008, J NEUROSCI, V28, P5007, DOI 10.1523/JNEUROSCI.0590-08.2008; Miller AW, 2004, AM J PHYSIOL-REG I, V287, pR157, DOI 10.1152/ajpregu.00647.2003; Mizuno M, 2003, MOL PSYCHIATR, V8, P217, DOI 10.1038/sj.mp.4001215; Mosconi L, 2008, ANN NY ACAD SCI, V1147, P180, DOI 10.1196/annals.1427.007; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nicolakakis N, 2008, J NEUROSCI, V28, P9287, DOI 10.1523/JNEUROSCI.3348-08.2008; Nicolakakis N, 2011, J CEREBR BLOOD F MET, V31, P200, DOI 10.1038/jcbfm.2010.78; Niwa K, 2002, NEUROBIOL DIS, V9, P61, DOI 10.1006/nbdi.2001.0460; Palop JJ, 2003, P NATL ACAD SCI USA, V100, P9572, DOI 10.1073/pnas.1133381100; Park L, 2008, P NATL ACAD SCI USA, V105, P1347, DOI 10.1073/pnas.0711568105; Park L, 2011, P NATL ACAD SCI USA, V108, P5063, DOI 10.1073/pnas.1015413108; Pedersen K, 2007, NEUROIMAGE, V35, P38, DOI 10.1016/j.neuroimage.2006.11.038; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Ramirez C, 2011, J ALZHEIMERS DIS, V24, P161, DOI 10.3233/JAD-2010-101653; Rockwood K, 2002, ARCH NEUROL-CHICAGO, V59, P223, DOI 10.1001/archneur.59.2.223; Sanchez-Mejia RO, 2008, NAT NEUROSCI, V11, P1311, DOI 10.1038/nn.2213; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Sparks DL, 2006, ACTA NEUROL SCAND, V114, P78, DOI 10.1111/j.1600-0404.2006.00689.x; Sugawara T, 2008, J NEUROSCI RES, V86, P3635, DOI 10.1002/jnr.21807; Tamboli IY, 2010, J BIOL CHEM, V285, P37405, DOI 10.1074/jbc.M110.149468; Tong XK, 2009, NEUROBIOL DIS, V35, P406, DOI 10.1016/j.nbd.2009.06.003; Tong XK, 2005, J NEUROSCI, V25, P11165, DOI 10.1523/JNEUROSCI.4031-05.2005; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yamin G, 2009, J NEUROSCI RES, V87, P1729, DOI 10.1002/jnr.21998; Yang XG, 2010, MOL NEUROBIOL, V41, P138, DOI 10.1007/s12035-010-8121-9; Yau JLW, 1996, MOL BRAIN RES, V42, P354, DOI 10.1016/S0169-328X(96)00220-3; Yoshida T, 2007, ANN NUCL MED, V21, P257, DOI 10.1007/s12149-007-0022-2; Yudoh K, 2010, AGING-US, V2, P990, DOI 10.18632/aging.100213	72	111	113	0	14	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 4	2012	32	14					4705	4715		10.1523/JNEUROSCI.0169-12.2012			11	Neurosciences	Neurosciences & Neurology	925TD	WOS:000302783500002	22492027	Green Published, Bronze			2021-06-18	
J	Schuss, P; Vatter, H; Marquardt, G; Imohl, L; Ulrich, CT; Seifert, V; Guresir, E				Schuss, Patrick; Vatter, Hartmut; Marquardt, Gerhard; Imoehl, Lioba; Ulrich, Christian T.; Seifert, Volker; Gueresir, Erdem			Cranioplasty after Decompressive Craniectomy: The Effect of Timing on Postoperative Complications	JOURNAL OF NEUROTRAUMA			English	Article						complications; cranioplasty; decompressive craniectomy; intracranial pressure	MIDDLE CEREBRAL-ARTERY; SUBARACHNOID HEMORRHAGE; HEMICRANIECTOMY; SURGERY; BRAIN; HYDROCEPHALUS; CONCUSSION; INFARCTION	Decompressive craniectomy (DC) due to intractably elevated intracranial pressure mandates later cranioplasty (CP). However, the optimal timing of CP remains controversial. We therefore analyzed our prospectively conducted database concerning the timing of CP and associated post-operative complications. From October 1999 to August 2011, 280 cranioplasty procedures were performed at the authors' institution. Patients were stratified into two groups according to the time from DC to cranioplasty (early, <= 2 months, and late, >2 months). Patient characteristics, timing of CP, and CP-related complications were analyzed. Overall CP was performed early in 19% and late in 81%. The overall complication rate was 16.4%. Complications after CP included epidural or subdural hematoma (6%), wound healing disturbance (5.7%), abscess (1.4%), hygroma (1.1%), cerebrospinal fluid fistula (1.1%), and other (1.1%). Patients who underwent early CP suffered significantly more often from complications compared to patients who underwent late CP (25.9% versus 14.2%; p = 0.04). Patients with ventriculoperitoneal (VP) shunt had a significantly higher rate of complications after CP compared to patients without VP shunt (p = 0.007). On multivariate analysis, early CP, the presence of a VP shunt, and intracerebral hemorrhage as underlying pathology for DC, were significant predictors of post-operative complications after CP. We provide detailed data on surgical timing and complications for cranioplasty after DC. The present data suggest that patients who undergo late CP might benefit from a lower complication rate. This might influence future surgical decision making regarding optimal timing of cranioplasty.	[Schuss, Patrick; Vatter, Hartmut; Marquardt, Gerhard; Imoehl, Lioba; Ulrich, Christian T.; Seifert, Volker; Gueresir, Erdem] Goethe Univ Frankfurt, Dept Neurosurg, D-60528 Frankfurt, Germany	Schuss, P (corresponding author), Goethe Univ Frankfurt, Dept Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	patrick.schuss@med.uni-frankfurt.de	Schuss, Patrick/ABC-6469-2020; guresir, erdem/AAL-4484-2020	Schuss, Patrick/0000-0002-5806-2576; guresir, erdem/0000-0002-6624-6885; Guresir, Erdem/0000-0001-8319-0847			Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Guresir E, 2011, J NEUROSURG, V114, P954, DOI 10.3171/2009.12.JNS091065; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Guresir E, 2008, NEUROSURGERY, V63, P1088, DOI 10.1227/01.NEU.0000335170.76722.B9; Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018; Marion DW, 2006, NEUROSURGERY, V58, P655; Rahme R, 2010, NEUROSURGERY, V67, P675, DOI 10.1227/01.NEU.0000383142.10103.0B; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543; Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; TABADDOR K, 1976, J NEUROSURG, V44, P506, DOI 10.3171/jns.1976.44.4.0506; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Winkler PA, 2000, NEUROSURG FOCUS, V8, pe9, DOI DOI 10.3171/INS.2000.93.1.0053; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Yeo R., 2010, J NEUROTRAUMA; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zemack G, 2000, J NEUROSURG, V92, P941, DOI 10.3171/jns.2000.92.6.0941	27	111	122	1	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1090	1095		10.1089/neu.2011.2176			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100008	22201297				2021-06-18	
J	Brenner, LA; Ignacio, RV; Blow, FC				Brenner, Lisa A.; Ignacio, Rosalinda V.; Blow, Frederic C.			Suicide and Traumatic Brain Injury Among Individuals Seeking Veterans Health Administration Services	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						suicide; traumatic brain	POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE-ABUSE; MORTALITY; BEHAVIOR; SYSTEM; IRAQ; CARE	Objective: To examine associations between history of traumatic brain injury (TBI) diagnosis and death by suicide among individuals receiving care within the Veterans Health Administration (VHA). Method: Individuals who received care between fiscal years 2001 to 2006 were included in analyses. Cox proportional hazards survival models for time to suicide, with time-dependent covariates, were utilized. Covariance sandwich estimators were used to adjust for the clustered nature of the data, with patients nested within VHA facilities. Analyses included all patients with a history of TBI (n = 49 626) plus a 5% random sample of patients without TBI (n = 389 053). Of those with a history of TBI, 105 died by suicide. Models were adjusted for demographic and psychiatric covariates. Results: Veterans with a history of TBI were 1.55 (95% confidence interval [CI], 1.24-1.92) times more likely to die by suicide than those without a history of TBI. Analyses by TBI severity were also conducted, and they suggested that in comparison to those without an injury history, those with (1) concussion/cranial fracture were 1.98 times more likely (95% CI, 1.39-2.82) to die by suicide and (2) cerebral contusion/traumatic intracranial hemorrhage were 1.34 times more likely (95% CI, 1.09-1.64) to die by suicide. This increased risk was not explained by the presence of psychiatric disorders or demographic factors. Conclusions: Among VHA users, those with a diagnosis of TBI were at greater risk for suicide than those without this diagnosis. Further research is indicated to identify evidence-based means of assessment and treatment for those with TBI and suicidal behavior.	[Brenner, Lisa A.] VISN 19 Mental Illness Res Educ & Clin Ctr MIRECC, Denver, CO 80220 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Denver, CO USA; [Ignacio, Rosalinda V.; Blow, Frederic C.] Vet Affairs Serious Mental Illness Treatment Res, Ann Arbor, MI USA; [Ignacio, Rosalinda V.; Blow, Frederic C.] Univ Michigan, Ann Arbor, MI 48109 USA	Brenner, LA (corresponding author), VISN 19 Mental Illness Res Educ & Clin Ctr MIRECC, Denver, CO 80220 USA.	Lisa.Brenner@va.gov	Brenner, Lisa A./AAG-2442-2019		VISN 19 MIRECC; VA SMITREC; VA Office of Mental Health Services	The project was supported by the VISN 19 MIRECC, VA SMITREC, and the VA Office of Mental Health Services.	Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BRENNER LA, 2010, 8 WORLD C BRAIN INJ; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; Department of Defense Task Force on Prevention of Suicide by Members of the Armed Forces, 2010, EX SUMM; Department of Veterans Affairs, 2008, REP BLUE RIBB WORK G; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; McCarthy JF, 2009, AM J EPIDEMIOL, V169, P1033, DOI 10.1093/aje/kwp010; Olson-Madden JH, 2010, J HEAD TRAUMA REHAB, V25, P470, DOI 10.1097/HTR.0b013e3181d717a7; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Sohn Min-Woong, 2006, Popul Health Metr, V4, P2, DOI 10.1186/1478-7954-4-2; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; WHO, 2004, INT STAT CLASS DIS R; World Health Organization, 1977, INT STAT CLASS DIS R	24	111	112	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2011	26	4					257	264		10.1097/HTR.0b013e31821fdb6e			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	789FZ	WOS:000292501700003	21734509				2021-06-18	
J	Naziroglu, M				Naziroglu, Mustafa			TRPM2 Cation Channels, Oxidative Stress and Neurological Diseases: Where Are We Now?	NEUROCHEMICAL RESEARCH			English	Article						TRPM2; Ca(2+); Neuronal cells; Oxidative stress; ADP-ribose; Glial cells; Alzheimer' disease	AMYOTROPHIC-LATERAL-SCLEROSIS; PEROXIDE-INDUCED TOXICITY; 2ND-MESSENGER ADP-RIBOSE; RAT STRIATAL NEURONS; HYDROGEN-PEROXIDE; CALCIUM INFLUX; CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; PARKINSONISM-DEMENTIA; HIPPOCAMPAL-NEURONS	The Na+ and Ca(2+)-permeable melastatin related transient receptor potential 2 (TRPM2) channels can be gated either by ADP-ribose (ADPR) in concert with Ca(2+) or by hydrogen peroxide (H(2)O(2)), an experimental model for oxidative stress, binding to the channel's enzymatic Nudix domain. Since the mechanisms that lead to TRPM2 gating in response to ADPR and H(2)O(2) are not understood in neuronal cells, I summarized previous findings and important recent advances in the understanding of Ca(2+) influx via TRPM2 channels in different neuronal cell types and disease processes. Considering that TRPM2 is activated by oxidative stress, mediated cell death and inflammation, and is highly expressed in brain, the channel has been investigated in the context of central nervous system. TRPM2 plays a role in H(2)O(2) and amyloid beta-peptide induced striatal cell death. Genetic variants of the TRPM2 gene confer a risk of developing Western Pacific amyotropic lateral sclerosis and parkinsonism-dementia complex and bipolar disorders. TRPM2 also contributes to traumatic brain injury processes such as oxidative stress, inflammation and neuronal death. There are a limited number of TRPM2 channel blockers and they seem to be cell specific. For example, ADPR-induced Ca(2+) influx in rat hippocampal cells was not blocked by N-(p-amylcinnomoyl)anthralic acid (ACA), the IP(3) receptor inhibitor 2-aminoethoxydiphenyl borate or PLC inhibitor flufenamic acid (FFA). However, the Ca(2+) entry in rat primary striatal cells was blocked by ACA and FFA. In conclusion TRPM2 channels in neuronal cells can be gated by either ADPR or H(2)O(2). It seems to that the exact relationship between TRPM2 channels activation and neuronal cell death still remains to be determined.	[Naziroglu, Mustafa] Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey	Naziroglu, M (corresponding author), Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey.	mnaziroglu@med.sdu.edu.tr					Amina S, 2010, J NEUROENDOCRINOL, V22, P460, DOI 10.1111/j.1365-2826.2010.01978.x; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Bai JZ, 2010, NEUROTOXICOLOGY, V31, P204, DOI 10.1016/j.neuro.2010.01.001; Bond CE, 2007, GLIA, V55, P1348, DOI 10.1002/glia.20547; Bove Jordi, 2005, NeuroRx, V2, P484, DOI 10.1602/neurorx.2.3.484; Cicchetti F, 2009, TRENDS PHARMACOL SCI, V30, P475, DOI 10.1016/j.tips.2009.06.005; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Cook NL, 2010, J MOL NEUROSCI, V42, P192, DOI 10.1007/s12031-010-9347-8; Dreses-Werringloer U, 2008, CELL, V133, P1149, DOI 10.1016/j.cell.2008.05.048; Fonfria E, 2006, J RECEPT SIG TRANSD, V26, P179, DOI 10.1080/10799890600637522; Fonfria E, 2005, J NEUROCHEM, V95, P715, DOI 10.1111/j.1471-4159.2005.03396.x; Fonfria E, 2004, BRIT J PHARMACOL, V143, P186, DOI 10.1038/sj.bjp.0705914; Freestone PS, 2009, EUR J NEUROSCI, V30, P1849, DOI 10.1111/j.1460-9568.2009.06990.x; Gasser A, 2006, J BIOL CHEM, V281, P2489, DOI 10.1074/jbc.M506525200; Guse AH, 2005, FEBS J, V272, P4590, DOI 10.1111/j.1742-4658.2005.04863.x; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Harteneck C, 2007, CARDIOVASC DRUG REV, V25, P61, DOI 10.1111/j.1527-3466.2007.00005.x; Heiner I, 2006, BIOCHEM J, V398, P225, DOI 10.1042/BJ20060183; Hermosura MC, 2008, P NATL ACAD SCI USA, V105, P18029, DOI 10.1073/pnas.0808218105; Hill K, 2006, NEUROPHARMACOLOGY, V50, P89, DOI 10.1016/j.neuropharm.2005.08.021; Hill K, 2004, N-S ARCH PHARMACOL, V370, P227, DOI 10.1007/s00210-004-0981-y; Hill K, 2004, NEUROPHARMACOLOGY, V47, P450, DOI 10.1016/j.neuropharm.2004.04.014; Hoffmann A, 2010, J NEUROCHEM, V114, P654, DOI 10.1111/j.1471-4159.2010.06644.x; Inamura K, 2003, J MEMBRANE BIOL, V191, P201, DOI 10.1007/s00232-002-1057-x; Kahlert S, 2005, J NEUROSCI RES, V79, P262, DOI 10.1002/jnr.20322; Kaneko S, 2006, J PHARMACOL SCI, V101, P66, DOI 10.1254/jphs.FP0060128; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Kuhn FJP, 2009, NEUROCHEM RES, V34, P227, DOI 10.1007/s11064-008-9755-0; Kuhn FJP, 2005, PFLUG ARCH EUR J PHY, V451, P212, DOI 10.1007/s00424-005-1446-y; Lange I, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000278; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; Lipski J, 2006, BRAIN RES, V1077, P187, DOI 10.1016/j.brainres.2006.01.016; Massullo P, 2006, SEMIN CELL DEV BIOL, V17, P654, DOI 10.1016/j.semcdb.2006.11.006; McQuillan A, 2006, MOL PSYCHIATR, V11, P134, DOI 10.1038/sj.mp.4001759; Morale MC, 2006, NEUROSCIENCE, V138, P869, DOI 10.1016/j.neuroscience.2005.07.060; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Naziroglu M., 2007, Reactive oxygen species and diseases, 2007, P239; Naziroglu M, 2008, NEUROCHEM RES, V33, P1256, DOI 10.1007/s11064-007-9577-5; Naziroglu M, 2008, J NEUROL SCI, V270, P152, DOI 10.1016/j.jns.2008.03.003; Naziroglu M, 2007, NEUROCHEM RES, V32, P1990, DOI 10.1007/s11064-007-9386-x; Naziroglu M, 2007, CELL BIOCHEM FUNCT, V25, P383, DOI 10.1002/cbf.1310; Naziroglu M, 2009, NEUROCHEM RES, V34, P2181, DOI 10.1007/s11064-009-0015-8; Nilius B, 2007, BBA-MOL BASIS DIS, V1772, P805, DOI 10.1016/j.bbadis.2007.02.002; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Ohana L, 2009, CHANNELS, V3, P129, DOI 10.4161/chan.3.2.8609; Olah ME, 2009, J PHYSIOL-LONDON, V587, P965, DOI 10.1113/jphysiol.2008.162289; Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P1, DOI 10.1016/j.proghi.2008.10.002; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Perraud AL, 2003, CELL CALCIUM, V33, P519, DOI 10.1016/S0143-4160(03)00057-5; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Smith MA, 2003, J PHYSIOL-LONDON, V547, P417, DOI 10.1113/jphysiol.2002.034561; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; Staaf S, 2010, GENE EXPR PATTERNS, V10, P65, DOI 10.1016/j.gep.2009.10.003; Togashi K, 2008, BRIT J PHARMACOL, V153, P1324, DOI 10.1038/sj.bjp.0707675; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Watanabe H, 2008, PHARMACOL THERAPEUT, V118, P337, DOI 10.1016/j.pharmthera.2008.03.008; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Xu C, 2006, AM J MED GENET B, V141B, P36, DOI 10.1002/ajmg.b.30239; Yamamoto S, 2008, NAT MED, V14, P738, DOI 10.1038/nm1758; Yamamoto S, 2007, BBA-MOL BASIS DIS, V1772, P958, DOI 10.1016/j.bbadis.2007.03.006; Yamamoto S, 2010, PROG BIOPHYS MOL BIO, V103, P18, DOI 10.1016/j.pbiomolbio.2010.05.005; YANAGIHARA R, 1984, ANN NEUROL, V15, P42, DOI 10.1002/ana.410150108; YASE Y, 1972, LANCET, V2, P292, DOI 10.1016/S0140-6736(72)92903-0; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5	67	111	113	0	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	MAR	2011	36	3					355	366		10.1007/s11064-010-0347-4			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	716RB	WOS:000286990100001	21140288				2021-06-18	
J	Beggs, S; Liu, XJ; Kwan, C; Salter, MW				Beggs, Simon; Liu, Xue Jun; Kwan, Chun; Salter, Michael W.			Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier	MOLECULAR PAIN			English	Article							GENE-RELATED PEPTIDE; NEUROPATHIC PAIN; SPINAL-CORD; ANTIDROMIC VASODILATATION; NEUROGENIC INFLAMMATION; UP-REGULATION; SUBSTANCE-P; TIME-COURSE; RAT; SKIN	Background: The blood-brain barrier (BBB) plays the crucial role of limiting exposure of the central nervous system (CNS) to damaging molecules and cells. Dysfunction of the BBB is critical in a broad range of CNS disorders including neurodegeneration, inflammatory or traumatic injury to the CNS, and stroke. In peripheral tissues, the vascular-tissue permeability is normally greater than BBB permeability, but vascular leakage can be induced by efferent discharge activity in primary sensory neurons leading to plasma extravasation into the extravascular space. Whether discharge activity of sensory afferents entering the CNS may open the BBB or blood-spinal cord barrier (BSCB) remains an open question. Results: Here we show that peripheral nerve injury (PNI) produced by either sciatic nerve constriction or transecting two of its main branches causes an increase in BSCB permeability, as assessed by using Evans Blue dye or horseradish peroxidase. The increase in BSCB permeability was not observed 6 hours after the PNI but was apparent 24 hours after the injury. The increase in BSCB permeability was transient, peaking about 24-48 hrs after PNI with BSCB integrity returning to normal levels by 7 days. The increase in BSCB permeability was prevented by administering the local anaesthetic lidocaine at the site of the nerve injury. BSCB permeability was also increased 24 hours after electrical stimulation of the sciatic nerve at intensity sufficient to activate C-fibers, but not when A-fibers only were activated. Likewise, BSCB permeability increased following application of capsaicin to the nerve. The increase in permeability caused by C-fiber stimulation or by PNI was not anatomically limited to the site of central termination of primary afferents from the sciatic nerve in the lumbar cord, but rather extended throughout the spinal cord and into the brain. Conclusions: We have discovered that injury to a peripheral nerve and electrical stimulation of C-fibers each cause an increase in the permeability of the BSCB and the BBB. The increase in permeability is delayed in onset, peaks at about 24 hours and is dependent upon action potential propagation. As the increase is mimicked by applying capsaicin to the nerve, the most parsimonious explanation for our findings is that the increase in permeability is mediated by activation of TRPV1-expressing primary sensory neurons. Our findings may be relevant to the development of pain and neuroplastic changes in the CNS following nerve injury. In addition, our findings may provide the basis for developing methods to purposefully open the BBB when needed to increase brain penetration of therapeutic agents that might normally be excluded by an intact BBB.	[Salter, Michael W.] Univ Toronto, Hosp Sick Children, Dept Physiol, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; Univ Toronto, Ctr Study Pain, Toronto, ON, Canada	Salter, MW (corresponding author), Univ Toronto, Hosp Sick Children, Dept Physiol, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada.	mike.salter@utoronto.ca	Beggs, Simon/AAI-4438-2021	Beggs, Simon/0000-0002-1582-8391	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MT 11219]; Krembil Foundation; Ontario Neurotrauma Foundation; Jacob's Ladder	Supported by Canadian Institutes of Health Research (CIHR) grant MT 11219 to MWS as well as by the Krembil Foundation, the Ontario Neurotrauma Foundation and Jacob's Ladder. CK was the recipient of a CIHR Fellowship. MWS is an International Research Scholar of the Howard Hughes Medical Institute and holds a Canada Research Chair (Tier I) in Neuroplasticity and Pain.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Bayliss WM, 1901, J PHYSIOL-LONDON, V26, P173; Beggs S, 2008, NAT MED, V14, P243, DOI 10.1038/nm0308-243; Beggs S, 2010, CURR OPIN NEUROBIOL, V20, P474, DOI 10.1016/j.conb.2010.08.005; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; BRODIN E, 1987, NEUROSCI LETT, V76, P357, DOI 10.1016/0304-3940(87)90429-0; Cao L, 2008, EUR J IMMUNOL, V38, P448, DOI 10.1002/eji.200737485; Carmichael NME, 2008, NEUROSCIENCE, V153, P832, DOI 10.1016/j.neuroscience.2008.02.068; Carvey PM, 2009, J NEUROCHEM, V111, P291, DOI 10.1111/j.1471-4159.2009.06319.x; Costigan M, 2009, J NEUROSCI, V29, P14415, DOI 10.1523/JNEUROSCI.4569-09.2009; Dale H H, 1934, Science, V80, P450; Decosterd I, 2000, PAIN, V87, P149, DOI 10.1016/S0304-3959(00)00276-1; Gee MD, 1997, J PHYSIOL-LONDON, V503, P31, DOI 10.1111/j.1469-7793.1997.031bi.x; Gonzalez HL, 2005, J PAIN, V6, P681, DOI 10.1016/j.jpain.2005.06.004; Gordh T, 2006, PAIN, V124, P211, DOI 10.1016/j.pain.2006.05.020; Hathway GJ, 2009, PAIN, V144, P110, DOI 10.1016/j.pain.2009.03.022; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; JANCSO G, 1992, EXP PHYSIOL, V77, P405, DOI 10.1113/expphysiol.1992.sp003603; Jin R, 2010, NEUROBIOL DIS, V38, P376, DOI 10.1016/j.nbd.2010.03.008; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; KOLTZENBURG M, 1990, BRAIN RES, V509, P145, DOI 10.1016/0006-8993(90)90322-3; KWAN C, 11 WORLD C IASP 2008; Lewis T, 1926, Br Med J, V2, P61; LYNN B, 1988, NEUROSCIENCE, V24, P769, DOI 10.1016/0306-4522(88)90065-6; Nasu-Tada K, 2006, GLIA, V53, P769, DOI 10.1002/glia.20339; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Pitcher GM, 1999, PAIN, V83, P37, DOI 10.1016/S0304-3959(99)00085-8; Romanovsky AA, 2004, FRONT BIOSCI-LANDMRK, V9, P494, DOI 10.2741/1247; SZOLCSANYI J, 1988, AGENTS ACTIONS, V23, P4, DOI 10.1007/BF01967170; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Tsuda M, 2008, GLIA, V56, P579, DOI 10.1002/glia.20641; VILLAR MJ, 1989, NEUROSCIENCE, V33, P587, DOI 10.1016/0306-4522(89)90411-9; Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Zhang J, 2007, J NEUROSCI, V27, P12396, DOI 10.1523/JNEUROSCI.3016-07.2007	37	111	114	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1744-8069			MOL PAIN	Mol. Pain	NOV 2	2010	6								74	10.1186/1744-8069-6-74			11	Neurosciences	Neurosciences & Neurology	680VE	WOS:000284263200001	21044346	DOAJ Gold, Green Published			2021-06-18	
J	Homsi, S; Piaggio, T; Croci, N; Noble, F; Plotkine, M; Marchand-Leroux, C; Jafarian-Tehrani, M				Homsi, Shadi; Piaggio, Tomaso; Croci, Nicole; Noble, Florence; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz			Blockade of Acute Microglial Activation by Minocycline Promotes Neuroprotection and Reduces Locomotor Hyperactivity after Closed Head Injury in Mice: A Twelve-Week Follow-Up Study	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; locomotor hyperactivity; microglial activation; minocycline; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; AMYOTROPHIC-LATERAL-SCLEROSIS; FLUID PERCUSSION INJURY; EXCITATORY AMINO-ACIDS; AXONAL INJURY; CEREBRAL EDEMA; MODEL; NEUROTOXICITY; EXPRESSION	Traumatic brain injury (TBI) causes a wide spectrum of consequences, such as microglial activation, cerebral inflammation, and focal and diffuse brain injury, as well as functional impairment. In this study we aimed to investigate the effects of acute treatment with minocycline as an inhibitor of microglial activation on cerebral focal and diffuse lesions, and on the spontaneous locomotor activity following TBI. The weight-drop model was used to induce TBI in mice. Microglial activation and diffuse axonal injury (DAI) were detected by immunohistochemistry using CD11b and beta-amyloid precursor protein (beta-APP) immunolabeling, respectively. Focal injury was determined by the measurement of the brain lesion volume. Horizontal and vertical locomotor activities were measured for up to 12 weeks post-injury by an automated actimeter. Minocycline or vehicle were administered three times post-insult, at 5 min (90mg/kg i.p.), 3 h, and 9 h post-TBI (45 mg/kg i.p.). Minocycline treatment attenuated microglial activation by 59% and reduced brain lesion volume by 58%, yet it did not affect DAI at 24 h post-TBI. More interestingly, minocycline significantly decreased TBI-induced locomotor hyperactivity at 48 h post-TBI, and its effect lasted for up to 8 weeks. Taken together, the results indicate that microglial activation appears to play an important role in the development of TBI-induced focal injury and the subsequent locomotor hyperactivity, and its short-term inhibition provides long-lasting functional recovery after TBI. These findings emphasize the fact that minocycline could be a promising new therapeutic strategy for head-injured patients.	[Homsi, Shadi; Piaggio, Tomaso; Croci, Nicole; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz] Univ Paris 05, Lab Pharmacol Circulat Cerebrale, EA 2510, Fac Sci Pharmaceut & Biol, F-75006 Paris, France; [Noble, Florence] Univ Paris 05, Lab Neuropsychopharmacol Addict, Fac Sci Pharmaceut & Biol, INSERM,U705,CNRS,UMR 7157, F-75006 Paris, France	Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Lab Pharmacol Circulat Cerebrale, EA 2510, Fac Sci Pharmaceut & Biol, 4 Ave Observ, F-75006 Paris, France.	mehrnaz.jafarian@parisdescartes.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856; Noble, Florence/0000-0003-4497-0212			Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Boto GR, 2009, NEUROSURG REV, V32, P343, DOI 10.1007/s10143-008-0178-9; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Elewa HF, 2006, PHARMACOTHERAPY, V26, P515, DOI 10.1592/phco.26.4.515; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fei Z, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-96; Fujinaka T, 2003, NEUROL RES, V25, P35, DOI 10.1179/016164103101201094; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Goldstein Larry B, 2006, NeuroRx, V3, P451, DOI 10.1016/j.nurx.2006.07.010; Gonzalez JC, 2007, EUR J NEUROSCI, V26, P2481, DOI 10.1111/j.1460-9568.2007.05873.x; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kita T, 2000, INT J LEGAL MED, V113, P221, DOI 10.1007/s004149900095; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manev R, 2009, PROG NEURO-PSYCHOPH, V33, P166, DOI 10.1016/j.pnpbp.2008.11.004; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; Romero-Perez D, 2008, J AM COLL CARDIOL, V52, P1086, DOI 10.1016/j.jacc.2008.06.028; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.ne.17.030194.002421; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Thomale UW, 2007, IMMUNOBIOLOGY, V212, P567, DOI 10.1016/j.imbio.2007.01.007; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Viggiano D, 2008, BEHAV BRAIN RES, V194, P1, DOI 10.1016/j.bbr.2008.06.033; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zawadzka M, 2005, GLIA, V49, P36, DOI 10.1002/glia.20092; Zhang L, 2007, NEUROPSYCHOPHARMACOL, V32, P2004, DOI 10.1038/sj.npp.1301313; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	74	111	112	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					911	921		10.1089/neu.2009.1223			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400013	20166806				2021-06-18	
J	Chaichana, KL; Pradilla, G; Huang, J; Tamargo, RJ				Chaichana, Kaisorn L.; Pradilla, Gustavo; Huang, Judy; Tamargo, Rafael J.			Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage	WORLD NEUROSURGERY			English	Article						Endothelial cells; Haptoglobin; Hemoglobin; Inflammation; Leukocytes; Subarachnoid hemorrhage; Vasospasm	CEREBRAL-BLOOD-FLOW; INTERCELLULAR-ADHESION MOLECULE-1; CONTROLLED-RELEASE POLYMER; SERINE-PROTEASE INHIBITOR; NITRIC-OXIDE DONOR; C-REACTIVE PROTEIN; TRANSLUMINAL BALLOON ANGIOPLASTY; HAPTOGLOBIN-HEMOGLOBIN COMPLEX; FUNCTION-ASSOCIATED ANTIGEN-1; VEHICLE-CONTROLLED TRIAL	Background: Delayed vasospasm is the leading cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage (aSAH). This phenomenon was first described more than 50 years ago, but only recently has the role of inflammation in this condition become better understood. Methods: The literature was reviewed for studies on delayed vasospasm and inflammation. Results: There is increasing evidence that inflammation and, more specifically, leukocyte-endothelial cell interactions play a critical role in the pathogenesis of vasospasm after aSAH, as well as in other conditions including meningitis and traumatic brain injury. Although earlier clinical observations and indirect experimental evidence suggested an association between inflammation and chronic vasospasm, recently direct molecular evidence demonstrates the central role of leukocyte-endothelial cell interactions in the development of chronic vasospasm. This evidence shows in both clinical and experimental studies that cell adhesion molecules (CAMs) are up-regulated in the perivasospasm period. Moreover, the use of monoclonal antibodies against these CAMs, as well as drugs that decrease the expression of CAMs, decreases vasospasm in experimental studies. It also appears that certain individuals are genetically predisposed to a severe inflammatory response after aSAH based on their haptoglobin genotype, which in turn predisposes them to develop clinically symptomatic vasospasm. Conclusion: Based on this evidence, leukocyte-endothelial cell interactions appear to be the root cause of chronic vasospasm. This hypothesis predicts many surprising features of vasospasm and explains apparently unrelated phenomena observed in aSAH patients. Therapies aimed at preventing inflammation may prevent and/or reverse arterial narrowing in patients with aSAH and result in improved outcomes. (C) 2010 Elsevier Inc. All rights reserved.	[Chaichana, Kaisorn L.; Pradilla, Gustavo; Huang, Judy; Tamargo, Rafael J.] Johns Hopkins Univ, Sch Med, Div Cerebrovasc Neurosurg, Dept Neurosurg, Baltimore, MD 21205 USA	Tamargo, RJ (corresponding author), Johns Hopkins Univ Hosp, Dept Neurosurg, Baltimore, MD 21287 USA.	rtamarg@jhmi.edu		Huang, Judy/0000-0002-0675-1935			Agarwal N, 2007, ADV EXP MED BIOL, V618, P195; AGIL A, 1995, CLIN CHEM, V41, P220; Aihara Y, 2001, STROKE, V32, P212, DOI 10.1161/01.STR.32.1.212; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.me.38.020187.001135; Ascenzi P, 2005, IUBMB LIFE, V57, P749, DOI 10.1080/15216540500380871; Ascer E, 2004, ATHEROSCLEROSIS, V177, P161, DOI 10.1016/j.atherosclerosis.2004.07.003; Asleh R, 2005, CIRC RES, V96, P435, DOI 10.1161/01.RES.0000156653.05853.b9; Atkinson SH, 2007, CLIN INFECT DIS, V44, P802, DOI 10.1086/511868; Bavbek M, 1998, STROKE, V29, P1930, DOI 10.1161/01.STR.29.9.1930; Beijani GK, 1997, NEUROCHIRURGIE, V43, P164; Blum S, 2007, J AM COLL CARDIOL, V49, P82, DOI 10.1016/j.jacc.2006.08.044; Borsody M, 2006, NEUROLOGY, V66, P634, DOI 10.1212/01.wnl.0000200781.62172.1d; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; BOWMAN BH, 1982, ADV HUM GENET, V12, P453; Bowman G, 2004, NEUROSURGERY, V54, P719, DOI 10.1227/01.NEU.0000108981.73153.6E; Bowman G, 2006, NEUROCRIT CARE, V5, P222, DOI 10.1385/NCC:5:3:222; Bruder N, 1998, ANESTH ANALG, V86, P320, DOI 10.1097/00000539-199802000-00020; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CHAICHANA K, 2007, NEUROSURGERY, V60, pE207; Chaichana Kaisorn, 2007, Neurosurgery, V60, pE206, DOI 10.1227/01.NEU.0000249193.68904.B4; Chaichana KL, 2007, STROKE, V38, P3266, DOI 10.1161/STROKEAHA.107.490003; Chan JR, 2001, J EXP MED, V193, P1149, DOI 10.1084/jem.193.10.1149; CHAPELLE JP, 1982, NEW ENGL J MED, V307, P457, DOI 10.1056/NEJM198208193070801; Chello M, 2004, J CARDIOTHOR VASC AN, V18, P605, DOI 10.1053/j.jvca.2004.07.019; CHYATTE D, 1984, J NEUROSURG, V60, P923, DOI 10.3171/jns.1984.60.5.0923; CHYATTE D, 1987, NEUROSURGERY, V21, P157, DOI 10.1227/00006123-198708000-00004; CHYATTE D, 1989, STROKE, V20, P1021, DOI 10.1161/01.STR.20.8.1021; CHYATTE D, 1983, J NEUROSURG, V59, P925, DOI 10.3171/jns.1983.59.6.0925; Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677; Clatterbuck RE, 2003, J NEUROSURG, V99, P376, DOI 10.3171/jns.2003.99.2.0376; Clatterbuck RE, 2002, J NEUROSURG, V97, P676, DOI 10.3171/jns.2002.97.3.0676; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; COSENTINO F, 1993, J CARDIOVASC PHARM, V22, pS332, DOI 10.1097/00005344-199322008-00087; Costacou T, 2008, DIABETES, V57, P1702, DOI 10.2337/db08-0095; CROMPTON MR, 1964, BRAIN, V87, P491, DOI 10.1093/brain/87.3.491; Cuzzocrea S, 2005, PHARMACOL RES, V52, P72, DOI 10.1016/j.phrs.2005.02.016; DAHLQVIST SR, 1985, HUM HERED, V35, P207; DAHLQVIST SR, 1988, HUM HERED, V38, P44; Datta PK, 2006, BIOMED PHARMACOTHER, V60, P561, DOI 10.1016/j.biopha.2006.07.087; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Dietrich HH, 2000, NEUROSURGERY, V46, P517, DOI 10.1097/00006123-200003000-00001; Doering TJ, 1996, AM J PHYS MED REHAB, V75, P408, DOI 10.1097/00002060-199611000-00002; Doo YC, 2005, CLIN CARDIOL, V28, P72, DOI 10.1002/clc.4960280206; DORSCH NWC, 1995, BRIT J NEUROSURG, V9, P403, DOI 10.1080/02688699550041403; DULKERIAN SJ, 1995, J PEDIATR-US, V126, P872, DOI 10.1016/S0022-3476(95)70199-0; ECKER A, 1951, J NEUROSURG, V8, P660, DOI 10.3171/jns.1951.8.6.0660; EDWARDS DH, 1992, J NEUROSURG, V76, P830, DOI 10.3171/jns.1992.76.5.0830; EDWARDS DH, 1986, CARDIOVASC RES, V20, P549, DOI 10.1093/cvr/20.8.549; EGEMEN N, 1993, NEUROL RES, V15, P310; Egge A, 2001, NEUROSURGERY, V49, P593, DOI 10.1097/00006123-200109000-00012; el Hendawy M, 2000, Neurol Neurochir Pol, V34, P114; Elenkov IJ, 2004, ANN NY ACAD SCI, V1024, P138, DOI 10.1196/annals.1321.010; Elnoamany MF, 2007, J AM SOC ECHOCARDIOG, V20, P462, DOI 10.1016/j.echo.2006.10.003; ENDO A, 1992, J LIPID RES, V33, P1569; Fassbender K, 1996, J NEUROL NEUROSUR PS, V61, P57, DOI 10.1136/jnnp.61.1.57; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; FASSBENDER K, 1997, J NEUROIMMUNOL; Feigin VL, 1998, NEUROLOGY, V50, P876, DOI 10.1212/WNL.50.4.876; FERRIS EJ, 1968, RADIOLOGY, V90, P727, DOI 10.1148/90.4.727; Filer Andrew, 2007, Discov Med, V7, P20; FINDLAY JM, 1995, NEUROSURGERY, V37, P168, DOI 10.1227/00006123-199507000-00041; Fisher C M, 1977, Neurosurgery, V1, P245; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Florey H, 1925, BRAIN, V48, P43, DOI 10.1093/brain/48.1.43; Frazier JL, 2004, J NEUROSURG, V101, P93, DOI 10.3171/jns.2004.101.1.0093; Gabikian P, 2002, STROKE, V33, P2681, DOI 10.1161/01.STR.0000033931.62992.B1; Gaetani P, 1998, NEUROL RES, V20, P337, DOI 10.1080/01616412.1998.11740528; Gallia GL, 2006, NEUROL RES, V28, P750, DOI 10.1179/016164106X152025; German JW, 1996, NEUROSURGERY, V39, P141, DOI 10.1097/00006123-199607000-00028; GIBLETT E R, 1963, J Forensic Sci, V8, P446; Green G A, 2001, Clin Cornerstone, V3, P50, DOI 10.1016/S1098-3597(01)90069-9; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; GULL W, 1859, GUYS HOSP REP, V5, P281; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; Haley EC, 1997, J NEUROSURG, V86, P467, DOI 10.3171/jns.1997.86.3.0467; HALEY EC, 1994, J NEUROSURG, V80, P788, DOI 10.3171/jns.1994.80.5.0788; HAMANN G, 1993, STROKE, V24, P383, DOI 10.1161/01.STR.24.3.383; HANDA Y, 1991, NEUROSURGERY, V28, P542, DOI 10.1227/00006123-199104000-00010; HANDA Y, 1995, ACTA NEUROCHIR, V132, P92, DOI 10.1007/BF01404854; HANDA Y, 1991, NEUROSURGERY, V28, P380, DOI 10.1227/00006123-199103000-00007; HASHI K, 1988, Brain and Nerve (Tokyo), V40, P373; Hendryk S, 2004, NEUROENDOCRINOL LETT, V25, P141; Henker R, 2007, AACN ADV CRIT CARE, V18, P76, DOI 10.1097/01256961-200701000-00010; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; Hino A, 1996, J CEREBR BLOOD F MET, V16, P688, DOI 10.1097/00004647-199607000-00020; Hofbauer R, 1999, LIFE SCI, V65, P2453, DOI 10.1016/S0024-3205(99)00511-1; Hoh BL, 2005, NEUROSURG CLIN N AM, V16, P501, DOI 10.1016/j.nec.2005.04.004; HOOPER DC, 1981, BIOCHIM BIOPHYS ACTA, V653, P118, DOI 10.1016/0005-2787(81)90110-6; HOSHI T, 1984, Neurologia Medico-Chirurgica, V24, P647, DOI 10.2176/nmc.24.647; Huang J, 2000, STROKE, V31, P3047, DOI 10.1161/01.STR.31.12.3047; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; HUGHES JT, 1978, J NEUROSURG, V48, P515, DOI 10.3171/jns.1978.48.4.0515; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JACKSON IJ, 1949, ARCH NEURO PSYCHIATR, V62, P572, DOI 10.1001/archneurpsyc.1949.02310170047004; Jaffar Z, 2007, J IMMUNOL, V179, P6193, DOI 10.4049/jimmunol.179.9.6193; JAVID J, 1965, VOX SANG, V10, P320, DOI 10.1111/j.1423-0410.1965.tb01396.x; Jost SC, 2005, J NEUROSURG, V103, P25, DOI 10.3171/jns.2005.103.1.0025; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kaminogo M, 1998, NEUROL MED-CHIR, V38, P704, DOI 10.2176/nmc.38.704; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kapiotis S, 1996, LIFE SCI, V58, P2167, DOI 10.1016/0024-3205(96)00210-X; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KASSELL NF, 1992, J NEUROSURG, V77, P848, DOI 10.3171/jns.1992.77.6.0848; KASSELL NF, 1990, J NEUROSURG, V73, P37, DOI 10.3171/jns.1990.73.1.0037; Kasuya H, 2005, NEUROSURGERY, V56, P895; KASUYA H, 1989, J NEUROSURG, V71, P741, DOI 10.3171/jns.1989.71.5.0741; Kaynar MY, 2004, J NEUROSURG, V101, P1030, DOI 10.3171/jns.2004.101.6.1030; Keyrouz SG, 2007, CRIT CARE, V11, DOI 10.1186/cc5958; KINO K, 1980, J BIOL CHEM, V255, P9616; KINO K, 1987, J HISTOCHEM CYTOCHEM, V35, P381, DOI 10.1177/35.3.3546486; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; Kinouchi H, 2004, NEUROL MED-CHIR, V44, P569, DOI 10.2176/nmc.44.569; Klimo P, 2004, J NEUROSURG, V100, P215, DOI 10.3171/jns.2004.100.2.0215; Koh KK, 2004, INT J CARDIOL, V95, P185, DOI 10.1016/j.ijcard.2003.05.018; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOHLER W, 1978, NATURE, V271, P373, DOI 10.1038/271373a0; Kordestani RK, 1997, NEUROSURGERY, V41, P351, DOI 10.1097/00006123-199708000-00003; Kramer AH, 2008, NEUROSURGERY, V62, P422, DOI 10.1227/01.neu.0000316009.19012.e3; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Lange V, 1992, Anthropol Anz, V50, P281; Langlois MR, 1996, CLIN CHEM, V42, P1589; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; Lennihan L, 2000, STROKE, V31, P383, DOI 10.1161/01.STR.31.2.383; Levy AP, 2007, ARTERIOSCL THROM VAS, V27, P134, DOI 10.1161/01.ATV.0000251020.24399.a2; Levy AP, 2003, ACTA DIABETOL, V40, pS330, DOI 10.1007/s00592-003-0114-y; LEY K, 1991, BLOOD, V77, P2553; Lin CL, 2005, SURG NEUROL, V64, P201, DOI 10.1016/j.surneu.2005.04.038; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; Mack WJ, 2007, NEUROSURGERY, V61, P255, DOI 10.1227/01.NEU.0000255518.96837.8E; Mack WJ, 2002, J NEUROSURG, V96, P71, DOI 10.3171/jns.2002.96.1.0071; Maiuri F, 1987, J Neurosurg Sci, V31, P45; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Manno EM, 1997, NEUROSURGERY, V40, P289, DOI 10.1097/00006123-199702000-00010; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Mascia L, 2001, STROKE, V32, P1185, DOI 10.1161/01.STR.32.5.1185; MATSUMURA Y, 1991, LIFE SCI, V49, P841, DOI 10.1016/0024-3205(91)90249-B; MCCORMICK DJ, 1990, J PROTEIN CHEM, V9, P735, DOI 10.1007/BF01024768; McGirt MJ, 2003, J NEUROSURG, V98, P1222, DOI 10.3171/jns.2003.98.6.1222; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; Melamed-Frank M, 2001, BLOOD, V98, P3693, DOI 10.1182/blood.V98.13.3693; Mocco J, 2002, J NEUROSURG, V97, P537, DOI 10.3171/jns.2002.97.3.0537; Moestrup SK, 2004, ANN MED, V36, P347, DOI 10.1080/07853890410033171; MORI T, 1995, NEUROPATH APPL NEURO, V21, P378, DOI 10.1111/j.1365-2990.1995.tb01074.x; MORI T, 1994, J VET MED SCI, V56, P535, DOI 10.1292/jvms.56.535; MORI T, 1993, J VET MED SCI, V55, P581, DOI 10.1292/jvms.55.581; Muizelaar JP, 1999, J NEUROSURG, V91, P51, DOI 10.3171/jns.1999.91.1.0051; Mukai AO, 2006, PEDIATR NEUROL, V34, P25, DOI 10.1016/j.pediatrneurol.2005.06.003; Nagata K, 1996, SURG NEUROL, V45, P442, DOI 10.1016/0090-3019(95)00455-6; NAGATA K, 1993, J NEUROSURG, V79, P710, DOI 10.3171/jns.1993.79.5.0710; Nam DH, 2001, NEUROSCI LETT, V312, P41, DOI 10.1016/S0304-3940(01)02194-2; NEILDWYER G, 1974, BRAIN, V97, P79, DOI 10.1093/brain/97.1.79; Niikawa S, 1998, NEUROL MED-CHIR, V38, P844, DOI 10.2176/nmc.38.844; Niikawa Shuji, 1997, Neurologia Medico-Chirurgica, V37, P881, DOI 10.2176/nmc.37.881; Nishizawa S, 2005, TRENDS CARDIOVAS MED, V15, P24, DOI 10.1016/j.tcm.2004.12.002; Nishizawa S, 2000, ACTA NEUROCHIR, V142, P1409, DOI 10.1007/s007010070013; NISHIZAWA S, 1993, NEUROSURGERY, V32, P986, DOI 10.1227/00006123-199306000-00018; Nissen JJ, 2000, ACT NEUR S, V76, P55; Nissen JJ, 2001, J NEUROL NEUROSUR PS, V71, P329, DOI 10.1136/jnnp.71.3.329; Nissim A., 2008, V181, P3; O'Shea JJ, 2008, IMMUNITY, V28, P477, DOI 10.1016/j.immuni.2008.03.002; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Oshiro EM, 1997, STROKE, V28, P2031, DOI 10.1161/01.STR.28.10.2031; OSTERGAARD JR, 1987, J NEUROSURG, V66, P891, DOI 10.3171/jns.1987.66.6.0891; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Parra A, 2005, NEUROSURGERY, V56, P476, DOI 10.1227/01.NEU.0000153925.96889.8A; PELLETTIERI L, 1981, EXPERIENTIA, V37, P1170, DOI 10.1007/BF01989900; PELLETTIERI L, 1986, NEUROSURGERY, V19, P767, DOI 10.1227/00006123-198611000-00008; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; PETERSON JW, 1990, STROKE, V21, P133, DOI 10.1161/01.STR.21.1.133; PETERSON JW, 1990, J NEUROSURG, V72, P767, DOI 10.3171/jns.1990.72.5.0767; PFISTER HW, 1992, NEUROLOGY, V42, P1497, DOI 10.1212/WNL.42.8.1497; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; PIMSTONE NR, 1971, J EXP MED, V133, P1264, DOI 10.1084/jem.133.6.1264; Pluta RM, 2005, JAMA-J AM MED ASSOC, V293, P1477, DOI 10.1001/jama.293.12.1477; Pluta RM, 1997, J NEUROSURG, V87, P287, DOI 10.3171/jns.1997.87.2.0287; Pluta RM, 1997, J NEUROSURG, V87, P746, DOI 10.3171/jns.1997.87.5.0746; Pluta RM, 2005, PHARMACOL THERAPEUT, V105, P23, DOI 10.1016/j.pharmthera.2004.10.002; Pluta RM, 2006, NEUROL RES, V28, P730, DOI 10.1179/016164106X152052; Polin RS, 1998, J NEUROSURG, V89, P559, DOI 10.3171/jns.1998.89.4.0559; Polin RS, 1998, NEUROSURGERY, V42, P1256, DOI 10.1097/00006123-199806000-00031; Pozzesi N, 2007, J CHEMOTHERAPY, V19, P562, DOI 10.1179/joc.2007.19.5.562; Pradilla G, 2005, NEUROSURGERY, V57, P184, DOI 10.1227/01.NEU.0000163604.52273.28; Pradilla G, 2004, NEUROSURGERY, V55, P1393, DOI 10.1227/01.NEU.0000143615.26102.1A; Pradilla G, 2004, J NEUROSURG, V101, P88, DOI 10.3171/jns.2004.101.1.0088; Pritchard DI, 2005, DRUG DISCOV TODAY, V10, P688, DOI 10.1016/S1359-6446(05)03395-7; Qureshi AI, 2000, CRIT CARE MED, V28, P984, DOI 10.1097/00003246-200004000-00012; Recinos PF, 2006, SURG NEUROL, V66, P463, DOI 10.1016/j.surneu.2006.04.010; Rezaie-Majd A, 2003, ARTERIOSCL THROM VAS, V23, P397, DOI 10.1161/01.ATV.0000059384.34874.F0; Ries S, 1997, J NEUROL, V244, P51; Rinkel GJ, 2004, COCHRANE DB SYST REV; Rittig MG, 2003, J LEUKOCYTE BIOL, V74, P1045, DOI 10.1189/jlb.0103015; Rittner Heike L, 2007, Curr Rheumatol Rep, V9, P503, DOI 10.1007/s11926-007-0081-3; ROBERTSON EG, 1949, BRAIN, V72, P150, DOI 10.1093/brain/72.2.150; Rosen S D, 1993, Semin Immunol, V5, P237, DOI 10.1006/smim.1993.1028; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Rothoerl RD, 2006, J NEUROSURG ANESTH, V18, P68, DOI 10.1097/01.ana.0000181693.30750.af; ROUSSEAUX P, 1980, SURG NEUROL, V14, P459; Rowe BH, 2008, CAN RESPIR J, V15, P20, DOI 10.1155/2008/431390; RYBA M, 1993, ACTA NEUROCHIR, V122, P194, DOI 10.1007/BF01405528; RYBA M, 1992, ACTA NEUROCHIR, V117, P34, DOI 10.1007/BF01400632; RYBA M, 1991, ACTA NEUROCHIR, V112, P25, DOI 10.1007/BF01402450; RYBA M, 1991, STROKE, V22, P531, DOI 10.1161/str.22.4.531a; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; Saeed SA, 2007, BIOCHEM BIOPH RES CO, V353, P915, DOI 10.1016/j.bbrc.2006.12.092; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V175, P44, DOI 10.1016/S0006-291X(05)81197-0; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; Satoh M, 2001, STROKE, V32, P225, DOI 10.1161/01.STR.32.1.225; Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051; Schoch B, 2007, NEUROSURGERY, V60, P828, DOI 10.1227/01.NEU.0000255440.21495.80; SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Sethi S, 2001, NITRIC OXIDE-BIOL CH, V5, P482, DOI 10.1006/niox.2001.0375; SHIMIZU T, 1982, Neurologia Medico-Chirurgica, V22, P613, DOI 10.2176/nmc.22.613; SHINYAMA H, 1991, BIOCHEM BIOPH RES CO, V178, P24, DOI 10.1016/0006-291X(91)91774-7; Shor M, 2007, AM J CARDIOL, V100, P1767, DOI 10.1016/j.amjcard.2007.07.052; Shreenivas S, 2007, CLIN HEMORHEOL MICRO, V37, P157; Sills AK, 1997, NEUROSURGERY, V41, P453, DOI 10.1097/00006123-199708000-00025; SMITHIES O, 1955, BIOCHEM J, V61, P629, DOI 10.1042/bj0610629; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; SPALLONE A, 1987, SURG NEUROL, V27, P253, DOI 10.1016/0090-3019(87)90038-3; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; Suarez JI, 2004, J NEUROSURG, V100, P585, DOI 10.3171/jns.2004.100.4.0585; SUZUKI SC, 2008, DEV GROWTH DIFFER; Takemae T, 1978, No To Shinkei, V30, P861; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Thai QA, 1999, STROKE, V30, P140, DOI 10.1161/01.STR.30.1.140; Tseng MY, 2007, STROKE, V38, P1545, DOI 10.1161/STROKEAHA.106.475905; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Ursino M, 1998, J NEUROSURG, V89, P255, DOI 10.3171/jns.1998.89.2.0255; Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009; Vajkoczy P, 2001, STROKE, V32, P498, DOI 10.1161/01.STR.32.2.498; Van Vlierberghe H, 2004, CLIN CHIM ACTA, V345, P35, DOI 10.1016/j.cccn.2004.03.016; VANDEUREN M, 1995, J INFECT DIS, V172, P433, DOI 10.1093/infdis/172.2.433; WALTON J N, 1955, Can Med Assoc J, V72, P165; Wang Yong, 2007, Neurosci Bull, V23, P151, DOI 10.1007/s12264-007-0022-1; Watanabe M, 2007, J ATHEROSCLER THROMB, V14, P325, DOI 10.5551/jat.E489; Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735-1097(97)00324-0; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; WEIR B, 1989, NEUROSURGERY, V25, P161, DOI 10.1227/00006123-198908000-00002; WEJMAN JC, 1984, J MOL BIOL, V174, P343, DOI 10.1016/0022-2836(84)90342-5; WEJMAN JC, 1984, J MOL BIOL, V174, P319, DOI 10.1016/0022-2836(84)90341-3; Weyerbrock A, 2003, J NEUROSURG, V99, P728, DOI 10.3171/jns.2003.99.4.0728; WHITE RP, 1983, NEUROSURGERY, V12, P40, DOI 10.1227/00006123-198301000-00008; Woodside DG, 2008, BIODRUGS, V22, P85, DOI 10.2165/00063030-200822020-00002; YAMASHIMA T, 1985, NEUROSURGERY, V16, P546, DOI 10.1227/00006123-198504000-00018; YAMASHIMA T, 1986, J NEUROL, V233, P348, DOI 10.1007/BF00313921; YAMAURA I, 1992, J NEUROSURG, V76, P99, DOI 10.3171/jns.1992.76.1.0099; YANAMOTO H, 1992, NEUROSURGERY, V30, P351, DOI 10.1227/00006123-199203000-00007; YANAMOTO H, 1994, SURG NEUROL, V42, P374, DOI 10.1016/0090-3019(94)90339-5; YANAMOTO H, 1992, NEUROSURGERY, V30, P358, DOI 10.1227/00006123-199203000-00008; YANAMOTO H, 1992, NEUROSURGERY, V30, P356; Yatsushige H, 2005, STROKE, V36, P1538, DOI 10.1161/01.STR.0000170713.22011.c8; Zhou CM, 2004, J CEREBR BLOOD F MET, V24, P419, DOI 10.1097/00004647-200404000-00007; Zubkov AY, 2000, STROKE, V31, P526, DOI 10.1161/01.STR.31.2.526; Zubkov ZY, 2000, SURG NEUROL, V53, P126; Zuccarello M, 1998, STROKE, V29, P1924, DOI 10.1161/01.STR.29.9.1924; Zucker MB, 1944, AM J PHYSIOL, V142, P12; 정진환, 2005, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V38, P1	272	111	112	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2010	73	1					22	41		10.1016/j.surneu.2009.05.027			20	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	790YE	WOS:000292625900005	20452866				2021-06-18	
J	McKinlay, A; Grace, R; Horwood, J; Fergusson, D; MacFarlane, M				McKinlay, Audrey; Grace, Randolph; Horwood, John; Fergusson, David; MacFarlane, Martin			Adolescent Psychiatric Symptoms Following Preschool Childhood Mild Traumatic Brain Injury: Evidence From a Birth Cohort	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						birth cohort; children; longitudinal; mild traumatic brain injury; psychiatric disorders	CLOSED-HEAD-INJURY; PSYCHOSOCIAL OUTCOMES; PERSONALITY-CHANGE; CHILDREN; PREVALENCE; DISORDERS; MEMORY; PREDICTORS; SEQUELAE; ADULTS	Objective: To determine whether childhood mild traumatic brain injury (MTBI) is associated with behavioral problems in adolescence. Participants: Children from a longitudinal birth cohort (initial N = 1265) were assigned to 1 of 3 groups: (1) inpatient group (n = 19) comprised children admitted to hospital for MTBI before age 5 years; (2) outpatient group (n = 57), children with any incidence of MTBI before age 5 seen by a general practitioner or at ail accident and emergency department and sent home; (3) reference control group (n = 839). Outcome measures: Maternal and self-report regarding attention deficit/hyperactivity disorder, conduct disorder, anxiety disorder, mood disorder, and alcohol or illicit substance abuse/dependence obtained using Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria. Results: At age 14 to 16 years, children who had been hospitalized for MTBI during preschool years were significantly more likely to show symptoms of attention deficit/hyperactivity disorder (odds ratio = 4.2), conduct disorder/oppositional defiant disorder (odds ratio = 6.2), substance abuse (odds ratio = 3.6), and mood disorder (odds ratio = 3.1) but not anxiety disorder. Conclusions: Preschool MTBI is associated with persistent negative effects on psychosocial development. These continuing problems are consistent with the view that preschool years represent a period of particular vulnerability following MTBI.	[McKinlay, Audrey; Grace, Randolph] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; [Horwood, John; Fergusson, David] Univ Otago, Christchurch Hlth & Dev Study, Christchurch, New Zealand; [MacFarlane, Martin] Christchurch Hosp, Dept Neurosurg, Christchurch, New Zealand	McKinlay, A (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	audrey.mckinlay@canterbury.ac.nz		Horwood, L./0000-0003-4881-1956; Fergusson, David/0000-0002-8117-017X; Grace, Randolph/0000-0003-1115-6089; McKinlay, Audrey/0000-0001-9846-8514	Health Research Council of New ZealandHealth Research Council of New Zealand; National Child Health Research Foundation; Canterbury Medical Research Foundation; New Zealand Lottery; Neurological Foundation of New Zealand; New Zealand Foundation for Research Science and TechnologyNew Zealand Foundation for Research, Science and Technology; Todd Foundation	The Christchurch Health and Development Study has been funded by grants from the Health Research Council of New Zealand, the National Child Health Research Foundation, the Canterbury Medical Research Foundation, and the New Zealand Lottery, Grants Board. This research was funded by a grant from the Neurological Foundation of New Zealand. Andrew McKinley was sponsored v a scholarship from the New Zealand Foundation for Research Science and Technology, a Todd Foundation award for research excellence.	Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; CASEY R, 1986, PEDIATRICS, V78, P497; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Costello A., 1982, DIAGNOSTIC INTERVIEW; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P295; Fergusson DM, 1998, J EMOT BEHAV DISORD, V6, P2, DOI 10.1177/106342669800600101; FERGUSSON DM, 1993, J AM ACAD CHILD PSY, V32, P1127, DOI 10.1097/00004583-199311000-00004; Fergusson DM, 2001, AUST NZ J PSYCHIAT, V35, P287, DOI 10.1046/j.1440-1614.2001.00902.x; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; MATTSON AJ, 1990, J CLIN EXP NEUROPSYC, V12, P104; Max JE, 1998, BRAIN INJURY, V12, P31; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1998, BRAIN INJURY, V12, P41; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MOFFITT TE, 1988, AUST NZ J CRIMINOL, V21, P227, DOI 10.1177/000486588802100405; Overweg-Plandsoen WCG, 1999, EUR J PEDIATR, V158, P249, DOI 10.1007/s004310051061; Peterson D. R., 1987, MANUAL REVISED BEHAV; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WHITE HR, 1989, J STUD ALCOHOL, V50, P30, DOI 10.15288/jsa.1989.50.30; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	52	111	111	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2009	24	3					221	227		10.1097/HTR.0b013e3181a40590			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	448HD	WOS:000266252800008	19461369				2021-06-18	
J	Chen, SF; Hsu, CW; Huang, WH; Wang, JY				Chen, S-F; Hsu, C-W; Huang, W-H; Wang, J-Y			Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						baicalein; inflammation; tumour necrosis factor-alpha; interleukin-1 beta; interleukin-6; cytokines; traumatic brain injury	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; FACTOR-ALPHA; TNF-ALPHA; CEREBROSPINAL-FLUID; CEREBRAL-ISCHEMIA; OXIDATIVE-STRESS; RAT-BRAIN; ENDOTHELIAL-CELL; GLIOMA-CELLS	Background and purpose: Traumatic brain injury (TBI) triggers a complex series of inflammatory responses that contribute to secondary tissue damage. The aim of this study was to investigate the effect of baicalein, a flavonoid possessing potent anti-inflammatory properties, on functional and histological outcomes and inflammatory cytokine expression, following TBI in rats. Experimental approach: Rats subjected to controlled cortical impact injury were injected with baicalein (30 mg kg(-1)) or vehicle immediately after injury or daily for 4 days. Neurological status was evaluated using the rotarod, adhesive removal, modified neurological severity scores and beam walk tests. Contusion volume and neuronal degeneration were measured using cresyl violet and FluoroJade B (FJB) histochemistry. Levels of tumour necrosis factor-beta (TNF-beta), interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) mRNA and protein were assessed by real-time quantitative reverse transcriptase-PCR, enzyme-linked immunosorbent assay and immunohistochemistry. Key results: Single-dose and multiple-dose treatment with baicalein significantly improved functional recovery and reduced contusion volumes up to day 28 post-injury, although multiple-dose baicalein was the more effective treatment. Single-dose baicalein also significantly reduced the number of degenerating neurons (31%) on post-injury day 1 as indicated by FJB staining. These changes were associated with significantly decreased levels, at the contusion site, of TNF-alpha, IL-1 beta and IL-6 mRNA at 6 h, and cytokine protein on day 1 post-injury. Conclusions and implications: Post-injury treatment with baicalein improved functional and histological outcomes and reduced induction of proinflammatory cytokines in rat TBI. The neuroprotective effect of baicalein may be related to a decreased inflammatory response following the injury.	[Hsu, C-W; Wang, J-Y] Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan; [Chen, S-F] Cheng Hsin Rehabil Med Ctr, Dept Phys Med & Rehabil, Taipei, Taiwan; [Huang, W-H] Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan	Wang, JY (corresponding author), Natl Def Med Ctr, Dept Physiol, 161 Sec 6,Ming Chuan E Rd, Taipei, Taiwan.	jywang@ndmctsgh.edu.tw	Chen, Szu-Fu/K-5040-2012	Wang, Jia-Yi/0000-0002-9106-3351	National Science Council of Taiwan, Republic of ChinaMinistry of Science and Technology, Taiwan [NSC 94-2314-B-350-001]; National Defense Medical Center [DOD94-02-14, DOD 95-02-18]; Cheng Hsin General Hospital	We thank Mr Kuei-Han Lin and Mr Jay-How Yang for their expert technical assistance in the experiments. This study was supported in part by grants from the National Science Council of Taiwan, Republic of China. (NSC 94-2314-B-350-001), National Defense Medical Center (DOD94-02-14 and DOD 95-02-18) and the Cheng Hsin General Hospital.	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chen YC, 2006, TOXICOL APPL PHARM, V216, P263, DOI 10.1016/j.taap.2006.05.008; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao ZH, 2001, PHARMACOL RES, V43, P173, DOI 10.1006/phrs.2000.0761; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; HAMADA H, 1993, ARCH BIOCHEM BIOPHYS, V306, P261, DOI 10.1006/abbi.1993.1509; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hong T, 2002, PLANTA MED, V68, P268, DOI 10.1055/s-2002-23143; Huang WH, 2006, BIOSCI BIOTECH BIOCH, V70, P2371, DOI 10.1271/bbb.50698; Huang WH, 2003, CHEM PHARM BULL, V51, P339; Hunter AJ, 1998, TRENDS PHARMACOL SCI, V19, P59, DOI 10.1016/S0165-6147(97)01157-7; Hwang YS, 2002, LIFE SCI, V71, P2105, DOI 10.1016/S0024-3205(02)01920-3; Im HI, 2005, J PHARMACOL SCI, V98, P185, DOI 10.1254/jphs.SC0050014; Ishige K, 2001, FREE RADICAL BIO MED, V30, P433, DOI 10.1016/S0891-5849(00)00498-6; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kimura Y, 2001, PLANTA MED, V67, P331, DOI 10.1055/s-2001-14328; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Lapchak PA, 2007, NEUROSCIENCE, V150, P585, DOI 10.1016/j.neuroscience.2007.09.033; LASTER SM, 1988, J IMMUNOL, V141, P2629; Li FQ, 2005, J NEURAL TRANSM, V112, P331, DOI 10.1007/s00702-004-0213-0; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nakahata N, 1998, AM J CHINESE MED, V26, P311, DOI 10.1142/S0192415X9800035X; Nakayama T., 2003, MONOGRAPHS MARINE MO, V6, P1; Phillis John W., 2003, Critical Reviews in Neurobiology, V15, P61, DOI 10.1615/CritRevNeurobiol.v15.i1.30; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shen YC, 2003, EUR J PHARMACOL, V465, P171, DOI 10.1016/S0014-2999(03)01378-5; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Suk K, 2003, J PHARMACOL EXP THER, V305, P638, DOI 10.1124/jpet.102.047373; TANNO Y, 1988, AM J CHINESE MED, V16, P145, DOI 10.1142/S0192415X88000212; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Tsai TH, 2002, BRIT J PHARMACOL, V137, P1314, DOI 10.1038/sj.bjp.0704959; van Leyen K, 2006, STROKE, V37, P3014, DOI 10.1161/01.STR.0000249004.25444.a5; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wen LL, 2007, EXP NEUROL, V205, P270, DOI 10.1016/j.expneurol.2007.02.011; Woo KJ, 2006, IMMUNOBIOLOGY, V211, P359, DOI 10.1016/j.imbio.2006.02.002; Wu PH, 2006, TOXICOLOGY, V226, P238, DOI 10.1016/j.tox.2006.06.015	64	111	117	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	DEC	2008	155	8					1279	1296		10.1038/bjp.2008.345			18	Pharmacology & Pharmacy	Pharmacology & Pharmacy	380YF	WOS:000261501300016	18776918	Green Published			2021-06-18	
J	Hauser, WA; Beghi, E				Hauser, W. Allen; Beghi, Ettore			First seizure definitions and worldwide incidence and mortality	EPILEPSIA			English	Article						first seizure; definition; incidence; mortality	SHORT-TERM MORTALITY; UNPROVOKED SEIZURES; EPILEPTIC SEIZURES; RISK; RECURRENCE; ROCHESTER; PREVALENCE; DISORDERS; MINNESOTA; EPISODE	While all patients with epilepsy experience seizures, not all individuals with seizures have epilepsy. Seizures may be acute symptomatic or unprovoked. Acute symptomatic seizures are seizures occurring at the time of a systemic insult or in close temporal association with a documented brain insult. Unprovoked seizures are seizures occurring in the absence of precipitating factors and may be caused by a static injury (remote symptomatic seizures) or a progressing injury (progressive symptomatic seizures). Unprovoked seizures may be single or recurrent (epilepsy). The incidence of acute symptomatic seizures is 29-39 per 100,000 per year. These predominate in men, in the youngest age class, and in the elderly. Traumatic brain injury, cerebrovascular disease, drug withdrawal, infarction, and metabolic insults are the commonest causes. The incidence of single unprovoked seizures is 23-61 per 100,000 person-years. As with epilepsy, single unprovoked seizures predominate in men and in patients less than 12 months and older than 65 years. Studies on the mortality of acute symptomatic seizures are lacking. A standardized mortality ratio (SMR) of 2.3 has been reported in patients experiencing a single unprovoked seizure. The SMR in patients with a newly diagnosed unprovoked seizure ranges from 2.5 to 4.1 according to the study population and design. The SMR is highest in the youngest patients and in those with symptomatic seizures.	[Beghi, Ettore] Mario Negri Inst Pharmacol Res, Lab Neurol Disorders, I-20157 Milan, Italy; [Hauser, W. Allen] Columbia Univ, Sergievsky Ctr, New York, NY USA; [Beghi, Ettore] Univ Milano Bicocca, Epilepsy Ctr, Monza, Italy	Beghi, E (corresponding author), Mario Negri Inst Pharmacol Res, Lab Neurol Disorders, Via Eritrea 62, I-20157 Milan, Italy.	beghi@marionegri.it	Beghi, Ettore/AAA-7426-2020; Hauser, W Allen/AAB-5277-2020	Beghi, Ettore/0000-0003-2542-0469; 			ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1993, EPILEPSIA, V34, P592; Beghi E, 2005, EPILEPSIA, V46, P40, DOI 10.1111/j.1528-1167.2005.00407.x; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; Forsgren L, 1996, EPILEPSIA, V37, P224, DOI 10.1111/j.1528-1157.1996.tb00017.x; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; Hauser WA, 1996, MAYO CLIN PROC, V71, P576, DOI 10.4065/71.6.576; Hauser WA, 1998, NEW ENGL J MED, V338, P429, DOI 10.1056/NEJM199802123380704; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; Hesdorffer DC, 2005, EPILEPSIA, V46, P43, DOI 10.1111/j.1528-1167.2005.00408.x; Hesdorffer DC, 1998, ANN NEUROL, V44, P908, DOI 10.1002/ana.410440609; Jallon P, 1997, EPILEPSIA, V38, P547, DOI 10.1111/j.1528-1157.1997.tb01139.x; Lindsten H, 2000, EPILEPSIA, V41, P1469, DOI 10.1111/j.1528-1157.2000.tb00124.x; Logroscino G, 2002, NEUROLOGY, V58, P537, DOI 10.1212/WNL.58.4.537; Logroscino G, 1997, EPILEPSIA, V38, P1344, DOI 10.1111/j.1528-1157.1997.tb00073.x; LOISEAU J, 1990, EPILEPSIA, V31, P391, DOI 10.1111/j.1528-1157.1990.tb05493.x; Loiseau J, 1999, EPILEPSIA, V40, P1388, DOI 10.1111/j.1528-1157.1999.tb02010.x; LUHDORF K, 1986, EPILEPSIA, V27, P135, DOI 10.1111/j.1528-1157.1986.tb03516.x; MacDonald BK, 2000, BRAIN, V123, P665, DOI 10.1093/brain/123.4.665; Olafsson E, 2005, LANCET NEUROL, V4, P627, DOI 10.1016/S1474-4422(05)70172-1; Olafsson E, 1998, EPILEPSIA, V39, P89, DOI 10.1111/j.1528-1157.1998.tb01279.x; Pal DK, 2000, J NEUROL NEUROSUR PS, V68, P137, DOI 10.1136/jnnp.68.2.137; PLACENCIA M, 1992, BRAIN, V115, P771, DOI 10.1093/brain/115.3.771; SIDENVALL R, 1993, ACTA PAEDIATR, V82, P60, DOI 10.1111/j.1651-2227.1993.tb12518.x	26	111	121	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia		2008	49			1			8	12		10.1111/j.1528-1167.2008.01443.x			5	Clinical Neurology	Neurosciences & Neurology	248FA	WOS:000252136200003	18184148	Bronze			2021-06-18	
J	Cohen, BA; Inglese, M; Rusinek, H; Babb, JS; Grossman, RI; Gonen, O				Cohen, B. A.; Inglese, M.; Rusinek, H.; Babb, J. S.; Grossman, R. I.; Gonen, O.			Proton MR spectroscopy and MRI-volumetry in mild traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; DIFFUSE AXONAL INJURY; HEAD-INJURY; N-ACETYLASPARTATE; WHITE-MATTER; GRAY-MATTER; QUANTITATIVE-ANALYSIS; CORPUS-CALLOSUM; UNITED-STATES; ATROPHY	BACKGROUND AND PURPOSE: More than 85% of brain traumas are classified as "mild"; MR imaging findings are minimal if any and do not correspond to clinical symptoms. Our goal, therefore, was to quantify the global decline of the neuronal marker N-acetylaspartate (NAA), as well as gray (GM) and white matter (WM) atrophy after mild traumatic brain injury (mTBI). MATERIALS AND METHODS: Twenty patients (11 male, 9 female; age range, 19-57 years; median, 35 years) with mTBI (Glasgow Coma Scale score 13-15 with loss of consciousness for at least 30 seconds) and 19 age- and sex-matched control subjects were studied. Seven patients were studied within 9 days of TBI; the other 13 ranged from 1.2 months to 31.5 years (average and median of 4.6 and 1.7 years, respectively) after injury. Whole-brain NAA (WBNAA) concentration was obtained in all subjects with nonlocalizing proton MR spectroscopy. Brain volume and GM and WM fractions were segmented from T1-weighted MR imaging and normalized to the total intracranial volume, suitable for intersubject comparisons. The data were analyzed with least squares regression. RESULTS: Patients with mTBI exhibited, on average, a 12% WBNAA deficit that increased with age, compared with the control subjects (p <.05). Adjusted for age effects, patients also suffered both global atrophy (-1.09%/year; P =.029) and GM atrophy (-0.89%/year; P =.042). Patients with and without visible MR imaging pathology, typically punctate foci of suspected shearing injury, were indistinguishable in both atrophy and WBNAA. CONCLUSION: WBNAA detected neuronal/axonal injury beyond the minimal focal MR-visible lesions in mTBI. Combined with GM atrophy, the findings may provide further, noninvasive insight into the nature and progression of mTBI.	NYU, Dept Radiol, Sch Med, New York, NY 10016 USA	Gonen, O (corresponding author), NYU, Dept Radiol, Sch Med, 650 1st Ave,6th Floor, New York, NY 10016 USA.	oded.gonen@med.nyu.edu	Inglese, Matilde/AAH-3189-2020	Inglese, Matilde/0000-0002-9610-0297; Babb, James/0000-0003-1798-1186; Gonen, Oded/0000-0002-3148-2028	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB001015, EB01015] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039135, NS39135] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; COLLINS JG, 1990, VITAL HLTH STAT, V10, P175; Conti AC, 1998, J NEUROSCI, V18, P5663; De Santi S, 2001, NEUROBIOL AGING, V22, P529, DOI 10.1016/S0197-4580(01)00230-5; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Ge YL, 2002, AM J NEURORADIOL, V23, P1327; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gonen O, 2000, NEUROLOGY, V54, P15, DOI 10.1212/WNL.54.1.15; Gonen O, 1998, MAGNET RESON MED, V40, P684, DOI 10.1002/mrm.1910400506; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Pierce JES, 1996, J NEUROSCI, V16, P1083; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; RINK A, 1995, AM J PATHOL, V147, P1575; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; RUSINEK H, 1991, RADIOLOGY, V178, P109, DOI 10.1148/radiology.178.1.1984287; SIMMONS ML, 1991, NEUROSCIENCE, V45, P37, DOI 10.1016/0306-4522(91)90101-S; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TSAI GC, 1995, PROG NEUROBIOL, V46, P531, DOI 10.1016/0301-0082(95)00014-M; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Van Den Heuvel C, 1998, ACT NEUR S, V71, P209; Wang Y, 1998, MAGNET RESON MED, V39, P28, DOI 10.1002/mrm.1910390107; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	54	111	114	0	10	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2007	28	5					907	913					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	169ON	WOS:000246601600030	17494667				2021-06-18	
J	Bayir, H; Kagan, VE; Clark, RSB; Janesko-Feldman, K; Rafikov, R; Huang, ZT; Zhang, XJ; Vagni, V; Billiar, TR; Kochanek, PM				Bayir, Hulya; Kagan, Valerian E.; Clark, Robert S. B.; Janesko-Feldman, Keri; Rafikov, Ruslan; Huang, Zhentai; Zhang, Xiaojing; Vagni, Vincent; Billiar, Timothy R.; Kochanek, Patrick M.			Neuronal NOS-mediated nitration and inactivation of manganese superoxide dismutase in brain after experimental and human brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						1400W; 7-nitroindazole; controlled cortical impact; head injury; myeloperoxidase	NITRIC-OXIDE SYNTHASE; CORTICAL IMPACT INJURY; EXACERBATES CEREBRAL INFARCTION; FREE-RADICAL SCAVENGERS; OXIDATIVE STRESS; TYROSINE NITRATION; LIPID-PEROXIDATION; PROTEIN NITRATION; MICE DEFICIENT; CYTOCHROME-C	Manganese superoxide dismutase (MnSOD) provides the first line of defense against superoxide generated in mitochondria. SOD competes with nitric oxide for reaction with superoxide and prevents generation of peroxynitrite, a potent oxidant that can modify proteins to form 3-nitrotyrosine. Thus, sufficient amounts of catalytically competent MnSOD are required to prevent mitochondrial damage. Increased nitrotyrosine immunoreactivity has been reported after traumatic brain injury (TBI); however, the specific protein targets containing modified tyrosine residues and functional consequence of this modification have not been identified. In this study, we show that MnSOD is a target of tyrosine nitration that is associated with a decrease in its enzymatic activity after TBI in mice. Similar findings were obtained in temporal lobe cortical samples obtained from TBI cases versus control patients who died of causes not related to CNS trauma. Increased nitrotyrosine immunoreactivity was detected at 2 h and 24 h versus 72 h after experimental TBI and co-localized with the neuronal marker NeuN. Inhibition and/or genetic deficiency of neuronal nitric oxide synthase (nNOS) but not endothelial nitric oxide synthase (eNOS) attenuated MnSOD nitration after TBI. At 24 h after TBI, there was predominantly polymorphonuclear leukocytes accumulation in mouse brain whereas macrophages were the predominant inflammatory cell type at 72 h after injury. However, a selective inhibitor or genetic deficiency of inducible nitric oxide synthase (iNOS) failed to affect MnSOD nitration. Nitration of MnSOD is a likely consequence of peroxynitrite within the intracellular milieu of neurons after TBI. Nitration and inactivation of MnSOD could lead to self-amplification of oxidative stress in the brain progressively enhancing peroxynitrite production and secondary damage.	Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Dept Crit Care Med, Pittsburgh, PA USA; Dept Surg, Pittsburgh, PA USA; Dept Environm & Occupat Hlth & Pharmacol, Pittsburgh, PA USA	Bayir, H (corresponding author), Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	bayihx@ccm.upmc.edu	Rafikov, Ruslan/AAG-9352-2019; Huang, Zhentai/C-6926-2012; Kochanek, Patrick M/D-2371-2015; zhang, xueji/B-1904-2010	Huang, Zhentai/0000-0002-8102-464X; Kochanek, Patrick M/0000-0002-2627-913X; Kagan, Valerian E./0000-0002-7245-1885; Rafikov, Ruslan/0000-0001-5950-4076	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL064145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318, R01NS038087] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL64145] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38087, NS30318] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U19A1068021] Funding Source: Medline		Aoyama K, 2000, ANN NEUROL, V47, P524, DOI 10.1002/1531-8249(200004)47:4<524::AID-ANA19>3.3.CO;2-X; Baldus S, 2001, J CLIN INVEST, V108, P1759; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bemeur C, 2004, NEUROCHEM INT, V45, P1167, DOI 10.1016/j.neuint.2004.06.010; Bidmon HJ, 1998, STROKE, V29, P203, DOI 10.1161/01.STR.29.1.203; Bolan EA, 2000, J NEUROSCI, V20, P4798; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; Brown GC, 2004, BBA-BIOENERGETICS, V1658, P44, DOI 10.1016/j.bbabio.2004.03.016; Cantuti-Castelvetri I, 2002, BRAIN RES, V930, P170, DOI 10.1016/S0006-8993(02)02244-8; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cobbs CS, 1996, CANCER RES, V56, P3192; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Comhair SAA, 2005, AM J PATHOL, V166, P663, DOI 10.1016/S0002-9440(10)62288-2; Cruthirds DL, 2003, ARCH BIOCHEM BIOPHYS, V412, P27, DOI 10.1016/S0003-9861(03)00039-0; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Earnhardt JN, 2002, J NEUROTRAUM, V19, P1065, DOI 10.1089/089771502760341974; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; GAETANI P, 1994, NEUROCHEM RES, V19, P839, DOI 10.1007/BF00967453; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Gow AJ, 2004, AM J PHYSIOL-LUNG C, V287, pL262, DOI 10.1152/ajplung.00295.2003; GRAY B, 1992, BIOCHEM J, V281, P795, DOI 10.1042/bj2810795; Gray Keith D, 2004, Surg Infect (Larchmt), V5, P166, DOI 10.1089/sur.2004.5.166; Guo W, 2003, AM J PHYSIOL-HEART C, V285, pH1396, DOI 10.1152/ajpheart.00096.2003; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; KATO H, 1995, J CEREBR BLOOD F MET, V15, P60, DOI 10.1038/jcbfm.1995.7; Keller JN, 1998, J NEUROSCI, V18, P687; Kifle Y, 1996, J NEUROCHEM, V66, P2128; Kim GW, 2002, STROKE, V33, P809, DOI 10.1161/hs0302.103745; Kissner R, 2003, IUBMB LIFE, V55, P567, DOI 10.1080/15216540310001628690; Koeck T, 2004, J BIOL CHEM, V279, P27257, DOI 10.1074/jbc.M401586200; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Lacza Z, 2004, J NEUROCHEM, V90, P942, DOI 10.1111/j.1471-4159.2004.02553.x; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lores-Arnaiz S, 2004, ARCH BIOCHEM BIOPHYS, V430, P170, DOI 10.1016/j.abb.2004.07.012; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MacMillan-Crow LA, 2001, FREE RADICAL BIO MED, V31, P1603, DOI 10.1016/S0891-5849(01)00750-X; MacMillan-Crow LA, 1999, ARCH BIOCHEM BIOPHYS, V366, P82, DOI 10.1006/abbi.1999.1202; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; MacMillan-Crow LA, 1999, METHOD ENZYMOL, V301, P135; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mehl M, 1999, NITRIC OXIDE-BIOL CH, V3, P142, DOI 10.1006/niox.1999.0217; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Murakami K, 1998, J NEUROSCI, V18, P205; Muscoli C, 2004, PAIN, V111, P96, DOI 10.1016/j.pain.2004.06.004; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Onishi Y, 1999, EUR J BIOCHEM, V261, P148, DOI 10.1046/j.1432-1327.1999.00247.x; Pittman KM, 2002, EXP EYE RES, V74, P463, DOI 10.1006/exer.2002.1141; Przedborski S, 2005, ANTIOXID REDOX SIGN, V7, P685, DOI 10.1089/ars.2005.7.685; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Ria F, 2001, BRIT J CANCER, V84, P529, DOI 10.1054/bjoc.2000.1594; Riobo NA, 2002, J BIOL CHEM, V277, P42447, DOI 10.1074/jbc.M204580200; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shaw IC, 1995, NEURODEGENERATION, V4, P391, DOI 10.1006/neur.1995.0047; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Strong MJ, 1998, BIOCHEM BIOPH RES CO, V248, P157, DOI 10.1006/bbrc.1998.8930; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Todorovic A, 2005, ANN NY ACAD SCI, V1048, P369, DOI 10.1196/annals.1342.041; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WAKAI M, 1994, ACTA NEUROPATHOL, V88, P151; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Wei EP, 1996, AM J PHYSIOL-HEART C, V271, pH1262; Wei G, 1999, BBA-MOL BASIS DIS, V1455, P23, DOI 10.1016/S0925-4439(99)00051-4; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Xu SQ, 2006, AM J PHYSIOL-HEART C, V290, pH2220, DOI 10.1152/ajpheart.01293.2005; Xu SQ, 2006, DIABETES, V55, P110, DOI 10.2337/diabetes.55.1.110; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085	91	111	115	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2007	101	1					168	181		10.1111/j.1471-4159.2006.04353.x			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	145SU	WOS:000244885600016	17394464				2021-06-18	
J	Stein, SC; Browne, KD; Chen, XH; Smith, DH; Graham, DI				Stein, Sherman C.; Browne, Kevin D.; Chen, Xiao-Han; Smith, Douglas H.; Graham, David I.			Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: An autopsy study	NEUROSURGERY			English	Article						cerebral ischemia; intracranial vasospasm; ruptured intracranial aneurysm; subarachnoid hemorrhage; thromboembolism	TRAUMATIC BRAIN-INJURY; DISSEMINATED INTRAVASCULAR COAGULATION; INTERCELLULAR-ADHESION MOLECULE-1; TISSUE FACTOR; SYMPTOMATIC VASOSPASM; BLOOD-COAGULATION; ATORVASTATIN REDUCTION; NEUROLOGICAL DEFICITS; CEREBROSPINAL-FLUID; RATS	OBJECTIVE: Recent findings have cast doubt on vasospasm as the sole cause of delayed cerebral ischemia after subarachnoid hemorrhage. METHODS: We reviewed the medical records of 29 patients who died after subarachnoid hemorrhage. Brain sections were taken from the insula, cingulate gyrus, and hippocampus. Adjacent sections were stained with, hematoxylin-eosin and immunostained for thromboemboli. The density (burden) of the latter was calculated blindly and correlated with evidence for ischemia and with the amount of subarachnoid blood. RESULTS: There is a strong correlation between microclot burden and delayed cerebral ischemia. Patients with clinical or radiological evidence of delayed ischemia had mean microclot burdens of 10.0/cm(2) (standard deviation [SD], +/- 6.6); those without had mean burdens of 2.8 (SD, +/- 2.6), a highly significant difference (P = 0.002). There is also significant association (P = 0.001) between microclot burden and histological evidence of ischemia, with the mean burdens being 10.9 in sections exhibiting severe ischemia and 4.1 in those in which ischemia was absent. Microclot burden is high in patients who died within 2 days of hemorrhage, decreasing on Days 3 and 4. In delayed ischemia, the numbers rise again late in the first week and remain high until after the second week. In contrast, the average clot burden is low in patients dying without developing delayed ischemia. The amount of blood on an individual slide influenced the microclot burden on that slide to a highly significant extent (P < 0.001). CONCLUSION: Thromboembolism after subarachnoid hemorrhage may contribute to delayed cerebral ischemia, which parallels that caused by vasospasm. The pathogenesis of thromboembolism is discussed.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Glasgow, Dept Neuropathol, Glasgow G12 8QQ, Lanark, Scotland	Stein, SC (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 310 Spruce St, Philadelphia, PA 19104 USA.	sherman.stein@uphs.upenn.edu	smith, douglas/A-1321-2007				ADAMS HP, 1992, NEUROL CLIN, V10, P251; Amin-Hanjani S, 2004, NEUROSURGERY, V54, P326, DOI 10.1227/01.NEU.0000103488.94855.4F; Antovic J, 2002, SCAND J CLIN LAB INV, V62, P195, DOI 10.1080/003655102317475452; Asakura H, 2002, CRIT CARE MED, V30, P161, DOI 10.1097/00003246-200201000-00023; BERGVALL U, 1973, NEURORADIOLOGY, V5, P24, DOI 10.1007/BF02464626; Bouchard BA, 1997, ARTERIOSCL THROM VAS, V17, P1, DOI 10.1161/01.ATV.17.1.1; Chow M, 2002, NEUROSURGERY, V51, P1333, DOI 10.1227/01.NEU.0000035902.55640.38; CLOWER BR, 1988, CEREBRAL VASOSPASM, P334; CROMPTON MR, 1964, BRAIN, V87, P263, DOI 10.1093/brain/87.2.263; Day SM, 2005, BLOOD, V105, P192, DOI 10.1182/blood-2004-06-2225; Deans KJ, 2005, J TRAUMA, V58, P867, DOI 10.1097/01.TA.0000158244.69179.94; Denton IC, 1971, STROKE, V2, P268, DOI 10.1161/01.STR.2.3.268; Dhainaut JF, 2004, CRIT CARE MED, V32, pS194, DOI 10.1097/01.CCM.0000128035.64448.45; Doshi SN, 2002, CRIT CARE MED, V30, pS241, DOI 10.1097/00003246-200205001-00012; Dreier JP, 2002, ANN NEUROL, V52, P825, DOI 10.1002/ana.10383; Echlin FA, 1942, ARCH NEURO PSYCHIATR, V47, P77, DOI 10.1001/archneurpsyc.1942.02290010087007; ECKER A, 1951, J NEUROSURG, V8, P660, DOI 10.3171/jns.1951.8.6.0660; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; Eichstaedt E, 1993, CAN J NEUROL SCI S1, V20, pS6; FINDLAY JM, 1989, NEUROSURGERY, V25, P736, DOI 10.1227/00006123-198911000-00008; Fisher C M, 1977, Neurosurgery, V1, P245; Frijns CJM, 2002, NEUROSURGERY, V50, P1223, DOI 10.1097/00006123-200206000-00009; Fujii Y, 1997, J NEUROSURG, V86, P594, DOI 10.3171/jns.1997.86.4.0594; GERAUD G, 1984, STROKE, V15, P301, DOI 10.1161/01.STR.15.2.301; Giller CA, 1998, NEUROSURGERY, V42, P490, DOI 10.1097/00006123-199803000-00010; Griffiths PD, 2001, AM J NEURORADIOL, V22, P1690; Harrod CG, 2005, NEUROSURGERY, V56, P633, DOI 10.1227/01.NEU.0000156644.45384.92; Hertel F, 2005, NEUROSURGERY, V56, P28, DOI 10.1227/01.NEU.0000144866.28101.6D; Hirashima Y, 2005, NEUROL MED-CHIR, V45, P177, DOI 10.2176/nmc.45.177; Hoh BL, 2005, NEUROSURGERY, V57, P432, DOI 10.1093/neurosurgery/57.2.432b; Hop JW, 2000, NEUROLOGY, V54, P872, DOI 10.1212/WNL.54.4.872; Iba T, 2005, INTENS CARE MED, V31, P1101, DOI 10.1007/s00134-005-2707-0; Ilveskero S, 2005, NEUROSURGERY, V57, P16, DOI 10.1227/01.NEU.0000163085.48999.D6; Juvela S, 2005, J NEUROSURG, V102, P194, DOI 10.3171/jns.2005.102.2.0194; Juvela S, 2002, J NEUROSURG, V97, P1287, DOI 10.3171/jns.2002.97.6.1287; Kagstrom E, 1966, EXCERPTA MED INT C S, V110, P629; Kasuya H, 2002, STROKE, V33, P1011, DOI 10.1161/01.STR.0000014563.75483.22; Kaynar MY, 2004, J NEUROSURG, V101, P1030, DOI 10.3171/jns.2004.101.6.1030; Kinouchi H, 2004, NEUROL MED-CHIR, V44, P569, DOI 10.2176/nmc.44.569; Klotzsch C, 1998, AM J NEURORADIOL, V19, P1315; Kobayashi T, 2001, SEMIN THROMB HEMOST, V27, P161, DOI 10.1055/s-2001-14076; Kusanagi H, 2002, NEUROL SURG TOKYO, V30, P399; Lee WL, 2000, INTENS CARE MED, V26, P1701, DOI 10.1007/s001340051349; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lu DY, 2004, J NEUROSURG, V101, P822, DOI 10.3171/jns.2004.101.5.0822; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; McGirt MJ, 2002, NEUROSURGERY, V51, P1128, DOI 10.1097/00006123-200211000-00005; Mchedlishvili G, 2004, CLIN HEMORHEOL MICRO, V31, P129; Mizukami M, 1980, CEREBRAL ARTERIAL SP, P97; Mocco J, 2002, J NEUROSURG, V97, P537, DOI 10.3171/jns.2002.97.3.0537; Naidech AM, 2005, ARCH NEUROL-CHICAGO, V62, P410, DOI 10.1001/archneur.62.3.410; NEILDWYER G, 1994, ACTA NEUROCHIR, V131, P137, DOI 10.1007/BF01401464; NICOLL JAR, 1992, J NEUROL SCI, V113, P144, DOI 10.1016/0022-510X(92)90242-D; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nina P, 2001, SURG NEUROL, V55, P197, DOI 10.1016/S0090-3019(01)00402-5; Ohkuma H, 2000, STROKE, V31, P1621, DOI 10.1161/01.STR.31.7.1621; Orlandi G, 2005, ARCH NEUROL-CHICAGO, V62, P1208, DOI 10.1001/archneur.62.8.1208; Park KW, 2001, ANESTH ANALG, V92, P990; Parra A, 2002, NEUROL RES, V24, P510, DOI 10.1179/016164102101200276; Rabinstein AA, 2005, STROKE, V36, P992, DOI 10.1161/01.STR.0000163090.59350.5a; Rabinstein AA, 2004, STROKE, V35, P1862, DOI 10.1161/01.STR.0000133132.76983.8e; Rabinstein AA, 2003, J NEUROSURG, V98, P319, DOI 10.3171/jns.2003.98.2.0319; Reilly C, 2004, J NEUROSURG, V101, P255, DOI 10.3171/jns.2004.101.2.0255; ROBERTSON EG, 1949, BRAIN, V72, P150, DOI 10.1093/brain/72.2.150; Romano JG, 2002, NEUROSURGERY, V50, P1026, DOI 10.1097/00006123-200205000-00016; SCHNECK SA, 1964, NEUROLOGY, V14, P691, DOI 10.1212/WNL.14.8_Part_1.691; Sehba FA, 2005, J NEUROSURG, V102, P1094, DOI 10.3171/jns.2005.102.6.1094; Shimoda M, 2001, NEUROSURGERY, V49, P1341, DOI 10.1097/00006123-200112000-00010; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; STOLTENBURGDIDI.G, 1987, STROKE MICROCIRCULAT, P471; Stroobandt G, 1998, ACTA NEUROCHIR, V140, P148, DOI 10.1007/s007010050076; SUZUKI S, 1990, Neurologia Medico-Chirurgica, V30, P309, DOI 10.2176/nmc.30.309; Thai QA, 1999, STROKE, V30, P140, DOI 10.1161/01.STR.30.1.140; Toh CH, 2003, BRIT MED J, V327, P974, DOI 10.1136/bmj.327.7421.974; Treggiari MM, 2003, J NEUROSURG, V98, P978, DOI 10.3171/jns.2003.98.5.0978; Tsurutani H, 2003, STROKE, V34, P1497, DOI 10.1161/01.STR.0000070424.38138.30; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Zhang Z, 2001, STROKE, V32, P1665, DOI 10.1161/01.STR.32.7.1665	80	111	117	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2006	59	4					781	787		10.1227/01.NEU.0000227519.27569.45			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	095FS	WOS:000241294200024	16915120				2021-06-18	
J	Lee, ST; Chu, K; Sinn, DI; Jung, KH; Kim, EH; Kim, SJ; Kim, JM; Ko, SY; Kim, M; Roh, JK				Lee, ST; Chu, K; Sinn, DI; Jung, KH; Kim, EH; Kim, SJ; Kim, JM; Ko, SY; Kim, M; Roh, JK			Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; endothelial nitric oxide synthase; extracellular signal-regulated kinase; erythropoietin; inflammation; intracerebral hemorrhage; STAT3	NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; BLOOD-BRAIN-BARRIER; FUNCTIONAL RECOVERY; CEREBRAL-ISCHEMIA; SENSORIMOTOR RECOVERY; ENHANCES NEUROGENESIS; APOPTOSIS; PROTECTS; STROKE	Erythropoietin (EPO), a pleiotropic cytokine involved in erythropoiesis, is tissue-protective in ischemic, traumatic, toxic and inflammatory injuries. In this study, we investigated the effect of EPO in experimental intracerebral hemorrhage (ICH). Two hours after inducing ICH via the stereotaxic infusion of collagenase, recombinant human EPO (500 or 5000 IU/kg, ICH + EPO group) or PBS (ICH + vehicle group) was administered intraperitoneally, then once daily afterwards for 1 or 3 days. ICH + EPO showed the better functional recovery in both rotarod and modified limb placing tests. The brain water content was decreased in ICH + EPO dose-dependently, as compared with ICH + vehicle. The effect of EPO on the brain water content was inhibited by N(omega)-Nitro-L-arginine methyl ester hydrochloride (L-NAME, 10 mg/kg). Mean hemorrhage volume was also decreased in ICH + EPO. EPO reduced the numbers of TUNEL +, myeloperoxidase + or OX-42 + cells in the perihematomal area. In addition, EPO reduced the mRNA level of TNF-alpha, Fas and Fas-L, as well as the activities of caspase-8, 9 and 3. EPO treatment showed up-regulations of endothelial nitric oxide synthase (eNOS) and p-eNOS, pAkt, pSTAT3 and pERK levels. These data suggests that EPO treatment in ICH induces better functional recovery with reducing perihematomal inflammation and apoptosis, coupled with activations of eNOS, STAT3 and ERK.	Seoul Natl Univ Hosp, Dept Neurol, Stem Cell Res Ctr, Stroke & Neural Stem Cell Lab,Clin Res Inst, Seoul 110744, South Korea; Seoul Natl Univ, Program Neurosci, Neurosci Res Inst, SNUMRC, Seoul, South Korea; Seoul Natl Univ Hosp, Ctr Alcohol & Drug Addict Res, Seoul 110744, South Korea; Korea Ctr Dis Control & Prevent, Div Epidem Intelligence Serv, Seoul, South Korea; Seoul Natl Univ, Brain Korea 21 Project Med Sci, Seoul, South Korea	Roh, JK (corresponding author), Seoul Natl Univ Hosp, Dept Neurol, Stem Cell Res Ctr, Stroke & Neural Stem Cell Lab,Clin Res Inst, 28,Yongondong, Seoul 110744, South Korea.	rohjk@snu.ac.kr	Lee, Soon-Tae/C-4663-2013; Roh, Jae Kyu/J-5459-2012; Kim, Manho/J-2738-2012				Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Agnoletti L, 1999, CIRCULATION, V100, P1983, DOI 10.1161/01.CIR.100.19.1983; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P452, DOI 10.1097/00004647-200003000-00002; Beleslin-Cokic BB, 2004, BLOOD, V104, P2073, DOI 10.1182/blood-2004-02-0744; Benn SC, 2004, NAT REV NEUROSCI, V5, P686, DOI 10.1038/nrn1477; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Bulotta S, 2001, J BIOL CHEM, V276, P6529, DOI 10.1074/jbc.M006535200; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen M, 2002, APOPTOSIS, V7, P313, DOI 10.1023/A:1016167228059; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Chu K, 2004, BRAIN RES, V1016, P145, DOI 10.1016/j.brainres.2004.04.038; DelBigio MR, 1996, STROKE, V27, P2312, DOI 10.1161/01.STR.27.12.2312; Diaz Z, 2005, J NEUROCHEM, V93, P392, DOI 10.1111/j.1471-4159.2005.03038.x; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Endres M, 2004, TRENDS NEUROSCI, V27, P283, DOI 10.1016/j.tins.2004.03.009; Furuke K, 1999, J IMMUNOL, V163, P1473; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004; Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456; Huang DM, 2004, EUR J PHARMACOL, V503, P17, DOI 10.1016/j.ejphar.2004.09.040; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Jung KH, 2004, STROKE, V35, P1744, DOI 10.1161/01.STR.0000131270.45822.85; KILIC E, 2005, IN PRESS FASEB J; Kilic U, 2004, FASEB J, V18, P249, DOI 10.1096/fj.04-2493fje; Kirito K, 1997, J BIOL CHEM, V272, P16507, DOI 10.1074/jbc.272.26.16507; Kretz A, 2005, MOL CELL NEUROSCI, V29, P569, DOI 10.1016/j.mcn.2005.04.009; Lee SR, 2003, STROKE, V34, P2704, DOI 10.1161/01.STR.0000096540.40826.BA; LEE ST, 2006, IN PRESS J CEREB BLO; Li WP, 2004, ANN NEUROL, V56, P767, DOI 10.1002/ana.20274; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Matsushita K, 2000, J CEREBR BLOOD F MET, V20, P396, DOI 10.1097/00004647-200002000-00022; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; Mendelow AD, 2005, LANCET, V365, P387; Park HK, 2005, BRAIN RES, V1041, P125, DOI 10.1016/j.brainres.2004.11.067; Peeling J, 2001, EXP NEUROL, V167, P341, DOI 10.1006/exnr.2000.7564; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Qureshi AI, 2003, NEUROSURGERY, V52, P1041, DOI 10.1227/01.NEU.0000057694.96978.BC; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; Sasaki R, 2003, INTERNAL MED, V42, P142, DOI 10.2169/internalmedicine.42.142; Silva Y, 2005, STROKE, V36, P86, DOI 10.1161/01.STR.0000149615.51204.0b; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Spandou E, 2005, BRAIN RES, V1045, P22, DOI 10.1016/j.brainres.2005.03.013; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Viviani B, 2005, J NEUROCHEM, V93, P412, DOI 10.1111/j.1471-4159.2005.03033.x; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; WANG L, 2005, IN PRESS J CEREB BLO; Watowich SS, 2000, J INTERF CYTOK RES, V20, P1065, DOI 10.1089/107999000750053726; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036	66	111	116	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2006	96	6					1728	1739		10.1111/j.1471-4159.2006.03697.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	019MX	WOS:000235842100022	16539688	Bronze			2021-06-18	
J	O'Connor, CA; Cernak, I; Vink, R				O'Connor, CA; Cernak, I; Vink, R			Both estrogen and progesterone attenuate edema formation following diffuse traumatic brain injury in rats	BRAIN RESEARCH			English	Article						neurotrauma; hormone; female; blood brain barrier; brain injury	LIPID-PEROXIDATION; MESSENGER-RNA; GENDER; CONTUSION; STEROIDS	Females have reduced brain edema compared to males after experimental brain trauma, although contradictory reports exist as to whether this is due to either estrogen or progesterone. In the present study, we demonstrate in both male and ovariectomized female rats that a single physiological dose of either hormone at 30 min after diffuse traumatic brain injury reduces both blood brain,barrier permeability and edema formation. We conclude that both hormones may contribute to reduce edema in females after brain injury. (c) 2005 Elsevier B.V. All rights reserved.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Surg, Adelaide, SA 5005, Australia; Georgetown Univ, Dept Neurosci, Washington, DC USA	Vink, R (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.	Robert.Vink@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Cernak, Ibolja/A-6399-2008; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Ayres S, 1998, AM J PHYSIOL-ENDOC M, V274, pE1002; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibbs RB, 1999, BRAIN RES, V844, P20, DOI 10.1016/S0006-8993(99)01880-6; Gibbs RB, 1998, BRAIN RES, V787, P259, DOI 10.1016/S0006-8993(97)01511-4; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; PLUM F, 1963, ARCH NEUROL-CHICAGO, V9, P571, DOI 10.1001/archneur.1963.00460120021002; Richard C, 2003, ENDOCRINOLOGY, V144, P1533, DOI 10.1210/en.2002-0033; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; STEIN DG, 2001, TRENDS NEUROSCI, P24; Vink R, 2003, ACT NEUR S, V86, P257; WOLFF JEA, 1992, J NEUROCHEM, V58, P1023, DOI 10.1111/j.1471-4159.1992.tb09357.x; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	27	111	114	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 16	2005	1062	1-2					171	174		10.1016/j.brainres.2005.09.011			4	Neurosciences	Neurosciences & Neurology	991CS	WOS:000233790500021	16256079				2021-06-18	
J	Houweling, AR; Bazhenov, M; Timofeev, I; Steriade, M; Sejnowski, TJ				Houweling, AR; Bazhenov, M; Timofeev, I; Steriade, M; Sejnowski, TJ			Homeostatic synaptic plasticity can explain post-traumatic epileptogenesis in chronically isolated neocortex	CEREBRAL CORTEX			English	Article						brain trauma; computational model; deafferentation; epilepsy; injury; slow oscillation	ACTIVITY-DEPENDENT REGULATION; SEIZURE-LIKE ACTIVITY; QUANTAL AMPLITUDE; PYRAMIDAL NEURONS; NEUROTRANSMITTER RELEASE; NMDA RECEPTORS; MODEL; AMPA; CONDUCTANCES; EXCITABILITY	Chronically isolated neocortex develops chronic hyperexcitability and focal epileptogenesis in a period of days to weeks. The mechanisms operating in this model of post-traumatic epileptogenesis are not well understood. We hypothesized that the spontaneous burst discharges recorded in chronically isolated neocortex result from homeostatic plasticity (a mechanism generally assumed to stabilize neuronal activity) induced by low neuronal activity after deafferentation. To test this hypothesis we constructed computer models of neocortex incorporating a biologically based homeostatic plasticity rule that operates to maintain firing rates. After deafferentation, homeostatic upregulation of excitatory synapses on pyramidal cells, either with or without concurrent downregulation of inhibitory synapses or upregulation of intrinsic excitability, initiated slowly repeating burst discharges that closely resembled the epileptiform burst discharges recorded in chronically isolated neocortex. These burst discharges lasted a few hundred ms, propagated at 1-3 cm/s and consisted of large (10-15 mV) intracellular depolarizations topped by a small number of action potentials. Our results support a role for homeostatic synaptic plasticity as a novel mechanism of post-traumatic epileptogenesis.	Salk Inst Biol Studies, Computat Neurobiol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Neurosci Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol Sci, San Diego, CA 92093 USA; Univ Laval, Neurophysiol Lab, Ste Foy, PQ G1K 7P4, Canada	Houweling, AR (corresponding author), Erasmus MC, Dept Neurosci, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	arthur@salk.edu	Timofeev, Igor/E-8828-2012; Timofeev, Igor/AAP-7529-2021	Timofeev, Igor/0000-0002-1389-5857	Howard Hughes Medical InstituteHoward Hughes Medical Institute Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40522] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040522] Funding Source: NIH RePORTER		Abbott LF, 1997, SCIENCE, V275, P220; Amitai Y, 2002, J NEUROSCI, V22, P4142, DOI 10.1523/JNEUROSCI.22-10-04142.2002; BRAILOWSKY S, 1988, BRAIN RES, V442, P175, DOI 10.1016/0006-8993(88)91448-5; BURNS BD, 1979, PROC R SOC SER B-BIO, V203, P347, DOI 10.1098/rspb.1979.0002; BURNS BD, 1951, J PHYSIOL-LONDON, V112, P156, DOI 10.1113/jphysiol.1951.sp004517; Burrone J, 2002, NATURE, V420, P414, DOI 10.1038/nature01242; Bush PC, 1999, J NEUROPHYSIOL, V82, P1748; Carmichael ST, 2002, J NEUROSCI, V22, P6062; CARPENTER GA, 1983, BIOL CYBERN, V48, P35, DOI 10.1007/BF00336883; Craig AM, 1998, NEURON, V21, P459, DOI 10.1016/S0896-6273(00)80555-3; Desai NS, 2002, NAT NEUROSCI, V5, P783, DOI 10.1038/nn878; Desai NS, 1999, NAT NEUROSCI, V2, P515; ECHLIN FA, 1963, ARCH NEUROL-CHICAGO, V9, P154, DOI 10.1001/archneur.1963.00460080064009; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Golomb D, 1997, J NEUROPHYSIOL, V78, P1199; Golowasch J, 1999, NEURAL COMPUT, V11, P1079, DOI 10.1162/089976699300016359; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; GRAFSTEIN B, 1957, ELECTROEN CLIN NEURO, V9, P723, DOI 10.1016/0013-4694(57)90096-2; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; HIRSCH JC, 1983, BRAIN RES, V259, P308, DOI 10.1016/0006-8993(83)91264-7; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; JAHR CE, 1990, J NEUROSCI, V10, P3178; KELLAWAY P, 1966, EXP NEUROL, V14, P281, DOI 10.1016/0014-4886(66)90115-4; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; LEMASSON G, 1993, SCIENCE, V259, P1915, DOI 10.1126/science.8456317; Leslie KR, 2001, J NEUROSCI, V21, part. no.; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Liao DH, 1999, NAT NEUROSCI, V2, P37; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; Liu Z, 1998, J NEUROSCI, V18, P2309; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; McAllister AK, 2000, P NATL ACAD SCI USA, V97, P6173, DOI 10.1073/pnas.100126497; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McNamara JO, 1999, NATURE, V399, pA15, DOI 10.1038/399a015; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Pare D, 1998, J NEUROPHYSIOL, V79, P1450; Prince D A, 1999, Adv Neurol, V79, P665; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; PURPURA DP, 1961, EXP NEUROL, V4, P377, DOI 10.1016/0014-4886(61)90025-5; RAMAKERS GJA, 1990, EXP BRAIN RES, V79, P157; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Rutherford LC, 1997, J NEUROSCI, V17, P4527; Salin P, 1995, J NEUROSCI, V15, P8234; Sanchez-Vives MV, 2000, NAT NEUROSCI, V3, P1027; SHARPLESS SK, 1962, ELECTROEN CLIN NEURO, V14, P244, DOI 10.1016/0013-4694(62)90034-2; Sharpless SK, 1969, BASIC MECH EPILEPSIE, P329; SIEGEL M, 1994, P NATL ACAD SCI USA, V91, P11308, DOI 10.1073/pnas.91.24.11308; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969; Timofeev I, 2000, CEREB CORTEX, V10, P1185, DOI 10.1093/cercor/10.12.1185; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; vandenPol AN, 1996, NEUROSCIENCE, V74, P653, DOI 10.1016/0306-4522(96)00153-4; VANOOYEN A, 1994, J THEOR BIOL, V167, P27, DOI 10.1006/jtbi.1994.1047; vanOoyen A, 1996, J THEOR BIOL, V179, P229, DOI 10.1006/jtbi.1996.0063; Wang XJ, 1999, J NEUROSCI, V19, P9587; Watt AJ, 2000, NEURON, V26, P659, DOI 10.1016/S0896-6273(00)81202-7	65	111	113	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	JUN	2005	15	6					834	845		10.1093/cercor/bhh184			12	Neurosciences	Neurosciences & Neurology	926HJ	WOS:000229113900015	15483049	Green Accepted, Green Published, Bronze			2021-06-18	
J	Gil, S; Caspi, Y; Ben-Ari, IZ; Koren, D; Klein, E				Gil, S; Caspi, Y; Ben-Ari, IZ; Koren, D; Klein, E			Does memory of a traumatic event increase the risk for posttraumatic stress disorder in patients with traumatic brain injury? A prospective study	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							FEAR	Objective: The present study examined prospectively the relationship between memory of the traumatic event and subsequent development of posttraumatic stress disorder ( PTSD). More specifically, the aims of this study were to 1) investigate the possibility that lack of memory of the traumatic event might be a protective factor; 2) assess whether memory of the traumatic event equally affects the three symptom clusters of PTSD: reexperiencing, avoidance, and hyperarousal; and 3) explore the predictive value of memory of the traumatic event for the development of subsequent PTSD in the immediate aftermath of the event. Method: One hundred twenty subjects with mild traumatic brain injury who were hospitalized for observation were assessed immediately after the trauma and followed up 1 week, 3 months, and 6 months later. All participants underwent psychiatric evaluation and self-assessment of their memory of the traumatic event. Results: Overall, 17 (14%) of the participants met full criteria for PTSD at 6 months. Subjects with memory of the traumatic event were significantly more likely to develop PTSD than those without memory of the traumatic event; the difference between the groups resulted primarily from the reexperiencing cluster. Logistic regression analysis revealed that memory of the traumatic event within the first 24 hours is a strong predictor of PTSD 6 months after the event. Conclusions: Our study indicated that memory of a traumatic event is a strong predictor and a potential risk factor for subsequent development of PTSD. Future studies are needed to show whether these findings can be generalized to other traumatic conditions.	Rambam Med Ctr, Dept Psychiat, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Univ Haifa, Sch Social Work, Fac Social Welf & Hlth Studies, IL-31999 Haifa, Israel; Univ Haifa, Dept Psychol, IL-31999 Haifa, Israel	Klein, E (corresponding author), Rambam Med Ctr, Dept Psychiat, POB 9602, IL-31096 Haifa, Israel.	e_klein@rambam.health.gov.il		Koren, Danny/0000-0003-0238-766X			*ASS ADV AUT MED, 1990, AIS ABBR INJ SCAL 19; Ballenger JC, 2000, J CLIN PSYCHIAT, V61, P60; Beck A.T., 1987, MANUAL REVISED BECK; Beck AT, 1988, MANUAL BECK ANXIETY; Blake D., 1990, CLIN ADM PTSD SCALE; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; First MB., 1997, STRUCTURED CLIN INTE; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; FOA EB, 1999, J CLIN PSYCHIAT, V60, P5; HOPPER JW, 2001, J AGGRESS MALTREAT T, V4, P33, DOI DOI 10.1300/J146V04N02; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Koren D, 1999, AM J PSYCHIAT, V156, P367; Lavie Peretz, 2001, TRAUMA DREAMS, P114; LeDoux J, 1998, BIOL PSYCHIAT, V44, P1229, DOI 10.1016/S0006-3223(98)00282-0; LEDOUX JE, 1994, SCI AM, V270, P50, DOI 10.1038/scientificamerican0694-50; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; MARMAR CR, 1994, AM J PSYCHIAT, V151, P902; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Parkin AJ, 1999, CURR BIOL, V9, pR582, DOI 10.1016/S0960-9822(99)80378-9; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; Reeves D, 1996, NCRFSR9601; SAPOLSKY RM, 1990, J NEUROSCI, V10, P2897, DOI 10.1523/jneurosci.10-09-02897.1990; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Siegel D. J., 1995, J PSYCHOTHERAPY PRAC, V4, P93; SQUIRE LR, 1990, COLD SH Q B, V55, P1007; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; TEASDALE G, 1974, LANCET, V2, P81; van der Kolk B. A., 2001, J AGGRESS MALTREAT T, V4, P9, DOI [10.1300/J146v04n02_, DOI 10.1300/J146V04N02, DOI 10.1300/J146V04N02_]; Van Der Kolk Bessel A., 1996, P279	32	111	113	1	7	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	MAY	2005	162	5					963	969		10.1176/appi.ajp.162.5.963			7	Psychiatry	Psychiatry	922JJ	WOS:000228833100020	15863799				2021-06-18	
J	Mahmood, O; Rapport, LJ; Hanks, RA; Fichtenberg, NL				Mahmood, O; Rapport, LJ; Hanks, RA; Fichtenberg, NL			Neuropsychological performance and sleep disturbance following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						neuropsychological assessment; sleep disturbance; traumatic brain injury	NEUROBEHAVIORAL SYMPTOMS; GENDER-DIFFERENCES; READING TEST; HEAD-INJURY; INSOMNIA; COMPLAINTS; CONSEQUENCES; POPULATION; DISORDERS; ATTENTION	Objective: To examine the relation between sleep disturbance and neurocognitive ability among persons with traumatic brain injury (TBI). Design: Correlational research evaluating demographic and neuropsychological predictors of sleep disturbance using multiple regression analysis and analysis of variance. Participants: Eighty-seven patients with mild to severe TBI admitted to a comprehensive outpatient neurorehabilitation program. Main Outcome Measures: Sleep disturbance assessed using the Pittsburgh Sleep Quality Index. Results: Hierarchical regression analysis revealed that performance on selected measures of cognitive functioning significantly improved prediction of sleep disturbance, accounting for 14% of variance beyond that accounted for by injury severity and gender. The total model accounted for 31% of the variance in Pittsburgh Sleep Quality Index scores. Patients with mild TBI reported more sleep disturbance (P < .01) than did patients with severe TBI. Conclusions: Sleep disturbance among patients with TBI may be associated with a particular constellation of neuropsychological abilities. These issues are discussed in relation to prior findings that indicate the involvement of additional neuropsychiatric factors associated with sleep disturbance in mild TBI.	Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Rehabil Inst Michigan, Detroit, MI 48202 USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	rapport@sun.science.wayne.edu	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604			Autret A, 2001, NEUROPHYSIOL CLIN, V31, P356, DOI 10.1016/S0987-7053(01)00282-9; Beck AT., 1996, BECK DEPRESSION INVE, V2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BENTON A, 1983, MULTILINGUAL APBASIA; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Call-Schmidt Tracy Ann, 2003, Pain Manag Nurs, V4, P124, DOI 10.1016/S1524-9042(02)54212-0; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Doi Y, 2003, SOC SCI MED, V56, P883, DOI 10.1016/S0277-9536(02)00089-8; Drummond SPA, 2001, NEUROPSYCHOPHARMACOL, V25, pS68, DOI 10.1016/S0893-133X(01)00325-6; Drummond SPA, 2001, J SLEEP RES, V10, P85, DOI 10.1046/j.1365-2869.2001.00245.x; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Fulda S, 2001, SLEEP MED REV, V5, P423, DOI 10.1053/smrv.2001.0157; Gasanov R L, 1998, Neurosci Behav Physiol, V28, P325, DOI 10.1007/BF02462964; Goldman-Rakic P. S., 1993, J HEAD TRAUMA REHAB, V8, P13; Hagen C., 1972, LEVELS COGNITIVE FUN; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hauri PJ, 1997, ACTA NEUROL BELG, V97, P113; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Jean-Louis G, 2000, BIOL PSYCHIAT, V47, P921, DOI 10.1016/S0006-3223(99)00169-9; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Li RHY, 2002, J PSYCHOSOM RES, V53, P601, DOI 10.1016/S0022-3999(02)00437-3; Mahowald Mark W., 1996, P285; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Ohayon MM, 2002, SLEEP MED, V3, P115, DOI 10.1016/S1389-9457(01)00158-7; PARSONS LC, 1982, NURS RES, V31, P260; Portas CM, 1998, J NEUROSCI, V18, P8979; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Quan SF, 2003, SLEEP MED, V4, P13, DOI 10.1016/S1389-9457(02)00235-6; REEDER KP, 1994, ARCH CLIN NEUROPSYCH, V9, P491, DOI 10.1016/0887-6177(94)90040-X; Reitan RM., 1985, HALSTEAD REITAN NEUR; RICHTER KJ, 1995, J HEAD TRAUMA REHAB, V10, P7, DOI 10.1097/00001199-199512000-00004; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Savis JC, 1997, INT J SPORT PSYCHOL, V28, P157; Smith MT, 2002, SLEEP, V25, P325; Tabachnick B., 2001, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Vignola A, 2000, J GERONTOL B-PSYCHOL, V55, pP54; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WIENS AN, 1993, CLIN NEUROPSYCHOL, V7, P70, DOI 10.1080/13854049308401889; WILKINGSON G, 1993, WRAT3 ADM MANUAL; Williams JM, 1991, MEMORY ASSESSMENT SC	53	111	112	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2004	19	5					378	390		10.1097/00001199-200409000-00003			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	858UB	WOS:000224216300003	15597029				2021-06-18	
J	Cernak, I; Savic, VJ; Lazarov, A; Joksimovic, M; Markovic, S				Cernak, I; Savic, VJ; Lazarov, A; Joksimovic, M; Markovic, S			Neuroendocrine responses following graded traumatic brain injury in male adults	BRAIN INJURY			English	Article							TRANSIENT HYPOGONADOTROPIC HYPOGONADISM; SEVERE CRANIOCEREBRAL TRAUMA; THYROID-FUNCTION; NERVOUS-SYSTEM; WAR CASUALTIES; BLAST INJURY; HEAD-INJURY; EPIDEMIOLOGY; HORMONES; ILLNESS	In an effort to characterize thyroid, gonadal and adrenal function following neurotrauma, the present study determined serum concentrations of thyroid-stimulating hormone (TSH), total triiodothyronine (T-3), thyroxine (T-4), testosterone and cortisol over a 7 day period in 31 patients with traumatic brain injury. The study group consisted of eight patients with mild closed head injury (Glasgow Coma Scale-GCS 13-15), 10 patients with extensive penetrating head injury (GCS 4-6) and 13 patients with blast injuries but without direct head trauma. The latter group was included in the study because the development of indirect brain trauma has previously been implicated in blast injuries. Patients with multiple injuries were not included. Following mild injury (GCS 13-15), TSH was increased up until day 3 after injury. T-3 levels were elevated on days 1, 5 and 7 after injury while T-4 remained unchanged throughout. While testosterone was decreased over only the first 2 days post-trauma, cortisol was increased over these first 2 days after injury. In contrast, following severe penetrating injury (GCS 4-6), there were significant declines in TSH, T-3 and testosterone over the 7 day observation period post trauma. Serum cortisol also declined in these patients between 1-3 days after injury, before increasing again on days 5 and 7 after injury. Following indirect neurotrauma, TSH was slightly decreased immediately after trauma but increased to above normal levels on days 5 and 7 post-trauma. Similarly, T-3 initially declined after injury, but then increased to above normal levels between 5 and 7 days after injury. T-4 and testosterone remained unchanged over the entire post-traumatic period. Serum cortisol was significantly increased after indirect neurotrauma but only up to day 2 post-trauma. In summary, patients with both direct and indirect traumatic brain injury demonstrated endocrine alterations after trauma, the dynamics of which may be a reflection of the severity of brain damage.	Mil Med Acad, YU-11002 Belgrade, Serbia	Cernak, I (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.	Ibolja.Cernak@jcu.edu.au	Cernak, Ibolja/A-6399-2008	Ibolja, Cernak/0000-0003-3214-698X			Aboutanos MB, 1997, J TRAUMA, V43, P719, DOI 10.1097/00005373-199710000-00031; Ansari SA, 1998, BRIT J NEUROSURG, V12, P340; BARTON RN, 1987, BAILLIERE CLIN ENDOC, V1, P355, DOI 10.1016/S0950-351X(87)80067-8; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BAUE AE, 1984, ARCH SURG-CHICAGO, V119, P1125; Cameron P, 1995, AUST NZ J SURG, V65, P848, DOI 10.1111/j.1445-2197.1995.tb00574.x; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; CAREY ME, 1982, ACTA CHIR SCAND, P351; Cemak I., 1997, INT REV ARMED FORCES, V70, P114; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 1997, WORLD J SURG, V21, P240, DOI 10.1007/s002689900223; Chaloner EJ, 1996, J ROY COLL SURG EDIN, V41, P398; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; GALLOE AM, 1993, DAN MED BULL, V40, P492; Gofrit ON, 1997, MIL MED, V162, P24; GOTTARDIS M, 1990, INTENS CARE MED, V16, P163, DOI 10.1007/BF01724795; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hetz W, 1996, J ACCID EMERG MED, V13, P243; HILL JF, 1979, ANN ROY COLL SURG, V61, P4; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; KUSHNER JP, 1996, ENDOCRINOL METAB, V3, P219; LEE SC, 1994, BRAIN INJURY, V8, P571; Munno I, 1998, IMMUNOPHARM IMMUNOT, V20, P519, DOI 10.3109/08923979809031513; Peng R, 1998, AM SURGEON, V64, P950; Pentelenyi T, 1992, Acta Neurochir Suppl (Wien), V55, P21; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; SHUTOV AA, 1993, ZH NEVROPATOL PSIKH, V93, P39; SHUTOV AA, 1980, ZH VOPROSY NEIROKHIR; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SPRATT DI, 1992, J CLIN ENDOCR METAB, V75, P1562, DOI 10.1210/jc.75.6.1562; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; VITEK V, 1987, INJURY, V18, P336, DOI 10.1016/0020-1383(87)90056-8; Vojvodic V, 1996, J TRAUMA, V40, pS180, DOI 10.1097/00005373-199603001-00040; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011	41	111	117	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	1999	13	12					1005	1015					11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	264UJ	WOS:000084200600006	10628505				2021-06-18	
J	Cordoba, J; Crespin, J; Gottstein, J; Blei, AT				Cordoba, J; Crespin, J; Gottstein, J; Blei, AT			Mild hypothermia modifies ammonia-induced brain edema in rats after portacaval anastomosis	GASTROENTEROLOGY			English	Article							FULMINANT HEPATIC-FAILURE; HYPERAMMONEMIA-INDUCED ENCEPHALOPATHY; CEREBRAL BLOOD-FLOW; LIVER-FAILURE; INTRACRANIAL HYPERTENSION; TOTAL HEPATECTOMY; BODY-TEMPERATURE; INJURY; GLUTAMINE; PRESSURE	Background & Aims: The pathogenesis of brain edema in fulminant hepatic failure is still unresolved. Mild hypothermia (33 degrees-35 degrees C) can ameliorate brain edema after traumatic brain injury. We evaluated mild hypothermia in a model of ammonia-induced brain edema in which accumulation of brain glutamine has been proposed as a key pathogenic factor, Methods: After portacaval anastomosis, anesthetized rats were infused with ammonium acetate at 33 degrees, 35 degrees, and 37 degrees C or vehicle at 37 degrees C. Water and glutamine levels in the brain, cardiac output, and regional and cerebral hemodynamics were measured when intracranial pressure increased 3-4-fold (ammonia infusion at 37 degrees) and matched times (other groups). Results: Mild hypothermia reduced ammonia-induced brain swelling and increased intracranial pressure. Brain glutamine level was not decreased by hypothermia, Brain edema was accompanied by a specific increase in cerebral blood flow and oxygen consumption, which were normal in both hypothermic groups. When the ammonia infusion was continued in hypothermic rats, plasma ammonia levels continued to increase and brain swelling eventually developed. Conclusions: Mild hypothermia delays ammonia-induced brain edema, In this moder, an increase in cerebral perfusion is required for brain edema to become manifest, Mild hypothermia could be tested for treatment of intracranial hypertension in fulminant hepatic failure.	Lakeside Vet Affairs Med Ctr, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Chicago, IL 60611 USA	Blei, AT (corresponding author), Lakeside Vet Affairs Med Ctr, Dept Med, Room 111 E,333 E Huron St, Chicago, IL 60611 USA.	andyblei@merle.acns.nwu.edu					Bergmeyer H., 1984, METHODS ENZYMATIC AN; BLEI AT, 1994, HEPATOLOGY, V19, P1437, DOI 10.1002/hep.1840190619; BRUSILOW SW, 1986, NEW ENGL J MED, V314, P786; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CARTHEUSER CF, 1993, COMP BIOCHEM PHYS A, V106, P775, DOI 10.1016/0300-9629(93)90396-L; CHODOBSKI A, 1986, J NEUROSURG, V65, P86, DOI 10.3171/jns.1986.65.1.0086; CLIFTON GL, 1995, J NEUROSURG ANESTH, V7, P152, DOI 10.1097/00008506-199504000-00023; Cordoba J, 1996, SEMIN LIVER DIS, V16, P271, DOI 10.1055/s-2007-1007240; Cordoba J, 1995, Liver Transpl Surg, V1, P187, DOI 10.1002/lt.500010310; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Donovan JP, 1998, LANCET, V351, P719, DOI 10.1016/S0140-6736(97)07373-X; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; FUNG HL, 1986, J PHARMACOL EXP THER, V239, P701; HEYMANN MA, 1977, PROG CARDIOVASC DIS, V20, P55, DOI 10.1016/S0033-0620(77)80005-4; Jalan R, 1998, HEPATOLOGY, V28, p492A; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; KINDT GW, 1975, JAMA-J AM MED ASSOC, V231, P822, DOI 10.1001/jama.231.8.822; LANIER WL, 1995, J NEUROSURG ANESTH, V7, P216, DOI 10.1097/00008506-199507000-00021; Larsen FS, 1996, J HEPATOL, V25, P145, DOI 10.1016/S0168-8278(96)80066-3; Larsen FS, 1996, SEMIN LIVER DIS, V16, P281, DOI 10.1055/s-2007-1007241; LEE SH, 1961, SURGERY, V50, P668; Lichtenstein GR, 1997, GASTROENTEROLOGY, V112, P236, DOI 10.1016/S0016-5085(97)70240-3; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MADSEN PL, 1988, J CEREBR BLOOD FLOW, V18, P742; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mas A, 1997, LANCET, V349, P1081, DOI 10.1016/S0140-6736(96)08054-3; MITCHELL RB, 1988, AM J MED, V85, P662; MUNOZ SJ, 1993, SEMIN LIVER DIS, V13, P395; NORENBERG MD, 1994, ACTA NEUROCHIR, P24; OLAFSSON S, 1995, GASTROENTEROLOGY, V108, P1097, DOI 10.1016/0016-5085(95)90208-2; PEIGNOUX M, 1982, CLIN SCI, V62, P273, DOI 10.1042/cs0620273; ROZGA J, 1993, LANCET, V342, P898, DOI 10.1016/0140-6736(93)91947-K; SCHENKER S, 1962, J LAB CLIN MED, V60, P291; SHAH V, 1993, HEPATOLOGY, V17, P1117, DOI 10.1002/hep.1840170627; TAKAHASHI H, 1991, AM J PHYSIOL, V261, pH825; TAKAHASHI H, 1992, CIRC RES, V71, P1220, DOI 10.1161/01.RES.71.5.1220; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; TRABER PG, 1986, GASTROENTEROLOGY, V91, P1347, DOI 10.1016/0016-5085(86)90186-1; Vogels BAPM, 1997, HEPATOLOGY, V25, P820, DOI 10.1002/hep.510250406; Vogels BAPM, 1997, J HEPATOL, V26, P387, DOI 10.1016/S0168-8278(97)80057-8; WENDON JA, 1994, HEPATOLOGY, V19, P1407, DOI 10.1002/hep.1840190614	43	111	112	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085	1528-0012		GASTROENTEROLOGY	Gastroenterology	MAR	1999	116	3					686	693		10.1016/S0016-5085(99)70191-5			8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	171ZG	WOS:000078894400026	10029628				2021-06-18	
J	HintonBayre, AD; Geffen, G; McFarland, K				HintonBayre, AD; Geffen, G; McFarland, K			Mild head injury and speed of information processing: A prospective study of professional rugby league players	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							AUSTRALIAN RULES FOOTBALLERS; CONCUSSION; GUIDELINES; SPORTS; MANAGEMENT; PREVENTION; SEQUELAE	The sensitivity of several short tests of speed of information processing to the effects of mild head injury in rugby league football was investigated. The measures used were the Symbol Digit Modalities Test, the Digit Symbol Substitution Test, and the Speed of Comprehension Test. Two studies were conducted, the first to examine the effect of practice, the second to determine sensitivity to cognitive impairment immediately following injury. The first study established alternate form equivalence and demonstrated that performance on the Speed of Comprehension and Digit Symbol Substitution tests improved with practice, whereas the Symbol Digit Modalities test remained stable. A second study of 10 players who subsequently sustained mild head injuries showed that measures of speed of information processing were sensitive to impairment in the postacute phase, whereas an untimed task of word recognition (Spot-the-Word) was not. Speed of Comprehension was more sensitive to postinjury impairment than either the Digit Symbol Substitution or Symbol Digit Modalities tests. A repeated baseline assessment before injury using the higher score to reflect a player's potential, allowed measurement of impaired performance on sensitive tests.	UNIV QUEENSLAND,COGNIT PSYCHOPHYSIOL LAB,HERSTON,QLD 4006,AUSTRALIA; QUEENSLAND HLTH,CLIN STUDIES UNIT,BRISBANE,QLD,AUSTRALIA							BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; Baddeley A.D., 1992, SPEED CAPACITY LANGU; Bashford G, 1993, Aust Fam Physician, V22, P2067; BRATH JT, 1989, MILD HEAD INJURY, P257; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; BROOKS DN, 1989, RECOVERY BRAIN INJUR, P67; BRUKNER P, 1993, CLIN SPORTS MED, P155; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Clark C., 1988, HDB DICHOTIC LISTENI, P71; Crawford J. R., 1992, HDB NEUROPSYCHOLOGIC, P21; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Dicker G, 1993, Aust Fam Physician, V22, P750; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; FICK DS, 1995, POSTGRAD MED, V97, P53; GARNHAM AP, 1992, TXB SCI MED SPORT, P279; GENTILINI M, 1989, MILD HEAD INJURY, P163; GIBBS N, 1993, AM J SPORT MED, V21, P696, DOI 10.1177/036354659302100510; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1992, NZ J SPORTS MED, V20, P19; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Halstead WC, 1985, HALSTEAD REITAN NEUR; HAZARD H, 1987, SPORTS COAHC, P9; HOY G, 1987, SPORT HLTH, V5, P26; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LEBLANC KE, 1994, AM FAM PHYSICIAN, V50, P801; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, AUST PSYCHOL, V30, P125, DOI 10.1080/00050069508258916; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; MCCRORY P, 1994, HEAD BRAIN INJURY SP; MILLER RE, 1984, HYPERTENSION, V6, P202, DOI 10.1161/01.HYP.6.2_Pt_1.202; *NAT HLTH MED RES, 1994, FOOTB INJ HEAD NECK; Nelson H., 1982, NATIONAL ADULT READI; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; Sacks T. L, 1991, CLIN NEUROPSYCHOL, V5, P220; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Smith A., 1982, SYMBOL DIGIT MODALIT; STRAUSS ME, 1987, NEUROBEHAVIORAL RECO, P88; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WRIGHTSON P, 1992, NZ J SPORTS MED, V20, P19; YOUNGJOHN JR, 1992, CLIN NEUROPSYCHOLOGI, V3, P276	49	111	111	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1997	19	2					275	289		10.1080/01688639708403857			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	XC634	WOS:A1997XC63400011	9240486				2021-06-18	
J	OKIYAMA, K; SMITH, DH; GENNARELLI, TA; SIMON, RP; LEACH, M; MCINTOSH, TK				OKIYAMA, K; SMITH, DH; GENNARELLI, TA; SIMON, RP; LEACH, M; MCINTOSH, TK			THE SODIUM-CHANNEL BLOCKER AND GLUTAMATE RELEASE INHIBITOR BW1003C87 AND MAGNESIUM ATTENUATE REGIONAL CEREBRAL EDEMA FOLLOWING EXPERIMENTAL BRAIN INJURY IN THE RAT	JOURNAL OF NEUROCHEMISTRY			English	Article						CEREBRAL EDEMA; BRAIN INJURY; EXCITOTOXICITY; GLUTAMALE; MAGNESIUM; NMDA	EXCITATORY AMINO-ACIDS; D-ASPARTATE RECEPTORS; NMDA ANTAGONISTS; ISCHEMIC DAMAGE; LAMOTRIGINE; NEUROTOXICITY; NEURONS; ASTROCYTES; KETAMINE; INVITRO	Excitatory amino acid (EAA) neurotransmitters may play a role in the pathophysiology of traumatic injury to the CNS. Although NMDA receptor antagonists have been reported to have therapeutic efficacy in animal models of brain injury, these compounds may have unacceptable toxicity for clinical use. One alternative approach is to inhibit the release of EAAs following traumatic injury. The present study examined the effects of administration of a novel sodium channel blocker and EAA release inhibitor, BW1003C87, or the NMDA receptor-associated ion channel blocker magnesium chloride on cerebral edema formation following experimental brain injury in the rat. Animals (n = 33) were subjected to fluid percussion brain injury of moderate severity (2.3 atm) over the left parietal cortex. Fifteen minutes after injury, the animals received a constant infusion of BW1003C87(10 mg/kg, i.v.), magnesium chloride (300 mu mol/kg, i.v.), or saline over 15 min (2.75 ml/kg/15 min). In all animals, regional tissue water content in brain was assessed at 48 h after injury, using the wet weight/dry weight technique. In saline-treated control animals, fluid percussion brain injury produced significant regional brain edema in injured left parietal cortex (p < 0.001), the cortical area adjacent to the site of maximal injury (p < 0.001), left hippocampus (p < 0.001), and left thalamus (p = 0.02) at 48 h after brain injury. Administration of BW1003C87 15 min postinjury significantly reduced focal brain edema in the cortical area adjacent to the site of maximal injury (p < 0.02) and left hippocampus (p < 0.01), whereas magnesium chloride attenuated edema in left hippocampus (p = 0.02). These results suggest that excitatory neurotransmission may play an important role in the pathogenesis of posttraumatic brain edema and that pre- or postsynaptic blockade of glutamate receptor systems may attenuate part of the deleterious sequelae of traumatic brain injury.	UNIV PENN,DEPT SURG,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PITTSBURGH,DEPT NEUROL,PITTSBURGH,PA 15260; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND			smith, douglas/A-1321-2007	Leach, Michael/0000-0002-9859-1325	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803, P50NS008803, R55NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 08803, NS 26818] Funding Source: Medline		BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; BUCHAN A, 1992, NEUROL CLIN, V10, P49; BUCHAN AM, 1992, ARCH NEUROL-CHICAGO, V49, P420, DOI 10.1001/archneur.1992.00530280114032; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; BUTCHER SP, 1987, J NEUROCHEM, V48, P722, DOI 10.1111/j.1471-4159.1987.tb05576.x; CHAN PH, 1990, ACT NEUR S, V51, P7; CHEUNG H, 1992, EPILEPSY RES, V13, P107; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; CLIFFORD DB, 1989, EXP NEUROL, V105, P272, DOI 10.1016/0014-4886(89)90130-1; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; FADEN AI, 1988, ANN NEUROL, V3, P623; FADEN AI, 1989, SCIENCE, V244, P789; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; IKEDA M, 1989, NEUROSCI LETT, V996, P202; ISHIGE N, 1987, J CEREB BLOOD FLOW M, V7, P750; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KIMELBERG HK, 1986, ASTROCYTES, V3, P129; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; KOYAMA Y, 1991, NEUROSCI LETT, V122, P210, DOI 10.1016/0304-3940(91)90860-V; KUFFLER SW, 1984, NEURON BRAIN, P323; LANG DG, 1993, J PHARMACOL EXP THER, V266, P829; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006-8993(93)91660-K; LUSTIG HS, 1992, NEUROSCI LETT, V143, P229, DOI 10.1016/0304-3940(92)90271-8; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MCGEER EG, 1990, NEUROSCI LETT, V112, P348, DOI 10.1016/0304-3940(90)90229-3; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; MELDRUM BS, 1988, NEUROL NEUR, V46, P195; MEYER FB, 1990, J CEREBR BLOOD F MET, V10, P895, DOI 10.1038/jcbfm.1990.146; MILLER AA, 1986, NEW ANTICONVULSANT D, P165; MRSULJA BB, 1990, ACT NEUR S, V51, P180; NEUWELT EA, 1989, IMPLICATIONS BLOOD B; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PICOZZI P, 1985, J NEUROSURG, V62, P704, DOI 10.3171/jns.1985.62.5.0704; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SANCHEZPRIETO J, 1987, J NEUROCHEM, V49, P58, DOI 10.1111/j.1471-4159.1987.tb03394.x; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SIRVIO J, 1992, NEUROSCI LETT, V146, P215, DOI 10.1016/0304-3940(92)90081-H; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1993, J NEUROSCI, V13, P5383; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STEINBERG GK, 1989, STROKE, V20, P1247, DOI 10.1161/01.STR.20.9.1247; STEINBERG GK, 1989, BRAIN RES, V497, P382, DOI 10.1016/0006-8993(89)90285-0; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	77	111	112	0	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	1995	64	2					802	809					8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	QD027	WOS:A1995QD02700040	7830074				2021-06-18	
J	SHARPLES, PM; STUART, AG; MATTHEWS, DSF; AYNSLEYGREEN, A; EYRE, JA				SHARPLES, PM; STUART, AG; MATTHEWS, DSF; AYNSLEYGREEN, A; EYRE, JA			CEREBRAL BLOOD-FLOW AND METABOLISM IN CHILDREN WITH SEVERE HEAD-INJURY .1. RELATION TO AGE, GLASGOW COMA SCORE, OUTCOME, INTRACRANIAL-PRESSURE, AND TIME AFTER INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						HEAD INJURY; CEREBRAL BLOOD FLOW; INTRACRANIAL PRESSURE	TRAUMATIC BRAIN INJURY; MITOCHONDRIAL RESPIRATION; ANOXIA ISCHEMIA; DYNAMIC CHANGES; ACUTE PHASE; OXYGEN; RATS; DETERIORATION; CONSCIOUSNESS; REPERFUSION	Understanding the pathophysiology of paediatric head trauma is essential for rational acute management. It has been proposed that the response to severe head injury in children differs from that in adults, with increased cerebral blood flow (cerebral hyperaemia) representing the most common cause of raised intracranial pressure, but this has recently been disputed. The relation between the pathophysiological response and time after injury has not been defined in children. This paper describes 151 serial measurements of cerebral blood flow, arteriojugular venous oxygen difference (AJVDo(2)), and cerebral metabolic rate for oxygen (CMRo(2)) that were performed in 21 children with severe head injury, mean age 8 (range 2-16) years, Glasgow coma score less than or equal to 8. Absolute cerebral hyperaemia was uncommon, only 10 (7%) of the 151 cerebral blood flow values being at or above the upper Limit of the range published in normal children. There was an inverse correlation between cerebral blood flow and intracranial pressure. (r= -0.24, p = 0.009). Contrary to the widespread assumption that cerebral metabolic rate in patients with head injury is always low, CMRo(2) was initially within the normal range in 17/21 (81%) children. Both CMRo(2) and AJVDo(2) fell significantly between the first and third days after injury. There was a non-significant rise in cerebral blood how over time. These data represent the first evidence that the temporal change in cerebral metabolic rate reported in experimental models of traumatic brain injury also occurs in patients with head injury. The in the pathophysiological over time suggest that the management may need to be modified accordingly. If cerebral metabolic rate and cerebral oxygen extraction are maximal shortly after injury in children with severe head injury then the children are most likely to sustain secondary damage during this period.	UNIV NEWCASTLE UPON TYNE, DEPT CHILD HLTH, PAEDIAT NEUROL RES UNIT, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND				Stuart, Alan Graham/0000-0003-2789-2216	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Benumof J.L., 1986, ANESTHESIA, V2, P1115; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BRUCE DA, 1985, BRAIN INSULTS INFANT, P83; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; CHAMBERS IR, 1990, NEUROSURGERY, V26, P421, DOI 10.1227/00006123-199003000-00007; CHRISTENSEN MS, 1974, BRIT J ANAESTH, V46, P348, DOI 10.1093/bja/46.5.348; COLD GE, 1980, ACTA ANAESTH SCAND, V24, P245, DOI 10.1111/j.1399-6576.1980.tb01544.x; CRAFT AW, 1972, HDB CLIN NEUROLOGY, V23, P445; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; EYRE JA, 1983, ARCH DIS CHILD, V58, P785, DOI 10.1136/adc.58.10.785; FERRARI R, 1989, MOL CELL BIOCHEM, V88, P161; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; HAYWARD R, 1987, ARCH DIS CHILD, V62, P1283, DOI 10.1136/adc.62.12.1283; James HE, 1985, BRAIN INSULTS INFANT, P179; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; KURUP CKR, 1990, J BIOENERG BIOMEMBR, V22, P61; LANGFITT TW, 1977, ANN SURG, V186, P411, DOI 10.1097/00000658-197710000-00002; LEVASSEUR JE, 1979, J APPL PHYSIOL, V46, P89; LINN F, 1987, EXP NEUROL, V96, P321, DOI 10.1016/0014-4886(87)90050-1; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCDOWALL DG, 1968, SCAND J CLIN LAB INV, VS 22, pE8; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MICHENFELDER JD, 1988, ANESTHESIA BRAIN, P113; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Nelson S, 1966, HEAD INJURY, P444; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PASCUCCI RC, 1988, INTENS CARE MED, V14, P185, DOI 10.1007/BF00717985; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SETTERGREN G, 1980, ACTA PAEDIATR SCAND, V69, P457, DOI 10.1111/j.1651-2227.1980.tb07114.x; SEVERINGHAUS JW, 1966, CIRC RES, V19, P274, DOI 10.1161/01.RES.19.2.274; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SHARPLES PM, 1991, ARCH DIS CHILD, V66, P1326, DOI 10.1136/adc.66.11.1326; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SWEDLOW D, 1984, BRAIN EDEMA, P365; TAKEO S, 1989, J PHARMACOL EXP THER, V248, P1207; TASKER RC, 1988, ARCH DIS CHILD, V63, P888, DOI 10.1136/adc.63.8.888; TEASDALE G, 1974, LANCET, V2, P81; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; WAGNER KR, 1990, J CEREBR BLOOD F MET, V10, P417, DOI 10.1038/jcbfm.1990.72; WAGNER KR, 1990, J NEUROL SCI, V100, P142, DOI 10.1016/0022-510X(90)90025-I; YANG MS, 1985, J NEUROSURG, V1, P297; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	57	111	111	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	1995	58	2					145	152		10.1136/jnnp.58.2.145			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	QG825	WOS:A1995QG82500003	7876842	Green Published, Bronze			2021-06-18	
J	PALMER, AM; MARION, DW; BOTSCHELLER, ML; BOWEN, DM; DEKOSKY, ST				PALMER, AM; MARION, DW; BOTSCHELLER, ML; BOWEN, DM; DEKOSKY, ST			INCREASED TRANSMITTER AMINO-ACID CONCENTRATION IN HUMAN VENTRICULAR CSF AFTER BRAIN TRAUMA	NEUROREPORT			English	Article						ASPARTATE; CSF; EXCITOTOXICITY; GLUTAMATE; HUMAN INJURY; TRAUMATIC BRAIN INJURY; GABA	INJURY; GLUTAMATE; EXCITOTOXICITY; ASPARTATE; RELEASE; RECEPTORS; TOXICITY; SCALE; RATS; COMA	THE concentrations of L-aspartate, L-glutamate, L-serine, glycine and gamma-aminobutyric acid (GABA) were determined in repeated samples of ventricular CSF from five patients with severe closed head injury. The values were compared with those obtained from five subjects undergoing surgical treatment for intractable depression. In the head-injured patients, the concentrations of aspartate, glutamate and glycine were 2- to 8-fold higher and the concentration of GABA 56- to 317-fold higher than control values; the concentration of serine was unaffected. Spearman correlation analysis indicated that the concentration of glutamate significantly increased after injury (R(s) = 0.60, p < 0.0001, n = 42), reaching an average concentration of about 7 mu M 3 days after the injury. This is probably sufficient to cause further excitotoxicity, which suggests the use of excitatory amino acid receptor antagonists as a treatment following severe head injury may require prolonged administration for maximum therapeutic benefit.	UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,DEPT NEUROL SURG,PITTSBURGH,PA 15261; INST NEUROL,DEPT NEUROCHEM,LONDON,ENGLAND	PALMER, AM (corresponding author), WYETH AYERST RES,HUNTERCOMBE LANE S,TAPLOW SL6 0PH,BERKS,ENGLAND.		Marion, Donald/AAR-5749-2021	DeKosky, Steven/0000-0003-3743-2758; Marion, Donald/0000-0003-4627-7702	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318] Funding Source: NIH RePORTER		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BENVENISTE H, 1990, CEREBROVAS BRAIN MET, V3, P213; BERNERT H, 1992, SOC NEUR ABSTR, V18, P4572; ENGELSEN BA, 1985, NEUROSCI LETT, V62, P97, DOI 10.1016/0304-3940(85)90290-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLECK MW, 1993, J NEUROSCI, V13, P3944; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HUTSON PH, 1985, J NEUROCHEM, V44, P1266, DOI 10.1111/j.1471-4159.1985.tb08753.x; JENNETT B, 1985, LANCET, V1, P480; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANGALOS MN, 1992, BRIT J PSYCHIAT, V160, P638, DOI 10.1192/bjp.160.5.638; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PERRY TL, 1975, J NEUROCHEM, V24, P587, DOI 10.1111/j.1471-4159.1975.tb07680.x; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; TEASDALE G, 1974, LANCET, V2, P81; WESTERGREN I, 1994, J NEUROCHEM, V62, P159; ZEEVALK GD, 1989, J NEUROCHEM, V53, P1610, DOI 10.1111/j.1471-4159.1989.tb08559.x; ZEEVALK GD, 1991, J PHARMACOL EXP THER, V257, P870; ZEEVALK GD, 1993, J NEUROCHEM, V61, P1445, DOI 10.1111/j.1471-4159.1993.tb13639.x	25	111	114	0	3	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	DEC 30	1994	6	1					153	156		10.1097/00001756-199412300-00039			4	Neurosciences	Neurosciences & Neurology	QD829	WOS:A1994QD82900038	7703404				2021-06-18	
J	SHOHAMI, E; SHAPIRA, Y; YADID, G; REISFELD, N; YEDGAR, S				SHOHAMI, E; SHAPIRA, Y; YADID, G; REISFELD, N; YEDGAR, S			BRAIN PHOSPHOLIPASE-A2 IS ACTIVATED AFTER EXPERIMENTAL CLOSED HEAD-INJURY IN THE RAT	JOURNAL OF NEUROCHEMISTRY			English	Article									HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91010 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT ANESTHESIOL,IL-91010 JERUSALEM,ISRAEL	SHOHAMI, E (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PHARMACOL,POB 1172,IL-91010 JERUSALEM,ISRAEL.						ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; ABE K, 1988, STROKE, V19, P480, DOI 10.1161/01.STR.19.4.480; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BAZAN NG, 1971, J NEUROCHEM, V18, P1379, DOI 10.1111/j.1471-4159.1971.tb00002.x; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1976, FUNCTION METABOLISM, P317; BORASCHI D, 1985, J IMMUNOL, V135, P502; Brenner T, 1988, Ann N Y Acad Sci, V540, P403, DOI 10.1111/j.1749-6632.1988.tb27115.x; DAGAN A, 1987, BIOCHEM INT, V15, P801; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DENGLER LA, 1986, PROG CLIN BIOL RES, V270, P291; EDGAR AD, 1982, J NEUROCHEM, V39, P1111, DOI 10.1111/j.1471-4159.1982.tb11503.x; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; GALLI C, 1976, J NEUROCHEM, V26, P401, DOI 10.1111/j.1471-4159.1976.tb04493.x; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; GARDINER M, 1981, J NEUROCHEM, V36, P1500, DOI 10.1111/j.1471-4159.1981.tb00592.x; GAUDET RJ, 1980, J NEUROCHEM, V35, P653, DOI 10.1111/j.1471-4159.1980.tb03704.x; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; HOVAV E, 1987, BIORHEOLOGY, V23, P377; JACOBS TP, 1987, STROKE, V18, P741, DOI 10.1161/01.STR.18.4.741; KEMPSKI O, 1987, STROKE, V18, P111, DOI 10.1161/01.STR.18.1.111; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LISTER MD, 1988, J BIOL CHEM, V263, P7506; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; ROSENTHAL MD, 1988, J CELL PHYSIOL, V136, P333, DOI 10.1002/jcp.1041360217; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1982, STROKE, V13, P494, DOI 10.1161/01.STR.13.4.494; SHOHAMI E, 1985, J NEUROCHEM, V45, P132, DOI 10.1111/j.1471-4159.1985.tb05484.x; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; SHOHAMI E, 1989, IN PRESS ANN NY ACAD; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; Slotboom A., 1982, PHOSPHOLIPIDS, P359; van den Bosch H, 1978, Adv Prostaglandin Thromboxane Res, V3, P69; VANDENBOSCH H, 1982, PHOSPHOLIPIDS, P313; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; WAITE M, 1987, PHOSPHOLIPASES, P243; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WEY HE, 1986, BIOCHIM BIOPHYS ACTA, V878, P380, DOI 10.1016/0005-2760(86)90246-8; WIELOCH T, 1984, J NEUROCHEM, V43, P160, DOI 10.1111/j.1471-4159.1984.tb06692.x; WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x; YASUDA H, 1985, J NEUROCHEM, V45, P168, DOI 10.1111/j.1471-4159.1985.tb05489.x; YEDGAR S, 1982, J BIOL CHEM, V257, P2188; YEDGAR S, 1987, BIOCHEMISTRY-US, V26, P3395, DOI 10.1021/bi00386a022; YOSHIDA S, 1980, J NEUROSURG, V53, P323, DOI 10.3171/jns.1980.53.3.0323	47	111	113	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	NOV	1989	53	5					1541	1546		10.1111/j.1471-4159.1989.tb08550.x			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AW235	WOS:A1989AW23500029	2477500				2021-06-18	
J	Houlden, A; Goldrick, M; Brough, D; Vizi, ES; Lenart, N; Martinecz, B; Roberts, IS; Denes, A				Houlden, A.; Goldrick, M.; Brough, D.; Vizi, E. S.; Lenart, N.; Martinecz, B.; Roberts, I. S.; Denes, A.			Brain injury induces specific changes in the caecal microbiota of mice via altered autonomic activity and mucoprotein production	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Stroke; Microbiota; Cerebral ischemia; Inflammation; Noradrenaline; Gut; Mucoprotein	EXPERIMENTAL STROKE; NERVOUS-SYSTEM; GUT MICROBIOTA; ACTIVATION; CATECHOLAMINES; ENDOCRINOLOGY; CONSTIPATION; DISORDERS; PATTERNS; BACTERIA	Intestinal microbiota are critical for health with changes associated with diverse human diseases. Research suggests that altered intestinal microbiota can profoundly affect brain function. However, whether altering brain function directly affects the microbiota is unknown. Since it is currently unclear how brain injury induces clinical complications such as infections or paralytic ileus, key contributors to prolonged hospitalization and death post-stroke, we tested in mice the hypothesis that brain damage induced changes in the intestinal microbiota. Experimental stroke altered the composition of caeca( microbiota, with specific changes in Peptococcaceae and Prevotellaceae correlating with the extent of injury. These effects are mediated by noradrenaline release from the autonomic nervous system with altered caecal mucoprotein production and goblet cell numbers. Traumatic brain injury also caused changes in the gut microbiota, confirming brain injury effects gut microbiota. Changes in intestinal microbiota after brain injury may affect recovery and treatment of patients should appreciate such changes. (C) 2016 The Authors. Published by Elsevier Inc.	[Houlden, A.; Goldrick, M.; Brough, D.; Roberts, I. S.; Denes, A.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Lenart, N.; Martinecz, B.; Denes, A.] Inst Expt Med, Lab Neuroimmunol, Budapest, Hungary; [Vizi, E. S.] Hungarian Acad Sci, Inst Expt Med, Lab Drug Res, POB 67, H-1450 Budapest, Hungary; [Vizi, E. S.] Semmelweis Univ, Dept Pharmacol & Pharmacotherapy, Budapest, Hungary	Roberts, IS (corresponding author), Univ Manchester, Fac Life Sci, Manchester, Lancs, England.; Denes, A (corresponding author), Inst Expt Med, Lab Neuroimmunol, Budapest, Hungary.	i.s.roberts@manchester.ac.uk; denesa@koki.hu		Brough, David/0000-0002-2250-2381	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1100076]; OTKAOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [K109743]; Hungarian Brain Research Program [KTIA_13_NAP-A-I/2]; Bolyai Janos Research Scholarship from the Hungarian Academy of Sciences	We are grateful to Thomas Curl-Roper and Erica Roche who performed experiments on this project as part of their degree programmes at the University of Manchester. We thank Maria Bako for her help and advice in histology. We thank Ping Wang for assistance in denoising sequencing data. We thank Prof. Ulrich Dirnagl and Prof. Andreas Meisel for the critical discussions of the work. We are also grateful to Prof. Mark Lyte (Texas Tech University Health Sciences Center) for useful discussions. This work was in part funded through Medical Research Council grant G1100076 to ISR. Funding for AD was provided by OTKA K109743 and the Hungarian Brain Research Program KTIA_13_NAP-A-I/2. AD is supported by the Bolyai Janos Research Scholarship from the Hungarian Academy of Sciences.	Abt MC, 2012, IMMUNITY, V37, P158, DOI 10.1016/j.immuni.2012.04.011; Asano Y, 2012, AM J PHYSIOL-GASTR L, V303, pG1288, DOI 10.1152/ajpgi.00341.2012; Ayres JS, 2012, NAT MED, V18, P799, DOI 10.1038/nm.2729; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bracci F, 2007, WORLD J GASTROENTERO, V13, P3967, DOI 10.3748/wjg.v13.i29.3967; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Caso JR, 2008, STROKE, V39, P1314, DOI 10.1161/STROKEAHA.107.498212; CECHETTO DF, 1989, BRAIN RES, V502, P296, DOI 10.1016/0006-8993(89)90625-2; de Jonge Wouter J, 2013, ISRN Gastroenterol, V2013, P630159, DOI 10.1155/2013/630159; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Denes A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-164; Denes A, 2011, J CEREBR BLOOD F MET, V31, P1036, DOI 10.1038/jcbfm.2010.198; Denes A, 2010, J NEUROSCI, V30, P10086, DOI 10.1523/JNEUROSCI.1227-10.2010; Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc; DuPont AW, 2011, NAT REV GASTRO HEPAT, V8, P523, DOI 10.1038/nrgastro.2011.133; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Mejia-Leon ME, 2014, SCI REP-UK, V4, DOI 10.1038/srep03814; Flint HJ, 2012, NAT REV GASTRO HEPAT, V9, P577, DOI 10.1038/nrgastro.2012.156; Ganal SC, 2012, IMMUNITY, V37, P171, DOI 10.1016/j.immuni.2012.05.020; GOOD IJ, 1953, BIOMETRIKA, V40, P237, DOI 10.2307/2333344; Goslee SC, 2007, J STAT SOFTW, V22, P1, DOI 10.18637/jss.v022.i07; Gu SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074957; Reyes-Garcia MG, 2009, J NEUROIMMUNOL, V216, P20, DOI 10.1016/j.jneuroim.2009.06.024; Hetze S, 2013, J CEREBR BLOOD F MET, V33, P846, DOI 10.1038/jcbfm.2013.6; Hilz MJ, 2011, STROKE, V42, P1528, DOI 10.1161/STROKEAHA.110.607721; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Jentsch HFR, 2013, ANAEROBE, V24, P49, DOI 10.1016/j.anaerobe.2013.09.001; Kang DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068322; Karavolos MH, 2013, MOL MICROBIOL, V87, P455, DOI 10.1111/mmi.12110; Kim Young S, 2010, Curr Gastroenterol Rep, V12, P319, DOI 10.1007/s11894-010-0131-2; Korpelainen JT, 1999, CLIN AUTON RES, V9, P325, DOI 10.1007/BF02318379; Le Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506; Luczynski P, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw020; Lyte M, 2004, TRENDS MICROBIOL, V12, P14, DOI 10.1016/j.tim.2003.11.004; Lyte M, 1997, J SURG RES, V70, P195, DOI 10.1006/jsre.1997.5130; Lyte M, 2014, GUT MICROBES, V5, P381, DOI 10.4161/gmic.28682; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695, DOI 10.1128/AEM.59.3.695-700.1993; MYERS MG, 1981, STROKE, V12, P200, DOI 10.1161/01.STR.12.2.200; Nguyen KD, 2011, NATURE, V480, P104, DOI 10.1038/nature10653; O'Mahony SM, 2009, BIOL PSYCHIAT, V65, P263, DOI 10.1016/j.biopsych.2008.06.026; Oksanen J., 2012, VEGAN COMMUNITY ECOL; Polz MF, 1998, APPL ENVIRON MICROB, V64, P3724; Prindiville T, 2004, INFLAMM BOWEL DIS, V10, P824, DOI 10.1097/00054725-200411000-00017; Pullinger GD, 2010, VET RES, V41, DOI 10.1051/vetres/2010040; Quince C, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-38; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Spor A, 2011, NAT REV MICROBIOL, V9, P279, DOI 10.1038/nrmicro2540; Su YJ, 2009, STROKE, V40, P1304, DOI 10.1161/STROKEAHA.108.534776; Thompson JR, 2002, NUCLEIC ACIDS RES, V30, P2083, DOI 10.1093/nar/30.9.2083; Umschweif G., 2014, J CEREB BLOOD FLOW M, V34, P1; VIZI ES, 1985, NEUROSCIENCE, V16, P907, DOI 10.1016/0306-4522(85)90105-8; VIZI ES, 1995, NEUROSCIENCE, V68, P1263, DOI 10.1016/0306-4522(95)00215-5; WILLIAMS JM, 1981, BRAIN RES BULL, V6, P83, DOI 10.1016/S0361-9230(81)80072-X; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899; Wright DP, 2000, FEMS MICROBIOL LETT, V190, P73, DOI 10.1111/j.1574-6968.2000.tb09265.x; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347	59	110	121	1	27	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	OCT	2016	57						10	20		10.1016/j.bbi.2016.04.003			11	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	DW0BP	WOS:000383306200003	27060191	Green Published, Other Gold, Green Accepted			2021-06-18	
J	Meehan, WP; Mannix, RC; O'Brien, MJ; Collins, MW				Meehan, William P., III; Mannix, Rebekah C.; O'Brien, Michael J.; Collins, Michael W.			The Prevalence of Undiagnosed Concussions in Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						mild traumatic brain injury; loss of consciousness; sports injury	FOOTBALL PLAYERS; RECURRENT CONCUSSION; HEAD-INJURY	Objective: Previous studies suggest athletes underreport concussions. We sought to determine whether athletes in our clinics have sustained previous concussions that went undiagnosed. Design: Multicentered cross sectional study. Setting: Two sport concussion clinics. Patients: Patients diagnosed with sport-related concussions or concussions with injury mechanisms and forces similar to those observed in sports were included. Main Outcome Measures: The proportion of patients who answered "yes" to the following question were defined as having a previously undiagnosed concussion: "Have you ever sustained a blow to the head which was NOT diagnosed as a concussion but was followed by one or more of the signs and symptoms listed in the Post Concussion Symptom Scale?" Results: Of the 486 patients included in the final analysis, 148 (30.5%) patients reported a previously undiagnosed concussion. Athletes reporting previously undiagnosed concussions had a higher mean Post Concussion Symptom Scale (PCSS) score (33 vs 25; P < 0.004) and were more likely to have lost consciousness (31% vs 22%; P = 0.038) with their current injury than athletes without previously undiagnosed concussions. Conclusions: Nearly one-third of athletes have sustained previously undiagnosed concussions, defined as a blow to the head followed by the signs and symptoms included in the PCSS. Furthermore, these previously undiagnosed concussions are associated with higher PCSS scores and higher loss of consciousness rates when future concussions occur.	[Meehan, William P., III; O'Brien, Michael J.] Boston Childrens Hosp, Sports Concuss Clin, Div Sports Med, Dept Orthopaed, Boston, MA 02115 USA; [Meehan, William P., III; O'Brien, Michael J.] Micheli Ctr Sports Injury Prevent, Boston, MA USA; [Meehan, William P., III; Mannix, Rebekah C.] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA; [Meehan, William P., III; Mannix, Rebekah C.] Boston Childrens Hosp, Dept Med, Div Emergency Med, Boston, MA 02115 USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Orthopaed, Sports Med Concuss Program, Pittsburgh, PA USA	Meehan, WP (corresponding author), Boston Childrens Hosp, Sports Concuss Clin, Div Sports Med, 319 Longwood Ave,Floor 6, Boston, MA 02115 USA.	concussion.sportsmed@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD052896]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD018655, K12HD052896, T32HD040128] Funding Source: NIH RePORTER	Supported by National Institutes of Health Grants T32 HD040128 to 06A1 (to W.P. Meehan) and National Institute of Child Health and Human Development Grants K12 HD052896 to 01A1 (to R.C. Mannix).	CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; LaBotz M, 2005, CLIN J SPORT MED, V15, P73, DOI 10.1097/01.jsm.0000157649.99867.fc; MacMullan J., BOSTON; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	14	110	110	0	55	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2013	23	5					339	342		10.1097/JSM.0b013e318291d3b3			4	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	212YD	WOS:000324017900003	23727697	Green Accepted			2021-06-18	
J	Magnoni, S; Esparza, TJ; Conte, V; Carbonara, M; Carrabba, G; Holtzman, DM; Zipfel, GJ; Stocchetti, N; Brody, DL				Magnoni, Sandra; Esparza, Thomas J.; Conte, Valeria; Carbonara, Marco; Carrabba, Giorgio; Holtzman, David M.; Zipfel, Greg J.; Stocchetti, Nino; Brody, David L.			Tau elevations in the brain extracellular space correlate with reduced amyloid-beta levels and predict adverse clinical outcomes after severe traumatic brain injury	BRAIN			English	Article						traumatic brain injury; microdialysis; amyloid-beta; tau; neurofilament	DIFFUSE AXONAL INJURY; NEUROFILAMENT LIGHT-CHAIN; REPETITIVE HEAD-INJURY; WHITE-MATTER INJURY; CEREBROSPINAL-FLUID; IN-VIVO; CEREBRAL MICRODIALYSIS; STRUCTURED INTERVIEWS; PRECURSOR PROTEIN; MILD	Axonal injury is believed to be a major determinant of adverse outcomes following traumatic brain injury. However, it has been difficult to assess acutely the severity of axonal injury in human traumatic brain injury patients. We hypothesized that microdialysis-based measurements of the brain extracellular fluid levels of tau and neurofilament light chain, two low molecular weight axonal proteins, could be helpful in this regard. To test this hypothesis, 100 kDa cut-off microdialysis catheters were placed in 16 patients with severe traumatic brain injury at two neurological/neurosurgical intensive care units. Tau levels in the microdialysis samples were highest early and fell over time in all patients. Initial tau levels were >3-fold higher in patients with microdialysis catheters placed in pericontusional regions than in patients in whom catheters were placed in normal-appearing right frontal lobe tissue (P = 0.005). Tau levels and neurofilament light-chain levels were positively correlated (r = 0.6, P = 0.013). Neurofilament light-chain levels were also higher in patients with pericontusional catheters (P = 0.04). Interestingly, initial tau levels were inversely correlated with initial amyloid-beta levels measured in the same samples (r = -0.87, P = 0.000023). This could be due to reduced synaptic activity in areas with substantial axonal injury, as amyloid-beta release is closely coupled with synaptic activity. Importantly, high initial tau levels correlated with worse clinical outcomes, as assessed using the Glasgow Outcome Scale 6 months after injury (r = -0.6, P = 0.018). Taken together, our data add support for the hypothesis that axonal injury may be related to long-term impairments following traumatic brain injury. Microdialysis-based measurement of tau levels in the brain extracellular space may be a useful way to assess the severity of axonal injury acutely in the intensive care unit. Further studies with larger numbers of patients will be required to assess the reproducibility of these findings and to determine whether this approach provides added value when combined with clinical and radiological information.	[Esparza, Thomas J.; Holtzman, David M.; Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Magnoni, Sandra; Conte, Valeria; Carbonara, Marco; Stocchetti, Nino] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Anaesthesia & Intens Care, I-20100 Milan, Italy; [Carrabba, Giorgio] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neurosurg, I-20100 Milan, Italy; [Holtzman, David M.; Zipfel, Greg J.; Brody, David L.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [Zipfel, Greg J.] Washington Univ, Dept Neurol Surg, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Carrabba, Giorgio/AAB-3925-2019; Stocchetti, Nino/O-7444-2017; Carbonara, Marco/N-3793-2015	Carrabba, Giorgio/0000-0002-0170-0653; Stocchetti, Nino/0000-0003-3250-6834; Carbonara, Marco/0000-0002-1431-8322	Burroughs Wellcome Career Award in the Biomedical SciencesBurroughs Wellcome Fund; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08 NS049237, R01 NS065069]; Fondazione IRCCS Ca Granda-Ospedale Maggiore Policlinico; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237, R01NS065069] Funding Source: NIH RePORTER	Burroughs Wellcome Career Award in the Biomedical Sciences (to D.L. B.); National Institutes of Health (grant numbers K08 NS049237 and R01 NS065069 to D.L.B.); Fondazione IRCCS Ca Granda-Ospedale Maggiore Policlinico, departmental funds.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Afinowi R, 2009, J NEUROSCI METH, V181, P95, DOI 10.1016/j.jneumeth.2009.02.021; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Arruda DL, 2009, EXPERT REV MOL DIAGN, V9, P749, DOI [10.1586/erm.09.47, 10.1586/ERM.09.47]; BENNETT M, 1995, IRISH MED J, V88, P59; Bero AW, 2011, NAT NEUROSCI, V14, P750, DOI 10.1038/nn.2801; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Chang MC, 2010, NEUROREHABILITATION, V26, P347, DOI 10.3233/NRE-2010-0572; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Cirrito JR, 2008, NEURON, V58, P42, DOI 10.1016/j.neuron.2008.02.003; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Fishman RA., 1992, CEREBROSPINAL FLUID; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; GUILLEMOT F, 1992, DEVELOPMENT, V114, P743; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kang JE, 2009, SCIENCE, V326, P1005, DOI 10.1126/science.1180962; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koel-Simmelink MJA, 2011, ANN NEUROL, V69, P1065, DOI 10.1002/ana.22438; Kondo K, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-147; Koura SS, 1998, ACT NEUR S, V71, P244; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Norgren N, 2003, BRAIN RES, V987, P25, DOI 10.1016/S0006-8993(03)03219-0; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Osuchowski MF, 2006, METHODS, V38, P304, DOI 10.1016/j.ymeth.2005.11.009; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; SHAW G, 1988, P NATL ACAD SCI USA, V85, P2854, DOI 10.1073/pnas.85.8.2854; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Timaru-Kast R, 2008, J NEUROTRAUM, V25, P1107, DOI 10.1089/neu.2008.0517; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Van Geel WJA, 2005, J IMMUNOL METHODS, V296, P179, DOI 10.1016/j.jim.2004.11.015; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; Zanier ER, 2011, J NEUROL NEUROSUR PS, V82, P157, DOI 10.1136/jnnp.2009.177667; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	88	110	116	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	APR	2012	135		4				1268	1280		10.1093/brain/awr286			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	927ZH	WOS:000302948700029	22116192	Green Published, Bronze			2021-06-18	
J	Gould, KR; Ponsford, JL; Johnston, L; Schonberger, M				Gould, K. R.; Ponsford, J. L.; Johnston, L.; Schoenberger, M.			The nature, frequency and course of psychiatric disorders in the first year after traumatic brain injury: a prospective study	PSYCHOLOGICAL MEDICINE			English	Article						Anxiety disorders; depressive disorders; psychiatric disorders; substance use disorders; traumatic brain injury	HEAD-INJURY; AXIS-I; DEPRESSION; PREVALENCE; ALCOHOL; SEVERITY; VALIDITY; RATES	Background. Psychiatric disorders are common following traumatic brain injury (TBI). However, few studies have examined the course of disorder development and the influence of pre-injury psychiatric history. The present study aimed to examine the frequency of, and association between, psychiatric disorders occurring pre- and post-injury, and to examine the post-injury course of disorders. Method. Participants were 102 adults (75.5% male) with predominantly moderate-severe TBI. Participants were initially assessed for pre-injury and current disorders, and reassessed at 3, 6 and 12 months post-injury using the Structured Clinical Interview for DSM-IV Disorders (SCID). Results. Over half of the participants had a pre-injury psychiatric disorder; predominantly substance use, mood, and anxiety disorders. In the first year post-injury, 60.8% of participants had a psychiatric disorder, commonly anxiety and mood disorders. Post-injury disorders were associated with the presence of a pre-injury history (p<0.01), with 74.5% of participants with a pre-injury psychiatric history experiencing a post-injury disorder, which commonly presented at initial assessment or in the first 6 months. However, 45.8% of participants without a pre-injury history developed a novel post-injury disorder, which was less likely to emerge at the initial assessment and generally developed later in the year. Conclusions. Despite evidence that most post-injury psychiatric disorders represent the continuation of pre-existing disorders, a significant number of participants developed novel psychiatric disorders. This study demonstrates that the timing of onset may differ according to pre-injury history. There seem to be different trajectories for anxiety and depressive disorders. This research has important implications for identifying the time individuals are most at risk of psychiatric disorders post-injury.	[Gould, K. R.; Ponsford, J. L.; Schoenberger, M.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Gould, K. R.; Ponsford, J. L.; Johnston, L.; Schoenberger, M.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia; [Schoenberger, M.] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol, D-7800 Freiburg, Germany	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au	Gould, Kate/AAA-5511-2020	Gould, Kate/0000-0002-3564-7408	Victorian Neurotrauma Initiative [d150]; Australian Postgraduate AwardAustralian Government	This research was supported by a grant from the Victorian Neurotrauma Initiative (Ref: d150). We acknowledge the use of Australian Bureau of Statistics data and thank J. Taffe for statistical assistance. The authors also acknowledge the assistance of Mary Karamitsios with data collection and recruitment.; This research and manuscript were prepared during the course of employment at the Monash-Epworth Rehabilitation Centre for the authors J. Ponsford, K. Gould, L. Johnston and M. Schonberger. This research was conducted as partial fulfilment of the Doctorate in Clinical Neuropsychology at Monash University by K. Gould, an Australian Postgraduate Award scholarship recipient.	ABS, 2009, NAT SURV MENT HLTH W; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; APA, 2000, DIAGN STAT MAN MENT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First MB., 2002, STRUCTURED CLIN INTE; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Harter M, 2007, PSYCHOTHER PSYCHOSOM, V76, P354, DOI 10.1159/000107563; Haro JM, 2006, INT J METH PSYCH RES, V15, P167, DOI 10.1002/mpr.196; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jablensky A, 2000, AUST NZ J PSYCHIAT, V34, P221, DOI 10.1046/j.1440-1614.2000.00728.x; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lewis A. J., 1942, P ROY SOC MED, V35, P607; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Nelson HE, 1982, NATL ADULT READING T; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; RUTHERFORD WH, 1977, LANCET, V1, P1; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SPITZER RL, 1983, COMPR PSYCHIAT, V24, P399, DOI 10.1016/0010-440X(83)90032-9; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wade TD, 2006, AUST NZ J PSYCHIAT, V40, P121, DOI 10.1111/j.1440-1614.2006.01758.x; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; Wells JE, 2006, AUST NZ J PSYCHIAT, V40, P845, DOI 10.1111/j.1440-1614.2006.01903.x; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026	46	110	110	0	26	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	OCT	2011	41	10					2099	2109		10.1017/S003329171100033X			11	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	826BR	WOS:000295326900008	21477420				2021-06-18	
J	Benson, BW; Meeuwisse, WH; Rizos, J; Kang, J; Burke, CJ				Benson, Brian W.; Meeuwisse, Willem H.; Rizos, John; Kang, Jian; Burke, Charles J.			A prospective study of concussions among National Hockey League players during regular season games: the NHL-NHLPA Concussion Program	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							SPORT-RELATED CONCUSSION; ICE HOCKEY; INJURIES; STATEMENT; RECOVERY; TIME; EPIDEMIOLOGY; PREDICTORS; SYMPTOMS; FOOTBALL	Background: In 1997, the National Hockey League (NHL) and NHL Players' Association (NHLPA) launched a concussion program to improve the understanding of this injury. We explored initial postconcussion signs, symptoms, physical examination findings and time loss (i.e., time between the injury and medical clearance by the physician to return to competitive play), experienced by male professional ice-hockey players, and assessed the utility of initial postconcussion clinical manifestations in predicting time loss among hockey players. Methods: We conducted a prospective case series of concussions over seven NHL regular seasons (1997-2004) using an inclusive cohort of players. The primary outcome was concussion and the secondary outcome was time loss. NHL team physicians documented postconcussion clinical manifestations and recorded the date when a player was medically cleared to return to play. Results: Team physicians reported 559 concussions during regular season games. The estimated incidence was 1.8 concussions per 1000 player-hours. The most common postconcussion symptom was headache (71%). On average, time loss (in days) increased 2.25 times (95% confidence interval [CI] 1.41-3.62) for every subsequent (i.e., recurrent) concussion sustained during the study period. Controlling for age and position, significant predictors of time loss were postconcussion headache (p < 0.001), low energy or fatigue (p = 0.01), amnesia (p = 0.02) and abnormal neurologic examination (p = 0.01). Using a previously suggested time loss cut-point of 10 days, headache (odds ratio [OR] 2.17, 95% CI 1.33-3.54) and low energy or fatigue (OR 1.72, 95% CI 1.04-2.85) were significant predictors of time loss of more than 10 days. Interpretation: Postconcussion headache, low energy or fatigue, amnesia and abnormal neurologic examination were significant predictors of time loss among professional hockey players.	[Benson, Brian W.; Meeuwisse, Willem H.; Kang, Jian] Univ Calgary, Fac Kinesiol, Sport Med Ctr, Roger Jackson Ctr Hlth & Wellness Res, Calgary, AB, Canada; [Rizos, John] Credit Valley Hosp, Dept Emergency Med, Mississauga, ON, Canada; [Rizos, John] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada; [Burke, Charles J.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Benson, BW (corresponding author), Univ Calgary, Fac Kinesiol, Sport Med Ctr, Roger Jackson Ctr Hlth & Wellness Res, Calgary, AB, Canada.	bbenson@ucalgary.ca			The Alberta Heritage Foundation for Medical ResearchAlberta Heritage Foundation for Medical Research; The Alberta Provincial CIHR; National Hockey League (NHL); National Hockey League Players Association (NHLPA)	The Alberta Heritage Foundation for Medical Research and The Alberta Provincial CIHR Training Program in Bone and Joint Health provided financial support as part of the principal investigator's Doctorate Program in Epidemiology, Department of Community Health Sciences, Faculty of Medicine, University of Calgary.; The authors acknowledge the following individuals, groups and funding organizations: the National Hockey League (NHL), the National Hockey League Players Association (NHLPA), the NHL team physicians, athletic therapists and athletic trainers who collected information for the NHL-NHLPA Concussion Program, members of the previous NHL Concussion Program Committee (including Dave Dryden, Dr. Mark Lovell and Kristen Hawn), the current NHL-NHLPA Concussion Working Group (including Dr. Ruben Echemendia (Chair), Dr. Mark Aubry, Dr. Paul Comper, Julie Grand, Jim McCrossin and Rob Zamuner), the Alberta Heritage Foundation for Medical Research and the Alberta Provincial CIHR Training Program in Bone and Joint Health.	Agel J, 2007, J ATHL TRAINING, V42, P241; Anderson AJ, 2000, PEDIATRICS, V105, P657; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Cantu RC, 1997, CLIN J SPORT MED, V7, P83, DOI 10.1097/00042752-199704000-00001; Cantu RC, 2007, NEW ENGL J MED, V356, P1787; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Kohl HW, 2003, CLIN J SPORT MED, V13, P277, DOI 10.1097/00042752-200309000-00001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Molsa JJ, 1999, INT J SPORTS MED, V20, P64, DOI 10.1055/s-2007-971095; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Wennberg RA, 2008, CAN J NEUROL SCI, V35, P647, DOI 10.1017/S031716710000946X	31	110	111	0	18	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	MAY 17	2011	183	8					905	911		10.1503/cmaj.092190			7	Medicine, General & Internal	General & Internal Medicine	762AZ	WOS:000290446000056	21502355	Bronze, Green Published			2021-06-18	
J	Wu, TC; Wilde, EA; Bigler, ED; Li, XQ; Merkley, TL; Yallampalli, R; McCauley, SR; Schnelle, KP; Vasquez, AC; Chu, ZL; Hanten, G; Hunter, JV; Levin, HS				Wu, Trevor C.; Wilde, Elisabeth A.; Bigler, Erin D.; Li, Xiaoqi; Merkley, Tricia L.; Yallampalli, Ragini; McCauley, Stephen R.; Schnelle, Kathleen P.; Vasquez, Ana C.; Chu, Zili; Hanten, Gerri; Hunter, Jill V.; Levin, Harvey S.			Longitudinal Changes in the Corpus Callosum following Pediatric Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Cognitive development; Developmental changes; Morphometry; Neurodevelopment; Traumatic brain injury; White matter; Diffusion tensor imaging	DIFFUSE AXONAL INJURY; WHITE-MATTER INJURY; CLOSED-HEAD-INJURY; TENSOR IMAGING METRICS; INTERHEMISPHERIC-TRANSFER; NEUROIMAGING TECHNIQUES; ALZHEIMERS-DISEASE; PROCESSING SPEED; SERIAL CHANGES; MILD	Background: Atrophy of the corpus callosum (CC) is a documented consequence of moderate-to-severe traumatic brain injury (TBI), which has been expressed as volume loss using quantitative magnetic resonance imaging (MRI). Other advanced imaging modalities such as diffusion tensor imaging (DTI) have also detected white matter microstructural alteration following TBI in the CC. The manner and degree to which macrostructural changes such as volume and microstructural changes develop over time following pediatric TBI, and their relation to a measure of processing speed is the focus of this longitudinal investigation. As such, DTI and volumetric changes in the CC in participants with TBI and a comparison group at approximately 3 and 18 months after injury as well as their relation to processing speed were determined. Methods: Forty-eight children and adolescents aged 7-17 years who sustained either complicated mild or moderate-to-severe TBI (n = 23) or orthopedic injury (OI; n = 25) were studied. The participants underwent brain MRI and were administered the Eriksen flanker task at both time points. Results: At 3 months after injury, there were significant group differences in DTI metrics in the total CC and its subregions (genu/anterior, body/central and splenium/posterior), with the TBI group demonstrating significantly lower fractional anisotropy (FA) and a higher apparent diffusion coefficient (ADC) in comparison to the OI group. These group differences were also present at 18 months after injury in all CC subregions, with lower FA and a higher ADC in the TBI group. In terms of longitudinal changes in DTI, despite the group difference in mean FA, both groups generally demonstrated a modest increase in FA over time though this increase was only significant in the splenium/posterior subregion. Interestingly, the TBI group also generally demonstrated ADC increases from 3 to 18 months though the OI group demonstrated ADC decreases over time. Volumetrically, the group differences at 3 months were marginal for the midanterior and body/central subregions and total CC. However, by 18 months, the TBI group demonstrated a significantly decreased volume in all subregions except the splenium/posterior area relative to the OI group. Unlike the OI group, which showed a significant volume increase in subregions of the CC over time, the TBI group demonstrated a significant and consistent volume decrease. Performance on a measure of processing speed did not differentiate the groups at either visit, and only the OI group showed significantly improved performance over time. Processing speed was related to FA in the splenium/posterior and total CC only in the TBI group on both occasions, with a stronger relation at 18 months. Conclusion: In response to TBI, macrostructural volume loss in the CC occurred over time; yet, at the microstructural level, DTI demonstrated both indicators of continued maturation and development even in the damaged CC, as well as evidence of potential degenerative change. Unlike volumetrics, which likely reflects the degree of overall neuronal loss and axonal damage, DTI may reflect some aspects of postinjury maturation and adaptation in white matter following TBI. Multimodality imaging studies may be important to further understand the long-term consequences of pediatric TBI. Copyright (C) 2010 S. Karger AG, Basel	[Wilde, Elisabeth A.] Univ Texas Houston, Sch Med, Baylor Coll Med, Cognit Neurosci Lab,Dept Radiol & Neurol, Houston, TX 77030 USA; [Wu, Trevor C.; Bigler, Erin D.; Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [McCauley, Stephen R.] Univ Texas Houston, Sch Med, Baylor Coll Med, Dept Neurol & Pediat, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Univ Texas Houston, Sch Med, Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Univ Texas Houston, Sch Med, Baylor Coll Med, Dept Neurol Neurosurg & Pediat, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA	Wilde, EA (corresponding author), Univ Texas Houston, Sch Med, Baylor Coll Med, Cognit Neurosci Lab,Dept Radiol & Neurol, 1709 Dryden Rd Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-21889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by grant NS-21889 awarded to H.S.L. by the National Institutes of Health. We would also like to acknowledge the generous support by Mission Connect of the TIRR Foundation. We acknowledge the contribution of Stacey K. Martin by assisting in manuscript preparation, and the technical assistance of Tracy J. Abildskov. We also wish to thank Ms. Lori Cook and Drs. Sandra B. Chapman and Gillian Hotz. We would also like to thank the patients and their families for involvement in this study. This research paper is also the work of a doctoral dissertation.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Aukema EJ, 2009, INT J RADIAT ONCOL, V74, P837, DOI 10.1016/j.ijrobp.2008.08.060; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Battistone M, 2008, APPL NEUROPSYCHOL, V15, P69, DOI 10.1080/09084280801917863; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BIEGON A, 1994, NEUROBIOL AGING, V15, P393, DOI 10.1016/0197-4580(94)90070-1; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bloom JS, 2005, NEUROPSYCHOL REV, V15, P59, DOI 10.1007/s11065-005-6252-y; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Canu E, 2010, J ALZHEIMERS DIS, V19, P963, DOI 10.3233/JAD-2010-1295; Chepuri NB, 2002, AM J NEURORADIOL, V23, P803; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Di Paola M, 2010, NEUROIMAGE, V49, P141, DOI 10.1016/j.neuroimage.2009.07.050; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Jokinen H, 2007, J NEUROL NEUROSUR PS, V78, P491, DOI 10.1136/jnnp.2006.096792; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; KOCHUNOV P, 2010, NEUROBIOL AGING; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lobel U, 2009, NEURORADIOLOGY, V51, P253, DOI 10.1007/s00234-008-0488-1; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Markham JA, 2009, BRAIN RES, V1288, P9, DOI 10.1016/j.brainres.2009.06.087; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; MOREY RA, 2010, HUM BRAIN MAPP; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; NETSCH T, 2001, INT C COMP VIS VANC, V1, P718; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pannek K, 2010, NEUROIMAGE, V50, P1044, DOI 10.1016/j.neuroimage.2010.01.020; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PATEL MD, 2010, MAGMA; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tanriverdi T, 2009, J NEUROSURG, V110, P332, DOI 10.3171/2008.3.17570; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Turken AU, 2008, NEUROIMAGE, V42, P1032, DOI 10.1016/j.neuroimage.2008.03.057; van der Zijden JP, 2008, EXP NEUROL, V212, P207, DOI 10.1016/j.expneurol.2008.03.027; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang SL, 2009, CANCER RES, V69, P1190, DOI 10.1158/0008-5472.CAN-08-2661; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zhang LJ, 2005, AM J NEURORADIOL, V26, P45	89	110	112	0	10	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					361	373		10.1159/000317058			13	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900004	20948181	Bronze, Green Published			2021-06-18	
J	Hartings, JA; Strong, AJ; Fabricius, M; Manning, A; Bhatia, R; Dreier, JP; Mazzeo, AT; Tortella, FC; Bullock, MR				Hartings, Jed A.; Strong, Anthony J.; Fabricius, Martin; Manning, Andrew; Bhatia, Robin; Dreier, Jens P.; Mazzeo, Anna Teresa; Tortella, Frank C.; Bullock, M. Ross		CoOperative Study Brain Injury Dep	Spreading Depolarizations and Late Secondary Insults after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						electroencephalography; hyperthermia; intracranial hypertension; spreading cortical depression; vascular hypotension	FOCAL CEREBRAL-ISCHEMIA; PERIINFARCT DEPOLARIZATIONS; BLOOD-FLOW; DEPRESSION; SEIZURES; PRESSURE; RISK; MECHANISMS; HEMORRHAGE; HYPEREMIA	Here we investigated the incidence of cortical spreading depolarizations (spreading depression and peri-infarct depolarization) after traumatic brain injury (TBI) and their relationship to systemic physiologic values during neurointensive care. Subdural electrode strips were placed on peri-contusional cortex in 32 patients who underwent surgical treatment for TBI. Prospective electrocorticography was performed during neurointensive care with retrospective analysis of hourly nursing chart data. Recordings were 84 hr (median) per patient and 2,503 hr in total. In 17 patients (53%), 280 spreading depolarizations (spreading depressions and peri-infarct depolarizations) were observed. Depolarizations occurred in a bimodal pattern with peak incidence on days 1 and 7. The probability of a depolarization occurring increased significantly as a function of declining mean arterial pressure (MAP; R-2 = 0.78; p < 0.001) and cerebral perfusion pressure (R-2 = 0.85; p < 0.01), and increasing core temperature (R-2 = 0.44; p < 0.05). Depolarization probability was 7% for MAP values of > 100 mm Hg but 33% for MAP of <= 70 mm Hg. Temperatures of <= 38.4 degrees C were associated with a 21% depolarization risk, compared to 63% for > 38.4 degrees C. Intracranial pressures were higher in patients with depolarizations (18.3 +/- 9.3 vs. 13.5 +/- 6.7 mm Hg; p < 0.001). We conclude that depolarization phenomena are a common cortical pathology in TBI. Their association with lower perfusion levels and higher temperatures suggests that the labile balance of energy supply and demand is an important determinant of their occurrence. Monitoring of depolarizations might serve as a functional measure to guide therapeutic efforts and their blockade may provide an additional line of defense against the effects of secondary insults.	[Hartings, Jed A.] Univ Cincinnati, Dept Neurosurg, Inst Neurosci, Cincinnati, OH 45219 USA; [Strong, Anthony J.; Manning, Andrew; Bhatia, Robin] Kings Coll Hosp London, Dept Neurosurg, London, England; [Fabricius, Martin] Glostrup Cty Hosp, Dept Clin Neurophysiol, Copenhagen, Denmark; [Dreier, Jens P.] Charite, Ctr Stroke Res Berlin, D-13353 Berlin, Germany; [Mazzeo, Anna Teresa; Bullock, M. Ross] Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA USA; [Mazzeo, Anna Teresa] Univ Messina, Dept Neurosci Psychiat & Anesthesiol Sci, Messina, Italy; [Tortella, Frank C.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD USA	Hartings, JA (corresponding author), Univ Cincinnati, Dept Neurosurg, Inst Neurosci, 260 Stetson St,Suite 2200, Cincinnati, OH 45219 USA.	jed.hartings@uc.edu		Mazzeo, Anna Teresa/0000-0002-8454-7243; Hartings, Jed/0000-0001-8583-3471; Dreier, Jens/0000-0001-7459-2828	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [PO1 NS12587-27]; German Research Foundation (DFG)German Research Foundation (DFG) [SFB Tr3 D10, DR 323/3-1]; Novo Nordisk FoundationNovo Nordisk Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587] Funding Source: NIH RePORTER	We thank Charlotte Gilman, Marinella Gugliotta, and Amedeo Merenda for their valuable contributions. This work was supported in part by NINDS PO1 NS12587-27 (to R. B.), the German Research Foundation (DFG) SFB Tr3 D10 and DR 323/3-1 (to J. D.), and the Novo Nordisk Foundation (to M. F.).	Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CHEN Q, 1993, J CEREBR BLOOD F MET, V13, P389, DOI 10.1038/jcbfm.1993.52; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Geffroy A, 2004, INTENS CARE MED, V30, P785, DOI 10.1007/s00134-004-2280-y; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; HABLITZ JJ, 1989, DEV BRAIN RES, V46, P243, DOI 10.1016/0165-3806(89)90288-5; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Hartings JA, 2008, NEUROL RES, V30, P876, DOI 10.1179/174313208X309739; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kempski O, 2000, ACT NEUR S, V76, P251; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mun-Bryce S, 2001, BRAIN RES, V888, P248, DOI 10.1016/S0006-8993(00)03068-7; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Shin HK, 2006, J CEREBR BLOOD F MET, V26, P1018, DOI 10.1038/sj.jcbfm.9600252; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Strong AJ, 2005, ADV TECH STAND NEUR, V30, P3, DOI 10.1007/3-211-27208-9_1; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Umegaki M, 2005, J NEUROSCI, V25, P1387, DOI 10.1523/JNEUROSCI.4182-04.2005; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750	41	110	111	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1857	1866		10.1089/neu.2009.0961			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600001	19508156	Green Published			2021-06-18	
J	Guo, JS; Leung, KKG; Su, HX; Yuan, QJ; Wang, L; Chu, TH; Zhang, WM; Pu, JKS; Ng, GKP; Wong, WM; Dai, X; Wu, WT				Guo, Jiasong; Leung, Ka Kit Gilberto; Su, Huanxing; Yuan, Qiuju; Wang, Li; Chu, Tak-Ho; Zhang, Wenming; Pu, Jenny Kan Suen; Ng, Gloria Kowk Po; Wong, Wai Man; Dai, Xiang; Wu, Wutian			Self-assembling peptide nanofiber scaffold promotes the reconstruction of acutely injured brain	NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE			English	Article						Self-assembling peptide nanofiber scaffold; Traumatic brain injury; Reconstruction; Inflammation	TISSUE REGENERATION; LESION; HYDROGEL; DELIVERY; CULTURE; GROWTH; VOLUME	Traumatic brain injury (TBI) or brain surgery may cause extensive loss of cerebral parenchyma. However, no strategy for reconstruction has been clinically effective. Our previous study had shown that self-assembling peptide nanofiber scaffold (SAPNS) can bridge the injured spinal cord, elicit axon regeneration, and eventually promote locomotor functional recovery. In the present study we investigated the effect of SAPNS for the reconstruction of acutely injured brain. The lesion cavity of the injured cortex was filled with SAPNS or saline immediately after surgically induced TBI, and the rats were killed 2 days, 2 weeks, or 6 weeks after the surgery for histology, immunohistochemistry, and TUNEL studies. Saline treatment in the control animals resulted in a large cavity in the injured brain, whereas no cavity of any significant size was found in the SAPNS-treated animals. Around the lesion site in control animals were many macrophages (ED1 positive) but few TUNEL-positive cells, indicating that the TBI caused secondary tissue loss mainly by means of necrosis, not apoptosis. In the SAPNS-treated animals the graft of SAPNS integrated well with the host tissue with no obvious gaps. Moreover, there were fewer astrocytes (GFAP positive) and macrophages (ED1 positive) around the lesion site in the SAPNS-treated animals than were found in the controls. Thus, SAPNS may help to reconstruct the acutely injured brain and reduce the glial reaction and inflammation in the surrounding brain tissue.	[Guo, Jiasong; Su, Huanxing; Yuan, Qiuju; Wang, Li; Chu, Tak-Ho; Zhang, Wenming; Wong, Wai Man; Wu, Wutian] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China; [Leung, Ka Kit Gilberto; Pu, Jenny Kan Suen; Ng, Gloria Kowk Po] Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Pokfulam, Hong Kong, Peoples R China; [Wu, Wutian] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Brain & Cognit Sci, Pokfulam, Hong Kong, Peoples R China; [Wu, Wutian] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Reprod Dev & Growth, Pokfulam, Hong Kong, Peoples R China; [Guo, Jiasong; Dai, Xiang] So Med Univ, Dept Histol & Embryol, Guangzhou, Guangdong, Peoples R China	Wu, WT (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China.	wtwu@hkucc.hku.hk	Chu, Tak-Ho/AAB-4608-2021; Su, Huanxing/X-3954-2019; Su, Huanxing/X-3980-2019; Guo, Jiasong/I-2206-2019; Chu, Tak Ho/C-4153-2009; Yuan, Qiuju/AAJ-3101-2020; Leung, Gilberto Ka Kit/C-4337-2009	Chu, Tak-Ho/0000-0002-3123-207X; Su, Huanxing/0000-0003-3254-825X; Su, Huanxing/0000-0002-0513-4943; Guo, Jiasong/0000-0002-7885-2903; Leung, Gilberto Ka Kit/0000-0003-3147-3057	University of Hong KongUniversity of Hong Kong; Hong Kong Research Grants CouncilHong Kong Research Grants Council	Financial support was provided by the University of Hong Kong and Hong Kong Research Grants Council.	Castillo-Ruiz MM, 2007, EXP GERONTOL, V42, P343, DOI 10.1016/j.exger.2006.10.008; Crooks Carol Y, 2008, Mo Med, V105, P140; Cui FZ, 2006, J MATER SCI-MATER M, V17, P1393, DOI 10.1007/s10856-006-0615-7; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; Davis ME, 2006, P NATL ACAD SCI USA, V103, P8155, DOI 10.1073/pnas.0602877103; Deguchi K, 2006, J CEREBR BLOOD F MET, V26, P1263, DOI 10.1038/sj.jcbfm.9600275; Ellis-Behnke RG, 2006, P NATL ACAD SCI USA, V103, P5054, DOI 10.1073/pnas.0600559103; Ellis-Behnke RG, 2006, NANOMED-NANOTECHNOL, V2, P207, DOI 10.1016/j.nano.2006.08.001; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; Guo J, 2007, NANOMED-NANOTECHNOL, V3, P311, DOI 10.1016/j.nano.2007.09.003; Holmes TC, 2000, P NATL ACAD SCI USA, V97, P6728, DOI 10.1073/pnas.97.12.6728; Holmes TC, 2002, TRENDS BIOTECHNOL, V20, P16, DOI 10.1016/S0167-7799(01)01840-6; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Navarro-Alvarez N, 2006, CELL TRANSPLANT, V15, P921, DOI 10.3727/000000006783981387; Oehmichen M, 2000, J NEUROTRAUM, V17, P155, DOI 10.1089/neu.2000.17.155; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang S, 2008, TISSUE ENG PT A, V14, P227, DOI 10.1089/tea.2007.0143; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willerth SM, 2007, ADV DRUG DELIVER REV, V59, P325, DOI 10.1016/j.addr.2007.03.014; Wong DY, 2007, TISSUE ENG, V13, P2515, DOI 10.1089/ten.2006.0440; Zhang HZ, 2007, BRAIN RES, V1132, P29, DOI 10.1016/j.brainres.2006.09.117; Zhang S, 2008, ADV CANCER RES, V99, P335, DOI 10.1016/S0065-230X(07)99005-3	24	110	114	0	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1549-9634	1549-9642		NANOMED-NANOTECHNOL	Nanomed.-Nanotechnol. Biol. Med.	SEP	2009	5	3					345	351		10.1016/j.nano.2008.12.001			7	Nanoscience & Nanotechnology; Medicine, Research & Experimental	Science & Technology - Other Topics; Research & Experimental Medicine	503VS	WOS:000270570000010	19268273				2021-06-18	
J	Bell, KR; Hoffman, JM; Temkin, NR; Powell, JM; Fraser, RT; Esselman, PC; Barber, JK; Dikmen, S				Bell, K. R.; Hoffman, J. M.; Temkin, N. R.; Powell, J. M.; Fraser, R. T.; Esselman, P. C.; Barber, J. K.; Dikmen, S.			The effect of telephone counselling on reducing post-traumatic symptoms after mild traumatic brain injury: A randomised trial	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							ROUTINE FOLLOW-UP; HEAD-INJURY; EARLY INTERVENTION; ADULTS; IMPACT; CARE	Background: Mild traumatic brain injury (MTBI) is a significant public health problem affecting approximately 1 million people annually in the USA. A total of 10 - 15% of individuals are estimated to have persistent post-traumatic symptoms. This study aimed to determine whether focused, scheduled telephone counselling during the first 3 months after MTBI decreases symptoms and improves functioning at 6 months. Methods: This was a two-group, parallel, randomised clinical trial with the outcome assessed by blinded examiner at 6 months after injury. 366 of 389 eligible subjects aged 16 years or older with MTBI were enrolled in the emergency department, with an 85% follow-up completion rate. Five telephone calls were completed, individualised for patient concerns and scripted to address education, reassurance and reactivation. Two composites were analysed, one relating to post-traumatic symptoms that developed or worsened after injury and their impact on functioning, the other related to general health status. Results: The telephone counselling group had a significantly better outcome for symptoms (6.6 difference in adjusted mean symptom score, 95% confidence interval (CI) 1.2 to 12.0), but no difference in general health outcome (1.5 difference in adjusted mean functional score, 95% CI 2.2 to 5.2). A smaller proportion of the treatment group had each individual symptom (except anxiety) at assessment. Similarly, fewer of the treatment group had daily functioning negatively impacted by symptoms with the largest differences in work, leisure activities, memory and concentration and financial independence. Conclusions: Telephone counselling, focusing on symptom management, was successful in reducing chronic symptoms after MTBI.	[Bell, K. R.; Hoffman, J. M.; Temkin, N. R.; Powell, J. M.; Fraser, R. T.; Esselman, P. C.; Dikmen, S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, N. R.; Barber, J. K.; Dikmen, S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, N. R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Fraser, R. T.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA	Bell, KR (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	krbell@u.washington.edu		Bell, Kathleen/0000-0002-0928-2046	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR023226-03]; Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	This research was funded by the Centers for Disease Control, Award No. R49/CCR023226-03. The Centers for Disease Control provided funding for the research but had no control over the design, data collection, analysis or interpretation of the data.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Bandura A., 1986, SOCIAL FDN THOUGHT A; *CDC, 1999, FACTS CONC BRAIN INJ; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Dunn C, 2001, ADDICTION, V96, P1725, DOI 10.1046/j.1360-0443.2001.961217253.x; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Liss HJ, 2002, REHABIL PSYCHOL, V47, P8, DOI 10.1037/0090-5550.47.1.8; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Miller WR, 1991, MOTIVATIONAL INTERVI; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; TEASDALE G, 1974, LANCET, V2, P81; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wallenstein S, 1997, STAT MED, V16, P1329, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1329::AID-SIM567>3.0.CO;2-I; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	31	110	112	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2008	79	11					1275	1281		10.1136/jnnp.2007.141762			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	363EB	WOS:000260248900017	18469027				2021-06-18	
J	Israelsson, C; Bengtsson, H; Kylberg, A; Kullander, K; Lewen, A; Hillered, L; Ebendal, T				Israelsson, Charlotte; Bengtsson, Henrik; Kylberg, Annika; Kullander, Klas; Lewen, Anders; Hillered, Lars; Ebendal, Ted			Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						Cxcl10; dendritic cells; inflammatory monocytes; integrin alpha X; TBI	CENTRAL-NERVOUS-SYSTEM; RAT CEREBRAL-CORTEX; DENDRITIC CELLS; GENE-EXPRESSION; MULTIPLE-SCLEROSIS; BLOOD MONOCYTES; MOUSE-BRAIN; RECEPTORS; RESPONSES; ISCHEMIA	Cerebral gene expressions change in response to traumatic brain injury (TBI), and future trauma treatment may improve with increased knowledge about these regulations. We subjected C57BL/6J mice to injury by controlled cortical impact (CCI). At various time points post-injury, mRNA from neocortex and hippocampus was isolated, and transcriptional alterations studied using quantitative real-time polymerase chain reaction (PCR) and gene array analysis. Spatial distribution of enhanced expression was characterized by in situ hybridization. Products of the upregulated transcripts serve functions in a range of cellular mechanisms, including stress, inflammation and immune responses, and tissue remodeling. We also identified increased transcript levels characterizing reactive astrocytes, oligodendrocytes, and microglia, and furthermore, we demonstrated a novel pattern of scattered cell clusters expressing the chemokine Cxcl10. Notably, a sustained increase in integrin alpha X (Itgax), characterizing antigen-presenting dendritic cells, was found with the transcript located to similar cell clusters. In contrast, T-cell receptor alpha transcript showed only a modest increase. The induced P-selectin (Selp) expression level in endothelial cells, and chemokines from microglia, may guide perivascular accumulation of extravasating inflammatory monocytes differentiating into dendritic cells. In conclusion, our study shows that following TBI, secondary injury chiefly involves inflammatory processes and chemokine signaling, which comprise putative targets for pharmaceutical neuroprotection.	[Israelsson, Charlotte; Bengtsson, Henrik; Kylberg, Annika; Ebendal, Ted] Uppsala Univ, Biomed Ctr, Dept Neurosci, SE-75123 Uppsala, Sweden; [Lewen, Anders; Hillered, Lars] Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden	Ebendal, T (corresponding author), Uppsala Univ, Biomed Ctr, Dept Neurosci, POB 587, SE-75123 Uppsala, Sweden.	Ted.Ebendal@neuro.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Hillered, Lars/0000-0002-2808-9292; Kullander, Klas/0000-0001-6418-5460	Swedish Research CouncilSwedish Research CouncilEuropean Commission [2006-3014, 2004-6210, 2004-5567, 2003-2258]; Swedish Brain Research Foundation/Sparbanksstiftelsen Upland	Kimberly Zaia kindly performed subcloning of the Ccl3 probe and assisted in the cluster analysis, and Nestor Carri gave advice regarding histology. Niklas Marklund critically read the manuscript. Ali Moshfegh, Malin Linde, Hanna Goransson, and Maria Rydaker carried out the GeneChip procedures. This research was supported by the Swedish Research Council ( grants 2006-3014 to T. E., 2004-6210 to L. H., and 2004-5567 and 2003-2258 to K. K.) and the Swedish Brain Research Foundation/Sparbanksstiftelsen Upland ( to T. E. and C. I.).	Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Esche C, 2005, J INVEST DERMATOL, V125, P615, DOI 10.1111/j.0022-202X.2005.23841.x; Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hedtjarn M, 2004, J CEREBR BLOOD F MET, V24, P1333, DOI 10.1097/01.WCB.0000141559.17620.36; Hedtjarn M, 2004, J CEREBR BLOOD F MET, V24, P1317, DOI 10.1097/01.WCB.0000141558.40491.75; Henkel JS, 2006, MOL CELL NEUROSCI, V31, P427, DOI 10.1016/j.mcn.2005.10.016; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Israelsson C, 2006, J NEUROSCI RES, V84, P47, DOI 10.1002/jnr.20856; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Karman J, 2006, J IMMUNOL, V177, P7750, DOI 10.4049/jimmunol.177.11.7750; Kieseier BC, 2002, BRAIN, V125, P823, DOI 10.1093/brain/awf070; Klein RS, 2004, J CELL BIOCHEM, V92, P213, DOI 10.1002/jcb.20052; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kury P, 2004, EUR J NEUROSCI, V19, P1708, DOI 10.1111/j.1460-9568.2004.03226.x; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Matyszak MK, 1996, NEUROSCIENCE, V74, P599, DOI 10.1016/0306-4522(96)00160-1; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McMahon EJ, 2006, NEUROCHEM INT, V49, P195, DOI 10.1016/j.neuint.2006.04.004; Muller M, 2007, J IMMUNOL, V179, P2774, DOI 10.4049/jimmunol.179.5.2774; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Newman TA, 2005, J NEUROIMMUNOL, V166, P167, DOI 10.1016/j.jneuroim.2005.04.026; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Potts Mathew B, 2006, NeuroRx, V3, P143; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Reichmann G, 2002, J NEUROIMMUNOL, V129, P125, DOI 10.1016/S0165-5728(02)00184-4; Savitz SI, 2007, EXP NEUROL, V205, P20, DOI 10.1016/j.expneurol.2007.03.003; Schroeter M, 2005, NEUROMOL MED, V7, P183, DOI 10.1385/NMM:7:3:183; Shaftel SS, 2007, J NEUROSCI, V27, P9301, DOI 10.1523/JNEUROSCI.1418-07.2007; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Sugawara T, 2002, J NEUROTRAUM, V19, P85, DOI 10.1089/089771502753460268; Szczucinski A, 2007, ACTA NEUROL SCAND, V115, P137, DOI 10.1111/j.1600-0404.2006.00749.x; Trifilo MJ, 2004, VIROLOGY, V327, P8, DOI 10.1016/j.virol.2004.06.027; Trifilo MJ, 2003, J NEUROVIROL, V9, P315, DOI 10.1080/13550280390201029; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Xu HP, 2005, J IMMUNOL, V175, P6915, DOI 10.4049/jimmunol.175.10.6915; Zozulya AL, 2007, J IMMUNOL, V178, P520, DOI 10.4049/jimmunol.178.1.520	46	110	112	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2008	25	8					959	974		10.1089/neu.2008.0562			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	343ZT	WOS:000258895700002	18665806				2021-06-18	
J	Bisson, E; Contant, B; Sveistrup, H; Lajoie, Y				Bisson, E.; Contant, B.; Sveistrup, H.; Lajoie, Y.			Functional balance and dual-task reaction times in older adults are improved by virtual reality and biofeedback training	CYBERPSYCHOLOGY & BEHAVIOR			English	Article							EXERCISE; STRENGTH; GAIT; POSTURE; RISK	Virtual reality (VR) training has been used successfully to rehabilitate functional balance and mobility in both traumatic brain injury (TBI) survivors and elderly subjects. Similarly, computer-based biofeedback (BF) training has resulted in decreased sway during quiet stance and decreased reaction times during a dual-task reaction time paradigm in elderly subjects. The objective of this study was to determine the effect of VR and BF training on balance and reaction time in older adults. Two groups of twelve healthy older adults completed 10-week training programs consisting of two 30-min sessions per week. VR training required that participants lean sideways to juggle a virtual ball. Participants in the BF group viewed a red dot representing their center of gravity on a screen and were required to move the dot to the four corners of the monitor. Measures of functional balance and mobility ( Community Balance and Mobility Scale [CB&M]), sway during quiet stance, and reaction time during a dual task paradigm were recorded before training, as well as 1 week and 1 month after the end of the program. Both groups showed significant improvements on the CB&M, as well as decreased reaction times with training. Postural sway during quiet stance did not change significantly.	Univ Ottawa, Fac Hlth Sci, Sch Human Kinet, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON K1N 6N5, Canada	Lajoie, Y (corresponding author), Univ Ottawa, Fac Hlth Sci, Sch Human Kinet, 125 Univ St, Ottawa, ON K1N 6N5, Canada.	ylajoie@uottawa.ca					Barrett C, 2002, AUST J PHYSIOTHER, V48, P215, DOI 10.1016/S0004-9514(14)60226-9; Bellew JW, 2003, J STRENGTH COND RES, V17, P121; BROWN DA, 2002, NEUROLOGY REPORT, V26, P105, DOI DOI 10.1097/01253086-200226020-00009; Buchner DM, 1997, J GERONTOL A-BIOL, V52, pM218, DOI 10.1093/gerona/52A.4.M218; Evans WJ, 1999, MED SCI SPORT EXER, V31, P12, DOI 10.1097/00005768-199901000-00004; Gallova J, 2004, COLLOID SURFACE B, V38, P11, DOI 10.1016/j.colsurfb.2004.07.012; GEURTS ACH, 1994, J MOTOR BEHAV, V26, P162, DOI 10.1080/00222895.1994.9941670; HAMMAN R, 1995, J OTOLARYNGOL, V24, P221; HOLDEN MK, 2002, NEUROLOGY REPORT, V26, P62; Hunter MC, 2001, GAIT POSTURE, V13, P41, DOI 10.1016/S0966-6362(00)00089-8; Inness E, 2000, PHYSIOTHER CAN, V52, pS72; Inness L, 2002, SYNAPSE, V22, P2; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Lajoie Y, 2004, AGING CLIN EXP RES, V16, P363; Lord S.R., 2001, FALLS OLDER PEOPLE R; Lord SR, 2003, J AM GERIATR SOC, V51, P1645, DOI 10.1046/j.1532-5415.2003.51518.x; MCCOMAS J, 2002, NEUROLOGY REPORT, V26, P55, DOI DOI 10.1097/01253086-200226020-00002; Pimentel Ken, 1995, VIRTUAL REALITY NEW; Ryushi Tomoo, 2000, Journal of Physiological Anthropology and Applied Human Science, V19, P143, DOI 10.2114/jpa.19.143; SCHMIDT RA, 1982, MOTOR CONTROL LEARN; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; Sveistrup H., 2004, J NEUROENG REHABIL, V1, P10, DOI [DOI 10.1186/1743-0003-1-10, 10.1186/1743-0003-1-10]; Taggart HM, 2002, APPL NURS RES, V15, P235, DOI 10.1053/apnr.2002.35975; Todorov E, 1997, J MOTOR BEHAV, V29, P147, DOI 10.1080/00222899709600829; Wolf SL, 1997, PHYS THER, V77, P371, DOI 10.1093/ptj/77.4.371; WOLFSON L, 1995, J GERONTOL A-BIOL, V50, P64; Wolfson L, 1996, J AM GERIATR SOC, V44, P498, DOI 10.1111/j.1532-5415.1996.tb01433.x; Woollacott M, 2002, GAIT POSTURE, V16, P1, DOI 10.1016/S0966-6362(01)00156-4	28	110	114	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1094-9313			CYBERPSYCHOL BEHAV	CyberPsychol. Behav.	FEB	2007	10	1					16	23		10.1089/cpb.2006.9997			8	Communication; Psychology, Applied	Communication; Psychology	143IK	WOS:000244713800003	17305444				2021-06-18	
J	Fork, M; Bartels, L; Ebert, AD; Grubich, C; Synowitz, H; Wallesch, CW				Fork, M; Bartels, L; Ebert, AD; Grubich, C; Synowitz, H; Wallesch, CW			Neuropsychological sequelae of diffuse traumatic brain injury	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; AXONAL INJURY; FOCAL LESIONS	Primary objectives: Description and analysis of neuropsychological deficits following brain trauma with diffuse lesion probably corresponding to diffuse axonal injury (DAI). Research design: A series of 111 patients suffering from traumatic brain injury could be investigated neuropsychologically within the first 4 weeks after injury and re-assessed after 5-8 months. They included 11 subjects with CT-evidence of diffuse axonal injury, but no C T-signs of focal contusions. Eleven patients with focal frontal contusions but no CT signs of DAI were matched to and compared with the DAI subjects. Seventeen TBI patients with normal CT scans served as controls. Results: When assessed within the first 4 weeks after TBI, both DAI and frontal contusion patients exhibited behavioural abnormalities and deficits in Wechsler Similarities. The DAI patients were also impaired in Digit Span backward and Stroop interference. When re-assessed, the DAI patients showed considerable deficits in the California Verbal Learning Test and in the Wisconsin Card Sorting Test. Conclusions: DAI leads to neuropsychological impairment dominated by executive and memory dysfunction.	Otto Von Guericke Univ, Dept Neurol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Div Neuropsychol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurosurg, D-39120 Magdeburg, Germany; Univ Bremen, Dept Neuropsychol, Bremen, Germany	Wallesch, CW (corresponding author), Otto Von Guericke Univ, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	wallesch@medizin.uni-magdeburg.de					DELIS C, 1987, CALIFORNIA VERBAL LE; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1994, HEAD INJURY, P137; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Harting C., 2000, WECHSLER GEDACHTNIST; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OSWALD WD, 1995, NURNBERGER ALTERSINV; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schellig D., 1997, BLOCK TAPPING TEST; TEWES U, 1994, HDB TESTANWEISUNG, V2; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1987, WMS R WECHSLER MEMOR; WILCOX D, 1996, IMAGE TOOL 2 00; ZIMMERMANN P, 1993, NEUROPSYCHOLOGISCHE	23	110	112	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2005	19	2					101	108		10.1080/02699050410001726086			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	990JR	WOS:000233739600004	15841754				2021-06-18	
J	Williams, AJ; Hartings, JA; Lu, XCM; Rolli, ML; Dave, JR; Tortella, FC				Williams, AJ; Hartings, JA; Lu, XCM; Rolli, ML; Dave, JR; Tortella, FC			Characterization of a new rat model of penetrating ballistic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						ballistic; bullet wound; head injury; penetrating; rat; trauma	FOCAL CEREBRAL-ISCHEMIA; GUNSHOT WOUNDS; HEAD-INJURY; QUANTITATIVE ELECTROENCEPHALOGRAPHY; INTRACEREBRAL HEMORRHAGE; NEUROBEHAVIORAL OUTCOMES; EPILEPTIFORM DISCHARGES; SUBARACHNOID SPACE; SPREADING ISCHEMIA; MISSILE INJURIES	Penetrating brain injury (PBI) is a leading cause of mortality and morbidity in modern warfare and accounts for a significant number of traumatic brain injuries worldwide. Here we characterize the pathophysiology of a new rat model of PBI that simulates the large temporary cavity caused by energy dissipation from a penetrating bullet round. Male Sprague-Dawley rats (250-300 g) were subjected to a simulated ballistic wound to the right frontal hemisphere implemented by an inflatable penetrating probe. Three levels of injury severity were compared to control animals. Neurological and physiological outcome was assessed over a 3-day recovery period and brain tissue collected at 72 h for histopathological evaluation. Brain-injured regions included the ipsilateral frontal cortex and striatum with volumetric increases in intracranial hemorrhage (5-18 mm(3)) and lesion size (9-86 mm3) related to severity. Similarly, hemispheric swelling increased (3-14%) following PBI, associated, ated with a significant rise in intracranial pressure. Astrogliosis was present in regions adjacent to the core-injury along with microglial and leukocyte infiltration. Injury remote to the lesion was observed in the cerebral peduncle that may have accounted, in part, for observed neurological deficits. Neurological and balance beam testing revealed sensorimotor deficits that persisted through 72 h. Severe electroencephalographic disturbances included the occurrence of cortical spreading depression, slow-waves, and brain seizure activity. In conclusion, this rat PBI model replicates diverse, salient features of clinical PBI pathology, generates reproducible and quantifiable measures of outcome, and is scalable by injury severity, rendering it an attractive vehicle for experimental brain trauma research.	Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD 20910 USA	Williams, AJ (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, 503 Robert Grant Ave,Rm 2A40, Silver Spring, MD 20910 USA.	anthony.williams@na.amedd.army.mil	Dave, Jitendra R/A-8940-2011	Hartings, Jed/0000-0001-8583-3471			ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BELLAMY R, 1998, TXB MILITARY MED 1, V5, P107; BELLAMY RF, 1984, MIL MED, V149, P55; Berti R, 2002, J CEREBR BLOOD F MET, V22, P1068, DOI 10.1097/00004647-200209000-00004; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Carey ME, 1998, MIL MED, V163, P581; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Carey ME, 1990, J NEUROTRAUM, V7, P13, DOI 10.1089/neu.1990.7.13; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Carmichael ST, 2004, STROKE, V35, P758, DOI 10.1161/01.STR.0000117235.11156.55; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; FAUGHT E, 1993, STROKE, V24, P609, DOI 10.1161/01.STR.24.4.609; Finger S, 2004, ARCH NEUROL-CHICAGO, V61, P283, DOI 10.1001/archneur.61.2.283; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Giese A, 2002, SURG NEUROL, V57, P268, DOI 10.1016/S0090-3019(02)00643-2; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Hotz GA, 2000, BRAIN INJURY, V14, P649; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; JACOBS DG, 1995, AM SURGEON, V61, P647; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; KAUFMAN HH, 1995, NEUROSURG CLIN N AM, V6, P701, DOI 10.1016/s1042-3680(18)30426-1; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; LEEDHAM CS, 1993, MIL MED, V158, P508; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Levy YS, 2002, NEUROTOX RES, V4, DOI 10.1080/1029842021000045624; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; Marin R, 2003, PHYSIOL BEHAV, V80, P167, DOI 10.1016/j.physbeh.2003.06.001; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MOSHANG E, 2003, DAMD170110742; Nallet H, 2000, BRAIN RES, V879, P122, DOI 10.1016/S0006-8993(00)02760-8; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Nuwer M R, 1994, J Neuroimaging, V4, P82; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Pintar F A, 2001, Biomed Sci Instrum, V37, P429; Prgomet D, 1998, MIL MED, V163, P482; REILLY P, 1997, HEAD INJURY, P385; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Sapsford W, 2003, J R Army Med Corps, V149, P5; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Schallert Tim, 2003, Phys Med Rehabil Clin N Am, V14, pS27, DOI 10.1016/S1047-9651(02)00055-4; SHAFFREY ME, 1992, J NEUROTRAUM, V9, pS279; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; Singh P, 2003, NEUROL INDIA, V51, P215; SNODGRASS SM, 1989, J CLIN NEUROPHYSIOL, V6, P159, DOI 10.1097/00004691-198904000-00003; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Tan YH, 1998, J ORAL MAXIL SURG, V56, P345, DOI 10.1016/S0278-2391(98)90113-6; Tortella FC, 1999, J PHARMACOL EXP THER, V291, P399; Vojvodic V, 1996, J TRAUMA, V40, pS180, DOI 10.1097/00005373-199603001-00040; Williams AJ, 2003, FUND CLIN PHARMACOL, V17, P581, DOI 10.1046/j.1472-8206.2003.00183.x; Williams AJ, 2004, STROKE, V35, P1186, DOI 10.1161/01.STR.0000125721.10606.dc; Wu JM, 2002, BRAIN RES, V953, P45, DOI 10.1016/S0006-8993(02)03268-7; Young G, 1988, AM J EEG TECHNOL, V28, P1; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226	65	110	112	0	6	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2005	22	2					313	331		10.1089/neu.2005.22.313			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	900XU	WOS:000227248400010	15716636				2021-06-18	
J	Peek-Asa, C; Zwerling, C; Stallones, L				Peek-Asa, C; Zwerling, C; Stallones, L			Acute traumatic injuries in rural populations	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							FIREARM INJURIES; BRAIN-INJURIES; RISK-FACTORS; URBAN; SYSTEM; COUNTY; CARE; IOWA; STABILIZATION; MORTALITY	In the United States, injuries are the leading cause of death among individuals aged 1 to 45 years and the fourth leading cause of death overall. Rural populations exhibit disproportionately high injury mortality rates. Deaths resulting from motor vehicle crashes, traumatic occupational injuries, drowning, residential fires, and suicide all increase with increasing rurality. We describe differences in rates and patterns of injury among rural and urban populations and discuss factors that contribute to these differences.	Univ Iowa, Coll Publ Hlth, Injury Prevent Res Ctr, Iowa City, IA 52242 USA	Peek-Asa, C (corresponding author), 100 Oakdale Blvd,114 IREH, Iowa City, IA 52242 USA.	corinne-peek-asa@uiowa.eda	Stallones, Lorann/AAC-6248-2021	Stallones, Lorann/0000-0001-7616-582X	ODCDC CDC HHS [CCR 811509, CCR703640] Funding Source: Medline		Baker D R, 2000, J Okla State Med Assoc, V93, P496; BAKER SP, 1988, J TRAUMA, V28, P741, DOI 10.1097/00005373-198806000-00003; BAKER SP, 1987, NEW ENGL J MED, V316, P1384, DOI 10.1056/NEJM198705283162206; Baker SP, 1992, THE INJURY FACT BOOK; Blatt J, 1998, ACCIDENT ANAL PREV, V30, P705, DOI 10.1016/S0001-4575(98)00014-1; Centers for Disease Control and Prevention, 1993, INJ CONTR 1990S NAT; Chevalley T, 2002, OSTEOPOROSIS INT, V13, P113, DOI 10.1007/s001980200002; Costello T M, 2003, J Agric Saf Health, V9, P19; Demetriades D, 1996, ARCH SURG-CHICAGO, V131, P133; Duhart DT., 2000, URBAN SUBURBAN RURAL; Eberhardt M., 2001, URBAN RURAL HLTH CHA; FALLON MJ, 1990, ANN EMERG MED, V19, P914, DOI 10.1016/S0196-0644(05)81570-7; FINGERHUT LA, 1997, NJURY CHARTBOOK HLTH; FUORTES LJ, 1990, AM J IND MED, V18, P211, DOI 10.1002/ajim.4700180213; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; GARRISON HG, 1989, AM J EMERG MED, V7, P384, DOI 10.1016/0735-6757(89)90043-0; GERBERICH SG, 1991, OLMSTEAD AGR TRAUMA; GRAHAM JD, 1993, ANNU REV PUBL HEALTH, V14, P515; Grossman DC, 1997, J TRAUMA, V42, P723, DOI 10.1097/00005373-199704000-00024; Hall J R Jr, 1994, NFPA J, V88, P36; Harlos S, 1999, Inj Prev, V5, P183; Harvey PA, 1998, PUBLIC HEALTH REP, V113, P459; *I MED, 1999, RED BURD INJ ADV PRE; Karlaftis MG, 2002, ACCIDENT ANAL PREV, V34, P357, DOI 10.1016/S0001-4575(01)00033-1; KARTER MJ, 1999, NATL FIRE PROTECTION, V93, P88; Layde Peter M., 1995, Annals of Epidemiology, V5, P419, DOI 10.1016/1047-2797(95)00056-9; LEE B, 2002, CHILDHOOD AGR INJURY; Leff M, 2003, INJURY PREV, V9, P332, DOI 10.1136/ip.9.4.332; Lundell JA, 2003, TEX J RURAL HLTH, V21, P2; MAIO RF, 1992, ACCIDENT ANAL PREV, V24, P631, DOI 10.1016/0001-4575(92)90015-B; Mann NC, 1999, J TRAUMA, V47, pS25, DOI 10.1097/00005373-199909001-00007; McCurdy SA, 2000, AM J IND MED, V38, P463, DOI 10.1002/1097-0274(200010)38:4&lt;463::AID-AJIM13&gt;3.0.CO;2-N; McGwin G, 2000, J BURN CARE REHABIL, V21, P75, DOI 10.1097/00004630-200021010-00016; Melton LJ, 1999, OSTEOPOROSIS INT, V9, P29, DOI 10.1007/s001980050113; MERCHANT JA, 1989, AGR RISK REPORT NATI; Merchant James, 1995, P267; Muelleman RL, 1996, J TRAUMA, V41, P315, DOI 10.1097/00005373-199608000-00020; Mullins Richard J., 1999, J TRAUMA, V47, pS9; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; Myers J, 1998, NIOSH PUBLICATION, V98-153; Nance ML, 2002, ARCH PEDIAT ADOL MED, V156, P781, DOI 10.1001/archpedi.156.8.781; *NAT SAF COUNC, 2003, INJ FACTS 2002; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; National Highway Traffic Safety Administration, 2001, TRAFF SAF FACTS 2001; PETREA RE, 2003, USING HIST ACCOMPLIS; Reed DB, 2000, AM J PREV MED, V18, P70, DOI 10.1016/S0749-3797(00)00143-4; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Rivara F P, 1997, Inj Prev, V3, P190, DOI 10.1136/ip.3.3.190; Rogers FB, 1999, J TRAUMA, V46, P328, DOI 10.1097/00005373-199902000-00022; Rogers FB, 2000, J TRAUMA, V48, P577; Rogers FB, 1997, ARCH SURG-CHICAGO, V132, P376; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; RUTLEDGE R, 1994, ANN SURG, V219, P547, DOI 10.1097/00000658-199405000-00013; Sampalis JS, 1999, J TRAUMA, V46, P565, DOI 10.1097/00005373-199904000-00004; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Schootman M, 1999, BRAIN INJURY, V13, P995; Schwab W, 1998, J TRAUMA, V44, P815, DOI 10.1097/00005373-199805000-00012; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; SHARAR SR, 1988, J TRAUMA, V28, P794, DOI 10.1097/00005373-198806000-00012; Sing RF, 1997, J TRAUMA, V43, P825, DOI 10.1097/00005373-199711000-00015; Sprince N L, 2003, J Agric Saf Health, V9, P5; Stallones L, 2003, INJURY PREV, V9, P241, DOI 10.1136/ip.9.3.241; STALLONES L, 1989, J RURAL HEALTH, V5, P246, DOI DOI 10.1111/J.1748-0361.1989.TB00985.X; Stennies G, 1999, ARCH PEDIAT ADOL MED, V153, P586; Svenson JE, 1996, ARCH PEDIAT ADOL MED, V150, P583, DOI 10.1001/archpedi.1996.02170310017002; *US FIR ADM, 1997, RUR FIR PROBL US; WALLER JA, 1992, J OCCUP ENVIRON MED, V34, P414; Xiang HY, 1999, J AGING HEALTH, V11, P65, DOI 10.1177/089826439901100104; Young JS, 1998, AM SURGEON, V64, P88; Zwerling C, 2001, AM J PREV MED, V20, P230, DOI 10.1016/S0749-3797(00)00316-0; Zwerling C, 1996, J OCCUP ENVIRON MED, V38, P698, DOI 10.1097/00043764-199607000-00013; ZWERLING C, 1995, AM J EPIDEMIOL, V141, P878, DOI 10.1093/oxfordjournals.aje.a117524; ZWERLING C, 2000, EPIDEMIOLOGY WORK RE, P267	73	110	110	0	9	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	OCT	2004	94	10					1689	1693		10.2105/AJPH.94.10.1689			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	860AQ	WOS:000224309900013	15451733	Green Published			2021-06-18	
J	Schafer, PW; Huisman, TAGM; Sorenson, AG; Gonzalez, RG; Schwamm, LH				Schafer, PW; Huisman, TAGM; Sorenson, AG; Gonzalez, RG; Schwamm, LH			Diffusion-weighted MR imaging in closed head injury: High correlation with initial Glasgow coma scale score and score on modified Rankin scale at discharge	RADIOLOGY			English	Article						brain, injuries; brain, MR; magnetic resonance (MR), comparative studies; magnetic resonance (MR), diffusion tensor; trauma	AXONAL INJURY; BRAIN INJURY; WHITE-MATTER; TRAUMA; STROKE; CT; EDEMA; CLASSIFICATION; FEATURES; HUMANS	PURPOSE: To determine whether diffusion-weighted magnetic resonance (MR) imaging findings and conventional MR imaging findings correlate with initial Glasgow Coma Scale score and score on modified Rankin scale at discharge. MATERIALS AND METHODS: Twenty-six patients (18 male and eight femald patients; mean age, 25.2 years; age range, 4-72 years) with diffuse axonal injury were examined with diffusion-weighted MR imaging and with fluid-attenuated inversion recovery, T2-weighted fast spin-echo, and T2*-weighted gradient-echo sequences. All images were evaluated by two neuroradiologists in consensus. Tissue volume with trauma-related signal-intensity abnormality on images form each sequence, number of lesions for teach sequence, number of lesions for all sequences, and number of lesions with reduced apparent diffusion coefficient were correlated with scores on Glasgow Coma Scale and modified Rankin scale. Involvement of brainstem, deep gray matter, and corpus callosum were also correlated with clinical scores. Spearman rank correlation coefficients (r) were calculated. RESULTS: The strongest correlation was between signal-intensity abnormality volume on diffusion-weighted images and modified Rankin score (r= 0.772, P < .001). The strength of this correlation did not improve when only volume of lesions with decreased apparent diffusion coefficient was considered. For lesion number, the strongest correlation was between lesion number on images acquired with all sequences and modified Rankin score (r=0.662, P < .001). For lesion location, the strongest correlation was between lesion location in the corpus callosum and modified Rankin score ( r=0.513, P = .007). CONCLUSION: Volume of lesions on diffusion-weighted MR images provides the strongest correlation with a score of subacute on modified Rankin scale at discharge. Total lesion number also correlates well with modified Rankin score. In future, diffusion-weighted images may be useful in determining treatment strategies for acute head injury. (C) RSNA, 2004.	Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA	Schafer, PW (corresponding author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Gray B285, Boston, MA 02114 USA.	pschaefer@partners.org	Schaefer, Pamela/AAA-1323-2019	Schwamm, Lee/0000-0003-0592-9145			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GEAN AD, 1994, IMAGING HEAD TRAUMA, P207; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, P824; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kuzma BB, 2000, SURG NEUROL, V53, P400; Lai SM, 1999, STROKE, V30, P1840, DOI 10.1161/01.STR.30.9.1840; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murray JG, 1996, SEMIN ULTRASOUND CT, V17, P185, DOI 10.1016/S0887-2171(96)90035-9; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PELLICANO G, 1997, NEURORADIOLOGY, V39, pS82; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; SEGATORE M, 1992, HEART LUNG, V21, P548; Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Sulter G, 1999, STROKE, V30, P1538, DOI 10.1161/01.STR.30.8.1538; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Unterberg AW, 1997, ACT NEUR S, V70, P106; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	41	110	122	0	3	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	OCT	2004	233	1					58	66		10.1148/radiol.2323031173			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	856WC	WOS:000224075000011	15304663				2021-06-18	
J	Lemay, S; Bedard, MA; Rouleau, I; Tremblay, PLG				Lemay, S; Bedard, MA; Rouleau, I; Tremblay, PLG			Practice effect and test-retest reliability of attentional and executive tests in middle-aged to elderly subjects	CLINICAL NEUROPSYCHOLOGIST			English	Article						executive functions; neuropsychological tests; practice effect; reliability; test-retest	VERBAL-LEARNING TEST; CHOICE-REACTION-TIME; REPEATED NEUROPSYCHOLOGICAL ASSESSMENTS; CLOSED-HEAD-INJURY; REPEATED ADMINISTRATIONS; ALZHEIMERS-DISEASE; COGNITIVE DEFICITS; PARKINSONS-DISEASE; HEALTHY-SUBJECTS; ALTERNATE FORMS	There is a lack of data about the practice effect and test-retest reliability (TRR) on many attentional and executive tests in neuropsychology. In this study, 37 subjects aged 52 to 80 were tested three times with an inter-assessment interval of 14 days. The battery included the Rey Auditory Verbal Learning Test, the Stroop interference test, the Letter-Number Sequencing test, Wechsler Adult Intelligence Scale-III (WAIS-III), the Ruff 2 and 7 Selective Attention Test, the Tower of London, the Verbal Fluency test, and simple, choice, and sequential reaction time tests. The results showed that tasks were generally subject to a practice effect, except for those with alternate forms. In all tests, there were a number of scores demonstrating good TRR, but others, although largely used in clinical practice, failed to reach acceptable TRR standards. Usually, time derived scores were associated with the best TRR.	Univ Quebec, Ctr Neurosci Cognit, Montreal, PQ H3C 3P8, Canada	Bedard, MA (corresponding author), Univ Quebec, Ctr Neurosci Cognit, Case Postale 8888,Succ Ctr Ville, Montreal, PQ H3C 3P8, Canada.	bedard.marc-andre@uqam.ca					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anastasi A, 1997, PSYCHOL TESTING, V7th; BAKER SJ, 1986, PERCEPT MOTOR SKILL, V63, P767, DOI 10.2466/pms.1986.63.2.767; BARDI CA, 1995, ARCH CLIN NEUROPSYCH, V10, P295; Basso MR, 1999, CLIN NEUROPSYCHOL, V13, P283, DOI 10.1076/clin.13.3.283.1743; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; Bruggemans EF, 1997, J CLIN EXP NEUROPSYC, V19, P543, DOI 10.1080/01688639708403743; Burgess P. W., 1997, METHODOLOGY FRONTAL, P81, DOI DOI 10.1024//1016-264X.10.2.123; *CAMBR COGN, 1998, TEMP STAB TEST RET R; CASEY JE, 1989, J CLIN EXP NEUROPSYC, V11, P461, DOI 10.1080/01688638908400906; CHATELOIS J, 1996, STROOP FLEXIBILITE, V4; Chiu HFK, 1997, J GERONTOL B-PSYCHOL, V52, pP247, DOI 10.1093/geronb/52B.5.P247; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; CONNOR A, 1988, INT J CLIN NEUROPSYC, V10, P1; Cooper DB, 2001, CLIN NEUROPSYCHOL, V15, P125, DOI 10.1076/clin.15.1.125.1914; CRAWFORD JR, 1989, J CLIN EXP NEUROPSYC, V11, P975, DOI 10.1080/01688638908400950; DAIGNEAULT S, 1992, DEV NEUROPSYCHOL, V8, P99, DOI 10.1080/87565649209540518; DEBRABANDER B, 1992, PERCEPT MOTOR SKILL, V75, P165, DOI 10.1177/003151259207500101; DESROSIERS G, 1987, INT J CLIN NEUROPSYC, V9, P162; Diesfeldt H F, 1985, Tijdschr Gerontol Geriatr, V16, P17; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Duff K, 2001, ARCH CLIN NEUROPSYCH, V16, P461; Fastenau PS, 2002, J INT NEUROPSYCH SOC, V8, P151; FEINSTEIN A, 1994, J CLIN EXP NEUROPSYC, V16, P436, DOI 10.1080/01688639408402654; Forrester G., 1991, CLIN NEUROPSYCHOL, V5, P345, DOI DOI 10.1080/13854049108404102; Frank R, 1996, NEUROEPIDEMIOLOGY, V15, P257, DOI 10.1159/000109915; Franzen M D, 1987, Arch Clin Neuropsychol, V2, P265, DOI 10.1016/0887-6177(87)90014-X; GEFFEN GM, 1994, ARCH CLIN NEUROPSYCH, V9, P303, DOI 10.1016/0887-6177(94)90018-3; GOLDEN CJ, 1975, J PERS ASSESS, V39, P386, DOI 10.1207/s15327752jpa3904_10; GOLDSTEIN G, 1990, HYPERTENSION, V15, P361, DOI 10.1161/01.HYP.15.4.361; GRAF P, 1995, J CLIN EXP NEUROPSYC, V17, P390, DOI 10.1080/01688639508405132; Harrison JE, 2000, BRIT J CLIN PSYCHOL, V39, P181, DOI 10.1348/014466500163202; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; HORTON AM, 1992, PERCEPT MOTOR SKILL, V75, P257, DOI 10.2466/PMS.75.4.257-258; IVNIK RJ, 1995, PSYCHOL ASSESSMENT, V7, P155, DOI 10.1037/1040-3590.7.2.155; Ivnik RJ, 1999, NEUROPSYCHOLOGY, V13, P121, DOI 10.1037/0894-4105.13.1.121; Jensen A R, 1965, Acta Psychol (Amst), V24, P398; JOHNSON BF, 1991, PROG NEURO-PSYCHOPH, V15, P625, DOI 10.1016/0278-5846(91)90052-3; KLAPP ST, 1995, J EXP PSYCHOL HUMAN, V21, P1015, DOI 10.1037/0096-1523.21.5.1015; Lepage M, 1996, BRAIN, V119, P1289, DOI 10.1093/brain/119.4.1289; LETOURNEAU JE, 1990, PERCEPT MOTOR SKILL, V70, P256, DOI 10.2466/PMS.70.1.256-258; LETOURNEAU JE, 1986, PERCEPT MOTOR SKILL, V62, P667, DOI 10.2466/pms.1986.62.2.667; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lowe C, 1998, NEUROPSYCHOLOGIA, V36, P915, DOI 10.1016/S0028-3932(98)00036-0; LOWE C, 1997, METHODOLOGY FRONTAL, P39; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; Majdan A, 1996, J CLIN EXP NEUROPSYC, V18, P416, DOI 10.1080/01688639608408998; Mattis S, 1976, GERIATRIC PSYCHIAT, P77; MCCAFFREY RJ, 1993, ARCH CLIN NEUROPSYCH, V8, P519; McCaffrey RJ, 2001, ARCH CLIN NEUROPSYCH, V16, P9, DOI 10.1016/S0887-6177(99)00055-4; McCaffrey RJ, 1995, NEUROPSYCHOL REV, V5, P203, DOI 10.1007/BF02214762; MCCAFFREY RJ, 1992, CLIN NEUROPSYCHOL, V6, P34; MITRUSHINA M, 1991, J CLIN PSYCHOL, V47, P790, DOI 10.1002/1097-4679(199111)47:6<790::AID-JCLP2270470610>3.0.CO;2-C; Owen AM, 1997, NEUROPSYCHOLOGIA, V35, P519, DOI 10.1016/S0028-3932(96)00101-7; Pantelis C, 1997, BRAIN, V120, P1823, DOI 10.1093/brain/120.10.1823; Purcell R, 1997, PSYCHOL MED, V27, P1277, DOI 10.1017/S0033291797005448; Rabbitt P., 1997, METHODOLOGY FRONTAL, P1; Rey A., 1970, EXAMEN CLIN PSYCHOL; ROBBINS TW, 1994, J NEUROL NEUROSUR PS, V57, P79, DOI 10.1136/jnnp.57.1.79; Rockstroh S, 1995, Int Psychogeriatr, V7, P377, DOI 10.1017/S1041610295002122; Ruff R.M., 1996, RUFF 2 7 SELECTIVE A; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; RUFF RM, 1992, PERCEPT MOTOR SKILL, V75, P1311, DOI 10.2466/PMS.75.8.1311-1319; RYAN JJ, 1986, J CLIN EXP NEUROPSYC, V8, P611, DOI 10.1080/01688638608405179; RYAN JJ, 1992, CLIN NEUROPSYCHOL, V6, P3, DOI DOI 10.1080/13854049208404111; Sacks T. L, 1991, CLIN NEUROPSYCHOL, V5, P220; Salinsky MC, 2001, J INT NEUROPSYCH SOC, V7, P597, DOI 10.1017/S1355617701755075; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Schnirman GM, 1998, ASSESSMENT, V5, P355, DOI 10.1177/107319119800500404; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shatz M W, 1981, J Clin Neuropsychol, V3, P171, DOI 10.1080/01688638108403123; Siegrist M, 1995, PERCEPT MOTOR SKILL, V81, P1295, DOI 10.2466/pms.1995.81.3f.1295; SNOW WG, 1988, J CLIN EXP NEUROPSYC, V10, P60; Solomon PR, 1998, ARCH NEUROL-CHICAGO, V55, P349, DOI 10.1001/archneur.55.3.349; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spreen O., 1998, COMPENDIUM NEUROPSYC; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; SUNDERLAND A, 1992, NEUROPSYCHOL REHABIL, V2, P137; Tabachnick B.G., 1989, USING MULTIVARIATE S; Theisen ME, 1998, ASSESSMENT, V5, P85, DOI 10.1177/107319119800500110; UCHIYAMA CL, 1995, ARCH CLIN NEUROPSYCH, V10, P133, DOI 10.1016/0887-6177(94)E0034-M; van den Burg W, 1999, ARCH CLIN NEUROPSYCH, V14, P545, DOI 10.1016/S0887-6177(98)00042-0; Versavel M, 1997, ARZNEIMITTEL-FORSCH, V47, P781; Wechsler, 1997, WAIS 3 WMS 3 TECHNIC; Wechsler D., 1997, WAIS 3 ADM SCORING M; Welsh MC, 2000, PERCEPT MOTOR SKILL, V90, P562, DOI 10.2466/PMS.90.2.562-572; Wilson BA, 2000, J INT NEUROPSYCH SOC, V6, P469, DOI 10.1017/S1355617700644053; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	91	110	113	0	40	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	2004	18	2					284	302		10.1080/13854040490501718			19	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	850HU	WOS:000223602600008	15587675				2021-06-18	
J	Ballesteros, MF; Dischinger, PC; Langenberg, P				Ballesteros, MF; Dischinger, PC; Langenberg, P			Pedestrian injuries and vehicle type in Maryland, 1995-1999	ACCIDENT ANALYSIS AND PREVENTION			English	Article						pedestrians; crashes; vehicle characteristics; fatalities	ROAD TRAFFIC ACCIDENTS; IMPACT SPEED; MASS; COLLISIONS; SAFETY; AGE	Pedestrian deaths constitute the second largest category of motor vehicle deaths in the US. The present study examined how pedestrian injury is associated with vehicle type, while controlling for vehicle weight and speed. Police, trauma registry, and autopsy data were linked for injured pedestrians. Logistic regression analyses were performed to control for vehicle weight and speed. Outcomes included pedestrian mortality, injury severity score, and injuries to specific body regions. Compared to conventional cars, pedestrians hit by sport utility vehicles and pick-up trucks were more likely to have higher injury severity scores (odds ratio = 1.48; 95% confidence interval: 1.18-1.87) and to die (odds ratio = 1.72; 95% confidence interval: 1.31-2.28). These relationships diminished when vehicle weight and speed were controlled for. At lower speeds, pedestrians struck by sport utility vehicles, pick-up trucks, and vans were approximately two times as likely to have traumatic brain, thoracic, and abdominal injuries; at higher speeds, there was no such association. The overall increased danger sport utility vehicles and pick-up trucks present to pedestrians may be explained by larger vehicle masses and faster speeds. At slower speeds being hit by sport utility vehicles, and pick-up trucks, and vans resulted in specific injuries, indicating that vehicle design may contribute to different injury patterns. (C) 2003 Elsevier Science Ltd. All rights reserved.	Univ Maryland, Charles McC Mathias Jr Natl Study Ctr Trauma & EM, Baltimore, MD 21201 USA; Univ Maryland, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	Dischinger, PC (corresponding author), Univ Maryland, Charles McC Mathias Jr Natl Study Ctr Trauma & EM, 701 W Pratt St,5th Floor, Baltimore, MD 21201 USA.	pdischin@som.umaryland.edu					ASHTON S, 1982, PEDESTRIAN ACCIDENTS; Ashton S.J, 1979, P 23 STAPP CAR CRASH, P353; ASHTON SJ, 1978, P 22 C AM ASS AUT ME, P216; ATKINS RM, 1988, BRIT MED J, V297, P1431, DOI 10.1136/bmj.297.6661.1431; Baker SP, 1992, THE INJURY FACT BOOK; BARANCIK JI, 1986, AM J EPIDEMIOL, V123, P846, DOI 10.1093/oxfordjournals.aje.a114314; Buzeman DG, 1998, ACCIDENT ANAL PREV, V30, P713, DOI 10.1016/S0001-4575(98)00020-7; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P465; GALLOWAY DJ, 1982, INJURY, V13, P294, DOI 10.1016/0020-1383(82)90324-2; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; GRIME G, 1979, ERGONOMICS, V22, P93, DOI 10.1080/00140137908924592; Harrison SP, 1998, EQUINE VET J, V30, P1, DOI 10.1111/j.2042-3306.1998.tb04078.x; *INS I HIGHW SAF, 1998, STATUS REPORT, V33, P1; Insurance Institute for Highway Safety, 1999, STATUS REPORT, V34, P1; KINGMA J, 1994, PERCEPT MOTOR SKILL, V79, P1680, DOI 10.2466/pms.1994.79.3f.1680; LANE PL, 1994, J TRAUMA, V36, P231, DOI 10.1097/00005373-199402000-00016; McGinnis G S, 1989, J Neurosci Nurs, V21, P201; MEYERS M, 2000, METRO PEDESTRIAN DEA, pC2; Mizuno K, 1999, ACCIDENT ANAL PREV, V31, P381, DOI 10.1016/S0001-4575(98)00076-1; MOORE VM, 1995, EPIDEMIOLOGY, V6, P258, DOI 10.1097/00001648-199505000-00012; *NAT HIGHW TRAFF S, 1996, WHY DAT LINK; National Highway Traffic Safety Administration, 1999, TRAFF SAF FACTS 1999; TOLONEN J, 1984, ANN CHIR GYNAECOL FE, V73, P14; ZIVOT U, 1993, AM J FOREN MED PATH, V14, P185, DOI 10.1097/00000433-199309000-00002	24	110	114	1	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	JAN	2004	36	1					73	81	PII S0001-4575(02)00129-X	10.1016/S0001-4575(02)00129-X			9	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	760VM	WOS:000187856000009	14572829				2021-06-18	
J	Li, RC; Row, BW; Gozal, E; Kheirandish, L; Fan, QA; Brittian, KR; Guo, SZ; Sachleben, LR; Gozal, D				Li, RC; Row, BW; Gozal, E; Kheirandish, L; Fan, QA; Brittian, KR; Guo, SZ; Sachleben, LR; Gozal, D			Cyclooxygenase 2 and intermittent hypoxia-induced spatial deficits in the rat	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						sleep apnea; neurocognitive deficits; inflammation; episodic hypoxia	TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; PROSTAGLANDIN E-2; CEREBRAL-CORTEX; INDUCIBLE CYCLOOXYGENASE; SPREADING DEPRESSION; SELECTIVE-INHIBITION; ALZHEIMERS-DISEASE; GLUTAMATE RELEASE; GENE-EXPRESSION	Intermittent hypoxia (IH) during sleep, a critical feature of sleep apnea, induces significant neurobehavioral deficits in the rat. Cyclooxygenase (COX)-2 is induced during stressful conditions such as cerebral ischemia and could play an important role in IH-induced learning deficits. We therefore examined COX-1 and COX-2 genes and COX-2 protein expression and activity (prostaglandin E2 [PGE2] tissue concentration) in cortical regions of rat brain after exposure to either IH (10% O-2 alternating with 21% O-2 every 90 seconds) or sustained hypoxia (10% O-2). In addition, the effect of selective COX-2 inhibition with NS-398 on IH-induced neurobehavioral deficits was assessed. IH was associated with increased COX-2 protein and gene expression from Day I to Day 14 of exposure. No changes were found in COX-1 gene expression after exposure to hypoxia. IH-induced COX-2 upregulation was associated with increased PGE2 tissue levels, neuronal apoptosis, and neurobehavioral deficits. Administration of NS-398 abolished IH-induced apoptosis and PGE2 increases without modifying COX-2 mRNA expression. Furthermore, NS-398 treatment attenuated IH-induced deficits in the acquisition and retention of a spatial task in the water maze. We conclude that IH induces upregulation and activation of COX-2 in rat cortex and that COX-2 may play a role in IH-mediated neurobehavioral deficits.	Univ Louisville, Kosair Childrens Hosp Res Inst, Dept Pediat, Louisville, KY 40202 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA	Gozal, D (corresponding author), Univ Louisville, Kosair Childrens Hosp Res Inst, Dept Pediat, 570 S Preston St,Suite 321, Louisville, KY 40202 USA.		Gozal, David/M-9492-2017	Gozal, Leila/0000-0003-3332-1057	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL69932, HL63912] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD42396] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL069932, R01HL063912] Funding Source: NIH RePORTER		Araki E, 2001, STROKE, V32, P2370, DOI 10.1161/hs1001.096057; Baik EJ, 1999, BRAIN RES, V843, P118, DOI 10.1016/S0006-8993(99)01797-7; Beebe DW, 2002, J SLEEP RES, V11, P1, DOI 10.1046/j.1365-2869.2002.00289.x; Bezzi P, 1998, NATURE, V391, P281; Bidmon HJ, 2000, J CHEM NEUROANAT, V20, P163, DOI 10.1016/S0891-0618(00)00081-8; Blom MAA, 1997, BRAIN RES, V777, P210, DOI 10.1016/S0006-8993(97)01204-3; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; CHEN J, 1995, NEUROREPORT, V6, P245; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Domoki F, 2000, NEUROREPORT, V11, P3435, DOI 10.1097/00001756-200011090-00007; Domoki F, 2001, NEUROREPORT, V12, P4065, DOI 10.1097/00001756-200112210-00041; Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x; Figueiredo-Pereira ME, 2002, J BIOL CHEM, V277, P25283, DOI 10.1074/jbc.M109145200; Futaki N, 1997, INFLAMM RES, V46, P496, DOI 10.1007/s000110050232; Gozal D, 2001, J NEUROSCI, V21, P2442; Hara K, 1998, NEUROSCI LETT, V256, P53, DOI 10.1016/S0304-3940(98)00755-1; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Ho L, 1998, J NEUROIMMUNOL, V89, P142, DOI 10.1016/S0165-5728(98)00132-5; Hoozemans JJM, 2001, EXP GERONTOL, V36, P559, DOI 10.1016/S0531-5565(00)00226-6; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Kim EJ, 2001, BRAIN RES, V908, P1, DOI 10.1016/S0006-8993(01)02432-5; Koistinaho J, 2000, NEUROCHEM RES, V25, P645, DOI 10.1023/A:1007559003261; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; McCown TJ, 1997, BRAIN RES, V767, P370, DOI 10.1016/S0006-8993(97)00773-7; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Miettinen S, 1997, P NATL ACAD SCI USA, V94, P6500, DOI 10.1073/pnas.94.12.6500; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; MITANI A, 1991, NEUROSCI LETT, V122, P167, DOI 10.1016/0304-3940(91)90849-O; Nagayama M, 1999, J CEREBR BLOOD F MET, V19, P1213, DOI 10.1097/00004647-199911000-00005; Nogawa S, 1997, J NEUROSCI, V17, P2746; PHILLIS JW, 1989, NEUROSCI LETT, V106, P147, DOI 10.1016/0304-3940(89)90217-6; Reese J, 2001, ENDOCRINOLOGY, V142, P3198, DOI 10.1210/en.142.7.3198; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Takadera T, 2002, NEUROSCI LETT, V317, P61, DOI 10.1016/S0304-3940(01)02449-1; Teather LA, 2002, LEARN MEMORY, V9, P41, DOI 10.1101/lm.43602; Toti P., 2001, Journal of Submicroscopic Cytology and Pathology, V33, P245; Vane JR, 2000, INT J CLIN PRACT, V54, P7; Xiang ZM, 2002, NEUROBIOL AGING, V23, P327, DOI 10.1016/S0197-4580(01)00282-2; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	50	110	116	0	3	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 15	2003	168	4					469	475		10.1164/rccm.200211-1264OC			7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	709ZC	WOS:000184655600014	12773326				2021-06-18	
J	Umile, EM; Sandel, ME; Alavi, A; Terry, CM; Plotkin, RC				Umile, EM; Sandel, ME; Alavi, A; Terry, CM; Plotkin, RC			Dynamic imaging in mild traumatic brain injury: Support for the theory of medial temporal vulnerability	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; postconcussion syndrome; rehabilitation; tomography, positron-emission; tomography, emission-computed, single-photon	MINOR HEAD-INJURY; ENDURING MEMORY IMPAIRMENT; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; CONCUSSION; SEQUELAE; SYMPTOMS; DEFICITS; HISTORY; LOBE	Objective: To determine whether patients with mild traumatic brain injury (TBI) and persistent postconcussive symptoms have evidence of temporal lobe injury on dynamic imaging. Design: Case series. Setting: An academic medical center. Participants: Twenty patients with a clinical diagnosis of mild TBI and persistent postconcussive symptoms were referred for neuropsychologic evaluation and dynamic imaging. Fifteen (75%) had normal magnetic resonance imaging (MRI) and/or computed tomography (CT) scans at the time of injury. Interventions: Neuropsychologic testing, positron-emission tomography (PET), and single-photon emission-computed tomography (SPECT). Main Outcome Measures: Temporal lobe findings on static imaging (MRI, CT) and dynamic imaging (PET, SPECT); neuropsychologic test findings on measures of verbal and visual memory. Results: Testing documented neurobehavioral deficits in 19 patients (95%). Dynamic imaging documented abnormal findings in 18 patients (90%). Fifteen patients (75%) had temporal lobe abnormalities on PET and SPECT (primarily in medial temporal regions); abnormal findings were bilateral in 10 patients (50%) and unilateral in 5 (25%). Six patients (30%) had frontal abnormalities, and 8 (40%) had nonfrontotemporal abnormalities. Correlations between neuropsychologic testing and dynamic imaging could be established but not consistently across the whole group. Conclusions: Patients with mild TBI and persistent postconcussive symptoms have a high incidence of temporal lobe injury (presumably involving the hippocampus and related structures), which may explain the frequent finding of memory disorders in this population. The abnormal temporal lobe findings on PET and SPECT in humans may be analogous to the neuropathologic evidence of medial temporal injury provided by animal studies after mild TBI.	St Lawrence Rehabil Ctr, Brain Injury Unit, Lawrenceville, NJ USA; Univ Penn, Med Ctr, Dept Rehabil Med, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA	Sandel, ME (corresponding author), Kaiser Fdn, Rehabil Ctr, Kaiser Permanente Med Ctr, 975 Sereno Dr, Vallejo, CA 94589 USA.	elizabeth.sandel@kp.org			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS 08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALVAREZ P, 1994, P NATL ACAD SCI USA, V91, P7041, DOI 10.1073/pnas.91.15.7041; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ALVES WM, 1985, CENTRAL NERVOUS SYST, P255; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; DELIS DC, 1989, HDB NEUROPSYCHOLOGY, V3, P26; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goldstone BP, 2001, READ TEACH, V55, P362; GRAY BG, 1992, J NUCL MED, V33, P52; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Holbourn AHS, 1943, LANCET, V2, P438; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; JACOBS A, 1994, J NUCL MED, V35, P942; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KAY T, 1992, Neurology, V42, P411; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; Meyers JE, 1996, REY COMPLEX FIGURE T; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Newberg AB, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199612000-00009; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; REBA RC, 1993, J CLIN PSYCHIAT, V54, P26; REEVES DW, 1994, CLIN ASSESSMENT MEMO; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Rey A, 1964, EXAMEN CLIN PSYCHOL; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHAPIRO SR, 1993, MINOR HEAD TRAUMA AS, P86; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Squire L. R., 1984, MEMORY CONSOLIDATION, P185; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; Williams J. M, 1990, MEMORY ASSESSMENT SC; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	56	110	112	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2002	83	11					1506	1513		10.1053/apmr.2002.35092			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	612TP	WOS:000179091800002	12422317				2021-06-18	
J	DeFord, SM; Wilson, MS; Rice, AC; Clausen, T; Rice, LK; Barabnova, A; Bullock, R; Hamm, RJ				DeFord, SM; Wilson, MS; Rice, AC; Clausen, T; Rice, LK; Barabnova, A; Bullock, R; Hamm, RJ			Repeated mild brain injuries result in cognitive impairment in B6C3F1 mice	JOURNAL OF NEUROTRAUMA			English	Article						cognitive performance; concussion; head injury; mild brain injury; repeated brain injury; traumatic brain injury	HEAD-INJURY; SOCCER PLAYERS; CELL-DEATH; RAT; REPERFUSION; TRAUMA; MODEL	Experimental investigations of single mild brain injury (SMI) show relatively little resultant cognitive impairment. However, repeated mild brain injuries (RMI), as those sustained by athletes (e.g., football, hockey, and soccer players) may have cumulative effects on cognitive performance and neuropathology. Numerous clinical studies show persistent, latent, and long-term consequences of RMI, unlike the episodic nature of SMI. The nature of repeated traumatic brain injury (TBI) introduces confounding factors in invasive and even semiinvasive animal models of brain injury (e.g., scar formation). Thus, the present study characterizes SMI and RMI in a noninvasive mouse weight drop model and the cumulative effects of RMI on cognitive performance. Investigation of drop masses and drop distances revealed masses of 50, 100, and 150 g dropped from 40 cm resulted in 0% mortality, no skull fracture, and no difference in acute neurological assessment following sham injury, SMI, or RMI. Cumulative effects of RMI were examined following four mild brain injuries 24 h apart induced by 50-, 100-, or 150-g masses dropped from 40 cm through histological measures, mean arterial pressure, and measures of complex/spatial learning. RMI produced no overt cell death within the cortex or hippocampus, no evidence of blood-brain barrier compromise, and no significant change in mean arterial pressure. Following testing in the Morris water maze (MWM) on days 7-11 after initial injury, mice in the RMI 100-g and RMI 150-g groups had significantly longer MWM goal latencies compared to sham, SMI 150-g, and RMI 50-groups. Additionally, the evident cognitive deficit manifested in the absence of observed cell death. This is the first study to show complex/spatial learning deficits following RMI, similar to the visual/spatial perception and planning deficits observed in clinical studies.	Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA	DeFord, SM (corresponding author), Univ Florida, Inst Brain, 100 Newell Dr,LI-126,POB 100244, Gainesville, FL 32610 USA.						Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAKER SP, 1994, AM J PUBLIC HEALTH, V84, P649, DOI 10.2105/AJPH.84.4.649; Barancik M, 2000, J CARDIOVASC PHARM, V35, P474, DOI 10.1097/00005344-200003000-00019; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; Chilian WM, 1999, AM J PHYSIOL-HEART C, V277, pH2416; Csonka C, 1999, CIRCULATION, V100, P2260, DOI 10.1161/01.CIR.100.22.2260; Dickson EW, 2000, ACAD EMERG MED, V7, P311, DOI 10.1111/j.1553-2712.2000.tb02228.x; EVANS RW, 1992, NEUROL CLIN, V10, P815; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Ghosh S, 2000, CARDIOVASC RES, V45, P934, DOI 10.1016/S0008-6363(99)00407-1; GOVER GJ, 2000, J MOL CELL CARDIOL, V32, P677; GRONWALL D, 1975, LANCET, V2, P955; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hearse DJ, 1999, J MOL CELL CARDIOL, V31, P1961, DOI 10.1006/jmcc.1999.1027; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kawabata K, 2000, AM J PHYSIOL-HEART C, V278, pH1008; LOWELL MR, 1998, J HEAD TRAUMA REHAB, V13, P9; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; MARMAROU A, 1994, J NEUROSURG, V80, P281; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Perrault LP, 1999, ANN THORAC SURG, V68, P1988, DOI 10.1016/S0003-4975(99)01024-3; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; Tang YP, 1997, BRIT J PHARMACOL, V122, P257, DOI 10.1038/sj.bjp.0701385; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	34	110	112	0	19	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2002	19	4					427	438		10.1089/08977150252932389			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	542XP	WOS:000175071200004	11990349				2021-06-18	
J	Paniak, C; Toller-Lobe, G; Reynolds, S; Melnyk, A; Nagy, J				Paniak, C; Toller-Lobe, G; Reynolds, S; Melnyk, A; Nagy, J			A randomized trial of two treatments for mild traumatic brain injury: 1 year follow-up	BRAIN INJURY			English	Article							HEAD-INJURY	The purpose of this study was to provide 1 year follow-up data to a previous paper that compared single-session (SS) treatment to treatment-as-needed (TAN) outcomes for mild traumatic brain injury (MTBI) survivors at 3 months post-injury. participants were 105 adults with MTBI who were recruited from consecutive admissions to two hospital emergency wards, and randomly assigned to either the SS or TAN modality. No group differences in outcome were evident at 12 months post-injury. As well, improvements seen in the groups after 3 months were maintained at 12 months. As improvements between 3 and 12 months were negligible, self-reported improvement after a treated MTBI typically occurred within the first 3 months. Brief educational intervention given soon after MTBI appears to be as helpful as more intensive treatment for most MTBI survivors for at least 12 months post-injury.	Glenrose Rehabil Hosp, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada	Paniak, C (corresponding author), Glenrose Rehabil Hosp, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.	cpaniak@cha.ab.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Hopkins K. D., 1996, STAT METHODS ED PSYC; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; PANIAK C, 1992, DISS ABSTR INT, V52, P6093; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; WARE JE, 1992, SF 36 HLTH SURVEY MA; Willer B., 1993, BRAIN INJURY REHABIL, P355	22	110	111	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2000	14	3					219	226					8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	294EE	WOS:000085897700002	10759039				2021-06-18	
J	Delaney, JS; Lacroix, VJ; Leclerc, S; Johnston, KM				Delaney, JS; Lacroix, VJ; Leclerc, S; Johnston, KM			Concussions during the 1997 Canadian Football League season	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; professional football; risk factors; symptom duration	ATHLETIC HEAD-INJURIES; CEREBRAL CONCUSSION; AMERICAN FOOTBALL; SOCCER INJURIES; CONTACT SPORTS; CERVICAL-SPINE; PLAYERS; GUIDELINES; PREVENTION; BRAIN	Objective: To examine the incidence and characteristics of concussions for one season in the Canadian Football League (CFL). Design: Retrospective survey. Participants: 289 players reporting to CFL training camp. Of these, 154 players had played in the CFL during the 1997 season. Main Outcome Measures: Based on self-reported symptoms, calculations were made to determine the number of concussions experienced during the previous season, the duration of symptoms, the time for return to play after concussion, and any associated risk factors for concussions. Results: Of all the athletes who played during the 1997 season, 44.8% experienced symptoms of a concussion. Only 18.8% of these concussed players recognized they had suffered a concussion. 69.6% of all concussed players experienced more than one episode. Symptoms lasted at least 1 day in 25.8% of cases. The odds of experiencing a concussion increased 13% with each game played. A past history of a loss of consciousness while playing football and a recognized concussion while playing football were both associated with increased odds of experiencing a concussion during the 1997 season. Conclusion: Many players experienced a concussion during the 1997 CFL season, but the majority of these players may not have recognized that fact. Players need to be better informed about the symptoms and effects of concussions.	McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; McGill Univ, Ctr Hlth, Dept Emergency Med, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ, Canada	Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.						Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Baum KA, 1996, NEURORADIOLOGY, V38, P755, DOI 10.1007/s002340050342; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; *COL MED SOC, 1991, REP SPORTS MED COMM; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P606; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; MUELLER FO, 1987, CLIN SPORT MED, V6, P185; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; SAAL JA, 1991, SPORTS MED, V12, P132, DOI 10.2165/00007256-199112020-00005; Schneider R., 1973, HEAD NECK INJURIES F; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Warren WL, 1998, CLIN SPORT MED, V17, P13, DOI 10.1016/S0278-5919(05)70057-0; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	39	110	111	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2000	10	1					9	14		10.1097/00042752-200001000-00003			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	284VU	WOS:000085354200003	10695844				2021-06-18	
J	Lombardi, WJ; Andreason, PJ; Sirocco, KY; Rio, DE; Gross, RE; Umhau, JC; Hommer, DW				Lombardi, WJ; Andreason, PJ; Sirocco, KY; Rio, DE; Gross, RE; Umhau, JC; Hommer, DW			Wisconsin card sorting test performance following head injury: Dorsolateral fronto-striatal circuit activity predicts perseveration	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							PROGRESSIVE SUPRANUCLEAR PALSY; CEREBRAL BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; PARKINSONS-DISEASE; PREFRONTAL CORTEX; LOBE LESIONS; MULTIPLE-SCLEROSIS; COGNITIVE DEFICITS; ALZHEIMERS-DISEASE; SCHIZOPHRENIA	The Wisconsin Card Sorting Test (WCST) has been argued to be a sensitive indicator of frontal lobe function. However, several recent studies have failed to find a consistent relationship between structural damage to this cortical area and perseveration on the test. In the present study, positron emission tomography (PET) imaging with F-18-fluorodeoxyglucose was used to examine the relationship of regional brain metabolism to perseverative responding on the WCST in patients with a history of closed-head injury. An inverse relationship was found between perseverative responses and metabolism in the right, but not the left, dorsolateral prefrontal cortex and caudate nucleus. Perseverative responding was not related to metabolism in several other regions of the frontal lobes and basal ganglia, including the putamen and the frontal poles bilaterally. These data suggest that the functional integrity of the right dorsolateral frontal-subcortical circuit is critical for WCST performance.	NIAAA, Clin Studies Lab, Bethesda, MD 20892 USA; Toronto Hosp, Dept Surg, Div Neurosurg, Toronto, ON, Canada; Univ Toronto, Toronto, ON, Canada	Lombardi, WJ (corresponding author), Univ Utah, Dept Neurosci, 50 N Med Dr, Salt Lake City, UT 84132 USA.	wjl@suzy.med.utah.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [Z01AA000082] Funding Source: NIH RePORTER		ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; ARNETT PA, 1994, NEUROLOGY, V44, P420, DOI 10.1212/WNL.44.3_Part_1.420; Axelrod BN, 1996, J CLIN EXP NEUROPSYC, V18, P338, DOI 10.1080/01688639608408991; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; BERMAN KF, 1995, NEUROPSYCHOLOGIA, V33, P1027, DOI 10.1016/0028-3932(95)00035-2; BORNSTEIN RA, 1986, INT J CLIN NEUROPSYC, V8, P18; BROOKS RA, 1982, J NUCL MED, V23, P538; BROWN RG, 1988, BRAIN, V111, P323, DOI 10.1093/brain/111.2.323; CALTAGIRONE C, 1989, J NEUROL NEUROSUR PS, V52, P334, DOI 10.1136/jnnp.52.3.334; CANAVAN AGM, 1989, NEUROPSYCHOLOGIA, V27, P141, DOI 10.1016/0028-3932(89)90167-X; CICERONE KD, 1983, NEUROPSYCHOLOGIA, V21, P513, DOI 10.1016/0028-3932(83)90007-6; CLARK C, 1985, J CEREBR BLOOD F MET, V5, P142, DOI 10.1038/jcbfm.1985.18; Cohen J., 1983, APPL MULTIPLE REGRES; COHEN RM, 1988, NEUROPSY NEUROPSY BE, V1, P3; COOLS AR, 1984, J NEUROL NEUROSUR PS, V47, P443, DOI 10.1136/jnnp.47.5.443; Damasio H., 1989, LESION ANAL NEUROPSY; DREWE E A, 1974, Cortex, V10, P159; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FLOWERS KA, 1985, J NEUROL NEUROSUR PS, V48, P517, DOI 10.1136/jnnp.48.6.517; GOTHAM AM, 1988, BRAIN, V111, P299, DOI 10.1093/brain/111.2.299; GRAFMAN J, 1990, ARCH NEUROL-CHICAGO, V47, P553, DOI 10.1001/archneur.1990.00530050077015; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.8.1120-1122; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton R. K, 1981, WISCONSIN CARD SORTI; HECK ET, 1986, J CLIN EXP NEUROPSYC, V8, P313, DOI 10.1080/01688638608401321; HIETANEN M, 1986, ACTA NEUROL SCAND, V73, P151; JOSIASSEN RC, 1983, ARCH NEUROL-CHICAGO, V40, P791, DOI 10.1001/archneur.1983.04050120041005; LEES AJ, 1983, BRAIN, V106, P257, DOI 10.1093/brain/106.2.257; MARENCO S, 1993, PSYCHIAT RES-NEUROIM, V50, P177, DOI 10.1016/0165-1781(93)80012-T; MATSUI T, 1978, ATLAS HUMAN BRAIN CO; MENDEZ MF, 1989, NEUROLOGY, V39, P349, DOI 10.1212/WNL.39.3.349; MILNER B, 1984, TRENDS NEUROSCI, V7, P403, DOI 10.1016/S0166-2236(84)80143-5; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; MOUNTAIN MA, 1993, CLIN NEUROPSYCHOL, V7, P108, DOI 10.1080/13854049308401893; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; OWEN AM, 1992, BRAIN, V115, P1727, DOI 10.1093/brain/115.6.1727; PENDLETON MG, 1982, J CLIN PSYCHOL, V38, P392, DOI 10.1002/1097-4679(198204)38:2<392::AID-JCLP2270380232>3.0.CO;2-W; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; PILLON B, 1995, NEUROLOGY, V45, P1477, DOI 10.1212/WNL.45.8.1477; PILLON B, 1986, NEUROLOGY, V36, P1179, DOI 10.1212/WNL.36.9.1179; Pirozzolo F J, 1982, Brain Cogn, V1, P71, DOI 10.1016/0278-2626(82)90007-0; REITAN RM, 1971, J CONSULT CLIN PSYCH, V37, P364, DOI 10.1037/h0032005; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; RICHARDS M, 1993, J CLIN EXP NEUROPSYC, V15, P266, DOI 10.1080/01688639308402562; Rio DE, 1996, COMPUT BIOMED RES, V29, P438, DOI 10.1006/cbmr.1996.0033; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RUBIN P, 1991, ARCH GEN PSYCHIAT, V48, P987; SOKOLOFF L, 1982, ADV NEUROCHEM, V4, P1; SWIRSKYSACCHETTI T, 1992, NEUROLOGY, V42, P1291, DOI 10.1212/WNL.42.7.1291; TEUBER HL, 1951, J NERV MENT DIS, V114, P413, DOI 10.1097/00005053-195111450-00006; VanHorn JD, 1996, BIOL PSYCHIAT, V39, P389, DOI 10.1016/0006-3223(95)00249-9; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WEINBERGER DR, 1988, ARCH GEN PSYCHIAT, V45, P609; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O	57	110	114	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1999	21	1					2	16		10.1076/jcen.21.1.2.940			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	214VN	WOS:000081348400002	10420997				2021-06-18	
J	Dixon, CE; Flinn, P; Bao, JL; Venya, R; Hayes, RL				Dixon, CE; Flinn, P; Bao, JL; Venya, R; Hayes, RL			Nerve growth factor attenuates cholinergic deficits following traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article							FIMBRIA-FORNIX TRANSECTION; CONTROLLED CORTICAL IMPACT; MEDIAL SEPTUM; HEAD-INJURY; AGED RATS; ACETYLCHOLINE SYNTHESIS; GLUTATHIONE-PEROXIDASE; MEMORY IMPAIRMENT; FACTOR RECEPTOR; NEURONS	Traumatic brain injury (TBI) results in chronic derangements in central cholinergic neurotransmission that may contribute to posttraumatic memory deficits. Intraventricular cannula (IVC) nerve growth factor (NGF) infusion can reduce axotomy-induced spatial memory deficits and morphologic changes observed in medial septal cholinergic neurons immunostained for choline acetyltransferase (ChAT). We examined the efficacy of NGF to (1) ameliorate reduced posttraumatic spatial memory performance, (2) release of hippocampal acetylcholine (ACh), and (3) ChAT immunoreactivity in the rat medial septum. Rats (n = 36) were trained prior to TBI on the functional tasks and retested on Days 1-5 (motor) and on Day 7 (memory retention). Immediately following injury, an IVC and osmotic pump were implanted, and NGF or vehicle was infused for 7 days. While there were no differences in motor performance, the NGF-treated group had significantly better spatial memory retention (P < 0.05) than the vehicle-treated group. The IVC cannula was then removed on Day 7, and a microdialysis probe was placed into the dorsal hippocampus. After a 22-h equilibration period, samples were collected prior to and after administration of scopolamine (1 mg/kg), which evoked ACh release by blocking autoreceptors. The posttraumatic reduction in scopolamine-evoked ACh release was completely reversed with NGF. Injury produced a bilateral reduction in the number and cross-sectional area of ChAT immunopositive medial septal neurons that was reversed by NGF treatment. These data suggest that cognitive but not motor deficits following TBI are, in part, mediated by chronic deficits in cholinergic systems that can be modulated by neurotrophic factors such as NGF. (C) 1997 Academic Press.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030	Dixon, CE (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT NEUROSURG,3434 5TH AVE,SUITE 201,PITTSBURGH,PA 15260, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, P01NS031998] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49-CCR303547] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NIH-NS33150, NIH-NS31998] Funding Source: Medline		ARMSTRONG DM, 1987, J COMP NEUROL, V264, P421, DOI 10.1002/cne.902640309; Backman C, 1996, J NEUROSCI, V16, P5437; BATCHELOR PE, 1989, J COMP NEUROL, V284, P187, DOI 10.1002/cne.902840204; BLAKER SN, 1988, J COMP NEUROL, V272, P127, DOI 10.1002/cne.902720109; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; COLLERTON D, 1986, NEUROSCIENCE, V19, P1, DOI 10.1016/0306-4522(86)90002-3; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dixon C. E., 1995, Journal of Neurotrauma, V12, P491; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; DUNNETT SB, 1982, BRAIN RES, V251, P335, DOI 10.1016/0006-8993(82)90751-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; GAGE FH, 1988, J COMP NEUROL, V269, P147, DOI 10.1002/cne.902690112; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HAGG T, 1993, EXP NEUROL, V119, P37, DOI 10.1006/exnr.1993.1005; HAGG T, 1989, BRAIN RES, V505, P29, DOI 10.1016/0006-8993(89)90112-1; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEFTI F, 1986, J NEUROSCI, V6, P2155; HEFTI F, 1990, BRAIN CHOLINERGIC SY, P173; JACKSON GR, 1994, BRAIN RES, V634, P69, DOI 10.1016/0006-8993(94)90259-3; JACKSON GR, 1994, DEV NEUROSCI-BASEL, V16, P285, DOI 10.1159/000112121; JIANG JY, 1994, BRAIN RES, V640, P240; JOPE RS, 1979, BRAIN RES REV, V1, P313, DOI 10.1016/0165-0173(79)90009-2; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KNIPPER M, 1994, EUR J NEUROSCI, V6, P668, DOI 10.1111/j.1460-9568.1994.tb00312.x; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; NEWCOMB JK, IN PRESS J NEUROTRAU; NISTICO G, 1992, FREE RADICAL BIO MED, V12, P177, DOI 10.1016/0891-5849(92)90024-B; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POSMANTUR R, 1997, J NEUROSCI, V77, P875; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; RYLETT RJ, 1993, J NEUROSCI, V13, P3956; RYLETT RJ, 1993, BRAIN RES, V626, P184, DOI 10.1016/0006-8993(93)90578-B; SCHMIDT RH, 1995, J NEUROSURG, V83, P406; SINSON B, 1995, J NEUROSCI; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITH ML, 1995, NEUROSCIENCE, V67, P679, DOI 10.1016/0306-4522(95)00076-U; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SPENCER DG, 1983, DRUG DEVELOP RES, V3, P489, DOI 10.1002/ddr.430030602; TUSZYNSKI MH, 1990, NEUROSCIENCE, V36, P33, DOI 10.1016/0306-4522(90)90349-9; VAHLSING HL, 1991, BRAIN RES, V552, P320, DOI 10.1016/0006-8993(91)90098-G; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415	70	110	110	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	AUG	1997	146	2					479	490		10.1006/exnr.1997.6557			12	Neurosciences	Neurosciences & Neurology	XR256	WOS:A1997XR25600022	9270059				2021-06-18	
J	Alderson, P; Roberts, I				Alderson, P; Roberts, I			Corticosteroids in acute traumatic brain injury: Systematic review of randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							SEVERE HEAD-INJURY; CLINICAL-TRIAL; DEXAMETHASONE THERAPY; MANAGEMENT; STEROIDS	Objective: To quantify the effectiveness and safety of corticosteroids in the treatment of acute traumatic brain injury. Design: Systematic review of randomised controlled trials of corticosteroids in acute traumatic brain injury. Summary odds ratios were estimated as an inverse variance weighted average of the odds ratios for each study. Setting: Randomised trials available by March 1996. Subjects: The included trials with outcome data comprised 2073 randomised participants. Results: The effect of corticosteroids on the risk of death was reported in 13 included trials. The pooled odds ratio for the 13 trials was 0.91 (95% confidence interval 0.74 to 1.12). Pooled absolute risk reduction was 1.8% (-2.5% to 5.7%). For the 10 trials that reported death or disability the pooled odds ratio was 0.90 (0.72 to 1.11). For infections of any type the pooled odds ratio was 0.92 (0.69 to 1.23) and for the seven trials reporting gastrointestinal bleeding it was 1.05 (0.44 to 2.52). With only those trials with the best quality of concealment of allocation, the pooled odds ratio estimates for death and death or disability became closer to unity. Conclusions: This systematic review of randomised controlled trials of corticosteroids in acute traumatic brain injury shows that there remains considerable uncertainty over their effects. Neither moderate benefits nor moderate harmful effects can be excluded. The widely practicable nature of the drugs and the importance of the health problem suggest that large simple trials are feasible and worth while to establish whether there are any benefits from use of corticosteroids in this setting.	UNIV LONDON,INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	Alderson, P (corresponding author), UK COCHRANE CTR,NHS RES & DEV PROGRAMME,OXFORD OX2 7LG,ENGLAND.						ALEXANDER E, 1972, CLIN NEUROSURG, V19, P210; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUN SR, 1986, CRIT CARE MED, V14, P198, DOI 10.1097/00003246-198603000-00006; *CDCP, 1996, EP INF  VERS 6 03; *COCHR COLL, 1996, COCHR LIB DAT DISK C; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; FANCONI S, 1988, INTENS CARE MED, V14, P163; FAUPEL G, 1976, DYNAMICS BRAIN EDEMA, P337; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; GALICICH JH, 1961, AM PRACT DIG TREAT, V12, P169; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Hernesniemi J, 1979, Acta Neurochir Suppl (Wien), V28, P499; HOYT HJ, 1972, PHARMACOL THERAPEUT, V13, P141; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; Kraus JF, 1993, HEAD INJURY, P1; MILLER JD, 1992, BRIT J SURG, V79, P60, DOI 10.1002/bjs.1800790122; Murray CJ, 1994, GLOBAL COMP ASSESSME; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; PITTS LH, 1980, INTRACRANIAL PRESSUR, V4, P638; Ransohoff J, 1972, STEROIDS BRAIN EDEMA, P211; ROBERTS I, 1995, BRIT MED J, V310, P1311, DOI 10.1136/bmj.310.6990.1311; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; TAHARA I, 1972, NEUROL MED CHIR TOKY, V12, P111; *TASK FORC AM ASS, 1995, GUID MAN SEV HEAD IN; *UPD SOFTW, 1996, REVM VERS 3 0 WIND; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; Zagara G, 1987, J Neurosurg Sci, V31, P207	35	110	116	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1855	1859		10.1136/bmj.314.7098.1855			5	Medicine, General & Internal	General & Internal Medicine	XH738	WOS:A1997XH73800018	9224126	Green Published			2021-06-18	
J	Rockwood, K; Joyce, B; Stolee, P				Rockwood, K; Joyce, B; Stolee, P			Use of goal attainment scaling in measuring clinically important change in cognitive rehabilitation patients	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						cognitive rehabilitation; change measures; goal attainment scaling; functional capacity; relative efficiency	TRAUMATIC BRAIN INJURY; HEALTH-STATUS; QUALITY; CARE; SENSITIVITY; ARTHRITIS; SYSTEM; INDEX; LIFE	Measuring the effectiveness of cognitive rehabilitation programs poses both conceptual and practical challenges. We compared several standardized outcome measures with goal attainment scaling (GAS) to assess their sensitivity to changes in health status in patients undergoing cognitive rehabilitation. GAS is a measurement. approach that accommodates multiple individual patient goals, and has a scoring system which allows for comparisons between patients. Forty-four patients were evaluated. GAS yielded a mean 4.4 goals per patient. The mean gain in the GAS score was compared with the change in the Rappaport Disability Rating Scale, the Kohlman Evaluation of Daily Living Skills, the Milwaukee Evaluation of Daily Living, the Klein-Bell elimination scale and mobility scale, the Instrumental Activities of Daily Living Scale, and the Spitzer Quality of Life Index. Using a relative efficiency statistic, GAS proved more responsive than any other measure. The effect size statistic also demonstrated greater responsiveness to change with GAS compared with standard measures. GAS shows promise as a responsive measure in cognitive rehabilitation. This study replicates a similar study of GAS in frail elderly patients, suggesting that individualized measures may have broad merit in evaluating rehabilitation programs. (C) 1997 Elsevier Science Inc.	DALHOUSIE UNIV, DIV GERIATR MED, HALIFAX, NS, CANADA; DALHOUSIE UNIV, DIV PHYS MED & REHABIL, HALIFAX, NS, CANADA; SW ONTARIO REG GERIATR PROGRAM, LONDON, ON, CANADA			Rockwood, Kenneth/AAD-8951-2019; Stolee, Paul/ABB-2660-2020	Stolee, Paul/0000-0002-5685-0843			*AN SOFTW INC, 1994, STAT VERS 4 1; ANDERSON JJ, 1989, ARTHRITIS RHEUM, V32, P844; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BERROL S, 1990, ARCH NEUROL-CHICAGO, V47, P219, DOI 10.1001/archneur.1990.00530020127025; FEINSTEIN Alvan R., 1967, CLIN JUDGEMENT; FEINSTEIN AR, 1994, ANN INTERN MED, V120, P799, DOI 10.7326/0003-4819-120-9-199405010-00012; Feinstein AR., 1987, CLINIMETRICS; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P145; HACHINSKI V, 1990, ARCH NEUROL-CHICAGO, V47, P224, DOI 10.1001/archneur.1990.00530020132028; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; KIRESUK TJ, 1978, EVALUATION HUMAN SER; KLEIN RM, 1982, ARCH PHYS MED REHAB, V63, P335; KRAEMER HC, 1987, HOW MANY SUBJECTS ST, pCH3; LACHS MS, 1993, J CLIN EPIDEMIOL, V46, P1091, DOI 10.1016/0895-4356(93)90107-C; Law M, 1990, Can J Occup Ther, V57, P82; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Leonardelli C. A., 1988, MILWAUKEE EVALUATION; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; LIANG MH, 1985, ARTHRITIS RHEUM, V28, P542, DOI 10.1002/art.1780280513; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MCGOURTY LK, 1988, MENTAL HLTH ASSESSME; OTTENBACHER KJ, 1990, AM J OCCUP THER, V44, P519, DOI 10.5014/ajot.44.6.519; PALISANO RJ, 1992, PHYS THER, V72, P432, DOI 10.1093/ptj/72.6.432; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROCKWOOD K, 1993, J CLIN EPIDEMIOL, V46, P1113, DOI 10.1016/0895-4356(93)90110-M; Rockwood K, 1996, NEUROEPIDEMIOLOGY, V15, P330, DOI 10.1159/000109923; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; Singh A C, 1989, Acta Psychiatr Scand Suppl, V347, P1; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; STOLEE P, 1992, J AM GERIATR SOC, V40, P574, DOI 10.1111/j.1532-5415.1992.tb02105.x; VOPLE B, 1990, ARCH NEUROL-CHICAGO, V47, P220	37	110	112	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	MAY	1997	50	5					581	588		10.1016/S0895-4356(97)00014-0			8	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	XD004	WOS:A1997XD00400009	9180650				2021-06-18	
J	Dixon, CE; Ma, XC; Marion, DW				Dixon, CE; Ma, XC; Marion, DW			Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release	JOURNAL OF NEUROTRAUMA			English	Article						acetylcholine; behavior; microdialysis; rats; traumatic brain injury; water maze	TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION INJURY; COGNITIVE IMPAIRMENT; HEAD-INJURY; RATS; RECEPTOR; MOTOR; HYPOTHERMIA; EXPERIENCE; IMPACT	The exogenous administration of cytidine-5'-diphosphate (CDP)-choline has been used extensively as a brain activator in different neurological disorders that are associated with memory deficits. A total of 50 rats were utilized to (a) determine whether exogenously administered CDP-choline could attenuate posttraumatic motor and spatial memory performance deficits and (b) determine whether intraperitoneal (i.p.) administration of CDP-choline increases acetylcholine (ACh) release in the dorsal hippocampus and neocortex. In the behavioral study, traumatic brain injury (TBI) was produced by lateral controlled cortical impact (2-mm deformation/6 m/sec) and administered CDP-choline (100 mg/kg) or saline daily for 18 days beginning 1 day postinjury. At 1 day postinjury, rats treated with CDP-choline 15 min prior to assessment performed significantly better than saline-treated rats. Between 14-18 days postinjury, CDP-choline-treated rats had significantly less cognitive (Morris water maze performance) deficits that injured saline-treated rats. CDP-choline treatment also attenuated the TBI-induced increased sensitivity to the memory-disrupting effects of scopolamine, a muscarinic antagonist. The microdialysis studies demonstrated for the first time that a single i.p. administration of CDP-choline can significantly increase extracellular levels of ACh in dorsal hippocampus and neocortex in normal, awake, freely moving rats. This article provides additional evidence that spatial memory performance deficits are, at least partially, associated with deficits in central cholinergic neurotransmission and that treatments that enhance ACh release in the chronic phase after TBI may attenuate cholinergic-dependent neurobehavioral deficits.		Dixon, CE (corresponding author), UNIV PITTSBURGH,DEPT NEUROL SURG,201 HILL BLDG,3434 5TH AVE,PITTSBURGH,PA 15260, USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150] Funding Source: NIH RePORTER; NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [CDE-CCR30347] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NIH-30318] Funding Source: Medline		AGUT J, 1993, ANN NY ACAD SCI, V695, P318, DOI 10.1111/j.1749-6632.1993.tb23075.x; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; CACABELOS R, 1994, ANN NY ACAD SCI, V16, P211; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cooper JR, 1996, BIOCH BASIS NEUROPHA; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1995, P SOC NEUR ANN M SOC, V21, P762; DIXON CE, 1996, IN PRESS BRAIN RES; DORLANDO KJ, 1995, NEUROL RES, V17, P281, DOI 10.1080/01616412.1995.11740327; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Jackson Darrell A., 1995, Life Sciences, V56, P45; KAKIHANA M, 1988, STROKE, V19, P217, DOI 10.1161/01.STR.19.2.217; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOPEZCOVIELLA I, 1995, J NEUROCHEM, V65, P889; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARSHALL DL, 1993, BRAIN RES, V269, P269; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PETKOV VD, 1993, ARZNEIMITTELFORSCH, V43-2, P822; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1993, J NEUROSCI, V13, P5383; VILLA RF, 1993, INT J DEV NEUROSCI, V11, P83, DOI 10.1016/0736-5748(93)90037-E; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	41	110	111	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1997	14	3					161	169		10.1089/neu.1997.14.161			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WT814	WOS:A1997WT81400004	9104933				2021-06-18	
J	OMALLEY, DE; MAZUR, JM; CUMMINGS, RJ				OMALLEY, DE; MAZUR, JM; CUMMINGS, RJ			FEMORAL-HEAD AVASCULAR NECROSIS ASSOCIATED WITH INTRAMEDULLARY NAILING IN AN ADOLESCENT	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						FEMORAL HEAD NECROSIS; FEMUR FRACTURE; INTRAMEDULLARY NAILING		An adolescent developed avascular necrosis of the femoral head after intramedullary nailing for a femoral diaphyseal fracture. This complication is most likely secondary to injury to the posterior superior ascending branch of the medial circumflex artery at the time of rod insertion. This artery is situated close to the proximal insertion hole just posterior to the trochanteric notch and piriformis fossa. Other methods of fracture treatment, either operative or nonoperative, should be considered in skeletally immature patients.	NATL NAVAL MED CTR, DEPT ORTHOPAED, BETHESDA, MD USA			yudong, LI/AAR-5902-2021					0	110	112	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-6798			J PEDIATR ORTHOPED	J. Pediatr. Orthop.	JAN-FEB	1995	15	1					21	23		10.1097/01241398-199501000-00005			3	Orthopedics; Pediatrics	Orthopedics; Pediatrics	PZ115	WOS:A1995PZ11500005	7883920				2021-06-18	
J	NILSSON, P; RONNEENGSTROM, E; FLINK, R; UNGERSTEDT, U; CARLSON, H; HILLERED, L				NILSSON, P; RONNEENGSTROM, E; FLINK, R; UNGERSTEDT, U; CARLSON, H; HILLERED, L			EPILEPTIC SEIZURE ACTIVITY IN THE ACUTE-PHASE FOLLOWING CORTICAL IMPACT TRAUMA IN RAT	BRAIN RESEARCH			English	Article						ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID; GLUTAMATE; ASPARTATE; RAT; SECONDARY ISCHEMIA; SEIZURE ACTIVITY; TRAUMATIC BRAIN INJURY	CONCUSSIVE BRAIN INJURY; CEREBRAL BLOOD-FLOW; EXTRACELLULAR AMINO-ACIDS; EXPERIMENTAL HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; METABOLITES; POTASSIUM; RELEASE	The aim of this investigation was to determine the incidence of seizure activity in the acute phase following traumatic brain injury. Compression contusion trauma was produced in the right parietal cortex in 19 artificially ventilated rats. Electroencephalographic recordings were carried out in 17 of the animals for 2 h following the impact. The extracellular levels of neuroactive amino acids were simultaneously monitored in 9 of the experiments using microdialysis. In 14 of the 17 animals a generalized seizure activity with an average duration of 59s (range 30-101s) was recorded. The mean time lag between trauma and seizure onset was 67s (range 26-90 s). The seizure activity was consistently followed by post-ictal depression. The trauma was accompanied by a transient increase of aspartate, taurine, glutamate and glycine, in decreasing rank order. The seizure activity occurred when the levels of these neuroactive amino acids were elevated. It is concluded that the high incidence of seizure activity observed may be an important factor contributing to secondary ischemia after traumatic brain injury. Aspartate and glutamate, potentiated by glycine, may play a role in post-traumatic seizure activity.	UNIV HOSP UPPSALA,DEPT CLIN CHEM,S-75285 UPPSALA,SWEDEN; UNIV HOSP UPPSALA,DEPT NEUROSURG,S-75285 UPPSALA,SWEDEN; UNIV HOSP UPPSALA,DEPT CLIN NEUROPHYSIOL,S-75185 UPPSALA,SWEDEN; KAROLINSKA INST,DEPT PHARMACOL,S-10401 STOCKHOLM,SWEDEN							ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; BRAZIER MAB, 1974, NEUROLOGY, V24, P903, DOI 10.1212/WNL.24.10.903; CARLSON H, 1992, NEUROSCI LETT, V140, P30, DOI 10.1016/0304-3940(92)90674-V; CARLSON H, 1992, J NEUROTRAUM, V9, P57; CHAPMAN AG, 1993, BIOCHEM SOC T, V21, P106, DOI 10.1042/bst0210106; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Delgado-Escueta A V, 1986, Adv Neurol, V44, P3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gade GF, 1990, NEUROLOGICAL SURG, P1965; GOVONS SR, 1972, EXP NEUROL, V34, P121, DOI 10.1016/0014-4886(72)90193-8; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; HILLERED L, 1992, J NEUROTRAUM, V9, P62; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; Lux H D, 1986, Adv Neurol, V44, P619; MELDRUM B, 1984, EPILEPSIA, V25, P140; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; MILLAN MH, 1993, EPILEPSY RES, V14, P139, DOI 10.1016/0920-1211(93)90018-3; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; REID MS, 1990, ACTA PHYSIOL SCAND, V140, P527, DOI 10.1111/j.1748-1716.1990.tb09030.x; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; RONNEENGSTROM E, 1992, J NEUROTRAUM, V9, P68; SIESJO BK, 1976, CRIT CARE MED, V4, P283, DOI 10.1097/00003246-197611000-00001; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V128, P9, DOI 10.1111/j.1748-1716.1986.tb07943.x; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	35	110	111	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 21	1994	637	1-2					227	232		10.1016/0006-8993(94)91237-8			6	Neurosciences	Neurosciences & Neurology	MY436	WOS:A1994MY43600028	8180800				2021-06-18	
J	Simon, MJ; Iliff, JJ				Simon, Matthew J.; Iliff, Jeffrey J.			Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						CSF; Glymphatic; Alzheimer's disease; Multiple sclerosis; Cerebral ischemia; Diurnal variation	TRAUMATIC BRAIN-INJURY; CEREBRAL AMYLOID ANGIOPATHY; CENTRAL-NERVOUS-SYSTEM; CHOROID-PLEXUS; INTERSTITIAL FLUID; ALZHEIMERS-DISEASE; BULK FLOW; AQUAPORIN 4; SUBARACHNOID HEMORRHAGE; NEUROMYELITIS-OPTICA	Cerebrospinal fluid (CSF) circulation and turnover provides a sink for the elimination of solutes from the brain interstitium, serving an important homeostatic role for the function of the central nervous system. Disruption of normal CSF circulation and turnover is believed to contribute to the development of many diseases, including neurodegenerative conditions such as Alzheimer's disease, ischemic and traumatic brain injury, and neuroinflammatory conditions such as multiple sclerosis. Recent insights into CSF biology suggesting that CSF and interstitial fluid exchange along a brain-wide network of perivascular spaces termed the 'glymphatic' system suggest that CSF circulation may interact intimately with glial and vascular function to regulate basic aspects of brain function. Dysfunction within this glial vascular network, which is a feature of the aging and injured brain, is a potentially critical link between brain injury, neuroinflammation and the development of chronic neurodegeneration. Ongoing research within this field may provide a powerful new framework for understanding the common links between neurodegenerative, neurovascular and neuroinflammatory disease, in addition to providing potentially novel therapeutic targets for these conditions. This article is part of a Special Issue entitled: Neuro Inflammation edited by Helga E. de Vries and Markus Schwaninger. (C) 2015 Elsevier B.V. All rights reserved.	[Simon, Matthew J.; Iliff, Jeffrey J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd,Mail Code HRC5N, Portland, OR 97239 USA; [Iliff, Jeffrey J.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA; [Simon, Matthew J.; Iliff, Jeffrey J.] Oregon Hlth & Sci Univ, Grad Program Neurosci, Portland, OR 97239 USA	Iliff, JJ (corresponding author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd,Mail Code HRC5N, Portland, OR 97239 USA.	iliffj@ohsu.edu		Simon, Matthew/0000-0002-0065-6486	American Heart AssociationAmerican Heart Association [12SDG11820014]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS089709]; Paul G. Allen Family Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089709] Funding Source: NIH RePORTER	Work in the authors' lab is supported by grants from the American Heart Association (12SDG11820014), the National Institutes of Health (NS089709) and the Paul G. Allen Family Foundation. The authors thank Douglas Zeppenfeld for helpful discussion of this review article.	Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Akanuma S, 2015, FLUIDS BARRIERS CNS, V12, DOI 10.1186/s12987-015-0006-x; Albeck MJ, 1998, J NEUROSURG, V89, P275, DOI 10.3171/jns.1998.89.2.0275; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Attems J, 2011, NEUROPATH APPL NEURO, V37, P75, DOI 10.1111/j.1365-2990.2010.01137.x; Bartholomaus I, 2009, NATURE, V462, P94, DOI 10.1038/nature08478; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; BLACK PM, 1985, NEUROSURGERY, V17, P57, DOI 10.1227/00006123-198507000-00009; BLASBERG R, 1981, NEUROSURGERY, V9, P686, DOI 10.1227/00006123-198112000-00012; BRINKER T, 1991, J NEUROSURG, V74, P789, DOI 10.3171/jns.1991.74.5.0789; Brinker T, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-10; Camassa LM., 2015, GLIA; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Crane JM, 2010, NEUROSCIENCE, V168, P892, DOI 10.1016/j.neuroscience.2009.08.034; Cserr H F, 1988, Ann N Y Acad Sci, V529, P9, DOI 10.1111/j.1749-6632.1988.tb51415.x; CSERR HF, 1981, AM J PHYSIOL, V240, pF319; CSERR HF, 1971, PHYSIOL REV, V51, P273; Damkier HH, 2013, PHYSIOL REV, V93, P1847, DOI 10.1152/physrev.00004.2013; Dandy WE, 1918, ANN SURG, V68, P569, DOI 10.1097/00000658-191812000-00001; Davson H., 1967, PHYSL CEREBROSPINAL; Davson H, 1996, PHYSL CSF BLOOD BRAI; de ROUGEMONT, 1960, J Neurophysiol, V23, P485; Deane R, 2009, CNS NEUROL DISORD-DR, V8, P16, DOI 10.2174/187152709787601867; Dreha-Kulaczewski S, 2015, J NEUROSCI, V35, P2485, DOI 10.1523/JNEUROSCI.3246-14.2015; Eid T, 2005, P NATL ACAD SCI USA, V102, P1193, DOI 10.1073/pnas.0409308102; Engelhardt B, 2012, TRENDS IMMUNOL, V33, P579, DOI 10.1016/j.it.2012.07.004; FEINBERG DA, 1987, RADIOLOGY, V163, P793, DOI 10.1148/radiology.163.3.3575734; Fenton RA, 2010, CELL MOL LIFE SCI, V67, P829, DOI 10.1007/s00018-009-0218-9; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Furman CS, 2003, P NATL ACAD SCI USA, V100, P13609, DOI 10.1073/pnas.2235843100; Gaberel T, 2014, STROKE, V45, P3092, DOI 10.1161/STROKEAHA.114.006617; Groothuis DR, 2007, J CEREBR BLOOD F MET, V27, P43, DOI 10.1038/sj.jcbfm.9600315; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Haglund M, 2006, INT J GERIATR PSYCH, V21, P681, DOI 10.1002/gps.1550; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Hawkes CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041636; Hawkes CA, 2011, ACTA NEUROPATHOL, V121, P431, DOI 10.1007/s00401-011-0801-7; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Hladky SB, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-26; Holmes BB, 2014, J BIOL CHEM, V289, P19855, DOI 10.1074/jbc.R114.549295; ICHIMURA T, 1991, BRAIN RES, V545, P103, DOI 10.1016/0006-8993(91)91275-6; Iliff JJ, 2015, LANCET NEUROL, V14, P977, DOI 10.1016/S1474-4422(15)00221-5; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, STROKE, V44, pS93, DOI 10.1161/STROKEAHA.112.678698; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Johanson C, 2011, TOXICOL PATHOL, V39, P186, DOI 10.1177/0192623310394214; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kang JE, 2009, SCIENCE, V326, P1005, DOI 10.1126/science.1180962; Kao LY, 2011, J BIOL CHEM, V286, P32563, DOI 10.1074/jbc.M111.249961; Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505; Kervezee L, 2014, AAPS J, V16, P1029, DOI 10.1208/s12248-014-9625-4; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Lee HD, 2015, J NEUROSCI, V35, P11034, DOI 10.1523/JNEUROSCI.1625-15.2015; Lehtinen MK, 2011, NEURON, V69, P893, DOI 10.1016/j.neuron.2011.01.023; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Lochhead JJ, 2015, J CEREBR BLOOD F MET, V35, P371, DOI 10.1038/jcbfm.2014.215; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lu DC, 2011, J NEUROTRAUMA; Lucchinetti CF, 2011, NEW ENGL J MED, V365, P2188, DOI 10.1056/NEJMoa1100648; MacAulay N, 2010, NEUROSCIENCE, V168, P941, DOI 10.1016/j.neuroscience.2009.09.016; Masseguin C, 2005, NEUROBIOL AGING, V26, P917, DOI 10.1016/j.neurobiolaging.2004.07.013; Matsumae M, 2014, J NEUROSURG, V120, P218, DOI 10.3171/2013.7.JNS121859; McCandless EE, 2008, AM J PATHOL, V172, P799, DOI 10.2353/ajpath.2008.070918; McCandless EE, 2006, J IMMUNOL, V177, P8053, DOI 10.4049/jimmunol.177.11.8053; Meyers SP, 2004, NEURORADIOLOGY, V46, P770, DOI 10.1007/s00234-004-1238-7; Millar ID, 2008, BIOCHEM BIOPH RES CO, V373, P550, DOI 10.1016/j.bbrc.2008.06.053; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Ohshiro K, 2001, ARCH HISTOL CYTOL, V64, P329, DOI 10.1679/aohc.64.329; Oi SZ, 2011, CHILD NERV SYST, V27, P1523, DOI 10.1007/s00381-011-1542-6; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Pascale Crissey L, 2011, Fluids Barriers CNS, V8, P21, DOI 10.1186/2045-8118-8-21; PFEFFERBAUM A, 1994, ARCH NEUROL-CHICAGO, V51, P874, DOI 10.1001/archneur.1994.00540210046012; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; POLLAY M, 1967, AM J PHYSIOL, V213, P1031; PULLEN RGL, 1987, AM J PHYSIOL, V253, pF538; Ramanathan A, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00136; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Rennels M L, 1990, Adv Neurol, V52, P431; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Roemer SF, 2007, BRAIN, V130, P1194, DOI 10.1093/brain/awl371; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; ROSENBERG GA, 1980, AM J PHYSIOL, V238, pF42; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P426; Sheldon CA, 2015, PEDIATR RES, V77, P282, DOI 10.1038/pr.2014.188; Silberstein C, 2004, AM J PHYSIOL-RENAL, V287, pF501, DOI 10.1152/ajprenal.00439.2003; Siler DA, 2014, TRANSL STROKE RES, V5, P227, DOI 10.1007/s12975-014-0329-y; Silverberg GD, 2001, NEUROLOGY, V57, P1763, DOI 10.1212/WNL.57.10.1763; Smith AJ, 2015, TRENDS NEUROSCI, V38, P331, DOI 10.1016/j.tins.2015.04.006; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; SPECTOR R, 1989, J NEUROCHEM, V53, P1667, DOI 10.1111/j.1471-4159.1989.tb09229.x; Spector R, 2006, PHARM RES-DORDR, V23, P2515, DOI 10.1007/s11095-006-9091-5; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; SZENTISTVANYI I, 1984, AM J PHYSIOL, V246, pF835; Thrane AS, 2015, TRENDS NEUROSCI, V38, P333, DOI 10.1016/j.tins.2015.04.009; Thrane AS, 2014, TRENDS NEUROSCI, V37, P620, DOI 10.1016/j.tins.2014.08.010; Thrane VR, 2013, SCI REP-UK, V3, DOI 10.1038/srep02582; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Vinters HV, 2000, J NEUROPATH EXP NEUR, V59, P931, DOI 10.1093/jnen/59.11.931; Wang MH, 2012, J NEUROSCI, V32, P17948, DOI 10.1523/JNEUROSCI.1860-12.2012; Weller RO, 2008, BRAIN PATHOL, V18, P253, DOI 10.1111/j.1750-3639.2008.00133.x; Weller RO, 2009, ACTA NEUROPATHOL, V117, P1, DOI 10.1007/s00401-008-0457-0; Wolburg H, 2001, NEUROSCI LETT, V307, P77, DOI 10.1016/S0304-3940(01)01927-9; Wolburg H, 2010, ACTA NEUROPATHOL, V119, P75, DOI 10.1007/s00401-009-0627-8; Wolburg-Buchholz K, 2009, ACTA NEUROPATHOL, V118, P219, DOI 10.1007/s00401-009-0558-4; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Yamada K, 2014, J EXP MED, V211, P387, DOI 10.1084/jem.20131685; Yamada S, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-36; Yang BX, 1996, J BIOL CHEM, V271, P4577; Yang J, 2011, J ALZHEIMERS DIS, V27, P711, DOI 10.3233/JAD-2011-110725; Yang LJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-107; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG ET, 1990, J ANAT, V170, P111; Zhao RB, 2009, J BIOL CHEM, V284, P4267, DOI 10.1074/jbc.M807665200	129	109	114	1	43	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439	1879-260X		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	MAR	2016	1862	3			SI		442	451		10.1016/j.bbadis.2015.10.014			10	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	DF9BD	WOS:000371654400014	26499397	Green Accepted, Bronze			2021-06-18	
J	Henry, LC; Elbin, RJ; Collins, MW; Marchetti, G; Kontos, AP				Henry, Luke C.; Elbin, R. J.; Collins, Michael W.; Marchetti, Gregory; Kontos, Anthony P.			Examining Recovery Trajectories After Sport-Related Concussion With a Multimodal Clinical Assessment Approach	NEUROSURGERY			English	Article						Comprehensive assessment; Recovery time; Sport-related concussion	TEST-RETEST RELIABILITY; ERROR SCORING SYSTEM; PREDICT PROTRACTED RECOVERY; HIGH-SCHOOL; POST-CONCUSSION; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; PROLONGED RECOVERY; SEX-DIFFERENCES	BACKGROUND:Previous research estimates that the majority of athletes with sport-related concussion (SRC) will recover between 7 and 10 days after injury. This short temporal window of recovery is based predominately on symptom resolution and cognitive improvement and does not accurately reflect recent advances in the clinical assessment model.OBJECTIVE:To characterize SRC recovery at 1-week postinjury time intervals on symptom, neurocognitive, and vestibular-oculomotor outcomes and to examine sex differences in SRC recovery time.METHODS:A prospective, repeated-measures design was used to examine the temporal resolution of neurocognitive, symptom, and vestibular-oculomotor impairment in 66 subjects (age, 16.5 1.9 years; range, 14-23 years; 64% male) with SRC.RESULTS:Recovery time across all outcomes was between 21 and 28 days after SRC for most athletes. Symptoms demonstrated the greatest improvement in the first 2 weeks, although neurocognitive impairment lingered across various domains up to 28 days after SRC. Vestibular-oculomotor decrements also resolved between 1 and 3 weeks after injury. There were no sex differences in neurocognitive recovery. Male subjects were more likely to be asymptomatic by the fourth week and reported less vestibular-oculomotor impairment than female subjects at weeks 1 and 2.CONCLUSION:When the recommended comprehensive approach is used for concussion assessment, recovery time for SRC is approximately 3 to 4 weeks, which is longer than the commonly reported 7 to 14 days. Sports medicine clinicians should use a variety of complementing assessment tools to capture the heterogeneity of SRC.ABBREVIATIONS:BESS, Balance Error Scoring SystemCI, confidence intervalDHI, Dizziness Handicap InventoryES, effect sizeImPACT, Immediate Post-Concussion Assessment and Cognitive TestPCSS, Post-Concussion Symptom ScaleSAC, Standard Assessment of ConcussionSRC, sport-related concussion	[Henry, Luke C.; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Off Sport Concuss Res, Fayetteville, AR 72701 USA; [Marchetti, Gregory] Duquesne Univ, Rangos Sch Hlth Sci, Dept Phys Therapy, Pittsburgh, PA 15219 USA	Henry, LC (corresponding author), 3200 S Water St, Pittsburgh, PA 15203 USA.	lch32@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; University of PittsburghUniversity of Pittsburgh; ElMindA, Ltd (Israel); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	This research was supported in part by grants to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1) to Dr Kontos and through a research contract between the University of Pittsburgh and ElMindA, Ltd (Israel) with Dr Kontos. Dr Collins is a codeveloper and board member of ImPACT Applications. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Balaban CD, 2001, J ANXIETY DISORD, V15, P27, DOI 10.1016/S0887-6185(00)00041-4; Balaban CD, 2001, J ANXIETY DISORD, V15, P53, DOI 10.1016/S0887-6185(00)00042-6; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2013, TRANSL STROKE RES, V4, P420, DOI 10.1007/s12975-012-0228-z; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, J NEUROSCI NURS, V44, P124, DOI 10.1097/JNN.0b013e318252737d; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mulligan IJ, 2013, SPORTS HEALTH, V5, P22, DOI 10.1177/1941738112467755; Murray N, 2014, J ATHL TRAINING, V49, P540, DOI 10.4085/1062-6050-49.3.32; Murray NG, 2014, BRAIN INJURY, V28, P496, DOI 10.3109/02699052.2014.887144; Pardini D., 2004, BR J SPORTS MED, V38, P661; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Quatman-Yates C, 2014, PHYSICIAN SPORTSMED, V42, P32, DOI 10.3810/psm.2014.09.2073; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Resch JE, 2013, CLIN NEUROPSYCHOL, V27, P1265, DOI 10.1080/13854046.2013.845247; Reynolds E, 2014, PROG NEUROL SURG, V28, P128, DOI 10.1159/000358770; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	59	109	109	1	44	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2016	78	2					232	241		10.1227/NEU.0000000000001041			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DB5WY	WOS:000368585600009	26445375	Green Accepted			2021-06-18	
J	Morganti, JM; Riparip, LK; Rosi, S				Morganti, Josh M.; Riparip, Lara-Kirstie; Rosi, Susanna			Call Off the Dog(ma): M1/M2 Polarization Is Concurrent following Traumatic Brain Injury	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; MACROPHAGE ACTIVATION; ALTERNATIVE ACTIVATION; CEREBRAL-CORTEX; WHITE-MATTER; SPINAL-CORD; MOUSE MODEL; IN-VIVO; INFLAMMATION; PARADIGM	Following the primary mechanical impact, traumatic brain injury (TBI) induces the simultaneous production of a variety of pro-and anti-inflammatory molecular mediators. Given the variety of cell types and their requisite expression of cognate receptors this creates a highly complex inflammatory milieu. Increasingly in neurotrauma research there has been an effort to define injury-induced inflammatory responses within the context of in vitro defined macrophage polarization phenotypes, known as "M1" and "M2". Herein, we expand upon our previous work in a rodent model of TBI to show that the categorization of inflammatory response cannot be so easily delineated using this nomenclature. Specifically, we show that TBI elicited a wide spectrum of concurrent expression responses within both pro-and anti-inflammatory arms. Moreover, we show that the cells principally responsible for the production of these inflammatory mediators, microglia/macrophages, simultaneously express both "M1" and "M2" phenotypic markers. Overall, these data align with recent reports suggesting thatmicroglia/macrophages cannot adequately switch to a polarized "M1-only" or "M2-only" phenotype, but display a mixed phenotype due to the complex signaling events surrounding them.	[Morganti, Josh M.; Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Morganti, Josh M.; Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy, San Francisco, CA 94143 USA; [Morganti, Josh M.; Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Dept Rehabil Sci, San Francisco, CA 94143 USA; [Rosi, Susanna] Univ Calif San Francisco, Neurol Surg, San Francisco, CA 94143 USA	Rosi, S (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Phys Therapy, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Rehabil Sci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Neurol Surg, San Francisco, CA 94143 USA.	susanna.rosi@ucsf.edu	Morganti, Josh/AAL-9727-2020	Morganti, Josh/0000-0002-4183-0049	National Institute Of Neurological Disorders And StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institute on Aging of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F32NS090805, R21NS087458, R21AG042016]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087458, F32NS090805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042016] Funding Source: NIH RePORTER	Funded by National Institute Of Neurological Disorders And Stroke and National Institute on Aging of the National Institutes of Health under award numbers F32NS090805 (J.M.M.), R21NS087458 (S.R.); R21AG042016 (S.R.).	Belarbi K, 2013, CANCER RES, V73, P1201, DOI 10.1158/0008-5472.CAN-12-2989; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chiu IM, 2013, CELL REP, V4, P385, DOI 10.1016/j.celrep.2013.06.018; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Davies LC, 2013, NAT IMMUNOL, V14, P986, DOI 10.1038/ni.2705; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Geissmann F, 2010, NAT REV IMMUNOL, V10, P453, DOI 10.1038/nri2784; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Josefowicz SZ, 2013, IMMUNOLOGY, V139, P299, DOI 10.1111/imm.12115; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; Micallef L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101717; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti JM, 2012, J NEUROSCI, V32, P14592, DOI 10.1523/JNEUROSCI.0539-12.2012; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; White TE, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-282; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006	44	109	111	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2016	11	1							e0148001	10.1371/journal.pone.0148001			13	Multidisciplinary Sciences	Science & Technology - Other Topics	DC9FZ	WOS:000369527800262	26808663	DOAJ Gold, Green Published			2021-06-18	
J	Hillary, FG; Roman, CA; Venkatesan, U; Rajtmajer, SM; Bajo, R; Castellanos, ND				Hillary, Frank G.; Roman, Cristina A.; Venkatesan, Umesh; Rajtmajer, Sarah M.; Bajo, Ricardo; Castellanos, Nazareth D.			Hyperconnectivity is a Fundamental Response to Neurological Disruption	NEUROPSYCHOLOGY			English	Article						brain injury; Multiple Sclerosis; Alzheimer's Disease; connectivity; default mode network	MILD COGNITIVE IMPAIRMENT; DEFAULT-MODE NETWORK; ALTERED FUNCTIONAL CONNECTIVITY; RESTING-STATE NETWORKS; MULTIPLE-SCLEROSIS PATIENTS; TRAUMATIC BRAIN-INJURY; EARLY ALZHEIMERS-DISEASE; WORKING-MEMORY NETWORK; SHORT-TERM-MEMORY; PROCESSING SPEED	Objective: In the cognitive and clinical neurosciences, the past decade has been marked by dramatic growth in a literature examining brain "connectivity" using noninvasive methods. We offer a critical review of the blood oxygen level dependent functional MRI (BOLD fMRI) literature examining neural connectivity changes in neurological disorders with focus on brain injury and dementia. The goal is to demonstrate that there are identifiable shifts in local and large-scale network connectivity that can be predicted by the degree of pathology. We anticipate that the most common network response to neurological insult is hyperconnectivity but that this response depends upon demand and resource availability. Method: To examine this hypothesis, we initially reviewed the results from 1,426 studies examining functional brain connectivity in individuals diagnosed with multiple sclerosis, traumatic brain injury, mild cognitive impairment, and Alzheimer's disease. Based upon inclusionary criteria, 126 studies were included for detailed analysis. Results: Results from 126 studies examining local and whole brain connectivity demonstrated increased connectivity in traumatic brain injury and multiple sclerosis. This finding is juxtaposed with findings in mild cognitive impairment and Alzheimer's disease where there is a shift to diminished connectivity as degeneration progresses. Conclusion: This summary of the functional imaging literature using fMRI methods reveals that hyperconnectivity is a common response to neurological disruption and that it may be differentially observable across brain regions. We discuss the factors contributing to both hyper- and hypoconnectivity results after neurological disruption and the implications these findings have for network plasticity.	[Hillary, Frank G.; Roman, Cristina A.; Venkatesan, Umesh] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Rajtmajer, Sarah M.] Penn State Univ, Dept Math, University Pk, PA 16802 USA; [Bajo, Ricardo; Castellanos, Nazareth D.] Univ Complutense Madrid, Dept Phys, E-28040 Madrid, Spain	Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, University Pk, PA 16802 USA.	fhillary@psu.edu; nazamadrid@yahoo.es	Bajo, Ricardo/AAA-5541-2019; Castellanos, Nazareth/AAA-8812-2020; Hillary, Frank/AAN-8622-2021	Castellanos, Nazareth/0000-0002-3508-7316			Agosta F, 2012, NEUROBIOL AGING, V33, P1564, DOI 10.1016/j.neurobiolaging.2011.06.007; Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Allen G, 2007, ARCH NEUROL-CHICAGO, V64, P1482, DOI 10.1001/archneur.64.10.1482; Alves J, 2013, BRAIN IMAGING BEHAV, V7, P353, DOI 10.1007/s11682-013-9236-1; Arenivas A, 2014, BRAIN IMAGING BEHAV, V8, P407, DOI 10.1007/s11682-012-9191-2; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Bai F, 2008, NEUROSCI LETT, V438, P111, DOI 10.1016/j.neulet.2008.04.021; Bai F, 2012, CORTEX, V48, P604, DOI 10.1016/j.cortex.2011.02.011; Bai F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024271; Bai F, 2011, J ALZHEIMERS DIS, V23, P87, DOI 10.3233/JAD-2010-101533; Bai F, 2011, BEHAV BRAIN RES, V216, P666, DOI 10.1016/j.bbr.2010.09.010; Bai F, 2009, BRAIN RES, V1302, P167, DOI 10.1016/j.brainres.2009.09.028; Bai F, 2009, BIOL PSYCHIAT, V65, P951, DOI 10.1016/j.biopsych.2008.10.017; Balthazar MLF, 2014, HUM BRAIN MAPP, V35, P1237, DOI 10.1002/hbm.22248; Bassett DS, 2011, P NATL ACAD SCI USA, V108, P7641, DOI 10.1073/pnas.1018985108; Binnewijzend MAA, 2012, NEUROBIOL AGING, V33, P2018, DOI 10.1016/j.neurobiolaging.2011.07.003; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Bokde ALW, 2006, BRAIN, V129, P1113, DOI 10.1093/brain/awl051; Bonavita S, 2011, MULT SCLER J, V17, P411, DOI 10.1177/1352458510394609; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Buzsaki G, 2004, NAT NEUROSCI, V7, P446, DOI 10.1038/nn1233; Cader S, 2006, BRAIN, V129, P527, DOI 10.1093/brain/awh670; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Canuet L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046289; Casanova B, 2003, J NEUROL, V250, P22, DOI 10.1007/s00415-003-0928-0; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Ceccarelli A, 2010, EUR J NEUROSCI, V31, P1273, DOI 10.1111/j.1460-9568.2010.07147.x; Cerasa A, 2012, EXP NEUROL, V237, P418, DOI 10.1016/j.expneurol.2012.07.020; Chawla D, 2000, NEURAL COMPUT, V12, P2805, DOI 10.1162/089976600300014737; Chawla D, 1999, NEURAL COMPUT, V11, P1389, DOI 10.1162/089976699300016287; Chen GY, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00456; Chhatwal JP, 2013, NEUROLOGY, V81, P736, DOI 10.1212/WNL.0b013e3182a1aafe; Ciftci K, 2011, ANN BIOMED ENG, V39, P1493, DOI 10.1007/s10439-011-0258-9; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Codeca C, 2010, MULT SCLER J, V16, P1308, DOI 10.1177/1352458510376957; Cole LJ, 2011, EUR J PAIN, V15, DOI 10.1016/j.ejpain.2010.10.010; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P500, DOI 10.1001/archneur.1985.04060050102019; Damoiseaux JS, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.06.024; Das SR, 2013, HIPPOCAMPUS, V23, P1, DOI 10.1002/hipo.22051; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Dogonowski AM, 2013, ACTA NEUROL SCAND, V128, P328, DOI 10.1111/ane.12121; Dogonowski AM, 2013, MULT SCLER J, V19, P559, DOI 10.1177/1352458512460416; Dolcos F, 2002, NEUROSCI BIOBEHAV R, V26, P819, DOI 10.1016/S0149-7634(02)00068-4; Dong L, 2012, CHINESE MED J-PEKING, V125, P604, DOI 10.3760/cma.j.issn.0366-6999.2012.04.009; Drzezga A, 2011, BRAIN, V134, P1635, DOI 10.1093/brain/awr066; Duong MVA, 2005, J CEREBR BLOOD F MET, V25, P1245, DOI 10.1038/sj.jcbfm.9600122; Duong MVA, 2005, NEUROIMAGE, V24, P533, DOI 10.1016/j.neuroimage.2004.08.038; Esposito R, 2013, PEERJ, V1, DOI 10.7717/peerj.135; Faivre A, 2012, MULT SCLER J, V18, P1251, DOI 10.1177/1352458511435930; Feng YY, 2012, MAGN RESON IMAGING, V30, P672, DOI 10.1016/j.mri.2012.01.003; Forn C, 2012, MULT SCLER J, V18, P153, DOI 10.1177/1352458511417744; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Franciotti R, 2013, NEUROBIOL AGING, V34, P1148, DOI 10.1016/j.neurobiolaging.2012.09.015; Gallo A, 2012, NEUROLOGY, V79, P1458, DOI 10.1212/WNL.0b013e31826d5eea; Galvin JE, 2011, NEUROLOGY, V76, P1797, DOI 10.1212/WNL.0b013e31821ccc83; Gates KM, 2012, NEUROIMAGE, V63, P310, DOI 10.1016/j.neuroimage.2012.06.026; GAZZANIGA MS, 1984, BRAIN, V107, P145, DOI 10.1093/brain/107.1.145; GAZZANIGA MS, 1979, BRAIN, V102, P805, DOI 10.1093/brain/102.4.805; Genon S, 2013, CORTEX, V49, P1566, DOI 10.1016/j.cortex.2012.11.017; GESCHWIN.N, 1965, BRAIN, V88, P585, DOI 10.1093/brain/88.3.585; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; Gili T, 2011, J NEUROL NEUROSUR PS, V82, P58, DOI 10.1136/jnnp.2009.199935; Gour N, 2011, NEUROIMAGE, V58, P687, DOI 10.1016/j.neuroimage.2011.05.090; Grady CL, 2001, BRAIN, V124, P739, DOI 10.1093/brain/124.4.739; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Han SD, 2012, J INT NEUROPSYCH SOC, V18, P39, DOI 10.1017/S1355617711001299; Hardmeier M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042087; Harriger L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046497; Hawellek DJ, 2011, P NATL ACAD SCI USA, V108, P19066, DOI 10.1073/pnas.1110024108; Helekar SA, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00219; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Hillebrand A, 2012, NEUROIMAGE, V59, P3909, DOI 10.1016/j.neuroimage.2011.11.005; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Huang SA, 2010, NEUROIMAGE, V50, P935, DOI 10.1016/j.neuroimage.2009.12.120; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jacobs HIL, 2012, NEUROLOGY, V78, P352, DOI 10.1212/WNL.0b013e318245287d; Jiang X., 2013, BRAIN IMAGING BEHAV; Jin MW, 2012, MAGN RESON IMAGING, V30, P48, DOI 10.1016/j.mri.2011.07.007; Jones DT, 2011, NEUROLOGY, V77, P1524, DOI 10.1212/WNL.0b013e318233b33d; Jones DT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039731; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kim J, 2013, BRAIN RES, V1495, P18, DOI 10.1016/j.brainres.2012.12.011; Kiviniemi V, 2011, BRAIN CONNECT, V1, P339, DOI 10.1089/brain.2011.0036; Leavitt VM, 2014, BRAIN IMAGING BEHAV, V8, P394, DOI 10.1007/s11682-012-9183-2; Leavitt VM, 2012, MULT SCLER J, V18, P409, DOI 10.1177/1352458511423651; Leonardi N, 2013, NEUROIMAGE, V83, P937, DOI 10.1016/j.neuroimage.2013.07.019; Li JJ, 2013, CEREB CORTEX, V23, P542, DOI [10.1093/cercor/bhs034, 10.1093/cercor/bhs410]; Li R, 2013, AM J NEURORADIOL, V34, P340, DOI 10.3174/ajnr.A3197; Li R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082104; Li R, 2012, HUM BRAIN MAPP, V33, P1076, DOI 10.1002/hbm.21269; Liang PP, 2012, J ALZHEIMERS DIS, V30, P475, DOI 10.3233/JAD-2012-111721; Liang PP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022153; Liu ZY, 2012, IEEE ENG MED BIO, P5454, DOI 10.1109/EMBC.2012.6347228; Liu ZY, 2012, NMR BIOMED, V25, P1311, DOI 10.1002/nbm.2803; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Loitfelder M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042862; Lowe MJ, 2008, HUM BRAIN MAPP, V29, P818, DOI 10.1002/hbm.20576; Lowe MJ, 2002, RADIOLOGY, V224, P184, DOI 10.1148/radiol.2241011005; LUCK SJ, 1989, NATURE, V342, P543, DOI 10.1038/342543a0; Medaglia JD, 2012, HUM BRAIN MAPP, V33, P979, DOI 10.1002/hbm.21264; MESULAM MM, 1985, PRINCIPLES BEHAVIORA, P1; Miao XY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025546; Minati L, 2014, J ALZHEIMERS DIS, V40, P213, DOI 10.3233/JAD-131766; Morbelli S, 2012, NEUROBIOL AGING, V33, P2533, DOI 10.1016/j.neurobiolaging.2012.01.005; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Neufang S, 2014, HUM BRAIN MAPP, V35, P954, DOI 10.1002/hbm.22226; Neufang S, 2011, J ALZHEIMERS DIS, V25, P309, DOI 10.3233/JAD-2011-102154; Pagani M, 2009, PSYCHIAT RES-NEUROIM, V173, P8, DOI 10.1016/j.pscychresns.2008.07.016; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Parisi L., 2012, BRAIN IMAGI IN PRESS; Petrella JR, 2011, NEUROLOGY, V76, P511, DOI 10.1212/WNL.0b013e31820af94e; Prakash RS, 2011, J INT NEUROPSYCH SOC, V17, P986, DOI 10.1017/S1355617711001093; Qi ZG, 2010, NEUROIMAGE, V50, P48, DOI 10.1016/j.neuroimage.2009.12.025; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Ranganath C, 2005, J COGNITIVE NEUROSCI, V17, P994, DOI 10.1162/0898929054475118; Ranganath C, 2005, CURR OPIN NEUROBIOL, V15, P175, DOI 10.1016/j.conb.2005.03.017; Richiardi J, 2012, NEUROIMAGE, V62, P2021, DOI 10.1016/j.neuroimage.2012.05.078; Ries ML, 2012, NEUROPSYCHOLOGIA, V50, P603, DOI 10.1016/j.neuropsychologia.2011.12.014; Rocca MA, 2007, NEUROLOGY, V69, P2136, DOI 10.1212/01.wnl.0000295504.92020.ca; Rocca MA, 2012, RADIOLOGY, V265, P864, DOI 10.1148/radiol.12120216; Rocca MA, 2012, NEUROLOGY, V79, P1449, DOI 10.1212/WNL.0b013e31826d5f10; Rocca MA, 2010, RADIOLOGY, V254, P541, DOI 10.1148/radiol.09090463; Rocca MA, 2009, HUM BRAIN MAPP, V30, P2412, DOI 10.1002/hbm.20679; Rocca MA, 2009, HUM BRAIN MAPP, V30, P276, DOI 10.1002/hbm.20504; Rombouts SARB, 2009, HUM BRAIN MAPP, V30, P256, DOI 10.1002/hbm.20505; Roosendaal SD, 2010, RADIOLOGY, V255, P595, DOI 10.1148/radiol.10091433; Rosenbaum RS, 2010, NEUROBIOL AGING, V31, P780, DOI 10.1016/j.neurobiolaging.2008.06.002; Rypma B, 2006, NEUROIMAGE, V33, P969, DOI 10.1016/j.neuroimage.2006.05.065; Rytsar R, 2011, NEUROIMAGE, V57, P1131, DOI 10.1016/j.neuroimage.2011.05.029; Saini S, 2004, J NEUROL NEUROSUR PS, V75, P840, DOI 10.1136/jnnp.2003.016782; SALTHOUSE TA, 1991, PSYCHOL AGING, V6, P118, DOI 10.1037/0882-7974.6.1.118; SALTHOUSE TA, 1993, J GERONTOL, V48, pP245, DOI 10.1093/geronj/48.5.P245; Sanz-Arigita EJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013788; Schoonheim MM, 2012, MULT SCLER J, V18, P164, DOI 10.1177/1352458511422245; Schwindt GC, 2013, CEREB CORTEX, V23, P1685, DOI 10.1093/cercor/bhs160; Seo EH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053922; SEYMOUR SE, 1994, BRAIN, V117, P105, DOI 10.1093/brain/117.1.105; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sheline YI, 2013, BIOL PSYCHIAT, V74, P340, DOI 10.1016/j.biopsych.2012.11.028; Sole-Padulles C, 2013, J CLIN PSYCHOPHARM, V33, P199, DOI 10.1097/JCP.0b013e3182825bfd; Song JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063727; Sorg C, 2007, P NATL ACAD SCI USA, V104, P18760, DOI 10.1073/pnas.0708803104; Sporns O., 2011, NETWORKS BRAIN; Sporns O, 2011, ANN NY ACAD SCI, V1224, P109, DOI 10.1111/j.1749-6632.2010.05888.x; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stam CJ, 2006, NEUROIMAGE, V32, P1335, DOI 10.1016/j.neuroimage.2006.05.033; Stam CJ, 2009, BRAIN, V132, P213, DOI 10.1093/brain/awn262; Steffener J, 2012, BBA-MOL BASIS DIS, V1822, P467, DOI 10.1016/j.bbadis.2011.09.012; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Supekar K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000100; Tecchio F, 2008, BRAIN, V131, P1783, DOI 10.1093/brain/awn087; Tijms BM, 2013, NEUROBIOL AGING, V34, P2023, DOI 10.1016/j.neurobiolaging.2013.02.020; Tsirka V, 2011, INT J PSYCHOPHYSIOL, V79, P89, DOI 10.1016/j.ijpsycho.2010.09.006; Turner G. R., 2012, FRONTIERS SYSTEMS NE, V5, P9; Turner GR, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00009; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Valsasina P, 2011, EUR J NEUROSCI, V33, P1256, DOI 10.1111/j.1460-9568.2011.07623.x; van den Heuvel MP, 2012, P NATL ACAD SCI USA, V109, P11372, DOI 10.1073/pnas.1203593109; van den Heuvel MP, 2009, J NEUROSCI, V29, P7619, DOI 10.1523/JNEUROSCI.1443-09.2009; Verdoorn TA, 2011, J ALZHEIMERS DIS, V26, P239, DOI 10.3233/JAD-2011-0056; Vlassenko AG, 2010, P NATL ACAD SCI USA, V107, P17763, DOI 10.1073/pnas.1010461107; Wang JH, 2013, BIOL PSYCHIAT, V73, P472, DOI 10.1016/j.biopsych.2012.03.026; Wang K, 2007, HUM BRAIN MAPP, V28, P967, DOI 10.1002/hbm.20324; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Wang L, 2013, RADIOLOGY, V268, P501, DOI 10.1148/radiol.13121573; Wang Y, 2013, J ALZHEIMERS DIS, V35, P751, DOI 10.3233/JAD-130080; Wang ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036838; Wang ZQ, 2012, EUR J RADIOL, V81, P277, DOI 10.1016/j.ejrad.2010.12.044; Wang ZQ, 2011, J NEUROL SCI, V309, P79, DOI 10.1016/j.jns.2011.07.017; Wee CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037828; Wen XY, 2013, BRAIN RES, V1509, P58, DOI 10.1016/j.brainres.2013.03.007; Werfel J, 2005, NEURAL COMPUT, V17, P2699, DOI 10.1162/089976605774320539; Wu X, 2011, HUM BRAIN MAPP, V32, P1868, DOI 10.1002/hbm.21153; Xia MR, 2014, J ALZHEIMERS DIS, V39, P527, DOI 10.3233/JAD-131583; Xie CM, 2013, NEUROIMAGE-CLIN, V3, P311, DOI 10.1016/j.nicl.2013.09.002; Xie CM, 2012, NEUROIMAGE, V63, P320, DOI 10.1016/j.neuroimage.2012.06.062; Yan H., 2010, J INT NEUROPSYCH SOC, V21, P1; Yao HX, 2013, EUR J RADIOL, V82, P1531, DOI 10.1016/j.ejrad.2013.03.019; Yao ZJ, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001006; Li YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044758; Zalesky A, 2012, HUM BRAIN MAPP, V33, P2535, DOI 10.1002/hbm.21379; Zamboni G, 2013, BIOL PSYCHIAT, V74, P375, DOI 10.1016/j.biopsych.2013.04.015; Zhang HY, 2010, RADIOLOGY, V256, P598, DOI 10.1148/radiol.10091701; Zhang HY, 2009, BEHAV BRAIN RES, V197, P103, DOI 10.1016/j.bbr.2008.08.012; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049; Zhao XH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033540; Zhou B, 2013, CURR ALZHEIMER RES, V10, P754, DOI 10.2174/15672050113109990146; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075; Zhou YX, 2008, ALZHEIMERS DEMENT, V4, P265, DOI 10.1016/j.jalz.2008.04.006; Zhu D., 2013, HUMAN BRAIN MAPPING; Zhu DC, 2013, J ALZHEIMERS DIS, V34, P969, DOI 10.3233/JAD-121879	206	109	109	2	66	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2015	29	1					59	75		10.1037/neu0000110			17	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	AX9OX	WOS:000347232800007	24933491	Green Accepted			2021-06-18	
J	Costello, JT; Bieuzen, F; Bleakley, CM				Costello, Joseph T.; Bieuzen, Francois; Bleakley, Chris M.			Where are all the female participants in Sports and Exercise Medicine research?	EUROPEAN JOURNAL OF SPORT SCIENCE			English	Article						exercise; ethics; Sport Medicine; muscle damage; gender bias	GENDER-DIFFERENCES; OLYMPIC-GAMES; MUSCLE DAMAGE; TITLE IX; SEX; CONCUSSION; INFLAMMATION; METAANALYSIS; PERFORMANCE; EQUALITY	The aim of this study is to estimate the ratio of male and female participants in Sports and Exercise Medicine research. Original research articles published in three major Sports and Exercise Medicine journals (Medicine and Science in Sports and Exercise, British Journal of Sports Medicine and American Journal of Sports Medicine) over a three-year period were examined. Each article was screened to determine the following: total number of participants, the number of female participants and the number of male participants. The percentage of females and males per article in each of the journals was also calculated. Cross tabulations and Chi-square analysis were used to compare the gender representation of participants within each of the journals. Data were extracted from 1382 articles involving a total of 6,076,580 participants. A total of 2,366,968 (39%) participants were female and 3,709,612 (61%) were male. The average percentage of female participants per article across the journals ranged from 35% to 37%. Females were significantly under-represented across all of the journals (chi(2) = 23,566, df = 2, p < 0.00001). In conclusion, Sports and Exercise Medicine practitioners should be cognisant of sexual dimorphism and gender disparity in the current literature.	[Costello, Joseph T.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia; [Bieuzen, Francois] INSEP, Lab Sport Expertise & Performance, Paris, France; [Bleakley, Chris M.] Univ Ulster, Ulster Sports Acad, Fac Life & Hlth Sci, Belfast, Antrim, North Ireland	Costello, JT (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, Sch Exercise & Nutr Sci, Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.	joseph.costello@qut.edu.au	Costello, Joseph/J-1374-2012; Costello, Joseph T/G-6294-2011; Bieuzen, Francois/F-8162-2013	Costello, Joseph/0000-0001-9510-7932; Costello, Joseph T/0000-0001-9510-7932; Bleakley, Chris/0000-0001-9032-9691; Bieuzen, Francois/0000-0002-9690-9168			ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Bennett M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004713.pub2; Bieuzen F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062356; Bleakley C, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2003.010553; Bleakley C, 2002, BRIT J SPORT MED, V36, P124, DOI 10.1136/bjsm.36.2.124; Bleakley C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008262.pub2; Brophy RH, 2009, INT J SPORTS MED, V30, P663, DOI 10.1055/s-0029-1225328; Capranica L, 2005, RES Q EXERCISE SPORT, V76, P212; Capranica L, 2008, RES Q EXERCISE SPORT, V79, P101, DOI 10.5641/193250308X13086753543095; Capranica L, 2013, INT J SPORT PHYSIOL, V8, P99, DOI 10.1123/ijspp.8.1.99; Convertino VA, 1998, AM J PHYSIOL-REG I, V275, pR1909; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Coyne MD, 2000, AM J PHYSIOL-REG I, V279, pR1316; Deaner RO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049168; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Enns DL, 2010, SPORTS MED, V40, P41, DOI 10.2165/11319760-000000000-00000; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Granito VJ., 2002, J SPORT BEHAV, V25, P243; Herbert RD, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004577.pub3; Hill J, 2014, BRIT J SPORT MED, V48, P1340, DOI 10.1136/bjsports-2013-092456; Jutte LS, 2012, J ATHL TRAINING, V47, P170; Kaciuba-Uscilko H, 2001, CURR OPIN CLIN NUTR, V4, P533, DOI 10.1097/00075197-200111000-00012; Kaestner R, 2010, EVALUATION REV, V34, P52, DOI 10.1177/0193841X09353539; Leeder J, 2012, BRIT J SPORT MED, V46, P233, DOI 10.1136/bjsports-2011-090061; LEWIS DA, 1986, SPORTS MED, V3, P357, DOI 10.2165/00007256-198603050-00005; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mendelsohn ME, 2005, SCIENCE, V308, P1583, DOI 10.1126/science.1112062; Mizuno K, 2009, KNEE, V16, P432, DOI 10.1016/j.knee.2009.04.008; Reider B, 2012, AM J SPORT MED, V40, P1231, DOI 10.1177/0363546512449812; Sandberg K, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042-6410-4-13; Savage KJ, 2002, CONTRACEPTION, V66, P67, DOI 10.1016/S0010-7824(02)00320-7; Spracklen K, 2006, J SPORT SOC ISSUES, V30, P289, DOI 10.1177/0193723506290083; Stupka N, 2000, J APPL PHYSIOL, V89, P2325; TARNOPOLSKY LJ, 1990, J APPL PHYSIOL, V68, P302; Tiidus PM, 2009, J APPL PHYSIOL, V106, P1010, DOI 10.1152/japplphysiol.90848.2008; U.S. Department of Justice, 2012, EQ ACC ED 40 YEARS T; West DWD, 2012, J APPL PHYSIOL, V112, P1805, DOI 10.1152/japplphysiol.00170.2012; Willoughby DS, 2006, J SPORT SCI MED, V5, P672	39	109	110	2	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1746-1391	1536-7290		EUR J SPORT SCI	Eur. J. Sport Sci.	NOV 17	2014	14	8					847	851		10.1080/17461391.2014.911354			5	Sport Sciences	Sport Sciences	AR0SK	WOS:000343281400012	24766579				2021-06-18	
J	Zatzick, D; Jurkovich, G; Rivara, FP; Russo, J; Wagner, A; Wang, J; Dunn, C; Lord, SP; Petrie, M; O'Connor, SS; Katon, W				Zatzick, Douglas; Jurkovich, Gregory; Rivara, Frederick P.; Russo, Joan; Wagner, Amy; Wang, Jin; Dunn, Chris; Lord, Sarah Peregrine; Petrie, Megan; O'Connor, Stephen S.; Katon, Wayne			A Randomized Stepped Care Intervention Trial Targeting Posttraumatic Stress Disorder for Surgically Hospitalized Injury Survivors	ANNALS OF SURGERY			English	Article						injury; physical function; PTSD; stepped care; surgical hospitalization; traumatic brain injury	COGNITIVE-BEHAVIORAL THERAPY; COLLABORATIVE CARE; FUNCTIONAL OUTCOMES; POPULATION-IMPACT; ANXIETY DISORDERS; TRAUMA CENTER; MAJOR TRAUMA; DEPRESSION; US; HEALTH	Objective: To test the effectiveness of a stepped care intervention model targeting posttraumatic stress disorder (PTSD) symptoms after injury. Background: Few investigations have evaluated interventions for injured patients with PTSD and related impairments that can be feasibly implemented in trauma surgical settings. Methods: The investigation was a pragmatic effectiveness trial in which 207 acutely injured hospitalized trauma survivors were screened for high PTSD symptom levels and then randomized to a stepped combined care management, psychopharmacology, and cognitive behavioral psychotherapy intervention (n = 104) or usual care control (n = 103) conditions. The symptoms of PTSD and functional limitations were reassessed at 1, 3, 6, 9, and 12 months after the index injury admission. Results: Regression analyses demonstrated that over the course of the year after injury, intervention patients had significantly reduced PTSD symptoms when compared with controls [group by time effect, CAPS (Clinician-Administered PTSD Scale): F(2, 185) = 5.50, P < 0.01; PCL-C (PTSD Checklist Civilian Version): F(4, 185) = 5.45, P < 0.001]. Clinically and statistically significant PTSD treatment effects were observed at the 6-, 9-, and 12-month postinjury assessments. Over the course of the year after injury, intervention patients also demonstrated significant improvements in physical function [MOS SF-36 PCS (Medical Outcomes Study Short Form 36 Physical Component Summary) main effect: F(1, 172) = 9.87, P < 0.01]. Conclusions: Stepped care interventions can reduce PTSD symptoms and improve functioning over the course of the year after surgical injury hospitalization. Orchestrated investigative and policy efforts could systematically introduce and evaluate screening and intervention procedures for PTSD at US trauma centers. (Trial Registration: clinicaltrials.gov identifier: NCT00270959)	[Zatzick, Douglas; Russo, Joan; Wagner, Amy; Wang, Jin; Dunn, Chris; Lord, Sarah Peregrine; Petrie, Megan; O'Connor, Stephen S.; Katon, Wayne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA; [Zatzick, Douglas; Jurkovich, Gregory; Rivara, Frederick P.; Wang, Jin; O'Connor, Stephen S.] Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Jurkovich, Gregory] Univ Washington, Sch Med, Dept Surg, Seattle, WA 98104 USA; [Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98104 USA; [Wagner, Amy] Portland VA Med Ctr, Portland, OR USA	Zatzick, D (corresponding author), Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, 325 9th Ave,Box 359911, Seattle, WA 98104 USA.	dzatzick@u.washington.edu			National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01/MH073613, K24/MH086814]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073613, K24MH086814] Funding Source: NIH RePORTER	This work was supported by the National Institute of Mental Health grants R01/MH073613 and K24/MH086814 (Dr Zatzick).	Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; American College of Surgeons Committee on Trauma, 2006, RES OPT CAR INJ PAT; Babor TF, 1989, ALCOHOL USE DISORDER; Bergen GS, 2008, INJURY US 2007 CHART; Bonnie R.J., 1999, REDUCING BURDEN INJU; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Craske MG, 2011, ARCH GEN PSYCHIAT, V68, P378, DOI 10.1001/archgenpsychiatry.2011.25; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; Fullerton CS, 2004, AM J PSYCHIAT, V161, P1370, DOI 10.1176/appi.ajp.161.8.1370; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Gilbody S, 2006, ARCH INTERN MED, V166, P2314, DOI 10.1001/archinte.166.21.2314; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holbrook TL, 2005, J TRAUMA, V58, P764, DOI 10.1097/01.TA.0000159247.48547.7D; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Johns Hopkins Health Services Research and Development Center, 1989, DET INJ SEV HOSP DIS; Kassam-Adams N, 2011, J TRAUMA STRESS, V24, P252, DOI 10.1002/jts.20640; Katon WJ, 2010, NEW ENGL J MED, V363, P2611, DOI 10.1056/NEJMoa1003955; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koepsell TD, 2011, AM J PREV MED, V40, P191, DOI 10.1016/j.amepre.2010.10.022; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lagomasino IT, 2010, GEN HOSP PSYCHIAT, V32, P477, DOI 10.1016/j.genhosppsych.2010.06.005; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; National Institute of Mental Health, 2002, MENT HLTH MASS VIOL; O'Donnell ML, 2009, MED J AUSTRALIA, V190, pS71; Ramchand R, 2008, J CONSULT CLIN PSYCH, V76, P668, DOI 10.1037/0022-006X.76.4.668; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Rivara FP, 1997, NEW ENGL J MED, V337, P543, DOI 10.1056/NEJM199708213370807; Roberts JC, 2010, J TRAUMA, V69, P231, DOI 10.1097/TA.0b013e3181e16e2a; Roberts NP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006869.pub2; Roy-Byrne P, 2010, JAMA-J AM MED ASSOC, V303, P1921, DOI 10.1001/jama.2010.608; Shalev AY, 2012, ARCH GEN PSYCHIAT, V69, P166, DOI 10.1001/archgenpsychiatry.2011.127; Shalev AY, 2011, PSYCHIAT SERV, V62, P765, DOI 10.1176/ps.62.7.pss6207_0765; Shih RA, 2010, J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; Terrell F, 2008, J AM COLL SURGEONS, V207, P630, DOI 10.1016/j.jamcollsurg.2008.05.021; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Trusz SG, 2011, PSYCHIATRY, V74, P207, DOI 10.1521/psyc.2011.74.3.207; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Wagner AW, 2007, COGN BEHAV PRACT, V14, P341, DOI 10.1016/j.cbpra.2006.05.002; Ware JE., 1993, SF 36 HLTH SURVEY MA; Weathers F., 1996, MEASUREMENT STRESS T, P250; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 2001, GEN HOSP PSYCHIAT, V23, P114, DOI 10.1016/S0163-8343(01)00140-2; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zatzick D, 2011, GEN HOSP PSYCHIAT, V33, P123, DOI 10.1016/j.genhosppsych.2011.01.001; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; Zatzick DF, 2009, PSYCHIATRY, V72, P346, DOI 10.1521/psyc.2009.72.4.346	55	109	111	1	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	MAR	2013	257	3					390	399		10.1097/SLA.0b013e31826bc313			10	Surgery	Surgery	088BN	WOS:000314808900004	23222034	Green Accepted			2021-06-18	
J	Muellenbach, RM; Kredel, M; Kunze, E; Kranke, P; Kuestermann, J; Brack, A; Gorski, A; Wunder, C; Roewer, N; Wurmb, T				Muellenbach, Ralf M.; Kredel, Markus; Kunze, Ekkehard; Kranke, Peter; Kuestermann, Julian; Brack, Alexander; Gorski, Armin; Wunder, Christian; Roewer, Norbert; Wurmb, Thomas			Prolonged heparin-free extracorporeal membrane oxygenation in multiple injured acute respiratory distress syndrome patients with traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Acute respiratory distress syndrome; traumatic brain injury; extracorporeal membrane oxygenation; multiple trauma	LUNG INJURY; FAILURE; ECMO; CRANIOTOMY; THERAPY; SUPPORT; ARDS	BACKGROUND: Extracorporeal membrane oxygenation (ECMO) can be used as an "ultima ratio" strategy in multiple injured patients with severe thoracic trauma. However, systemic anticoagulation during ECMO is recommended and thus traumatic brain injury (TBI) and intracranial bleeding are well-accepted contraindications for ECMO therapy. METHODS: This report describes three cases of prolonged heparin-free venovenous ECMO in multiple injured acute respiratory distress syndrome patients with severe TBI failing conventional mechanical ventilation. RESULTS: Using this strategy, neither ECMO-associated bleeding nor clotting of the extracorporeal circuit occurred. All patients survived. CONCLUSIONS: Based on our experience, we recommend the use of heparin-free ECMO in multiple injured patients with pulmonary failure that is not successfully controlled by lung-protective ventilation even if severe TBI is present. (J Trauma. 2012;72: 1444-1447. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Muellenbach, Ralf M.; Kredel, Markus; Kranke, Peter; Kuestermann, Julian; Brack, Alexander; Wunder, Christian; Roewer, Norbert; Wurmb, Thomas] Univ Wurzburg, Dept Anaesthesia & Crit Care, D-97070 Wurzburg, Germany; [Kunze, Ekkehard] Univ Wurzburg, Dept Neurosurg, D-97070 Wurzburg, Germany; [Gorski, Armin] Univ Wurzburg, Dept Heart Lung & Vasc Surg, D-97070 Wurzburg, Germany	Muellenbach, RM (corresponding author), Univ Klinikum Wurzburg, Klin & Poliklin Anasthesiol, Zentrum Operat Med, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.	muellenbac_r@klinik.uni-wuerzburg.de	Kunze, Ekkehard/AAE-6926-2019	Kredel, Markus/0000-0003-2183-033X			Arlt M, 2010, RESUSCITATION, V81, P804, DOI 10.1016/j.resuscitation.2010.02.020; Bui JD, 2002, J THORAC CARDIOV SUR, V124, P852, DOI 10.1067/mtc.2002.126038; Cordell-Smith JA, 2006, INJURY, V37, P29, DOI 10.1016/j.injury.2005.03.027; Friesenecker BE, 2005, ACTA NEUROCHIR, V147, P993, DOI 10.1007/s00701-005-0568-5; Kopp R, 2010, ARTIF ORGANS, V34, P13, DOI 10.1111/j.1525-1594.2009.00791.x; Madershahian N, 2007, J CARDIAC SURG, V22, P180, DOI 10.1111/j.1540-8191.2007.00381.x; Michaels AJ, 1999, J TRAUMA, V46, P638, DOI 10.1097/00005373-199904000-00013; Moller T, 2010, ANASTH INTENSIV NOTF, V45, P544, DOI 10.1055/s-0030-1265745; Muellenbach RM, 2011, ANAESTHESIST, V60, P647, DOI 10.1007/s00101-011-1872-5; Muller T, 2009, CRIT CARE, V13, DOI 10.1186/cc8213; Peek GJ, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14350; Peek GJ, 1997, CHEST, V112, P759, DOI 10.1378/chest.112.3.759; Yen TS, 2008, CLIN NEUROL NEUROSUR, V110, P295, DOI 10.1016/j.clineuro.2007.10.017; Young N, 2010, CURR OPIN CRIT CARE, V16, P45, DOI 10.1097/MCC.0b013e32833546fa	14	109	112	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2012	72	5					1444	1447		10.1097/TA.0b013e31824d68e3			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	944JD	WOS:000304195100059	22673280				2021-06-18	
J	Shultz, SR; Bao, F; Omana, V; Chiu, C; Brown, A; Cain, DP				Shultz, Sandy R.; Bao, Feng; Omana, Vanessa; Chiu, Charlotte; Brown, Arthur; Cain, Donald Peter			Repeated Mild Lateral Fluid Percussion Brain Injury in the Rat Causes Cumulative Long-Term Behavioral Impairments, Neuroinflammation, and Cortical Loss in an Animal Model of Repeated Concussion	JOURNAL OF NEUROTRAUMA			English	Article						behavior; inflammation; learning and memory; models of injury; traumatic brain injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; NATIONAL-FOOTBALL-LEAGUE; ANXIETY-RELATED BEHAVIOR; ELEVATED PLUS-MAZE; HEAD-INJURY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; WATER MAZE; FUNCTIONAL ABNORMALITIES; SPATIAL NAVIGATION	There is growing evidence that repeated brain concussion can result in cumulative and long-term behavioral symptoms, neuropathological changes, and neurodegeneration. Little is known about the factors and mechanisms that contribute to these effects. The current study addresses the need to investigate and better understand the effects of repeated concussion through the development of an animal model. Male Long-Evans rats received 1, 3, or 5 mild lateral fluid percussion injuries or sham injuries spaced 5 days apart. After the final injury, rats received either a short (24 h) or long (8 weeks) post-injury recovery period, followed by a detailed behavioral analysis consisting of tests for rodent anxiety-like behavior, cognition, social behavior, sensorimotor function, and depression-like behavior. Brains were examined immunohistochemically to assess neuroinflammation and cortical damage. Rats given 1, 3, or 5 mild percussion injuries displayed significant short-term cognitive impairments. Rats given repeated mild percussion injuries displayed significantly worse short- and long-term cognitive impairments. Rats given 5 mild percussion injuries also displayed increased anxiety- and depression-like behaviors. Neuropathological analysis revealed short-term neuroinflammation in 3-injury rats, and both short- and long-term neuroinflammation in 5-injury rats. There was also evidence that repeated injuries induced short- and long-term cortical damage. These cumulative and long-term changes are consistent with findings in human patients suffering repeated brain concussion, provide support for the use of repeated mild lateral fluid percussion injuries to study repeated concussion in the rat, and suggest that neuroinflammation may be important for understanding the cumulative and chronic effects of repeated concussion.	[Shultz, Sandy R.; Cain, Donald Peter] Univ Western Ontario, Grad Program Neurosci, London, ON, Canada; [Shultz, Sandy R.; Chiu, Charlotte; Cain, Donald Peter] Univ Western Ontario, Dept Psychol, London, ON, Canada; [Bao, Feng; Omana, Vanessa; Brown, Arthur] Univ Western Ontario, Robarts Res Inst, London, ON, Canada	Shultz, SR (corresponding author), Univ Melbourne, Melbourne Brain Ctr, Dept Med, Parkville, Vic 3010, Australia.	sshultz@unimelb.edu.au	Brown, Arthur/K-8328-2013; Brown, Arthur/K-6837-2013	Brown, Arthur/0000-0002-8725-3195; Shultz, Sandy/0000-0002-2525-8775	Natural Science and Engineering Research Council (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); CIHRCanadian Institutes of Health Research (CIHR)	This research was supported by a grant from the Natural Science and Engineering Research Council (NSERC) to Dr. Donald P. Cain, a scholarship from NSERC to Dr. Sandy R. Shultz, and a grant from CIHR to Dr. Arthur Brown. We thank Drs. R. Sutton and D. Hovda, UCLA Brain Injury Research Center, for training. Additional thanks go to Drs. K.-P. Ossenkopp and D. MacFabe, and to F. Boon, L. Tichenoff, and R. Taylor for technical assistance. Dr. Sandy R. Shultz is now at the Department of Medicine (Royal Melbourne Hospital), Melbourne Brain Centre, University of Melbourne, Parkville, Victoria, Australia.	AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Beiko J, 1997, BEHAV BRAIN RES, V88, P201, DOI 10.1016/S0166-4328(97)02298-5; Beiko J, 2004, BEHAV BRAIN RES, V151, P239, DOI 10.1016/j.bbr.2003.08.019; Bissiere S, 2006, BEHAV BRAIN RES, V175, P195, DOI 10.1016/j.bbr.2006.08.022; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cain DP, 2006, BEHAV BRAIN RES, V170, P241, DOI 10.1016/j.bbr.2006.02.023; Cain DP, 2003, BRAIN RES, V972, P64, DOI 10.1016/S0006-8993(03)02486-7; CAIN DP, 1993, HIPPOCAMPUS, V3, P153, DOI 10.1002/hipo.450030208; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cantu RC, 2009, CURR SPORT MED REP, V8, P6, DOI 10.1249/JSR.0b013e31819677db; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Drevets WC, 2008, BRAIN STRUCT FUNCT, V213, P93, DOI 10.1007/s00429-008-0189-x; Dringen R, 2005, ANTIOXID REDOX SIGN, V7, P1223, DOI 10.1089/ars.2005.7.1223; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Giza CC, 2001, J ATHL TRAINING, V36, P228; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hein AM, 2009, MOL NEUROBIOL, V40, P15, DOI 10.1007/s12035-009-8066-z; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253; Lemstra AW, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-4; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; O'Sullivan JB, 2009, INT J NEUROPSYCHOPH, V12, P687, DOI 10.1017/S146114570800967X; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shultz SR, 2008, NEUROPHARMACOLOGY, V54, P901, DOI 10.1016/j.neuropharm.2008.01.013; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Spalletta G, 2006, MOL PSYCHIATR, V11, P984, DOI 10.1038/sj.mp.4001879; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Weaver LC, 2001, J NEUROTRAUM, V18, P1107, DOI 10.1089/08977150152693782; Whishaw IQ, 1995, HIPPOCAMPUS, V5, P595, DOI 10.1002/hipo.450050610; Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Zilka N, 2006, Bratisl Lek Listy, V107, P374	66	109	111	3	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					281	294		10.1089/neu.2011.2123			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300008	21933013				2021-06-18	
J	Babikian, T; Satz, P; Zaucha, K; Light, R; Lewis, RS; Asarnow, RF				Babikian, Talin; Satz, Paul; Zaucha, Ken; Light, Roger; Lewis, Richard S.; Asarnow, Robert F.			The UCLA Longitudinal Study of Neurocognitive Outcomes Following Mild Pediatric Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Child and adolescent; Cognitive; Mild TBI; Concussion; Longitudinal study	HEAD-INJURY; CRYSTALLIZED INTELLIGENCE; UNINTENTIONAL INJURY; AGED CHILDREN; RISK-FACTORS; ADOLESCENTS; SYMPTOMS; RECOVERY; SEQUELAE; FLUID	Comprehensive reviews of neurocognitive outcomes following mild, uncomplicated traumatic brain injury (TBI) in children have shown minimal effects on neurocognition, especially in methodologically rigorous studies. In this study, we report longitudinal (1,6, and 12 months post injury) results in four domains of neurocognitive functioning in a large sample of children with mild TBI (n = 124, ages 8-17 at injury) relative to two demographically matched control groups (other injury: 11 = 94 and non-injury: it = 106). After accounting for age and parental education, significant main effects of group were observed on 7 of the 10 neurocognitive tests. However, these differences were not unique to the TBI sample but were found between both the TBI and other injury groups relative to the non-injured group, suggesting a general injury effect. Effects were primarily within the domains measuring memory, psychomotor processing speed, and language. This is the largest longitudinal study to date of neurocognitive outcomes at discrete time points in pediatric mild TBI. When controlling for pre-injury factors, there is no evidence of long-term neurocognitive impairment in this group relative to another injury control group. The importance of longitudinal analyses and use of appropriate control groups are discussed in the context of evaluating the effects of mild TBI on cognition. (ENS, 2011, 17, 886-895)	[Light, Roger] Centinela Freeman Reg Med Ctr, Inglewood, CA USA; [Lewis, Richard S.] Pomona Coll, Dept Neurosci, Claremont, CA 91711 USA; [Lewis, Richard S.] Pomona Coll, Dept Psychol, Claremont, CA 91711 USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA	Babikian, T (corresponding author), Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,Room C8-746, Los Angeles, CA 90024 USA.	tbabikian@mednet.ucla.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD061504, R01HD061504] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1F32NS053169, R01NS026801, F32 NS053169] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026801, F32NS053169] Funding Source: NIH RePORTER		Achenbach T. M., 1991, CHILD BEHAV CHECKLIS; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bruce B, 2007, PAED CHILD HEALT-CAN, V12, P749, DOI 10.1093/pch/12.9.749; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; CATTELL RB, 1963, J EDUC PSYCHOL, V54, P1, DOI 10.1037/h0046743; Dunn L., 1981, PEABODY PICTURE VOCA; DURKIN MS, 1994, AM J PUBLIC HEALTH, V84, P587, DOI 10.2105/AJPH.84.4.587; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; GOLDEN JC, 1976, J CLIN PSYCHOL, V32, P654; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Halstead WC, 1985, HALSTEAD REITAN NEUR; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; KOGAN MD, 1995, AM J PREV MED, V11, P99; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; NUECHTERLEIN KH, 1983, J ABNORM PSYCHOL, V92, P4, DOI 10.1037/0021-843X.92.1.4; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Ramsay LJ, 2003, PUBLIC HEALTH, V117, P404, DOI 10.1016/S0033-3506(03)00072-6; RUSSELL EW, 1980, PERCEPT MOTOR SKILL, V51, P121, DOI 10.2466/pms.1980.51.1.121; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SATZ P, 1989, PIN TEST PROFESSIONA; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwebel DC, 2007, J DEV BEHAV PEDIATR, V28, P245, DOI 10.1097/01.DBP.0000268561.80204.2a; Smith A., 1968, LEARNING DISORDERS, P83; WICKENS DD, 1970, PSYCHOL REV, V77, P1, DOI 10.1037/h0028569; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	36	109	109	0	32	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2011	17	5					886	895		10.1017/S1355617711000907			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	821KV	WOS:000294974800013	21813031	Green Accepted			2021-06-18	
J	Datta, A; Bikson, M; Fregni, F				Datta, Abhishek; Bikson, Marom; Fregni, Felipe			Transcranial direct current stimulation in patients with skull defects and skull plates: High-resolution computational FEM study of factors altering cortical current flow	NEUROIMAGE			English	Article						tDCS; TBI; Skull defects; Skull plates; Finite element modeling; MRI human head model	EXPERIMENTAL CEREBRAL-ISCHEMIA; NONINVASIVE BRAIN-STIMULATION; MRI TISSUE CHARACTERIZATION; PREFRONTAL CORTEX; DC-STIMULATION; PAIN; RAT; POLARIZATION; EXCITABILITY; MODULATION	Preliminary positive results of transcranial direct current stimulation (tDCS) in enhancing the effects of cognitive and motor training indicate that this technique might also be beneficial in traumatic brain injury or patients who had decompressive craniectomy for trauma and cerebrovascular disease. One perceived hurdle is the presence of skull defects or skull plates in these patients that would hypothetically alter the intensity and location of current flow through the brain. We aimed to model tDCS using a magnetic resonance imaging (MRI)-derived finite element head model with several conceptualized skull injuries. Cortical electric field (current density) peak intensities and distributions were compared with the healthy (skull intact) case. The factors of electrode position (C3-supraorbital or O1-supraorbital), electrode size skull defect size, skull defect state (acute and chronic) or skull plate (titanium and acrylic) were analyzed. If and how electric current through the brain was modulated by defects was found to depend on a specific combination of factors. For example, the condition that led to largest increase in peak cortical electric field was when one electrode was placed directly over a moderate sized skull defect. In contrast, small defects midway between electrodes did not significantly change cortical currents. As the conductivity of large skull defects/plates was increased (chronic to acute to titanium), current was shunted away from directly underlying cortex and concentrated in cortex underlying the defect perimeter. The predictions of this study are the first step to assess safety of transcranial electrical therapy in subjects with skull injuries and skull plates. (C) 2010 Elsevier Inc. All rights reserved.	[Datta, Abhishek] CUNY City Coll, Grove Sch Engn, Dept Biomed Engn, Neural Engn Lab, New York, NY 10031 USA; [Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Lab Neuromodulat, Boston, MA 02114 USA; [Fregni, Felipe] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA	Datta, A (corresponding author), CUNY City Coll, Grove Sch Engn, Dept Biomed Engn, Neural Engn Lab, T-463 Steinman Hall,160 Convent Ave, New York, NY 10031 USA.	abhishek.datta@gmail.com; ffregni@partners.org		Fregni, Felipe/0000-0001-9359-8643	CIMIT (Center for Integration of Medicine and Innovative Technology); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S06GM008168, NS054783]; Wallace H. Coulter Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [S06GM008168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS054783] Funding Source: NIH RePORTER	We acknowledge Viet Bui Xuan of Simpleware Ltd.; and Varun Bansal and Davide Reato of The City College of New York. Felipe Fregni is partially funded by CIMIT (Center for Integration of Medicine and Innovative Technology). Marom Bikson is partially funded by NIH (nos. S06GM008168 NS054783) and the Wallace H. Coulter Foundation.	Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; Bikson M, 2004, J PHYSIOL-LONDON, V557, P175, DOI 10.1113/jphysiol.2003.055772; Bikson Marom, 2008, Curr Treat Options Neurol, V10, P377, DOI 10.1007/s11940-008-0040-y; Boggio PS, 2007, J AFFECT DISORDERS, V101, P91, DOI 10.1016/j.jad.2006.10.026; Boggio PS, 2009, NEUROPSYCHOLOGIA, V47, P212, DOI 10.1016/j.neuropsychologia.2008.07.022; Boggio PS, 2009, NEUROSCI LETT, V463, P82, DOI 10.1016/j.neulet.2009.07.041; Butson CR, 2007, ACTA NEUROCHIR SUPPL, V97, P569; CHEW E, 2009, 5 WORLD C ISPRM; Datta A, 2008, J NEURAL ENG, V5, P163, DOI 10.1088/1741-2560/5/2/007; Datta A, 2009, IEEE ENG MED BIO, P670, DOI 10.1109/IEMBS.2009.5333673; Datta A, 2009, BRAIN STIMUL, V2, P201, DOI 10.1016/j.brs.2009.03.005; Fregni F, 2006, EPILEPSIA, V47, P335, DOI 10.1111/j.1528-1167.2006.00426.x; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2005, J NEUROL NEUROSUR PS, V76, P1614, DOI 10.1136/jnnp.2005.069849; Fregni F, 2007, LANCET NEUROL, V6, P188, DOI 10.1016/S1474-4422(07)70032-7; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Jacobs MA, 2001, STROKE, V32, P943, DOI 10.1161/01.STR.32.4.943; Leahy RM, 1998, ELECTROEN CLIN NEURO, V107, P159, DOI 10.1016/S0013-4694(98)00057-1; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Liebetanz D, 2006, EPILEPSIA, V47, P1216, DOI 10.1111/j.1528-1167.2006.00539.x; Liebetanz D, 2009, CLIN NEUROPHYSIOL, V120, P1161, DOI 10.1016/j.clinph.2009.01.022; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Miranda PC, 2009, CLIN NEUROPHYSIOL, V120, P1183, DOI 10.1016/j.clinph.2009.03.023; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Radman T, 2009, BRAIN STIMUL, V2, P215, DOI 10.1016/j.brs.2009.03.007; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Rotenberg A, 2007, CLIN NEUROPHYSIOL, V118, P2536, DOI 10.1016/j.clinph.2007.08.003; Rotenberg A, 2009, CLIN NEUROPHYSIOL, V120, P1417, DOI 10.1016/j.clinph.2009.05.004; RUSH S, 1968, ANESTH ANAL CURR RES, V47, P717; Sekhar LN, 2006, ATLAS NEUROSURGICAL; Soltanian-Zadeh H, 2003, J MAGN RESON IMAGING, V17, P398, DOI 10.1002/jmri.10256; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027	35	109	112	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	OCT 1	2010	52	4					1268	1278		10.1016/j.neuroimage.2010.04.252			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	635YY	WOS:000280695200016	20435146	Green Accepted			2021-06-18	
J	Chamoun, R; Suki, D; Gopinath, SP; Goodman, JC; Robertson, C				Chamoun, Roukoz; Suki, Dima; Gopinath, Shankar P.; Goodman, J. Clay; Robertson, Claudia			Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						Severe head injury; microdialysis; glutamate; outcome	EXCITATORY AMINO-ACIDS; INTRACEREBRAL MICRODIALYSIS; RELEASE	Object. Authors of several studies have implied a key role of glutamate, an excitatory amino acid, in the pathophysiology of traumatic brain injury (TBI). However, the place of glutamate measurement in clinical practice and its impact on the management of TBI has yet to be elucidated. The authors' objective in the present study was to evaluate glutamate levels in TBI, analyzing the factors affecting them and determining their prognostic value. Methods. A prospective study of patients with severe TBI was conducted with an inclusion criterion of a Glasgow Coma Scale score <= 8 within 48 hours of injury. Invasive monitoring included intracranial pressure measurements, brain tissue PO(2), jugular venous O(2) saturation, and cerebral microdialysis. Patients received standard care including mass evacuation when indicated and treatment of elevated intracranial pressure values. Demographic data, CT findings, and outcome at 6 months of follow-up were recorded. Results. One hundred sixty-five patients were included in the study. Initially high glutamate values were predictive of a poor outcome. The mortality rate was 30.3% among patients with glutamate levels > 20 mu mol/L, compared with 18% among those with levels <= 20 mu mol/L. Two general patterns were recognized: Pattern 1, glutamate levels tended to normalize over the monitoring period (120 hours): and Pattern 2, glutamate levels tended to increase with time or remain abnormally elevated. Patients showing Pattern 1 had a lower mortality rate (17.1 vs 39.6%) and a better 6-month functional outcome among survivors (41.2 vs 20.7%). Conclusions. Glutamate levels measured by microdialysis appear to have an important role in TBI. Data in this study suggest that glutamate levels are correlated with the mortality rate and 6-month functional outcome. (DOI: 10.3171/2009.12.JNS09689)	[Chamoun, Roukoz; Gopinath, Shankar P.; Robertson, Claudia] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Goodman, J. Clay] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Suki, Dima] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	Gopinath, SP (corresponding author), Baylor Coll Med, Dept Neurosurg, 1709 Dryden,Suite 750, Houston, TX 77030 USA.	shankarg@bcm.tmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [PO1-NS38660]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health Grant No. PO1-NS38660.	BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHOI DW, 1987, J NEUROSCI, V7, P369; DUHAIME AC, 1994, PEDIATR NEUROSURG, V21, P117, DOI 10.1159/000120825; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; Greenwood SM, 2007, NEUROPHARMACOLOGY, V53, P891, DOI 10.1016/j.neuropharm.2007.10.003; Hickenbottom SL, 1998, SEMIN NEUROL, V18, P485, DOI 10.1055/s-2008-1040901; Hillered L, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p695A; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Willis C, 2004, COCHRANE DB SYST REV	18	109	117	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					564	570		10.3171/2009.12.JNS09689			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100020	20113156	Green Accepted			2021-06-18	
J	Honeybul, S				Honeybul, S.			Complications of decompressive craniectomy for head injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Complications; Decompressive craniectomy; Neurotrauma; Head injury	TRAUMATIC BRAIN-INJURY; NEUROSURGICAL SITE INFECTIONS; SURGICAL DECOMPRESSION; SUBDURAL HYGROMA; RISK-FACTORS; CRANIOPLASTY; CRANIOTOMY; CHILDREN; EDEMA; PATHOGENESIS	There is much interest in the use of decompressive craniectomy for intracranial hypertension. Whilst technically straightforward, the procedure is not without significant complications. A retrospective analysis was undertaken of 41 patients who had had a decompressive craniectomy for severe head injury in the years 2006 and 2007 at the two major hospitals in Western Australia, Sir Charles Gairdner Hospital and Royal Perth Hospital. Complications attributable to the decompressive surgery were: herniation of the cortex through the bone defect, 18 patients (51%); subdural effusion, 22 patients (62%); seizures, five patients (14%) and hydrocephalus, four patients (11%). Complications attributable to the subsequent cranioplasty were: infection, four patients (11%) and bone flap resorption, six patients (17%). Syndrome of the trephined occurred in three (7%) of those patients whose bone flap had significantly resorbed. Two deaths (5.5%) occurred as a direct complication of the craniectomy or cranioplasty procedure. I attempted to define what may be regarded as a complication of the decompressive procedure rather than what may be a consequence of the primary pathological process of traumatic brain injury. (C) 2009 Elsevier Ltd. All rights reserved.	[Honeybul, S.] Sir Charles Gairdner Hosp, Dept Neurosurg, Nedlands, WA 6009, Australia; [Honeybul, S.] Royal Perth Hosp, Nedlands, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Nedlands, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Adamo MA, 2008, J NEUROSURG, V108, P174, DOI 10.3171/JNS/2008/108/01/0174; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BLOMSTEDT GC, 1985, ACTA NEUROCHIR, V78, P81, DOI 10.1007/BF01808684; Csokay A, 2001, NEUROSURG REV, V24, P209, DOI 10.1007/s101430100158; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Groswasser Z, 1988, Brain Inj, V2, P267, DOI 10.3109/02699058809150897; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Guyot LL, 2000, NEUROL RES, V22, P25; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2009, J CLIN NEUROSCI, V16, P727, DOI 10.1016/j.jocn.2008.06.015; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Idali B, 2004, MED MALADIES INFECT, V34, P221, DOI 10.1016/j.medmal.2003.12.011; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Korinek AM, 2005, BRIT J NEUROSURG, V19, P155, DOI 10.1080/02688690500145639; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359; Licata C, 2001, J Neurosurg Sci, V45, P141; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Tokoro K, 1989, Neurol Med Chir (Tokyo), V29, P196, DOI 10.2176/nmc.29.196; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	34	109	122	1	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	APR	2010	17	4					430	435		10.1016/j.jocn.2009.09.007			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	574SU	WOS:000276014600004	20181482				2021-06-18	
J	Khan, M; Im, YB; Shunmugavel, A; Gilg, AG; Dhindsa, RK; Singh, AK; Singh, I				Khan, Mushfiquddin; Im, Yeong-Bin; Shunmugavel, Anandakumar; Gilg, Anne G.; Dhindsa, Ramanpreet K.; Singh, Avtar K.; Singh, Inderjit			Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact	JOURNAL OF NEUROINFLAMMATION			English	Article							NITRIC-OXIDE SYNTHASE; RECEPTOR AGONIST 8-OH-DPAT; CEREBRAL-BLOOD-FLOW; MATRIX METALLOPROTEINASES; COGNITIVE DEFICITS; FLAP SURVIVAL; RECOVERY; NEUROPROTECTION; NITROSYLATION; MODULATION	Background: Traumatic brain injury (TBI) is a major cause of preventable death and serious morbidity in young adults. This complex pathological condition is characterized by significant blood brain barrier (BBB) leakage that stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain. Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. Following other brain injuries, nitric oxide modulators such as S-nitrosoglutathione (GSNO) maintain not only redox balance but also inhibit the mechanisms of secondary injury. Therefore, we tested whether GSNO shows efficacy in a rat model of experimental TBI. Methods: TBI was induced by controlled cortical impact (CCI) in adult male rats. GSNO (50 mu g/kg body weight) was administered at two hours after CCI. GSNO-treated injured animals (CCI+GSNO group) were compared with vehicle-treated injured animals (CCI+VEH group) in terms of tissue morphology, BBB leakage, edema, inflammation, cell death, and neurological deficit. Results: Treatment of the TBI animals with GSNO reduced BBB disruption as evidenced by decreased Evan's blue extravasation across brain, infiltration/activation of macrophages (ED1 positive cells), and reduced expression of ICAM-1 and MMP-9. The GSNO treatment also restored CCI-mediated reduced expression of BBB integrity proteins ZO-1 and occludin. GSNO-mediated improvements in tissue histology shown by reduction of lesion size and decreased loss of both myelin (measured by LFB staining) and neurons (assayed by TUNEL) further support the efficacy of GSNO therapy. GSNO-mediated reduced expression of iNOS in macrophages as well as decreased neuronal cell death may be responsible for the histological improvement and reduced exacerbations. In addition to these biochemical and histological improvements, GSNO-treated injured animals recovered neurobehavioral functions as evaluated by the rotarod task and neurological score measurements. Conclusion: GSNO is a promising candidate to be evaluated in humans after brain trauma because it not only protects the traumatic penumbra from secondary injury and improves overall tissue structure but also maintains the integrity of BBB and reduces neurologic deficits following CCI in a rat model of experimental TBI.	[Khan, Mushfiquddin; Im, Yeong-Bin; Shunmugavel, Anandakumar; Gilg, Anne G.; Dhindsa, Ramanpreet K.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	khanm@musc.edu; imyb@musc.edu; anandak@musc.edu; gilg@musc.edu; mushfiquddinkhan@gmail.com; singha@musc.edu; singhi@musc.edu			Betty and Guy Beatty Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-22576, NS-34741, NS-37766]; Veteran Administration Merit; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR018823, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS022576, R01NS037766, R01NS034741, R37NS022576] Funding Source: NIH RePORTER	These studies were supported by grants from Betty and Guy Beatty Foundation, National Institutes of Health (NS-22576, NS-34741 and NS-37766) and Veteran Administration Merit Award. This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Dr Md Nasrul Hoda and Dr Bilgen Mehmet for their valuable technical assistance. We are grateful to Dr Tom Smith from the MUSC Writing Center for his valuable editing and correction of the manuscript. We would like to thank Ms. Joyce Bryan for procurement of animals and chemicals and Chara Williams for secretarial assistance.	Avila MA, 2008, J CEREBR BLOOD F MET, V28, P1733, DOI 10.1038/jcbfm.2008.66; Barbaccia J J, 2001, Curr Opin Anaesthesiol, V14, P227, DOI 10.1097/00001503-200104000-00016; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Botteri M, 2008, CRIT CARE MED, V36, P3089, DOI 10.1097/CCM.0b013e31818bd7df; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Chiueh Chuang C., 2002, Pediatric Research, V51, P414, DOI 10.1203/00006450-200204000-00002; Choi YB, 2000, NAT NEUROSCI, V3, P15; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gaston Benjamin M, 2003, Mol Interv, V3, P253, DOI 10.1124/mi.3.5.253; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Heiss C, 2006, J AM COLL CARDIOL, V47, P573, DOI 10.1016/j.jacc.2005.06.089; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jatana M, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-12; Kaposzta Z, 2002, CIRCULATION, V106, P3057, DOI 10.1161/01.CIR.0000041251.07332.28; Kaposzta Z, 2002, CIRCULATION, V105, P1480, DOI 10.1161/01.CIR.0000012347.47001.97; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Khan M, 2006, NITRIC OXIDE-BIOL CH, V15, P114, DOI 10.1016/j.niox.2006.01.008; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Kluge I, 1997, J NEUROCHEM, V69, P2599; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kuo YR, 2004, SURGERY, V135, P437, DOI 10.1016/j.surg.2003.07.006; Kuo YR, 2004, J SURG RES, V119, P92, DOI 10.1016/j.jss.2003.08.006; LANE P, 2001, SCI STKE, pRE1; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; Megson IL, 2000, DRUG FUTURE, V25, P701, DOI 10.1358/dof.2000.025.07.858691; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Molloy J, 1998, CIRCULATION, V98, P1372, DOI 10.1161/01.CIR.98.14.1372; Monville C, 2006, J NEUROSCI METH, V158, P219, DOI 10.1016/j.jneumeth.2006.06.001; Nakamura T, 2009, NEURON, V63, P3, DOI 10.1016/j.neuron.2009.06.013; Nath N, 2009, BIOCHEM BIOPH RES CO, V386, P16, DOI 10.1016/j.bbrc.2009.05.106; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Parathath SR, 2006, J CELL SCI, V119, P339, DOI 10.1242/jcs.02734; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Prasad R, 2007, GLIA, V55, P65, DOI 10.1002/glia.20436; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; RAPOPORT SI, 1980, AM J PHYSIOL, V238, pR421; Rashid Parveen A, 2003, J Stroke Cerebrovasc Dis, V12, P82, DOI 10.1053/jscd.2003.9; Rauhala P, 1998, FASEB J, V12, P165; Salama NN, 2006, ADV DRUG DELIVER REV, V58, P15, DOI 10.1016/j.addr.2006.01.003; Savidge TC, 2007, GASTROENTEROLOGY, V132, P1344, DOI 10.1053/j.gastro.2007.01.051; Schonhoff CM, 2006, P NATL ACAD SCI USA, V103, P2404, DOI 10.1073/pnas.0507243103; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; Sehba FA, 1999, STROKE, V30, P1955, DOI 10.1161/01.STR.30.9.1955; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Steffen M, 2001, BIOCHEM J, V356, P395, DOI 10.1042/0264-6021:3560395; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Tuzgen S, 2003, NEUROL RES, V25, P31, DOI 10.1179/016164103101201085; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; WEISSMAN DE, 1988, J NEURO-ONCOL, V6, P339; Zeng H, 2001, AM J PHYSIOL-HEART C, V281, pH432; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	77	109	114	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	NOV 4	2009	6								32	10.1186/1742-2094-6-32			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	525XX	WOS:000272252200001	19889224	DOAJ Gold, Green Published			2021-06-18	
J	McCrory, P; Meeuwisse, W; Johnston, K; Dvorak, J; Aubry, M; Molloy, M; Cantu, R				McCrory, Paul; Meeuwisse, Willem; Johnston, Karen; Dvorak, Jiri; Aubry, Mark; Molloy, Mick; Cantu, Robert			Consensus Statement on Concussion in Sport - The Third International Conference on Concussion in Sport Held in Zurich, November 2008	PHYSICIAN AND SPORTSMEDICINE			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; POSTURAL CONTROL; HEAD-INJURIES; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; AUSTRALIAN RULES		[McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; [Meeuwisse, Willem] Univ Calgary, Calgary, AB, Canada; [Johnston, Karen] Toronto Rehabil Inst, Toronto, ON, Canada; [Dvorak, Jiri] FIFA Med Assessment & Res Ctr F MARC, Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin, Zurich, Switzerland; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Molloy, Mick] Int Rugby Board, Dublin, Ireland; [Cantu, Robert] Emerson Hosp, Concord, MA USA	McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh A, 2005, RUGBY HEADGEAR STUDY; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; PENG RY, 2003, WEI ZHONG BING JI JI, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; WIESS MR, 2005, RES Q EXERCISE SPORT, V76, pS71; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	146	109	110	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0091-3847	2326-3660		PHYSICIAN SPORTSMED	Physician Sportsmed.	JUN	2009	37	2					141	159		10.3810/psm.2009.06.1721			19	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	V17IM	WOS:000207930900030	20048521				2021-06-18	
J	Byrnes, KR; Stoica, B; Loane, DJ; Riccio, A; Davis, MI; Faden, AI				Byrnes, Kimberly R.; Stoica, Bogdan; Loane, David J.; Riccio, Angela; Davis, Margaret I.; Faden, Alan I.			Metabotropic Glutamate Receptor 5 Activation Inhibits Microglial Associated Inflammation and Neurotoxicity	GLIA			English	Article						metabotropic glutamate receptor; neurotoxic; nitric oxide; ROS; signal transduction	NECROSIS-FACTOR-ALPHA; TRAUMATIC NEURONAL INJURY; SPINAL-CORD-INJURY; CELL-DEATH; NITRIC-OXIDE; BRAIN-INJURY; GROUP-I; NEUROPROTECTIVE ACTIVITY; DEPENDENT MECHANISM; FUNCTIONAL RECOVERY	The Group I metabotropic glutamate receptor 5 (mGluR5) can modulate addiction, pain, and neuronal cell death. Expression of some mGluRs, such as Group II and III mGluRs, has been reported in microglia and may affect their activation. However, the expression and role of mGluR5 in microglia is unclear. Using immunocytochemistry and Western blot, we demonstrate that mGluR5 protein is expressed in primary microglial cultures. Activation of mGluR5 using the selective agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) significantly reduces microglial activation in response to lipopolysaccharide, as indicated by a reduction in nitric oxide, reactive oxygen species, and TNF alpha production. Microglial induced neurotoxicity is also markedly reduced by CHPG treatment. The anti-inflammatory effects of CHPG are not observed in microglial cultures from mGluR5 knockout mice and are blocked by selective mGluR5 antagonists, suggesting that these actions are mediated by the mGluR5 receptor. Anti-inflammatory actions of mGluR5 activation are attenuated by phospholipase C and protein kinase C inhibitors, as well as by calcium chelators, suggesting that the mGluR5 activation in microglia involves the G(alpha q)-protein signal transduction pathway. These data indicate that microglial mGluR5 may represent a novel target for modulating neuroinflammation, an important component of both acute and chronic neurodegenerative disorders. (C) 2008 Wiley-Liss, Inc.	[Byrnes, Kimberly R.; Stoica, Bogdan; Loane, David J.; Riccio, Angela; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; [Davis, Margaret I.] NIAAA, NIH, Rockville, MD 20852 USA	Byrnes, KR (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Room EP12A,New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	krb27@georgetown.edu	STOICA, BOGDAN/H-9782-2013; Davis, Margaret/F-4165-2010	STOICA, BOGDAN/0000-0002-2501-6434; Byrnes, Kimberly/0000-0002-7501-7734; Loane, David/0000-0003-0393-3503; Davis, Margaret/0000-0002-0489-8351	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037313-08, R01 NS037313, 5R01 NS 037313-08] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER		Akundi RS, 2005, GLIA, V51, P199, DOI 10.1002/glia.20198; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Barger SW, 2007, J NEUROCHEM, V101, P1205, DOI 10.1111/j.1471-4159.2007.04487.x; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Biber K, 1999, J NEUROCHEM, V72, P1671, DOI 10.1046/j.1471-4159.1999.721671.x; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bond A, 1999, NEUROSCI LETT, V273, P191, DOI 10.1016/S0304-3940(99)00663-1; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Endoh T, 2004, BRAIN RES, V1024, P212, DOI 10.1016/j.brainres.2004.07.074; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Fei Z, 2006, J CLIN NEUROSCI, V13, P1023, DOI 10.1016/j.jocn.2005.11.042; Folbergrova J, 2005, EXP NEUROL, V192, P420, DOI 10.1016/j.expneurol.2004.12.019; Geurts JJG, 2003, BRAIN, V126, P1755, DOI 10.1093/brain/awg179; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; He Y, 2003, J NEUROCHEM, V86, P1338, DOI 10.1046/j.1471-4159.2003.01938.x; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Jeohn GH, 2000, BRAIN RES, V880, P173, DOI 10.1016/S0006-8993(00)02737-2; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kim GM, 2001, J NEUROSCI, V21, P6617; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Lea PM, 2005, BRIT J PHARMACOL, V145, P527, DOI 10.1038/sj.bjp.0706219; Lee JS, 2007, NEUROSCIENCE, V146, P375, DOI 10.1016/j.neuroscience.2007.01.015; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li JM, 2005, MOL CELL BIOL, V25, P2320, DOI 10.1128/MCB.25.6.2320-2330.2005; Mander P, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-20; Mannaioni G, 2001, J NEUROSCI, V21, P5925; Movsesyan VA, 2006, J NEUROTRAUM, V23, P117, DOI 10.1089/neu.2006.23.117; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; Munch G, 2003, EXP BRAIN RES, V150, P1, DOI 10.1007/s00221-003-1389-5; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Nikodemova M, 2007, J BIOL CHEM, V282, P15208, DOI 10.1074/jbc.M611907200; Olive MF, 2005, MOL PHARMACOL, V67, P349, DOI 10.1124/mol.104.003319; Pacheco R, 2004, J BIOL CHEM, V279, P33352, DOI 10.1074/jbc.M401761200; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Rezzani R, 2003, ACTA HISTOCHEM, V105, P81, DOI 10.1078/0065-1281-00688; Surin A, 2007, NEUROPHARMACOLOGY, V52, P744, DOI 10.1016/j.neuropharm.2006.09.018; Szydlowska K, 2007, EUR J PHARMACOL, V554, P18, DOI 10.1016/j.ejphar.2006.09.061; Tansey MG, 2007, EXP NEUROL, V208, P1, DOI 10.1016/j.expneurol.2007.07.004; Taylor DL, 2002, J NEUROCHEM, V82, P1179, DOI 10.1046/j.1471-4159.2002.01062.x; Taylor DL, 2005, J NEUROSCI, V25, P2952, DOI 10.1523/JNEUROSCI.4456-04.2005; Taylor DL, 2003, J NEUROSCI, V23, P2150; Vernon AC, 2007, J PHARMACOL EXP THER, V320, P397, DOI 10.1124/jpet.106.108159; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Zhao XR, 2001, J NEUROSCI RES, V64, P121, DOI 10.1002/jnr.1059; Zou JY, 2005, BRAIN RES, V1034, P11, DOI 10.1016/j.brainres.2004.11.014	53	109	111	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR 1	2009	57	5					550	560		10.1002/glia.20783			11	Neurosciences	Neurosciences & Neurology	416NE	WOS:000264012000008	18816644	Green Accepted			2021-06-18	
J	Fox, ZG; Mihalik, JP; Blackburn, JT; Battaglini, CL; Guskiewicz, KM				Fox, Zachary G.; Mihalik, Jason P.; Blackburn, J. Troy; Battaglini, Claudio L.; Guskiewicz, Kevin M.			Return of postural control to baseline after anaerobic and aerobic exercise protocols	JOURNAL OF ATHLETIC TRAINING			English	Article						balance; fatigue; recovery; concussions; mild head injuries; mild traumatic brain injuries	ERROR SCORING SYSTEM; SPORT-RELATED CONCUSSION; MILD HEAD-INJURY; STANDARDIZED ASSESSMENT; PERCEIVED EXERTION; ANKLE FATIGUE; STABILITY; BALANCE; RECOVERY; RELIABILITY	Context: With regard to sideline concussion testing, the effect of fatigue associated with different types of exercise on postural control is unknown. Objective: To evaluate the effects of fatigue on postural control in healthy college-aged athletes performing anaerobic and aerobic exercise protocols and to establish an immediate recovery time course from each exercise protocol for postural control measures to return to baseline status. Design: Counterbalanced, repeated measures. Setting: Research laboratory. Patients or Other Participants: Thirty-six collegiate athletes (18 males, 18 females; age = 19.00 +/- 1.01 years, height = 172.44 +/- 10.47 cm, mass = 69.72 +/- 12.84 kg). Intervention(s): Participants completed 2 counterbalanced sessions within 7 days. Each session consisted of 1 exercise protocol followed by postexercise measures of postural control taken at 3-, 8-, 13-, and 18-minute time intervals. Baseline measures were established during the first session, before the specified exertion protocol was performed. Main Outcome Measure(s): Balance Error Scoring System (BESS) results, sway velocity, and elliptical sway area. Results: We found a decrease in postural control after each exercise protocol for all dependent measures. An interaction was noted between exercise protocol and time for total BESS score (P = .002). For both exercise protocols, all measures of postural control returned to baseline within 13 minutes. Conclusions: Postural control was negatively affected after anaerobic and aerobic exercise protocols as measured by total BESS score, elliptical sway area, and sway velocity. The effect of exertion lasted up to 13 minutes after each exercise was completed. Certified athletic trainers and clinicians should be aware of these effects and their recovery time course when determining an appropriate time to administer sideline assessments of postural control after a suspected mild traumatic brain injury.	[Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, 204 Fetzer Gymnasium,South Rd, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Battaglini, Claudio L/D-7247-2013; Mihalik, Jason P/E-7059-2010	Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322			Adlerton Anna-Karin, 2003, Physiother Res Int, V8, P187, DOI 10.1002/pri.289; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Caron O, 2003, NEUROSCI LETT, V340, P83, DOI 10.1016/S0304-3940(02)01455-6; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; CROWELL DH, 2000, J ATHL TRAIN S2, V36, pS33; Derave W, 1998, ERGONOMICS, V41, P782, DOI 10.1080/001401398186630; Gauchard GC, 2002, INT J NEUROSCI, V112, P1191, DOI 10.1080/00207450290026157; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Harkins KM, 2005, J ATHL TRAINING, V40, P191; Krustrup P, 2003, MED SCI SPORT EXER, V35, P697, DOI 10.1249/01.MSS.0000058441.94520.32; Lepers R, 1997, EUR J APPL PHYSIOL, V76, P55, DOI 10.1007/s004210050212; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Moyna NM, 2001, MED SCI SPORT EXER, V33, P1404, DOI 10.1097/00005768-200108000-00025; Nardone A, 1997, ELECTROMYOGR MOTOR C, V105, P309, DOI 10.1016/S0924-980X(97)00040-4; Nardone A, 1998, ARCH PHYS MED REHAB, V79, P920, DOI 10.1016/S0003-9993(98)90088-0; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Robertson RJ, 2000, MED SCI SPORT EXER, V32, P2120, DOI 10.1097/00005768-200012000-00024; SELIGA R, 1991, AM IND HYG ASSOC J, V52, P417, DOI 10.1202/0002-8894(1991)052<0417:EOWLAR>2.0.CO;2; Susco TM, 2004, J ATHL TRAINING, V39, P241; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Yaggie J, 2004, J SPORT REHABIL, V13, P312, DOI 10.1123/jsr.13.4.312; Yaggie JA, 2002, ARCH PHYS MED REHAB, V83, P224, DOI 10.1053/apmr.2002.28032	33	109	113	0	20	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2008	43	5					456	463		10.4085/1062-6050-43.5.456			8	Sport Sciences	Sport Sciences	356FQ	WOS:000259764500002	18833307	Green Published, Bronze			2021-06-18	
J	McDonald, S; Tate, R; Togher, L; Bornhofen, C; Long, E; Gertler, P; Bowen, R				McDonald, Skye; Tate, Robyn; Togher, Leanne; Bornhofen, Cristina; Long, Esther; Gertler, Paul; Bowen, Rebecca			Social skills treatment for people with severe, chronic acquired brain injuries: A multicenter trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						behavior therapy; cognition; higher nervous activity; psychology; clinical; psychotherapy; multiple; rehabilitation	EMOTION PERCEPTION DEFICITS; PERFORMANCE SURVEY SCHEDULE; KATZ ADJUSTMENT SCALE; COMMUNICATION-SKILLS; BEHAVIOR; INDIVIDUALS; VALIDITY; DEPRESSION; THERAPY; RECOGNITION	Objective: To determine whether social skills deficits including unskilled, inappropriate behavior, problems reading social cues (social perception), and mood disturbances (such as depression and anxiety.) could be remediated after severe traumatic brain injuries. Design: Randomized controlled trial comparing a social skills program with social activity alone or with waitlist control. Several participants were reassigned after randomization. Setting: Hospital Outpatient and community facilities. Participants: Fifty-one outpatients from 3 brain injury units in Sydney, Australia, with severe, chronic acquired brain injuries were recruited. A total of 39 people (13 in skills training, 13 in social activity, 13 in waitlist) completed all phases of the Study. Intervention: Twelve-week social skills treatment program encompassing weekly 3-hour group sessions focused on shaping social behavior and remediating social perception and 1-hour individual sessions to address psychologic issues with mood, self-esteem, etc. Main Outcome Measures: Primary Outcomes were: (1) social behavior during encounters with a confederate as rated on the Behaviorally Referenced Rating System of Intermediary Social Skills-Revised (BRISS-R), (2) social perception as measured by The Awareness of Social Inference Test, and (3) depression and anxiety as measured by the Depression, Anxiety and Stress Scale. Secondary outcomes were: relative report off social behavior and participation using: the Katz Adjustment Scale-R1: the Social Performance Survey Schedule; the La Trobe Communication Questionnaire. and the Sydney Psychosocial Reintegration Scale (both relative and self-report). Results: Repeated-measures analysis of variance indicated that social activity alone did not lead to improved performance relative to waitlist (placebo effect) on any outcome variable. On the other hand, the skills training group improved differentially on the Partner Directed Behavior Scale of the BRISS-R, specifically the self-centered behavior and partner involvement behavior sub-scales. No treatment effects were found for the remaining primary outcomes (social perception, emotional adjustment) or for secondary Outcome variables (relative and self-report measures of social function). Conclusions: This study Suggested that treatment effects after social skills training in people with severe, chronic brain injuries are modest and are limited to direct measures of social behavior.	[McDonald, Skye; Bornhofen, Cristina; Long, Esther; Gertler, Paul] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Tate, Robyn] Univ Sydney, Fac Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Togher, Leanne] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [Bowen, Rebecca] Liverpool Brain Injury Unit, Sydney, NSW, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014; Togher, Leanne/AAC-7083-2019	McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [222754]	Supported by the Australian National Health and Medical Research Council (project grant no. 222754).	Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Bellack A., 2004, SOCIAL SKILLS TRAINI; Benton A., 1994, MULTILINGUAL APHASIA; BENTON MK, 1990, J CONSULT CLIN PSYCH, V58, P741, DOI 10.1037/0022-006X.58.6.741; BIRD K, 2001, PSY PROGRAM CONTRAST; Bolte S, 2006, BEHAV NEUROSCI, V120, P211, DOI 10.1037/0735-7044.120.1.211; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; BRAMSTON P, 1985, BEHAV RES THER, V23, P239, DOI 10.1016/0005-7967(85)90001-4; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Combs DR, 2006, SCHIZOPHR RES, V87, P340, DOI 10.1016/j.schres.2006.05.003; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Deb S, 1999, AM J PSYCHIAT, V156, P374; Delis DC, 2001, DELISKAPLAN EXECUTIV; Demakis GJ, 2007, ARCH CLIN NEUROPSYCH, V22, P123, DOI 10.1016/j.acn.2006.09.004; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Ekman P., 2003, EMOTIONS REVEALED RE; FABIANO RJ, 1992, REHABIL PSYCHOL, V37, P75, DOI 10.1037/h0079096; FARRELL AD, 1985, BEHAV ASSESS, V7, P155; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Furukawa TA, 2006, BRIT J PSYCHIAT, V188, P305, DOI 10.1192/bjp.188.4.305; GIANNINI AJ, 1995, PERCEPT MOTOR SKILL, V81, P555, DOI 10.1177/003151259508100239; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; GOTLIB IH, 1989, J ABNORM PSYCHOL, V98, P23, DOI 10.1037/0021-843X.98.1.23; Hale WW, 1998, J AFFECT DISORDERS, V47, P63, DOI 10.1016/S0165-0327(97)00112-2; Hale WW, 2005, BRAIN IMPAIR, V6, P169; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Heaton R., 1993, WISCONSIN CARD SORTI; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; Johnson K, 1998, BEHAV MODIF, V22, P502, DOI 10.1177/01454455980224004; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; Kavale KA, 1996, J LEARN DISABIL, V29, P226, DOI 10.1177/002221949602900301; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; LIBET JM, 1973, J CONSULT CLIN PSYCH, V40, P304, DOI 10.1037/h0034530; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; LOWE MR, 1978, BEHAV THER, V9, P535, DOI 10.1016/S0005-7894(78)80126-9; LOWE MR, 1982, PSYCHOL REP, V50, P83, DOI 10.2466/pr0.1982.50.1.83; LOWE MR, 1985, J PSYCHOPATHOL BEHAV, V7, P13, DOI 10.1007/BF00961843; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; MCFALL RM, 1982, BEHAV ASSESS, V4, P1; McKenzie K., 2000, BRIT J LEARN DISABIL, V28, P143; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; MEDONALD S, 2003, BRAIN IMPAIR, V4, P36; Meghji C, 2002, J COGN REHABIL, V20, P12; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MILLER LS, 1984, BEHAV ASSESS, V6, P33; OZONOFF S, 1995, J AUTISM DEV DISORD, V25, P415, DOI 10.1007/BF02179376; Ponsford J., 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Spence S.H., 1995, SOCIAL SKILLS TRAINI; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE RL, 1987, SCAND J REHABIL MED, V19, P13; Togher L., 2000, BRAIN DAM B, P1; TROWER P, 1980, J CONSULT CLIN PSYCH, V48, P327, DOI 10.1037/0022-006X.48.3.327; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; WALLANDER JL, 1985, BEHAV ASSESS, V7, P137; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M	75	109	111	0	43	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2008	89	9					1648	1659		10.1016/j.apmr.2008.02.029			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	346GR	WOS:000259057300003	18760150				2021-06-18	
J	Gioia, GA; Collins, M; Isquith, PK				Gioia, Gerard A.; Collins, Michael; Isquith, Peter K.			Improving identification and diagnosis of mild traumatic brain injury with evidence: Psychometric support for the Acute Concussion Evaluation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acute concussion evaluation; assessment; concussion; mild traumatic brain injury; postconcussion symptoms; triage	SYMPTOMS; PERFORMANCE; RECOVERY; CHILDREN; IMPACT	Objectives: A dearth of standardized assessment tools exists to properly assess and triage mild traumatic brain injury (mTBI) in primary care and acute care settings. This article presents evidence of appropriate psychometric properties for the Acute Concussion Evaluation (ACE), a new structured clinical interview. Participants: Parent informants of 354 patients, aged 3 to 18 years, with suspected mTBI completed the ACE via telephone interview. Measure: Acute Concussion Evaluation. Results: Evidence is presented for appropriate item-scale membership, internal consistency reliability as well as content, predictive, convergent/divergent, and construct validity of the ACE symptom checklist. Conclusions: Overall, the ACE symptom checklist exhibits reasonably strong psychometric properties as an initial assessment tool for mTBI.	[Gioia, Gerard A.] George Washington Univ, Sch Med, Childrens Natl Med Ctr, Dept Pediat & Psychiat & Behav Med, Washington, DC 20010 USA; George Washington Univ, Sch Med, Childrens Natl Med Ctr, Div Pediat Neuropsychol,Safe Consuss Outcome Reco, Washington, DC 20010 USA; [Collins, Michael] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA USA; [Isquith, Peter K.] Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA	Gioia, GA (corresponding author), George Washington Univ, Sch Med, Childrens Natl Med Ctr, Dept Pediat & Psychiat & Behav Med, Washington, DC 20010 USA.		Isquith, Peter/AAY-4851-2020		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [5-M01-RR-020359-02] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU323352-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER		Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bergman DA, 1999, PEDIATRICS, V104, P1407; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; (CDC). National Center for Injury Prevention and Control, 2007, HEADS BRAIN INJ YOUR; *CDCP, 2003, REP C MIL TRAUM BRAI; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; CRONBACH LJ, 1951, PSYCHOMETRIKA, V42, P438; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Gioia G.A., 2006, ACUTE CONCUSSION EVA; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gorsuch R. L., 1983, FACTOR ANAL; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, BRAIN INJURY, V18, P1; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kennedy JE, 2006, MIL MED, V171, P516, DOI 10.7205/MILMED.171.6.516; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LESCOHIER I, 1993, PEDIATRICS, V91, P721; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Mather FJ, 2003, BRAIN INJURY, V17, P1077, DOI 10.1080/0269905031000114045; McCrea MA, 2007, MILD TRAUMATIC BRAIN; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Piland SG, 2003, J ATHL TRAINING, V38, P104; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; World Health Organization, 1992, ICD 10 INT STAT CLAS; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	40	109	109	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2008	23	4					230	242		10.1097/01.HTR.0000327255.38881.ca			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	331KU	WOS:000258011900005	18650767				2021-06-18	
J	Wallister, TW				Wallister, Thomas W.			Neurobehavioral sequelae of traumatic brain injury: evaluation and management	WORLD PSYCHIATRY			English	Article						traumatic brain injury; neurobehavioral sequelae; regional brain damage; cognitive deficits; personality changes	CLOSED HEAD-INJURY; FOLLOW-UP; AXIS-I; NEUROPSYCHIATRIC SEQUELAE; PSYCHIATRIC-DISORDERS; IMPAIRED AWARENESS; UNITED-STATES; RAT-BRAIN; MEMORY; MOOD	Traumatic brain injury (TBI) is a worldwide public health problem. Over the last several decades, improvements in acute care have resulted in higher survival rates. Unfortunately, the majority of survivors of moderate and severe TBI have chronic neurobehavioral sequelae, including cognitive deficits, changes in personality and increased rates of psychiatric illness. These neurobehavioral problems are understandable in the context of the typical profile of regional brain damage associated with trauma. This paper presents an overview of the neurobehavioral sequelae of TBI and outlines issues to consider in the evaluation and management of these challenges.	Dartmouth Coll, Hitchcock Med Ctr, Dept Psychiat, Lebanon, NH 03756 USA	Wallister, TW (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176, R01 HD048638] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055020, R01 NS040472] Funding Source: Medline		Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Arciniegas DB, 2005, CNS SPECTRUMS, V10, P1, DOI 10.1017/S1092852900026602; ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chau David T, 2004, Curr Psychiatry Rep, V6, P391, DOI 10.1007/s11920-004-0026-8; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CUESTA MJ, 1995, AM J PSYCHIAT, V152, P1380; CUESTA MJ, 1994, SCHIZOPHRENIA BULL, V20, P359, DOI 10.1093/schbul/20.2.359; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; EWINGCOBBS L, 1987, SEMIN PEDIAT NEUROL, V9, P209; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FAHY TJ, 1967, LANCET, V2, P475; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Flashman LA, 2001, J NEUROPSYCH CLIN N, V13, P255, DOI 10.1176/appi.neuropsych.13.2.255; FLASHMAN LA, UNPUB SELF REFLECTIO; FORD B, 1976, MED J AUSTRALIA, V1, P603, DOI 10.5694/j.1326-5377.1976.tb140904.x; FREEDMAN PE, 1987, J NEUROL NEUROSUR PS, V50, P398, DOI 10.1136/jnnp.50.4.398; GENNARELLI T, 2005, NEUROPSYCHIATRY TRAU, P27; Hart T, 2006, ARCH PHYS MED REHAB, V87, P647, DOI 10.1016/j.apmr.2006.01.016; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRAUS JF, 2005, NEUROPSYCHIATRY TRAU, P3; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell Mark R., 1994, P133; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McAllister T W, 2000, Semin Clin Neuropsychiatry, V5, P275, DOI 10.1053/scnp.2000.9557; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MILLER H, 1965, LANCET, V1, P225; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; O'Jile JR, 2006, ARCH CLIN NEUROPSYCH, V21, P293, DOI 10.1016/j.acn.2006.03.003; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OTA Y, 1969, LATE EFFECTS HEAD IN, P110; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; Perry EK, 2004, PROG BRAIN RES, V145, P287, DOI 10.1016/S0079-6123(03)45020-6; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; Ruff R.M., 1989, MILD HEAD INJURY, P176; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Shytle RD, 2002, DEPRESS ANXIETY, V16, P89, DOI 10.1002/da.10035; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V5, P1; SOSIN DM, 1991, BRAIN INJURY, V10, P47, DOI DOI 10.1080/026990596124719; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tariot PN, 2002, ADV DRUG DELIVER REV, V54, P1567, DOI 10.1016/S0169-409X(02)00153-9; Tariot PN, 1999, J CLIN PSYCHIAT, V60, P29; TRUDEL TM, 1996, NEW HAMPSH BRAIN INJ; TSUIKI K, 1995, J NEUROCHEM, V64, P1319; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; *US DEP HHS, 1989, INT HEAD INJ TASK FO; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wei WH, 2005, ARCH PHYS MED REHAB, V86, P905, DOI 10.1016/j.apmr.2004.09.026; WEINTRAUB S, 1981, ARCH NEUROL-CHICAGO, V38, P742, DOI 10.1001/archneur.1981.00510120042004; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274	84	109	113	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2051-5545			WORLD PSYCHIATRY	World Psychiatry	FEB	2008	7	1					3	10					8	Psychiatry	Psychiatry	265VF	WOS:000253389000002	18458777				2021-06-18	
J	Sullivan, PG; Krishnamurthy, S; Patel, SP; Pandya, JD; Rabchevsky, AG				Sullivan, Patrick G.; Krishnamurthy, Sairam; Patel, Samir P.; Pandya, Jignesh D.; Rabchevsky, Alexander G.			Temporal characterization of mitochondrial bioenergetics after spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						free radicals; lipid peroxidation; mitochondrial dysfunction; neuronal injury; oxidative stress; reactive oxygen species	AMYOTROPHIC-LATERAL-SCLEROSIS; LIPID-PEROXIDATION PRODUCT; EXCITOTOXIC NEURONAL DEATH; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CELL-DEATH; PERMEABILITY TRANSITION; OXIDATIVE STRESS; FREE-RADICALS; THERAPEUTIC INTERVENTIONS	Mitochondrial dysfunction following spinal cord injury (SCI) may be critical for the development of secondary pathophysiology and neuronal cell death. Previous studies have demonstrated a loss of mitochondrial bioenergetics at 24 h following SCI. To begin to understand the evolution and study the contribution of mitochondrial dysfunction in pathophysiology of SCI, we investigated mitochondrial bioenergetics in the mid-thoracic region at 6, 12, and 24 h following contusion SCI. It is widely accepted that increased free radical generation plays a critical role in neuronal damage after SCI. Hence, to ascertain the role of free radicals in SCI-induced mitochondrial dysfunction, markers for oxidative damage, including nitrotyrosine (3-NT), lipid peroxidation byproduct (4-hydroxynonenal [HNE]), and protein oxidation (protein carbonyls) were quantified in the same samples of isolated mitochondria during the 24-h time course. The results demonstrate that a significant decline in mitochondrial function begins to occur 12 h post-injury and persists for a least 24 h following SCI. Furthermore, there was a progressive increase in mitochondrial oxidative damage that preceded the loss of mitochondrial bioenergetics, suggesting that free radical damage may be a major mitochondrial secondary injury process. Based on the present results, the temporal profile of mitochondrial dysfunction indicates that interventions targeting mitochondrial oxidative damage and dysfunction may serve as a beneficial pharmacological treatment for acute SCI.	Spinal Cord& Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA	Rabchevsky, AG (corresponding author), Spinal Cord& Brain Injury Res Ctr, Biomed & Biolog Sci Res Bldg 741 S Limestone St, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 048191] Funding Source: Medline		ANDERSON DK, 1982, J NEUROSURG, V56, P106, DOI 10.3171/jns.1982.56.1.0106; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Azbill RD, 2000, BRAIN RES, V871, P175, DOI 10.1016/S0006-8993(00)02430-6; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bracken MB, 2001, SPINE, V26, pS47, DOI 10.1097/00007632-200112151-00010; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; BRAUGHLER JM, 1983, J NEUROSURG, V59, P256, DOI 10.3171/jns.1983.59.2.0256; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; CHANCE B, 1979, PHYSIOL REV, V59, P527; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Finkel E, 2001, SCIENCE, V292, P624, DOI 10.1126/science.292.5517.624; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; Hunot S, 2001, SCIENCE, V292, P865, DOI 10.1126/science.1060885; ITO T, 1978, J NEUROSURG, V48, P434, DOI 10.3171/jns.1978.48.3.0434; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Kalayci M, 2005, NEUROCHEM RES, V30, P403, DOI 10.1007/s11064-005-2615-2; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; Kristal BS, 1997, J NEUROCHEM, V69, P524; Lai J C, 1979, Methods Enzymol, V55, P51; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Lopez-Vales R, 2005, J NEUROSCI RES, V81, P827, DOI 10.1002/jnr.20605; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; MATTSON MP, 1990, INT J DEV NEUROSCI, V8, P399, DOI 10.1016/0736-5748(90)90073-B; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; MATTSON MP, 1995, NEUROBIOL AGING, V16, P679, DOI 10.1016/0197-4580(95)00063-K; MATTSON MP, 1993, J NEUROSCI, V13, P4575; Mattson MP, 1998, INT REV NEUROBIOL, V42, P103, DOI 10.1016/S0074-7742(08)60609-1; Mu XJ, 2000, BRAIN RES, V870, P66, DOI 10.1016/S0006-8993(00)02402-1; Mu XJ, 2002, J NEUROTRAUM, V19, P917, DOI 10.1089/089771502320317078; Mu XJ, 2000, J NEUROTRAUM, V17, P773, DOI 10.1089/neu.2000.17.773; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Rabchevsky AG, 2001, ARCH NEUROL-CHICAGO, V58, P721, DOI 10.1001/archneur.58.5.721; Rosen CJ, 1999, J CLIN DENSITOM, V2, P3, DOI 10.1385/JCD:2:1:3; SANDERS DC, 1977, SURG FORUM, V28, P446; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SIESJO BK, 1989, ANN NY ACAD SCI, V568, P234; SIESJO BK, 1991, LIFE SCI R, V51, P35; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Smith RG, 1998, ANN NEUROL, V44, P696, DOI 10.1002/ana.410440419; Springer JE, 1997, J NEUROCHEM, V68, P2469; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; Young W, 1985, Cent Nerv Syst Trauma, V2, P109; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1	57	109	113	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					991	999		10.1089/neu.2006.0242			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700007	17600515				2021-06-18	
J	Ayalon, L; Borodkin, K; Dishon, L; Kanety, H; Dagan, Y				Ayalon, L.; Borodkin, K.; Dishon, L.; Kanety, H.; Dagan, Y.			Circadian rhythm sleep disorders following mild traumatic brain injury	NEUROLOGY			English	Article							PHASE SYNDROME; WAKE SYNDROME; MELATONIN; PAIN; INSOMNIA; HUMANS; ONSET	Objective: To describe the physiologic and behavioral characteristics of circadian rhythm sleep disorders (CRSDs) following minor traumatic brain injury (mTBI) in patients complaining of insomnia. Methods: Forty two patients with insomnia complaints following mTBI were screened. Those suspected of having CRSD underwent actigraphy, saliva melatonin and oral temperature measurement, and polysomnography. All patients also filled out a self- reported questionnaire to determine their circadian preference. Results: Fifteen of the 42 patients (36%) with complaints of insomnia following mTBI were diagnosed with CRSD. Eight patients displayed a delayed sleep phase syndrome (DSPS), whereas seven displayed an irregular sleep-wake pattern (ISWP). Whereas all patients with DSPS exhibited a 24- hour periodicity of oral temperature rhythm, three of seven patients with ISWP lacked such a daily rhythm. In addition, ISWP patients exhibited smaller amplitude of oral temperature rhythm vs the DSPS group. Subjective Morningness-Eveningness Questionnaire scores were in accordance with the clinical diagnosis of DSPS or ISWP based on actigraphy. Conclusions: Minor traumatic brain injury might contribute to the emergence of circadian rhythm sleep disorders. Two types of these disorders were observed: delayed sleep phase syndrome and irregular sleep-wake pattern. The types differed in the subjective questionnaire scores and had distinct profiles of melatonin and temperature circadian rhythms.	Univ Calif San Diego, Dept Psychiat, San Diego, CA 92161 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; Tel Aviv Univ, Sackler Fac Med, Dept Behav Sci, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sheba Med Ctr, Inst Endocrinol, IL-69978 Tel Aviv, Israel	Ayalon, L (corresponding author), Univ Calif San Diego, Dept Psychiat, 3350 La Jolla Village Dr,115B, San Diego, CA 92161 USA.	layalon@ucsd.edu	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Borodkin, Katy/0000-0001-5960-6865			American Academy of Sleep, 2005, INT CLASS SLEEP DIS; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; Dagan Y, 1999, CHRONOBIOL INT, V16, P213, DOI 10.3109/07420529909019087; Dagan Y, 1998, J PSYCHOSOM RES, V45, P15, DOI 10.1016/S0022-3999(97)00299-7; Dagan Y, 1996, J PSYCHOSOM RES, V41, P357, DOI 10.1016/S0022-3999(96)00165-1; Dagan Y, 1998, CHRONOBIOL INT, V15, P181, DOI 10.3109/07420529808998682; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; HORNE J A, 1976, International Journal of Chronobiology, V4, P97; Kamei Y, 2000, PSYCHIAT CLIN NEUROS, V54, P381, DOI 10.1046/j.1440-1819.2000.00724.x; MINORS DS, 1989, BIOL RHYTHMS CLIN PR, P272; Nagtegaal JE, 1997, FUNCT NEUROL, V12, P345; Nagtegaal JE, 1998, J SLEEP RES, V7, P135, DOI 10.1046/j.1365-2869.1998.00102.x; Nagtegaal JE, 2000, J PSYCHOSOM RES, V48, P45, DOI 10.1016/S0022-3999(99)00075-6; OLDANI A, 1994, J NEUROL NEUROSUR PS, V55, P665; Onen SH, 2005, CLIN J PAIN, V21, P422, DOI 10.1097/01.ajp.0000129757.31856.f7; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; RECHTSCHAFFEN A, 1968, PHS PUBLICATION, V204; ROBERTSTHOMSON IC, 1988, AUST NZ J MED, V18, P569, DOI 10.1111/j.1445-5994.1988.tb00126.x; Shibui K, 1999, J BIOL RHYTHM, V14, P72, DOI 10.1177/074873099129000371; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Tuunainen A, 2001, CHRONOBIOL INT, V18, P957, DOI 10.1081/CBI-100107971; Uchiyama M, 2000, NEUROSCI LETT, V294, P101, DOI 10.1016/S0304-3940(00)01551-2; Voultsios A, 1997, J BIOL RHYTHM, V12, P457, DOI 10.1177/074873049701200507; WEITZMAN ED, 1981, ARCH GEN PSYCHIAT, V38, P737	28	109	114	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	APR 3	2007	68	14					1136	1140		10.1212/01.wnl.0000258672.52836.30			5	Clinical Neurology	Neurosciences & Neurology	152ZY	WOS:000245402400014	17404196				2021-06-18	
J	Vespa, PM; O'Phelan, K; McArthur, D; Miller, C; Eliseo, M; Hirt, D; Glenn, T; Hovda, DA				Vespa, Paul M.; O'Phelan, Kristine; McArthur, David; Miller, Chad; Eliseo, Matthew; Hirt, Daniel; Glenn, Thomas; Hovda, David A.			Pericontusional brain tissue exhibits persistent elevation of lactate/pyruvate ratio independent of cerebral perfusion pressure	CRITICAL CARE MEDICINE			English	Article						brain injury; microdialysis; cerebral perfusion pressure; coma; lactate/pyruvate ratio; intracranial pressure	INTRACEREBRAL MICRODIALYSIS; INJURY; GLUCOSE; LACTATE; ISCHEMIA; INCREASE	Objective. To determine whether pericontusional tissue exhibits neurochemical responsiveness to changes in cerebral perfusion pressure as measured by microdialysis lactate/pyruvate ratio. Design: Prospective monitoring with retrospective data analysis. Setting, Single-center academic neurologic intensive care unit. Patients: Twenty-one patients with severe traumatic brain injury (Glasgow Coma Scale score 3-8). Interventions, None. Measurements and Main Results., Cerebral microdialysis was performed for the initial 7 days after traumatic brain injury. Thirteen patients had microdialysis probes in normal tissue and eight had two probes, one of which was located in pericontusional tissue. Retrospective analysis was performed to determine if microdialysis levels in pericontusional tissue demonstrates higher levels of lactate/pyruvate ratio than normal tissue and if lactate/ pyruvate ratio increased with reductions in cerebral perfusion pressure. Univariate analysis revealed higher values for glutamate and lactate/pyruvate ratio in pericontusional tissue compared with normal tissue. However, based on the mixed-effects model analysis, the percent time of elevated lactate/pyruvate ratio was significantly higher in pericontusional tissue (40 +/- 59% vs. 17 +/- 37%, p <.05), and the mean lactate/pyruvate ratio values showed only a trend relationship (62 +/- 134 vs. 34 +/- 78, p <.06). When examined by cerebral perfusion pressure threshold, cerebral perfusion pressure < 60 mm Hg was not associated with higher lactate/pyruvate ratio values in normal or pericontusional tissue. In addition, no single cerebral perfusion pressure threshold was associated with a significant reduction in lactate/pyruvate ratio in either pericontusional or normal tissue (p <.08). Conclusions. Sustained increases in lactate/pyruvate ratio occurred more frequently in pericontusional tissue compared with normal brain tissue. The lactate/pyruvate ratio was not related to cerebral perfusion pressure, nor was the percent time-burden of elevated lactate/pyruvate ratio related to any particular sustained cerebral perfusion pressure threshold. Lactate/pyruvate ratio values appear to be elevated despite cerebral perfusion pressure values customarily considered to be adequate.	Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Hawaii, Honolulu, HI 96822 USA	Vespa, PM (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA.	PVespa@mednet.ucla.edu		Glenn, Thomas/0000-0003-4273-3408			Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; Alessandri B, 1999, ACT NEUR S, V75, P25; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Faraway J.J., 2006, MIXED EFFECTS NONPAR; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Pinheiro J., 2000, MIXED EFFECTS MODELS; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42	23	109	111	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2007	35	4					1153	1160		10.1097/01.CCM.0000259466.66310.4F			8	Critical Care Medicine	General & Internal Medicine	151PJ	WOS:000245302400021	17334254				2021-06-18	
J	Babikian, T; Freier, MC; Tong, KA; Nickerson, JP; Wall, CJ; Holshouser, BA; Burley, T; Riggs, ML; Ashwal, S				Babikian, T; Freier, MC; Tong, KA; Nickerson, JP; Wall, CJ; Holshouser, BA; Burley, T; Riggs, ML; Ashwal, S			Susceptibility weighted imaging: Neuropsychologic outcome and pediatric head injury	PEDIATRIC NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; EXECUTIVE FUNCTION; FOCAL LESIONS; CHILDREN; ADOLESCENTS; SEVERITY; COHORT; MRI; COMPONENTS	Traumatic brain injury is among the most frequent pediatric neurologic disorders in the United States, affecting multiple aspects of neuropsychologic functioning. This study assessed the efficacy of susceptibility weighted imaging as a predictor of long-term neuropsychologic functioning after pediatric brain injury compared with magnetic resonance spectroscopic imaging. Susceptibility weighted imaging is a relatively new method that is considered superior to traditional magnetic resonance imaging sequences for detecting hemorrhagic diffuse axonal injury. In this study, imaging and spectroscopy were acquired 6 +/- 4 days after injury. Measures of neuropsychologic functioning were administered to 18 children and adolescents 1-4 years post injury. Negative correlations between lesion number and volume with neuropsychologic functioning were demonstrated. Lesion volume explained over 32% of the variance in cognitive performance, explaining at least an additional 20% beyond injury severity and age at injury alone and 19% beyond magnetic resonance spectroscopic metabolite variables. Exploratory analyses resulted in notable trends, with lesions in deeper brain regions more strongly associated with poorer neuropsychologic performance. Improved detection of the extent of diffuse axonal injury following a brain injury will allow for a better understanding of its association with long-term outcome, which in turn can improve prognostic efficacy for effective treatment planning. (c) 2005 by Elsevier Inc. All rights reserved.	Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; Loma Linda Univ, Dept Psychol, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Pediat, Loma Linda, CA 92350 USA; Childrens Hosp, Loma Linda, CA USA; Loma Linda Univ, Dept Radiol, Med Ctr, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Loma Linda, CA 92350 USA; Univ Saskatchewan, Royal Univ Hosp, Dept Med Imaging, Saskatoon, SK, Canada; Portland State Univ, Dept Psychol, Portland, OR 97207 USA; Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA	Babikian, T (corresponding author), Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat & Biobehav Sci, Room C8-746,760 Westwood Plaza, Los Angeles, CA 90024 USA.						Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; FRANZEN MD, 1998, SCREENING CHILDREN B; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GILLES EE, 1999, PEDIAT NEUROLOGY PRI, P898; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Goethals I, 2004, J NEUROTRAUM, V21, P1059, DOI 10.1089/0897715041651051; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; ROSMAN NP, 1999, PEDIAT NEUROLOGY PRI; Signoretti S, 2002, ACT NEUR S, V81, P373; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Verger K, 2001, BRAIN INJURY, V15, P211; Vriezen ER, 2000, BRAIN COGNITION, V44, P67; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; WILSON J T L, 1990, Brain Injury, V4, P349	39	109	123	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	SEP	2005	33	3					184	194		10.1016/j.pediatrneurol.2005.03.015			11	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	967TN	WOS:000232114200006	16139733				2021-06-18	
J	Tavazzi, B; Signoretti, S; Lazzarino, G; Delfini, R; Cimatti, M; Marmarou, A; Vagnozzi, R				Tavazzi, B; Signoretti, S; Lazzarino, G; Delfini, R; Cimatti, M; Marmarou, A; Vagnozzi, R			Cerebral oxidative stress and depression of energy metabolism correlate with severity of diffuse brain injury in rats	NEUROSURGERY			English	Article						energy metabolism; N-acetylaspartate; nicotinic coenzymes; oxidative stress; secondary insult; traumatic brain injury	POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE; LIQUID-CHROMATOGRAPHIC METHOD; ACETYL-L-ASPARTATE; N-ACETYLASPARTATE; LIPID-PEROXIDATION; SECONDARY INSULTS; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; VERTEBRATE BRAIN; CORTICAL IMPACT	OBJECTIVE: The combined effect of traumatic brain injury (TBI) and secondary insult on biochemical changes of cerebral tissue is not well known. For this purpose, we studied the time-course changes of parameters reflecting ROS-mediated oxidative stress and modifications of cell energy metabolism determined in rats subjected to cerebral insult of increasing severity. METHODS: Rats were divided into four groups: 1) sham-operated, 2) subjected to 10 minutes of hypoxia and hypotension (HH), 3) subjected to severe diffuse TBI, and 4) subjected to severe diffuse TBI + HH. Rats were killed at different times after injury, and analyses of malonclialclehyde, ascorbate, high-energy phosphates, nicotinic co-enzymes, oxypurines, nucleosides, and 4-acetylaspartate (NAA) were made by high-performance liquid chromatography on whole-brain tissue extracts. RESULTS: Data indicated a close relationship between degree of oxidative stress and severity of brain insult, as evidenced by the highest malondialdehyde values and lowest ascorbate levels in rats subjected to TBI + HH. Similarly, modifications of parameters related to cell energy metabolism were modulated by increasing severity of brain injury, as demonstrated by the lowest values of energy charge potential, nicotinic coenzymes, and NAA and the highest levels of oxypurines and nucleosides recorded in TBI + HH rats. Both the intensity of oxidative stress-mediated cerebral damage and perturbation of energy metabolism were minimally affected in rats subjected to HH only. CONCLUSION: These results showed that the severity of brain insult can be graded by measuring biochemical modifications, specifically, reactive oxygen species-mediated damage, energy metabolism depression, and NAA, thereby validating the rodent model of closed-head diffuse TBI coupled with HH and proposing NAA as a marker with diagnostic relevance to monitor the metabolic state of post-injured brain.	Univ Catania, Dept Chem Sci, Biochem Lab, I-95125 Catania, Italy; Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; Virginia Commonwealth Univ, Div Neurosurg, Med Coll Virginia, Richmond, VA USA; Univ Roma La Sapienza, Dept Neurol Sci Neurosurg, Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, Brain Trauma Res Ctr, Rome, Italy	Lazzarino, G (corresponding author), Univ Catania, Dept Chem Sci, Biochem Lab, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@mbox.unict.it	TAVAZZI, BARBARA/AAB-9830-2019; Signoretti, stefano/AAL-5631-2020; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Signoretti, stefano/0000-0002-8086-1622; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, R01NS019235] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01-NS-19235, P50-NS-12587] Funding Source: Medline		Ang BT, 2003, J NEUROSURG, V99, P125, DOI 10.3171/jns.2003.99.1.0125; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Baslow MH, 2000, J NEUROCHEM, V75, P453, DOI 10.1046/j.1471-4159.2000.0750453.x; Baslow MH, 2002, NEUROCHEM INT, V40, P295, DOI 10.1016/S0197-0186(01)00095-X; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Davie CA, 1997, J NEUROL NEUROSUR PS, V63, P736, DOI 10.1136/jnnp.63.6.736; DIGIACOMO JE, 1992, BIOL NEONATE, V61, P25, DOI 10.1159/000243527; DIPIERRO D, 1995, ANAL BIOCHEM, V231, P407, DOI 10.1006/abio.1995.0071; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; EBISU T, 1994, J CEREBR BLOOD F MET, V14, P373, DOI 10.1038/jcbfm.1994.48; Fatouros PP, 2000, ACT NEUR S, V76, P35; Harms L, 1997, J NEUROL NEUROSUR PS, V62, P27, DOI 10.1136/jnnp.62.1.27; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; KEHRER JP, 1994, FREE RADICAL BIO MED, V17, P65, DOI 10.1016/0891-5849(94)90008-6; KIRSCH I, 1992, CONT HYPNOSIS, V9, P1; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; LAUTIER D, 1994, BBA-MOL CELL RES, V1221, P215, DOI 10.1016/0167-4889(94)90243-7; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; Nanavaty UB, 2002, EXP LUNG RES, V28, P591, DOI 10.1080/01902140260426715; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; Sager TN, 1999, J CEREBR BLOOD F MET, V19, P164; Sawauchi S, 2002, ACT NEUR S, V81, P241; Shadid M, 1998, PEDIATR RES, V44, P119, DOI 10.1203/00006450-199807000-00019; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Slatter DA, 1999, J BIOL CHEM, V274, P19661, DOI 10.1074/jbc.274.28.19661; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Srinivasan KN, 1998, CLIN CHIM ACTA, V275, P197, DOI 10.1016/S0009-8981(98)00071-0; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Tavazzi B, 1998, FREE RADICAL RES, V28, P25, DOI 10.3109/10715769809097873; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; Tavazzi B, 2000, FREE RADICAL RES, V33, P1, DOI 10.1080/10715760000300561; Vagnozzi R, 1997, EXP BRAIN RES, V117, P411, DOI 10.1007/s002210050235; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhou F, 2001, J CLIN NEUROSCI, V8, P561, DOI 10.1054/jocn.2001.0980	50	109	110	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2005	56	3					582	588		10.1227/01.NEU.0000156715.04900.E6			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	905IP	WOS:000227562100047	15730584				2021-06-18	
J	Wehman, P; Targett, P; West, M; Kregel, J				Wehman, P; Targett, P; West, M; Kregel, J			Productive work and employment for persons with traumatic brain injury - What have we learned after 20 years?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						employment; return to work; supported employment; traumatic brain injury	SUPPORTED EMPLOYMENT; FOLLOW-UP; VOCATIONAL-REHABILITATION; PROGRAM-DEVELOPMENT; ACUTE PREDICTORS; RETURN; PLACEMENT; MODEL; AWARENESS; OUTCOMES	This article describes return to work outcomes for individuals with traumatic brain injury (TBI) through a selective review of the published literature and an examination of TBI labor force participation from the Rehabilitation Services Administration 911 and the Social Security Administration Benefits Planning, Assistance and Outreach databases. Implications and recommendations to further our understanding about the different parts of the work outcome profile of individuals with TBI are offered.	Virginia Commonwealth Univ, Rehabil Res & Training Ctr Workplace Supports, Richmond, VA 23284 USA	Wehman, P (corresponding author), Virginia Commonwealth Univ, Rehabil Res & Training Ctr Workplace Supports, 1314 W Main St, Richmond, VA 23284 USA.	pwehman@vcu.edu					Ben-Yishay Y., 1989, NEUROPSYCHOLOGICAL T, P271; BISSONETTE D, 1994, TRADITION JOB DEV; Bond GR, 2004, PSYCHIATR REHABIL J, V27, P345, DOI 10.2975/27.2004.345.359; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drake RE, 1999, PSYCHIAT QUART, V70, P289, DOI 10.1023/A:1022086131916; EZARACHI O, 1991, J HEAD TRAUMA REHAB, V6, P71; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; Fraser RT, 2000, TRAUMATIC BRAIN INJU; FRASER RT, 2001, BRAIN INJ SOURCS FEB, P222; GARDNER M, 2004, PERSENTATION STATE P; GILSON B, 2004, INCLUSIVE EMPLOYMENT; Griffin C, 2003, MAKING SELF EMPLOYME; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Johnstone B, 2003, NEUROREHABILITATION, V18, P197; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kowalske K, 2000, J HEAD TRAUMA REHAB, V15, P989, DOI 10.1097/00001199-200008000-00003; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LONDONER P, IN PRESS INCLUSIVE E; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Partridge T M, 1996, Work, V7, P63, DOI 10.3233/WOR-1996-7108; Pettifer S., 1993, J OCCUP SCI, V1, P20, DOI 10.1080/14427591.1993.9686380.; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; THORNTON C, 2004, EVALUATION TICKET WO; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Wehman P, 1999, EDUC TRAIN MENT RET, V34, P3; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; WEHMAN P, 1988, REHABIL COUNS BULL, V31, P298; WEHMAN P, 1994, AM J PHYS MED REHAB, V73, P280, DOI 10.1097/00002060-199407000-00010; WEHMAN P, IN PRESS INCLUSIVE E; Wehman P., 2001, SUPPORTED EMPLOYMENT; WEHMAN P, 2000, MENTAL RETARDATION 2; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; West M, 2002, MENT RETARD, V40, P142, DOI 10.1352/0047-6765(2002)040<0142:MHWASE>2.0.CO;2; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Zafonte RD, 1996, NEUROREHABILITATION, V6, P19, DOI 10.3233/NRE-1996-6104	52	109	110	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2005	20	2					115	127		10.1097/00001199-200503000-00001			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	910VV	WOS:000227961200001	15803036				2021-06-18	
J	Dockree, PM; Kelly, SP; Roche, RAP; Hogan, MJ; Reilly, RB; Robertson, IH				Dockree, PM; Kelly, SP; Roche, RAP; Hogan, MJ; Reilly, RB; Robertson, IH			Behavioural and physiological impairments of sustained attention after traumatic brain injury	COGNITIVE BRAIN RESEARCH			English	Article						alpha power; no-go task; desynchronization; frontal lobes	CLOSED-HEAD-INJURY; EEG ALPHA; OSCILLATIONS; SYNCHRONIZATION; PERFORMANCE; FAILURES; DEFICITS; AROUSAL; MEMORY; DAMAGE	Sustaining attention under conditions of low external demand taxes our ability to stay on task and to avoid more appealing trains of thought or environmental distractions. By contrast, a stimulating, novel environment engages attention far more freely without the subjective feeling of having to override monotony. Our ability to maintain a goal-directed focus without support from the environment requires the endogenous control of behaviour. This control can be modulated by fronto-parietal circuits and this ability is compromised following traumatic brain injury (TBI) leading to increased lapses of attention. In this paper, we further explore a laboratory paradigm that we argue is particularly sensitive to sustained attention as opposed to other aspects of attentional control involving the selection and management of goals in working memory. The paradigm (fixed sequence Sustained Attention to Response Task-SART(fixed)) involves withholding a key press to an infrequent no-go target embedded within a predictable sequence of numbers. We demonstrate that TBI patients in this study make disproportionately more errors than controls on this task. An analysis of response times (RTs) and EEG alpha power across the task demonstrates group differences preceding the critical no-go trial. Controls demonstrate a lengthening of RTs accompanied by desynchronization of power within the alpha band (similar to 10 Hz) preceding the no-go trial. Conversely, the TBI group showed a shortening of RTs during this period with no evidence of alpha desynchronization. These findings suggest that TBI patients may have dysfunctional alpha generators as a consequence of their injury that impairs endogenous control during the task. (C) 2004 Elsevier B.V. All rights reserved.	Trinity Coll Dublin, Dept Psychol, Dublin, Ireland; Trinity Coll Dublin, Trinity Coll Inst Neurosci, Dublin, Ireland; Univ Coll Dublin, Dept Elect & Elect Engn, Dublin 4, Ireland; Natl Univ Ireland, Dept Psychol, Galway, Ireland	Dockree, PM (corresponding author), Trinity Coll Dublin, Dept Psychol, Aras Phiarsaigh,D2, Dublin, Ireland.	dockreep@tcd.ie	Reilly, Richard/N-1080-2019; Roche, Richard AP/C-4798-2009; Reilly, Richard B/F-7034-2011	Reilly, Richard/0000-0001-8578-1245; Roche, Richard AP/0000-0001-6606-4187; Reilly, Richard B/0000-0001-8578-1245; Kelly, Simon/0000-0003-4981-3099; Kelly, Simon/0000-0001-9983-3595; Robertson, Ian H/0000-0001-8637-561X			AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Basar E, 1997, INT J PSYCHOPHYSIOL, V26, P5, DOI 10.1016/S0167-8760(97)00753-8; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Burgess PW, 2003, NEUROPSYCHOLOGIA, V41, P906, DOI 10.1016/S0028-3932(02)00327-5; DASILVA FHL, 1980, ELECTROEN CLIN NEURO, V50, P449, DOI 10.1016/0013-4694(80)90011-5; FASSBENDER C, IN PRESS COGNITIVE B; Foxe JJ, 1998, NEUROREPORT, V9, P3929, DOI 10.1097/00001756-199812010-00030; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Klimesch W, 1998, EVOKED POTENTIAL, V108, P123, DOI 10.1016/S0168-5597(97)00078-6; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Laufs H, 2003, P NATL ACAD SCI USA, V100, P11053, DOI 10.1073/pnas.1831638100; Laufs H, 2003, NEUROIMAGE, V19, P1463, DOI 10.1016/S1053-8119(03)00286-6; LEVIN HS, 1989, COMPREHENSIVE NEUROL, V2, P53; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lindgren KA, 1999, BIOL PSYCHIAT, V45, P943, DOI 10.1016/S0006-3223(98)00350-3; MACKWORTH JF, 1968, PSYCHOL REV, V75, P308, DOI 10.1037/h0025896; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PFURTSCHELLER G, 1992, ELECTROEN CLIN NEURO, V83, P62, DOI 10.1016/0013-4694(92)90133-3; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Portas CM, 1998, J NEUROSCI, V18, P8979; Posner MI, 2000, PSYCHOL BULL, V126, P873, DOI 10.1037/0033-2909.126.6.873; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RICHARDSON JTE, 2000, CLIN NEUROPSYCHOLOGI; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shaw JC, 1996, INT J PSYCHOPHYSIOL, V24, P7, DOI 10.1016/S0167-8760(96)00052-9; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	37	109	109	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0926-6410			COGNITIVE BRAIN RES	Cognit. Brain Res.	AUG	2004	20	3					403	414		10.1016/j.cogbrainres.2004.03.019			12	Computer Science, Artificial Intelligence; Neurosciences; Neuroimaging	Computer Science; Neurosciences & Neurology	850YP	WOS:000223650600007	15268918				2021-06-18	
J	Stiefel, MF; Heuer, GG; Smith, MJ; Bloom, S; Maloney-Wilensky, E; Gracias, VH; Grady, MS; LeRoux, PD				Stiefel, MF; Heuer, GG; Smith, MJ; Bloom, S; Maloney-Wilensky, E; Gracias, VH; Grady, MS; LeRoux, PD			Cerebral oxygenation following decompressive hemicraniectomy for the treatment of refractory intracranial hypertension	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; cerebral oxygenation; hemicraniectomy; decompression surgery	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; COMATOSE PATIENTS; TISSUE OXYGEN; SUBARACHNOID HEMORRHAGE; SUBSTRATE DELIVERY; PERFUSION-PRESSURE; CARBON-DIOXIDE; CRANIECTOMY	Object. Medically intractable intracranial hypertension is a major cause of morbidity and mortality after severe brain injury. One potential treatment for intracranial hypertension is decompressive hemicraniectomy (DCH). Whether and when to use DCH, however, remain unclear. The authors therefore studied the effects of DCH on cerebral 0, to develop a better understanding of the effects of this treatment on the recovery from injury and disease. Methods. The study focused on seven patients (mean age 30.6 +/- 9.7 years) admitted to the hospital after traumatic brain injury (five patients) or subarachnoid hemorrhage (two patients) as part of a prospective observational database at a Level I trauma center. At admission the Glasgow Coma Scale (GCS) score was 6 or less in all patients. Patients received continuous monitoring of intracranial pressure (ICP), cerebral perfusion pressure (CPP), blood pressure, and arterial 0, saturation. Cerebral oxygenation was measured using the commercially available Licox Brain Tissue Oxygen Monitoring System manufactured by Integra NeuroSciences. A DCH was performed when the patient's ICP remained elevated despite maximal medical management. Conclusions. All patients tolerated DCH without complications. Before the operation, the mean ICP was elevated in all patients (26 +/- 4 rum Hg), despite maximal medical management. After surgery, there was an immediate and sustained decrease in ICP (19 +/- 11 turn Hg) and an increase in CPP (81 +/- 17 mm Hg). Following DCH, cerebral oxygenation improved from a mean of 21.2 +/- 13.8 turn Hg to 45.5 +/- 25.4 rum Hg, a 114.8% increase. The change in brain tissue 0, and the change in ICP after DCH demonstrated only a modest relationship (r(2) = 0.3). These results indicate that the use of DCH in the treatment of severe brain injury is associated with a significant improvement in brain O-2.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19107 USA; Univ Penn, Div Trauma Surg & Crit Care, Sch Med, Philadelphia, PA 19107 USA	LeRoux, PD (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 330 S 9th St, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1995, GUIDELINES MANAGEMEN; BURNETT M, 2004, MANAGEMENT CEREBRAL, P127; Chesnut RM, 1997, CRIT CARE MED, V25, P1275, DOI 10.1097/00003246-199708000-00011; CHESTNUT RM, 2000, HEAD INJURY, P229; Clay H D, 2000, J Neurosci Nurs, V32, P194; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Filippi R, 2000, NEUROSURG REV, V23, P94; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McKhann GM, 2004, MANAGEMENT CEREBRAL, P431; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Procaccio F, 2000, J Neurosurg Sci, V44, P11; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RIEKE K, 1993, CEREBROVASC DIS, V3, P45, DOI 10.1159/000108670; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schwab S, 1997, NEUROLOGY, V48, P1608, DOI 10.1212/WNL.48.6.1608; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; TEASDALE G, 1974, LANCET, V2, P81; UMEZAWA H, 1990, ACT NEUR S, V51, P351; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Yundt KD, 1998, J CEREBR BLOOD F MET, V18, P419, DOI 10.1097/00004647-199804000-00010; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	72	109	117	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2004	101	2					241	247		10.3171/jns.2004.101.2.0241			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	842JQ	WOS:000223000600011	15309914				2021-06-18	
J	Zhao, XR; Ahram, A; Berman, RF; Muizelaar, JP; Lyeth, BG				Zhao, XR; Ahram, A; Berman, RF; Muizelaar, JP; Lyeth, BG			Early loss of astrocytes after experimental traumatic brain injury	GLIA			English	Article						fluid percussion; traumatic brain injury; immunohistochemistry; glial fibrillary acidic protein; hippocampus	FIBRILLARY ACIDIC PROTEIN; EXTRACELLULAR ION SHIFTS; FLUID-PERCUSSION MODEL; EXCITATORY AMINO-ACIDS; SYNAPTIC TRANSMISSION; ARBITRARY PARTICLES; TRANSIENT HYPOXIA; NEURONAL INJURY; RAT ASTROCYTES; GLIAL-CELLS	Neuronal-glial interactions are important for normal brain function and contribute to the maintenance of the brain's extracellular environment. Damage to glial cells following traumatic brain injury (TBI) could therefore be an important contributing factor to brain dysfunction and neuronal injury. We examined the early fate of astrocytes and neurons after TBI in rats. A total of 27 rats were euthanized at 0.5, 1, 2, 4, or 24 h after moderate lateral fluid percussion TBI or after sham TBI. Ipsilateral and contralateral hippocampi were examined in coronal sections from -2.12 to -4.80 mm relative to bregma. Adjacent sections were processed with markers for either astrocytes or degenerating neurons. Astrocytes were visualized using glial fibrillary acidic protein (GFAP) or glutamine I synthetase immunohistochemistry. Neuronal degeneration was visualized using Fluoro-Jade (FJ) histofluorescence. At 30 min, there was a significant loss of GFAP immunoreactivity in ipsilateral hippocampal CA3 with some loss of normal astrocyte morphology in the remaining cells. The number of normal staining astrocytes decreased progressively over time with extensive astrocyte loss at 24 h. At 4 h, lightly stained FJ-positive neurons were scattered in the ipsilateral CA3. The intensity and number of FJ-positive neurons progressively increased over time with moderate numbers of degenerating neurons in the ipsilateral hippocampal CA3 evident at 24 h. We conclude that astrocyte loss occurs in the hippocampus early after TBI. The data suggest that loss of supporting glial cell may contribute to subsequent neuronal degeneration. (C) 2003 Wiley-Liss, Inc.	Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, Davis, CA 95616 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045136] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45136] Funding Source: Medline		AMADUCCI L, 1981, NEUROSCI LETT, V21, P27, DOI 10.1016/0304-3940(81)90052-5; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Baldwin SA, 1996, GLIA, V16, P266; Bignami A, 1991, DISCUSSIONS NEUROSCI, V8, P1; Bondarenko A, 2001, GLIA, V34, P134, DOI 10.1002/glia.1048; Bondarenko A, 2001, GLIA, V34, P143, DOI 10.1002/glia.1049; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Castejon OJ, 1998, BRAIN INJURY, V12, P409, DOI 10.1080/026990598122539; CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fitch MT, 1999, J NEUROSCI, V19, P8182; GLAUM SR, 1990, P NATL ACAD SCI USA, V87, P3454, DOI 10.1073/pnas.87.9.3454; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOLZWARTH JA, 1994, J NEUROSCI, V14, P1879; JENKINS LW, 1982, RECENT PROGR STUDY T, P523; Jiang ZW, 2000, BRAIN RES, V852, P37, DOI 10.1016/S0006-8993(99)02230-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLEHER JA, 1993, STROKE, V24, P855, DOI 10.1161/01.STR.24.6.855; KIM WT, 1994, GLIA, V11, P173, DOI 10.1002/glia.440110211; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KIMELBERG HK, 1992, ASTROCYTES PHARM FUN; KONDOU H, 1994, NEUROSCI LETT, V180, P131, DOI 10.1016/0304-3940(94)90504-5; Labourdette G., 1995, P441; Largo C, 1996, NEUROL RES, V18, P445; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MULLER HW, 1995, PHARMACOL THERAPEUT, V65, P1, DOI 10.1016/0163-7258(94)00047-7; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; OLNEY JW, 1970, NATURE, V227, P609, DOI 10.1038/227609b0; Parri HR, 2001, NAT NEUROSCI, V4, P803, DOI 10.1038/90507; PEAKMAN MC, 1995, BRIT J PHARMACOL, V115, P801, DOI 10.1111/j.1476-5381.1995.tb15004.x; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; RANSOM BR, 1992, J CLIN NEUROPHYSIOL, V9, P224, DOI 10.1097/00004691-199204010-00005; Reier PJ, 1983, SPINAL CORD RECONSTR, P163; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SHAO Y, 1995, CELL CALCIUM, V17, P187, DOI 10.1016/0143-4160(95)90033-0; SOCHOCKA E, 1994, BRAIN RES, V638, P21, DOI 10.1016/0006-8993(94)90628-9; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; SWANSON LW, 1998, BRAIN MAPS STRUCTURE; Swanson RA, 1997, GLIA, V21, P142, DOI 10.1002/(SICI)1098-1136(199709)21:1<142::AID-GLIA16>3.0.CO;2-S; TIFFANYCASTIGLI.E, 1986, ASTROCYTES CELL BIOL, P401; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Verkhratsky A, 1998, PHYSIOL REV, V78, P99; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; Vesce S, 1999, CELL MOL LIFE SCI, V56, P991, DOI 10.1007/s000180050488; Vesce S, 2001, NEWS PHYSIOL SCI, V16, P178; Vesce Sabino, 1999, Science Progress, V82, P251; VIBULSRETH S, 1987, BRAIN RES, V422, P303, DOI 10.1016/0006-8993(87)90937-1; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; YU ACH, 1989, J CEREBR BLOOD F MET, V9, P20, DOI 10.1038/jcbfm.1989.3	68	109	113	2	9	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	NOV	2003	44	2					140	152		10.1002/glia.10283			13	Neurosciences	Neurosciences & Neurology	733BQ	WOS:000185980400006	14515330				2021-06-18	
J	Magnoni, S; Ghisoni, L; Locatelli, M; Caimi, M; Colombo, A; Valeriani, V; Stocchetti, N				Magnoni, S; Ghisoni, L; Locatelli, M; Caimi, M; Colombo, A; Valeriani, V; Stocchetti, N			Lack of improvement in cerebral metabolism after hyperoxia in severe head injury: a microdialysis study	JOURNAL OF NEUROSURGERY			English	Article						brain metabolism; head injury; hyperoxia; lactate; microdialysis	BRAIN INJURY; BLOOD-FLOW; INTRACEREBRAL MICRODIALYSIS; PHYSIOLOGICAL STIMULATION; INTRACRANIAL-PRESSURE; CEREBROSPINAL-FLUID; ARTERIAL HYPEROXIA; ENERGY-METABOLISM; LACTIC-ACIDOSIS; OXYGEN	Object. The authors investigated the effects of hyperoxia on brain tissue PO2 and on glucose metabolism in cerebral and adipose tissue after traumatic brain injury (TBI). Methods. After 3 hours of ventilation with pure O-2, 18 tests were performed on different days in eight comatose patients with TBI. Lactate, pyruvate, glucose, glutamate, and brain tissue PO2 were measured in the cerebral extracellular fluid (ECF) by using microdialysis. Analytes were also measured in the ECF of abdominal adipose tissue. After 3 hours of increase in the fraction of inspired O-2, brain tissue PO2 rose from the baseline value of 32.7 +/- 18 to 122.6 +/- 45.2 mm Hg (p < 0.0001), whereas brain lactate dropped from its baseline (3.21 +/- 2.77 mmol/L), reaching its lowest value (2.90 +/- 2.58 mmol/L) after 3 hours of hyperoxia (p < 0.01). Pyruvate dropped as well, from 153 +/- 56 to 141 +/- 56 mumol/L (p < 0.05), so the lactate/pyruvate ratio did not change. No significant changes were observed in glucose and glutamate. The arteriovenous difference in O-2 content dropped, although not significantly, from a baseline of 4.52 +/- 1.22 to 4.15 +/- 0.76 ml/100 ml. The mean concentration of lactate in adipose tissue fell significantly as well (p < 0.01), but the lactate/pyruvate ratio did not change. Conclusions. Hyperoxia slightly reduced lactate levels in brain tissue after TBI. The estimated redox status of the cells, however, did not change and cerebral O-2 extraction seemed to be reduced. These data indicate that oxidation of glucose was not improved by hyperoxia in cerebral and adipose tissue, and might even be impaired.	Univ Milan, Dept Anesthesia, I-20122 Milan, Italy; Univ Milan, Dept Intens Care, I-20122 Milan, Italy; Osped Maggiore, Div Neurosurg, IRCCS, Milan, Italy	Stocchetti, N (corresponding author), Osped Policlin IRCCS, Terapia Intens Neurosci, Via F Sforza 35,Padiglione Beretta Neuro, I-20122 Milan, Italy.		Stocchetti, Nino/O-7444-2017	Stocchetti, Nino/0000-0003-3250-6834; locatelli, marco/0000-0003-0778-3653			ALBERTI KGM, 1974, LANCET, V2, P1519; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BISSONNETTE B, 1991, CAN J ANAESTH, V38, P654, DOI 10.1007/BF03008204; Boveris A, 2000, ANN NY ACAD SCI, V899, P121; Cady L D Jr, 1973, Crit Care Med, V1, P75, DOI 10.1097/00003246-197303000-00003; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DICKENS F, 1946, BIOCHEM J, V40, P145, DOI 10.1042/bj0400145; Edwards J. D., 1993, OXYGEN TRANSPORT PRI; FELLOWS LK, 1993, J NEUROCHEM, V60, P1258, DOI 10.1111/j.1471-4159.1993.tb03285.x; Gnaiger E, 1995, J BIOENERG BIOMEMBR, V27, P583, DOI 10.1007/BF02111656; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HOLBACH KH, 1977, J NEUROL, V217, P17, DOI 10.1007/BF00316313; HOWSE DC, 1975, J NEUROCHEM, V24, P935, DOI 10.1111/j.1471-4159.1975.tb03658.x; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; JACKSON RM, 1990, CLIN CHEST MED, V11, P73; JACOBSON I, 1964, SURG GYNECOL OBSTET, V119, P737; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471; Love S, 1999, BRAIN PATHOL, V9, P119; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Moberg E, 1997, DIABETOLOGIA, V40, P1320, DOI 10.1007/s001250050827; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PERETZ DI, 1965, ANN NY ACAD SCI, V119, P1133, DOI 10.1111/j.1749-6632.1965.tb47467.x; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Ronning OM, 1999, STROKE, V30, P2033, DOI 10.1161/01.STR.30.10.2033; Rosdahl H, 1998, AM J PHYSIOL-ENDOC M, V274, pE936; Rossi S, 2001, J NEUROTRAUM, V18, P163, DOI 10.1089/08977150150502596; Siesj_o B K, 1978, BRAIN ENERGY METABOL; Singhal AB, 2002, J CEREBR BLOOD F MET, V22, P861, DOI 10.1097/00004647-200207000-00011; Sjoberg F, 1999, ACTA PHYSIOL SCAND, V165, P33; STOGNER SW, 1992, ANN PHARMACOTHER, V26, P1554, DOI 10.1177/106002809202601214; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WEIL MH, 1970, CIRCULATION, V41, P989, DOI 10.1161/01.CIR.41.6.989; WILLIAMS CD, 1970, J NEUROCHEM, V17, P709, DOI 10.1111/j.1471-4159.1970.tb03341.x; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; ZUPPING R, 1970, J NEUROSURG, V33, P498, DOI 10.3171/jns.1970.33.5.0498	47	109	111	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2003	98	5					952	958		10.3171/jns.2003.98.5.0952			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	674CJ	WOS:000182619000009	12744353				2021-06-18	
J	Erlanger, D; Saliba, E; Barth, J; Almquist, J; Webright, W; Freeman, J				Erlanger, D; Saliba, E; Barth, J; Almquist, J; Webright, W; Freeman, J			Monitoring resolution of postconcussion symptoms in athletes: Preliminary results of a web-based neuropsychological test protocol	JOURNAL OF ATHLETIC TRAINING			English	Article						brain injury; return-to-play guidelines; computerized testing; Internet testing	TEST-PERFORMANCE; HEAD-INJURY; SPORTS; CONCUSSION	Objective: A new Web-based neuropsychological test was field tested to determine usefulness in detecting and monitoring resolution of symptoms after sport-related concussions and in providing objective information for return-to-play decisions. Design and Setting: We obtained neuropsychological baseline data on all subjects, After concussion, subjects; were administered alternate, equivalent follow-up tests until symptoms resolved. Follow-up testing typically occurred at 1- to 2-day intervals after the concussion. Subjects: Baseline testing was obtained for 834 athletes as part of ongoing field trials. Subsequently, 26 athletes sustained concussions and were studied. Measurements: We administered The Concussion Resolution Index (CRI) at baseline and alternate forms posttrauma. Follow-up tests included a self-report inventory of neurophysiologic symptoms. Results: A total of 88% of patients were identified as symptomatic on initial postconcussion testing. The CRI appeared relatively resistant to retest effects, and multiple administrations tracked resolution of symptoms over short and extended time periods. Conclusions: Although the CRI is still in field trials, preliminary data indicate that the CRI may be a useful method for athletic trainers and other professionals to expeditiously track resolution of symptoms after sport-related concussion.	HeadMinder Inc, New York, NY 10038 USA; Columbia Univ, New York, NY USA; Univ Virginia, Charlottesville, VA USA; Fairfax Cty Sch, Vienna, VA USA	Erlanger, D (corresponding author), HeadMinder Inc, 15 Maiden Lane,Suite 205, New York, NY 10038 USA.	david@headminder.com					Barth JT., 1989, MILD HEAD INJURY, P257; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1991, ADOLESCENT MED STATE, P17; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Echemendia R. J., 1999, 107 ANN M AM PSYCH A; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger DM, 2000, ARCH CLIN NEUROPSYCH, V15, P675; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Erlanger DM, 1999, CONCUSSION RESOLUTIO; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; KUTNER KC, 1998, NATL ACAD NEUROPSYCH, V14, P19; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Spreen O., 1998, COMPENDIUM NEUROPSYC; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	22	109	110	0	4	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					280	287					8	Sport Sciences	Sport Sciences	557NC	WOS:000175913800011					2021-06-18	
J	Popovich, PG; Hickey, WE				Popovich, PG; Hickey, WE			Bone marrow chimeric rats reveal the unique distribution of resident and recruited macrophages in the contused rat spinal cord	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						macrophage; microglia; neuroinflammation; secondary injury; spinal cord injury; wound repair	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HEMATOGENOUS MACROPHAGES; INFLAMMATORY RESPONSE; MICROGLIAL CELLS; MESSENGER-RNA; INJURY; BRAIN; EXPRESSION; PHAGOCYTES; CYTOKINE	Brain and spinal cord inflammation that develops after traumatic injury is believed to differentially influence the structural and/or physiological integrity of surviving neurons and glia. It is possible that the functional dichotomy of CNS inflammation results from the activity of a heterogeneous macrophage population elicited by trauma. Indeed. unique functions have been attributed to macrophages derived from resident microglia versus those originating from infiltrating monocytes. Thus, whether progressive tissue injury or repair is favored could be explained by the disproportionate contributions of one macrophage subset relative to the other. Descriptive neuroanatomical studies are a reasonable first approach to revealing a relationship between microglia, recruited blood monocytes/macrophages, and regions of tissue degeneration and/or repair. Unfortunately, it is not possible to differentiate between CNS macrophage subsets using conventional immunohistochemical approaches. In the present study, we have used radiation bone marrow chimeric rats to definitively characterize the macrophage reaction elicited by experimental spinal contusion injury. In chimeric animals, antibodies raised against unique cell surface molecules expressed on bone marrow-derived cells (BMCs) were used to distinguish infiltrating BMCs from resident microglial-derived macrophages. Our findings indicate that the onset and plateau of macrophage activation (previously shown to be 3 and 7 days postinjury, respectively) is dominated initially by microglial-derived macrophages and then is supplanted by hematogenous cells. While resident macrophages are ubiquitously distributed throughout the injury site, leukocyte-derived monocytes exclusively infiltrate the gray matter and ro a lesser extent subpial white matter. Generally, monocyte foci in white matter remain associated with the lumen or abluminal surface of blood vessels. i.e. few cells actually infiltrate the parenchyma. If functional differences exist between CNS macrophage subsets, differences in the time-dependent accumulation and distribution of these cell types could differentially influence the survival of surrounding neurons and glia.	Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Dartmouth Med Sch, DHMC, Pathol Dept WFH, Lebanon, NH USA	Popovich, PG (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, 2078 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.		Popovich, Phillip/C-9187-2009	Popovich, Phillip/0000-0003-1329-7395	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37846] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037846] Funding Source: NIH RePORTER		Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Bauer J, 1995, GLIA, V15, P437, DOI 10.1002/glia.440150407; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LASSMANN H, 1993, CLIN NEUROPATHOL, V12, P284; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Li H, 1996, NEUROPATH APPL NEURO, V22, P207; McTigue DM, 1998, J NEUROSCI, V18, P5354; POPOVICH PG, 1993, J NEUROTRAUM, V10, P37, DOI 10.1089/neu.1993.10.37; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 1997, J NEUROPATH EXP NEUR, V56, P1323, DOI 10.1097/00005072-199712000-00007; RINNER WA, 1995, GLIA, V14, P257, DOI 10.1002/glia.440140403; Schroeter M, 1997, STROKE, V28, P382, DOI 10.1161/01.STR.28.2.382; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355	25	109	110	0	3	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2001	60	7					676	685		10.1093/jnen/60.7.676			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	450PB	WOS:000169751400003	11444796	Bronze			2021-06-18	
J	Downard, C; Hulka, F; Mullins, RJ; Piatt, J; Chesnut, R; Quint, P; Mann, NC				Downard, C; Hulka, F; Mullins, RJ; Piatt, J; Chesnut, R; Quint, P; Mann, NC			Relationship of cerebral perfusion pressure and survival in pediatric brain-injured patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	59th Annual Meeting of the American-Association-of-Trauma	SEP 16-18, 1999	BOSTON, MA	Amer Assoc Trauma			SEVERE HEAD-INJURY; BLOOD-FLOW; MANAGEMENT; HYPOTENSION; METABOLISM; CHILDREN; RESISTANCE	Background: Adult brain injury studies recommend maintaining cerebral perfusion pressure (CPP) above 70 mm Hg, We evaluated CPP and outcome in brain-injured children. Methods: We retrospectively reviewed the hospital courses of children at two Level I trauma centers who required insertion of intracranial pressure (ICP) monitors for management of traumatic brain injury. ICP, CPP, and mean arterial pressure were evaluated hourly, and means were calculated for the first 48 hours after injury. Results: Of 188 brain-injured children, 118 had ICP monitors placed within 24 hours of injury. They suffered severe brain injury, with average admitting Glasgow Coma Scale scores of 6 +/- 3, Overall mortality rate was 28%, No patient with mean CPP less than 40 mm Hg survived. among patients with mean CPP in deciles of 40 to 49, 50 to 59, 60 to 69, or 70 mm Bg, no significant difference in Glasgow Outcome Scale distribution existed. Conclusion: Low mean CPP was lethal. In children with survivable brain injury (mean CPP > 40 mm Hg), CPP did not stratify patients for risk of adverse outcome.	Oregon Hlth & Sci Univ, Div Gen Surg, Dept Surg, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; Emanuel Hosp & Hlth Ctr, Dept Pediat, Portland, OR USA	Mullins, RJ (corresponding author), Oregon Hlth & Sci Univ, Div Gen Surg, Dept Surg, L223A,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Chesnut, Randall/0000-0001-6377-3666; Piatt, Joseph/0000-0002-9332-8376			*AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP S, P181; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1987, PEDIATRICS, V79, P501; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER B, 1993, J PEDIATR-US, V123, P871, DOI 10.1016/S0022-3476(05)80382-8; Rosner Michael J., 1993, P57; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533	21	109	114	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2000	49	4					654	658		10.1097/00005373-200010000-00012			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	362VF	WOS:000089798400016	11038082				2021-06-18	
J	Douglas, JM; O'Flaherty, CA; Snow, PC				Douglas, JM; O'Flaherty, CA; Snow, PC			Measuring perception of communicative ability: the development and evaluation of the La Trobe communication questionnaire	APHASIOLOGY			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD-INJURY; SPEECH STYLE; DEFICITS; ADULTS; RELATIVES; GENDER; ISSUES	The La Trobe communication questionnaire (LCQ) was designed to measure perceived communicative ability. It was developed to enable collection of information from various sources including the self-perceptions of individuals as well as the perceptions of close others. In this paper we report the development of the questionnaire, its psychometric properties and normative data for the perceptions of young adults and the comparative perceptions of their close others. Participants in the study were 256 adults comprising 147 primary subjects and 109 close others. Primary subjects ranged in age from 16-39 years with a mean age of 20.6 years. The 30 item questionnaire was structured using a modified Likert-type scale with four possible levels of response: (1) never or rarely; (2) sometimes; (3) often; and (4) usually or always. Internal consistency was high (Cronbach's alpha = 0.8596) and good stability over time for self-report was demonstrated (r = 0.7558). There was a significant difference (p < 0.0001) between the perceptions of primary subjects and close others with primary subjects perceiving themselves to have more frequent communication difficulties, than did their close others. Overall, our findings suggest that the LCQ is a promising means of measuring perceived communicative ability in young adults.	La Trobe Univ, Sch Human Commun Sci, Melbourne, Vic, Australia	Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Melbourne, Vic, Australia.		Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624; Snow, Pamela/0000-0002-2426-8349			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anastasi, 1982, PSYCHOL TESTING; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Chelune GJ, 1986, ADV CLIN NEUROPSYCHO, P95, DOI DOI 10.1007/978-1-4613-2211-5_; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COMREY AL, 1992, FIRST COURSE FACTOR; CRAWFORD M, 1987, J PSYCHOLINGUIST RES, V16, P83; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Damico JS, 1985, COMMUNICATION SKILLS, P165; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; DILLER L, 1981, J CONSULT CLIN PSYCH, V49, P822, DOI 10.1037/0022-006X.49.6.822; DOUGLAS J, 1994, THESIS U VICTORIA BR; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Enderby P, 1997, THERAPY OUTCOME MEAS; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FURROW D, 1990, J PSYCHOLINGUIST RES, V19, P375, DOI 10.1007/BF01068885; GILLIES S, 1990, UNPUB PERCEPTIONS CO; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GOLDSTEIN G, 1995, INT J REHABILITATION, V1, P23; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; MARTIN CL, 1990, CHILD DEV, V61, P1891, DOI 10.2307/1130845; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; RUBIN DL, 1983, LANG SPEECH, V26, P273, DOI 10.1177/002383098302600308; Selltiz C., 1976, RES METHODS SOCIAL R; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; SNOW P, 1999, 22 ANN BRAIN IMP C S; Spender D., 1981, MAN MADE LANGUAGE; STRAHAN R, 1972, J CLIN PSYCHOL, V28, P191, DOI 10.1002/1097-4679(197204)28:2<191::AID-JCLP2270280220>3.0.CO;2-G; Tabachnick BG, 2013, USING MULTIVARIATE S; TANNER DC, 1988, APHASIOLOGY, V2, P79; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002	43	109	111	0	16	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology	MAR	2000	14	3					251	268		10.1080/026870300401469			18	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	294DV	WOS:000085896800002					2021-06-18	
J	Tate, R; Hodgkinson, A; Veerabangsa, A; Maggiotto, S				Tate, R; Hodgkinson, A; Veerabangsa, A; Maggiotto, S			Measuring psychosocial recovery after traumatic brain injury: Psychometric properties of a new scale	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							COMMUNITY INTEGRATION QUESTIONNAIRE; BLUNT HEAD-INJURY; RATING-SCALE; DISABILITY; RELATIVES; OUTCOMES	Objectives: To determine the psychometric properties of the Sydney Psychosocial Reintegration Scale (SPRS), an instrument developed to quantify disability and handicap in persons with traumatic brain injury (TBI). Design: Descriptive correlational study. Setting: Brain Injury Rehabilitation Unit and Brain Injury Outpatient Clinic. Participants: Two samples, a "subacute" group (n = 20) and a "long-term" group (n = 40), were studied to examine responsiveness (subacute group), reliability, and validity (long-term group) of the SPRS. Main Outcome Measure: The SPRS is a 12-item questionnaire measuring three domains of everyday Living commonly disrupted after severe TBI: occupational activities, interpersonal relationships, and independent living skills. Procedure: Patients in the subacute group were rated with the SPRS by a clinician at admission to the rehabilitation unit and again three months later or at discharge from the unit (whichever occurred first). For individuals from the long-term group attending the outpatient clinic, a close relative was interviewed with the SPRS and other validating measures. The SPRS was readministered one month later Results: Internal consistency of the SPRS was high (alpha coefficient = .90), as was agreement between raters and stability over a one-month period (r(i) = .95 and .90, respectively). Reliability and stability coefficients for the three domains of the scale were also high, ranging from .86 to .94 for reliability and .77 to .93 for stability Preliminary evidence for construct validity was established with a number of standard instruments, with evidence of both convergent and discriminant construct validity from the Sickness Impact Profile (SIP). The SPRS was sensitive to group differences on the Glasgow Outcome Scale (GOS) and to changes occurring during the period of active recovery Conclusions: The results suggest that the SPRS has sound psychometric properties, being a reliable, stable, sensitive, and valid instrument. It is potentially useful in both clinical and research settings.	Univ Sydney, Royal Rehabil Ctr, Dept Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Liverpool Hosp, Brain Injury Rehabil Unit, Liverpool, NSW, Australia; Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia	Tate, R (corresponding author), Univ Sydney, Royal Rehabil Ctr, Dept Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.						BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BROE GA, 1982, BRAIN IMPAIRMENT; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BRUININKS RH, 1985, DEV STANDARDIZATIION; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DODWELL D, 1988, J NEUROL NEUROSUR PS, V51, P833, DOI 10.1136/jnnp.51.6.833; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; Hobart JC, 1996, J NEUROL NEUROSUR PS, V60, P127, DOI 10.1136/jnnp.60.2.127; Howell D. C., 1997, STAT METHODS PSYCHOL; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Livingston M G, 1985, Int Rehabil Med, V7, P145; McDowell I., 1987, MEASURING HLTH GUIDE; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; MURPHY KR, 1994, PSYCHOL TESTING PRIN; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Smith H.E., 1992, CLIN REHABIL, V6, P31; TABACHNIK BG, 1996, USING MULTIVARIATE; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; *WHO, 1997, ICIDH 2 INT CLASS IM; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA	33	109	110	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1999	14	6					543	557		10.1097/00001199-199912000-00003			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	269AV	WOS:000084454300002	10671700				2021-06-18	
J	Oyesiku, NM; Evans, CO; Houston, S; Darrell, RS; Smith, JS; Fulop, ZL; Dixon, CE; Stein, DG				Oyesiku, NM; Evans, CO; Houston, S; Darrell, RS; Smith, JS; Fulop, ZL; Dixon, CE; Stein, DG			Regional changes in the expression of neurotrophic factors and their receptors following acute traumatic brain injury in the adult rat brain	BRAIN RESEARCH			English	Article						neurotrophic factor; receptor; mRNA expression; traumatic brain injury	NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; CORTICAL IMPACT INJURY; DIFFERENTIAL REGULATION; HYPOGLYCEMIC DAMAGE; NEURONAL DEATH; CNTF RECEPTOR; TRKB; BDNF; NGF	We have analyzed the effect of severe traumatic brain injury (TBI) on the levels of mRNA expression of neurotrophic factors (NTFs): brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF) and their respective receptors: trkB, trkA and CNTFR alpha. The expression was examined in the region of the lesion as well as a region remote from the lesion at 12, 24, and 36 h following the injury. Our data suggest that after the brain injury, the expression of NGF and BDNF mRNAs were early, transiently and significantly upregulated while that of CNTF was a slow and less amplified response in both areas of the brain. We also found that trkA mRNA expression was only upregulated significantly in the remote area; trkB mRNA showed no significant change in either area except an upregulation at 12 h in the remote area. CNTFR alpha was downregulated significantly by 24-36 h in the lesion area and by 24 h in the remote area. These changes suggest that TBI regulates the expression of NTFs and their receptors. These alterations in expression may be involved in modulating the neuronal response after brain injury. (C) 1999 Elsevier Science B.V. All rights reserved.	Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Psychol, Atlanta, GA 30322 USA; Wagner Coll, Dept Biol, Staten Isl, NY 10301 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA	Oyesiku, NM (corresponding author), Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.		Stein, Donald/AAJ-5139-2020	Smith, Jeffrey/0000-0001-5499-4475	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR49/CCR412307] Funding Source: Medline		ASADA H, 1995, J NEUROSCI RES, V40, P22, DOI 10.1002/jnr.490400104; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES AM, 1988, TRENDS NEUROSCI, V11, P243, DOI 10.1016/0166-2236(88)90099-9; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; FINGER S, 1982, BRAIN DAMAGE RECOVER, P153; Finklestein S P, 1990, Restor Neurol Neurosci, V1, P387, DOI 10.3233/RNN-1990-1603; GAGE FH, 1986, NEUROSCIENCE, V17, P89, DOI 10.1016/0306-4522(86)90227-7; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HEFTI F, 1989, NEUROBIOL AGING, V10, P515, DOI 10.1016/0197-4580(89)90118-8; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HUTTON LA, 1995, J NEUROSCI RES, V41, P185, DOI 10.1002/jnr.490410206; IKEDA K, 1995, ANN NEUROL, V37, P505, DOI 10.1002/ana.410370413; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KELLY ME, 1994, BRAIN RES, V634, P245, DOI 10.1016/0006-8993(94)91927-5; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOKAIA Z, 1994, NEUROREPORT, V5, P1241, DOI 10.1097/00001756-199406020-00021; KORSCHING S, 1993, J NEUROSCI, V13, P2739; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Lamballe F, 1991, Princess Takamatsu Symp, V22, P153; Lee MY, 1997, J NEUROSCI, V17, P1137; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; MAIESE K, 1993, J CEREB BLOOD FLOW S, V13, pS43; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MOORE DS, 1993, INTRO PRACTICE STAT; NANES MS, 1991, ENDOCRINOLOGY, V128, P2577, DOI 10.1210/endo-128-5-2577; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; Oyesiku NM, 1997, J CLIN ENDOCR METAB, V82, P4184, DOI 10.1210/jc.82.12.4184; Oyesiku NM, 1996, J COMP NEUROL, V364, P68, DOI 10.1002/(SICI)1096-9861(19960101)364:1<68::AID-CNE6>3.0.CO;2-Q; POVLISHOCK J, 1985, NIH NINCDS CENTRAL N, P443; REGLI L, 1993, J CEREB BLOOD FLOW M, V13, P566; SAKAGUCHI J, 1993, J CEREB BLOOD FLOW S, V13, pS49; SIESJO BK, 1993, PROG BRAIN RES, V96, P1; Taga T, 1992, Nihon Rinsho, V50, P1802; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WANG AM, 1990, P NATL ACAD SCI USA, V87, P2865; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; Wong JYF, 1997, EXP NEUROL, V148, P83, DOI 10.1006/exnr.1997.6670; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415	52	109	122	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 3	1999	833	2					161	172		10.1016/S0006-8993(99)01501-2			12	Neurosciences	Neurosciences & Neurology	214HN	WOS:000081322700004	10375691				2021-06-18	
J	Saatman, KE; Graham, DI; McIntosh, TK				Saatman, KE; Graham, DI; McIntosh, TK			The neuronal cytoskeleton is at risk after mild and moderate brain injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; calpain; cytoskeleton; microtubule-associated protein-2; neurofilament; proteolysis; traumatic brain injury	DIFFUSE AXONAL INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; AMYLOID PRECURSOR PROTEIN; CORTICAL IMPACT INJURY; MINOR HEAD-INJURY; INTERMEDIATE FILAMENTS; NEUROFILAMENT SUBUNITS; LEVELS DECREASE; RAT; HUMANS	Recent studies have described alterations in cytoskeletal proteins such as microtubule-associated protein 2 (MAP-2) and neurofilament (NF) resulting from moderate and severe experimental brain injury; however, few have investigated the consequences of mild injury, which is associated clinically and experimentally with cognitive dysfunction and neuronal damage, To contrast cytoskeletal changes within 7 days following mild injury with those following moderate injury, we subjected anesthetized, adult rats to mild (1.1-1.3 atm) or moderate (2.3-2.5 atm) lateral fluid percussion brain injury or sham injury, Rats were sacrificed at 6 h (n = 4 mild; n = 4 moderate; n = 2 sham), 24 h (n = 4 mild; n = 4 moderate; n = 1 sham), or 7 days (n = 5 mild; n = 4 moderate; rt = 1 sham) following injury, and immunohistochemistry was performed for MAP-2 and NF, Both mild and moderate injury produced notable cytoskeletal changes in multiple brain regions; however, mild injury generally resulted in a lesser degree of MAP-2 and NF loss over a smaller spatial extent, When compared to moderately injured animals, animals subjected to mild injury showed substantially delayed MAP-2 and NF alterations within the cortex and hippocampal dentate gyrus and no evidence of MAP-2 loss in the hippocampal CA3 region, While mild and moderate injury resulted for the most part in similar patterns of axonal injury, tissue tears in the fimbria and loss of NF immunoreactivity in regions containing injured axons were only observed following moderate injury. Elucidating the effects of modulating injury severity may yield insight into the mechanisms involved in traumatic damage to the cytoskeleton and guide future treatment strategies.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Glasgow, So Gen Hosp, Dept Neuropathol, Inst Neurol Sci, Glasgow, Lanark, Scotland	Saatman, KE (corresponding author), Univ Penn, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDMAN R, 1985, ANN NY ACAD SCI, V455, P1, DOI 10.1111/j.1749-6632.1985.tb50400.x; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1989, MILD MODERATE HEAD I, P63; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; Kraus Jess F., 1994, P3; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RICH KM, 1992, J NEUROTRAUM, V9, pS61; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SCHLAEPFER WW, 1990, INTRACELLULAR CALCIU, P241; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; STRICH SJ, 1961, LANCET, V2, P443; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	67	109	111	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1998	15	12					1047	1058		10.1089/neu.1998.15.1047			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	148FW	WOS:000077495200005	9872461				2021-06-18	
J	Raghupathi, R; Fernandez, SC; Murai, H; Trusko, SP; Scott, RW; Nishioka, WK; McIntosh, TK				Raghupathi, R; Fernandez, SC; Murai, H; Trusko, SP; Scott, RW; Nishioka, WK; McIntosh, TK			BCL-2 overexpression attenuates cortical cell loss after traumatic brain injury in transgenic mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; cell death; BCL-2; transgenic mice; neuroprotection; behavior	HUMAN HEAD-INJURY; SYNAPSIN-I GENE; SYMPATHETIC NEURONS; MEMORY DEFICITS; IMPACT INJURY; DEATH; RAT; EXPRESSION; APOPTOSIS; DAMAGE	The proto-oncogene, BCL-2, has been suggested to participate in cell survival during development of, and after injury to, the CNS. Transgenic (TG) mice overexpressing human Bcl-2 (n = 21) and their wild-type (WT) littermates (n = 18) were subjected to lateral controlled cortical impact brain injury. Lateral controlled cortical impact brain injury resulted in the formation of a contusion in the injured cortex at 2 days, which developed into a well-defined cavity by 7 days in both WT and TG mice. At 7 days after injury, brain-injured TG mice had a significantly reduced cortical lesion (volume = 1.99 mm(3)) compared with that of the injured WT mice (volume = 5.1 mm(3), P < 0.01). In contrast, overexpression of BCL-2 did not affect the extent of hippocampal cell death after lateral controlled cortical impact brain injury. Analysis of motor function revealed that both brain-injured WT and TG mice exhibited significant right-sided deficits at 2 and 7 days after injury (P < 0.05 compared with the uninjured controls). Although composite neuroscores (sum of scores from forelimb and hind limb flexion, lateral pulsion, and inclined plane tests) were not different between WT and TG brain-injured mice, TC mice had a slightly but significantly reduced deficit in the inclined plane test (P < 0.05 compared to the WT mice). These data suggest that the cell death regulatory gene, BCL-2, may play a protective role in the pathophysiology of traumatic brain injury.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Cephalon Inc, W Chester, PA USA; VICAL, La Jolla, CA USA	Raghupathi, R (corresponding author), Univ Penn, Dept Neurosurg, 102B Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER		ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ALLSOPP TE, 1995, EUR J NEUROSCI, V7, P1266, DOI 10.1111/j.1460-9568.1995.tb01116.x; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; DeBilbao F, 1996, NEUROSCIENCE, V71, P1111, DOI 10.1016/0306-4522(95)00505-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Franklin K.P.G., 1996, MOUSE BRAIN STEREOTA; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; GROSCHE J, 1995, NEUROSCI LETT, V185, P119, DOI 10.1016/0304-3940(94)11239-F; GRUBBS FE, 1972, TECHNOMETRICS, V14, P847, DOI 10.2307/1267134; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOESCHE C, 1993, J BIOL CHEM, V268, P26494; HOGAN B, 1982, MANIPULATING MOUSE E; HOWLAND DS, 1995, NEUROBIOL AGING, V16, P685, DOI 10.1016/0197-4580(95)00078-S; HOWLAND DS, 1991, MOL BRAIN RES, V11, P345, DOI 10.1016/0169-328X(91)90044-X; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jia WWG, 1996, MOL BRAIN RES, V42, P350, DOI 10.1016/S0169-328X(96)00223-9; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Lawrence MS, 1996, J NEUROSCI, V16, P486; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; RAGHUPATHI R, 1995, J NEUROTRAUM, V12, P966; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RINK A, 1995, AM J PATHOL, V147, P1575; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; STRAUSS KI, 1996, J NEUROTRAUM, V13, P620; Su JH, 1996, NEUROREPORT, V7, P437, DOI 10.1097/00001756-199601310-00015; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Troost D, 1995, NEUROPATH APPL NEURO, V21, P498, DOI 10.1111/j.1365-2990.1995.tb01096.x; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Young W, 1992, J NEUROTRAUMA S1, V9, P9; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	64	109	115	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	1998	18	11					1259	1269		10.1097/00004647-199811000-00013			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	134VP	WOS:000076764600013	9809516	Bronze			2021-06-18	
J	Christiansen, C; Abreu, B; Ottenbacher, K; Huffman, K; Masel, B; Culpepper, R				Christiansen, C; Abreu, B; Ottenbacher, K; Huffman, K; Masel, B; Culpepper, R			Task performance in virtual environments used for cognitive rehabilitation after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Annual Conference of the American-Occupational-Therapy-Association	APR 13, 1997	ORLANDO, FL	Amer Occupat Therapy Assoc			REALITY	Objective: This report describes a reliability study using a prototype computer-simulated virtual environment to assess basic daily living skills in a sample of persons with traumatic brain injury (TBI). The benefits of using virtual reality in training for situations where safety is a factor have been established in defense and industry, but have not been demonstrated in rehabilitation. Subjects: Thirty subjects with TBI receiving comprehensive rehabilitation services at a residential facility. Methods: An immersive virtual kitchen was developed in which a meal preparation task involving multiple steps could be performed. The prototype was tested using subjects who completed the task twice within 7 days. Results: The stability of performance was estimated using intraclass correlation coefficients (ICCs). The ICC value for total performance based on all steps involved in the meal preparation task was .73, When three items with low variance were removed the ICC improved to .81. Little evidence of vestibular optical side-effects was noted in the subjects tested. Conclusion: Adequate initial reliability exists to continue development of the environment as an assessment and training prototype for persons with brain injury. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Texas, Med Branch, Sch Allied Hlth Sci, Off Dean, Galveston, TX 77555 USA; Transit Learning Community, Houston, TX USA; LinCom Corp, Houston, TX USA	Christiansen, C (corresponding author), Univ Texas, Med Branch, Sch Allied Hlth Sci, Off Dean, 301 Univ Blvd, Galveston, TX 77555 USA.		, Charles/V-6218-2019	Christiansen, Charles/0000-0003-0542-1042; Ottenbacher, Kenneth/0000-0001-5990-3982			Andreae MH, 1996, BMJ-BRIT MED J, V312, P4, DOI 10.1136/bmj.312.7022.4; BARFIELD W, 1995, VIRTUAL ENV ADV INTE, P503; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bricken M., 1991, Computer Graphics, V25, P178; Brown D., 1995, ABILITY, V15, P24; Byrne C.M., 1996, THESIS U WASHINGTON; Christiansen C, 1996, J MED VIRTUAL REALIT, V1, P6; Delis DC, 1987, CALIFORNIA VERBAL LE; ELLIS SR, 1995, VIRTUAL ENV ADV INTE, P14; HETTINGER LJ, 1992, PRESENCE-TELEOP VIRT, V1, P306; INMAN D, 1994, VIRT REAL PERS DIS C; JENNETT B, 1975, LANCET, V1, P480; LOFTIN RB, 1995, IEEE COMPUT GRAPH, V15, P31, DOI 10.1109/38.403825; Portney LG., 1993, FDN CLIN RES APPL PR, V3rd; PROTHERO JD, 1997, INT WORKSH MOT SICKN; REGAN EC, 1994, AVIAT SPACE ENVIR MD, V65, P527; ROTHBAUM BO, 1995, AM J PSYCHIAT, V152, P626; SATAVA RM, 1992, MINIM INVASIV THER, V1, P357; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; TAUBES G, 1994, SCIENCE, V265, P884, DOI 10.1126/science.8052844; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; WANN JP, 1993, BAILLIERE CLIN NEUR, V2, P15; Wechsler D., 1939, MEASUREMENT ADULT IN; Whyte J, 1993, REHABILITATION MED P, P825; WILKINSON GS, 1984, WIDE RANGE ACHIEVEME; Winn W., 1993, DESIGNING ENV CONSTR, P189, DOI DOI 10.1007/978-3-642-78069-1_10	26	109	115	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1998	79	8					888	892		10.1016/S0003-9993(98)90083-1			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	108MJ	WOS:000075269800002	9710158				2021-06-18	
J	Koizumi, H; Povlishock, JT				Koizumi, H; Povlishock, JT			Posttraumatic hypothermia in the treatment of axonal damage in an animal model of traumatic axonal injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; axonal injury; beta-amyloid precursor protein immunohistochemistry; rat	AMYLOID PRECURSOR PROTEIN; CONTROLLED CORTICAL IMPACT; DIFFUSE BRAIN INJURY; MODERATE HYPOTHERMIA; HEAD-INJURY; THERAPEUTIC HYPOTHERMIA; GLUTAMATE RELEASE; MILD HYPOTHERMIA; RATS; PROTECTION	Object. Many investigators have demonstrated the protective effects of hypothermia following traumatic brain injury (TBI) in both animals and humans. Typically,:his protection has been evaluated in relation to the preservation of neurons and/or the blunting of behavioral abnormalities. However, little consideration has been given to any potential protection afforded in regard to TBI-induced axonal injury, a feature of human TBI. In this study, the authors evaluated the protective effects of hypothermia on axonal injury after TBT in rats. Methods. Male Sprague-Dawley rats weighing 380 to 400 g were subjected to experimental TBI induced by an impact-acceleration device. These rats were subjected to hypothermia either before or after injury, with their temporalis muscle and rectal temperatures maintained at 32 degrees C for 1 hour. After this I-hour period of hypothermia, rewarming to normothermic levels was accomplished over a 90-minute period. Twenty-four hours later, the animals were killed and semiserial sagittal sections of the brain were reacted for visualization of the amyloid precursor protein (APP), a marker of axonal injury. The density of APP-marked damaged axons within the corticospinal tract at the pontomedullary junction was calculated for each animal. In all hypothermic animals, a significant reduction in APP-marked damaged axonal density was found. In animals treated with preinjury, immediate postinjury, and delayed hypothermia, the density of damaged axons was dramatically reduced in comparison with the untreated controls (p < 0.05). Conclusions. The authors infer from these findings that early as well as delayed posttraumatic hypothermia results in substantial protection in TBI, at least in terms of the injured axons.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi, Japan	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, POB 980709, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; KATSURA K, 1992, BRAIN RES, V590, P6, DOI 10.1016/0006-8993(92)91075-P; KOIZUMI H, 1997, JBRAIN RES, V747, P304; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Novack TA, 1996, J CLIN EXP NEUROPSYC, V18, P685, DOI 10.1080/01688639608408292; PADILLA S, 1986, J NEUROCHEM, V46, P1227, DOI 10.1111/j.1471-4159.1986.tb00642.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PATEL PM, 1994, BRAIN RES, V650, P205, DOI 10.1016/0006-8993(94)91783-3; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; SAKAMOTO K, 1995, J NEUROTRAUM, V14, P349; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SIMONS M, 1995, J NEUROSCI RES, V41, P121, DOI 10.1002/jnr.490410114; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stone J., 1997, Society for Neuroscience Abstracts, V23, P2194; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TOMLINSON DR, 1984, MED BIOL, V62, P34; WHITELEY SJ, 1985, DIABETOLOGIA, V28, P847, DOI 10.1007/BF00291076	47	109	111	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	1998	89	2					303	309		10.3171/jns.1998.89.2.0303			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	104CM	WOS:000074994900018	9688127				2021-06-18	
J	Carbonell, WS; Maris, DO; McCall, T; Grady, MS				Carbonell, WS; Maris, DO; McCall, T; Grady, MS			Adaptation of the fluid percussion injury model to the mouse	JOURNAL OF NEUROTRAUMA			English	Article						axonal degeneration; C57B1/6; cell death; gliosis; mice; Morris water maze; traumatic brain injury	TRAUMATIC BRAIN INJURY; MORRIS WATER-MAZE; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; CELL-DEATH; RAT; MICE; PERFORMANCE; HIPPOCAMPUS; EXPRESSION	Fluid percussion injury (FPI) is a well-characterized experimental model of traumatic brain injury (TBI) in the rat. Many pathophysiologic consequences and mechanisms of recovery after TBI rely on neurochemical pathways that can be examined in genetically altered mice. Therefore, FPI applied to mice may be a useful experimental tool to investigate TBI at the molecular level. In the present study, we establish FPI as a viable model of TBI in the mouse by characterizing acute neurological, histopathological, and behavioral changes. Right-sided parasagittal FPI or sham treatment was administered in male C57BL/6 mice. Acute neurological evaluation revealed righting reflexes in the injured animals (p < 0.001). Deficits in spatial learning and memory were observed in the Morris water maze (MWM) 5 and 6 days after injury. A novel MWM data analysis protocol is described. The injured group (n = 18) demonstrated impaired performance in the MWM during acquisition (p < 0.05) and probe trials (p < 0.025) compared to sham animals (n = 16). At 7 days postinjury, glial fibrillary acidic protein immunohistochemistry revealed intense cortical, callosal, and hippocampal gliosis. The modified Gallyas silver degeneration stain consistently labeled cell bodies and terminals throughout the ipsilateral cortex, axons in the gray matter-white matter interface above the corpus callosum and within the corpus callosum bilaterally, and terminals and fibers in the thalamus bilaterally. Additionally, the mouse FPI model described is immediately employable in labs already using the FPI rat model with no modifications to a pre-existing PPI apparatus.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA	Grady, MS (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, 700 9th Ave,Box 359766, Seattle, WA 98104 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33107, NS30305] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030305, R01NS033107] Funding Source: NIH RePORTER		BERNASCONIGUASTALLA S, 1994, HIPPOCAMPUS, V4, P53, DOI 10.1002/hipo.450040107; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; CRAWLEY JN, 1996, TRENDS NEUROSCI, V19, P186; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; DAMBROSIO R, IN PRESS BRAIN RES; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ERREBOE I, 1995, PHARMACOL TOXICOL, V76, P376, DOI 10.1111/j.1600-0773.1995.tb00165.x; FRANCIS DD, 1995, PHYSIOL BEHAV, V58, P57, DOI 10.1016/0031-9384(95)00009-8; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GAVRIELI Y, 1992, JCELL BIOL, V119, P463; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRADY MS, 1996, SOC NEUR ABS, V26, P93; GRANT SG, 1993, SCIENCE, V262, P760; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; INSEL TR, 1993, J NEUROENDOCRINOL, V5, P619, DOI 10.1111/j.1365-2826.1993.tb00531.x; Jursky F, 1996, J NEUROCHEM, V67, P336; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Lathe R, 1996, TRENDS NEUROSCI, V19, P183, DOI 10.1016/S0166-2236(96)20022-0; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; Logue SE, 1997, BEHAV NEUROSCI, V111, P104, DOI 10.1037/0735-7044.111.1.104; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; McNamara RK, 1996, MOL BRAIN RES, V40, P177, DOI 10.1016/0169-328X(96)00048-4; MIZUMORI SJY, 1982, BEHAV NEURAL BIOL, V35, P33, DOI 10.1016/S0163-1047(82)91253-5; Montkowski A, 1997, BRAIN RES, V762, P12, DOI 10.1016/S0006-8993(97)00370-3; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; MORRIS RGM, 1990, COLD SH Q B, V55, P161; Morrison RS, 1996, J NEUROSCI, V16, P1337; NADLER JV, 1983, METHOD ENZYMOL, V103, P393; NITATORI T, 1995, J NEUROSCI, V15, P1001; Owen EH, 1997, NEUROSCIENCE, V80, P1087, DOI 10.1016/S0306-4522(97)00165-6; REEVES TM, 1995, EXP BRAIN RES, V106, P248; REINSTEIN DK, 1983, BRAIN RES, V263, P172, DOI 10.1016/0006-8993(83)91217-9; RINK A, 1995, AM J PATHOL, V147, P1575; ROULLET P, 1995, PHYSIOL BEHAV, V58, P1189, DOI 10.1016/0031-9384(95)02066-7; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHWEGLER H, 1988, BEHAV GENET, V18, P153, DOI 10.1007/BF01067837; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SILVA AJ, 1993, SCIENCE, V262, P760; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SYMONDS H, 1994, COLD SPRING HARB SYM, V59, P247, DOI 10.1101/SQB.1994.059.01.029; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; UPCHURCH M, 1987, PHARMACOL BIOCHEM BE, V27, P143, DOI 10.1016/0091-3057(87)90488-6; UPCHURCH M, 1988, PHARMACOL BIOCHEM BE, V29, P325, DOI 10.1016/0091-3057(88)90164-5; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075	58	109	114	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					217	229		10.1089/neu.1998.15.217			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500006	9528921				2021-06-18	
J	JENNETT, WB; LEWIN, W				JENNETT, WB; LEWIN, W			TRAUMATIC EPILEPSY AFTER CLOSED HEAD INJURIES	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article																ASCROFT PB, 1941, BRIT MED J, V1, P739; FEINBERG P, 1934, EPILEPSIE TRAUMA; GARLAND HG, 1942, P ROY SOC MED, V35, P773; GURDJIAN ES, 1958, HEAD INJURIES; LEWIN W, 1953, BMJ-BRIT MED J, V1, P1239, DOI 10.1136/bmj.1.4822.1239; Penfield W, 1954, EPILEPSY FUNCTIONAL; PENFIELD W, 1945, RES PUBL ASSOC RES N, V24, P620; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; Rowbotham GF, 1942, ACUTE INJURIES HEAD; RUSSELL WR, 1952, J NEUROL NEUROSUR PS, V15, P93, DOI 10.1136/jnnp.15.2.93; RUSSELL WR, 1932, P ROY SOC MED, V25, P751; SYMONDS CP, 1935, LANCET, V2, P1217; Wagstaffe WW, 1928, LANCET, V2, P861; Walton JN, 1956, SUBARACHNOID HAEMORR	14	109	109	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1960	23	4					295	301		10.1136/jnnp.23.4.295			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	XG402	WOS:A1960XG40200004	13789853	Bronze, Green Published			2021-06-18	
J	Bazarian, JJ; Biberthaler, P; Welch, RD; Lewis, LM; Barzo, P; Bogner-Flatz, V; Brolinson, PG; Buki, A; Chen, JY; Christenson, RH; Hack, D; Huff, JS; Johar, S; Jordan, JD; Leidel, BA; Lindner, T; Ludington, E; Okonkwo, DO; Ornato, J; Peacock, WF; Schmidt, K; Tyndall, JA; Vossough, A; Jagoda, AS				Bazarian, Jeffrey J.; Biberthaler, Peter; Welch, Robert D.; Lewis, Lawrence M.; Barzo, Pal; Bogner-Flatz, Viktoria; Brolinson, P. Gunnar; Buki, Andras; Chen, James Y.; Christenson, Robert H.; Hack, Dallas; Huff, J. Stephen; Johar, Sandeep; Jordan, J. Dedrick; Leidel, Bernd A.; Lindner, Tobias; Ludington, Elizabeth; Okonkwo, David O.; Ornato, Joseph; Peacock, W. Frank; Schmidt, Kara; Tyndall, Joseph A.; Vossough, Arastoo; Jagoda, Andy S.			Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study	LANCET NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY FINDINGS; FIBRILLARY ACIDIC PROTEIN; TERMINAL HYDROLASE-L1; EMERGENCY-DEPARTMENTS; MILD; ADULTS; S100B; METAANALYSIS; LESIONS	Background More than 50 million people worldwide sustain a traumatic brain injury (TBI) annually. Detection of intracranial injuries relies on head CT, which is overused and resource intensive. Blood-based brain biomarkers hold the potential to predict absence of intracranial injury and thus reduce unnecessary head CT scanning. We sought to validate a test combining ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), at predetermined cutoff values, to predict traumatic intracranial injuries on head CT scan acutely after TBI. Methods This prospective, multicentre observational trial included adults (>= 18 years) presenting to participating emergency departments with suspected, non-penetrating TBI and a Glasgow Coma Scale score of 9-15. Patients were eligible if they had undergone head CT as part of standard emergency care and blood collection within 12 h of injury. UCH-L1 and GFAP were measured in serum and analysed using prespecified cutoff values of 327 pg/mL and 22 pg/mL, respectively. UCH-L1 and GFAP assay results were combined into a single test result that was compared with head CT results. The primary study outcomes were the sensitivity and the negative predictive value (NPV) of the test result for the detection of traumatic intracranial injury on head CT. Findings Between Dec 6, 2012, and March 20, 2014, 1977 patients were recruited, of whom 1959 had analysable data. 125 (6%) patients had CT-detected intracranial injuries and eight (<1%) had neurosurgically manageable injuries. 1288 (66%) patients had a positive UCH-L1 and GFAP test result and 671 (34%) had a negative test result. For detection of intracranial injury, the test had a sensitivity of 0.976 (95% CI 0.931-0.995) and an NPV of 0.996 (0.987-0.999). In three (<1%) of 1959 patients, the CT scan was positive when the test was negative. Interpretation These results show the high sensitivity and NPV of the UCH-L1 and GFAP test. This supports its potential clinical role for ruling out the need for a CT scan among patients with TBI presenting at emergency departments in whom a head CT is felt to be clinically indicated. Future studies to determine the value added by this biomarker test to head CT clinical decision rules could be warranted. Copyright (C) 2018 Elsevier Ltd. All rights reserved.	[Bazarian, Jeffrey J.] Univ Rochester, Sch Med & Dent, Dept Emergency Med, Rochester, NY USA; [Biberthaler, Peter] Tech Univ Munich, Klinikum Rechts Isar, Munich, Germany; [Welch, Robert D.] Wayne State Univ, Detroit Receiving Hosp, Dept Emergency Med, Detroit, MI USA; [Lewis, Lawrence M.] Washington Univ, Div Emergency Med, St Louis, MO USA; [Barzo, Pal] Univ Szeged, Szeged, Hungary; [Bogner-Flatz, Viktoria] Ludwig Maximilians Univ Munchen, Dept Trauma Surg, Munich, Germany; [Brolinson, P. Gunnar] New River Valley Hosp, Edward Via Coll Osteopath Med, Blacksburg, VA USA; [Buki, Andras] Univ Pecs, MTA PTE Clin Neurosci MR Res Grp, Dept Neurosurg,Janos Szentagothai Res Ctr, Hungarian Brain Res Program,Med Sch, Pecs, Hungary; [Chen, James Y.] Univ Calif San Diego Hlth Syst, VA San Diego Healthcare Syst, Dept Radiol, La Jolla, CA USA; [Christenson, Robert H.] Univ Maryland, Med Ctr, Dept Pathol, Sch Med, Baltimore, MD 21201 USA; [Hack, Dallas; Schmidt, Kara] US Army Med Res & Mat Command, Ft Detrick, MD USA; [Huff, J. Stephen] Univ Virginia, Charlottesville, VA USA; [Jordan, J. Dedrick] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA; [Leidel, Bernd A.; Lindner, Tobias] Charite Univ Med Berlin, Berlin, Germany; [Ludington, Elizabeth] Agil Clin, Carlsbad, CA USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurosurg Sci, Pittsburgh, PA USA; [Ornato, Joseph] Virginia Commonwealth Univ Hlth Syst, Dept Emergency Med, Richmond, VA USA; [Peacock, W. Frank] Baylor Coll Med, Dept Emergency Med, Houston, TX 77030 USA; [Schmidt, Kara] US Army Med Res & Mat Command, Ft Detrick, MD USA; [Tyndall, Joseph A.] Univ Florida, Dept Emergency Med, Gainesville, FL USA; [Vossough, Arastoo] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Jagoda, Andy S.] Mt Sinai Hlth Syst, Dept Emergency Med, New York, NY USA	Welch, RD (corresponding author), Wayne State Univ, Sch Med, Dept Emergency Med, UHC 6G, Detroit, MI 48201 USA.	rwelch@med.wayne.edu		LEIDEL, Bernd A./0000-0002-5149-8764; Jordan, Dedrick/0000-0002-0706-9583	Banyan Biomarkers; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	Banyan Biomarkers and US Army Medical Research and Materiel Command.	Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Easter JS, 2015, JAMA-J AM MED ASSOC, V314, P2672, DOI 10.1001/jama.2015.16316; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Heidari K, 2015, BRAIN INJURY, V29, P33, DOI 10.3109/02699052.2014.948068; Huff JS, 2014, AM J EMERG MED, V32, P606, DOI 10.1016/j.ajem.2014.03.010; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sharp AL, 2017, ACAD EMERG MED, V24, P22, DOI 10.1111/acem.13061; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Tavender EJ, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-8; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149	27	108	112	6	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2018	17	9					782	789		10.1016/S1474-4422(18)30231-X			8	Clinical Neurology	Neurosciences & Neurology	GQ3AO	WOS:000441532100013	30054151	Green Accepted	Y	N	2021-06-18	
J	Kerr, ZY; Register-Mihalik, JK; Kroshus, E; Baugh, CM; Marshall, SW				Kerr, Zachary Y.; Register-Mihalik, Johna K.; Kroshus, Emily; Baugh, Christine M.; Marshall, Stephen W.			Motivations Associated With Nondisclosure of Self-Reported Concussions in Former Collegiate Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						epidemiology; sport; reporting; traumatic brain injury	PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; NCAA CONCUSSION; HOCKEY PLAYERS; ICE HOCKEY; KNOWLEDGE; SYMPTOMS; SPORTS; RISK; DEPRESSION	Background: Previous studies examining nondisclosure among athletes in various settings have found substantial proportions of athletes with undisclosed concussions. Substantial gaps exist in our understanding of the factors influencing athletes' disclosure of sports-related concussions. Purpose: To examine the prevalence of, and factors associated with, nondisclosure of recalled concussions in former collegiate athletes. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Former collegiate athletes (N = 797) completed an online questionnaire. Respondents recalled self-identified sports-related concussions (SISRCs) that they sustained while playing sports in high school, college, or professionally, and whether they disclosed these SISRCs to others. Respondents also recalled motivations for nondisclosure. The prevalence of nondisclosure was calculated among those who recalled SISRCs. Multivariate binomial regression estimated adjusted prevalence ratios (PRs) with 95% CIs, controlling for sex, level of contact in sports, and year the athletes began playing collegiate sports. Results: A total of 214 respondents (26.9%) reported sustaining at least 1 SISRC. Of these, 71 (33.2%) reported not disclosing at least 1 SISRC. Former football athletes were most likely to report nondisclosure (68.3% of those recalling SISRCs); female athletes who participated in low/noncontact sports were the least likely to report nondisclosure (11.1% of those recalling SISRC). The prevalence of nondisclosure was higher among men than women in the univariate analysis (PR, 2.88; 95% CI, 1.62-5.14), multivariate analysis (PR, 2.11; 95% CI, 1.13-3.96), and multivariate analysis excluding former football athletes (PR, 2.11; 95% CI, 1.12-3.94). The most commonly reported motivations were as follows: did not want to leave the game/practice (78.9%), did not want to let the team down (71.8%), did not know it was a concussion (70.4%), and did not think it was serious enough (70.4%). Conclusion: Consistent with previous studies, a substantial proportion of former athletes recalled SISRCs that were not disclosed. Male athletes were less likely to disclose all of their SISRCs than female athletes.	[Kerr, Zachary Y.] Datalys Ctr Sports Injury Res & Prevent Inc, Indianapolis, IN 46202 USA; [Kerr, Zachary Y.; Register-Mihalik, Johna K.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Kerr, Zachary Y.; Register-Mihalik, Johna K.; Marshall, Stephen W.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Kerr, Zachary Y.; Register-Mihalik, Johna K.; Marshall, Stephen W.] Univ N Carolina, Ctr Study Retired Athletes, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Kerr, Zachary Y.; Register-Mihalik, Johna K.; Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Kerr, Zachary Y.; Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Kroshus, Emily] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Baugh, Christine M.] Harvard Univ, Harvard Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Baugh, Christine M.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Kerr, Zachary Y.; Register-Mihalik, Johna K.; Kroshus, Emily; Baugh, Christine M.; Marshall, Stephen W.] Univ N Carolina, Chapel Hill, NC USA	Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Kerr, Zachary/0000-0003-1423-1259	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH019733, T32MH019733] Funding Source: Medline; NCIPC CDC HHS [R49-CE002479] Funding Source: Medline; ACL HHS [R49CE002479] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE002479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; ALLCDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [5R49CE002479-02] Funding Source: Federal RePORTER		[Anonymous], CONC GUID; Broglio SP, 2010, J SPORT SCI MED, V9, P418; Casa DJ, 2012, J ATHL TRAINING, V47, P96; Covassin T, 2003, J ATHL TRAINING, V38, P238; Cusimano MD, 2014, BRIT J SPORT MED, V48, P141, DOI 10.1136/bjsports-2012-091660; Fraas MR, 2014, PHYS THER SPORT, V15, P136, DOI 10.1016/j.ptsp.2013.08.002; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Mueller FO, 2012, FATAL CATASTROPHIC I; National Collegiate Athletic Association, SSI TASK FORC EXPL I; Patel AV, 2007, J ATHL TRAINING, V42, P66; Piland SG, 2003, J ATHL TRAINING, V38, P104; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	32	108	109	1	34	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JAN	2016	44	1					220	225		10.1177/0363546515612082			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DA2GU	WOS:000367614100034	26582799	Green Accepted			2021-06-18	
J	Vaccari, JPD; Brand, F; Adamczak, S; Lee, SW; Perez-Barcena, J; Wang, MY; Bullock, MR; Dietrich, WD; Keane, RW				Vaccari, Juan Pablo de Rivero; Brand, Frank, III; Adamczak, Stephanie; Lee, Stephanie W.; Perez-Barcena, Jon; Wang, Michael Y.; Bullock, M. Ross; Dietrich, W. Dalton; Keane, Robert W.			Exosome-mediated inflammasome signaling after central nervous system injury	JOURNAL OF NEUROCHEMISTRY			English	Article						brain injury; caspase 1; exosomes; inflammasome; spinal cord injury	BRAIN-INJURY; CEREBROSPINAL-FLUID; BARRIER PERMEABILITY; CELL-DEATH; BIOMARKERS; ASSOCIATION; IL-1-BETA; SECRETION; RELEASE; MARKERS	Neuroinflammation is a response against harmful effects of diverse stimuli and participates in the pathogenesis of brain and spinal cord injury (SCI). The innate immune response plays a role in neuroinflammation following CNS injury via activation of multiprotein complexes termed inflammasomes that regulate the activation of caspase 1 and the processing of the pro-inflammatory cytokines IL-1 and IL-18. We report here that the expression of components of the nucleotide-binding and oligomerization domain (NOD)-like receptor protein-1 (NLRP-1) inflammasome, apoptosis speck-like protein containing a caspase recruitment domain (ASC), and caspase 1 are significantly elevated in spinal cord motor neurons and cortical neurons after CNS trauma. Moreover, NLRP1 inflammasome proteins are present in exosomes derived from CSF of SCI and traumatic brain-injured patients following trauma. To investigate whether exosomes could be used to therapeutically block inflammasome activation in the CNS, exosomes were isolated from embryonic cortical neuronal cultures and loaded with short-interfering RNA (siRNA) against ASC and administered to spinal cord-injured animals. Neuronal-derived exosomes crossed the injured blood-spinal cord barrier, and delivered their cargo in vivo, resulting in knockdown of ASC protein levels by approximately 76% when compared to SCI rats treated with scrambled siRNA. Surprisingly, siRNA silencing of ASC also led to a significant decrease in caspase 1 activation and processing of IL-1 after SCI. These findings indicate that exosome-mediated siRNA delivery may be a strong candidate to block inflammasome activation following CNS injury.	[Vaccari, Juan Pablo de Rivero; Adamczak, Stephanie; Lee, Stephanie W.; Perez-Barcena, Jon; Wang, Michael Y.; Bullock, M. Ross; Dietrich, W. Dalton; Keane, Robert W.] Univ Miami, Miller Sch Med, Neurol Surg & Miami Project Cure Paralysis, Miami, FL 33136 USA; [Brand, Frank, III; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol, Miami, FL 33136 USA; [Brand, Frank, III; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Biophys, Miami, FL 33136 USA	Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave, Miami, FL 33136 USA.	rkeane@med.miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; Zhang, Xiaolei/E-2761-2012; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	Zhang, Xiaolei/0000-0003-0117-7599; de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS 1RO1NS59836]; Craig Neilsen Foundation [221346]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059836, R01NS042133] Funding Source: NIH RePORTER	This work was supported by grants to RWK (NIH Grant NINDS 1RO1NS59836 and Craig Neilsen Foundation grant 221346) and The Miami Project to Cure Paralysis. We thank Dr Michael D. Norenberg and Dr Alex Marcillo for their expertise with the Human Spinal Cord sections, Dr Marine Dididze for obtaining the CSF samples from SCI patients, and the SCI core facility at the Miami Project to Cure Paralysis.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chivet M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00145; Clayton A, 2012, ONCOIMMUNOLOGY, V1, P78, DOI 10.4161/onci.1.1.17826; DeFazio MV, 2014, WORLD NEUROSURG, V81, P151, DOI 10.1016/j.wneu.2013.01.015; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Figley SA, 2014, J NEUROTRAUM, V31, P541, DOI 10.1089/neu.2013.3034; Filipazzi P, 2012, SEMIN CANCER BIOL, V22, P342, DOI 10.1016/j.semcancer.2012.02.005; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604; Gomes C, 2007, NEUROSCI LETT, V428, P43, DOI 10.1016/j.neulet.2007.09.024; Haneklaus M, 2013, CURR OPIN IMMUNOL, V25, P40, DOI 10.1016/j.coi.2012.12.004; Harrington MG, 2009, FLUIDS BARRIERS CNS, V6, DOI 10.1186/1743-8454-6-10; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Pant S, 2012, BIOCHEM PHARMACOL, V83, P1484, DOI 10.1016/j.bcp.2011.12.037; Papa L, 2015, NEUROCRIT CARE, V22, P52, DOI 10.1007/s12028-014-0028-2; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26; Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Saman S, 2012, J BIOL CHEM, V287, P3842, DOI 10.1074/jbc.M111.277061; Street JM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-5; Taylor DD, 2011, SEMIN IMMUNOPATHOL, V33, P441, DOI 10.1007/s00281-010-0234-8; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jb/mvj128; Viaud S, 2010, CANCER RES, V70, P1281, DOI 10.1158/0008-5472.CAN-09-3276; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012	41	108	109	0	41	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2016	136			1	SI		39	48		10.1111/jnc.13036			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DB8SH	WOS:000368786400005	25628216	Green Accepted, Bronze			2021-06-18	
J	Dompier, TP; Kerr, ZY; Marshall, SW; Hainline, B; Snook, EM; Hayden, R; Simon, JE				Dompier, Thomas P.; Kerr, Zachary Y.; Marshall, Stephen W.; Hainline, Brian; Snook, Erin M.; Hayden, Ross; Simon, Janet E.			Incidence of Concussion During Practice and Games in Youth, High School, and Collegiate American Football Players	JAMA PEDIATRICS			English	Article							LONGITUDINAL MRI; INJURIES; BRAIN; ADOLESCENCE; CHILDHOOD; SPORT	IMPORTANCE A report by the Institute of Medicine called for comprehensive nationwide concussion incidence data across the spectrum of athletes aged 5 to 23 years. OBJECTIVE To describe the incidence of concussion in athletes participating in youth, high school, and collegiate American football. DESIGN, SETTING, AND PARTICIPANTS Data were collected by athletic trainers at youth, high school, and collegiate football practices and games to create multiple prospective observational cohorts during the 2012 and 2013 football seasons. Data were collected from July 1, 2012, through January 31, 2013, for the 2012 season and from July 1, 2013, through January 31, 2014, for the 2013 season. The Youth Football Surveillance System included 118 youth football teams, providing 4092 athlete-seasons. The National Athletic Treatment, Injury and Outcomes Network program included 96 secondary school football programs, providing 11 957 athlete-seasons. The National Collegiate Athletic Association Injury Surveillance Program included 24 member institutions, providing 4305 athlete-seasons. EXPOSURES All injuries regardless of severity, including concussions, and athlete exposure information were documented by athletic trainers during practices and games. MAIN OUTCOMES AND MEASURES Injury rates, injury rate ratios, risks, risk ratios, and 95% Cls were calculated. RESULTS Concussions comprised 9.6%, 4.0%, and 8.0% of all injuries reported in the Youth Football Surveillance System; National Athletic Treatment, Injury and Outcomes Network; and National Collegiate Athletic Association Injury Surveillance Program, respectively. The game concussion rate was higher than the practice concussion rate across all 3 competitive levels. The game concussion rate for college athletes (3.74 per 1000 athlete exposures) was higher than those for high school athletes (injury rate ratio, 1.86; 95% Cl, 1.50-2.31) and youth athletes (injury rate ratio, 1.57; 95% Cl, 1.17-2.10). The practice concussion rate in college (0.53 per 1000 athlete exposures) was lower than that in high school (injury rate ratio, 0.80; 95% Cl, 0.67-0.96). Youth football had the lowest 1-season concussion risks in 2012(3.53%) and 2013(3.13%). The 1-season concussion risk was highest in high school (9.98%) and college (5.54%) in 2012. CONCLUSIONS AND RELEVANCE Football practices were a major source of concussion at all 3 levels of competition. Consussions during practice might be mitigated and should prompt an evaluation of technique and head impact exposure. Although it is more difficult to change the intensity or conditions of a game, many strategies can be used during practice to limit player-to-player contact and other potentially injurious behaviors.	[Dompier, Thomas P.; Kerr, Zachary Y.; Snook, Erin M.; Hayden, Ross] Datalys Ctr Sports Injury Res & Prevent Inc, Indianapolis, IN 46202 USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Hainline, Brian] Natl Coll Athlet Assoc, Sport Sci Inst, Indianapolis, IN USA; [Simon, Janet E.] Univ Toledo, Dept Kinesiol, Toledo, OH 43606 USA	Dompier, TP (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 W Michigan St,Ste 500, Indianapolis, IN 46202 USA.	tdompier@datalyscenter.org		Kerr, Zachary/0000-0003-1423-1259	USA Football; National Athletic Trainers Association Research and Education Foundation; BioCrossroads; Central Indiana Corporate Partnership Foundation; National Collegiate Athletic Association	Funding for this study was provided by USA Football, the National Athletic Trainers Association Research and Education Foundation, BioCrossroads in partnership with the Central Indiana Corporate Partnership Foundation, and the National Collegiate Athletic Association.	Bailey R, 2006, J SCHOOL HEALTH, V76, P397, DOI 10.1111/j.1746-1561.2006.00132.x; Dompier T, 2011, J ATHL TRAI IN PRESS; Dompier TP, 2007, J ATHL TRAINING, V42, P395; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giedd JN, 2004, ANN NY ACAD SCI, V1021, P77, DOI 10.1196/annals.1308.009; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giedd JN, 1999, PROG NEURO-PSYCHOPH, V23, P571; GOLDBERG B, 1988, PEDIATRICS, V81, P255; Institute of Medicine, 2013, SPORTS REL CONC YOUT; Jacobson NA, 2013, ORTHOP J SPORTS MED, V1, DOI 10.1177/2325967113517860; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mello MJ, 2009, ACAD EMERG MED, V16, P243, DOI 10.1111/j.1553-2712.2009.00357.x; Nation AD, 2011, CLIN PEDIATR, V50, P200, DOI 10.1177/0009922810388511; National Collegiate Athletic Association, STUD ATHL PART 1981; National Council of Youth Sports, REP TRENDS PART ORG; National Federation of State High School Associations, PART STAT; Parsons J, 2013, 2013 14 SPORTS MED H, P63; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014	20	108	108	2	46	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	JUL	2015	169	7					659	665		10.1001/jamapediatrics.2015.0210			7	Pediatrics	Pediatrics	CR0BF	WOS:000360982500013	25938704	Green Published, Bronze			2021-06-18	
J	Kroshus, E; Baugh, CM; Daneshvar, DH; Viswanath, K				Kroshus, Emily; Baugh, Christine M.; Daneshvar, Daniel H.; Viswanath, Kasisomayajula			Understanding Concussion Reporting Using a Model Based on the Theory of Planned Behavior	JOURNAL OF ADOLESCENT HEALTH			English	Article						Adolescent; Brain concussion; Sports; Education	FOOTBALL PLAYERS; INJURY; SPORT; EDUCATION; KNOWLEDGE; COLLEGE; HOCKEY; RETURN; BRAIN; RISK	Purpose: Athlete's report of concussion symptoms to coaching or medical personnel is an important component of concussion risk reduction. This study applies a model based on the Theory of Planned Behavior (TPB) to the prediction of concussive symptom underreporting among late adolescent and young adult male ice hockey players. Methods: Participants were members of an American Tier III Junior A ice hockey league (ages 18-21 years; male; n - 256). Twelve of 14 league teams and 97% of players within these teams agreed to participate. Written survey items assessed symptom reporting behavior, intention, perceived norms, self-efficacy, perceived outcomes of reporting, and concussion knowledge. Structural equation modeling was used to assess the significance of relationships hypothesized by the TPB-based model and the overall model fit. Data were collected in January 2013. Results: Results supported the fit of the TPB-based model in explaining reporting behavior; all model pathways were significant in the hypothesized direction. Of the perceived reporting outcomes assessed, those related to athletic performance were identified as most strongly associated with reporting intention. Conclusions: Results of this study suggest the importance of considering factors such as perceived outcomes of reporting, perceived norms, and self-efficacy, in addition to knowledge, when analyzing concussion underreporting among adolescent athletes. As concussion education for athletes becomes increasingly mandated, testing and applying psychosocial theories such as TPB may help increase program efficacy. (C) 2014 Society for Adolescent Health and Medicine. All rights reserved.	[Kroshus, Emily; Viswanath, Kasisomayajula] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Baugh, Christine M.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Baugh, Christine M.; Daneshvar, Daniel H.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Viswanath, Kasisomayajula] Dana Farber Canc Inst, Boston, MA 02115 USA	Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave,Kresge Bldg 172, Boston, MA 02115 USA.	emk329@mail.harvard.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513			Ajzen I, 2002, J APPL SOC PSYCHOL, V32, P665, DOI 10.1111/j.1559-1816.2002.tb00236.x; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Ajzen I, 2011, BASIC APPL SOC PSYCH, V33, P101, DOI 10.1080/01973533.2011.568834; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bandura A., 1980, SOCIAL FOUNDATIONS O; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Gielen AC, 2003, EPIDEMIOL REV, V25, P65, DOI 10.1093/epirev/mxg004; Glanz K, 2008, HEALTH BEHAVIOR AND; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kroshus E, 2013, BR J SPORTS MED; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Marar M, 2012, AM J SPORTS MED, V20, P1; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; Miller WL., 1999, DOING QUALITATIVE RE; National Collegiate Athletic Association, 2011, 2011 12 NCAA SPORTS; National Federation of state high school associations, HIGH SCHOOL SPORTS P; Pate RR, 2000, ARCH PEDIAT ADOL MED, V154, P904, DOI 10.1001/archpedi.154.9.904; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Provvidenza C, 2013, BRIT J SPORT MED, V47, P1; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Richmond SA, 2013, BR J SPORTS MED; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Sarris CE, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12224; Schreiber JB, 2006, J EDUC RES, V99, P323, DOI 10.3200/JOER.99.6.323-338; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Tator CH, 2012, J CLIN SPORT PSYCHOL, V6, P293, DOI 10.1123/jcsp.6.3.293; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	40	108	108	0	41	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1054-139X	1879-1972		J ADOLESCENT HEALTH	J. Adolesc. Health	MAR	2014	54	3					269	+		10.1016/j.jadohealth.2013.11.011			8	Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics	Psychology; Public, Environmental & Occupational Health; Pediatrics	AB3XF	WOS:000331722800006	24560034				2021-06-18	
J	Llewellyn, T; Burdette, GT; Joyner, AB; Buckley, TA				Llewellyn, Tracy; Burdette, G. Trey; Joyner, A. Barry; Buckley, Thomas A.			Concussion Reporting Rates at the Conclusion of an Intercollegiate Athletic Career	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; reporting rates	PROFESSIONAL FOOTBALL PLAYERS; HISTORY; SPORT	Objective: The purpose of this study was to explore the current reported, unreported, and potentially unrecognized concussion rates among collegiate student-athletes who have completed their collegiate athletic career. Design: Retrospective survey. Setting: College and University athletic training rooms. Participants: One hundred sixty-one collegiate student-athletes (56.5% women; aged 21.5 +/- 1.3; 3.7 +/- 1.0 years of collegiate athletic experience) from 10 institutions who had either completed their intercollegiate athletic eligibility or were no longer participating. Main Outcome Measures: The self-reported concussion rate, the unreported rate and reasons, and the potentially unrecognized concussion rate. Results: The self-reported concussion rate was 33.5% (54/161), and 22.2% (12) self-reported at least 3 concussions. The unreported rate was 11.8% (19/161), and the potentially unrecognized rate was 26.1% (42/161) with the most common unrecognized symptom being "knocked silly/seen stars" (23.6% [38/161]). Conclusions: Overall, 49.7% of all respondents (80/161) reported 1 acknowledged, unreported, or potential concussion. The unreported rate was lower than previous high school studies; however, the potentially unrecognized rate remains high and should be clinically concerning. These findings suggest educational interventions targeting collegiate student-athletes should remain and continue to focus on identifying concussion symptoms and dispelling the common misconception that "bell ringers" and "dings" are not concussions.	[Llewellyn, Tracy] Valdosta State Univ, Dept Intercollegiate Athlet, Valdosta, GA USA; [Burdette, G. Trey; Joyner, A. Barry; Buckley, Thomas A.] Georgia So Univ, Dept Hlth & Kinesiol, Statesboro, GA 30460 USA	Buckley, TA (corresponding author), Georgia So Univ, Dept Hlth & Kinesiol, POB 8076, Statesboro, GA 30460 USA.	TBuckley@Georgiasouthern.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; Llewellyn, Tracy/0000-0002-6483-2776			Boswell D, 2004, ARCH CLIN NEUROPSYCH, V19, P958; Echlin P. S., 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2010.9FOCUS10187; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Register-Mihalik JK, 2011, J ATHL TRAINING, V46, pS15; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	10	108	108	1	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2014	24	1					76	79		10.1097/01.jsm.0000432853.77520.3d			4	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	AE0RZ	WOS:000333675200010	24157468				2021-06-18	
J	Hertle, DN; Dreier, JP; Woitzik, J; Hartings, JA; Bullock, R; Okonkwo, DO; Shutter, LA; Vidgeon, S; Strong, AJ; Kowoll, C; Dohmen, C; Diedler, J; Veltkamp, R; Bruckner, T; Unterberg, AW; Sakowitz, OW				Hertle, Daniel N.; Dreier, Jens P.; Woitzik, Johannes; Hartings, Jed A.; Bullock, Ross; Okonkwo, David O.; Shutter, Lori A.; Vidgeon, Steven; Strong, Anthony J.; Kowoll, Christina; Dohmen, Christian; Diedler, Jennifer; Veltkamp, Roland; Bruckner, Thomas; Unterberg, Andreas W.; Sakowitz, Oliver W.		Cooperative Study Brain Injury	Effect of analgesics and sedatives on the occurrence of spreading depolarizations accompanying acute brain injury	BRAIN			English	Article						spreading depolarization; isoelectric spreading; depolarization; ketamine; midazolam	RANDOMIZED CONTROLLED-TRIAL; HUMAN CEREBRAL-CORTEX; SUBARACHNOID HEMORRHAGE; GLYCINE ANTAGONIST; NMDA RECEPTOR; ACUTE STROKE; BLOOD-FLOW; DEPRESSION; KETAMINE; RAT	Spreading depolarizations are waves of mass neuronal and glial depolarization that propagate across the injured human cortex. They can occur with depression of neuronal activity as spreading depressions or isoelectric spreading depolarizations on a background of absent or minimal electroencephalogram activity. Spreading depolarizations are characterized by the loss of neuronal ion homeostasis and are believed to damage functional neurons, leading to neuronal necrosis or neurological degeneration and poor outcome. Analgesics and sedatives influence activity-dependent neuronal ion homeostasis and therefore represent potential modulators of spreading depolarizations. In this exploratory retrospective international multicentre analysis, we investigated the influence of midazolam, propofol, fentanyl, sufentanil, ketamine and morphine on the occurrence of spreading depolarizations in 115 brain-injured patients. A surface electrode strip was placed on the cortex, and continuous electrocorticographical recordings were obtained. We used multivariable binary logistic regression to quantify associations between the investigated drugs and the hours of electrocorticographical recordings with and without spreading depolarizations or clusters of spreading depolarizations. We found that administration of ketamine was associated with a reduction of spreading depolarizations and spreading depolarization clusters (P < 0.05). Midazolam anaesthesia, in contrast, was associated with an increased number of spreading depolarization clusters (P < 0.05). By using a univariate odds ratio analysis, we also found a significant association between ketamine administration and reduced occurrence of isoelectric spreading depolarizations in patients suffering from traumatic brain injury, subarachnoid haemorrhage and malignant hemispheric stroke (P < 0.05). Our findings suggest that ketamine-or another N-methyl-d-aspartate receptor antagonist-may represent a viable treatment for patients at risk for spreading depolarizations. This hypothesis will be tested in a prospective study.	[Hertle, Daniel N.; Unterberg, Andreas W.; Sakowitz, Oliver W.] Univ Heidelberg Hosp, Dept Neurosurg, D-69120 Heidelberg, Germany; [Dreier, Jens P.] Charite, Dept Expt Neurol, D-10117 Berlin, Germany; [Woitzik, Johannes] Charite, Dept Neurosurg, D-10117 Berlin, Germany; [Hartings, Jed A.; Shutter, Lori A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH 45219 USA; [Bullock, Ross] Univ Miami, Dept Neurosurg, Miami, FL 33136 USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Vidgeon, Steven; Strong, Anthony J.] Kings Coll London, Dept Clin Neurosci, London SE5 8AF, England; [Kowoll, Christina; Dohmen, Christian] Univ Cologne, Dept Neurol, D-50931 Cologne, Germany; [Diedler, Jennifer; Veltkamp, Roland] Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany; [Bruckner, Thomas] Univ Heidelberg, Inst Med Biometry & Informat, D-69120 Heidelberg, Germany	Hertle, DN (corresponding author), Univ Heidelberg Hosp, Dept Neurosurg, INF 400, D-69120 Heidelberg, Germany.	daniel.hertle@med.uni-heidelberg.de	Shutter, Lori A/G-2957-2013	Dreier, Jens/0000-0001-7459-2828; Hartings, Jed/0000-0001-8583-3471; Shutter, Lori/0000-0002-1390-0628	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG DR 323/5-1]; Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin)Federal Ministry of Education & Research (BMBF) [01 EO 0801]; Bundesministerium fur Bildung und Forschung (Bernstein Center for Computational Neuroscience Berlin)Federal Ministry of Education & Research (BMBF) [01GQ1001C B2]; US Army CDMRP PH/traumatic brain injury Research Program [W81XWH-08-2-0016]	The Deutsche Forschungsgemeinschaft (grant DFG DR 323/5-1 to J.P.D., O.W.S. and J.W.) and the Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO 0801; Bernstein Center for Computational Neuroscience Berlin 01GQ1001C B2 to J.P.D.). This work was funded in part by the US Army CDMRP PH/traumatic brain injury Research Program (Contract No. W81XWH-08-2-0016).	AITKEN PG, 1988, NEUROSCI LETT, V89, P187, DOI 10.1016/0304-3940(88)90379-5; Albanese J, 1997, ANESTHESIOLOGY, V87, P1328, DOI 10.1097/00000542-199712000-00011; Alkire MT, 1999, ANESTHESIOLOGY, V90, P701, DOI 10.1097/00000542-199903000-00011; AVOLI M, 1991, ANN NEUROL, V30, P589, DOI 10.1002/ana.410300412; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; Canals S, 2005, J NEUROPHYSIOL, V94, P943, DOI 10.1152/jn.01145.2004; DAWSON B, 1971, ANESTH ANAL CURR RES, V50, P443; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Gorji A, 2001, BRAIN RES, V906, P74, DOI 10.1016/S0006-8993(01)02557-4; Hartings JA, 2012, LANCET NEUROL, V11, P389, DOI 10.1016/S1474-4422(12)70085-6; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hudetz JA, 2010, J CARDIOTHOR VASC AN, V24, P131, DOI 10.1053/j.jvca.2009.05.008; IIJIMA T, 1992, J CEREBR BLOOD F MET, V12, P727, DOI 10.1038/jcbfm.1992.103; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kager H, 2002, J NEUROPHYSIOL, V88, P2700, DOI 10.1152/jn.00237.2002; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; Langsjo JW, 2003, ANESTHESIOLOGY, V99, P614, DOI 10.1097/00000542-200309000-00016; Largo C, 1996, J NEUROSCI, V16, P1219; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; Obrenovitch TP, 1996, BRIT J PHARMACOL, V117, P931, DOI 10.1111/j.1476-5381.1996.tb15283.x; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Sacco RL, 2001, JAMA-J AM MED ASSOC, V285, P1719, DOI 10.1001/jama.285.13.1719; Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303; Shulman RG, 2009, P NATL ACAD SCI USA, V106, P11096, DOI 10.1073/pnas.0903941106; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09	38	108	111	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	AUG	2012	135		8				2390	2398		10.1093/brain/aws152			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	984DQ	WOS:000307170300018	22719001	Bronze			2021-06-18	
J	Bass, CR; Panzer, MB; Rafaels, KA; Wood, G; Shridharani, J; Capehart, B				Bass, Cameron R.; Panzer, Matthew B.; Rafaels, Karen A.; Wood, Garrett; Shridharani, Jay; Capehart, Bruce			Brain Injuries from Blast	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Post-traumatic stress disorder; Shock tube; Animal models; Injury mechanisms; Pathophysiology; Military; Civilian	POSTTRAUMATIC-STRESS-DISORDER; OPERATION-IRAQI-FREEDOM; NAVY-MARINE-CORPS; CLOSED-HEAD INJURY; SMOKE-INHALATION; RISK-ASSESSMENT; WHITE-MATTER; AFGHANISTAN; CARE; EXPLOSIONS	Traumatic brain injury (TBI) from blast produces a number of conundrums. This review focuses on five fundamental questions including: (1) What are the physical correlates for blast TBI in humans? (2) Why is there limited evidence of traditional pulmonary injury from blast in current military field epidemiology? (3) What are the primary blast brain injury mechanisms in humans? (4) If TBI can present with clinical symptoms similar to those of Post-Traumatic Stress Disorder (PTSD), how do we clinically differentiate blast TBI from PTSD and other psychiatric conditions? (5) How do we scale experimental animal models to human response? The preponderance of the evidence from a combination of clinical practice and experimental models suggests that blast TBI from direct blast exposure occurs on the modern battlefield. Progress has been made in establishing injury risk functions in terms of blast overpressure time histories, and there is strong experimental evidence in animal models that mild brain injuries occur at blast intensities that are similar to the pulmonary injury threshold. Enhanced thoracic protection from ballistic protective body armor likely plays a role in the occurrence of blast TBI by preventing lung injuries at blast intensities that could cause TBI. Principal areas of uncertainty include the need for a more comprehensive injury assessment for mild blast injuries in humans, an improved understanding of blast TBI pathophysiology of blast TBI in animal models and humans, the relationship between clinical manifestations of PTSD and mild TBI from blunt or blast trauma including possible synergistic effects, and scaling between animals models and human exposure to blasts in wartime and terrorist attacks. Experimental methodologies, including location of the animal model relative to the shock or blast source, should be carefully designed to provide a realistic blast experiment with conditions comparable to blasts on humans. If traditional blast scaling is appropriate between species, many reported rodent blast TBI experiments using air shock tubes have blast overpressure conditions that are similar to human long-duration nuclear blasts, not high explosive blasts.	[Bass, Cameron R.; Panzer, Matthew B.; Wood, Garrett; Shridharani, Jay] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Rafaels, Karen A.] Univ Virginia, Charlottesville, VA USA; [Capehart, Bruce] Duke Univ, Durham VA Med Ctr, Durham, NC USA	Bass, CR (corresponding author), Duke Univ, Dept Biomed Engn, 136 Hudson Hall, Durham, NC 27708 USA.	dale.bass@duke.edu		Wood, Garrett/0000-0002-5619-5527	Duke University Pratt School of Engineering; Department of Biomedical Engineering	The authors gratefully acknowledge support from Duke University Pratt School of Engineering and the Department of Biomedical Engineering.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], SIAD INDEPENDENT PAN; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Aschkenasy-Steuer G, 2005, CRIT CARE, V9, P490, DOI 10.1186/cc3762; Baker F.W., 2008, SENSORS MAY LEAD FAS; Baker WE., 1973, EXPLOSIONS AIR; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bass Cameron R Dale, 2005, Int J Occup Saf Ergon, V11, P347; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bell Monte K, 2008, Mil Med, V173, pv; Bochicchio GV, 2008, AM SURGEON, V74, P267; Bogo V., 1971, 2659 DASA LOV FDN ME; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bowen I.G., 1968, DASA2113 LOV FDN MED; Bowen I.G., 1965, DASA1675 LOV FDN MED; Breeze J., 2010, BR J ORAL MAXILLOFAC; Brethauer SA, 2008, ARCH SURG-CHICAGO, V143, P564, DOI 10.1001/archsurg.143.6.564; Brolen P, 2007, PREHOSP DISASTER MED, V22, P246, DOI 10.1017/S1049023X00004763; Brown W. T., 2005, SHOCK COMPR COND MAT; Burns JC, 2008, J PEDIATR-US, V153, P833, DOI 10.1016/j.jpeds.2008.06.011; Capehart B., 2011, DEP VET AFF OFF MENT; CELANDER H, 1955, ACTA PHYSIOL SCAND, V33, P6, DOI 10.1111/j.1748-1716.1955.tb01188.x; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chalton LD, 2009, BRAIN INJURY, V23, P77, DOI 10.1080/02699050802635273; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Ciraulo DL, 2006, J AM COLL SURGEONS, V203, P942, DOI 10.1016/j.jamcollsurg.2006.07.028; CLEMEDSON CJ, 1953, AM J PHYSIOL, V174, P316; CLEMEDSON CJ, 1956, AM J PHYSIOL, V184, P119, DOI 10.1152/ajplegacy.1955.184.1.119; CLEMEDSON CJ, 1956, ACTA PHYSIOL SCAND, V37, P202; Cripps NPJ, 1996, J TRAUMA, V40, pS206, DOI 10.1097/00005373-199603001-00045; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Eppinger R. H., 1984, SAE GOV IND M EXPL M; First M. B., 1995, HDB DIFFERENTIAL DIA; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gomez AM, 2007, EUR J EMERG MED, V14, P247; Goroshin S, 2006, PROPELL EXPLOS PYROT, V31, P169, DOI 10.1002/prep.200600024; Guy RJ, 2004, J ROY SOC MED, V97, P255, DOI 10.1258/jrsm.97.5.255-a; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Heitger MH, 2005, BRAIN INJURY, V19, P109, DOI 10.1080/02699050410001720095; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hooker DR, 1924, AM J PHYSIOL, V67, P219; Hyde DW, 2004, CONWEP 2 1 0 8 CONVE; IREMONGER MJ, 1997, SCI FDN TRAUMA, P189; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kauvar DS, 2006, BURNS, V32, P853, DOI 10.1016/j.burns.2006.03.008; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kincaid J., 1830, ADVENTURES RIFLE BRI; KOLSKY H, 1954, NATURE, V173, P77, DOI 10.1038/173077a0; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krohn PL, 1941, 249 RC MIN HOM SEC C; Larray D. J., 1812, MEMOIRES CHIRURG CAM, P440; Lee KYK, 2011, NEUROIMAGE, V54, pS30, DOI 10.1016/j.neuroimage.2010.05.042; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lockey DJ, 2005, RESUSCITATION, V66, pIX, DOI 10.1016/j.resuscitation.2005.07.005; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mairet A., 1917, PRESSE MED, V25, P478; Mekel Michal, 2009, Am J Disaster Med, V4, P233; Montanarelli N., 1975, LIGHTWEIGHT BODY ARM; Mott F. W., 1919, AM J MED SCI, V159, P136; Mott FW, 1916, LANCET, V1, P331; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Palm E. J., 2010, PERS ARM SYST S QUEB; Panzer M. B., 2011, J TRAUMA IN PRESS; Panzer MB, 2010, PERS ARM SYST S QUEB; Pare A., 1985, OUEVRES A PARE CONSE, P1585; Perry VH, 2010, ACTA NEUROPATHOL, V120, P277, DOI 10.1007/s00401-010-0722-x; PHILLIPS YY, 1988, J TRAUMA, V28, pS149, DOI 10.1097/00005373-198801001-00030; Rafaels K. A., 2011, J NEUROTRAU IN PRESS; Rafaels K. A., 2011, THESIS U VIRGINIA; Rafaels K. A., 2011, J NEUROTRAUMA UNPUB; Rafaels KA, 2010, PERS ARM SYST S QUEB; Rafaels KA, 2010, J TRAUMA, V69, P368, DOI 10.1097/TA.0b013e3181e88122; Raftenberg MN, 2004, ARLTR3343; Reper P, 2002, BURNS, V28, P503, DOI 10.1016/S0305-4179(02)00051-7; Richmond D. R., 1959, TID6056 US AT EN COM; Richmond D. R., 1966, 1854 DASA; Richmond D. R., 1985, 9 INT S MABS OXF ENG; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Rodoplu Ulkumen, 2004, Prehosp Disaster Med, V19, P133; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Rusca F, 1915, Z CHIR, V132, P315; Rutland-Brown W, 2007, PREHOSP DISASTER MED, V22, P157, DOI 10.1017/S1049023X00004593; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seal KH, 2011, DRUG ALCOHOL DEPEN, V116, P93, DOI 10.1016/j.drugalcdep.2010.11.027; Sharma SP, 1996, J THERMOPHYS HEAT TR, V10, P169, DOI 10.2514/3.768; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith JE, 2011, PHILOS T R SOC B, V366, P291, DOI 10.1098/rstb.2010.0251; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Sterner James B., 2009, Inflammation & Allergy Drug Targets, V8, P63; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Svetlov S, 2009, J NEUROTRAUM, V26, pA75; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Wang Y, 2006, NAT NEUROSCI, V9, P534, DOI 10.1038/nn1670; Wang Y., 2011, J NEUROTRAUMA; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Warden DL, 2005, J NEUROTRAUM, V22, P1178; White C. S., 1971, DNA2738T NUCL DEF AG; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Wood GW, 2010, PERS ARM SYST S QUEB; Yoganandan N, 2011, CLIN ANAT, V24, P282, DOI 10.1002/ca.21106; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; ZOROYA G, 2005, KEY IRAQ WOUND BRAIN; Zouris JM, 2006, MIL MED, V171, P246, DOI 10.7205/MILMED.171.3.246	125	108	110	1	43	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		185	202		10.1007/s10439-011-0424-0			18	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700017	22012085				2021-06-18	
J	Lopez-Larson, MP; Bogorodzki, P; Rogowska, J; McGlade, E; King, JB; Terry, J; Yurgelun-Todd, D				Lopez-Larson, Melissa P.; Bogorodzki, Piotr; Rogowska, Jadwiga; McGlade, Erin; King, Jace B.; Terry, Janine; Yurgelun-Todd, Deborah			Altered prefrontal and insular cortical thickness in adolescent marijuana users	BEHAVIOURAL BRAIN RESEARCH			English	Article						Marijuana; Adolescents; Imaging; Cortical thickness	TRAUMATIC BRAIN-INJURY; SURFACE-BASED ANALYSIS; ONSET CANNABIS USE; MAGNETIC-RESONANCE; AFFECTIVE-DISORDERS; SMOKING MARIJUANA; DECISION-MAKING; TISSUE VOLUME; SUBSTANCE USE; GRAY-MATTER	Introduction: There are limited data regarding the impact of marijuana (MJ) on cortical development during adolescence. Adolescence is a period of substantial brain maturation and cortical thickness abnormalities may be indicative of disruptions of normal cortical development. This investigation applied cortical-surface based techniques to compare cortical thickness measures in MJ using adolescents compared to non-using controls. Methods: Eighteen adolescents with heavy MJ use and 18 non-using controls similar in age received MRI scans using a 3T Siemens scanner. Cortical reconstruction and volumetric segmentation was performed with FreeSurfer. Group differences in cortical thickness were assessed using statistical difference maps covarying for age and gender. Results: Compared to non-users, MJ users had decreased cortical thickness in right caudal middle frontal, bilateral insula and bilateral superior frontal cortices. Marijuana users had increased cortical thickness in the bilateral lingual, right superior temporal, right inferior parietal and left paracentral regions. In the MJ users, negative correlations were found between frontal and lingual regions for urinary cannabinoid levels and between age of onset of use and the right superior frontal gyrus. Conclusion: This is one of the first studies to evaluate cortical thickness in a group of adolescents with heavy MJ use compared to non-users. Our findings are consistent with prior studies that documented abnormalities in prefrontal and insular regions. Our results suggest that age of regular use may be associated with altered prefrontal cortical gray matter development in adolescents. Furthermore, reduced insular cortical thickness may be a biological marker for increased risk of substance dependence. Published by Elsevier B.V.	[Lopez-Larson, Melissa P.; McGlade, Erin; King, Jace B.; Terry, Janine; Yurgelun-Todd, Deborah] Univ Utah, Inst Brain, Salt Lake City, UT 84108 USA; [Lopez-Larson, Melissa P.; Yurgelun-Todd, Deborah] Univ Utah, Sch Med, Salt Lake City, UT 84108 USA; [Lopez-Larson, Melissa P.; McGlade, Erin; Yurgelun-Todd, Deborah] VISN 19 MIRREC, Salt Lake City, UT USA; [Bogorodzki, Piotr] Tech Univ Warsaw, Inst Radioelect, PL-00662 Warsaw, Poland; [Rogowska, Jadwiga] Harvard Univ, McLean Hosp, Sch Med, Brain Imaging Ctr, Belmont, MA 02178 USA	Lopez-Larson, MP (corresponding author), Univ Utah, Inst Brain, 383 Colorow Dr, Salt Lake City, UT 84108 USA.	mlopez-larson@hsc.utah.edu	McGlade, Erin C/K-1157-2016	McGlade, Erin C/0000-0003-2234-1984; King, Jace/0000-0002-0206-0475; Bogorodzki, Piotr/0000-0001-6596-5274	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01 DA020269-01]; American Psychiatric Association [5T32 MH19126]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019126, K23MH087831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA020269] Funding Source: NIH RePORTER	This work was supported by research grants from an NIH: 1R01 DA020269-01 to DYT and training awards through the American Psychiatric Association's Program for Minority Research Training in Psychiatry (5T32 MH19126)	ALMEIDA LG, 2010, J PSYCHIAT RES; *APA, 2000, GLOB ASS FUNCT DIAGN, P32; Bachman JG, 1998, AM J PUBLIC HEALTH, V88, P887, DOI 10.2105/AJPH.88.6.887; Batty MJ, 2010, J AM ACAD CHILD PSY, V49, P229, DOI 10.1016/j.jaac.2009.11.008; Bava S, 2009, PSYCHIAT RES-NEUROIM, V173, P228, DOI 10.1016/j.pscychresns.2009.04.005; Becker B, 2010, PROG NEURO-PSYCHOPH, V34, P837, DOI 10.1016/j.pnpbp.2010.03.032; Block RI, 2000, NEUROREPORT, V11, P491, DOI 10.1097/00001756-200002280-00013; Bogorodzki P, 2005, IEEE T MED IMAGING, V24, P389, DOI 10.1109/TMI.2004.843183; BOGOUSSLAVSKY J, 1987, J NEUROL NEUROSUR PS, V50, P607, DOI 10.1136/jnnp.50.5.607; Bolla KI, 2005, NEUROIMAGE, V26, P480, DOI 10.1016/j.neuroimage.2005.02.012; Borgwardt SJ, 2008, BIOL PSYCHIAT, V64, P966, DOI 10.1016/j.biopsych.2008.05.011; Brody AL, 2002, ARCH GEN PSYCHIAT, V59, P1162, DOI 10.1001/archpsyc.59.12.1162; CAMPBELL AM, 1971, LANCET, V2, P1219; Chang L, 2006, BRAIN, V129, P1096, DOI 10.1093/brain/awl064; Chugani HT, 1998, PREV MED, V27, P184, DOI 10.1006/pmed.1998.0274; Churchwell JC, 2011, INHIBITORY CONTROL AND DRUG ABUSE PREVENTION: FROM RESEARCH TO TRANSLATION, P101, DOI 10.1007/978-1-4419-1268-8_6; Committeri G, 2004, J COGNITIVE NEUROSCI, V16, P1517, DOI 10.1162/0898929042568550; Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Delisi Lynn E, 2006, Harm Reduct J, V3, P17, DOI 10.1186/1477-7517-3-17; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; DOLMATOVA LS, 1995, VOP MED KHIM, V41, P57; Ehrenreich H, 1999, PSYCHOPHARMACOLOGY, V142, P295, DOI 10.1007/s002130050892; Eldreth DA, 2004, NEUROIMAGE, V23, P914, DOI 10.1016/j.neuroimage.2004.07.032; Ennett ST, 1997, J HEALTH SOC BEHAV, V38, P55, DOI 10.2307/2955361; Filbey FM, 2009, P NATL ACAD SCI USA, V106, P13016, DOI 10.1073/pnas.0903863106; First M.B., 1996, STRUCTURED CLIN INTE; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fletcher JM, 1996, ARCH GEN PSYCHIAT, V53, P1051; Frangou S, 2004, NEUROIMAGE, V23, P800, DOI 10.1016/j.neuroimage.2004.05.027; GarciaSevilla JA, 1997, NEUROREPORT, V8, P1561, DOI 10.1097/00001756-199705060-00003; Geller B, 2001, J AM ACAD CHILD PSY, V40, P450, DOI 10.1097/00004583-200104000-00014; Giancola PR, 1998, J GEN PSYCHOL, V125, P297, DOI 10.1080/00221309809595339; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Gruber SA, 2005, COGNITIVE BRAIN RES, V23, P107, DOI 10.1016/j.cogbrainres.2005.02.016; Gruber SA, 2000, FORENSIC SCI MED, P199; Gruber SA, 2009, DRUG ALCOHOL DEPEN, V105, P139, DOI 10.1016/j.drugalcdep.2009.06.019; HABETS P, 2010, BIOL PSYCHIAT; HAMILTON A, 1969, BRIT J PSYCHIAT, P76; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hester R, 2009, NEUROPSYCHOPHARMACOL, V34, P2450, DOI 10.1038/npp.2009.67; Huestegge L, 2002, PROG BRAIN RES, V140, P377; Jacobsen LK, 2007, BIOL PSYCHIAT, V61, P31, DOI 10.1016/j.biopsych.2006.02.014; Jacobsen LK, 2004, ANN NY ACAD SCI, V1021, P384, DOI 10.1196/annals.1308.053; JAGER G, 2010, J AM ACAD CHILD ADOL, V49, pE1; Jager G, 2007, EUR NEUROPSYCHOPHARM, V17, P289, DOI 10.1016/j.euroneuro.2006.10.003; Jager G, 2010, J AM ACAD CHILD PSY, V49, P561, DOI 10.1016/j.jaac.2010.02.001; Kanayama G, 2004, PSYCHOPHARMACOLOGY, V176, P239, DOI 10.1007/s00213-004-1885-8; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kilts CD, 2001, ARCH GEN PSYCHIAT, V58, P334, DOI 10.1001/archpsyc.58.4.334; KUHN S, 2010, BIOL PSYCHIAT; Lange N, 2010, DEV NEUROPSYCHOL, V35, P296, DOI 10.1080/87565641003696833; Lawyer Glenn, 2010, BMC Pharmacology, V10, P5, DOI 10.1186/1471-2210-10-5; Luks TL, 2004, NEUROIMAGE, V22, P1515, DOI 10.1016/j.neuroimage.2004.04.008; Macaluso E, 2000, SCIENCE, V289, P1206, DOI 10.1126/science.289.5482.1206; Martin-Santos R, 2010, PSYCHOL MED, V40, P383, DOI 10.1017/S0033291709990729; Mata I, 2010, BRAIN RES, V1317, P297, DOI 10.1016/j.brainres.2009.12.069; McNair D., 1992, REVISED MANUAL PROFI; Mobbs D, 2004, NEUROLOGY, V62, P2070, DOI 10.1212/01.WNL.0000129536.95274.DC; Moss HB, 1997, PSYCHIAT RES-NEUROIM, V76, P101, DOI 10.1016/S0925-4927(97)00067-X; Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926; Naqvi NH, 2009, TRENDS NEUROSCI, V32, P56, DOI 10.1016/j.tins.2008.09.009; NARR KL, 2009, J AM ACAD CHILD ADOL; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; O'Leary DS, 2007, HUM PSYCHOPHARM CLIN, V22, P135, DOI 10.1002/hup.832; O'Leary DS, 2002, NEUROPSYCHOPHARMACOL, V26, P802, DOI 10.1016/S0893-133X(01)00425-0; Ozaita A, 1998, J NEUROCHEM, V70, P1249; Paulus MP, 2007, SCIENCE, V318, P602, DOI 10.1126/science.1142997; Paulus MP, 2006, BIOL PSYCHIAT, V60, P383, DOI 10.1016/j.biopsych.2006.03.042; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P521, DOI 10.1001/jama.275.7.521; Pope HG, 2003, DRUG ALCOHOL DEPEN, V69, P303, DOI 10.1016/S0376-8716(02)00334-4; Ray S, 2010, ALCOHOL ALCOHOLISM, V45, P437, DOI 10.1093/alcalc/agq042; Schultz CC, 2010, SCHIZOPHR RES, V116, P204, DOI 10.1016/j.schres.2009.11.001; SCHWEINSBURG AD, 2010, J PSYCHOACTIVE DRUGS, P42; Schweinsburg AD, 2008, PSYCHIAT RES-NEUROIM, V163, P40, DOI 10.1016/j.pscychresns.2007.04.018; Schweinsburg Alecia D, 2008, Curr Drug Abuse Rev, V1, P99; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; SHAW P, 2010, AM J PSYCHIAT; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; SOLOWIJ N, 1995, LIFE SCI, V56, P2127, DOI 10.1016/0024-3205(95)00198-F; Sowell ER, 2008, CEREB CORTEX, V18, P136, DOI 10.1093/cercor/bhm039; Spielberger C.D., 1970, STATE TRAIT ANXIETY; Squeglia LM, 2009, CLIN EEG NEUROSCI, V40, P31, DOI 10.1177/155005940904000110; Stoppel CM, 2009, HUM BRAIN MAPP, V30, P3759, DOI 10.1002/hbm.20804; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tapert SF, 2007, PSYCHOPHARMACOLOGY, V194, P173, DOI 10.1007/s00213-007-0823-y; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tzilos GK, 2005, AM J ADDICTION, V14, P64, DOI 10.1080/10550490590899862; von Sydow K, 2001, DRUG ALCOHOL DEPEN, V64, P347, DOI 10.1016/S0376-8716(01)00137-5; WALLACE GI, 2010, BRAIN; Weinberg NZ, 1998, J AM ACAD CHILD PSY, V37, P252, DOI 10.1097/00004583-199803000-00009; Wilson W, 2000, J ADDICT DIS, V19, P1, DOI 10.1300/J069v19n01_01; YAMANOUCHI N, 1995, AM J NEURORADIOL, V16, P1643; Yurgelun-Todd DA, 2002, PSYCHOL REP, V91, P743, DOI 10.2466/PR0.91.7.743-757	98	108	109	0	41	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 20	2011	220	1					164	172		10.1016/j.bbr.2011.02.001			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	752PC	WOS:000289703600021	21310189	Green Accepted			2021-06-18	
J	Slobounov, SM; Gay, M; Zhang, K; Johnson, B; Pennell, D; Sebastianelli, W; Horovitz, S; Hallett, M				Slobounov, S. M.; Gay, M.; Zhang, K.; Johnson, B.; Pennell, D.; Sebastianelli, W.; Horovitz, S.; Hallett, M.			Alteration of brain functional network at rest and in response to YMCA physical stress test in concussed athletes: RsFMRI study	NEUROIMAGE			English	Article						Mild traumatic brain injury (mTBI); Resting state fMRI (rsFMRI); YMCA physical stress test	DIFFUSE AXONAL INJURY; ALZHEIMERS-DISEASE; CORPUS-CALLOSUM; MILD; CONNECTIVITY; ABNORMALITIES; MRI; FMRI; SYMPTOMS; SCALE	There is still controversy in the literature whether a single episode of mild traumatic brain injury (mTBI) results in short- and/or long-term functional and structural deficits in the concussed brain. With the inability of traditional brain imaging techniques to properly assess the severity of brain damage induced by a concussive blow, there is hope that more advanced applications such as resting state functional magnetic resonance imaging (rsFMRI) will be more specific in accurately diagnosing mTBI. In this rsFMRI study, we examined 17 subjects 10 +/- 2 days post-sports-related mTBI and 17 age-matched normal volunteers (NVs) to investigate the possibility that the integrity of the resting state brain network is disrupted following a single concussive blow. We hypothesized that advanced brain imaging techniques may reveal subtle alterations of functional brain connections in asymptomatic mTBI subjects. There are several findings of interest. All mTBI subjects were asymptomatic based upon clinical evaluation and neuropsychological (NP) assessments prior to the MRI session. The mTBI subjects revealed a disrupted functional network both at rest and in response to the YMCA physical stress test. Specifically, interhemispheric connectivity was significantly reduced in the primary visual cortex, hippocampal and dorsolateral prefrontal cortex networks (p < 0.05). The YMCA physical stress induced nonspecific and similar changes in brain network connectivity patterns in both the mTBI and NV groups. These major findings are discussed in relation to underlying mechanisms, clinical assessment of mTBI, and current debate regarding functional brain connectivity in a clinical population. Overall, our major findings clearly indicate that functional brain alterations in the acute phase of injury are overlooked when conventional clinical and neuropsychological examinations are used. (C) 2011 Elsevier Inc. All rights reserved.	[Slobounov, S. M.; Gay, M.; Zhang, K.; Johnson, B.] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Slobounov, S. M.; Horovitz, S.; Hallett, M.] NINDS, NIH, Bethesda, MD USA; [Pennell, D.] Penn State Univ, Chandlee Lab, Social Life & Engn Sci Imaging Ctr, University Pk, PA 16802 USA; [Slobounov, S. M.; Gay, M.; Sebastianelli, W.] Penn State Univ, Dept Orthopaed & Med Rehabil, HMC, University Pk, PA 16802 USA	Slobounov, SM (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	Li, Yiou/G-4991-2010; Zhang, Kai/F-3261-2015	Zhang, Kai/0000-0002-5460-6150; Horovitz, Silvina G./0000-0002-5501-5918	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002667, R01NS056227, ZIANS002669] Funding Source: NIH RePORTER	This study was supported by NIH Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury" awarded to Dr. Slobounov, PI.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Allen G, 2007, ARCH NEUROL-CHICAGO, V64, P1482, DOI 10.1001/archneur.64.10.1482; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cao C, CLIN NEUROP IN PRESS; Cao C., 2009, IEEE T NEURAL SYST R; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cole DM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00008; ELBERT T, 1992, BIOL PSYCHIAT, V32, P595, DOI 10.1016/0006-3223(92)90072-8; FITZPATRICK NM, 2008, 36 ANN M INT NEUR SO; Fornito A, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00022; FOSTER JK, 1994, COGNITIVE NEUROPSYCH, V11, P133, DOI 10.1080/02643299408251971; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Gates KM, 2011, NEUROIMAGE, V54, P1151, DOI 10.1016/j.neuroimage.2010.08.051; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Guye M, 2010, MAGN RESON MATER PHY, V23, P409, DOI 10.1007/s10334-010-0205-z; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jeong J, 1998, ELECTROEN CLIN NEURO, V106, P220, DOI 10.1016/S0013-4694(97)00079-5; Jerbi K, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00027; Johnston JM, 2008, J NEUROSCI, V28, P6453, DOI 10.1523/JNEUROSCI.0573-08.2008; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marquez de la Plata C., ARCH NEUROL IN PRESS; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purves D., 2007, NEUROSCIENCE, V3d ed; Quigley M, 2003, AM J NEURORADIOL, V24, P208; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010; Rosenbaum RS, 2010, NEUROBIOL AGING, V31, P780, DOI 10.1016/j.neurobiolaging.2008.06.002; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Silberstein RB, 2004, BRAIN TOPOGR, V16, P249; Slobounov S, 2009, EXP BRAIN RES, V199, P1, DOI 10.1007/s00221-009-1956-5; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sporns O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001049; Trimble MR, 2008, HBK BEHAV NEUROSCI, V18, P363, DOI 10.1016/S1569-7339(08)00220-8; TRIMBLE MR, 1990, SEMIN NEUROL, V10, P287, DOI 10.1055/s-2008-1041280; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Wang K, 2006, LECT NOTES COMPUT SC, V4191, P340; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhou YX, 2008, ALZHEIMERS DEMENT, V4, P265, DOI 10.1016/j.jalz.2008.04.006	58	108	112	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 15	2011	55	4					1716	1727		10.1016/j.neuroimage.2011.01.024			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	741DO	WOS:000288843500033	21255654	Green Accepted			2021-06-18	
J	Greer, JE; McGinn, MJ; Povlishock, JT				Greer, John E.; McGinn, Melissa J.; Povlishock, John T.			Diffuse Traumatic Axonal Injury in the Mouse Induces Atrophy, c-Jun Activation, and Axonal Outgrowth in the Axotomized Neuronal Population	JOURNAL OF NEUROSCIENCE			English	Article							RAT CORTICOSPINAL NEURONS; EXPERIMENTAL BRAIN-INJURY; ADULT-RAT; TRANSCRIPTION FACTOR; PROTEIN EXPRESSION; WHITE-MATTER; RED NUCLEUS; CELL-DEATH; REGENERATION; RECOVERY	Traumatic axonal injury (TAI) is a consistent component of traumatic brain injury (TBI) and is associated with much of its morbidity. Little is known regarding the long-term retrograde neuronal consequences of TAI and/or the potential that TAI could lead to anterograde axonal reorganization and repair. To investigate the repertoire of anterograde and retrograde responses triggered by TIA, Thy1-YFP-H mice were subjected to mild central fluid percussion injury and killed at various times between 15 min and 28 d post-injury. Based upon confocal assessment of the endogenous neuronal fluorescence, such injury was found to result in diffuse TAI throughout layer V of the neocortex within yellow fluorescent protein (YFP)-positive axons. When these fluorescent approaches were coupled with various quantitative and immunohistochemical approaches, we found that this TAI did not result in neuronal death over the 28 d period assessed. Rather, it elicited neuronal atrophy. Within these same axotomized neuronal populations, TAI was also found to induce an early and sustained activation of the transcription factors c-Jun and ATF-3 (activating transcription factor 3), known regulators of axon regeneration. Parallel ultrastructural studies confirmed that these reactive changes are consistent with atrophy in the absence of neuronal death. Concurrent with those events ongoing in the neuronal cell bodies, their downstream axonal segments revealed, as early as 1 d post-injury, morphological changes consistent with reactive sprouting that was accompanied by significant axonal elongation over time. Collectively, these TAI-linked events are consistent with sustained neuronal recovery, an activation of a regenerative genetic program, and subsequent axonal reorganization suggestive of some form of regenerative response.	[Greer, John E.; McGinn, Melissa J.; Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Greer, JE (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu	Greer, John/K-1008-2012		National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD055813, NS047463, NS007288]; NIH-NINDS CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463-02]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045824, P30NS047463, T32NS007288] Funding Source: NIH RePORTER	This research was supported by National Institutes of Health (NIH) Grants HD055813, NS047463, and NS007288. Microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS Center core grant (5P30NS047463-02). We thank Scott Henderson, PhD, Robert J Hamm, PhD, Thomas Reeves, PhD, Susan A Walker, Carol Lynn Davis, and Audrey Lafrenaye, PhD, for their technical assistance and guidance in various aspects of this study.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARRON KD, 1988, J NEUROPATH EXP NEUR, V47, P62, DOI 10.1097/00005072-198801000-00008; BARRON KD, 1979, J NEUROPATH EXP NEUR, V38, P128, DOI 10.1097/00005072-197903000-00005; Barron KD, 2004, J NEUROL SCI, V220, P119, DOI 10.1016/j.jns.2004.03.009; BARRON KD, 1975, J NEUROPATH EXP NEUR, V34, P222, DOI 10.1097/00005072-197505000-00002; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; BRECHT S, 1995, EXP NEUROL, V134, P112, DOI 10.1006/exnr.1995.1042; Broude E, 1997, EXP NEUROL, V148, P367, DOI 10.1006/exnr.1997.6665; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Campbell G, 2005, EXP NEUROL, V192, P340, DOI 10.1016/j.expneurol.2004.11.026; Carter LM, 2008, J NEUROSCI, V28, P14107, DOI 10.1523/JNEUROSCI.2217-08.2008; Casafont I, 2007, J STRUCT BIOL, V159, P451, DOI 10.1016/j.jsb.2007.05.004; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dray C, 2009, P NATL ACAD SCI USA, V106, P9459, DOI 10.1073/pnas.0900222106; Emery DL, 2000, J COMP NEUROL, V424, P521; ERB DE, 1991, EXP BRAIN RES, V83, P253; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Gervasi NM, 2008, REGEN MED, V3, P907, DOI 10.2217/17460751.3.6.907; Giehl KM, 1997, EUR J NEUROSCI, V9, P2479, DOI 10.1111/j.1460-9568.1997.tb01665.x; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, J NEUROSCI, V18, P5124; Huber AB, 2002, J NEUROSCI, V22, P3553; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iseda T, 2003, J COMP NEUROL, V464, P343, DOI 10.1002/cne.10786; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kenney AM, 1998, J NEUROSCI, V18, P1318; Kreutzberg Georg W., 1995, P355; Li P, 2008, J NEUROSCI, V28, P11970, DOI 10.1523/JNEUROSCI.3724-08.2008; Li Y, 1998, J NEUROSCI, V18, P10514; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mandolesi G, 2004, FASEB J, V18, P1934, DOI 10.1096/fj.04-1805fje; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCBRIDE RL, 1989, J NEUROPATH EXP NEUR, V48, P568, DOI 10.1097/00005072-198909000-00007; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MERLINE M, 1990, J COMP NEUROL, V296, P506, DOI 10.1002/cne.902960313; Nakagomi S, 2003, J NEUROSCI, V23, P5187; Pan YA, 2003, J NEUROSCI, V23, P11479; Paxinos G., 2003, MOUSE BRAIN STEREOTA; Peters A, 1991, FINE STRUCTURE NERVO; Pettigrew DB, 1999, J NEUROSCI, V19, P8358; PETTIGREW DB, 2001, BMC NEUROSCI, V2, pNIL14; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raisman G, 2004, NAT REV NEUROSCI, V5, P157, DOI 10.1038/nrn1328; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Raivich G, 2008, J NEUROCHEM, V107, P898, DOI 10.1111/j.1471-4159.2008.05684.x; Raivich G, 2007, BRAIN RES REV, V53, P287, DOI 10.1016/j.brainresrev.2006.09.005; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Reid AJ, 2010, BRAIN RES, V1310, P1, DOI 10.1016/j.brainres.2009.11.011; Richardson PM, 2009, NEUROSURGERY, V65, pA74, DOI 10.1227/01.NEU.0000352378.26755.C3; Seijffers R, 2007, J NEUROSCI, V27, P7911, DOI 10.1523/JNEUROSCI.5313-06.2007; Seijffers R, 2006, MOL CELL NEUROSCI, V32, P143, DOI 10.1016/j.mcn.2006.03.005; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Sugino K, 2006, NAT NEUROSCI, V9, P99, DOI 10.1038/nn1618; Tang XQ, 2004, NEUROREPORT, V15, P425, DOI 10.1097/00001756-200403010-00009; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	73	108	109	0	12	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAR 30	2011	31	13					5089	5105		10.1523/JNEUROSCI.5103-10.2011			17	Neurosciences	Neurosciences & Neurology	742JM	WOS:000288938200034	21451046	Bronze, Green Accepted, Green Published			2021-06-18	
J	Silverberg, ND; Iverson, GL				Silverberg, Noah D.; Iverson, Grant L.			Etiology of the post-concussion syndrome: Physiogenesis and psychogenesis revisited	NEUROREHABILITATION			English	Article						Mild traumatic brain injury; etiology; rehabilitation	TRAUMATIC BRAIN-INJURY; ACUTE STRESS DISORDER; MILD HEAD-INJURY; RANDOMIZED CONTROLLED-TRIALS; SYMPTOMS FOLLOWING MILD; POSTCONCUSSION SYNDROME; PSYCHOLOGICAL TREATMENT; ILLNESS PERCEPTIONS; MISERABLE MINORITY; EARLY INTERVENTION	In his seminal article, Physiogenesis and Psychogenesis in the 'Post-Concussional Syndrome,' Lishman (1988) proposed that neurobiological factors account for the development of the post-concussion syndrome and psychological factors become primarily responsible for maintaining it in the chronic phase. Over the 20 years that followed, researchers have advanced our understanding of the etiology of the post-concussion syndrome. Our review of this evidence suggests that neurobiological and psychological factors play a causal role in post-concussion symptoms from the outset, and thus, Lishman's causal model should be updated. If we can clinically identify individuals on a trajectory of poor recovery in the acute post-injury stage, then we can direct secondary prevention towards modifiable risk factors.	[Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC V5Z 2G9, Canada; [Silverberg, Noah D.] Univ British Columbia, Dept Med, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada	Silverberg, ND (corresponding author), GF Strong Rehab Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Iverson, Grant/0000-0001-7348-9570	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) Funding Source: Medline		Acarturk C, 2009, PSYCHOL MED, V39, P241, DOI 10.1017/S0033291708003590; Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Allen EA, 2007, TRAUMA, V9, P181, DOI 10.1177/1460408607087717; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Asmundson GJG, 2009, DEPRESS ANXIETY, V26, P888, DOI 10.1002/da.20600; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Beltman MW, 2010, BRIT J PSYCHIAT, V197, P11, DOI 10.1192/bjp.bp.109.064675; Bisson J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub3; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P1016, DOI 10.1080/13854040802441135; Bortolotti B, 2008, GEN HOSP PSYCHIAT, V30, P293, DOI 10.1016/j.genhosppsych.2008.04.001; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Brown RJ, 2004, PSYCHOL BULL, V130, P793, DOI 10.1037/0033-2909.130.5.793; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Dhawan P, 2006, BCMJ, V9, P442; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Donkin L, 2006, PSYCHOL HEALTH, V21, P421, DOI 10.1080/14768320500329292; Ekers D, 2008, PSYCHOL MED, V38, P611, DOI 10.1017/S0033291707001614; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Ferguson JM, 2003, INT CLIN PSYCHOPHARM, V18, P9, DOI 10.1097/00004850-200301000-00002; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Herrera-Guzman I, 2009, J PSYCHIATR RES, V43, P855, DOI 10.1016/j.jpsychires.2008.10.015; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hunot V, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001848; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson G. L., PTSD MILD T IN PRESS; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P745, DOI 10.1007/978-0-387-76978-3_24; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kongsted A, 2008, EUR J PAIN, V12, P455, DOI 10.1016/j.ejpain.2007.07.008; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Levkovitz Y, 2002, BRAIN RES BULL, V58, P345, DOI 10.1016/S0361-9230(01)00780-8; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Nemiah J.C., 1970, MODERN TRENDS PSYCHO, P26, DOI 10.1017/; Pampallona S, 2004, ARCH GEN PSYCHIAT, V61, P714, DOI 10.1001/archpsyc.61.7.714; Panayiotou A, 2010, J CLIN EXP NEUROPSYC, V32, P463, DOI 10.1080/13803390903164371; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; SALKOVSKIS PM, 1986, BEHAV RES THER, V24, P597, DOI 10.1016/0005-7967(86)90041-0; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Snell D. L., BRAIN INJUR IN PRESS; Snell D. L., 2010, THESIS U OTAGO NZ; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; STEELE CM, 1995, J PERS SOC PSYCHOL, V69, P797, DOI 10.1037/0022-3514.69.5.797; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; van Straten A., 2002, J PSYCHOSOM RES, VJournal of Psychosomatic Research, P23; van Veldhoven LM, 2011, J NEUROL NEUROSUR PS, V82, P782, DOI 10.1136/jnnp.2010.228254; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Zeitzer J.M., 2008, STAT ART SOTA	96	108	108	0	22	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2011	29	4					317	329		10.3233/NRE-2011-0708			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	870YW	WOS:000298705800001	22207058				2021-06-18	
J	Dai, SS; Zhou, YG; Li, W; An, JH; Li, P; Yang, N; Chen, XY; Xiong, RP; Liu, P; Zhao, Y; Shen, HY; Zhu, PF; Chen, JF				Dai, Shuang-Shuang; Zhou, Yuan-Guo; Li, Wei; An, Jian-Hong; Li, Ping; Yang, Nan; Chen, Xing-Yun; Xiong, Ren-Ping; Liu, Ping; Zhao, Yan; Shen, Hai-Ying; Zhu, Pei-Fang; Chen, Jiang-Fan			Local Glutamate Level Dictates Adenosine A(2A) Receptor Regulation of Neuroinflammation and Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							ACTIVATED PROTEIN-KINASES; CORTICAL IMPACT MODEL; NERVE GROWTH-FACTOR; EXTRACELLULAR CONCENTRATIONS; METABOTROPIC GLUTAMATE-5; INDUCED EXCITOTOXICITY; SYNAPTIC-TRANSMISSION; HUNTINGTONS-DISEASE; PARKINSONS-DISEASE; RAT HIPPOCAMPUS	During brain injury, extracellular adenosine and glutamate levels increase rapidly and dramatically. We hypothesized that local glutamate levels in the brain dictates the adenosine-adenosineA(2A) receptor (A(2A)R) effects on neuroinflammation and brain damage outcome. Here, we showed that, in the presence of low concentrations of glutamate, the A(2A)R agonist 3-[4-[2-[[6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid (CGS21680) inhibited lipopolysaccharide (LPS)-induced nitric oxide synthase (NOS) activity of cultured microglial cells, an effect that was dependent on the protein kinase A (PKA) pathway. However, in high concentrations of glutamate, CGS21680 increased LPS-induced NOS activity in a protein kinase C (PKC)-dependent manner. Thus, increasing the local level of glutamate redirects A(2A)R signaling from the PKA to the PKC pathway, resulting in a switch in A(2A)R effects from antiinflammatory to proinflammatory. In a cortical impact model of traumatic brain injury (TBI) in mice, brain water contents, behavioral deficits, and expression of tumor necrosis factor-alpha, interleukin-1 mRNAs, and inducible NOS were attenuated by administering CGS21680 at post-TBI time when brain glutamate levels were low, or by administering the A(2A)R antagonist ZM241385 [4-(2-{[5-amino-2-(2-furyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl] amino}ethyl)phenol] at post-TBI time when brain glutamate levels were elevated. Furthermore, pre-TBI treatment with the glutamate release inhibitor (S)-4C3HPG [(S)-4-carboxy-3-hydroxyphenylglycine] converted the debilitating effect of CGS21680 administered at post-TBI time with high glutamate level to a neuroprotective effect. This further indicates that the switch in the effect of A(2A)R activation in intact animals from antiinflammatory to proinflammatory is dependent on glutamate concentration. These findings identify a novel role for glutamate in modulation of neuroinflammation and brain injury via the adenosine-A(2A)R system.	[Dai, Shuang-Shuang; Zhou, Yuan-Guo; Li, Wei; An, Jian-Hong; Li, Ping; Yang, Nan; Chen, Xing-Yun; Xiong, Ren-Ping; Liu, Ping; Zhao, Yan; Shen, Hai-Ying; Zhu, Pei-Fang] Third Mil Med Univ, Inst Surg Res, Ctr Mol Biol, State Key Lab Trauma Burn & Combined Injury, Chongqing 400042, Peoples R China; [Dai, Shuang-Shuang; Zhou, Yuan-Guo; Li, Wei; An, Jian-Hong; Li, Ping; Yang, Nan; Chen, Xing-Yun; Xiong, Ren-Ping; Liu, Ping; Zhao, Yan; Shen, Hai-Ying; Zhu, Pei-Fang] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China; [Shen, Hai-Ying; Chen, Jiang-Fan] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Dai, Shuang-Shuang] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China	Zhou, YG (corresponding author), Third Mil Med Univ, Inst Surg Res, Ctr Mol Biol, State Key Lab Trauma Burn & Combined Injury, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China.	ygzhou@cta.cq.cn	Li, ping/J-6507-2019	Shen, Hai-Ying/0000-0001-8430-2978; Chen, Xingyun/0000-0001-7699-4425	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30328015, 30671918]; U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health Service [NS41083, NS48995]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041083, R01NS048995] Funding Source: NIH RePORTER	This work was supported by National Natural Science Foundation of China Grants 30328015 and 30671918, and U.S. Public Health Service Grants NS41083 and NS48995. We gratefully acknowledge the technical and equipment support provided by Drs. Minghui Xu and Guansong Wang. We thank Chun Hu and Hao Wang for handling of the animals and Dr. Susan E. Lewis for editing this manuscript.	BEGLEY DJ, 1994, J CHROMATOGR B, V657, P185, DOI 10.1016/0378-4347(94)80085-5; Blum D, 2003, J NEUROSCI, V23, P5361; Bracken N, 2006, BRIT J PHARMACOL, V148, P1108, DOI 10.1038/sj.bjp.0706809; Canas PM, 2009, J NEUROSCI, V29, P14741, DOI 10.1523/JNEUROSCI.3728-09.2009; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Chen JF, 2007, PROG NEUROBIOL, V83, P310, DOI 10.1016/j.pneurobio.2007.09.002; Cheng HC, 2002, J BIOL CHEM, V277, P33930, DOI 10.1074/jbc.M201206200; Chou SY, 2005, J NEUROCHEM, V93, P310, DOI 10.1111/j.1471-4159.2005.03029.x; Cobine CA, 2007, AM J PHYSIOL-HEART C, V292, pH3079, DOI 10.1152/ajpheart.01261.2006; Coccurello R, 2004, NEUROPSYCHOPHARMACOL, V29, P1451, DOI 10.1038/sj.npp.1300444; Corsi C, 1999, NEUROREPORT, V10, P687, DOI 10.1097/00001756-199903170-00005; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5; Cunha RA, 2000, NEUROSCI LETT, V289, P127, DOI 10.1016/S0304-3940(00)01295-7; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Dall'Igna OP, 2007, EXP NEUROL, V203, P241, DOI 10.1016/j.expneurol.2006.08.008; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; Ferre S, 2002, P NATL ACAD SCI USA, V99, P11940, DOI 10.1073/pnas.172393799; Fredholm BB, 2007, PROG NEUROBIOL, V83, P263, DOI 10.1016/j.pneurobio.2007.07.005; Genovese T, 2009, SHOCK, V32, P578, DOI 10.1097/SHK.0b013e3181a20792; Gianfriddo M, 2004, NEUROBIOL DIS, V17, P77, DOI 10.1016/j.nbd.2004.05.008; Gill SS, 2001, TOXICOL PATHOL, V29, P208, DOI 10.1080/019262301317052486; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Ikeda K, 2002, J NEUROCHEM, V80, P262, DOI 10.1046/j.0022-3042.2001.00694.x; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Kachroo A, 2005, J NEUROSCI, V25, P10414, DOI 10.1523/JNEUROSCI.3660-05.2005; Khoa ND, 2006, MOL PHARMACOL, V69, P1311, DOI 10.1124/mol.105.016857; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Li Y, 2006, NEUROSCIENCE, V141, P2029, DOI 10.1016/j.neuroscience.2006.05.014; Lorenc-Koci E, 2001, BRAIN RES, V903, P177, DOI 10.1016/S0006-8993(01)02438-6; Malek RL, 1999, J BIOL CHEM, V274, P35499, DOI 10.1074/jbc.274.50.35499; Marchi M, 2002, BRIT J PHARMACOL, V136, P434, DOI 10.1038/sj.bjp.0704712; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Melani A, 2006, BRAIN RES, V1073, P470, DOI 10.1016/j.brainres.2005.12.010; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; Pedata F, 2001, ANN NY ACAD SCI, V939, P74; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Pinto-Duarte A, 2005, J NEUROCHEM, V93, P595, DOI 10.1111/j.1471-4159.2005.03071.x; Popoli P., 2003, Neurology, V61, pS69; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Popoli P, 1995, EUR J PHARMACOL, V287, P215, DOI 10.1016/0014-2999(95)00679-6; Popoli P, 2008, CURR PHARM DESIGN, V14, P1500, DOI 10.2174/138161208784480117; Saura J, 2005, J NEUROCHEM, V95, P919, DOI 10.1111/j.1471-4159.2005.03395.x; Schulte G, 2003, CELL SIGNAL, V15, P813, DOI 10.1016/S0898-6568(03)00058-5; Si QS, 1996, EXP NEUROL, V137, P345, DOI 10.1006/exnr.1996.0035; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Stone TW, 2007, J NEUROSCI RES, V85, P1077, DOI 10.1002/jnr.21212; Tebano MT, 2005, J NEUROCHEM, V95, P1188, DOI 10.1111/j.1471-4159.2005.03455.x; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Yu LQ, 2008, ANN NEUROL, V63, P338, DOI 10.1002/ana.21313; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103	56	108	115	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 21	2010	30	16					5802	5810		10.1523/JNEUROSCI.0268-10.2010			9	Neurosciences	Neurosciences & Neurology	586PQ	WOS:000276923700032	20410132	Green Published, Bronze			2021-06-18	
J	White, B; Driver, S; Warren, AM				White, Brian; Driver, Simon; Warren, Ann Marie			Resilience and Indicators of Adjustment During Rehabilitation From a Spinal Cord Injury	REHABILITATION PSYCHOLOGY			English	Article						resilience; depressive symptomatology; functional independence; satisfaction with life; spirituality	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; PERSONALITY PROTOTYPES; MAJOR DEPRESSION; SPIRITUALITY; HEALTH; ADOLESCENTS; COMMUNITY; RELIGION; PEOPLE	Objectives: The purposes of this study were to (a) identify changes in resilience and indicators of adjustment (i.e., satisfaction with life, depressive symptomatology, spirituality, functional independence) during inpatient rehabilitation after spinal cord injury (SCI) and (b) examine the relationship between each variable at different stages of the rehabilitation process. Design: The sample consisted of 42 individuals with a SCI, including 33 men and 9 women who were inpatients for a mean stay of 51 days (SD = 14.63). A repeated measures design was employed, with questionnaires completed at 3 times during the rehabilitation program (admit, 3 weeks, and discharge). Results: Results front the repeated measures multivariate analysis of covarance and post hoc follow-up tests indicated that there was no significant change in resilience, but that there was significant change for each indicator of adjustment during inpatient rehabilitation. Findings also indicated significant correlations between resilience, satisfaction with life, spirituality. and depressive symptoms. Conclusion: Future studies that focus oil developing interventions and examine the factors that predict resilience could help build resilience, which in turn may improve rehabilitation outcomes.	[White, Brian; Driver, Simon] Univ N Texas, Dept Kinesiol Hlth Promot & Recreat, Denton, TX 76203 USA; [Warren, Ann Marie] Baylor Inst Rehabil, Dept Phys Med & Rehabil, Dallas, TX USA	Driver, S (corresponding author), Univ N Texas, Dept Kinesiol Hlth Promot & Recreat, POB 310769, Denton, TX 76203 USA.	simon.driver@unt.edu		driver, simon/0000-0003-2356-432X; Warren, Ann Marie/0000-0002-3753-5573			*AM PSYCH ASS PSYC, 2009, ROAD RES; Amatea E.S, 2020, PROF SCH COUNS, V9, P177, DOI [10.5330/prsc.9.3.43751461038m4m68, DOI 10.5330/PRSC.9.3.43751461038M4M68]; Anderson NB, 2003, EMOTIONAL LONGEVITY; Asendorpf JB, 2001, EUR J PERSONALITY, V15, P169, DOI 10.1002/per.408; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Bonanno GA, 2007, J CONSULT CLIN PSYCH, V75, P671, DOI 10.1037/0022-006X.75.5.671; Burnett DM, 2002, NEUROREHABILITATION, V17, P187; Campbell-Sills L, 2006, BEHAV RES THER, V44, P585, DOI 10.1016/j.brat.2005.05.001; Charlifue S, 2004, NEUROREHABILITATION, V19, P91; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Connor KM, 2003, J TRAUMA STRESS, V16, P487, DOI 10.1023/A:1025762512279; Davey M, 2003, J ADOLESCENT RES, V18, P347, DOI 10.1177/0743558403018004002; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dimidjian S, 2006, J CONSULT CLIN PSYCH, V74, P658, DOI 10.1037/0022-006X.74.4.658; Dixon GS, 2005, DISABIL REHABIL, V27, P643, DOI 10.1080/09638280400018429; Elliott TR, 2004, REHABIL PSYCHOL, V49, P134, DOI 10.1037/0090-5550.49.2.134; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; FRANK RG, 1987, CLIN PSYCHOL REV, V7, P611, DOI 10.1016/0272-7358(87)90009-2; Froehlich JP, 2006, PASTOR PSYCHOL, V54, P465, DOI 10.1007/s11089-005-0011-0; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Hodge DR, 2003, J SOC SERV RES, V30, P41, DOI 10.1300/J079v30n01_03; Hodges S, 2002, J ADULT DEV, V9, P109, DOI 10.1023/A:1015733329006; Idler EL, 2003, RES AGING, V25, P327, DOI 10.1177/0164027503025004001; Johnstone B, 2007, DISABIL REHABIL, V29, P1153, DOI 10.1080/09638280600955693; Johnstone B, 2009, REHABIL PSYCHOL, V54, P422, DOI 10.1037/a0017758; Kennedy P, 2000, SPINAL CORD, V38, P498, DOI 10.1038/sj.sc.3101021; LaFromboise TD, 2006, J COMMUNITY PSYCHOL, V34, P193, DOI 10.1002/jcop.20090; Luthar SS, 1996, J RES ADOLESCENCE, V6, P581; Luthar SS, 2000, DEV PSYCHOPATHOL, V12, P857, DOI 10.1017/S0954579400004156; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Mancini AD, 2006, J CLIN PSYCHOL, V62, P971, DOI 10.1002/jclp.20283; Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227; Matheis EN, 2006, REHABIL PSYCHOL, V51, P265, DOI 10.1037/0090-5550.51.3.265; McCrae RR, 1997, AM PSYCHOL, V52, P509, DOI 10.1037/0003-066X.52.5.509; Munce SEP, 2007, PSYCHOSOMATICS, V48, P394, DOI 10.1176/appi.psy.48.5.394; *NAT SPIN CORD INJ, 2009, FACTS FIG GLANC SEPT; Newman R, 2005, PROF PSYCHOL-RES PR, V36, P227, DOI 10.1037/0735-7028.36.3.227; NORUSIS MJ, 1998, SPSS ADV STAT USERS; Nyland J, 2000, SPINAL CORD, V38, P649, DOI 10.1038/sj.sc.3101070; Rammstedt B, 2004, EUR J PERSONALITY, V18, P1, DOI 10.1002/per.495; Ray O, 2004, AM PSYCHOL, V59, P29, DOI 10.1037/0003-066X.59.1.29; Richardson GE, 2002, J CLIN PSYCHOL, V58, P307, DOI 10.1002/jclp.10020; Riolli L, 2002, J APPL SOC PSYCHOL, V32, P1604, DOI 10.1111/j.1559-1816.2002.tb02765.x; Scherer MJ, 2001, DISABIL REHABIL, V23, P387; Schoon I, 2006, RISK AND RESILIENCE: ADAPTATIONS IN CHANGING TIMES, P1, DOI 10.2277/ 0521833744; Seligman MEP, 2000, AM PSYCHOL, V55, P5, DOI 10.1037/0003-066X.55.1.5; Sherman JE, 2004, REHABIL PSYCHOL, V49, P140, DOI 10.1037/0090-5550.49.2.140; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tabachnick B., 2001, USING MULTIVARIATE S; Vera EA, 2006, COUNS PSYCHOL, V34, P80, DOI 10.1177/0011000005282365; Weed K, 2006, J APPL DEV PSYCHOL, V27, P60, DOI 10.1016/j.appdev.2005.12.007; Westphal M, 2007, APPL PSYCHOL-INT REV, V56, P417, DOI 10.1111/j.1464-0597.2007.00298.x; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; Woolrich Rachel A, 2006, Psychol Health Med, V11, P80, DOI 10.1080/13548500500294211; World Health Organization, 2001, INT CLASS FUNCT DIS	57	108	123	0	21	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2010	55	1					23	32		10.1037/a0018451			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	563NJ	WOS:000275139000003	20175631				2021-06-18	
J	Yang, CY; Song, BB; Ao, Y; Nowak, AP; Abelowitz, RB; Korsak, RA; Havton, LA; Deming, TJ; Sofroniew, MV				Yang, Chu-Ya; Song, Bingbing; Ao, Yan; Nowak, Andrew P.; Abelowitz, Ryan B.; Korsak, Rose A.; Havton, Leif A.; Deming, Timothy J.; Sofroniew, Michael V.			Biocompatibility of amphiphilic diblock copolypeptide hydrogels in the central nervous system	BIOMATERIALS			English	Article						Scaffolds; Brain; Spinal cord; Biocompatibility; Drug delivery; Hydrogels	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; POLYPEPTIDE HYDROGELS; BLOCK COPOLYPEPTIDES; IN-VIVO; DELIVERY; REPAIR; CELLS; SCAFFOLDS; NEURONS	Amphiphilic diblock copolypeptide hydrogels (DCHs) are synthetic materials whose properties can be varied readily and predictably by altering copolymer chain length or composition and which are of potential interest for biomaterial applications. We tested the biocompatibility in the central nervous system (CNS) of DCH composed of lysine, homoarginine or glutamate in combination with leucine. A range of DCH formulations with theological properties similar to brain tissue were injected into mouse forebrain and examined after 1-8 weeks using light microscopy, immunohistochemistry and electron microscopy. DCH deposits elicited no more gliosis, inflammation, or toxicity to neurons, myelin or axons than did injections of physiological saline. The size, rigidity, and density of DCH deposits could be varied subtly by altering DCH composition and concentration. For any given DCH formulation, increased concentration correlated with increased gel strength in vitro and increased deposit size in vivo. DCHs of lysine and leucine (KmLn) were selected for detailed analyses because these formed deposits with desirable physical properties and since lysine is routinely used as a substrate for neural cell cultures. Deposits of unmodified K180L20 exhibited time-dependent in-growth of blood vessels and of certain glial cells, and limited in-growth of nerve fibers. These findings show that DCHs are injectable, re-assemble in vivo to form 3-dimensional deposits, exhibit little or no detectable toxicity in the CNS, integrate well with brain tissue and represent a new class of synthetic biomaterials with potential for applications as depots or scaffolds in the CNS. (C) 2009 Elsevier Ltd. All rights reserved.	[Song, Bingbing; Ao, Yan; Abelowitz, Ryan B.; Korsak, Rose A.; Sofroniew, Michael V.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; [Yang, Chu-Ya; Nowak, Andrew P.; Deming, Timothy J.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA; [Havton, Leif A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	Sofroniew, MV (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, 10833 Conte Ave, Los Angeles, CA 90095 USA.	sofroniew@mednet.ucla.edu	Sofroniew, Michael/ABE-8857-2020; Deming, Timothy/I-5411-2013	Deming, Timothy/0000-0002-0594-5025	Adelson Medical Research Foundation	This study was supported by the Adelson Medical Research Foundation (Adelson Program in Neural Rehabilitation and Repair). We thank Dr. A. Katapodis, Novartis Insitute, Basel, Switzerland, for the anti-poly-lysine antibody, Prof. T.G. Mason and Dr. J.N. Wilking for rheology assistance, and Ms. B. Sjostrand for ultrastructural assistance.	Beardsley RL, 2002, ANAL CHEM, V74, P1884, DOI 10.1021/ac015613o; Bocchiaro CM, 2004, P NATL ACAD SCI USA, V101, P4292, DOI 10.1073/pnas.0305712101; Breedveld V, 2004, MACROMOLECULES, V37, P3943, DOI 10.1021/ma049885f; Deming TJ, 2005, SOFT MATTER, V1, P28, DOI 10.1039/b500307e; Deming TJ, 2002, ADV DRUG DELIVER REV, V54, P1145, DOI 10.1016/S0169-409X(02)00062-5; Deming TJ, 1999, MACROMOLECULES, V32, P4500, DOI 10.1021/ma9902899; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Ford MC, 2006, P NATL ACAD SCI USA, V103, P2512, DOI 10.1073/pnas.0506020102; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Hartgerink JD, 2002, P NATL ACAD SCI USA, V99, P5133, DOI 10.1073/pnas.072699999; Havton LA, 2005, J NEUROSCI METH, V149, P101, DOI 10.1016/j.jneumeth.2005.03.014; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Holmes TC, 2000, P NATL ACAD SCI USA, V97, P6728, DOI 10.1073/pnas.97.12.6728; Holowka EP, 2007, NAT MATER, V6, P52, DOI 10.1038/nmat1794; Hou SP, 2005, J NEUROSCI METH, V148, P60, DOI 10.1016/j.jneumeth.2005.04.016; HUSEK P, 1991, J CHROMATOGR, V552, P289, DOI 10.1016/S0021-9673(01)95945-X; Ilan N, 2003, CURR OPIN CELL BIOL, V15, P515, DOI 10.1016/S0955-0674(03)00100-5; Jain A, 2006, BIOMATERIALS, V27, P497, DOI 10.1016/j.biomaterials.2005.07.008; Katopodis AG, 2002, J CLIN INVEST, V110, P1869, DOI 10.1172/JCI200216526; KIMMEL JR, 1967, METHOD ENZYMOL, V11, P584, DOI DOI 10.1016/S0076-6879(67)11072-0; KLEIN HF, 1975, CHEM BER-RECL, V108, P944, DOI 10.1002/cber.19751080327; Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nisbet DR, 2008, J BIOMED MATER RES B, V87B, P251, DOI 10.1002/jbm.b.31000; Nishiyama A, 2007, NEUROSCIENTIST, V13, P62, DOI 10.1177/1073858406295586; Nowak AP, 2003, J AM CHEM SOC, V125, P15666, DOI 10.1021/ja0381050; Nowak AP, 2002, NATURE, V417, P424, DOI 10.1038/417424a; Pangborn AB, 1996, ORGANOMETALLICS, V15, P1518, DOI 10.1021/om9503712; Peppas NA, 2000, ANNU REV BIOMED ENG, V2, P9, DOI 10.1146/annurev.bioeng.2.1.9; Peters A, 1991, FINE STRUCTURE NERVO; Pochan DJ, 2002, MACROMOLECULES, V35, P5358, DOI 10.1021/ma025526d; Sanjana NE, 2004, J NEUROSCI METH, V136, P151, DOI 10.1016/j.jneumeth.2004.01.011; Schmidt CE, 2003, ANNU REV BIOMED ENG, V5, P293, DOI 10.1146/annurev.bioeng.5.011303.120731; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Stokols S, 2006, TISSUE ENG, V12, P2777, DOI 10.1089/ten.2006.12.2777; SVENDSEN CN, 1994, J NEUROSCI, V14, P75; Taylor SJ, 2006, J CONTROL RELEASE, V113, P226, DOI 10.1016/j.jconrel.2006.05.005; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540; Zhang N, 2005, BRAIN RES REV, V49, P48, DOI 10.1016/j.brainresrev.2004.11.002; Zhong YH, 2008, J R SOC INTERFACE, V5, P957, DOI 10.1098/rsif.2008.0071	43	108	109	4	43	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	MAY	2009	30	15					2881	2898		10.1016/j.biomaterials.2009.01.056			18	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	435FA	WOS:000265328100004	19251318				2021-06-18	
J	Lumpkins, KM; Bochicchio, GV; Keledjian, K; Simard, JM; McCunn, M; Scalea, T				Lumpkins, Kimberly M.; Bochicchio, Grant V.; Keledjian, Kaspar; Simard, J. Marc; McCunn, Maureen; Scalea, Thomas			Glial Fibrillary Acidic Protein is Highly Correlated With Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Glial fibrillary acidic protein	NEURON-SPECIFIC-ENOLASE; TRAUMATIC BRAIN; CEREBROSPINAL-FLUID; HEMORRHAGIC-SHOCK; SERUM-LEVELS; RELEASE; SEVERITY; S-100B; STROKE; BLOOD	Background. Glial fibrillary acidic protein (GFAP) is an intermediate filament protein found in the cytoskeleton of astroglia. Recent work has indicated that GFAP may serve as a serum marker of traumatic brain injury (TBI) that is released after central nervous system cell damage. Methods: Serum from 51 critically injured trauma patients was prospectively collected on admission and on hospital day 2. All patients underwent an admission head computed tomography (CT) scan as a part of their clinical evaluation. Patients with facial fractures in the absence of documented TBI and patients with spinal cord injury were excluded. Demographic and outcome data were collected prospectively. Serum GFAP was measured in duplicate using enzyme-linked immunosorbent assay techniques. Results: Thirty-nine (76%) of the 51 patients had CT-documented TBI. The study cohort was 72.5% men with a mean age of 43 years and mean Injury Severity Score (ISS) of 30.2. There were no statistically significant demographic differences between the two groups. At admission day, the mean GFAP level in non-TBI patients was 0.07 pg/mL compared with 6.77 pg/mL in TBI patients (p = 0.002). On day 2 the mean GFAP level was 0.02 in non-TBI patients compared with 2.17 in TBI patients (p = 0.003). Using regression analysis to control for age, sex, and ISS, the Head Abbreviated Injury Scale was predictive of the level of GFAP on both days I and 2 (p values 0.006 and 0.026, respectively). Although GFAP levels were not predictive of increased hospital length of stay, intensive care unit length of stay, or ventilator days, high GFAP levels on hospital day 2 were predictive of mortality when controlling for age, sex, and ISS (odds ratio 1.45, p value 0.028). The area under the receiver operating characteristic curve for GFAP was 0.90 for day I and 0.88 for day 2. A GFAP cutoff point of I pg/mL yielded 100% specificity and 50% to 60% sensitivity for TBI. Conslusions: GFAP is a serum marker of TBI, and persistent elevation on day 2 is predictive of increased mortality. Excellent specificity for CT-documented brain injury was found using a cutoff point of I pg/mL.	[Lumpkins, Kimberly M.; Bochicchio, Grant V.; Keledjian, Kaspar; Simard, J. Marc; McCunn, Maureen; Scalea, Thomas] R Adams Cowley Shock Trauma Ctr, Div Clin & Outcomes Res, Baltimore, MD 21201 USA	Bochicchio, GV (corresponding author), R Adams Cowley Shock Trauma Ctr, Div Clin & Outcomes Res, 22 S Greene St, Baltimore, MD 21201 USA.	gbochicchio@umm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM075767] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [1T32GM075767] Funding Source: Medline		AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Missler U, 1999, CLIN CHEM, V45, P138; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Steiner J, 2006, J NEUROL NEUROSUR PS, V77, P1284, DOI 10.1136/jnnp.2006.093427; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Vissers JLM, 2006, CLIN CHIM ACTA, V366, P336, DOI 10.1016/j.cca.2005.11.017; Vos PE, 2006, EUR J NEUROL, V13, P632, DOI 10.1111/j.1468-1331.2006.01332.x; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wunderlich MT, 2006, EUR J NEUROL, V13, P1118, DOI 10.1111/j.1468-1331.2006.01435.x	17	108	111	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2008	65	4					778	784		10.1097/TA.0b013e318185db2d			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	361JS	WOS:000260124500007	18849790				2021-06-18	
J	Colville, G; Kerry, S; Pierce, C				Colville, Gillian; Kerry, Sally; Pierce, Christine			Children's factual and delusional memories of intensive care	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						post-traumatic stress; hallucinations; memory; opiates; benzodiazepines	POSTTRAUMATIC-STRESS-DISORDER; MECHANICALLY VENTILATED PATIENTS; PRINCIPAL-COMPONENTS-ANALYSIS; CRITICAL ILLNESS; EVENT SCALE; DELIRIUM; WITHDRAWAL; IMPACT; PHENOMENOLOGY; MORTALITY	Rationale Delusional memories are significantly associated with post-traumatic stress in adult patients after intensive care. Objectives: In this study, we attempted to establish whether this relationship was found in children. We also examined the association between factual memory and distress. Methods: One hundred two consecutive children, aged between 7 and 17 years, were interviewed about their pediatric intensive care unit (PICU) experience 3 months after discharge from a PICU. Principal measures were the ICU Memory Tool (a checklist of intensive care memories) and an abbreviated version of the Impact of Event Scale (a screen for post-traumatic stress disorder). Measurements and Main Results: In total, 64 of 102 (63%) children reported at least one factual memory of their admission and 33 of 102 (32%) reported delusional memories, including disturbing hallucinations. Traumatic brain injury was negatively associated with factual memory (odds ratio, 0.23; 95% confidence interval [CI], 0.09-0.58; P = 0.002). Longer duration of opiates/benzodiazepines was associated with delusional memory (odds ratio, 4.98; 95% CI, 1.3-20.0; P = 0.023). Post-traumatic stress scores were higher in children reporting delusional memories (adjusted difference, 3.0; 95% Cl, 0.06-5.9; P = 0.045) when illness severity and emergency status were controlled for. Factual memory was not significantly associated with post-traumatic stress. Conclusions: This study indicates that delusional memories are reported by almost one-third of children and are associated both with the duration of opiates/benzodiazepines and risk of post-traumatic stress. More research is needed on the presence of delusional memories and associated risk factors in children receiving intensive care treatment.	[Colville, Gillian] Gen Hosp St Georg, Pediat Psychol Serv, London SW17 0QT, England; [Kerry, Sally] St Georges Univ London, Community Hlth Sci, London, England; [Pierce, Christine] Great Ormond St Hosp Sick Children, Pediat Intens Care Unit, London WC1N 3JH, England	Colville, G (corresponding author), Gen Hosp St Georg, Pediat Psychol Serv, London SW17 0QT, England.	gcolvill@sgul.ac.uk	Colville, Gillian/ABH-3180-2020	Colville, Gillian/0000-0001-8530-2822			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Capuzzo M, 2004, CRIT CARE, V8, pR48, DOI 10.1186/cc2416; Colville G, 2006, CRIT CARE MED, V34, pA20, DOI 10.1097/00003246-200612002-00080; CUTTING J, 1987, BRIT J PSYCHIAT, V151, P324, DOI 10.1192/bjp.151.3.324; Ducharme Celine, 2005, Intensive Crit Care Nurs, V21, P179; Ely EW, 2007, CRIT CARE MED, V35, P112, DOI 10.1097/01.CCM.0000251925.18961.CA; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Fonsmark L, 1999, CRIT CARE MED, V27, P196, DOI 10.1097/00003246-199901000-00052; Gaudreau JD, 2005, PSYCHOSOMATICS, V46, P302, DOI 10.1176/appi.psy.46.4.302; Griffiths J, 2007, INTENS CARE MED, V33, P1506, DOI 10.1007/s00134-007-0730-z; HUGHES J, 1994, ACTA PAEDIATR, V83, P1194; HUGHES J, 1998, INTENSIVE CRIT CARE, V4, P8; Hulst JM, 2005, INTENS CARE MED, V31, P880, DOI 10.1007/s00134-005-2647-8; Ista E, 2007, INTENS CARE MED, V33, P1396, DOI 10.1007/s00134-007-0696-x; Jones C, 2007, INTENS CARE MED, V33, P978, DOI 10.1007/s00134-007-0600-8; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Jones C, 1999, INTENS CARE MED, V25, P1183, DOI 10.1007/s001340051035; Jones C., 2000, CLIN INTENSIVE CARE, V11, P252; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; Magarey Judith M, 2005, Intensive Crit Care Nurs, V21, P344; Meagher DJ, 2007, BRIT J PSYCHIAT, V190, P135, DOI 10.1192/bjp.bp.106.023911; Meagher DJ, 2001, BMJ-BRIT MED J, V322, P144, DOI 10.1136/bmj.322.7279.144; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; *PAED INT CAR AUD, 2005, ANN REP 2003 2004; Pandharipande P, 2006, CRIT CARE CLIN, V22, P313, DOI 10.1016/j.ccc.2006.02.010; Pearson GA, 2001, ARCH DIS CHILD, V84, P125, DOI 10.1136/adc.84.2.125; Perrin S, 2005, BEHAV COGN PSYCHOTH, V33, P487, DOI 10.1017/S1352465805002419; Playfor S, 2000, ARCH DIS CHILD, V83, P445, DOI 10.1136/adc.83.5.445; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Rees G, 2004, INTENS CARE MED, V30, P1607, DOI 10.1007/s00134-004-2310-9; Rennick Janet E, 2004, Pediatr Crit Care Med, V5, P358, DOI 10.1097/01.PCC.0000128603.20501.0D; Ringdal Mona, 2006, Intensive Crit Care Nurs, V22, P346, DOI 10.1016/j.iccn.2006.03.001; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; Schieveld JNM, 2007, INTENS CARE MED, V33, P1033, DOI 10.1007/s00134-007-0637-8; Scott CK, 2006, J TRAUMA STRESS, V19, P757, DOI 10.1002/jts.20186; Scragg P, 2001, ANAESTHESIA, V56, P9, DOI 10.1046/j.1365-2044.2001.01714.x; Shudy M, 2006, PEDIATRICS, V118, pS203, DOI 10.1542/peds.2006-0951B; Smith P, 2003, PERS INDIV DIFFER, V34, P315, DOI 10.1016/S0191-8869(02)00047-8; Stallard P, 1999, J CHILD PSYCHOL PSYC, V40, P1075, DOI 10.1111/1469-7610.00525; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; Townsend P., 1988, HLTH DEPRIVATION INE; Truog RD, 2005, INTENS CARE MED, V31, P760, DOI 10.1007/s00134-005-2646-9; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; Turkel SB, 2003, J NEUROPSYCH CLIN N, V15, P431, DOI 10.1176/appi.neuropsych.15.4.431; YULE W, 1994, PERS INDIV DIFFER, V16, P685, DOI 10.1016/0191-8869(94)90210-0; Yule W., 1997, CHILD PSYCHOL PORTFO, P35	50	108	111	2	11	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAY 1	2008	177	9					976	982		10.1164/rccm.200706-857OC			7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	295PJ	WOS:000255486100010	18244955				2021-06-18	
J	Clark, RSB; Bayir, H; Chu, CT; Alber, SM; Kochanek, PM; Watkins, SC				Clark, Robert S. B.; Bayir, Hulya; Chu, Charleen T.; Alber, Sean M.; Kochanek, Patrick M.; Watkins, Simon C.			Autophagy is increased in mice after traumatic brain injury and is detectable in human brain after trauma and critical illness	AUTOPHAGY			English	Article						autophagosome; controlled cortical impact; antioxidant; head injury; LC3; mitophagy	HEAD-INJURY; DISEASE; PROTEOLYSIS; LYSOSOMES	Autophagy is a homeostatic process for recycling of proteins and organelles, that increases during times of nutrient deprivation and is regulated by reactive oxygen species. We reported that autophagy can also be induced after traumatic brain injury (TBI) in mice.1 Specifically, autophagosomes and multilamellar bodies were frequently observed in cell processes and axons in injured brain regions by electron microscopy, and lipidated microtubule-associated protein light chain 3 (LC3-II), was increased after TBI vs. controls. To determine if antioxidants could reduce autophagy, separate mice were treated with the antioxidant gamma-glutamylcysteinyl ethyl ester (GCEE). Treatment with GCEE preserved total antioxidant reserves, reduced LC3-II in injured brains, and improved both behavioral and histological outcome after TBI. Here we report that LC3-II and autophagosomes were detectable in brain tissue from humans after TBI. Taken together, we show that autophagy occurs after both experimental and clinical TBI, and that oxidative stress contributes to overall neuropathology after TBI in mice, at least in part by initiating or influencing autophagy. Addendum to: Lai Y, Hickey RW, Chen Y, Bayir H, Sullivan M, Chu CT, Kochanek PM, Dixon CE, Jenkins LW, Graham SH, Watkins SC, Clark RSB. Autophagy is increased after traumatic brain injury in mice and is partially inhibited by the antioxidant gamma-glutamylcysteinyl ethyl ester. J Cereb Blood Flow Metab 2007; In press.	[Clark, Robert S. B.; Bayir, Hulya; Kochanek, Patrick M.] Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; [Bayir, Hulya] Safar Ctr Resuscitat Res, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; [Chu, Charleen T.] Safar Ctr Resuscitat Res, Dept Pathol, Pittsburgh, PA 15260 USA; [Alber, Sean M.; Watkins, Simon C.] Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA	Clark, RSB (corresponding author), Safar Ctr Resuscitat Res, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Chu, Charleen T/B-1601-2008; Kochanek, Patrick M/D-2371-2015	Chu, Charleen T/0000-0002-5052-8271; Kochanek, Patrick M/0000-0002-2627-913X; watkins, simon/0000-0003-4092-1552	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS30318, R01 NS38620] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [AHA 0535365N] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, P50NS030318] Funding Source: NIH RePORTER		Clark RSB, 1999, FASEB J, V13, P813; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Koike M, 2005, AM J PATHOL, V167, P1713, DOI 10.1016/S0002-9440(10)61253-9; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; LAI Y, 2007, J CEREB BLOOD F EPUB; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Mizushima N, 2006, AUTOPHAGY, V2, P302, DOI 10.4161/auto.2945; NEELY N, 1974, BIOCHEM BIOPH RES CO, V59, P680; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Wang QJ, 2006, J NEUROSCI, V26, P8057, DOI 10.1523/JNEUROSCI.2261-06.2006; Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje; Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524	16	108	118	0	3	LANDES BIOSCIENCE	AUSTIN	1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA	1554-8627			AUTOPHAGY	Autophagy	JAN 1	2008	4	1					88	90		10.4161/auto.5173			3	Cell Biology	Cell Biology	249FB	WOS:000252211800033	17957135	Bronze			2021-06-18	
J	Nortje, J; Coles, JP; Timofeev, I; Fryer, TD; Aigbirhio, FI; Smielewski, P; Outtrim, JG; Chatfield, DA; Pickard, JD; Hutchinson, PJ; Gupta, AK; Menon, DK				Nortje, Jurgens; Coles, Jonathan P.; Timofeev, Ivan; Fryer, Tim D.; Aigbirhio, Franklin I.; Smielewski, Peter; Outtrim, Joanne G.; Chatfield, Doris A.; Pickard, John D.; Hutchinson, Peter J.; Gupta, Arun K.; Menon, David K.			Effect of hyperoxia on regional oxygenation and metabolism after severe traumatic brain injury: Preliminary findings	CRITICAL CARE MEDICINE			English	Article						brain injuries; brain ischemia; oxidative phosphorylation; positron-emission tomography; microdialysis; hyperoxia	SEVERE HEAD-INJURY; CEREBRAL-ISCHEMIA; TISSUE OXYGEN; NITRIC-OXIDE; DEPENDENT REGULATION; ENERGY-METABOLISM; DAMAGE; HYPOXIA; MICRODIALYSIS; CARE	Objective: To determine the effect of normobaric hyperoxia on cerebral metabolism in patients with severe traumatic brain injury. Design: Prospective clinical investigation. Setting: Neurosciences critical care unit of a university hospital. Patients: Eleven patients with severe traumatic brain injury. Interventions. Cerebral microdialysis, brain tissue oximetry (Pb0(2)), and oxygen-15 positron emission tomography ((15)0-PET) were undertaken at normoxia and repeated at hyperoxia (F10(2) increase of between 0.35 and 0.50). Measurements and Main Results. Established models were used to image cerebral blood flow, blood volume, oxygen metabolism, and oxygen extraction fraction. Physiology was characterized in a focal region of interest (surrounding the microdialysis catheter) and correlated with microdialysis and oximetry. Physiology was also characterized in a global region of interest (including the whole brain), and a physiologic region of interest (defined using a critical cerebral metabolic rate of oxygen threshold). Hyperoxia increased mean +/- SD Pb0(2) from 28 +/- 21 mm Hg to 57 +/- 47 mm Hg (p = .015). Microdialysate lactate and pyruvate were unchanged, but the lactate/pyruvate ratio showed a statistically significant reduction across the study population (34.1 +/- 9.5 vs. 32.5 +/- 9.0, p = .018). However, the magnitude of reduction was small, and its clinical significance doubtful. The focal region of interest and global (15)0-PET variables were unchanged. "Atrisk" tissue defined by the physiologic region of interest, however, showed a universal increase in cerebral metabolic rate of oxygen from a median (interquartile range) of 23 (22-25) mu mol(.)100 mL(-1)-min(-1) to 30 (28-36) mu mol(.)100 mL(-1.)min(-1) (p < .01). Conclusions: In severe traumatic brain injury, hyperoxia increases Pb0(2) with a variable effect on lactate and lactate/pyruvate ratio. Microdialysis does not, however, predict the universal increases in cerebral metabolic rate of oxygen in at-risk tissue, which imply preferential metabolic benefit with hyperoxia.	[Nortje, Jurgens; Coles, Jonathan P.; Outtrim, Joanne G.; Chatfield, Doris A.; Gupta, Arun K.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; [Timofeev, Ivan; Smielewski, Peter; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; [Nortje, Jurgens; Coles, Jonathan P.; Timofeev, Ivan; Fryer, Tim D.; Aigbirhio, Franklin I.; Smielewski, Peter; Outtrim, Joanne G.; Chatfield, Doris A.; Pickard, John D.; Hutchinson, Peter J.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England	Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Timofeev, Ivan/AAE-7019-2019	Outtrim, Joanne/0000-0001-8118-6430; Timofeev, Ivan/0000-0002-1168-0393; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G9439390, G0001237, G0600986] Funding Source: Medline		Alessandri B, 1999, ACT NEUR S, V75, P25; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1975, LANCET, V1, P480; Kietzmann T, 2001, EUR ARCH PSY CLIN N, V251, P170, DOI 10.1007/s004060170037; Kim CH, 2002, CIRC RES, V90, pE25, DOI 10.1161/hh0202.104923; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Li J, 2004, FREE RADICAL BIO MED, V36, P1460, DOI 10.1016/j.freeradbiomed.2004.03.005; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Magnusson L, 2003, BRIT J ANAESTH, V91, P61, DOI 10.1093/bja/aeg085; Mander P, 2005, J NEUROSCI RES, V79, P208, DOI 10.1002/jnr.20285; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARTIN WJ, 1981, J CLIN INVEST, V68, P1277, DOI 10.1172/JCI110374; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Menzaghi C, 1999, THYROID, V9, P1, DOI 10.1089/thy.1999.9.1; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Reber A, 1996, ANAESTHESIA, V51, P733, DOI 10.1111/j.1365-2044.1996.tb07885.x; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; ROTHEN HU, 1995, LANCET, V345, P1387, DOI 10.1016/S0140-6736(95)92595-3; Schwarzmaier S, 2006, J NEUROTRAUM, V23, P769; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Shiga T, 2006, EUR J NUCL MED MOL I, V33, P817, DOI 10.1007/s00259-005-0033-y; Smielewski Peter, 2002, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; TAKEHARA Y, 1995, ARCH BIOCHEM BIOPHYS, V323, P27, DOI 10.1006/abbi.1995.0005; TEASDALE G, 1974, LANCET, V2, P81; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; WEISDORF DJ, 1982, INFLAMMATION, V6, P245, DOI 10.1007/BF00916406; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42	59	108	109	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2008	36	1					273	281		10.1097/01.CCM.0000292014.60835.15			9	Critical Care Medicine	General & Internal Medicine	291YA	WOS:000255232100039	18090356				2021-06-18	
J	Alexander, DM; Williams, LM; Gatt, JM; Dobson-Stone, C; Kuan, SA; Todd, EG; Schofield, PR; Cooper, NJ; Gordon, E				Alexander, D. M.; Williams, L. M.; Gatt, J. M.; Dobson-Stone, C.; Kuan, S. A.; Todd, E. G.; Schofield, P. R.; Cooper, N. J.; Gordon, E.			The contribution of apolipoprotein E alleles on cognitive performance and dynamic neural activity over six decades	BIOLOGICAL PSYCHOLOGY			English	Article						apolipoprotein E; development; electro-encephalogram; spatio-temporal waves; cognition; verbal fluency	TRAUMATIC BRAIN-INJURY; E EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; E POLYMORPHISM; E GENOTYPE; APOE GENOTYPE; LIPOPROTEIN RECEPTORS; MEMORY PERFORMANCE; YOUNG-ADULTS; OLDER ADULTS	Neuroimaging shows brain-functional differences due to apolipoprotein E (APOE) polymorphisms may exist decades before the increased risk period for Alzheimer's disease, but little is known about their effect on cognition and brain function in children and young adults. This study assessed 415 healthy epsilon 2 and epsilon 4 carriers and matched epsilon 3/epsilon 3 controls, spanning ages 6-65, on a range of cognitive tests. Subjects were also compared on a new dynamical measure of EEG activity during a visual working memory task using alphabetical stimuli. epsilon 4 subjects had better verbal fluency compared to epsilon 3, an effect that was strongest in 51-65 year-olds. No epsilon 4 deficits in cognition were found. In 6-15 year-olds, there were differences in total spatio-temporal wave activity between epsilon 3 and epsilon 4 subjects in the theta band, approximately 200 ms post-stimulus. Differences in brain function in younger epsilon 4 subjects and superior verbal fluency across the entire age range suggest that the APOE epsilon 4 allele is an example of antagonistic pleiotropy. (c) 2007 Elsevier B.V. All rights reserved.	RIKEN BSI, Lab Perceptual Dynam, Wako, Saitama 3510198, Japan; Brain Resource Co, Broadway, NSW 2007, Australia; Brain Resource Int Database, Broadway, NSW 2007, Australia; Univ Technol Sydney, Fac Informat Technol, Broadway, NSW 2007, Australia; Westmead Millennium Inst, Brain Dynam Ctr, Westmead, NSW 2145, Australia; Univ Sydney, Westmead Hosp, Western Clin Sch, Sydney, NSW 2145, Australia; Univ Sydney, Westmead Hosp, Western Clin Sch, Westmead, NSW 2145, Australia; Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia; Prince Wales Med Res Inst, Randwick, NSW 2031, Australia; Univ New S Wales, Kensington, NSW 2052, Australia	Alexander, DM (corresponding author), RIKEN BSI, Lab Perceptual Dynam, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	dalex@brain.riken.jp	Williams, Leanne M/B-4095-2012; Alexander, David M/J-5829-2017; Cooper, Nicholas J/C-6467-2013; Gatt, Justine M/C-4624-2008; Schofield, Peter/C-9669-2011	Gatt, Justine M/0000-0002-9276-6358; Alexander, David/0000-0003-4583-8950; Dobson-Stone, Carol/0000-0002-2211-0257; Schofield, Peter/0000-0003-2967-9662; Cooper, Nicholas/0000-0003-0049-2204			Alexander D, 2006, Acta Neuropsychiatr, V18, P240, DOI 10.1111/j.1601-5215.2006.00158.x; Alexander DM, 2006, J NEUROSCI METH, V156, P111, DOI 10.1016/j.jneumeth.2006.02.016; Alexander David M., 2006, Journal of Integrative Neuroscience, V5, P49, DOI 10.1142/S0219635206001021; ALEXANDER DM, 2006, CLIN EEG NEUROSCI, V37, P144; Beffert U, 1998, BRAIN RES REV, V27, P119, DOI 10.1016/S0165-0173(98)00008-3; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; Bothwell M, 2000, CELL, V102, P271, DOI 10.1016/S0092-8674(00)00032-5; Buzsaki G, 1994, TEMPORAL CODING BRAI, P145, DOI [DOI 10.1007/978-3-642-85148-3_9, 10.1007/978-3-642-85148-3_9]; Clark CR, 2006, ARCH CLIN NEUROPSYCH, V21, P449, DOI 10.1016/j.acn.2006.06.005; Cohen RM, 2001, NEUROLOGY, V57, P2223, DOI 10.1212/WNL.57.12.2223; Cooper JA, 1999, CELL, V97, P671, DOI 10.1016/S0092-8674(00)80778-3; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Deary IJ, 2002, NATURE, V418, P932, DOI 10.1038/418932a; den Heijer T, 2002, NEUROLOGY, V59, P746, DOI 10.1212/WNL.59.5.746; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fillenbaum GG, 2001, J AM GERIATR SOC, V49, P1148, DOI 10.1046/j.1532-5415.2001.49230.x; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gordon E, 2005, CLIN EEG NEUROSCI, V36, P64, DOI 10.1177/155005940503600205; Gordon E, 2003, NEUROPSYCHOPHARMACOL, V28, pS2, DOI 10.1038/sj.npp.1300136; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Green J, 1999, ARCH NEUROL-CHICAGO, V56, P1398, DOI 10.1001/archneur.56.11.1398; HELKALA EL, 1995, NEUROSCI LETT, V191, P141, DOI 10.1016/0304-3940(95)11575-H; Helkala EL, 2001, DIABETIC MED, V18, P991, DOI 10.1046/j.0742-3071.2001.00588.x; HERRMANN W, 1994, PEDIATRICS, V93, P296; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Hofer SM, 2002, PSYCHOL AGING, V17, P194, DOI 10.1037//0882-7974.17.2.194; Hubacek JA, 2001, NEUROPSYCHOBIOLOGY, V43, P200, DOI 10.1159/000054890; Ito J, 2005, BIOL CYBERN, V92, P54, DOI 10.1007/s00422-004-0533-z; Jelic V, 1997, J NEUROL NEUROSUR PS, V63, P59, DOI 10.1136/jnnp.63.1.59; Jordan J, 1998, J NEUROSCI, V18, P195; Kim KW, 2002, INT J GERIATR PSYCH, V17, P635, DOI 10.1002/gps.664; Klages J, 2002, BRAIN COGNITION, V49, P201, DOI 10.1006/brcg.2001.1465; Klimesch W, 2004, COGNITIVE BRAIN RES, V19, P302, DOI 10.1016/j.cogbrainres.2003.11.016; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; Lehtovirta M, 1996, NEUROBIOL AGING, V17, P523; Lehtovirta M, 2000, DEMENT GERIATR COGN, V11, P29, DOI 10.1159/000017210; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Marquis S, 2002, ARCH NEUROL-CHICAGO, V59, P601, DOI 10.1001/archneur.59.4.601; Massimini M, 2004, J NEUROSCI, V24, P6862, DOI 10.1523/JNEUROSCI.1318-04.2004; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NELSON CA, 1995, DEV PSYCHOL, V31, P723, DOI 10.1037/0012-1649.31.5.723; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; Oria RB, 2005, PEDIATR RES, V57, P310, DOI 10.1203/01.PDR.0000148719.82468.CA; Paul RH, 2005, INT J NEUROSCI, V115, P1549, DOI 10.1080/00207450590957890; Paul RH, 2007, INT J NEUROSCI, V117, P549, DOI 10.1080/00207450600773665; Pendleton N, 2002, NEUROSCI LETT, V324, P74, DOI 10.1016/S0304-3940(02)00135-0; Pitas RE, 1998, BIOCHEM SOC T, V26, P257, DOI 10.1042/bst0260257; Poirier J, 1998, J NEURAL TRANSM-SUPP, P199; PRITCHARD WS, 1986, INT J NEUROSCI, V29, P199, DOI 10.3109/00207458608986151; Puttonen S, 2003, NEUROPSYCHOBIOLOGY, V48, P35, DOI 10.1159/000071827; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; Reiman EM, 2005, P NATL ACAD SCI USA, V102, P8299, DOI 10.1073/pnas.0500579102; Reiman EM, 2004, P NATL ACAD SCI USA, V101, P284, DOI 10.1073/pnas.2635903100; Reinvang I, 2005, NEUROSCI LETT, V382, P346, DOI 10.1016/j.neulet.2005.03.024; RIBARY U, 1991, P NATL ACAD SCI USA, V88, P11037, DOI 10.1073/pnas.88.24.11037; Sager MA, 2005, J GERIATR PSYCH NEUR, V18, P245, DOI 10.1177/0891988705281882; Sauseng P, 2002, NEUROSCI LETT, V324, P121, DOI 10.1016/S0304-3940(02)00225-2; Scarmeas N, 2005, J NEUROL NEUROSUR PS, V76, P1440, DOI 10.1136/jnnp.2004.053645; Small BJ, 2000, NEUROLOGY, V54, P2082, DOI 10.1212/WNL.54.11.2082; Smith CD, 1999, NEUROLOGY, V53, P1391, DOI 10.1212/WNL.53.7.1391; Smith CD, 2002, NEUROLOGY, V58, P1197, DOI 10.1212/WNL.58.8.1197; Smith GE, 1998, NEUROLOGY, V50, P355, DOI 10.1212/WNL.50.2.355; SNYDER E, 1976, BEHAV BIOL, V16, P319, DOI 10.1016/S0091-6773(76)91447-4; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; Tammi A, 2000, ATHEROSCLEROSIS, V152, P135, DOI 10.1016/S0021-9150(99)00436-0; Teter B, 1999, J NEUROCHEM, V73, P2613, DOI 10.1046/j.1471-4159.1999.0732613.x; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Turic D, 2001, NEUROSCI LETT, V299, P97, DOI 10.1016/S0304-3940(00)01789-4; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; Wetter S, 2001, NEUROBIOL AGING, V22, P439, DOI 10.1016/S0197-4580(01)00215-9; Williams LM, 2005, INT J NEUROSCI, V115, P1605, DOI 10.1080/00207450590958475; Wilson RS, 2002, J NEUROL NEUROSUR PS, V73, P672, DOI 10.1136/jnnp.73.6.672; Winnock M, 2002, J NEUROL NEUROSUR PS, V72, P794, DOI 10.1136/jnnp.72.6.794; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yu VWY, 2000, NEUROSCI LETT, V294, P179, DOI 10.1016/S0304-3940(00)01569-X; Zetterberg H, 2002, NEUROSCI LETT, V324, P189, DOI 10.1016/S0304-3940(02)00198-2	81	108	110	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0301-0511	1873-6246		BIOL PSYCHOL	Biol. Psychol.	JUL	2007	75	3					229	238		10.1016/j.biopsycho.2007.03.001			10	Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental	Psychology; Behavioral Sciences	191EQ	WOS:000248113400002	17433528				2021-06-18	
J	Stiefel, MF; Udoetuk, JD; Spiotta, AM; Gracias, VH; Goldberg, A; Maloney-Wilensky, E; Bloom, S; Le Roux, PD				Stiefel, Michael F.; Udoetuk, Joshua D.; Spiotta, Alejandro M.; Gracias, Vicente H.; Goldberg, Aaron; Maloney-Wilensky, Eileen; Bloom, Stephanie; Le Roux, Peter D.			Conventional neurocritical care and cerebral oxygenation after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; conventional care; brain oxygen; intracranial pressure	SEVERE HEAD-INJURY; PERFUSION-PRESSURE; TISSUE OXYGEN; BLOOD-FLOW; END-POINTS; INTRACRANIAL HYPERTENSION; LACTATE CLEARANCE; RANDOMIZED-TRIAL; INTENSIVE-CARE; CARBON-DIOXIDE	Object. Control of intracranial pressure (ICP) and cerebral perfusion pressure (CPP) is the foundation of traumatic brain injury (TBI) management. In this study, the authors examined whether conventional ICP- and CPP-guided neurocritical care ensures adequate brain tissue O-2 in the first 6 hours after resuscitation. Methods. Resuscitated patients with severe TBI (Glasgow Coma Scale score <= 8 and Injury Severity Scale score >= 16) who were admitted to a Level I trauma center and who underwent brain tissue O-2 monitoring within 6 hours of injury were evaluated as part of a prospective observational database. Therapy was directed to maintain an ICP of 25 mm Hg or less and a CPP of 60 mm Hg or higher. Data from a group of 25 patients that included 19 men and six women (mean age 39 +/- 20 years) were examined. After resuscitation, ICP was 25 mm Hg or less in 84% and CPP was 60 mm Hg or greater in 88% of the patients. Brain O-2 probes were allowed to stabilize; the initial brain tissue O-2 level was 25 mm Hg or less in 68% of the patients, 20 mm Hg or less in 56%, and 10 mm Hg or less in 36%. Nearly one third (29%) of patients with ICP readings of 25 mm Hg or less and 27% with CPP levels of 60 mm Hg or greater had severe cerebral hypoxia (brain tissue O-2 <= 10 mm Hg). Nineteen patients had both optimal ICP (< 25 mm Hg) and CPP (> 60 mm Hg); brain tissue O-2 was 20 mm Hg or less in 47% and 10 mm Hg or less in 21% of these patients. The mortality rate was higher in patients with reduced brain tissue O-2. Conclusions. Brain resuscitation based on current neurocritical care standards (that is, control of ICP and CPP) does not prevent cerebral hypoxia in some patients. This finding may help explain why secondary neuronal injury occurs in some patients with adequate CPP and suggests that the definition of adequate brain resuscitation after TBI may need to be reconsidered.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19107 USA; Univ Penn, Div Trauma Surg & Surg Crit Care, Sch Med, Philadelphia, PA 19107 USA	Le Roux, PD (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 330 S 9th St, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu					ABOUKHALIL B, 1994, CRIT CARE MED, V22, P633, DOI 10.1097/00003246-199404000-00020; ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP C; Bardt TF, 1998, ACT NEUR S, V71, P153; BISHOP MH, 1995, J TRAUMA, V38, P780, DOI 10.1097/00005373-199505000-00018; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN A, 2000, MAN PROGN SEV TRAUM; Bruzzone P, 1998, ACT NEUR S, V71, P111; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clay H D, 2000, J Neurosci Nurs, V32, P194; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Dings J, 1998, NEUROL RES, V20, pS71; FIDDIANGREEN RG, 1993, CRIT CARE MED, V21, pS25, DOI 10.1097/00003246-199302001-00006; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kern JW, 2002, CRIT CARE MED, V30, P1686, DOI 10.1097/00003246-200208000-00002; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Mapstone J, 2003, J TRAUMA, V55, P571, DOI 10.1097/01.TA.0000062968.69867.6F; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McIntyre L, 2004, J TRAUMA, V57, P563, DOI 10.1097/01.TA.0000136158.93864.54; McNelis J, 2001, AM J SURG, V182, P481, DOI 10.1016/S0002-9610(01)00755-3; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Miller PR, 1998, J TRAUMA, V45, P868, DOI 10.1097/00005373-199811000-00004; MOORE FA, 1992, J TRAUMA, V33, P58, DOI 10.1097/00005373-199207000-00012; MURR R, 1995, NEUROL RES, V17, P329, DOI 10.1080/01616412.1995.11740338; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; ROBERTSON C, 1996, YOUMANS NEUROLOGICAL, P5103; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; SCALEA TM, 1994, CRIT CARE MED, V22, P1610; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHOEMAKER WC, 1983, AM J SURG, V146, P43, DOI 10.1016/0002-9610(83)90257-X; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stocchetti N, 1998, ACT NEUR S, V71, P162; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Tisherman SA, 2004, J TRAUMA, V57, P898, DOI 10.1097/01.TA.0000133577.25793.E5; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Velmahos GC, 2000, ANN SURG, V232, P409, DOI 10.1097/00000658-200009000-00013; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wilensky Eileen Maloney, 2005, J Neurosci Nurs, V37, P278; 2000, J NEUROTRAUMA, V17, P549	65	108	114	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2006	105	4					568	575		10.3171/jns.2006.105.4.568			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	092AZ	WOS:000241070700014	17044560				2021-06-18	
J	Wade, SL; Carey, J; Wolfe, CR				Wade, Shari L.; Carey, JoAnne; Wolfe, Christopher R.			The efficacy of an online cognitive-behavioral family intervention in improving child behavior and social competence following pediatric brain injury	REHABILITATION PSYCHOLOGY			English	Article; Proceedings Paper	66th Annual Assembly of the American-Academy-for-Physical-Medicine-and-Rehabilitation	OCT 27-30, 2005	Philadelphia, PA	Amer Acad Phys Med & Rehabil		brain injury; telehealth; family; adaptation; problem solving	PROBLEM-SOLVING INTERVENTION; LONG-TERM OUTCOMES; ADOLESCENTS; RELIABILITY; MODERATOR; PIECES	Objective: To examine whether an online cognitive-behavioral intervention could improve child adjustment following traumatic brain injury (TBI). Participants: Thirty-nine families of children with moderate to severe TBI. Intervention: Families were randomly assigned to the online family problem-solving (FPS) group or to the Internet resources comparison (IRC) group. Main Outcome Measures: Outcomes included child behavior problems, social competence, and self-management/compliance. Results: The FPS group reported better child self-management/compliance at follow-up than did the IRC group. The child's age and socioeconomic status (SES) moderated treatment effects, with older children and those of lower SES who received FPS showing greater improvements in self-management and behavior problems, respectively. Conclusions: Findings suggest that an online cognitive-behavioral approach can improve child adjustment after TBI, particularly in older children and children of lower SES.	Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Miami Univ, Sch Interdisciplinary Studies, Oxford, OH 45056 USA	Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org					Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Foster SL., 1989, NEGOTIATING PARENT A; Gurdin LS, 2005, BEHAV INTERVENT, V20, P3, DOI 10.1002/bin.172; Hauser RM, 1997, SOCIOL METHODOL, V27, P177, DOI 10.1111/1467-9531.271028; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; NEZU AM, 1998, HELPING CANC PATIENT; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Selznick L, 2000, BEHAV INTERVENT, V15, P243, DOI 10.1002/1099-078X(200007/09)15:3<243::AID-BIN59>3.0.CO;2-1; Sohlberg MM, 1998, APHASIOLOGY, V12, P1047, DOI 10.1080/02687039808249469; Suzman KB, 1997, J BEHAV THER EXP PSY, V28, P203, DOI 10.1016/S0005-7916(97)00023-2; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; WADE SL, IN PRESS J CONSULTIN; WADE SL, 2006, TREATING NEURODEVELO, P170; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393; Ylvisaker M., 1998, COLLABORATIVE BRAIN	37	108	108	1	21	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2006	51	3					179	189		10.1037/0090-5550.51.3.179			11	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	072OK	WOS:000239682500001					2021-06-18	
J	Kamm, K; VanderKolk, W; Lawrence, C; Jonker, M; Davis, AT				Kamm, K; VanderKolk, W; Lawrence, C; Jonker, M; Davis, AT			The effect of traumatic brain injury upon the concentration and expression of interieukin-1 beta and interleukin-10 in the rat	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	18th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 11-15, 2005	Ft Lauderdale, FL	Eastern Assoc Surg Trauma		cytokines; traumatic brain injury; animal model	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; FACTOR-ALPHA; TNF-ALPHA; CYTOKINE EXPRESSION; BARRIER; TRANSPORT; BETA; MICE	Background: Using a model of traumatic brain injury (TBI) in the rat, this study was undertaken to characterize the short-term biochemical changes of IL-1 beta, IL-10, and tumor necrosis factor TNF-alpha to determine whether injury in the brain elicits a systemic cytokine response. Methods: Sprague-Dawley rats were subjected to a TBI using a weight-drop model and then killed at various time points after injury. Samples of blood, brain, and liver were recovered and analyzed for concentrations of IL-1 beta, IL-10, and TNF-alpha as well as IL-1 beta and IL-10 mRNA expression in liver and brain. Results: In brain, IL-1 beta increased in the first hour after injury, peaked at 8 hours, and declined during the final 16 hours. IL-10 quickly increased during the first 4 hours and then gradually rose over the last 20 hours. Analysis of liver showed no upregulation of these markers and plasma IL-1 beta and IL-10 were unchanged compared with controls. Although not upregulated in brain, TNF-alpha showed a statistically significant (p < 0.05) rise in plasma from 14 +/- 16 pg/mL at 20 minutes to 91 +/- 28 pg/mL at 24 hours. Conclusion: Using a model of TBI, we have demonstrated that there is a rise in both IL-1 beta and IL-10 in the injured rat brain within the first 24 hours after injury without a corresponding rise in either plasma or liver. Therefore, it appears as if two strong indicators of brain injury severity are expressed and possibly carry out their actions solely in the brain.	Michigan State Univ, Dept Trauma Spectrum Butterworth Hosp, Grand Rapids, MI USA; Univ Wisconsin, Madison, WI 53706 USA	Kamm, K (corresponding author), 221 Michigan St NE,Suite 200A, Grand Rapids, MI 49503 USA.	kkamm@siumed.edu					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Banks WA, 2001, J PHARMACOL EXP THER, V299, P536; BANKS WA, 1989, BRAIN RES BULL, V23, P433, DOI 10.1016/0361-9230(89)90185-8; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; CHAO CC, 1995, DEV NEUROSCI-BASEL, V17, P97, DOI 10.1159/000111278; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; FAN L, 1995, MOL BRAIN RES, V30, P125; FINK MP, 2004, SABISTON TXB SURG, P50; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; HOEDEMA RE, 2001, 14 ANN M E ASS SURG; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Kastin AJ, 2003, MOL BRAIN RES, V114, P168, DOI 10.1016/S0169-328X(03)00167-0; Kipnis J, 2003, J NEUROTRAUM, V20, P559, DOI 10.1089/089771503767168483; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; MALEFYT RD, 1991, J EXP MED, V174, P915; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Osburg B, 2002, AM J PHYSIOL-ENDOC M, V283, pE899, DOI 10.1152/ajpendo.00436.2001; Plotkin SR, 2000, BRAIN RES, V881, P57, DOI 10.1016/S0006-8993(00)02772-4; Raff T, 1997, BIOTECHNIQUES, V23, P456, DOI 10.2144/97233st02; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; Yokoyama Y, 2004, AM J PHYSIOL-GASTR L, V286, pG942, DOI 10.1152/ajpgi.00502.2003; YONG VW, 1991, P NATL ACAD SCI USA, V88, P7016, DOI 10.1073/pnas.88.16.7016	44	108	113	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2006	60	1					152	157		10.1097/01.ta.0000196345.81169.a1			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	008UN	WOS:000235066300033	16456449				2021-06-18	
J	McCarthy, ML; MacKenzie, EJ; Durbin, DR; Aitken, ME; Jaffe, KM; Paidas, CN; Slomine, BS; Dorsch, AM; Berk, RA; Christensen, JR; Ding, R				McCarthy, ML; MacKenzie, EJ; Durbin, DR; Aitken, ME; Jaffe, KM; Paidas, CN; Slomine, BS; Dorsch, AM; Berk, RA; Christensen, JR; Ding, R		CHAT Study Grp	The pediatric quality of life inventory: An evaluation of its reliability and validity for children with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	7th World Conference on Injury Prevention and Safety Promotion	JUN 06-09, 2004	Vienna, AUSTRIA			brain injuries; pediatrics; quality of life; rehabilitation	BEHAVIOR RATING INVENTORY; GENERIC CORE SCALES; EXECUTIVE FUNCTION; HEALTH-STATUS; INTELLECTUAL ABILITY; HEAD-INJURY; PEDSQL(TM)-4.0; ADOLESCENTS; SENSITIVITY; PREVALENCE	Objectives: To assess the reliability and validity of the Pediatric Quality of Life Inventory, version 4.0 (PedsQL), and to compare it with that of the Behavior Rating Inventory of Executive Function (BRIEF) among children with traumatic brain injury (TBI). Design: Prospective cohort study that documented the health-related quality of life of 391 children at 3 and 12 months postinjury. Setting: Four level I pediatric trauma centers. Participants: Children (age range, 5-15y) hospitalized with a TBI or an extremity fracture. Interventions: Not applicable. Main Outcome Measures: Parent-reported PedsQL and BRIEF scale scores. Results: Both the PedsQL and BRIEF scales showed good internal consistency (PedsQL a range,.74-.93; BRIEF alpha range,.82-98) and test-retest reliability (PedsQL r range, .75-90; BRIEF r range, .82-92), respectively. Factor analysis revealed that most PedsQL items loaded most highly on their conceptually derived scale. The PedsQL cognitive function scale detected the largest differences among groups of children with varying severities of TBI as well as parents' assessment of change in cognition postinjury. Conclusions: Although the reliability of the 2 instruments is comparable, the PedsQL discriminates better among children with TBI. The PedsQL is a promising instrument for measuring the health of children after TBI.	Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, John Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD 21205 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Arkansas Med Sci, Dept Pediat, Coll Med, Little Rock, AR 72205 USA; Childrens Hosp & Reg Med Ctr, Dept Rehabil Med, Seattle, WA USA; Childrens Hosp & Reg Med Ctr, Dept Pediat, Seattle, WA USA; Univ Washington, Sch Med, Seattle, WA 98195 USA; Univ S Florida, Dept Surg, Tampa, FL 33620 USA; Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Childrens Hosp & Reg Med Ctr, Div Rehabil Psychol, Seattle, WA USA; Johns Hopkins Sch Nursing, Baltimore, MD USA	McCarthy, ML (corresponding author), 1830 E Monument St,Ste 6-111, Baltimore, MD 21205 USA.	mmccarth@jhmi.edu	ding, ru/B-1615-2009	Aitken, Mary/0000-0002-8318-9755	ODCDC CDC HHS [R49/CCR319701] Funding Source: Medline		Bastiaansen D, 2004, QUAL LIFE RES, V13, P489, DOI 10.1023/B:QURE.0000018483.01526.ab; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Daltroy LH, 1998, J PEDIATR ORTHOPED, V18, P561, DOI 10.1097/00004694-199809000-00001; Denckla MB, 1996, DEV NEUROPSYCHOL, V12, P5, DOI 10.1080/87565649609540637; Friefeld S, 2004, CNS SPECTRUMS, V9, P465; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Haley S.M., 1992, PEDIAT EVALUATION DI; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KAPLAN RM, 1976, HEALTH SERV RES, V11, P478; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; LANDGRAF JM, 1996, CHQ USERS MANUAL BOS; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LIANG MH, 1985, ARTHRITIS RHEUM, V28, P542, DOI 10.1002/art.1780280513; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P52, DOI 10.1076/chin.8.1.52.8719; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; PETRUCELLI E, 1981, ACCIDENT ANAL PREV, V13, P29, DOI 10.1016/0001-4575(81)90040-3; Powers SW, 2004, CEPHALALGIA, V24, P120, DOI 10.1111/j.1468-2982.2004.00652.x; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Schwimmer JB, 2003, JAMA-J AM MED ASSOC, V289, P1813, DOI 10.1001/jama.289.14.1813; SPILKER B, 1998, QUALITY LIFE PHARMAC; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STARFIELD B, 1995, MED CARE, V33, P553, DOI 10.1097/00005650-199505000-00008; STEIN REK, 1990, MED CARE, V28, P1041, DOI 10.1097/00005650-199011000-00006; Streiner D., 1995, HLTH MEASUREMENT SCA, V2; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Varni JW, 2002, ARTHRITIS RHEUM, V46, P714, DOI 10.1002/art.10095; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Varni JW, 2003, DIABETES CARE, V26, P631, DOI 10.2337/diacare.26.3.631; Varni JW, 2004, J BEHAV MED, V27, P297, DOI 10.1023/B:JOBM.0000028500.53608.2c	48	108	109	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2005	86	10					1901	1909		10.1016/j.apmr.2005.03.026			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	972KB	WOS:000232451600001	16213229				2021-06-18	
J	Wong, EYH; Herbert, J				Wong, EYH; Herbert, J			Roles of mineralocorticoid and glucocorticoid receptors in the regulation of progenitor proliferation in the adult hippocampus	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						adrenal-derived corticoids; adrenalectomy; dentate gyrus; mifepristone; neurogenesis; spironolactone	RAT DENTATE GYRUS; TRAUMATIC BRAIN INJURY; CORTICOSTERONE TREATMENT; DEPENDENT MECHANISM; NEUROTROPHIC FACTOR; NEURAL PROGENITORS; CELL-PROLIFERATION; ADRENAL-STEROIDS; NEUROGENESIS; EXPRESSION	New neurons are produced continually in the dentate gyrus of the hippocampus. Numerous factors modulate the rate of neuron production. One of the most important is the adrenal-derived corticoids. Raised levels of corticoids suppress proliferation of progenitor cells, while removal of corticoids by adrenalectomy reverses this. The exact mechanisms by which corticoids mediate such regulation are unknown, but corticoids are believed to act through the receptors for mineralocorticoids (MR) and glucocorticoids (GR). Previous reports regarding the roles of these receptors in regulating cell proliferation came to contrasting conclusions. Here we use both agonists and antagonists to these receptors in adult male rats to investigate and clarify their roles. Blockade of MR with spironolactone in adrenalectomised male rats implanted with a corticosterone pellet to reproduce basal levels enhanced proliferation, whereas treatment with the GR antagonist mifepristone had no effect. However, mifepristone reversed the suppressive effect of additional corticosterone in intact rats. Both aldosterone and RU362, agonists of MR and GR, respectively, reduced proliferation in adrenalectomised rats, and combined treatment with both agonists had an additional suppressive action. These results clearly show that occupancies of both receptors act in the same direction on progenitor proliferation. The existence of two receptors with different affinities for corticoids may ensure that proliferation of progenitor cells in the adult dentate gyrus is regulated across the range of adrenal corticoid activity, including both basal and stressful contexts. Although a small proportion of newly formed cells may express GR and MR, corticosterone probably regulates proliferation indirectly through other local cells.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge CB2 1TN, England	Herbert, J (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.	jh24@cam.ac.uk	Herbert, Joe/K-5877-2013		Wellcome TrustWellcome TrustEuropean Commission [070288] Funding Source: Medline		Aberg MAI, 2000, J NEUROSCI, V20, P2896; Alonso G, 2000, GLIA, V31, P219, DOI 10.1002/1098-1136(200009)31:3<219::AID-GLIA30>3.0.CO;2-R; Ambrogini P, 2002, NEUROENDOCRINOLOGY, V76, P366, DOI 10.1159/000067581; Brezun JM, 1999, NEUROSCIENCE, V89, P999, DOI 10.1016/S0306-4522(98)00693-9; CAMERON HA, 1993, BRAIN RES, V611, P342, DOI 10.1016/0006-8993(93)90524-Q; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; Conrad CD, 1999, NEUROBIOL LEARN MEM, V72, P39, DOI 10.1006/nlme.1998.3898; COROTTO FS, 1993, NEUROSCI LETT, V149, P111, DOI 10.1016/0304-3940(93)90748-A; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fischer AK, 2002, BRAIN RES, V947, P290, DOI 10.1016/S0006-8993(02)03042-1; Garcia A, 2004, AGING CELL, V3, P363, DOI 10.1111/j.1474-9728.2004.00130.x; Goodyer IM, 2000, BRIT J PSYCHIAT, V176, P142, DOI 10.1192/bjp.176.2.142; Gould E, 1997, DEV BRAIN RES, V103, P91, DOI 10.1016/S0165-3806(97)00079-5; GOULD E, 1992, J NEUROSCI, V12, P3642; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Gubba EM, 2004, MOL BRAIN RES, V127, P48, DOI 10.1016/j.molbrainres.2004.05.004; Harris TO, 2000, BRIT J PSYCHIAT, V177, P505, DOI 10.1192/bjp.177.6.505; Hastings NB, 2003, NAT MED, V9, P264, DOI 10.1038/nm0303-264; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Hellsten J, 2002, EUR J NEUROSCI, V16, P283, DOI 10.1046/j.1460-9568.2002.02093.x; Islam A, 1998, BRAIN RES, V797, P342, DOI 10.1016/S0006-8993(98)00389-8; Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kulkarni VA, 2002, EUR J NEUROSCI, V16, P2008, DOI 10.1046/j.1460-9568.2002.02268.x; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Liu JL, 1998, J NEUROSCI, V18, P7768; Malberg JE, 2004, J PSYCHIATR NEUROSCI, V29, P196; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; Montaron MF, 2003, EUR J NEUROSCI, V18, P3105, DOI 10.1111/j.1460-9568.2003.03048.x; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; Pham K, 2003, EUR J NEUROSCI, V17, P879, DOI 10.1046/j.1460-9568.2003.02513.x; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Sapolsky RM, 2004, BIOL PSYCHIAT, V56, P137, DOI 10.1016/j.biopsych.2004.04.012; Schaaf M J, 2000, Stress, V3, P201, DOI 10.3109/10253890009001124; Seki Tatsunori, 2003, Anatomical Science International, V78, P69, DOI 10.1046/j.0022-7722.2003.00043.x; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Tanapat P, 2001, J COMP NEUROL, V437, P496, DOI 10.1002/cne.1297; Ueki T, 2003, J NEUROSCI, V23, P11732; VANEEKELEN JAM, 1988, J NEUROSCI RES, V21, P88, DOI 10.1002/jnr.490210113; Wong EYH, 2004, EUR J NEUROSCI, V20, P2491, DOI 10.1111/j.1460-9568.2004.03717.x	44	108	114	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	AUG	2005	22	4					785	792		10.1111/j.1460-9568.2005.04277.x			8	Neurosciences	Neurosciences & Neurology	957UB	WOS:000231397700001	16115202	Green Accepted			2021-06-18	
J	Agha, A; Sherlock, M; Phillips, J; Tormey, W; Thompson, CJ				Agha, A; Sherlock, M; Phillips, J; Tormey, W; Thompson, CJ			The natural history of post-traumatic neurohypophysial dysfunction	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ANTI-DIURETIC HORMONE; UNUSUAL DELAYED-ONSET; DIABETES-INSIPIDUS; HEAD-INJURY; INAPPROPRIATE SECRETION; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; VASOPRESSIN RELEASE; PRACTICAL SCALE	Background and objectives: Posterior pituitary function remains poorly investigated after traumatic brain injury (TBI). We report the results of a study designed to prospectively define the natural history of post-traumatic diabetes insipidus (DI) and syndrome of inappropriate antidiuretic hormone secretion (SIADH) using standard reliable methodology. Design and methods: 50 consecutive patients with severe or moderate TBI (initial Glasgow Coma Scale (GCS) score 3/15-13/15) were prospectively studied on three occasions: at the acute phase and at 6 months and at 12 months following TBI. In the acute phase, DI was diagnosed either by the presence of hypernatraemia in association with hypotonic polyuria or by the water-deprivation test (WDT) and. at 6 and 12 months by the WDT in all patients. Normative data on response to the WDT were obtained from healthy matched volunteers. Functional outcome was assessed using the Glasgow Outcome Scale (GOS). Results: 13 patients (26%) had DI in the acute post-TBI phase, of whom nine patients recovered by 6 months and one additional patient recovered by 12 months. Of the remaining three patients with permanent DI, two had partial vasopressin deficiency. Acute-phase peak plasma osmolality correlated negatively with the initial GCS scores (r = -0.39, P = 0.005) and with the GOS scores (r = -0.45, P = 0.001). Seven patients had SIADH in the acute phase of TBI but none did at 6 or 12 months. No new cases of DI or SIADH were noted after the acute phase. Conclusion: This prospective study shows that posterior pituitary dysfunction is common following TBI. Most cases recover completely but there is an appreciable frequency of long-term DI which can be subtle and should be recognized and managed appropriately.	Beaumont Hosp, Acad Dept Endocrinol, Dublin, Ireland; Beaumont Hosp, Dept Neurosurg, Dublin, Ireland; Beaumont Hosp, Dept Clin Chem, Dublin, Ireland	Thompson, CJ (corresponding author), Beaumont Hosp, Acad Dept Endocrinol, Dublin, Ireland.	christhompson@beaumont.ie					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Alaca R, 2002, AM J PHYS MED REHAB, V81, P788, DOI 10.1097/00002060-200210000-00013; ANDERSON RJ, 1986, KIDNEY INT, V29, P1237, DOI 10.1038/ki.1986.134; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; Baylis P, 2001, PRINCIPLES PRACTICE; BECKER RM, 1973, J TRAUMA, V13, P112, DOI 10.1097/00005373-197302000-00003; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BOHNEN N, 1993, EUR NEUROL, V33, P77, DOI 10.1159/000116907; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Boughey JC, 2004, AM SURGEON, V70, P500; DASHE AM, 1963, JAMA-J AM MED ASSOC, V185, P699, DOI 10.1001/jama.1963.03060090031011; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; EDWARDS OM, 1986, MEDICINE, V65, P281; HADANI M, 1985, J NEUROSURG, V63, P456, DOI 10.3171/jns.1985.63.3.0456; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; SECKL J, 1989, BRIT MED J, V298, P2, DOI 10.1136/bmj.298.6665.2; Smith D, 2002, J CLIN ENDOCR METAB, V87, P4564, DOI 10.1210/jc.2002-020090; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; THOMPSON CJ, 1986, CLIN SCI, V71, P651, DOI 10.1042/cs0710651; THOMPSON CJ, 1991, AM J PHYSIOL, V260, pR533; TRAINER PJ, 1995, BARTS ENDOCRINE PROT, P19; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; VERBALIS JG, 1989, BAILLIERE CLIN ENDOC, V3, P499, DOI 10.1016/S0950-351X(89)80013-8; VERBALIS JG, 2001, PRINCIPLES PRACTICE, P293; VIGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340; World Health Organization, 1980, INT CLASS IMP DIS HA; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	33	108	115	0	2	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	MAR	2005	152	3					371	377		10.1530/eje.1.01861			7	Endocrinology & Metabolism	Endocrinology & Metabolism	910CE	WOS:000227906200008	15757853	Bronze			2021-06-18	
J	Lew, HL; Poole, JH; Lee, EH; Jaffe, DL; Huang, HC; Brodd, E				Lew, HL; Poole, JH; Lee, EH; Jaffe, DL; Huang, HC; Brodd, E			Predictive validity of driving-simulator assessments following traumatic brain injury: a preliminary study	BRAIN INJURY			English	Article						closed head injuries; cognition; computer simulation; driving behavior; ecological validity; predictive value of tests; risk assessment; safety standards; virtual reality systems	DIVIDED ATTENTION; ON-ROAD; PERFORMANCE; DAMAGE; DRIVERS; FITNESS; VISION; SAFETY; TESTS; CAR	Objective: To evaluate whether driving simulator and road test evaluations can predict long- term driving performance, we conducted a prospective study on 11 patients with moderate to severe traumatic brain injury. Sixteen healthy subjects were also tested to provide normative values on the simulator at baseline. Method: At their initial evaluation ( time- 1), subjects' driving skills were measured during a 30- minute simulator trial using an automated 12- measure Simulator Performance Index ( SPI), while a trained observer also rated their performance using a Driving Performance Inventory ( DPI). In addition, patients were evaluated on the road by a certified driving evaluator. Ten months later ( time- 2), family members observed patients driving for at least 3 hours over 4 weeks and rated their driving performance using the DPI. Results: At time- 1, patients were significantly impaired on automated SPI measures of driving skill, including: speed and steering control, accidents, and vigilance to a divided- attention task. These simulator indices significantly predicted the following aspects of observed driving performance at time- 2: handling of automobile controls, regulation of vehicle speed and direction, higher- order judgment and self- control, as well as a trend- level association with car accidents. Automated measures of simulator skill ( SPI) were more sensitive and accurate than observational measures of simulator skill ( DPI) in predicting actual driving performance. To our surprise, the road test results at time- 1 showed no significant relation to driving performance at time- 2. Conclusion: Simulator- based assessment of patients with brain injuries can provide ecologically valid measures that, in some cases, may be more sensitive than a traditional road test as predictors of long- term driving performance in the community.	VA Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, Palo Alto, CA 94304 USA; Def & Vet Brain Injury Ctr, Palo Alto, CA USA; Stanford Univ, Sch Med, Div Phys Med & Rehabil, Stanford, CA 94305 USA; VA Palo Alto Hlth Care Syst, Rehabil Res & Dev Ctr, Palo Alto, CA USA	Poole, JH (corresponding author), VA Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, 140-117,3801 Miranda Ave, Palo Alto, CA 94304 USA.	john.poole@med.va.gov					BLAAUW GJ, 1982, HUM FACTORS, V24, P473, DOI 10.1177/001872088202400408; Blana E, 2002, HUM FACTORS, V44, P303, DOI 10.1518/0018720024497899; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; BROUWER WH, 1991, HUM FACTORS, V33, P573; Bylsma FW, 1997, ALZ DIS ASSOC DIS, V11, P17, DOI 10.1097/00002093-199706001-00005; Cameron, 2002, AUSTR OCCUPATIONAL T, V49, DOI 10.1046/j.1440-1630.2002.00314.x; EDWARDS DS, 1977, J APPL PSYCHOL, V62, P559, DOI 10.1037/0021-9010.62.5.559; Fisk GD, 1998, BRAIN INJURY, V12, P683; Freund B, 2002, J AM GERIATR SOC, V50, P1309, DOI 10.1046/j.1532-5415.2002.50325.x; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GIANUTSOS R, 1994, BEHAV RES METH INSTR, V26, P183, DOI 10.3758/BF03204615; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Huchler S., 2001, EURA MEDICOPHYS, V37, P283; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Keller M, 2003, NEUROREHAB NEURAL RE, V17, P168, DOI 10.1177/0888439003256048; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Lam LT, 2002, J SAFETY RES, V33, P411, DOI 10.1016/S0022-4375(02)00034-8; Lansdown T, 2004, ERGONOMICS, V47, P91, DOI 10.1080/00140130310001629775; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Liu L, 1999, Cyberpsychol Behav, V2, P53, DOI 10.1089/cpb.1999.2.53; Lundqvist A, 2000, APPL COGNITIVE PSYCH, V14, P135, DOI 10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S; NETZ J, 2001, EUROPA MEDICOPHYSICA, V37, P275; NOURI FM, 1988, CLIN REHABIL, V2, P99; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Reed MP, 1999, ERGONOMICS, V42, P1015, DOI 10.1080/001401399185117; Roge J, 2003, VISION RES, V43, P1465, DOI 10.1016/S0042-6989(03)00143-3; Stutts J C, 2001, Annu Proc Assoc Adv Automot Med, V45, P287; SZLYK JP, 1995, HUM FACTORS, V37, P430, DOI 10.1518/001872095779064645; Szlyk JP, 2002, J REHABIL RES DEV, V39, P467; Szlyk JP, 2002, J REHABIL RES DEV, V39, P483; Tornros J, 1998, ACCIDENT ANAL PREV, V30, P497, DOI 10.1016/S0001-4575(97)00099-7; VOLKERTS ER, 1992, HUM PSYCHOPHARM CLIN, V7, P297, DOI 10.1002/hup.470070502; Zesiewicz TA, 2002, NEUROLOGY, V59, P1787, DOI 10.1212/01.WNL.0000035636.83680.C6	35	108	110	0	21	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2005	19	3					177	188		10.1080/02699050400017171			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	906WJ	WOS:000227675000004	15832892				2021-06-18	
J	Stocchetti, N; Pagan, F; Calappi, E; Canavesi, K; Beretta, L; Citerio, G; Cormio, M; Colombo, A				Stocchetti, N; Pagan, F; Calappi, E; Canavesi, K; Beretta, L; Citerio, G; Cormio, M; Colombo, A			Inaccurate early assessment of neurological severity in head injury	JOURNAL OF NEUROTRAUMA			English	Article						Glasgow Coma Scale; head injury; neurological assessment; outcome; sedation	INTENSIVE-CARE; BRAIN-INJURY; SCALE; COMA; HYPOTENSION; GUIDELINES; ABUSE	Intubation, which requires sedation and myorelaxants, may lead to inaccurate neurological evaluation of severely head-injured patients. Aims of this study were to describe the early clinical evolution of traumatic brain injured (TBI) patients admitted to intensive care unit (ICU), to identify cases of over-estimated neurological severity, and to quantify the risk factors for this over-estimation. A total of 753 TBI patients consecutively admitted to ICU of three academic neurosurgical hospitals (NSH) were assessed. Cases whose severity was potentially over-estimated were identified by four criteria and indicated as "mistakenly severe" (MS): (1) no surgical intracranial masses; (2) could not follow commands at neurological assessment; (3) were dismissed from the ICU in :53 days to a regular ward; and (4) had regained the ability to obey commands. A total of 675 patients were intubated and/or sedated-paralyzed at the post-stabilization evaluation. In all, 304 patients had surgically treated intracranial masses. Among the 449 non-surgical cases, 58 patients fulfilling the criteria for MS were identified. The main features distinguishing MS from truly severe cases were younger age, higher Glasgow Coma Scale (GCS) score at all time points, Marshall classification of Computerized Tomographic (CT) scan mostly Diffuse Injury I and II, fewer pupillary abnormalities, and a lower frequency of hypoxia, hypotension, and extra-cranial injuries. In a certain proportion of non-surgical TBI patients, mostly intubated and sedated, neurological examination is difficult and severity can be over-estimated. Risk factors for this inaccurate evaluation can be identified, and clinical decisions should be based on further examination.	Univ Milan, IRCCS, Osped Policlin, Dept Anesthesia & Intens Care, I-20122 Milan, Italy; Osped San Raffaele, Dept Anesthesia & Intens Care, Milan, Italy; Osped San Gerardo, Dept Anesthesia & Intens Care, Monza, Italy	Stocchetti, N (corresponding author), Univ Milan, IRCCS, Osped Policlin, Dept Anesthesia & Intens Care, Padiglione Beretta Neuro,Via F Sforza 35, I-20122 Milan, Italy.	stocchet@policlinico.mi.it	; Stocchetti, Nino/O-7444-2017	Citerio, Giuseppe/0000-0002-5374-3161; Stocchetti, Nino/0000-0003-3250-6834			*BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Citerio G, 2000, ACTA NEUROCHIR, V142, P769, DOI 10.1007/s007010070091; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; Livingston BM, 2000, CRIT CARE MED, V28, P389, DOI 10.1097/00003246-200002000-00017; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marshall SB, 1991, J NEUROSURG S, V75, P14; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; TEASDALE G, LANCET, V2, P81; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	16	108	109	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1131	1140		10.1089/neu.2004.21.1131			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900003	15453984				2021-06-18	
J	Zurita, M; Vaquero, J				Zurita, M; Vaquero, J			Functional recovery in chronic paraplegia after bone marrow stromal cells transplantation	NEUROREPORT			English	Article						bone marrow stromal cells; paraplegia; nervous system regeneration; spinal cord injury; transplantation	SPINAL-CORD-INJURY; INTRACEREBRAL TRANSPLANTATION; INTERMEDIATE FILAMENT; RATS; EXPRESSION; MIGRATION; NESTIN; BRAIN	Previous reports showed the therapeutic effect of transplants of bone marrow stromal cells (BMSC) after incomplete traumatic spinal cord lesions. We studied the effect of this form of therapy in chronically paraplegic Wistar rats due to severe spinal cord injury (SCI). Rats were subjected to weight-drop impact causing paraplegia, and BMSC or phosphate buffered saline (PBS) was injected into spinal cord 3 months after injury. Functional outcome was measured using the Basso-Beattie-Bresnehan score until sacrifice of the animals, 4 weeks after transplantation. At this time, samples of spinal cord tissue were studied histologically. The results showed a clear and progressive functional recovery of the animals treated with BMSC transplantation, compared to controls. Grafted BMSC survived into spinal cord tissue, forming cell bridges within the traumatic centromedullary cavity. In this tissue, cells expressing neuronal and astroglial markers can be seen, together with a marked ependymal proliferation, showing nestin-positivity. These findings suggest the utility of BMSC transplantation in chronically established paraplegia.	Autonomous Univ Madrid, Dept Surg, Puerta Hierro Hosp, Neurosurg Serv,Mapfre Med Fdn,Neurosci Res Unit, E-28049 Madrid, Spain	Vaquero, J (corresponding author), Autonomous Univ Madrid, Dept Surg, Puerta Hierro Hosp, Neurosurg Serv,Mapfre Med Fdn,Neurosci Res Unit, E-28049 Madrid, Spain.	jvaqueroc@telefonica.net					Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BARONVANEVERCOOREN A, 1991, NEUROSCI LETT, V131, P241, DOI 10.1016/0304-3940(91)90623-2; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Namiki J, 1999, J NEUROPATH EXP NEUR, V58, P489, DOI 10.1097/00005072-199905000-00008; Shibuya S, 2002, NEUROSCIENCE, V114, P905, DOI 10.1016/S0306-4522(02)00323-8; Zurita M, 2000, SURG NEUROL, V54, P117, DOI 10.1016/S0090-3019(00)00287-1; Zurita M, 2001, SURG NEUROL, V55, P249, DOI 10.1016/S0090-3019(01)00442-6; ZURITA M, 1994, POLYTRAUMATIZED, P343	17	108	122	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	MAY 19	2004	15	7					1105	1108		10.1097/00001756-200405190-00004			4	Neurosciences	Neurosciences & Neurology	871NM	WOS:000225140400004	15129154				2021-06-18	
J	Levi, O; Jongen-Relo, AL; Feldon, J; Roses, AD; Michaelson, DM				Levi, O; Jongen-Relo, AL; Feldon, J; Roses, AD; Michaelson, DM			ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory	NEUROBIOLOGY OF DISEASE			English	Article						Alzheimer's disease; apolipoprotein E; enriched environment; learning; synaptogenesis; synaptophysin; transgenic mice; working memory	CLOSED-HEAD INJURY; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; TRANSGENIC MICE; ENRICHED ENVIRONMENT; DEFICIENT MICE; E4; ALLELE; E3; EDUCATION	Alzheimer's disease (AD) is associated with genetic risk factors, of which the allele E4 of apolipoprotein E (apoE4) is the most prevalent, and is affected by environmental factors that include education early in life and socioeconomic background. The extent to which environmental factors affect the phenotypic expression of the AD genetic risk factors is not known. Here we show that the neuronal and cognitive stimulations, which are elicited by environmental enrichment at a young age, are markedly affected by the apoE genotype. Accordingly, exposure to an enriched environment of young mice transgenic for human apoE3, which is the benign AD apoE allele, resulted in improved learning and memory, whereas mice transgenic for human apoE4 were unaffected by the enriched environment and their learning and memory were similar to those of the nonenriched apoE3 transgenic mice. These cognitive effects were associated with higher hippocampal levels of the presynaptic protein synaptophysin and of NGF in apoE3 but not apoE4 transgenic mice. In contrast, cortical synaptophysin and NGF levels of the apoE3 and apoE4 transgenic mice were similarly elevated by environmental enrichment. These findings show that apoE4 impairs hippocampal plasticity and isoform-specifically blocks the environmental stimulation of synaptogenesis and memory. This provides a novel mechanism by which environmental factors can modulate the function and phenotypic expression of the apoE genotype. (C) 2003 Elsevier Science (USA). All rights reserved.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Ramat Aviv, Israel; Swiss Fed Inst Technol, Dept Biol, Lab Behav Neurobiol, Zurich, Switzerland; Duke Univ, Dept Neurol, Durham, NC USA	Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Ramat Aviv, Israel.						ANGER WK, 1991, NEUROTOXICOLOGY, V12, P403; Arendt T, 1997, J NEUROSCI, V17, P516; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Chapman J, 2001, NEUROLOGY, V57, P1482, DOI 10.1212/WNL.57.8.1482; Chapman J, 1996, NEUROLOGY, V46, P1484, DOI 10.1212/WNL.46.5.1484-a; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DIAMOND MC, 1966, J COMP NEUROL, V128, P117, DOI 10.1002/cne.901280110; Fagan AM, 2000, MICROSC RES TECHNIQ, V50, P297, DOI 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Herz J, 2001, TRENDS NEUROSCI, V24, P193, DOI 10.1016/S0166-2236(00)01768-9; JONES BJ, 1968, N-S ARCH PHARMAKOL, V259, P211, DOI 10.1007/BF00537801; Kalmijn S, 1997, BRIT MED J, V314, P34, DOI 10.1136/bmj.314.7073.34; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; KAWAS CH, 1999, ALZHEIMERS DIS; Li S, 2002, NEUROSCIENCE, V115, P1221, DOI 10.1016/S0306-4522(02)00485-2; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Masliah E, 1997, BRAIN RES, V751, P307, DOI 10.1016/S0006-8993(96)01420-5; Moceri VM, 2000, NEUROLOGY, V54, P415, DOI 10.1212/WNL.54.2.415; Moceri VM, 2001, EPIDEMIOLOGY, V12, P383, DOI 10.1097/00001648-200107000-00007; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; OPHIR S, 2003, IN PRESS NEUROBIOL D; Pham TM, 1999, NEUROSCIENCE, V94, P279, DOI 10.1016/S0306-4522(99)00316-4; Pitas RE, 1998, BIOCHEM SOC T, V26, P257, DOI 10.1042/bst0260257; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Ramirez-Amaya V, 2001, J NEUROSCI, V21, P7340; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Roses AD, 1998, AM J MED GENET, V81, P49, DOI 10.1002/(SICI)1096-8628(19980207)81:1<49::AID-AJMG10>3.0.CO;2-W; ROSES AD, 1996, A REV MED, V47, P378; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SAITO S, 1994, J NEUROSCI RES, V39, P57, DOI 10.1002/jnr.490390108; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SELKOE DJ, 2001, PHYSIOL REV, V81, P751; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Veinbergs I, 1999, NEUROSCIENCE, V91, P401, DOI 10.1016/S0306-4522(98)00602-2; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412	43	108	111	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	AUG	2003	13	3					273	282		10.1016/S0969-9961(03)00045-7			10	Neurosciences	Neurosciences & Neurology	708GT	WOS:000184559400011	12901842				2021-06-18	
J	Sveistrup, H; McComas, J; Thornton, M; Marshall, S; Finestone, H; McCormick, A; Babulic, K; Mayhew, A				Sveistrup, H; McComas, J; Thornton, M; Marshall, S; Finestone, H; McCormick, A; Babulic, K; Mayhew, A			Experimental studies of virtual reality-delivered compared to conventional exercise programs for rehabilitation	CYBERPSYCHOLOGY & BEHAVIOR			English	Article; Proceedings Paper	1st Annual Cybertherapy Advanced Technologies in the Behavioral Social and Neurosciences Conference	JAN 19-21, 2003	SAN DIEGO, CALIFORNIA				FROZEN SHOULDER; MANIPULATION	This paper presents preliminary data from two clinical trials currently underway using flat screen virtual reality (VR) technology for physical rehabilitation. In the first study, we are comparing a VR-delivered exercise program to a conventional exercise program for the rehabilitation of shoulder joint range-of-motion in patients with chronic frozen shoulder. In the second study, we are comparing two exercise programs, VR and conventional, for balance retraining in subjects post-traumatic brain injury. Effective VR-based rehabilitation that is easily adapted for individuals to use both in inpatient, outpatient and home-based care could be used as a supplement or alternative to conventional therapy. If this new treatment approach is found to be effective, it could provide a way to encourage exercise and treatment compliance, provide safe and motivating therapy and could lead to the ability to provide exercises to clients in distant locations through telehealth applications of VR treatment. VR is a new technology and the possibilities for rehabilitation are only just beginning to be assessed.	Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON K1H 8M5, Canada; Ottawa Hosp, Rehabil Ctr, Div Phys Med & Rehabil, Ottawa, ON, Canada; Univ Ottawa, Elizabeth Bruyere Hlth Ctr, Dept Phys Med & Rehabil, Ottawa, ON, Canada; Ottawa Hosp, Rehabil Serv, Ottawa, ON, Canada; Univ Ottawa, Inst Heart, Prevent & Rehabil Ctr, Ottawa, ON, Canada	Sveistrup, H (corresponding author), Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.						Beaton D E, 2001, J Hand Ther, V14, P128; BERG K, 1989, Physiotherapy Canada, V41, P304; Chipchase LS, 2000, J SHOULDER ELB SURG, V9, P12, DOI 10.1016/S1058-2746(00)90003-X; Codman EA., 1934, SHOULDER; Dodenhoff RM, 2000, J SHOULDER ELB SURG, V9, P23, DOI 10.1016/S1058-2746(00)90005-3; DUETSCH JE, 2002, NEUROLOGY REPORT, V26, P79; Green S, 1998, BRIT MED J, V316, P354, DOI 10.1136/bmj.316.7128.354; Hillier SL, 1997, BRAIN INJURY, V11, P661; HOLDEN MK, 2002, NEUROLOGY REPORT, V26, P62; Inness L, 2002, SYNAPSE, V22, P2; MANN NR, 1996, MED REHABILITATION T, P479; MCCOMAS J, 2002, NEUROLOGY REPORT, V26, P55, DOI DOI 10.1097/01253086-200226020-00002; MCCONNELL S, 1999, DASH OUTCOME MEASURE; OGILVIEHARRIS DJ, 1995, CLIN ORTHOP RELAT R, P238; REKOLA KE, 1993, J EPIDEMIOL COMMUN H, V47, P153, DOI 10.1136/jech.47.2.153; RIZK TE, 1994, ARCH PHYS MED REHAB, V75, P803; Rizzo AA, 2002, HUM FAC ER, P1027; ROSE FD, 1998, VIRTUAL ENV CLIN PSY, P233; RYAN L, 1997, PHYSIOTHERAPY CANADA, V4, P113; Tolfts Annabel, 1997, Physiotherapy Theory and Practice, V13, P197; Whitney S, 2002, NEUROLOGY REPORT, V26, P72	21	108	113	0	20	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	1094-9313			CYBERPSYCHOL BEHAV	CyberPsychol. Behav.	JUN	2003	6	3					245	249		10.1089/109493103322011524			5	Communication; Psychology, Applied	Communication; Psychology	693BA	WOS:000183693700004	12855079				2021-06-18	
J	Joshi, M; Fehlings, MG				Joshi, M; Fehlings, MG			Development and characterization of a novel, graded model of clip compressive spinal cord injury in the mouse: Part 2. Quantitative neuroanatomical assessment and analysis of the relationships between axonal tracts, residual tissue, and locomotor recovery	JOURNAL OF NEUROTRAUMA			English	Article						in vivo model; knockout mouse; locomotion assessment; motor tract axons; neurotrauma; pathophysiology	RUBROSPINAL NEURONS; OVERGROUND LOCOMOTION; NEUROLOGICAL FUNCTION; LESIONS; RATS; CATS; CONTUSION	A detailed examination of the histopathological features of the clip compression injury in mice was performed to understand the relationships between neurological function and existing pathology of the spinal cord. Adult, female CD1 mice underwent three grades of extradural clip compression injury (3-g, 8-g, and 24-g FEJOTA(TM) Mouse clips), transection, and sham injury at T3-4. Quantitative behavioural assessments were performed for 4 weeks following SCI. After 4 weeks, Fluoro-Gold was introduced caudal to the SCI site, at T9, and was retrogradely transported for 5 days to the origin of spared axons through the injury site. Counts of retrogradely labeled neurons in the brain-stem, midbrain, and sensory-motor cortex indicated that the number of intact descending axons that traversed the lesion decreased with increasing injury severity (F > 28; df = 4; p < 0.0001; one-way ANOVA). Independent linear correlation analyses were performed between indices of neurological recovery (BBB and IP test), counts of retrogradely labeled neurons and morphometric assessments of normal residual tissue at the injury epicenter. The BBB test correlated strongly with the amount of residual tissue at the injury epicenter (R = 0.945, df = 28, p < 0.0001). Counts of neurons retrogradely labeled with Fluoro-Gold were also strongly correlated with the BBB scores. The extrapyramidal (raphespinal, reticulospinal, vestibulospinal, and rubrospinal) tracts had Pearson correlation coefficients (R) of 0.814, 0.812, 0.813, and 0.747, respectively (df = 28, p < 0.0001). The pyramidal (corticospinal) tract had a correlation of R = 0.747, df = 28, p < 0.0001 with the BBB scores. The IP scores also correlated strongly with the persistence of extrapyramidal (raphespinal, reticulospinal, vestibulospinal and rubrospinal) tracts with correlation coefficients of 0.801, 0.782, 0.790, and 0.836, respectively (df = 28, p < 0.0001). These data indicate that the counts of retrogradely labeled neurons at the origin of distinct descending motor pathways are predictors of the variance of the functional recovery measured by the BBB and IP tests following spinal cord injury. In addition, we provide a detailed neuroanatomical study of clip compression injury in mice that can be used to study the molecular mechanisms of SCI in knockout and transgenic mice.	Univ Toronto, Toronto Western Hosp, Dept Surg, Div Neurosurg, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Univ Toronto, Univ Hlth Network, Dept Surg, 399 Bathurst St,Suite 2-417, Toronto, ON M5T 2S8, Canada.			Fehlings, Michael/0000-0002-5722-6364			Agrawal SK, 1997, J NEUROTRAUM, V14, P81, DOI 10.1089/neu.1997.14.81; ARMSTRONG DM, 1988, J PHYSIOL-LONDON, V405, P1, DOI 10.1113/jphysiol.1988.sp017319; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BLIGHT AR, 1991, J NEUROSURG SCI, V35, P131; BRESNAHAN JC, 1987, EXP NEUROL, V96, P82; EIDELBERG E, 1981, EXP BRAIN RES, V42, P81; Eidelberg E, 1976, Surg Neurol, V6, P35; EIDELBERG E, 1981, EXP BRAIN RES, V43, P101; Farooque M, 2000, ACTA NEUROPATHOL, V100, P13, DOI 10.1007/s004010051187; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gruner JA, 1996, BRAIN RES, V729, P90, DOI 10.1016/S0006-8993(96)00366-6; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; JENKINS R, 1993, EUR J NEUROSCI, V5, P203, DOI 10.1111/j.1460-9568.1993.tb00486.x; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; LITTLE JW, 1988, NEUROSCI LETT, V87, P189, DOI 10.1016/0304-3940(88)90168-1; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; MIDHA R, 1987, BRAIN RES, V410, P299, DOI 10.1016/0006-8993(87)90328-3; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; Muir GD, 2000, EUR J NEUROSCI, V12, P1113, DOI 10.1046/j.1460-9568.2000.00987.x; NASO WB, 1993, NEUROSCI LETT, V155, P125, DOI 10.1016/0304-3940(93)90688-H; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; Norman G.R., 1998, BIOSTATISTICS BARE E; Paxinos G., 1995, RAT NERVOUS SYSTEM; Pikov V, 2001, J NEUROSCI, V21, P559, DOI 10.1523/JNEUROSCI.21-02-00559.2001; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Schwartz G, 2001, J NEUROSURG, V94, P245, DOI 10.3171/spi.2001.94.2.0245; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; YU J, 1981, BRAIN RES, V220, P179, DOI 10.1016/0006-8993(81)90222-5	31	108	113	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2002	19	2					191	203		10.1089/08977150252806956			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	526ER	WOS:000174117100002	11893022				2021-06-18	
J	Dennis, M; Purvis, K; Barnes, MA; Wilkinson, M; Winner, E				Dennis, M; Purvis, K; Barnes, MA; Wilkinson, M; Winner, E			Understanding of literal truth, ironic criticism, and deceptive praise following childhood head injury	BRAIN AND LANGUAGE			English	Article						closed head injury; irony; deception; nonliteral language; intentionality	VERBAL IRONY; PRETENSE THEORY; BRAIN INJURY; CHILDREN; DISCOURSE; ADOLESCENTS; COMPREHENSION; NARRATIVES; KNOWLEDGE; SARCASM	Children with closed head injury (CHI) have semantic-pragmatic language problems that include difficulty in understanding and producing both literal and nonliteral statements. For example, they are relatively insensitive to some of the social messages in nonstandard communication as well as to words that code distinctions among mental states. This suggests that they may have difficulty with comprehension tasks involving first- and second-order intentionality, such as those involved in understanding irony and deception. We studied how 6- to 15-year-old children, typically developing or with CHI, interpret scenarios involving literal truth, ironic criticism, and deceptive praise. Children with severe CHI had overall poorer mastery of the task. Even mild CHI impaired the ability to understand the intentionality underlying deceptive praise. CHI, especially biologically significant CI-II, appears to place children at risk for failure to understand language as externalized thought. (C) 2001 Academic Press.	Hosp Sick Children, Dept Psychol Res, Toronto, ON M5G 1X8, Canada; Boston Coll, Dept Psychol, Chestnut Hill, MA 02167 USA; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada	Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS 21889-16] Funding Source: Medline		AIRENTI G, 1993, J PRAGMATICS, V20, P303, DOI 10.1016/0378-2166(93)90055-T; ANDREWS J, 1986, COMMUN COGNITION, V19, P281; ASTINGTON J, 1995, CHILDS DISCOVERY MIN; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; BARA BG, 1998, COGNITION CONTEX; Bara Bruno G., 1995, COGNITIVE SCI DEV AP; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Barnes MA, 1996, J EXP CHILD PSYCHOL, V61, P216, DOI 10.1006/jecp.1996.0015; BARNES MA, 1992, J PEDIATR PSYCHOL, V17, P445, DOI 10.1093/jpepsy/17.4.445; BARONCOHEN S, 1994, BRIT J PSYCHIAT, V165, P640, DOI 10.1192/bjp.165.5.640; BJORKLUND DF, 1986, J EXP CHILD PSYCHOL, V41, P367, DOI 10.1016/0022-0965(86)90045-7; BOCK JK, 1982, PSYCHOL REV, V89, P1, DOI 10.1037/0033-295X.89.1.1; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CAPELLI CA, 1990, CHILD DEV, V61, P1824, DOI 10.1111/j.1467-8624.1990.tb03568.x; Carlson SM, 1998, CHILD DEV, V69, P672, DOI 10.2307/1132197; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, 1999, COMMUNICATION DISORD; CLARK HH, 1984, J EXP PSYCHOL GEN, V113, P121, DOI 10.1037/0096-3445.113.1.121; DEMOREST A, 1984, CHILD DEV, V55, P1527, DOI 10.2307/1130022; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dews S, 1996, CHILD DEV, V67, P3071, DOI 10.2307/1131767; Dews S, 1999, J PRAGMATICS, V31, P1579, DOI 10.1016/S0378-2166(99)00005-3; Dews Shelly, 1995, AM PSYCH ASS NEW YOR; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1985, SPEECH LANGUAGE EVAL; FELDMAN RS, 1991, CHILDRENS INTERPERSO; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Gazdar G., 1981, ELEMENTS DISCOURSE U; Gibbs R.W., 1989, METAPHOR SYMBOLIC AC, V3, P145; GIBBS RW, 1995, DISCOURSE PROCESS, V20, P187, DOI 10.1080/01638539509544937; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; GIBBS RW, 1984, COGNITIVE SCI, V8, P275, DOI 10.1016/S0364-0213(84)80004-X; Giora R., 1997, COGN LINGUIST, V7, P182; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; HALL WS, 1987, J PSYCHOLINGUIST RES, V16, P289, DOI 10.1007/BF01069284; HAVERKATE H, 1990, J PRAGMATICS, V14, P77, DOI 10.1016/0378-2166(90)90065-L; JASZCZOLT K, 1999, DISCOURSE BELIEFS IN; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORGENSEN J, 1984, J EXP PSYCHOL GEN, V113, P112, DOI 10.1037/0096-3445.113.1.112; KAUFER DS, 1981, J PRAGMATICS, V5, P494; KREUZ RJ, 1991, METAPHOR SYMB ACT, V6, P149, DOI 10.1207/s15327868ms0603_1; KREUZ RJ, 1989, J EXP PSYCHOL GEN, V118, P374, DOI 10.1037/0096-3445.118.4.374; KREUZ RJ, 1993, METAPHOR SYMB ACT, V8, P97, DOI 10.1207/s15327868ms0802_2; KUMONNAKAMURA S, 1995, J EXP PSYCHOL GEN, V124, P3, DOI 10.1037/0096-3445.124.1.3; Leggitt JS, 2000, DISCOURSE PROCESS, V29, P1, DOI 10.1207/S15326950dp2901_1; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levinson S.C., 1983, PRAGMATICS; LONG DL, 1988, DISCOURSE PROCESS, V11, P35, DOI 10.1080/01638538809544690; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; McDonald S., 2000, ADV UNDERSTANDING CO; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MORROW DG, 1990, INFERENCES TEXT COMP; Muecke, 1969, COMPASS IRONY; Peskin J, 1996, CHILD DEV, V67, P1735, DOI 10.1111/j.1467-8624.1996.tb01824.x; PESKIN J, 1989, CONCEALING ONES INTE; PETERSON CC, 1991, CHILDRENS INTERPERSO; Pexman PM, 2000, DISCOURSE PROCESS, V29, P201, DOI 10.1207/S15326950dp2903_2; SCHOLNICK EK, 1991, PERSPECTIVES LANGUAG; SODIAN B, 1994, CHILDRENS EARLY UNDE; Sperber D., 1986, RELEVANCE COMMUNICAT; Sperber Dan, 1981, RADICAL PRAGMATICS; Srinivas, 2000, METAPHOR SYMBOL, V15, P47, DOI [10.1080/10926488.2000.9678864, DOI 10.1080/10926488.2000.9678864]; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1991, WECHSLER INTELLIGENC; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; Winner E., 1988, POINT WORDS CHILDREN; Winner E., 1997, PROBLEM MEANING BEHA; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WOODCOCK RW, 1990, WOOCKCOCKJOHNSON PSY	81	108	110	0	14	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JUL	2001	78	1					1	16		10.1006/brln.2000.2431			16	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	445WF	WOS:000169481000001	11412012				2021-06-18	
J	Gupta, RC; Milatovic, D; Dettbarn, WD				Gupta, RC; Milatovic, D; Dettbarn, WD			Depletion of energy metabolites following acetylcholinesterase inhibitor-induced status epilepticus: Protection by antioxidants	NEUROTOXICOLOGY			English	Article; Proceedings Paper	39th Annual Meeting of the Society-of-Toxicology	MAR 19-23, 2000	PHILADELPHIA, PA	Soc Toxicol		DFP; carbofuran; spin trap PEN; vitamin E; high-energy phosphates; nitric oxide (NO); NO synthesis; citrulline; antioxidants; seizures	NITRIC-OXIDE; ALPHA-TOCOPHEROL; RAT-BRAIN; VITAMIN-E; LIPID-PEROXIDATION; LITHIUM-CHLORIDE; DIAPHRAGM MUSCLE; OXIDATIVE STRESS; SKELETAL-MUSCLE; CELL INJURY	Status epilepticus (SE)-induced neuronal injury may involve excitotoxicity, energy impairment and increased generation of reactive oxygen species (ROS). Potential treatment therefore should consider agents that protect mitochondrial function and ROS scavengers. In the present study we examined whether the spin trapping agent N-tert-butyl-alpha -phenylnitrone (PBN) and the antioxidant vitamin E (DL-alpha -tocopherol) protect levels of high-energy phosphates during SE. In rats, SE was induced by either of two inhibitors of acetylcholinesterase (AChE), the organophosphate diisopropylphosphorofluoridate (DFP, 1.25 mg/kg, sc)- or the carbamate carbofuran (1.25 mg/kg, sc). Rats were sacrificed 1 h or 3 days after onset of seizures by head-focused microwave (power, 10 kW; duration 1.7 s) and levels of the energy-rich phosphates adenosine triphosphate (ATP) and phosphocreatine (PCr) and their metabolites adenosine diphosphate (ADP) and adenosine monophosphate (AMP), and creatine (Cr), respectively, were determined in the cortex, amygdala and hippocampus. Within 1 h of seizure activity, marked declines were seen in ATP (34-60%) and PCr (25-52%). Total adenine nucleotides (TAN = ATPS + ADP + AMP) and total creatine compounds (TCC = PCr + Cr) were also reduced (TAN 38-60% and TCC 25-47%). No changes in ATP/AMP ratio were seen. Three days after the onset of seizures, recovery of ATP and PCr was significant in the amygdala and hippocampus, but not in the cortex. Pretreatment of rats with PEN (200 mg/kg, ip, in a single dose), 30 min before DFP or carbofuran administration, prevented induced seizures and partially prevented depletion of high-energy phosphates. Pretreatment with the natural antioxidant vitamin E (100 mg/kg, ip.day for 3 days), partially prevented loss of high energy phosphates without affecting seizures. In controls, citrulline, a product of nitric oxide synthesis, was found so be highest in the amygdala, followed by hippocampus, and lowest in the cortex. DFP- or carbofuran-induced seizures caused elevation of citrulline levels seven- to eight-fold in the cortex and three- to four-fold in the amygdala and hippocampus. These results suggest a close relationship between SE, excitotoxicity and energy metabolism. The involvement of oxidative stress is supported by the findings that DFP and carbofuran trigger an excessive nitric oxide (NO) production in the seizure relevant regions of the brain. (C) 2001 Elsevier Science Inc. All rights reserved.	Murray State Univ, Breathitt Vet Ctr, Dept Toxicol, Hopkinsville, KY 42240 USA; Vanderbilt Univ, Med Ctr S, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr S, Dept Neurol, Nashville, TN 37232 USA	Gupta, RC (corresponding author), Murray State Univ, Breathitt Vet Ctr, Dept Toxicol, Hopkinsville, KY 42240 USA.	ramesh.gupta@murraystate.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES004597] Funding Source: NIH RePORTER; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES04597] Funding Source: Medline		ANDERSON DE, 1993, BIOCHEM BIOPH RES CO, V193, P878, DOI 10.1006/bbrc.1993.1707; ANDREOLI SP, 1993, J LAB CLIN MED, V122, P232; BAGETTA G, 1993, EUR J PHARMACOL, V237, P61, DOI 10.1016/0014-2999(93)90093-W; Bagetta G, 1995, EUR J PHARMACOL, V294, P341, DOI 10.1016/0014-2999(95)00689-3; Barclay LRC, 2000, FREE RADICAL BIO MED, V28, P1079, DOI 10.1016/S0891-5849(00)00197-0; BAST A, 1991, AM J MED, V91, pS2, DOI 10.1016/0002-9343(91)90278-6; BJORNEBOE A, 1991, J NUTR, V121, P1208; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; BOSE R, 1992, TOXICOL LETT, V60, P211, DOI 10.1016/0378-4274(92)90276-P; Boyer PD, 1998, BIOSCIENCE REP, V18, P97, DOI 10.1023/A:1020188311092; Brorson JR, 1999, J NEUROSCI, V19, P147; CASTANO A, 1994, B ENVIRON CONTAM TOX, V53, P309; CHOW CK, 1991, FREE RADICAL BIO MED, V11, P215; Chow CK, 1999, FREE RADICAL BIO MED, V27, P580, DOI 10.1016/S0891-5849(99)00121-5; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Delanty N, 1998, ACTA NEUROL SCAND, V98, P145, DOI 10.1111/j.1600-0404.1998.tb07285.x; Dettbarn W-D., 2001, INT C ANT, P183; ERECINSKA M, 1995, J NEUROCHEM, V65, P2699; FARBER E, 1973, FED PROC, V32, P1534; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Fukushima T, 1997, EXP TOXICOL PATHOL, V49, P381, DOI 10.1016/S0940-2993(97)80123-6; GOLLNICK PD, 1990, PFLUG ARCH EUR J PHY, V415, P407, DOI 10.1007/BF00373617; Gupta R. C., 1998, TOXICOL SCI, V42, P156; Gupta R.C., 1999, TOXICOL SCI, V48, P188; GUPTA RC, 1989, J TOXICOL ENV HEALTH, V28, P111, DOI 10.1080/15287398909531332; GUPTA RC, 1985, FUND APPL TOXICOL, V5, pS17, DOI 10.1016/0272-0590(85)90111-3; Gupta RC, 2000, PFLUG ARCH EUR J PHY, V440, pR160, DOI 10.1007/s004240000047; Gupta RC, 2000, HUM EXP TOXICOL, V19, P297, DOI 10.1191/096032700678815927; GUPTA RC, 1991, ARCH TOXICOL, V65, P304, DOI 10.1007/BF01968964; GUPTA RC, 1994, J TOXICOL ENV HEALTH, V43, P291, DOI 10.1080/15287399409531922; GUPTA RC, 1994, NEUROTOXICOLOGY, V15, P321; GUPTA RC, 1991, ARCH ENVIRON CON TOX, V21, P263, DOI 10.1007/BF01055345; Gupta RC, 2000, ARCH TOXICOL, V74, P13, DOI 10.1007/s002040050646; GUPTA RC, 2000, IN PRESS TOXICOL SCI; KEMP RB, 1986, FOOD CHEM TOXICOL, V24, P465, DOI 10.1016/0278-6915(86)90093-1; Kim YB, 1997, ENVIRON TOXICOL PHAR, V3, P53, DOI 10.1016/S1382-6689(96)00139-1; KOTEGAWA M, 1993, J MOL CELL CARDIOL, V25, P1067, DOI 10.1006/jmcc.1993.1119; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; LUFT R, 1995, BBA-MOL BASIS DIS, V1271, P1, DOI 10.1016/0925-4439(95)00002-L; MARUBAYASHI S, 1986, SURGERY, V99, P184; MCDONOUGH JH, 1993, NEUROSCI BIOBEHAV R, V17, P203, DOI 10.1016/S0149-7634(05)80151-4; Milatovic D, 2000, NEUROSCI LETT, V278, P25, DOI 10.1016/S0304-3940(99)00904-0; Milatovic D, 2000, FREE RADICAL BIO MED, V28, P597, DOI 10.1016/S0891-5849(99)00270-1; MILATOVIC D, 2000, IN PRESS BRAIN RES; MISULIS KE, 1987, TOXICOL APPL PHARM, V89, P391, DOI 10.1016/0041-008X(87)90158-X; MORRISETT RA, 1987, EXP NEUROL, V98, P594, DOI 10.1016/0014-4886(87)90268-8; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Nicotera P, 1998, TOXICOL LETT, V103, P139; Olney J W, 1986, Adv Neurol, V44, P857; Pazos AJ, 1999, BRAIN RES, V846, P186, DOI 10.1016/S0006-8993(99)02010-7; Pedersen PL, 1999, J BIOENERG BIOMEMBR, V31, P291, DOI 10.1023/A:1005453700533; PLANAS AM, 1995, EUR J NEUROSCI, V7, P293, DOI 10.1111/j.1460-9568.1995.tb01065.x; Punz A, 1998, CLIN NUTR, V17, P85, DOI 10.1016/S0261-5614(98)80311-7; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Raveh L, 1999, NEUROTOXICOLOGY, V20, P551; SAVOLAINEN KM, 1988, TOXICOL APPL PHARM, V96, P305, DOI 10.1016/0041-008X(88)90089-0; SCHLIEBS R, 1989, J NEUROCHEM, V53, P212, DOI 10.1111/j.1471-4159.1989.tb07316.x; Solberg Y, 1997, TRENDS PHARMACOL SCI, V18, P183, DOI 10.1016/S0165-6147(97)90617-9; SPERK G, 1985, BRAIN RES, V338, P289, DOI 10.1016/0006-8993(85)90159-3; Sperlagh B, 1996, SEMIN NEUROSCI, V8, P175, DOI 10.1006/smns.1996.0023; Tavazzi B, 2000, EUR J BIOCHEM, V267, P684, DOI 10.1046/j.1432-1327.2000.01042.x; Taylor DL, 1999, BRAIN PATHOL, V9, P93; TAYYABA K, 1985, ACTA PHARMACOL TOX, V57, P190, DOI 10.1111/bcpt.1985.57.3.190; Tsujimoto Y, 1997, CELL DEATH DIFFER, V4, P429, DOI 10.1038/sj.cdd.4400262; VANACKER SABE, 1993, FREE RADICAL BIO MED, V15, P311, DOI 10.1016/0891-5849(93)90078-9; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WASTERLAIN CG, 1994, BRAIN DEV-JPN, V16, P279, DOI 10.1016/0387-7604(94)90025-6; WECKER L, 1978, J PHARMACOL EXP THER, V206, P97; Yang PY, 2000, J TOXICOL-CLIN TOXIC, V38, P43, DOI 10.1081/CLT-100100914; Yang ZP, 1998, J PHYSIOLOGY-PARIS, V92, P157, DOI 10.1016/S0928-4257(98)80002-8; Zivin M, 1999, BRAIN RES, V850, P63, DOI 10.1016/S0006-8993(99)02101-0; Zivin M, 1999, FASEB J, V13, pA1102	73	108	115	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	APR	2001	22	2					271	282		10.1016/S0161-813X(01)00013-4			12	Neurosciences; Pharmacology & Pharmacy; Toxicology	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	439NE	WOS:000169122400010	11405258				2021-06-18	
J	LaPlaca, MC; Zhang, J; Raghupathi, R; Li, JH; Smith, F; Bareyre, FM; Snyder, SH; Graham, DI; McIntosh, TK				LaPlaca, MC; Zhang, J; Raghupathi, R; Li, JH; Smith, F; Bareyre, FM; Snyder, SH; Graham, DI; McIntosh, TK			Pharmacologic inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; DNA damage; DNA repair; experimental brain injury; NAD; PARP	FOCAL CEREBRAL-ISCHEMIA; DNA STRAND BREAKS; CELL-DEATH; FOREBRAIN ISCHEMIA; SUPPRESSOR GENE; APOPTOSIS; DAMAGE; MICE; FRAGMENTATION; ACTIVATION	The nuclear enzyme poly(ADP-ribose) polymerase (PARP), which has been shown to be activated following experimental traumatic brain injury (TBI), binds to DNA strand breaks and utilizes nicotinamide adenine dinucleotide (NAD) as a substrate. Since consumption of NAD may be deleterious to recovery in the setting of CNS injury, we examined the effect of a potent PARP inhibitor, GPI 6150, on histological outcome following TBI in the rat. Rats (n = 16) were anesthetized, received a preinjury dose of GPI 6150 (30 min; 15 mg/kg, i.p.), subjected to lateral fluid percussion (FP) brain injury of moderate severity (2.5-2.8 atm), and then received a second dose 3 h postinjury (15 mg/kg, i.p.). Lesion area was examined using Nissl staining, while DNA fragmentation and apoptosis-associated cell death was assessed with terminal deoxynucleotidyl-transferase-mediated biotin-dUTP nick end labeling (TUNEL) with stringent morphological evaluation. Twenty-four hours after brain injury, a significant cortical lesion and number of TUNEL-positive/nonapoptotic cells and TUNEL-positive/apoptotic cells in the injured cortex of vehicle-treated animals were observed as compared to uninjured rats. The size of the trauma-induced Lesion area was significantly attenuated in the GPI 6150-treated animals versus vehicle-treated animals (p < 0.05), Treatment of GPI 6150 did not significantly affect the number of TUNEL-positive apoptotic cells in the injured cortex. The observed neuroprotective effects on lesion size, however, offer a promising option for further evaluation of PARP inhibition as a means to reduce cellular damage associated with TBI.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Guilford Pharmaceut Inc, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; So Gen Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland	LaPlaca, MC (corresponding author), Georgia Inst Technol, Dept Biomed Engn, 315 Ferst Dr,Rm 1120, Atlanta, GA 30332 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, 950-NS08803] Funding Source: Medline		BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; Chen J, 1997, J NEUROCHEM, V69, P232; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FUNG KM, 1995, AM J PATHOL, V146, P1376; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HUANG S, 2000, 30 ANN M SOC NEUR NE; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LAUTAR S, 1998, 28 ANN M SOC NEUR LO, V24, P1226; LI Y, 1995, MOL BRAIN RES, V28, P164, DOI 10.1016/0169-328X(94)00220-9; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lindahl T, 1995, J CELL SCI, P73; Liu PK, 1996, J NEUROSCI, V16, P6795; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; LU XCM, 2000, 30 ANN M SOC NEUR NE; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; MANEV H, 1994, NEUROREPORT, V5, P2661, DOI 10.1097/00001756-199412000-00064; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RINK A, 1995, AM J PATHOL, V147, P1575; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; SchmidtKastner R, 1997, STROKE, V28, P163, DOI 10.1161/01.STR.28.1.163; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; States BA, 1996, J CEREBR BLOOD F MET, V16, P1165, DOI 10.1097/00004647-199611000-00011; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; ZHANG J, 1999, 6 INT M BIOL NI S645, V167, P90; ZHANG J, 1998, 28 ANN M SOC NEUR LO, V24, P1226	49	108	109	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2001	18	4					369	376		10.1089/089771501750170912			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	425TP	WOS:000168308000001	11336438				2021-06-18	
J	Bryant, RA; Marosszeky, JE; Crooks, H; Gurka, JA				Bryant, RA; Marosszeky, JE; Crooks, H; Gurka, JA			Posttraumatic stress disorder after severe traumatic brain injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							PSEUDOMEMORIES; SCALE	Objective: This study indexed the profile of posttraumatic stress disorder (PTSD) after severe traumatic injury to the brain. Method: Patients who sustained a severe traumatic brain injury (N=96) were assessed for PTSD 6 months after the injury with the PTSD Interview, a structured clinical interview based on DSM-III-R criteria. Results: PTSD was diagnosed in 26 (27.1%) of the patients. While only 19.2% (N=5) of the patients with PTSD reported intrusive memories of the trauma, 96.2% (N=25) reported emotional reactivity. Intrusive memories, nightmares, and emotional reactivity had very strong positive predictive values for the presence of PTSD. Conclusions: These findings indicate that PTSD can develop after severe traumatic brain injury, The predominance of emotional reactivity and the relative absence of traumatic memories in patients with PTSD who suffered impaired consciousness during trauma suggest that traumatic experiences can mediate PTSD at an implicit level.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Westmead Hosp, Dept Rehabil Med, Sydney, NSW, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; FOA EB, 1995, AM J PSYCHIAT, V152, P116; LOGHREY GC, 1993, INT HDB TRAUMATIC ST, P377; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; TEASDALE G, 1974, LANCET, V2, P81; Van Der Kolk Bessel A., 1996, P214; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P	11	108	108	0	3	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	APR	2000	157	4					629	631		10.1176/appi.ajp.157.4.629			3	Psychiatry	Psychiatry	300BE	WOS:000086232300022	10739426				2021-06-18	
S	Blass, JP		Khachaturian, ZS; Mesulam, MM		Blass, JP			The mitochondrial spiral - An adequate cause of dementia in the Alzheimer's syndrome	ALZHEIMERS DISEASE: A COMPENDIUM OF CURRENT THEORIES	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on Towards a Comprehensive Theory for Alzheimers Disease	APR 30-MAY 02, 1999	ORLANDO, FL	Bayer, EISAI, Hoechst Marion Roussel, Pfizer, Roche		mitochondria; energy; KGDHC; reactive oxygen species; calcium	AMYLOID-BETA-PEPTIDE; KETOGLUTARATE DEHYDROGENASE COMPLEX; APOLIPOPROTEIN-E GENOTYPE; TRAUMATIC BRAIN INJURY; OXIDATIVE STRESS; REACTIVE OXYGEN; PRECURSOR PROTEIN; IN-VIVO; COGNITIVE IMPAIRMENT; GLUCOSE-METABOLISM	A variety of chronic, relatively low-grade injuries to the brain occur in Alzheimer's disease (AD). The extent to which each of these contributes to the clinical syndrome is unclear. Several of the abnormalities that occur in AD brain can cause dementia by themselves, even in people who do not have the neuropathological hallmarks of AD. Prominent among these abnormalities is a deleterious "mitochondrial spiral," which consists of reduced brain metabolism, oxidative stress, and calcium dysregulation. The hypothesis presented in this paper is that the mitochondrial spiral contributes to dementia in AD and presents a reasonable target for the development of new approaches to the treatment of this syndrome.	Weill Cornell Med Coll, Burke Med Res Inst, White Plains, NY 10605 USA	Blass, JP (corresponding author), Weill Cornell Med Coll, Burke Med Res Inst, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	jpblass@mail.med.cornell.edu					Albers DS, 2000, J NEUROCHEM, V74, P878, DOI 10.1046/j.1471-4159.2000.740878.x; Ashok BT, 1999, EXP GERONTOL, V34, P293, DOI 10.1016/S0531-5565(99)00005-4; BICK K, 1987, EARLY STORY ALZHEIME; BLASS JP, 1990, ARCH NEUROL-CHICAGO, V47, P864, DOI 10.1001/archneur.1990.00530080046009; Blass JP, 1999, NEW ENGL J MED, V341, P1694, DOI 10.1056/NEJM199911253412213; Blass JP, 1999, DEMENT GERIATR COGN, V10, P335, DOI 10.1159/000017165; Blass JP, 2000, ANN NY ACAD SCI, V903, P204, DOI 10.1111/j.1749-6632.2000.tb06370.x; BLASS JP, 1999, ANN NY ACAD SCI, V893; BLASS JP, 1999, ANN NY ACAD SCI, V893, P11; BLASS JP, 1997, ALZHEIMERS DIS CAUSE, P187; BLASS JP, 1997, ADV CELL AGING GERON, V2, P109; BOBINSKI M, 1995, DEMENTIA, V6, P205, DOI 10.1159/000106948; Butterfield DA, 1999, ANN NY ACAD SCI, V893, P265, DOI 10.1111/j.1749-6632.1999.tb07833.x; Cadroy Y, 2000, J IMMUNOL, V164, P3822, DOI 10.4049/jimmunol.164.7.3822; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Chandrasekaran K, 1998, BRAIN RES, V796, P13, DOI 10.1016/S0006-8993(98)00248-0; Coon AL, 1999, NEUROBIOL AGING, V20, P597, DOI 10.1016/S0197-4580(99)00068-8; CoreyBloom J, 1997, NEUROLOGY, V48, P154, DOI 10.1212/WNL.48.1.154; Craft S, 2000, ANN NY ACAD SCI, V903, P222, DOI 10.1111/j.1749-6632.2000.tb06371.x; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Drachman DA, 1997, NEW ENGL J MED, V336, P1245, DOI 10.1056/NEJM199704243361710; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; FISCHER P, 1991, WIEN MED WOCHENSCHR, V141, P455; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; Gibson GE, 1999, ANN NY ACAD SCI, V893, P79, DOI 10.1111/j.1749-6632.1999.tb07819.x; Gibson GE, 1997, NEUROBIOL AGING, V18, P573, DOI 10.1016/S0197-4580(97)00149-8; GIBSON GE, 1981, AM J MED, V70, P1247, DOI 10.1016/0002-9343(81)90834-2; GIBSON GE, 2000, IN PRESS ANN NEUROL; Hachinski V, 2000, ANN NY ACAD SCI, V903, P1, DOI 10.1111/j.1749-6632.2000.tb06343.x; Harding AJ, 2000, ACTA NEUROPATHOL, V99, P199, DOI 10.1007/PL00007425; HEVNER RF, 1993, J NEUROSCI, V13, P1805; Ishii K, 1996, J NUCL MED, V37, P1159; Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KALARIA RN, 2000, ANN NY ACAD SCI, V903; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Keller JN, 1997, J NEUROSCI RES, V50, P522, DOI 10.1002/(SICI)1097-4547(19971115)50:4<522::AID-JNR3>3.0.CO;2-G; Klann E, 1998, J NEUROPHYSIOL, V80, P452; KO L, 1990, ACTA NEUROPATHOL, V81, P30, DOI 10.1007/BF00662635; Kobayashi T, 1998, ANN NEUROL, V43, P120, DOI 10.1002/ana.410430121; Kokmen E, 1996, MAYO CLIN PROC, V71, P275, DOI 10.4065/71.3.275; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Markesbery WR, 1999, ARCH NEUROL-CHICAGO, V56, P1449, DOI 10.1001/archneur.56.12.1449; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Mastrogiacomo F, 1996, ANN NEUROL, V39, P592, DOI 10.1002/ana.410390508; Mattson MP, 1997, NEUROREPORT, V8, P2275, DOI 10.1097/00001756-199707070-00036; Mattson MP, 2000, J NEUROSCI, V20, P1358; Mattson MP, 1999, ANN NY ACAD SCI, V893, P154, DOI 10.1111/j.1749-6632.1999.tb07824.x; Mattson MP, 1997, PHYSIOL REV, V77, P1081; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; McGeer EG, 1999, CURR PHARM DESIGN, V5, P821; Melov S, 1999, MUTAT RES-DNA REPAIR, V434, P233, DOI 10.1016/S0921-8777(99)00031-2; Morris JC, 1999, J CLIN INVEST, V104, P1171, DOI 10.1172/JCI8560; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Nolan KA, 1998, J AM GERIATR SOC, V46, P597, DOI 10.1111/j.1532-5415.1998.tb01076.x; Pedersen WA, 2000, J NEUROCHEM, V74, P1426, DOI 10.1046/j.1471-4159.2000.0741426.x; Perry G, 2000, FREE RADICAL BIO MED, V28, P831, DOI 10.1016/S0891-5849(00)00158-1; POIRIER J, 1999, CLIN DIAGNOSIS MANAG, P17; Rego AC, 1999, FREE RADICAL BIO MED, V26, P1405, DOI 10.1016/S0891-5849(98)00337-2; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; Rhodin J, 2000, ANN NY ACAD SCI, V903, P345, DOI 10.1111/j.1749-6632.2000.tb06385.x; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sheu KFR, 1999, ANN NY ACAD SCI, V893, P61; Small DH, 1999, J NEUROCHEM, V73, P443, DOI 10.1046/j.1471-4159.1999.0730443.x; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; Smith CD, 1999, J NEUROIMAGING, V9, P2, DOI 10.1111/jon1999912; Spillantini MG, 2000, BRAIN, V123, P857, DOI 10.1093/brain/123.5.857; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Sulger J, 1999, BIOL PSYCHIAT, V45, P737, DOI 10.1016/S0006-3223(98)00218-2; Vendite D, 1998, NEUROCHEM RES, V23, P211, DOI 10.1023/A:1022437110269; VOLPE BT, 1986, NEUROLOGY, V36, P408, DOI 10.1212/WNL.36.3.408; VOLPE BT, 1992, BEHAV NEUROSCI, V106, P457, DOI 10.1037/0735-7044.106.3.457; VOLPE BT, 1985, NEUROLOGY, V35, P1793, DOI 10.1212/WNL.35.12.1793; Yatin SM, 1999, NEUROBIOL AGING, V20, P325; Zsurka G, 1998, BIOL PSYCHIAT, V44, P371, DOI 10.1016/S0006-3223(97)00461-7	79	108	109	0	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-297-5	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2000	924						170	183					14	Multidisciplinary Sciences; Clinical Neurology	Science & Technology - Other Topics; Neurosciences & Neurology	BT10Q	WOS:000171966500025	11193795				2021-06-18	
J	Goss, JR; O'Malley, ME; Zou, LL; Styren, SD; Kochanek, PM; DeKosky, ST				Goss, JR; O'Malley, ME; Zou, LL; Styren, SD; Kochanek, PM; DeKosky, ST			Astrocytes are the major source of nerve growth factor upregulation following traumatic brain injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article						astrocyte; hippocampus; hypothermia; in situ hybridization; nerve growth factor; traumatic brain injury	FACTOR MESSENGER-RNA; PHYSIOLOGICAL STOP PATHWAY; KAINIC ACID INJECTION; C-FOS; NEUROTROPHIC FACTOR; LIMBIC SEIZURES; FACTOR GENE; DIFFERENTIAL REGULATION; AXONAL REGENERATION; CORTICAL ASTROCYTES	Previous studies from our group have demonstrated an upregulation in nerve growth factor (NGF) RNA and protein in the cortex 24 h following traumatic brain injury (TBI) in a rat model. This increase in NGF is suppressed if rats are subjected to 4 h of whole-body hypothermia following TBI. In the present study we used in situ hybridization to extend our initial RNA gel-blot (Northern) hybridization findings by demonstrating that NGF RNA is increased in the cortex following TBI and that hypothermia diminishes this response. Further, by combining in situ hybridization with immunocytochemistry for glial fibrillary acidic protein we demonstrate that astrocytes are the major cellular source for the upregulation in NGF and that this upregulation can be observed in the hippocampus as early as 3 h posttrauma. The predominantly astrocytic origin suggests that the NGF upregulation is not related primarily to cholinotrophic activities. We hypothesize that its function is to stimulate upregulation of antioxidant enzymes, as part of an injury-induced cascade, and that supplementation of NGF or antioxidants may be warranted in hypothermic therapies for head injury. (C) 1998 Academic Press.	Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Neurobiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Neurol, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Goss, JR (corresponding author), Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER		ARENDT T, 1995, NEUROSCIENCE, V65, P647, DOI 10.1016/0306-4522(94)00523-8; AWATSUJI H, 1993, J NEUROSCI RES, V34, P539, DOI 10.1002/jnr.490340506; BAKHIT C, 1991, BRAIN RES, V560, P76, DOI 10.1016/0006-8993(91)91217-O; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BRODIE C, 1995, NEUROSCI LETT, V186, P5, DOI 10.1016/0304-3940(95)11267-Z; BRUCE AJ, 1995, FREE RADICAL BIO MED, V18, P993, DOI 10.1016/0891-5849(94)00218-9; CARMANKRZAN M, 1993, J NEUROSCI RES, V34, P225, DOI 10.1002/jnr.490340210; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEKOSKY ST, 1994, J NEUROTRAUMA, V11, P106; DREYFUS CF, 1989, TRENDS PHARMACOL SCI, V10, P145, DOI 10.1016/0165-6147(89)90166-1; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; FREDERICKSON RCA, 1991, BIOTECHNOLOGY, V9, P1; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; GOSS JR, 1995, J NEUROCHEM, V64, P1351; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GUTHRIE KM, 1995, J COMP NEUROL, V352, P147, DOI 10.1002/cne.903520111; HAHN M, 1994, GLIA, V10, P286, DOI 10.1002/glia.440100407; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HERRERA DG, 1993, BRAIN RES, V602, P99, DOI 10.1016/0006-8993(93)90247-K; HOFF SF, 1982, J COMP NEUROL, V205, P246, DOI 10.1002/cne.902050304; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; LANDFIELD PW, 1977, J GERONTOL, V32, P3, DOI 10.1093/geronj/32.1.3; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDSAY RM, 1982, BRAIN RES, V243, P329, DOI 10.1016/0006-8993(82)90257-8; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LIUZZI FJ, 1990, BRAIN RES, V512, P277, DOI 10.1016/0006-8993(90)90637-Q; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MOCCHETTI I, 1989, P NATL ACAD SCI USA, V86, P3891, DOI 10.1073/pnas.86.10.3891; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; NISHO T, 1994, NEUROSCIENCE, V1, P67; ODERFELDNOWAK B, 1992, NEUROCHEM INT, V21, P455, DOI 10.1016/0197-0186(92)90197-Y; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; POLITIS MJ, 1985, BRAIN RES, V346, P186, DOI 10.1016/0006-8993(85)91114-X; PSHENICHKIN SP, 1995, J BIOL CHEM, V270, P5994, DOI 10.1074/jbc.270.11.5994; PSHENICHKIN SP, 1994, J NEUROCHEM, V63, P419; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; RUDGE JS, 1989, EXP NEUROL, V103, P1, DOI 10.1016/0014-4886(89)90180-5; SCHWARTZ JP, 1994, BRAIN RES BULL, V35, P403, DOI 10.1016/0361-9230(94)90151-1; STRAUSS S, 1994, NEUROSCI LETT, V168, P193, DOI 10.1016/0304-3940(94)90448-0; TIMMUSK T, 1992, SOC NEUR ABSTR, V18; VIGE X, 1991, MOL PHARMACOL, V40, P186; VIGE X, 1992, BRAIN RES, V591, P345, DOI 10.1016/0006-8993(92)91718-T; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P429; WHITTEMORE SR, 1987, J NEUROSCI, V7, P247; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; ZHENG M, 1988, MOL BRAIN RES, V3, P133, DOI 10.1016/0169-328X(88)90058-7	56	108	110	0	5	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	FEB	1998	149	2					301	309		10.1006/exnr.1997.6712			9	Neurosciences	Neurosciences & Neurology	ZA117	WOS:000072330600001	9500953				2021-06-18	
J	Cantu, RC				Cantu, RC			Return to play guidelines after a head injury	CLINICS IN SPORTS MEDICINE			English	Article							FOOTBALL; CONCUSSION; SPORTS; SPINE	Presently there are no universally accepted definitions of the grades of concussion or criteria for when to allow the athlete to return to competition after a head injury. What is agreed upon is that in order to avoid cumulative brain damage and the second impact syndrome, no athlete still suffering post-concussion symptoms should return to competition. This article is meant to serve only as a guideline as the final decision in every instance is a clinical judgement.	Emerson Hosp, Serv Sports Med, Concord, MA 01742 USA; Emerson Hosp, Neurosurg Serv, Concord, MA 01742 USA	Cantu, RC (corresponding author), Emerson Hosp, Serv Sports Med, Concord, MA 01742 USA.						ADAMS H, 1972, SCI F NEUROLOGY, P478; ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; BARBER HM, 1973, BRIT MED J, V3, P532, DOI 10.1136/bmj.3.5879.532; BARCLAY WR, 1978, JAMA-J AM MED ASSOC, V240, P1892, DOI 10.1001/jama.1978.03290170074037; Bodnar L M, 1977, Curr Pract Orthop Surg, V7, P116; CANTU RC, 1990, J SPINAL DISORD, V3, P227; CLARKE K, 1979, MED SCI SPORTS EXERC, V10, P94; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1977, PERCEPT MOTOR SKILL, V4, P367; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HOLTZ HH, 1982, CAN MED ASSOC J, V127, P827; JENNET B, 1971, SCI FDN NEUROLOGY, P441; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KREL FW, 1965, JAMA-J AM MED ASSOC, V194, P264; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Maroon J C, 1980, Clin Neurosurg, V27, P414; MCCOY GF, 1984, J BONE JOINT SURG BR, V66, P500; MCLATCHIE GR, 1980, J TRAUMA, V20, P956, DOI 10.1097/00005373-198011000-00009; Meggyesy Dave, 1970, OUT THEIR LEAGUE, P125; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETRAS AF, 1983, AM J SPORT MED, V11, P325, DOI 10.1177/036354658301100508; PUTNAM P, 1983, SPORTS ILLUSTRA 0606, P23; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHNEIDE.RC, 1970, J NEUROSURG, V33, P363, DOI 10.3171/jns.1970.33.4.0363; Schneider R., 1973, HEAD NECK INJURIES F; SCHNEIDER RC, 1954, J NEUROSURG, V11, P546, DOI 10.3171/jns.1954.11.6.0546; SCHNEIDER RC, 1961, JAMA-J AM MED ASSOC, V177, P106; SCHNEIDER RC, 1985, SPORTS INJURIES; STRICH SJ, 1961, LANCET, V2, P443; SYMONDS C, 1962, LANCET, V1, P1; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196	37	108	108	0	9	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0278-5919			CLIN SPORT MED	Clin. Sports Med.	JAN	1998	17	1					45	+		10.1016/S0278-5919(05)70060-0			17	Sport Sciences	Sport Sciences	YU153	WOS:000071687600006	9475970				2021-06-18	
J	Teasdale, TW; Christensen, AL; Willmes, K; Deloche, G; Braga, L; Stachowiak, F; Vendrell, JM; CastroCaldas, A; Laaksonen, RK; Leclercq, M				Teasdale, TW; Christensen, AL; Willmes, K; Deloche, G; Braga, L; Stachowiak, F; Vendrell, JM; CastroCaldas, A; Laaksonen, RK; Leclercq, M			Subjective experience in brain-injured patients and their close relatives: A European brain injury questionnaire study	BRAIN INJURY			English	Article							KATZ ADJUSTMENT SCALE; REHABILITATION SAMPLE	Results are reported from an international project the aim of which has been to develop and validate a wide-ranging questionnaire suitable for administration to brain-injured patients and their relatives. A self-report questionnaire concerning subjective experience of cognitive, emotional and social difficulties (The European Brain Injury Questionnaire, EBIQ) was administered to a group of 905 brain injured patients, and close relatives to these competed a parallel version of the questionnaire concerning the brain-injured person. The sample was drawn from seven European countries together with Brazil. The same questionnaire was also administered to a group of 203 non-brain-injured controls, similarly in self-report and relative-report versions. Scales relating to eight specific areas of functioning, together with a global scale, are derived from the questionnaire and their internal reliability was estimated in the present data. Analyses of the 63 items of the questionnaire showed consistently greater levels of problems for the brain-injured group, especially as indicated by relatives. This pattern was substantially replicated among the nine scales. The scales discriminated well between stroke patients and those who had suffered a traumatic brain injury. There was also a tendency for reported problems to be greater for patients who were surveyed later post-injury (greater than or equal to 19 months) rather than earlier. Comparison of sets of controls derived from two countries (France and Brazil) showed small but important differences. It is concluded that the questionnaire has an acceptable reliability and validity, but that it will be necessary to obtain culturally relevant non-brain-injured control data when employing it in different countries.	UNIV COPENHAGEN, CTR REHABIL BRAIN INJURY, COPENHAGEN, DENMARK; RHEIN WESTFAL TH AACHEN, INST PSYCHOL, AACHEN, GERMANY; RHEIN WESTFAL TH AACHEN, NEUROL CLIN, AACHEN, GERMANY; UNIV STRASBOURG 1, DEPT PSYCHOL, STRASBOURG, FRANCE; HOSP SARAH KUBISTCHEK, BRASILIA, DF, BRAZIL; UNIV LEIPZIG, INST FORDERPADAG, D-7010 LEIPZIG, GERMANY; HOSP SANTA CRUZ & SAN PABLO, BARCELONA, SPAIN; HOSP SANTA MARIA, LISBON, PORTUGAL; KL INST, HELSINKI, FINLAND; CTR NEUROL WILLIAM LENNOX, OTTIGNIES, BELGIUM	Teasdale, TW (corresponding author), UNIV COPENHAGEN, DEPT PSYCHOL, COPENHAGEN, DENMARK.		Willmes, Klaus F/A-1268-2014; Braga, Lucia/AAQ-1030-2020; Castro-Caldas, Alexandre/M-4156-2013	Willmes, Klaus F/0000-0002-9012-0553; Castro-Caldas, Alexandre/0000-0002-9148-3719			Borg I., 1995, FACET THEORY FORM CO; Borg I., 1987, MULTIDIMENSIONAL SIM; BROOKS C, 1992, J AM STUD, V26, P126, DOI 10.1017/S002187580003053X; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Butcher J. N., 1989, MANUAL RESTANDARDIZE; Canter D., 1985, FACET THEORY APPROAC; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; DELOCHE G, 1996, ANN READAPTION MED P, V39, P21; DEROGATIS LR, 1983, SCL 90 R ADM SCONING; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; FABIANO RJ, 1992, REHABIL PSYCHOL, V37, P75, DOI 10.1037/h0079096; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; LEVY S, 1975, SOC INDIC RES, V2, P361, DOI 10.1007/BF00293253; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MCCLELLAND RJ, 1988, BRIT J PSYCHIAT, V153, P141, DOI 10.1192/bjp.153.2.141; MONGA TN, 1986, ARCH PHYS MED REHAB, V67, P19; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Prigatano G. P, 1988, BRAIN INJURY RECOVER, P335; SERON X, 1989, COGNITIVE APPROACHES; STACHOWIAK FJ, 1993, DEV ASSESSMENT REHAB; Teasdale T W, 1995, Appl Neuropsychol, V2, P116; TUOKKO H, 1991, Brain Injury, V5, P287, DOI 10.3109/02699059109008098; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009; ZASLER ND, 1990, J HEAD TRAUMA REHAB, V5, P14, DOI DOI 10.1097/00001199-199005020-00004	29	108	109	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1997	11	8					543	563		10.1080/026990597123250			21	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XL930	WOS:A1997XL93000001	9251864				2021-06-18	
J	Wood, RL; Yurdakul, LK				Wood, RL; Yurdakul, LK			Change in relationship status following traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; SOCIAL-ADJUSTMENT; RELATIVES; REHABILITATION	Previous studies have highlighted the burden placed on family members and close partners of individuals who have sustained traumatic brain injury. This burden of stress has been attributed to the neurobehavioural sequelae of such injuries. However, the extent to which brain injury affects marriages and close relationships has never been statistically evaluated. This study looked at 131 adults with traumatic brain injury in order to determine the incidence of divorce/separation; 49 per cent of our sample reported chat they had divorced or separated from their partners during a 5-8-year period following brain injury. Factors which may predict the outcome of relationships include severity of injury (as determined by length of post-traumatic amnesia), length of relationship, and time since injury. The influence of these factors in determining the risk of relationship breakdown is discussed.		Wood, RL (corresponding author), BRAIN INJURY REHABIL TRUST, ACORN HOUSE, 397A MIDSUMMER BLVD, MILTON KEYNES MK9 2HP, BUCKS, ENGLAND.						BLAZYK S, 1983, SOC WORK HEALTH CARE, V8, P55, DOI 10.1300/J010v08n04_05; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; JACOBS HE, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P37; JACOBS HE, 1989, TRAUMATIC BRAIN INJU; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; *OFF POP CENS SURV, 1993, SER OFF POP CENS SUR; Panting A., 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; RUSSELL WR, 1971, TRAUMATIC ANNESIAS; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	22	108	109	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	1997	11	7					491	501		10.1080/713802183			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XF661	WOS:A1997XF66100003	9210986				2021-06-18	
J	McLaughlin, MR; Marion, DW				McLaughlin, MR; Marion, DW			Cerebral blood flow and vasoresponsivity within and around cerebral contusions	JOURNAL OF NEUROSURGERY			English	Article						contusion; carbon dioxide reactivity; head injury; hyperventilation; regional cerebral blood flow; xenon-enhanced computerized tomography	SEVERE HEAD-INJURY; ISCHEMIC BRAIN-DAMAGE; STABLE-XENON-CT; INTRAVENTRICULAR PRESSURE; SUBDURAL-HEMATOMA; COMATOSE PATIENTS; HYPERVENTILATION; METABOLISM; CIRCULATION; TOMOGRAPHY	There is increasing evidence that regional ischemia plays a major role in secondary brain injury. Although the cortex underlying subdural hematomas seems particularly vulnerable to ischemia, little is known about the adequacy of cerebral blood flow (CBF) or the vasoresponsivity within the vascular bed of contusions. The authors used the xenon-enhanced computerized tomography (CT) CBF technique to define the CBF and vasoresponsivity of contusions, pericontusional parenchyma, and the remainder of the brain 24 to 48 hours after severe closed head injury in 10 patients: six patients with one contusion and four with two contusions, defined as mixed or high-density lesions on CT scanning. The CBF within the contusions (29.3 +/- 16.4 ml/100 g/minute, mean +/- standard deviation) was significantly lower than both that found in the adjacent I-cm perimeter of normal-appearing tissue (42.5 +/- 15.8 ml/100 g/minute) and the mean global CBF (52.5 +/- 17.5 ml/100 g/minute) (p < 0.004, repeated-measures analysis of variance). A subset of seven patients (10 contusions) also underwent a second Xe-CT CBF study during mild hyperventilation (a PaCO2 of 24-32 mm Hg). In only two of these: 10 contusions was vasoresponsivity less than 1% (range 0%-7.6%); in the rim of normal-appearing pericontusional tissue, it was 0.4% to 9.1%. The authors conclude that CBF within intracerebral contusions is highly variable and is often above 18 ml/100 g/minute, the reported threshold for irreversible ischemia. Intracontusional CBF is significantly reduced relative to surrounding brain parenchyma, and CO2 vasoresponsivity is usually present. In the contusion and the surrounding parenchyma, vasoresponsivity may be nearly three times normal, suggesting hypersensitivity to hyperventilation therapy. Given this possible hypersensitivity and relative hypoperfusion within and around cerebral contusions, these lesions are particularly vulnerable to secondary injury such as that which may be caused by hypotension or aggressive hyperventilation.		McLaughlin, MR (corresponding author), PRESBYTERIAN UNIV HOSP, DEPT NEUROL SURG, MED CTR, SUITE B-400, 200 LOTHROP ST, PITTSBURGH, PA 15213 USA.		Marion, Donald/AAR-5749-2021		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER		ADAMS H, 1972, SCI F NEUROLOGY, P478; BARCLAY L, 1985, BIOL PSYCHIAT, V20, P146, DOI 10.1016/0006-3223(85)90074-5; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DARBY JM, 1988, NEUROSURGERY, V23, P84, DOI 10.1227/00006123-198807000-00014; DARBY JM, 1989, INTRACRANIAL PRESSUR, V7, P643; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; GOOD WF, 1987, MED PHYS, V14, P557, DOI 10.1118/1.596067; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GUR D, 1982, SCIENCE, V215, P1267, DOI 10.1126/science.7058347; HARRINGTON T., 1986, INTRACRANIAL PRESSUR, VVI, P680; HOLL K, 1987, ACTA NEUROCHIR, V87, P129, DOI 10.1007/BF01476063; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LATCHAW RE, 1987, RADIOLOGY, V163, P251, DOI 10.1148/radiology.163.1.3823444; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, J CEREBR BLOOD F MET, V11, P347, DOI 10.1038/jcbfm.1991.69; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1983, ADV NEUROTRAUMATOLOG, P92; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; PAUL RL, 1972, J NEUROSURG, V36, P714, DOI 10.3171/jns.1972.36.6.0714; Pistolese GR, 1972, STROKE, V3, P456, DOI 10.1161/01.STR.3.4.456; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSSANDA M, 1972, EUR NEUROL, V8, P169, DOI 10.1159/000114573; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966	39	108	109	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	1996	85	5					871	876		10.3171/jns.1996.85.5.0871			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VP489	WOS:A1996VP48900018	8893726				2021-06-18	
J	Greenspan, AI; Wrigley, JM; Kresnow, M; BrancheDorsey, CM; Fine, PR				Greenspan, AI; Wrigley, JM; Kresnow, M; BrancheDorsey, CM; Fine, PR			Factors influencing failure to return to work due to traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; SOCIAL RECOVERY; REHABILITATION; IMPAIRMENT; DISABILITY	About 63% of all traumatic brain injuries (TBI) occur in teenagers and adults aged 15-64 years, the primary working population. Since reports of failure to return to work (FTRTW) vary, understanding the factors that influence FTRTW is key to improving work outcomes for this primarily working-age population Our study sample consists of 343 previously employed persons who were hospitalized following TBI and had either returned to work at 1 year or had failed to return to work because of their injury (injury-related FTRTW). Medical records were reviewed and participants were interviewed by telephone at 1 year post-discharge. Individuals with injury-related FTRTW were far more likely to report dependence or modified independence on the Functional Independence Measure (FIM) than those who were employed at 1 year. The joint distribution of motor and cognitive items suggests that, for a given level of cognitive function, the addition of a motor limitation will result in greater injury-related FTRTW. In addition as motor function declines, FTRTW is further increased. Injury-related FTRTW is also associated with being unmarried and not completing high school. While the importance of behavioural, economic, and psychosocial factors should not be minimized, services aimed at improving function can be expected to have an impact on RTW after TBI.	UNIV ALABAMA,INJURY CONTROL RES CTR,BIRMINGHAM,AL	Greenspan, AI (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,4770 BUFORD HIGHWAY NE,MAILSTOP K-41,ATLANTA,GA 30341, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR403641] Funding Source: Medline		AGRESTI A, 1990, CATEGORICAL DATA ANA, P43; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BULL JP, 1985, ACCIDENT ANAL PREV, V17, P355; *COMM INJ SCAL, 1985, ABBR INJ SCAL 1985 R; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hamilton B., 1987, REHABILITATION OUTCO; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kaplan S. P., 1988, J APPLIED REHABILITA, V19, P3; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KRAUS J, 1985, HEAD INJURY, P1; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; MACKENZIE EJ, 1989, J TRAUMA, V29, P757, DOI 10.1097/00005373-198906000-00011; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; TYERMAN A, 1985, INT J REHABILITATION, V7, P21; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	36	108	109	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAR	1996	10	3					207	218		10.1080/026990596124520			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UC765	WOS:A1996UC76500004	8777392				2021-06-18	
J	BULLOCK, R; FUJISAWA, H				BULLOCK, R; FUJISAWA, H			THE ROLE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CNS INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	9TH ANNUAL MEETING OF THE NEUROTRAUMA SOC	NOV 09-10, 1991	NEW ORLEANS, LA	NEUROTRAUMA SOC			TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; ACUTE SUBDURAL-HEMATOMA; CEREBROCORTICAL NEURONS; RECEPTOR ANTAGONIST; GLUCOSE-UTILIZATION; BLOOD-FLOW; RAT-BRAIN; MK-801; DAMAGE	Ischemic damage, chiefly of the focal type, and axonal disruption (diffuse axonal injury) are the major factors causing brain damage after human head injury. About one third of this damage may be delayed hours or days after the injury. Evidence from four animal models, each relevant to different aspects of human head injury, has shown that excitatory amino acid-induced changes are responsible for a proportion of the posttraumatic sequelae and that these effects can be blocked by EAA antagonists. This evidence is reviewed, and the implications for the conduct of human trials with EAA antagonists are discussed.		BULLOCK, R (corresponding author), UNIV GLASGOW,SO GEN HOSP,INST NEUROL SCI,DEPT NEUROSURG,GLASGOW G51 4TF,SCOTLAND.						Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ALLEN HL, 1990, SCIENCE, V247, P221, DOI 10.1126/science.2403696; BIELENBERG GW, 1989, J CEREB BLOOD FLOW M, V9, pS298; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BNECKER DP, 1989, J CBF METABOL S1, V9, pS302; BUCHAN AM, 1990, STROKE, V21, P163; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; BULLOCK R, 1990, STROKE, V21, P32; BULLOCK R, 1991, J CEREB BLOOD FLO S2, V11, pS109; BULLOCK R, 1990, VINKEN BRUYNS HDB CL, V24, P249; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; CHAPMAN A, 1990, EXCITATORY AMINO ACI, P265; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; COYLE P, 1989, CEREBRAL ISCHAEMIA C, P69; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIRNAGL U, 1990, BRAIN RES, V527, P62, DOI 10.1016/0006-8993(90)91060-T; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRANCE CP, 1990, BRAIN RES, V526, P355, DOI 10.1016/0006-8993(90)91247-E; GENTLEMAN D, 1981, LANCET, V2, P853; GERMANO IM, 1987, ANN NEUROL, V22, P730, DOI 10.1002/ana.410220609; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GOTI B, 1988, J PHARM EXPT THERAPE, V247, P1211; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HAYES R, 1991, IN PRESS CNS TRAUMA; INGLIS FM, 1991, J CEREB BLOOD FLO S2, V11, pS307; INGLIS FM, 1991, J CEREB BLOOD FLO S2, V11, pS225; INGLIS FM, 1990, 8TH P INT S BRAIN OE, P277; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENNETT B, 1981, MANAGEMENT HEAD INJU, P287; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, IN PRESS J CBF METAB; KIRINO T, 1984, ACTA NEUROPATHOL, V64, P139, DOI 10.1007/BF00695577; KOTAPKA M, 1992, IN PRESS J NEUROL NE; KURODA Y, 1991, J CBF METABOL S2, V11, pS74; KURODA Y, 1991, IN PRESS 8TH P INT S, V3; KURODA Y, 1992, IN PRESS J NEUROSURG; KURUMAJI A, 1989, J CEREBR BLOOD F MET, V9, P786, DOI 10.1038/jcbfm.1989.112; LYTHGOE D, 1989, British Journal of Pharmacology, V98, p903P; MCCULLOCH J, 1991, EXCITATORY AMINO ACI, P287; MELDRUM B, 1990, CEREBROVAS BRAIN MET, V2, P27; MELDRUM B, 1991, IN PRESS P KEY W SAT; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NEHLS DG, 1990, BRAIN RES, V511, P271, DOI 10.1016/0006-8993(90)90172-8; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OZYURT E, 1988, J CEREBR BLOOD F MET, V8, P138, DOI 10.1038/jcbfm.1988.18; PANETTA JA, 1989, J CEREB BLOOD FLO S1, V9, pS635; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; PINARD E, 1992, IN PRESS P KEY W S; ROMAN R, 1989, NEUROSCI LETT, V104, P19, DOI 10.1016/0304-3940(89)90322-4; ROUSSEL S, 1989, NEUROTRANSMISSION CE, P453; SCHELLER MS, 1989, NEUROPHARMACOLOGY, V28, P677, DOI 10.1016/0028-3908(89)90150-0; SHIRAISHI K, 1989, J CEREBR BLOOD F MET, V9, P765, DOI 10.1038/jcbfm.1989.110; STEINBERG GK, 1988, STROKE, V19, P1112, DOI 10.1161/01.STR.19.9.1112; STEINBERG GK, 1989, J CEREB BLOOD FLOW M, V9, pS283; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; TAKIZAWA S, 1991, J CEREBR BLOOD F MET, V11, P786, DOI 10.1038/jcbfm.1991.136; TAMURA A, 1988, J CLIN EXP MED, V146, P131; TEASDALE GM, 1992, IN PRESS 1ST P NEUR; UEMATSU D, 1991, NEUROLOGY, V41, P88, DOI 10.1212/WNL.41.1.88; UEMATSU D, 1990, STROKE S1, V21, P132; WALLACE MC, 1992, J NEUROSURG, V76, P127, DOI 10.3171/jns.1992.76.1.0127; WYPER DJ, 1991, J CEREB BLOOD FLOW M, V11, pS831; YOSHINO A, 1992, IN PRESS BRAIN RES	69	108	108	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1992	9			2			S443	S462					20	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HU819	WOS:A1992HU81900003	1613806				2021-06-18	
J	GENTRY, LR; GODERSKY, JC; THOMPSON, BH				GENTRY, LR; GODERSKY, JC; THOMPSON, BH			TRAUMATIC BRAIN-STEM INJURY - MR IMAGING	RADIOLOGY			English	Article									UNIV IOWA HOSP & CLIN, DEPT SURG, DIV NEUROSURG, IOWA CITY, IA 52242 USA; UNIV IOWA HOSP & CLIN, DEPT RADIOL, IOWA CITY, IA 52242 USA	GENTRY, LR (corresponding author), UNIV WISCONSIN, HOSP & CLIN, DEPT RADIOL, NEURORADIOL SECT, 600 HIGHLAND AVE, MADISON, WI 53792 USA.						ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; BRITT RH, 1980, NEUROSURGERY, V6, P623, DOI 10.1227/00006123-198006000-00002; CAPLAN LR, 1977, ANN NEUROL, V1, P587, DOI 10.1002/ana.410010613; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; COOPER PR, 1979, NEUROSURGERY, V4, P115, DOI 10.1227/00006123-197902000-00002; CROMPTON MR, 1971, LANCET, V1, P669; DELAPAZ RL, 1984, J COMPUT ASSIST TOMO, V8, P599, DOI 10.1097/00004728-198408000-00004; DOOMS GC, 1986, NEURORADIOLOGY, V28, P132, DOI 10.1007/BF00327885; FRENCH BN, 1977, SURG NEUROL, V7, P171; FRIEDE RL, 1966, NEUROLOGY, V16, P1210, DOI 10.1212/WNL.16.12.1210; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, IN PRESS AJNR; GEORGE B, 1981, ACTA NEUROCHIR, V59, P35, DOI 10.1007/BF01411189; GIBSON PH, 1983, NEUROPATH APPL NEURO, V9, P135, DOI 10.1111/j.1365-2990.1983.tb00331.x; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; Gruszkiewicz J, 1973, Surg Neurol, V1, P197; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; GYORI E, 1985, CLIN NEUROPATHOL, V4, P121; Hardman J M, 1979, Adv Neurol, V22, P15; Holbourn AHS, 1943, LANCET, V2, P438; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; JENKINS A, 1986, LANCET, V2, P445; JOHNSON RT, 1956, ACTA RADIOL, V46, P250, DOI 10.3109/00016925609170834; LINDENBERG R, 1966, CLIN NEUROSURG, V12, P129; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MATSUOKA K., 1967, MED J OSAKA UNIV, V17, P257; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETERS G, 1977, APALLIC SYNDROME, P78; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P75; ROPPER AH, 1985, ANN NEUROL, V18, P80, DOI 10.1002/ana.410180114; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; SAEKI N, 1985, Neurologia Medico-Chirurgica, V25, P939, DOI 10.2176/nmc.25.939; SEELIG JM, 1981, J NEUROSURG, V55, P516, DOI 10.3171/jns.1981.55.4.0516; SNOEK J, 1979, J NEUROL NEUROSUR PS, V42, P215, DOI 10.1136/jnnp.42.3.215; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; STOVRING J, 1977, NEURORADIOLOGY, V14, P101, DOI 10.1007/BF00333050; STRICH SJ, 1961, LANCET, V2, P443; SUNDERLAND S, 1958, BRIT J SURG, V45, P422, DOI 10.1002/bjs.18004519306; TANDON PN, 1964, ACTA NEUROL SCAND, V40, P375; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; TSAI FY, 1980, J COMPUT ASSIST TOMO, V4, P291, DOI 10.1097/00004728-198006000-00002; TSAI FY, 1980, AM J ROENTGENOL, V134, P717, DOI 10.2214/ajr.134.4.717; TSAI FY, 1978, J COMPUT ASSIST TOMO, V2, P323, DOI 10.1097/00004728-197807000-00018; Turazzi S, 1975, J Neurosurg Sci, V19, P215; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215; ZUCCARELLO M, 1983, ACTA NEUROCHIR, V67, P103, DOI 10.1007/BF01401670	61	108	111	0	1	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	APR	1989	171	1					177	187		10.1148/radiology.171.1.2928523			11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	T8006	WOS:A1989T800600035	2928523				2021-06-18	
J	Nordstrom, P; Michaelsson, K; Gustafson, Y; Nordstrom, A				Nordstrom, Peter; Michaelsson, Karl; Gustafson, Yngve; Nordstrom, Anna			Traumatic brain injury and young onset dementia: A nationwide cohort study	ANNALS OF NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; HEAD-INJURY; RISK-FACTOR; LATE-LIFE; COGNITIVE FUNCTION; MILD; MEN; IMPACT	Objective To investigate the association between traumatic brain injuries (TBIs) and the risk of young onset dementia (YOD), that is, dementia before 65 years of age. Methods The study cohort comprised 811,622 Swedish men (mean age = 18 years) conscripted for military service between 1969 and 1986. TBIs, dementia, and covariates were extracted from national registers. Time-dependent exposures using Cox proportional hazard regression models were evaluated. Results During a median follow-up period of 33 years, there were 45,249 men with at least 1 TBI in the cohort. After adjustment for covariates, 1 mild TBI (hazard ratio [HR] = 1.0, 95% confidence interval [CI] = 0.5-2.0), at least 2 mild TBIs (HR = 2.5, 95% CI = 0.8-8.1), or 1 severe TBI (HR = 0.7, 95% CI = 0.1-5.2) were not associated with Alzheimer dementia (AD). Other types of dementia were strongly associated with the risk of 1 mild TBI (HR = 3.8, 95% CI = 2.8-5.2), at least 2 mild TBIs (HR = 10.4, 95% CI = 6.3-17.2), and 1 severe TBI (HR = 11.4, 95% CI = 7.4-17.5) in age-adjusted analysis. However, these associations were largely attenuated after adjustment for covariates (1 mild TBI: HR = 1.7; at least 2 mild TBIs: HR = 1.7; 1 severe TBI: HR = 2.6; p < 0.05 for all). Interpretation In the present study, we found strong associations between YOD of non-AD forms and TBIs of different severity. These associations were, however, markedly attenuated after multivariate adjustment. Ann Neurol 2014;75:374-381	[Nordstrom, Peter; Gustafson, Yngve] Umea Univ, Dept Community Med & Rehabil, S-90187 Umea, Sweden; [Michaelsson, Karl] Uppsala Univ, Dept Surg Sci, Sect Orthoped, Uppsala, Sweden; [Nordstrom, Anna] Umea Univ, Dept Surg & Perioperat Sci, S-90187 Umea, Sweden	Nordstrom, P (corresponding author), Umea Univ, Dept Community Med & Rehabil, S-90187 Umea, Sweden.	peter.nordstrom@germed.umu.se	Nordstrom, Anna/F-2238-2010; Nordstrom, Anna/O-2504-2018; Michaelsson, Karl/AAM-9094-2021	Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Peter/0000-0003-2924-508X; Michaelsson, Karl/0000-0003-2815-1217; Gustafson, Yngve/0000-0002-0999-377X	Swedish research councilSwedish Research CouncilEuropean Commission; Swedish Dementia Foundation; Swedish Alzheimer Foundation	The study was supported by grants from the Swedish research council, Swedish Dementia Foundation, and Swedish Alzheimer Foundation. The funding bodies did not have any active role in any part of the research performed within the present study.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; Ashman TA, 2006, MT SINAI J MED, V73, P999; Atkins ER, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001764; CARLSTEDT B, 1993, SCAND J PSYCHOL, V34, P353, DOI 10.1111/j.1467-9450.1993.tb01131.x; Carlstedt B, 2005, SCAND J PSYCHOL, V46, P31, DOI 10.1111/j.1467-9450.2005.00432.x; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107; Lee Y, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0056284, 10.1371/journal.pone.0063255]; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murray CJL., 1996, GLOBAL HLTH STAT COM; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Nordstrom A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001151; Nordstrom P, 2013, JAMA INTERN MED, V173, P1612, DOI 10.1001/jamainternmed.2013.9079; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rossor MN, 2010, LANCET NEUROL, V9, P793, DOI 10.1016/S1474-4422(10)70159-9; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Svanberg E, 2011, INT PSYCHOGERIATR, V23, P356, DOI 10.1017/S1041610210001353; Whalley LJ, 2001, BRIT MED J, V322, P819, DOI 10.1136/bmj.322.7290.819; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	33	107	109	1	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	MAR	2014	75	3					374	381		10.1002/ana.24101			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AD8WS	WOS:000333547000008	24812697				2021-06-18	
J	Cifu, DX; Taylor, BC; Carne, WF; Bidelspach, D; Sayer, NA; Scholten, J; Campbell, EH				Cifu, David X.; Taylor, Brent C.; Carne, William F.; Bidelspach, Douglas; Sayer, Nina A.; Scholten, Joel; Campbell, Emily Hagel			Traumatic brain injury, posttraumatic stress disorder, and pain diagnoses in OIF/OEF/OND Veterans	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						military healthcare; military Veterans; Operation Enduring Freedom; Operation Iraqi Freedom; Operation New Dawn; pain; posttraumatic stress disorder; PTSD; TBI; traumatic brain injury	MENTAL-HEALTH; IRAQI FREEDOM; WAR; PREVALENCE; MILITARY; ACCURACY; PROGRAM; CARE	To identify the prevalence of traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), and pain in Veterans from Operation Iraqi Freedom/Operation Enduring Freedom/Operation New Dawn (OIF/OEF/OND), Veterans who received any inpatient or outpatient care from Veterans Health Administration (VHA) facilities from 2009 to 2011 were studied. A subset of Veterans was identified who were diagnosed with TBI, PTSD, and/or pain (head, neck, or back) as determined by their International Classification of Diseases-9th Revision-Clinical Modification codes. Between fiscal years 2009 and 2011, 613,391 Veterans accessed VHA services at least once (age: 31.9 +/- 9.6 yr). TBI diagnosis in any 1 year was slightly less than 7%. When data from 3 years were pooled, 9.6% were diagnosed with TBI, 29.3% were diagnosed with PTSD, and 40.2% were diagnosed with pain. The full polytrauma triad expression (TBI, PTSD, and pain) was diagnosed in 6.0%. Results show that increasing numbers of Veterans from OIF/OEF/OND accessed VHA over a 3 year period. Among those with a TBI diagnosis, the majority also had a mental health disorder, with approximately half having both PTSD and pain. While the absolute number of Veterans increased by over 40% from 2009 to 2011, the proportion of Veterans diagnosed with TBI and the high rate of comorbid PTSD and pain in this population remained relatively stable.	[Cifu, David X.; Bidelspach, Douglas; Scholten, Joel] Dept Vet Affairs VA, Phys Med & Rehabil Program Off, Washington, DC USA; [Cifu, David X.; Carne, William F.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Cifu, David X.; Carne, William F.] Hunter Holmes McGuire VA Med Ctr VAMC, Richmond, VA USA; [Taylor, Brent C.; Sayer, Nina A.; Campbell, Emily Hagel] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Taylor, Brent C.; Sayer, Nina A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Carne, William F.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Bidelspach, Douglas] Lebanon VAMC, Rehabil & Prosthet Serv, Lebanon, PA USA; [Sayer, Nina A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Scholten, Joel] Washington VAMC, Dept Phys Med & Rehabil, Washington, DC USA; [Scholten, Joel] Georgetown Univ, Med Ctr, Dept Phys Med & Rehabil, Washington, DC 20007 USA	Cifu, DX (corresponding author), Dept Phys Med & Rehabil, 1223 East Marshall St, Richmond, VA 23298 USA.	dcifu@vcu.edu	Taylor, Brent C/A-8069-2009; Sayer, Nina/E-3249-2016	Taylor, Brent C/0000-0002-2140-8377; Cifu, David/0000-0003-1600-9387	VA Office of Research and Development Health Services Research and Development ServiceUS Department of Veterans Affairs [PLY 05-2010-2]; PTBRI QUERI; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	This material was based on work supported by the VA Office of Research and Development Health Services Research and Development Service (grant PLY 05-2010-2) from the PTBRI QUERI and the Defense and Veterans Brain Injury Center. The funding source had no role in the study design, analysis, interpretation of the data, writing of the manuscript, or decision to submit the article for publication.	[Anonymous], 2012, QUERI POL BLAST REL; [Anonymous], 2011, QUERI POL BLAST REL; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bray RM, 2009, DEP DEFENSE SURVEY H; Carlson KF, 2010, J REHABIL RES DEV, V47, P689, DOI 10.1682/JRRD.2009.08.0118; Cifu D, 2011, OVERCOMING POSTDEPLO; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Department of Veterans Affairs, 2013, VHA HDB, V1172; Friedman MJ, 2005, NEW ENGL J MED, V352, P1287, DOI 10.1056/NEJMp058028; Gravely AA, 2011, J REHABIL RES DEV, V48, P21, DOI 10.1682/JRRD.2009.08.0116; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Independent Review Group on Rehabilitative Care and Administrative Processes at Walter Reed Army Medical Center and National Naval Medical Center, 2007, REB TRUST REP REH CA; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lorence Daniel, 2003, J Med Syst, V27, P435, DOI 10.1023/A:1025607805588; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; McNaughton H, 2000, NEW ZEAL MED J, V113, P184; Reeves RR, 2005, J PSYCHOSOC NURS MEN, V43, P18, DOI 10.3928/02793695-20050701-06; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Roemer L, 1998, J TRAUMA STRESS, V11, P597, DOI 10.1023/A:1024469116047; Rosen CS, 2004, J TRAUMA STRESS, V17, P213, DOI 10.1023/B:JOTS.0000029264.23878.53; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Todd KH, 2005, EMERG MED CLIN N AM, V23, P285, DOI 10.1016/j.emc.2004.12.002; U.S. Health Care Financing Administration U.S. National Center for Health Statistics, 2006, ICM 9 CM INT CLASS D; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004	30	107	107	0	8	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2013	50	9					1169	1176		10.1682/JRRD.2013.01.0006			8	Rehabilitation	Rehabilitation	287IE	WOS:000329534500004	24458958	Bronze			2021-06-18	
J	Ciurli, P; Formisano, R; Bivona, U; Cantagallo, A; Angelelli, P				Ciurli, Paola; Formisano, Rita; Bivona, Umberto; Cantagallo, Anna; Angelelli, Paola			Neuropsychiatric Disorders in Persons With Severe Traumatic Brain Injury: Prevalence, Phenomenology, and Relationship With Demographic, Clinical, and Functional Features	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						neuropsychiatric disorders; Neuropsychiatric Inventory; severe traumatic brain injury	CLOSED-HEAD-INJURY; APATHY EVALUATION SCALE; DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; QUALITY-OF-LIFE; PSYCHIATRIC-DISORDERS; ALZHEIMER-DISEASE; PRACTICAL SCALE; AXIS-I; DEPRESSION	Objective: To characterize neuropsychiatric symptoms in a large group of individuals with severe traumatic brain injury (TBI) and to correlate these symptoms with demographic, clinical, and functional features. Methods: The Neuropsychiatric Inventory (NPI), a frequently used scale to assess behavioral, emotional, and motivational disorders in persons with neurological diseases, was administered to a sample of 120 persons with severe TBI. Controls were 77 healthy subjects. Results: A wide range of neuropsychiatric symptoms was found in the population with severe TBI: apathy (42%), irritability (37%), dysphoria/depressed mood (29%), disinhibition (28%), eating disturbances (27%), and agitation (24%). A clear relationship was also found with other demographic and clinical variables. Conclusion: Neuropsychiatric disorders constitute an important part of the comorbidity in populations with severe TBI. Our study emphasizes the importance of integrating an overall assessment of cognitive disturbances with a specific neuropsychiatric evaluation to improve clinical understanding and treatment of persons with TBI.	[Ciurli, Paola; Formisano, Rita; Bivona, Umberto] IRCCS Santa Lucia Fdn, Rome, Italy; [Cantagallo, Anna] Hosp & Univ Ferrara, Dept Neurosci Rehabil, Ferrara, Italy; [Angelelli, Paola] Univ Bari, Dept Psychol, Bari, Italy	Ciurli, P (corresponding author), IRCCS Santa Lucia Hosp, Via Ardeatina 306, Rome, Italy.	p.ciurli@hsantalucia.it		Angelelli, Paola/0000-0001-9870-6009			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; American Psychiatric Association, 1995, DIAGN STAT MAN MENT; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Angelelli P, 2004, ACTA PSYCHIAT SCAND, V110, P55, DOI 10.1111/j.1600-0447.2004.00297.x; Arciniegas DB, 2000, CURR TREAT OPTION NE, V2, P186; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Binetti G, 1998, ARCH NEUROL-CHICAGO, V55, P539, DOI 10.1001/archneur.55.4.539; BROWN RG, 1990, PSYCHOL MED, V20, P77, DOI 10.1017/S0033291700013246; Cantagallo A, 2003, EUR MED PHYS, V38, P167; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; Craig AH, 1996, ARCH NEUROL-CHICAGO, V53, P1116, DOI 10.1001/archneur.1996.00550110056012; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Finset A, 2000, BRAIN INJURY, V14, P887; First MB, 1995, BECK STRUCTURED CLIN; Giugni E, 2005, AM J NEURORADIOL, V26, P1140; Glenn MB, 2002, BRAIN INJURY, V16, P509, DOI 10.1080/02699050110119132; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Graham DI, 1996, NEUROTRAUMA, P43; Greve KW, 2001, BRAIN INJURY, V15, P255; Hagen C, 1979, REHABILITATION HEAD, P87; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1986, ACTA NEUROCHIR, V36, P90; Jorge R, 2002, NEUROREHABILITATION, V17, P311; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kraus MF, 1999, TRAUMATIC BRAIN INJU, V14, P173; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levy M, 2005, NEUROREHABILITATION, V20, P279; Lippert-Gruner M, 2002, J REHABIL MED, V34, P211, DOI 10.1080/165019702760279198; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; MARIN RS, 1993, J AFFECT DISORDERS, V28, P117, DOI 10.1016/0165-0327(93)90040-Q; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; Marin RS, 2005, J HEAD TRAUMA REHAB, V20, pCP1; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; McAllister TW, 2002, NEUROREHABILITATION, V17, P263; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McAllister TW, 2002, AM J PSYCHIAT, V17, P357; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mega MS, 1996, NEUROLOGY, V46, P130, DOI 10.1212/WNL.46.1.130; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rao V, 2007, PSYCHOSOMATICS, V48, P217, DOI 10.1176/appi.psy.48.3.217; Resnick B, 1998, Rehabil Nurs, V23, P141; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Silver JM, 1994, AM PSYCHIAT PRESS TX, P313; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V5, P1; STARKSTEIN SE, 1987, ARCH NEUROL-CHICAGO, V44, P1069, DOI 10.1001/archneur.1987.00520220065019; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; van der Naalt J, 2000, BRAIN INJURY, V14, P781; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412; ZWIL AS, 1992, INT J PSYCHIAT MED, V22, P377, DOI 10.2190/J71J-FTML-JY1E-RKKG	72	107	107	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2011	26	2					116	126		10.1097/HTR.0b013e3181dedd0e			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	732OR	WOS:000288197200002	20485191				2021-06-18	
J	Wood, JN; Hall, M; Schilling, S; Keren, R; Mitra, N; Rubin, DM				Wood, Joanne N.; Hall, Matthew; Schilling, Samantha; Keren, Ron; Mitra, Nandita; Rubin, David M.			Disparities in the Evaluation and Diagnosis of Abuse Among Infants With Traumatic Brain Injury	PEDIATRICS			English	Article						child abuse; nonaccidental trauma; traumatic brain injury; bone/radiography; skeletal survey; disparity	HEAD-INJURY	OBJECTIVE: To evaluate in a national database the association of race and socioeconomic status with radiographic evaluation and subsequent diagnosis of child abuse after traumatic brain injury (TBI) in infants. METHODS: We conducted a retrospective study of infants with nonmotor vehicle-associated TBI who were admitted to 39 pediatric hospitals from January 2004 to June 2008. Logistic regression controlling for age, type, and severity of TBI and the presence of other injuries was performed to examine the association of race and socioeconomic status with the principal outcomes of radiographic evaluation for suspected abuse and diagnosis of abuse. Regression coefficients were transformed to probabilities. RESULTS: After adjustment for type and severity of TBI, age, and other injuries, publicly insured/uninsured infants were more likely to have had skeletal surveys performed than were privately insured infants (81% vs 59%). The difference in skeletal survey performance for infants with public or no insurance versus private insurance was greater among white (82% vs 53%) infants than among black (85% vs 75%) or Hispanic (72% vs 55%) infants (P = .022). Although skeletal surveys were performed in a smaller proportion of white than black or Hispanic infants, the adjusted probability for diagnosis of abuse among infants evaluated with a skeletal survey was higher among white infants (61%) than among black (51%) or Hispanic (53%) infants (P = .009). CONCLUSIONS: National data suggest continued biases in the evaluation for abusive head trauma. The conflicting observations of fewer skeletal surveys among white infants and higher rates of diagnosis among those screened elicit concern for overevaluation in some infants (black or publicly insured/uninsured) or underevaluation in others (white or privately insured). Pediatrics 2010; 126: 408-414	[Wood, Joanne N.; Schilling, Samantha; Keren, Ron; Rubin, David M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Hall, Matthew; Keren, Ron; Mitra, Nandita; Rubin, David M.] Univ Penn, Sch Med, Leonard Davis Inst, Philadelphia, PA 19104 USA; [Mitra, Nandita] Univ Penn, Sch Med, Dept Biostat, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Keren, Ron; Rubin, David M.] Univ Penn, Sch Med, Dept Epidemiol, Philadelphia, PA 19104 USA	Wood, JN (corresponding author), Childrens Hosp Philadelphia, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA.	woodjo@email.chop.edu					*AM COLL RAD, ACR PRACT GUID SKEL; Belfer RA, 2001, AM J EMERG MED, V19, P122, DOI 10.1053/ajem.2001.21345; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Flaherty EG, 2008, PEDIATRICS, V122, P611, DOI 10.1542/peds.2007-2311; Graubard BI, 1999, BIOMETRICS, V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Lane WG, 2007, CLIN ORTHOP RELAT R, P219, DOI 10.1097/BLO.0b013e31805c0849; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Myhre MC, 2007, ACTA PAEDIATR, V96, P1159, DOI 10.1111/j.1651-2227.2007.00356.x; Rangel EL, 2009, J PEDIATR SURG, V44, P1229, DOI 10.1016/j.jpedsurg.2009.02.044; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Schnitzer PG, 2006, AM FAM PHYSICIAN, V74, P1864; Sege RD, 2008, ARCH DIS CHILD, V93, P822, DOI 10.1136/adc.2006.100545; *STAT CORP LP, 2009, STAT CORP STAT BAS R, V2, P957; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; U.S. Department of Health and Human Services Administration on Children Youth and Families, 2009, CHILD MALTR 2007; Wood JN, 2009, PEDIATRICS, V123, pE247, DOI 10.1542/peds.2008-2467	20	107	107	0	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2010	126	3					408	414		10.1542/peds.2010-0031			7	Pediatrics	Pediatrics	646JK	WOS:000281535700002	20713477				2021-06-18	
J	Homsi, S; Federico, F; Croci, N; Palmier, B; Plotkine, M; Marchand-Leroux, C; Jafarian-Tehrani, M				Homsi, Shadi; Federico, Fabiola; Croci, Nicole; Palmier, Bruno; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz			Minocycline effects on cerebral edema: Relations with inflammatory and oxidative stress markers following traumatic brain injury in mice	BRAIN RESEARCH			English	Article						Traumatic brain injury; Mice; Minocycline; Cerebral edema; Interleukin-1 beta; Matrix metalloproteinase-9; Glutathione	MATRIX METALLOPROTEINASES; IN-VIVO; INTRACEREBRAL HEMORRHAGE; MICROGLIAL ACTIVATION; VASOGENIC EDEMA; MOUSE-BRAIN; ISCHEMIA; NEUROPROTECTION; MATRIX-METALLOPROTEINASE-9; INTERLEUKIN-1	One of the severe complications following traumatic brain injury (TBI) is cerebral edema and its effective treatment is of great interest to prevent further brain damage. This study investigated the effects of minocycline, known for its anti-inflammatory properties, on cerebral edema and its respective inflammatory markers by comparing different dose regimens, on oxidative stress and on neurological dysfunction following TBI. The weight drop model was used to induce TBI in mice. The brain water content was measured to evaluate cerebral edema. Inflammatory markers were detected by ELISA (IL-1 beta), zymography and Western blot (MMP-9). The oxidative stress marker (glutathione levels) and neurological function were measured by Griffith technique and string test, respectively. Minocycline was administered i.p. once (5 min), twice (5 min and 3 h) or triple (5 min, 3 h and 9 h) following TBI. The first dose of minocycline only varied (45 or 90 mg/kg), whereas the following doses were all at 45 mg/kg. The single and double administrations of minocycline reduced the increase of inflammatory markers at 6 h post-TBI. Minocycline also reduced cerebral edema at this time point, only after double administration and at the high dose regimen, although with no effect on the TBI-induced oxidized glutathione increase. The anti-edematous effect of minocycline persisted up to 24 h, upon a triple administration, and accompanied by a neurological recovery. In conclusion, we reported an anti-edematous effect of minocycline after TBI in mice according to a specific treatment regimen. These findings emphasize that the beneficial effects of minocycline depend on the treatment regimen following a brain injury. (C) 2009 Elsevier B.V. All rights reserved.	[Homsi, Shadi; Federico, Fabiola; Croci, Nicole; Palmier, Bruno; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz] Univ Paris 05, Lab Pharmacol Circulat Cerebrale, EA 2510, Fac Sci Pharmaceut & Biol, F-75006 Paris, France	Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Lab Pharmacol Circulat Cerebrale, EA 2510, Fac Sci Pharmaceut & Biol, 4 Ave Observ, F-75006 Paris, France.	mehrnaz.jafarian@parisdescartes.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856			Andes D, 2002, INT J ANTIMICROB AG, V19, P261, DOI 10.1016/S0924-8579(02)00022-5; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cardozo-Pelaez F, 1999, MOVEMENT DISORD, V14, P972, DOI 10.1002/1531-8257(199911)14:6<972::AID-MDS1010>3.0.CO;2-0; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Colovic M, 2003, J CHROMATOGR B, V791, P337, DOI 10.1016/S1570-0232(03)00247-2; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Elewa HF, 2006, PHARMACOTHERAPY, V26, P515, DOI 10.1592/phco.26.4.515; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Fujimura M, 1999, BRAIN RES, V842, P92, DOI 10.1016/S0006-8993(99)01843-0; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; Haorah J, 2007, J NEUROCHEM, V101, P566, DOI 10.1111/j.1471-4159.2006.04393.x; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Kawakita Kenya, 2006, J Stroke Cerebrovasc Dis, V15, P88, DOI 10.1016/j.jstrokecerebrovasdis.2006.01.002; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Lee CZ, 2006, J CEREBR BLOOD F MET, V26, P1157, DOI 10.1038/sj.jcbfm.9600268; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Morimoto N, 2005, BRAIN RES, V1044, P8, DOI 10.1016/j.brainres.2005.02.062; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; SAIVIN S, 1988, CLIN PHARMACOKINET, V15, P355, DOI 10.2165/00003088-198815060-00001; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; YAMASAKI Y, 1994, ACTA NEUROCHIR, P300; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	55	107	109	0	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 21	2009	1291						122	132		10.1016/j.brainres.2009.07.031			11	Neurosciences	Neurosciences & Neurology	497GF	WOS:000270045200013	19631631				2021-06-18	
J	Fay, TB; Yeates, KO; Wade, SL; Drotar, D; Stancin, T; Taylor, HG				Fay, Taryn B.; Yeates, Keith Owen; Wade, Shari L.; Drotar, Dennis; Stancin, Terry; Taylor, H. Gerry			Predicting Longitudinal Patterns of Functional Deficits in Children With Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; children; functional deficits; outcomes	NEUROBEHAVIORAL SYMPTOMS; CLINICAL-SIGNIFICANCE; HEAD-INJURIES; SHORT-TERM; FAMILY; ADOLESCENTS; OUTCOMES; ACHIEVEMENT; PREVALENCE; SEVERITY	Longitudinal patterns of functional deficits were investigated in 37 children with severe traumatic brain injury (TBI), 40 children with moderate TBI, and 44 children with orthopedic injuries. They were from 6 to 12 years of age when injured. Their neuropsychological, behavioral, adaptive, and academic functioning were assessed at 6 months, 12 months, and 3-5 years postinjury. Functional deficits (<10th percentile for age) were identified within each outcome domain at each occasion. Children were classified into 4 a priori longitudinal patterns of outcomes within domains (i.e., no deficits, improvement, deterioration, persistent deficits). In multinomial logistic regression analyses, severe TBI predicted an increased likelihood of persistent deficits in all outcome domains, as well as deterioration in behavioral functioning and improvement in neuropsychological, adaptive, and academic functioning. Severe TBI also predicted a greater total number of functional deficits across domains at each occasion. However, many children with severe TBI showed no deficits from 6 months to 4 years postinjury in I or more outcome domains. The findings help clarify the course of recovery for individual children following TBI.	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Columbus, OH 43205 USA; [Fay, Taryn B.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Fay, Taryn B.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Dept Psychiat Med & Rehabil, Cincinnati, OH USA; [Drotar, Dennis; Stancin, Terry; Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Drotar, Dennis; Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892; Fay-McClymont, Taryn/0000-0002-2706-6179	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MC-J-390611]; Maternal and Child Health Bureau (Tide V, Social Security Act, Health Resources and Services Administration, Department of Health and Human Services)United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER	This work was supported by National Institute of Neurological Disorders and Stroke Grant NS36335, National Institutes of Health, and by Grant MC-J-390611, Maternal and Child Health Bureau (Tide V, Social Security Act, Health Resources and Services Administration, Department of Health and Human Services). We wish to acknowledge the contributions of Elizabeth Shaver, Barbara Shapero, Madeline Polonia, Marla Kemmerer, Matt Diamond, and Nichole Wood in data collection and coding. We also wish to acknowledge the participation of the Children's Hospital Medical Center of Akron and the collaboration of George Thompson, G. Dean Timmons, and Dennis Weiner. Assistance with recruitment was provided by the Rainbow Pediatric Trauma Center, Rainbow Babies & Children's Hospital, Columbus Children's Hospital Trauma Program, and MetroHealth Center Trauma Registry.	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Anderson P., 2000, CLIN NEUROPSYCHOL AS, V1, P247, DOI DOI 10.1076/chin.8.4.231.13509; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BEERY KE, 1989, REVISED ADM SCORING; Bergman LR, 2006, MERRILL PALMER QUART, V52, P601, DOI 10.1353/mpq.2006.0023; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Connell AM, 2006, MERRILL PALMER QUART, V52, P421, DOI 10.1353/mpq.2006.0025; DELIS D, 1986, CALIFORNIA VERBAL LE; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Francis DJ, 2005, J LEARN DISABIL-US, V38, P98, DOI 10.1177/00222194050380020101; Golden CJ, 1991, LURIA NEBRASKA NEURO; HANNAY HJ, 2004, NEUROPSYCHOLOGICAL A, P133; Heaton R.K., 1991, COMPREHENSIVE NORMS; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Jacobson NS, 1999, J CONSULT CLIN PSYCH, V67, P300, DOI 10.1037/0022-006X.67.3.300; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KNIGHTS RM, 1980, REVISED SMOOTHED NOR; Laursen B, 2006, MERRILL PALMER QUART, V52, P377, DOI 10.1353/mpq.2006.0029; LINDGREN S, 1984, PEDIAT ASSESSMENT CO; Magnusson D, 2003, NEW DIR CHILD ADOLES, V101, P3, DOI 10.1002/cd.79; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos R, 1994, LIFE STRESSORS SOCIA; Muthen B, 2000, ALCOHOL CLIN EXP RES, V24, P882, DOI 10.1111/j.1530-0277.2000.tb02070.x; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Semel E., 1987, CELF R CLIN EVALUATI; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; Strauss E, 2006, COMPENDIUM NEUROPSYC, P3; Taylor HG, 1998, CHILD NEUROPSYCHOL, V4, P21, DOI 10.1076/chin.4.1.21.3188; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1992, CLIN NEUROPSYCHOL, V6, P259; Taylor HG., 2006, EXCEPTIONALITY, V14, P141, DOI [10.1207/s15327035ex1403_3, DOI 10.1207/S15327035EX1403_3, DOI 10.1207/S15327035EX1403_]; TEASDALE G, 1974, LANCET, V2, P81; von Eye A, 2006, MERRILL PALMER QUART, V52, P390, DOI 10.1353/mpq.2006.0032; WECHSLER D, 1991, WISC 03 WECHSLER INT; WOODCOCK RW, 1989, WOODCOCKJOHNSON TEST; YEATES KO, 1994, CLIN NEUROPSYCHOL, V8, P91, DOI 10.1080/13854049408401546; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	62	107	107	0	20	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2009	23	3					271	282		10.1037/a0014936			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	439XW	WOS:000265662000001	19413442	Green Accepted			2021-06-18	
J	Chen, G; Zhang, SM; Shi, JX; Ai, JL; Qi, M; Hang, CH				Chen, Gang; Zhang, Shiming; Shi, Jixin; Ai, Jinglu; Qi, Meng; Hang, Chunhua			Simvastatin reduces secondary brain injury caused by cortical contusion in rats: Possible involvement of TLR4/NF-kappa B pathway	EXPERIMENTAL NEUROLOGY			English	Article						Simvastatin; Traumatic brain injury; Cerebral inflammation; Toll-like receptor 4; Nuclear factor-kappa B	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; ENDOTHELIAL NITRIC-OXIDE; COA REDUCTASE INHIBITOR; DELAYED NEURONAL DEATH; TOLL-LIKE RECEPTORS; INFLAMMATORY RESPONSE; BARRIER PERMEABILITY; ADHESION MOLECULES; CEREBRAL-ISCHEMIA	Simvastatin, a cholesterol-lowering agent, has demonstrated neuroprotective effects against brain injury, but the underlying mechanisms remain unclear. This study was undertaken to evaluate the effect of simvastatin on the Toll-like receptor 4 (TLR4) and nuclear factor-kappa B (NF-kappa B) related signaling pathway and secondary brain injury in rats after traumatic brain injury (TBI). Adult male Wistar rats were divided into four groups: (1) Sham group (n=25); (2) Sham+vehicle group (n=25): (3) TBI+vehicle group (n=30): and (4) TBI+simvastatin group (n=30). Right parietal cortical contusion was made by using a weight-dropping method. In TBI+simvastatin group, simvastatin was administered orally at a dose of 37.5 mg/kg at 1 and 6 h after TBI. Brain samples were extracted at 24 h after trauma. As a result, we found that treatment with simvastatin markedly inhibited the mRNA and protein expressions of TLR4, NF-kappa B and the downstream inflammatory agents, such as interleukin-1 beta (IL-beta), tumor necrosis factor-alpha (TNF-alpha), interleukin-6(IL-6),and intercellular adhesion molecule-1 (ICAM-1). Administration of simvastatin following TBI significantly ameliorated the secondary brain damage, such as cortical apoptosis, brain edema, blood-brain barrier (BBB) impairment, and motor deficits. In conclusion, post-TBI simvastatin administration may attenuate TLR4/NF-kappa B-mediated inflammatory response in the injured rat brain, and this may be one mechanism by which simvastatin improves outcome following TBI. (c) 2009 Elsevier Inc. All rights reserved.	[Chen, Gang; Zhang, Shiming] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Peoples R China; [Shi, Jixin; Qi, Meng; Hang, Chunhua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China; [Ai, Jinglu] Univ Toronto, Sch Med, St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada	Chen, G (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Peoples R China.	Dr.Chen@utoronto.ca; nju_neurosurgery@163.com	QI, Meng/F-2802-2012	Chen, Gang/0000-0002-0758-1907; AI, JINGLU/0000-0001-7414-0207	Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [2007153]; Natural Science Foundation of Nanjing Military AreaNational Natural Science Foundation of China (NSFC) [07M080]	We thank Dr. Bo Wu and Dr. Geng-bao Feng for their technical assistance. This work was supported by a grant from the Natural Science Foundation of Jiangsu Province (No. BI(2007153) and a grant from the Natural Science Foundation of Nanjing Military Area (No. 07M080).	Ahn KS, 2008, BIOCHEM PHARMACOL, V75, P907, DOI 10.1016/j.bcp.2007.10.010; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Daimon M, 2004, NEUROSCI LETT, V362, P122, DOI 10.1016/j.neulet.2004.03.012; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Kariko K, 2004, J CEREBR BLOOD F MET, V24, P1288, DOI 10.1097/01.WCB.0000145666.68576.71; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Laflamme N, 2001, FASEB J, V15, P155, DOI 10.1096/fj.00-0339com; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; Lazzerini PE, 2007, CLIN EXP RHEUMATOL, V25, P696; Lee Sung Joong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P181; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Niessner A, 2006, ATHEROSCLEROSIS, V189, P408, DOI 10.1016/j.atherosclerosis.2005.12.022; Niwa S, 1996, INT J IMMUNOPHARMACO, V18, P669, DOI 10.1016/S0192-0561(96)00068-9; Omi H, 2003, MICROVASC RES, V65, P118, DOI 10.1016/S0026-2862(02)00033-X; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Shao HT, 2007, ANN THORAC SURG, V84, P2011, DOI 10.1016/j.athoracsur.2007.07.022; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	46	107	118	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2009	216	2					398	406		10.1016/j.expneurol.2008.12.019			9	Neurosciences	Neurosciences & Neurology	424ZK	WOS:000264606600020	19166837				2021-06-18	
J	Oluellet, MC; Morin, CM				Oluellet, Marie-Christine; Morin, Charles M.			Efficacy of cognitive-behavioral therapy for insomnia associated with traumatic brain injury: A single-case experimental design	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						behavior therapy; brain injuries; cognitive therapy; insomnia; rehabilitation	MULTIDIMENSIONAL FATIGUE INVENTORY; PSYCHOMETRIC PROPERTIES; PSYCHIATRIC-DISORDERS; SLEEP COMPLAINTS; DISTURBANCES; METAANALYSIS; CANCER; INDIVIDUALS; VALIDATION; FREQUENCY	Objective: To test the efficacy of a cognitive-behavioral therapy (CBT) for insomnia in persons having sustained traumatic brain injury (TBI). Design: Single-case design with multiple baselines across participants. Setting: Outpatient rehabilitation center. Participants: Eleven subjects having sustained mild to severe TBI who developed insomnia after the injury. Intervention: Eight-week CBT for insomnia including stimulus control, sleep restriction, cognitive restructuring, sleep hygiene education, and fatigue management. Main Outcome Measures: Total wake time, sleep efficiency, and diagnostic criteria. Results: Visual analyses, corroborated by intervention time series analyses and t tests, revealed clinically and statistically significant reductions in total wake time and sleep efficiency for 8 (73%) of 11 participants. An average reduction of 53.9% in total wake time was observed across participants from pre- to post-treatment. Progress was in general well maintained at the 1-month and 3-month follow-ups. The average sleep efficiency augmented significantly from pretreatment (77.2%) to post-treatment (87.9%), and also by the 3-month follow-up (90.9%). Improvements in sleep were accompanied by a reduction in symptoms of general and physical fatigue. Conclusions: The results of this study show that psychologic interventions for insomnia are a promising therapeutic avenue for TBI survivors.	[Oluellet, Marie-Christine] Hop Enfants Jesus, Ctr Hosp Affilie, Rech Traumatol Med Urgence, Quebec City, PQ G1J 1Z4, Canada; [Morin, Charles M.] Univ Laval, Ecole Psychol, Quebec City, PQ, Canada	Oluellet, MC (corresponding author), Hop Enfants Jesus, Ctr Hosp Affilie, Rech Traumatol Med Urgence, 1401 18E Rue, Quebec City, PQ G1J 1Z4, Canada.	marie-christine.ouellet@mail.mcgill.ca	Morin, Charles M./A-4700-2008; Morin, Charles/G-1021-2011	Morin, Charles M./0000-0002-8649-8895; Ouellet, Marie-Christine/0000-0003-3477-1893			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Sleep Disorders Association, 1997, INT CLASS SLEEP DIS; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Blais FC, 1997, ENCEPHALE, V23, P447; BOOTZIN RR, 1991, STIMULUS CONTROL INS, P19; BOURQUE P, 1982, REV CANADIENNE SCI C, V14, P211, DOI DOI 10.1037/H0081254; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fillion L, 2003, CANCER NURS, V26, P143, DOI 10.1097/00002820-200304000-00008; Flanagan SR, 2007, J HEAD TRAUMA REHAB, V22, P67, DOI 10.1097/00001199-200701000-00009; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; FREESTON MH, 1994, ENCEPHALE, V20, P47; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; GEORGE B, 1981, NEUROCHIRURGIE, V27, P35; GERVAIS M, 1999, QUEBEC RAPPORT RECHE; GORMAN BS, 1996, DESIGN ANAL SINGLE C, P159; Hauri PJ, 1991, CASE STUDIES INSOMNI; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holbrook AM, 2000, CAN MED ASSOC J, V162, P225; Holzner B, 2003, CANCER, V97, P1564, DOI 10.1002/cncr.11253; Holzner B, 2002, ANN ONCOL, V13, P965, DOI 10.1093/annonc/mdf122; Huitema BE, 2000, EDUC PSYCHOL MEAS, V60, P38, DOI 10.1177/00131640021970358; Kazdin A., 1998, RES DESIGN CLIN PSYC; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; Lichstein KL, 2000, PSYCHOL AGING, V15, P232, DOI 10.1037/0882-7974.15.2.232; MELLINGER GD, 1985, ARCH GEN PSYCHIAT, V42, P225, DOI 10.1001/archpsyc.1985.01790260019002; Morin CM, 2006, SLEEP, V29, P1398, DOI 10.1093/sleep/29.11.1398; MORIN CM, 1994, AM J PSYCHIAT, V151, P1172; Morin CM, 2002, BEHAV RES THER, V40, P741, DOI 10.1016/S0005-7967(01)00055-9; Morin CM, 1996, CLIN PSYCHOL REV, V16, P521, DOI 10.1016/0272-7358(96)00027-X; MORIN CM, 1994, BEHAV THER, V25, P291, DOI 10.1016/S0005-7894(05)80289-8; MORIN CM, 1993, INDOMNIA PSYCHOL ASS; MURTAGH DR, 1994, J CONSULT CLIN PSYCH, V63, P79; Nowell PD, 1997, JAMA-J AM MED ASSOC, V278, P2170; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Ouellet MC, 2004, ARCH PHYS MED REHAB, V85, P1298, DOI 10.1016/j.apmr.2003.11.036; Parrino L, 1996, PSYCHOPHARMACOLOGY, V126, P1, DOI 10.1007/BF02246405; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Quesnel C, 2003, J CONSULT CLIN PSYCH, V71, P189, DOI 10.1037/0022-006X.71.1.189; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Shan RSLP, 2004, AM J PHYS MED REHAB, V83, P421, DOI 10.1097/00002060-200406000-00003; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Smith MT, 2005, CLIN PSYCHOL REV, V25, P559, DOI 10.1016/j.cpr.2005.04.004; SPIELMAN AJ, 1987, SLEEP, V10, P45	51	107	108	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2007	88	12					1581	1592		10.1016/j.apmr.2007.09.006			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	242OE	WOS:000251734200004	18047872				2021-06-18	
J	Brandt, C; Gastens, AM; Sun, MZ; Hausknecht, M; Loscher, W				Brandt, Claudia; Gastens, Alexandra M.; Sun, Mei zhen; Hausknecht, Maria; Loescher, Wolfgang			Treatment with valproate after status epilepticus: Effect on neuronal damage, epileptogenesis, and behavioral alterations in rats	NEUROPHARMACOLOGY			English	Article						epilepsy; antiepileptic drugs; neuroprotection; Morris water maze; dentate hilus	LITHIUM-PILOCARPINE MODEL; ELECTRICAL-STIMULATION; ANTIEPILEPTIC DRUGS; BRAIN-DAMAGE; ANIMAL-MODELS; EPILEPSY; SEIZURES; ANXIETY; PREVENTION; DIAZEPAM	Epileptogenesis, i.e. the process leading to epilepsy with spontaneous recurrent seizures, can be initiated by a number of brain damaging insults, including traumatic brain injury, status epilepticus (SE), and stroke. Such acquired epilepsy is often associated with memory impairment and behavioral problems. There has been a growing interest in the use of antiepileptic drugs (AEDs) for neuroprotection and prevention or modification of epileptogenesis induced by such brain insults. One promising candidate in this respect is valproic acid (VPA), a widely used AED that has been reported to exert neuroprotective activity in a number of in vitro and in vivo models. The present study investigated whether VPA reduces brain damage and improves functional outcome in a rat model of post-SE epilepsy. A self-sustaining SE was induced by prolonged electrical stimulation of the basal amygdala via a depth electrode. SE was terminated after 4 h by diazepam, immediately followed by onset of treatment with VPA. VPA was injected i.p. at a bolus dose of 400 mg/kg, followed by three times daily administration of 200 mg/kg for 4 weeks. A control group received vehicle instead of VPA after SE. Spontaneous seizures were recorded in all rats of both groups following termination of treatment, without significant inter-group difference in seizure frequency or severity. However, treatment with VPA after SE prevented the hyperexcitability and locomotor hyperactivity observed in vehicle-treated epileptic rats. Furthermore, VPA completely counteracted the neuronal damage in the hippocampal formation, including the dentate hilus. The data demonstrate that, although VPA does not prevent the occurrence of spontaneous seizures after SE, it exerts powerful neuroprotective effects and prevents part of the behavioral alterations, demonstrating that administration of VPA immediately after SE exerts a favorable effect on long-term functional outcome. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany	Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de					Aerden LAM, 2004, NEUROSCI LETT, V367, P76, DOI 10.1016/j.neulet.2004.05.083; Andre V, 2001, EPILEPSY RES, V47, P99, DOI 10.1016/S0920-1211(01)00299-6; Bachmann RF, 2005, MOL NEUROBIOL, V32, P173, DOI 10.1385/MN:32:2:173; Barch DM, 2003, J ABNORM PSYCHOL, V112, P132, DOI 10.1037/0021-843X.112.1.132; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Bolanos AR, 1998, NEUROLOGY, V51, P41, DOI 10.1212/WNL.51.1.41; Brandt C, 2003, EPILEPSY RES, V55, P83, DOI 10.1016/S0920-1211(03)00114-1; Brandt C, 2003, NEUROSCIENCE, V118, P727, DOI 10.1016/S0306-4522(03)00027-7; Cilio MR, 2001, NEUROPHARMACOLOGY, V40, P139, DOI 10.1016/S0028-3908(00)00103-9; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; DeLorenzo RJ, 2005, PHARMACOL THERAPEUT, V105, P229, DOI 10.1016/j.pharmthera.2004.10.004; Detour J, 2005, EPILEPSIA, V46, P499, DOI 10.1111/j.0013-9580.2005.38704.x; Devinsky O, 2004, EPILEPSIA, V45, P34, DOI 10.1111/j.0013-9580.2004.452003.x; dos Santos JG, 2005, BRAIN RES, V1066, P37, DOI 10.1016/j.brainres.2005.09.037; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; FILE SE, 1993, BEHAV BRAIN RES, V58, P199, DOI 10.1016/0166-4328(93)90103-W; Fujikawa DG, 2000, TRENDS NEUROSCI, V23, P410, DOI 10.1016/S0166-2236(00)01601-5; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Fujikawa TG, 2000, EPILEPSIA, V41, P981, DOI 10.1111/j.1528-1157.2000.tb00283.x; Gaitatzis A, 2004, ACTA NEUROL SCAND, V110, P207, DOI 10.1111/j.1600-0404.2004.00324.x; GOODMAN JH, 1998, NEUROPHARMACOLOGY ME, P95; Halonen T, 2001, NEUROPHARMACOLOGY, V40, P536, DOI 10.1016/S0028-3908(00)00183-0; Kalviainen R, 2005, CNS DRUGS, V19, P759; Kanner AM, 2004, EPILEPSIA, V45, P22, DOI 10.1111/j.0013-9580.2004.452004.x; LANDOLT H, 1953, ELECTROEN CLIN NEURO, V5, P121; Loscher W, 2004, EPILEPSY RES, V60, P77, DOI 10.1016/j.eplepsyres.2004.06.004; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; Loscher W, 2002, CNS DRUGS, V16, P669; MILGRAM NW, 1988, NEUROTOXICOLOGY, V9, P611; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MOSER VC, 1988, FUND APPL TOXICOL, V11, P189, DOI 10.1016/0272-0590(88)90144-3; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pitkanen A, 2004, IDRUGS, V7, P471; Pitkanen A, 2004, EXPERT OPIN PHARMACO, V5, P777, DOI 10.1517/14656566.5.4.777; Pitkanen A, 2002, NEUROLOGY, V59, pS27, DOI 10.1212/WNL.59.9_suppl_5.S27; Pitkanen A, 2002, EPILEPSY RES, V50, P141, DOI 10.1016/S0920-1211(02)00076-1; Pitkanen A, 2002, PROG BRAIN RES, V135, P67; PORSOLT RD, 1979, EUR J PHARMACOL, V57, P201, DOI 10.1016/0014-2999(79)90366-2; Potschka H, 2001, EPILEPSIA, V42, P1231, DOI 10.1046/j.1528-1157.2001.01901.x; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Rice AC, 1998, EPILEPSIA, V39, P1148, DOI 10.1111/j.1528-1157.1998.tb01305.x; Rigoulot MA, 2004, J PHARMACOL EXP THER, V308, P787, DOI 10.1124/jpet.103.057091; Rosenow F, 2002, EPILEPTIC DISORD, V4, pS41; SCHWARTZ RD, 1995, J NEUROSCI, V15, P529; Sloviter RS, 2002, TRENDS PHARMACOL SCI, V23, P19, DOI 10.1016/S0165-6147(00)01867-8; Stafstrom CE, 2006, MODELS OF SEIZURES AND EPILEPSY, P613, DOI 10.1016/B978-012088554-1/50051-7; STAFSTROM CE, 1993, EPILEPSIA, V34, P420, DOI 10.1111/j.1528-1157.1993.tb02582.x; Szot P, 2005, MOL BRAIN RES, V135, P285, DOI 10.1016/j.molbrainres.2004.11.011; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; van den Buuse M, 2005, AUST NZ J PSYCHIAT, V39, P550, DOI 10.1111/j.1440-1614.2005.01626.x; Volk HA, 2006, NEUROBIOL DIS, V21, P633, DOI 10.1016/j.nbd.2005.09.006; VOLL CL, 1991, NEUROLOGY, V41, P423, DOI 10.1212/WNL.41.3.423	57	107	112	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	SEP	2006	51	4					789	804		10.1016/j.neuropharm.2006.05.021			16	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	088LB	WOS:000240812100012	16806297				2021-06-18	
J	Ouellet, MC; Morin, CM				Ouellet, Marie-Christine; Morin, Charles M.			Subjective and objective measures of insomnia in the context of traumatic brain injury: A preliminary study	SLEEP MEDICINE			English	Article						traumatic brain injury; insomnia; polysomnography; subjective; objective	MULTIDIMENSIONAL FATIGUE; PSYCHOMETRIC PROPERTIES; SLEEP DISTURBANCES; EEG SLEEP; LONG-TERM; INVENTORY; COMPLAINTS; PATTERNS; VALIDATION; DEPRESSION	Background and purpose: To compare subjective and objective measures of sleep in traumatic brain injury patients (TBI) suffering from insomnia and in controls. Patients and methods: Fourteen patients with mild to severe TBI were compared to 14 healthy good sleepers. Subjective measures of insomnia were obtained from a sleep diary (morning questionnaire), and objective measures from two nights of polysomnography (PSG). Results: All subjective measures of sleep revealed significant sleep disturbance in the TBI group. TBI patients with insomnia have a tendency to overestimate their sleep disturbance compared to PSG measures of sleep. With PSG, 10 out of 14 participants with TBI could be defined as having objective insomnia. Nonetheless, when groups were compared, no significant differences were found on sleep continuity variables, although large effect sizes were seen for several measures suggesting sleep fragmentation. In terms of sleep architecture, no significant differences were found in the percentage of stage 2, slow-wave (stages 3 and 4), and rapid eye movement (REM) sleep, but a higher proportion of stage I sleep was found in the TBI participants. When patients using psychotropic medication were excluded, TBI patients were found to have more awakenings lasting longer than 5 min and a shorter REM sleep latency. Conclusions: These results are similar to those found in patients with either primary insomnia or insomnia related to depression. (C) 2006 Elsevier B.V. All rights reserved.	Univ Laval, Ecole Psychol, Quebec City, PQ G1K 7P4, Canada	Ouellet, MC (corresponding author), Hop Enfants Jesus, CHA Pavillon Notre Dame,1401 18E Rue, Quebec City, PQ G1J 1Z4, Canada.	marie-christine.ouellet.1@ulaval.ca	Morin, Charles/G-1021-2011; Morin, Charles M./A-4700-2008	Morin, Charles M./0000-0002-8649-8895; Ouellet, Marie-Christine/0000-0003-3477-1893			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Sleep Disorders Association, 1997, INT CLASS SLEEP DIS; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; Blais FC, 1997, ENCEPHALE, V23, P447; BOURQUE P, 1982, REV CANADIENNE SCI C, V14, P211, DOI DOI 10.1037/H0081254; BRICOLO A, 1968, ACTA NEUROL SCAND, V44, P512, DOI 10.1111/j.1600-0404.1968.tb05589.x; CARSKADON MA, 1976, AM J PSYCHIAT, V133, P1382; CHATRIAN GE, 1963, ELECTROEN CLIN NEURO, V15, P272, DOI 10.1016/0013-4694(63)90096-8; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; DEMENT WC, 1972, SLEEP MATURING NERVO, P319; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EDINGER JD, 1995, SLEEP, V18, P232, DOI 10.1093/sleep/18.4.232; Edinger JD, 1997, SLEEP, V20, P1119, DOI 10.1093/sleep/20.12.1119; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fillion L, 2003, CANCER NURS, V26, P143, DOI 10.1097/00002820-200304000-00008; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; FRANKEL BL, 1976, ARCH GEN PSYCHIAT, V33, P615; FREESTON MH, 1994, ENCEPHALE, V20, P47; GEORGE B, 1981, NEUROCHIRURGIE, V27, P35; GEORGE B, 1986, NEUROCHIRURGIA, V29, P45; Gervais M, 1999, ETUDE EXPLORATOIRE B; HUBAIN PP, 1990, J AFFECT DISORDERS, V18, P67, DOI 10.1016/0165-0327(90)90118-R; JOHNSON LC, 1983, MIL MED, V148, P727; JOHNSON LC, 1981, ELECTROEN CLIN NEURO, V52, P89, DOI 10.1016/0013-4694(81)90193-0; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kaynak H, 2004, SLEEP MED, V5, P15, DOI 10.1016/j.sleep.2003.06.006; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KUPFER DJ, 1972, LANCET, V2, P684; LENARD HG, 1970, ACTA PAEDIATR SCAND, V59, P565, DOI 10.1111/j.1651-2227.1970.tb16809.x; Lustberg L, 2000, SLEEP MED REV, V4, P253, DOI 10.1053/smrv.1999.0075; Mahowald Mark W., 1996, P285; Mahowald MW, 2000, NEUROL DIS, V49, P365; MCCALL WV, 1993, J AMBULATORY MONITOR, V6, P135; MELLINGER GD, 1985, ARCH GEN PSYCHIAT, V42, P225, DOI 10.1001/archpsyc.1985.01790260019002; Morin CM, 1993, PSYCHOL ASSESSMENT M; MOURET J, 1988, PSYCHOPHARMACOLOGY, V95, pS37; Ott GE, 2004, INT J NEUROPSYCHOPH, V7, P275, DOI 10.1017/S1461145704004298; OUELLET MC, IN PRESS J HEAD TRAU; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Rechtschaffen A, 1968, MANUAL STANDARDIZED; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; ROTH T, 1976, COMPR PSYCHIAT, V17, P217, DOI 10.1016/0010-440X(76)90072-9; Saletu-Zyhlarz GM, 2002, PROG NEURO-PSYCHOPH, V26, P249, DOI 10.1016/S0278-5846(01)00262-7; SALINPASCUAL RJ, 1992, AM J PSYCHIAT, V149, P904; SEWITCH DE, 1984, SLEEP, V7, P147, DOI 10.1093/sleep/7.2.147; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SPINWEBER CL, 1982, PSYCHOPHARMACOLOGY, V76, P5, DOI 10.1007/BF00430746; Wohlgemuth WK, 1999, PSYCHOPHYSIOLOGY, V36, P233, DOI 10.1111/1469-8986.3620233; Yamadera H, 1998, PSYCHIAT CLIN NEUROS, V52, P439, DOI 10.1046/j.1440-1819.1998.00403.x	56	107	109	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	SEP	2006	7	6					486	497		10.1016/j.sleep.2006.03.017			12	Clinical Neurology	Neurosciences & Neurology	094AW	WOS:000241212400004	16934524				2021-06-18	
J	Farkas, O; Lifshitz, J; Povlishock, JT				Farkas, O; Lifshitz, J; Povlishock, JT			Mechanoporation induced by diffuse traumatic brain injury: An irreversible or reversible response to injury?	JOURNAL OF NEUROSCIENCE			English	Article						diffuse traumatic brain injury; neuron; dextrans; membrane disruption; membrane resealing; calpain	PLASMA-MEMBRANE DISRUPTIONS; SPECTRIN BREAKDOWN PRODUCTS; CORTICAL IMPACT INJURY; SEVERE HEAD-INJURY; SPINAL-CORD AXONS; IN-VITRO MODEL; CALPAIN ACTIVATION; NEURONAL DEATH; CELL-DEATH; CEREBROSPINAL-FLUID	Diffuse traumatic brain injury (DTBI) is associated with neuronal plasmalemmal disruption, leading to either necrosis or reactive change without cell death. This study examined whether enduring membrane perturbation consistently occurs, leading to cell death, or if there is the potential for transient perturbation followed by resealing/recovery. We also examined the relationship of these events to calpain-mediated spectrin proteolysis (CMSP). To assess plasmalemmal disruption, rats ( n = 21) received intracerebroventricular infusion 2 h before DTBI of a normally excluded 10 kDa fluorophore-labeled dextran. To reveal plasmalemmal resealing or enduring disruption, rats were infused with another labeled dextran 2 h ( n = 10) or 6 h ( n = 11) after injury. Immunohistochemistry for the 150 kDa spectrin breakdown product evaluated the concomitant role of CMSP. Neocortical neurons were followed with confocal and electron microscopy. After DTBI at 4 and 8 h, 55% of all tracer-flooded neurons contained both dextrans, demonstrating enduring plasmalemmal leakage, with many demonstrating necrosis. At 4 h, 12.0% and at 8 h, 15.7% of the dual tracer-flooded neurons showed CMSP, yet, these demonstrated less advanced cellular change. At 4 h, 39.0% and at 8 h, 24.4% of all tracer-flooded neurons revealed only preinjury dextran uptake, consistent with membrane resealing, whereas 7.6 and 11.1%, respectively, showed CMSP. At 4 h, 35% and at 8 h, 33% of neurons demonstrated CMSP without dextran flooding. At 4 h, 5.5% and at 8 h, 20.9% of tracer-flooded neurons revealed only postinjury dextran uptake, consistent with delayed membrane perturbation, with 55.0 and 35.4%, respectively, showing CMSP. These studies illustrate that DTBI evokes evolving plasmalemmal changes that highlight mechanical and potential secondary events in membrane poration.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Univ Pecs, Fac Med, Dept Neurosurg, H-7623 Pecs, Hungary	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD049343, F32 HD-49343] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-045834, NS-47463] Funding Source: Medline		Amorini AM, 2003, ACT NEUR S, V86, P261; ANDREWS NW, 2005, SCI STKE, pE19; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brana C, 1999, EUR J NEUROSCI, V11, P2375, DOI 10.1046/j.1460-9568.1999.00653.x; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; DERESKI MO, 1993, ACTA NEUROPATHOL, V85, P327; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1987, J CEREBR BLOOD F MET, V7, P300, DOI 10.1038/jcbfm.1987.67; Dietrich WD, 1998, INT REV NEUROBIOL, V42, P55, DOI 10.1016/S0074-7742(08)60608-X; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; FISHMAN HM, 1990, BIOCHIM BIOPHYS ACTA, V1023, P421, DOI 10.1016/0005-2736(90)90135-B; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Godell CM, 1997, P NATL ACAD SCI USA, V94, P4751, DOI 10.1073/pnas.94.9.4751; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Liu XL, 2003, J PHARMACOL EXP THER, V304, P63, DOI 10.1124/jpet.102.043406; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; MCNEIL PL, 1990, J CELL SCI, V96, P549; McNeil PL, 2000, J CELL SCI, V113, P1891; MCNEIL PL, 1989, GASTROENTEROLOGY, V96, P1238, DOI 10.1016/S0016-5085(89)80010-1; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; Mennel HD, 2000, EXP TOXICOL PATHOL, V52, P395, DOI 10.1016/S0940-2993(00)80070-6; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prado GR, 2004, J NEUROTRAUM, V21, P1331; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Shi R, 2001, J NEUROCYTOL, V30, P829, DOI 10.1023/A:1019645505848; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; SIMAN R, 1989, J NEUROSCI, V9, P1579; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; The Brain Trauma Foundation; The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P479; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WHITE BC, 1993, ACTA NEUROPATHOL, V86, P1, DOI 10.1007/BF00454891; XIE XY, 1991, J NEUROSCI, V11, P3257; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457; YAWO H, 1985, J NEUROSCI, V5, P1626; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901; YU QC, 1992, AM J PATHOL, V141, P1349	71	107	110	0	10	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 22	2006	26	12					3130	3140		10.1523/JNEUROSCI.5119-05.2006			11	Neurosciences	Neurosciences & Neurology	024NM	WOS:000236202200006	16554464	Bronze, Green Published			2021-06-18	
J	Park, JH; Gimbel, DA; GrandPre, T; Lee, JK; Kim, JE; Li, WW; Lee, DHS; Strittmatter, SM				Park, JH; Gimbel, DA; GrandPre, T; Lee, JK; Kim, JE; Li, WW; Lee, DHS; Strittmatter, SM			Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition	JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; beta-amyloid plaque; Nogo; transgenic mice; Nogo-66 receptor; gene targeting; amyloid precursor protein; APP	NICOTINIC ACETYLCHOLINE-RECEPTOR; AXON REGENERATION; NEURITE OUTGROWTH; RECOVERY; DISEASE; MYELIN; INHIBITION; OLIGOMERS; BINDS; BETA-AMYLOID(1-42)	Pathophysiologic hypotheses for Alzheimer's disease (AD) are centered on the role of the amyloid plaque A beta peptide and the mechanism of its derivation from the amyloid precursor protein (APP). As part of the disease process, an aberrant axonal sprouting response is known to occur near A beta deposits. A Nogo to Nogo-66 receptor (NgR) pathway contributes to determining the ability of adult CNS axons to extend after traumatic injuries. Here, we consider the potential role of NgR mechanisms in AD. Both Nogo and NgR are mislocalized in AD brain samples. APP physically associates with the NgR. Overexpression of NgR decreases A beta production in neuroblastoma culture, and targeted disruption of NgR expression increases transgenic mouse brain A beta levels, A beta plaque deposition, and dystrophic neurites. Infusion of a soluble NgR fragment reduces A beta levels, amyloid plaque deposits, and dystrophic neurites in a mouse transgenic AD model. Changes in NgR level produce parallel changes in secreted APP alpha and A beta, implicating NgR as a blocker of secretase processing of APP. The NgR provides a novel site for modifying the course of AD and highlights the role of axonal dysfunction in the disease.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Biogen Idec Inc, Cambridge, MA 02140 USA	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, POB 208018, New Haven, CT 06510 USA.	stephen.strittmatter@yale.edu	Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092; Park, James/0000-0002-1377-1707	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS033020, R01NS042304, R01NS039962, R01NS056485] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37 NS033020, R01 NS042304-08, R01 NS056485, R01 NS039962-10, R01 NS042304, R01 NS056485-04, R37 NS033020-17, R01 NS039962] Funding Source: Medline		Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fournier AE, 2002, J NEUROSCI, V22, P8876; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Jankowsky JL, 2003, J NEUROPATH EXP NEUR, V62, P1220, DOI 10.1093/jnen/62.12.1220; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Kuner P, 1998, J NEUROSCI RES, V54, P798, DOI 10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.0.CO;2-T; Lazarov O, 2002, J NEUROSCI, V22, P9785; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Li SX, 2003, J NEUROSCI, V23, P4219; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; Lombardo JA, 2003, J NEUROSCI, V23, P10879, DOI 10.1523/jneurosci.23-34-10879.2003; McGee AW, 2003, TRENDS NEUROSCI, V26, P193, DOI 10.1016/S0166-2236(03)00062-6; Nagele RG, 2002, NEUROSCIENCE, V110, P199, DOI 10.1016/S0306-4522(01)00460-2; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; SCOTT JN, 1991, MOL BRAIN RES, V10, P315, DOI 10.1016/0169-328X(91)90090-K; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Sheng JG, 2002, J NEUROSCI, V22, P9794; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang XX, 2002, J NEUROSCI, V22, P5505; Yang XJ, 1996, P NATL ACAD SCI USA, V93, P475, DOI 10.1073/pnas.93.1.475	36	107	113	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	FEB 1	2006	26	5					1386	1395		10.1523/JNEUROSCI.3291-05.2006			10	Neurosciences	Neurosciences & Neurology	008MC	WOS:000235043800007	16452662	Bronze, Green Published, Green Accepted			2021-06-18	
J	Baumann, CR; Stocker, R; Imhof, HG; Trentz, O; Hersberger, M; Mignot, E; Bassetti, CL				Baumann, CR; Stocker, R; Imhof, HG; Trentz, O; Hersberger, M; Mignot, E; Bassetti, CL			Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury	NEUROLOGY			English	Article							NARCOLEPSY	Hypocretin-1 is involved in the regulation of the sleep-wake cycle. The authors prospectively assessed CSF hypocretin-1 levels in 44 consecutive patients with acute traumatic brain injury (TBI). Compared with controls, hypocretin-1 levels were abnormally lower in 95% of patients with moderate to severe TBI and in 97% of patients with posttraumatic brain CT changes. Hypocretin-1 deficiency after TBI may reflect hypothalamic damage and be linked with the frequent development of posttraumatic sleep-wake disorders.	Univ Spital Zurich, Dept Neurol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Intens Care Med, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Traumat Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Inst Clin Chem, CH-8091 Zurich, Switzerland; Stanford Ctr Narcolepsy, Palo Alto, CA USA	Bassetti, CL (corresponding author), Univ Spital Zurich, Dept Neurol, Frauenklinikstr 26, CH-8091 Zurich, Switzerland.	claudio.bassetti@usz.ch		Baumann, Christian/0000-0003-3417-1978; Hersberger, Martin/0000-0002-4472-329X			Dauvilliers Y, 2003, J NEUROL NEUROSUR PS, V74, P1667, DOI 10.1136/jnnp.74.12.1667; Estabrooke IV, 2001, J NEUROSCI, V21, P1656; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mochizuki T, 2003, CURR BIOL, V13, pR563, DOI 10.1016/S0960-9822(03)00474-3; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; Ripley B, 2001, NEUROLOGY, V57, P2253, DOI 10.1212/WNL.57.12.2253; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698	7	107	108	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 12	2005	65	1					147	149		10.1212/01.wnl.0000167605.02541.f2			3	Clinical Neurology	Neurosciences & Neurology	944KP	WOS:000230427200032	16009905				2021-06-18	
J	Scott, GS; Cuzzocrea, S; Genovese, T; Koprowski, H; Hooper, DC				Scott, GS; Cuzzocrea, S; Genovese, T; Koprowski, H; Hooper, DC			Uric acid protects against secondary damage after spinal cord injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						blood-brain barrier; neutrophils; peroxynitrite; spinal cord neurons; cytotoxicity	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; INFLAMMATORY CELL INVASION; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; POLY(ADP-RIBOSE) POLYMERASE; PEROXYNITRITE SCAVENGER; PARKINSONS-DISEASE; PERMEABILITY CHANGES; ALZHEIMERS-DISEASE	Peroxynitrite contributes to the pathogenesis of various neurodegenerative disorders through multiple mechanisms and is thought to mediate secondary neuronal cell death after spinal cord injury (SCI). Here we establish that physiologically relevant levels of uric acid (UA), a selective inhibitor of certain peroxynitrite-mediated reactions, block the toxic effects of peroxynitrite on primary spinal cord neurons in vitro. Furthermore, administration of UA at the onset of SCI in a mouse model inhibits several pathological changes in the spinal cord including general tissue damage, nitrotyrosine formation, lipid peroxidation, activation of poly(ADP-ribose) polymerase, and neutrophil invasion. More importantly, UA treatment improves functional recovery from the injury. Taken together, our findings support the concept that peroxynitrite contributes to the pathophysiology of secondary damage after SCI. They also raise the possibility that elevating UA levels may provide a therapeutic approach for the treatment of SCI as well as other neurological diseases with a peroxynitrite-mediated pathological component.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Messina, Policlin Univ, Sch Med, Dept Clin & Expt Med & Pharmacol, I-98100 Messina, Italy	Hooper, DC (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, 1020 Locust St, Philadelphia, PA 19107 USA.	douglas.hooper@jefferson.edu		Hooper, Douglas/0000-0002-8578-5104; GENOVESE, Tiziana/0000-0002-3335-7327			Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BRAUGHLER JM, 1992, J NEUROTRAUMA, V9, P1; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; CHURCH WH, 1994, BRAIN RES BULL, V33, P419, DOI 10.1016/0361-9230(94)90285-2; Cookson MR, 1998, J NEUROCHEM, V70, P501; Cuzzocrea S, 2004, EUR J PHARMACOL, V483, P79, DOI 10.1016/j.ejphar.2003.10.056; Davis JW, 1996, AM J EPIDEMIOL, V144, P480, DOI 10.1093/oxfordjournals.aje.a008954; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Drulovic J, 2001, J NEUROL, V248, P121, DOI 10.1007/s004150170246; HOLTZ A, 1992, Neurological Research, V14, P49; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Hooper DC, 2000, FASEB J, V14, P691; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Hooper DC, 2001, J IMMUNOL, V167, P3470, DOI 10.4049/jimmunol.167.6.3470; Joosten EAJ, 2004, NEUROREPORT, V15, P1163, DOI 10.1097/00001756-200405190-00016; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; Kastenbauer S, 2001, EUR J PHARMACOL, V425, P149, DOI 10.1016/S0014-2999(01)01137-2; Kean RB, 2000, J IMMUNOL, V165, P6511, DOI 10.4049/jimmunol.165.11.6511; Koprowski H, 2001, ANN NEUROL, V49, P139, DOI 10.1002/1531-8249(200101)49:1<139::AID-ANA28>3.0.CO;2-A; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; MAESAKA JK, 1993, J AM GERIATR SOC, V41, P501, DOI 10.1111/j.1532-5415.1993.tb01885.x; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Muraoka S, 2003, PHARMACOL TOXICOL, V93, P284, DOI 10.1111/j.1600-0773.2003.pto930606.x; Nakazawa H, 2000, FREE RADICAL RES, V33, P771, DOI 10.1080/10715760000301291; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rinaldi P, 2003, NEUROBIOL AGING, V24, P915, DOI 10.1016/S0197-4580(03)00031-9; Santos CXC, 1999, ARCH BIOCHEM BIOPHYS, V372, P285, DOI 10.1006/abbi.1999.1491; Scott GS, 2002, P NATL ACAD SCI USA, V99, P16303, DOI 10.1073/pnas.212645999; Scott GS, 2004, J NEUROTRAUM, V21, P1255, DOI 10.1089/neu.2004.21.1255; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2004, J NEUROIMMUNOL, V155, P32, DOI 10.1016/j.jneuroim.2004.05.011; Scott GS, 2003, GLIA, V41, P105, DOI 10.1002/glia.10137; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; Spitsin S, 2001, MULT SCLER, V7, P165, DOI 10.1177/135245850100700305; Spitsin SV, 2000, NEUROSCI LETT, V292, P137, DOI 10.1016/S0304-3940(00)01446-4; Spitsin SV, 2002, FREE RADICAL BIO MED, V33, P1363, DOI 10.1016/S0891-5849(02)01048-1; Squadrito GL, 2000, ARCH BIOCHEM BIOPHYS, V376, P333, DOI 10.1006/abbi.2000.1721; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Terwel D, 2000, EUR J PHARMACOL, V400, P19, DOI 10.1016/S0014-2999(00)00379-4; Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x; TOHGI H, 1993, J NEURAL TRANSM-PARK, V6, P119, DOI 10.1007/BF02261005; TONEV G, 2002, EUR J NEUROL, V9, P221; Whalen MJ, 2000, ACT NEUR S, V76, P61; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Whiteman M, 2002, ANN NY ACAD SCI, V962, P242, DOI 10.1111/j.1749-6632.2002.tb04072.x; WU XW, 1992, J MOL EVOL, V34, P78, DOI 10.1007/BF00163854; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; YELDANDI AV, 1991, GENE, V109, P281, DOI 10.1016/0378-1119(91)90622-I; Yu ZF, 1998, J NEUROSCI RES, V53, P613, DOI 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1	59	107	116	1	5	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAR 1	2005	102	9					3483	3488		10.1073/pnas.0500307102			6	Multidisciplinary Sciences	Science & Technology - Other Topics	903KC	WOS:000227423700057	15728348	Green Published, Bronze			2021-06-18	
J	Hoffer, ME; Gottshall, KR; Moore, R; Balough, BJ; Wester, D				Hoffer, ME; Gottshall, KR; Moore, R; Balough, BJ; Wester, D			Characterizing and treating dizziness after mild head trauma	OTOLOGY & NEUROTOLOGY			English	Article						traumatic brain injury (TBI); migraines; dizziness; vertigo; positional vertigo; vestibular rehabilitation	HISTORY; INJURY	Objective: The objectives of this study were to characterize patterns of dizziness seen after mild head trauma and to examine the diagnosis and treatment of this disorder. Study Design: Prospective patient registry. Setting: Tertiary referral center. Patients: Fifty-eight cases of active duty and retired military personnel who sustained mild head trauma and had resultant dizziness. Interventions: Vestibular evaluation, characterization by group, and treatment. Main Outcome Measures: Outcome measures include characterization of diagnosis types, patient distribution by diagnosis type, and patient outcome. Results: Individuals suffering from dizziness after mild head injury were divided into three diagnostic groups. Forty-one percent of the individuals suffered from posttraumatic vestibular migraines, 28% of the individuals had posttraumatic positional vertigo, and 19% of the individuals were classified as posttraumatic spatial disorientation. The remaining 12% of the patients could not be characterized. The positional group had objective physical examination findings, which cleared with treatment in all cases. The migraine group of patients and the disorientation group of patients had distinct abnormalities of the vestibulo-ocular reflex (VOR) and the vestibulo-spinal reflex (VSR). Eighty-four percent of the migraine group demonstrated an improvement of these test results as compared with 27% of the disorientation group. Mean time to return to work was less than 1 week for the positional group, 3.8 weeks for the migraine group, and greater than 3 months for the disorientation group. Conclusions: Using our patient registry of individuals suffering from dizziness after mild head trauma, we were able to characterize the majority of these cases into one of three more specific diagnostic groups. We present diagnostic criteria, suggested treatment guidelines, and our prognostic data.	USN, Med Ctr, Dept Otolaryngol, Dept Def,Spatial Orientat Ctr, San Diego, CA 92134 USA	Hoffer, ME (corresponding author), USN, Med Ctr, Dept Otolaryngol, Dept Def,Spatial Orientat Ctr, San Diego, CA 92134 USA.	mehoffer@nmcsd.med.navy.mil					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; DIKMEN SS, 1989, MILD HEAD INJURY, P229; GOTTSHALL KR, 1999, P 4 INT MEN M PAR, P663; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; KURTZKE JF, 1993, CLIN NEUROLOGY; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Whitney SL, 2000, LARYNGOSCOPE, V110, P1528, DOI 10.1097/00005537-200009000-00022	13	107	112	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1531-7129	1537-4505		OTOL NEUROTOL	Otol. Neurotol.	MAR	2004	25	2					135	138		10.1097/00129492-200403000-00009			4	Clinical Neurology; Otorhinolaryngology	Neurosciences & Neurology; Otorhinolaryngology	803XJ	WOS:000220263500009	15021772				2021-06-18	
J	Ng, I; Lim, J; Wong, HB				Ng, I; Lim, J; Wong, HB			Effects of head posture on cerebral hemodynamics: Its influences on intracranial pressure, cerebral perfusion pressure, and cerebral oxygenation	NEUROSURGERY			English	Article						cerebral perfusion pressure; cerebral tissue oxygenation; head posture; severe head injury	INTRA-CRANICAL PRESSURE; BLOOD-FLOW; COMATOSE PATIENTS; BODY POSITION; SATURATION; ELEVATION; VENTILATION; MANAGEMENT; METABOLISM; INJURY	OBJECTIVE: Severely head-injured patients have traditionally been maintained in the head-up position to ameliorate the effects of increased intracranial pressure (ICP). However, it has been reported that the supine position may improve cerebral perfusion pressure (CPP) and outcome. We sought to determine the impact of supine and 30 degrees semirecumbent postures on cerebrovascular dynamics and global as well as regional cerebral oxygenation within 24 hours of trauma. METHODS: Patients with a closed head injury and a Glasgow Coma Scale score of 8 or less were included in the study. On admission to the neurocritical care unit, a standardized protocol aimed at minimizing secondary insults was instituted, and the influences of head posture were evaluated after all acute necessary interventions had been performed. ICP, CPP, mean arterial pressure, global cerebral oxygenation, and regional cerebral oxygenation were noted at 0 and 30 degrees of head elevation. RESULTS: We studied 38 patients with severe closed head injury. The median Glasgow Coma Scale score was 7.0, and the mean age was 34.05 +/- 16.02 years. ICP was significantly lower at 30 degrees than at 0 degrees of head elevation (P = 0.0005). Mean arterial pressure remained relatively unchanged. CPP was slightly but not significantly higher at 30 degrees than at 0 degrees (P = 0.412). However, global venous cerebral oxygenation and regional cerebral oxygenation were not affected significantly by head elevation. All global venous cerebral oxygenation values were above the critical threshold for ischemia at 0 and 30 degrees. CONCLUSION: Routine nursing of patients with severe head injury at 30 degrees of head elevation within 24 hours after trauma leads to a consistent reduction of ICP (statistically significant) and an improvement in CPP (although not statistically significant) without concomitant deleterious changes in cerebral oxygenation.	Natl Inst Neurosci, Dept Neurosurg, Neurocrit Care Unit, Singapore 308433, Singapore; Natl Univ Singapore, Fac Med, Singapore, Singapore; Clin Trials & Epidemiol Res Unit, Singapore, Singapore	Ng, I (corresponding author), Natl Inst Neurosci, Dept Neurosurg, Neurocrit Care Unit, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	ivan_ng@ttsh.com.sg					ABBUSHI W, 1980, ANAESTHESIST, V29, P521; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; deDeyne C, 1996, ACTA NEUROCHIR, V138, P1409, DOI 10.1007/BF01411119; DeWitt D S, 1995, New Horiz, V3, P376; DURWARD QJ, 1983, J NEUROSURG, V59, P938, DOI 10.3171/jns.1983.59.6.0938; EMERY JR, 1983, J PEDIATR-US, V103, P950, DOI 10.1016/S0022-3476(83)80728-8; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hulme A, 1976, INTRACRANIAL PRESSUR, VIII, P259; KENNING JA, 1981, SURG NEUROL, V15, P148, DOI 10.1016/0090-3019(81)90037-9; MAGNAES B, 1976, J NEUROSURG, V44, P687, DOI 10.3171/jns.1976.44.6.0687; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Meixensberger J, 1997, NEUROL RES, V19, P249, DOI 10.1080/01616412.1997.11740808; Moraine JJ, 2000, J NEUROSURG, V92, P606, DOI 10.3171/jns.2000.92.4.0606; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PINSKY MR, 1991, CARDIOPULMONARY CRIT, P87; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROPPER AH, 1982, NEUROLOGY, V32, P1288, DOI 10.1212/WNL.32.11.1288; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROTHE CF, 1983, PHYSIOL REV, V63, P1281; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SCHNEIDER GH, 1993, ACTA NEUROCHIR, P107; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Smielewski P, 1996, STROKE, V27, P2197, DOI 10.1161/01.STR.27.12.2197; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; WINKELMAN C, 2000, AM J CRIT CARE, V6, P373	32	107	110	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2004	54	3					593	598		10.1227/01.NEU.0000108639.16783.39			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	802FN	WOS:000220149500021	15028132				2021-06-18	
J	Ashendorf, L; Constantinou, M; McCaffrey, RJ				Ashendorf, L; Constantinou, M; McCaffrey, RJ			The effect of depression and anxiety on the TOMM in community-dwelling older adults	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; neuropsychological; TOMM; depression; anxiety	MEMORY MALINGERING TOMM; SYMPTOMS; VALIDITY	Tests of possible malingering are in increasing demand among neuropsychologists. The Test of Memory Malingering (TOMM) is resistant to many neurological conditions, including traumatic brain injury, dementia, and aphasia. Less clear is the impact of psychological conditions on TOMM performance. This study examined a sample of community-based older adults (55-75) to determine whether scores on the TOMM are influenced by the presence of symptoms of depression or anxiety, as measured by the Beck Depression Inventory (BDI) and State-Trait Anxiety Inventory (STAI), respectively. The results indicate that, regardless of BDI or STAI scores, all subjects scored above 45 correct out of 50 on TOMM Trial 2. These findings demonstrate that depression and anxiety levels in an older community-dwelling sample do not negatively affect performance on the TOMM. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	SUNY Albany, Dept Psychol, Albany, NY 12222 USA	McCaffrey, RJ (corresponding author), SUNY Albany, Dept Psychol, 1400 Washington Ave, Albany, NY 12222 USA.		Constantinou, Marios/AAL-2899-2020; Ashendorf, Lee/R-7206-2019	Ashendorf, Lee/0000-0003-0479-4023; CONSTANTINOU, MARIOS/0000-0002-6646-5877			BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; HIMMELFARB S, 1983, J GERONTOL, V38, P333, DOI 10.1093/geronj/38.3.333; HIMMELFARB S, 1984, J PSYCHOL, V116, P159, DOI 10.1080/00223980.1984.9923632; Kessler RC, 1996, BRIT J PSYCHIAT, V168, P17, DOI 10.1192/S0007125000298371; Kizilbash AH, 2002, ARCH CLIN NEUROPSYCH, V17, P57, DOI 10.1016/S0887-6177(00)00101-3; Pankratz, 1997, CLIN ASSESSMENT MALI, P223; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Spielberger CD, 1983, STATE TRAIT ANXIETY; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260	13	107	107	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2004	19	1					125	130	PII S0887-6177(02)00218-4	10.1016/S0887-6177(02)00218-4			6	Psychology, Clinical; Psychology	Psychology	759MB	WOS:000187740500011	14670385				2021-06-18	
J	Green, REA; Turner, GR; Thompson, WF				Green, REA; Turner, GR; Thompson, WF			Deficits in facial emotion perception in adults with recent traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						affect; neuropsychology; diffuse axonal injury; TBI; right hemisphere	RIGHT-HEMISPHERE; HUMAN AMYGDALA; RECOGNITION; DAMAGE; EXPRESSIONS; FACE; COMMUNICATION; CORTICES; SYSTEMS; STIMULI	We examined whether facial emotion perception was compromised in adults with recent traumatic brain injury (TBI). Few studies have examined emotion perception in TBI; those that have, examined chronic patients only. Recent and chronic TBI populations differ according to degree of functional reorganization of the brain, use of compensatory strategies, and severity of cognitive impairments-any of which might differentially affect presentation of emotion perception deficits. A secondary aim of the study was to utilize the TBI population-in whom diffuse axonal injury (DAI) is a cardinal neurological feature-to examine the suggestion of Adolphs et al. [Journal of Neuroscience 20(7) (2000) 2683] that damage to white matter tracts should give rise to emotion perception deficits. Methods: Thirty TBI participants and 30 age-matched controls were tested. A 2 x 3 mixed design was employed. The dependent variable was accuracy on neutral and emotional face perception tests. Results: (1) The TBI group performed significantly less accurately than the matched controls on the facial emotion perception tasks, whereas the groups performed equivalently on a non-emotional face perception control task. (2) A sub-group. of TBI participants without evidence of focal injury to areas of the brain most commonly implicated in facial emotion perception was as impaired on the emotion perception tasks as a second sub-group who had sustained focal lesions to these areas. This suggests an alternative neurological mechanism for deficits in the first sub-group, such as DAI Conclusions: Patients with recently acquired TBI are impaired in their ability to perceive emotions in faces. DAI alone may cause facial emotion perception deficits. (C) 2003 Elsevier Ltd. All rights reserved.	Toronto Rehabiol Inst, Toronto, ON M5G 2A2, Canada; Univ Toronto, Toronto, ON, Canada	Green, REA (corresponding author), Toronto Rehabiol Inst, 550 Univ Ave,Room 1004, Toronto, ON M5G 2A2, Canada.	green.robin@torontorehab.on.ca		Green, Robin/0000-0001-9451-3963; Thompson, William/0000-0002-4256-1338			Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 1996, J NEUROSCI, V16, P7678; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; Borod J, 1996, BLACKWELL DICT NEURO, P312; BOROD JC, 1990, J COMMUN DISORD, V23, P247, DOI 10.1016/0021-9924(90)90003-H; Borod JC, 1998, NEUROPSYCHOLOGY, V12, P446, DOI 10.1037/0894-4105.12.3.446; BOWERS D, 1991, BRAIN, V114, P2593, DOI 10.1093/brain/114.6.2593; Bowers D., 1999, FLORIDA AFFECT BATTE; Bowers D., 1993, NEUROPSYCHOLOGY, V7, P433, DOI DOI 10.1037/0894-4105.7.4.433; Bowers D., 1989, FLORIDA AFFECT BATTE; BOWERS D, 1998, UNPUB FLORIDA AFFECT; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; CANCELLIERE AEB, 1990, BRAIN COGNITION, V13, P133, DOI 10.1016/0278-2626(90)90046-Q; Feinstein A., 1999, COGNITIVE NEUROREHAB, P230; Hart AJ, 2000, NEUROREPORT, V11, P2351, DOI 10.1097/00001756-200008030-00004; Heilman KM, 1998, J CLIN NEUROPHYSIOL, V15, P409, DOI 10.1097/00004691-199809000-00005; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kawasaki H, 2001, NAT NEUROSCI, V4, P15; Keane J, 2002, NEUROPSYCHOLOGIA, V40, P655, DOI 10.1016/S0028-3932(01)00156-7; Leppanen JM, 2001, SCAND J PSYCHOL, V42, P429, DOI 10.1111/1467-9450.00255; Luria A.R., 1975, HDB CLIN NEUROLOGY, P368; Luria A. R., 1963, RESTORATION FUNCTION; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; RAO SM, 1992, J CONSULT CLIN PSYCH, V60, P369, DOI 10.1037/0022-006X.60.3.369; RASKIN S A, 1990, Neuropsychology Review, V1, P185, DOI 10.1007/BF01112571; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rolls E. T., 2002, PRINCIPLES FRONTAL L; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; STARKSTEIN SE, 1988, CEREBRAL HEMISPHERE, P25; STRAUSS E, 1981, BRAIN LANG, V13, P308, DOI 10.1016/0093-934X(81)90098-5; Szaflarski JP, 2002, NEUROLOGY, V59, P238, DOI 10.1212/WNL.59.2.238; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001	40	107	113	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2004	42	2					133	141		10.1016/j.neuropsychologia.2003.07.005			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	753FC	WOS:000187220600001	14644100				2021-06-18	
J	Emanuelson, I; Holmkvist, EA; Bjorklund, R; Stalhammar, D				Emanuelson, I; Holmkvist, EA; Bjorklund, R; Stalhammar, D			Quality of life and post-concussion symptoms in adults after mild traumatic brain injury: a population-based study in western Sweden	ACTA NEUROLOGICA SCANDINAVICA			English	Article						brain injury; mild; quality of life	ROUTINE FOLLOW-UP; HEAD-INJURY; SUBJECTIVE EXPERIENCE; SEQUELAE; MODERATE; INDIVIDUALS	Objectives - To study quality of life and subjective post-concussion symptoms in adults (16-60 years) with a mild traumatic brain injury (MTBI) 3 months and 1 year after injury. Methods - Of a total of 489 patients 173 responded to questionnaires at 3 months and at 1 year, including the SF-36 health-related quality of life survey, which is a standardized measure validated for Swedish conditions. Post-concussion symptoms were rated as either existing or non-existing in a 21-item checklist [a modified version of Comprehensive Psychopathological Rating Scale (CPRS)]. Results - SF-36 showed impaired scores in all dimensions. Existing post-concussion symptoms were reported by 15-45%. Significantly, more symptoms were present at 3 months than at 3 weeks after injury. Furthermore, a significant correlation between higher rates of post-concussion symptoms and lower SF-36 scores was found. Conclusions- The SF-36 results were significantly impaired compared with an age- and gender-matched normative control group and the rate of post-concussion symptoms was significantly higher at 3 months than at 3 weeks after injury. As a significant correlation between higher rates of symptoms and lowSF-36 scores was also found we assume SF-36 to be a sensitive enough measure of MTBI-related effects.	Univ Gothenburg, Dept Hlth Women & Children, Gothenburg, Sweden; Boras Hosp, Dept Rehabil Med, Boras, Sweden; Univ Gothenburg, Dept Neurosci, Gothenburg, Sweden	Emanuelson, I (corresponding author), Reg Rehabil Unit, PB 210 62, S-41804 Gothenburg, Sweden.	ingrid.emanuelson@vgregion.se					*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P704; ANDERSSON HE, 2002, 54 ANN C SCAND NEUR; ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; EVANS RW, 1992, NEUROL CLIN, V10, P815; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P891, DOI 10.1016/S0895-4356(98)00080-8; Gerard J M, 2000, Rev Med Brux, V21, P85; GOOD P, 2000, PERMUTATION TESTS PR, P36; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Martin C, 2001, BRAIN INJURY, V15, P947, DOI 10.1080/02699050110065655; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2000, BRAIN INJURY, V14, P219; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	35	107	108	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	NOV	2003	108	5					332	338		10.1034/j.1600-0404.2003.00155.x			7	Clinical Neurology	Neurosciences & Neurology	731FV	WOS:000185874600005	14616303				2021-06-18	
J	Bogod, NM; Mateer, CA; MacDonald, SWS				Bogod, NM; Mateer, CA; MacDonald, SWS			Self-awareness after traumatic brain injury: A comparison of measures and their relationship to executive functions	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						self-awareness; executive function; frontal lobes; brain injury	WORKING-MEMORY TASKS; IMPAIRED AWARENESS; FRONTAL-CORTEX; STROOP INTERFERENCE; DEFICITS; REHABILITATION; IMPAIRMENTS; DISABILITY; ADULTS; LOBES	Poor awareness of deficit is common after brain injury. Recent literature has examined various tools for measurement of this phenomenon; the most widely used being self-other rating scales. Although self-other scale measures have face validity, their criterion-related validity has not been adequately demonstrated, and there is little information as to whether and how they relate to other neuropsychological measures. The present study compared measurement of awareness by the Dysexecutive (DEX) Questionnaire self-other rating scale with the Self-Awareness of Deficits Interview (SADI), a semistructured interview measure. Evaluation of awareness by these measures was compared to tests of executive functioning and IQ. Results indicated significant, albeit marginal relationships between the two measures, and better correlation of the SADI with measures of frontal lobe functioning. The SADI also predicted injury severity.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada	Bogod, NM (corresponding author), Univ Victoria, Dept Psychol, POB 3050 STN CSC, Victoria, BC V8W 3P5, Canada.						ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; CAVELLO MM, 1992, BRAIN INJURY, V6, P327; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Damasio A. R., 1993, CLIN NEUROPSYCHOLOGY, V3, P409; deZubicaray GI, 1997, J NEUROL NEUROSUR PS, V63, P309, DOI 10.1136/jnnp.63.3.309; DIAMOND A, 1991, FRONTAL LOBE FUNCTIO, P189; Eslinger PJ, 1999, NEUROCASE, V5, P299, DOI 10.1080/13554799908411983; EVANS JJ, 1997, PSYCHOL MED, V27, P1; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GANS JS, 1983, ARCH PHYS MED REHAB, V64, P176; GOLDMANRAKIC PS, 1996, PHILOS T ROY SOC B, V35, P1145; Handler J., 1994, HANDB NEUR, P125; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LAPIERRE D, 1995, NEUROPSYCHOLOGIA, V33, P139, DOI 10.1016/0028-3932(94)00110-B; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MALLOY P, 1993, ARCH CLIN NEUROPSYCH, V8, P185, DOI 10.1016/0887-6177(93)90035-Y; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Petrides M, 1996, PHILOS T ROY SOC B, V351, P1455, DOI 10.1098/rstb.1996.0130; PETRIDES M, 1995, J NEUROSCI, V15, P359; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P263; Petrides Michael, 1994, Current Opinion in Neurobiology, V4, P207, DOI 10.1016/0959-4388(94)90074-4; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; PRIGATANO GP, 1987, BARROW NEUROL I Q, V3, P18; Purdon SE, 1998, J PSYCHIATR NEUROSCI, V23, P163; REGARD M, 1991, STROOP TEST VICTORIA; Robbins TW, 1996, PHILOS T ROY SOC B, V351, P1463, DOI 10.1098/rstb.1996.0131; Rolls ET, 1996, PHILOS T ROY SOC B, V351, P1433, DOI 10.1098/rstb.1996.0128; Sattler J. M., 1992, ASSESSMENT CHILDREN; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Shimamura AP, 1995, ANN NY ACAD SCI, V769, P151, DOI 10.1111/j.1749-6632.1995.tb38136.x; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1991, SELF : INTERDISCIPLINARY APPROACHES, P255; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331; Wilson BA, 1996, BEHAV ASSESSMENT DYS; ZAJANO MJ, 1986, PERCEPT MOTOR SKILL, V63, P1087, DOI 10.2466/pms.1986.63.3.1087	49	107	108	0	17	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2003	9	3					450	458		10.1017/S1355617703930104			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	661HR	WOS:000181885600010	12666769				2021-06-18	
J	Rao, VLR; Dhodda, VK; Song, GQ; Bowen, KK; Dempsey, RJ				Rao, VLR; Dhodda, VK; Song, GQ; Bowen, KK; Dempsey, RJ			Traumatic brain injury-induced acute gene expression changes in rat cerebral cortex identified by GeneChip analysis	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						cerebral cortex; controlled cortical impact; microarray; real-time PCR; GeneChip	MESSENGER-RNA EXPRESSION; HEAT-SHOCK-PROTEIN; GLUTAMATE TRANSPORTER GLT-1; CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; SPINAL MUSCULAR-ATROPHY; NERVE GROWTH-FACTOR; DIFFERENTIAL EXPRESSION; REGIONAL EXPRESSION; UP-REGULATION	Proper CNS function depends on concerted expression of thousands of genes in a controlled and timely manner. Traumatic brain injury (TBI) in mammals results in neuronal death and neurological dysfunction, which might be mediated by altered expression of several genes. By employing a CNS-specific GeneChip and real-time polymerase chain reaction (PCR), the present study analyzed the gene expression changes in adult rat cerebral cortex in the first 24 hr after a controlled cortical impact injury. Many functional families of genes not previously implicated in TBI-induced brain damage are altered in the injured cortex. These include up-regulated transcription factors (SOCS-3, JAK-2, STAT-3, CREM, IRF-1, SMN, silencer factor-B, ANIA-3, ANIA-4, and HES-1) and signal transduction pathways (cpg21, Narp, and CRBP) and down-regulated transmitter release mechanisms (CITRON, synaptojanin 11, ras-related rab3, neurexin-1beta, and SNAP25A and -B), kinases (IP-3-kinase, Pak1, Ca2+/CaM-dependent protein kinases), and ion channels (K+ channels TWIK, RK5, X62839, and Na+ channel 1). In addition, several genes previously shown to play a role in TBI pathophysiology, including proinflammatory genes, proapoptotic genes, heat shock proteins, immediate early genes, neuropeptides, and glutamate receptor subunits, were also observed to be altered in the injured cortex. Real-time PCR analysis confirmed the GeneChip data for many of these transcripts. The novel physiologically relevant gene expression changes observed here might explain some of the molecular mechanisms of TBI-induced neuronal damage. (C) 2002 Wiley-Liss, Inc.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA	Rao, VLR (corresponding author), Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA.	vemugant@neurosurg.wisc.edu					Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dhillon HS, 2001, EXP NEUROL, V170, P140, DOI 10.1006/exnr.2001.7685; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Franz G, 1999, J NEUROCHEM, V73, P1615, DOI 10.1046/j.1471-4159.1999.0731615.x; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Gong QZ, 1999, J NEUROTRAUM, V16, P893, DOI 10.1089/neu.1999.16.893; Grabs D, 1996, EUR J NEUROSCI, V8, P162, DOI 10.1111/j.1460-9568.1996.tb01177.x; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hevroni D, 1998, J MOL NEUROSCI, V10, P75, DOI 10.1007/BF02737120; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Iadecola C, 1999, J EXP MED, V189, P719, DOI 10.1084/jem.189.4.719; Imagawa M, 1996, NEUROCHEM INT, V29, P565, DOI 10.1016/S0197-0186(96)00058-7; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; IWAMOTO Y, 1994, LIFE SCI, V55, P1651, DOI 10.1016/0024-3205(94)00332-7; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Keyvani K, 2001, ACTA NEUROPATHOL, V101, P79; Kile BT, 2001, CELL MOL LIFE SCI, V58, P1627, DOI 10.1007/PL00000801; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Lejeune D, 2001, BIOCHEM J, V353, P109, DOI 10.1042/bj3530109; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; Lowenstein D, 2001, ANN NEUROL, V50, P696, DOI 10.1002/ana.10090; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; Magrangeas F, 2001, BIOCHEM J, V353, P223, DOI 10.1042/0264-6021:3530223; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mazzucchelli C, 1999, MOL CELL ENDOCRINOL, V155, P101, DOI 10.1016/S0303-7207(99)00103-3; MCINTOSH TK, 1992, J CEREBR BLOOD F MET, V12, P697, DOI 10.1038/jcbfm.1992.95; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; NGUYEN H, 1997, CYTOINE GROWTH FACTO, V8, P2934; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rao VLR, 2001, BRAIN RES, V911, P96; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; RAO VLR, 2002, IN PRESS J NEUROCHEM; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; SANDERS JE, 1996, IEEE T REHABIL ENG, V4, P285; Sassone-Corsi P, 2000, MOL REPROD DEV, V56, P228, DOI 10.1002/(SICI)1098-2795(200006)56:2+<228::AID-MRD2>3.0.CO;2-B; Sendtner M, 2001, CURR OPIN NEUROL, V14, P629, DOI 10.1097/00019052-200110000-00012; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; Song GQ, 2002, J NEUROSCI RES, V68, P730, DOI 10.1002/jnr.10268; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tsui CC, 1996, J NEUROSCI, V16, P2463; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; Wang JH, 2000, CHINESE CHEM LETT, V11, P1; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Zhang WD, 1999, J NEUROSCI, V19, P96; Zou LL, 1998, J NEUROCHEM, V71, P887	77	107	108	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN 15	2003	71	2					208	219		10.1002/jnr.10486			12	Neurosciences	Neurosciences & Neurology	631YU	WOS:000180196500005	12503083				2021-06-18	
J	Sullivan, PG; Keller, JN; Bussen, WL; Scheff, SW				Sullivan, PG; Keller, JN; Bussen, WL; Scheff, SW			Cytochrome c release and caspase activation after traumatic brain injury	BRAIN RESEARCH			English	Article						apoptosis; brain injury; cortical impact; mitochondria; neurotrauma; oncosis	CORTICAL IMPACT INJURY; SPINAL-CORD INJURY; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; PROGRAMMED CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; CYCLOSPORINE-A; NEURONAL APOPTOSIS; DNA FRAGMENTATION; NERVOUS-SYSTEM	Experimental traumatic brain injury (TBI) results in a rapid and significant necrosis of cortical tissue at the site of injury. In the ensuing hours and days, secondary injury exacerbates the primary damage resulting in significant neurological dysfunction. The identification of cell death pathways that mediate this secondary traumatic injury have not been elucidated, however recent studies have implicated a role for apoptosis in the neuropathology of traumatic brain injury. The present study utilized a controlled cortical impact model of brain injury to assess the involvement of apoptotic pathways: release of cytochrome c from mitochondria and the activation of caspase-1- and caspase-3-like proteases in the injured cortex at 6, 12 and 24 h post-injury. Collectively, these results demonstrate cytochrome c release from mitochondria and its redistribution into the cytosol occurs in a time-dependent manner following TBI. The release of cytochrome c is accompanied by a time-dependent increase in caspase-3-like protease activity with no apparent increase in caspase-l-like activity. However, pretreatment with a general caspase inhibitor had no significant effect on the amount of cortical damage observed at 7 days post-injury. Our data suggest that several pro-apoptotic events occur following TBI, however the translocation of cytochrome c itself and/or other events upstream of caspase activation/inhibition may be sufficient to induce neuronal cell death. (C) 2002 Published by Elsevier Science B.V.	Univ Kentucky, Sanders Brown Ctr Aging 229, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging 229, Lexington, KY 40536 USA.	sscheff@pop.uky.edu	Keller, Jeffrey N/N-1975-2017	keller, jeffrey/0000-0002-9892-7423	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Brent K.J., 1998, FUNGICIDE RESISTANCE, V2, P1; Buki A, 2000, J NEUROSCI, V20, P2825; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Choi D W, 1990, Adv Exp Med Biol, V268, P501; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan L, 1999, J NEUROTRAUM, V16, P357, DOI 10.1089/neu.1999.16.357; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 1999, J NEUROSCI, V19, P3414; HALL ED, 1993, RES P ARNMD, V71, P81; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keller JN, 1998, J NEUROSCI, V18, P687; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McNair ND, 1999, NURS CLIN N AM, V34, P637; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Richter C, 1997, BIOSCIENCE REP, V17, P53, DOI 10.1023/A:1027387301845; RINK A, 1995, AM J PATHOL, V147, P1575; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tibbs RE, 1998, ANAT REC, V253, P167; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Ye X, 2001, BIOCHEM BIOPH RES CO, V286, P401, DOI 10.1006/bbrc.2001.5396; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572	76	107	108	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 13	2002	949	1-2					88	96	PII S0006-8993(02)02968-2	10.1016/S0006-8993(02)02968-2			9	Neurosciences	Neurosciences & Neurology	599CQ	WOS:000178316900010	12213303				2021-06-18	
J	Thatcher, RW; North, DM; Curtin, RT; Walker, RA; Biver, CJ; Gomez, JF; Salazar, AM				Thatcher, RW; North, DM; Curtin, RT; Walker, RA; Biver, CJ; Gomez, JF; Salazar, AM			An EEG severity index of traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							HEAD-INJURY; COMA; SCALE	EEG spectral analyses were conducted from 19 scalp locations for patients with mild (n = 40), moderate (n = 25), and severe (n = 43) traumatic brain injury (TBI), 15 days to 4 years after injury. Severity of TBI was judged by emergency hospital admission records (Glasgow Coma Score and duration of coma and amnesia). Highest-loading EEG variables on each factor that differed significantly between severe and mild TBI by univariate t-test were entered into a multivariate discriminant analysis, yielding 16 variables. Discriminant analysis between mild and severe TBI groups showed classification accuracy of 96.39%, sensitivity 95.45%, and specificity 97.44%. The EEG discriminant score also measured intermediate severity in moderate TBI patients. Results were cross-validated in 503 VA patients. Significant correlations between EEG discriminant scores, emergency admission measures, and post-trauma neuropsychological test scores validated the discriminant function as an index of severity of injury and a classifier of the extremes of severity.	Vet Affairs Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33744 USA; Def & Vet Head Injury Program, Washington, DC USA	Thatcher, RW (corresponding author), Vet Affairs Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33744 USA.						BARTH J, 1983, NEUROSURGERY, V13, P520; CAVENESS W, 1977, TRAUMA, V18, P61; COHEN WC, 1971, MULTIVARIATE DATA AN; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Hoffman D. A., 1995, J NEUROTHERAPY, V1, P14, DOI [10.1300/ J184v01n01_03, DOI 10.1300/J184V01N01_03]; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; JENNETT B, 1986, DIS NERV SYST, P1282; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; JOHN ER, 1977, SCIENCE, V196, P1393, DOI 10.1126/science.867036; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Norusis M. J., 1994, SPSS ADV STAT 6 1; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; Ommaya AK, 1968, J BIOMECH; Otnes R. K., 1972, DIGITAL TIME SERIES; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; RUSSELL WR, 1946, BRAIN, V69, P183; TEASDALE G, 1974, LANCET, V2, P81; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; THATCHER RW, 1986, ELECTROEN CLIN NEURO, V64, P123, DOI 10.1016/0013-4694(86)90107-0; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; VELLEMAN PF, 1997, DATADESK VERSION 6 0; WILDER CS, 1976, HLTH INTERVIEW SURVE	29	107	109	2	12	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2001	13	1					77	87		10.1176/appi.neuropsych.13.1.77			11	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	401TR	WOS:000166944800010	11207333				2021-06-18	
J	Konrad, KN; Gauggel, S; Manz, A; Scholl, M				Konrad, KN; Gauggel, S; Manz, A; Scholl, M			Inhibitory control in children with traumatic brain injury (TBI) and children with attention deficit/hyperactivity disorder (ADHD)	BRAIN INJURY			English	Article							DEFICIT-HYPERACTIVITY DISORDER; CLOSED-HEAD INJURY; CHOICE REACTION-TIME; SUSTAINED ATTENTION; EXECUTIVE FUNCTIONS; ADOLESCENTS; PERFORMANCE; BEHAVIOR; TASK; METHYLPHENIDATE	The behavioural and cognitive sequelae of traumatic brain injury (TBI) have features in common with attention deficit/hyperactivity disorder (ADHD), best characterized by deficits in response inhibition. The performance was, therefore, examined of 27 children with TBI, 31 children with developmental ADHD, and 26 matched controls aged 8-12, on two inhibition tasks: the Stop-Signal Task and a Delayed-Response-Task. Children with TBI and children with ADHD showed a pervasive deficit in their inhibitory control processes with respect to inhibition of both pre-potent and on-going responses. In addition, children with TBI were found to suffer from a general slowing of their information processing, which was not correlated with the inhibition deficit. TBI children with and without a secondary ADHD differed only tendentially in their Mean Go-Reaction time in the stop-task. However, subdividing TBI children according to actigraph data into hypo-, hyper- and normokinetic subgroups revealed that the hyperactive TBI children had inhibitory deficit patterns that were similar to children with developmental ADHD. It is concluded that slowing of information processing speed seems to be a general consequence of TBI in childhood, whereas slowing of the stop-processes or inhibitory deficits, specifically, are associated with post-injury hypo- or hyperactivity.	Rhein Westfal TH Aachen, Clin Child & Adolescent Psychiat, D-52072 Aachen, Germany	Konrad, KN (corresponding author), Rhein Westfal TH Aachen, Clin Child & Adolescent Psychiat, Neuenhofer Weg 21, D-52072 Aachen, Germany.	Kerstin.Konrad@t-online.de	Konrad, Kerstin/H-7747-2013	Konrad, Kerstin/0000-0001-9039-2615; Gauggel, Siegfried/0000-0002-2742-4917			Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Barkley R. A., 1997, ADHD NATURE SELF CON; BARKLEY RA, 1993, PEDIATRICS, V92, P212; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BENTON A, 1991, DEV NEUROPSYCHOL, V7, P275, DOI 10.1080/87565649109540495; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; BLACK P, 1970, HEAD INJURIES, P131; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; CORKUM PV, 1993, J CHILD PSYCHOL PSYC, V34, P1217, DOI 10.1111/j.1469-7610.1993.tb01784.x; DAUGHERTY TK, 1993, J GENET PSYCHOL, V154, P177, DOI 10.1080/00221325.1993.9914731; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Dopfner M., 1998, DIAGNOSTIK SYSTEM PS; DUPAUL GJ, 1992, J CLIN CHILD PSYCHOL, V21, P394, DOI 10.1207/s15374424jccp2104_10; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; HALPERIN JM, 1994, DEV NEUROPSYCHOLOGIC, P1; Harlow JM, 1848, BOSTON MED SURG J, V39, P389, DOI DOI 10.1056/NEJM184812130392001; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; IABONI F, 1995, J ABNORM PSYCHOL, V104, P232, DOI 10.1037/0021-843X.104.1.232; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Logan Gordon D., 1994, P189; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; MCCLURE FD, 1984, J ABNORM CHILD PSYCH, V12, P561, DOI 10.1007/BF00916850; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; Milich R., 1994, DISRUPTIVE BEHAV DIS, P109, DOI 10.1007/978-1-4899-1501-6_5; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Oosterlaan J, 1998, J CHILD PSYCHOL PSYC, V39, P411, DOI 10.1111/1469-7610.00336; OSMAN A, 1986, J EXP PSYCHOL HUMAN, V12, P243, DOI 10.1037/0096-1523.12.3.243; PARKER RS, 1994, SEMIN NEUROL, V14, P67, DOI 10.1055/s-2008-1041061; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; SCHACHAR R, 1989, PARENT INTERVIEW CHI; SHUE KL, 1992, BRAIN COGNITION, V20, P104, DOI 10.1016/0278-2626(92)90064-S; SOLANTO MV, 1990, J CHILD PSYCHOL PSYC, V31, P803, DOI 10.1111/j.1469-7610.1990.tb00819.x; SONUGABARKE EJS, 1992, J CHILD PSYCHOL PSYC, V33, P387, DOI 10.1111/j.1469-7610.1992.tb00874.x; Tabachnick BG, 2013, USING MULTIVARIATE S; TANNOCK R, 1989, J ABNORM CHILD PSYCH, V17, P473, DOI 10.1007/BF00916508; TANNOCK R, 1995, J ABNORM CHILD PSYCH, V23, P235, DOI 10.1007/BF01447091; Tannock R, 1998, J CHILD PSYCHOL PSYC, V39, P65, DOI 10.1111/1469-7610.00304; UNNEWEHR S, 1995, DIAGNOSTISCHES INTER; WEYANDT LL, 1994, DEV NEUROPSYCHOL, V10, P27, DOI 10.1080/87565649409540564; YLVISAKER M, 1992, ED DIMENSIONS ACQUIR, P121	51	107	109	0	21	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2000	14	10					859	875					17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	364QG	WOS:000089902900002	11076133				2021-06-18	
J	Stone, JR; Singleton, RH; Povlishock, JT				Stone, JR; Singleton, RH; Povlishock, JT			Antibodies to the C-terminus of the beta-amyloid precursor protein (APP): a site specific marker for the detection of traumatic axonal injury	BRAIN RESEARCH			English	Article						traumatic axonal injury; traumatic brain injury; amyloid precursor protein C-terminus; axoplasmic transport; ultrastructure; rat	CLOSED-HEAD INJURY; MICROWAVE ANTIGEN RETRIEVAL; EXCITATORY AMINO-ACIDS; HEPARIN-BINDING DOMAIN; DIFFUSE BRAIN INJURY; ALZHEIMERS-DISEASE; TISSUE-SECTIONS; CYCLOSPORINE-A; RAT-BRAIN; POSTTRAUMATIC HYPOTHERMIA	Antibodies to the amyloid precursor protein (APP) are commonly used to detect traumatic axonal injury (TBI). Carried by fast anterograde axoplasmic transport, APP will pool at regions of impaired transport associated with TAI. Based primarily upon commercial antibody availability, previous studies have targeted the N-terminus of APP, which, with respect to antigen detection, is suboptimally located within anterogradely transported vesicles. Recently, antibodies to the APP C-terminus, located on the external surface of anterogradely transported vesicles, have become available, allowing for the exploration of their utility in detecting TAI. To this end, rats were subjected to an impact acceleration injury, surviving 30 min to 24 h post-injury. They were then perfused, their brains sectioned and prepared for dual label immunofluorescent microscopy, single label bright field microscopy, and electron microscopy (EM). antibodies to the APP C-terminus yielded the ready detection of intensely labeled TAI with significantly reduced diffuse background staining in comparison to antibodies to the APP N-terminus in both dual label immunofluorescent and single label bright-field approaches. EM examination of antibodies to the APP C-terminus in TAI revealed intense labeling of pooled intra-axonal vesicular profiles, confirming the anterogradely transported vesicular source of the APP seen in TAI. Interestingly, in addition to providing a technically superior approach and new detailed information on the subcellular localization of APP, antibodies to the APP C-terminus also proved more cost effective. Immunofluorescent studies of APP C-terminus immunoreactivity involved 1/3 the cost of targeting the N-terminus, while bright field APP C-terminus studies were performed for 1/20 the cost. (C) 2000 Elsevier Science B.V. All rights reserved.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA	Stone, JR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ahlgren S, 1996, ACTA NEUROPATHOL, V92, P49, DOI 10.1007/s004010050488; Aplin AE, 1996, J NEUROCHEM, V67, P699; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BARGER SW, 1995, BIOCHEM J, V311, P45, DOI 10.1042/bj3110045; BENDOTTI C, 1988, P NATL ACAD SCI USA, V85, P3628, DOI 10.1073/pnas.85.10.3628; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; IGARASHI H, 1994, APMIS, V102, P295, DOI 10.1111/j.1699-0463.1994.tb04879.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Maeda T, 1998, J NEUROTRAUM, V15, P655, DOI 10.1089/neu.1998.15.655; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MULTHAUP G, 1994, FEBS LETT, V355, P151, DOI 10.1016/0014-5793(94)01176-1; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMITH RS, 1980, J NEUROCYTOL, V9, P39, DOI 10.1007/BF01205226; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TSUKITA S, 1980, J CELL BIOL, V84, P513, DOI 10.1083/jcb.84.3.513; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; VONWASIELEWSKI R, 1994, HISTOCHEMISTRY, V102, P165, DOI 10.1007/BF00268892; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WOLOZIN B, 1992, J NEUROSCI RES, V33, P163, DOI 10.1002/jnr.490330121; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAZAKI T, 1993, VIRCHOWS ARCH B, V63, P173, DOI 10.1007/BF02899258	86	107	109	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 21	2000	871	2					288	302		10.1016/S0006-8993(00)02485-9			15	Neurosciences	Neurosciences & Neurology	337TG	WOS:000088377300013	10899295				2021-06-18	
J	Albrecht, RF; Wass, CT; Lanier, WL				Albrecht, RF; Wass, CT; Lanier, WL			Occurrence of potentially detrimental temperature alterations in hospitalized patients at risk for brain injury	MAYO CLINIC PROCEEDINGS			English	Article							COMPLETE CEREBRAL-ISCHEMIA; ACUTE STROKE; HYPOTHERMIA; THERMOREGULATION; MANAGEMENT; NIMODIPINE; PROGNOSIS; DAMAGE; HUMANS; ARREST	Objective: To ascertain the incidence and timing of fever in patients at risk for temperature modulation of brain injury resulting from ischemia or trauma. Design: We retrospectively reviewed the medical records of patients admitted between January 1991 and December 1994, Material and Methods: We investigated three groups of hospitalized patients considered at risk fdr ongoing brain injury resulting from a prior cerebral insult: successful resuscitation from out-of-hospital cardiac arrest (CA), subarachnoid hemorrhage (SAH), or traumatic closed-head injury (CHI), Forty patients per condition were randomly selected from those who survived for more than 24 hours after hospital admission. Results: During the initial 72 hours of hospitalization, temperature increases to 38 degrees C or more (that is, temperatures previously reported to worsen neurologic outcome after brain injury) were noted in 83% of patients with CA, 70% of those with SAH, and 68% of those with CHI. Within the cohort of febrile patients, 18 to 44% of all temperature measurements were 38 degrees C or higher, and the febrile episodes occurred randomly throughout the study interval. Fewer than one-eighth of the febrile patients received drugs possessing antipyretic properties (such as aspirin or acetaminophen) in a dose appropriate to treat fever, No other method of temperature control (for example, physical means) was used in any patient. The fractions of patients who mere dismissed; from the hospital with permanent neurologic injury were as follows: CA, 20%; SAH, 45%; and CHI, 43%. Conclusion: In these hospitalized patients at risk for ongoing brain injury, the incidence of temperature increases within the range reported to worsen neurologic outcome (elevations of 1.0 degrees C or more) was very high. The characterization of these potentially injurious, randomly occurring, and traditionally undertreated temperature increases may have implications for thf design of future protocols aimed at providing cerebral protection.	Mayo Clin & Mayo Fdn, Dept Anesthesiol, Rochester, MN 55905 USA	Lanier, WL (corresponding author), Mayo Clin & Mayo Fdn, Dept Anesthesiol, 200 1St St SW, Rochester, MN 55905 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 08288] Funding Source: Medline		AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BAENA RC, 1997, J CEREB BLOOD FLO S1, V17, pS34; BECKSTEAD JE, 1978, STROKE, V9, P569, DOI 10.1161/01.STR.9.6.569; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Crowder CM, 1996, J NEUROSURG, V85, P98, DOI 10.3171/jns.1996.85.1.0098; DIEM K, 1971, SCI TALBES, P85; DRUMMOND JC, 1994, ANESTHESIA, V1, P689; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; KAKUDA W, 1997, J CEREB BLOOD FLO S1, V17, pS43; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; LANIER WL, 1992, RESUSCITATION, V23, P121, DOI 10.1016/0300-9572(92)90197-K; LANLER WL, 1995, J NEUROSURG ANESTHES, V7, P216; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C; MILDE LN, 1994, ANESTHESIA NEUROSURG, P59; MILDE LN, 1990, CLIN NEUROANESTHESIA, P171; MILLS SA, 1993, ANN THORAC SURG, V56, pS86, DOI 10.1016/0003-4975(93)91142-A; Nurse S, 1996, J CEREBR BLOOD F MET, V16, P474, DOI 10.1097/00004647-199605000-00014; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; ROOT RK, 1991, HARRISONS PRINCIPLES, P125; ROUSSEAUX P, 1993, NEUROCHIRURGIE, V39, P157; ROWLAND JP, 1995, MERRITTS TXB NEUROLO, P417; SESSLER DI, 1993, FASEB J, V7, P638; SEWESTER CS, 1996, DRUG FACTS COMP, pA247; SMITHSON WA, 1983, CANCER TREAT REP, V67, P318; STEEN PA, 1985, ANESTHESIOLOGY, V62, P406, DOI 10.1097/00000542-198504000-00007; WARNER DS, 1993, ANESTHESIOLOGY, V79, P985, DOI 10.1097/00000542-199311000-00017; Wass CT, 1996, INT ANESTHESIOL CLIN, V34, P95, DOI 10.1097/00004311-199603440-00008; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; WASS CT, 1995, ANESTHESIOL CLIN N A, V13, P869	33	107	108	0	1	MAYO CLINIC PROCEEDINGS	ROCHESTER	660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA	0025-6196			MAYO CLIN PROC	Mayo Clin. Proc.	JUL	1998	73	7					629	635					7	Medicine, General & Internal	General & Internal Medicine	ZY221	WOS:000074598400003	9663190				2021-06-18	
J	Shannon, P; Smith, CR; Deck, J; Ang, LC; Ho, M; Becker, L				Shannon, P; Smith, CR; Deck, J; Ang, LC; Ho, M; Becker, L			Axonal injury and the neuropathology of shaken baby syndrome	ACTA NEUROPATHOLOGICA			English	Article						shaken baby syndrome; shaken infant; axonal injury; beta-amyloid precursor protein	AMYLOID PRECURSOR PROTEIN; PERMANENT BRAIN-DAMAGE; MENTAL-RETARDATION; INFANT SYNDROME; CHILD-ABUSE; SHAKING; TRAUMA	We examined an autopsy series of 14 children with shaken baby syndrome (SBS) who lacked skull fracture. Evidence of axonal injury was sought using immunohistochemical stains for neurofilament, 68-kDa neurofilament and beta-amyloid precursor protein (beta APP). beta APP-positive axons were present in the cerebral white matter of all cases of SBS but were also present in 6 of 7 children dying of non-traumatic hypoxic ischemic encephalopathy (HIE). Swollen axons were present in 11 of 14 cases of SBS and in 6 of 7 cases of HIE. beta APP-positive axons were present in both groups in the midbrain and medulla. The cervical spinal cord in SBS contained beta APP-positive axons in 7 of 11 cases; 5 of 7 contained swollen axons within the white matter tracts; in 2 immunoreactivity was localized to spinal nerve roots; in all 7 there was a predilection for staining at the glial head of the nerve root. Among cases of HIE, none showed abnormal axons or beta APP-positive reactivity in the cervical cord white matter. We con elude that cerebral axonal injury is common in SBS, and may be due in part to hypoxic/ischemic injury. Cervical cord injury is also common, and cannot be attributed to HIE. These findings corroborate suggestions that flexion extension injury about the cervical spinal column may be important in the pathogenesis of SBS.	Hosp Sick Children, Dept Pediat Lab Med, Div Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada; Off Chief Coroner, Div Forens Pathol, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Dept Lab Med, Div Pathol, Toronto, ON M4N 3M5, Canada	Becker, L (corresponding author), Hosp Sick Children, Dept Pediat Lab Med, Div Pathol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.						ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; JACOBI G, 1986, MONATSSCHR KINDERH, V134, P307; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; PIATT JH, 1995, PEDIATRICS, V96, P780; RUGE JR, 1988, J NEUROSURG, V68, P25, DOI 10.3171/jns.1988.68.1.0025; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185	20	107	107	0	9	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	JUN	1998	95	6					625	631		10.1007/s004010050849			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	ZR230	WOS:000073953300011	9650755				2021-06-18	
J	Gennarelli, TA; Thibault, LE; Graham, DI				Gennarelli, TA; Thibault, LE; Graham, DI			Diffuse axonal injury: An important form of traumatic brain damage	NEUROSCIENTIST			English	Article						axonal injury; brain trauma; head injury	AMYLOID PRECURSOR PROTEIN; NONMISSILE HEAD-INJURY; OPTIC-NERVE; BETA-APP; PATHOGENESIS; AXOPLASM; HUMANS; DEGENERATION; SHEARING; STRETCH	Diffuse axonal injury (DAI) is a frequent form of traumatic brain injury in which a clinical spectrum of increasing injury severity is paralleled by progressively increasing amounts of axonal damage in the brain. When less severe, DAI is associated with concussive syndromes; when most severe, it causes prolonged traumatic coma that is not related to mass lesions, increased intracranial pressure, or ischemia. Pathological investigations of DAI demonstrate widespread but heterogeneous microscopic damage to axons throughout the white matter of the cerebral and cerebellar hemispheres and brainstem, There is a propensity for injury to occur in the central third of the brain, and the corpus callosum and brain stem are especially prone to injury. In these locations, traumatic axonal damage can occur in several degrees of severity, ranging from transient disturbances of ionic homeostasis to swelling, impairment of axoplasmic transport with secondary (delayed) axotomy and primary axotomy (tearing). A more detailed understanding of the processes involved in axonal damage is crucial to the development of effective treatment for the clinical syndromes of DAI.	Allegheny Univ Hlth Sci, Dept Neurosurg, Philadelphia, PA 19102 USA; Allegheny Univ Hlth Sci, Ctr Neurosci, Philadelphia, PA 19102 USA; Univ Glasgow, Dept Neuropathol, Glasgow G12 8QQ, Lanark, Scotland		gennarelli@auhs.edu					AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P485; ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; CAJAL SR, 1928, DENERVATION REGENERA, P631; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; DUCHEN LW, 1992, GREENFIELDS NEUROPAT, P811; FERN R, 1995, NEUROSCIENTIST, V1, P253; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GALLANT PE, 1992, J NEUROPATH EXP NEUR, V51, P220, DOI 10.1097/00005072-199203000-00011; GANOT G, 1981, BIOCHIM BIOPHYS ACTA, V649, P487, DOI 10.1016/0005-2736(81)90440-5; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gennarelli TA, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P185; GENNARELLI TA, 1987, 31ST P STAPP CAR CRA, P49; Gennarelli TA, 1993, HEAD INJURY, P137; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATHOL EXP NE, V31, P299; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; GRAHAM DI, 1981, MILD MODERATE HEAD I, P63; GRCEVIC N, 1977, APALLIC SYNDROME, P109; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; HASHIN Z, 1969, INT J ENG SCI, V7, P11, DOI 10.1016/0020-7225(69)90020-2; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; Jellinger KA, 1977, APALLIC SYNDROME, P88; Kreutzberg GW, 1997, GREENFIELDS NEUROPAT, V1, P85; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LAPLACA MC, 1996, J NEUROTRAUM, V13, P608; LAPLACA MC, 1994, J NEUROTRAUM, V11, P116; LAPLACA MC, 1995, J NEUROTRAUM, V12, P128; LAPLACA MC, 1995, J NEUROTRAUM, V12, P969; MATA M, 1986, J NEUROBIOL, V17, P449, DOI 10.1002/neu.480170508; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; McLellan D, 1986, COMA TRAUMATIQUE, P165; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETERS G, 1977, APALLIC SYNDROME, P78; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; SAATMAN K, 1991, INT RES COUNC BIOM I, V13, P115; SAATMAN KE, 1994, J NEUROTRAUMA, V11, P125; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SCHLAEPFER WW, 1978, J CELL BIOL, V78, P369, DOI 10.1083/jcb.78.2.369; SCHLAEPFER WW, 1974, BRAIN RES, V69, P203, DOI 10.1016/0006-8993(74)90002-X; Seitelberger F., 1971, ACTA NEUROPATHOLOGY, V5, P17; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; STRICH SJ, 1968, J NEUROL NEUROSUR PS, V31, P110, DOI 10.1136/jnnp.31.2.110; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; TERAKAWA S, 1982, PFLUG ARCH EUR J PHY, V395, P59, DOI 10.1007/BF00584969; THIBAULT LE, 1992, INT RES COUNCIL BIOM, V14, P3; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	90	107	110	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	MAY	1998	4	3					202	215		10.1177/107385849800400316			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ZR036	WOS:000073929300015					2021-06-18	
J	Kreuter, M; Sullivan, M; Dahllof, AG; Siosteen, A				Kreuter, M; Sullivan, M; Dahllof, AG; Siosteen, A			Partner relationships, functioning, mood and global quality of life in persons with spinal cord injury and traumatic brain injury	SPINAL CORD			English	Article						spinal cord injuries; traumatic brain injuries; sexuality; partner relationship; divorce; functioning	GLASGOW OUTCOME SCALE; CLOSED HEAD-INJURY; SOCIAL SUPPORT; FOLLOW-UP; OF-LIFE; ADJUSTMENT; COMMUNITY; SATISFACTION; RELIABILITY; IMPAIRMENT	The aim of this study was to assess and compare spinal cord injured (SCI) and traumatic brain injured (TBI) persons and people from the general population concerning partner relationships, functioning, mood and global quality of life. One hundred and sixty seven SCI persons, 92 TBI persons and 264 controls participated in the study. The median age was: SCI persons 33 years (range 19 to 79 years), TBI persons 40 years (range 20 to 70 years), and controls 31 years (range 19 to 79 years). Age at injury ranged among SCI persons from 14 to 76 years (Md 28 years), and among TBI persons from 16 to 56 years (Md 32 years). Half of the SCI group (51%), 58% of the TBI group and 59% of the controls had a stable partner relationship at the time of the investigation. Many of these SCI and TBI relationships (38% and 55% respectively) were established after injury, Both SCI and TBI persons showed significantly more depressive feelings compared with the controls. Perceived quality of life (global QL rating) was significantly lower in the SCI group compared with the controls, whereas the ratings of TBI persons and controls did not differ significantly, SCI and TBI persons did not differ significantly in level of education, perceived duality of life or distress. In all three groups, global quality-of-life ratings were significantly lower among single persons compared to those with a partner relationship. It was concluded that both SCI and TBI appear to affect overall quality of life and mental well-being negatively. The number of partner relationships contracted after-injury among both SCI and TBI persons indicates, however, that the injury is not a major barrier to establishing close partner relationships. Being in good spirits, that is, lack of depressive feelings has a profound impact on the perception of a high quality of life in all three groups. For the SCI and TBI persons, a high level of physical and social independence were further positive determinants of a perceived high quality of life.	Sahlgrens Univ Hosp, Spinal Injuries Unit, Dept 12, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Hlth Care Res Unit, S-41345 Gothenburg, Sweden	Kreuter, M (corresponding author), Sahlgrens Univ Hosp, Spinal Injuries Unit, Dept 12, S-41345 Gothenburg, Sweden.						Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERKMAN AH, 1978, ARCH PHYS MED REHAB, V59, P29; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P68; CALMAN KC, 1984, J MED ETHICS, V10, P124, DOI 10.1136/jme.10.3.124; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; CARPENTER C, 1994, PHYS THER, V74, P614, DOI 10.1093/ptj/74.7.614; COMARR AE, 1978, AM J PHYS MED REHAB, V57, P215; Crewe N M, 1992, J Am Paraplegia Soc, V15, P14; CREWE NM, 1988, ARCH PHYS MED REHAB, V69, P435; CUSHMAN LA, 1992, PARAPLEGIA, V30, P690, DOI 10.1038/sc.1992.135; DEVIVO MJ, 1985, ARCH PHYS MED REHAB, V66, P501; DEVIVO MJ, 1995, ARCH PHYS MED REHAB, V76, P130, DOI 10.1016/S0003-9993(95)80022-0; EISENBERG MG, 1991, PARAPLEGIA, V29, P514, DOI 10.1038/sc.1991.74; ELGHATIT AZ, 1975, J CHRON DIS, V28, P383, DOI 10.1016/0021-9681(75)90034-X; ELLIOTT TR, 1992, REHABIL PSYCHOL, V37, P37, DOI 10.1037/h0079091; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; JACOBS HE, 1987, J HEAD TRAUMA REHAB, V2, P37; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JUDD FK, 1991, PARAPLEGIA, V29, P173, DOI 10.1038/sc.1991.25; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Krause JS, 1996, REHABIL COUNS BULL, V39, P244; Kreuter M, 1996, ARCH PHYS MED REHAB, V77, P541, DOI 10.1016/S0003-9993(96)90292-0; KREUTER M, IN PRESS BRAIN INJUR; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LUNDQVIST C, 1991, SPINE, V16, P78, DOI 10.1097/00007632-199101000-00014; Lundqvist C, 1997, SPINAL CORD, V35, P17, DOI 10.1038/sj.sc.3100347; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCCOLL MA, 1994, PARAPLEGIA, V32, P261, DOI 10.1038/sc.1994.46; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Panting A., 1972, REHABILITATION, V38, P33; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RINTALA DH, 1992, REHABIL PSYCHOL, V37, P155, DOI 10.1037/0090-5550.37.3.155; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Shumaker SO, 1995, INT ASSESSMENT HLTH; SILLER J, 1976, REHABILITATIVE MED P; SIOSTEEN A, 1990, PARAPLEGIA, V28, P285; SIOSTEEN A, 1990, PARAPLEGIA, V28, P476, DOI 10.1038/sc.1990.64; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trieschmann R.B., 1988, SPINAL CORD INJURIES, V2nd edition; Walker A E, 1972, Scand J Rehabil Med, V4, P5; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	50	107	107	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	1362-4393			SPINAL CORD	Spinal Cord	APR	1998	36	4					252	261		10.1038/sj.sc.3100592			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZG571	WOS:000073017000006	9589525	Bronze			2021-06-18	
J	Kant, R; SmithSeemiller, L; Isaac, G; Duffy, J				Kant, R; SmithSeemiller, L; Isaac, G; Duffy, J			Tc-HMPAO SPECT in persistent postconcussion syndrome after mild head injury: Comparison with MRI/CT	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; HM-PAO-SPECT; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; CEREBRAL PERFUSION; CT; HISTORY; SCALE	The purposes of this study were: (1) to determine the prevalence of abnormal (99)mTc-HMPAO SPECT scans in patients suffering persistent post-concussive syndrome (PPCS) after mild closed head injury (CHI); (2) to compare SPECT with structural neuroimaging (MRI and CT) in patients with mild CHI; and (3) to investigate correlations between SPECT and clinical data obtained from the patient sample (neuropsychological testing, demographics, psychiatric diagnoses). Forty-three patients were included. SPECT was read as abnormal in 53% of patients and showed a total of 37 lesions while MRI was read as abnormal in 9% and CT scan in only 4.6% of patients after mild CHI. SPECT appears to be more sensitive in detecting cerebral abnormalities after mild CHI, especially in patients with PPCS symptoms, than either CT or MRI. No statistically significant relationship was found between SPECT scan abnormalities and age, past psychiatric history, history of substance abuse, or history of multiple CHI. Education level did differ between patients with normal and abnormal SPECT. Current neuropsychiatric symptoms did not seem to have any impact on the results oi SPECT scan.	ALLEGHENY GEN HOSP,PITTSBURGH,PA 15212; UNIV CONNECTICUT,FARMINGTON,CT	Kant, R (corresponding author), ST FRANCIS MED CTR,HEAD INJURY CLIN,4608 PENN AVE,PITTSBURGH,PA 15224, USA.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; GRAY BG, 1992, J NUCL MED, V33, P52; Heaton R., 1993, WISCONSIN CARD SORTI; JACOBS A, 1994, J NUCL MED, V35, P942; Kraus Jess F., 1994, P3; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1991, INTENS CARE MED, V17, P149, DOI 10.1007/BF01704718; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; Reitan RM., 1985, HALSTEAD REITAN NEUR; ROPER SN, 1991, J NUCL MED, V32, P1684; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; STERN Y, 1991, Society for Neuroscience Abstracts, V17, P1258; TEASDALE G, 1974, LANCET, V2, P81; TIKOFSKY RS, 1994, J NUCL MED, V35, P947; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wechsler D., 1987, WECHSLER MEMORY SCAL; Zimmerman RA, 1989, NEUROPSYCHOLOGY, V3, P191, DOI 10.1037/h0091791; 1996, NEUROLOGY, V46, P278	26	107	107	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1997	11	2					115	124		10.1080/026990597123700			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WD430	WOS:A1997WD43000003	9012944				2021-06-18	
J	WHYTE, J; POLANSKY, M; FLEMING, M; COSLETT, HB; CAVALLUCCI, C				WHYTE, J; POLANSKY, M; FLEMING, M; COSLETT, HB; CAVALLUCCI, C			SUSTAINED AROUSAL AND ATTENTION AFTER TRAUMATIC BRAIN INJURY	NEUROPSYCHOLOGIA			English	Article						BRAIN INJURY; ATTENTION; VIGILANCE; REACTION TIME; AROUSAL	CLOSED-HEAD-INJURY; VARIABILITY; SCALE; COMA	Clinicians report that patients with traumatic brain injury (TBI) often have difficulty with tasks requiring sustained attention, and there are neuroanatomical and neurophysiological reasons to expect such deficits. Nevertheless, laboratory measures of sustained attention or vigilance in TBI have produced conflicting results. These inconsistencies may be due to patient heterogeneity as well as the fact that vigilance performance is dependent on highly specific features of the task design. We developed a visual vigilance task in which the influence of non-attentional factors was minimized and task difficulty for patients and controls made comparable. Performance was characterized with respect to vigilance level as well as vigilance decrement, using measures of perceptual discrimination, response bias, reaction time and reaction time variability. Twenty-six patients with recent TBI and 18 control subjects were tested on this task. A MANOVA of ranked scores revealed significantly different patient and control performance overall. Initial level of performance (vigilance level) was slower and more variable for patients than controls, and patients showed more conservative response biases. Deterioration over time (vigilence decrement) was also steeper for patients than controls for reaction time, reaction time variability, and response bias. Deterioration in accuracy (D') did not differ significantly between patients and controls. Performance was not related to available measures of injury severity. Hypotheses relating arousal mechanisms to vigilance performance are discussed.	TEMPLE UNIV, SCH MED, DEPT PHYS MED & REHABIL, PHILADELPHIA, PA 19122 USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA; TEMPLE UNIV, SCH MED, DEPT NEUROL, PHILADELPHIA, PA 19122 USA	WHYTE, J (corresponding author), MOSS REHABIL RES INST, 1200 W TABOR RD, PHILADELPHIA, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS027715] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS27715] Funding Source: Medline		AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BRUHN P, 1977, CORTEX, V13, P373, DOI 10.1016/S0010-9452(77)80018-X; BUCHTEL HA, 1987, NEUROBEHAVIORAL RECO; COSLETT HB, 1987, NEUROLOGY, V37, P957, DOI 10.1212/WNL.37.6.957; DENCKER SJ, 1958, ACTA PSYCHIAT NEUROL, V33, P122; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JUTAI JW, 1984, INT J PSYCHOPHYSIOL, V1, P219, DOI 10.1016/0167-8760(84)90042-4; Kleinbaum DG, 1988, APPLIED REGRESSION A; LEVIN HS, 1989, TRAUMATIC BRAIN INJU, V2, P53; LISPER H, 1972, J EXP PSYCHOL, V96, P287, DOI 10.1037/h0033615; Macmillan NA, 1991, DETECTION THEORY USE; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MELAMED S, 1985, SCAND J REHABIL MED, P16; PARASURAMAN R, 1984, VARIETIES ATTENTION, P243; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1986, ENERGETICS HUMAN INF; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROBBINS TW, 1986, ENERGETICS HUMAN INF; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; TEASDALE G, 1974, LANCET, V2, P81; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANWOERKOM TCAM, 1977, LANCET, V1, P812; VANZOMEREN AH, 1981, REACTION TIME ATTENT, P9; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; VECHT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792, DOI 10.1001/archneur.1975.00490540036004; Warm J. S., 1993, WORKLOAD TRANSITION, P139; WHYTE J, 1993, REHABILITATION MED P; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8	32	107	108	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JUL	1995	33	7					797	813		10.1016/0028-3932(95)00029-3			17	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	RJ268	WOS:A1995RJ26800001	7477808				2021-06-18	
J	YAKOVLEV, AG; FADEN, AI				YAKOVLEV, AG; FADEN, AI			SEQUENTIAL EXPRESSION OF C-FOS PROTOONCOGENE, TNF-ALPHA, AND DYNORPHIN GENES IN SPINAL-CORD FOLLOWING EXPERIMENTAL TRAUMATIC INJURY	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						C-FOS; DYNORPHIN; MESSENGER-RNA; PCR; SPINAL CORD INJURY; TUMOR NECROSIS FACTOR	BRAIN INJURY; MESSENGER-RNA; AMINO-ACIDS; RAT-BRAIN; TISSUE; INFLAMMATION; METABOLISM; MECHANISM; PROTEIN; NEURONS	Reverse transcription-polymerase chain reaction (RT-PCR) was used to estimate dynamic changes in levels of c-fos protooncogene, tumor necrosis factor alpha (TNF-alpha), and preprodynorphin messenger ribonucleic acid (mRNA) isolated from individual segments (T1 to T12) of rat spinal cord following graded impact trauma (50 or 100 g/cm) to the T9 segment of pentobarbital-anesthetized rats. Trauma caused elevation of c-fos mRNA at the trauma site by 30 min after injury that was related to injury severity. At this time, increased levels of TNF-alpha (but not of preprodynorphin) mRNA were also found. By 24 h, c-fos and TNF-alpha mRNA had returned to normal levels at trauma site, but were now increased at more distal segments (T5 and T12). At 4 h after trauma, induction of preprodynorphin mRNA was detected at the trauma site; levels continued to be elevated at 24 h when they were also detected at T5 and T12. Increases for each mRNA were greater for severe as compared to moderate trauma. The injury dose- and time-dependent changes in c-fos, TNF-alpha, and preprodynorphin gene expression suggest that their respective proteins are synthesized in response to trauma, and may play a part in the secondary injury response. Later accumulation of message distant from the trauma site may reflect a progression of delayed damage along the spinal cord.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR306634] Funding Source: Medline		BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; BAKSHI R, 1990, J NEUROSCI, V10, P3793; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; BLUMENFELD KS, 1992, J CEREBR BLOOD F MET, V12, P987, DOI 10.1038/jcbfm.1992.136; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1993, CRITICAL REV NEUROBI, P175; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1994, NEUROBIOLOGY CNS TRA, P155; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; HSU CY, 1994, NEUROBIOLOGY CENTRAL, P145; HYLDEN JLK, 1992, J NEUROSCI, V12, P1716; Lemke M, 1990, J NEUROTRAUM, V7, P41, DOI 10.1089/neu.1990.7.41; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Panter S. S., 1992, PRINCIPLES PRACTICE, P32; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PHILIPP E, 1990, INT J EAT DISORDER, V9, P323, DOI 10.1002/1098-108X(199005)9:3&lt;323::AID-EAT2260090310&gt;3.0.CO;2-K; PRZEWLOCKI R, 1983, NEUROPEPTIDES, V3, P233, DOI 10.1016/0143-4179(83)90019-7; RAWE SE, 1981, NEUROSURGERY, V9, P40, DOI 10.1227/00006123-198107000-00007; SANDLER AN, 1967, J NEUROSURG, V5, P638; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SHARMA HS, 1992, NEUROSCI RES, V14, P195; STEWART P, 1989, LIFE SCI, V44, P1505, DOI 10.1016/0024-3205(89)90330-5; VINK R, 1991, AM J PHYSIOL, V261, pR1527; VINK R, 1989, ANN NEUROL, V25, P26, DOI 10.1002/ana.410250105; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; ZIVIN JA, 1976, NEUROLOGY, V26, P99, DOI 10.1212/WNL.26.2.99	38	107	114	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07012	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	OCT-DEC	1994	23	2-3					179	190		10.1007/BF02815410			12	Neurosciences; Pathology	Neurosciences & Neurology; Pathology	PY906	WOS:A1994PY90600009	7702707				2021-06-18	
J	LEROUX, PD; HAGLUND, MM; NEWELL, DW; GRADY, MS; WINN, HR; TEASDALE, G				LEROUX, PD; HAGLUND, MM; NEWELL, DW; GRADY, MS; WINN, HR; TEASDALE, G			INTRAVENTRICULAR HEMORRHAGE IN BLUNT HEAD TRAUMA - AN ANALYSIS OF 43 CASES	NEUROSURGERY			English	Article						COMPUTED TOMOGRAPHY; HEAD INJURY; INTRAVENTRICULAR HEMORRHAGE; VENTRICLE	DIFFUSE AXONAL INJURY; CEREBRAL BLOOD-FLOW; COMPUTED-TOMOGRAPHY; BASAL GANGLIA; BRAIN; CONSCIOUSNESS; INSULTS; COMA	BEFORE THE ADVENT of computed tomography, intraventricular hemorrhage (IVH) from any source was thought rare and invariably fatal. Although intraventricular blood is readily identifiable with computed tomography,there has been little systematic study of its significance in blunt head trauma. Forty-three patients with traumatic IVH were prospectively identified in 1 year at Harborview Medical Center (University of Washington). Most were victims of motor vehicle accidents and suffered severe head injuries. IVH occurred alone in two patients; superficial contusions and subarachnoid hemorrhage were the most common associated finding. Blood was present in only one or both lateral ventricles in 25 patients; only the 3rd or 4th ventricles in 4 and all ventricles in 14 instances. There were 3 intracerebral hematomas and 14 basal ganglion hemorrhages. All of the former and half of the latter communicated with the adjacent lateral ventricle. Extra-axial hematomas appeared more common when only the lateral ventricles were involved, whereas corpus callosum or brain-stem hemorrhage appeared more likely when all the ventricles were involved. Acute hydrocephalus was rare, and ventricular drainage was needed in only four cases. Intracranial pressure (ICP) was elevated (> 15 mm Hg) in 46% of patients. The amount of IVH was related inversely with the Glasgow Coma Scale, but not with increased ICP. The presence of IVH indicated a poor outcome, with only half of the patients being independent at a 6-month follow-up. Poor outcome was associated with increasing age, low admission Glasgow Coma Scale, the presence of space occupying lesions if only the lateral ventricles were involved, and hemorrhage in all four ventricles. IVH after blunt head trauma is uncommon and reflects the severity of the head injury. The pattern of associated lesions suggests that the extent of IVH may be related to the direction of force applied to the head.	UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT NEUROL SURG, SEATTLE, WA 98104 USA	LEROUX, PD (corresponding author), UNIV WASHINGTON, DEPT NEUROSURG, 325 9TH AVE ZA-86, SEATTLE, WA 98104 USA.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1990, HDB CLIN NEUROLOGY H, V13; Chan K H, 1988, Br J Neurosurg, V2, P465, DOI 10.3109/02688698809029600; Christie M, 1988, Br J Neurosurg, V2, P343, DOI 10.3109/02688698809001005; CORDOBES F, 1983, J NEUROSURG, V58, P217, DOI 10.3171/jns.1983.58.2.0217; DEWEERD AW, 1979, J NEUROL, V222, P45; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FRENCH BN, 1977, SURG NEUROL, V7, P171; FUJITSU K, 1988, NEUROSURGERY, V23, P423, DOI 10.1227/00006123-198810000-00003; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795; GREVIC N, 1983, ACTA NEUROCHIR SUPP, V32, P79; GROSS A, 1989, Z RECHTSMED, V102, P409; Hayashi M, 1988, Br J Neurosurg, V2, P23, DOI 10.3109/02688698808999655; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; KIM CH, 1981, SURG NEUROL, V16, P415, DOI 10.1016/0090-3019(81)90233-0; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LITTLE JR, 1977, SURG NEUROL, V8, P143; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MARSHALL LF, 1985, NEUROSURGERY, P1605; MCCALLUM JE, 1978, NEUROSURGERY, V3, P22, DOI 10.1227/00006123-197807000-00004; MENT LR, 1986, J NEUROSURG, V65, P847, DOI 10.3171/jns.1986.65.6.0847; MILLER JD, 1985, ARCH NEUROL-CHICAGO, V42, P1191, DOI 10.1001/archneur.1985.04060110073018; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MOHR G, 1983, J NEUROSURG, V58, P482, DOI 10.3171/jns.1983.58.4.0482; MULLER H, 1987, SURG NEUROL, V27, P398, DOI 10.1016/0090-3019(87)90021-8; OLIFF M, 1978, J COMPUT ASSIST TOMO, V2, P625, DOI 10.1097/00004728-197811000-00020; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PIA HW, 1973, ACTA NEUROCHIR, V27, P149; PIEK J, 1986, ACTA NEUROCHIR, V83, P105, DOI 10.1007/BF01402386; STRICH SJ, 1961, LANCET, V2, P443; TEASDALE G, 1974, LANCET, V2, P81; UNTERHANRSCHEIDT F, 1963, MONOGRAPHIEN GESANTG; VILLASANTE JM, 1976, AM J ROENTGENOL, V126, P765; VOLPE JJ, 1989, ANN NEUROL, V25, P3, DOI 10.1002/ana.410250103; WILBERGER JE, 1990, NEUROSURGERY, V27, P208, DOI 10.1227/00006123-199008000-00006; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZUCCARELLO M, 1981, ACTA NEUROCHIR, V55, P283, DOI 10.1007/BF01808444	40	107	109	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	1992	31	4					678	685		10.1227/00006123-199210000-00010			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	JR981	WOS:A1992JR98100010	1407453				2021-06-18	
J	PANDA, S; JONAS, JB				PANDA, S; JONAS, JB			DECREASED PHOTORECEPTOR COUNT IN HUMAN EYES WITH SECONDARY ANGLE-CLOSURE GLAUCOMA	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article						GLAUCOMA; GLAUCOMATOUS OPTIC NERVE DAMAGE; RETINAL PHOTORECEPTORS; RETINAL PIGMENT EPITHELIUM; CYANDYSCHROMATOPSIA	NERVE-FIBER LAYER; INCLUDING FLOW DETERMINATIONS; BLOOD-FLOW; INTRAOCULAR PRESSURES; ATROPHY; TISSUES; DAMAGE; UVEAL; BRAIN	Glaucoma has been known to be associated with a loss of retinal ganglion cells and their axons throughout the fundus and a decreased count of photoreceptors and retinal pigment epithelial (RPE) cells in the parapapillary region. This study investigated whether glaucomatous changes of the deep retinal layer occur outside the parapapillary region. The nuclei of the retinal photoreceptors and RPE cells were counted in histologic slides of 23 eyes with painful secondary angle-closure glaucoma resulting from perforating corneal injuries. Fourteen eyes with malignant choroidal melanoma not involving the ciliary body or trabecular meshwork served as the control group. No surgical procedure, including laser treatment, had been performed posterior to the ora serrata. There were no hints of retinal vessel occlusion and localized traumatic retinopathy, historically, ophthalmoscopically, or histologically. Pbotoreceptor count was significantly lower (P < 0.05) in the glaucoma eyes than in the control group. Count of RPE cells did not differ between the two groups. This may indicate that glaucoma can be associated with a loss of photoreceptors. This could be important for psychophysical testing and may point to a more widespread involvement of ocular tissues in glaucoma than believed.	UNIV ERLANGEN NURNBERG,HOSP EYE,SCHWABACHANLAGE 6,W-8520 ERLANGEN,GERMANY; UNIV ERLANGEN NURNBERG,DEPT OPHTHALMOL,W-8520 ERLANGEN,GERMANY							AIRAKSINEN PJ, 1985, AM J OPHTHALMOL, V99, P1; ALM A, 1970, ACTA PHYSIOL SCAND, V80, P19, DOI 10.1111/j.1748-1716.1970.tb04765.x; ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1; ALM A, 1972, ACTA PHYSIOL SCAND, V84, P306, DOI 10.1111/j.1748-1716.1972.tb05182.x; Anderson DR., 1983, DOC OPHTHALMOL P SER, V35, P1; BETZ P, 1982, GRAEF ARCH CLIN EXP, V218, P70, DOI 10.1007/BF02153714; BRETON ME, 1989, GLAUCOMAS, P179; DECARVALHO CA, 1962, ARCH OPHTHALMOL-CHIC, V67, P483; DRANCE SM, 1981, ARCH OPHTHALMOL-CHIC, V99, P829, DOI 10.1001/archopht.1981.03930010829007; Drance SM, 1989, GLAUCOMAS, P393; FLOCKS M, 1959, AM J OPHTHALMOL, V48, P11, DOI 10.1016/0002-9394(59)90236-3; GREEN WR, 1985, OPHTHALMIC PATHOLOGY, V1, P792; HAMASAKI DI, 1965, ARCH OPHTHALMOL-CHIC, V73, P843; HOYT WF, 1973, INVEST OPHTH VISUAL, V12, P814; JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P908; JONAS JB, 1991, AM J OPHTHALMOL, V111, P559, DOI 10.1016/S0002-9394(14)73698-0; JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P134, DOI 10.1007/BF00164651; KALVIN NH, 1966, ARCH OPHTHALMOL-CHIC, V76, P82, DOI 10.1001/archopht.1966.03850010084017; LAMPERT PW, 1968, INVEST OPHTH VISUAL, V7, P199; MAUMENEE AE, 1960, TRANS AMER ACAD OPHT, V64, P33; NAUMANN GOH, 1980, PATHOLOGIE AUGES, P783; Primrose J, 1971, T OPHTHAL SOC UK, V89, P585; QUIGLEY HA, 1980, ARCH OPHTHALMOL-CHIC, V98, P1564; QUIGLEY HA, 1982, ARCH OPHTHALMOL-CHIC, V100, P135, DOI 10.1001/archopht.1982.01030030137016; Ritch R., 1989, GLAUCOMAS; SAMPLE PA, 1988, AM J OPHTHALMOL, V106, P686, DOI 10.1016/0002-9394(88)90701-5; SHIELDS MB, 1987, TXB GLAUCOMA; SOMMER A, 1977, ARCH OPHTHALMOL-CHIC, V95, P2149; SPENCER WH, 1985, OPHTHALMIC PATHOLOGY, V1, P537; UENO M, 1989, GRAEF ARCH CLIN EXP, V227, P380, DOI 10.1007/BF02169417; WILENSKY JT, 1976, AM J OPHTHALMOL, V81, P341, DOI 10.1016/0002-9394(76)90251-8; ZIMMERMAN LORENZ E., 1967, INVEST OPHTHALMOL, V6, P109	32	107	114	0	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0146-0404			INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	JUL	1992	33	8					2532	2536					5	Ophthalmology	Ophthalmology	JE509	WOS:A1992JE50900024	1634350				2021-06-18	
J	WOOLF, PD				WOOLF, PD			HORMONAL RESPONSES TO TRAUMA	CRITICAL CARE MEDICINE			English	Article						ADRENOCORTICOTROPIN HORMONE; GROWTH HORMONE; PROLACTIN; GLASGOW COMA SCORE; TRAUMA; PITUITARY GLAND; THYROID HORMONES; HYPOPITUITARISM; SEVERITY OF ILLNESS INDEX; GONADOTROPIN	TRANSIENT HYPOGONADOTROPIC HYPOGONADISM; RECENTLY INJURED PATIENTS; LOW-THYROXINE STATE; CLOSED HEAD TRAUMA; THYROID-HORMONE; BRAIN INJURY; THERMAL-INJURY; NONTHYROIDAL ILLNESSES; PLASMA-CORTISOL; CRITICALLY ILL	Objectives: To review the hormonal changes that have been reported after trauma, to define their etiologies, and to describe their consequences. Data Sources: Literature review using MEDLINE and original data. Data Synthesis: Hormonal responses to trauma are bidirectional. Functional derangements include increases in adrenocorticotropin hormone and cortisol, growth hormone, and prolactin levels. In contrast, gonadotropin and gonadal steroid, and thyroid hormone concentrations decrease. The response is immediate but not necessarily sustained for those hormones that respond with increased secretion, whereas the effect may not become apparent for several hours, may be maximal after 1 to 4 days, and may persist for the duration of illness for those hormones that decrease. The reduction in hormone concentrations generally reflect diminished secretion, with the exception of the thyroid hormones where altered metabolic pathways and enhanced metabolic clearance play a major role. Conclusions: The changes in circulating levels do not appear to be injury specific, but tend to reflect the severity of the traumatic insult, and there are some data for cortisol and thyroxine that show their concentrations may be of predictive value. In head-injured patients, structural as well as functional pituitary changes may be present. Patients may show varying degrees of pituitary insufficiency. However, the presence of hyperprolactinemia strongly suggests involvement of the hypothalamus. With the exception of bonafide hypopituitarism, the relevance of the hormonal changes after trauma awaits clarification.	UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ENDOCRINE METAB UNIT, ROCHESTER, NY 14642 USA					NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA7066] Funding Source: Medline		AGRIMONTI F, 1981, J ENDOCRINOL INVEST, V4, P49, DOI 10.1007/BF03349414; AUN F, 1983, J TRAUMA, V23, P1048, DOI 10.1097/00005373-198312000-00005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARTALENA L, 1990, J CLIN ENDOCR METAB, V70, P293, DOI 10.1210/jcem-70-1-293; BARTON RN, 1981, CLIN SCI, V61, P399, DOI 10.1042/cs0610399; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BECKER RA, 1980, ARCH SURG-CHICAGO, V115, P439; BECKER RA, 1980, J TRAUMA, V20, P713, DOI 10.1097/00005373-198009000-00001; BECKER RA, 1982, CRIT CARE MED, V10, P870, DOI 10.1097/00003246-198212000-00014; BLACK JA, 1977, BURNS, V3, P218, DOI 10.1016/0305-4179(77)90044-4; BRENT GA, 1986, J CLIN ENDOCR METAB, V63, P1; BRIZIOMOLTENI L, 1984, J TRAUMA, V24, P1, DOI 10.1097/00005373-198401000-00001; CAREY LC, 1971, ANN SURG, V174, P451, DOI 10.1097/00000658-197109000-00014; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHERNOW B, 1987, ARCH INTERN MED, V147, P1273, DOI 10.1001/archinte.147.7.1273; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; CHOPRA IJ, 1980, J CLIN ENDOCR METAB, V51, P135, DOI 10.1210/jcem-51-1-135; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; COPE O, 1953, ANN SURG, V137, P165, DOI 10.1097/00000658-195302000-00003; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CYRAU E, 1918, BERL KLIN WCHNSCHR, V55, P1059; CYTOWIC RE, 1986, NEW ENGL J MED, V314, P715; DANIEL PM, 1959, LANCET, V2, P927; Daniel PM, 1961, MOD TRENDS ENDOCR, P55; DESAI D, 1989, J TRAUMA, V29, P719, DOI 10.1097/00005373-198906000-00003; DOLECEK R, 1983, ENDOCRINOL EXP, V17, P33; DOLECEK R, 1979, SCAND J PLAST RECONS, V13, P9, DOI 10.3109/02844317909013013; EDWARDS OM, 1986, MEDICINE, V65, P281; ESTEP HL, 1966, J CLIN ENDOCR METAB, V26, P513, DOI 10.1210/jcem-26-5-513; FAGLIA G, 1979, J CLIN ENDOCR METAB, V48, P989, DOI 10.1210/jcem-48-6-989; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; FOK ACK, 1989, AUST NZ J MED, V19, P354, DOI 10.1111/j.1445-5994.1989.tb00279.x; FRAYN KN, 1984, CLIN ENDOCRINOL, V20, P179, DOI 10.1111/j.1365-2265.1984.tb00073.x; FRAYN KN, 1983, AGE AGEING, V12, P70, DOI 10.1093/ageing/12.1.70; GANN DS, 1979, NEPHRON, V23, P119, DOI 10.1159/000181620; HARRISON TS, 1967, ANN SURG, V165, P169, DOI 10.1097/00000658-196702000-00002; HOLNESS RO, 1983, J NEUROSURG, V59, P677, DOI 10.3171/jns.1983.59.4.0677; HUME DM, 1959, ANN SURG, V150, P697, DOI 10.1097/00000658-195910000-00013; JACKSON RD, 1989, AM J PHYS MED REHAB, V68, P18, DOI 10.1097/00002060-198902000-00006; JENNETT B, 1975, LANCET, V1, P480; KAPTEIN EM, 1982, CLIN ENDOCRINOL, V16, P565, DOI 10.1111/j.1365-2265.1982.tb03173.x; KAPTEIN EM, 1982, J CLIN INVEST, V69, P526, DOI 10.1172/JCI110478; KENNEY PR, 1983, J TRAUMA, V23, P712, DOI 10.1097/00005373-198308000-00006; KIKUCHI K, 1988, J CLIN ENDOCR METAB, V67, P817, DOI 10.1210/jcem-67-4-817; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; LEE LA, 1986, CLIN CHEM, V32, P797; LEEBAW WF, 1978, J CLIN ENDOCR METAB, V47, P480, DOI 10.1210/jcem-47-3-480; LEPHART ED, 1987, J CLIN ENDOCR METAB, V64, P842, DOI 10.1210/jcem-64-4-842; MADSEN M, 1986, ACTA CHIR SCAND, V152, P91; MADSEN M, 1986, ACTA CHIR SCAND, V152, P413; MASTERS JN, 1989, ENDOCRINOLOGY, V124, P3083, DOI 10.1210/endo-124-6-3083; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; MILLER WL, 1980, NEW ENGL J MED, V302, P724, DOI 10.1056/NEJM198003273021305; MOLTENI A, 1979, ANN CLIN LAB SCI, V9, P518; MOUSSALLI C, 1986, MIL MED, V151, P120; PARKER CR, 1985, J TRAUMA, V25, P508, DOI 10.1097/00005373-198506000-00006; PARKER LN, 1985, J CLIN ENDOCR METAB, V60, P947, DOI 10.1210/jcem-60-5-947; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; PHILLIPS RH, 1984, J TRAUMA, V24, P116, DOI 10.1097/00005373-198402000-00004; PLYMATE SR, 1987, HORM RES, V27, P152, DOI 10.1159/000180803; POPP MB, 1977, SURG GYNECOL OBSTET, V145, P517; ROMIJN JA, 1990, J CLIN ENDOCR METAB, V70, P35, DOI 10.1210/jcem-70-1-35; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; SAPOLSKY RM, 1987, TRENDS NEUROSCI, V10, P346, DOI 10.1016/0166-2236(87)90065-8; SEMPLE CG, 1987, BRIT MED J, V295, P403, DOI 10.1136/bmj.295.6595.403; SHAUL PW, 1985, AM J DIS CHILD, V139, P467, DOI 10.1001/archpedi.1985.02140070041029; SMITH PJ, 1984, ENDOCR REV, V5, P514, DOI 10.1210/edrv-5-4-514; SOCKALOSKY JJ, 1987, J PEDIATR-US, V110, P373, DOI 10.1016/S0022-3476(87)80497-3; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; STONER HB, 1979, CLIN SCI, V56, P563, DOI 10.1042/cs0560563; TAMASAWA N, 1988, J ENDOCRINOL INVEST, V11, P429, DOI 10.1007/BF03349076; THOMASSON B, 1959, Scand J Clin Lab Invest, V11 Suppl 42, P1; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; VAUGHAN GM, 1982, J TRAUMA, V22, P263, DOI 10.1097/00005373-198204000-00001; VELDHUIS JD, 1988, CLIN RES, V36, P11; VOGEL AV, 1985, J CLIN ENDOCR METAB, V60, P658, DOI 10.1210/jcem-60-4-658; WADE CE, 1988, J CLIN ENDOCR METAB, V67, P223, DOI 10.1210/jcem-67-2-223; WARTOFSKY L, 1982, ENDOCR REV, V3, P164, DOI 10.1210/edrv-3-2-164; WEHMANN RE, 1985, NEW ENGL J MED, V312, P546, DOI 10.1056/NEJM198502283120904; WILMORE DW, 1975, J TRAUMA, V15, P697, DOI 10.1097/00005373-197508000-00012; WILMORE DW, 1974, ANN SURG, V180, P653, DOI 10.1097/00000658-197410000-00031; WISE L, 1972, ARCH SURG-CHICAGO, V105, P213; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; WOOLF PD, 1974, J CLIN ENDOCR METAB, V38, P71, DOI 10.1210/jcem-38-1-71; ZALOGA GP, 1985, ANN SURG, V201, P456, DOI 10.1097/00000658-198504000-00010; ZIEGLER MG, 1990, CRIT CARE MED, V18, P253, DOI 10.1097/00003246-199003000-00001	93	107	109	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	1992	20	2					216	226		10.1097/00003246-199202000-00011			11	Critical Care Medicine	General & Internal Medicine	HC983	WOS:A1992HC98300011	1737456				2021-06-18	
J	EWINGCOBBS, L; LEVIN, HS; EISENBERG, HM; FLETCHER, JM				EWINGCOBBS, L; LEVIN, HS; EISENBERG, HM; FLETCHER, JM			LANGUAGE FUNCTIONS FOLLOWING CLOSED-HEAD INJURY IN CHILDREN AND ADOLESCENTS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550; UNIV HOUSTON,HOUSTON,TX 77004	EWINGCOBBS, L (corresponding author), UNIV TEXAS,SCH MED,DEPT PSYCHIAT & BEHAV SCI,POB 20708,HOUSTON,TX 77225, USA.		fletcher, jack/Q-5975-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889-02] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; ARAM DM, 1983, ARCH NEUROL-CHICAGO, V40, P614, DOI 10.1001/archneur.1983.04050090050007; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Benton AL, 1978, MULTILINGUAL APHASIA; BENTON ARTHUR L., 1962, PSYCHIAT ET NEUROL, V144, P321; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DENNIS M, 1985, J CLIN EXP NEUROPSYC, V7, P526, DOI 10.1080/01688638508401283; DENNIS M, 1980, LANGUAGE DEV APHASIA, P45; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; EWINGCOBBS L, 1985, CLOSED HEAD INJURY R, P71; EWINGCOBBS L, 1985, SPEECH LANGUAGE EVAL, P71; FLETCHER JM, IN PRESS HDB PEDIATR; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Gibson E. J., 1975, PSYCHOL READING; Guttmann E, 1942, BRAIN, V65, P205, DOI 10.1093/brain/65.2.205; HALSTEAD WC, 1959, J SPEECH HEAR DISORD, V14, P9; HEBB DO, 1942, P AM PHILOS SOC, V1, P265; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; HECAEN H, 1984, EARLY BRAIN DAMAGE, V1, P277; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; JENNETT B, 1972, DEV MED CHILD NEUROL, V14, P137; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1985, SEMIN NEUROL, V5, P221, DOI 10.1055/s-2008-1041519; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; RUTTER M, 1982, Journal of Clinical Neuropsychology, V4, P91, DOI 10.1080/01688638208401121; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; SATZ P, 1981, ACQUIRED APHASIA, P399; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; Spreen O, 1969, NEUROSENSORY CTR COM; TEASDALE G, 1974, LANCET, V2, P81; VANDONGEN HR, 1977, CORTEX, V13, P131, DOI 10.1016/S0010-9452(77)80004-X; VERMEULEN J, 1982, CORTEX, V18, P287; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	44	107	107	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1987	9	5					575	592		10.1080/01688638708410770			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	K0801	WOS:A1987K080100007	2444619				2021-06-18	
J	Fang, Q; Li, H; Luo, XC; Ding, LY; Luo, HB; Rose, TM; An, WP				Fang, Qi; Li, Heng; Luo, Xiaochun; Ding, Lieyun; Luo, Hanbin; Rose, Timothy M.; An, Wangpeng			Detecting non-hardhat-use by a deep learning method from far -field surveillance videos	AUTOMATION IN CONSTRUCTION			English	Article						Construction safety; Non-hardhat-use; Far-field surveillance video; Deep learning; Faster R-CNN	TRAUMATIC BRAIN-INJURIES; CONSTRUCTION; RECOGNITION; ERGONOMICS	Hardhats are an important safety measure used to protect construction workers from accidents. However, accidents caused in ignorance of wearing hardhats still occur. In order to strengthen the supervision of construction workers to avoid accidents, automatic non-hardhat-use (NHU) detection technology can play an important role. Existing automatic methods of detecting hardhat avoidance are commonly limited to the detection of objects in near-field surveillance videos. This paper proposes the use of a high precision, high speed and widely applicable Faster R-CNN method to detect construction workers' NHU. To evaluate the performance of Faster R-CNN, more than 100,000 construction worker image frames were randomly selected from the far-field surveillance videos of 25 different construction sites over a period of more than a year. The research analyzed various visual conditions of the construction sites and classified image frames according to their visual conditions. The image frames were input into Faster R-CNN according to different visual categories. The experimental results demonstrate that the high precision, high recall and fast speed of the method can effectively detect construction workers' NHU in different construction site conditions, and can facilitate improved safety inspection and supervision.	[Fang, Qi; Ding, Lieyun; Luo, Hanbin] Huazhong Univ Sci & Technol, Sch Civil Engn & Mech, Wuhan, Hubei, Peoples R China; [Fang, Qi; Li, Heng; Luo, Xiaochun] Hong Kong Polytech Univ, Dept Bldg & Real Estate, Hong Kong, Hong Kong, Peoples R China; [Rose, Timothy M.] Queensland Univ Technol, Sch Civil Engn & Built Environm, Brisbane, Qld, Australia; [An, Wangpeng] Hong Kong Polytech Univ, Dept Comp, Hong Kong, Hong Kong, Peoples R China	Li, H (corresponding author), Hong Kong Polytech Univ, Dept Bldg & Real Estate, Hong Kong, Hong Kong, Peoples R China.	bshengli@polyu.edu.hk	Li, Heng/B-2821-2015; Hanbin, Luo/AAH-7441-2019; li, chengqian/AAH-7343-2019; LUO, Xiaochun/AAX-7943-2020	Li, Heng/0000-0002-3187-9041; LUO, Xiaochun/0000-0002-2497-848X; An, Wangpeng/0000-0002-1869-1837; Rose, Timothy/0000-0003-2368-6714; Chen, Yun/0000-0002-3706-9883	National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [51678265]; Research Grants Council of Hong KongHong Kong Research Grants Council [PolyU 152093/14E]; National 12th Five-Year Plan Major Scientific and Technological Issues (NFYPMSTI) [2015BAK33B04]	The authors would like to acknowledge Lei Zhang, Xianbiao Qi, Chengqian Li, Tianshui Chen and Yachun Huang for their help. We are also thankful for the financial support of 1) National Science Foundation of China (grant no.51678265). 2) The Research Grants Council of Hong Kong grant titled "Proactively Monitoring Construction Progress by Integrating 3D Laser-scanning and BIM" (PolyU 152093/14E). 3) National 12th Five-Year Plan Major Scientific and Technological Issues (NFYPMSTI) through Grant 2015BAK33B04.	Akbar-Khanzadeh F, 1998, J Hum Ergol (Tokyo), V27, P70; [Anonymous], 2017, CONSTR NAICS 23, V23; Barro-Torres S, 2012, COMPUT COMMUN, V36, P42, DOI 10.1016/j.comcom.2012.01.005; Bucak SS, 2014, IEEE T PATTERN ANAL, V36, P1354, DOI 10.1109/TPAMI.2013.212; Cabahug RR, 2014, MINDANAO J SCI TECHN, V12, P12; Cavazza N, 2009, J SAFETY RES, V40, P277, DOI 10.1016/j.jsr.2009.06.002; Chen CS, 2009, 2009 FIRST INTERNATIONAL CONFERENCE ON ADVANCES IN FUTURE INTERNET, P1, DOI [10.1109/AFIN.2009.8, 10.1109/CLEOE-EQEC.2009.5192905]; Colantonio A, 2009, BRAIN INJURY, V23, P873, DOI 10.1080/02699050903036033; Dalal N, 2005, PROC CVPR IEEE, P886, DOI 10.1109/cvpr.2005.177; Dong S, 2015, ICCREM 2015: ENVIRONMENT AND THE SUSTAINABLE BUILDING, P204; Flin R, 2000, SAFETY SCI, V34, P177, DOI 10.1016/S0925-7535(00)00012-6; Fung IWH, 2014, SAFETY SCI, V65, P70, DOI 10.1016/j.ssci.2013.12.014; Girshick R, 2015, IEEE I CONF COMP VIS, P1440, DOI 10.1109/ICCV.2015.169; Girshick R, 2014, PROC CVPR IEEE, P580, DOI 10.1109/CVPR.2014.81; GitHub, 2005, LAB GRAPH IM ANN TOO; Han S, 2014, J COMPUT CIVIL ENG, V28, DOI 10.1061/(ASCE)CP.1943-5487.0000339; Han S, 2013, AUTOMAT CONSTR, V35, P131, DOI 10.1016/j.autcon.2013.05.001; He KM, 2014, LECT NOTES COMPUT SC, V8691, P346, DOI 10.1007/978-3-319-10578-9_23; Health Safety Executive, 2016, STAT FAT INJ WORKPL; Hinze J, 2013, SAFETY SCI, V51, P23, DOI 10.1016/j.ssci.2012.05.016; Huang XY, 2003, J CONSTR ENG M ASCE, V129, P262, DOI 10.1061/(ASCE)0733-9364(2003)129:3(262); HUME A, 1995, P INT IRCOBI C BIOM; Jeong BY, 1998, APPL ERGON, V29, P355, DOI 10.1016/S0003-6870(97)00077-X; Jiang HZ, 2017, IEEE INT CONF AUTOMA, P650, DOI [10.1109/FG.2017.82, 10.1109/MWSYM.2017.8058653]; Kelm A, 2013, AUTOMAT CONSTR, V36, P38, DOI 10.1016/j.autcon.2013.08.009; Kim HJ, 2017, INT ORTHOP, V41, P101, DOI 10.1007/s00264-016-3303-3; Konda S, 2016, AM J IND MED, V59, P212, DOI 10.1002/ajim.22557; Krizhevsky A, 2012, NEURAL INFORM PROCES, P1097, DOI DOI 10.1145/3065386; LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; Li H., 2017, AUTOM CONSTR; Liu MY, 2016, CONSTRUCTION RESEARCH CONGRESS 2016: OLD AND NEW CONSTRUCTION TECHNOLOGIES CONVERGE IN HISTORIC SAN JUAN, P951; Liu W, 2016, LECT NOTES COMPUT SC, V9905, P21, DOI 10.1007/978-3-319-46448-0_2; Lombardi DA, 2009, ACCIDENT ANAL PREV, V41, P755, DOI 10.1016/j.aap.2009.03.017; Naticchia B, 2013, AUTOMAT CONSTR, V29, P148, DOI 10.1016/j.autcon.2012.09.016; Occupational Safety & Health Administration, 2004, DET NEED HARD HAT EY; Ott P, 2009, IEEE I CONF COMP VIS, P723, DOI 10.1109/ICCV.2009.5459238; Park MW, 2015, J CONSTR ENG M, V141, DOI 10.1061/(ASCE)CO.1943-7862.0000974; PASCAL VOC, 2017, PASCAL VOC DETECTION; Paul M, 2013, EURASIP J ADV SIG PR, DOI 10.1186/1687-6180-2013-11; Peng QW, 2016, INT C INTEL HUM MACH, P562, DOI 10.1109/IHMSC.2016.130; Rangesh A., 2016, INT TRANSP SYST ITSC, P2545; Ray SJ, 2012, ADV ENG INFORM, V26, P439, DOI 10.1016/j.aei.2012.02.011; Redmon J, 2016, PROC CVPR IEEE, P779, DOI 10.1109/CVPR.2016.91; Ren Shaoqing, 2017, IEEE Trans Pattern Anal Mach Intell, V39, P1137, DOI 10.1109/TPAMI.2016.2577031; Rubaiyat AM, 2016, 2016 IEEE/WIC/ACM INTERNATIONAL CONFERENCE ON WEB INTELLIGENCE WORKSHOPS (WIW 2016), P135, DOI [10.1109/WIW.2016.10, 10.1109/WIW.2016.045]; SCHNEIDER S, 1994, AM IND HYG ASSOC J, V55, P635, DOI 10.1080/15428119491018727; Shan Du, 2011, 2011 3rd International Conference on Computer Research and Development (ICCRD 2011), P25, DOI 10.1109/ICCRD.2011.5763846; Shrestha K., 2015, J CONSTR ENG, V2015; Starbuck Richmond, 2014, 2014 International Conference on Computing in Civil and Building Engineering. Proceedings, P1094; Suderman BL, 2014, ACCIDENT ANAL PREV, V73, P116, DOI 10.1016/j.aap.2014.08.011; Szegedy C., 2013, PROC C ADV NEURAL IN, P2553; Tian YL, 2011, IEEE T SYST MAN CY C, V41, P565, DOI 10.1109/TSMCC.2010.2065803; Zhang J., 2016, COMP INT DES ISCID 2, V1, P363; Zhang LL, 2016, LECT NOTES COMPUT SC, V9906, P443, DOI 10.1007/978-3-319-46475-6_28; Zhou Y., 2016, 2016 IEEE INT C DIG; Zhu L, 2010, PROC CVPR IEEE, P1062, DOI 10.1109/CVPR.2010.5540096; Zhu Z., 2015, 11 CONSTR SPEC C	57	106	111	14	128	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0926-5805	1872-7891		AUTOMAT CONSTR	Autom. Constr.	JAN	2018	85						1	9		10.1016/j.autcon.2017.09.018			9	Construction & Building Technology; Engineering, Civil	Construction & Building Technology; Engineering	FU7ZP	WOS:000424071900001			Y	N	2021-06-18	
J	Babl, FE; Borland, ML; Phillips, N; Kochar, A; Dalton, S; McCaskill, M; Cheek, JA; Gilhotra, Y; Furyk, J; Neutze, J; Lyttle, MD; Bressan, S; Donath, S; Molesworth, C; Jachno, K; Ward, B; Williams, A; Baylis, A; Crowe, L; Oakley, E; Dalziel, SR				Babl, Franz E.; Borland, Meredith L.; Phillips, Natalie; Kochar, Amit; Dalton, Sarah; McCaskill, Mary; Cheek, John A.; Gilhotra, Yuri; Furyk, Jeremy; Neutze, Jocelyn; Lyttle, Mark D.; Bressan, Silvia; Donath, Susan; Molesworth, Charlotte; Jachno, Kim; Ward, Brenton; Williams, Amanda; Baylis, Amy; Crowe, Louise; Oakley, Ed; Dalziel, Stuart R.		Paediat Res Emergency Dept Int	Accuracy of PECARN, CATCH, and CHALICE head injury decision rules in children: a prospective cohort study	LANCET			English	Article							CRANIAL COMPUTED-TOMOGRAPHY; EMERGENCY-DEPARTMENT; RADIATION-EXPOSURE; CT SCANS; TRAUMA; PREDICTION; METHODOLOGY; DERIVATION; SEDATION; RISK	Background Clinical decision rules can help to determine the need for CT imaging in children with head injuries. We aimed to validate three clinical decision rules (PECARN, CATCH, and CHALICE) in a large sample of children. Methods In this prospective observational study, we included children and adolescents (aged <18 years) with head injuries of any severity who presented to the emergency departments of ten Australian and New Zealand hospitals. We assessed the diagnostic accuracy of PECARN (stratified into children aged <2 years and >= 2 years), CATCH, and CHALICE in predicting each rule-specific outcome measure (clinically important traumatic brain injury [TBI], need for neurological intervention, and clinically significant intracranial injury, respectively). For each calculation we used rule-specific predictor variables in populations that satisfied inclusion and exclusion criteria for each rule (validation cohort). In a secondary analysis, we compiled a comparison cohort of patients with mild head injuries (Glasgow Coma Scale score 13-15) and calculated accuracy using rule-specific predictor variables for the standardised outcome of clinically important TBI. This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12614000463673. Findings Between April 11, 2011, and Nov 30, 2014, we analysed 20 137 children and adolescents attending with head injuries. CTs were obtained for 2106 (10%) patients, 4544 (23%) were admitted, 83 (<1%) underwent neurosurgery, and 15 (<1%) died. PECARN was applicable for 4011 (75%) of 5374 patients younger than 2 years and 11 152 (76%) of 14 763 patients aged 2 years and older. CATCH was applicable for 4957 (25%) patients and CHALICE for 20 029 (99%). The highest point validation sensitivities were shown for PECARN in children younger than 2 years (100.0%, 95% CI 90.7-100.0; 38 patients identified of 38 with outcome [38/38]) and PECARN in children 2 years and older (99.0%, 94.4-100.0; 97/98), followed by CATCH (high-risk predictors only; 95.2%; 76.2-99.9; 20/21; medium-risk and high-risk predictors 88.7%; 82.2-93.4; 125/141) and CHALICE (92.3%, 89.2-94.7; 370/401). In the comparison cohort of 18 913 patients with mild injuries, sensitivities for clinically important TBI were similar. Negative predictive values in both analyses were higher than 99% for all rules. Interpretation The sensitivities of three clinical decision rules for head injuries in children were high when used as designed. The findings are an important starting point for clinicians considering the introduction of one of the rules. Funding National Health and Medical Research Council, Emergency Medicine Foundation, Perpetual Philanthropic Services, WA Health Targeted Research Funds, Townsville Hospital Private Practice Fund, Auckland Medical Research Foundation, A + Trust.	[Babl, Franz E.; Cheek, John A.; Baylis, Amy; Oakley, Ed] Royal Childrens Hosp, Melbourne, Vic, Australia; [Babl, Franz E.; Cheek, John A.; Lyttle, Mark D.; Bressan, Silvia; Donath, Susan; Molesworth, Charlotte; Jachno, Kim; Williams, Amanda; Crowe, Louise; Oakley, Ed] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Babl, Franz E.; Donath, Susan; Oakley, Ed] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Paediat, Melbourne, Vic, Australia; [Borland, Meredith L.] Princess Margaret Hosp Children, Perth, WA, Australia; [Borland, Meredith L.] Univ Western Australia, Sch Paediat & Child Hlth, Crawley, WA, Australia; [Borland, Meredith L.] Univ Western Australia, Sch Primary Aboriginal & Rural Healthcare, Crawley, WA, Australia; [Phillips, Natalie; Gilhotra, Yuri] Lady Cilento Childrens Hosp, Brisbane, Qld, Australia; [Phillips, Natalie; Gilhotra, Yuri] Univ Queensland, Sch Med, Child Hlth Res Ctr, Brisbane, Qld, Australia; [Kochar, Amit] Womens & Childrens Hosp, Adelaide, SA, Australia; [Dalton, Sarah; McCaskill, Mary] Childrens Hosp Westmead, Sydney, NSW, Australia; [Cheek, John A.] Monash Med Ctr, Melbourne, Vic, Australia; [Furyk, Jeremy] Townsville Hosp, Townsville, Qld, Australia; [Neutze, Jocelyn] Kidzfirst Middlemore Hosp, Auckland, New Zealand; [Lyttle, Mark D.] Bristol Royal Hosp Children, Bristol, Avon, England; [Lyttle, Mark D.] Univ West England, Acad Dept Emergency Care, Bristol, Avon, England; [Bressan, Silvia] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy; [Dalziel, Stuart R.] Starship Childrens Hlth, Auckland, New Zealand; [Dalziel, Stuart R.] Univ Auckland, Liggins Inst, Auckland, New Zealand	Babl, FE (corresponding author), Murdoch Childrens Res Inst, Emergency Res, Melbourne, Vic 3052, Australia.	franz.babl@rch.org.au		Jachno, Kim/0000-0003-2550-9674; Lyttle, Mark/0000-0002-8634-7210; Crowe, Louise/0000-0003-4619-9708; Donath, Susan/0000-0003-2489-3977	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Emergency Medicine Foundation; Perpetual Philanthropic Services; WA Health Targeted Research Funds; Townsville Hospital Private Practice Fund; Auckland Medical Research Foundation; A + Trust; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [GNT1046727, GNT1058560]; Murdoch Childrens Research Institute; Emergency Medicine Foundation [EMPJ-11162]; Perpetual Philanthropic Services Australia [2012/1140]; Auckland Medical Research Foundation [3112011]; A + Trust (Auckland District Health Board); Townsville Hospital and Health Service Private Practice Research and Education Trust Fund; Victorian Government's Infrastructure Support Program; Royal Children's Hospital Foundation, Melbourne, Australia; Health Research Council of New ZealandHealth Research Council of New Zealand [HRC13/556]	National Health and Medical Research Council, Emergency Medicine Foundation, Perpetual Philanthropic Services, WA Health Targeted Research Funds, Townsville Hospital Private Practice Fund, Auckland Medical Research Foundation, A + Trust.; The study was funded by grants from the National Health and Medical Research Council (project grant GNT1046727, Centre of Research Excellence for Paediatric Emergency Medicine GNT1058560); the Murdoch Childrens Research Institute; the Emergency Medicine Foundation (EMPJ-11162); Perpetual Philanthropic Services (2012/1140) Australia; Auckland Medical Research Foundation (number 3112011); the A + Trust (Auckland District Health Board); WA Health Targeted Research Funds 2013; the Townsville Hospital and Health Service Private Practice Research and Education Trust Fund; and supported by the Victorian Government's Infrastructure Support Program. FEB's time was part funded by a grant from the Royal Children's Hospital Foundation, Melbourne, Australia. SRD's time was part funded by the Health Research Council of New Zealand (HRC13/556). We thank the participating families and emergency department staff at participating sites. We thank research staff from the following sites: Kaya Gardiner, Nicola Williams, Elle Goss, Triona Stephens, Marta Arpone, and Joseph Mabuti (The Royal Children's Hospital, Melbourne, VIC, Australia); Sharon O'Brien, Timothy Loy, Jeremy Rogers, Samantha Oosterhof, and Verity Watt (Princess Margaret Hospital, Perth, WA, Australia); Susan Montgomery (The Townsville Hospital, Townsville, QLD, Australia); Rebecca Saul, Meegan Price, Petrina Hetherington, Emily Casey, Mary Lang, Jane O'Shea, Anne Cook, Kerrie-Ann Abel, and Bronwyn Griffin (The Royal Children's Hospital, Brisbane, QLD, Australia); Tamara Brunton (Monash Medical Centre, Melbourne, VIC, Australia); Shirley Lawrence (Kidzfirst Children's Hospital, Middlemore, Auckland, New Zealand); Megan Bonisch (Starship Children's Hospital, Auckland, New Zealand); Carey Alymer and Simone Green (Women's and Children's Hospital Adelaide, SA, Australia); Laura Phillips and Elizabeth Moss (Children's Hospital Westmead, Sydney, NSW, Australia); and Meg Jepperson (Mater Children's Hospital, Brisbane, QLD, Australia).	American Academy of Pediatrics, 2013, COMP TOM CT SCANS AR; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Babl Franz, 2006, Emerg Med Australas, V18, P143, DOI 10.1111/j.1742-6723.2006.00823.x; Babl FE, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-148; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Farrell CA, 2013, MANAGEMENT PAEDIATRI; Goldwasser T, 2015, EUR J EMERG MED, V22, P413, DOI 10.1097/MEJ.0000000000000201; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hoyle JD, 2014, PEDIATR EMERG CARE, V30, P1, DOI 10.1097/PEC.0000000000000059; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lockie FD, 2013, EMERG MED AUSTRALAS, V25, P75, DOI 10.1111/1742-6723.12019; Lyttle MD, 2013, EMERG MED J, V30, P790, DOI 10.1136/emermed-2012-201887; Lyttle MD, 2012, EMERG MED J, V29, P785, DOI 10.1136/emermed-2011-200225; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; National Institute for Health and Care Excellence, 2014, HEAD INJ ASS EARL MA; Nigrovic LE, 2015, PEDIATRICS, V136, pE227, DOI 10.1542/peds.2014-3588; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Stanley RM, 2014, J PEDIATR-US, V165, P1201, DOI 10.1016/j.jpeds.2014.08.008; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Thiam DW, 2015, ANN ACAD MED SINGAP, V44, P335	29	106	108	0	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 17	2017	389	10087					2393	2402		10.1016/S0140-6736(17)30555-X			10	Medicine, General & Internal	General & Internal Medicine	EX6ED	WOS:000403334400025	28410792		Y	N	2021-06-18	
J	Waljas, M; Iverson, GL; Lange, RT; Hakulinen, U; Dastidar, P; Huhtala, H; Liimatainen, S; Hartikainen, K; Ohman, J				Waljas, Minna; Iverson, Grant L.; Lange, Rael T.; Hakulinen, Ullamari; Dastidar, Prasun; Huhtala, Heini; Liimatainen, Suvi; Hartikainen, Kaisa; Ohman, Juha			A Prospective Biopsychosocial Study of the Persistent Post-Concussion Symptoms following Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; cognitive function; diffusion tensor imaging; prospective study; outcome measures	TENSOR IMAGING FINDINGS; POSTTRAUMATIC-STRESS-DISORDER; MINOR HEAD-INJURY; DSM-IV CRITERIA; TASK-FORCE; POSTCONCUSSIONAL DISORDER; COLLABORATING-CENTER; WHITE-MATTER; DIAGNOSTIC-CRITERIA; AXONAL INJURY	This study examined multiple biopsychosocial factors relating to post-concussion symptom (PCS) reporting in patients with mild traumatic brain injuries (mTBI), including structural (computed tomography and magnetic resonance imaging [MRI]) and microstructural neuroimaging (diffusion tensor imaging [DTI]). Patients with mTBIs completed several questionnaires and cognitive testing at approximately one month (n=126) and one year (n=103) post-injury. At approximately three weeks post-injury, DTI was undertaken using a Siemens 3T scanner in a subgroup (n=71). Measures of fractional anisotropy were calculated for 16 regions of interest (ROIs) and measures of apparent diffusion coefficient were calculated for 10 ROIs. Patients were compared with healthy control subjects. Using International Classification of Diseases, Tenth Revision (ICD-10) PCS criteria and mild or greater symptom reporting, 59% of the mTBI sample met criteria at one month and 38% met criteria at one year. However, 31% of the healthy control sample also met criteria for the syndrome-illustrating a high false-positive rate. Significant predictors of ICD-10 PCS at one month were pre-injury mental health problems and the presence of extra-cranial bodily injuries. Being symptomatic at one month was a significant predictor of being symptomatic at one year, and depression was significantly related to PCS at both one month and one year. Intracranial abnormalities visible on MRI were present in 12.1% of this sample, and multifocal areas of unusual white matter as measured by DTI were present in 50.7% (compared with 12.4% of controls). Structural MRI abnormalities and microstructural white matter findings were not significantly associated with greater post-concussion symptom reporting. The personal experience and reporting of post-concussion symptoms is likely individualized, representing the cumulative effect of multiple variables, such as genetics, mental health history, current life stress, medical problems, chronic pain, depression, personality factors, and other psychosocial and environmental factors. The extent to which damage to the structure of the brain contributes to the persistence of post-concussion symptoms remains unclear.	[Waljas, Minna; Liimatainen, Suvi; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland; [Hakulinen, Ullamari; Dastidar, Prasun] Tampere Univ Hosp, Dept Radiol, Tampere, Finland; [Waljas, Minna; Dastidar, Prasun; Ohman, Juha] Univ Tampere Med Sch, Tampere, Finland; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Lange, Rael T.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Hakulinen, Ullamari] Tampere Univ Technol, Dept Elect & Commun Engn, FIN-33101 Tampere, Finland; [Huhtala, Heini] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland; [Hartikainen, Kaisa] Pirkanmaa Hosp Dist, Behav Neurol Res Unit, Tampere, Finland	Waljas, M (corresponding author), Tampere Univ Hosp, Dept Neurosurg, POB 2000, FIN-3521 Tampere, Finland.	minna.waljas@pshp.fi		Ohman, Juha/0000-0002-6592-1367; Iverson, Grant/0000-0001-7348-9570; Hartikainen, Kaisa/0000-0001-7278-9635	Pirkanmaa Hospital District, Tampere University Hospital; University of Tampere; INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]	This research was funded by Competitive Research Funding of the Pirkanmaa Hospital District, Tampere University Hospital and Research Funding of University of Tampere. This study was done as part of the first author's PhD thesis research program. Dr. Iverson notes that he was supported in part by the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (X81XWH-07-CC-CSDoD). The authors thank Pasi Jolma (MD, PhD) for recruiting the patients and conducting neurological examinations and Annika Vuorinen (MSc) for assistance in recruitment and assessment of the control sample. Preliminary results of this study were presented at the International Neuropsychological Society, Boston, MA, in February 2011.	Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Bay Esther H, 2009, Res Theory Nurs Pract, V23, P42; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Hakulinen U, 2012, BMC MED IMAGING, V12, DOI 10.1186/1471-2342-12-30; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson G.L., 2012, PTSD MILD TRAUMATIC, P37; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/415740; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2011, BRAIN INJURY, V25, P1325, DOI 10.3109/02699052.2011.608409; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mitrushina M., 2005, NORMATIVE DATA NEURO; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stalnacke BM, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/528265; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Waljas M, 2014, J HEAD TRAUMA REHAB, V29, P443, DOI 10.1097/HTR.0000000000000002; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson J. T. L, 1996, RECOVERY TRAUMATIC B, P29; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wood RL, 2007, J NEUROL NEUROSUR PS, V78, P552, DOI 10.1136/jnnp.2006.113845; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986	107	106	109	0	43	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2015	32	8					534	547		10.1089/neu.2014.3339			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CF2BS	WOS:000352352900003	25363626				2021-06-18	
J	Fulk, GD; Combs, SA; Danks, KA; Nirider, CD; Raja, B; Reisman, DS				Fulk, George D.; Combs, Stephanie A.; Danks, Kelly A.; Nirider, Coby D.; Raja, Bhavana; Reisman, Darcy S.			Accuracy of 2 Activity Monitors in Detecting Steps in People With Stroke and Traumatic Brain Injury	PHYSICAL THERAPY			English	Article							BERG BALANCE SCALE; PHYSICAL-ACTIVITY; COMMUNITY AMBULATION; WALKING SPEED; GAIT SPEED; RELIABILITY; REHABILITATION; PEDOMETERS; VALIDITY; AGREEMENT	Background. Advances in sensor technologies and signal processing techniques provide a method to accurately measure walking activity in the home and community. Activity monitors geared toward consumer or patient use may be an alternative to more expensive monitors designed for research to measure stepping activity. Objective. The objective of this study was to examine the accuracy of 2 consumer/patient activity monitors, the Fitbit Ultra and the Nike+ Fuelband, in identifying stepping activity in people with stroke and traumatic brain injury (TBI). Secondarily, the study sought to compare the accuracy of these 2 activity monitors with that of the Step Watch Activity Monitor (SAM) and a pedometer, the Yamax Digi-Walker SW-701 pedometer (YDWP). Design. A cross-sectional design was used for this study. Method. People with chronic stroke and TBI wore the 4 activity monitors while they performed the Two-Minute Walk Test (2MWT), during which they were video-taped. Activity monitor estimated steps taken were compared with actual steps taken counted from videotape. Accuracy and agreement between activity monitor estimated steps and actual steps were examined using intraclass correlation coefficients ([CC [2,11) and the Bland-Altman method. Results. The SAM demonstrated the greatest accuracy (ICC [2,1] =.97, mean difference between actual steps and SAM estimated steps=4.7 steps) followed by the Fitbit Ultra (ICC [2,1] =.73, mean difference between actual steps and Fitbit Ultra estimated steps=-9.7 steps), the YDWP (ICC [2,1] =.42, mean difference between actual steps and YDWP estimated steps=-28.8 steps), and the Nike+ Fuelband (ICC [2,1] =.20, mean difference between actual steps and Nike+ Fuelband estimated steps=-66.2 steps). Limitations. Walking activity was measured over a short distance in a closed environment, and participants were high functioning ambulators, with a mean gait speed of 0.93 m/s. Conclusions. The Fitbit Ultra may be a low-cost alternative to measure the stepping activity in level, predictable environments of people with stroke and TBI who can walk at speeds >= 0.58 m/s.	[Fulk, George D.] Clarkson Univ, Phys Therapy Dept, Potsdam, NY 13699 USA; [Combs, Stephanie A.] Univ Indianapolis, Krannert Sch Phys Therapy, Indianapolis, IN 46227 USA; [Danks, Kelly A.; Reisman, Darcy S.] Univ Delaware, Dept Phys Therapy, Newark, DE USA; [Nirider, Coby D.] Touchstone Neurorecovery Ctr, Conroe, TX USA; [Raja, Bhavana] Western Univ, Coll Allied Hlth Profess, Pomona, CA USA	Fulk, GD (corresponding author), Clarkson Univ, Phys Therapy Dept, 8 Clarkson Ave, Potsdam, NY 13699 USA.	gfulk@clarkson.edu		Miller, Stephanie A./0000-0002-7810-186X			Altman D, 1991, PRACTICAL STAT MED R; ALTMAN DG, 1991, PRACTICAL STAT MED R, P398; ANDREWS K, 1979, RHEUMATOL REHABIL, V18, P43, DOI 10.1093/rheumatology/18.1.43; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; BOHANNON RW, 1988, INT J REHABIL RES, V11, P181, DOI 10.1097/00004356-198806000-00012; Bravata DM, 2007, JAMA-J AM MED ASSOC, V298, P2296, DOI 10.1001/jama.298.19.2296; Carroll SL, 2012, ARCH PHYS MED REHAB, V93, P466, DOI 10.1016/j.apmr.2011.08.047; Chen KY, 2005, MED SCI SPORT EXER, V37, pS490, DOI 10.1249/01.mss.0000185571.49104.82; Dalton C, 2012, CLIN REHABIL, V26, P165, DOI 10.1177/0269215511405230; Dobkin BH, 2011, NEUROREHAB NEURAL RE, V25, P788, DOI 10.1177/1545968311425908; Elsworth C, 2009, CLIN REHABIL, V23, P171, DOI 10.1177/0269215508098895; Feito Y, 2012, MED SCI SPORT EXER, V44, P733, DOI 10.1249/MSS.0b013e3182351913; Feld JA, 2001, NEUROREHAB NEURAL RE, V15, P239, DOI 10.1177/154596830101500312; Fulk George D, 2008, J Neurol Phys Ther, V32, P8, DOI 10.1097/NPT0b013e31816593c0; Fulk GD, 2011, TOP STROKE REHABIL, V18, P746, DOI 10.1310/tsr1806-746; Fulk GD, 2011, J NEUROL PHYS THER, V35, P82, DOI 10.1097/NPT.0b013e318218e2f2; Gebruers N, 2010, ARCH PHYS MED REHAB, V91, P288, DOI 10.1016/j.apmr.2009.10.025; Gorter JW, 2012, INT J PEDIAT, V2012, DOI 10.1155/2012/329284; Haeuber E, 2004, ARCH PHYS MED REHAB, V85, P1997, DOI 10.1016/j.apmr.2003.11.035; Ivey F M, 2005, Top Stroke Rehabil, V12, P1; Jain NB, 2007, AM J PHYS MED REHAB, V86, P387, DOI 10.1097/PHM.0b013e31804a7d00; Le Masurier GC, 2004, MED SCI SPORT EXER, V36, P905, DOI 10.1249/01.MSS.0000126777.50188.73; Lexell JE, 2005, AM J PHYS MED REHAB, V84, P719, DOI 10.1097/01.phm.0000176452.17771.20; Lord SE, 2005, STROKE, V36, P1457, DOI 10.1161/01.STR.0000170698.20376.2e; Lord SE, 2004, ARCH PHYS MED REHAB, V85, P234, DOI 10.1016/j.apmr.2003.05.002; Lord S, 2008, STROKE, V39, pE75, DOI 10.1161/STROKEAHA.107.502203; Macko RF, 2002, MED SCI SPORT EXER, V34, P394, DOI 10.1097/00005768-200203000-00002; Mannini A, 2010, SENSORS-BASEL, V10, P1154, DOI 10.3390/s100201154; Miller PA, 2002, PHYSIOTHER CAN, V54, P241; Moseley AM, 2004, J HEAD TRAUMA REHAB, V19, P341, DOI 10.1097/00001199-200407000-00008; Motl RW, 2011, DISABIL HEALTH J, V4, P52, DOI 10.1016/j.dhjo.2010.02.003; Newstead Ann H, 2005, J Neurol Phys Ther, V29, P18; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Richards CL, 1999, CLIN GERIATR MED, V15, P833; Ryan CG, 2006, BRIT J SPORT MED, V40, P779, DOI 10.1136/bjsm.2006.027276; Saremi K, 2006, NEUROREHAB NEURAL RE, V20, P297, DOI 10.1177/1545968306287171; Schmid A, 2007, STROKE, V38, P2096, DOI 10.1161/STROKEAHA.106.475921; Sedgwick P, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1630; Shany T, 2012, IEEE SENS J, V12, P658, DOI 10.1109/JSEN.2011.2146246; Shaughnessy M, 2005, STROKE, V36, P1305, DOI 10.1161/01.STR.0000166202.00669.d2; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Shuger SL, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-41; Skidmore FM, 2008, J REHABIL RES DEV, V45, P1343, DOI 10.1682/JRRD.2008.01.0002; Storti KL, 2008, MED SCI SPORT EXER, V40, P59, DOI 10.1249/mss.0b013e318158b504; Taraldsen K, 2011, PHYS THER, V91, P277, DOI 10.2522/ptj.20100159; Tudor-Locke CE, 2001, RES Q EXERCISE SPORT, V72, P1; Van Loo MA, 2004, BRAIN INJURY, V18, P1041, DOI 10.1080/02699050410001672314	48	106	106	0	34	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	FEB	2014	94	2					222	229		10.2522/ptj.20120525			8	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	304MK	WOS:000330750800006	24052577	Bronze			2021-06-18	
J	Smith, C; Gentleman, SM; Leclercq, PD; Murray, LS; Griffin, WST; Graham, DI; Nicoll, JAR				Smith, C.; Gentleman, S. M.; Leclercq, P. D.; Murray, L. S.; Griffin, W. S. T.; Graham, D. I.; Nicoll, J. A. R.			The neuroinflammatory response in humans after traumatic brain injury	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						microglia; neuroinflammation; neurotrauma; traumatic axonal injury	GLIAL-NEURONAL INTERACTIONS; SITU DNA FRAGMENTATION; ALZHEIMERS-DISEASE; HEAD-INJURY; MICROGLIAL ACTIVATION; SYSTEMIC INFECTION; TDP-43 PROTEINOPATHY; WHITE-MATTER; RISK-FACTORS; INTERLEUKIN-1	Aims: Traumatic brain injury is a significant cause of morbidity and mortality worldwide. An epidemiological association between head injury and long-term cognitive decline has been described for many years and recent clinical studies have highlighted functional impairment within 12 months of a mild head injury. In addition chronic traumatic encephalopathy is a recently described condition in cases of repetitive head injury. There are shared mechanisms between traumatic brain injury and Alzheimer's disease, and it has been hypothesized that neuroinflammation, in the form of microglial activation, may be a mechanism underlying chronic neurodegenerative processes after traumatic brain injury. Methods: This study assessed the microglial reaction after head injury in a range of ages and survival periods, from < 24-h survival through to 47-year survival. Immunohistochemistry for reactive microglia (CD68 and CR3/43) was performed on human autopsy brain tissue and assessed ` blind' by quantitative image analysis. Head injury cases were compared with age matched controls, and within the traumatic brain injury group cases with diffuse traumatic axonal injury were compared with cases without diffuse traumatic axonal injury. Results: A major finding was a neuroinflammatory response that develops within the first week and persists for several months after traumatic brain injury, but has returned to control levels after several years. In cases with diffuse traumatic axonal injury the microglial reaction is particularly pronounced in the white matter. Conclusions: These results demonstrate that prolonged microglial activation is a feature of traumatic brain injury, but that the neuroinflammatory response returns to control levels after several years.	[Smith, C.] Univ Edinburgh, Acad Dept Neuropathol, Edinburgh EH8 9AG, Midlothian, Scotland; [Smith, C.; Murray, L. S.; Graham, D. I.] So Gen Hosp, Inst Neurol Sci, Univ Acad Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Gentleman, S. M.; Leclercq, P. D.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Neuropathol Unit, London, England; [Nicoll, J. A. R.] Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England; [Griffin, W. S. T.] Univ Arkansas Med Sci, Donald W Reynolds Dept Geriatr, Little Rock, AR 72205 USA; [Griffin, W. S. T.] Cent Arkansas Vet Healthcare Syst, Geriatr Res Educ Clin Ctr, Little Rock, AR USA	Smith, C (corresponding author), Univ Edinburgh, Dept Acad Neuropathol, Wilkie Bldg,Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	col.smith@ed.ac.uk	Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG12411]; Scottish Council for Postgraduate Medical and Dental Education; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG012411] Funding Source: NIH RePORTER	This work was funded by NIH Grant AG12411. Dr C. Smith was supported by a Clinical Research Fellow grant from the Scottish Council for Postgraduate Medical and Dental Education.	Armon C, 2011, J NEUROPATH EXP NEUR, V70, P97, DOI 10.1097/01.JNEN.0000392910.86750.32; Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Bedlack RS, 2011, J NEUROPATH EXP NEUR, V70, P96, DOI 10.1097/NEN.0b013e318204782b; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Edison P, 2008, NEUROBIOL DIS, V32, P412, DOI 10.1016/j.nbd.2008.08.001; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Eyupoglu IY, 2003, FASEB J, V17, P1110, DOI 10.1096/fj.02-0825fje; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAGA S, 1989, ACTA NEUROPATHOL, V77, P569, DOI 10.1007/BF00687883; Holmes C, 2003, J NEUROL NEUROSUR PS, V74, P788, DOI 10.1136/jnnp.74.6.788; HOLNESS CL, 1993, BLOOD, V81, P1607; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; KALARIA RN, 1990, BRAIN RES, V516, P349, DOI 10.1016/0006-8993(90)90941-4; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Klegeris A, 2003, BRIT J PHARMACOL, V139, P775, DOI 10.1038/sj.bjp.0705304; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Mandolesi G, 2010, NEUROL SCI, V31, P255, DOI 10.1007/s10072-010-0369-3; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mrak RE, 1996, J NEUROPATH EXP NEUR, V55, P273, DOI 10.1097/00005072-199603000-00002; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; NAGATA K, 1993, J NEUROSCI RES, V34, P357, DOI 10.1002/jnr.490340313; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rebola N, 2011, J NEUROCHEM, V117, P100, DOI 10.1111/j.1471-4159.2011.07178.x; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Salminen A, 2009, PROG NEUROBIOL, V87, P181, DOI 10.1016/j.pneurobio.2009.01.001; Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38; Sheng JG, 1997, J NEUROPATH EXP NEUR, V56, P285, DOI 10.1097/00005072-199703000-00007; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; STREIT WJ, 1989, J NEUROIMMUNOL, V21, P117, DOI 10.1016/0165-5728(89)90167-7; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2; van Munster BC, 2011, REJUV RES, V14, P615, DOI 10.1089/rej.2011.1185; Venneti S, 2007, EXP NEUROL, V207, P118, DOI 10.1016/j.expneurol.2007.06.003; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Witting A, 2004, P NATL ACAD SCI USA, V101, P3214, DOI 10.1073/pnas.0306707101; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	63	106	109	0	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	OCT	2013	39	6					654	666		10.1111/nan.12008			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	213ID	WOS:000324048500007	23231074	Green Accepted			2021-06-18	
J	Jin, XM; Ishii, H; Bai, ZB; Itokazu, T; Yamashita, T				Jin, Xuemei; Ishii, Hiroshi; Bai, Zhongbin; Itokazu, Takahide; Yamashita, Toshihide			Temporal Changes in Cell Marker Expression and Cellular Infiltration in a Controlled Cortical Impact Model in Adult Male C57BL/6 Mice	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; CERVICAL LYMPH-NODES; FUNCTIONAL RECOVERY; IMMUNE-RESPONSE; T-CELLS; INFLAMMATION; MICROGLIA; SYSTEM; CNS	Background: Traumatic injury to the central nervous system (CNS) triggers a robust inflammatory response that leads to axonal damage and secondary degeneration of spared tissue. In contrast, some immune responses have neuroprotective effects. However, detailed information regarding the dynamics of immune responses after traumatic CNS injury is still unavailable. Methods: In the present study, changes in the immune cells present in the injured brain, spleen, and cervical lymph nodes (CLNs), which are draining lymphatic organs from the CNS, were analyzed after controlled cortical impact (CCI) by flow cytometry and immunohistochemistry. Results: The number of neutrophils and macrophages that infiltrated the injured brain immediately increased 1 d post-injury and declined rapidly thereafter. In the injured brain, resident microglia showed a bimodal increase during the first week and in the chronic phase (>= 3 weeks) after injury. Increase in the Iba-1(+) microglia/macrophages was observed around the injured site. Morphologic analysis showed that Iba-1(+) cells were round at 1 week, whereas those at 3 weeks were more ramified. Furthermore, CD86(+)/CD11b(+) M1-like microglia increased at 4 weeks after CCI, whereas CD206(+)/CD11b(+) M2-like microglia increased at 1 week. These results suggest that different subsets of microglia increased in the acute and chronic phases after CCI. Dendritic cells and T cells increased transiently within 1 week in the injured brain. In the CLNs and the spleen, T cells showed dynamic changes after CCI. In particular, the alteration in the number of T cells in the CLNs showed a similar pattern, with a 1-week delay, to that of microglia in the injured brain. Conclusion: The data from this study provide useful information on the dynamics of immune cells in CNS injuries.	[Jin, Xuemei; Ishii, Hiroshi; Itokazu, Takahide; Yamashita, Toshihide] Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Suita, Osaka, Japan; [Jin, Xuemei; Ishii, Hiroshi; Itokazu, Takahide; Yamashita, Toshihide] Japan Sci & Technol Agcy JST, CREST, Chiyoda Ku, Tokyo, Japan; [Bai, Zhongbin] Yunnan Agr Univ, Key Lab Puer Tea Sci, Minist Educ, Kunming, Peoples R China	Jin, XM (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Suita, Osaka, Japan.	yamashita@molneu.med.osaka-u.ac.jp		Yamashita, Toshihide/0000-0003-4559-7018; Meng, Yuhuan/0000-0001-7464-3103; Mailund, Thomas/0000-0001-6206-9239; Itokazu, Takahide/0000-0003-2977-7190; Hvilsom, Christina/0000-0001-7870-6888	Core Research for Evolutional Science and Technology (CREST)Core Research for Evolutional Science and Technology (CREST); Japan Science and Technology Agency (JST)Japan Science & Technology Agency (JST)	This work was supported by Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Arneth BM, 2010, J NEUROIMMUNOL, V219, P123, DOI 10.1016/j.jneuroim.2009.12.011; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399; Carson MJ, 2006, CLIN NEUROSCI RES, V6, P237, DOI 10.1016/j.cnr.2006.09.004; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; CSERR HF, 1992, IMMUNOL TODAY, V13, P507, DOI 10.1016/0167-5699(92)90027-5; Dardiotis E, 2012, BRAIN INJURY PATHOGE; De Haas AH, 2007, GLIA, V55, P1374, DOI 10.1002/glia.20554; de Vos AF, 2002, J IMMUNOL, V169, P5415, DOI 10.4049/jimmunol.169.10.5415; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Foley LM, 2009, J NEUROTRAUM, V26, P1509, DOI 10.1089/neu.2008.0747; FORD AL, 1995, J IMMUNOL, V154, P4309; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Gensel JC, 2011, EXPERT OPIN THER TAR, V15, P505, DOI 10.1517/14728222.2011.553605; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Hatterer E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003321; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Herz J, 2010, EXP NEUROL, V225, P9, DOI 10.1016/j.expneurol.2009.11.019; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Klemann C, 2009, AM J PATHOL, V174, P2234, DOI 10.2353/ajpath.2009.081084; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nguyen HX, 2011, JOVE-J VIS EXP, DOI 10.3791/2698; Omoto S, 2010, J NEUROSCI, V30, P13045, DOI 10.1523/JNEUROSCI.3228-10.2010; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Sagar D, 2012, J NEUROIMMUNE PHARM, V7, P74, DOI 10.1007/s11481-011-9302-7; Saunders NR, 1999, CLIN EXP PHARMACOL P, V26, P11, DOI 10.1046/j.1440-1681.1999.02986.x; Schroeter M, 2005, NEUROMOL MED, V7, P183, DOI 10.1385/NMM:7:3:183; Schwartz M, 2005, ACTA NEUROCHIR SUPPL, V93, P147; Shichita T, 2009, NAT MED, V15, P946, DOI 10.1038/nm.1999; Soares HD, 1995, J NEUROSCI, V15, P8223; Veenith Tonny, 2009, World J Emerg Surg, V4, P7, DOI 10.1186/1749-7922-4-7; WIDNER H, 1988, SCAND J IMMUNOL, V28, P563, DOI 10.1111/j.1365-3083.1988.tb01488.x; Wilson EH, 2010, J CLIN INVEST, V120, P1368, DOI 10.1172/JCI41911; YAMADA S, 1991, AM J PHYSIOL, V261, pH1197; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zindler E, 2010, BEST PRACT RES-CLIN, V24, P551, DOI 10.1016/j.bpa.2010.11.001	48	106	110	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2012	7	7							e41892	10.1371/journal.pone.0041892			13	Multidisciplinary Sciences	Science & Technology - Other Topics	978NX	WOS:000306751300081	22911864	DOAJ Gold, Green Published			2021-06-18	
J	Zhu, YG; Nwabuisi-Heath, E; Dumanis, SB; Tai, LM; Yu, CJ; Rebeck, GW; Ladu, MJ				Zhu, Yuangui; Nwabuisi-Heath, Evelyn; Dumanis, Sonya B.; Tai, Leon M.; Yu, Chunjiang; Rebeck, G. William; Ladu, Mary Jo			APOE genotype alters glial activation and loss of synaptic markers in mice	GLIA			English	Article						Alzheimer's disease; microglia; astrocyte; inflammation; cytokine; synaptic protein loss; lipopolysaccharide	TARGETED-REPLACEMENT MICE; SYSTEM INFLAMMATORY RESPONSE; TRAUMATIC BRAIN-INJURY; INNATE IMMUNE-RESPONSE; APOLIPOPROTEIN-E GENE; N-TERMINAL KINASE; ALZHEIMERS-DISEASE; COMMON VARIANTS; TYPE-4 ALLELE; IN-VIVO	The ?4 allele of the Apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer's disease (AD), and affects clinical outcomes of chronic and acute brain damages. The mechanisms by which apoE affect diverse diseases and disorders may involve modulation of the glial response to various types of brain damage. We examined glial activation in a mouse model where each of the human APOE alleles are expressed under the endogenous mouse APOE promoter, as well as in APOE knock-out mice. APOE4 mice displayed increased glial activation in response to intracerebroventricular lipopolysaccharide (LPS) compared to APOE2 and APOE3 mice by several measures. There were higher levels of microglia/macrophage, astrocytes, and invading T-cells after LPS injection in APOE4 mice. APOE4 mice also displayed greater and more prolonged increases of cytokines (IL-1 beta, IL-6, TNF-a) than APOE2 and APOE3 mice. We found that APOE4 mice had greater synaptic protein loss after LPS injection, as measured by three markers: PSD-95, drebin, and synaptophysin. In all assays, APOE knock-out mice responded similar to APOE4 mice, suggesting that the apoE4 protein may lack anti-inflammatory characteristics of apoE2 and apoE3. Together, these findings demonstrate that APOE4 predisposes to inflammation, which could contribute to its association with Alzheimer's disease and other disorders. (c) 2012 Wiley Periodicals, Inc.	[Zhu, Yuangui; Nwabuisi-Heath, Evelyn; Tai, Leon M.; Yu, Chunjiang; Ladu, Mary Jo] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA; [Zhu, Yuangui] Fujian Med Univ, Union Hosp, Dept Neurol, Fuzhou, Fujian, Peoples R China; [Dumanis, Sonya B.; Rebeck, G. William] Georgetown Univ, Dept Neurosci, Washington, DC USA	Ladu, MJ (corresponding author), Univ Illinois, Dept Anat & Cell Biol, 808 S Wood St,CME Rm 578,M-C 512, Chicago, IL 60612 USA.	mladu@uic.edu	Rebeck, George William/J-2192-2012; Yu, Chunjiang/E-9419-2012	Rebeck, George William/0000-0001-6276-248X; LaDu, Mary Jo/0000-0003-2141-1450; Dumanis, Sonya/0000-0002-3345-9497	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 AG030128, P01 AG030128-03S1]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG030128] Funding Source: NIH RePORTER	Grant sponsor: NIH; Grant numbers: P01 AG030128, P01 AG030128-03S1.	Baitsch D, 2011, ARTERIOSCL THROM VAS, V31, P1160, DOI 10.1161/ATVBAHA.111.222745; Bour A, 2008, BEHAV BRAIN RES, V193, P174, DOI 10.1016/j.bbr.2008.05.008; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Dumanis SB, 2009, J NEUROSCI, V29, P15317, DOI 10.1523/JNEUROSCI.4026-09.2009; Egensperger R, 1998, BRAIN PATHOL, V8, P439; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fukaya M, 2000, J COMP NEUROL, V426, P572; Genin E, 2011, MOL PSYCHIATR, V16, P903, DOI 10.1038/mp.2011.52; Grootendorst J, 2005, BEHAV BRAIN RES, V159, P1, DOI 10.1016/j.bbr.2004.09.019; Herrup K, 2010, J NEUROSCI, V30, P16755, DOI 10.1523/JNEUROSCI.4521-10.2010; Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803; Jones L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013950; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Korwek KM, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-21; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; Li FQ, 2010, J PHARMACOL EXP THER, V334, P106, DOI 10.1124/jpet.110.167882; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Maezawa I, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-10; Maezawa I, 2006, FASEB J, V20, P797, DOI 10.1096/fj.05-5423fje; McGeer PL, 2007, NEUROBIOL AGING, V28, P639, DOI 10.1016/j.neurobiolaging.2006.03.013; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Ophir G, 2005, NEUROBIOL DIS, V20, P709, DOI 10.1016/j.nbd.2005.05.002; Ophir G, 2003, NEUROBIOL DIS, V12, P56, DOI 10.1016/S0969-9961(02)00005-0; Pocivavsek A, 2009, J NEUROIMMUNOL, V214, P25, DOI 10.1016/j.jneuroim.2009.06.010; Pocivavsek A, 2009, BIOCHEM BIOPH RES CO, V387, P516, DOI 10.1016/j.bbrc.2009.07.048; Pocivavsek A, 2009, GLIA, V57, P444, DOI 10.1002/glia.20772; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; REBECK GW, 1993, NEURON, V11, P575; Riddell DR, 2008, J NEUROSCI, V28, P11445, DOI 10.1523/JNEUROSCI.1972-08.2008; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sullivan PM, 2011, NEUROBIOL AGING, V32, P791, DOI 10.1016/j.neurobiolaging.2009.05.011; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Szekely CA, 2008, NEUROLOGY, V70, P17, DOI 10.1212/01.wnl.0000284596.95156.48; Trommer BL, 2004, NEUROREPORT, V15, P2655, DOI 10.1097/00001756-200412030-00020; Tukhovskaya EA, 2009, J NEUROSCI RES, V87, P677, DOI 10.1002/jnr.21874; Varvel NH, 2009, J CLIN INVEST, V119, P3692, DOI 10.1172/JCI39716; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Wang CS, 2005, NEUROBIOL DIS, V18, P390, DOI 10.1016/j.nbd.2004.10.013; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006; Yip Agustin G, 2005, BMC Geriatr, V5, P2, DOI 10.1186/1471-2318-5-2	53	106	109	1	13	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0894-1491			GLIA	Glia	APR	2012	60	4					559	569		10.1002/glia.22289			11	Neurosciences	Neurosciences & Neurology	888MC	WOS:000300006700004	22228589	Green Accepted			2021-06-18	
J	Anderson, V; Brown, S; Newitt, H; Hoile, H				Anderson, Vicki; Brown, Sandra; Newitt, Heidi; Hoile, Hannah			Long-Term Outcome From Childhood Traumatic Brain Injury: Intellectual Ability, Personality, and Quality of Life	NEUROPSYCHOLOGY			English	Article						child traumatic brain injury; adult outcome; IQ; personality; quality of life	HEAD-INJURY; EXECUTIVE FUNCTION; CHILDREN; RECOVERY; TBI; AGE	Objective: Only a handful of studies have attempted to explore very long-term outcomes from childhood traumatic brain injury (TB!). These studies have generally failed to fully consider the impact of injury severity or employ measures sensitive to the survivor's day-to-day function. This study examined outcomes in adulthood, with a focus on functional abilities including education, employment, and quality of life (QOL), and employed predictors including injury severity, age at injury, socioeconomic factors, intelligence, and personality. Method: The study was retrospective and cross-sectional and included 50 adult survivors of child TBI (31 males), aged 19-30 years at evaluation (M = 24.2, SD = 3.6), with injury on average 13.3 years prior to evaluation. Participants were divided according to injury severity mild (n = 20), moderate (n = 12), and severe (n = 18) completed an intellectual evaluation and questionnaires regarding educational and employment status, personality, and quality of life. Results: Intellectual and personality measures indicated good outcomes, with mean scores for all groups in the average range and few severity-based findings. In contrast, those with more severe TBI were more likely to have educational and employment problems. QOL was significantly reduced in the context of severe insult, with lower IQ and personality factors most predictive of outcome in this domain. Mild and moderate TBI were generally more benign. Conclusions: Findings suggest that, while TBI is a lifelong problem, its impact is most dramatic in the domain of QOL, where a complex interaction occurs between injury factors, cognition, and personality.	[Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Australian Ctr Child Neuropsychol Studies, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Newitt, Heidi; Hoile, Hannah] Univ Melbourne, Dept Psychol Sci, Melbourne, Vic 3010, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Australian Ctr Child Neuropsychol Studies, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au					Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; *AUSTR BUR STAT, 2006, DIS LONG TERM HLTH C; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Costa P., 1992, REVISED NEO PERSONAL; Daniel A. E., 1983, POWER PRIVILEGE PRES; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; MAX J, 1997, J AM ACAD CHILD ADOL, V36, P83; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; WARD LC, 1990, J CLIN PSYCHOL, V46, P436, DOI 10.1002/1097-4679(199007)46:4<436::AID-JCLP2270460411>3.0.CO;2-M; Wechsler D, 1997, WAIS 3 ADM SCORING M; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	36	106	106	0	30	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2011	25	2					176	184		10.1037/a0021217			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	731ZF	WOS:000288149000005	21219074				2021-06-18	
J	Fay, TB; Yeates, KO; Taylor, HG; Bangert, B; Dietrich, A; Nuss, KE; Rusin, J; Wright, M				Fay, Taryn B.; Yeates, Keith Owen; Taylor, H. Gerry; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn E.; Rusin, Jerome; Wright, Martha			Cognitive reserve as a moderator of postconcussive symptoms in children with complicated and uncomplicated mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Nervous system trauma; Pediatric; Prospective studies; Head injury; Concussion; Head trauma; Cognitive ability	HEAD-INJURY	The Occurrence of postconcussive symptoms (PCS) following mild traumatic brain injury (TBI) in children may depend on cognitive reserve capacity. This prospective, longitudinal study examined whether the relationship between mild TBI and PCS is moderated by cognitive ability, which served as a proxy for cognitive reserve. Participants included 182 children with mild TBI and 99 children with orthopedic injuries (OI). ranging from 8 to 15 years of age when injured. Mild TBI were classified as complicated (n = 32) or uncomplicated (n = 150) depending oil whether they were associated with trauma-related intracranial abnormalities on magnetic resonance imaging. PCS were assessed initially within 3 weeks of injury, and again at 1, 3, and 12 months post injury. The initial assessment also included standardized tests of children's cognitive skills and retrospective parent ratings of pre-injury symptoms. Hierarchical linear modeling indicated that ratings of PCS were moderated jointly by cognitive ability and injury severity. Children of lower cognitive ability with a complicated mild TBI were especially prone to cognitive symptoms across time according to parents and to high acute levels of PCS according to children's self-ratings. Cognitive reserve is an important moderator of the outcomes of mild TBI in children and adolescents. (JINS, 2010, 16, 94-105.)	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Columbus, OH 43205 USA; [Fay, Taryn B.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Fay, Taryn B.; Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn E.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn E.] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Nuss, Kathryn/0000-0003-2185-7364; Fay-McClymont, Taryn/0000-0002-2706-6179	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD39834, K02 HD44099]; National Center for Medical Rehabilitation Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER	The research reported here served as the basis for a dissertation submitted by the first author to The Ohio State University in partial fulfillment of the requirements for a doctoral degree. Portions of the research were presented at the annual meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February, 2008. The larger study On which the research was based was supported by grants R01 HD39834 and K02 HD44099 from the National Institute of Child Health and Human Development and the National Center for Medical Rehabilitation Research to Keith Owen Yeates. The authors wish to acknowledge the contributions of Lauren Ayr, Anne Birnbaum, Amy Clemens, Kalaichelvi Ganesalingham, Christine Hajek, Amanda Lininger, Melissa Ginn. Katie Pestro, Elizabeth Roth, Elizabeth Shaver, and Heidi Walker in conducting the Study.	Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; *AM ASS ADV AUT ME, 1990, ABBR INJ SCAL; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beery K.E., 2004, BEERY BUKTENICA DEV, V5th; Bergman DA, 1999, PEDIATRICS, V104, P1407; BIJUR PE, 1990, PEDIATRICS, V86, P337; BURCHINAL MR, 1994, J EARLY INTERVENTION, V18, P403, DOI 10.1177/105381519401800409; Choi YY, 2008, J NEUROSCI, V28, P10323, DOI 10.1523/JNEUROSCI.3259-08.2008; Delis D, 1994, MANUAL CALIFORNIA VE; Dennis M., 2006, COGNITIVE RESERVE TH, P53; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; Koenen KC, 2009, AM J PSYCHIAT, V166, P50, DOI 10.1176/appi.ajp.2008.08030343; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; McDaniel MA, 2005, INTELLIGENCE, V33, P337, DOI 10.1016/j.intell.2004.11.005; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SAHAKIAN BJ, 1992, J ROY SOC MED, V85, P399; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; TAYLOR HG, NEUROPSYCHO IN PRESS; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WECHSLER D, 1999, WECHSLER ABBREVIATEL; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	46	106	108	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2010	16	1					94	105		10.1017/S1355617709991007			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	543LR	WOS:000273579600011	19835663	Green Accepted			2021-06-18	
J	Harrison-Felix, CL; Whiteneck, GG; Jha, A; DeVivo, MJ; Hammond, FM; Hart, DM				Harrison-Felix, Cynthia L.; Whiteneck, Gale G.; Jha, Amitabh; DeVivo, Michael J.; Hammond, Flora M.; Hart, Denise M.			Mortality Over Four Decades After Traumatic Brain Injury Rehabilitation: A Retrospective Cohort Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cause of death; Life expectancy; Mortality; Rehabilitation	LONG-TERM SURVIVAL; SUDDEN UNEXPECTED DEATH; LIFE EXPECTANCY; HEAD-INJURY; EARLY PREDICTORS; RISK-FACTORS; EPILEPSY; AGE; DETERMINANTS; DISCHARGE	Objective: To investigate mortality, life expectancy, risk factors for death, and causes of death in persons with traumatic brain injury (TBI). Design: Retrospective cohort study. Setting: Used data from an inpatient rehabilitation facility, the Social Security Death Index, death certificates, and the U:S. population age-race-sex-specific and cause-specific mortality rates. Participants: Persons with TBI (N=1678) surviving to their first anniversary of injury admitted to rehabilitation from an acute care hospital within I year of injury between 1961 and 2002. Interventions: Not applicable. Main Outcome Measures: Vital status, standardized mortality ratio, life expectancy, cause of death. Results: Persons with TBI were 1.5 times more likely to die than persons in the general population of similar age, sex, and race, resulting in an estimated average life expectancy reduction of 4 years. Within the TBI population, the strongest independent risk factors for death after I year postinjury were being older, being male, having less education, having a longer hospitalization, having an earlier year of injury, and being in a vegetative state at rehabilitation discharge. After I year postinjury, persons with TBI were 49 times more likely to die of aspiration pneumonia, 22 times more likely to die of seizures, 4 times more likely to die of pneumonia, 3 times more likely to commit suicide, and 2.5 times more likely to die of digestive conditions than persons in the general population of similar age, sex, and race. Conclusions: This study demonstrated life expectancy after TBI rehabilitation is reduced and associated with specific risk factors and causes of death.	[Harrison-Felix, Cynthia L.; Whiteneck, Gale G.; Jha, Amitabh] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA; [DeVivo, Michael J.] Univ Alabama Birmingham, Birmingham, AL USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Harrison-Felix, Cynthia L.; Whiteneck, Gale G.; Jha, Amitabh; Hart, Denise M.] Craig Hosp, Englewood, CO 80113 USA	Harrison-Felix, CL (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80113 USA.	charrison-felix@craighospital.org			National Institute on Disability Rehabilitation and Research [H133G020182]	Supported by a Field Initiated Study from the National Institute on Disability Rehabilitation and Research (grant no. H133G020182). The opinions expressed are those of the authors and do not necessarily reflect the views of the National Institute on Disability Rehabilitation and Research.	ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Baguley I, 2000, BRAIN INJURY, V14, P505; BRESLOW N.E., 1987, STAT METHODS CANC RE, VII; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; DEVIVO MJ, 1995, CHEST, V108, P226, DOI 10.1378/chest.108.1.226; Donohue JT, 2007, J TRAUMA, V62, P419, DOI 10.1097/01.ta.0000219286.88179.18; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Ficker DM, 1998, NEUROLOGY, V51, P1270, DOI 10.1212/WNL.51.5.1270; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P184, DOI 10.1097/00002060-200003000-00012; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; GARDNER P, 1996, LEADING CAUSES DE 20; Gordis L., 2000, EPIDEMIOLOGY; Hammond F. M., 2000, ARCH PHYS MED REHAB, V81, P1260; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KOCHANEK KD, 1995, ADV REPORT FINAL M S, V43; KOCHANEK KD, 2004, DEATHS FINAL DATA 20, P53; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Lhatoo SD, 2001, ANN NEUROL, V49, P336; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; Morgan CL, 2002, EPILEPSIA, V43, P1251, DOI 10.1046/j.1528-1157.2002.38701.x; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nashef L, 2007, EPILEPSIA, V48, P859, DOI 10.1111/j.1528-1167.2007.01082.x; Opeskin K, 2003, SEIZURE-EUR J EPILEP, V12, P456, DOI 10.1016/S1059-1311(02)00352-7; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; *PRACT MAN INF COR, 2006, ICD9CM PRACT MAN INF; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Roberts A.V., 1979, SEVERE ACCIDENTAL HE, P140; Rosner B., 2000, FUNDAMENTALS BIOSTAT; Ryvlin P, 2006, CURR OPIN NEUROL, V19, P194, DOI 10.1097/01.wco.0000218238.90711.f4; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Sesso HD, 2000, AM J EPIDEMIOL, V152, P107, DOI 10.1093/aje/152.2.107; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shavelle RM, 2007, BRAIN INJURY MED PRI, P247; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; *SOC SEC ADM, 2009, SOC SEC DEATH MAST F; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Sperling MR, 1999, ANN NEUROL, V46, P45, DOI 10.1002/1531-8249(199907)46:1<45::AID-ANA8>3.0.CO;2-I; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Strauss DJ, 2003, NEUROLOGY, V60, P395, DOI 10.1212/WNL.60.3.395; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; THURMAN D, 2001, EPIDEMIOLOGY EC HEAD; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomson T, 2005, EPILEPSIA, V46, P54, DOI 10.1111/j.1528-1167.2005.00411.x; *TRAUM BRAIN INJ M, 2009, TRAUM BRAIN INJ MOD, V25, P2009; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WALKER AE, 1970, EPILEPSIA, V11, P17, DOI 10.1111/j.1528-1157.1970.tb03861.x; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270	77	106	107	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2009	90	9					1506	1513		10.1016/j.apmr.2009.03.015			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	496AA	WOS:000269938100008	19735778				2021-06-18	
J	Utomo, WK; Gabbe, BJ; Simpson, PM; Cameron, PA				Utomo, Wesley K.; Gabbe, Belinda J.; Simpson, Pamela M.; Cameron, Peter A.			Predictors of in-hospital mortality and 6-month functional outcomes in older adults after moderate to severe traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Trauma registry; Older adults; Outcome study; Glasgow Outcome Scale	HEAD-INJURY; AGE; POPULATION; EPIDEMIOLOGY; HYPOTENSION; AUSTRALIA; DISCHARGE; REGISTRY; PATIENT	Introduction: Traumatic brain injury (TBI) is the single largest cause of death and disability following injury worldwide. While TBI in older adults is less common, it still contributes to significant morbidity and mortality in this group. Understanding the patient characteristics that result in good and poor outcome after TBI is important in the clinical management and prognosis of older adult TBI patients. This population-based study investigated predictors of mortality and longer term functional outcomes following serious TBI in older adults. Methods: All older adults (aged > 64 years), isolated moderate to severe TBI cases from the population based Victorian State Trauma Registry for the period July 2005 to June 2007 (inclusive) were extracted for analysis. Demographic, injury event, injury diagnosis, management and comorbid status information were obtained and the outcomes of interest were in-hospital mortality, and the Glasgow Outcome Scale-Extended (GOS-E) score at 6 months post-injury. Multivariate logistic regression analyses were used to identify independent predictors of in-hospital mortality and independent living (GOS-E > 4) status at 6 months. Results: Of the 428 isolated, older adult TBI cases, the majority were the result of a fall (88%), male (55%), and aged > 74 years (76%). The in-hospital death rate was 28% and increasing age (p = 0.009), decreasing GCS (p < 0.001) and injury type (p = 0.002) were significant independent predictors of in-hospital mortality. Of the 310 patients who survived to discharge, 65% were successfully followed-up 6 months following injury. There was no difference between patients lost to follow-up and those successfully followed-up with respect to the key population indicators of age, gender, or head injury severity. Younger (<75 years) patients, and those with an SBP on arrival at hospital of 131-150 mmHg, were at increased odds of living independently at follow-up. No patients with a GCS < 9 had a good 6-month outcome, and most of them died. The survival rate for brainstem injury was also low (21%). Conclusion: In this population-based study, we found that age. GCS, brainstem injury, and systolic blood pressure were the most important factors in predicting outcome in older adults with an isolated moderate to severe TBI. (C) 2009 Elsevier Ltd. All rights reserved.	[Utomo, Wesley K.; Gabbe, Belinda J.; Simpson, Pamela M.; Cameron, Peter A.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Utomo, Wesley K.] Erasmus Univ, Sch Med, Erasmus Med Ctr, Rotterdam, Netherlands; [Gabbe, Belinda J.; Cameron, Peter A.] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Cameron, Peter A.] Emergency & Trauma Ctr, Melbourne, Vic, Australia	Cameron, PA (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Commercial Rd, Melbourne, Vic 3004, Australia.	peter.cameron@med.monash.edu.au	Utomo, Wesley Kristian/P-5442-2014	Utomo, Wesley Kristian/0000-0002-9060-3547; Cameron, Peter/0000-0002-1443-557X; Gabbe, Belinda/0000-0001-7096-7688	Victorian State Trauma Registry is a Department of Human Services (Victoria); TAC Health Research; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	The Victorian State Trauma Registry is a Department of Human Services (Victoria) and TAC Health Research funded and approved initiative. Dr Belinda Gabbe was supported by a Career Development Award from the National Health and Medical Research Council of Australia. The authors would like to acknowledge the considerable help provided by VSTR staff, data collectors and members of the Steering Committee over the study period.	Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Cameron PA, 2005, J TRAUMA, V59, P1469, DOI 10.1097/01.ta.0000198350.15936.a1; Cameron PA, 2004, ANZ J SURG, V74, P424, DOI 10.1111/j.1445-1433.2004.03029.x; Camilloni L, 2008, INT J INJ CONTROL SA, V15, P25, DOI 10.1080/17457300701800118; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; HELPS Y, 2008, AUSTR I HLTH WELFARE; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Mitra B, 2008, ANZ J SURG, V78, P588, DOI 10.1111/j.1445-2197.2008.04579.x; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Shafi S, 2005, J TRAUMA, V59, P830, DOI 10.1097/01.ta.0000188147.36232.c0; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	23	106	107	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2009	40	9					973	977		10.1016/j.injury.2009.05.034			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	487KE	WOS:000269271500013	19540490				2021-06-18	
J	Sun, D; Bullock, MR; McGinn, MJ; Zhou, Z; Altememi, N; Hagood, S; Hamm, R; Colello, RJ				Sun, Dong; Bullock, M. Ross; McGinn, Melissa J.; Zhou, Zhengwen; Altememi, Nabil; Hagood, Sarah; Hamm, Robert; Colello, Raymond J.			Basic fibroblast growth factor-enhanced neurogenesis contributes to cognitive recovery in rats following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Neurogenesis; bFGF; Traumatic brain injury; Hippocampus; SVZ; Morris water maze	NEURAL STEM-CELLS; DENTATE GYRUS; HIPPOCAMPAL-NEURONS; SUBVENTRICULAR ZONE; GRANULE CELLS; ADULT RATS; IN-VITRO; PROLIFERATION; FGF-2; DIFFERENTIATION	Stem/progenitor cells reside throughout the adult CNS and are actively dividing in the subventricular zone (SVZ) and the dentate gyrus (DG) of the hippocampus. This neurogenic capacity of the SVZ and DG is enhanced following traumatic brain injury (TBI) suggesting that the adult brain has the inherent potential to restore populations lost to injury. This raises the possibility of developing strategies aimed at harnessing the neurogenic capacity of these regions to repair the damaged brain. One strategy is to enhance neurogenesis with mitogenic factors. As basic fibroblast growth factor (bFGF) is a potent stem cell mitogen, we set out to determine if an intraventricular administration of bFGF following TBI could affect the levels of injury-induced neurogenesis in the SVZ and DG, and the degree to which this is associated with cognitive recovery. Specifically, adult rats received a bFGF intraventricular infusion for 7 days immediately following TBI. BrdU was administered to animals daily at 2-7 days post-injury to label cell proliferation. At 1 or 4 weeks post-injury, brain sections were immunostained for BrdU and neuronal or astrocytic markers. We found that injured animals infused with bFGF exhibited significantly enhanced cell proliferation in the SVZ and the DG at 1 week post-TBI as compared to vehicle-infused animals. Moreover, following bFGF infusion, a greater number of the newly generated cells survived to 4 weeks post-injury, with the majority being neurons. Additionally, animals infused with bFGF showed significant cognitive improvement. Collectively, the current findings suggest that bFGF-enhanced neurogenesis contributes to cognitive recovery following TBI. (C) 2008 Elsevier Inc. All rights reserved.	[Sun, Dong; Bullock, M. Ross; Zhou, Zhengwen; Altememi, Nabil; Hagood, Sarah] Virginia Commonwealth Univ, Med Coll Virginia Campus, Dept Neurosurg, Richmond, VA 23298 USA; [McGinn, Melissa J.; Colello, Raymond J.] Virginia Commonwealth Univ, Med Coll Virginia Campus, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Hamm, Robert] Virginia Commonwealth Univ, Med Coll Virginia Campus, Dept Psychol, Richmond, VA 23298 USA	Sun, D (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia Campus, Dept Neurosurg, Richmond, VA 23298 USA.	dsun@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1. NS055086]; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055086, P30NS047463] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health Grant RO1. NS055086 (D. Sun). Microscopy work was performed at the VCU - Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS center core grant 5P30NS047463.	AKANEYA Y, 1993, J CEREBR BLOOD F MET, V13, P1029, DOI 10.1038/jcbfm.1993.130; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; AOYAGI A, 1994, BRAIN RES, V661, P117, DOI 10.1016/0006-8993(94)91188-6; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; Calof Anne L., 1995, Current Opinion in Neurobiology, V5, P19, DOI 10.1016/0959-4388(95)80082-4; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CASPER D, 1995, J NEUROCHEM, V65, P1016; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Fitzsimonds RM, 1998, PHYSIOL REV, V78, P143; FREESE A, 1992, BRAIN RES, V575, P351, DOI 10.1016/0006-8993(92)90104-H; FRESSINAUD C, 1993, DEV BIOL, V158, P317, DOI 10.1006/dbio.1993.1191; GONZALEZ AM, 1995, BRAIN RES, V701, P201, DOI 10.1016/0006-8993(95)01002-X; Gould E, 1996, DEV NEUROSCI-BASEL, V18, P22, DOI 10.1159/000111392; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Gritti A, 1996, J NEUROSCI, V16, P1091; Hagood SK, 2006, J NEUROTRAUM, V23, P205, DOI 10.1089/neu.2006.23.205; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Keuker JIH, 2001, BRAIN RES PROTOC, V7, P211, DOI 10.1016/S1385-299X(01)00064-2; Kuhn HG, 1997, J NEUROSCI, V17, P5820; KUMON Y, 1993, BRAIN RES, V605, P169, DOI 10.1016/0006-8993(93)91369-4; Li AJ, 2002, EUR J NEUROSCI, V16, P1313, DOI 10.1046/j.1460-9568.2002.02193.x; LOGAN A, 1992, J NEUROSCI, V12, P3828; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Maric D, 2007, J NEUROSCI, V27, P1836, DOI 10.1523/JNEUROSCI.5141-06.2007; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; Monfils MH, 2008, EXP BRAIN RES, V185, P453, DOI 10.1007/s00221-007-1172-0; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; NAKATA N, 1993, BRAIN RES, V605, P354, DOI 10.1016/0006-8993(93)91766-L; Palmer TD, 1999, J NEUROSCI, V19, P8487; PATEL MN, 1995, NEUROSCIENCE, V69, P763, DOI 10.1016/0306-4522(95)00281-M; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; Raballo R, 2000, J NEUROSCI, V20, P5012; Rai KS, 2007, EUR J NEUROSCI, V26, P1765, DOI 10.1111/j.1460-9568.2007.05820.x; Ramirez JJ, 1999, NEUROREPORT, V10, P1201, DOI 10.1097/00001756-199904260-00008; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Shetty AK, 2005, GLIA, V51, P173, DOI 10.1002/glia.20187; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Tao Y, 1997, J NEUROBIOL, V33, P289, DOI 10.1002/(SICI)1097-4695(199709)33:3<289::AID-NEU7>3.3.CO;2-X; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Tureyen K, 2005, NEUROSURGERY, V57, P1254, DOI 10.1227/01.NEU.0000186040.96929.8A; Vicario-Abejon Carlos, 2004, Curr Protoc Neurosci, VChapter 3, DOI 10.1002/0471142301.ns0302s26; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Weickert CS, 2005, NEUROSCIENCE, V131, P219, DOI 10.1016/j.neuroscience.2004.09.070; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998	57	106	122	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2009	216	1					56	65		10.1016/j.expneurol.2008.11.011			10	Neurosciences	Neurosciences & Neurology	413UK	WOS:000263817800008	19100261	Green Accepted			2021-06-18	
J	Hesdorffer, DC; Ghajar, J				Hesdorffer, Dale C.; Ghajar, Jamshid			Marked improvement in adherence to traumatic brain injury guidelines in United States trauma centers	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						TBI; guidelines; US trauma centers	SEVERE HEAD-INJURY; CENTER DESIGNATION; CLINICAL PATHWAY; CENTER VOLUME; MANAGEMENT; CARE; MORTALITY; OUTCOMES; IMPACT; TRIAL	Background: Prior surveys of acute medical management of severe traumatic brain injury (TBI) indicate that care is fragmented and inconsistent, although Guidelines for the management of severe traumatic brain injury (guidelines) were distributed and endorsed by the American Association of Neurologic Surgeons. We conducted a survey of US trauma centers to evaluate guideline adherence, to examine predictors of adherence, and to compare our results with similar surveys conducted in 1991 and 2000. Methods: A Web-based survey was conducted in 413 designated trauma centers admitting patients with severe TBI. Good adherence was defined as adherence to the median number of guidelines (median = 6, interquartile range 5-7). Results: In adjusted analysis, good adherence was predicted by Level I trauma center designation and presence of treatment protocols. Compared with trauma centers without these predictive factors, the likelihood of good guideline adherence increased 2.4-fold with each additional predictor (95% confidence interval = 1.8-3.3). Routine intracranial pressure monitor use increased from 32.4% in 1991 and 50.8% in 2000 to 77.4% in the current survey (p < 0.0001). Avoidance of steroids in TBI rose from 47.8% in 1991 and 52.4% in 2000 to 86.0% in 2006 (p < 0.0001). Lack of guideline adherence decreased significantly from 67% in 2006 to 34.5%. Conclusions: Adherence to evidence-based guidelines for severe TBI has improved dramatically since 1991. Trauma center level and treatment protocols were associated with good adherence, suggesting that directing patients with severe TBI to Level I and Level II trauma centers with treatment protocols will improve outcome for these patients.	Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA; Brain Trauma Foundat, New York, NY USA; Presbyterian Hosp, WeillCornell Med Ctr, Dept Neurosurg, New York, NY USA	Hesdorffer, DC (corresponding author), Columbia Univ, Sergievsky Ctr, 630 W 168th St,P&S Unit 16, New York, NY 10032 USA.	dch5@columbia.edu					*AMA, 1990, AMA OFF QUAL INS HLT; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P8; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COULDWELL WT, 2006, AM ASS NEUROLOGICAL, V15, P7; Demetriades D, 2006, J AM COLL SURGEONS, V202, P212, DOI 10.1016/j.jamcollsurg.2005.09.027; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Demetriades D, 2006, J AM COLL SURGEONS, V202; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Glance LG, 2004, J TRAUMA, V56, P682, DOI 10.1097/01.TA.0000053469.92142.40; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; London JA, 2003, J TRAUMA, V54, P16, DOI 10.1097/00005373-200301000-00003; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2003, JAMA-J AM MED ASSOC, V289, P1515, DOI 10.1001/jama.289.12.1515; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Mcilvoy L, 2001, J Neurosci Nurs, V33, P72; McIlvoy L, 2001, J NEUROSCI NURS, V33, P82, DOI DOI 10.1097/01376517-200104000-00002; McKinely BA, 1999, J TRAUMA, V46, P271, DOI 10.1097/00005373-199902000-00013; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; *NIH, 1994, REP TASK FORC TRAUM; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; Vitaz TW, 2001, J TRAUMA, V51, P369, DOI 10.1097/00005373-200108000-00025	38	106	108	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2007	63	4					841	847		10.1097/TA.0b013e318123fc21			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	219XL	WOS:000250121400020	18090015				2021-06-18	
J	Marx, CE; Trost, WT; Shampine, LJ; Stevens, RD; Hulette, CM; Steffens, DC; Ervin, JF; Butterfield, MI; Blazer, DG; Massing, MW; Lieberman, JA				Marx, Christine E.; Trost, William T.; Shampine, Lawrence J.; Stevens, Robert D.; Hulette, Christine M.; Steffens, David C.; Ervin, John F.; Butterfield, Marian I.; Blazer, Daniel G.; Massing, Mark W.; Lieberman, Jeffrey A.			The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease	BIOLOGICAL PSYCHIATRY			English	Article						allopregnanolone; Alzheimer's disease; dehydroepiandrosterone; neurosteroid; postmortem; prefrontal cortex	TRAUMATIC BRAIN-INJURY; STEROID-HORMONE METABOLITES; OXIDATIVE STRESS; NEUROACTIVE STEROIDS; DEHYDROEPIANDROSTERONE DHEA; PREGNENOLONE SULFATE; HIPPOCAMPAL-NEURONS; GABA-RECEPTOR; CELL-DEATH; RAT-BRAIN	Background: Few data are currently available investigating neurosteroids (NS) in Alzheimer's disease (AD). The NS allopregnanolone may be decreased in serum and plasma in patients with AD, but it is unclear if allopregnanolone is also reduced in brain. Because a number of NS exhibit neuroprotective effects and impact cognitive performance in rodent models, these molecules may be relevant to the pathophysiology of neurodegenerative disorders. We therefore investigated prefrontal cortex (PFC) NS levels in AD. Methods: Neurosteroid levels (allopregnanolone, pregnenolone, dehydroepiandrosterone [DHEA]) were determined in postmortem PFC in 14 male subjects with AD and 15 cognitively intact male control subjects by gas chromatography mass spectrometry preceded by high-performance liquid chromatography purification. Results: Subjects with AD exhibit significant reductions in allopregnanolone compared with cognitively intact control subjects (median levels = 2.50 ng/g vs, 5.59 ng/g, respectively; p = .02). Allopregnanolone levels are inversely correlated with neuropathological disease stage (Braak), r = -.49, p = .007. Median DHEA levels are elevated in subjects with AD (p = .01). Conclusions: Subjects with AD demonstrate significant reductions in PFC allopregnanolone levels, a finding that may be relevant to neuropathological disease stage severity. Neurosteroids may have utility as candidate biomarkers in AD.	Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Mental Hlth Serv Line 116A, Durham, NC 27705 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27705 USA; Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC 27705 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27705 USA; Durham Vet Affairs Med Ctr, Durham, NC 27705 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Marx, CE (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Mental Hlth Serv Line 116A, 508 Fulton St, Durham, NC 27705 USA.	marx0001@mc.duke.edu	Lieberman, Jeffrey/AAY-8239-2020		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH070448, K23MH065080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005128] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG05128] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH65080, T32 MH70448] Funding Source: Medline		Ahmad I, 2005, J NEUROSCI RES, V82, P811, DOI 10.1002/jnr.20685; Akwa Y, 2001, P NATL ACAD SCI USA, V98, P14033, DOI 10.1073/pnas.241503698; ALHAJ HA, 2005, PSYCHOPHARMACOLOGY B, P1; Alomary AA, 2001, INT REV NEUROBIOL, V46, P97; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Barbaccia ML, 2001, NEUROPSYCHOPHARMACOL, V25, P489, DOI 10.1016/S0893-133X(01)00254-8; Bartzokis G, 2004, NEUROBIOL AGING, V25, P5, DOI 10.1016/j.neurobiolaging.2003.03.001; Bastianetto S, 1999, MOL BRAIN RES, V66, P35, DOI 10.1016/S0169-328X(99)00002-9; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Benes FM, 2004, NEUROBIOL AGING, V25, P41, DOI 10.1016/j.neurobiolaging.2003.06.003; Bergeron R, 1996, J NEUROSCI, V16, P1193; Bernardi F, 2000, EUR J ENDOCRINOL, V142, P466, DOI 10.1530/eje.0.1420466; Bixo M, 1997, BRAIN RES, V764, P173, DOI 10.1016/S0006-8993(97)00455-1; Boccuzzi G, 1997, FREE RADICAL BIO MED, V22, P1289, DOI 10.1016/S0891-5849(96)00543-6; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brown RC, 2000, J NEUROCHEM, V74, P847, DOI 10.1046/j.1471-4159.2000.740847.x; Brown RC, 2003, NEUROBIOL AGING, V24, P57, DOI 10.1016/S0197-4580(02)00048-9; Cardounel A, 1999, P SOC EXP BIOL MED, V222, P145, DOI 10.1046/j.1525-1373.1999.d01-124.x; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; CORPECHOT C, 1981, P NATL ACAD SCI-BIOL, V78, P4704, DOI 10.1073/pnas.78.8.4704; Counterman AE, 2006, P NATL ACAD SCI USA, V103, P5262, DOI 10.1073/pnas.0504134103; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Debonnel G, 1996, NEUROSCIENCE, V71, P977, DOI 10.1016/0306-4522(96)80001-7; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dong E, 2001, P NATL ACAD SCI USA, V98, P2849, DOI 10.1073/pnas.051628598; Ebner MJ, 2006, ENDOCRINOLOGY, V147, P179, DOI 10.1210/en.2005-1065; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; Francis PT, 2005, CNS SPECTRUMS, V10, P6, DOI 10.1017/S1092852900014164; Genazzani AR, 1998, J CLIN ENDOCR METAB, V83, P2099, DOI 10.1210/jc.83.6.2099; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Girdler SS, 2001, BIOL PSYCHIAT, V49, P788, DOI 10.1016/S0006-3223(00)01044-1; Glantz LA, 2000, ARCH GEN PSYCHIAT, V57, P65, DOI 10.1001/archpsyc.57.1.65; Griffin LD, 2001, ENDOCRINOLOGY, V142, P4617, DOI 10.1210/en.142.11.4617; Griffin LD, 1999, P NATL ACAD SCI USA, V96, P13512, DOI 10.1073/pnas.96.23.13512; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Higashi T, 2003, J PHARMACEUT BIOMED, V30, P1907, DOI 10.1016/S0731-7085(02)00534-4; Hulette CM, 1997, ARCH PATHOL LAB MED, V121, P615; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jin LW, 2004, AM J PATHOL, V164, P975, DOI 10.1016/S0002-9440(10)63185-9; Karishma KK, 2002, EUR J NEUROSCI, V16, P445, DOI 10.1046/j.1460-9568.2002.02099.x; Kim SB, 2003, J CLIN ENDOCR METAB, V88, P5199, DOI 10.1210/jc.2003-030646; Kimonides VG, 1999, NEUROSCIENCE, V89, P429, DOI 10.1016/S0306-4522(98)00347-9; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; Korolainen MA, 2006, NEUROBIOL AGING, V27, P42, DOI 10.1016/j.neurobiolaging.2004.11.010; Liere P, 2004, J LIPID RES, V45, P2287, DOI 10.1194/jlr.M400244-JLR200; Lipton Stuart A., 2005, Current Alzheimer Research, V2, P155, DOI 10.2174/1567205053585846; Liu SY, 2003, ANAL CHEM, V75, P5835, DOI 10.1021/ac0346297; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Mariani E, 2005, J CHROMATOGR B, V827, P65, DOI 10.1016/j.jchromb.2005.04.023; Marx CE, 2000, BIOL PSYCHIAT, V47, P1000, DOI 10.1016/S0006-3223(99)00305-4; Marx CE, 2003, NEUROPSYCHOPHARMACOL, V28, P1, DOI 10.1038/sj.npp.1300015; MARX CE, IN PRESS PHARM BIOCH; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; Maurice T, 1998, NEUROSCIENCE, V83, P413, DOI 10.1016/S0306-4522(97)00405-3; Mellon SH, 2002, ENDOCR RES, V28, P463, DOI 10.1081/ERC-120016823; Meunier J, 2004, NEUROTOXICOL TERATOL, V26, P783, DOI 10.1016/j.ntt.2004.07.003; MORROW AL, 1990, MOL PHARMACOL, V37, P263; MORROW AL, 1987, EUR J PHARMACOL, V142, P483, DOI 10.1016/0014-2999(87)90094-X; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Papassotiropoulos A, 2005, J CLIN PSYCHIAT, V66, P940, DOI 10.4088/JCP.v66n0720; PAUL SM, 1992, FASEB J, V6, P2311; Pinna G, 2003, P NATL ACAD SCI USA, V100, P2035, DOI 10.1073/pnas.0337642100; Prabakaran S, 2004, MOL PSYCHIATR, V9, P684, DOI 10.1038/sj.mp.4001511; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; PURDY R, 2006, HDB NEUROCHEMISTRY M, V18, P1; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Ramassamy C, 1999, FREE RADICAL BIO MED, V27, P544, DOI 10.1016/S0891-5849(99)00102-1; ROBERTS E, 1987, BRAIN RES, V406, P357, DOI 10.1016/0006-8993(87)90807-9; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Shobab LA, 2005, LANCET NEUROL, V4, P841, DOI 10.1016/S1474-4422(05)70248-9; Shu HJ, 2004, J NEUROSCI, V24, P6667, DOI 10.1523/JNEUROSCI.1399-04.2004; Smith AB, 2003, ORG LETT, V5, P1, DOI 10.1021/ol0202520; Suzuki M, 2004, P NATL ACAD SCI USA, V101, P3202, DOI 10.1073/pnas.0307325101; Torrey EF, 2005, BIOL PSYCHIAT, V57, P252, DOI 10.1016/j.biopsych.2004.10.019; Treiber-Held S, 2003, J PATHOL, V200, P95, DOI 10.1002/path.1345; Tunez I, 2005, PHARMACOLOGY, V74, P113, DOI 10.1159/000084169; Uzunov DP, 1996, P NATL ACAD SCI USA, V93, P12599, DOI 10.1073/pnas.93.22.12599; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Vallee M, 2003, J STEROID BIOCHEM, V85, P329, DOI 10.1016/S0960-0760(03)00227-9; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Vance JE, 2005, SEMIN CELL DEV BIOL, V16, P193, DOI 10.1016/j.semcdb.2005.01.005; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Wenk GL, 2006, J CLIN PSYCHIAT, V67, P3; Wolf OT, 1999, BRAIN RES REV, V30, P264, DOI 10.1016/S0165-0173(99)00021-1; Wolkowitz OM, 2003, NEUROLOGY, V60, P1071, DOI 10.1212/01.WNL.0000052994.54660.58; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; Yu WX, 2005, J BIOL CHEM, V280, P27296, DOI 10.1074/jbc.M503922200	94	106	112	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	DEC 15	2006	60	12					1287	1294		10.1016/j.biopsych.2006.06.017			8	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	115LL	WOS:000242735700001	16997284				2021-06-18	
J	Lloyd, V; Gatherer, A; Kalsy, S				Lloyd, Vicki; Gatherer, Amanda; Kalsy, Sunny			Conducting qualitative interview research with people with expressive language difficulties	QUALITATIVE HEALTH RESEARCH			English	Article						qualitative interviews; expressive language deficits; intellectual disability; dementia; stroke; traumatic brain injury	TRAUMATIC BRAIN INJURY; MENTALLY-RETARDED PERSONS; OF-LIFE ASSESSMENT; LEARNING-DISABILITIES; INTELLECTUAL DISABILITY; ALZHEIMERS-DISEASE; STROKE PATIENTS; COMMUNITY INTEGRATION; HEALTH RESEARCH; DEMENTIA	Despite the increasing application of qualitative interviewing and analysis approaches, individuals with expressive language difficulties are still frequently excluded from such research. In this article, the authors seek to clarify the role for and importance of conducting qualitative interviews with respondents with impaired expressive language. They review current research with reference to studies conducted with individuals with intellectual disabilities or dementia, or those who have experienced stroke or traumatic brain injury, and identify deficits within existing research. They consider the challenges and difficulties that contribute to the limited inclusion of individuals with impaired expressive communication in qualitative interviews and discuss the way forward with suggestions of possible means of overcoming these obstacles. They argue that a willingness to adapt methods appropriately and to modify expectations is an important factor in ensuring that researchers hear the voice of respondents with expressive language deficits.	Coventry Univ, Coventry, W Midlands, England			Parsons, Treena/B-7891-2009				Abbeduto L, 1997, MENT RETARD DEV D R, V3, P313, DOI 10.1002/(SICI)1098-2779(1997)3:4<313::AID-MRDD6>3.0.CO;2-O; Aggarwal N, 2003, J Psychiatr Ment Health Nurs, V10, P187; BAKRE C, 2002, RES METHODS CLIN PSY; BAMFORD C, 1998, CONSULTING OLDER PEO; Banister P., 1994, QUALITATIVE METHODS; Barnes C., 1992, DISABILITY, V7, P115, DOI DOI 10.1080/02674649266780151; Bays C L, 2001, Rehabil Nurs, V26, P18; Beard RL, 2004, J AGING STUD, V18, P415, DOI 10.1016/j.jaging.2004.06.005; Beattie A, 2004, HEALTH SOC CARE COMM, V12, P359, DOI 10.1111/j.1365-2524.2004.00505.x; BEDROSIAN JL, 1993, TOP LANG DISORD, V13, P36, DOI 10.1097/00011363-199305000-00006; BIKLEN SK, 1988, J ASSOC PERS SEVERE, V13, P155; Bogdan R, 1998, INTRO QUALITATIVE RE; Booth T, 1996, DISABIL SOC, V11, P55, DOI 10.1080/09687599650023326; BOURGEOIS MS, 1991, J SPEECH HEAR RES, V34, P831, DOI 10.1044/jshr.3404.831; BRINTON B, 1993, TOP LANG DISORD, V13, P9, DOI 10.1097/00011363-199305000-00004; BRINTON B, 1994, J SPEECH HEAR RES, V37, P369, DOI 10.1044/jshr.3702.369; BURTON A, 1997, DEMENTIA CHALLENGES, P194; Carnaby S, 1997, J INTELL DISABIL RES, V41, P225, DOI 10.1046/j.1365-2788.1997.03636.x; Cheston R., 2000, J MENT HEALTH, V9, P471, DOI [10.1080/09638230020005200, DOI 10.1080/09638230020005200]; Cinamon RG, 2004, CAREER DEV Q, V52, P212, DOI 10.1002/j.2161-0045.2004.tb00643.x; Clare L, 2003, SOC SCI MED, V57, P1017, DOI 10.1016/S0277-9536(02)00476-8; Clare L, 2002, AGING MENT HEALTH, V6, P139, DOI 10.1080/13607860220126826; Clare L., 2002, DEMENTIA, V1, P295, DOI DOI 10.1177/147130120200100303; Clarke P, 2003, J AGING STUD, V17, P171, DOI 10.1016/S0890-4065(03)00005-7; Cohen D., 1991, AM J ALZHEIMERS CARE, V6, P6, DOI DOI 10.1177/153331759100600303; Cohen D, 1986, LOSS SELF FAMILY RES; COHEN L, 1994, ANNU REV ANTHROPOL, V23, P137, DOI 10.1146/annurev.an.23.100194.001033; Conneeley A. L., 2003, BRIT J OCCUPATIONAL, V66, P440; Cox E. O., 1998, TOP STROKE REHABIL, V4, P76; Darragh AR, 2001, AM J OCCUP THER, V55, P191, DOI 10.5014/ajot.55.2.191; Davies CA, 1997, DISABIL SOC, V12, P95, DOI 10.1080/09687599727498; Davies T, 2002, J VOCATIONAL REHABIL, V17, P65; DOCHERTY S, 1998, RES NURSING HLTH, V77, P177; Dowswell G, 2002, J EVAL CLIN PRACT, V8, P361, DOI 10.1046/j.1365-2753.2002.00302.x; Faircloth CA, 2004, J AGING STUD, V18, P399, DOI 10.1016/j.jaging.2004.06.006; Finlay WML, 2001, PSYCHOL ASSESSMENT, V13, P319, DOI 10.1037//1040-3590.13.3.319; FLYNN MC, 1986, J MENT DEFIC RES, V30, P369; GARRO L, 1994, SOC SCI MED, V38, P118; GILLEARD CJ, 1984, J EPIDEMIOL COMMUN H, V38, P319, DOI 10.1136/jech.38.4.319; Gillies BA, 2000, AGING MENT HEALTH, V4, P366, DOI 10.1080/713649961; Gillman M, 1997, DISABIL SOC, V12, P675, DOI 10.1080/09687599726985; Good Byron J., 1994, MED RATIONALITY EXPE; Goodley D, 1996, DISABIL SOC, V11, P333, DOI 10.1080/09687599627642; HAEGGSTROEM T, 1994, QUALITATIVE HLTH RES, V4, P321; Hagner D, 1996, MENT RETARD, V34, P159; Hamill LB, 2003, MENT RETARD, V41, P340, DOI 10.1352/0047-6765(2003)41<340:GTCTEO>2.0.CO;2; Harker-Longton W., 2002, J LEARNING DISABILIT, V6, P137, DOI [https://doi.org/10.1177/146900470200600203, DOI 10.1177/146900470200600203]; Harr? R, 1992, AGEING SOC, V12, P443, DOI DOI 10.1017/S0144686X00005262; Harris PB, 1999, J AGING STUD, V13, P241, DOI 10.1016/S0890-4065(99)80096-6; HEAL LW, 1995, J INTELL DISABIL RES, V39, P331, DOI 10.1111/j.1365-2788.1995.tb00525.x; Higgins EL, 2002, LEARN DISABILITY Q, V25, P3, DOI 10.2307/1511187; Holst Goran, 2003, Am J Alzheimers Dis Other Demen, V18, P359, DOI 10.1177/153331750301800605; Howorth P, 2003, AGING MENT HEALTH, V7, P113, DOI 10.1080/1360786031000072286; Hubbard G, 2003, AGING MENT HEALTH, V7, P351, DOI 10.1080/1360786031000150685; KANE MN, 1998, AM J ALZHEIMERS DIS, V13, P179; Katsuno T., 2003, DEMENTIA, V2, P315, DOI [DOI 10.1177/14713012030023003, 10.1177/14713012030023003]; Keady J, 1996, J CLIN NURS, V5, P275, DOI 10.1111/jocn.1996.5.5.275; KEADY J, 1995, J DEMENTIA CARE, V13, P15; King C., 1997, CARE GIVING DEMENTIA, V2, P269; KITWOOD T, 1993, WORLDS ILLNESS BIOGR, P143; Kitwood T., 1990, AGEING SOC, V10, P177, DOI [DOI 10.1017/S0144686X00008060, 10.1017/S0144686x00008060]; Kitwood Tom, 1992, Ageing Soc, V12, P269, DOI 10.1017/S0144686X0000502X; Kleinman A, 1988, ILLNESS NARRATIVES S; Koch T, 2001, J CLIN NURS, V10, P352, DOI 10.1046/j.1365-2702.2001.00503.x; Kroese BS, 2002, J APPL RES INTELLECT, V15, P324; Kvigne K, 2003, QUAL HEALTH RES, V13, P1291, DOI 10.1177/1049732303257224; LEVIN E, 1989, FAMILIES SERVICES CO; Lilley SA, 2003, CLIN REHABIL, V17, P540, DOI 10.1191/0269215503cr647oa; Lofgren-Martenson L, 2004, SEX DISABIL, V22, P197, DOI 10.1023/B:SEDI.0000039062.73691.cb; Macdonald J, 2003, PSYCHOL PSYCHOTHER-T, V76, P433, DOI 10.1348/147608303770584764; Maclean N, 2000, BMJ-BRIT MED J, V321, P1051, DOI 10.1136/bmj.321.7268.1051; Mactavish JB, 2000, MENT RETARD, V38, P216, DOI 10.1352/0047-6765(2000)038<0216:ICSFMI>2.0.CO;2; McLean LK, 1996, AM J MENT RETARD, V100, P580; MCVILLY KR, 1996, BRIT J LEARN DISABIL, V23, P138; MEADAN H, 2004, LEARNING DISABILITIE, V19, P71, DOI DOI 10.1111/J.1540-5826.2004.00091.X; MENNE HL, 2002, INT J SOCIAL RES PRA, V1, P367; Miceli G, 2000, COGN NEUROPSYCHOL, V17, P489, DOI 10.1080/02643290050110629; Mishna F, 1996, INT J GROUP PSYCHOTH, V46, P265, DOI 10.1080/00207284.1996.11491498; Morningstar ME, 1996, EXCEPT CHILDREN, V62, P249; Morris, 1992, DISABILITY HANDICAP, V7, P157, DOI [DOI 10.1080/02674649266780181, 10.1080/02674649266780181]; Mozley CG, 1999, INT J GERIATR PSYCH, V14, P776, DOI 10.1002/(SICI)1099-1166(199909)14:9<776::AID-GPS13>3.0.CO;2-C; Murray CD, 2004, DISABIL REHABIL, V26, P808, DOI 10.1080/09638280410001696746; Myers F, 1998, DISABIL SOC, V13, P389, DOI 10.1080/09687599826704; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Nygard L, 1998, OCCUP THER J RES, V18, P109, DOI 10.1177/153944929801800203; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Oliver M., 1992, DISABILITY HANDICAP, V7, P101, DOI [10.1080/02674649266780141, DOI 10.1080/02674649266780141]; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Patton M.Q., 2002, QUALITATIVE RES EVAL; Pearce A., 2002, DEMENTIA, V1, P173, DOI DOI 10.1177/147130120200100205; Perry J, 2002, MENT RETARD, V40, P445, DOI 10.1352/0047-6765(2002)040<0445:SAOQOL>2.0.CO;2; Phinney A, 2003, J AGING STUD, V17, P283, DOI 10.1016/S0890-4065(03)00029-X; PHINNEY A, 2002, INT J SOCIAL RES PRA, V1, P329; Pilgrim D., 1998, J MENT HEALTH, V7, P95, DOI [10.1080/09638239818373, DOI 10.1080/09638239818373]; Ping E, 2004, INT J REHABIL RES, V27, P241, DOI 10.1097/00004356-200409000-00011; Poston D, 2003, MENT RETARD, V41, P313, DOI 10.1352/0047-6765(2003)41<313:FQOLAQ>2.0.CO;2; Pottie C, 2004, MENT RETARD, V42, P55, DOI 10.1352/0047-6765(2004)42<55:FBPWAW>2.0.CO;2; Pound P, 1994, Qual Health Care, V3, P69, DOI 10.1136/qshc.3.2.69; POUND P, 1995, BMJ-BRIT MED J, V311, P18, DOI 10.1136/bmj.311.6996.18; Proctor G, 2001, DISABIL SOC, V16, P361, DOI 10.1080/09687590120045932; PROUT HT, 1994, COUNSELING PSYCHOTHE, P79; Quayhagen MP, 1996, WESTERN J NURS RES, V18, P120, DOI 10.1177/019394599601800202; Rapley M, 1996, J COMMUNITY APPL SOC, V6, P207, DOI 10.1002/(SICI)1099-1298(199608)6:3<207::AID-CASP370>3.0.CO;2-T; Reid D, 2001, DISABIL SOC, V16, P377, DOI 10.1080/09687590120045941; Rey GJ, 2001, CLIN NEUROPSYCHOL, V15, P13, DOI 10.1076/clin.15.1.13.1911; Robinson P, 1998, INT J AGING HUM DEV, V47, P143, DOI 10.2190/PJY4-WB9F-CN2D-1P2B; Rogers NB, 1998, J INTELL DISABIL RES, V42, P122, DOI 10.1046/j.1365-2788.1998.00103.x; Rogler LH, 1999, AM PSYCHOL, V54, P424, DOI 10.1037/0003-066X.54.6.424; Ross KB, 2001, J MED SPEECH-LANG PA, V9, P31; Ruef MB, 2002, RES PRACT PERS SEV D, V27, P125, DOI 10.2511/rpsd.27.2.125; Scior K, 2003, DISABIL SOC, V18, P779, DOI 10.1080/0968759032000119514; Shakespeare T, 1996, DISABIL SOC, V11, P115, DOI 10.1080/09687599650023380; SIGELMAN CK, 1981, MENT RETARD, V19, P53; SIGELMAN CK, 1980, AM J MENT DEF, V84, P479; SIGELMAN CK, 1981, APPL RES MENT RETARD, V2, P347, DOI 10.1016/0270-3092(81)90029-1; SIMONS K, 1989, RES POLICY PLANNING, V7, P1; Sinason V., 1992, MENTAL HANDICAP HUMA; Smith J., 2003, QUALITATIVE PSYCHOL; Smith J. A., 2003, QUALITATIVE PSYCHOL, P51; Stalker K, 1999, INT J GERIATR PSYCH, V14, P120, DOI 10.1002/(SICI)1099-1166(199902)14:2<120::AID-GPS947>3.0.CO;2-9; Svanstrom R, 2004, WESTERN J NURS RES, V26, P671, DOI 10.1177/0193945904265920; Swain J, 1998, DISABIL SOC, V13, P21, DOI 10.1080/09687599826894; Szivos-Bach SE, 1993, MENT HANDICAP RES, V6, P217, DOI DOI 10.1111/J.1468-3148.1993.TB00054.X; Thorne S E, 2000, Annu Rev Nurs Res, V18, P3; TOMPSON D, 2002, J GERONTOLOGICAL SOC, V37, P7; Usher KJ, 1998, J ADV NURS, V27, P692, DOI 10.1046/j.1365-2648.1998.00589.x; Whitehouse PJ, 1997, ALZ DIS ASSOC DIS, V11, P56; Willig C., 2001, INTRO QUALITATIVE RE; WORTH A, 1993, J ADV NURS, V18, P1077, DOI 10.1046/j.1365-2648.1993.18071077.x; Yardley L, 2000, PSYCHOL HEALTH, V15, P215, DOI 10.1080/08870440008400302; Zigman W, 1997, J INTELL DISABIL RES, V41, P76, DOI 10.1111/j.1365-2788.1997.tb00679.x	133	106	106	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323	1552-7557		QUAL HEALTH RES	Qual. Health Res.	DEC	2006	16	10					1386	1404		10.1177/1049732306293846			19	Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	104YO	WOS:000241996700006	17079800				2021-06-18	
J	Wade, SL; Gerry Taylor, H; Yeates, KO; Drotar, D; Stancin, T; Minich, NM; Schluchter, M				Wade, Shari L.; Gerry Taylor, H.; Yeates, Keith Owen; Drotar, Dennis; Stancin, Terry; Minich, Nori M.; Schluchter, Mark			Long-term parental and family adaptation following pediatric brain injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						brain injury; family adaptation; stressors; support	CLOSED-HEAD-INJURY; ASSESSMENT DEVICE; TRAUMATIC INJURY; INITIAL YEAR; CHILDREN; PREDICTORS; RELIABILITY; VALIDITY; STRESSORS; CAREGIVER	Objective. To determine whether parents of children with traumatic brain injuries (TBI) report increased injury-related burden, distress, and family dysfunction and to examine the effects of attrition on the results. Methods. Children with severe TBI, moderate TBI, and orthopedic injuries were followed at six time points from baseline to 6 years after injury. Parents completed measures of injury-related burden, psychological distress, and family functioning at each assessment. Mixed model analysis was used to examine long-term changes. Results. Attrition was higher among families in the severe TBI group with lower burden thereby amplifying group differences. The severe TBI group reported higher injury-related burden over time after injury than the other groups. Family functioning was moderated by social resources. Families of children with severe TBI and low resources reporting deteriorating functioning over the follow-up interval. Conclusions. Although environmental advantages moderate long-term effects on family functioning, families of children with severe TBI experience long-standing injury-related burden.	Univ Cincinnati, Med Ctr, Cincinnati Childrens Hosp, Coll Med,Dept Pediat, Cincinnati, OH 45229 USA; Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Sch Med, Cleveland, OH 44106 USA; Ohio State Univ, Columbus Childrens Hosp, Dept Pediat, Columbus, OH 43210 USA; Case Western Reserve Univ, Sch Med, Dept Pediat, MetroHlth Med Ctr, Cleveland, OH 44106 USA	Wade, SL (corresponding author), Univ Cincinnati, Med Ctr, Cincinnati Childrens Hosp, Coll Med,Dept Pediat, 333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Derogatis L., 1982, BRIEF SYMPTOM INVENT; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Duncan GJ, 2000, CHILD DEV, V71, P188, DOI 10.1111/1467-8624.00133; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hedeker D, 1997, PSYCHOL METHODS, V2, P64, DOI 10.1037/1082-989X.2.1.64; HEDEKER D, 2000, MULT APPL BK SER, P79; JENNETT B, 1975, LANCET, V1, P480; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Lazarus R.S., 1984, STRESS APPRAISAL COP; Littell R. C. G. A., 1996, SAS SYSTEM MIXED MOD; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Miller W. R., 2002, MOTIVATIONAL INTERVI; Moos R, 1994, LIFE STRESSORS SOCIA; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; *SAS I I, 1990, STAT AN SYST VERS 6; Schafer JL., 1997, ANAL INCOMPLETE MULT; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Silverberg S. B., 1996, PARENTAL EXPERIENCE, P215; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wallander JL, 1998, J CHILD PSYCHOL PSYC, V39, P29, DOI 10.1111/1469-7610.00302	40	106	106	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	NOV-DEC	2006	31	10					1072	1083		10.1093/jpepsy/jsj077			12	Psychology, Developmental	Psychology	104JU	WOS:000241955500007	16150875	Bronze, Green Published			2021-06-18	
J	Anson, K; Ponsford, J				Anson, K; Ponsford, J			Evaluation of a coping skills group following traumatic brain injury	BRAIN INJURY			English	Article						coping; psychological outcome; cognitive behaviour therapy	SICKNESS IMPACT PROFILE; CLOSED-HEAD-INJURY; SELF-AWARENESS; DEPRESSION SCALE; HOSPITAL ANXIETY; ADULTS; DEFICITS; REHABILITATION; AGGRESSION; VALIDATION	Primary objective: To examine the impact of a cognitive behaviour therapy (CBT) based intervention programme, termed the Coping Skills Group (CSG), on coping strategy use and emotional adjustment. Research design: Thirty-one individuals with TBI participated and a wait-list control design was used. Methods and procedures: The CSG ran twice a week, for 5 weeks and focused on developing adaptive coping skills for the management of emotional and adjustment issues. Main outcomes and results: Following the CSG, the majority of participants subjectively reported that they had a better understanding of emotional issues and an improved ability to implement strategies to manage these issues. Adaptive coping, as measured on the Coping Scale for Adults, increased significantly immediately following intervention. However, no significant changes in anxiety, depression, self-esteem and psychosocial function were observed on the measures used. Conclusions: The results suggest that it may be possible to modify coping strategy use following brain injury, through CBT.	Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3168, Australia; Epworth Med Fdn, Melbourne, Vic, Australia	Anson, K (corresponding author), 36 Auburn Parade, Hawthorn, Vic 3123, Australia.	katie.anson@gmail.com					ADAMS N, 1996, AUSTR NZ J FAMILY TH, V17, P75; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; ANSON K, IN PRESS BRAIN INJUR; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Beck J.S., 1995, COGNITIVE THERAPY BA; BenYishay Y, 1996, NEUROPSYCHOL REHABIL, V6, P327, DOI 10.1080/713755514; BENYISHAY Y, 1980, DEV CORE CURRICULUM, P175; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BLASCOVICH J, 1993, MEASURES PERSONALITY, P115; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Christensen A., 2000, INT HDB NEUROPSYCHOL, P183; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DOUGLAS J, 2003, 25 ANN C AUSTR SOC S; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Frydenberg E., 1996, COPING SCALE ADULTS; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GrayLittle B, 1997, PERS SOC PSYCHOL B, V23, P443, DOI 10.1177/0146167297235001; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; KENDALL E, 2001, BRAIN IMPAIR, V2, P81; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kortte KB, 2003, REHABIL PSYCHOL, V48, P131, DOI 10.1037/0090-5550.48.3.131; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; O'Leary CA, 2000, BEHAV INTERVENT, V15, P205, DOI 10.1002/1099-078X(200007/09)15:3<205::AID-BIN56>3.3.CO;2-B; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; OWNSWORTH T, 2001, ASSBI 24 BRAIN IMP C; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; PONSFORD JL, 2003, INT NEUR SOC ANN C H; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP., 1999, PRINCIPLES NEUROPSYC, P244; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Rosenberg M., 1986, CONCEIVING SELF; Scheutzow MH, 1999, BRAIN INJURY, V13, P705; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; SIMPSON GK, 2001, SUICIDE PREVENTION T; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Spreen O., 1998, COMPENDIUM NEUROPSYC; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wilson, 1991, NATL ADULT READING T; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wiseman-Hakes C, 1998, J HEAD TRAUMA REHAB, V13, P23, DOI 10.1097/00001199-199812000-00005; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12	64	106	108	0	16	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2006	20	2					167	178		10.1080/02699050500442956			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	003KX	WOS:000234681700007	16421066				2021-06-18	
J	McMurtray, A; Clark, DG; Christine, D; Mendez, MF				McMurtray, A; Clark, DG; Christine, D; Mendez, MF			Early-onset dementia: Frequency and causes compared to late-onset dementia	DEMENTIA AND GERIATRIC COGNITIVE DISORDERS			English	Article						dementia, early onset, late onset; Alzheimer's disease	FRONTOTEMPORAL LOBAR DEGENERATION; PRESENILE-DEMENTIA; VASCULAR DEMENTIA; PREVALENCE; YOUNG; ASCERTAINMENT; POPULATION; MINNESOTA; ROCHESTER; SCOTLAND	Background: Research on the epidemiology of dementia has focused on the elderly. Few investigations have studied differences in etiologic frequencies between early-onset dementia (EOD), with onset at an age of less than 65 years old, and the more common late-onset disorder. Objectives: To determine relative frequencies and characteristics of EOD versus late-onset dementia (LOD; age of onset 6 65 years) diagnosed in a large memory disorders program over a 4-year period. Methods: We reviewed medical records, including an extensive neurobehavioral and neurological evaluation, of all patients seen at a large Veteran's Affairs Medical Center Memory Disorders clinic between 2001 and 2004 and assessed demographic variables, final diagnoses, presence of dementia, and differential diagnosis of dementing illnesses. Results: Among 1,683 patients presenting for evaluation of an acquired decline in memory or cognition, 948 (56%) met established clinical criteria for a dementing illness. About 30% (n = 278) of these had an age of onset of <65 years, compared to 670 with LOD. Patients were predominantly male (98%). Compared to the late-onset group, the EOD patients were less severely impaired on presentation, but they did not differ in gender distribution or educational background. The EOD group had significantly more dementia attributed to traumatic brain injury, alcohol, human immunodeficiency virus (HIV), and frontotemporal lobar degeneration compared to the LOD patients. In contrast, the LOD group had significantly more Alzheimer's disease compared to the EOD group. Conclusions: This study, conducted at a Veterans Affairs Hospital, is the largest series to date on EOD, and found a previously unexpectedly large number of patients below the age of 65 with cognitive deficits and impaired functioning consequent to head trauma, alcohol abuse, and HIV. These findings highlight the differential distribution and importance of preventable causes of dementia in the young. Copyright (C) 2006 S. Karger AG, Basel.	VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA	McMurtray, A (corresponding author), VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, 116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	amcmurtray@mednet.ucla.edu					American Psychiatric Association, 1994, DIAGN STAT MAN, V4th; DELANY N, 1995, INT J GERIATR PSYCH, V10, P597, DOI 10.1002/gps.930100710; Elberling TV, 2002, NEUROLOGY, V59, P1259, DOI 10.1212/WNL.59.8.1259; Ferran J, 1996, INT J GERIATR PSYCH, V11, P863, DOI 10.1002/(SICI)1099-1166(199610)11:10<863::AID-GPS394>3.0.CO;2-7; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fujihara S, 2004, ARQ NEURO-PSIQUIAT, V62, P592, DOI 10.1590/S0004-282X2004000400005; Harvey RJ, 2003, J NEUROL NEUROSUR PS, V74, P1206, DOI 10.1136/jnnp.74.9.1206; Harvey RJ, 1998, YOUNG ONSET DEMENTIA; HOFFMAN A, 1991, INT J EPIDEMIOL, V20, P736; Ikeda M, 2001, NEUROLOGY, V57, P839, DOI 10.1212/WNL.57.5.839; Johnson JK, 2005, ARCH NEUROL-CHICAGO, V62, P925, DOI 10.1001/archneur.62.6.925; Knopman DS, 2004, NEUROLOGY, V62, P506, DOI 10.1212/01.WNL.0000106827.39764.7E; KOKMEN E, 1989, NEUROLOGY, V39, P773, DOI 10.1212/WNL.39.6.773; MCGONIGAL G, 1993, BRIT MED J, V306, P680, DOI 10.1136/bmj.306.6879.680; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; MENDEZ MF, 2003, CLIN APPROACH; Nestor P, 2000, SEMIN NEUROL, V20, P439, DOI 10.1055/s-2000-13176; NEWENS AJ, 1993, PSYCHOL MED, V23, P631, DOI 10.1017/S0033291700025411; Panegyres PK, 2000, MED J AUSTRALIA, V173, P279, DOI 10.5694/j.1326-5377.2000.tb125651.x; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; Sampson EL, 2004, POSTGRAD MED J, V80, P125, DOI 10.1136/pgmj.2003.011171; Smith DM, 1995, INT J ADDICT, V30, P1843, DOI 10.3109/10826089509071058; TREVES T, 1986, ARCH NEUROL-CHICAGO, V43, P26, DOI 10.1001/archneur.1986.00520010022014; Varma AR, 2002, ACTA NEUROL SCAND, V105, P261, DOI 10.1034/j.1600-0404.2002.1o148.x; Woodburn K, 1999, INT J GERIATR PSYCH, V14, P362, DOI 10.1002/(SICI)1099-1166(199905)14:5<362::AID-GPS914>3.3.CO;2-L; World Health Organization, 1992, INT CLASS DIS	27	106	111	1	22	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1420-8008			DEMENT GERIATR COGN	Dement. Geriatr. Cogn. Disord.		2006	21	2					59	64		10.1159/000089546			6	Geriatrics & Gerontology; Clinical Neurology; Psychiatry	Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry	002ZL	WOS:000234651300001	16276111				2021-06-18	
J	Yang, LQ; Jones, NR; Blumbergs, PC; Van Den Heuvel, C; Moore, EJ; Manavis, J; Sarvestani, GT; Ghabriel, MN				Yang, LQ; Jones, NR; Blumbergs, PC; Van Den Heuvel, C; Moore, EJ; Manavis, J; Sarvestani, GT; Ghabriel, MN			Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						interleukin-1b; interleukin-6; tumour necrosis factor-a; traumatic spinal cord injury; microglia; inflammatory response	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL BRAIN-INJURY; FACTOR-ALPHA; MESSENGER-RNA; GROWTH-FACTOR; CELLULAR-LOCALIZATION; CEREBROSPINAL-FLUID; MICROGLIA; INTERLEUKIN-6	The post-traumatic inflammatory response in acute spinal cord contusion injury was studied in the rat. Mild and severe spinal cord injury (SCI) was produced by dropping a 10 g weight from 3 and 12 cm at the T12 vertebral level. Increased immunoreactivity of TNF-a in mild and severe SCI was detected in neurons at 1 h post-injury, and in neurons and microglia. at 6 h post-injury, with a less significant increase in mild SCL Expression was short-lived and declined sharply by 1 d post-injury. RT-PCR showed an early significant up-regulation of IL-1b, IL-6 and TNF-a mRNAs, maximal at 6 h post-injury with return to control levels by 24 h post-injury, the changes being less statistically significantly in mild SCI. Western blot showed early transient increases of IL-1b, IL-6 and TNF-a proteins in severe SCI but not mild SCI. Immunocytochemical, western blotting and RT-PCR analyses suggest that endogenous cells (neurons and microglia) in the spinal cord, not blood-borne leucocytes, contribute to IL-1b, IL-6 and TNF-a production in the post-traumatic inflammatory response and that their up-regulation is greater in severe than mild SCI. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Adelaide, Dept Surg Neurosurg, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Anat Sci, Adelaide, SA 5005, Australia; Inst Med & Vet Sci, Neuropathol Lab, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Div Haematol, Adelaide, SA 5000, Australia	Yang, LQ (corresponding author), Royal Adelaide Hosp, Dept Neurosurg, Level 5 McEwin Bldg, Adelaide, SA 5000, Australia.	Yangliqun98@hotmail.com		, Corinna/0000-0003-0664-8935			ALOISI F, 1992, J IMMUNOL, V149, P2358; Ausubel F. M., 1990, CURRENT PROTOCOLS MO; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BERRY M, 1997, GREENFIELDS NEUROPAT, P78; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; DICKSON DW, 1997, TXB NEUROPATHOLOGY, P165; Dinarello Charles A., 1998, P35; DSOUZA S, 1995, J NEUROSCI, V15, P7293; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Graeber M.B., 2002, GREENFIELDS NEUROPAT, P158; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Hirano Toshio, 1998, P197; Ito T, 1997, ACTA NEUROPATHOL, V93, P13; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; MCLAURIN J, 1995, INT J DEV NEUROSCI, V13, P369, DOI 10.1016/0736-5748(95)00012-6; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Moore S, 1996, PROG NEUROBIOL, V48, P441, DOI 10.1016/0301-0082(95)00051-8; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; PSHENICHKIN SP, 1994, J NEUROCHEM, V63, P419; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; REDFORD EJ, 1995, BRAIN, V118, P869, DOI 10.1093/brain/118.4.869; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; SAWADA M, 1992, BRAIN RES, V583, P296, DOI 10.1016/S0006-8993(10)80037-X; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; SUTHERLAND JC, 1987, ANAL BIOCHEM, V163, P446, DOI 10.1016/0003-2697(87)90247-8; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Taoka Y, 2000, J NEUROTRAUM, V17, P219, DOI 10.1089/neu.2000.17.219; Taoka Y, 1997, CRIT CARE MED, V25, P874, DOI 10.1097/00003246-199705000-00026; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tuna M, 2001, J NEUROSURG, V95, P64, DOI 10.3171/spi.2001.95.1.0064; Tzeng SF, 1999, GLIA, V26, P139, DOI 10.1002/(SICI)1098-1136(199904)26:2<139::AID-GLIA5>3.0.CO;2-1; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Wagner JA, 1996, J EXP MED, V183, P2417, DOI 10.1084/jem.183.6.2417; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Watanabe D, 1996, EUR J NEUROSCI, V8, P1630, DOI 10.1111/j.1460-9568.1996.tb01307.x; WOOD PL, 1995, NEUROL RES, V17, P242, DOI 10.1080/01616412.1995.11740321; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; Zhang Minghuang, 1998, P517	64	106	111	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	APR	2005	12	3					276	284		10.1016/j.jocn.2004.06.011			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	929YU	WOS:000229383400015	15851082				2021-06-18	
J	Mazzini, L; Campini, R; Angelino, E; Rognone, F; Pastore, I; Oliveri, G				Mazzini, L; Campini, R; Angelino, E; Rognone, F; Pastore, I; Oliveri, G			Posttraumatic hydrocephalus: A clinical, neuroradiologic, and neuropsychologic assessment of long-term outcome	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						diagnosis; hydrocephalus; outcome assessment (health care); rehabilitation; treatment outcome	CLOSED-HEAD-INJURY; NORMAL-PRESSURE HYDROCEPHALUS; TRAUMATIC BRAIN INJURY; COMPUTED-TOMOGRAPHY; PRACTICAL SCALE; RATING-SCALE; DIAGNOSIS; SPECT; COMA; CT	Objectives: To detect the clinical and radiologic characteristics of posttraumatic hydrocephalus (PTH), to define its prognostic value, and to assess the effects of shunt surgery. Design: Correlational study on a prospective cohort. Setting: Brain injury rehabilitation center. Participants: One hundred forty patients with severe traumatic brain injury (TBI) referred to an inpatient intensive rehabilitation unit of primary care in a university-based system. Interventions: Not applicable. Main Outcome Measures: The Glasgow Outcome Scale (GOS), Disability Rating Scale (DRS), FIM(TM) instrument, and Neurobehavioural Rating Scale (NRS), as well as single-photon emission computed tomography (SPECT) and magnetic resonance imaging. Results: PTH was found in 45% of patients. Risk factors for PTH were as follows: age (P<.04), duration of coma (P<.0001), and decompressive craniectomy (P<.0001). PTH correlated with the degree of hypoperfusion in the temporal lobes (P<.001). Patients who showed clinical deterioration improved after surgery. PTH correlated significantly with GOS, DRS. FIM, and NRS (P<.0001) I year after the trauma, and it influenced the appearance of posttraumatic epilepsy (P<.02). Conclusions: PTH concerns about 50% of patients with severe TBI. It influences functional and behavioral outcome and the appearance of posttraumatic epilepsy. The selection of patients for surgery can be defined principally on a clinical basis. SPECT may be helpful for differentiating ventricular enlargement due to cortical atrophy and hydrocephalus.	San Giovanni Bosco Hosp, Dept Neurol, Turin, Italy; San Giovanni Bosco Hosp, Dept Neurosurg, Turin, Italy; Sci Inst Pavia, Pavia, Italy; Univ Amedeo Avogadro, Dept Neurol, Novara, Italy	Mazzini, L (corresponding author), San Giovanni Bosco Hosp, Dept Neurol, Largo Donatori Sangue 3, Turin, Italy.		Mazzini, Letizia/AAA-2262-2021				BARKOVICH AJ, 1992, PEDIATR NEUROSURG, V18, P65; BEYRL B, 1984, NEUROSURGERY, V15, P257; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; GRAY BG, 1992, J NUCL MED, V33, P52; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; Guyot LL, 2000, NEUROL RES, V22, P25; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; JENNETT B, 1975, LANCET, V1, P480; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; KOO AH, 1977, RADIOLOGY, V123, P345, DOI 10.1148/123.2.345; Kristensen B, 1996, J NEUROL NEUROSUR PS, V60, P282, DOI 10.1136/jnnp.60.3.282; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; MEYERS CA, 1983, J NEUROL NEUROSUR PS, V46, P1092, DOI 10.1136/jnnp.46.12.1092; NAIDICH TP, 1982, RADIOL CLIN N AM, V20, P143; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; PHILIPPON J, 1976, NEUROCHIRURGIE, V22, P111; Piatt JH, 1996, NEUROSURGERY, V39, P722, DOI 10.1097/00006123-199610000-00014; PRAYER L, 1993, ACTA RADIOL, V34, P593; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SELIGER G M, 1992, Brain Injury, V6, P71, DOI 10.3109/02699059209008125; SHEFFLER LR, 1994, ARCH PHYS MED REHAB, V75, P338, DOI 10.1016/0003-9993(94)90039-6; TEASDALE G, 1974, LANCET, V2, P81; Vanneste JAL, 2000, J NEUROL, V247, P5, DOI 10.1007/s004150050003; WOOD JH, 1974, NEUROLOGY, V24, P517, DOI 10.1212/WNL.24.6.517	27	106	120	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2003	84	11					1637	1641		10.1053/S0003-9993(03)00314-9			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	741PR	WOS:000186466900010	14639563				2021-06-18	
J	Baskin, YK; Dietrich, WD; Green, EJ				Baskin, YK; Dietrich, WD; Green, EJ			Two effective behavioral tasks for evaluating sensorimotor dysfunction following traumatic brain injury in mice	JOURNAL OF NEUROSCIENCE METHODS			English	Article						controlled cortical impact (CCI); gridwalk; insult location; spontaneous forelimb use; forebrain injury; mouse; hindlimb; forelimb	RECOVERY; FORELIMB; PLASTICITY; DEFICITS; MOUSE	Variants of two sensorimotor tasks, the gridwalk and spontaneous forelimb use (SFL) tasks, were assessed for their ability to reveal behavioral dysfunction following traumatic brain injury (TBI) in mice. These tests have previously been used almost exclusively in evaluating models of spinal injury, ischemia and other forebrain lesions in rats. Male C57BL/6 mice were anesthetized and given unilateral parasagittal controlled cortical impact injury or sham (n = 9) procedures, targeting right anterior (17 = 9), middle (n = 9), or posterior (n = 10) locations relative to bregma. Significant forelimb and hindlimb deficits contralateral to the injured hemisphere were observed for at least I month and 3 weeks, respectively, on the gridwalk task depending upon insult location. The SFL task revealed a significant asymmetry in forelimb use for at least 5 months following injury. These results demonstrate the effectiveness of the SFL and gridwalk tests in evaluating sensorimotor deficits in mouse injury models involving unilateral forebrain damage. (C) 2003 Elsevier B.V. All rights reserved.	Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA; Univ Miami, Dept Neurol Surg, Coral Gables, FL 33124 USA	Green, EJ (corresponding author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.	cgreen@miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox S, 1998, INFECT MED, V15, P8; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Kolb B, 1997, NEUROSCIENCE, V76, P1139, DOI 10.1016/S0306-4522(96)00448-4; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; PAXINOS G, 2001, MOUSE BRAN STEREOTAX; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; SCHALLERT T, 2000, INNOVATIVE MODELS CN; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Soblosky JS, 1997, J NEUROSCI METH, V78, P75, DOI 10.1016/S0165-0270(97)00131-3; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	24	106	109	2	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 15	2003	129	1					87	93		10.1016/S0165-0270(03)00212-7			7	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	721GF	WOS:000185308100010	12951236				2021-06-18	
J	Monson, KL; Goldsmith, W; Barbaro, NM; Manley, GT				Monson, KL; Goldsmith, W; Barbaro, NM; Manley, GT			Axial mechanical properties of fresh human cerebral blood vessels	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							HUMAN AORTIC TISSUE; FAILURE PROPERTIES; TENSION TESTS; INJURY; VEINS	Human cerebral blood vessels are frequently damaged in head impact, whether accidental or deliberate, resulting in intracranial bleeding. Additionally, the vasculature constitutes the support structure for the brain and, hence, plays a key role in the cranial load response. Quantification of its mechanical behavior including limiting loads, is thus required for a proper understanding and modeling of traumatic brain injury-as well as providing substantial assistance in the development and application of preventive measures. It is believed that axial, stretching is the dominant loading mode for the blood vessels, regardless of the nature of the insult. Eighteen arteries and fourteen veins were obtained from the cortical surface of the cerebral temporal lobe of patients undergoing surgery. These vessels were stretched to failure in the longitudinal direction, either quasistatically or dynamically. The significance of specimen and experiment parameters was determined using multivariate analysis of variance (MANOVA) testing. Results demonstrate that the arteries were considerably stiffer than the veins, carrying approximately twice as much stress at failure but withstanding only half as much stretch. No significant rate dependence was measured over a strain rate range of more than four orders of magnitude (0.01 to 500 s(-1)).	Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Monson, KL (corresponding author), Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA.		Monson, Ken/L-4702-2019	Monson, Ken/0000-0002-8461-6034	ODCDC CDC HHS [R49/CCR919722-01, R49/CCR903697] Funding Source: Medline		Bandak F.A., 1994, P 38 STAPP CAR CRASH; BOOCK RJ, 1990, 1990 INT IRCOBI C BI, P169; Brossollet LJ, 1997, J BIOMECH ENG-T ASME, V119, P1, DOI 10.1115/1.2796059; BUSBY DE, 1965, CAN J PHYSIOL PHARM, V43, P185, DOI 10.1139/y65-018; CHALUPNIK JD, 1971, ME7111 U WASH; FUNG YCB, 1967, AM J PHYSIOL, V213, P1532; Gean A, 1994, IMAGING HEAD TRAUMA; HAYASHI K, 1980, J BIOMECH, V13, P175, DOI 10.1016/0021-9290(80)90191-8; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LEE MC, 1985, ADV BIOENG, P111; LOWENHIELM P, 1978, J BIOENG, V2, P509; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; MEANEY DF, 1991, THESIS U PENN PHILAD; Melvin J.W., 1993, ACCIDENTAL INJURY BI, P268; MOHAN D, 1983, J BIOMECH, V16, P31, DOI 10.1016/0021-9290(83)90044-1; MOHAN D, 1982, J BIOMECH, V15, P887, DOI 10.1016/0021-9290(82)90055-0; Monson K. L., 2001, THESIS U CALIFORNIA; OMORI K, 2000, CRASHWORTHINESS OCCU, V49, P167; STEHBENS WE, 1972, PAHTOLOGY CEREBRAL B; STEIGER H J, 1989, Heart and Vessels, V5, P41, DOI 10.1007/BF02058357; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vossoughi J., 1996, TRAUMATIC BRAIN INJU, P207; Yamada H, 1970, STRENGTH BIOL MAT	24	106	108	0	22	ASME-AMER SOC MECHANICAL ENG	NEW YORK	THREE PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731			J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	APR	2003	125	2					288	294		10.1115/1.1554412			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	675YV	WOS:000182725900016	12751292				2021-06-18	
J	Schreiber, MA; Aoki, N; Scott, BG; Beck, JR				Schreiber, MA; Aoki, N; Scott, BG; Beck, JR			Determinants of mortality in patients with severe blunt head injury	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	14th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 10-13, 2001	TARPON SPRINGS, FLORIDA	Eastern Assoc Surg Trauma			OUTCOME PREDICTION; BRAIN INJURY; TRAUMA; EPIDEMIOLOGY; MANAGEMENT; POPULATION	Context: Head injury is the leading cause of traumatic death in the United States. Hypothesis: A set of clinical parameters available soon after injury can be used to accurately predict outcome in patients with severe blunt head trauma. Design: Validation cohort study. Setting: Urban level I trauma center. Patients and Methods: Data from patients with severe blunt head injury, as defined by inability to follow commands, were prospectively entered into a neurosurgical database and analyzed. The impact on survival of 23 potentially predictive parameters was studied using univariate analysis. Logistic regression models were used to control for confounding factors and to assess interactions between variables, whose significance was determined by univariate analysis, Goodness of fit was calculated with the Hosmer-Lemeshow c statistic. The predictability of the logistic model was evaluated by measuring the area under the receiver operating characteristic curve (AUC). Results: Logistic regression analysis revealed that 5 risk factors were independently associated with death. These variables included systemic hypotension in the emergency department, midline shift on computed tomographic scan, intracranial hypertension, and absence of pupillary light reflex. A low Glasgow Coma Scale score and advanced age were found to be highly correlated risk factors that, when combined, were independently associated with mortality, The model showed acceptable goodness of fit, and the AUC was 80.5%. Conclusions: Systemic hypotension and intracranial hypertension are the only independent risk factors for mortality that can be readily treated during the initial management of patients with severe head injuries. When used together, Glasgow Coma Scale score and age are significant predictors of mortality.	Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Ben Taub Gen Hosp, Houston, TX 77030 USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA	Schreiber, MA (corresponding author), 11 Garibaldi St, Lake Oswego, OR 97035 USA.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Baltas I, 1998, J Neurosurg Sci, V42, P85; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P561; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GIBSON RM, 1989, LANCET, V2, P369; Kotzan JA, 1999, CLIN THER, V21, P1988, DOI 10.1016/S0149-2918(00)86744-2; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nissen JJ, 1999, J NEUROL NEUROSUR PS, V67, P796, DOI 10.1136/jnnp.67.6.796; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001; Vollmer DG, 1991, J NEUROSURG S, V75, P37; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7	32	106	111	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	MAR	2002	137	3					285	290		10.1001/archsurg.137.3.285			6	Surgery	Surgery	530YU	WOS:000174387800009	11888450	Bronze			2021-06-18	
J	Stahel, PF; Morganti-Kossmann, MC; Perez, D; Redaelli, C; Gloor, B; Trentz, O; Kossmann, T				Stahel, PF; Morganti-Kossmann, MC; Perez, D; Redaelli, C; Gloor, B; Trentz, O; Kossmann, T			Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; cerebrospinal fluid; complement; membrane attack complex; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; ACTIVATED TERMINAL COMPLEMENT; CEREBROSPINAL-FLUID; NEUROLOGICAL DISORDERS; MULTIPLE-SCLEROSIS; IGG ANALYSES; HEAD-INJURY; INTERLEUKIN-8; EXPRESSION; PRINCIPLES	It has become evident in recent years that intracranial inflammation after traumatic brain injury (TBI) is, at least in part, mediated by activation of the complement system. However, most conclusions have been drawn from experimental studies, and the intrathecal activation of the complement cascade after TBI has not yet been demonstrated in humans. In the present study, we analyzed the levels of the soluble terminal complement complex sC5b-9 by ELISA in ventricular cerebrospinal fluid (CSF) of patients with severe TBI (n = 11) for up to 10 days after trauma. The mean sC5b-9 levels in CSF were significantly elevated in 10 of 11 TBI patients compared to control CSF from subjects without trauma or inflammatory neurological disease (n = 12; p < 0.001). In some patients, the maximal sC5b-9 concentrations were up to 1,800-fold higher than in control CSF. The analysis of the extent of posttraumatic blood-brain barrier (BBB) dysfunction, as determined by CSF/serum albumin quotient (Q(A)), revealed that patients with a moderate to severe BBB impairment (mean Q(A) > 0.01) had significantly higher intrathecal sC5b-9 levels as compared to patients with normal BBB function (mean Q(A) < 0.007; p < 0.0001). In addition, a significant correlation between the individual daily Q(A) values and the corresponding sC5b-9 CSF levels was detected in 8 of 11 patients (r = 0.72-0.998; p < 0.05). These data demonstrate for the first time that terminal pathway complement activation occurs after head injury and suggest a possible pathophysiological role of complement with regard to posttraumatic BBB dysfunction.	Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Hosp Bern, Dept Visceral & Transplantat Surg, Bern, Switzerland	Stahel, PF (corresponding author), Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Davoust N, 1999, J IMMUNOL, V163, P6551; FAUSTUMANN PM, 1995, ACTA NEUROPATHOL, V89, P239; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HOLLERHAGE HG, 1989, ACTA NEUROPATHOL, V77, P307, DOI 10.1007/BF00687583; JENNETT B, 1975, LANCET, V1, P480; Johnson SA, 1996, EXP NEUROL, V138, P198, DOI 10.1006/exnr.1996.0058; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kilgore KS, 1997, AM J PATHOL, V150, P2019; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Lindsberg PJ, 1996, ANN NEUROL, V40, P587, DOI 10.1002/ana.410400408; LINK H, 1977, SCAND J CLIN LAB INV, V37, P391, DOI 10.3109/00365517709091497; Loeffler DA, 1997, NEUROCHEM RES, V22, P209, DOI 10.1023/A:1027323809229; Marshall SB, 1991, J NEUROSURG S, V75, P14; Matsumoto T, 1997, LAB INVEST, V77, P119; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Morgan BP, 1997, IMMUNOPHARMACOLOGY, V38, P43; MORGANTIKOSSMAN.MC, 2000, CURR OPIN CRIT CARE, V6, P98; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; SANDERS ME, 1987, J IMMUNOL, V138, P2095; SANDERS ME, 1986, J IMMUNOL, V136, P4456; Sellebjerg F, 1998, J NEUROL SCI, V157, P168, DOI 10.1016/S0022-510X(98)00086-0; Sherwood ER, 2000, CRIT CARE MED, V28, P1221, DOI 10.1097/00003246-200004000-00054; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; TEASDALE G, 1974, LANCET, V2, P81; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; VANGURI P, 1988, J BIOL CHEM, V263, P7228; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003	34	106	107	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2001	18	8					773	781		10.1089/089771501316919139			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	464AG	WOS:000170509600003	11526983				2021-06-18	
J	Hinton-Bayre, AD; Geffen, GM; Geffen, LB; McFarland, KA; Friis, P				Hinton-Bayre, AD; Geffen, GM; Geffen, LB; McFarland, KA; Friis, P			Concussion in contact sports: Reliable change indices of impairment and recovery	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MINOR HEAD-INJURY; CLINICAL-SIGNIFICANCE; NEUROPSYCHOLOGICAL DEFICITS; AUSTRALIAN RULES; MEANINGFUL CHANGE; FOOTBALL PLAYERS; MILD CONCUSSION; GUIDELINES; PSYCHOTHERAPY; THERAPY	This paper reports a follow-up study to an article on the sensitivity of three tests of speed of information processing to impairment after concussion (Hinton-Bayre, Geffen, BL McFarland, 1997). Group analyses showed that practice effects can obscure the effects of concussion on information processing, thereby making the assessment of functional impairment and recovery after injury unreliable. A Reliable Change Index (RCI) was used to assess individual variations following concussion. It was found that 16 of the 20 concussed professional rugby league players were impaired 1-3 days following injury. It was also demonstrated that 7 players still displayed cognitive deficits at 1-2 weeks, before returning to preseason levels at 3-5 weeks. The RCI permits comparisons between different tests, players, and repeated assessments, thereby providing a quantitative basis for decisions regarding return to play.	Univ Queensland, Sch Psychol, Dept Psychiat, Brisbane, Qld, Australia; Queensland Hlth, Brisbane, Qld, Australia; Holy Spirit Hosp, Sports Med Clin, Brisbane, Qld, Australia	Hinton-Bayre, AD (corresponding author), Univ Queensland, Cognit Psychophysiol Lab, Edith Cavell Bldg, Herston, Qld 4006, Australia.						ANKUTA GY, 1993, PROF PSYCHOL-RES PR, V24, P70, DOI 10.1037/0735-7028.24.1.70; BADDELEY A, 1992, SPEEC CAPACITY LANGU; BEIDEL DC, 1993, BEHAV RES THER, V31, P331, DOI 10.1016/0005-7967(93)90033-Q; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Broadbent DE, 1958, PERCEPTION COMMUNICA; Brukner P, 1996, Aust Fam Physician, V25, P1445; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P10; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Chomsky Noam, 1957, SYNTACTIC STRUCTURES; *COL MED SOC SPORT, 1991, GUID MAN CONC SPORTS; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; Crawford J. R., 1992, HDB NEUROPSYCHOLOGIC, P21; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; DEBEURS E, 1994, BEHAV THER, V25, P147, DOI 10.1016/S0005-7894(05)80150-9; Dicker G, 1993, Aust Fam Physician, V22, P750; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DORMAAR M, 1988, PSYCHOTHER PSYCHOSOM, V50, P95, DOI 10.1159/000288106; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1992, NZ J SPORTS MED, V20, P19; HAWLEY DR, 1995, FAM RELAT, V44, P278, DOI 10.2307/585526; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HINTONBAYRE AD, IN PRESS P 21 ANN BR; HOY G, 1987, SPORT HLTH, V5, P26; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; LACKS P, 1992, J CONSULT CLIN PSYCH, V60, P586, DOI 10.1037/0022-006X.60.4.586; LEBLANC KE, 1994, AM FAM PHYSICIAN, V50, P801; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, AUST PSYCHOL, V30, P125, DOI 10.1080/00050069508258916; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCCRORY P, 1994, HEAD BRAIN INJURY SP; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McKay D, 1996, J ANXIETY DISORD, V10, P47, DOI 10.1016/0887-6185(95)00034-8; MILLER RE, 1984, HYPERTENSION, V6, P202, DOI 10.1161/01.HYP.6.2_Pt_1.202; *NAT HLTH MED RES, 1994, FOOTB INJ HEAD NECK; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; Sacks T. L, 1991, CLIN NEUROPSYCHOL, V5, P220; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; SCOTT MJ, 1990, BEHAV PSYCHOTHER, V18, P1, DOI 10.1017/S014134730001795X; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WHISMAN MA, 1989, ADV BEHAV RES THER, V11, P175, DOI 10.1016/0146-6402(89)90021-0; WRIGHTSON P, 1992, NZ J SPORTS MED, V20, P18; YOUNGJOHN JR, 1992, CLIN NEUROPSYCHOL, V0006, P00276, DOI DOI 10.1080/13854049208404129	70	106	107	0	23	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1999	21	1					70	86		10.1076/jcen.21.1.70.945			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	214VN	WOS:000081348400008	10421003				2021-06-18	
J	Mukhin, A; Fan, L; Faden, AI				Mukhin, A; Fan, L; Faden, AI			Activation of metabotropic glutamate receptor subtype mGluR1 contributes to post-traumatic neuronal injury	JOURNAL OF NEUROSCIENCE			English	Article						antisense oligodeoxynucleotides; brain trauma; metabotropic glutamate receptors; neuronal injury; neuroprotection; phosphoinositide hydrolysis	EXPERIMENTAL BRAIN INJURY; SODIUM-CHANNEL BLOCKER; SPINAL-CORD INJURY; PHENYLGLYCINE DERIVATIVES; CORTICAL CULTURES; RAT HIPPOCAMPUS; AGONIST; ACID; ANTAGONISTS; NMDA	The role of phospholipase C-coupled (group I) metabotropic glutamate receptors (mGluR1 and mGluR5) in post-traumatic neuronal injury was examined using rat in vivo and in vitro models. Traumatic injury to mixed neuronal/glial cultures induced phosphoinositide hydrolysis and caused neuronal death. Pharmacological blockade of group I receptors significantly reduced these effects in vitro and decreased neurological deficits as well as neuronal loss produced by traumatic brain injury in vivo. In contrast, activation of group I receptors by a specific agonist in vitro exacerbated post-traumatic neuronal death in a dose-dependent manner. Antisense oligodeoxynucleotide directed to mGluR1, but not to mGluR5, was neuroprotective in vitro, although each oligodeoxynucleotide reduced the respective receptor-stimulated accumulation of inositol phosphates to a similar degree. Together, these findings suggest that activation of mGluR1 contributes to post-traumatic neuronal injury and that mGluR1 antagonists may have therapeutic potential in brain injury.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,INST COGNIT & COMPUTAT SCI,WASHINGTON,DC 20007					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR306634] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER		ABE T, 1992, J BIOL CHEM, V267, P13361; AMADOR E, 1963, CLIN CHEM, V9, P391; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BIRRELL GJ, 1993, NEUROPHARMACOLOGY, V32, P1351, DOI 10.1016/0028-3908(93)90030-7; BRABET I, 1995, NEUROPHARMACOLOGY, V34, P895, DOI 10.1016/0028-3908(95)00079-L; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Buisson A, 1996, EUR J NEUROSCI, V8, P138, DOI 10.1111/j.1460-9568.1996.tb01174.x; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHIAMULERA C, 1992, EUR J PHARMACOL, V216, P335, DOI 10.1016/0014-2999(92)90382-E; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P98; Fitzjohn SM, 1996, NEUROSCI LETT, V203, P211, DOI 10.1016/0304-3940(96)12301-6; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KINGSTON AE, 1995, NEUROPHARMACOLOGY, V34, P887, DOI 10.1016/0028-3908(95)00069-I; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCDONALD JW, 1992, EUR J PHARMACOL, V215, P353, DOI 10.1016/0014-2999(92)90058-C; MCDONALD JW, 1993, J NEUROSCI, V13, P4445; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1993, RECENT ADV EXCITATOR, P653; Mukhin A. G., 1995, Society for Neuroscience Abstracts, V21, P764; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1994, PRINCIPLES PRACTICE, P32; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1993, CURR DRUGS NEURODEGE, V12, P111; PRASAD MR, 1994, J NEUROCHEM, V63, P773; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; REID SNM, 1995, J COMP NEUROL, V355, P470, DOI 10.1002/cne.903550311; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; SACAAN AI, 1992, NEUROSCI LETT, V139, P77, DOI 10.1016/0304-3940(92)90862-2; SAUGSTAD JA, 1995, EUR J PHARM-MOLEC PH, V289, P395, DOI 10.1016/0922-4106(95)90120-5; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHOEPP DD, 1994, J NEUROCHEM, V63, P769; SHARPIRA Y, 1990, J NEUROTRAUM, V1, P131; SILIPRANDI R, 1992, EUR J PHARMACOL, V219, P173, DOI 10.1016/0014-2999(92)90598-X; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SMITH DH, 1993, J NEUROSCI, V13, P5383; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; WATKINS J, 1994, TRENDS PHARMACOL SCI, V15, P333, DOI 10.1016/0165-6147(94)90028-0; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q	56	106	107	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513	0270-6474			J NEUROSCI	J. Neurosci.	OCT 1	1996	16	19					6012	6020					9	Neurosciences	Neurosciences & Neurology	VH858	WOS:A1996VH85800013	8815884				2021-06-18	
J	COPE, DN				COPE, DN			THE EFFECTIVENESS OF TRAUMATIC BRAIN INJURY REHABILITATION - A REVIEW	BRAIN INJURY			English	Article							DISABILITY RATING-SCALE; CLOSED HEAD-INJURY; EARLY INTERVENTION; FOLLOW-UP; RECOVERY; PROGRAM	The rehabilitation of traumatic brain injury (TBI) has undergone tremendous development over the past 20 years. A much more aggressive, extended and comprehensive approach is now common and clinically accepted. Multiple new forms and sites of treatment are utilized such as cognitive, behavioural, sub-acute and post-acute rehabilitation programmes. While there has been widespread clinical acceptance of these treatments the appearance of well-designed experimental or quasi-experimental studies actually evaluating the results of such treatment have been, until recently, generally lacking. This review article selects, analyses, and critiques the most salient of recent studies published regarding the overall clinical benefit, and to some extent the cost benefit, of TBI treatment programmes in their multiple forms. A conclusion which is reached following this survey is that while truly randomized controlled studies still have not been achieved, an impressive variety of studies of quasi-experimental design have been completed. The overall conclusion from these studies is that the efficacy (and cost-effectiveness) of TBI rehabilitation is strongly supported.		COPE, DN (corresponding author), PARADIGM HLTH CORP,1001 GALAXY WAY,SUITE 400,CONCORD,CA 94520, USA.						ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; ASHLEY MJ, 1990, J INSURANCE MED, V22, P156; BACHYRITA P, 1990, CAN J PSYCHOL, V44, P148, DOI 10.1037/h0084247; BARLOW DH, 1984, SINGLE CASE EXPT DES; BBUTLER RH, J NEUROLOGICAL REHAB, V2, P97; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BERROL SM, 1982, SEVERE HEAD TRAUMA C, V1; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; BLACKERBY WF, 1992, NOV AM C AC REH MED; Brooks N, 1989, Brain Inj, V3, P325, DOI 10.3109/02699058909004556; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; BURKE W H, 1990, Brain Injury, V4, P371, DOI 10.3109/02699059009026190; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; COPE DN, 1985, SEMIN NEUROL, V5, P212, DOI 10.1055/s-2008-1041518; COPE DN, 1993, IN PRESS PERSPECTIVE; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DILLER L, 1987, NEUROBEHAVIORAL RECO, P146; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1985, Int Rehabil Med, V7, P130; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; FINGER S, 1988, BRAIN INJURY RECOVER; FREY WD, 1984, FUNCTIONAL ASSESSMEN, P11; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL K, UNPUB TRAUMATIC BRAI; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; JOHNSTON MV, 1992, ARCH PHYSICAL MED RE, V73; JOHNSTON MV, 1992, COMMUNICATION    MAY; KAPLAN MS, 1988, ARCH PHYS MED REHAB, V69, P984; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; MORGAN AS, 1988, 1ST E ASS SURG TRAUM; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; RUSK H A, 1969, Medical Clinics of North America, V53, P677; RUSK HA, 1966, CLIN NEUROSURG, V12, P312; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; SUNDANCE PL, 1992, NOV AAPM R ANN M SAN; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140	56	106	106	0	5	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1995	9	7					649	670		10.3109/02699059509008224			22	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RZ814	WOS:A1995RZ81400001	8680395				2021-06-18	
J	JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; SHURTLEFF, HA; RIVARA, JB; WINN, HR				JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; SHURTLEFF, HA; RIVARA, JB; WINN, HR			SEVERITY OF PEDIATRIC TRAUMATIC BRAIN INJURY AND NEUROBEHAVIORAL RECOVERY AT ONE-YEAR - A COHORT STUDY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						CHILDREN; CLOSED-HEAD INJURY; OUTCOME; TRAUMATIC BRAIN INJURY	CLOSED-HEAD-INJURY; CHILDREN; ADOLESCENTS		UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98195	JAFFE, KM (corresponding author), UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,SCH SOCIAL WORK,POB 5371,4800 SAND POINT WAY NE,SEATTLE,WA 98105, USA.			Shurtleff, Hillary/0000-0003-0959-2842	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 002299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Achenbach TM, 1986, MANUAL TEACHERS REPO; Bruininks R.H., 1984, SCALES INDEPENDENT B; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DELIS DC, 1989, CALIFORNIA VERBAL LE; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; GOTTFRIED AW, 1985, MERRILL PALMER QUART, V31, P85; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Jastak S, 1984, WIDE RANGE ACHIEVEME; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; RATTAN G, 1987, COGNITIVE REHABILITA; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; Shurtleff H. A., 1988, J PSYCHOEDUCATIONAL, V6, P298, DOI 10.1177/073428298800600313; Snedecor G.W., 1967, STATISTICAL METHODS; Wechsler D., 1974, MANUAL WECHSLER INTE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	23	106	106	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1993	74	6					587	595		10.1016/0003-9993(93)90156-5			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	LG423	WOS:A1993LG42300005	8503748				2021-06-18	
J	SHOHAMI, E; NOVIKOV, M; MECHOULAM, R				SHOHAMI, E; NOVIKOV, M; MECHOULAM, R			A NONPSYCHOTROPIC CANNABINOID, HU-211, HAS CEREBROPROTECTIVE EFFECTS AFTER CLOSED-HEAD INJURY IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article							TRANSIENT ISCHEMIA; BRAIN INJURY; ANTAGONISTS; RECEPTORS; GERBIL	HU-211 is a synthetic, nonpsychotropic cannabinoid, which has been shown to act as a noncompetitive N-methyl-D-asparate (NMDA) receptor antagonist. The cerebroprotective effects of this compound were assessed in a model of closed head injury in rats. Head trauma (HT) was induced in ether-anesthetized rats by a weight-drop device; recovery was followed up to 48 h. The clinical status of the rats was evaluated at 1, 24, and 48 h after injury, and the extent of edema formation was determined by specific gravity (SG) and water content measurements at 24 or 48 h. The integrity of the blood-brain barrier (BBB) was investigated using Evans-Blue extravasation at 4 h after HT. HU-211 at a dose of 25 mg/kg in middle-chain triglycerides (MCT) oil was given intraperitoneally immediately and 1, 2, or 3 h after impact, and its effect on the various parameters was studied. The drug was found to be very effective in improving motor function recovery. When the drug was given 1 h after HT, the percent of rats able to perform beam walking task on 8.5- and 5-cm wide beams was increased from 30% and 0% to 79% (p = 0.0172) and 57% (p = 0.0029), respectively. The percent of rats able to balance on a 1.5-cm beam for 20 and 40 sec was also significantly increased, from 9% and 0% to 72% (p = 0.0037) and 50% (p = 0.078), respectively. The drug was also effective in reducing the BBB breakdown by more than four fold, as compared with control (548 +/- 94 versus 128 +/- 19 ng Evans blue/g tissue; p < 0.05) and attenuating cerebral edema. SG was 1.0367 +/- 0.0007 versus 1.0399 +/- 0.0005, and percent water content was 83.06 +/- 0.57 versus 80.78 +/- 0.36 (p < 0.05) in control and HU-211 treated rats, respectively. Similar significant protection was found when the drug was injected 2 h after the injury; however, at 3 h the effect was somewhat less pronounced. We suggest that this novel drug is a potential cerebroprotector in head trauma with a therapeutic window of at least 2 to 3 h.	HEBREW UNIV JERUSALEM,FAC MED,DEPT PHARMACOL,JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,FAC MED,DEPT NAT PROD,JERUSALEM,ISRAEL	SHOHAMI, E (corresponding author), HEBREW UNIV JERUSALEM,SCH PHARM,DEPT PHARMACOL,JERUSALEM,ISRAEL.						BENVENISTE H, 1984, J NEUROCHEM, V43, P169; CHAN P, 1992, J NEUROTRAUM, V9, P417; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Domino EF, 1990, STATUS KETAMINE ANES; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; FISCHER JB, 1992, J NERUOTRAUMA S2, V9, P531; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; HALL ED, 1992, J NEUROTRAUMA, V9, P425; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KATAYAMA Y, 1988, Society for Neuroscience Abstracts, V14, P1154; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KOENIG H, 1991, SOC NEUR ABSTR, V17, P12; KOENIG H, 1992, SOC NEUR ABS, V18, P11; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MARMAROU A, 1978, J NEUROSURG, V49, P536; MCINTOSH TK, 1988, 7TH INT S INTR PRESS, P199; MECHOULAM R, 1990, TETRAHEDRON-ASYMMETR, V1, P315, DOI 10.1016/S0957-4166(00)86322-3; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; ROD MR, 1989, CAN J NEUROL SCI, V16, P340, DOI 10.1017/S031716710002919X; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1993, IN PRESS ANESTH ANAL; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; SHOHAMI E, 1992, 4TH INT S PHARM CER; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WARNER MA, 1991, J CEREBR BLOOD F MET, V11, P600, DOI 10.1038/jcbfm.1991.110; WROBLEWSKI JT, 1987, P NATL ACAD SCI USA, V84, P5068, DOI 10.1073/pnas.84.14.5068	34	106	108	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SUM	1993	10	2					109	119		10.1089/neu.1993.10.109			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	LM056	WOS:A1993LM05600003	8411215				2021-06-18	
J	Huang, S; Ge, XT; Yu, JW; Han, ZL; Yin, ZY; Li, Y; Chen, FL; Wang, HC; Zhang, JN; Lei, P				Huang, Shan; Ge, Xintong; Yu, Jinwen; Han, Zhaoli; Yin, Zhenyu; Li, Ying; Chen, Fanglian; Wang, Haichen; Zhang, Jianning; Lei, Ping			Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons	FASEB JOURNAL			English	Article						extracellular vesicles; glia cells; polarization; PDE4B; mTOR signaling	MESENCHYMAL STROMAL CELLS; EXTRACELLULAR VESICLES; PHOSPHODIESTERASE 4B; IN-VITRO; PATHWAY; POLARIZATION; APOPTOSIS; DISEASE; AKT; NEUROINFLAMMATION	Neuronal inflammation is the characteristic pathologic change of acute neurologic impairment and chronic traumatic encephalopathy after traumatic brain injury (TBI). Inhibiting the excessive inflammatory response is essential for improving the neurologic outcome. To clarify the regulatory mechanism of microglial exosomes on neuronal inflammation in TBI, we focused on studying the impact of microglial exosomal miRNAs on injured neurons in this research. We used a repetitive (r) TBI mousemodel and harvested the injured brain extracts from the acute to the chronic phase of TBI to treat cultured BV2 microglia in vitro. The microglial exosomes were collected for miRNA microarray analysis, which showed that the expression level of miR-124-3p increased most apparently in the miRNAs. We found that miR-124-3p promoted the anti-inflamed M2 polarization in microglia, and microglial exosomal miR-124-3p inhibited neuronal inflammation in scratch-injured neurons. Further, the mammalian target of rapamycin (mTOR) signaling was implicated as being involved in the regulation of miR-124-3p by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses. Using the mTOR activator MHY1485 we confirmed that the inhibitory effect of exosomalmiR-124-3p on neuronal inflammation was exerted by suppressing the activity of mTOR signaling. PDE4B was predicted to be the target gene of miR-124-3p by pathway analysis. We proved that it was directly targeted by miR-124-3p with a luciferase reporter assay. Using a PDE4B overexpressed lentivirus transfection system, we suggested that miR-124-3p suppressed the activity of m TOR signaling mainly through inhibiting the expression of PDE4B. In addition, exosomal miR-124-3p promoted neurite outgrowth after scratch injury, characterized by an increase on the number of neurite branches and total neurite length, and a decreased expression on RhoA and neurodegenerative proteins [A beta-peptide and p-Tau]. It also improved the neurologic outcome and inhibited neuro-inflammation in mice with rTBI. Taken together, increased miR-124-3p in microglial exosomes after TBI can inhibit neuronal inflammation and contribute to neurite outgrowth via their transfer into neurons. miR-124-3p exerted these effects by targeting PDE4B, thus inhibiting the activity of mTOR signaling. Therefore, miR-124-3p could be a promising therapeutic target for interventions of neuronal inflammation after TBI. miRNAs manipulated microglial exosomes may provide a novel therapy for TBI and other neurologic diseases.	[Huang, Shan; Ge, Xintong; Yu, Jinwen; Yin, Zhenyu; Lei, Ping] Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin, Peoples R China; [Huang, Shan; Ge, Xintong; Yu, Jinwen; Han, Zhaoli; Yin, Zhenyu; Li, Ying; Chen, Fanglian; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [Huang, Shan; Yu, Jinwen; Yin, Zhenyu; Li, Ying; Chen, Fanglian; Zhang, Jianning] Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin, Peoples R China; [Ge, Xintong; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Han, Zhaoli; Lei, Ping] Tianjin Med Univ, Gen Hosp, Dept Geriatr, Anshan Rd, Tianjin 300054, Peoples R China; [Wang, Haichen] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA	Lei, P (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Geriatr, Anshan Rd, Tianjin 300054, Peoples R China.	leiping1974@163.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501055, 81471252, 81772060]; Tianjin Municipal Science and Technology Commission Natural Fund Project [13JCYBJC23700]	This work was supported by Grants 81501055, 81471252, and 81772060 from the National Natural Science Foundation of China, and Grant 13JCYBJC23700 from the Tianjin Municipal Science and Technology Commission Natural Fund Project. The authors appreciate Chunsheng Kang, Lei Han, Anling Zhang, Li Liu, Weiyun Cui, and Lei Zhou (Tianjin Neurological Institute) for their technical support. The authors declare no conflicts of interest.	Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Bai R., 2017, NEUROCHEM RES; Bai RJ, 2017, MED SCI MONITOR, V23, P1707, DOI 10.12659/MSM.901124; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Byles V, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3834; Chen ZQ, 2014, CANCER LETT, V350, P43, DOI 10.1016/j.canlet.2014.04.010; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Chopp M, 2015, EXPERT OPIN EMERG DR, V20, P523, DOI 10.1517/14728214.2015.1061993; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Cunha C, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6986175; Dadsetan S, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00106; Edwards P, 2005, LANCET, V365, P1957; Ejlerskov P, 2015, CELL, V163, P324, DOI 10.1016/j.cell.2015.08.069; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gao C, 2017, MOL NEUROBIOL, V54, P8348, DOI 10.1007/s12035-016-0318-0; Gao HB, 2017, BRAIN RES, V1657, P1, DOI 10.1016/j.brainres.2016.11.028; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Glebov K, 2015, GLIA, V63, P626, DOI 10.1002/glia.22772; Gong X, 2016, AM J TRANSL RES, V8, P2127; Goto T, 2013, BIOORG MED CHEM LETT, V23, P3325, DOI 10.1016/j.bmcl.2013.03.104; Gurney ME, 2015, NEUROTHERAPEUTICS, V12, P49, DOI 10.1007/s13311-014-0309-7; Han RR, 2016, EXP NEUROL, V280, P106, DOI 10.1016/j.expneurol.2016.04.005; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Hartmann H, 2015, CELL TISSUE RES, V362, P9, DOI 10.1007/s00441-015-2183-y; Hooper C, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-144; Hu XK, 2016, MOL MED REP, V14, P3662, DOI 10.3892/mmr.2016.5729; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kim J, 2015, GENE, V558, P173, DOI 10.1016/j.gene.2015.01.001; Kim SW, 2011, CLIN CANCER RES, V17, P6723, DOI 10.1158/1078-0432.CCR-11-0770; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Li DJ, 2016, FASEB J, V30, P3388, DOI 10.1096/fj.201600495R; Mantovani A, 2004, SEMIN CANCER BIOL, V14, P155, DOI 10.1016/j.semcancer.2003.10.001; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Naganuma K, 2009, BIOORG MED CHEM LETT, V19, P3174, DOI 10.1016/j.bmcl.2009.04.121; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Potolicchio A, 2005, J IMMUNOL, V175, P2237, DOI 10.4049/jimmunol.175.4.2237; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Takano T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00044-2; Thompson AG, 2016, NAT REV NEUROL, V12, P346, DOI 10.1038/nrneurol.2016.68; Wang YJ, 2016, ONCOTARGET, V7, P13328, DOI 10.18632/oncotarget.7798; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Xin HQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009027; Xiong Y, 2015, EXPERT OPIN INV DRUG, V24, P743, DOI 10.1517/13543784.2015.1021919; Yu AY, 2017, IMMUNOL LETT, V182, P1, DOI 10.1016/j.imlet.2016.12.003; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zhang H, 2016, BIOCHEM RES INT, V2016, DOI 10.1155/2016/7498706; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang YQ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-253; Zhang Y, 2017, MOL NEUROBIOL, V54, P2659, DOI 10.1007/s12035-016-9851-0; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126; Zhu H, 2013, BRAIN RES, V1541, P69, DOI 10.1016/j.brainres.2013.10.002; Zhu LN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5696; Zhu XX, 2014, J CEREBR BLOOD F MET, V34, P1531, DOI 10.1038/jcbfm.2014.113	64	105	112	5	69	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2018	32	1					512	528		10.1096/fj.201700673R			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FR6JU	WOS:000419172700045	28935818		Y	N	2021-06-18	
J	Ham, PB; Raju, R				Ham, P. Benson, III; Raju, Raghavan			Mitochondrial function in hypoxic ischemic injury and influence of aging	PROGRESS IN NEUROBIOLOGY			English	Article; Proceedings Paper	International Conference on Aging and Disease (ICAD)	NOV 01-02, 2014	Beijing, PEOPLES R CHINA	Int Soc Aging & Dis, Xuanwu Hosp, Beijing Capital Univ, Wenzhou Med Univ, First Affiliated Hosp		Ischemia/reperfusion; Hypoxia; Mitokine; Oxidative phosphorylation; Resveratrol, SIRT1, sirtuins; Mitoquinone; Tempol; Blood brain barrier; Tunneling nanotube; Nuclear-mitochondria cross-talk; Intermitochondrial signal propagation; Pseudohypoxia; Stroke, myocardial infarction; Alzheimer's disease; Parkinson's disease; Autophagy; Apoptosis	EXTENDS LIFE-SPAN; NF-KAPPA-B; TARGETED ANTIOXIDANT MITOQ; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; PERMEABLE RADICAL SCAVENGER; INFORMATION REGULATOR 1; AGE-RELATED DIFFERENCES; REDUCES INFARCT SIZE; PYRUVATE-DEHYDROGENASE KINASE	Mitochondria are a major target in hypoxic/ischemic injury. Mitochondrial impairment increases with age leading to dysregulation of molecular pathways linked to mitochondria. The perturbation of mitochondrial homeostasis and cellular energetics worsens outcome following hypoxic-ischemic insults in elderly individuals. In response to acute injury conditions, cellular machinery relies on rapid adaptations by modulating posttranslational modifications. Therefore, post-translational regulation of molecular mediators such as hypoxia-inducible factor lot (HIF-1 alpha), peroxisome proliferator-activated receptor gamma coactivator alpha (PGC-1 alpha), c-MYC, SIRT1 and AMPK play a critical role in the control of the glycolytic-mitochondrial energy axis in response to hypoxic-ischemic conditions. The deficiency of oxygen and nutrients leads to decreased energetic reliance on mitochondria, promoting glycolysis. The combination of pseudohypoxia, declining autophagy, and dysregulation of stress responses with aging adds to impaired host response to hypoxic-ischemic injury. Furthermore, intermitochondrial signal propagation and tissue wide oscillations in mitochondrial metabolism in response to oxidative stress are emerging as vital to cellular energetics. Recently reported intercellular transport of mitochondria through tunneling nanotubes also play a role in the response to and treatments for ischemic injury. In this review we attempt to provide an overview of some of the molecular mechanisms and potential therapies involved in the alteration of cellular energetics with aging and injury with a neurobiological perspective. (C) 2016 Elsevier Ltd. All rights reserved.	[Ham, P. Benson, III; Raju, Raghavan] Georgia Regents Univ, Dept Surg, Augusta, GA USA; [Raju, Raghavan] Georgia Regents Univ, Dept Lab Sci, Augusta, GA USA; [Raju, Raghavan] Georgia Regents Univ, Dept Biochem & Mol Biol, Augusta, GA USA	Raju, R (corresponding author), Georgia Regents Univ, CB 2601,Sanders Bldg,1479 Laney Walker Blvd, Augusta, GA 30912 USA.	RRaju@augusta.edu		Raju, Raghavan/0000-0002-4516-8654	National Institute of General Medical Sciences, National Institutes of Health, Bethesda, MDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM 101927]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM101927] Funding Source: NIH RePORTER	The corresponding author (RR) acknowledges financial support from the National Institute of General Medical Sciences (R01 GM 101927), National Institutes of Health, Bethesda, MD.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Adam T, 2013, J CARDIOVASC PHARM T, V18, P46, DOI 10.1177/1074248412458723; Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; Adler A, 2003, AM J PHYSIOL-HEART C, V285, pH1015, DOI 10.1152/ajpheart.01047.2002; Ahmad T, 2014, EMBO J, V33, P994, DOI 10.1002/embj.201386030; Ahmadiasl N, 2014, ADV PHARM BULL, V4, P49, DOI 10.5681/apb.2014.008; Alberts B., 2008, MOL BIOL CELL, V5th edn; Alcain FJ, 2009, EXPERT OPIN THER PAT, V19, P403, DOI 10.1517/13543770902762893; Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Aliev G, 2002, BRAIN PATHOL, V12, P21; Anderson R, 2009, BBA-GEN SUBJECTS, V1790, P1059, DOI 10.1016/j.bbagen.2009.04.005; Andres-Lacueva C, 2012, J AGR FOOD CHEM, V60, P4833, DOI 10.1021/jf3001108; Antonenko YN, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1273, DOI 10.1134/S0006297908120018; Aon MA, 2004, P NATL ACAD SCI USA, V101, P4447, DOI 10.1073/pnas.0307156101; Arrington DD, 2006, AM J PHYSIOL-CELL PH, V291, pC1159, DOI 10.1152/ajpcell.00207.2006; Atamna H, 2008, FASEB J, V22, P703, DOI 10.1096/fj.07-9610com; Atsma F, 2006, MENOPAUSE, V13, P265, DOI 10.1097/01.gme.0000218683.97338.ea; Avraham Y, 2010, CURR NEUROVASC RES, V7, P136, DOI 10.2174/156720210791184943; Ayub A, 2015, MOL MED, V21, P305, DOI 10.2119/molmed.2015.00013; Baarine M, 2011, GENES NUTR, V6, P161, DOI 10.1007/s12263-011-0232-z; Bai B., 2014, BIOMED RES INT, V2014, P1; Ballinger SW, 2005, FREE RADICAL BIO MED, V38, P1278, DOI 10.1016/j.freeradbiomed.2005.02.014; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bavaresco L, 2003, DRUG EXP CLIN RES, V29, P181; BEAUCHAMP RO, 1984, CRC CR REV TOXICOL, V13, P25, DOI 10.3109/10408448409029321; Berdichevsky A, 2006, CELL, V125, P1165, DOI 10.1016/j.cell.2006.04.036; Bhat AH, 2015, BIOMED PHARMACOTHER, V74, P101, DOI 10.1016/j.biopha.2015.07.025; Biala AK, 2015, J MOL CELL CARDIOL, V83, P37, DOI 10.1016/j.yjmcc.2015.04.015; Biermann J, 2011, MOL VIS, V17, P1275; Bonanni L, 2006, J NEUROSCI, V26, P6851, DOI 10.1523/JNEUROSCI.5444-05.2006; Boocock DJ, 2007, J CHROMATOGR B, V848, P182, DOI 10.1016/j.jchromb.2006.10.017; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brenmoehl J, 2013, MITOCHONDRION, V13, P755, DOI 10.1016/j.mito.2013.04.002; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Bruning CA, 2012, NEUROCHEM RES, V37, P2249, DOI 10.1007/s11064-012-0853-7; Bruintjes JJ, 2014, NEUROSCI LETT, V563, P135, DOI 10.1016/j.neulet.2014.01.049; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Buga AM, 2008, ROM J MORPHOL EMBRYO, V49, P279; Bukoreshtliev NV, 2009, FEBS LETT, V583, P1481, DOI 10.1016/j.febslet.2009.03.065; Burkon A, 2008, MOL NUTR FOOD RES, V52, P549, DOI 10.1002/mnfr.200700290; Cairns CB, 1997, J TRAUMA, V42, P532, DOI 10.1097/00005373-199703000-00023; Calvo SE, 2010, ANNU REV GENOM HUM G, V11, P25, DOI 10.1146/annurev-genom-082509-141720; Camins A, 2010, BBA-GENE REGUL MECH, V1799, P740, DOI 10.1016/j.bbagrm.2010.06.005; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Cao L, 2013, BRAZ J MED BIOL RES, V46, P659, DOI 10.1590/1414-431X20132903; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cechella JL, 2014, AGE, V36, DOI 10.1007/s11357-014-9666-8; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chang CC, 2012, CHINESE J PHYSIOL, V55, P192, DOI [10.4077/CJP.2012.BAA012, 10.4077/CJP.2011.BAA012]; Chang DTW, 2006, PROG NEUROBIOL, V80, P241, DOI 10.1016/j.pneurobio.2006.09.003; Chatterjee PK, 2000, KIDNEY INT, V58, P658, DOI 10.1046/j.1523-1755.2000.00212.x; Chen G, 2005, CHEM PHARM BULL, V53, P1587, DOI 10.1248/cpb.53.1587; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen N, 2008, BIOL PHARM BULL, V31, P1387, DOI 10.1248/bpb.31.1387; Chen Q, 2011, BIOCHEM BIOPH RES CO, V415, P533, DOI 10.1016/j.bbrc.2011.10.037; Chen Q, 2007, AM J PHYSIOL-CELL PH, V292, pC137, DOI 10.1152/ajpcell.00270.2006; Chen TS, 2015, AM J PHYSIOL-HEART C, V308, pH424, DOI 10.1152/ajpheart.00454.2014; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng G, 2009, NEUROSCI LETT, V451, P105, DOI 10.1016/j.neulet.2008.12.045; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chiu PY, 2006, BIOGERONTOLOGY, V7, P199, DOI 10.1007/s10522-006-9017-y; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Chung HY, 2000, J AM AGING ASSOC, V23, P123, DOI 10.1007/s11357-000-0013-x; Chung JH, 2012, TRENDS CELL BIOL, V22, P546, DOI 10.1016/j.tcb.2012.07.004; Clark D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047792; Clouser CL, 2012, BIOORG MED CHEM LETT, V22, P6642, DOI 10.1016/j.bmcl.2012.08.108; Cohen A., 2015, MOL MED; CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G; Correia-Melo C., 2015, BIOCH BIOPHYS ACTA; Corsini Fabrizio, 2006, Monaldi Arch Chest Dis, V66, P13; Cui J, 2013, TRENDS MOL MED, V19, P197, DOI 10.1016/j.molmed.2012.12.007; Curry N, 2011, CRIT CARE, V15, DOI 10.1186/cc10096; Cuzzocrea S, 2000, J PINEAL RES, V29, P217, DOI 10.1034/j.1600-0633.2002.290404.x; Cuzzocrea S, 2000, BRAIN RES, V875, P96, DOI 10.1016/S0006-8993(00)02582-8; Dai H, 2010, J BIOL CHEM, V285, P32695, DOI 10.1074/jbc.M110.133892; Dai SH, 2014, INT J MOL MED, V34, P1159, DOI 10.3892/ijmm.2014.1876; Davalos A, 2012, LANCET, V380, P349, DOI 10.1016/S0140-6736(12)60813-7; Davis M, 1997, ACT NEUR S, V70, P56; DAY JJ, 1987, AGE AGEING, V16, P239; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Dessolin J, 2002, EUR J PHARMACOL, V447, P155, DOI 10.1016/S0014-2999(02)01839-3; Di Y., 2015, MOL MED; Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119; Dobrachinski F, 2014, NEUROTOX RES, V26, P317, DOI 10.1007/s12640-014-9463-2; Dong WP, 2008, J VASC SURG, V48, P709, DOI 10.1016/j.jvs.2008.04.007; Dong XB, 2012, MOL CELL BIOCHEM, V362, P149, DOI 10.1007/s11010-011-1137-2; Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861; Durand G, 2008, J PHYS CHEM A, V112, P12498, DOI 10.1021/jp804929d; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Durrant JR, 2009, J PHYSIOL-LONDON, V587, P3271, DOI 10.1113/jphysiol.2009.169771; Ehninger D, 2014, CELL MOL LIFE SCI, V71, P4325, DOI 10.1007/s00018-014-1677-1; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Erfani S, 2015, J MOL NEUROSCI, V56, P237, DOI 10.1007/s12031-014-0486-1; Esplugues JV, 2006, CIRC RES, V99, P1067, DOI 10.1161/01.RES.0000250430.62775.99; Fardoun RZ, 2006, AM J PHYSIOL-RENAL, V291, pF945, DOI 10.1152/ajprenal.00111.2006; Ferrara N, 2008, REJUV RES, V11, P139, DOI 10.1089/rej.2007.0576; Fillingame RH, 2014, BBA-BIOENERGETICS, V1837, P1063, DOI 10.1016/j.bbabio.2014.03.005; Finck BN, 2007, CIRCULATION, V115, P2540, DOI 10.1161/CIRCULATIONAHA.107.670588; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fischer H., 2014, GUIDE US MILITARY CA; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Forester BP, 2010, NMR BIOMED, V23, P242, DOI 10.1002/nbm.1444; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Fresta M, 1997, LIFE SCI, V61, P1227, DOI 10.1016/S0024-3205(97)00667-X; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; FUNAHASHI T, 1994, NEUROBIOL AGING, V15, P161, DOI 10.1016/0197-4580(94)90107-4; Gao DK, 2006, LIFE SCI, V78, P2564, DOI 10.1016/j.lfs.2005.10.030; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Gao L, 2008, VET CLIN N AM-SMALL, V38, P137, DOI 10.1016/j.cvsm.2007.10.004; GELLERICH FN, 1992, FEBS LETT, V297, P55, DOI 10.1016/0014-5793(92)80326-C; Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071; Ghosh S, 2010, NEUROSCIENCE, V171, P1287, DOI 10.1016/j.neuroscience.2010.09.049; Gioscia-Ryan RA, 2014, J PHYSIOL-LONDON, V592, P2549, DOI 10.1113/jphysiol.2013.268680; Godfrey R., 2013, BMJ CASE REP; Gomes AP, 2013, CELL, V155, P1624, DOI 10.1016/j.cell.2013.11.037; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Gong Y, 2005, ACT NEUR S, V95, P425; Gong Y, 2004, STROKE, V35, P2571, DOI 10.1161/01.STR.0000145485.67827.d0; Gong ZW, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00210; Goyal MS, 2014, CELL METAB, V19, P49, DOI 10.1016/j.cmet.2013.11.020; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gu CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074050; Gupta A, 2004, MOL CELL BIOCHEM, V259, P9, DOI 10.1023/B:MCBI.0000021339.34784.81; Gurke S, 2008, EXP CELL RES, V314, P3669, DOI 10.1016/j.yexcr.2008.08.022; Haberman F, 2007, NEUROMOL MED, V9, P315, DOI 10.1007/s12017-007-8010-1; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Hallberg BM, 2014, CELL METAB, V20, P226, DOI 10.1016/j.cmet.2014.07.001; HANSFORD RG, 1982, MECH AGEING DEV, V19, P5, DOI 10.1016/0047-6374(82)90044-6; Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hattori Y, 2015, NEUROREPORT, V26, P113, DOI 10.1097/WNR.0000000000000308; Hattori Y, 2014, STROKE, V45, P3403, DOI 10.1161/STROKEAHA.114.006265; Hernandez-Jimenez M, 2013, STROKE, V44, P2333, DOI 10.1161/STROKEAHA.113.001715; Hernando V, 2010, J MOL CELL CARDIOL, V49, P271, DOI 10.1016/j.yjmcc.2010.02.024; Herrmann JM, 2010, ANTIOXID REDOX SIGN, V13, P1341, DOI 10.1089/ars.2009.3063; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Hirst J, 2010, BIOCHEM J, V425, P327, DOI 10.1042/BJ20091382; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hsu CP, 2010, CIRCULATION, V122, P2170, DOI 10.1161/CIRCULATIONAHA.110.958033; Hsu CP, 2009, CIRC RES, V105, P481, DOI 10.1161/CIRCRESAHA.109.203703; Hu YY, 2015, J STROKE CEREBROVASC, V24, P601, DOI 10.1016/j.jstrokecerebrovasdis.2014.10.006; Huang SS, 2001, LIFE SCI, V69, P1057, DOI 10.1016/S0024-3205(01)01195-X; Ide T, 2001, CIRC RES, V88, P529, DOI 10.1161/01.RES.88.5.529; Imai S, 2000, NATURE, V403, P795; Imai S, 2011, FEBS LETT, V585, P1657, DOI 10.1016/j.febslet.2011.04.060; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Itoh T, 2013, BRAIN STRUCT FUNCT, V218, P209, DOI 10.1007/s00429-012-0394-5; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Izmaylov DM, 1996, MECH AGEING DEV, V91, P155, DOI 10.1016/S0047-6374(96)01776-9; Jannin B, 2004, BIOCHEM PHARMACOL, V68, P1113, DOI 10.1016/j.bcp.2004.04.028; Jastroch M, 2010, ESSAYS BIOCHEM, V47, P53, DOI [10.1042/BSE0470053, 10.1042/bse0470053]; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jian BX, 2014, MOL MED, V20, P10, DOI 10.2119/molmed.2013.00077; Jian BX, 2012, MOL MED, V18, P209, DOI 10.2119/molmed.2011.00365; Jian BX, 2011, BBA-MOL BASIS DIS, V1812, P1446, DOI 10.1016/j.bbadis.2011.04.010; Jian BX, 2011, MOL MED, V17, P542, DOI 10.2119/molmed.2010.00195; Jiang HK, 2014, CLIN EXP PHARMACOL P, V41, P192, DOI 10.1111/1440-1681.12211; Jiang JF, 2007, J PHARMACOL EXP THER, V320, P1050, DOI 10.1124/jpet.106.114769; Jiang ML, 2012, NAT MED, V18, P153, DOI 10.1038/nm.2558; Jordan JE, 2003, J PHARMACOL EXP THER, V307, P1007, DOI 10.1124/jpet.103.055970; Judge S, 2005, FASEB J, V19, P419, DOI 10.1096/fj.04-2622fje; Judge S, 2007, AM J PHYSIOL-CELL PH, V292, pC1983, DOI 10.1152/ajpcell.00285.2006; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kaeberlein M, 2006, SCIENCE, V312, DOI 10.1126/science.1124608; Kane LA, 2010, J MOL MED, V88, P971, DOI 10.1007/s00109-010-0674-6; Kanfi Y, 2012, NATURE, V483, P218, DOI 10.1038/nature10815; Kang D, 2005, ANN NY ACAD SCI, V1042, P101, DOI 10.1196/annals.1338.010; Kato N, 2003, BRAIN RES, V979, P188, DOI 10.1016/S0006-8993(03)02918-4; Kauppinen A, 2013, CELL SIGNAL, V25, P1939, DOI 10.1016/j.cellsig.2013.06.007; Kawai Y, 2011, J BIOL CHEM, V286, P7629, DOI 10.1074/jbc.M110.208173; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Khalil PN, 2005, EUR J PHARMACOL, V528, P124, DOI 10.1016/j.ejphar.2005.10.032; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; KIM JH, 1988, MECH AGEING DEV, V46, P279, DOI 10.1016/0047-6374(88)90130-3; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim TH, 2015, CNS NEUROSCI THER, V21, P327, DOI 10.1111/cns.12346; Kimura S, 2005, HYPERTENSION, V45, P438, DOI 10.1161/01.HYP.0000157169.27818.ae; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; King RW, 1996, ACAD EMERG MED, V3, P1041, DOI 10.1111/j.1553-2712.1996.tb03351.x; Kireev RA, 2012, J SURG RES, V178, P922, DOI 10.1016/j.jss.2012.04.060; KLAR AJS, 1979, GENETICS, V93, P37; Korzick DH, 2013, PFLUG ARCH EUR J PHY, V465, P669, DOI 10.1007/s00424-013-1255-7; Kowald A, 2014, P NATL ACAD SCI USA, V111, P2972, DOI 10.1073/pnas.1314970111; Kowald A, 2013, AGING CELL, V12, P728, DOI 10.1111/acel.12098; Koyanagi M, 2005, CIRC RES, V96, P1039, DOI 10.1161/01.RES.0000168650.23479.0c; Laemmle A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033433; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lapointe J, 2010, CELL MOL LIFE SCI, V67, P1, DOI 10.1007/s00018-009-0138-8; Las G, 2014, EMBO J, V33, P939, DOI 10.1002/embj.201488441; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Lee CH, 2013, TRENDS ENDOCRIN MET, V24, P222, DOI 10.1016/j.tem.2013.01.005; Lee Hahn-Ey, 2013, J Biomark, V2013, P413853, DOI 10.1155/2013/413853; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Lee TH, 2012, FOOD CHEM TOXICOL, V50, P4239, DOI 10.1016/j.fct.2012.08.047; Leiser SF, 2010, BIOL CHEM, V391, P1131, DOI 10.1515/BC.2010.123; Leite MR, 2015, CYTOKINE, V71, P119, DOI 10.1016/j.cyto.2014.09.006; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Lesnefsky EJ, 2009, J MOL CELL CARDIOL, V46, P1008, DOI 10.1016/j.yjmcc.2009.03.007; LESNEFSKY EJ, 1994, J LAB CLIN MED, V124, P843; Lesniewski LA, 2009, J GERONTOL A-BIOL, V64, P9, DOI 10.1093/gerona/gln049; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li H, 2011, NEUROPHARMACOLOGY, V60, P252, DOI 10.1016/j.neuropharm.2010.09.005; Li NL, 2011, REJUV RES, V14, P261, DOI 10.1089/rej.2010.1115; Li X, 2014, AM J RESP CELL MOL, V51, P455, DOI 10.1165/rcmb.2013-0529OC; Li XJ, 1997, ACTA PHARMACOL SIN, V18, P394; Li Z, 2012, BRAIN RES, V1450, P116, DOI 10.1016/j.brainres.2012.02.019; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Lin AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046585; Lin MY, 2015, EXP CELL RES, V334, P35, DOI 10.1016/j.yexcr.2015.01.004; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Ling X, 1999, ACTA PHARMACOL SIN, V20, P409; Liou CM, 2010, CELL BIOCHEM FUNCT, V28, P521, DOI 10.1002/cbf.1687; Liu AJ, 2013, J CEREBR BLOOD F MET, V33, P906, DOI 10.1038/jcbfm.2013.28; Liu B, 2013, CELL PHYSIOL BIOCHEM, V32, P1050, DOI 10.1159/000354505; Liu B, 2013, CELL PHYSIOL BIOCHEM, V32, P655, DOI 10.1159/000354469; Liu Tie Fu, 2013, Genes Cancer, V4, P135, DOI 10.1177/1947601913476948; Lowicka E, 2007, PHARMACOL REP, V59, P4; Lu KT, 2006, J AGR FOOD CHEM, V54, P3126, DOI 10.1021/JF053011Q; Lu TM, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-57; Lund DD, 2009, AM J PHYSIOL-HEART C, V296, pH1920, DOI 10.1152/ajpheart.01342.2008; Luo YG, 2013, NEUROCHEM INT, V63, P826, DOI 10.1016/j.neuint.2013.06.004; Lynn EG, 2008, FEBS LETT, V582, P2857, DOI 10.1016/j.febslet.2008.07.016; Ma H, 2009, J NEUROSCI, V29, P13019, DOI 10.1523/JNEUROSCI.2517-09.2009; Ma J, 2012, J BIOL CHEM, V287, P27480, DOI 10.1074/jbc.M112.358929; Maksin-Matveev A, 2015, EXP CELL RES, V330, P81, DOI 10.1016/j.yexcr.2014.07.013; Manev H, 1996, FASEB J, V10, P1546; Mariappan N, 2009, FREE RADICAL BIO MED, V46, P462, DOI 10.1016/j.freeradbiomed.2008.10.049; Marzetti E, 2013, AM J PHYSIOL-HEART C, V305, pH459, DOI 10.1152/ajpheart.00936.2012; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; Mayhan WG, 2008, MICROCIRCULATION, V15, P225, DOI 10.1080/10739680701641421; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; McDonald MC, 1999, FREE RADICAL BIO MED, V27, P493, DOI 10.1016/S0891-5849(99)00100-8; McManus MJ, 2014, MOL CELL NEUROSCI, V63, P13, DOI 10.1016/j.mcn.2014.09.002; Mees ST, 2008, SHOCK, V29, P670, DOI 10.1097/SHK.0b013e31815c3ea0; Meli E, 2003, TOXICOL LETT, V139, P153, DOI 10.1016/S0378-4274(02)00429-0; Menghini R, 2009, CIRCULATION, V120, P1524, DOI 10.1161/CIRCULATIONAHA.109.864629; MERCADIER JJ, 1981, CIRC RES, V49, P525, DOI 10.1161/01.RES.49.2.525; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130; Miller RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/gerona/glq178; Mitchell JB, 2003, FREE RADICAL BIO MED, V34, P93, DOI 10.1016/S0891-5849(02)01193-0; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Mitchell SJ, 2014, CELL REP, V6, P836, DOI 10.1016/j.celrep.2014.01.031; MOORADIAN AD, 1988, NEUROBIOL AGING, V9, P31, DOI 10.1016/S0197-4580(88)80013-7; Morselli E, 2010, AUTOPHAGY, V6, P186, DOI 10.4161/auto.6.1.10817; Mota-Filipe H, 1999, SHOCK, V12, P255, DOI 10.1097/00024382-199910000-00002; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; MOZAFFARIAN D, 2015, CIRCULATION, V131, pE29, DOI [DOI 10.1161/CIR.0000000000000152, 10.1161/CIR.0000000000000152]; Mukhopadhyay P, 2012, FREE RADICAL BIO MED, V53, P1123, DOI 10.1016/j.freeradbiomed.2012.05.036; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Murphy E, 2008, PHYSIOL REV, V88, P581, DOI 10.1152/physrev.00024.2007; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Nadtochiy SM, 2011, AM J PHYSIOL-HEART C, V301, pH1506, DOI 10.1152/ajpheart.00587.2011; Nadtochiy SM, 2011, CARDIOVASC RES, V89, P643, DOI 10.1093/cvr/cvq287; Nasrin N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008414; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Neuhof C, 2004, BIOL CHEM, V385, P1077, DOI 10.1515/BC.2004.139; Neuhof C, 2003, BIOL CHEM, V384, P1597, DOI 10.1515/BC.2003.177; Neuhof C, 2014, WORLD J CARDIOL, V6, P638, DOI 10.4330/wjc.v6.i7.638; Neuhof C, 2008, BIOL CHEM, V389, P1505, DOI 10.1515/BC.2008.172; Ng LF, 2014, FREE RADICAL BIO MED, V71, P390, DOI 10.1016/j.freeradbiomed.2014.03.003; Nicolini G, 2001, NEUROSCI LETT, V302, P41, DOI 10.1016/S0304-3940(01)01654-8; NOHL H, 1980, MECH AGEING DEV, V14, P137, DOI 10.1016/0047-6374(80)90112-8; Nohl H, 1997, EXP GERONTOL, V32, P485, DOI 10.1016/S0531-5565(96)00169-6; Ohsawa S, 2006, FEBS LETT, V580, P5875, DOI 10.1016/j.febslet.2006.09.051; Ohtsuji M, 2008, J BIOL CHEM, V283, P33554, DOI 10.1074/jbc.M804597200; ONODERA H, 1986, J NEUROCHEM, V46, P1704; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Palacios HH, 2011, CNS NEUROL DISORD-DR, V10, P149; PALADE GE, 1953, J HISTOCHEM CYTOCHEM, V1, P188, DOI 10.1177/1.4.188; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; PARADIES G, 1990, BIOCHIM BIOPHYS ACTA, V1016, P207, DOI 10.1016/0005-2728(90)90060-H; PARADIES G, 1991, ARCH BIOCHEM BIOPHYS, V284, P332, DOI 10.1016/0003-9861(91)90304-2; Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017; Patel NSA, 2002, FREE RADICAL BIO MED, V33, P1575, DOI 10.1016/S0891-5849(02)01116-4; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Payne JA, 2003, AM J PHYSIOL-REG I, V285, pR542, DOI 10.1152/ajpregu.00056.2003; PEARCE FJ, 1985, J SURG RES, V39, P390, DOI 10.1016/0022-4804(85)90092-7; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Pervaiz S, 2009, ANTIOXID REDOX SIGN, V11, P2851, DOI [10.1089/ars.2008.2412, 10.1089/ARS.2008.2412]; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pillai JB, 2008, AM J PHYSIOL-HEART C, V294, pH1388, DOI 10.1152/ajpheart.01339.2007; Plotnikov EY, 2008, J CELL MOL MED, V12, P1622, DOI 10.1111/j.1582-4934.2007.00205.x; POEGGELER B, 1994, ANN NY ACAD SCI, V738, P419, DOI 10.1111/j.1749-6632.1994.tb21831.x; Polster BM, 2013, NEUROCHEM INT, V62, P695, DOI 10.1016/j.neuint.2012.12.002; Porat-Shliom N, 2014, CELL REP, V9, P514, DOI 10.1016/j.celrep.2014.09.022; Porter GA, 2014, AM J PHYSIOL-HEART C, V306, pH1602, DOI 10.1152/ajpheart.00027.2014; Poulose N, 2015, BBA-MOL BASIS DIS, V1852, P2442, DOI 10.1016/j.bbadis.2015.08.017; Poulose N, 2014, AGING DIS, V5, P101, DOI 10.14336/AD.2014.0500101; Powell RD, 2015, J TRAUMA ACUTE CARE, V78, P573, DOI 10.1097/TA.0000000000000533; Powell RD, 2014, J TRAUMA ACUTE CARE, V76, P409, DOI 10.1097/TA.0000000000000096; Prentice RL, 2014, SEMIN REPROD MED, V32, P419, DOI 10.1055/s-0034-1384624; Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Pung YF, 2012, ARTERIOSCL THROM VAS, V32, P325, DOI 10.1161/ATVBAHA.111.241802; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Qabazard B, 2014, ANTIOXID REDOX SIGN, V20, P2621, DOI 10.1089/ars.2013.5448; Qabazard B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080135; Raju R, 2011, AGING DIS, V2, P174; Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Rane S, 2009, CIRC RES, V104, P879, DOI 10.1161/CIRCRESAHA.108.193102; Raval AP, 2008, CURR MED CHEM, V15, P1545, DOI 10.2174/092986708784638861; Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262; Regnier-Vigouroux A, 2003, INT REV CYTOL, V226, P321, DOI 10.1016/S0074-7696(03)01006-4; Reiter RJ, 1998, ANN NY ACAD SCI, V854, P410, DOI 10.1111/j.1749-6632.1998.tb09920.x; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Riera CE, 2015, NAT CELL BIOL, V17, P196, DOI 10.1038/ncb3107; RINE J, 1987, GENETICS, V116, P9; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rogers RS, 2013, PHYSIOLOGY, V28, P414, DOI 10.1152/physiol.00032.2013; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133; Ryou M. G., 2015, NEUROSCIENCE; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Saretzki G, 2003, AGING CELL, V2, P141, DOI 10.1046/j.1474-9728.2003.00040.x; Sasaki T, 2008, AGING CELL, V7, P459, DOI 10.1111/j.1474-9726.2008.00394.x; Sasaki T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004020; Satoh A, 2013, CELL METAB, V18, P416, DOI 10.1016/j.cmet.2013.07.013; Saver Jeffrey L, 2008, Rev Neurol Dis, V5, P167; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006; Schmeisser S, 2013, MOL METAB, V2, P92, DOI 10.1016/j.molmet.2013.02.002; Schonfeld P, 2010, BBA-BIOENERGETICS, V1797, P929, DOI 10.1016/j.bbabio.2010.01.010; Sebastian D, 2012, P NATL ACAD SCI USA, V109, P5523, DOI 10.1073/pnas.1108220109; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; SEMENZA GL, 2010, BIOCHIM BIOPHYS ACTA, V1813, P1263, DOI DOI 10.1016/J.BBAMCR.2010.08.006; Semenza GL, 2007, SCI STKE, V2007, pcm8, DOI [DOI 10.1126/STKE.4072007CM8, 10.1126/stke.4072007cm8]; Sepodes B, 2004, TRANSPL P, V36, P849, DOI 10.1016/j.transproceed.2004.03.050; Shalwala M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086977; Shao AW, 2014, CNS NEUROSCI THER, V20, P182, DOI 10.1111/cns.12194; Shen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079833; Shin JA, 2012, NEUROCHEM RES, V37, P2686, DOI 10.1007/s11064-012-0858-2; Shinmura K, 2008, AM J PHYSIOL-HEART C, V295, pH2348, DOI 10.1152/ajpheart.00602.2008; Shinozaki S, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005375; Simao F, 2011, J NUTR BIOCHEM, V22, P921, DOI 10.1016/j.jnutbio.2010.07.013; Simpkins JW, 2008, MOL CELL ENDOCRINOL, V290, P51, DOI 10.1016/j.mce.2008.04.013; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Snow BJ, 2010, MOVEMENT DISORD, V25, P1670, DOI 10.1002/mds.23148; Solaini G, 2010, BBA-BIOENERGETICS, V1797, P1171, DOI 10.1016/j.bbabio.2010.02.011; Spanier G, 2009, J PHYSIOL PHARMACOL, V60, P111; Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Stowe DF, 2009, ANTIOXID REDOX SIGN, V11, P1373, DOI [10.1089/ars.2008.2331, 10.1089/ARS.2008.2331]; Strong R, 2013, J GERONTOL A-BIOL, V68, P6, DOI 10.1093/gerona/gls070; Sun AY, 2010, MOL NEUROBIOL, V41, P375, DOI 10.1007/s12035-010-8111-y; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00095; Sun T, 2013, CELL REP, V4, P413, DOI 10.1016/j.celrep.2013.06.040; Suzman R., 2011, GLOBAL HLTH AGING; Tani M, 1997, J MOL CELL CARDIOL, V29, P3081, DOI 10.1006/jmcc.1997.0533; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; Tatarkova Z, 2011, PHYSIOL RES, V60, P281, DOI 10.33549/physiolres.932019; Tay AS, 2010, NEUROSCIENCE, V167, P277, DOI 10.1016/j.neuroscience.2010.02.006; Tegla CA, 2014, EXP MOL PATHOL, V96, P139, DOI 10.1016/j.yexmp.2013.12.010; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TOKUMITSU Y, 1973, BIOCHIM BIOPHYS ACTA, V292, P310, DOI 10.1016/0005-2728(73)90038-8; Tomasello F, 2009, CELL RES, V19, P1363, DOI 10.1038/cr.2009.98; Tong C, 2013, FASEB J, V27, P4332, DOI 10.1096/fj.12-216473; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; Tsai SK, 2007, J VASC SURG, V46, P346, DOI 10.1016/j.jvs.2007.04.044; Tsai YF, 2012, J SURG RES, V176, P171, DOI 10.1016/j.jss.2011.05.039; Tsuchiya M, 2006, AGING CELL, V5, P505, DOI 10.1111/j.1474-9726.2006.00240.x; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TUMMINO PJ, 1991, MECH AGEING DEV, V59, P177, DOI 10.1016/0047-6374(91)90083-C; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Udenigwe CC, 2008, NUTR REV, V66, P445, DOI 10.1111/j.1753-4887.2008.00076.x; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vaishnavi SN, 2010, P NATL ACAD SCI USA, V107, P17757, DOI 10.1073/pnas.1010459107; Vaquero A, 2007, ONCOGENE, V26, P5505, DOI 10.1038/sj.onc.1210617; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H., 2001, HSIR2 SIRT1 FUNCTION, P53; Vemuganti R, 2010, TRANSL STROKE RES, V1, P158, DOI 10.1007/s12975-010-0030-8; Vinciguerra M, 2010, AGING-US, V2, P43; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wakatsuki A, 1999, J PINEAL RES, V26, P147, DOI 10.1111/j.1600-079X.1999.tb00576.x; Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885; Walle T, 2011, ANN NY ACAD SCI, V1215, P9, DOI 10.1111/j.1749-6632.2010.05842.x; Walters JW, 2016, CURR OPIN PHARMACOL, V27, P50, DOI 10.1016/j.coph.2016.01.006; Wan WH, 2007, AM J MED SCI, V334, P265, DOI 10.1097/MAJ.0b013e318068b5ed; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang H, 2015, SHOCK, V44, P173, DOI 10.1097/SHK.0000000000000390; Wang JH, 2011, GASTROENTEROLOGY, V141, P2188, DOI 10.1053/j.gastro.2011.08.005; Wang P, 2012, AUTOPHAGY, V8, P77, DOI 10.4161/auto.8.1.18274; Wang P, 2011, ANN NEUROL, V69, P360, DOI 10.1002/ana.22236; Wang R, 2014, CELL PHYSIOL BIOCHEM, V34, P854, DOI 10.1159/000366304; Wang SP, 2008, STROKE, V39, P2587, DOI 10.1161/STROKEAHA.107.509158; Wang T, 2009, FREE RADICAL BIO MED, V47, P229, DOI 10.1016/j.freeradbiomed.2009.02.027; Wang X, 2015, CELL DEATH DIFFER, V22, P1181, DOI 10.1038/cdd.2014.211; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Wang Y, 2011, CELL DEATH DIFFER, V18, P732, DOI 10.1038/cdd.2010.147; Wang Y, 2015, J NANOMATER, V2015, P5, DOI DOI 10.1038/SREP18296; Wang Y, 2015, SCIENCE, V350, P1204, DOI 10.1126/science.aac4357; Wani WY, 2011, NEUROPHARMACOLOGY, V61, P1193, DOI 10.1016/j.neuropharm.2011.07.008; Warach S, 2000, ANN NEUROL, V48, P713, DOI 10.1002/1531-8249(200011)48:5<713::AID-ANA4>3.0.CO;2-#; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Wei YZ, 2009, AM J PATHOL, V174, P1329, DOI 10.2353/ajpath.2009.080697; Wen Y, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.208447; Wenz Tina, 2011, J Aging Res, V2011, P810619, DOI 10.4061/2011/810619; Wheaton WW, 2011, AM J PHYSIOL-CELL PH, V300, pC385, DOI 10.1152/ajpcell.00485.2010; Whitaker R, 2013, AGING-US, V5, P682, DOI 10.18632/aging.100599; Wilcox CS, 2010, PHARMACOL THERAPEUT, V126, P119, DOI 10.1016/j.pharmthera.2010.01.003; Winterbourn CC, 2013, METHOD ENZYMOL, V528, P3, DOI 10.1016/B978-0-12-405881-1.00001-X; Wipf P, 2005, J AM CHEM SOC, V127, P12460, DOI 10.1021/ja053679l; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu CC, 2013, ANTIOXID REDOX SIGN, V19, P546, DOI 10.1089/ars.2012.4905; Wu CT, 2008, CHINESE J PHYSIOL, V51, P363; Wu YC, 2011, NEUROSIGNALS, V19, P163, DOI 10.1159/000328516; Xing GQ, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00196; Xu K, 2008, ADV EXP MED BIOL, V614, P379, DOI 10.1007/978-0-387-74911-2_42; Xu K, 2010, BRAIN RES, V1328, P181, DOI 10.1016/j.brainres.2010.02.080; XUE JY, 1992, FREE RADICAL BIO MED, V12, P127, DOI 10.1016/0891-5849(92)90006-3; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yamamoto T, 2011, TRENDS CARDIOVAS MED, V21, P27, DOI 10.1016/j.tcm.2012.01.005; Yang C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016229; Yang XL, 2010, CARDIOVASC DRUG THER, V24, P225, DOI 10.1007/s10557-010-6236-x; Yang Y, 2013, NEUROBIOL AGING, V34, P2879, DOI 10.1016/j.neurobiolaging.2013.06.008; Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yoon H, 2014, BIOCHEM BIOPH RES CO, V444, P36, DOI 10.1016/j.bbrc.2014.01.001; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yousuf S, 2009, BRAIN RES, V1250, P242, DOI 10.1016/j.brainres.2008.10.068; Yu HP, 2011, SHOCK, V35, P517, DOI 10.1097/SHK.0b013e318209e931; Yu HP, 2010, SURGERY, V148, P103, DOI 10.1016/j.surg.2009.12.008; Yu HP, 2010, CRIT CARE MED, V38, P1147, DOI 10.1097/CCM.0b013e3181cd124e; Yu ZF, 1998, J NEUROSCI RES, V53, P613, DOI 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1; Yuan J, 2009, J CELL BIOL, V185, P203, DOI 10.1083/jcb.200809167; Zang QS, 2014, AGING DIS, V5, P137, DOI 10.14336/AD.2014.0500137; Zang QS, 2012, AM J PHYSIOL-HEART C, V302, pH1847, DOI 10.1152/ajpheart.00203.2011; Zarzaur BL, 2008, J SURG RES, V147, P229, DOI 10.1016/j.jss.2008.03.025; Zhang F, 2011, PROG NEUROBIOL, V95, P373, DOI 10.1016/j.pneurobio.2011.09.001; Zhao G, 2012, NEUROBIOL AGING, V33, P176, DOI 10.1016/j.neurobiolaging.2010.02.013; Zhao G, 2011, J NUTR BIOCHEM, V22, P929, DOI 10.1016/j.jnutbio.2010.07.014; Zhao G, 2010, NEUROCHEM INT, V56, P168, DOI 10.1016/j.neuint.2009.09.015; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zheng YQ, 2014, J PHARMACOL SCI, V124, P354, DOI 10.1254/jphs.13220FP; Zhou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.530; Zhu HR, 2010, NEUROPHARMACOLOGY, V59, P70, DOI 10.1016/j.neuropharm.2010.03.017; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	470	105	108	2	83	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0301-0082	1873-5118		PROG NEUROBIOL	Prog. Neurobiol.	OCT	2017	157				SI		92	116		10.1016/j.pneurobio.2016.06.006			25	Neurosciences	Neurosciences & Neurology	FJ7TG	WOS:000412961200006	27321753	Green Accepted			2021-06-18	
J	Bahrami, N; Sharma, D; Rosenthal, S; Davenport, EM; Urban, JE; Wagner, B; Jung, Y; Vaughan, CG; Gioia, GA; Stitzel, JD; Whitlow, CT; Maldjian, JA				Bahrami, Naeim; Sharma, Dev; Rosenthal, Scott; Davenport, Elizabeth M.; Urban, Jillian E.; Wagner, Benjamin; Jung, Youngkyoo; Vaughan, Christopher G.; Gioia, Gerard A.; Stitzel, Joel D.; Whitlow, Christopher T.; Maldjian, Joseph A.			Subconcussive Head Impact Exposure and White Matter Tract Changes over a Single Season of Youth Football	RADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; DIFFUSION-TENSOR; TRACTOGRAPHY; ADOLESCENCE; PLAYERS; INTEGRITY; GRAY; ACCELERATION; BIOMECHANICS	Purpose: To examine the effects of subconcussive impacts resulting from a single season of youth (age range, 8-13 years) football on changes in specific white matter (WM) tracts as detected with diffusion-tensor imaging in the absence of clinically diagnosed concussions. Materials and Methods: Head impact data were recorded by using the Head Impact Telemetry system and quantified as the combined-probability risk-weighted cumulative exposure (RWE CP). Twenty-five male participants were evaluated for seasonal fractional anisotropy (FA) changes in specific WM tracts: the inferior fronto-occipital fasciculus (IFOF), inferior longitudinal fasciculus, and superior longitudinal fasciculus (SLF). Fiber tracts were segmented into a central core and two fiber terminals. The relationship between seasonal FA change in the whole fiber, central core, and the fiber terminals with RWE CP was also investigated. Linear regression analysis was conducted to determine the association between RWE CP and change in fiber tract FA during the season. Results: There were statistically significant linear relationships between RWEcp and decreased FA in the whole (R-2 = 0.433; P = .003), core (R-2 = 0.3649; P =.007), and terminals (R-2 = 0.5666; P < .001) of left IFOF. A trend toward statistical significance (P = .08) in right SLF was observed. A statistically significant correlation between decrease in FA of the right SLF terminal and RWE CP was also observed (R-2 = 0.2893; P = .028). Conclusion: This study found a statistically significant relationship between head impact exposure and change of FA value of whole, core, and terminals of left IFOF and right SLF's terminals where WM and gray matter intersect, in the absence of a clinically diagnosed concussion. (C) RSNA, 2016	[Bahrami, Naeim; Sharma, Dev; Davenport, Elizabeth M.; Jung, Youngkyoo; Whitlow, Christopher T.; Maldjian, Joseph A.] Wake Forest Sch Med, Adv Neurosci Imaging Res ANSIR Lab, Winston Salem, NC 27101 USA; [Rosenthal, Scott] Wake Forest Sch Med, Winston Salem, NC USA; [Jung, Youngkyoo; Whitlow, Christopher T.] Virginia Tech Wake Forest Sch Biomed Engn, Dept Radiol Neuroradiol, Blacksburg, VA 24061 USA; [Bahrami, Naeim; Urban, Jillian E.; Jung, Youngkyoo; Stitzel, Joel D.; Whitlow, Christopher T.] Virginia Tech Wake Forest Sch Biomed Engn, Dept Biomed Engn, Blacksburg, VA 24061 USA; [Whitlow, Christopher T.] Virginia Tech Wake Forest Sch Biomed Engn, Dept Family & Community Med, Blacksburg, VA 24061 USA; [Whitlow, Christopher T.] Virginia Tech Wake Forest Sch Biomed Engn, Dept Neurosurg, Blacksburg, VA 24061 USA; [Bahrami, Naeim; Urban, Jillian E.; Jung, Youngkyoo; Stitzel, Joel D.; Whitlow, Christopher T.] Virginia Tech Wake Forest Sch Biomed Engn, Blacksburg, VA 24061 USA; [Vaughan, Christopher G.; Gioia, Gerard A.] George Washington Univ, Sch Med, Childrens Natl Hlth Syst, Div Pediat Neuropsychol, Rockville, MD USA; [Stitzel, Joel D.] Wake Forest Sch Med, Childress Inst Pediat Trauma, Winston Salem, NC USA; [Davenport, Elizabeth M.; Wagner, Benjamin; Maldjian, Joseph A.] Univ Texas Southwestern Med Ctr Dallas, Dept Radiol, Dallas, TX USA	Whitlow, CT (corresponding author), Wake Forest Sch Med, Adv Neurosci Imaging Res ANSIR Lab, Winston Salem, NC 27101 USA.; Whitlow, CT (corresponding author), Virginia Tech Wake Forest Sch Biomed Engn, Dept Radiol Neuroradiol, Blacksburg, VA 24061 USA.; Whitlow, CT (corresponding author), Virginia Tech Wake Forest Sch Biomed Engn, Dept Biomed Engn, Blacksburg, VA 24061 USA.; Whitlow, CT (corresponding author), Virginia Tech Wake Forest Sch Biomed Engn, Dept Family & Community Med, Blacksburg, VA 24061 USA.; Whitlow, CT (corresponding author), Virginia Tech Wake Forest Sch Biomed Engn, Dept Neurosurg, Blacksburg, VA 24061 USA.; Whitlow, CT (corresponding author), Virginia Tech Wake Forest Sch Biomed Engn, Blacksburg, VA 24061 USA.	cwhitlow@wakehealth.edu	Stitzel, Joel/B-4045-2012	Stitzel, Joel/0000-0001-9762-3033; Jung, Youngkyoo/0000-0002-7236-8897; Maldjian, Joseph/0000-0002-6384-1072	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082453 NINDS, R03NS088082 NINDS]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS088082, R01NS082453] Funding Source: NIH RePORTER	Supported by National Institutes of Health (grant no. R01NS082453 NINDS and R03NS088082 NINDS).	Asato MR, 2010, CEREB CORTEX, V20, P2122, DOI 10.1093/cercor/bhp282; Ashtari M, 2007, NEUROIMAGE, V35, P501, DOI 10.1016/j.neuroimage.2006.10.047; Bachynski KE, 2014, J LAW MED ETHICS, V42, P323, DOI 10.1111/jlme.12149; Barnea-Goraly N, 2004, BIOL PSYCHIAT, V55, P323, DOI 10.1016/j.biopsych.2003.10.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Budday S, 2015, J MECH BEHAV BIOMED, V46, P318, DOI 10.1016/j.jmbbm.2015.02.024; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Christ AF, 2010, J BIOMECH, V43, P2986, DOI 10.1016/j.jbiomech.2010.07.002; Ciccarelli O, 2003, NEUROIMAGE, V19, P1545, DOI 10.1016/S1053-8119(03)00190-3; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; De Maesschalck R, 2000, CHEMOMETR INTELL LAB, V50, P1, DOI 10.1016/S0169-7439(99)00047-7; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gajawelli N, 2013, WORLD NEUROSURG, V80, P824, DOI 10.1016/j.wneu.2013.10.020; Giorgio A, 2010, NEUROIMAGE, V49, P94, DOI 10.1016/j.neuroimage.2009.08.003; Held K, 1997, IEEE T MED IMAGING, V16, P878, DOI 10.1109/42.650883; Holl N, 2011, SURG RADIOL ANAT, V33, P713, DOI 10.1007/s00276-011-0816-8; Houston SM, 2014, CURR TOP BEHAV NEURO, V16, P3, DOI 10.1007/7854_2013_265; HUTTENLOCHER PR, 1990, NEUROPSYCHOLOGIA, V28, P517, DOI 10.1016/0028-3932(90)90031-I; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; MCARDLE CB, 1987, RADIOLOGY, V162, P223, DOI 10.1148/radiology.162.1.3786767; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Peters BD, 2012, SCHIZOPHRENIA BULL, V38, P1308, DOI 10.1093/schbul/sbs054; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Thomas C, 2011, CORTEX, V47, P863, DOI 10.1016/j.cortex.2010.07.006; Tozer DJ, 2012, NEUROIMAGE, V59, P3094, DOI 10.1016/j.neuroimage.2011.10.088; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Voelbel GT, 2012, NEUROREHABILITATION, V31, P281, DOI 10.3233/NRE-2012-0796; Xiong KL, 2014, BRAIN IMAGING BEHAV, V8, P487, DOI 10.1007/s11682-013-9288-2; Yeatman JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049790; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	52	105	105	0	15	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	DEC	2016	281	3					919	926		10.1148/radiol.2016160564			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	EJ4QI	WOS:000393201500025	27775478	Green Published, Bronze			2021-06-18	
